"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04447430","Light Therapy to Improve Symptoms in Pregnant Women With Major Depressive Disorder","GZPHBLT","Recruiting","No Results Available","Major Depressive Disorder","Device: bright light|Device: dim red light","Changes in depressive symptoms from baseline|Changes in anxious symptoms from baseline","Guangzhou Psychiatric Hospital|The Third Affiliated Hospital of Guangzhou Medical University","Female","18 Years to 45 Years   (Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GuangzhouPHBLT","June 12, 2020","December 30, 2021","December 30, 2021","June 25, 2020",,"June 25, 2020","Guangzhou Brain Hospital (Guangzhou Huiai Hospital), Guanzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04447430"
2,"NCT04637620","NMDA Modulation in Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: NMDAE|Drug: Sertraline|Drug: Placebo Cap","Change in Hamilton Rating Scale for Depression|Change in Global Assessment of Functioning|Change in Perceived Stress Scale|Visual Analogue Scale (VAS)|Clinical Global Impression|Quality of life (SF-36)|Visual Continuous Performance Test|Wisconsin Card Sorting Test|Logical Memory Test of the Wechsler Memory Scale|Digit Span|Spatial Span|Category Fluency|Trail Marking A|WAIS-III Digit Symbol-Coding|Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0","China Medical University Hospital|Ministry of Science and Technology, Taiwan","All","18 Years to 55 Years   (Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMUH103-REC2-130","June 1, 2017","September 2022","December 2022","November 20, 2020",,"November 20, 2020","Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04637620"
3,"NCT03295708","Fish Oil as Adjunct Treatment for Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Dietary Supplement: fish oil capsule|Dietary Supplement: soybean oil capsule","Changes in Hamilton Depression Scale (HAMD) HAMD|Changes in Clinical Global Impression (CGI)|Changes in Hamilton Anxiety Scale (HAMA)|Changes in Beck Depression Rating Scale (BDI)|Changes in Self-Rating Anxiety Scale (SAS)","Second Xiangya Hospital of Central South University|Xiangya Hospital of Central South University","All","18 Years to 50 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MDD201610","October 1, 2017","October 1, 2019","April 1, 2020","September 28, 2017",,"October 10, 2017","Mental Health Institute, Second Xiangya Hospital of Central South University, Changsha, Hunan, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03295708/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03295708"
4,"NCT04364997","Study of Desvenlafaxine in Treating Major Depressive Disorder.",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Drug: Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Drug: Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Drug: Duloxetine Hydrochloride Enteric-coated Capsule","Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8|Hamilton Rating Scale for Depression, 17-item (HAM-D17) Response Rate|Hamilton Rating Scale for Depression, 17-item (HAM-D17) Remission Rate|Change From Baseline on the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change From Baseline on the Clinical Global Impression Scale-Improvement (CGI-I)|Change From Baseline on the Clinical Global Impression-Severity Score (CGI-S)|Change From Baseline on the Visual Analog Scale (VAS) for Pain","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HF124-CSP-001","June 18, 2020","December 31, 2021","December 31, 2021","April 28, 2020",,"June 25, 2021","Beijing Anding Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04364997"
5,"NCT04347577","Intestinal Flora and Major Depressive Disorders","IFMDD","Recruiting","No Results Available","Major Depressive Disorder","Drug: duloxetine","the difference between the flora|the dynamic succession change of the intestinal flora","Beijing Chao Yang Hospital|Capital Medical University","All","20 Years to 40 Years   (Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HShi","April 10, 2020","October 1, 2022","April 1, 2023","April 15, 2020",,"April 17, 2020","Beijing Chao-Yang Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04347577"
6,"NCT01741142","Efficacy and Safety Study of ABT-436 in Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Drug: ABT-436|Drug: Escitalopram|Drug: Placebo","Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.|Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-733","January 2012","October 2013","August 2015","December 4, 2012",,"October 8, 2013","Site Reference ID/Investigator# 85593, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 87228, Garden Grove, California, United States|Site Reference ID/Investigator# 87214, National City, California, United States|Site Reference ID/Investigator# 87220, Oakland, California, United States|Site Reference ID/Investigator# 87215, Bradenton, Florida, United States|Site Reference ID/Investigator# 87225, South Miami, Florida, United States|Site Reference ID/Investigator# 85594, Atlanta, Georgia, United States|Site Reference ID/Investigator# 85580, Marlton, New Jersey, United States|Site Reference ID/Investigator# 87227, Brooklyn, New York, United States|Site Reference ID/Investigator# 87223, New York, New York, United States|Site Reference ID/Investigator# 87217, Dayton, Ohio, United States|Site Reference ID/Investigator# 87226, Portland, Oregon, United States|Site Reference ID/Investigator# 87221, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 87219, Austin, Texas, United States|Site Reference ID/Investigator# 87216, Dallas, Texas, United States|Site Reference ID/Investigator# 87933, Houston, Texas, United States|Site Reference ID/Investigator# 88874, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 88876, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01741142"
7,"NCT04497493","Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorders","Device: Transcranial Direct Current Stimulation (tDCS)-active|Device: Transcranial Direct Current Stimulation (tDCS)-sham","The change of scores in Hamilton Depression Rating Scale (HAMD)-17 from baseline to week 4.|The change of scores in Hamilton Anxiety Rating Scale (HAMA) from baseline to Week 4.|The change of scores in Pittsburgh Sleep Quality Index (PSQI) from basline to week 8.|The change of scores in quality of life (QOL) from baseline to week 8.|The change of sores in suicidal risk assessment scale from baseline to week 8|The change of scores in Repeatable Battery for the Assessment of neuropsychological Status (Rebans).|The changes of levels of biomarkers in peripheral blood from baseline to week 4|Adverse events from baseline to week 4","Tianjin Anding Hospital","All","18 Years to 50 Years   (Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","tDCS-2020-TJAH","May 22, 2020","October 2021","March 2022","August 4, 2020",,"August 4, 2020","Tianjin Anding Hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04497493"
8,"NCT03053830","Open Label Ketamine Treatment for Major Depressive Disorder in Veterans","Ket-MDD","Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine","Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Quick Inventory of Depressive Symptomatology-Self Report (QUIDS-SR)|Change in Hamilton Anxiety Rating Scale (HAM-A)|Clinical Global Impression Scale|Change in Brief Psychotic Rating Scale (BPRS)|Change in Clinician-Administered Dissociative States Scale (CADSS)|Change in Visual Analog Scale (VAS) of Mood States|Time Line Follow Back (TLFB)|Columbia-Suicide Severity Rating Scale (C-SSRS)|Quality of life enjoyment and satisfaction survey (Q-LES-Q)|Cognition","VA Connecticut Healthcare System","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","11","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MR0012","January 31, 2017","June 30, 2021","June 30, 2021","February 15, 2017",,"October 6, 2020","VA Healthcare System, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03053830"
9,"NCT03487198","The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Drug: Brexpiprazole|Drug: Placebo","Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in the MADRS Total Score|Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in SDS Mean Score|Change from the end of Phase A (Week 8 visit) in MADRS Total Score for every trial week visit in Phase B other than Week 14 visit|Change from the end of Phase A (Week 8 visit) for every trial week visit in Phase B in CGI - Severity of Illness scale (CGI-S) score|Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in HAM-D17 Score|CGI - Improvement scale (CGI-I) score for every trial week visit in Phase B|MADRS Response Rate at every trial week visit in Phase B|CGI-I Response rate at every trial week visit in Phase B|Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16) Score|QIDS-SR16 Response Rate at every trial week visit in Phase B|QIDS-SR16 Complete Remission Rate (recovery) at every trial week visit in Phase B","Otsuka Beijing Research Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-403-00023","May 30, 2018","May 30, 2019","May 30, 2019","April 3, 2018",,"December 29, 2020","Beijing Anding Hospital of Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03487198"
10,"NCT03446846","A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: MIN-117 5.0 mg|Drug: MIN-117 2.5 mg|Drug: Placebo","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change in Hamilton Anxiety Scale (HAM-A)|Change in Clinical Global Impression of Severity Scale (CGI-S)|Change in Clinical Global Impression of Improvement Scale (CGI-I) at Week 6","Minerva Neurosciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MIN-117C03","March 30, 2018","November 21, 2019","December 13, 2019","February 27, 2018","December 17, 2020","December 17, 2020","Woodland International Research Group, LLC, Little Rock, Arkansas, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Collaborative Neuroscience Network, LLC, Torrance, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Neurobehavioral Research, Inc, Cedarhurst, NY, Cedarhurst, New York, United States|Neuro-Behavorial Clinical Research Inc, Canton, Ohio, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|FutureSearch Trials, Dallas, Texas, United States|Mental Health Centre ""Prof. Dr. Ivan-Temkov - Burgas"" EOOD Complex Lazur, Burgas, Bulgaria|""University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski"" EAD, First psychiatric clinic, Pleven, Bulgaria|UMHAT ""Sveti Georgi"" EAD - Psychiatry Clinic, Plovdiv, Bulgaria|Mental Health Center, Ruse, Ruse, Bulgaria|""Diagnostic-Consultative Center St. Vrach and St. St. Kuzma and Damyan"" OOD, Psychiatric office, Sofia, Bulgaria|""Medical Center Stimul"" OOD, Psychiatric office, Sofia, Bulgaria|MC Intermedika, Sofia, Bulgaria|MC Sveti Naum, Sofia, Sofia, Bulgaria|DCC Mladost-M OOD, Varna, Bulgaria|Helsingin Psykiatripalvelu Oy at Mehilainen Clinic, Lääkärikeskus Mehiläinen, Helsinki, Finland|Oulu Mentalcare Oy, Oulu, Finland|Satakunnan Psykiatripalvelu Oy at Mehiläinen Pori, Pori, Finland|Mentoria, Tampere, Finland|Center for Mental Health and Prevention of Addiction Ltd, Tbilisi, Georgia|Tbilisi Mental Health Center Ltd, Tbilisi, Georgia|Department of Psychiatry, Addiction and Medical Psychology, Chisinau, Moldova, Republic of|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Ośrodek Badań Klinicznych - Clinsante S.C., Bydgoszcz, Poland|Zespół Opieki Zdrowotnej w Chełmnie, Poradnia Zdrowia Psychicznego, Chełmno, Poland|ISPL, Gdańsk, Poland|NZOZ Syntonia, Pruszcz Gdański, Poland|Prywatna Klinika Psychiatryczna Inventiva, Tuszyn, Poland|Communal Institution ""Dnipropetrovsk Regional Clinical Hospital n.a. I.I.Mechnykov"", Regional Center of Psychosomatic Disorders based on Psychoneurology, Dnipro, Ukraine|Municipal non-Profit enterprise ""Carpathian Regional Mental, Ivano-Frankivsk, Ukraine|State Institution ""Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine"" Department of Neuroses and Borderline States, Kharkiv, Ukraine|The Training and Research Medical Complex ""The Clinic"" otharkiv National Medical University, Kharkiv, Ukraine|Municipal non-profit enterprise ""Kherson Regional Psychiatric Care Facility"", Kherson, Ukraine|Municipal Non-Profit Enterprise ""Kirovohrad Regional Psychoneurological Hospital of Kirovohrad Regional Council, Kropyvnytskyi, Ukraine|Municipal enterprise ""Heikiv Psychoneurological Hospital, Dnipropetrovsk Regional Council"", Kryvyy Rih, Ukraine|Kyiv Clinical Hospital on Railway Transport #1 of the branch ""Health Center"" of the joint-stock company ""Ukrainian Railway"", Kyiv, Ukraine|Kyiv Regional Medical Incorporation Psychiatry Center of Novel Treatment and Rehabilitation of Psychotic Disorders, Kyiv, Ukraine|Municipal Institution of Kyiv Regional Council ""Regional Psychiatric and Narcological Medical Association"", Kyiv, Ukraine|National Military-Medical Clinical Center Main Military, Kyiv, Ukraine|Municipal non-profit enterprise of Lviv Regional Council ""Lviv Regional Clinical Psychiatric Hospital"", Lviv, Ukraine|Municipal Non-Profit Enterprise ""Odessa Regional Psychiatric Hospital # 2"" ""of Odessa Regional Council"", Odessa, Ukraine|Communal enterprise ""Poltava Regional Clinical Psychiatric Hospital named O.F. Maltsev Poltava Regional Council"", Poltava, Ukraine|Municipal non-profit enterprise""Vinnytsya Regional Psychoneurological Hospital named Acad. O.I. Yushchenko of Vinnytsya Regional Council, Vinnytsya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03446846/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03446846/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03446846"
11,"NCT04903522","Can the Affects Conveyed by Baroque Music Reduce Anxiety in Patients With Major Depressive Disorder ?","BARHEPSY","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Baroque music listening","Anxiety assessed by State Trait Anxiety Inventory questionnaire|Qualitative assessment scale of the fluency of consciousness (EQFC)|Experiential phenomenological interviews (EPE)|Depression assessed by Beck Depression Inventory-Second Edition (BDI-II) questionnaire","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2021-CHITS-002|2021-A00216-35","May 21, 2021","November 20, 2021","November 20, 2021","May 26, 2021",,"June 9, 2021","Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, Var, France",,"https://ClinicalTrials.gov/show/NCT04903522"
12,"NCT03093025","A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: TS-121 10 mg|Drug: TS-121 50 mg|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Hamilton Anxiety Scale (HAM-A)|Symptoms of Depression Questionnaire (SDQ)|Clinical Global Impression-Severity (CGI-S)|Clinical Global Impression-Improvement (CGI-I)","Taisho Pharmaceutical R&D Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TS121-US201","July 3, 2017","November 8, 2018","December 4, 2018","March 28, 2017","December 9, 2019","July 14, 2020","Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|PAREXEL Early Phase Clinical Unit, Glendale, California, United States|Synergy East, Lemon Grove, California, United States|NRC Research Institute, Orange, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Compass Research, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Chicago Research Center, Chicago, Illinois, United States|Alexian Brothers Behavioral Health Hospital, Hoffman Estates, Illinois, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Midwest Research Group - St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|Hassman Research Institute, Berlin, New Jersey, United States|Global Medical Institutes, Princeton, New Jersey, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03093025/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03093025/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03093025"
13,"NCT04536714","Efficacy of Pythagorean Self-Awareness Intervention for Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Pythagorean Self-Awareness Intervention program","Beck Depression Inventory-II|Healthy Lifestyle and Personal Control Questionnaire|Depression-Anxiety-Stress Scale-21|Positive and Negative Affect Schedule|Pittsburg Sleep Quality Index|Brief International Assessment of Cognition for Multiple Sclerosis|Hair cortisol concentration|Salivary cortisol concentration","Evgenia E. Psarraki|National and Kapodistrian University of Athens","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Prot.1 26/8/2020","December 3, 2018","January 21, 2020","January 21, 2020","September 3, 2020",,"September 3, 2020","Mental Health Center of Peristeri, department of the Psychiatric Hospital of Attica, Ploutonos 19, Peristeri, Attica, Greece",,"https://ClinicalTrials.gov/show/NCT04536714"
14,"NCT04638231","Supportive Text Messaging Versus Supportive E-mail Messaging for Patients With Major Depressive Disorder","STEM","Recruiting","No Results Available","Major Depressive Disorder","Other: Supportive messages","Change in Patient Health Questionnaire (PHQ)-9 scores|Change in the WHO (Five) Well-Being Index (WHO-5)|Change in the Generalized Anxiety Disorder Assessment (GAD-7) score","University of Alberta","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","Pro00105429","April 8, 2021","December 2021","December 2022","November 20, 2020",,"April 14, 2021","Urgent Psychiatric Clinic, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04638231"
15,"NCT02925325","Music Therapy for Major Depressive Disorder Residual Symptoms","MTMDDRS","Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Music therapy|Other: Usual Treatment","Hamilton Depression Rating Scale|Clinical Interview for Depression and Related Syndromes|Symptom Checklist 90 Revised (SCL-90-R)|Beck Depression Inventory|WHO Quality of Life-BREF (WHOQOL-BREF)|Personal and social performance scale (PSP)|Perceived stress scale (PSS)","Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente","All","20 Years to 45 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INPRF_MUS_THER_MDD","October 2016","December 2016","June 2017","October 5, 2016",,"October 5, 2016","Instituto Nacional de Psiquiatria Ramon de la Fuente Muñiz, Mexico City, DF, Mexico",,"https://ClinicalTrials.gov/show/NCT02925325"
16,"NCT03514810","Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder","Srt+ktpMDD","Completed","No Results Available","Major Depressive Disorder","Combination Product: Combined Sertraline & Ketoprofen|Other: Interleukins in MDD after treatment","Reduction in the Beck Depression Inventory-II Score|Decrease in Serum of IL-1β, IL-6, and IL-18 Levels|Body mass index (BMI)","Kufa University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KufaU|Arafataldujaili","January 10, 2017","September 10, 2017","December 31, 2017","May 2, 2018",,"May 3, 2018",,,"https://ClinicalTrials.gov/show/NCT03514810"
17,"NCT01670279","Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Brexpiprazole|Drug: Placebo","Number of Participants Who Tolerated Brexpiprazole|Number of AEs Reported.|Incidence of Laboratory Values of Potential Clinical Significance|Incidence of Vital Signs of Potential Clinical Significance|Incidence of ECG Evaluations of Potential Clinical Significance|Incidence of Physical Examination Evaluation of Potential Clinical Significance|Mean Change From Baseline to Study Completion in Simpson-Angus Scale (SAS) Total Score|Mean Change From Baseline to Study Completion in Barnes Akathisia Global Score|Mean Change From Baseline to Study Completion in Abnormal Involuntary Movement Scale (AIMS) Rating Score.|Change From Baseline to Study Completion in C-SSRS Score.","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","70 Years to 85 Years   (Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","331-12-291","July 2012","May 2013","May 2013","August 22, 2012","February 4, 2016","February 4, 2016","Accurate Clinical Trials, Kissimmee, Florida, United States|Miami Jewish Health System, Miami, Florida, United States|St. Louis Clinical Trials, St. Louis, Missouri, United States|CRI Lifetree- Philadelphia Research Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01670279"
18,"NCT04593563","The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Psilocybin","The Montgomery-Åsberg Depression Rating Scale (MADRS)|Quick Inventory of Depressive Symptomatology Self reported (QIDS-SR)|Maudsley Visual Analogue Scale (VAS) current|Maudley Visual Analogue Scale (VAS) Change.|Pain Visual Analogue Score (VAS)|Hamilton Anxiety Rating Scale-A (HAM-A)|State-Trait Anxiety Inventory (STAI)|National Institute of Health Healing Experience of All Life Stressors (NIH-HEALS)|Patient EQ-5D-5L|Caregiver Oncology Quality of Life Questionnaire (CarGOQol)|DS-II|5 Dimension Altered State of Consciousness (5D-ASC)|Sheehan Disability Score (SDS)|Scale To Assess Therapeutic Relationship: Patient (STAR-P)|Scale To Assess Therapeutic Relationship: Clinician. (STAR-C)|Changes in electrocardiographs.","Maryland Oncology Hematology, PA","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","49347","September 1, 2020","October 2022","October 2023","October 20, 2020",,"October 20, 2020","Maryland Oncology Hematology PA, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04593563"
19,"NCT01573598","Safety and Efficacy of Vilazodone in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: Vilazodone","Time to first relapse during the double-blind treatment phase","Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","1219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VLZ-MD-02","April 2012","October 2014","January 2015","April 9, 2012",,"May 18, 2015","Forest Investigative Site 030, Beverly Hills, California, United States|Forest Investigative Site 012, Chino, California, United States|Forest Investigative Site 022, Costa Mesa, California, United States|Forest Investigative Site 017, Los Angeles, California, United States|Forest Investigative Site 005, Newport Beach, California, United States|Forest Investigative Site 027, Riverside, California, United States|Forest Investigative Site 026, San Diego, California, United States|Forest Investigative Site 016, Cromwell, Connecticut, United States|Forest Investigative Site 029, Hartford, Connecticut, United States|Forest Investigative Site 020, Doral, Florida, United States|Forest Investigative Site 006, Fort Myers, Florida, United States|Forest Investigative Site 007, Ft. Lauderdale, Florida, United States|Forest Investigative Site 004, Hallandale Beach, Florida, United States|Forest Investigative Site 008, Jacksonville Beach, Florida, United States|Forest Investigative Site 039, Jacksonville, Florida, United States|Forest Investigative Site 015, Leesburg, Florida, United States|Forest Investigative Site 035, Orlando, Florida, United States|Forest Investigative Site 001, West Palm Beach, Florida, United States|Forest Investigative Site 034, Winter Park, Florida, United States|Forest Investigative Site 019, Hoffman Estates, Illinois, United States|Forest Investigative Site 021, Indianapolis, Indiana, United States|Forest Investigative Site 003, Boston, Massachusetts, United States|Forest Investigative Site 013, Weymouth, Massachusetts, United States|Forest Investigative Site 028, Rochester Hills, Michigan, United States|Forest Investigative Site 038, Brooklyn, New York, United States|Forest Investigative Site 037, New York, New York, United States|Forest Investigative Site 032, New York, New York, United States|Forest Investigative Site 009, New York, New York, United States|Forest Investigative Site 014, Durham, North Carolina, United States|Forest Investigative Site 025, Oklahoma City, Oklahoma, United States|Forest Investigative Site 024, Oklahoma City, Oklahoma, United States|Forest Investigative Site 036, Memphis, Tennessee, United States|Forest Investigative Site 023, Dallas, Texas, United States|Forest Investigative Site 011, Houston, Texas, United States|Forest Investigative Site 010, Plano, Texas, United States|Forest Investigative Site 002, San Antonio, Texas, United States|Forest Investigative Site 031, Richmond, Virginia, United States|Forest Investigative Site 033, Bellevue, Washington, United States|Forest Investigative Site 103, Pleven, Bulgaria|Forest Investigative Site 104, Plovdiv, Bulgaria|Forest Investigative Site 106, Sofia, Bulgaria|Forest Investigative Site 102, Sofia, Bulgaria|Forest Investigative Site 304, Helsinki, Etelä-Suomen lääni, Finland|Forest Investigative Site 305, Helsinki, Etelä-Suomen lääni, Finland|Forest Investigative Site 301, Helsinki, Etelä-Suomen lääni, Finland|Forest Investigative Site 303, Rauma, Länsi-Suomen lääni, Finland|Forest Investigative Site 302, Kuopio, Finland|Forest Investigative Site 306, Turku, Finland|Forest Investigative Site 307, Turku, Finland|Forest Investigative Site 401, Hannover, Niedersachsen, Germany|Forest Investigative Site 405, Dresden, Sachsen, Germany|Forest Investigative Site 403, Berlin, Germany|Forest Investigative Site 408, Berlin, Germany|Forest Investigative Site 407, Chemnitz, Germany|Forest Investigative Site 402, Hüttenberg, Germany|Forest Investigative Site 409, Münster, Germany|Forest Investigative Site 404, Nürnberg, Germany|Forest Investigative Site 406, Westerstede, Germany|Forest Investigative Site 602, Bucuresti, Bucureşti, Romania|Forest Investigative Site 601, Arad, Romania|Forest Investigative Site 603, Iasi, Romania|Forest Investigative Site 705, Petrozavodsk, Kareliya, Respublika, Russian Federation|Forest Investigative Site 701, Moscow, Russian Federation|Forest Investigative Site 804, Belgrade, Beograd, Serbia|Forest Investigative Site 806, Nis, Nišava, Serbia|Forest Investigative Site 801, Beograd, Serbia|Forest Investigative Site 802, Beograd, Serbia|Forest Investigative Site 803, Kragujevac, Serbia|Forest Investigative Site 805, Kragujevac, Šumadija, Serbia|Forest Investigative Site 903, Kherson, Khersons'ka Oblast', Ukraine|Forest Investigative Site 901, Lviv, L'vivs'ka Oblast', Ukraine|Forest Investigative Site 905, Lugansk, Luhans'ka Oblast', Ukraine|Forest Investigative Site 906, Odesa, Odes'ka Oblast', Ukraine|Forest Investigative Site 902, Dnipropetrovsk, Ukraine|Forest Investigative Site 904, Simferopol, Ukraine",,"https://ClinicalTrials.gov/show/NCT01573598"
20,"NCT01473381","Safety and Efficacy of Vilazodone in Major Depressive Disorder","VLZ-MD-01","Completed","Has Results","Major Depressive Disorder","Drug: Vilazodone|Drug: Placebo to citalopram|Drug: Placebo to vilazodone|Drug: Citalopram","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 10|Change From Baseline to Week 10 in the Clinical Global Impressions-Severity (CGI-S) Scale Score|Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response","Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","1162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VLZ-MD-01","December 2011","June 2013","June 2013","November 17, 2011","August 8, 2014","August 8, 2014","Forest Investigative Site 036, Birmingham, Alabama, United States|Forest Investigative Site 016, Dothan, Alabama, United States|Forest Investigative Site 033, Scottsdale, Arizona, United States|Forest Investigative Site 027, Fayetteville, Arkansas, United States|Forest Investigative Site 029, Cerritos, California, United States|Forest Investigative Site 002, Costa Mesa, California, United States|Forest Investigative Site 019, Murrieta, California, United States|Forest Investigative Site 025, Oceanside, California, United States|Forest Investigative Site 043, Orange, California, United States|Forest Investigative Site 003, Redlands, California, United States|Forest Investigative Site 046, Sherman Oaks, California, United States|Forest Investigative Site 057, Upland, California, United States|Forest Investigative Site 034, Cromwell, Connecticut, United States|Forest Investigative Site 038, Fort Myers, Florida, United States|Forest Investigative Site 018, Gainsville, Florida, United States|Forest Investigative Site 055, Hallandale Beach, Florida, United States|Forest Investigative Site 063, Jacksonville, Florida, United States|Forest Investigative Site 035, Miami, Florida, United States|Forest Investigative Site 030, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 045, Pembroke Pines, Florida, United States|Forest Investigative Site 051, Tampa, Florida, United States|Forest Investigative Site 032, West Palm Beach, Florida, United States|Forest Investigative Site 022, Winter Park, Florida, United States|Forest Investigative Site 060, Atlanta, Georgia, United States|Forest Investigative Site 037, Chicago, Illinois, United States|Forest Investigative Site 050, Chicago, Illinois, United States|Forest Investigative Site 040, Indianapolis, Indiana, United States|Forest Investigative Site 012, Lafayette, Indiana, United States|Forest Investigative Site 053, Prairie Village, Kansas, United States|Forest Investigative Site 020, Baltimore, Maryland, United States|Forest Investigative Site 031, Boston, Massachusetts, United States|Forest Investigative Site 061, Las Vegas, Nevada, United States|Forest Investigative Site 024, Willingboro, New Jersey, United States|Forest Investigative Site 010, Albuquerque, New Mexico, United States|Forest Investigative Site 011, Albuquerque, New Mexico, United States|Forest Investigative Site 004, Brooklyn, New York, United States|Forest Investigative Site 007, Cedarhurst, New York, United States|Forest Investigative Site 058, New York City, New York, United States|Forest Investigative Site 047, New York, New York, United States|Forest Investigative Site 039, Cincinnati, Ohio, United States|Forest Investigative Site 042, Oklahoma City, Oklahoma, United States|Forest Investigative Site 048, Oklahoma City, Oklahoma, United States|Forest Investigative Site 066, Portland, Oregon, United States|Forest Investigative Site 014, Allentown, Pennsylvania, United States|Forest Investigative Site 049, Bridgeville, Pennsylvania, United States|Forest Investigative Site 064, Memphis, Tennessee, United States|Forest Investigative Site 013, Austin, Texas, United States|Forest Investigative Site 021, Dallas, Texas, United States|Forest Investigative Site 059, Bellevue, Washington, United States|Forest Investigative Site 065, Seattle, Washington, United States|Forest Investigative Site 054, Spokane, Washington, United States|Forest Investigative Site 052, Middleton, Wisconsin, United States|Forest Investigative Site 056, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01473381"
21,"NCT00863798","Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release 10mg|Drug: Desvenlafaxine Succinate Sustained-Release 50 mg|Drug: placebo","Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)|Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)|Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)|Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)|Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)|Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)|Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)|Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)|Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)","Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","682","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-3362|B2061005|3151A1-3362-US","April 2009","March 2010","March 2010","March 18, 2009","May 6, 2011","May 6, 2011","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Cromwell, Connecticut, United States|Pfizer Investigational Site, Maitland, Florida, United States|Pfizer Investigational Site, North Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Salem, Oregon, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Herndon, Virginia, United States|Pfizer Investigational Site, Midlothian, Virginia, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States|Pfizer Investigational Site, Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00863798"
22,"NCT00887224","Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Desvenlafaxine succinate sustained release 50 mg|Drug: Desvenlafaxine succinate sustained release 25 mg|Drug: Placebo","Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185|Number of Participants Per Categorical Score for Change From Baseline on Clinical Global Impression-Improvement (CGI-I) Scale|Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score in the Double-blind Phase|Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score in the Double-blind Phase|Change From Baseline in Hamilton Psychiatric Scale for Depression-6 Item (HAM-D6) Score in the Double-blind Phase|Number of Participants With Remission Based on Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score at Double-blind Phase Week 26|Change From Baseline of Double-blind Phase in World Health Organization (Five-Item) Well-Being Index|Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score in the Double-blind Phase","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","874","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-3360|B2061004","June 2009","March 2011","March 2011","April 23, 2009","June 27, 2012","November 21, 2014","Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Smyrna, Georgia, United States|Pfizer Investigational Site, Hoffman Estates, Illinois, United States|Pfizer Investigational Site, Rockville, Maryland, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Medicine Hat, Alberta, Canada|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Bathurst, New Brunswick, Canada|Pfizer Investigational Site, Burlington, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Gatineau, Quebec, Canada|Pfizer Investigational Site, Pointe-Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Bucamaranga, Santander, Colombia|Pfizer Investigational Site, Rijeka, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Voru, Estonia|Pfizer Investigational Site, Vöru, Estonia|Pfizer Investigational Site, Espoo, Finland|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Joensuu, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Seinajoki, Finland|Pfizer Investigational Site, Tampere, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Caen, France|Pfizer Investigational Site, Dole, France|Pfizer Investigational Site, Douai, France|Pfizer Investigational Site, Orvault, France|Pfizer Investigational Site, Rennes, France|Pfizer Investigational Site, Liepaja, Latvia|Pfizer Investigational Site, Sigulda, Latvia|Pfizer Investigational Site, Sigulda, Latvia|Pfizer Investigational Site, Strenci, Latvia|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Vilius, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Skorzewo, Poznan, Poland|Pfizer Investigational Site, Szczecin, Poland|Pfizer Investigational Site, Torun, Poland|Pfizer Investigational Site, Tuszyn, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Zuromin, Poland|Pfizer Investigational Site, Craiova, Dolj, Romania|Pfizer Investigational Site, Brasov, Romania|Pfizer Investigational Site, Bucharest, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Cluj Napoca, Romania|Pfizer Investigational Site, Bojnice, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Liptovsky Mikulas, Slovakia|Pfizer Investigational Site, Michalovce, Slovakia|Pfizer Investigational Site, Rimavska Sobota, Slovakia|Pfizer Investigational Site, Trencin, Slovakia|Pfizer Investigational Site, Cape Town, Western Cape, South Africa|Pfizer Investigational Site, Durban, South Africa|Pfizer Investigational Site, Paarl, South Africa",,"https://ClinicalTrials.gov/show/NCT00887224"
23,"NCT01473394","Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Dose-matched placebo|Drug: Vilazodone","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8|Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 8|Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response Rate","Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","518","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VLZ-MD-03","December 2011","February 2013","February 2013","November 17, 2011","April 3, 2014","April 3, 2014","Forest Investigative Site 009, Beverly Hills, California, United States|Forest Investigative Site 003, Encino, California, United States|Forest Investigative Site 010, New port Beach, California, United States|Forest Investigative Site 005, Jacksonville, Florida, United States|Forest Investigative Site 004, Orlando, Florida, United States|Forest Investigative Site 012, Atlanta, Georgia, United States|Forest Investigative Site 001, Baltimore, Maryland, United States|Forest Investigative Site 002, Dayton, Ohio, United States|Forest Investigative Site 011, Philadelphia, Pennsylvania, United States|Forest Investigative Site 015, Lincoln, Rhode Island, United States|Forest Investigative Site 008, Memphis, Tennessee, United States|Forest Investigative Site 016, San Antonio, Texas, United States|Forest Investigative Site 006, Bellevue, Washington, United States|Forest Investigative Site 013, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01473394"
24,"NCT00985725","SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Matching placebo","Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)|Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)|Change From Baseline in BRIEF-A T-scores at Week 9, LOCF|Change From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint|Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline|Percent of Participants With CGI-S at up to 9 Weeks/Endpoint|Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF|Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint|Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF|Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF|Change From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9|Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint|Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11|Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF|Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9","Shire|Takeda","All","18 Years to 55 Years   (Adult)","Phase 2","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD489-205","October 29, 2009","April 18, 2011","April 18, 2011","September 28, 2009","April 6, 2012","June 8, 2021","Sun Valley Research Center, Imperial, California, United States|Pharmacology Research Center, Los Alamitos, California, United States|Excell Research, Oceanside, California, United States|Neuropsychiatric Resesarch Center of Orange County, Santa Ana, California, United States|Connecticut Clincal Research, Cromwell, Connecticut, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Amit Vijapura, MD, Jacksonville, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Atlanta Institute of Medicine & Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Joliet Center for Clinical Research, Joliet, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|AccelRx Research, Fall River, Massachusetts, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Richmond Behavioral Associates, Staten Island, New York, United States|North Carolina Neuropsychiatry, PA, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Richard H. Weisler, MD, PA & Associates, Raleigh, North Carolina, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Bayou City Resesarch, LTD, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Wharton Research Center, Wharton, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00985725"
25,"NCT00798707","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: placebo","Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)|Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)|Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)|Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)|Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)|Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)|Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)|Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)|Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","709","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-3359|B2061003|3151A1-3359-WW","December 2008","April 2010","April 2010","November 26, 2008","June 6, 2011","June 10, 2011","Pfizer Investigational Site, Arcadia, California, United States|Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Cerritos, California, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Smyrna, Georgia, United States|Pfizer Investigational Site, Libertyville, Illinois, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Kirkland, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Brown Deer, Wisconsin, United States|Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Toyoake, Aichi, Japan|Pfizer Investigational Site, Noda, Chiba, Japan|Pfizer Investigational Site, Kitakyusyu, Fukuoka, Japan|Pfizer Investigational Site, Kitakyusyu, Fukuoka, Japan|Pfizer Investigational Site, Shirakawa, Fukushima, Japan|Pfizer Investigational Site, Fujioka, Gunma, Japan|Pfizer Investigational Site, Kumagaya, Gunma, Japan|Pfizer Investigational Site, Hatsukaichi, Hiroshima, Japan|Pfizer Investigational Site, Kure, Hiroshima, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Kobe, Hyogo, Japan|Pfizer Investigational Site, Kanazawa, Ishikawa, Japan|Pfizer Investigational Site, Minamiashigara, Kanagawa, Japan|Pfizer Investigational Site, Yokohama, Kanagawa, Japan|Pfizer Investigational Site, Yokohama, Kanagawa, Japan|Pfizer Investigational Site, Yokohama, Kanagawa, Japan|Pfizer Investigational Site, Yatsushiro, Kumamoto, Japan|Pfizer Investigational Site, Matsumoto, Nagano, Japan|Pfizer Investigational Site, Sakai, Osaka, Japan|Pfizer Investigational Site, Kanzaka, Saga, Japan|Pfizer Investigational Site, Misato, Saitama, Japan|Pfizer Investigational Site, Kusatsu, Shiga, Japan|Pfizer Investigational Site, Bunkyo, Tokyo, Japan|Pfizer Investigational Site, Chiyoda, Tokyo, Japan|Pfizer Investigational Site, Chiyoda, Tokyo, Japan|Pfizer Investigational Site, Itabashi, Tokyo, Japan|Pfizer Investigational Site, Katsushika, Tokyo, Japan|Pfizer Investigational Site, Kodaira, Tokyo, Japan|Pfizer Investigational Site, Minato, Tokyo, Japan|Pfizer Investigational Site, Nakano, Tokyo, Japan|Pfizer Investigational Site, Setagaya-ku, Tokyo, Japan|Pfizer Investigational Site, Setagaya, Tokyo, Japan|Pfizer Investigational Site, Shibuya, Tokyo, Japan|Pfizer Investigational Site, Shibuya, Tokyo, Japan|Pfizer Investigational Site, Shinagawa, Tokyo, Japan|Pfizer Investigational Site, Shinagawa, Tokyo, Japan|Pfizer Investigational Site, Shinagawa, Tokyo, Japan|Pfizer Investigational Site, Shinjyuku, Tokyo, Japan|Pfizer Investigational Site, Suginami, Tokyo, Japan|Pfizer Investigational Site, Taito, Tokyo, Japan|Pfizer Investigational Site, Toshima, Tokyo, Japan|Pfizer Investigational Site, Meguro, Toyko, Japan|Pfizer Investigational Site, Ube, Yamaguchi, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Fukushima, Japan|Pfizer Investigational Site, Hiroshima, Japan|Pfizer Investigational Site, Kumamoto, Japan|Pfizer Investigational Site, Kumamoto, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Osaka, Japan|Pfizer Investigational Site, Saitama, Japan|Pfizer Investigational Site, Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT00798707"
26,"NCT01418638","The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder",,"the influence of antidepressant medications on the metabolic profiles (5) of patients suffering from Major Depressive Disorder.","Ziv Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","01-11 ZIV","May 2012","October 2013",,"August 17, 2011",,"February 20, 2013","Ziv MC, Safed, Israel",,"https://ClinicalTrials.gov/show/NCT01418638"
27,"NCT04827901","XEN1101 for Major Depressive Disorder",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: XEN1101|Drug: Placebo","Change in activation within the reward circuit by fMRI|Change in Montgomery-Åsberg Depression Rating Scale Score|Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score|Change in Snaith-Hamilton Pleasure Scale (SHAPS)|Change in Temporal Experience of Pleasure Scale-Anticipatory Subscore [TEPS-ant]|Change in Beck Anxiety Inventory [BAI] Score|Change in Clinical Global Impression Scale","James Murrough|Baylor College of Medicine|National Institute of Mental Health (NIMH)|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 16-0374-02|4R33MH111932-03","June 2021","January 2024","March 2024","April 1, 2021",,"May 28, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04827901"
28,"NCT01469377","Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Cariprazine","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8|Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8","Forest Laboratories|Gedeon Richter Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","819","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RGH-MD-75","December 15, 2011","December 12, 2013","December 12, 2013","November 10, 2011","May 1, 2018","May 1, 2018","Forest Investigative Site 077, Garden Grove, California, United States|Forest Investigative Site 019, National City, California, United States|Forest Investigative Site 039, Oceanside, California, United States|Forest Investigative Site 015, Orange, California, United States|Forest Investigative Site 050, Orange, California, United States|Forest Investigative Site 008, Redlands, California, United States|Forest Investigative Site 066, Sherman Oaks, California, United States|Forest Investigative Site 063, Gainesville, Florida, United States|Forest Investigative Site 029, Jacksonville, Florida, United States|Forest Investigative Site 012, Kissimmee, Florida, United States|Forest Investigative Site 023, Miami, Florida, United States|Forest Investigative Site 026, Orlando, Florida, United States|Forest Investigative Site 062, Atlanta, Georgia, United States|Forest Investigative Site 065, Smyrna, Georgia, United States|Forest Investigative Site 074, Prairie Village, Kansas, United States|Forest Investigative Site 040, Flowood, Mississippi, United States|Forest Investigative Site 068, Creve Coeur, Missouri, United States|Forest Investigative Site 061, Cherry Hill, New Jersey, United States|Forest Investigative Site 038, Marlton, New Jersey, United States|Forest Investigative Site 030, Albuquerque, New Mexico, United States|Forest Investigative Site 076, Brooklyn, New York, United States|Forest Investigative Site 037, Mount Kisco, New York, United States|Forest Investigative Site 067, New York, New York, United States|Forest Investigative Site 049, New York, New York, United States|Forest Investigative Site 047, Canton, Ohio, United States|Forest Investigative Site 021, Dayton, Ohio, United States|Forest Investigative Site 022, Portland, Oregon, United States|Forest Investigative Site 027, Salem, Oregon, United States|Forest Investigative Site 069, Bridgeville, Pennsylvania, United States|Forest Investigative Site 025, Philadelphia, Pennsylvania, United States|Forest Investigative Site 031, Reading, Pennsylvania, United States|Forest Investigative Site 048, Memphis, Tennessee, United States|Forest Investigative Site 024, Austin, Texas, United States|Forest Investigative Site 020, Dallas, Texas, United States|Forest Investigative Site 070, Houston, Texas, United States|Forest Investigative Site 080, San Antonio, Texas, United States|Forest Investigative Site 028, Salt Lake City, Utah, United States|Forest Investigative Site 032, Bellevue, Washington, United States|Forest Investigative Site 034, Kirkland, Washington, United States|Forest Investigative Site 203, Tallinn, Estonia|Forest Investigative Site 201, Tallinn, Estonia|Forest Investigative Site 206, Tallinn, Estonia|Forest Investigative Site 205, Tallinn, Estonia|Forest Investigative Site 204, Tartu, Estonia|Forest Investigative Site 208, Tartu, Estonia|Forest Investigative Site 207, Tartu, Estonia|Forest Investigative Site 202, Võru, Estonia|Forest Investigative Site 301, Helsinki, Finland|Forest Investigative Site 302, Helsinki, Finland|Forest Investigative Site 304, Helsinki, Finland|Forest Investigative Site 303, Helsinki, Finland|Forest Investigative Site 305, Kuopio, Finland|Forest Investigative Site 308, Oulu, Finland|Forest Investigative Site 307, Pori, Finland|Forest Investigative Site 602, Banska Stiavnica, Slovakia|Forest Investigative Site 603, Bardejov, Slovakia|Forest Investigative Site 604, Bratislava, Slovakia|Forest Investigative Site 606, Bratislava, Slovakia|Forest Investigative Site 601, Michalovce, Slovakia|Forest Investigative Site 605, Rimavska Sobota, Slovakia|Forest Investigative Site 607, Rimavska Sobota, Slovakia|Forest Investigative Site 803, Lund, Sweden|Forest Investigative Site 802, Malmö, Sweden|Forest Investigative Site 801, Stockholm, Sweden|Forest Investigative Site 705, Stepanivka, Kherson, Ukraine|Forest Investigative Site 703, Kharkiv, Ukraine|Forest Investigative Site 704, Kharkiv, Ukraine|Forest Investigative Site 702, Kyiv, Ukraine|Forest Investigative Site 701, Kyiv, Ukraine|Forest Investigative Site 710, Lugansk, Ukraine|Forest Investigative Site 709, Odesa, Ukraine|Forest Investigative Site 706, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01469377"
29,"NCT01715805","Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: Cariprazine|Drug: Placebo|Drug: Antidepressant Therapy (ADT)","Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind Period|Change From Baseline in Sheehan Disability Scale (SDS) Score in the Double-Blind Period","Forest Laboratories|Gedeon Richter Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1022","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RGH-MD-72","November 15, 2012","June 24, 2016","June 24, 2016","October 29, 2012","August 28, 2019","August 28, 2019","Forest Investigative Site 032, Tucson, Arizona, United States|Forest Investigative Site 018, Little Rock, Arkansas, United States|Forest Investigative Site 029, Little Rock, Arkansas, United States|Forest Investigative Site 084, Cerritos, California, United States|Forest Investigative Site 085, Culver City, California, United States|Forest Investigative Site 082, Garden Grove, California, United States|Forest Investigative Site 022, Newport Beach, California, United States|Forest Investigative Site 004, Oceanside, California, United States|Forest Investigative Site 090, Rancho Mirage, California, United States|Forest Investigative Site 078, Redlands, California, United States|Forest Investigative Site 080, Redlands, California, United States|Forest Investigative Site 007, San Diego, California, United States|Forest Investigative Site 054, San Diego, California, United States|Forest Investigative Site 031, Temecula, California, United States|Forest Investigative Site 048, Denver, Colorado, United States|Forest Investigative Site 037, Coral Springs, Florida, United States|Forest Investigative Site 053, Fort Myers, Florida, United States|Forest Investigative Site 023, Hallandale Beach, Florida, United States|Forest Investigative Site 071, Hialeah, Florida, United States|Forest Investigative Site 006, Leesburg, Florida, United States|Forest Investigative Site 026, Miami, Florida, United States|Forest Investigative Site 075, Miami, Florida, United States|Forest Investigative Site 027, North Miami, Florida, United States|Forest Investigative Site 074, North Miami, Florida, United States|Forest Investigative Site 036, Oakland Park, Florida, United States|Forest Investigative Site 051, Orlando, Florida, United States|Forest Investigative Site 044, South Miami, Florida, United States|Forest Investigative Site 008, Tampa, Florida, United States|Forest Investigative Site 019, Winter Park, Florida, United States|Forest Investigative Site 060, Atlanta, Georgia, United States|Forest Investigative Site 024, Atlanta, Georgia, United States|Forest Investigative Site 017, Marietta, Georgia, United States|Forest Investigative Site 047, Smyrna, Georgia, United States|Forest Investigative Site 070, Chicago, Illinois, United States|Forest Investigative Site 013, Hoffman Estates, Illinois, United States|Forest Investigative Site 063, Libertyville, Illinois, United States|Forest Investigative Site 062, Maywood, Illinois, United States|Forest Investigative Site 072, Naperville, Illinois, United States|Forest Investigative Site 010, Oak Brook, Illinois, United States|Forest Investigative Site 068, Skokie, Illinois, United States|Forest Investigative Site 061, Indianapolis, Indiana, United States|Forest Investigative Site 042, Lafayette, Indiana, United States|Forest Investigative Site 065, Overland Park, Kansas, United States|Forest Investigative Site 073, New Orleans, Louisiana, United States|Forest Investigative Site 049, Gaithersburg, Maryland, United States|Forest Investigative Site 077, Rockville, Maryland, United States|Forest Investigative Site 012, Rockville, Maryland, United States|Forest Investigative Site 046, Boston, Massachusetts, United States|Forest Investigative Site 045, Natick, Massachusetts, United States|Forest Investigative Site 086, Saint Charles, Missouri, United States|Forest Investigative Site 014, Toms River, New Jersey, United States|Forest Investigative Site 058, Albuquerque, New Mexico, United States|Forest Investigative Site 076, Bronx, New York, United States|Forest Investigative Site 028, Brooklyn, New York, United States|Forest Investigative Site 016, New York, New York, United States|Forest Investigative Site 083, New York, New York, United States|Forest Investigative Site 025, Staten Island, New York, United States|Forest Investigative Site 050, Durham, North Carolina, United States|Forest Investigative Site 067, Bismarck, North Dakota, United States|Forest Investigative Site 088, Canton, Ohio, United States|Forest Investigative Site 089, Cincinnati, Ohio, United States|Forest Investigative Site 011, Cincinnati, Ohio, United States|Forest Investigative Site 015, Cincinnati, Ohio, United States|Forest Investigative Site 055, Columbus, Ohio, United States|Forest Investigative Site 066, Mason, Ohio, United States|Forest Investigative Site 064, Middleburg Heights, Ohio, United States|Forest Investigative Site 035, Oklahoma City, Oklahoma, United States|Forest Investigative Site 038, Oklahoma City, Oklahoma, United States|Forest Investigative Site 039, Oklahoma City, Oklahoma, United States|Forest Investigative Site 003, Portland, Oregon, United States|Forest Investigative Site 052, Allentown, Pennsylvania, United States|Forest Investigative Site 059, Lincoln, Rhode Island, United States|Forest Investigative Site 001, Charleston, South Carolina, United States|Forest Investigative Site 079, Austin, Texas, United States|Forest Investigative Site 005, Houston, Texas, United States|Forest Investigative Site 087, The Woodlands, Texas, United States|Forest Investigative Site 069, Wichita Falls, Texas, United States|Forest Investigative Site 030, Orem, Utah, United States|Forest Investigative Site 041, Charlottesville, Virginia, United States|Forest Investigative Site 081, Bellevue, Washington, United States|Forest Investigative Site 043, Seattle, Washington, United States|Forest Investigative Site 056, Milwaukee, Wisconsin, United States|Forest Investigative Site 057, Waukesha, Wisconsin, United States|Forest Investigative Site 033, San Juan, Puerto Rico|Forest Investigative Site 034, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01715805"
30,"NCT01197508","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",,"Completed","Has Results","Major Depressive Disorder","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in Hamilton Anxiety Scale (HAM-A) Total Score From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","696","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00005","September 2010","January 2012","January 2012","September 9, 2010","October 29, 2012","April 11, 2014","Research Site, Buenos Aires, Caba, Argentina|Research Site, Ciudad Autonoma Bs As, Cba, Argentina|Research Site, Dublin, Argentina|Research Site, Mendoza, Argentina|Research Site, Rio de Janeiro, Brazil|Research Site, Novi Iskar, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Antofagasta, Chile|Research Site, Providencia Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bello, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Pereira, Risaralda, Colombia|Research Site, Cali, Valle, Colombia|Research Site, Rijeka, Croatia|Research Site, Bully Les Mines, France|Research Site, Caen, France|Research Site, Cherbourg, France|Research Site, Colmar Cedex, France|Research Site, Dole Cedex, France|Research Site, Douai, France|Research Site, Elancourt, France|Research Site, Montpellier, France|Research Site, Sartrouville, France|Research Site, Strasbourg, France|Research Site, Toulon, France|Research Site, Toulouse, France|Research Site, Tours Cedex 9, France|Research Site, Huttenberg, HE, Germany|Research Site, Bad Homburg, Germany|Research Site, Bielefeld, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Schwerin, Germany|Research Site, Siegen, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Leszno, Poland|Research Site, Lublin, Poland|Research Site, Torun, Poland|Research Site, Arad, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-napoca, Romania|Research Site, Focsani, Romania|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chita, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Kragujevac, Serbia and Montenegro, Serbia|Research Site, NIS, Serbia|Research Site, Banska Stiavnica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Levice, Slovakia|Research Site, Presov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Bloemfontein, Free State, South Africa|Research Site, Vereeniging, Free State, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, George, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Sama de Langreo, Asturias, Spain|Research Site, Alcala de Henares, Madrid, Spain|Research Site, Coslada, Madrid, Spain|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferpool, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01197508"
31,"NCT01377194","Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Placebo","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.|Change in Sheehan Disability Scale (SDS) Total Score","Forest Laboratories","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-10","June 2011","March 2012","March 2012","June 21, 2011","October 29, 2013","October 29, 2013","Forest Investigative Site 039, Birmingham, Alabama, United States|Forest Investigative Site 037, Beverly Hills, California, United States|Forest Investigative Site 012, Encino, California, United States|Forest Investigative Site 038, Newport Beach, California, United States|Forest Investigative Site 024, Oceanside, California, United States|Forest Investigative Site 001, Redlands, California, United States|Forest Investigative Site 031, San Diego, California, United States|Forest Investigative Site 050, Sherman Oaks, California, United States|Forest Investigative Site 034, Cromwell, Connecticut, United States|Forest Investigative Site 021, Coral Springs, Florida, United States|Forest Investigative Site 043, Fort Myers, Florida, United States|Forest Investigative Site 018, Gainesville, Florida, United States|Forest Investigative Site 060, Hallandale Beach, Florida, United States|Forest Investigative Site 020, Jacksonville, Florida, United States|Forest Investigative Site 005, Ocala, Florida, United States|Forest Investigative Site 014, Orlando, Florida, United States|Forest Investigative Site 028, Orlando, Florida, United States|Forest Investigative Site 046, Atlanta, Georgia, United States|Forest Investigative Site 041, Chicago, Illinois, United States|Forest Investigative Site 054, Chicago, Illinois, United States|Forest Investigative Site 026, Hoffman Estates, Illinois, United States|Forest Investigative Site 045, Indianapolis, Indiana, United States|Forest Investigative Site 056, Prairie Village, Kansas, United States|Forest Investigative Site 049, Haverhill, Massachusetts, United States|Forest Investigative Site 044, Cherry Hill, New Jersey, United States|Forest Investigative Site 023, Willingboro, New Jersey, United States|Forest Investigative Site 004, Brooklyn, New York, United States|Forest Investigative Site 002, Mount Kisco, New York, United States|Forest Investigative Site 016, New York City, New York, United States|Forest Investigative Site 051, New York, New York, United States|Forest Investigative Site 042, Orangeburg, New York, United States|Forest Investigative Site 061, Raleigh, North Carolina, United States|Forest Investigative Site 010, Dayton, Ohio, United States|Forest Investigative Site 048, Oklahoma City, Oklahoma, United States|Forest Investigative Site 053, Portland, Oregon, United States|Forest Investigative Site 017, Salem, Oregon, United States|Forest Investigative Site 011, Allentown, Pennsylvania, United States|Forest Investigative Site 052, Bridgeville, Pennsylvania, United States|Forest Investigative Site 027, Philadelphia, Pennsylvania, United States|Forest Investigative Site 059, Lincoln, Rhode Island, United States|Forest Investigative Site 029, Memphis, Tennessee, United States|Forest Investigative Site 009, Dallas, Texas, United States|Forest Investigative Site 007, San Antonio, Texas, United States|Forest Investigative Site 035, San Antonio, Texas, United States|Forest Investigative Site 022, Bellevue, Washington, United States|Forest Investigative Site 055, Seattle, Washington, United States|Forest Investigative Site 057, Spokane, Washington, United States|Forest Investigative Site 025, Kelowna, British Columbia, Canada|Forest Investigative Site 036, Sydney, Nova Scotia, Canada|Forest Investigative Site 006, Chatham, Ontario, Canada|Forest Investigative Site 003, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01377194"
32,"NCT03899285","Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders","CRY-MOOD","Completed","No Results Available","Major Depressive Disorder","Drug: Citalopram 20mg or 40 mg (phase 2)","Primary outcomes determined by the proportion of non-responders (< 30 % improvement on the MADRS) after 2 weeks of treatment and the proportion of non-responders randomized patients who completed the study.|Proportion of eligible subjects|Recruitment rate|Retention rate|Adherence rate to treatment|Unblinding rate|Length of interviews|Side effects reported to the assessors and measured by the Frequency, Intensity, and Burden of Side Effect Rating (FIBSER).|Response curves for all patients according to the results from the MADRS.|Correlation between the results of Patient Health Questionnaire-9 (PHQ-9) and the MADRS at each follow-up (T2, T4, T6 and T8).","Ciusss de L'Est de l'Île de Montréal","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018-1215","January 8, 2018","December 8, 2018","December 8, 2018","April 2, 2019",,"April 4, 2019","GMF-U Maisonneuve-Rosemont hospital, Montréal-Est, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03899285"
33,"NCT01034267","Safety Study of F2695 SR in Major Depressive Disorder","LVM-MD-04","Completed","No Results Available","Major Depressive Disorder","Drug: F2695 SR","Adverse events, clinical laboratory tests, vital sign measurements, electrocardiograms, physical examinations, Columbia-Suicide Severity Rating Scale","Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","828","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LVM-MD-04","December 2009","June 2012",,"December 17, 2009",,"August 17, 2012","Forest Investigative Site 55, Dothan, Alabama, United States|Forest Investigative Site 29, Scottsdale, Arizona, United States|Forest Investigative Site 31, Beverly Hills, California, United States|Forest Investigative Site 3, Costa Mesa, California, United States|Forest Investigative Site 12, Encino, California, United States|Forest Investigative Site 6, Escondido, California, United States|Forest Investigative Site 22, Oceanside, California, United States|Forest Investigative Site 38, Sherman Oaks, California, United States|Forest Investigative Site 36, Denver, Colorado, United States|Forest Investigative Site 28, Denver, Colorado, United States|Forest Investigative Site 65, Highlands Ranch, Colorado, United States|Forest Investigative Site 30, Cromwell, Connecticut, United States|Forest Investigative Site 57, Boca Raton, Florida, United States|Forest Investigative Site 60, Boca Raton, Florida, United States|Forest Investigative Site 18, Coral Springs, Florida, United States|Forest Investigative Site 34, Fort Myers, Florida, United States|Forest Investigative Site 64, Gainesville, Florida, United States|Forest Investigative Site 45, Hallandale Beach, Florida, United States|Forest Investigative Site 17, Jacksonville, Florida, United States|Forest Investigative Site 53, Ocala, Florida, United States|Forest Investigative Site 13, Orlando, Florida, United States|Forest Investigative Site 61, Orlando, Florida, United States|Forest Investigative Site 27, West Palm Beach, Florida, United States|Forest Investigative Site 59, Winter Park, Florida, United States|Forest Investigative Site 70, Atlanta, Georgia, United States|Forest Investigative Site 66, Smyrna, Georgia, United States|Forest Investigative Site 33, Chicago, Illinois, United States|Forest Investigative Site 23, Hoffman Estates, Illinois, United States|Forest Investigative Site 50, Oak Brook, Illinois, United States|Forest Investigative Site 63, Indianapolis, Indiana, United States|Forest Investigative Site 71, Prairie Village, Kansas, United States|Forest Investigative Site 5, Wichita, Kansas, United States|Forest Investigative Site 52, Shreveport, Louisiana, United States|Forest Investigative Site 1, Baltimore, Maryland, United States|Forest Investigative Site 2, Glen Burnie, Maryland, United States|Forest Investigative Site 37, Rockville, Maryland, United States|Forest Investigative Site 32, Fall River, Massachusetts, United States|Forest Investigative Site 15, East Lansing, Michigan, United States|Forest Investigative Site 35, Cherry Hill, New Jersey, United States|Forest Investigative Site 21, Willingboro, New Jersey, United States|Forest Investigative Site 51, Brooklyn, New York, United States|Forest Investigative Site 42, Brooklyn, New York, United States|Forest Investigative Site 4, Mount Kisco, New York, United States|Forest Investigative Site 16, New York, New York, United States|Forest Investigative Site 39, New York, New York, United States|Forest Investigative Site 9, Staten Island, New York, United States|Forest Investigative Site 46, Raleigh, North Carolina, United States|Forest Investigative Site 25, Canton, Ohio, United States|Forest Investigative Site 10, Dayton, Ohio, United States|Forest Investigative Site 56, Oklahoma City, Oklahoma, United States|Forest Investigative Site 67, Oklahoma City, Oklahoma, United States|Forest Investigative Site 40, Portland, Oregon, United States|Forest Investigative Site 58, Salem, Oregon, United States|Forest Investigative Site 54, Allentown, Pennsylvania, United States|Forest Investigative Site 14, Media, Pennsylvania, United States|Forest Investigative Site 43, Norristown, Pennsylvania, United States|Forest Investigative Site 24, Philadelphia, Pennsylvania, United States|Forest Investigative Site 44, Lincoln, Rhode Island, United States|Forest Investigative Site 26, Memphis, Tennessee, United States|Forest Investigative Site 20, Dallas, Texas, United States|Forest Investigative Site 47, Dallas, Texas, United States|Forest Investigative Site 62, San Antonio, Texas, United States|Forest Investigative Site 7, San Antonio, Texas, United States|Forest Investigative Site 8, Woodstock, Vermont, United States|Forest Investigative Site 68, Virginia Beach, Virginia, United States|Forest Investigative Site 19, Bellevue, Washington, United States|Forest Investigative Site 41, Seattle, Washington, United States|Forest Investigative Site 69, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01034267"
34,"NCT03433339","Spinal Cord Stimulation for the Treatment of Major Depressive Disorder","SPIDEP","Recruiting","No Results Available","Major Depressive Disorder","Device: Active transcutaneous spinal direct current stimulation|Device: Sham transcutaneous spinal direct current stimulation","MADRS score change|Adverse Event frequency difference|Clinical Global Impression-Severity (CGI-S)|Clinical Global Impression-Improvement (CGI-I)|MADRS Sub-component score|PHQ-9 score change|Multidimensional Assessment of Interoceptive Awareness (MAIA) score change|Binge Eating Scale (BES) score change|Four-Dimensional Symptom Questionnaire (4-DSQ) score change|Blood Pressure score change|Heart Rate score change|Body Mass Index change|Waist Circumference change|Hip Circumference change|Adiponectin level change|Leptin level change|Cortisol level change|Insulin level change|FGF-21 level change|Fatty Acid (LCn-3) level change","University of Cincinnati|Lindner Center of HOPE|Brain & Behavior Research Foundation","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPIDEP 2017-7424","August 29, 2018","December 2021","December 2021","February 14, 2018",,"January 5, 2021","Lindner Center of HOPE/University of Cincinnati, Mason, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03433339"
35,"NCT01034462","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Placebo","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change in Sheehan Disability Scale (SDS) Total Score","Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","442","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-03","December 2009","December 2011","December 2011","December 17, 2009","October 25, 2013","October 25, 2013","Forest Investigative Site 055, Dothan, Alabama, United States|Forest Investigative Site 065, Highlands Ranch, Colorado, United States|Forest Investigative Site 057, Boca Raton, Florida, United States|Forest Investigative Site 060, Boca Raton, Florida, United States|Forest Investigative Site 064, Gainesville, Florida, United States|Forest Investigative Site 053, Ocala, Florida, United States|Forest Investigative Site 061, Orlando, Florida, United States|Forest Investigative Site 059, Winter Park, Florida, United States|Forest Investigative Site 070, Atlanta, Georgia, United States|Forest Investigative Site 066, Smyrna, Georgia, United States|Forest Investigative Site 072, Chicago, Illinois, United States|Forest Investigative Site 050, Oakbrook, Illinois, United States|Forest Investigative Site 063, Indianapolis, Indiana, United States|Forest Investigative Site 071, Prairie Village, Kansas, United States|Forest Investigative Site 052, Shreveport, Louisiana, United States|Forest Investigative Site 051, Brooklyn, New York, United States|Forest Investigative Site 056, Oklahoma City, Oklahoma, United States|Forest Investigative Site 067, Oklahoma City, Oklahoma, United States|Forest Investigative Site 058, Salem, Oregon, United States|Forest Investigative Site 054, Allentown, Pennsylvania, United States|Forest Investigative Site 062, San Antonio, Texas, United States|Forest Investigative Site 068, Virginia Beach, Virginia, United States|Forest Investigative Site 069, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01034462"
36,"NCT04006834","Hypersomnia in Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Other: No intervention involved","Hypersomnia|Depression severity|Fatigue|Function as indicated quality of life","Chinese University of Hong Kong","All","18 Years to 64 Years   (Adult)",,"350","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CREC2018.317","July 1, 2019","February 28, 2020","August 31, 2020","July 5, 2019",,"September 6, 2019","Department of psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04006834"
37,"NCT00969150","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Placebo","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change in Sheehan Disability Scale (SDS) Total Score","Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","362","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-02","September 2009","November 2010",,"September 1, 2009","October 25, 2013","October 25, 2013","Forest Investigative Site, Scottsdale, Arizona, United States|Forest Investigative Site, Encino, California, United States|Forest Investigative Site, Los Alamitos, California, United States|Forest Investigative Site, Oceanside, California, United States|Forest Investigative Site, Denver, Colorado, United States|Forest Investigative Site, Denver, Colorado, United States|Forest Investigative Site, Jacksonville, Florida, United States|Forest Investigative Site, Orlando, Florida, United States|Forest Investigative Site, Chicago, Illinois, United States|Forest Investigative Site, Wichita, Kansas, United States|Forest Investigative Site, Glen Burnie, Maryland, United States|Forest Investigative Site, Fall River, Massachusetts, United States|Forest Investigative Site, East Lansing, Michigan, United States|Forest Investigative Site, Cherry Hill, New Jersey, United States|Forest Investigative Site, Brooklyn, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, Staten Island, New York, United States|Forest Investigative Site 013, Canton, Ohio, United States|Forest Investigative Site, Dayton, Ohio, United States|Forest Investigative Site, Portland, Oregon, United States|Forest Investigative Site, Philadelphia, Pennsylvania, United States|Forest Investigative Site, Lincoln, Rhode Island, United States|Forest Investigative Site, Woodstock, Vermont, United States|Forest Investigative Site, Bellevue, Washington, United States|Forest Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00969150"
38,"NCT00969709","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Placebo","Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Change in Sheehan Disability Scale (SDS) Total Score","Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","724","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-01","September 2009","May 2011",,"September 1, 2009","October 25, 2013","October 25, 2013","Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Scottsdale, Arizona, United States|Forest Investigative Site, Beverly Hills, California, United States|Forest Investigative Site, Costa Mesa, California, United States|Forest Investigative Site, Escondido, California, United States|Forest Investigative Site, Oceanside, California, United States|Forest Investigative Site, Sherman Oaks, California, United States|Forest Investigative Site, Denver, Colorado, United States|Forest Investigative Site, Cromwell, Connecticut, United States|Forest Investigative Site, Coral Springs, Florida, United States|Forest Investigative Site, Fort Myers, Florida, United States|Forest Investigative Site, Hallandale Beach, Florida, United States|Forest Investigative Site, Jacksonville, Florida, United States|Forest Investigative Site, Orlando, Florida, United States|Forest Investigative Site, West Palm Beach, Florida, United States|Forest Investigative Site, Hoffman Estates, Illinois, United States|Forest Investigative Site, Wichita, Kansas, United States|Forest Investigative Site, Baltimore, Maryland, United States|Forest Investigative Site, Rockville, Maryland, United States|Forest Investigative Site, Cherry Hill, New Jersey, United States|Forest Investigative Site, Willingboro, New Jersey, United States|Forest Investigative Site, Brooklyn, New York, United States|Forest Investigative Site, Mt. Kisco, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, Staten Island, New York, United States|Forest Investigative Site, Raleigh, North Carolina, United States|Forest Investigative Site, Canton, Ohio, United States|Forest Investigative Site, Portland, Oregon, United States|Forest Investigative Site, Media, Pennsylvania, United States|Forest Investigative Site, Norristown, Pennsylvania, United States|Forest Investigative Site, Lincoln, Rhode Island, United States|Forest Investigative Site, Memphis, Tennessee, United States|Forest Investigative Site, Dallas, Texas, United States|Forest Investigative Site, Dallas, Texas, United States|Forest Investigative Site, San Antonio, Texas, United States|Forest Investigative Site, Bellevue, Washington, United States|Forest Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00969709"
39,"NCT04392947","Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation","TBS-D","Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation|Device: Sham Transcranial Magnetic Stimulation","Response rate of Montgomery-Asberg Depression Rating Scale (MADRS)|Remission rate after treatment|Reduction of raw score: Montgomery-Asberg Depression Rating Scale (MADRS)|Reduction of raw score: Hamilton Depression Rating Scale 17 items (HDRS17)|Reduction of raw score: Clinical Global Impression (CGI)|Reduction of raw score: Beck Depression Inventory (BDI-II)|Reduction of raw score: WHO-5 well-being index|Work Productivity and Activity Impairment Questionnaire (WPAI)|Frequency of adverse events|Deterioration rate after treatment period|Examination of the influence of Childhood Trauma Questionnaire (CTQ) at baseline as possible predictor for change of MADRS|Examination of the influence of cognitive performance at baseline as possible predictor for change of MADRS","University Hospital Tuebingen|Federal Ministry of Health, Germany|Institute of Clinical Epidemiology and applied Biometry, University Tuebingen, Germany|Center of Clinical Trials, University Tuebingen, Germany|University of Ulm|Department of Psychiatry and Psychotherapy, University Regensburg, Germany|Department of Psychiatry and Psychotherapy, University Wuerzburg, Germany|Department of Psychiatry and Psychotherapy, University Munich (LMU), Germany","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01KG2003","September 29, 2020","January 2023","April 2023","May 19, 2020",,"December 3, 2020","University of Munich, Munich, Germany|University of Regensburg, Dept. Psychiatry and Psychotherapy, Regensburg, Germany|University of Tuebingen, Dept Psychiatry and Psychotherapy, Tuebingen, Germany|University of Um, Dept. Psychiatry and Psychotherapy, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT04392947"
40,"NCT03188185","A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: ALKS 5461|Drug: ALKS 5461 Placebo","Change From Baseline to the End of Treatment (EOT) in the Montgomery Asberg Depression Rating Scale-10 (MADRS-10) Scores|Montgomery Asberg Depression Rating Scale (MADRS) Response Rate|Montgomery Asberg Depression Rating Scale (MADRS) Remission Rate","Alkermes, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK5461-217","June 12, 2017","February 26, 2020","March 5, 2020","June 15, 2017","March 15, 2021","April 8, 2021","Alkermes Investigational Site, Tucson, Arizona, United States|Alkermes Investigational Site, Little Rock, Arkansas, United States|Alkermes Investigational Site, Los Alamitos, California, United States|Alkermes Investigational Site, Oceanside, California, United States|Alkermes Investigational Site, Pico Rivera, California, United States|Alkermes Investigational Site, Redlands, California, United States|Alkermes Investigational Site, Santa Ana, California, United States|Alkermes Investigational Site, Sherman Oaks, California, United States|Alkermes Investigational Site, Temecula, California, United States|Alkermes Investigative Site, Upland, California, United States|Alkermes Investigational Site, Hollywood, Florida, United States|Alkermes Investigational Site, Jacksonville, Florida, United States|Alkermes Investigational Site, Lauderhill, Florida, United States|Alkermes Investigational Site, Orlando, Florida, United States|Alkermes Investigative Site, Palm Bay, Florida, United States|Alkermes Investigational Site, Atlanta, Georgia, United States|Alkermes Investigational Site, Decatur, Georgia, United States|Alkermes Investigational Site, Pikesville, Maryland, United States|Alkermes Investigational Site, O'Fallon, Missouri, United States|Alkermes Investigational Site, Jamaica, New York, United States|Alkermes Investigational Site, Mount Kisco, New York, United States|Alkermes Investigational Site, Canton, Ohio, United States|Alkermes Investigational Site, Cincinnati, Ohio, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Allentown, Pennsylvania, United States|Alkermes Investigational Site, Memphis, Tennessee, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, DeSoto, Texas, United States|Alkermes Investigational Site, Woodstock, Vermont, United States|Alkermes Investigative Site, Bellevue, Washington, United States|Alkermes Investigational Site, Frankston, Victoria, Australia|Alkermes Investigational Site, Noble Park, Victoria, Australia|Alkermes Investigational Site, Richmond, Victoria, Australia|Alkermes Investigational Site, San Juan, Puerto Rico|Alkermes Investigational Site, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03188185/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03188185/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03188185"
41,"NCT00570050","Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Diluent / Insulin|Drug: Insulin / Diluent","Montgomery-Asberg Depression Rating Scale|Affective Go/No-Go and Emotional Recognition Tasks; CGI Severity of Illness, Improvements in subjective mood (PANAS) and quality of life (Q-LES-Q)","University Health Network, Toronto|McMaster University","All","18 Years to 60 Years   (Adult)","Phase 3","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Insulin-MDD","June 2013","September 2014","September 2014","December 10, 2007",,"February 24, 2015","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00570050"
42,"NCT00797966","Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: OPC-34712|Drug: Placebo|Drug: ADT","Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.|Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.|Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).|Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).|Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.|Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.|Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).|Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).|Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.|Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.|Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.|Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).|Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).|Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","850","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-08-211","May 2009","June 2010","July 2010","November 25, 2008","December 3, 2015","February 29, 2016","Pacific Clinical Research Medical Group, Arcadia, California, United States|Southwestern Research, Beverly Hills, California, United States|Synergy Escondido, Escondido, California, United States|Collaborative Neuroscience Network Inc., Garden Grove, California, United States|Synergy Clinical Research Center, National City, California, United States|Excell Research, Oceanside, California, United States|Affiliated Research Institute, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Radiant Research Center, Denver, Colorado, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|CNS Clinical Research Group, Coral Springs, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Accurate Clinical Trials, Kissimee, Florida, United States|Clinical Neurosciences Solutions, Orlando, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida College of Medicine Psychiatry Center, Tampa, Florida, United States|Janus Center, West Palm Beach, Florida, United States|Carman Research, Smyrna, Georgia, United States|Uptown Research Institute, Chicago, Illinois, United States|Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace, Illinois, United States|The Davis Clinic, PC, Indianapolis, Indiana, United States|Vince & Associates Clinical Research, Overland Park, Kansas, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Bioscience Research, Mount Kisco, New York, United States|Eastside Comprehensive Medical Center, New York City, New York, United States|Medical & Behavioral Health Research, PC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Carolinas HealthCare - Behavioral Heath Center, Charlotte, North Carolina, United States|NorthCoast Clinical Trials, Inc, Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|Patient Priority Clinical Sites, LLC, Cinncinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|NorthStar Medical Research, LLC, Middleburg Heights, Ohio, United States|Summitt Research Network (Oregon), Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|USC School of Medicine- Department of Neuropsychiatry and Behavioral Science, Columbia, South Carolina, United States|Clinical Neurosciences Solutions, Inc., Memphis, Tennessee, United States|Community Clinical Research, Inc., Austin, Texas, United States|FutureSearch Clinical Trials, Austin, Texas, United States|Radiant Research, Salt Lake City, Utah, United States|Mood Disorders Clinic, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Charlottesville, Virginia, United States|NeuroScience, Inc., Herndon, Virginia, United States|Dominion Clinical Research, Midlothian, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00797966"
43,"NCT02012218","Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy",,"Completed","Has Results","Major Depressive Disorder (MDD)","Drug: ADT|Drug: Brexpiprazole","Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","61","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-13-001","November 2013","October 2014","October 2014","December 16, 2013","October 8, 2015","December 29, 2015","Collaborative NeuroScience Network, Inc., Garden Grove, California, United States|Viking Clinical Research, Ltd., Temecula, California, United States|Clinical Neuroscience Solutions Pharmacology, Orlando, Florida, United States|Carman Research, Smyrna, Georgia, United States|Goldpoint Clinical Research, Indianapolis, Indiana, United States|Alpine Clinic, Lafayette, Indiana, United States|Pharmasite Research, Baltimore, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Coastal Research Associates, Inc., Weymouth, Massachusetts, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|St. Louis Clinical Trials, St. Louis, Missouri, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Midwest Clinical Research Center MCRC, Dayton, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Lincoln Research, LLC, Lincoln, Rhode Island, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Future Search Trials of Dallas, LP, Dallas, Texas, United States|NeuropsychiatricAssociates, Woodstock, Vermont, United States|Frontier Institute, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02012218"
44,"NCT00705185","Exploring a Potential Blood Test to Diagnose Major Depressive Disorder","Bio-TestMDD","Completed","No Results Available","Major Depressive Disorder",,"16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls","Massachusetts General Hospital|Precision Human Biolaboratories|Cambridge Health Alliance|University of Connecticut|Vanderbilt University|Psychiatric Medicine Associates, L.L.C.","All","18 Years to 65 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2007-P-002525","April 2008","June 2010","June 2010","June 25, 2008",,"June 8, 2010","University of Connecticut Health Center, Farmington, Connecticut, United States|Psychiatric Medicine Associates, L.L.C., Chicago, Illinois, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00705185"
45,"NCT02657980","The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: Yband(YDT-201N)|Device: Sham-Yband(YDT-201N)","Change in depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)|Effect of tDCS on Depressive Symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)|Effect of tDCS on questionnaire results as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)|Average change in results for 2, 4, 6 weeks after treatment as assessed by the clinician-rated Clinical Global Impression-Severity of Illness Scale (CGISI)|Average change in results for 2, 4, 6 weeks after treatment as assessed by Korean-Beck Depression Inventory-II (K-BDI-II)|Average change in results for 2, 4, 6 weeks after treatment as assessed by Korean-Beck Anxiety Depression Inventory (K-BAI)","Ybrain Inc.|Severance Hospital|Gangnam Severance Hospital|Myongji Hospital|CHA University|National Health Insurance Service Ilsan Hospital|Ajou University|Hallym University Medical Center","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 3","96","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MUL003MDD","April 2015","December 2016","December 2016","January 18, 2016",,"January 26, 2017","Ybrain, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02657980"
46,"NCT00049972","Major Depressive Disorder Study In Adults",,"Completed","No Results Available","Major Depressive Disorder","Drug: paroxetine CR","The proportion of patients who prematurely terminated treatment due to treatment emergent adverse events|Recurrence rates of adverse events causing intolerability of previous SSRI/SNRI, Adverse event incidence rates, Mean change from baseline in the Beck Depression Inventory-II total score, Proportion of responsers based on teh CGI Global Improvement Item","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","646","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","SB29060.833","September 2002","September 2003","September 2003","November 19, 2002",,"September 11, 2017","GSK Clinical Trial Call Center, Birmingham, Alabama, United States|GSK Clinical Trial Call Center, Birmingham, Alabama, United States|GSK Clinical Trial Call Center, Fairfield, Alabama, United States|GSK Clinical Trial Call Center, Mobile, Alabama, United States|GSK Clinical Trial Call Center, Phoenix, Arizona, United States|GSK Clinical Trial Call Center, Little Rock, Arkansas, United States|GSK Clinical Trial Call Center, Little Rock, Arkansas, United States|GSK Clinical Trial Call Center, Anaheim Hills, California, United States|GSK Clinical Trial Call Center, Anaheim, California, United States|GSK Clinical Trial Call Center, Bellflower, California, United States|GSK Clinical Trial Call Center, Cerritos, California, United States|GSK Clinical Trial Call Center, Clovis, California, United States|GSK Clinical Trial Call Center, Encino, California, United States|GSK Clinical Trial Call Center, Petaluma, California, United States|GSK Clinical Trial Call Center, Riverside, California, United States|GSK Clinical Trial Call Center, Sacramento, California, United States|GSK Clinical Trial Call Center, Sacramento, California, United States|GSK Clinical Trial Call Center, San Francisco, California, United States|GSK Clinical Trial Call Center, Temecula, California, United States|GSK Clinical Trial Call Center, Vista, California, United States|GSK Clinical Trial Call Center, Colorado Springs, Colorado, United States|GSK Clinical Trial Call Center, Wilmington, Delaware, United States|GSK Clinical Trial Call Center, Wilmington, Delaware, United States|GSK Clinical Trial Call Center, Boynton Beach, Florida, United States|GSK Clinical Trial Call Center, Delray Beach, Florida, United States|GSK Clinical Trial Call Center, Fort Myers, Florida, United States|GSK Clinical Trial Call Center, Melbourne, Florida, United States|GSK Clinical Trial Call Center, Miami, Florida, United States|GSK Clinical Trial Call Center, Ocala, Florida, United States|GSK Clinical Trial Call Center, Atlanta, Georgia, United States|GSK Clinical Trial Call Center, Idaho Falls, Idaho, United States|GSK Clinical Trial Call Center, Gurnee, Illinois, United States|GSK Clinical Trial Call Center, Greenwood, Indiana, United States|GSK Clinical Trial Call Center, Lafayette, Louisiana, United States|GSK Clinical Trial Call Center, Lake Charles, Louisiana, United States|GSK Clinical Trial Call Center, New Orleans, Louisiana, United States|GSK Clinical Trial Call Center, Prince Frederick, Maryland, United States|GSK Clinical Trial Call Center, Springfield, Massachusetts, United States|GSK Clinical Trial Call Center, Excelsior Springs, Missouri, United States|GSK Clinical Trial Call Center, Kansas City, Missouri, United States|GSK Clinical Trial Call Center, Saint Charles, Missouri, United States|GSK Clinical Trial Call Center, Saint Louis, Missouri, United States|GSK Clinical Trial Call Center, Las Vegas, Nevada, United States|GSK Clinical Trial Call Center, Reno, Nevada, United States|GSK Clinical Trial Call Center, Blackwood, New Jersey, United States|GSK Clinical Trial Call Center, Mercerville, New Jersey, United States|GSK Clinical Trial Call Center, Princeton, New Jersey, United States|GSK Clinical Trial Call Center, Carrboro, North Carolina, United States|GSK Clinical Trial Call Center, Cary, North Carolina, United States|GSK Clinical Trial Call Center, Cincinnati, Ohio, United States|GSK Clinical Trial Call Center, Cincinnati, Ohio, United States|GSK Clinical Trial Call Center, Cleveland, Ohio, United States|GSK Clinical Trial Call Center, Independence, Ohio, United States|GSK Clinical Trial Call Center, Oklahoma City, Oklahoma, United States|GSK Clinical Trial Call Center, Eugene, Oregon, United States|GSK Clinical Trial Call Center, Downingtown, Pennsylvania, United States|GSK Clinical Trial Call Center, Bartlett, Tennessee, United States|GSK Clinical Trial Call Center, Cordova, Tennessee, United States|GSK Clinical Trial Call Center, Selmer, Tennessee, United States|GSK Clinical Trial Call Center, Conroe, Texas, United States|GSK Clinical Trial Call Center, Corsicana, Texas, United States|GSK Clinical Trial Call Center, Dallas, Texas, United States|GSK Clinical Trial Call Center, DeSoto, Texas, United States|GSK Clinical Trial Call Center, Fort Worth, Texas, United States|GSK Clinical Trial Call Center, Galveston, Texas, United States|GSK Clinical Trial Call Center, Richardson, Texas, United States|GSK Clinical Trial Call Center, Sugar Land, Texas, United States|GSK Clinical Trial Call Center, West Valley City, Utah, United States|GSK Clinical Trial Call Center, Lebanon, Virginia, United States|GSK Clinical Trial Call Center, Richmond, Virginia, United States|GSK Clinical Trial Call Center, Kirkland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00049972"
47,"NCT01742832","Double-Blind Treatment of Major Depressive Disorder With Vilazodone",,"Completed","Has Results","Major Depressive Disorder","Drug: Vilazodone|Drug: Citalopram","Montgomery-Åsberg Depression Rating Scale (MADRS)","University of Chicago","All","18 Years to 60 Years   (Adult)","Phase 2","79","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012MDDVilaz","May 2013","March 2016","March 2016","December 5, 2012","May 30, 2017","May 30, 2017","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01742832"
48,"NCT02348827","Family Psychoeducation for Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Family psychoeducation|Behavioral: Social support group","Number of relpase|Time to relapse|Reduction of depressive symptoms","Mental Health Services in the Capital Region, Denmark|Mental Health Centre North Zealand","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H-4-2014-044","January 2015","July 2016","September 2017","January 28, 2015",,"April 29, 2016","Psychiatric Research Unit, Mental Health Centre North Zealand, Hilleroed, Denmark",,"https://ClinicalTrials.gov/show/NCT02348827"
49,"NCT01838876","Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Cariprazine|Drug: Antidepressant Therapy (ADT)","Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period|Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period|Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters|Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters|Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)|Number of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs|Number of Participants in the Most Severe Suicidal Ideation and Suicidal Behavior Recorded on the C-SSRS During the Treatment Period|Number of Participants With Treatment-Emergent Ocular Events|Change From Baseline in the Arizona Sexual Experiences Scale (ASEX) Score","Forest Laboratories|Gedeon Richter Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","442","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RGH-MD-76","April 29, 2013","July 27, 2015","July 27, 2015","April 24, 2013","August 21, 2019","August 21, 2019","Forest Investigative Site 032, Tucson, Arizona, United States|Forest Investigative Site 109, Tucson, Arizona, United States|Forest Investigative Site 105, Fayetteville, Arkansas, United States|Forest Investigative Site 018, Little Rock, Arkansas, United States|Forest Investigative Site 029, Little Rock, Arkansas, United States|Forest Investigative Site 082, Garden Grove, California, United States|Forest Investigative Site 107, Long Beach, California, United States|Forest Investigative Site 104, National City, California, United States|Forest Investigative Site 022, Newport Beach, California, United States|Forest Investigative Site 004, Oceanside, California, United States|Forest Investigative Site 078, Rancho Mirage, California, United States|Forest Investigative Site 080, Redlands, California, United States|Forest Investigative Site 113, San Diego, California, United States|Forest Investigative Site 054, San Diego, California, United States|Forest Investigative Site 007, San Diego, California, United States|Forest Investigative Site 031, Temecula, California, United States|Forest Investigative Site 048, Denver, Colorado, United States|Forest Investigative Site 114, Norwich, Connecticut, United States|Forest Investigative Site 037, Coral Springs, Florida, United States|Forest Investigative Site 053, Fort Myers, Florida, United States|Forest Investigative Site 023, Hallandale Beach, Florida, United States|Forest Investigative Site 071, Hialeah, Florida, United States|Forest Investigative Site 006, Leesburg, Florida, United States|Forest Investigative Site 112, Maitland, Florida, United States|Forest Investigative Site 026, Miami, Florida, United States|Forest Investigative Site 075, Miami, Florida, United States|Forest Investigative Site 027, North Miami, Florida, United States|Forest Investigative Site 074, North Miami, Florida, United States|Forest Investigative Site 036, Oakland Park, Florida, United States|Forest Investigative Site 051, Orlando, Florida, United States|Forest Investigative Site 044, South Miami, Florida, United States|Forest Investigative Site 008, Tampa, Florida, United States|Forest Investigative Site 019, Winter Park, Florida, United States|Forest Investigative Site 060, Atlanta, Georgia, United States|Forest Investigative Site 024, Atlanta, Georgia, United States|Forest Investigative Site 017, Marietta, Georgia, United States|Forest Investigative Site 047, Smyrna, Georgia, United States|Forest Investigative Site 070, Chicago, Illinois, United States|Forest Investigative Site 013, Hoffman Estates, Illinois, United States|Forest Investigative Site 063, Libertyville, Illinois, United States|Forest Investigative Site 062, Maywood, Illinois, United States|Forest Investigative Site 072, Naperville, Illinois, United States|Forest Investigative Site 010, Oak Brook, Illinois, United States|Forest Investigative Site 068, Skokie, Illinois, United States|Forest Investigative Site 061, Indianapolis, Indiana, United States|Forest Investigative Site 042, Lafayette, Indiana, United States|Forest Investigative Site 065, Overland Park, Kansas, United States|Forest Investigative Site 073, New Orleans, Louisiana, United States|Forest Investigative Site 049, Gaithersburg, Maryland, United States|Forest Investigative Site 077, Rockville, Maryland, United States|Forest Investigative Site 110, Rockville, Maryland, United States|Forest Investigative Site 046, Boston, Massachusetts, United States|Forest Investigative Site 045, Natick, Massachusetts, United States|Forest Investigative Site 103, Saint Charles, Missouri, United States|Forest Investigative Site 106, Berlin, New Jersey, United States|Forest Investigative Site 014, Toms River, New Jersey, United States|Forest Investigative Site 058, Albuquerque, New Mexico, United States|Forest Investigative Site 076, Bronx, New York, United States|Forest Investigative Site 028, Brooklyn, New York, United States|Forest Investigative Site 016, New York, New York, United States|Forest Investigative Site 025, Staten Island, New York, United States|Forest Investigative Site 050, Durham, North Carolina, United States|Forest Investigative Site 067, Bismarck, North Dakota, United States|Forest Investigative Site 011, Cincinnati, Ohio, United States|Forest Investigative Site 015, Cincinnati, Ohio, United States|Forest Investigative Site 055, Columbus, Ohio, United States|Forest Investigative Site 066, Mason, Ohio, United States|Forest Investigative Site 064, Middleburg Heights, Ohio, United States|Forest Investigative Site 038, Oklahoma City, Oklahoma, United States|Forest Investigative Site 035, Oklahoma City, Oklahoma, United States|Forest Investigative Site 039, Oklahoma City, Oklahoma, United States|Forest Investigative Site 003, Portland, Oregon, United States|Forest Investigative Site 052, Allentown, Pennsylvania, United States|Forest Investigative Site 102, Norristown, Pennsylvania, United States|Forest Investigative Site 059, Lincoln, Rhode Island, United States|Forest Investigative Site 001, Charleston, South Carolina, United States|Forest Investigative Site 079, Austin, Texas, United States|Forest Investigative Site 005, Houston, Texas, United States|Forest Investigative Site 108, The Woodlands, Texas, United States|Forest Investigative Site 069, Wichita Falls, Texas, United States|Forest Investigative Site 111, Murray, Utah, United States|Forest Investigative Site 041, Charlottesville, Virginia, United States|Forest Investigative Site 081, Bellevue, Washington, United States|Forest Investigative Site 100, Bothell, Washington, United States|Forest Investigative Site 043, Seattle, Washington, United States|Forest Investigative Site 101, Middleton, Wisconsin, United States|Forest Investigative Site 056, Milwaukee, Wisconsin, United States|Forest Investigative Site 057, Waukesha, Wisconsin, United States|Forest Investigative Site 033, San Juan, Puerto Rico|Forest Investigative Site 034, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01838876"
50,"NCT03899194","Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: fish oil capsules|Drug: escitalopram","remission of acute phase|remission of consolidate and maintenance phase","Shanghai Mental Health Center","All","18 Years to 60 Years   (Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81771465","January 1, 2019","December 31, 2021","December 31, 2021","April 2, 2019",,"April 2, 2019","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03899194"
51,"NCT03302611","Trial of Surf and Hike Therapy for Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Physical Activity-based Interventions","Montgomery-Asberg Depression Rating Scale (MADRS)|PTSD Checklist (PCL-5)|Generalized Anxiety Disorder (GAD-7)|Short Form Health Survey - 36 Item, Version 2 (SF-36)|Positive and Negative Affect scales (PANAS)|Insomnia Severity Index (ISI)|Patient Health Questionnaire (PHQ-9)","United States Naval Medical Center, San Diego|Naval Health Research Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","110","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NMCSD.2017.0007","January 1, 2018","September 1, 2020","September 1, 2020","October 5, 2017",,"March 12, 2021","Naval Medical Center San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03302611"
52,"NCT01919008","Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: FK949E","Maximum plasma concentration (Cmax) of unchanged quetiapine|AUC24h (area under the curve for 24hr) of unchanged quetiapine|Trough value of plasma concentration of unchanged quetiapine|t1/2 of plasma concentration of unchanged quetiapine|Maximum plasma concentration (Cmax) of quetiapine metabolites|AUC (area under the curve) of quetiapine metabolites|trough value of plasma concentration of quetiapine metabolites|tmax of plasma concentration of quetiapine metabolites|t1/2 of plasma concentration of quetiapine metabolites|Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","6949-CL-0006","March 26, 2012","June 22, 2012","June 22, 2012","August 8, 2013",,"July 23, 2019","Kanto, Japan",,"https://ClinicalTrials.gov/show/NCT01919008"
53,"NCT01582945","Ketamine Infusion for Treatment-resistant Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Ketamine","Response to Ketamine as Measured by Hamilton Depression Rating Scale -28 Items (HAMD28)","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-P-002800","April 2012","September 2014","December 2014","April 23, 2012","April 20, 2017","April 20, 2017","Depression Clinical and Research Program - MGH, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01582945"
54,"NCT00467402","Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: agomelatine|Drug: placebo","Time to relapse, where relapse is defined by the occurrence of any one of the following:|Hamilton Depression Rating Scale total score ≥16 at two consecutive visits;|hospitalization due to depression;|suicide attempt or suicide;|discontinuation due to lack of efficacy according to Investigator judgment.|Proportion of patients who demonstrate clinical improvement at the end of the double-blind continuation phase, where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale.|Proportion of patients experiencing relapse during the double-blind continuation phase.|Proportion of patients who achieve remission at the end of the double-blind continuation phase, where remission is defined by a total score of ≤7 on the HAM-D.|Change from randomization to the end of the double-blind continuation phase, on the Hospital Anxiety and Depression (HAD) total score and subscale scores.","Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","644","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CAGO178A2304","April 2007","September 2009",,"April 30, 2007",,"December 23, 2020","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Peoria, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Costa Mesa, California, United States|Novartis Investigative Site, Encino, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Newport Beach, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Sherman Oaks, California, United States|Novartis Investigative Site, Temecula, California, United States|Novartis Investigative Site, Wheat Ridge, Colorado, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Coral Springs, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Saint Petersburg, Florida, United States|Novartis Investigative Site, Venice, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Libertyville, Illinois, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Braintree, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Farmington Hills, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Rhododendron, Oregon, United States|Novartis Investigative Site, Allentown, Pennsylvania, United States|Novartis Investigative Site, Lansdale, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, DeSoto, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lake Jackson, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Virginia Beach, Virginia, United States|Novartis Investigative Site, Edmonds, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00467402"
55,"NCT01460212","Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: SSRI antidepressants|Behavioral: Cognitive-Behavior Therapy","Hamilton Rating Scale for Depression (HAMD)|Magnetic Resonance Imaging","Nanjing Medical University","All","20 Years to 50 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QYK09184","December 2011","December 2014","October 2015","October 26, 2011",,"September 25, 2014","Nanjing Brain Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01460212"
56,"NCT00759395","Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)",,"Completed","Has Results","Anxious Major Depressive Disorder","Drug: AZD2327|Drug: Placebo","Hamilton Rating Scale for Depression (HAM-D) Total Score.|Hamilton Rating Scale for Anxiety (HAM-A) Total Score.|Psychic Anxiety Item of the Hamilton Rating Scale for Depression (HAM-D).|The Number of Participants With at Least 50% Reduction of Hamilton Rating Scale for Depression (HAM-D)Total Score.|The Number of Participants With at Least 50% Reduction of Hamilton Rating Scale for Anxiety (HAM-A)Total Score.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D0880C00021","January 2009","October 2011","October 2011","September 25, 2008","November 8, 2012","November 8, 2012","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00759395"
57,"NCT00411099","Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: agomelatine|Drug: placebo","To evaluate the change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17)|To evaluate the proportion of patients who demonstrate clinical improvement at Week 8, where improvement is defined by a score of 1 or 2 on the CGI-I scale|To evaluate the proportion of patients who achieve remission at Week 8, where remission is defined by a total score of < or =7 on the HAM-D17|To evaluate efficacy with respect to the proportion of patients who demonstrate clinical response, where response is defined by a reduction of at least 50% in the baseline HAM-D17 at week 8|To evaluate the change from baseline to week 8 on the subscale scores (Maier, anxiety, retardation and sleep) of the clinician-rated HAM-D17|To evaluate subjective sleep (onset and quality), as measured by the scores on the Leeds Sleep Evaluation Questionnaire (LSEQ) at week 8","Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAGO178A2301","December 2006","January 2008",,"December 13, 2006",,"December 23, 2020","Novartis Investigative Site, Scottsdale, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Cerritos, California, United States|Novartis Investigative Site, El Centro, California, United States|Novartis Investigative Site, Garden Grove, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, Lafayette, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Temecula, California, United States|Novartis Investigative Site, Cromwell, Connecticut, United States|Novartis Investigative Site, Hamden, Connecticut, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Maitland, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Salisbury, Maryland, United States|Novartis Investigative Site, Pittsfield, Massachusetts, United States|Novartis Investigative Site, Farmington Hills, Michigan, United States|Novartis Investigative Site, Rochester Hills, Michigan, United States|Novartis Investigative Site, Saint Peters, Missouri, United States|Novartis Investigative Site, Princeton, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Beachwood, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, North Charleston, South Carolina, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Bennington, Vermont, United States|Novartis Investigative Site, Midlothian, Virginia, United States|Novartis Investigative Site, Bothell, Washington, United States|Novartis Investigative Site, Bayamon, Puerto Rico|Novartis Investigative Site, Rio Piedras, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00411099"
58,"NCT01309542","Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Desvenlafaxine Succinate","Number (%) of Subjects Reporting Adverse Events during Treatment|Number (%) of Subjects With Changes in Vital Signs (Blood Pressure, Pulse Rate, Weight) of Potential Clinical Importance|Number (%) of Subjects With Laboratory Test Results (Hematology, Blood Chemistry, Lipid Profile, Urinalysis) of Potential Clinical Importance|Number (%) of Subjects With Electrocardiogram Results (Heart Rate, QTc interval) of Potential Clinical Importance|Change in Hamilton Depression Rating scale - 17 items version - (HAM-D17) mean score from baseline|Change in Montgomery Asberg Depression Rating Scale (MADRS)mean score from baseline|Change in Clinical Global Improvement Scale-Severity (CGI-S)mean score from baseline","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1403","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-303|B2061069","August 2003","March 2006","March 2006","March 7, 2011",,"April 26, 2011","Birmingham Research Group Inc., Birmingham, Alabama, United States|Pivotal Research Centers 13128 North 94th Drive, Suite 200, Mesa, Arizona, United States|Pivotal Research, Peoria, Arizona, United States|Southwestern Research, Inc., Beverly Hills, California, United States|Feighner Research Institute, Chula Vista, California, United States|California Clinical Trials Medical Group, Inc., Glendale, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pacific Clinical Research, Orange, California, United States|UCSD Department of Psychiatry Psychopharmacology Research, San Diego, California, United States|Southwestern Research, Inc., Tustin, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Feiger Health Research Center, Lakewood, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|New Britain General Hospital, New Britain, Connecticut, United States|The George Washington University Medical Center, Washington, District of Columbia, United States|CORE Research, Inc.1006 NW 14, Leesburg, Florida, United States|Lifestream Behavioral Center, Leesburg, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Miami Research Associates, Inc., South Miami, Florida, United States|Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Kolin Research Group 1065 West Morse Blvd. Suite 202, Winter Park, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine & Research, Marietta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Radiant Research - Chicago, Chicago, Illinois, United States|Ingenium Clinical Research, Libertyville, Illinois, United States|Capital Clinical Research Associates, LLP, Rockville, Maryland, United States|DuPont Clinical Research, Inc., Rockville, Maryland, United States|Institute for Health Studies, Okemos, Michigan, United States|Creighton University, Omaha, Nebraska, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|CRI Worldwide, LLC, Clementon, New Jersey, United States|Anxiety & Depression Clinic, Bronx, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|The Medical Research Network, New York, New York, United States|Piedmont Neuropsychiatry, Charlotte, North Carolina, United States|Hartford Research Group, Cincinatti, Ohio, United States|Midwest Clinical Research Center, LLC, Dayton, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Southeastern Pennsylvania Medical Institute, Havertown, Pennsylvania, United States|RI Mood & Memory Research Institute, East Providence, Rhode Island, United States|Southeast Health Consultants, LLC, Charleston, South Carolina, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|FutureSearch Trials, Austin, Texas, United States|University of Texas Southwestern, Dallas, Texas, United States|Research Testing, Inc., Houston, Texas, United States|Radiant Research Salt Lake City, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Center for Anxiety and Depression, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|West Tallinn Central Hospital, Tallinn, Estonia|Jaanson-Lääne Outpatient Clinic, Tartu, Estonia|Viljandi Hospital Foundation Psychiatric Clinic, Viljandi, Estonia|Psykiatripalvelu AT Oy, Espoo, Finland|FF Research, Helsinki, Finland|Mehilainen clinic, Helsinki, Finland|Mehiläinen, HUCH, Helsinki, Finland|Hakaniemen Lääkäriasema, Helsinki, Finland|Psychiatric Research Clinic of Kupio, Kuopio, Finland|Satakunnanpsykiatripalvelu, Rauma, Finland|MediRoi Oy, Rovaniemi, Finland|Psychiatric Research clinic of Salo, Salo, Finland|Psykoforum OY, Tampere, Finland|Länsi-Suomen Erikoislaakaripalvelu Oy, Turku, Finland|Turku Psychiatric Services Aurakatu 14 B 3 Krs, Turku, Finland|Klinicko-bolnicki centar Dr Dragisa Misovic - Dedinje, Belgrade, Former Serbia and Montenegro|Institut za mentalno zdravlje, Beograd, Former Serbia and Montenegro|1, avenue du 6 Juin, Caen, France|88 Rue Emmanuel Liais, Cherbourg, France|Centre Médico-Psychologique, Dole, France|Résidence St Michel, Douai, France|57 rue Gamard, Joué-Les-Tours, France|Immeuble Impérial, La Valette du Var, France|16 avenue Robert Schuman, Mulhouse, France|3 rue Marceau, Nantes, France|Office of Dr Marce Zins-Ritter, Orvault, France|22 rue de Nemours, Rennes, France|7, rue Georges Politzer, Saint Cyr l'Ecole, France|13 place Gaston Paillhou, Tours, France|emovis GmbH, Berlin, Germany|Praxis fuer Psychiatrie, Dr. Franz, Berlin, Germany|Praxis für Psychiatrie, Dr. Alexander Schulze, Berlin, Germany|Psychiatrische Praxis Dr. Hans-Peter Wunderlich, Dresden, Germany|Praxis f. Neurologie u. Psychiatrie Dr. Lutz D. Lohse, Dresden, Germany|Dr. D. Backhaus, Hildesheim, Hildesheim, Germany|Psychoneurological hospital of Jelgava, Dept No12, Jelgava, Latvia|Riga Mental Health Care Center, Dept of Psychiatry, Riga, Latvia|Strenci Psychiatric Hospital, Strenci, Latvia|Medical center Neuromeda, Kaunas, Lithuania|Klaipeda Psychiatry Hospital, Klaipeda, Lithuania|Vilnius Mental Health Care, Vilnius, Lithuania|Poradnia Zdrowia Psychicznego w Chelmnie, Chelmno, Poland|Akademii Medycznej w Bialymstoku, Choroszcz, Poland|Wojewodzki Szpital Psychiatryczny, Gdansk, Poland|Poradnia Zdrowia Psychicznego, Kutno, Poland|Specjalistyczny Psychiatryczny ZOZ w Lodzi, Lodz, Poland|Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych, Lubiaz, Poland|SP ZOZ Swietokrzyskie Centrum Psychiatrii w Morawicy, Morawica, Poland|Wojewodzki Osrodek Lecznictwa Psychiatrycznego w Toruniu, Torun, Poland|Wojewodzki Osrodek Lecznictwa Psychiatrycznego, Torun, Poland|Inventiva Biomedical and Sport Research Sp. z o.o., Tuszyn, Poland|NZOZ Centrum Zdrowia Psychicznego, Wroclaw, Poland|University Hospital Bratislava, Bratislava, Slovakia|Nemocnica s poliklinikou Liptovsky Mikulas, Liptovsky Mikulas, Slovakia|General Hospital in Trencín, Trencin, Slovakia|Westville Hospital, Westville, Durban, South Africa|Vista Clinic, Pretoria, Gauteng, South Africa|Westdene Research Centre, Bloemfontein, Republic of South Africa, South Africa|Vista Clinic, Pretoria, Republic of South Africa, South Africa|Dey Clinic, Pretoria, Republic of South Africa, South Africa|Paarl Medical Centre, Paarl, Western Cape, South Africa|Knighton Surgery, Cape Town, South Africa|2B Tre Mondi Office Park, Somerset West, South Africa|Welkom Mediclinic, Welkom, South Africa",,"https://ClinicalTrials.gov/show/NCT01309542"
59,"NCT01608399","Clinical Trial of the Effectiveness of Metacognitive Therapy in the Treatment of Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Metacognitive therapy","Change in depression|Change in diagnosis|Change in anxiety|Change in automatic thought|Change in rumination|Change in positive beliefs|Change in negative beliefs|Change in metacognitions|Change in resilience|Change in interpersonal problems|Change in worry|Quality of working alliance","Norwegian University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCTDEP","March 2012","June 2016","June 2016","May 31, 2012",,"August 28, 2019","Department of psychology, Norwegian University of Science and Technology, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT01608399"
60,"NCT00514865","Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: ONO-2333Ms","Change from baseline to treatment endpoint in the MADRS total score|Change from baseline to treatment endpoint in the HAM-D17, QIDS-SR16, CGI-S, CGI-I, PGI score","Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd","All","18 Years to 55 Years   (Adult)","Phase 2","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ONO-2333POU007","June 2007","April 2008","June 2008","August 10, 2007",,"December 25, 2013","Ono Pharma Investigtional Site, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00514865"
61,"NCT00463242","A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Drug: Agomelatine|Drug: paroxetine|Drug: placebo","Change from Baseline to Week 8 on the total score Hamilton Depression Rating Scale|To demonstrate less sexual dysfunction in patients with MDD receiving agomelatine compared to paroxetine, as measured by the change from baseline to Week 8 on the total score of the Arizona Sexual Experience Scale (ASEX).|Proportion of patients who demonstrate clinical improvement where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale at Week 8.|Proportion of patients with MDD who achieve remission,|Change from baseline to Week 8 on the total score and Anxiety subscale of the Hospital Anxiety and Depression Scale (HAD).","Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAGO178A2303","March 2007","June 2008",,"April 20, 2007",,"December 23, 2020","Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, National City, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Pasadena, California, United States|Novartis Investigative Site, Pico Rivera, California, United States|Novartis Investigative Site, Redlands, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Winter Park, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Fall River, Massachusetts, United States|Novartis Investigative Site, Okemos, Michigan, United States|Novartis Investigative Site, Saint Charles, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Willingboro, New Jersey, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Corvallis, Oregon, United States|Novartis Investigative Site, Erie, Pennsylvania, United States|Novartis Investigative Site, Media, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Friendswood, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Herndon, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Bellevue, Washington, United States|Novartis Investigative Site, Waukesha, Wisconsin, United States|Novartis Investigative Site, Hato Rey, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00463242"
62,"NCT01446692","Badalona Major Depressive Disorder Database Study",,"Completed","No Results Available","Major Depressive Disorder",,"Description of the antidepressant strategies switches|Health care resource utilization|Health care costs|Hamilton Depression Rating Scale|Medication possession rate to evaluate adherence|Referral to psychiatrist office","AstraZeneca","All","18 Years and older   (Adult, Older Adult)",,"2260","Industry","Observational","Time Perspective: Retrospective","NIS-NES-XXX-2011/2","November 2011",,"January 2012","October 5, 2011",,"January 12, 2012","Research Site, Badalona, Spain",,"https://ClinicalTrials.gov/show/NCT01446692"
63,"NCT02934334","Wellness Monitoring for Major Depressive Disorder","CBN-Well","Completed","No Results Available","Major Depressive Disorder","Other: Observational","Rate of MDD Patients with Near Term Relapse","Sidney Kennedy|University Health Network, Toronto","All","18 Years to 65 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","REB 15-9780-AE","May 31, 2016","January 14, 2019","February 25, 2019","October 14, 2016",,"November 4, 2020","University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|McMaster University, Hamilton, Ontario, Canada|Queen's University, Kingston, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02934334"
64,"NCT02476058","A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: JNJ-42847922|Drug: Diphenhydramine|Drug: Placebo","Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Participants Leeds Sleep Evaluation Questionnaire (LSEQ) Score|Computerized Cognitive Test Battery: ISLT (Verbal Learning and Memory) Test|Computerized Cognitive Test Battery: Detection (DET) Test|Computerized Cognitive Test Battery: Identification (IDN) Test|Computerized Cognitive Test Battery: One Back (OBK) Test|Computerized Cognitive Test Battery: Groton Maze Learning Test (GMLT)|Polysomnography (PSG) Objective Assessment of Latency To Persistent Sleep|Subjective Assessment of Latency To Persistent Sleep|PSG Objective Assessment of Total Sleep Time|Subjective Assessment of Total Sleep Time|PSG Objective Assessment of Wake Time After Sleep Onset (WASO)|Subjective Assessment of Wake Time After Sleep Onset (WASO)|Inventory of Depressive Symptomatology-clinician Rated 30 (IDSC30) Score and Structured Interview Guide for Hamilton Depression Scale (SIGH-D) (as combined SIGHD-IDS)|Quick Inventory of Depressive Symptoms-16 (QIDS-SR16) Score|Ruminative Response Scale (RRS) Score|Changes in Major Depressive Disorder (MDD)-related Biomarkers|Plasma concentrations for JNJ-42847922","Janssen-Cilag International NV","All","18 Years to 64 Years   (Adult)","Phase 1","109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CR107002|42847922MDD1001|2014-005182-75","June 11, 2015","January 4, 2016","January 4, 2016","June 19, 2015",,"April 4, 2017","Aalst, Belgium|Brussel, Belgium|Duffel, Belgium|Berlin, Germany|Hamburg, Germany|Schwerin, Germany|Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02476058"
65,"NCT01415154","Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: NeuroStar TMS","Examining the proportion of patients maintaining a sustained response throughout a 12 month maintenance treatment phase.|Compare the average time to first reintroduction of TMS between the two maintenance treatment arms.","Neuronetics","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","44-03001-000","August 2011","September 2013","July 2014","August 11, 2011",,"November 13, 2015","Rush University Medical Center, Chicago, Illinois, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Premier Psychiatric Group, L.L.C., Lincoln, Nebraska, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Center for Anxiety and Depression, Mercer Island, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01415154"
66,"NCT03721900","Ketamine for Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: SHX-001 Active low dose|Drug: Placebo|Drug: SHX-001 Active High dose","Pharmacokinetics of SHX-001 (Cmax)|Pharmacokinetics of SHX-001 (Tmax)|Pharmacokinetics of SHX-001 (T1/2)|Anti-depressive effects of SHX-001","Shenox Pharmaceuticals, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SHX-C301","December 28, 2018","June 6, 2019","June 6, 2019","October 26, 2018",,"April 25, 2019","Clinical Research Site, Gaithersburg, Maryland, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03721900"
67,"NCT04799405","Home-based tDCS in Major Depressive Disorder","MoodStim","Recruiting","No Results Available","Major Depressive Disorder","Device: tDCS","Clinical response|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Activities of daily living|Mood depressive symptomatology|Cognitive assessment of global cognition|Cognitive assessment of verbal working memory","Hebrew SeniorLife","All","50 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00044198","September 24, 2020","September 24, 2022","September 24, 2023","March 16, 2021",,"March 16, 2021","Hinda and Arthur Marcus Institute for Aging Research, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04799405"
68,"NCT03193398","BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: BTRX-246040 oral capsule(s)|Drug: Placebo oral capsule(s)","Change in Investigator-administered MADRS Total Score From Baseline BTRX-246040 and Placebo|Change From Baseline in Investigator-administered MADRS-6 Total Score|Change From Baseline in Investigator-administered HADS-A (Hospital Anxiety and Depression Scale - Anxiety Subscale) Score|Change From Baseline in Investigator-administered HADS-D (Hospital Anxiety and Depression Scale - Depression Subscale) Score|Change From Baseline in Investigator-administered Dimensional Anhedonia Rating Scale (DARS)|Change From Baseline in Investigator-administered Snaith-Hamilton Pleasure Scale (SHAPS) Score","BlackThorn Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEP-MDD-201","June 12, 2017","November 12, 2018","December 12, 2018","June 20, 2017","May 11, 2021","May 11, 2021","United States, Cerritos, California, United States|United States, Garden Grove, California, United States|United States, Florida, Jacksonville, Florida, United States|United States, Lauderhill, Florida, United States|United States, Florida, Orlando, Florida, United States|United States, Libertyville, Illinois, United States|United States, Rochester, New York, United States|United States, Memphis, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03193398/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03193398/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03193398"
69,"NCT00388973","Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Quetiapine","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9.|Change From Baseline in Health-related Quality of Life, Enjoyment and Satisfaction (Q-LES-Q)|Change From Baseline for Satisfaction With Medication From Quality of Life, Enjoyment, Satisfaction Questionaire (Q-LES-Q)|Change From Baseline in Anxiety Symptoms Measured by Hamilton Anxiety 14 Item Scale (HAM-A)|Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index|Change From Baseline in Suicidal Thoughts as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Item 10|Change From Baseline in Somatic Symptoms Cluster From the Hamilton Anxiety Scale (HAM-A)|Tolerability as Measured by Adverse Event Withdrawals During Treatment","AstraZeneca","All","66 Years and older   (Older Adult)","Phase 3","338","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00014|EUDRACT No: 2006-001196-38","September 2006","December 2007","December 2007","October 17, 2006","April 1, 2010","April 1, 2010","Research Site, Birmingham, Alabama, United States|Research Site, San Diego, California, United States|Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Roswell, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Brooklyn, New York, United States|Research Site, Eugene, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, City Bell, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Viljandi, Estonia|Research Site, Helsinki, Finland|Research Site, Jarvenpaa, Finland|Research Site, Kuopio, Finland|Research Site, Salo, Finland|Research Site, Seinajoki, Finland|Research Site, Tampere, Finland|Research Site, Arkhangelsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, St.-petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Glevakha, Kiev Region, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Odessa, Ukraine|Research Site, Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00388973"
70,"NCT04216095","Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: Electroconvulsive Therapy (n=30)|Device: Magnetic Seizure Therapy (n=30)","Time to reorientation (TRO)|Depression Scale|Wechsler Memory Scale - Revised:|Wisconsin Card Sorting Test|Brain Single Photon Emission Computed Tomography (SPECT)","Tanta University|Nagy A. Youssef (Consultant on the MST technique)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","025","June 7, 2013","October 7, 2015","October 7, 2015","January 2, 2020",,"January 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04216095"
71,"NCT02067793","Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: NRX-1074 1 mg|Drug: Placebo|Drug: NRX-1074 5 mg|Drug: NRX-1074 10 mg","To evaluate the mean change from baseline in Hamilton Depression Rating Scale 17 (HDRS-17) score for each NRX-1074 dose group versus the placebo group's mean change|Change in Brief Psychiatric Rating Scale positive symptoms (BPRS+) scale|Change in Clinician Administered Dissociative States Scale (CADSS)|Change in Columbia-Suicide Severity Rating Scale (C-SSRS)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX1074-C-201","March 2014","February 2015","February 2015","February 20, 2014",,"March 17, 2016","Pacific Research Partners, Oakland, California, United States|Psychiatric Medicine Associates, Skokie, Illinois, United States|University of Kansas School of Medicine Clinical Trial Unit, Wichita, Kansas, United States|Boston Clinical Trials, Inc., Roslindale, Massachusetts, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|Mount Sinai School of Medicine, Elmsford, New York, United States|New York State Psychiatric Institute, New York, New York, United States|Lindner Center of HOPE, Mason, Ohio, United States|Research Strategies Memphis, Memphis, Tennessee, United States|Research Across America, Dallas, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02067793"
72,"NCT03610048","A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)",,"Terminated","Has Results","Refractory Major Depressive Disorder","Drug: ALKS 5461","Number of Subjects With Treatment-emergent Adverse Events (TEAEs)","Alkermes, Inc.","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 3","175","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALK5461-218","August 9, 2018","May 1, 2020","May 1, 2020","August 1, 2018","July 16, 2021","July 16, 2021","Alkermes Investigational Site, Tucson, Arizona, United States|Alkermes Investigational Site, Little Rock, Arkansas, United States|Alkermes Investigational Site, Los Alamitos, California, United States|Alkermes Investigational Site, Oceanside, California, United States|Alkermes Investigational Site, Pico Rivera, California, United States|Alkermes Investigational Site, Redlands, California, United States|Alkermes Investigational Site, Santa Ana, California, United States|Alkermes Investigational Site, Sherman Oaks, California, United States|Alkermes Investigational Site, Temecula, California, United States|Alkermes Investigational Site, Hollywood, Florida, United States|Alkermes Investigational Site, Jacksonville, Florida, United States|Alkermes Investigational Site, Lauderhill, Florida, United States|Alkermes Investigational Site, Orlando, Florida, United States|Alkermes Investigational Site, Palm Bay, Florida, United States|Alkermes Investigational Site, Atlanta, Georgia, United States|Alkermes Investigational Site, Decatur, Georgia, United States|Alkermes Investigational Site, Pikesville, Maryland, United States|Alkermes Investigational Site, O'Fallon, Missouri, United States|Alkermes Investigational Site, Jamaica, New York, United States|Alkermes Investigational Site, Mount Kisco, New York, United States|Alkermes Investigational Site, Canton, Ohio, United States|Alkermes Investigational Site, Cincinnati, Ohio, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Allentown, Pennsylvania, United States|Alkermes Investigational Site, Memphis, Tennessee, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, DeSoto, Texas, United States|Alkermes Investigational Site, Woodstock, Vermont, United States|Alkermes Investigational Site, Bellevue, Washington, United States|Alkermes Investigational Site, Frankston, Victoria, Australia|Alkermes Investigational Site, Noble Park, Victoria, Australia|Alkermes Investigational Site, Richmond, Victoria, Australia|Alkermes Investigational Site, San Juan, Puerto Rico|Alkermes Investigational Site, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03610048/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03610048/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03610048"
73,"NCT02695472","Study of NSI-189 for Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: 80 Milligrams NSI-189|Drug: Placebo|Drug: 40 Milligrams NSI-189","Montgomery-Asberg Depression Rating Scale (MADRS)|Symptoms of Depression Questionnaire (SDQ)|The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH CPFQ)|17-item Hamilton Rating Scale for Depression (HAMD17)|Clinical Global Impressions - Severity and Improvement (CGI-S, CGI-I)|Cogstate Brief Battery|CogScreen","Neuralstem Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NS2014-1","March 2016","June 2017","December 2017","March 1, 2016",,"February 24, 2017","Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Synergy San Diego, National City, California, United States|Clinical Trials of the Rockies, Denver, Colorado, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Psychiatric Medicine Associates, LLC, Skokie, Illinois, United States|St. Louis Clinical Trials, LC, St. Louis, Missouri, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Midwest Clinical Research Center, LLC, Dayton, Ohio, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02695472"
74,"NCT00668525","Escitalopram in Adult Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo","Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.|Change From Baseline in Hamiltion Rating Scale for Depression (HAM-D) at Week 8","Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","877","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SCT-MD-49","April 2008","February 2009",,"April 29, 2008","May 6, 2010","May 11, 2010","Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Arcadia, California, United States|Forest Investigative Site, Encino, California, United States|Forest Investigative Site, Garden Grove, California, United States|Forest Investigative Site, Irvine, California, United States|Forest Investigative Site, Los Alamitos, California, United States|Forest Investigative Site, Denver, Colorado, United States|Forest Investigative Site, Washington, District of Columbia, United States|Forest Investigative Site, Bradenton, Florida, United States|Forest Investigative Site, Jacksonville, Florida, United States|Forest Investigative Site, Orlando, Florida, United States|Forest Investigative Site, West Palm Beach, Florida, United States|Forest Investigative Site, Atlanta, Georgia, United States|Forest Investigative Site, Newton, Kansas, United States|Forest Investigative Site, Overland, Kansas, United States|Forest Investigative Site, Baltimore, Maryland, United States|Forest Investigative Site, Glen Burnie, Maryland, United States|Forest Investigative Site, Rockville, Maryland, United States|Forest Investigative Site, Okemos, Michigan, United States|Forest Investigative Site, St. Louis, Missouri, United States|Forest Investigative Site, Omaha, Nebraska, United States|Forest Investigative Site, Omaha, Nebraska, United States|Forest Investigative Site, Cherry Hill, New Jersey, United States|Forest Investigative Site, Clementon, New Jersey, United States|Forest Investigative Site, Bronx, New York, United States|Forest Investigative Site, Brooklyn, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, Staten Island, New York, United States|Forest Investigative Site, Canton, Ohio, United States|Forest Investigative Site, Dayton, Ohio, United States|Forest Investigative Site, Portland, Oregon, United States|Forest Investigative Site, Media, Pennsylvania, United States|Forest Investigative Site, Philadelphia, Pennsylvania, United States|Forest Investigative Site, Charleston, South Carolina, United States|Forest Investigative Site, Memphis, Tennessee, United States|Forest Investigative Site, Memphis, Tennessee, United States|Forest Investigative Site, Austin, Texas, United States|Forest Investigative Site, Houston, Texas, United States|Forest Investigative Site, San Antonio, Texas, United States|Forest Investigative Site, Salt Lake City, Utah, United States|Forest Investigative Site, Woodstock, Vermont, United States|Forest Investigative Site, Richmond, Virginia, United States|Forest Investigative Site, Bellevue, Washington, United States|Forest Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00668525"
75,"NCT00351169","Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","AMBER","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine SR|Drug: Escitalopram","To evaluate the efficacy of quetiapine SR compared with placebo in the treatment of patients with major depressive disorder (MDD) as assessed by change from randomisation to week 8 score in the MADRS total score.|If quetiapine SR improves health-related quality of life of patients with MDD, compared to placebo","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00004|AMBER|EUDRACT No: 2005-005052-40","May 2006",,"June 2007","July 12, 2006",,"December 22, 2008","Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Ha Erbing, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Wu Han, China|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Seoul, Korea, Republic of|Research Site, Johor Bahru, Malaysia|Research Site, Perak, Malaysia|Research Site, Petaling Jaya, Malaysia|Research Site, Aguascalientes, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Guadalajara, Mexico|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Krugersdorp, South Africa|Research Site, Sama de Langreo, Spain|Research Site, Vigo, Spain|Research Site, Zamora, Spain",,"https://ClinicalTrials.gov/show/NCT00351169"
76,"NCT04768361","Behavioral Activation for Major Depression With and Without Mindfulness",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Behavioral: Behavioral Activation without Mindfulness|Behavioral: Behavioral Activation with Mindfulness","Depressive symptoms|Behavioral Activation|Automatic Thought Questionnarie (ATQ)|Daily Activity Record (RAD)","Hospital Miguel Servet","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","BA11.2019","August 10, 2020","September 9, 2020","May 30, 2021","February 24, 2021",,"February 24, 2021","Department of Psychiatry. Miguel Servet University Hospital, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT04768361"
77,"NCT04751331","Neural Response to Inflammatory Challenge in Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Biological: LPS|Biological: Saline","Inflammatory response|Neural response to interoceptive vs exteroceptive stimuli (interoceptive awareness task)|Symptoms of anhedonia","Laureate Institute for Brain Research, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2020-004-00","May 15, 2021","April 30, 2026","April 30, 2027","February 12, 2021",,"June 10, 2021","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04751331"
78,"NCT01254305","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.|Drug: Placebo","Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score|Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score|Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward","Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-06","April 2011","July 2012","July 2012","December 6, 2010","August 6, 2014","August 6, 2014","Forest Investigative Site 010, Birmingham, Alabama, United States|Forest Investigative Site 002, Little Rock, Arkansas, United States|Forest Investigative Site 001, Cerritos, California, United States|Forest Investigative Site 014, Fort Myers, Florida, United States|Forest Investigative Site 006, Jacksonville, Florida, United States|Forest Investigative Site 017, Orange City, Florida, United States|Forest Investigative Site 005, Orlando, Florida, United States|Forest Investigative Site 012, Tampa, Florida, United States|Forest Investigative Site 009, Atlanta, Georgia, United States|Forest Investigative Site 016, Joliet, Illinois, United States|Forest Investigative Site 004, New Orleans, Louisiana, United States|Forest Investigative Site 022, Boston, Massachusetts, United States|Forest Investigative Site 011, Bronx, New York, United States|Forest Investigative Site 015, Cedarhurst, New York, United States|Forest Investigative Site 003, Cincinnati, Ohio, United States|Forest Investigative Site 013, Dayton, Ohio, United States|Forest Investigative Site 020, Lincoln, Rhode Island, United States|Forest Investigative Site 018, Memphis, Tennessee, United States|Forest Investigative Site 008, Dallas, Texas, United States|Forest Investigative Site 007, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01254305"
79,"NCT00351910","Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","ONYX","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine|Drug: Amitriptyline|Drug: Bupropion|Drug: Citalopram|Drug: Duloxetine|Drug: Escitalopram|Drug: Fluoxetine|Drug: Paroxetine|Drug: Sertraline|Drug: Venlafaxine","To evaluate the efficacy of quetiapine fumarate sustained release|(Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.|If quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1448C00007|ONYX|EUDRACT No: 2005-0055053-22","May 2006",,"April 2007","July 13, 2006",,"January 26, 2011","Research Site, Everton Park, Queensland, Australia|Research Site, Southport, Queensland, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Brisbane, Australia|Research Site, Assebroek, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Liege, Belgium|Research Site, Mechelen, Belgium|Research Site, Tielt, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-claire, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Havirov, Czech Republic|Research Site, Havlickuv Brod, Czech Republic|Research Site, Nove Mesto nad Metuji, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Helsinki, Finland|Research Site, Jarvenpaa, Finland|Research Site, Salo, Finland|Research Site, Turku, Finland|Research Site, Angouleme, France|Research Site, Arcachon, France|Research Site, Caen, France|Research Site, Chateau Gontier, France|Research Site, Elancourt, France|Research Site, Le Pecq, France|Research Site, Nimes, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Toulouse, France|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Koln, Germany|Research Site, Munster, Germany|Research Site, Bergen, Norway|Research Site, Flekkefjord, Norway|Research Site, Fyllingsdalen, Norway|Research Site, Hamar, Norway|Research Site, Lysaker, Norway|Research Site, Oslo, Norway|Research Site, Skien, Norway|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Nowy Targ, Poland|Research Site, Szczecin, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Bucharest, Romania|Research Site, Pitesti, Romania|Research Site, Pretoria, Gauteng, South Africa|Research Site, Durban, Kwazulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Falkoping, Sweden|Research Site, Göteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Malmo, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Trollhattan, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00351910"
80,"NCT02869035","Treatment Outcome in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Duloxetine","Binary treatment outcome in terms of remission from depression.|Baseline cerebral 5-HT4R binding as imaged by 11C-SB207145 PET.|Changes from baseline in cerebral 5-HT4R binding as imaged by 11C-SB207145 PET|Baseline hippocampus volume|Changes from baseline in hippocampus volume.|Baseline fMRI BOLD response to an emotional faces paradigm|Changes from baseline in fMRI BOLD response to an emotional faces paradigm|Baseline fMRI BOLD response to reward paradigm.|Changes from baseline in fMRI BOLD response to reward paradigm|Baseline rsfMRI based spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)|Changes from baseline in rsfMRI spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)|Sexual function in depression|Changes in sexual function|Baseline EEG including event related potentials (ERP)|Changes in EEG including event related potentials (ERP)|Cortisol awakening response|Changes in cortisol awakening response (HPA-axis dynamics)|Systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Changes in systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine|Changes in systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine|Early life Stress|Performance on Verbal Affective Memory Tasks (VAMT-26).|Performance on Moral Judgement Task|Performance on Letter-Number Sequence Task.|Changes from baseline in HAMD-6 score|HAMD-6 score after 8 and 12 weeks of antidepressant treatment|Regional 5-HT4R binding|Sexual side-effects from antidepressant treatment|Baseline latent variable construct of self-reported mental state|Baseline self reported family history of mood disorders|Changes from baseline in self-reported mental state questionnaire-based latent variable construct|Total daily cortisol output|Changes in total daily cortisol output|Parental bonding quality|5-HTTLPR genotype status|Epigenetic FK506-binding protein 51 (FKBP5) status at baseline|Changes in epigenetic FKBP5 status from baseline|Epigenetic 5-HTTLPR status at baseline|Changes in epigenetic 5-HTTLPR status from baseline|Epigenetic spindle and kinetochore associated complex subunit 2 (SKA2) status at baseline|Changes in epigenetic SKA2 status from baseline|Performance on Face and Eyes Emotion Recognition Task|Performance on Intensity Morphing Task|Performance on Social Information Preference Task|Performance on Simple Reaction Time.","Rigshospitalet, Denmark|Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak|Psychiatric Centre Copenhagen|Central Visitation, Region Hovedstaden","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NP1","August 2016","July 2019","July 2019","August 16, 2016",,"October 16, 2019","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02869035"
81,"NCT04593537","Action Tendencies and Prognosis in Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Other: No intervention","Self-rated Quick Inventory of Depressive Symptomatology -16|General Anxiety Disorder-7|Maudsley-Modified Patient Health Questionniare -9","King's College London|Scients Institute, USA","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VR_depression_study","June 1, 2020","September 30, 2023","September 30, 2023","October 20, 2020",,"November 3, 2020","King's College London, IoPPN, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04593537"
82,"NCT03787290","Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Tocilizumab|Drug: Placebo|Device: Whole-Body Hyperthermia","Inventory of Depressive Symptomatology Self-Report (IDS-SR)","Massachusetts General Hospital|heckel medizintechnik GmbH","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020P002424","September 1, 2021","July 1, 2023","July 1, 2023","December 26, 2018",,"June 14, 2021",,,"https://ClinicalTrials.gov/show/NCT03787290"
83,"NCT00105196","A Study of Aripiprazole in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Aripiprazole+ ADT|Drug: Placebo+ ADT","Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)|Mean Change in Sheehan Disability Scale (SDS) Mean Score|Mean Change in SDS Item Score (Social Life)|Mean Change in SDS Item Score (Family Life)|Mean Change in SDS Item Score (Work/School)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","349","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","CN138-165","March 2005","March 2008","March 2008","March 10, 2005","May 18, 2009","December 2, 2013","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|George Washington University Medical Center, Washington, District of Columbia, United States|Cns Clinical Research Group, Coral Springs, Florida, United States|Medical College Of Georgia, Augusta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Uptown Research Institute, Llc, Chicago, Illinois, United States|Cunningham Clinical Research, Llc, Edwardsville, Illinois, United States|Comprehensive Neuroscience, Inc., Hoffman Estates, Illinois, United States|Vine Street Clinical Research Center, Springfield, Illinois, United States|Clinical Research Institute, Witchita, Kansas, United States|Lsu Health Sciences Center, New Orleans, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Summit Research Network, Farmington Hills, Michigan, United States|Summit Research Network, Flint, Michigan, United States|University Of Minnesota, Minneapolis, Minnesota, United States|Regions Hospital, St. Paul, Minnesota, United States|Radiant Research Las Vegas, Las Vegas, Nevada, United States|Behavioral Health Center, Charlotte, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Phebe Tucker, Md, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Southeast Health Consultants, Charleston, South Carolina, United States|Usc School Of Medicine, Columbia, South Carolina, United States|Community Clinical Research, Inc., Austin, Texas, United States|Radiant Research, Slc, Salt Lake City, Utah, United States|University Of Utah School Of Medicine, Salt Lake City, Utah, United States|University Of Virginia, Charlottesville, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00105196"
84,"NCT00278941","Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder","AMETHYST","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine Fumarate Sustained Release","To evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to a depressed event in patients with Major Depressive Disorder (MDD)|Evaluate quetiapine SR compared to placebo on health related quality of life.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","3000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00005|Amethyst","December 2005",,"August 2007","January 19, 2006",,"March 25, 2009","Research Site, Birmingham, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Cerritos, California, United States|Research Site, Costa Mesa, California, United States|Research Site, El Centro, California, United States|Research Site, Fresno, California, United States|Research Site, La Mesa, California, United States|Research Site, Los Angeles, California, United States|Research Site, Oceanside, California, United States|Research Site, Pasadena, California, United States|Research Site, Pico Rivera, California, United States|Research Site, Redlands, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Stanford, California, United States|Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Vista, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Pueblo, Colorado, United States|Research Site, Cromwell, Connecticut, United States|Research Site, Farmington, Connecticut, United States|Research Site, Middletown, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersberg, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, W Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Sandy Springs, Georgia, United States|Research Site, Coeur D'Alene, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Granite City, Illinois, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Libertyville, Illinois, United States|Research Site, Northfield, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Terre Haute, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Topeka, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Clinton Twp, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Portage, Michigan, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Flowood, Mississippi, United States|Research Site, Ridgeland, Mississippi, United States|Research Site, St Peters, Missouri, United States|Research Site, St. Charles, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Kenilworth, New Jersey, United States|Research Site, Princeton, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Cedarhurst, New York, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Olean, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Chagrin Falls, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Bala Cynwyd, Pennsylvania, United States|Research Site, Coatesville, Pennsylvania, United States|Research Site, Havertown, Pennsylvania, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Media, Pennsylvania, United States|Research Site, Moon Township, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Reading, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Desoto, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lake Jackson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Woodstock, Vermont, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Vratza, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Miramichi, New Brunswick, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Rio Predia, Puerto Rico|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Moscow, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Piestany, Slovakia|Research Site, Presov, Slovakia|Research Site, Sered, Slovakia|Research Site, Trencin, Slovakia|Research Site, Ayrshire, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Reading, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00278941"
85,"NCT03181529","Effects of Psilocybin in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Psilocybin","GRID-HAMD","Johns Hopkins University","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00101821","August 10, 2017","December 2, 2020","December 2, 2020","June 8, 2017",,"December 11, 2020","Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03181529"
86,"NCT00810069","Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine Hydrochloride|Drug: Escitalopram","Time to Confirmed Response by ≥ 50% Change From Baseline Reduction in the Hamilton Depression Rating Scale-17 Items (HAMD-17)|Estimated Probability of Not Reaching Confirmed Response at 12 Weeks Based on the Survival Function for the Time to Confirmed Response|Time to Confirmed Remission by a Hamilton Depression Rating Scale-17 Items (HAMD-17) Score of ≤ 7 That is Maintained for Two Consecutive Visits|Estimated Probability of Not Reaching Confirmed Remission at 12 Weeks Based on the Survival Function for the Time to Confirmed Remission|Time to Confirmed Response as Defined by ≥ 50% Reduction From Baseline Reduction in the 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) That is Reported for Two Consecutive Visits|Time to Confirmed Remission as Defined by a 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) Score of ≤ 5 That is Maintained for Two Consecutive Visits.|Clinical Global Impressions of Severity (CGI-S) Scale|Visual Analog Scale (VAS) - Overall Pain Severity|Euro Quality of Life Questionnaire-5 Dimensions (EQ-5D) Scale - Health State Score|Euro Quality of Life Questionnaire-5 Dimensions (EQ-5D) Scale - United Kingdom (UK) Population Based Index Score|Sheehan Disability Scale (SDS) Normal Functioning Total Score|Resource Utilisation - Number of Hours Worked Per Week|Resource Utilisation - Number of Work Hours Missed in the Last 4 Weeks|Resource Utilisation - Number of Work Hours Missed Due to Depression in the Last 4 Weeks|Resource Utilisation - Number of Visits to Primary Healthcare Provider Due to Depression in the Last 4 Weeks|Resource Utilisation - Number of Visits to Other Specialists Due to Depression in the Last 4 Weeks|Resource Utilisation - Has the Participant Been Hospitalized Due to Depression in the Last 4 Weeks - Number of Participants With a Yes Response|Number of Participants With Adverse Events (AEs)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","840","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12329|F1J-EW-HMGD","November 2008","February 2010","March 2010","December 17, 2008","June 21, 2011","June 21, 2011","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Copenhagen, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Angouleme, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Arcachon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Dole, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Gujan Mestras, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nimes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Orvault, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Haidari, Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tripoli, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Balassagyarmat, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chieti, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Foggia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Modena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Siena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Teramo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Terracina, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beek En Donk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brummen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brunssum, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Deurne, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Heerde, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Constanta, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Timisoara, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ljubljana, Slovenia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Alcala De Henares, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ferrol, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Foios, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Palma De Mallorca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Salamanca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Vigo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Zamora, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Zaragoza, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Göteborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Halmstad, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lulea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sundsvall, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Antakya, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Capa, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Diskapi, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sisli, Turkey",,"https://ClinicalTrials.gov/show/NCT00810069"
87,"NCT03228953","Pharmacogenomic Testing in Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Other: Pharmacogenomic testing","Score on the Hamilton Rating Scale for Depression (HAMD-17)|Score on Subject-Rated 16-item Quick Inventory of Depression Symptomatology Scales (QIDS-SR)|Score on the 9-item Patient Health Questionnaire (PHQ-9)","Columbia University","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","AAAR4283","August 2017","May 15, 2021","May 15, 2021","July 25, 2017",,"August 4, 2017","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03228953"
88,"NCT01052077","Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder","STEP-D222","Completed","Has Results","Major Depressive Disorder","Drug: OPC-34712|Drug: Placebo|Drug: ADT","Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.|Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.|Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Trial Week Visit in Phase B.|Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression- Severity Illness Scale (CGI-S) Score.|Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.|Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.|Clinical Global Impression- Improvement Scale (CGI-I) Score by Study Week in Phase B Relative to End of Phase A.|Number of Participants With MADRS Response During Phase B Relative to the End of Phase A (Week 8) Visit.|Number of Participants With MADRS Remission During Phase B Relative to the End of Phase A (Week 8) Visit.|Number of Participants With CGI-Improvement Response During Phase B Relative to the End of Phase A (Week 8).","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","773","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","331-09-222","March 2010","October 2011","November 2011","January 20, 2010","November 1, 2015","November 1, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Pacific Clinical Research Medical Group, Arcadia, California, United States|Southwestern Research, Beverly Hills, California, United States|Excell Research, Oceanside, California, United States|Affiliated Research Institute, San Diego, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|CNS Clinical Research Group, Coral Springs, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Clinical InSights, Glen Burnie, Maryland, United States|Pharmasite Research, Inc., Pikesville, Maryland, United States|MSU/Institute for Health Studies, East Lansing, Michigan, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Medical & Behavioral Health Research, PC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Northcoast Clinical Trials, Beachwood, Ohio, United States|Patient Priority Clinical sites, LLC, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon), LLC, Portland, Oregon, United States|City Line Avenue Family Practice, Bala Cynwyd, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Clinical NeuroScience Solutions, Inc., Memphis, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Radiant Research, Salt Lake City, Utah, United States|Psychiatric Alliance of The Blue Ridge, Charlottesville, Virginia, United States|NeuroScience, Inc., Herndon, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle), LLC, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01052077"
89,"NCT00854100","Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Antidepressant + placebo|Drug: Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant + cariprazine (1-2 mg/d)","Montgomery-Asberg Depression Rating Scale (MADRS)|Clinical Global Impression - Improvement (CGI-I)","Forest Laboratories|Gedeon Richter Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","231","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RGH-MD-71","June 30, 2009","December 6, 2010","December 6, 2010","March 2, 2009","March 5, 2019","March 5, 2019","Forest Investigative Site 040, Phoenix, Arizona, United States|Forest Investigative Site 038, Scottsdale, Arizona, United States|Forest Investigative Site, Arcadia, California, United States|Forest Investigative Site, Encino, California, United States|Forest Investigative Site, Garden Grove, California, United States|Forest Investigative Site, Irvine, California, United States|Forest Investigative Site 013, Los Alamitos, California, United States|Forest Investigative Site 041, National City, California, United States|Forest Investigative Site, Oceanside, California, United States|Forest Investigative Site 025, Denver, Colorado, United States|Forest Investigative Site, Norwich, Connecticut, United States|Forest Investigative Site, Washington, District of Columbia, United States|Forest Investigative Site 007, Jacksonville, Florida, United States|Forest Investigative Site 012, West Palm Beach, Florida, United States|Forest Investigative Site 033, Atlanta, Georgia, United States|Forest Investigative Site, Roswell, Georgia, United States|Forest Investigative Site, Overland Park, Kansas, United States|Forest Investigative Site 042, Fall River, Massachusetts, United States|Forest Investigative Site 034, Pittsfield, Massachusetts, United States|Forest Investigative Site, Omaha, Nebraska, United States|Forest Investigative Site, Cherry Hill, New Jersey, United States|Forest Investigative Site 001, Bronx, New York, United States|Forest Investigative Site 043, Brooklyn, New York, United States|Forest Investigative Site 020, Mount Kisco, New York, United States|Forest Investigative Site 039, New York, New York, United States|Forest Investigative Site 029, New York, New York, United States|Forest Investigative Site 032, Raleigh, North Carolina, United States|Forest Investigative Site, Canton, Ohio, United States|Forest Investigative Site, Dayton, Ohio, United States|Forest Investigative Site 015, Portland, Oregon, United States|Forest Investigative Site 006, Media, Pennsylvania, United States|Forest Investigative Site, Philadelphia, Pennsylvania, United States|Forest Investigative Site, Philadelphia, Pennsylvania, United States|Forest Investigative Site 023, Memphis, Tennessee, United States|Forest Investigative Site 031, Memphis, Tennessee, United States|Forest Investigative Site, Nashville, Tennessee, United States|Forest Investigative Site, San Antonio, Texas, United States|Forest Investigative Site, Woodstock, Vermont, United States|Forest Investigative Site, Richmond, Virginia, United States|Forest Investigative Site, Bellevue, Washington, United States|Forest Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00854100"
90,"NCT01273376","Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder","MDD","Completed","No Results Available","Major Depressive Disorder","Drug: RX-10100","Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS)at week 9|Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at weeks 3, 5, and 7","Rexahn Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2010MDD01","December 2010","September 2011","October 2011","January 10, 2011",,"November 19, 2013","Rexahn Investigative Site, Cerritos, California, United States|Rexahn Investigative Site, Escondido, California, United States|Rexahn Investigative Site, Los Angeles, California, United States|Rexahn Investigative Site, National City, California, United States|Rexahn Investigative Site, Oceanside, California, United States|Rexahn Investigative Site, Orange, California, United States|Rexahn Investigative Site, San Diego, California, United States|Rexahn Investigative Site, Denver, Colorado, United States|Rexahn Investigative Site, Brooksville, Florida, United States|Rexahn Investigative Site, Gainesville, Florida, United States|Rexahn Investigative Site, Jacksonville, Florida, United States|Rexahn Investigative Site, Miami Beach, Florida, United States|Rexahn Investigative Site, Orlando, Florida, United States|Rexahn Investigative Site, St. Petersburg, Florida, United States|Rexahn Investigative Site, Tampa, Florida, United States|Rexahn Investigative Site -2, Atlanta, Georgia, United States|Rexahn Investigative Site, Atlanta, Georgia, United States|Rexahn Investigative Site, Oak Brook, Illinois, United States|Rexahn Investigative Site, Vernon Hills, Illinois, United States|Rexahn Investigative Site, Owensboro, Kentucky, United States|Rexahn Investigative Site, Novi, Michigan, United States|Rexahn Investigative Site, Las Vegas, Nevada, United States|Rexahn Investigative site, Cherry Hill, New Jersey, United States|Rexahn Investigative Site, Albuquerque, New Mexico, United States|Rexahn Investigative Site, Fresh Meadows, New York, United States|Rexahn Investigative Site, New York City, New York, United States|Rexahn Investigative Site, Cincinnati, Ohio, United States|Rexahn Investigative site, Garfield Heights, Ohio, United States|Rexahn Investigative Site, Oklahoma City, Oklahoma, United States|Rexahn Investigative site, Allentown, Pennsylvania, United States|Rexahn Investigative Site, Media, Pennsylvania, United States|Rexahn Investigative Site, Scranton, Pennsylvania, United States|Rexahn Investigative Site, Anderson, South Carolina, United States|Rexahn Investigative Site, Memphis, Tennessee, United States|Rexahn Investigative Site, Austin, Texas, United States|Rexahn Investigative site, Dallas, Texas, United States|Rexahn Investigative Site, Dallas, Texas, United States|Rexahn Investigative Sites, Lake Jackson, Texas, United States|Rexahn Investigative Site, San Antonio, Texas, United States|Rexahn Investigative Site, The Woodlands, Texas, United States|Rexahn Investigative Site, Orem, Utah, United States|Rexahn Investigative Site, Richmond, Virginia, United States|Rexahn Investigative Site (2), Bellevue, Washington, United States|Rexahn Investigative Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01273376"
91,"NCT04874077","Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder",,"Sensitivity and specificity of the Kintsugi's technology's prediction|Sensitivity and specificity to depression at the PHQ-9 score of 10|Sensitivity and specificity to depression at the GAD-7 score of 10","Kintsugi Mindful Wellness, Inc.|San Francisco Psychiatry Group|Frontier Psychiatry","All","18 Years to 100 Years   (Adult, Older Adult)",,"225","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2021/03/20","April 21, 2021","June 21, 2021","July 21, 2021","May 5, 2021",,"May 7, 2021","San Francisco Psychiatrists, Inc., San Francisco, California, United States|Frontier Psychiatry, Billings, Montana, United States",,"https://ClinicalTrials.gov/show/NCT04874077"
92,"NCT04594616","Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Device: Smartphone-delivered CBT for MDD","Difference in MDD severity (SIGH-D) at the end of treatment/waitlist period.|Difference in functional impairment at the end of treatment/waitlist period|Difference in quality of life at the end of treatment/waitlist period: Q-LES-Q-SF","Koa Health B.V.|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","112","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P001670","September 1, 2021","September 1, 2022","December 1, 2022","October 20, 2020",,"October 20, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04594616"
93,"NCT01699490","Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Fluoxetine + Valsartan|Drug: Fluoxetine + Placebo","Hamilton Depression Rating Scale (HDRS)|fasting plasma glucose|fasting serum insulin|C-reactive Protein, and IL-6","National Cheng-Kung University Hospital|National Science Council, Taiwan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NSC 101-2314-B-006 -064 -MY3","August 2012","July 2015","July 2015","October 3, 2012",,"September 29, 2014","Department of Psychiatry, National Cheng-Kung University Hospital, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01699490"
94,"NCT02724735","A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: NSI-189","Primary Objective: Durability of Effect defined as the time until the start of a new antidepressant treatment (ADT)|Montgomery-Asberg Depression Rating Scale (MADRS)|Quick Inventory of Depressive Symptomatology - Self-Rated (QIDS-SR)|Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH CPFQ)|Cogscreen Battery|Symptoms of Depression Questionnaire (SDQ)|Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI)|The Columbia Suicide Severity Rating Scale (C-SSRS)|17-item Hamilton Depression Rating Scale (HAMD17)|Discontinuation rates","Neuralstem Inc.","All","18 Years to 61 Years   (Adult)",,"220","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NS2015-2","August 2016","December 2017","January 2018","March 31, 2016",,"September 21, 2016","Garden Grove, California, United States|National City, California, United States|Denver, Colorado, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Alpharetta, Georgia, United States|St. Louis, Missouri, United States|Staten Island, New York, United States|Dayton, Ohio, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02724735"
95,"NCT01441440","Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: venlafaxine ER 75 mg/day (fixed dose)|Drug: venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Drug: Placebo","Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination|Changes From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or Early Termination|Changes From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 8 or Early Termination|Changes From Baseline in 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score at Week 8 or Early Termination|Changes From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) Total Score at Week 8 or Early Termination|Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 8 or Early Termination","Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer","All","20 Years and older   (Adult, Older Adult)","Phase 3","538","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2411263","November 2011","March 2014","March 2014","September 27, 2011","March 13, 2015","January 28, 2021","Narumi Himawari Clinic, Nagoya, Aichi, Japan|Mizuho Clinic, Nagoya, Aichi, Japan|Nippon Medical School Chiba Hokusoh Hospital, Inzai, Chiba, Japan|Hida Clinic, Nagareyama, Chiba, Japan|Nakamoto Clinic, Noda City, Chiba, Japan|Hatsuki Shinryo Clinic, Fukuoka-city, Fukuoka, Japan|Hatakeyama Clinic, Kitakyushu-shi, Fukuoka, Japan|Oka Clinic, Omuta-city, Fukuoka, Japan|Shiranui Hospital, Omuta, Fukuoka, Japan|Fujikawa Clinic, Hatsukaichi, Hiroshima, Japan|Hayakawa Clinic, Kure, Hiroshima, Japan|Kawamura Mental Clinic, Sapporo, Hokkaido, Japan|Maruyamapark Mentalclinic, Sapporo, Hokkaido, Japan|Arai Clinic, Amagasaki, Hyogo, Japan|Takahashi Psychiatric Clinic, Ashiya, Hyogo, Japan|Tatsuta Clinic, Kobe, Hyogo, Japan|Ikeuchi Psycho Induced Internal Med.Clinic, Kobe, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Medical Corporation Seishinkai Kishiro Mental Clinic, Kawasaki, Kanagawa, Japan|Yutaka Clinic, Sagamihara, Kanagawa, Japan|Azamino Mental Clinic, Yokohama-Shi, Kanagawa, Japan|Shioiri Mental Clinic, Yokosuka city, Kanagawa, Japan|Yuge Hospital, Kumamoto-shi, Kumamoto, Japan|Kuginuki Clinic, Hirakata, Osaka, Japan|Shibamoto Clinic, Osakasayama-shi, Osaka, Japan|Sakai Mental Clinic, Saitama-city, Saitama, Japan|Suzuki Hospital, Adachi-ku, Tokyo, Japan|Iidabashi Mental Clinic, Chiyoda-ku, Tokyo, Japan|Tutujigaoka Mental Clinic, Chofu, Tokyo, Japan|Fuku Clinic, Katsushika-ku, Tokyo, Japan|SAKURAZAKA CLINIC SophyAnce, Minato-ku, Tokyo, Japan|Akasaka Clinic, Minato-ku, Tokyo, Japan|Harikae mental clinic, Nakano-Ku, Tokyo, Japan|Heartcare Ginga Clinic, Nakano-ku, Tokyo, Japan|Sangenjaya Nakamura Mental Clinic, Setagaya-ku, Tokyo, Japan|Komazawa Mental Clinic, Setagaya-ku, Tokyo, Japan|Omotesando Mental Clinic, Shibuya-ku, Tokyo, Japan|Maynds Tower Mental Clinic, Shibuya-ku, Tokyo, Japan|Yoyoginomori Mental Clinic, Shibuyaku, Tokyo, Japan|Meguro sta.East Mental Clinic, Shinagawa-ku, Tokyo, Japan|Himeno Tomomi Clinic, Shinagawa-Ku, Tokyo, Japan|Nishi-Shinjuku Concieria Clinic, Shinjuku-ku, Tokyo, Japan|Tamaki Clinic, Shinjuku-ku, Tokyo, Japan|Kagurazaka Stress Clinic, Shinjuku-ku, Tokyo, Japan|Tokyo Kosei Nenkin Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Himorogi Psychiatric Institute, Toshima-ku, Tokyo, Japan|Sugahara Tenjin Clinic, Fukuoka, Japan|Hiro Mental Clinic Tenjinminami, Fukuoka, Japan|Tenjin Mental Clinic, Fukuoka, Japan|Medical Corporation Shinseikai Kaku Mental Clinic, Fukuoka, Japan|Ange Psychiatric Clinic, Fukuoka, Japan|Stress Care Yoshimura Clinic, Fukuoka, Japan|Kuranari Psychiatry Clinic, Fukuoka, Japan|Akasaka Kato Clinic, Fukuoka, Japan|Imato Clinic, Fukuoka, Japan|Tsuji Mental Clinic, Hiroshima, Japan|Medical Corporation Toyokokai Tawara Clinic, Kanagawa, Japan|Sagaarashiyama-Tanaka Clinic, Kyoto, Japan|Kyo Mental Clinic, Nara, Japan|JIN clinic, Osaka, Japan|Misato Ekimae Clinic, Saitama, Japan|Eto Mental Clinic Meguro, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01441440"
96,"NCT04855760","Open Label Study to Assess the Safety of REL-1017 for Major Depressive Disorder","RELIANCE-OLS","Recruiting","No Results Available","Major Depressive Disorder","Drug: REL-1017","Safety and tolerability of REL-1017 as incidence of treatment emergent adverse events (TEAEs)","Relmada Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REL-1017-310","April 1, 2021","July 2023","July 2023","April 22, 2021",,"April 22, 2021","Relmada Site 117, Watertown, Massachusetts, United States|Relmada Site 122, Marlton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04855760"
97,"NCT04975100","Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Sarcosine and SSRI|Drug: Placebo and SSRI","Change in severity of depressive symptoms from baseline.|Response rate|Remission rate|Severity of symptoms|Change in severity of symptoms|Change in serum Brain Derived Neurotrophic Factor (BDNF) from baseline|Change in serum Glycine from baseline|Incidence of adverse drug reactions","All India Institute of Medical Sciences, Bhubaneswar","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IEC/AIIMSBBSR/PGThesis/21/07","August 1, 2021","April 30, 2023","June 30, 2023","July 23, 2021",,"July 29, 2021","AIIMS, Bhubaneswar, Odisha, India",,"https://ClinicalTrials.gov/show/NCT04975100"
98,"NCT02158546","A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study",,"Completed","Has Results","Major Depressive Disorder","Drug: ALKS 5461|Drug: Placebo","Change From Baseline to End of Treatment (Week 6) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Proportion of Patients Who Exhibited Treatment Response (MADRS-10)|Remission Rate|Number of Subjects With Adverse Events (AEs)","Alkermes, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK5461-206","May 2014","December 2015","December 2015","June 9, 2014","June 25, 2019","June 25, 2019","Alkermes Investigational Site, Little Rock, Arkansas, United States|Alkermes Investigational Site, Bellflower, California, United States|Alkermes Investigational Site, Beverly Hills, California, United States|Alkermes Investigational Site, Glendale, California, United States|Alkermes Investigational Site, Los Alamitos, California, United States|Alkermes Investigational Site, Orange, California, United States|Alkermes Investigational Site, Redlands, California, United States|Alkermes Investigational Site, Temecula, California, United States|Alkermes Investigational Site, Washington, District of Columbia, United States|Alkermes Investigational Site, Hallandale Beach, Florida, United States|Alkermes Investigational Site, Hialeah, Florida, United States|Alkermes Investigational Site, Jacksonville, Florida, United States|Alkermes Investigational Site, Leesburg, Florida, United States|Alkermes Investigational Site, Maitland, Florida, United States|Alkermes Investigational Site, Tampa, Florida, United States|Alkermes Investigational Site, Atlanta, Georgia, United States|Alkermes Investigational Site, Chicago, Illinois, United States|Alkermes Investigational Site, Oak Brook, Illinois, United States|Alkermes Investigational Site, Vernon Hills, Illinois, United States|Alkermes Investigational Site, Indianapolis, Indiana, United States|Alkermes Investigational Site, Lafayette, Indiana, United States|Alkermes Investigational Site, Edgewood, Kentucky, United States|Alkermes Investigational, Washington DC, Maryland, United States|Alkermes Investigational Site, Brockton, Massachusetts, United States|Alkermes Investigational Site, Watertown, Massachusetts, United States|Alkermes Investigational Site, Kansas City, Missouri, United States|Alkermes Investigational Site, O'Fallon, Missouri, United States|Alkermes Investigational Site, Saint Louis, Missouri, United States|Alkermes Investigational Site, Cherry Hill, New Jersey, United States|Alkermes Investigational Site, Albuquerque, New Mexico, United States|Alkermes Investigational Site, Jamaica, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, Staten Island, New York, United States|Alkermes Investigational Site, Charlotte, North Carolina, United States|Alkermes Investigational Site, Beachwood, Ohio, United States|Alkermes Investigational Site, Cincinnati, Ohio, United States|Alkermes Investigational Site, Cincinnati, Ohio, United States|Alkermes Investigational Site, Mason, Ohio, United States|Alkermes Investigational Site, Middleburg Heights, Ohio, United States|Alkermes Investigational Site, Portland, Oregon, United States|Alkermes Investigational Site, Salem, Oregon, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, United States|Alkermes Investigational Site, Charleston, South Carolina, United States|Alkermes Investigational Site, Memphis, Tennessee, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, Houston, Texas, United States|Alkermes Investigational Site, Sugar Land, Texas, United States|Alkermes Investigational Site, Bellevue, Washington, United States|Alkermes Investigational Site, Waukesha, Wisconsin, United States|Alkermes Investigational Site, Bourgas, Bulgaria|Alkermes Investigational Site, Kazanlak, Bulgaria|Alkermes Investigational Site, Sofia, Bulgaria|Alkermes Investigational Site, Sofia, Bulgaria|Alkermes Investigational Site, Sofia, Bulgaria|Alkermes Investigational Site, Varna, Bulgaria|Alkermes Investigational Site, Veliko Tarnovo, Bulgaria|Alkermes Investigational Site, Vratza, Bulgaria",,"https://ClinicalTrials.gov/show/NCT02158546"
99,"NCT02158533","A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study",,"Completed","Has Results","Major Depressive Disorder","Drug: High Dose ALKS 5461|Drug: Low Dose ALKS 5461|Drug: Placebo","Change From Baseline to Week 5 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Proportion of Patients Who Exhibited Treatment Response (MADRS-10)|Remission Rate|Number of Subjects With Adverse Events (AEs)","Alkermes, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","385","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK5461-205","May 2014","December 2015","December 2015","June 9, 2014","March 27, 2019","August 14, 2019","Alkermes Investigational Site, Birmingham, Alabama, United States|Alkermes Investigational Site, Tucson, Arizona, United States|Alkermes Investigational Site, Carson, California, United States|Alkermes Investigational Site, National City, California, United States|Alkermes Investigational Site, Orange, California, United States|Alkermes Investigational Site, Sherman Oaks, California, United States|Alkermes Investigational Site, Torrance, California, United States|Alkermes Investigational Site, Upland, California, United States|Alkermes Investigational Site, Hartford, Connecticut, United States|Alkermes Investigational Site, Norwich, Connecticut, United States|Alkermes Investigational Site, Coral Springs, Florida, United States|Alkermes Investigational Site, Gainesville, Florida, United States|Alkermes Investigational Site, Lauderhill, Florida, United States|Alkermes Investigational Site, Orlando, Florida, United States|Alkermes, Investigational Site, Alpharetta, Georgia, United States|Alkermes Investigational Site, Decatur, Georgia, United States|Alkermes Investigational Site, Chicago, Illinois, United States|Alkermes Investigational Site, Joliet, Illinois, United States|Alkermes Investigational Site, Skokie, Illinois, United States|Alkermes Investigational Site, Newburgh, Indiana, United States|Alkermes Investigational Site, Valparaiso, Indiana, United States|Alkermes Investigational Site, Owensboro, Kentucky, United States|Alkermes Investigational Site, Baltimore, Maryland, United States|Alkermes Investigational Site, Baltimore, Maryland, United States|Alkermes Investigational Site, Berlin, New Jersey, United States|Alkermes Investigational Site, Brooklyn, New York, United States|Alkermes Investigational Site, Mount Kisco, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, Staten Island, New York, United States|Alkermes Investigational Site, Canton, Ohio, United States|Alkermes Investigational Site, Dayton, Ohio, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Allentown, Pennsylvania, United States|Alkermes Investigational Site, Media, Pennsylvania, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, United States|Alkermes Investigational Site, Lincoln, Rhode Island, United States|Alkermes Investigational Site, Austin, Texas, United States|Alkermes Investigational Site, Houston, Texas, United States|Alkermes Investigational Site, San Antonio, Texas, United States|Alkermes Investigational Site, Woodstock, Vermont, United States|Alkermes Investigational Site, Middleton, Wisconsin, United States|Alkermes Investigational Site, Brisbane, Queensland, Australia|Alkermes Investigational Site, Towong, Queensland, Australia|Alkermes Investigational Site, Frankston, Victoria, Australia|Alkermes Investigational Site, Melbourne, Victoria, Australia|Alkermes Investigational Site, Penticton, British Columbia, Canada|Alkermes Investigational Site, Gatineau, Quebec, Canada|Alkermes Investigational Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02158533"
100,"NCT04221230","Study in Major Depressive Disorder With BTRX-335140 vs Placebo",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: BTRX-335140|Drug: Placebo","Hamilton Depression Rating Scale (HAMD-17)|Clinical Global Impression of Improvement (CGI-I) score|Change from baseline in Snaith-Hamilton Pleasure Scale (SHAPS) score|Change from baseline in Hospital Anxiety and Depression Scale (HADS) subscales (ie, anxiety subscale [HADS-A] and depression subscale [HADS-D]) scores|Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) score|Change from baseline in Sheehan Disability Scale (SDS) score|6. Assessment of safety through the occurrence of TEAEs, SAEs, and adverse events of special interest (AESIs)","BlackThorn Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","K2-MDD-201","December 14, 2019","December 31, 2021","December 31, 2021","January 9, 2020",,"July 22, 2021","Pillar Clinical Research, Bentonville, Arkansas, United States|Atria Clinical Research, Little Rock, Arkansas, United States|CITrials, Bellflower, California, United States|ProScience Research Group, Culver City, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Behavioral Research Specialist, LLC, Glendale, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|CITrials, Riverside, California, United States|Lumos Clinical Research Center, San Jose, California, United States|CITrials, Santa Ana, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Pacific Clinical Research Management Group LLC, Upland, California, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|West Broward Outpatient Clinic, Lauderhill, Florida, United States|Miami Lakes Medical Research Outpatient Division, Miami Lakes, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Headlands Research Sarasota, Sarasota, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Uptown Research Institute, Chicago, Illinois, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Grayline Research Center, Wichita Falls, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04221230"
101,"NCT03937596","Adjunctive D-Cycloserine in Major Depressive Disorder",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: D-cycloserine|Device: Transcranial Magnetic Stimulator|Drug: Placebo oral capsule","Montgomery-Asberg Depression Rating Scale (MADRS)|Functional Magnetic Resonance Imaging (fMRI)|Magnetic Resonance (MR) spectroscopy|Clinical Remission|Clinical Response|Quality of Life as measured by the World Health Organization Quality of Life (WHOQOL-BREF) questionnaire|Anxiety Symptoms|Workplace Productivity|Functional Disability|Clinical Global Impression|Cognitive Function|Implicit Suicidal Thoughts|Personality Measures- BFI|Personality Measures- DEQ|Anhedonia|Self-reported Cognition|Depressive Symptoms|VAS for General Health|Perception of Illness","University of Calgary","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REB18-2142","December 1, 2019","February 2021","February 2021","May 6, 2019",,"January 15, 2021","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03937596"
102,"NCT02218008","A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study",,"Completed","Has Results","Major Depressive Disorder","Drug: ALKS 5461|Drug: Placebo","Change in Montgomery Asberg Depression Rating Scale (MADRS)-6 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for Stage 1, Week 6 for Stage 2)|Change in MADRS-10 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for Stage 1, Week 6 for Stage 2)|Change From Baseline to End of Treatment in the MADRS-10|Proportion of Patients Who Exhibited Treatment Response (MADRS-10)|Remission Rate|Number of Subjects With Adverse Events (AEs)","Alkermes, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","407","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK5461-207","July 2014","September 2016","October 2016","August 15, 2014","March 27, 2019","August 14, 2019","Alkermes Investigational Site, Birmingham, Alabama, United States|Alkermes Investigational Site, Colton, California, United States|Alkermes Investigational Site, Garden Grove, California, United States|Alkermes Investigational Site, Los Angeles, California, United States|Alkermes Investigational Site, Oakland, California, United States|Alkermes Investigational Site, Oceanside, California, United States|Alkermes Investigational Site, Pico Rivera, California, United States|Alkermes Investigational Site, San Gabriel, California, United States|Alkermes Investigational Site, Colorado Springs, Colorado, United States|Alkermes Investigational Site, Bradenton, Florida, United States|Alkermes Investigational Site, Fort Myers, Florida, United States|Alkermes Investigational Site, Melbourne, Florida, United States|Alkermes Investigational Site, North Miami, Florida, United States|Alkermes Investigational Site, Oakland Park, Florida, United States|Alkermes Investigational Site, Winter Haven, Florida, United States|Alkermes Investigational Site, Smyrna, Georgia, United States|Alkermes Investigational Site, Hoffman Estates, Illinois, United States|Alkermes Investigational Site, Flowood, Mississippi, United States|Alkermes Investigational Site, Saint Charles, Missouri, United States|Alkermes Investigational Site, Saint Louis, Missouri, United States|Alkermes Investigational Site, Princeton, New Jersey, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, High Point, North Carolina, United States|Alkermes Investigational Site, Canton, Ohio, United States|Alkermes Investigational Site, Portland, Oregon, United States|Alkermes Investigational Site, Memphis, Tennessee, United States|Alkermes Investigational Site, DeSoto, Texas, United States|Alkermes Investigational Site, Wichita Falls, Texas, United States|Alkermes Investigational Site, Clinton, Utah, United States|Alkermes Investigational Site, Bellevue, Washington, United States|Alkermes Investigational Site, Seattle, Washington, United States|Alkermes Investigational Site, Spokane, Washington, United States|Alkermes Investigational Site, Gatineau, Canada|Alkermes Investigational Site, Halifax, Canada|Alkermes Investigational Site, Penticton, Canada|Alkermes Investigational Site, Quebec, Canada|Alkermes Investigational Site, Berlin, Germany|Alkermes Investigational Site, Berlin, Germany|Alkermes Investigational Site, Hannover, Germany|Alkermes Investigational Site, Oranienburg, Germany|Alkermes Investigational Site, Schwerin, Germany|Alkermes Investigational Site, Stralsund, Germany|Alkermes Investigational Site, San Juan, Puerto Rico|Alkermes Investigational Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02218008"
103,"NCT01525524","Treatment of Major Depressive Disorder Post Stroke With Transcranial Direct Current Stimulation",,"Completed","No Results Available","Major Depressive Disorder 1","Device: Transcranial Direct Current Stimulation","Treatment response","University of Sao Paulo","All","30 Years to 90 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1180/12","January 2012","December 2013","August 2014","February 3, 2012",,"September 9, 2014","University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01525524"
104,"NCT04830215","Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Brexpiprazole","Inventory of Depressive Symptomatology Self-Report (IDS-SR) 10-life engagement|Inventory of Depressive Symptomatology Self-Report (IDS-SR) Total score","Otsuka Pharmaceutical Development & Commercialization, Inc.|Lundbeck Canada Inc.|Otsuka Canada Pharmaceutical Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","210","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-201-00289","April 2021","June 2022","October 2022","April 5, 2021",,"April 6, 2021","Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04830215"
105,"NCT04832425","A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: PRAX-114|Drug: Placebo","Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15|Change from baseline in HAM-D17 total score at Day 29|Change from baseline in HAM-D17 total score at all other time points|Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points|Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points|HAM-D17 response (reduction from baseline score of ≥50%) at Day 15, Day 29, and all other time points|HAM-D17 remission (total score of ≤7) at Day 15, Day 29, and all other time points|Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points|Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points|Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points|Change from baseline in the 12-Item Short Form Survey (SF-12) at Day 15 and all other time points|Incidence and severity of Adverse Events (AE)|Incidence of AEs by preferred term|Incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) measured suicidal ideation or behavior","Praxis Precision Medicines","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRAX-114-213","March 30, 2021","April 2022","April 2022","April 5, 2021",,"July 7, 2021","Praxis Research Site, Garden Grove, California, United States|Praxis Research Site, Lemon Grove, California, United States|Praxis Research Site, Oceanside, California, United States|Praxis Research Site, Pico Rivera, California, United States|Praxis Research Site, Jacksonville, Florida, United States|Praxis Research Site, Orlando, Florida, United States|Praxis Research Site, Atlanta, Georgia, United States|Praxis Research Site, O'Fallon, Missouri, United States|Praxis Research Site, Las Vegas, Nevada, United States|Praxis Research Site, Berlin, New Jersey, United States|Praxis Research Site, Marlton, New Jersey, United States|Praxis Research Site, Cedarhurst, New York, United States|Praxis Research Site, Portland, Oregon, United States|Praxis Research Site, Media, Pennsylvania, United States|Praxis Research Site, Memphis, Tennessee, United States|Praxis Research Site, Austin, Texas, United States|Praxis Research Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04832425"
106,"NCT00305045","Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation",,"Completed","No Results Available","Major Depressive Disorder","Device: Repetitive Transcranial Magnetic Stimulation","Degree of change on the 17-item Hamilton Rating Scale for Depression (HAM-D)","Centre for Addiction and Mental Health","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","73","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","237/2004","March 2005","May 2009","May 2009","March 21, 2006",,"January 24, 2012","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00305045"
107,"NCT04826614","Comparing Efficacy of Optimal Treatment and Conventional Treatment for Major Depressive Disorder in Viet Nam",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Other: optimized treatment","Comparison of rate of respond patient between optimization and routine treatment group","University of Medicine and Pharmacy at Ho Chi Minh City","All","18 Years and older   (Adult, Older Adult)","Not Applicable","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNTPhuong","March 1, 2021","April 2022","December 2023","April 1, 2021",,"April 1, 2021","University Medical Center, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT04826614"
108,"NCT01568307","Major Depressive Disorder - Understanding The Link Between The Brain And The Heart","MDD","Unknown status","No Results Available","Major Depressive Disorder","Drug: Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.","Proportion of MDD patients carrying the s allele of the 5-HTT transporter that have higher sympathetic activity than homozygous ll patients.|To determine the association between sympathetic activity and left ventricular hypertrophy.|Change from baseline in the magnitude of morning surge in blood pressure.|Change from baseline in insulin resistance.|Change from baseline on markers of cardiac risk.","Baker Heart and Diabetes Institute|The Alfred|Monash Medical Centre|Ballarat Health Services","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","74/12|1022791","May 2012","December 2020","December 2020","April 2, 2012",,"November 5, 2018","Ballarat Health Service Psychiatric Services, Ballarat, Victoria, Australia|Monash Medical Centre - Monash Health, Clayton, Victoria, Australia|Alfred and Baker Medical Unit - Alfred Hospital, Melbourne, Victoria, Australia|Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01568307"
109,"NCT04317495","Augmenting rTMS With Cognitive Control Training in Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Other: Computerized Cognitive Training (CCT)","Feasibility assessed by percentage of CCT sessions completed during rTMS|Time on task during treatment|Acceptability of CCT|Cognitive Control Performance change over course of treatment","University of Michigan","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM00161598","August 27, 2019","April 1, 2021","April 1, 2021","March 23, 2020",,"April 8, 2021","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04317495"
110,"NCT04082806","Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: GHB|Drug: Trazodone|Drug: Placebos","slow wave sleep amount|performance in emotional memory consolidation tasks by Emotional Picture Memory Task (EPMT)|performance in procedural memory consolidation tasks by Finger Sequence-Tapping Task (FSTT)|performance in declarative memory consolidation tasks by Paired Word List Task (PAWL)|Blood levels of Brain Derived Neurotrophic Factor (BDNF).|homeostatic sleep pressure by Psychomotor Vigilance Task|homeostatic sleep pressure by N-back Task|Sleep quality assessed by Morgen Questionionnaire (MQ)|Sleep quality assessed by Karolinska Schläfrigkeitsskala (SKK)|Cortisol Saliva Response (CAR)|Score on Positive and Negative Affect Schedule (PANAS)","Erich Seifritz|Psychiatric University Hospital, Zurich","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mem-GHB-TRA-Study","August 6, 2020","December 31, 2021","December 31, 2021","September 9, 2019",,"August 12, 2020","Psychiatric University Hospital, Zürich, ZH, Switzerland",,"https://ClinicalTrials.gov/show/NCT04082806"
111,"NCT04975724","Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Liposom Forte|Drug: Citalopram","Change of depressive symptoms atV5(day30)as change from baseline withHamiltonRatingScaleforDepression(HAM-D).HAM-D has21items,scoring based on the first17.9items from0=not present;to4=severe.8 from0-2.Scores from the first17items summed:≥16=MajorDep|Change of latency of antidepressant therapy with citalopram. It will be evaluated at V2,V3,V4 andV5 using HAM-D.Latency time:the time from baseline to response (a≥50% improvement in HAM-D score vs baseline)|ClinicalGlobalImpression as change from baseline withCGI up toV8Day90.CGI:7point scale clinician-rated(severity of illness)from1(normal)to7(severely ill).CGI score from1(very much improved)to7(very much worse).Treatment response consider efficacy andAEs|Safety of study treatments by tracking number and type of adverse events at each visit, up to V8 (Day 90)|Safety of study treatments by tracking, up to V8 (Day 90), 12-lead ECG, QTcF interval (Fridericia equation) will be measured|Safety of study treatments by tracking, up to V8 (Day 90), blood pressure measurements in mmHg|Safety of study treatments by tracking, up to V8 (Day 90), heart rate measurements in bpm|Safety of study treatments by tracking, up to V8 (Day 90), oxygen saturation measurements in percentage with a pulse oximetry device|Change of depressive symptoms during the entire study as change from baseline therapy with citalopram over the entire study|Percentage of patients responders at V2, V3, V4 and V5. ≥50% improvement in HAM-D score vs baseline will be considered as responder.|Change of depressive symptoms as change from baseline using GeriatricDepressionScale(GDS-15) at each visit, up to V8(Day90). GDS:brief questionnaire:15questions with options yes or no in reference to how patients felt on the day of administration","Fidia Farmaceutici s.p.a.","All","65 Years to 84 Years   (Older Adult)","Phase 4","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","QQ05.16.02","April 18, 2019","November 2023","December 2023","July 23, 2021",,"July 23, 2021","UOC Geriatria e Lungodegenza Geriatrica PO San Filippo e Nicola di Avezzano - ASL1 Avezzano Sulmona L'aquila, Avezzano, Italy|UO Psichiatria - ASST Papa Giovanni XXIII, Bergamo, Italy|Unità Operativa di Psichiatria, Azienda Ospedaliero-Universitaria Mater Domini, Catanzaro, Italy|Ambulatorio Psichiatrico, UOC Psichiatria Presidio Ospedaliero di Codogno - ASST Lodi, Codogno, Italy|SOD Geriatria-UTIG Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Servizio Psichiatrico di Diagnosi e Cura (SPDC) Foggia, Ospedali Riuniti di Foggia, Foggia, Italy|Servizio Psichiatrico di Diagnosi e Cura (SPDC) - ASL3 Ente Ospedaliero Ospedali Galliera, Genova, Italy|Ambulatorio Clinica Psichiatrica, Ospedale Policlinico S. Martino, Genova, Italy|UOC Geriatria PO San Salvatore - ASL1 Avezzano Sulmona L'Aquila, L'Aquila, Italy|SPDC Ospedale Fatebenefratell, UOC Psichiatria 1 ASST Fatebenefratelli Sacco, Milano, Italy|Centro Depressione Anziani S.C. Psichiatria 51, ASST Santi Paolo e Carlo - Presidio San Paolo, Milano, Italy|UO Medicina a indirizzo geriatrico ASST degli Spedali Civili di Brescia - Ospedale di Montichiari, Montichiari, Italy|U.O. Psichiatria 2 Universitaria AOU Pisana - P.O. Santa Chiara, Pisa, Italy|UOC Psichiatria - Azienda Ospedaliero-Universitaria Sant'Andrea, Roma, Italy|Centro Salute Mentale - UO Psichiatria Ambito Territoriale Est Ospedale San Lorenzo Borgo Valsugana - Azienda Provinciale per i Servizi Sanitari di Trento, Trento, Italy|Clinica Psichiatrica, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy",,"https://ClinicalTrials.gov/show/NCT04975724"
112,"NCT04199845","8-week of PS128 RCT in Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: PS128","Changes of Hamilton Depression Rating Scale- 17 items (HAMD-17)|Changes of Depression and Somatic Symptoms Scale (DSSS)|Changes of serum zonulin|Changes of serum IFABP|Changes of serum hs-CRP level|Changes of serum IL-6 level|Changes of serum IL-10 level|Changes of serum TNF-alpha level|Changes of composition of gut microbiota","Taipei Medical University WanFang Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","N201906056","August 28, 2019","May 2022","July 2022","December 16, 2019",,"December 19, 2019","WanFang Hospital, Taipei Medical University, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04199845"
113,"NCT01482221","A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: AZD6765 iv|Drug: Placebo","Change From Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline to Week 12 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Percentage of Patients With Sustained Response From Week 6 to Week 12 (Defined as ≥50% Reduction From Baseline in the MADRS Total Score at Week 6 and Which is Maintained Through Week 12)|Percentage of Patients Who Were Responders (Defined as a ≥50% Reduction From Baseline in MADRS Total Score) at Week 6|Percentage of Patients Who Were Responders (Defined as a ≥50% Reduction From Baseline in MADRS Total Score) at Week 12|Percentage of Patients Who Were Remitted (Defined as MADRS Total Score ≤10) at Week 6|Percentage of Patients Who Were Remitted (Defined as MADRS Total Score ≤10) at Week 12|Change From Baseline in Functional Impairment as Measured by the Change From Baseline in the Sheehan Disability Scale (SDS) Total Score|Change in Severity of Depressive Symptoms as Measured by Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score|Change in Severity of Depressive Symptoms as Measured by the CGI-I Response (Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"") at Week 6|Change in Severity of Depressive Symptoms as Measured by the CGI-I Response (Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"") at Week 12|Change From Baseline in Self-rated Severity of Depressive Symptoms as Measured by Quick Inventory of Depressive Symptomatology Self-Rated 16-item Scale (QIDS-SR-16) Total Score","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","542","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D6702C00031|EudraCT number 2011-004690-87","December 16, 2011","August 26, 2013","August 26, 2013","November 30, 2011","April 11, 2017","April 11, 2017","Research Site, Chino, California, United States|Research Site, Lond Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, New Heaven, Connecticut, United States|Research Site, Ft. Lauderdale, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Lake City, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Bellevue, Washington, United States|Research Site, Antofagasta, Chile|Research Site, Santiago, Chile|Research Site, Bratislava, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Michalovce Stranany, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trnava, Slovakia|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Tygervalley, South Africa",,"https://ClinicalTrials.gov/show/NCT01482221"
114,"NCT04504253","A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: Creatine monohydrate","HAMD-17|QIDS","University of Utah","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB_00129040","August 3, 2020","August 2, 2021","August 2, 2021","August 7, 2020",,"August 7, 2020","University of Utah Department of Psychiatry, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04504253"
115,"NCT04244253","A Phase 2 Trial of OPC-64005 for Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: OPC-64005 20 mg , Once-daily|Drug: OPC-64005 10 mg , Once-daily|Drug: Placebo, Once-daily","Mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score|Responder rate in MADRS total score|Remission rate in MADRS total score|Improvement rate in CGI-I score|Mean change from baseline in CGI-S score|Mean change from baseline in HAM-D 17 items total score|Mean change from baseline in Apathy Scale Score|Mean change from baseline in MADRS-S total score|Mean change from baseline in anhedonia factor of MADRS","Otsuka Pharmaceutical Co., Ltd.","All","20 Years to 64 Years   (Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","277-102-00027","March 3, 2020","November 2021","November 2021","January 28, 2020",,"March 17, 2021","Medical Corporation Jisenkai Himorogi Psychiatric Institute, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04244253"
116,"NCT04780152","TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial Direct Current Stimulation|Device: Placebo-simulation of transcranial direct current stimulation|Drug: Fluoxetine Tablets","Change of Children Depression Inventory score from the beginning to the end of the study|Change of Columbia-Suicide Severity Rating Scale score from the beginning to the end of the study|Change of Young Mania Rating Scale score from the begining to the end of the study","El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico","All","10 Years to 17 Years   (Child)","Phase 2|Phase 3","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","54/20","October 2021","August 2022","September 2022","March 3, 2021",,"June 4, 2021","Instituto Nacional de Neurología y Neurocirugía, Mexico City, Ciudad De México, Mexico",,"https://ClinicalTrials.gov/show/NCT04780152"
117,"NCT04410341","The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Vildagliptin 50 MG|Drug: Escitalopram 20 mg","Effect on Hamilton Depression rating scale score (HAM-D score)|Effect on biological markers|Interleukin-6|BDNF","Sadat City University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0055/2020","May 1, 2020","December 1, 2021","May 1, 2022","June 1, 2020",,"June 4, 2021","Faculty of Medicine, Shibīn Al Kawm, Egypt",,"https://ClinicalTrials.gov/show/NCT04410341"
118,"NCT04985942","Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Lumateperone|Drug: Placebo","Montgomery-Åsberg Depression Rating Scale|Clinical Global Impression Scale-Severity","Intra-Cellular Therapies, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","470","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ITI-007-501","July 2021","August 2023","August 2023","August 2, 2021",,"August 2, 2021","Clinical Site, Phoenix, Arizona, United States|Clinical Site, Bentonville, Arkansas, United States|Clinical Site, Glendale, California, United States|Clinical Site, Oceanside, California, United States|Clinical Site, Redlands, California, United States|Clinical Site, Temecula, California, United States|Clinical Site, Upland, California, United States|Clinical Site, Fort Lauderdale, Florida, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, Orlando, Florida, United States|Clinical Site, Decatur, Georgia, United States|Clinical Site, Joliet, Illinois, United States|Clinical Site, Boston, Massachusetts, United States|Clinical Site, Toms River, New Jersey, United States|Clinical Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04985942"
119,"NCT04497350","Transcranial Magnetic Stimulation vs Theta Burst Stimulation in Major Depressive Disorder",,"Enrolling by invitation","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation|Device: Theta Burst Stimulation","Beck Depression Inventory (BDI-II)|Patient Depression Questionnaire (PDQ-9)|Hamilton Depression Rating Scale (HAM-D)|Global Rating of Change (GRC)","Neurological Associates of West Los Angeles","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20193262","January 6, 2020","December 2021","December 2022","August 4, 2020",,"August 4, 2020","Neurological Associates of West Los Angeles, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04497350"
120,"NCT04209166","A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Drug: SSRIs/SNRIs+Mood Stabilizer|Drug: SSRIs/SNRIs+Quetiapine|Drug: Usual Treatment","remission of acute phase|switch rate","Shanghai Mental Health Center|Air Force Military Medical University, China|Guangzhou Psychiatric Hospital|Dalian Seventh People's Hospital|Wuhan Union Hospital, China|Shanghai Jiao Tong University School of Medicine","All","16 Years to 60 Years   (Child, Adult)","Not Applicable","780","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CRC2018ZD05","August 12, 2019","October 31, 2022","October 31, 2022","December 23, 2019",,"December 23, 2019","Guangzhou Psychiatric Hospital, Guanzhou, Guangdong, China|Wuhan Mental Health Center, Wuhan, Hubei, China|Dalian Seventh People's Hospital, Dalian, Liaoning, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Fourth Military Medical University, Xian, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT04209166"
121,"NCT04846829","Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Placebo|Device: intermittent theta burst stimulation|Drug: intravenous citalopram hydrochloride (CIT)|Device: continuous theta burst stimulation","Percent change in Hamilton Depression Scale|Percent. change in The Inventory of Depressive Symptomatology-Self Report","University of California, Los Angeles","All","21 Years to 55 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","16-002086","April 24, 2017","April 24, 2022","April 24, 2022","April 15, 2021",,"April 19, 2021","UCLA Depression Research and Clinic Program, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04846829"
122,"NCT04969510","A Clinical Trial of Adjunctive PRAX-114 in Participants With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: 10 mg PRAX-114|Drug: 20 mg PRAX-114|Drug: 40 mg PRAX-114|Drug: 60 mg PRAX-114|Drug: Placebo","Change from baseline in HAM-D17 total score at Day 15|Change from baseline in HAM-D17 total score at Day 29|Change from baseline in HAM-D17 total score at all other time points|Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points|Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points|HAM-D17 response (reduction from baseline score of ≥50%) at Day 15, Day 29, and all other time points|HAM-D17 remission (total score of ≤7) at Day 15, Day 29, and all other time points|Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points|Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points|Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points","Praxis Precision Medicines","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRAX-114-214","June 24, 2021","April 2022","April 2022","July 20, 2021",,"July 20, 2021","Praxis Research Site, Lemon Grove, California, United States|Praxis Research Site, Oceanside, California, United States|Praxis Research Site, Jacksonville, Florida, United States|Praxis Research Site, Atlanta, Georgia, United States|Praxis Research Site, Worcester, Massachusetts, United States|Praxis Research Site, O'Fallon, Missouri, United States|Praxis Research Site, Las Vegas, Nevada, United States|Praxis Research Site, Memphis, Tennessee, United States|Praxis Research Site, Austin, Texas, United States|Praxis Research Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04969510"
123,"NCT04770285","Trial to Evaluate the Effectiveness of Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder","MIRAI","Recruiting","No Results Available","Major Depressive Disorder","Device: MIRAI Depression Study Digital Therapetic","Montgomery-Asberg Depression Rating Scale (MADRS)|Generalized Anxiety Disorder-7 (GAD-7)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Click Therapeutics, Inc.","All","22 Years to 64 Years   (Adult)","Not Applicable","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","345-201-00002","February 19, 2021","October 2022","October 2022","February 25, 2021",,"March 29, 2021","For additional information regarding sites, contact 844-687-8522, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04770285"
124,"NCT04855747","A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)","RELIANCE-II","Recruiting","No Results Available","Major Depressive Disorder","Drug: REL-1017|Drug: Placebo","Change in the MADRS10 total score|Change in CGI-S score","Relmada Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REL-1017-302","March 30, 2021","June 2022","June 2022","April 22, 2021",,"July 27, 2021","Relmada Site 203, Little Rock, Arkansas, United States|Relmada Site 225, Encino, California, United States|Relmada Site 200, Glendale, California, United States|Relmada Site 201, Orange, California, United States|Relmada Site 220, Santa Ana, California, United States|Relmada Site 211, Norwich, Connecticut, United States|Relmada Site 213, Hallandale Beach, Florida, United States|Relmada Site 219, Lakeland, Florida, United States|Relmada Site 226, Lauderhill, Florida, United States|Relmada Site 206, Maitland, Florida, United States|Relmada Site 218, Miami, Florida, United States|Relmada Site 229, Miami, Florida, United States|Relmada Site 232, Orange City, Florida, United States|Relmada Site 208, Tampa, Florida, United States|Relmada Site 207, Savannah, Georgia, United States|Relmada Site 222, Boise, Idaho, United States|Relmada Site 224, Prairie Village, Kansas, United States|Relmada Site 204, Las Vegas, Nevada, United States|Relmada Site 212, Oklahoma City, Oklahoma, United States|Relmada Site 233, Plano, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04855747"
125,"NCT04509102","Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder","Stimulant-rTMS","Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Adderall-XR|Drug: Placebo","Mean Percent Change in Self-rated Inventory of Depressive Symptoms","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-000050","August 19, 2020","June 19, 2022","June 19, 2022","August 11, 2020",,"August 11, 2020","UCLA Semel, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04509102"
126,"NCT04479852","A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: SP-624|Drug: Placebo","Change from Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) total score|Change from Baseline to Weeks 1, 2, and 3 in Montgomery Asberg Depression Rating Scale total score|Change from Baseline to Weeks 1, 2, 3, and 4 in Clinical Global Impression - Severity (CGI-S) total score|Change from Baseline to Week 5 and change from Week 4 to Week 5 in MADRS total score|Change from Baseline to Week 5 and change from Week 4 to Week 5 in CGI-S total score|Change from Baseline to Week 2 and Week 4 in the 17-item Hamilton Depression Rating Scale (HAM D-17) total score|Change from Baseline to Week 2 and Week 4 in the Sheehan Disability Scale (SDS)|Change from Baseline to Week 2 and Week 4 in the Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR)|Change from Baseline to Week 2 and Week 4 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)","Sirtsei Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SP-624-201","September 30, 2020","November 2021","November 2021","July 21, 2020",,"July 19, 2021","Alea Research, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Collaborative Neuroscience Research, Garden Grove, California, United States|Pacific Research Partners, Oakland, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Collaborative Neuroscience Research, Torrance, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|CBH Health, Gaithersburg, Maryland, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Hassman Research Institute, Marlton, New Jersey, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Richard H. Weisler, MD, PA & Associates, Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Oregon Center for Clinical Investigations, Salem, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Future Search Trials of Dallas, Dallas, Texas, United States|Core Clinical Research, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04479852"
127,"NCT03769350","Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)",,"Withdrawn","No Results Available","Major Depressive Disorder","Device: Smartphone-delivered CBT for MDD","Difference in MDD severity (QIDS-C) at the end of treatment/waitlist period.|Difference in functional impairment at the end of treatment/waitlist period|Difference in quality of life at the end of treatment/waitlist period","Massachusetts General Hospital|Telefónica S.A.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P001670","July 1, 2019","June 1, 2022","June 1, 2022","December 7, 2018",,"May 13, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03769350"
128,"NCT03558256","The Study of Mindfulness-based Cognitive Therapy and Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Mindfulness-based Cognitive Therapy|Drug: Medication","Change of Hamilton Depression Scale-24 from baseline to 32 weeks|Change of Hamilton Anxiety Scale from baseline to 32 weeks|Change of Self Compassion Scale from baseline to 32 weeks","Shanghai Mental Health Center","All","18 Years to 55 Years   (Adult)","Not Applicable","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MBCT2018","May 16, 2016","December 31, 2018","December 31, 2018","June 15, 2018",,"October 15, 2018","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03558256"
129,"NCT00108979","Study of Escitalopram in Adult Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Montgomery Asberg Depression Rating Scale (MADRS)|Hamilton Depression Rating Scale (HAMD)","Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SCT-MD-23","March 2005","July 2006","July 2006","April 22, 2005",,"March 5, 2012","Southwest Health, Ltd., Phoenix, Arizona, United States|Summit Research Network, Okemos, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Summit Research Network, Portland, Oregon, United States|CNS Research Institute, Philadelphia, Pennsylvania, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, United States|Radiant Research, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00108979"
130,"NCT04688164","A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)","RELIANCE-I","Recruiting","No Results Available","Major Depressive Disorder","Drug: REL-1017|Drug: Placebo","Change in the MADRS10 total score|Change in CGI-S score","Relmada Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REL-1017-301","December 4, 2020","June 2022","June 2022","December 29, 2020",,"July 27, 2021","Relmada Site 116, Phoenix, Arizona, United States|Relmada Site 142, Tucson, Arizona, United States|Relmada Site 135, Rogers, Arkansas, United States|Relmada Site 136, Garden Grove, California, United States|Relmada Site 138, Irvine, California, United States|Relmada Site 128, Lemon Grove, California, United States|Relmada Site 130, Torrance, California, United States|Relmada Ste 125, Colorado Springs, Colorado, United States|Relmada Site 151, Denver, Colorado, United States|Relmada Site 157, Cromwell, Connecticut, United States|Relmada Site 140, Fort Myers, Florida, United States|Relmada Site 148, Gainesville, Florida, United States|Relmada Site 129, Jacksonville, Florida, United States|Relmada Site 118, Miami Springs, Florida, United States|Relmada Site 100, Miami, Florida, United States|Relmada Site 114, Miami, Florida, United States|Relmada Site 124, Orlando, Florida, United States|Relmada Site 121, Orlando, Florida, United States|Relmada Site 110, Palm Bay, Florida, United States|Relmada Site 133, Pensacola, Florida, United States|Relmada Site 105, Tampa, Florida, United States|Relmada Site 113, Decatur, Georgia, United States|Relmada Site 101, Chicago, Illinois, United States|Relmada Site 107, Chicago, Illinois, United States|Relmada Site 158, Boston, Massachusetts, United States|Relmada Site 134, New Bedford, Massachusetts, United States|Relmada Site 117, Watertown, Massachusetts, United States|Relmada Site 147, Flowood, Mississippi, United States|Relmada Site 145, O'Fallon, Missouri, United States|Relmada Site 122, Marlton, New Jersey, United States|Relmada Site 154, Brooklyn, New York, United States|Relmada Site 146, Mount Kisco, New York, United States|Relmada Site 126, New York, New York, United States|Relmada Site 139, Charlotte, North Carolina, United States|Relmada Site 109, Beachwood, Ohio, United States|Relmada Site 132, Canton, Ohio, United States|Relmada Site 144, Cincinnati, Ohio, United States|Relmada Site 150, Columbus, Ohio, United States|Relmada Site 143, Dayton, Ohio, United States|Relmada Site 123, Oklahoma City, Oklahoma, United States|Relmada Site 112, Oklahoma City, Oklahoma, United States|Relmada Site 106, Oklahoma City, Oklahoma, United States|Relmada Site 104, Portland, Oregon, United States|Relmada Site 137, Plymouth Meeting, Pennsylvania, United States|Relmada Site 119, Memphis, Tennessee, United States|Relmada Site 115, Austin, Texas, United States|Relmada Site 153, Austin, Texas, United States|Relmada Site 149, DeSoto, Texas, United States|Relmada Site 111, Houston, Texas, United States|Relmada Site 103, Wichita Falls, Texas, United States|Relmada Site 102, Woodstock, Vermont, United States|Relmada Site 156, Charlottesville, Virginia, United States|Relmada Site 108, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04688164"
131,"NCT00408031","D-cycloserine for Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: D-cycloserine","Change in 24 item Hamilton Depression Rating Scale (HAMD) scores. Safety measures: UKU scale, vital signs assessments, laboratory parameters (SMA-20, CBC, UA)|Change in Hamilton Rating Scale for Anxiety (HAMA) scores.","Herzog Hospital|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Heresco 4 CTIL|Herzog - protocol 5372","January 2007","May 2010","May 2010","December 5, 2006",,"August 3, 2012","Ezrath Nashim - Herzog Memorial Hospital & Community Clinics, Jerusalem, Israel|Ezrath Nashim - Herzog Memorial Hospital, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00408031"
132,"NCT02133001","A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide",,"Completed","Has Results","Major Depressive Disorder","Drug: Esketamine|Drug: Placebo","Change From Baseline to Day 1: 4-Hour Post-dose in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Double-blind Phase)|Percentage of Participants With Sustained Response Based on MADRS Total Score (Double-blind Phase)|Change From Baseline to Day 2 in MADRS Total Score (Double-blind Phase)|Change From Baseline to Double-blind Phase-End Point (Day 25) in MADRS Total Score (Double-blind Phase)|Percentage of Participants With Response Based on MADRS Total Score During the Double-Blind Phase|Percentage of Participants With Response Based on MADRS Total Score at Follow up Phase Endpoint|Change From Baseline to Day 1: 4-hours Post-dose in Suicide Ideation and Behavior Assessment Tool (SIBAT)-Clinical Global Judgment of Suicide Risk (CGJ-SR) Module 8 Score (Double-blind Phase)|Change From Baseline to Day 2 in Suicide Ideation and Behavior Assessment Tool (SIBAT)-Clinical Global Judgment of Suicide Risk (SIBAT CGJ-SR) Module 8 Score (Double-blind Phase)|Change From Baseline to Double-blind Phase-Endpoint (Day 25) Suicide Ideation and Behavior Assessment Tool (SIBAT)-Clinical Global Judgment of Suicide Risk (SIBAT CGJ-SR) Module 8 (Double-blind Phase)|Change From Baseline to Follow-up Phase-Endpoint (Day 81) in Suicide Ideation and Behavior Assessment Tool (SIBAT)-Clinical Global Judgment of Suicide Risk Score (Follow-up Phase)|Change From Baseline to Day 1: 4- Hours Postdose in SIBAT-Patient-Reported Global Assessment of Suicide Risk (Module 6) Score (Double-blind Phase)|Change From Baseline to Day 2 in Suicide Ideation and Behavior Assessment Tool Patient-Reported Global Assessment of Suicide Risk (Module 6) Score (Double-blind Phase)|Change From Baseline to Double Blind Phase-Endpoint (Day 25) in Suicide Ideation and Behavior Assessment Tool Patient-Reported Global Assessment of Suicide Risk (Module 6) Score (Double-blind Phase)|Change From Baseline to Follow-up Phase-Endpoint (Day 81) in Suicide Ideation and Behavior Assessment Tool Patient-Reported Global Assessment of Suicide Risk (Module 6) Score (Follow-up Phase)|Change From Baseline to Day 1: 4-Hours Postdose in Beck Scale for Suicidal Ideation (BSS) Total Score (Double-blind Phase)|Change From Baseline to Day 2 in Beck Scale for Suicidal Ideation (BSS) Total Score (Double-blind Phase)|Change From Baseline to Double-blind Phase-Endpoint (Day 25) in Beck Scale for Suicidal Ideation Total Score (Double-blind Phase)|Change From Baseline to Follow-up Phase-Endpoint (Day 81) in Beck Scale for Suicidal Ideation Total Score (Follow-up Phase)|Change From Baseline to Day 1: 4-Hours Postdose in Beck Hopelessness Scale (BHS) Total Score (Double-blind Phase)|Change From Baseline to Double-blind Phase-Endpoint (Day 25) in Beck Hopelessness Scale Total Score (Double-blind Phase)","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR103162|ESKETINSUI2001","May 23, 2014","February 1, 2016","February 1, 2016","May 7, 2014","April 24, 2019","May 14, 2020","Birmingham, Alabama, United States|San Diego, California, United States|Hartford, Connecticut, United States|New Haven, Connecticut, United States|Atlanta, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Towson, Maryland, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02133001"
133,"NCT03554174","Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Low Dose Psilocybin|Drug: Placebo|Drug: Medium Dose Psilocybin","Changes in electrical brain activity associated with neuroplasticity measured by Electroencephalography (EEG)|Changes in verbal memory|Changes in electrical brain activity associated with emotion processing|Change in mood symptoms using the GRID-Hamilton Depression Rating Scale (GRID-HAM-D)|Change in mood symptoms using the Quick Inventory of Depressive Symptoms (QIDS-SR16)|Change in blood pressure|Change in heart rate|Change in peripheral oxygenation","Yale University|Heffter Research Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2000022394","June 30, 2018","June 2022","April 2023","June 13, 2018",,"July 30, 2021","VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03554174"
134,"NCT04208932","A Kynurenine Pathway-based Molecular Imaging Study of Individualized Diagnosis and Treatment for Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: SSRIs","remission of acute phase","Shanghai Mental Health Center|Shanghai Jiao Tong University School of Medicine","All","18 Years to 60 Years   (Adult)",,"440","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZH2018ZDA29","August 12, 2019","December 31, 2021","December 31, 2021","December 23, 2019",,"December 26, 2019","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04208932"
135,"NCT04466345","Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Biological: Semaglutide|Biological: Placebo","Trail Making Test B (TMTB)|Digit Symbol Substitution Test (DSST)|Rey Auditory Verbal Learning Test (RAVLT)|Stroop Test|Trail Making Test A (TMTA)|Perceived Deficits Questionnaire (PDQ)|36-Item Short Form Health Survey (SF-36)|Sheehan Disability Scale (SDS)|Endicott Workplace Productivity Scale (EWPS)|Height|Weight|fasting glucose - Blood laboratorial marker|Diet History Questionnaire III (DHQ)|Physical Activity Questionnaire (IPAQ)|Pittsburgh Sleep Quality Index (PSQI)","University Health Network, Toronto","All","18 Years to 50 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19-6283","October 2021","December 2022","December 2022","July 10, 2020",,"April 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04466345"
136,"NCT04206969","Assessment of Transcultural Psychotherapy in Child Major Depressive Disorder","EDPT-ADOS","Not yet recruiting","No Results Available","Major Depressive Disorder","Behavioral: Transcultural psychotherapy","Severity Score on the Improved Global Impression Scale (iCGI) to assess remission|Severity score on the iCGI|Score on the French version of the Children's Depression Rating Scale-Revised (CDRS-R)|Score on the French version of the State-Trait Anxiety Inventory for children (STAI-C)|Score changes in Depression and anxiety Scores between Week 34 and week 52|analysis of the content of the clinical data collected during the visits|analysis of the content of the interview with the families and therapists at the end of the treatment","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France","All","6 Years to 20 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","P180601|2019-A01830-57","April 2020","October 2022","October 2023","December 20, 2019",,"March 16, 2020","Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne, Bobigny, France|Service de médecine interne, unité de consultation transculturelle, CHRU Saint-André (CHU Bordeaux), Bordeaux, France|Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied, Clermont-Ferrand, France|Maison de Solenn, Cochin Hospital, Paris, France|Secteur 75G23, Centre Médico-psychologique (CMP), GHU PARIS, Maison blanche, Paris, France|Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04206969"
137,"NCT01764867","Algorithm Guided Treatment Strategies for Major Depressive Disorder","AGTs-MDD","Unknown status","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Mirtazapine|Other: modified electroconvulsive therapy|Other: repetitive transcranial magnetic stimulation|Drug: Fluoxetine|Drug: Citalopram|Drug: Paroxetine|Drug: Sertraline|Drug: Fluvoxamine|Drug: Venlafaxine|Drug: Duloxetine|Drug: Bupropion|Drug: Trazodone","Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7|Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5|Frequency and intensity of adverse events|Quality of life","Shanghai Mental Health Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1080","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012BAI01B04-MDD|2012BAI01B04","June 2012","October 2014","December 2014","January 10, 2013",,"January 10, 2013","Shanghai Mental Health Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01764867"
138,"NCT04344678","The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Sildenafil Citrate|Drug: Placebo oral tablet","Effect on Hamilton Depression rating scale score (HAM-D score)|Effect on biological markers","Sadat City University","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0044/2020","January 1, 2020","October 31, 2021","December 31, 2021","April 14, 2020",,"April 19, 2021","Faculty of Medicine, Shibīn Al Kawm, Egypt",,"https://ClinicalTrials.gov/show/NCT04344678"
139,"NCT03726658","AGN-241751 in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: AGN-241751|Drug: Placebo","Part A: To evaluate the efficacy at 1 day post the initial single oral dose of AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD)|Part B: To evaluate the efficacy at Day 7 of AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD) dosed twice daily (BID)|Part A: To evaluate the efficacy at Day 9 and Day15 of AGN-241751 administered orally once daily and at Day 22 (7 days after completion of AGN-241751 dosing) compared with placebo in participants with MDD|Part B: To evaluate the efficacy on Day 2, Day 11, Day 14, Day 18 of AGN-241751 administered orally twice daily (BID) and at Day 21 (7 days after completion of dosing) compared with placebo in participants with MDD","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","223","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3125-104-002","November 8, 2018","October 23, 2019","October 23, 2019","October 31, 2018",,"October 28, 2020","Alea Research, Phoenix, Arizona, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Hassman Research Institute, Berlin, New Jersey, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03726658"
140,"NCT01156415","Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)",,"Terminated","No Results Available","Major Depressive Disorder","Drug: AGO178","Reports of adverse events, serious adverse events, changes in laboratory values, ECGs, vital signs, physical examination, and Columbia Suicidality Severity Rating Scale|Change from Baseline to Week 6, 8, 12, 28, 36 and 52 on total score of the Hamilton Depression Rating Scale|Proportion of patients who demonstrate clinical improvement at Week 6,8,12, 28,36 and 52, where improvement is defined by a score of 1 or 2 on the CGI-I scale|Overall illness severity as measured by change from Baseline on CGI-S (Clinical Global Impression of severity scale) at week 52|Patients' ability to function in daily life as measured by change from Baseline on total score of Sheehan Disability Scale at week 52","Novartis Pharmaceuticals|Novartis","All","18 Years to 71 Years   (Adult, Older Adult)","Phase 3","837","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAGO178C2399","June 2010","October 2011","October 2011","July 2, 2010",,"December 24, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Advanced Research Associates, Glendale, Arizona, United States|Southwest Health Ltd dba The Mollen Clinic, Scottsdale, Arizona, United States|Clinical Study Centers, LLC, Little Rock, Arkansas, United States|Southwestern Research Institute, Beverly Hills, California, United States|Comprehensive Neuroscience, Cerritos, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|CNRI-San Diego, LLC, San Diego, California, United States|University of California, San Diego Medical Center, San Diego, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Viking Clinical Research Center, Temecula, California, United States|Collaborative Neuroscience, Torrance, California, United States|University of Colorado, Aurora, Colorado, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Middlesex Hospital, Middletown, Connecticut, United States|Clinical Studies, Altamonte Springs, Florida, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Arocha Research Center, Coral Gables, Florida, United States|CNS Clinical Research, Coral Springs, Florida, United States|Sjs Clinical Research, Destin, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|CNS Healthcare, Jacksonville, Florida, United States|Florida Clinical Research Center, Maitland, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Quantum Lab. at N. Broward Memory Disorder Center, Pompano Beach, Florida, United States|Comprehensive NeuroScience, Inc., Saint Petersburg, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Hawaii Clinical Research Center, Honolulu, Hawaii, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Joliet Center for Clinical Research, Joliet, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Rush University Medical Center, Skokie, Illinois, United States|Deaconess Clinic Gateway, Newburgh, Indiana, United States|Pharmasite Research, Pikesville, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Mount Auburn Medical Associates, Watertown, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Pine Rest Christian Mental Health Services, Grand Rapids, Michigan, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|Comprehensive Psychiatric Associates, Gladstone, Missouri, United States|Robert Wood Johnson Medical School, Piscataway, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|CRI Worldwide, Willingboro, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates Of Albany, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Social Psychiatry Research, Inc./ SPRI, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Eastside Comprehensive Medical Service, New York, New York, United States|Medical & Behavior Health Research, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Pharmquest, Greensboro, North Carolina, United States|Zarzar Psychiatric Associates, Raleigh, North Carolina, United States|Piedmont Medical Research Associates, Inc., Winston-Salem, North Carolina, United States|Odyssey Research Services, Fargo, North Dakota, United States|Neuro Behavioral Clinical Research, Canton, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|North Star Medical Research, Cleveland, Ohio, United States|The Ohio State Universtiy - Harding Hospital, Columbus, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|SP Research, Oklahoma City, Oklahoma, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Sunstone Medical Research, LLC, Medford, Oregon, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Summit Research, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Research Strategies of Memphis, Memphis, Tennessee, United States|Clinical Research Associates, Nashville, Tennessee, United States|Millwood Hospital, Arlington, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Bayou City Research Limited, Houston, Texas, United States|Claghorn Lesem Research Clinic, Inc., Houston, Texas, United States|Texas Center for Drug Development, Houston, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Radiant Research, Salt Lake City, Utah, United States|University of Utah Mood Disorders Clinic, Salt Lake City, Utah, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Frontier Institute, Spokane, Washington, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Centro de Investigacion Clinica Psiquiatrica, Ponce, Puerto Rico|Dharma Institute and Research Center, San Juan, Puerto Rico|INSPIRA Clinical Research, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01156415"
141,"NCT03265340","Clinical Effect of dTMS in Major Depressive Disorder",,"Completed","No Results Available","MAjor Depressive Disorder","Device: dTMS","Montgomery Asberg Depression Rating Scale (MADRS) score|Clinical Global Impression Severity (CGI-S)|Montgomery Asberg Depression Rating Scale (MADRS) response|Montgomery Asberg Depression Rating Scale (MADRS) remission|memory objective|memory subjective|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","Section for Affective Disorders; Northern Stockholm Psychiatry","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","dTMS dos-respons studie","September 2014","September 2016","September 2016","August 29, 2017",,"March 13, 2019","Norra Stockholms Psykiatri, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03265340"
142,"NCT01288079","A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.",,"Terminated","Has Results","Major Depressive Disorder","Drug: TC-5214|Drug: Duloxetine|Drug: Placebo","Change in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4131C00001","February 2011","August 2012","August 2012","February 2, 2011","October 29, 2012","November 20, 2012","Research Site, Beverly Hills, California, United States|Research Site, Chino, California, United States|Research Site, Garden Grove, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Bradenton, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Joliet, Illinois, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Flowood, Mississippi, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Dayton, Ohio, United States|Research Site, Mason, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Tallinn, Estonia|Research Site, Tallin, Estonia|Research Site, Tartu, Estonia|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Kuopio, Finland|Research Site, Tampere, Finland|Research Site, Visakhapatnam, Andh Prad, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Kamataka, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Nashik, Mahara, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kanpur, India|Research Site, Pune, India|Research Site, Nagoya, Aichi, Japan|Research Site, Ichikawa, Chiba, Japan|Research Site, Noda City, Chiba, Japan|Research Site, Fukuoka-city, Fukuoka, Japan|Research Site, Omuta-City, Fukuoka, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Sapproro, Hokkaido, Japan|Research Site, Akashi, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yokohama-city, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yatsushiro-city, Kumamoto, Japan|Research Site, Yatsushiro, Kumamoto, Japan|Research Site, Ukyo-ku ,Kyoto, Kyoto, Japan|Research Site, Kurashiki-shi, Okayama, Japan|Research Site, Kodaira-shi, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Kumamoto, Japan",,"https://ClinicalTrials.gov/show/NCT01288079"
143,"NCT00109044","Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Montgomery Asberg Depression Rating Scale (MADRS)|Hamilton Depression Rating Scale (HAMD)","Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SCT-MD-35","March 2005","May 2006","May 2006","April 25, 2005",,"March 5, 2012","Southwest Health, Ltd, Phoenix, Arizona, United States|Alpine Clinical Research, Boulder, Colorado, United States|Radiant Research, Inc., Denver, Colorado, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Cunningham Clinical Research, LLC, Edwardsville, Illinois, United States|Midwest Center for Neurobiological Medicine, Oakbrook Terrace, Illinois, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|Summit Research Network (Michigan), Inc., Okemos, Michigan, United States|CNS Research Institute, Clementon, New Jersey, United States|Center for Emotional Fitness, Moorestown, New Jersey, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Piedmont Medical Research Associates, Inc., Winston-Salem, North Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|Croft Group Research Center, San Antonio, Texas, United States|Dominion Clinical Research, Midlothian, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle), LLC, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00109044"
144,"NCT03864614","A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: SAGE-217","Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence and severity of adverse events.|Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in clinical laboratory measures.|Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in vital signs.|Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in electrocardiograms (ECGs).|The safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by suicidal ideation and behavior using the Columbia Suicide Severity Rating Scale (C-SSRS).|The need for re-treatment with SAGE-217 as assessed by the time to first re-treatment.|The need for re-treatment with SAGE-217 as assessed by the number of participants achieving the requirements for re-treatment.|The need for re-treatment with SAGE-217 as assessed by the number of re-treatment cycles for each participant.|The response of initial treatment and/or re-treatment as assessed by change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) score.|The response of initial treatment and/or re-treatment as assessed by percent of participants achieving HAM-D response at the end of each 14-day treatment period, defined as a ≥50% reduction in HAM-D score from baseline.|The response of initial treatment and/or re-treatment as assessed by percent of participants achieving HAM-D remission at the end of each 14-day treatment (initial and/or re-treatment) period, defined as HAM-D total score ≤7.|The response of initial treatment and/or re-treatment as assessed by percent of participants achieving Clinical Global Impression - Improvement (CGI-I) score.|The response of initial treatment and/or re-treatment as assessed by change from baseline in Clinical Global Impression - Severity (CGI-S) score.","Sage Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1550","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","217-MDD-303","February 27, 2019","February 2022","February 2022","March 6, 2019",,"July 8, 2021","Sage Investigational Site, Dothan, Alabama, United States|Sage Investigational Site, Phoenix, Arizona, United States|Sage Investigational Site, Little Rock, Arkansas, United States|Sage Investigational Site, Anaheim, California, United States|Sage Investigational Site, Cerritos, California, United States|Sage Investigational Site, Costa Mesa, California, United States|Sage Investigational Site, Glendale, California, United States|Sage Investigational Site, Irvine, California, United States|Sage Investigational Site, Los Alamitos, California, United States|Sage Investigational Site, Newport Beach, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Riverside, California, United States|Sage Investigational Site, San Diego, California, United States|Sage Investigational Site, Temecula, California, United States|Sage Investigational Site, Torrance, California, United States|Sage Investigational Site, Colorado Springs, Colorado, United States|Sage Investigational Site, Denver, Colorado, United States|Sage Investigational Site, Cromwell, Connecticut, United States|Sage Investigational Site, New Haven, Connecticut, United States|Sage Investigational Site, Norwich, Connecticut, United States|Sage Investigational Site, Brandon, Florida, United States|Sage Investigational Site, Coral Springs, Florida, United States|Sage Investigational Site, Hialeah, Florida, United States|Sage Investigational Site, Hialeah, Florida, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Lakeland, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Tampa, Florida, United States|Sage Investigational Site, Alpharetta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Marietta, Georgia, United States|Sage Investigational Site, Savannah, Georgia, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Wichita, Kansas, United States|Sage Investigational Site, Towson, Maryland, United States|Sage Investigational Site, Watertown, Massachusetts, United States|Sage Investigational Site, Saint Charles, Missouri, United States|Sage Investigational Site, Lincoln, Nebraska, United States|Sage Investigational Site, Cherry Hill, New Jersey, United States|Sage Investigational site, Marlton, New Jersey, United States|Sage Investigational Site, Princeton, New Jersey, United States|Sage Investigational Site, Albuquerque, New Mexico, United States|Sage Investigational Site, Brooklyn, New York, United States|Sage Investigational Site, Brooklyn, New York, United States|Sage Investigational Site, Glen Oaks, New York, United States|Sage Investigational Site, Mount Kisco, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, Beachwood, Ohio, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational site, Cincinnati, Ohio, United States|Sage Investigational Site, North Canton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Salem, Oregon, United States|Sage Investigational Site, Norristown, Pennsylvania, United States|Sage Investigational Site, Plymouth Meeting, Pennsylvania, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Dallas, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Wichita Falls, Texas, United States|Sage Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03864614"
145,"NCT04088448","The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients",,"Completed","No Results Available","Major Depressive Disorder","Drug: Placebo oral tablet|Drug: Metformin","Effect on Hamilton Depression rating scale score (HAM-D score)|TNF-α|BDNF|CRP|IGF-1","Sadat City University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0056/2018","January 1, 2017","June 1, 2020","June 1, 2020","September 12, 2019",,"June 16, 2020","Faculty of Medicine, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04088448"
146,"NCT03737474","A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Brexpiprazole","The frequency of Adverse Events|Mean changes from baseline in Montgomery Åsberg Depression Rating Scale（MADRS) at Week 52.|The proportion of subjects who score 1 or 2 on the Clinical Global Impression-Improvement(CGI-I) scale at Week 52|Mean changes from baseline in Clinical Global Impression-Severity of illness(CGI-S) at Week 52|Mean changes from baseline in Hamiliton Depression Rating Scale(HAM-D) item total scores at Week 52|Mean changes from baseline in Sheehan Disability Scale (SDS) scores at Week 52","Otsuka Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)","Phase 3","248","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-102-00059","October 4, 2018","March 17, 2021","April 13, 2021","November 9, 2018",,"July 1, 2021","Nanko-kokorono clinic, Shirakawa, Japan",,"https://ClinicalTrials.gov/show/NCT03737474"
147,"NCT01148979","Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.",,"Completed","Has Results","Major Depressive Disorder","Drug: Lisdexamfetamine Dimesylate (Vyvanse)|Drug: Placebo","Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.","Mclean Hospital|Shire","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2010-P-000871","September 2010","September 2014","October 2014","June 23, 2010","May 23, 2017","May 23, 2017","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01148979"
148,"NCT02134808","Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Creatine|Drug: Placebo","Brain phosphocreatine (PCr) concentrations|Children's Depression Rating Scale-Revised (CDRS-R); Montgomery-Asberg Depression Rating Scale (MADRS)","Perry Renshaw|University of Utah","Female","12 Years to 21 Years   (Child, Adult)","Phase 4","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00073442","November 21, 2014","June 27, 2017","June 27, 2017","May 9, 2014",,"April 9, 2019","University of Utah School of Medicine, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02134808"
149,"NCT03703414","Characterization of Microbial, Immune and Epigenetic Biomarkers for Major Depressive Disorder and ECT Treatment",,"Unknown status","No Results Available","Major Depressive Disorder","Diagnostic Test: Fecal microbiota composition analysis and blood cytokine level analysis","Correlation between MDD and fecal microbial communities (as determined by NGS sequencing) and as well as immune components (cytokine levels in blood)|Correlation between ECT treatment and fecal microbial communities (as determined by NGS) as well as blood cytokines in MDD patients|Correlation between SSRI treatment and fecal microbial communities (as determined by NGS) as well as blood cytokines in MDD patients","Ziv Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0069-18-ZIV","November 1, 2018","October 31, 2019","October 31, 2019","October 12, 2018",,"October 16, 2018",,,"https://ClinicalTrials.gov/show/NCT03703414"
150,"NCT03697603","A Study of Brexpiprazole in Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Brexpiprazole|Drug: Placebo","Mean changes from baseline in Montgomery Åsberg Depression Rating Scale (MADRS) total scores at last visit of the double-blind period|The proportion of subjects who score 1 or 2 on the Clinical Global Impression-Improvement (CGI-I) scale at Week 14","Otsuka Pharmaceutical Co., Ltd.","All","20 Years to 64 Years   (Adult)","Phase 2|Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-102-00058","July 30, 2018","July 2022","July 2022","October 5, 2018",,"July 19, 2021","Nanko-kokorono clinic, Fukushima, Japan",,"https://ClinicalTrials.gov/show/NCT03697603"
151,"NCT04353921","A Two-Year Observational Follow-up Study of Subjects With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control",,"Enrolling by invitation","No Results Available","Major Depressive Disorder","Other: No intervention will be administered as part of this study.","Montgomery-Asberg Depression Rating Scale","Usona Institute","All","21 Years to 65 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PSIL201-LTFU","April 2020","October 2022","October 2022","April 21, 2020",,"April 21, 2020","Segal Trials, Lauderhill, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04353921"
152,"NCT00411242","Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: agomelatine|Drug: placebo","Change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale (HAM-D17)|To evaluate the proportion of patients who demonstrate clinical improvement at Week 8, where improvement is defined by a score of 1 or 2 on the CGI-I scale|To evaluate the proportion of patients who achieve remission at Week 8, where remission is defined by a total score of < or =7 on the HAM-D17|To evaluate efficacy with respect to the proportion of patients who demonstrate clinical response, where response is defined by a reduction of at least 50% in the baseline HAM-D17 at week 8|To evaluate the change from baseline to week 8 on the subscale scores (Maier, anxiety, retardation and sleep) of the clinician-rated HAM-D17|To evaluate subjective sleep (onset and quality), as measured by the scores on the Leeds Sleep Evaluation Questionnaire (LSEQ) at week 8","Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","503","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAGO178A2302","December 2006","January 2008",,"December 13, 2006",,"December 23, 2020","Novartis Investigative Site, Mesa, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, North Miami, Florida, United States|Novartis Investigative Site, North Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Smyrna, Georgia, United States|Novartis Investigative Site, Hoffman Estates, Illinois, United States|Novartis Investigative Site, Hoffman Estates, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Prairie Village, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Shreveport, Louisiana, United States|Novartis Investigative Site, Glen Burnie, Maryland, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Kenilworth, New Jersey, United States|Novartis Investigative Site, Summit, New Jersey, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Cedarhurst, New York, United States|Novartis Investigative Site, Fresh Meadows, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Staten Island, New York, United States|Novartis Investigative Site, West Allis, New York, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Medford, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Irving, Texas, United States|Novartis Investigative Site, Arlington, Virginia, United States|Novartis Investigative Site, Bellevue, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00411242"
153,"NCT01110889","Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Agomelatine (AGO178C)|Drug: Placebo","Change from Baseline to endpoint at Week 8 using the total score of the Hamilton Depression Rating Scale|Effect on subjective sleep, as measured by the score of the Leeds Sleep Evaluation Questionnaire (LSEQ) domain ""quality of sleep"" at Week 8|Proportion of patients who demonstrate clinical response, where response is defined by a reduction of at least 50% in the Baseline clinician-rated HAM-D total score at Week 8 endpoint|Proportion of patients who demonstrate clinical improvement at Week 8, where improvement is defined by a score of 1 or 2 on the CGI-I scale|Proportion of patients who achieve remission|Safety and tolerability by adverse events and serious adverse events, and assessment of suicidal ideation and behavior by Columbia Suicide Severity Rating Scale.","Novartis Pharmaceuticals|Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","582","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAGO178C2301","May 2010","July 2011",,"April 27, 2010",,"December 23, 2020","Birmingham Psychiatry, Birmingham, Alabama, United States|Southwestern Research Institute, Beverly Hills, California, United States|Pharmacology Research Institute, Encino, California, United States|Mood & Anxiety Research, Fresno, California, United States|Excell Research, Inc, Oceanside, California, United States|Cnri-La, Llc, Pico Rivera, California, United States|CNRI San Diego, San Diego, California, United States|University of California San Diego Medical Center, San Diego, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Clinical Research Institute of South Florida, Hialeah, Florida, United States|Florida Clinical Research Center LLC, Maitland, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Broward Research Group, Pembroke Pines, Florida, United States|Quantum Lab. N. Broward Memory Disorder Center, Pompano Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Hawaii Clinical Research Center, Honolulu, Hawaii, United States|Mountain West Clinical Trials, Eagle, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|CTT Clinical Trials Technology, Prairie Village, Kansas, United States|Clinical Trials Management, Metairie, Louisiana, United States|Mount Auburn Medical Associates, Watertown, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|Comprehensive Psychiatric Associates, Gladstone, Missouri, United States|Psychopharmacology Research Association of Princeton, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates Of Albany, P.C., Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Neurobehavioral Research Inc., Cedarhurst, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Odyssey Research Services, Fargo, North Dakota, United States|The Ohio State University - Harding Hospital, Columbus, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Sunstone Medical Research, LLC, Medford, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Psychiatric Consultants, Franklin, Tennessee, United States|KRK Medical Research, Dallas, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Texas Center for Drug Development, Houston, Texas, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Inspira Clinical Research, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01110889"
154,"NCT04007367","A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder",,"Suspended","No Results Available","Major Depressive Disorder","Drug: SAGE-217|Drug: Placebo","Time to relapse during the Double-Blind (DB) Phase (days; from first dose of study drug in the DB Phase to relapse [date] during the DB Phase).|Percentage of subjects who relapse during the DB Phase.|Change from baseline in the 17-item HAM-D total score at the end of each 14-day treatment period in the DB Phase.|HAM-D response at the end of each 14-day treatment period in the DB Phase, defined as a ≥50% reduction in HAM-D score from baseline.|HAM-D remission at the end of each 14-day treatment period in the DB Phase, defined as HAM-D total score ≤7.|CGI-I response, defined as ""much improved"" or ""very much improved"", at the end of each 14-day treatment period in the DB Phase.|Change from baseline in Clinical Global Impression - Severity (CGI-S) score at the end of each 14-day treatment period in the DB Phase.|Change from baseline in 9-item Patient Health Questionnaire (PHQ-9) score at the end of each 14-day treatment period in the DB Phase.|Time to relapse during the DB phase (days; from first dose of study drug in DB Phase to relapse [date] during the DB Phase) for subjects who achieved HAM-D remission in the OL Phase.|Incidence of treatment-emergent adverse events (TEAEs).","Sage Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-MDD-302","August 21, 2019","December 2021","December 2021","July 5, 2019",,"February 17, 2021","Sage Investigational Site, Bentonville, Arkansas, United States|Sage Investigational Site, Bellflower, California, United States|Sage Investigational Site, Garden Grove, California, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Riverside, California, United States|Sage Investigational Site, San Diego, California, United States|Sage Investigational Site, San Marcos, California, United States|Sage Investigational Site, Sherman Oaks, California, United States|Sage Investigational Site, Coral Springs, Florida, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Lauderhill, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Alpharetta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Lincolnwood, Illinois, United States|Sage Investigational Site, Lake Charles, Louisiana, United States|Sage Investigational Site, Gaithersburg, Maryland, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Methuen, Massachusetts, United States|Sage Investigational Site, Watertown, Massachusetts, United States|Sage Investigational Site, Ann Arbor, Michigan, United States|Sage Investigational Site, Las Vegas, Nevada, United States|Sage Investigational Site, Berlin, New Jersey, United States|Sage Investigational Site, Cherry Hill, New Jersey, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Albuquerque, New Mexico, United States|Sage Investigational Site, Jamaica, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, Rochester, New York, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, North Canton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Allentown, Pennsylvania, United States|Sage Investigational Site, Memphis, Tennessee, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Dallas, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, Wichita Falls, Texas, United States|Sage Investigational Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04007367"
155,"NCT04069819","The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Cilostazol 50 MG Oral Tablet|Drug: Escitalopram|Drug: Placebo","Effect on Hamilton Depression rating scale score (HAM-D score)|Effect on biological markers","Sadat City University","All","18 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0044/2019","August 1, 2019","December 31, 2020","October 30, 2021","August 28, 2019",,"July 20, 2021","Faculty of Medicine, Shibīn Al Kawm, Egypt",,"https://ClinicalTrials.gov/show/NCT04069819"
156,"NCT03554447","Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Drug: Escitalopram 20 mg tablet + Placebo","Effect on Hamilton Depression rating scale score (HAM-D score)|Effect on biological markers","Mahmoud Samy Abdallah|Sadat City University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0074/2015","April 20, 2015","December 1, 2017","December 31, 2018","June 13, 2018",,"June 16, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03554447/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03554447"
157,"NCT01110902","Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Drug: Agomelatine (AGO178C)|Drug: Placebo","Change from Baseline to endpoint at Week 8 using the total score of the Hamilton Depression Rating Scale|Effect on subjective sleep, as measured by the score of the Leeds Sleep Evaluation Questionnaire (LSEQ) domain ""quality of sleep"" at Week 8|Proportion of patients who demonstrate clinical response, where response is defined by a reduction of at least 50% in the Baseline clinician-rated HAM-D total score at Week 8 endpoint|Proportion of patients who demonstrate clinical improvement at Week 8, where improvement is defined by a score of 1 or 2 on the CGI-I scale|Proportion of patients who achieve remission|Safety and tolerability by adverse events and serious adverse events, and assessment of suicidal ideation and behavior by Columbia Suicide Severity Rating Scale.","Novartis Pharmaceuticals|Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","589","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAGO178C2302","May 2010","June 2011","June 2011","April 27, 2010",,"December 24, 2020","University of Alabama at Birmingham, Department of Psychiatry, Birmingham, Alabama, United States|ATP Clinical Research, Costa Mesa, California, United States|Valley Clinical Research, El Centro, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Anderson Clinical Research, Redlands, California, United States|Affiliated Research Institute, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|ICSL Clinical Studies, Altamonte Springs, Florida, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Arocha Research Center, Coral Gables, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Joliet Center for Clinical Research, Joliet, Illinois, United States|CNS Clinical Trials, Park Ridge, Illinois, United States|Deaconess Clinic, Evansville, Indiana, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Pharmasite Research, Pikesville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Clinical Trials, Brighton, Massachusetts, United States|Mercy Health Research, Saint Louis, Missouri, United States|Premier Psychiatry Group, LLC, Lincoln, Nebraska, United States|CRI Worldwide, LLC - Lourdes Division, Willingboro, New Jersey, United States|Social Psychiatric Research Institute, Brooklyn, New York, United States|Eastside Comprehensive Medical Service, New York, New York, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|SP Research, Oklahoma City, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Summit Research Network, Portland, Oregon, United States|CRI Worldwide, LLC - Kirkbride Division, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|CNS Healthcare, Memphis, Tennessee, United States|Research Strategies, Memphis, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|Claghorn-Lesem Research Clinic, Inc., Houston, Texas, United States|University of Utah, Department of Psychiatry, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research, Seattle, Washington, United States|Caribbean Research and Education Center, Bayamon, Puerto Rico|Dharma Institute and Research Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01110902"
158,"NCT01583998","Electronic-Measurement Based Care for Major Depressive Disorder","e-MBC","Withdrawn","No Results Available","Major Depressive Disorder","Behavioral: e-MBC","Patient Health Questionnaire (PHQ-9)|Frequency, Intensity, and Burden of Side Effect Rating (FIBSER)|Patient Satisfaction Questionnaire (PSQ)|Physician Evaluation of Ease of Use Survey (EEUS)|Physician Evaluation of Usefulness Survey (EUS)","University of Texas Southwestern Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R03MH092509-01","June 2011","December 2016","December 2016","April 24, 2012",,"February 5, 2019","The University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01583998"
159,"NCT04751071","The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Roflumilast 250Mcg Tab|Drug: Placebo","Effect on Hamilton Depression rating scale score (HAM-D score)|Effect on biological markers","Sadat City University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NS10/2021","February 1, 2021","July 1, 2022","July 1, 2022","February 11, 2021",,"February 11, 2021","Faculty of Pharmacy, Shibeen Elkom, Menoufia, Egypt",,"https://ClinicalTrials.gov/show/NCT04751071"
160,"NCT02685982","Treating Major Depressive Disorder With Music and Low-frequency Rhythmic Sensory Stimulation",,"Completed","No Results Available","Major Depressive Disorder","Device: Rhythmic Sensory Stimulation","Change in MADRS (Montgomery-Asberg Depression Rating Scale) scores from baseline","University Health Network, Toronto|University of Toronto","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-9799","April 2016","August 2017","August 2017","February 19, 2016",,"December 13, 2017",,,"https://ClinicalTrials.gov/show/NCT02685982"
161,"NCT01569711","Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder","PRESTHYM","Completed","No Results Available","Major Depressive Disorder, Recurrent, Unspecified","Procedure: Deep brain stimulation of nucleus accumbens","response after four months (M5) of DBS months defined as a 50% decrease in HDRS score|Remission (defined as a score in the HDRS ≤ 7) after 4 months|Duration of remission in the year of postoperative follow-up|Obtaining an overall score on the scale Anxiety Hamilton (HARS) ≤ 10 during the year of postoperative follow-up|Getting a score from 1 (""very much improved"") or 2 (""strongly improved "") to item 2 of the Clinical Global Impression (CGI) during the year of postoperative follow-up|Obtaining a score ≥ 60 at the level of Global Assessment of Functioning (GAF) during the year of postoperative follow-up|Changes in score on the scale of social adjustment in its self-assessment by (SAS-SR) in the year of postoperative follow-up|Evaluation of tolerance to treatment by clinicians, and by the patient and his family circle, reporting by the patient for adverse events at each follow-up visits after surgery, completion of the initial neuropsychological checkup|Effect of DBS at M9 after the DBS on caudate nucleus in case of non response at M5 after the DBS.","Rennes University Hospital","All","30 Years to 60 Years   (Adult)",,"6","Other","Observational","Time Perspective: Prospective","2008-A00234-51","February 2009","May 2013","May 2013","April 3, 2012",,"May 27, 2015","Bordeaux UH, Bordeaux, France|Gabriel montpied University Hospital, Clermont-Ferrand, France|Grenoble University Hospital (Nord Hospital), Grenoble, France|Lille UH (Roger Salengro Hospital), Lille, France|Lyon UH (Pierre Wertheimer Hospital), Lyon, France|La Salpétrière UH, Paris, France|Sainte Anne UH, Paris, France|Poitiers UH, Poitiers, France|Rennes UH, Rennes, France|Toulouse UH, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01569711"
162,"NCT01325532","Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Device: Active CES|Device: Sham CES","Change in Hamilton Depression Rating Scale (HAM-D 17) Score From Baseline to Week 3|Reported Side Effects Based on PRISE AE Scores|Change in Global Sleep Scores on the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Week 3.","Massachusetts General Hospital|Fisher Wallace Labs, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2010 P000461","November 2010","January 2014","January 2015","March 29, 2011","June 1, 2016","June 1, 2016","Depression Clinical and Research Program at Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01325532"
163,"NCT03672175","A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: SAGE-217|Drug: Placebo","Change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score.|Change from baseline in the 17-item HAM-D total score at other timepoints.|Change from baseline in the Clinical Global Impression - Improvement (CGI-I) response, defined as ""much improved"" or ""very much improved"".|Change from baseline in Clinical Global Impression - Severity (CGI-S) score.|Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score.|Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS).|Incidence and severity of adverse events/serious adverse events.","Sage Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","581","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-MDD-301","December 7, 2018","September 24, 2019","March 17, 2020","September 14, 2018",,"October 22, 2020","Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Bellflower, California, United States|Sage Investigational Site, Garden Grove, California, United States|Sage Investigational Site, Glendale, California, United States|Sage Investigational Site, National City, California, United States|Sage Investigational Site, Oakland, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Pico Rivera, California, United States|Sage Investigational Site, Redlands, California, United States|Sage Investigational Site, San Diego, California, United States|Sage Investigational Site, Sherman Oaks, California, United States|Sage Investigational Site, Temecula, California, United States|Sage Investigational Site, Coral Springs, Florida, United States|Sage Investigational Site, Hollywood, Florida, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Lauderhill, Florida, United States|Sage Investigational Site, Maitland, Florida, United States|Sage Investigational Site, North Miami, Florida, United States|Sage Investigational Site, Orange City, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Site Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Skokie, Illinois, United States|Sage Investigational Site, Pikesville, Maryland, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, O'Fallon, Missouri, United States|Sage Investigational Site, Saint Louis, Missouri, United States|Sage Investigational Site, Las Vegas, Nevada, United States|Sage Investigational Site, Berlin, New Jersey, United States|Sage Investigational Site, Jamaica, New York, United States|Sage Investigational Site, Rochester, New York, United States|Sage Investigational Site, Charlotte, North Carolina, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, North Canton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Portland, Oregon, United States|Sage Investigational Site, Portland, Oregon, United States|Sage Investigational Site, Allentown, Pennsylvania, United States|Sage Investigational Site, Charleston, South Carolina, United States|Sage Investigational Site, Memphis, Tennessee, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Bellaire, Texas, United States|Sage Investigational Site, DeSoto, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, Wichita Falls, Texas, United States|Sage Investigational Site, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03672175"
164,"NCT01198795","Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram","Patients With Any Treatment Emergent Adverse Events (TEAEs)","Forest Laboratories","All","7 Years to 11 Years   (Child)","Phase 4","162","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCT-MD-55","September 2010","January 2013","April 2013","September 10, 2010","March 14, 2014","March 14, 2014","Forest Investigative Site 001, Dothan, Alabama, United States|Forest Investigative Site 006, San Diego, California, United States|Forest Investigative Site 018, Santa Ana, California, United States|Forest Investigative Site 008, Washington, District of Columbia, United States|Forest Investigative Site 013, Jacksonville Beach, Florida, United States|Forest Investigative Site 017, Atlanta, Georgia, United States|Forest Investigative Site 004, Overland Park, Kansas, United States|Forest Investigative Site 011, Creve Coeur, Missouri, United States|Forest Investigative Site 007, Omaha, Nebraska, United States|Forest Investigative Site 002, Cleveland, Ohio, United States|Forest Investigative Site 012, Oklahoma City, Oklahoma, United States|Forest Investigative Site 003, Philadelphia, Pennsylvania, United States|Forest Investigative Site 010, Dallas, Texas, United States|Forest Investigative Site 014, Clinton, Utah, United States|Forest Investigative Site 005, Bellevue, Washington, United States|Forest Investigative Site 015, Kirkland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01198795"
165,"NCT02860962","A Trial of Dextromethorphan for Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Dextromethorphan Hydrobromide","Montgomery-Åsberg Depression Rating Scale (MADRS)","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00052508","August 2016","June 2017","June 2017","August 10, 2016",,"October 25, 2018",,,"https://ClinicalTrials.gov/show/NCT02860962"
166,"NCT01428661","Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder","MAGELLAN","Completed","Has Results","Major Depressive Disorder","Drug: tasimelteon|Drug: placebo","Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)","Vanda Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","507","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VP-VEC-162-2301","September 2011","January 2013","May 2013","September 5, 2011","June 19, 2015","June 19, 2015","Vanda Investigational Site, Garden Grove, California, United States|Vanda Investigational Site, Irvine, California, United States|Vanda Investigational Site, Los Alamitos, California, United States|Vanda Investigational Site, Oakland, California, United States|Vanda Investigational Site, Oceanside, California, United States|Vanda Investigational Site, San Diego, California, United States|Vanda Investigational Site, Sherman Oaks, California, United States|Vanda Investigational Site, Torrance, California, United States|Vanda Investigational Site, Denver, Colorado, United States|Vanda Investigational Site, Bradenton, Florida, United States|Vanda Investigational Site, Jacksonville, Florida, United States|Vanda Investigational Site, Maitland, Florida, United States|Vanda Investigational Site, N. Miami, Florida, United States|Vanda Investigational Site, Orlando, Florida, United States|Vanda Investigational Site, Atlanta, Georgia, United States|Vanda Investigational Site, Atlanta, Georgia, United States|Vanda Investigational Site, Chicago, Illinois, United States|Vanda Investigational Site, Joliet, Illinois, United States|Vanda Investigational Site, Prairie Village, Kansas, United States|Vanda Investigational Site, Baltimore, Maryland, United States|Vanda Investigational Site, Boston, Massachusetts, United States|Vanda Investigational Site, Omaha, Nebraska, United States|Vanda Investigational Site, Las Vegas, Nevada, United States|Vanda Investigational Site, Toms River, New Jersey, United States|Vanda Investigational Site, Willingboro, New Jersey, United States|Vanda Investigational Site, Brooklyn, New York, United States|Vanda Investigational Site, Mt. Kisco, New York, United States|Vanda Investigational Site, New York, New York, United States|Vanda Investigational Site, Rochester, New York, United States|Vanda Investigational Site, Staten Island, New York, United States|Vanda Investigational Site, Cincinnati, Ohio, United States|Vanda Investigational Site, Dayton, Ohio, United States|Vanda Investigational Site, Portland, Oregon, United States|Vanda Investigational Site, Lincoln, Rhode Island, United States|Vanda Investigational Site, Memphis, Tennessee, United States|Vanda Investigational Site, Austin, Texas, United States|Vanda Investigational Site, Dallas, Texas, United States|Vanda Investigational Site, Salt Lake City, Utah, United States|Vanda Investigational Site, Seattle, Washington, United States|Vanda Investigational Site, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01428661"
167,"NCT02085135","A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: ALKS 5461","Number of Subjects With Adverse Events (AEs)","Alkermes, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK5461-210","February 2014","September 2014","September 2014","March 12, 2014","March 27, 2019","August 14, 2019","Alkermes Investigational Site, Jacksonville, Florida, United States|Alkermes Investigational Site, Orlando, Florida, United States|Alkermes Investigational Site, Atlanta, Georgia, United States|Alkermes Investigational Site, Saint Charles, Missouri, United States|Alkermes Investigational Site, Staten Island, New York, United States|Alkermes Investigational Site, Dayton, Ohio, United States|Alkermes Investigational Site, Allentown, Pennsylvania, United States|Alkermes Investigational Site, Bellevue, Washington, United States|Alkermes Investigational Site, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT02085135"
168,"NCT02616549","Multicomponent Yoga Intervention for Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Sudarshan Kriya Yoga","17-item Hamilton Depression Rating Scale|Beck Depression Inventory|Beck Anxiety Inventory|Columbia Suicide Severity Rating Scale","University of Pennsylvania","All","18 Years to 67 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","820672","October 2014","December 2015","December 2015","November 30, 2015",,"December 8, 2015","Mood & Anxiety Disorders Research and Treatment Program, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02616549"
169,"NCT02660528","Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: Tocilizumab","Absolute Change on Hamilton Depression Rating Scale (HDRS)|Proportion of Subjects Achieving Remission (HDRS Score < 7)|Proportion of Subjects Achieving Response (HDRS Score Decreased >50% From Baseline)","Brigham and Women's Hospital","All","30 Years to 60 Years   (Adult)","Phase 2","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015P001263","April 2016","June 2020","June 2020","January 21, 2016","October 20, 2020","October 20, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02660528/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02660528"
170,"NCT03095820","Multidomain Intervention for Older Adults With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Supportive therapy|Behavioral: Multidomain intervention","Montgomery-Asberg Depression Rating Scale(MADRS)|resting-state fMRI","Ajou University School of Medicine","All","60 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AJIRB-SBR-SUR-15-132","March 1, 2016","December 31, 2016","January 31, 2017","March 30, 2017",,"August 22, 2018","Ajou University Hospital, Suwon, Gyunggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03095820"
171,"NCT03569475","Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Fluoxetine|Drug: Placebo","Change from baseline in Children's Depression Rating Scale- Revised (CDRS-R)|Change from baseline in Clinical Global Impression-Severity (CGI-S) scale","Allergan","All","7 Years to 17 Years   (Child)","Phase 3","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-14","July 6, 2018","March 1, 2021","March 1, 2021","June 26, 2018",,"May 7, 2021","Woodland International Research Group, Little Rock, Arkansas, United States|Care Access Research, Beverly Hills, Beverly Hills, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Alliance Research, Long Beach, California, United States|Excell Research, Inc, Oceanside, California, United States|Orange County Neuropsychiatric Research Center, LLC, Orange, California, United States|Children's National Health System, Washington, District of Columbia, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Zynak Clinical, Lauderdale Lakes, Florida, United States|Columbus Clinical Services, LLC, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|INOVA clinical trials and research center, Tyrone, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR Conventions Limited, Naperville, Illinois, United States|AMR-Baber Research, Inc., Naperville, Illinois, United States|KU Wichita Center for Clinical Research, Wichita, Kansas, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Millennium Center for Clinical Research, Creve Coeur, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, Bellaire, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|Mech Healthcare Associates, Frisco, Texas, United States|Biopharma Informatic, LLC, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Northpointe Psychiatry, Lewisville, Texas, United States|Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States|AIM Trials, Plano, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03569475"
172,"NCT01957410","A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: Ketamine|Drug: Placebo","Comparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Somatosensory Evoked Potential (SEPs) Amplitudes at 4 Hours Postdose on Day 1|Comparison of Ketamine Responders and Ketamine Non-responders in the Change From Baseline in Motor Evoked Potential (MEPs) Amplitudes at 4 Hours Postdose on Day 1","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR102607|KETIVTRD2004","February 2014","September 2015","September 2015","October 8, 2013","January 27, 2017","January 27, 2017","Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01957410"
173,"NCT00761306","Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine (Lu AA21004)","Number of Patients With Adverse Events (AEs)|Percentage of Patients Who Withdrew Due to Intolerance to Treatment|Change From Baseline in MADRS Total Score After 52 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment|Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)|Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11492C|2007-000905-31","June 2007","September 2008","October 2008","September 29, 2008","December 17, 2013","January 29, 2014",,,"https://ClinicalTrials.gov/show/NCT00761306"
174,"NCT00672958","Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine|Drug: Placebo","Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6|Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed|Percentage of Responders in HAM-D24 Total Score by Study Visit|Percentage of Participants in MADRS Remission at Week 6|Percentage of Participants With a Sustained Response in HAM-D24|Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in Hamilton Anxiety Scale (HAM-A)|Change From Baseline in Clinical Global Impression Scale-Severity of Illness|Clinical Global Impression Scale-Global Improvement Scale|Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)|Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6|Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire","Takeda|H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LuAA21004_303|U1111-1114-2328","April 2008","November 2008","November 2008","May 6, 2008","December 13, 2013","December 13, 2013","Birmingham, Alabama, United States|Cerritos, California, United States|Encino, California, United States|Fresno, California, United States|San Diego, California, United States|Farmington, Connecticut, United States|Jacksonville, Florida, United States|North Miami, Florida, United States|Tampa, Florida, United States|Hoffman Estate, Illinois, United States|Lafayette, Indiana, United States|Valparaiso, Indiana, United States|Shreveport, Louisiana, United States|St. Paul, Minnesota, United States|Florissant, Missouri, United States|St. Charles, Missouri, United States|Las Vegas, Nevada, United States|Rochester, New York, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Lincoln, Rhode Island, United States|North Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Lake Jackson, Texas, United States|Wichita Falls, Texas, United States|Brown Deer, Wisconsin, United States|Middleton, Wisconsin, United States|Hull, Quebec, Canada|Mexico, D.F., Mexico|San Luis Potosi, Mexico",,"https://ClinicalTrials.gov/show/NCT00672958"
175,"NCT01149213","Follow-up Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: transcranial direct current stimulation","Relapse from depression","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","42","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USP-HU-003","June 2010","December 2011","March 2012","June 23, 2010",,"March 27, 2012","University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01149213"
176,"NCT02922556","Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD)","MDD","Completed","No Results Available","Major Depressive Disorder","Other: Computerized Plasticity-Based Adaptive Cognitive Training|Other: Commercially available computerized training","Change scores for depressive symptoms using Beck Depression Scale (BDI)|Change scores for anxiety symptoms using Generalized Anxiety Disorder (GAD-7)|Change scores for functional health and well being using the 12-Item Short Form Health Survey (SF-12)|Change scores for depressive symptoms using Patient Health Questionnaire (PHQ-9)","Posit Science Corporation","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSC-1008-2015","September 2015","June 21, 2019","June 21, 2019","October 4, 2016",,"June 25, 2019","Posit Science Corporation, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02922556"
177,"NCT00672620","Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo","Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8|Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed|Percentage of Responders in HAM-D 24 Total Score by Study Visit|Percentage of Participants With a Sustained Response in HAM-D24|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score|Clinical Global Impression Scale-Global Improvement Scale|Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8|Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire","Takeda|H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","611","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LuAA21004_304|U1111-1114-3497","April 2008","November 2008","December 2008","May 6, 2008","December 18, 2013","December 18, 2013","Beverly Hills, California, United States|Irvine,, California, United States|Santa Ana, California, United States|Torrance, California, United States|Upland, California, United States|Bradenton, Florida, United States|Coral Springs,, Florida, United States|Fort Walton Beach, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Maitland, Florida, United States|Orlando, Florida, United States|South Miami,, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Smyrna, Georgia, United States|Chicago,, Illinois, United States|Libertyville, Illinois, United States|Oak Brook, Illinois, United States|Prairie Village, Kansas, United States|Owensboro,, Kentucky, United States|Baltimore, Maryland, United States|Pittsfield, Massachusetts, United States|Worcester,, Massachusetts, United States|Flowood, Mississippi, United States|New York, New York, United States|Olean, New York, United States|Beachwood, Ohio, United States|Toledo, Ohio, United States|Oklahoma City,, Oklahoma, United States|Allenton, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Memphis, Tennessee, United States|Austin, Texas, United States|San Antonio, Texas, United States|Salt Lake City,, Utah, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00672620"
178,"NCT02972398","N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders",,"Unknown status","No Results Available","Major Depressive Disorders","Drug: N-acetylcysteine|Drug: placebo comparator of N-acetylcysteine","The change from baseline Hamilton Depression Rating Scale (HAMD)-17 items at week2,4,6,8,10,and 12.|The change from baseline HAMD-17 items at week14,16,18,and 20.|The effects of augmentation treatment with NAC on scores in Beck Anxiety Inventory (BAI)|The effects of augmentation treatment with NAC on scores in Inventory of Depressive Symptoms-Self-Rated (IDS-SR)|The effects of augmentation treatment with NAC on scores in WHO Disability Assessment Schedule Ⅱ (WHODAS-Ⅱ)|The effects of augmentation treatment with NAC on scores in Montreal Cognitive Assessment (MoCA)|The effects of augmentation treatment with NAC on local brain activity (fMRI and DTI)|The effects of augmentation treatment with NAC on a range of biomarkers representing the alleged underlying pathophysiological mechanisms|Assessments the side effects measured with Checklist of 52 Somatic Items (CSI)","Tianjin Anding Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NAC-2015-TJAH","September 2015","March 2020","September 2020","November 23, 2016",,"April 10, 2019","Tianjin Anding Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02972398"
179,"NCT01221935","Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Other: Pristiq first-line treatment charts|Other: Pristiq second-line treatment charts|Other: SNRI or SSRI first-line treatment charts|Other: SNRI or SSRI second-line treatment charts","300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment.|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI).|800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment.|800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).|Incidence of adverse events and Incidence of discontinuation due to adverse events|Percent of patients experiencing relapse|Length of time to relapse|Percent of discontinuation / medication switches due to lack of efficacy|Subjective physician assessment of symptom control","Pfizer","All","18 Years and older   (Adult, Older Adult)",,"2701","Industry","Observational","Time Perspective: Retrospective","3151A1-4431|B2061039","September 2009","January 2010","January 2010","October 18, 2010",,"January 26, 2011",,,"https://ClinicalTrials.gov/show/NCT01221935"
180,"NCT03785652","Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Drug: LY03005 extended-release tablets 40 mg|Drug: LY03005 extended-release tablets 80 mg group|Drug: LY03005 extended-release tablets 120 mg group|Drug: LY03005 extended-release tablets 160 mg group|Drug: Placebo group","Hamilton Depression Scale|Montgomery- Åsberg Depression Rating Scale(MADRS)|Clinical Global Impression Scale - improvement (CGI-I)","Luye Pharma Group Ltd.|Shandong Luye Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LY03005-CHN-204","October 9, 2015","October 31, 2015","October 31, 2015","December 24, 2018",,"December 24, 2018","Approval Letter of Ethics Committee of The Sixth Hospital of Peking University, Haidian District,, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03785652"
181,"NCT00729755","Creatine Augmentation Treatment in Major Depressive Disorder Subjects",,"Completed","No Results Available","Major Depressive Disorder","Dietary Supplement: Creatine monohydrate|Dietary Supplement: Placebo","Hamilton depression rating scale|Clinical global impression scale|Side effects assessment: the interview and examination by the investigators|Serum inflammatory mediators (eg., IL-1, -2, PGE2, interferon gamma) level|Serum creatinine level|Brain MRI|Montgomery-Asberg depression scale","Ewha Womans University","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIC-08DE00101B","August 2008","May 2012","May 2012","August 7, 2008",,"July 5, 2017","Holy Family Hospital, Bucheon City, Kyunggi-Do, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|St. Paul's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00729755"
182,"NCT00694304","Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine (Lu AA21004)","Number of Patients With Adverse Events (AEs)|Percentage of Patients Who Withdrew Due to Intolerance to Treatment|Change From Baseline in MADRS Total Score After 52 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment|Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment|Change From Baseline in CGI-S Score After 52 Weeks of Treatment|Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)|Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)|Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment|Change From Baseline in SDS Total Score After 52 Weeks of Treatment","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","535","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11984B|EudraCT 2007-004992-21","May 2008","March 2010","April 2010","June 10, 2008","April 1, 2014","April 1, 2014",,,"https://ClinicalTrials.gov/show/NCT00694304"
183,"NCT02180607","Neuronal Responses to Social Feedback in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder",,"fMRI blood-oxygen-level-dependent (BOLD) response","University of Michigan|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)",,"58","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","K01MH085035","October 2013","October 2014","October 2014","July 2, 2014",,"May 28, 2015","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02180607"
184,"NCT01423240","Major Depressive Disorder With Mixed Features","RESOLVE2","Withdrawn","No Results Available","Major Depressive Disorder","Drug: Lurasidone 20 mg|Drug: Lurasidone 60 mg|Drug: Placebo","MADRS|CGI-S","Sunovion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1050305","January 2012","December 2012","December 2012","August 25, 2011",,"December 13, 2012","Birmingham Research Group, Birmingham, Alabama, United States|Sun Valley Behavioral Medical, Imperial, California, United States|Synergy Clinical Research Center, National City, California, United States|Excell Research, Oceanside, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|SMRI, Sherman Oaks, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Florida Research Center, Maitland, Florida, United States|University of Miami, Miller School, Miami, Florida, United States|Miami Research, Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Comprehensive NeuroScience Inc., Atlanta, Georgia, United States|Hawaii Clinical Research Center, Honolulu, Hawaii, United States|Psychiatric Medicine Associates, Skokie, Illinois, United States|Goldpoint Clinical Research, Indianapolis, Indiana, United States|CRI Worldwide, Willingboro, New Jersey, United States|Montefiore Medical Center; Anxiety & Depression Clinic; Dept. of Psychiatry, Bronx, New York, United States|Medical & Behavioral Health Research, New York, New York, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Harry Croft and Associates, San Antonio, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Department of Psychiatry, University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01423240"
185,"NCT03067506","Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology",,"Completed","Has Results","Major Depressive Disorder","Other: No intervention","Percentage of Days on Which Daily N-back Sessions Were Completed|Percentage of Days on Which Daily Mood Assessment Tests Were Completed|Correlation Coefficient Between Measures of Cognition (N-back Scores) and Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) Tests: Spatial Working Memory Between Errors (SWMBE) and Spatial Working Memory Strategy (SWMS)|Correlation Coefficient Between Measures of Cognition (N-back Scores) and Performance on the CANTAB Test: Rapid Visual Information Processing (RVP)","Takeda","All","18 Years to 65 Years   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MDD-5003","March 1, 2017","July 3, 2017","July 3, 2017","March 1, 2017","January 10, 2019","January 10, 2019","Takeda Investigative Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03067506/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03067506/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03067506"
186,"NCT04138290","Post Marketing Study for the Evaluation of Predictix Antidepressant Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Device: Predictix Antidepressant Software tool","success rate of the Predictix tool|Usability","Taliaz Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CL-01-IBR-02","December 2019","December 2020","December 2020","October 24, 2019",,"October 24, 2019","Hospital Pitié Salpétrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04138290"
187,"NCT03222752","Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Cranial Electrotherapy Stimulation|Device: Sham Cranial Electrotherapy Stimulation","Hamilton Depression Scale|Clinical Global Impression - Severity of Illness|Clinical Global Impression - Global Improvement","Electromedical Products International, Inc.","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MDD1","June 5, 2017","December 2021","December 2021","July 19, 2017",,"June 28, 2021","Advanced Psychotherapeutics, Forest, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03222752"
188,"NCT00985504","A Study of Patients With Major Depressive Disorder and Residual Apathy",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine|Drug: Escitalopram","Change From Baseline in the Apathy Evaluation Scale - Clinician Rated Version (AES-C) Total Score at Week 8|Change From Baseline in the Apathy Evaluation Scale-Clinician Rated Version (AES-C) Subscale Scores at Week 8|Change From Baseline in the Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) Total and Individual Item Scores at Week 8|Patient's Global Impressions of Improvement Scale (PGI-I) Rating Scale Score at Week 8|Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Rating Scale at Week 8|Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Item 8 (Inability to Feel) at Week 8|Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total and Item Scores at Week 8|Change From Baseline in the Sheehan Disability Scale (SDS) Total and Individual Scores at Week 8|Percentage of Participants Who Relapsed During 8 Weeks|Number of Days From Baseline to Relapse as Defined by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score ≥16 During 8 Weeks|Percentage of Participants Who Discontinue Due to Lack of Efficacy During 8 Weeks","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","483","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13018|F1J-CR-HMGM","September 2009","December 2010","December 2010","September 28, 2009","October 3, 2011","December 13, 2011","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Everton Park, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Hill, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glenside, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dandenong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prahran, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durango, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frac. Hacienda De Las Cruces, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Douliou City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kao Hsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00985504"
189,"NCT03538691","A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Brexpiprazole|Drug: Placebo|Drug: Citalopram Hydrobromide|Drug: Escitalopram|Drug: Fluoxetine|Drug: Paroxetine|Drug: Sertraline|Drug: Duloxetine|Drug: Venlafaxine Extended Release Oral Capsule","Time-to-Relapse by any criteria as defined in blinded addendum|Change from randomization at week 20 in Sheehan Disability Scale (SDS) mean total score at Week 46|Time-to-functional relapse based on SDS criteria.|Percentage of subjects who relapse|Percentage of subjects maintaining remission|Mean change from randomization at week 20 in Montgomery Asberg Depression Rating Scale (MADRS) total score at Week 46|Mean change from randomization at week 20 in Clinical Global Impression - Severity of Illness (CGI-S) score at Week 46|Mean change from randomization at week 20 in each of the SDS individual item scores at Week 46","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-201-00079","July 13, 2018","September 2022","September 2022","May 29, 2018",,"April 12, 2021","For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03538691"
190,"NCT02436239","A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder","VLZ-MD-23","Completed","Has Results","Major Depressive Disorder","Drug: Vilazodone","Number of Participants to Experience a Treatment Emergent Adverse Event (TEAE)|Change From Baseline in the CDRS-R Total Score|Change From Baseline in the CGI-S Score|Change From Baseline in Clinical Global Impressions-Improvement (CGI-I)","Forest Laboratories","All","7 Years to 17 Years   (Child)","Phase 3","330","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VLZ-MD-23","May 2, 2015","July 23, 2018","July 23, 2018","May 6, 2015","September 11, 2019","September 11, 2019","Alliance Clinical Research, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Woodland International Research Group, INC, Little Rock, Arkansas, United States|CITrials - Bellflower, Bellflower, California, United States|ATP Clinical Research, Costa Mesa, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|PCSD - Feighner Research, San Diego, California, United States|Pacific Clinical Research Medical Group, Hartford, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Palm Springs Research, LLC, Hialeah, Florida, United States|IMIC Inc., Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlantic Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|Neuroscience Research Institute Inc., Oak Park, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Hugo W Moser Research Institute at Kennedy Krieger, Inc., Baltimore, Maryland, United States|Pharmsite Research Inc., Baltimore, Maryland, United States|NeuroScientific Insights, Rockville, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Adams Clinical Trials, LLC, Watertown, Massachusetts, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Erie County Medical Center/State University of New York of Buffalo Affiliate, Buffalo, New York, United States|BioScience Research LLC, Mount Kisco, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Haidar Almhana Nieding LLC, Avon Lake, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Psychiatr, Cleveland, Ohio, United States|Ohio State Univ. Dept of Psychiatry, Columbus, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Research Strategies of Memphis LLC, Memphis, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|UT Health Science Center at Houston, Houston, Texas, United States|Houston Endoscopy and Research Ctr, Houston, Texas, United States|Research Across America, Plano, Texas, United States|Focus and Balance, San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|UVA Center for Psychopharmacology Research in Youth, Charlottesville, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Core Clinical Research, Kirkland, Washington, United States|Okanagan Clinical Trials Inc., Kelowna, British Columbia, Canada|Paediatric Sleep Research Inc, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02436239/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02436239/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02436239"
191,"NCT00555997","A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder","Geodon","Completed","Has Results","Major Depressive Disorder","Drug: Ziprasidone|Drug: Placebo","Hamilton Depression Rating Scale (HAM-D-17) Scores|Responder/Non-responder|Change in 6-VAS-D Scores During Each Phase.","Massachusetts General Hospital|Cambridge Health Alliance|University of Connecticut|Vanderbilt University|Psychiatric Medicine Associates, L.L.C.|Cedars-Sinai Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-P-000623","March 2008","June 2010","June 2010","November 9, 2007","July 3, 2014","July 3, 2014","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Psychiatric Medicine Associates, L.L.C., Chicago, Illinois, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00555997"
192,"NCT03738215","Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Cariprazine|Drug: Placebo","Total score change from baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3111-301-001","November 9, 2018","September 27, 2021","September 27, 2021","November 13, 2018",,"July 30, 2021","Alea Research, Phoenix, Arizona, United States|Atria Clinical Research, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Axiom Research, LLC, Colton, California, United States|California Pharmaceutical Research Institute, Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Synergy Clinical Research, National City, California, United States|Anderson Clinical Research, Redlands, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Viking Clinical Research Ltd, Temecula, California, United States|Collaborative Neuro Science Network, Torrance, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Space Coast Neuropsychiatric Research Institute, Palm Bay, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Medicine and Research Centre, Marietta, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Pillar Clinical Research, LLC, Lincolnwood, Illinois, United States|Neuroscience Research Institute, Winfield, Illinois, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|CBH Health, Gaithersburg, Maryland, United States|Michigan Clinical Research Institute, Ann Arbor, Michigan, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Coastal Carolina Research Center, Charleston, North Carolina, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Richard H. Weisler, MD., Raleigh, North Carolina, United States|Quest therapeutics of Avon Lake, Avon Lake, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|CincyScience (Formerly Professional Psychiatric Services), West Chester, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Houston Clinical Trials, Bellaire, Texas, United States|FutureSearch Trials of Dallas LP, Dallas, Texas, United States|Earle Research, Houston, Texas, United States|AIM Trials, LLC, Plano, Texas, United States|Pillar Clinical Research, Richardson, Texas, United States|Woodstock Research Center d/b/a Neuropsychiatric Associates, LLC, Woodstock, Vermont, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Core Clinical Research, Everett, Washington, United States|State Psychiatric Hospital- Kardzhali, EOOD, Kardzhali, Bulgaria|MHAT, Kazanlak, Bulgaria|First Psychiatric Clinic, Pleven, Bulgaria|Regional Psychiatric Dispensary Ruse, Ruse, Bulgaria|Medical Center Sveti Naum EOOD, Sofia, Bulgaria|Medical Centre - VAS, Targovishte, Bulgaria|DCC Mladost -M, Varna, Bulgaria|DCC Mladost-M, Varna, Bulgaria|Mental Health Center-Veliko Tarnovo, EOOD, Veliko Tarnovo, Bulgaria|Mental Health Center - Vratsa EOOD, Vratsa, Bulgaria|Marienthali Kliinik, Tallinn, Estonia|West Tallinn Central Hospital, Tallinn, Estonia|OU Jaanson and Laane, Tartu, Estonia|Tartu University Hospital Psychiatry Clinic, Tartu, Estonia|Emovis GmbH, Berlin, Germany|MVZ LIO Berlin, Berlin, Germany|Klinikum Chemnitz gGmbH, Klinik fur Psychiatrie, Chemnitz, Germany|Studienzentrum Nordwest, Westerstede, Germany|Obudai Egeszsegugyi Centrum, Budapest, Hungary|Jozsefvarosi szent Kozma Healthcare Center, Budapest, Hungary|Processus Kft - Varoskapu rendelo, Budapest, Hungary|Clinexpert Gyógycentrum, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Nyiro Gyula OPAI, National Institute of Psychiatry and Addic, Budapest, Hungary|Bugat Pal Hospital, Gyongyos, Hungary|Kalocsai Szent Kereszt Korhaz, Kalocsa, Hungary|PsychoTech Kft., Pecs, Hungary|Szt. Borbala County Hospital, Tatabanya, Hungary|Communal institution Cherkasy regional psychiatric hospital of Cherkasy regional Council, Cherkasy, Ukraine|Department of Psychiatry of Narcology and Medical Psychology of IFNMU, Ivano-Frankivsk, Ukraine|Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine"" State Institution , Department of Borderline Psychiatry, Kharkiv, Ukraine|Kharkiv Regional Clinical Psychiatric Hospital No. 3, Kharkiv, Ukraine|SI ""Institution of Neurology, Psychiatry and Narcology NAMS, Kharkiv, Ukraine|Kherson Regional Psychiatric Hospital of Kherson RC, Kherson, Ukraine|Geikivka Regional Psychiatric Hospital, Kryvyy Ryg, Geikivka, Ukraine|Kiev City Psychoneurological Hospital No. 2, Kyiv, Ukraine|Kyiv Railway Clinical Hospital #2 of Branch Health Center of the Public Joint Stock Company Ukrainian Railway, Kyiv, Ukraine|Communal Institution of Lviv Regional Council Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Odesa Regional Psychiatric Hospital No.2, Odesa, Ukraine|Odessa Regional Clinical Psychiatric Hospital, Odessa, Ukraine|Ternopil Regional Municipal Clinical Psychoneurological Hospital, Ternopil, Ukraine|Chair of Neurosurgery, Neurology and Psychiatry, Uzhhorod National University Medical faculty, Uzhhorod, Ukraine|KNP ""Vinnytsia Regional Clinical Psychoneurological Hospital, Vinnitsa, Ukraine|Vinnytsia Regional Psycho-Neurological Hospital, Vinnytsia, Ukraine|MAC Clinical Research-Blackpool, Blackpool, United Kingdom|MAC Clinical Research-Cannock, Cannock, United Kingdom|MAC Clinical Research-Leeds, Leeds, United Kingdom|MAC Clinical Research-Liverpool, Liverpool, United Kingdom|MAC Clinical Research-Manchester, Manchester, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Surrey and Borders Partnership NHS FT, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03738215"
193,"NCT02086929","Trazodone Once a Day in Major Depression Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Trazodone|Drug: Venlafaxine","Hamilton Depression Rating Scale (HAMD) score|Montgomery-Asberg Depression Rating Scale (MADRS) score|Clinical Global Impression (CGI) Severity of Illness score|Clinical Global Impression (CGI) Global improvement score|Percentage of responders|Percentage of patients with remission|Safety profile of trazodone OAD compared to venlafaxine XR","Aziende Chimiche Riunite Angelini Francesco S.p.A","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","364","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","039(C)SC11063","December 2012","April 2014","April 2014","March 13, 2014",,"December 30, 2015","Institute für Psychosomatik, Vienna, Austria|AKH Wien, Vienna, Austria|PRAGTIS, s.r.o., Praha 2, Praha, Czech Republic|Psychiatry Trial, s.r.o., Praha 5, Praha, Czech Republic|MEDICAL SERVICES PRAGUE, s.r.o., Praha 6, Praha, Czech Republic|Neuropsychiatrie s.r.o., Praha 6, Praha, Czech Republic|Saint Anne, s.r.o., Brno-mesto, Czech Republic|SUPERVIZE, s.r.o., Kutna Hora, Czech Republic|BIALBI s.r.o., Litomerice, Czech Republic|Fakultni Nemocnice Olomouc, Klinika Psychiatrie, Olomouc, Czech Republic|MUDr. Eva Soukupová-Psychiatrická praxe, s.r.o., Plzeň, Czech Republic|NZZ- MUDr. Jaroslav Hronek, psychiatrická ambulance, Plzeň, Czech Republic|UOPI di Psichiatria Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Presidio ""Gaspare Rodolico"", Catania, Italy|Clinica Psichiatrica Nuovo Ospedale S. Salvatore Università degli Studi del L'Aquila, L'Aquila, Italy|Ospedale Santa Maria della Misericordia Unità di Degenza Psichiatrica-SPDC, Perugia, Italy|Azienda Ospedaliera Sant'Andrea Università La Sapienza Unità Operativa Complessa di Psichiatria, Rome, Italy|AOUS-Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte Clinica Psichiatrica Universitaria, Siena, Italy|Department of Neurosciences University of Turin, Turin, Italy|Quantum Medical Center Srl, Bucharest, Romania|Spitalul clinic de psihiatrie ""Prof. Dr. Al. Obregia""/Sectia 13, Bucharest, Romania|Spitalul Clinic de Psihiatrie ""Prof. Dr. Al. Obregia""/Sectia 1, Bucharest, Romania|Spitalul Clinc de Urgenta Militar ""Dr. Stefan Odobleja"", Craiova, Craiova, Romania|Spital Clinic de Psihiatrie SOCOLA / Iasi, Iasi, Romania|Spitalul de Psihiatrie ""Dr. Gh.Preda"" Sibiu, Sibiu, Romania|Spitalul Clinc Judetean Mures, Centrul de Sanatate Mintala, Targu Mures, Romania|Psychiatricka ambulancia, Bratislava, Slovakia|MENTUM, s.r.o., Bratislava, Slovakia|EPAMED, s.r.o., Kosice, Slovakia|Psychiatricka nemocnica, Michalovce, Slovakia|Psycholine, s.r.o., Rimavska Sobota, Slovakia|Psychiatricke oddelenie, NsP sv Barbory Roznava, Roznava, Slovakia|Instituto de Investigacion y Asistencia Psiquiatrica - IIAP, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02086929"
194,"NCT00998569","Neurocognitive Enhancement in Major Depressive Disorder","MDDNET","Completed","No Results Available","Major Depressive Disorder","Behavioral: Neurocognitive Enhancement|Behavioral: Wait List","Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance","Queen's University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PSYC-092-09","October 2009","March 2012","March 2012","October 20, 2009",,"August 31, 2015","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00998569"
195,"NCT01423253","Major Depressive Disorder With Mixed Features - Extension","RESOLVE3","Completed","Has Results","Major Depressive Disorder","Drug: Lurasidone","Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)|Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)|Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)|Mean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores|Change From Baseline to Week 12 (LOCF) in CGI-S Score|Change From Baseline to Week 12 (LOCF) in the YMRS Total Score|Change From Baseline to Week 12 (LOCF) in the HAM-A Total Score|Change From Baseline to Week 12 (LOCF) in the SDS Total Score","Sunovion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","48","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1050306","September 2011","October 2013","October 2013","August 25, 2011","October 14, 2015","April 8, 2016","Birmingham Psychiatry Pharmaceutical Studies, Inc, Birmingham, Alabama, United States|Synergy Clinical Research Center, Escondido, California, United States|Collaborative Neuro Science Network, Inc., Garden Grove, California, United States|Stanford -VA Palo Alto Health Care System, Palo Alto, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Florida Clinical Research Center, LLC, Sarasota, Florida, United States|Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders, Boston, Massachusetts, United States|St. Charles Psychiatric Associates/Midwest Research Group, St. Charles, Missouri, United States|Village Clinical Research Inc., New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Psychiatry and Behavioral Sciences, Duke, Durham, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|CRI Worldwide - Kirkbride, Philadelphia, Pennsylvania, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Dept. of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01423253"
196,"NCT02362529","Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Minocycline|Drug: Placebo|Drug: Celecoxib","Translocator total distribution volume (TSPO VT): Treatment Effect of Minocycline in MDE Subjects|Translocator total distribution volume (TSPO VT): Difference between MDE and healthy subjects|Change in Hamilton Depression Rating Scale Score","Centre for Addiction and Mental Health","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","REB056/2014","February 2015","April 2019","April 2019","February 13, 2015",,"May 23, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02362529"
197,"NCT02972632","Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine","Percentage of Participants Who Achieved Goal Attainment Scale (GAS) Score of ≥50 at Week 12|Change From Baseline in Total Goal Attainment Scale Score at Weeks 6 and 12|Change From Baseline in Patient Health Questionnaire (PHQ-9) Score at Weeks 6 and 12|Change From Baseline in Perceived Deficits Questionnaire-Depression (PDQ-D) at Weeks 6 and 12|Change From Baseline in Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) Total Score at Week 12|Change From Baseline in 5-Item World Health Organization Well-being Index (WHO-5) Score at Week 12|Change From Baseline in Clinical Global Impression Scale Severity (CGI-S) at Week 12|Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 12","Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","123","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vortioxetine-4003|U1111-1185-6902","December 22, 2016","February 6, 2018","February 6, 2018","November 23, 2016","July 11, 2019","July 11, 2019","ATP Clinical Research, Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Pacific Research Partners, Oakland, California, United States|Excell Research, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|University Medical Group, Upland, California, United States|MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States|Suncoast Clinical Research Inc., New Port Richey, Florida, United States|Behavioral Clinical Research , Inc, North Miami, Florida, United States|Compass Research Main, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|Deaconess Clinic, Evansville, Indiana, United States|Novex Clinical Research, LLC, New Bedford, Massachusetts, United States|Coastal Research Associates, Inc., South Weymouth, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Dayton Clinical Research, Dayton, Ohio, United States|Green & Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02972632/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02972632/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02972632"
198,"NCT03739203","The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Cariprazine|Drug: Placebo","Total score change from baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3111-302-001","November 10, 2018","September 6, 2021","September 6, 2021","November 13, 2018",,"July 30, 2021","Harmonex, Dothan, Alabama, United States|California Pharmaceutical Research Institute, Anaheim, California, United States|Axiom Research, LLC, Colton, California, United States|Collaborative Neuro Science, Garden Grove, California, United States|Behavioral Research Specialist, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Excell Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Anderson Clinical Research, Redlands, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Psykeria Research Institute LLC, Palm Bay, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|AMR Conventions Limited, Naperville, Illinois, United States|Phoenix Medical Research, Leawood, Kansas, United States|Boston Clinical Trails, Boston, Massachusetts, United States|The Coastal Research Associates, Inc, South Weymouth, Massachusetts, United States|Bio Behavioral Health, Toms River, New Jersey, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Fieve Clinical Research, Inc, New York, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Quest Therapeutics of Avon Lake, Avon Lake, Ohio, United States|Patient Priority Clinical Sites, Cincinnati, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|North Star Medical Research, Middleburg Heights, Ohio, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Research Strategies of Memphis, Memphis, Tennessee, United States|Earle Research, Houston, Texas, United States|AIM Trials, Plano, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Woodstock Research Center d/b/a Neuropsychiatric Associates, Woodstock, Vermont, United States|SSM Health Dean Medical Group, Madison, Wisconsin, United States|Chatham-Kent Clinical Trials, Chatham, Ontario, Canada|Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic, Ottawa, Ontario, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|MUDr. Marta Holanova; Privat Out-patient Department Brno, Brno, Czechia|Neuropsychiatriehk, s.r.o., Hradec Kralove, Czechia|A-Shine s.r.o., Plzen, Czechia|Pragtis s.r.o., Prague, Czechia|Institute of Neuropsychiatric Care, Prague, Czechia|Medical Services Prague, Praha 6, Czechia|Clintrial, Praha, Czechia|Mederon Ltd at ARTES, Helsinki, Finland|Mehilainen Toolo, Helsinki, Finland|Savon Psykiatripalvelu Oy, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Psykiatri- ja psykologikeskus MENTORIA, Tampere, Finland|Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski, Belchatow, Poland|MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk, Bialystok, Poland|Wlokiennicza Med, Bialystok, Poland|Przychodnia Srodmiescie Sp. Z o.o., Bydgoszcz, Poland|MED-ART, Bydgoszcz, Poland|Poradnia Zdrowia Psychicznego Chelmno, Chelmno, Poland|Centrum Badań Klinicznych, Gdansk/ Pomorskie, Poland|Centrum Zdrowia Psychicznego BioMed - Jan Latala, Kielce, Poland|Nzop Mentis, Leszno, Poland|Centrum Medyczne Luxmed, Lublin, Poland|Centrum Medyczne Neuromedica, Lublin, Poland|Krzysztof Klinke Prywatny Gabinet Psychiatryczny, Sosnowiec, Poland|Zachodniopomorski Instytut Psychoterapii, Szczecin, Poland|Gabinet Lekarski Toruńskie Centrum Psychiatrii Neuromed, Toru, Poland|Osrodek Badan Klinicznych Clinsante, Toruń, Poland|Przychodnia Lekarsko-Psychologiczna PERSONA, Wroclaw, Poland|INSPIRA Clinical research, San Juan, Puerto Rico|Bel Medic - General Hospital, Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Institute of Mental Health, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|University Clinical Hospital Center ""Dr. Dragisa Misovic - Dedinje"", Belgrade, Serbia|Special Hospital for Psychiatric Diseases ""Kovin"", Kovin, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Centre Kragujevac- Clinic of Psychiatry, Kragujevac, Serbia|Psychiatry clinic Clinical center Kragujevac, Kragujevac, Serbia|Center for mental health protection, Clinical Centre Nis, Nis, Serbia|Special hospital for psychiatric disease Sveti Vracev, Novi Knezevac, Serbia|Special Psychiatric Hospital, Vrsac, Serbia|Nestatna psychiatricka ambulancia, Bratislava, Slovakia|J&J SMART, Ltd., Bratislava, Slovakia|Psychiatrická ambulancia MENTUM, Bratislava, Slovakia|EPAMED s.r.o., Kosice, Slovakia|Psychiatric Department of LNSP MUDr. Ivana Stodolu, Liptovsky Mikulasa, Slovakia|Psycholine s.r.o, Rimavska Sobota, Slovakia|Centrum zdravia R.B.K sro, Svidnik, Slovakia|Crystal Comfort s.r.o., Vranov nad Toplou, Slovakia",,"https://ClinicalTrials.gov/show/NCT03739203"
199,"NCT02805881","Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)","CTO-TNS","Recruiting","No Results Available","Major Depressive Disorder","Device: Neurolief system","Incidence of Treatment-Emergent Adverse Events|Hamilton Depression Rating Scale (HDRS21)","Neurolief Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NRLF-BY531-CTIL","May 2016","May 2021","May 2021","June 20, 2016",,"May 14, 2020","Beer- Yakov Nees-Ziona Mental Health Center, Ness Ziona, Israel",,"https://ClinicalTrials.gov/show/NCT02805881"
200,"NCT02508493","Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Other: THINC-it Tool|Other: Pencil-and-paper Cognitive Tests","Composite THINC-it Tool Score|Digit Symbol Substitution Test (DSST) - THINC-it tool version|Choice Reaction Time (CRT) - THINC-it tool version|One-back working memory test - THINC-it tool version|Trail Making Test B - THINC-it tool version|Perceived Deficits Questionnaire 5 item for depression (PDQ-5-D) - THINC-it tool version|Digit Symbol Substitution Test (DSST) - Pencil-and-paper version|Choice Reaction Time (CRT) - Pencil-and-paper version|One-back working memory test - Pencil-and-paper version|Trail Making Test B - Pencil-and-paper version|Perceived Deficits Questionnaire 5 item for depression (PDQ-5-D) - Pencil-and paper version|Endicott Workplace Productivity Scale (EWPS)|Sheehan Disability Scale (SDS)|Pittsburgh Sleep Quality Index (PSQI)|Clinical Global Impression (CGI)|Montgomery Asberg Depression Rating Scale (MADRS)|Generalized Anxiety Disorder 7-Item (GAD-7)|WHO-5 Well-being Index (WHO-5)|Visual Analog Scale (VAS)","Brain and Cognition Discovery Foundation|Co-Principal Investigators: Dr. Roger S. McIntyre & Dr. John Harrison|Imperial College London","All","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","BCDF-THINC.it","November 2015","July 2016","July 2016","July 27, 2015",,"September 15, 2016","Toronto Sleep Clinic, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02508493"
201,"NCT02749721","The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: vortioxetine","Change in Montgomery and Asberg Depression Rating Scale (MADRS)","Rush University Medical Center|Takeda Pharmaceuticals North America, Inc.|ElMindA Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","31","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IISR-2014-100702a","December 2016","January 31, 2019","January 31, 2019","April 25, 2016",,"February 19, 2019","Rush University Medical Center, Chicago, Illinois, United States|Rush University Medical Center, Skokie, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02749721"
202,"NCT02389816","A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8|MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))|MADRS Remission at Week 8 (LOCF)|Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)|Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)|Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)|Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)|Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)|Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)","Takeda","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","493","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004/CCT-004|U1111-1167-1520|JapicCTI-152831","April 10, 2015","March 16, 2018","March 16, 2018","March 17, 2015","June 26, 2019","March 24, 2021","Nagoya, Aichi, Japan|Nagareyama, Chiba, Japan|Noda, Chiba, Japan|Iizuka, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Koriyama, Fukushima, Japan|Shirakawa, Fukushima, Japan|Sapporo, Hokkaido, Japan|Ashiya, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Kurashiki, Okayama, Japan|Kadoma, Osaka, Japan|Kita-ku, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Karatsu, Saga, Japan|Kawagoe, Saitama, Japan|Kusatsu, Shiga, Japan|Anan, Tokushima, Japan|Arakawa-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Katsushika-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Musashino, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinagawa-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Suginami-ku, Tokyo, Japan|Taito-ku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Kofu, Yamanashi, Japan|Fukuoka, Japan|Hiroshima, Japan|Kumamoto, Japan|Okayama, Japan|Saitama, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02389816/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02389816/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02389816"
203,"NCT01123707","To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)","ACES 257","Terminated","No Results Available","Major Depressive Disorder (MDD)","Drug: Aripiprazole/Escitalopram combination therapy","Safety - based on the frequency and severity of AEs & SAEs|Efficacy","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 66 Years   (Adult, Older Adult)","Phase 3","170","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","31-08-257","November 2010","July 2011","December 2011","May 14, 2010",,"August 31, 2012","Birmingham, Alabama, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Cerritos, California, United States|Chino, California, United States|Costa Mesa, California, United States|Garden Grove, California, United States|Imperial, California, United States|Irvine, California, United States|Mission Viejo, California, United States|Redlands, California, United States|Riverside, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Torrance, California, United States|Denver, Colorado, United States|Cromwell, Connecticut, United States|Fort Walton Beach, Florida, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Hoffman Estates, Illinois, United States|Libertyville, Illinois, United States|Terre Haute, Indiana, United States|Overland Park, Kansas, United States|Prairie Village, Kansas, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Belmont, Massachusetts, United States|Fall River, Massachusetts, United States|Weymouth, Massachusetts, United States|St. Louis, Missouri, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Brooklyn, New York, United States|Fresh Meadows, New York, United States|New York, New York, United States|Staten Island, New York, United States|Cary, North Carolina, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|East Providence, Rhode Island, United States|Bartlett, Tennessee, United States|Memphis, Tennessee, United States|De Soto, Texas, United States|Wichita Falls, Texas, United States|Kirkland, Washington, United States|Brown Deer, Wisconsin, United States|Everton Park, Queensland, Australia|Jamejala, Estonia|Tartu, Estonia|Tartu, Estonia|Ostfildern, Germany|Ahmedabad, Gujarat, India|Catania, Italy|Siena, Italy|Gwangju, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Mexico, DF, Mexico",,"https://ClinicalTrials.gov/show/NCT01123707"
204,"NCT02395978","A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: PDC-1421 Capsule|Drug: placebo","Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II.|Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 2, 4 and 7 Part II.|Change of Hamilton Depression Rating Scale (HAM-D-17) Total Score From Baseline to Week 2, 4, 6 and 7 for Part II.|Change of Hamilton Anxiety Rating Scale (HAM-A) Total Score From Baseline to Week 2, 4, 6 and 7 for Part II.|Change of Depression and Somatic Symptoms Scale (DSSS) From Baseline to Week 2, 4, 6 and 7 for Part II|Change of Clinical Global Impression Scale - Severity (CGI-S) From Baseline to Week 2, 4, 6 and 7 for Part II.|Percentage of Responders and Partial Responders in MADRS by Week 2, 4, 6 and 7 Weeks for Part II.|Number of Subjects With Suicidal Ideations Collected by Columbia-Suicide Severity Rating Scale (C-SSRS) From Baseline to Week 2, 4, 6 and 7 for Part II.|Number of Subjects With Suicidal Behaviors Collected by Columbia-Suicide Severity Rating Scale (C-SSRS) From Baseline to Week 2, 4, 6 and 7 for Part II.|Clinical Global Impression Scale -Improvement (CGI-I) From Baseline to Week 2, 4, 6 and 7 for Part II.","BioLite, Inc.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Phase II BLI-1005-002","April 10, 2015","March 12, 2019","March 18, 2019","March 24, 2015","September 29, 2020","July 22, 2021","Stanford Depression Research Clinic, San Francisco, California, United States|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Neihu Main Facility, Taipei, Taiwan|Wan Fang Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02395978/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02395978/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02395978"
205,"NCT02184221","Deep-brain Magnetic Stimulation (DMS) in the Treatment of Major Depressive Disorder","DTMS","Completed","No Results Available","Major Depressive Disorder","Device: High frequency stimulation|Device: Low frequency stimulation","Improvement of Depression|Improvement of Anxiety|Remission rate|Response rate|Safety outcome 1|Safety outcome 2","Capital Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DMS-2010","May 2010","January 2011","April 2011","July 9, 2014",,"August 31, 2017","Beijing Anding Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02184221"
206,"NCT01787240","Neurobiological Bases of Placebo Response in Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: Escitalopram 10mg|Drug: Placebo","Feasibility|Effects of Acute Tryptophan Depletion on Mood","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2012P001241","November 2012","August 2016","August 2016","February 8, 2013","April 14, 2017","May 16, 2017","Massachusetts General Hospital Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01787240"
207,"NCT01924520","Oral Multiple-dose Study in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: FK949E","Maximum plasma concentration (Cmax) of unchanged quetiapine|AUC24h (area under the curve for 24hr) of unchanged quetiapine|trough value of plasma concentration of unchanged quetiapine|t1/2 of plasma concentration of unchanged quetiapine|Maximum plasma concentration (Cmax) of quetiapine metabolites|AUC (area under the curve) of quetiapine metabolites|trough value of plasma concentration of quetiapine metabolites|tmax of plasma concentration of quetiapine metabolites|t1/2 of plasma concentration of quetiapine metabolites|Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","6949-CL-0009","November 2010","May 2011","May 2011","August 16, 2013",,"February 16, 2017","Kansai, Japan|Kantou, Japan",,"https://ClinicalTrials.gov/show/NCT01924520"
208,"NCT02431806","Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Levomilnacipran|Drug: Fluoxetine","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score|Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale","Forest Laboratories","All","12 Years to 17 Years   (Child)","Phase 3","552","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-11","June 23, 2015","August 19, 2019","August 19, 2019","May 1, 2015","September 7, 2020","September 7, 2020","Harmonex, Inc, Dothan, Alabama, United States|University of Arizona Department of Psychiatry, Tucson, Arizona, United States|Advanced Research Center, Inc., Anaheim, California, United States|ProScience Research Group, Culver City, California, United States|Sun Valley Research Center, Imperial, California, United States|Alliance for Research, Long Beach, California, United States|Asclepes Research Centers, Panorama City, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Florida Clinical Research Center; LLC, Bradenton, Florida, United States|Coastal Clinical Research Specialists, Fernandina Beach, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Research in Miami Inc, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|University of South Florida Board of Trustee, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|Sandeep Gaonkar, MD, Naperville, Illinois, United States|NeuroMedical Institute, Panama City, Illinois, United States|Kentucky Pediatric Research, Bardstown, Kentucky, United States|Adams Clinical Trials, LLC, Watertown, Massachusetts, United States|Alivation Research, Lincoln, Nebraska, United States|Kolade Research Institute, Las Vegas, Nevada, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Manhattan Behavioral Medicine, New York, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, LLC, Tulsa, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|UTHSC-Houston, Houston, Texas, United States|Bay Area Clinical Services dba Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|UVA Child and Family Psychiatry Clinic, Charlottesville, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Eastside Therapeutic Resource dba Core Clinical, Everett, Washington, United States|INSPIRA Clinical Research, San Juan, Puerto Rico","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02431806/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02431806/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02431806"
209,"NCT01111565","Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)","ACES 263","Terminated","No Results Available","Major Depressive Disorder (MDD)","Drug: Escitalopram|Drug: Aripiprazole|Drug: Aripiprazole/Escitalopram combination","Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","31-08-263","July 2010","July 2011","December 2011","April 27, 2010",,"August 31, 2012","Tucson, Arizona, United States|Chino, California, United States|Riverside, California, United States|Torrance, California, United States|Hamden, Connecticut, United States|Marietta, Georgia, United States|Belmont, Massachusetts, United States|Weymouth, Massachusetts, United States|Saint Charles, Missouri, United States|St. Louis, Missouri, United States|Brooklyn, New York, United States|Garfield Heights, Ohio, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Kirkland, Washington, United States|Penticton, British Columbia, Canada|Vancouver, British Columbia, Canada|Burlington, Ontario, Canada|Osijek, Croatia|Rijeka, Croatia|Zagreb, Croatia|Zagreb, Croatia|Douai, France|Elancourt, France|Baja, Hungary|Balassagyarmat, Hungary|Budapest, Hungary|Budapest, Hungary|Gyula, Hungary|Hyderabad, Andhra Pradesh, India|Vishakhapatnam, Andhra Pradesh, India|Mumbai, Maharashtra, India|Tampoi, Johor Bahru, Malaysia|Tampoi, Johor Bahru, Malaysia|Kajang, Selangor, Malaysia|Kuala Lumpur, Malaysia|Belchatow, Poland|Bialystok, Poland|Bialystok, Poland|Study Site 1, Choroszcz, Poland|Study Site 2, Choroszcz, Poland|Sosnowiec, Poland|Tuszyn, Poland|Study Site 1, Cape Town, South Africa|Study Site 2, Cape Town, South Africa|Durban, South Africa|Pretoria, South Africa|Pretoria, South Africa|Pretoria, South Africa|Barcelona, Spain|Salamanca, Spain|Göteborg, Sweden|Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT01111565"
210,"NCT01111552","Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)","ACES 256","Terminated","No Results Available","Major Depressive Disorder (MDD)","Drug: Escitalopram|Drug: Aripiprazole|Drug: Aripiprazole/Escitalopram combination","Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","31-08-256","July 2010","July 2011","December 2011","April 27, 2010",,"August 31, 2012","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Carson, California, United States|Garden Grove, California, United States|Imperial, California, United States|Mission Viejo, California, United States|Redlands, California, United States|San Diego, California, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Hoffman Estates, Illinois, United States|Terre Haute, Indiana, United States|Overland Park, Kansas, United States|Prairie Village, Kansas, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|New York, New York, United States|Toledo, Ohio, United States|Bartlett, Tennessee, United States|Wichita Falls, Texas, United States|Brisbane, Queensland, Australia|Everton Park, Queensland, Australia|Malvern, Victoria, Australia|Melbourne, Victoria, Australia|Fremantle, Western Australia, Australia|Bourgas, Bulgaria|Lovech, Bulgaria|Novi Iskar, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Rousse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Tsarev Brod, Bulgaria|Tserova Koriya, Bulgaria|Varna, Bulgaria|Tirupati, Andhra Pradesh, India|Vijaywada, Andhra Pradesh, India|Manipal, Karnataka, India|Pune, Maharashtra, India|Ludhiana, Punjab, India|Chennai, Tamil Nadu, India|Kanpur, Uttar Pradesh, India|Quezon City, NCR, Philippines|Quezon City, NCR, Philippines|Bucuresti, Romania|Bucuresti, Romania|Study Site 1, Bucuresti, Romania|Study Site 2, Bucuresti, Romania|Craiova, Romania|Craiova, Romania|Iasi, Romania|Targoviste, Romania|Targu Mures, Romania|Michalovce, Slovakia|Rimavska Sobota, Slovakia|Svidnik, Slovakia|Trencin, Slovakia|Zlate Moravce, Slovakia",,"https://ClinicalTrials.gov/show/NCT01111552"
211,"NCT01111539","Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)","ACES 255","Terminated","No Results Available","Major Depressive Disorder (MDD)","Drug: Escitalopram|Drug: Aripiprazole|Drug: Aripiprazole/Escitalopram combination","Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","31-08-255","July 2010","July 2011","December 2011","April 27, 2010",,"August 31, 2012","Cerritos, California, United States|Costa Mesa, California, United States|Irvine, California, United States|San Diego, California, United States|Santa Ana, California, United States|Denver, Colorado, United States|Cromwell, Connecticut, United States|Hartford, Connecticut, United States|Fort Walton Beach, Florida, United States|Gainesville, Florida, United States|Chicago, Illinois, United States|Libertyville, Illinois, United States|Boston, Massachusetts, United States|Fall River, Massachusetts, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Fresh Meadows, New York, United States|Staten Island, New York, United States|Cary, North Carolina, United States|Oklahoma City, Oklahoma, United States|Memphis, Tennessee, United States|DeSoto, Texas, United States|Richmond, Virginia, United States|Brown Deer, Wisconsin, United States|Jamejala, Estonia|Tallinn, Estonia|Tartu, Estonia|Tartu, Estonia|Helsinki, Finland|Helsinki, Finland|Kuopio, Finland|Oulu, Finland|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Munich, Germany|Ostfildern, Germany|Study Site 1, Ahmedabad, Gujarat, India|Study Site 2, Ahmedabad, Gujarat, India|Mangalore, Karnataka, India|Mumbai, Maharashtra, India|Pune, Maharashtra, India|Varanasi, Uttar Pradesh, India|Catania, Italy|Siena, Italy|Gwangju, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Mexico, DF, Mexico|Tlalnepantla de Baz, Estado do Mexico, Mexico|Zapopan, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Culiacan, Sinaloa, Mexico|Villahermosa, Tabasco, Mexico|Durango, Mexico|San Luis Potosi, Mexico|Changhua, Taiwan|Kaohsiung, Taiwan|Keelung, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01111539"
212,"NCT01997580","Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: escitalopram","Change in baseline frequency of maximum of cross-spectrum during 6 weeks (Hz)|Change in cardiorespiratory coupling during 6 weeks|Change in HF during 6 weeks|Change in persistent homology during 6 weeks","Seoul National University Bundang Hospital|Ministry of Health & Welfare, Korea","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 4","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A121987","July 2013","December 2016","December 2018","November 28, 2013",,"November 28, 2013","Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01997580"
213,"NCT02372799","Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)","VLZ-MD-22","Completed","Has Results","Major Depressive Disorder","Drug: Vilazodone|Drug: Placebo|Drug: Fluoxetine","Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score|Change in Clinical Global Impressions-Severity (CGI-S) Score","Forest Laboratories","All","7 Years to 17 Years   (Child)","Phase 3","473","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VLZ-MD-22","February 28, 2015","September 11, 2018","September 11, 2018","February 26, 2015","October 1, 2019","October 1, 2019","Alliance Clinical Research, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Woodland International Research Group, INC, Little Rock, Arkansas, United States|CITrials - Bellflower, Bellflower, California, United States|ATP Clinical Research, Costa Mesa, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|PCSD - Feighner Research, San Diego, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Palm Springs Research, LLC, Hialeah, Florida, United States|IMIC Inc., Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Osceola Mental Health dba Park Place Behavioral Health Care, Kissimmee, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlantic Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|Neuroscience Research Institute Inc., Oak Park, Illinois, United States|Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States|Psychiatric Associates, Overland Park, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Hugo W Moser Research Institute at Kennedy Krieger, Inc., Baltimore, Maryland, United States|Pharmsite Research Inc., Baltimore, Maryland, United States|NeuroScientific Insights, Rockville, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Adams Clinical Trials, LLC, Watertown, Massachusetts, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|BioScience Research LLC, Mount Kisco, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Haidar Almhana Nieding LLC, Avon Lake, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Psychiatry, Cleveland, Ohio, United States|Ohio State Univ. Dept of Psychiatry, Columbus, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Research Strategies of Memphis LLC, Memphis, Tennessee, United States|FutureSearch Clinical trials, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|University of TX Southwestern Medical Ctr, Dallas, Texas, United States|Bayou City Research Ltd, Houston, Texas, United States|Houston Endoscopy and Research Ctr, Houston, Texas, United States|Research Across America, Plano, Texas, United States|Focus and Balance, San Antonio, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|UVA Center for Psychopharmacology Research in Youth, Charlottesville, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Core Clinical Research, Everett, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Paediatric Sleep Research Inc, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02372799/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02372799/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02372799"
214,"NCT02473783","The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD","STAPMDDTDM","Completed","Has Results","Major Depressive Disorder","Drug: Sertraline HCl|Other: I-123-ADAM SPECT","The SERT Binding Potential (BP) --(Only the Treatment Group Was Assessed)|Hamilton Depression Rating Scale (HAM-D) Total Scores|Safety Assessments - the Tolerability of Injection of I-123-ADAM Solution","Tri-Service General Hospital|Institute of Nuclear Energy Research, Taiwan","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","37","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","INEI-1A20090409","October 2011","November 2012","November 2012","June 17, 2015","December 21, 2017","January 19, 2018",,,"https://ClinicalTrials.gov/show/NCT02473783"
215,"NCT01533285","Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients",,"Completed","No Results Available","Major Depressive Disorder","Biological: Placebo|Biological: Salmonella typhi vaccine (Typhim Vi)","Change in Profile of Mood States (POMS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Visual Analogue Scale (VAS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Snaith-Hamilton Pleasure Scale (SHAPS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from Baseline to Day 1 of Period 1 and Period 2.|Change in Cognitive Test Battery performance from Baseline to Day 1 of Period 1 and Period 2.|Changes in levels of hormones and cytokines from Baseline to Day 1 of Period 1 and Period 2.","Janssen Pharmaceutica N.V., Belgium","Female","25 Years and older   (Adult, Older Adult)","Early Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR100698|NOCOMPOUNDEDI0002|2011-004898-80","May 2012","November 2013","November 2013","February 15, 2012",,"March 28, 2014","Duffel, Belgium|Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT01533285"
216,"NCT02269540","A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)",,"Completed","No Results Available","Major Depressive Disorder","Drug: Sertraline|Drug: Citalopram|Drug: N-acetylcysteine (NAC)|Drug: Existing depression medication treatment","MAO-A distribution volume with positron emission tomography|Hamilton Depression Rating Scale Score|Magnetic Resonance Spectroscopy (n-acetylaspartate and glutathione levels)|Blood markers of monoamine oxidase-A fragment level and glutathione level","Centre for Addiction and Mental Health","All","18 Years to 49 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","137/2013","October 2014","June 2018","July 2018","October 21, 2014",,"May 24, 2019","Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02269540"
217,"NCT02046564","Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: ASC-01|Drug: Placebo","The Mean Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|The Montgomery-Åsberg Depression Rating Scale (MADRS) Response Rate|The Montgomery-Åsberg Depression Rating Scale (MADRS) Remission Rate|The Clinical Global Impression - Improvement (CGI-I) Improvement Rate|The Mean Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S)|The Mean Change From Baseline in the Hamilton Depression Rating Scale 17 (HAM-D17) Total Score|The Mean Change From Baseline in the Social Adaptation Self-evaluation Scale (SASS) Total Score|The Mean Change From Baseline in the Apathy Scale (AS) Total Score|The Mean Change From Baseline in the Self-rating Version of Montgomery-Åsberg Depression Rating Scale (MADRS-S) Total Score","Otsuka Pharmaceutical Co., Ltd.","All","20 Years to 64 Years   (Adult)","Phase 3","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","031-12-005|JapicCTI-142413","February 2014","September 2016","September 2016","January 28, 2014","May 21, 2018","May 21, 2018","Everton Park, Queensland, Australia|Melbourne, Australia|Chubu Region, Japan|Chugoku Region, Japan|Hokkaido Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan|Tohoku Region, Japan|Busan, Korea, Republic of|Chungcheongnam-do, Korea, Republic of|Deagu, Korea, Republic of|Gangwon-do, Korea, Republic of|Gwangju, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Jeollabuk-do, Korea, Republic of|Seoul, Korea, Republic of|Ipoh, Malaysia|Johor Bahru, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Chiayi, Taiwan|Kaohsiung, Taiwan|Keelung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02046564"
218,"NCT02371980","Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine|Drug: Placebo","Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period|Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed|Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score|Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period","Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_402|U1111-1161-4956","February 10, 2015","March 1, 2019","April 25, 2019","February 26, 2015","April 17, 2020","January 6, 2021","NoesisPharma, Phoenix, Arizona, United States|SW Biomedical Research, LLC, Tucson, Arizona, United States|CNS Research Science, Inc., Cerritos, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Irvine Center for Clinical Research, Inc., Irvine, California, United States|Synergy Clinical Research of Escondido, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|CNRI - Los Angeles, LLC, Pico Rivera, California, United States|CNRI - San Diego, LLC, San Diego, California, United States|Artemis Institute for Clinical Research, LLC, San Diego, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Pasadena Research Institute, San Gabriel, California, United States|Collaborative Neuroscience Network, LLC, Torrance, California, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|CNS Clinical Research Group, Coral Springs, Florida, United States|Gulfcoast Medical Research Center, LLC, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|Sarkis Clinical Trials - Parent, Ocala, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Janice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach, West Palm Beach, Florida, United States|Radiant Research, Inc., Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Arlington Heights, Illinois, United States|Rush St Lukes Presbyterian Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Inc., Libertyville, Illinois, United States|Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Phoenix Medical Research, Inc., Prairie Village, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Potomac Grove Clinical Research Center, Gaithersburg, Maryland, United States|Boston Clinical Trials & Medical Research, Boston, Massachusetts, United States|Univ. of Massachussetts Memorial Health Care Systems, Worcester, Massachusetts, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Montefiore Medical Center PRIME, Bronx, New York, United States|Erie County Medical Center Corporation, Buffalo, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|CNS Research Science, Inc., Jamaica, New York, United States|Village Clinical Research, Inc., New York, New York, United States|Manhattan Behavioral Medicine, PLLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|NorthCoast Clinical Trials, Inc., Beachwood, Ohio, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Inc., Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Coastal Carolina Research Center, Inc, Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|FutureSearch Clinical Trials, L.P., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Houston Clinical Trials, LLC, Houston, Texas, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Radiant Research, Inc., Murray, Utah, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Eastside Therapeutic Resource, Everett, Washington, United States|Summit Research Network (Seattle), LLC, Seattle, Washington, United States|Frontier Institute, Spokane, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02371980/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02371980/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02371980"
219,"NCT01468610","Neurocognition and Work Productivity in Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Drug: desvenlafaxine","cognitive functioning as determined by neuropsychological testing|work productivity as determined by rating scales","University of British Columbia|Pfizer","All","19 Years to 55 Years   (Adult)","Not Applicable","47","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H11-02646|WS2087153","January 2012","September 2014","December 2014","November 9, 2011",,"April 10, 2015","University of British Columbia, Department of Psychiatry, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01468610"
220,"NCT00593879","Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Mecamylamine","HAMD-17 group mean change from baseline to endpoint and/or the proportion of subjects considered to be full responders or in remission with a HAMD-17 score less than or equal to 7 at the end of treatment.|Montgomery Asbery depression rating sclae, Clinical Global Impression Scale - Severity, Clinical Global Impression Sacle - Change, Sheehan irritability scale, Sheehan disability scale|Blood biochemistry, urnie analysis, blood pressure, heart rate, ECG|Citalopram plasma bloods at week 6 and 14.","Targacept Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TC-5231-023-CRD-003","February 2005",,"August 2006","January 15, 2008",,"January 15, 2008",,,"https://ClinicalTrials.gov/show/NCT00593879"
221,"NCT02129751","Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: bupropion hydrobromide|Drug: Placebo","Mean change from Baseline to EOT in total CDRS-R (raw) score","Bausch Health Americas, Inc.","All","7 Years to 17 Years   (Child)","Phase 4","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","V01-BUPA-401","November 2021","November 2024","November 2024","May 2, 2014",,"June 1, 2021","Valeant, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02129751"
222,"NCT01877447","Comparison of Two tDCS Protocols for the Treatment of Major Depressive Disorder",,"Completed","No Results Available","MAjor Depressive Disorder","Device: Transcranial Direct Current Stimulation","Hamilton Rating Scale for Depression, 17 items (HAMD17)|Montgomery-Asberg Depression Rating Scale (MADRS)|Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Hamilton Anxiety Inventory (HAI)|The Montreal Cognitive Assessment (Moca)","University of Sao Paulo","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","aF3_cF4_F32","July 2013","October 2013","November 2013","June 13, 2013",,"December 16, 2013","Hospital Universitário - USP, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01877447"
223,"NCT01808651","A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing",,"Completed","Has Results","Major Depressive Disorder","Drug: Fluoxetine","Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs)|Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)|Mean Change From Baseline to Week 52 on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score|Percentage of Participants Achieving a Response at Week 52|Percentage of Participants Achieving a Remission at Week 52|Mean Change From Baseline to Week 52 on the Clinical Global Impression of Severity (CGI-S) Scale|Mean Change From Baseline to Week 52 on the HAMD21 Subscale Scores|Change From Baseline to Week 52 in Sheehan Disability Scale (SDS) Total Score and Subscale Scores","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14596|B1Y-JE-HCLW","May 2013","March 2015","March 2015","March 11, 2013","November 26, 2015","November 26, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagano, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shiga, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01808651"
224,"NCT01878292","Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","VLZ-MD-21","Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vilazodone","Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score|Change in Clinical Global Impressions-Severity (CGI-S) Score","Forest Laboratories","All","12 Years to 17 Years   (Child)","Phase 3","529","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VLZ-MD-21","July 11, 2013","March 17, 2016","October 5, 2016","June 14, 2013","December 24, 2019","December 24, 2019","Forest Investigative Site 073, Imperial, California, United States|Forest Investigative Site 052, Los Angeles, California, United States|Forest Investigative Site 023, Murrieta, California, United States|Forest Investigative Site 004, Orange, California, United States|Forest Investigative Site 037, San Diego, California, United States|Forest Investigative Site 006, Washington, District of Columbia, United States|Forest Investigative Site 039, Gainesville, Florida, United States|Forest Investigative Site 009, Jacksonville Beach, Florida, United States|Forest Investigative Site 063, Miami, Florida, United States|Forest Investigative Site 034, Oakland Park, Florida, United States|Forest Investigative Site 016, Orlando, Florida, United States|Forest Investigative Site 064, Orlando, Florida, United States|Forest Investigative Site 014, Atlanta, Georgia, United States|Forest Investigative Site 030, Roswell, Georgia, United States|Forest Investigative Site 032, Libertyville, Illinois, United States|Forest Investigative Site 048, Naperville, Illinois, United States|Forest Investigative Site 051, Terre Haute, Indiana, United States|Forest Investigative Site 013, Overland Park, Kansas, United States|Forest Investigative Site 070, Lake Charles, Louisiana, United States|Forest Investigative Site 050, Baltimore, Maryland, United States|Forest Investigative Site 054, Baltimore, Maryland, United States|Forest Investigative Site 049, Rockville, Maryland, United States|Forest Investigative Site 026, Watertown, Massachusetts, United States|Forest Investigative Site 024, Rochester Hills, Michigan, United States|Forest Investigative Site 015, Creve Coeur, Missouri, United States|Forest Investigative Site 055, Saint Charles, Missouri, United States|Forest Investigative Site 072, Saint Louis, Missouri, United States|Forest Investigative Site 066, Las Vegas, Nevada, United States|Forest Investigative Site 007, Cherry Hill, New Jersey, United States|Forest Investigative Site 071, Neptune, New Jersey, United States|Forest Investigative Site 008, Albuquerque, New Mexico, United States|Forest Investigative Site 057, Rochester, New York, United States|Forest Investigative Site 059, Durham, North Carolina, United States|Forest Investigative Site 053, Avon Lake, Ohio, United States|Forest Investigative Site 021, Canton, Ohio, United States|Forest Investigative Site 012, Cincinnati, Ohio, United States|Forest Investigative Site 029, Columbus, Ohio, United States|Forest Investigative Site 018, Oklahoma City, Oklahoma, United States|Forest Investigative Site 011, Oklahoma City, Oklahoma, United States|Forest Investigative Site 065, Tulsa, Oklahoma, United States|Forest Investigative Site 040, Philadelphia, Pennsylvania, United States|Forest Investigative Site 074, Charleston, South Carolina, United States|Forest Investigative Site 062, Memphis, Tennessee, United States|Forest Investigative Site 001, Dallas, Texas, United States|Forest Investigative Site 027, Houston, Texas, United States|Forest Investigative Site 041, Plano, Texas, United States|Forest Investigative Site 045, The Woodlands, Texas, United States|Forest Investigative Site 019, Clinton, Utah, United States|Forest Investigative Site 060, Richmond, Virginia, United States|Forest Investigative Site 035, Bellevue, Washington, United States|Forest Investigative Site 068, Bothell, Washington, United States|Forest Investigative Site 022, Kirkland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01878292"
225,"NCT01078948","Transcranial Direct Current Stimulation (tDCS) in the Treatment of Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Device: transcranial direct current stimulation (tDCS)","Hamilton Rating Scale for Depression (HAMD), 17-item version","Centre for Addiction and Mental Health","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","157/2007","February 2008","October 2010","October 2010","March 2, 2010",,"February 10, 2012","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01078948"
226,"NCT01977378","A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Sustained-Release Desvenlafaxine Hydrochloride|Drug: Sustained-Release Venlafaxine Hydrochloride","Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17)|Change From Baseline on the Clinical Global Impression Scale|Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Scale|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 10|Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS)|Change From Baseline on the Visual Analogue Scale-Pain Intensity (VAS-PI)|Number of Participants in Remission Based on the HAM-D17 at Week 10","Jiangsu Hansoh Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DVS20130806","October 2013","September 2014",,"November 6, 2013",,"November 6, 2013","Guangdong General Hospital, Guangzhou, Guangdong, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|West China Hospital, Chengdu, Sichuan, China|Beijing An Ding Hospital, Beijing, China|Beijing HuiLongGuan Hospital, Beijing, China|The Shanghai Mental Health, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01977378"
227,"NCT00707980","Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine","Physical Examination Findings|Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings|Number of Participants With Adverse Events (AEs)|Number of Participants With Potentially Clinically Significant Vital Sign Findings|Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score|Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline in the Clinical Global Impression of Severity of Illness Scale|Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)|Change From Baseline to the Final Visit in the Sheehan Disability Scale|Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire","Takeda|H. Lundbeck A/S","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 3","836","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LuAA21004_301|2008-001581-91|U1111-1113-9564","June 2008","July 2010","August 2010","July 2, 2008","December 13, 2013","December 13, 2013","Beverly Hills, California, United States|Irvine, California, United States|Santa Ana, California, United States|Torrance, California, United States|Upland, California, United States|Bradenton, Florida, United States|Coral Springs, Florida, United States|Fort Walton Beach, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Maitland, Florida, United States|Orlando, Florida, United States|South Miami, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Smyrna, Georgia, United States|Chicago, Illinois, United States|Libertyville, Illinois, United States|Oak Brook, Illinois, United States|Prairie Village, Kansas, United States|Owensboro, Kentucky, United States|Baltimore, Maryland, United States|Pittsfield, Massachusetts, United States|Worcester, Massachusetts, United States|Flowood, Mississippi, United States|New York, New York, United States|Olean, New York, United States|Beachwood, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Allenton, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Memphis, Tennessee, United States|Austin, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Elizabeth Vale, Australia|Richmond, Australia|Southport, Australia|Osijek, Croatia|Zagreb, Croatia|Bully les Mines, France|Marseille, France|Strasbourg, France|Berlin, Germany|Bochum, Germany|Chemnitz, Germany|Huettenberg, Germany|Leipzig, Germany|München, Germany|Nuernberg, Germany|Wiesbaden, Germany|Buchon, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Liepaja, Latvia|Riga, Latvia|Sigulda, Latvia|Siauliai, Lithuania|Vilnius, Lithuania|Kuala Lumpur, Malaysia|SchHoogfliet, Netherlands|Wildervank, Netherlands|Zwijndrecht, Netherlands|Białystok, Poland|Leszno, Poland|Pruszków, Poland|Skórzewo, Poland|Toruń, Poland|Tuszyn, Poland|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Bryanston, South Africa|Durban, South Africa|Lyttelton, South Africa|NoordHeuwel, South Africa|Pretoria, South Africa|Kaohsiung, Taiwan|Dnepropetrovsk, Ukraine|Kiev, Ukraine|Lugansk, Ukraine|Simferopol, Ukraine|Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00707980"
228,"NCT01541475","Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Bupropion, Escitalopram|Drug: Escitalopram","Change from Baseline in Depressive Symptom Scores at 8 Weeks|Change from Baseline in Depressive Symptom Scores at 4 Weeks|Change from Baseline in Depressive Symptom Scores at 1 Week|Number of Participants with Adverse Events|Change from Baseline in Neurocognitive Function as Expressed as Z Scores Transformed Using the Control Group Mean and Distribution Values at 8 Weeks|Changes from Baseline in Brain Structure and Function, Analyzed Using the Computational Approach|Changes in Fatigue Severity Scale scores","Ewha Womans University|GlaxoSmithKline","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","112063|GSK IIT","March 2009","January 2011","January 2011","March 1, 2012",,"April 10, 2014","Seoul National University Hospital, Biomedical Research Institute, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01541475"
229,"NCT01454635","Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder","AFADTRMDD","Completed","No Results Available","Major Depressive Disorder","Drug: Sertraline","Hamilton Rating Scale for Depression","Showa University","All","20 Years and older   (Adult, Older Adult)","Not Applicable","96","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-GEC-84","June 2008","March 2010","March 2010","October 19, 2011",,"October 31, 2011","Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan",,"https://ClinicalTrials.gov/show/NCT01454635"
230,"NCT01696617","Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Aripiprazole 6-week group|Drug: Aripiprazole 8-week group","Quality of Life Scale (QOLS)|Montgomery-Åsberg Depression Rating Scale","Seoul National University Hospital|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","031-KOC-1108i","February 10, 2012","December 2016","February 2019","October 1, 2012",,"April 9, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01696617"
231,"NCT01103271","Pilot Study of Open-label Placebo to Treat Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Other: Open-label Placebo","Feasibility|Pre-Post Efficacy","Massachusetts General Hospital|Harvard University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2009p002469|K24AT004095","May 2010","May 2011","May 2011","April 14, 2010","January 14, 2013","January 14, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01103271"
232,"NCT01808612","A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing",,"Completed","Has Results","Major Depressive Disorder","Drug: Fluoxetine|Drug: Placebo","Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score|Mean Change From Baseline to 6-Week Endpoint on the HAMD21 Subscale Scores|Percentage of Participants Achieving a Response at 6-Week Endpoint|Percentage of Participants Achieving a Remission at 6-Week Endpoint|Mean Change From Baseline to 6-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale|Mean Change From Baseline to 6-Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores|Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)","Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","513","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14595|B1Y-JE-HCLV","March 2013","July 2014","July 2014","March 11, 2013","May 12, 2015","May 12, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagano, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shiga, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01808612"
233,"NCT01140906","Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine (Lu AA21004)|Drug: Duloxetine","Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.|Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)|Change in Clinical Status Using CGI-I Score at Week 8|Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20|Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)|Change From Baseline in SDS Total Score After 8 Weeks of Treatment|Change From Baseline in ASEX Total Score After 8 Weeks of Treatment|Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","607","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13267A|2009-017523-26","May 2010","September 2011",,"June 10, 2010","February 11, 2014","February 11, 2014",,,"https://ClinicalTrials.gov/show/NCT01140906"
234,"NCT01944969","Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: Brexpiprazole","Number of Participants With Treatment-Emergent Adverse Events|Number of Withdrawals|Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)|Change in Depressive Symptoms|Proportion of Patients in Remission|Change in Clinical Global Impression|Change in Health-related Quality of Life","H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","26","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14767B|2012-004169-42","October 2013","May 2014","May 2014","September 18, 2013","March 3, 2016","October 17, 2018","US008, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01944969"
235,"NCT01380704","Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: ABT-436|Drug: Matching Placebo","Pharmacology assays|ABT-436 drug levels|Vital signs|Clinical safety labs|Psychiatric symptom scales","AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-674","June 2011","September 2011","September 2011","June 27, 2011",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01380704"
236,"NCT02279966","Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Vortioxetine 10 mg|Drug: Paroxetine 20 mg|Drug: Placebo","Change in Digit Symbol Substitution Test (DSST): number of correct symbols|Change in Trail Making Test (TMT) score: TMT-A; speed of processing|Change in TMT-B; executive functioning|Change in reaction time score: Choice Reaction Time (CRT); attention|Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed)|Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning|Change in STROOP: congruent score; speed of processing|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score|Change in Montgomery and Asberg Depression Rating Scale (MADRS) total score|Change in Clinical Global Impression - Severity of Illness (CGI-S)|Clinical Global Impression - Global Improvement (CGI-I) score|Change in the Functioning Assessment Short Test (FAST) total score|Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15906A|2014-000230-34","October 2014","February 2016","February 2016","October 31, 2014",,"February 28, 2017","EE001, Tallinn, Estonia|EE002, Tallinn, Estonia|EE004, Voru, Estonia|FI002, Helsinki, Finland|FI003, Helsinki, Finland|FI001, Kuopio, Finland|FI008, Oulu, Finland|FI007, Tampere, Finland|DE002, Berlin, Germany|DE001, Bielefeld, Germany|DE003, Frankfurt, Germany|DE007, Frankfurt, Germany|DE008, Schwerin, Germany|LT002, Kaunas, Lithuania|LT006, Palanga, Lithuania|LT003, Silute, Lithuania|LT001, Vilnius, Lithuania|LT005, Vilnius, Lithuania",,"https://ClinicalTrials.gov/show/NCT02279966"
237,"NCT02014363","Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)","ETS6103-003","Completed","Has Results","Major Depressive Disorder","Drug: ETS6103 (low dose)|Drug: ETS6103 (high dose)|Drug: Amitriptyline","Change From Baseline in Baseline-adjusted (Montgomery-Asberg Depression Scale) MADRS Score at the End of Treatment.","e-Therapeutics PLC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ETS6103-003|2013-000719-26","October 2013","October 2015","October 2015","December 18, 2013","January 11, 2017","January 11, 2017","CPS Research, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02014363"
238,"NCT00107120","The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo","Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score|Clinical Global Impressions - Improvement","Forest Laboratories","All","12 Years to 17 Years   (Child)","Phase 3","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SCT-MD-32","March 2005","May 2007",,"April 6, 2005","November 4, 2009","April 6, 2012","University of California at Davis, MIND Institute, Health Services, Sacramento, California, United States|UCSD Outpatient Psychiatry Services, San Diego, California, United States|PCSD - Feighner Research, San Diego, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida - Child Study Program, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Kolin Research Group, Winter Park, Florida, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Clinco, Terre Haute, Indiana, United States|Psychiatric Associates, Overland, Kansas, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Capitol Clinical Research Associates, Rockville, Maryland, United States|St. Charles Psychiatric Associates, St. Charles, Missouri, United States|Creighton University Medical School, Department of Psychiatry, Omaha, Nebraska, United States|CNS Research Institute, Clementon, New Jersey, United States|Pulmonary and Allergy Associates, P. A., Summit, New Jersey, United States|North Carolina Neuropsychiatry, PA, Chapel Hill, North Carolina, United States|University of Cincinnati College of Medicine, Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Division of Child & Adolescent Psychiatry, Cleveland, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Department of Psychiatry, Mood & Anxiety Disorders Section, Philadelphia, Pennsylvania, United States|Drexel University College of Medicine, Friends Hospital, Philadelphia, Pennsylvania, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Center for Pediatric Psychiatry, Dallas, Texas, United States|University of Texas Medical Branch, Department of Psychiatry & Behavioral Sciences, Galveston, Texas, United States|Brighton Research Group, LLC, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00107120"
239,"NCT01371383","The Effect of Fish Oil in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Dietary Supplement: Omega-3 fatty acids|Dietary Supplement: placebo","Changes in Hamilton Depression Rating Scale (HDRS)|Changes in Beck Depression Inventory (BDI)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","National Science Council, Taiwan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DOH94F044","January 2005","April 2012","April 2012","June 10, 2011",,"May 14, 2012","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01371383"
240,"NCT02279953","Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Vortioxetine 10-20 mg|Drug: Placebo|Drug: SSRI","Change in Digit Symbol Substitution Test (DSST): number of correct symbols|Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])|Change in Trail Making Test (TMT) score: TMT-A; speed of processing|Change in TMT score: TMT-B; executive functioning|Change in reaction time score: Choice Reaction Time (CRT); attention|Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed|Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning|Change in STROOP: congruent score; speed of processing|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score|Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score|Change in Clinical Global Impression - Severity of Illness (CGI-S)|Clinical Global Impression - Global Improvement (CGI-I) score|Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score|Number of adverse events|Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15905A|2014-000229-19","October 2014","April 2016","April 2016","October 31, 2014",,"May 24, 2017","EE001, Tallinn, Estonia|EE002, Tallinn, Estonia|FI002, Helsinki, Finland|FI003, Helsinki, Finland|FI005, Helsinki, Finland|FI001, Kuopio, Finland|FI006, Kupio, Finland|FI004, Turku, Finland|DE002, Berlin, Germany|DE001, Bielefeld, Germany|DE005, Bochum, Germany|DE003, Frankfurt, Germany|DE004, Mittweida, Germany|RS002, Belgrade, Serbia|RS001, Kragujevac, Serbia|SK003, Levice, Slovakia|SK002, Rimavska Sobota, Slovakia",,"https://ClinicalTrials.gov/show/NCT02279953"
241,"NCT01517503","Acceptance and Commitment Therapy Versus Cognitive Therapy for the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Therapy|Behavioral: Acceptance and Commitment Therapy","QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (QIDS-SR)|Hamilton Rating Scale for Depression|Decentering subscale of the Experiences Questionnaire|Acceptance and Action Questionnaire|Dysfunctional Attitude Scale-revised|Working Alliance Inventory|Eurohis Quality of Life Scale|Relationship Scales|Implicit Attitude Test|Structured Clinical Interview for DSM-IV (Major Depression Module)","VU University of Amsterdam","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","METC 10/103","December 2011","August 2015","August 2015","January 25, 2012",,"July 30, 2019","PsyQ, Zaandam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01517503"
242,"NCT01485887","Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: Venlafaxine ER","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinical Significant Vital Changes|Number of Participants With Clinical Significant Laboratory Tests Changes|Number of Participants With Clinical Significant Electrocardiogram (ECG) Changes|Number of Participants With no at Baseline and Yes at Any Post Baseline for Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories|Change From Baseline in 17-item Hamilton Rating Scale for Depression (HAM-D17) at Each Post Baseline Time Point|Change From Baseline in Clinical Global Impression - Severity (CGI-S) at Each Post Baseline Time Point|Mean Clinical Global Impression - Improvement (CGI-I) Score at Each Post Baseline Time Point|Change From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) at Each Post Baseline Time Point","Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer","All","20 Years and older   (Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2411264","January 2012","January 2014","January 2014","December 6, 2011","May 15, 2015","January 28, 2021","Nippon Medical School Chiba Hokusoh Hospital, Inzai, Chiba, Japan|Nakamoto Clinic, Noda City, Chiba, Japan|Stress Care Yoshimura Clinic, Fukuoka-shi, Fukuoka, Japan|Hatakeyama Clinic, Kitakyushu, Fukuoka, Japan|Shiranui Hospital, Omuta, Fukuoka, Japan|Fujikawa Clinic, Hatsukaichi, Hiroshima, Japan|Takahashi Psychiatric Clinic, Ashiya, Hyogo, Japan|Ikeuchi Psycho Induced Internal Med.Clinic, Kobe, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Medical Corporation Seishinkai Kishiro Mental Clinic, Kawasaki, Kanagawa, Japan|Yutaka Clinic, Sagamihara-shi, Kanagawa, Japan|Tawara Clinic, Yokohama, Kanagawa, Japan|Shioiri Mental Clinic, Yokosuka city, Kanagawa, Japan|Shibamoto Clinic, Osakasayama-shi, Osaka, Japan|Suzuki Hospital, Adachi-ku, Tokyo, Japan|Sangenjaya Nakamura Mental Clinic, Setagaya-ku, Tokyo, Japan|Omotesando Mental Clinic, Shibuya-ku, Tokyo, Japan|Maynds Tower Mental Clinic, Shibuya-ku, Tokyo, Japan|Tokyo Kosei Nenkin Hospital, Shinjuku-ku, Tokyo, Japan|Himorogi Psychiatric Institute, Toshima-ku, Tokyo, Japan|Tenjin Mental Clinic, Fukuoka, Japan|Stress Care Yoshimura Clinic, Fukuoka, Japan|Kuranari Psychiatry Clinic, Fukuoka, Japan|Medical Corporation Toyokokai Tawara Clinic, Kanagawa, Japan|Sagaarashiyama-Tanaka Clinic, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT01485887"
243,"NCT01330485","Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Affect Regulation Training|Behavioral: Common Factor Control Condition","Change in depressive symptoms|Emotion regulation skills","Friedrich-Alexander-Universität Erlangen-Nürnberg|German Research Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","218","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BE4510/3-1","November 2010","April 2014","September 2014","April 7, 2011",,"April 10, 2019","Philipps-University of Marburg, Marburg, Hessen, Germany|Aus- und Weiterbildungszentrum für Klinische Verhaltenstherapie, Kassel, Germany|University of Mainz, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT01330485"
244,"NCT02272517","Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Vortioxetine 10-20 mg|Drug: Escitalopram 10-20 mg","Change in Digit Symbol Substitution Test (DSST)|Change in Rey Auditory Verbal Learning Test (RAVLT)|Change in Trail Making Test A (TMT-A)|Change in Trail Making Test B (TMT-B)|Change in Reaction time score; CRT attention|Change in reaction time score SRT - simple reaction time|Change in STROOP incongruent score|Change in STROOP congruent score|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score|Change in Patient Health Questionnaire-9 (depressive symptoms) (PHQ-9) total score|Change in Clinical Global Improvement - Severity (CGI-S)|Clinical Global Improvement (CGI-I)|Change in Functioning Assessment Short Test (FAST)|Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15907A|2014-000231-16","December 2014","March 2016","March 2016","October 23, 2014",,"February 28, 2017","FI005, Helsinki, Finland|FI001, Kuopio, Finland|FI006, Kupio, Finland|FI007, Tampere, Finland|FI004, Turku, Finland|DE005, Bochum, Germany|DE004, Mittweida, Germany|RS002, Belgrade, Serbia|RS003, Belgrade, Serbia|RS004, Belgrade, Serbia|RS005, Belgrade, Serbia|RS001, Kragujevac, Serbia|SK004, Bratislava, Slovakia|SK001, Hronovce, Slovakia|SK003, Levice, Slovakia|SK002, Rimavska Sobota, Slovakia",,"https://ClinicalTrials.gov/show/NCT02272517"
245,"NCT01427439","A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder","PERFORM","Completed","No Results Available","Major Depressive Disorder",,"Patients' functioning assessed by the Sheehan Disability Scale (SDS) total score|Patients' functioning assessed by the SDS total score|Associations between the patients' clinical condition measured as score on Clinical Global Improvement Severity scale (CGI-S) and of patients' functioning measured as total score on SDS|Associations between the patients' clinical condition measured as score on CGI-S and of patients' functioning measured as total score on SDS","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)",,"1455","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13504A","February 2011","February 2015",,"September 1, 2011",,"July 8, 2015","FR, Paris, France",,"https://ClinicalTrials.gov/show/NCT01427439"
246,"NCT00766870","Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Drug: Lu AA34893|Drug: Venlafaxine extended release|Drug: Placebo","Depressive symptoms as measured by the change from baseline in MADRS total score|HAM-D, CGI, responders and remitters, HAM-A, adverse events, clinical safety laboratory tests, vital signs, weight, ECG, physical examination","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12279A|2007-007025-51","September 2008","January 2009","February 2009","October 6, 2008",,"September 29, 2010","CA009, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00766870"
247,"NCT01357083","The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder",,"Depression status(measured by Beck depression inventory (BDII-II))|Measurements of morning and nocturnal melatonin levels by ELISA kit (cat no. RE54021) from the IBL-Hamburg.","Science & Research Islamic Azad University Branch Khozestan","All","22 Years to 48 Years   (Adult)",,"92","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","9460|CCT-NAPN-21087","August 2010","October 2010","October 2010","May 20, 2011",,"May 20, 2011","Shahnaz Khaleghipour, Isfahan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01357083"
248,"NCT00448292","A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: PRX-00023|Drug: Placebo for PRX-00023","Change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS).|Side effects during and immediately following the treatment period|changes from baseline on the Hamilton Anxiety Rating (HAM-A) scale|changes from baseline on the Quick Inventory of Depressive Symptomatology-self report (QIDS-SR)|changes from baseline on the Clinical Global Impressions (CGI) scale|responder and remission rates|changes from baseline on the Changes in Sexual Function (CSFQ) scale.","Epix Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","EPX-CP-020","March 2007",,"November 2007","March 16, 2007",,"November 14, 2007","Vista Medical Research, Inc., Mesa, Arizona, United States|Pharmacology Research Institute, Encino, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Synergy Clinical Research Center, National City, California, United States|Excell Research, Oceanside, California, United States|Pacific Clinical Research Medical Group, Riverside, California, United States|AVI Clinical Research, Torrance, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|GWU Clinical Psychiatric Research Center, Washington, District of Columbia, United States|CNS Healthcare of Jacksonville, Jacksonville, Florida, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|Chicago Research Center, Inc., Chicago, Illinois, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Brentwood Research Institute, Shreveport, Louisiana, United States|Piedmont Neuropsychiatry, Charlotte, North Carolina, United States|University of Pennsylvannia, Philadelphia, Pennsylvania, United States|SE Health Consultants, LLC, Charleston, South Carolina, United States|University of Texas - Southwestern Medical Center, Dallas, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00448292"
249,"NCT01725282","Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: quetiapine extended release (XR)|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in Hamilton Rating Score for Depression (HAM-D17)|Percentage of Participants With Improvement in Clinical Global Impressions-Improvement (CGI-I)|Change From Baseline in Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)|Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)|Safety Assessed by the Incidence of Adverse Events (AE), Vital Signs, Electrocardiogram (ECG) and Laboratory Tests","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 2","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6949-CL-0005","December 14, 2011","August 24, 2013","August 24, 2013","November 12, 2012","August 28, 2014","July 30, 2019","Hokkaidou, Japan|Kantou, Japan|Kinki, Japan",,"https://ClinicalTrials.gov/show/NCT01725282"
250,"NCT01724112","Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Drug: LY2940094|Drug: Placebo","Change from Baseline to Week 8 on the GRID Hamilton Depression Rating Scale 17 Item Version (GRID-HAMD17) Total Score|Proportion of Participants Responding to Treatment|Proportion of Participants who Achieved Remission|Change from Baseline to Week 8 in Maier-Philipp Subscale (MPS) Score|Clinical Global Impression - Improvement (CGI-I) Score at Week 8|Change from Baseline to Week 8 in the Clinical Global Impression - Severity (CGI-S) Score|Change from Baseline to Week 4 in the Hamilton Anxiety Rating Scale (HAM-A) Total Score|Change from Baseline to Week 8 in the Hospital Anxiety and Depression Scale (HADS) Score|Population Pharmacokinetic (PK) Model: Estimate of LY2940094 Area Under the Curve (AUC)","BlackThorn Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14791|I5J-MC-NOAC","November 2012","March 2014","March 2014","November 9, 2012",,"February 3, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakland Park, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., University Park, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clinton, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01724112"
251,"NCT01752608","Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depressive Disorder","Behavioral: eCBT Mood","Montgomery-Åsberg Depression Rating Scale (MADRS)|Automatic Thoughts Questionnaire-Revised (ATQ-R)|Beck Depression Inventory, 2nd Edition|Profile of Mood States, Short-Form (POMS-SF)","MindApps","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","eCBT 201","October 2012","May 2015","May 2015","December 19, 2012",,"October 14, 2015","Compass Research, LLC: North Clinic, Leesburg, Florida, United States|Compass Research LLC, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01752608"
252,"NCT01571453","Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine (Lu AA21004)|Drug: Venlafaxine extended release","Change From Baseline in MADRS Total Score at Week 8|Change in CGI-S Score From Baseline to Week 8|CGI-I Score at Week 8|Change in HAM-A Total Score From Baseline to Week 8|MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)|Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)|Number of Adverse Events","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","437","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13926A","May 2012","October 2013",,"April 5, 2012","October 13, 2014","October 13, 2014",,,"https://ClinicalTrials.gov/show/NCT01571453"
253,"NCT01500200","A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: ALKS 5461|Drug: Placebo","Change From Baseline to Week 4 in Hamilton Rating Scale for Depression (HAM-D17) Total Score|Proportion of Patients Who Exhibited Treatment Response (HAM-D17)|Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score","Alkermes, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK5461-202","December 2011","March 2013","March 2013","December 28, 2011","May 21, 2019","May 21, 2019","Alkermes Investigational Site, Tucson, Arizona, United States|Alkermes Investigational Site, Oceanside, California, United States|Alkermes Investigational Site, Santa Ana, California, United States|Alkermes Investigational Site, Torrance, California, United States|Alkermes Investigational Site, Fort Myers, Florida, United States|Alkermes Investigational Site, Lauderhill, Florida, United States|Alkermes Investigational Site, Leesburg, Florida, United States|Alkermes Investigational Site, North Miami, Florida, United States|Alkermes Investigational Site, Saint Petersburg, Florida, United States|Alkermes Investigational Site, Atlanta, Georgia, United States|Alkermes Investigational Site, Hoffman Estates, Illinois, United States|Alkermes Investigational Site, Baltimore, Maryland, United States|Alkermes Investigational Site, Boston, Massachusetts, United States|Alkermes Investigational Site, Haverhill, Massachusetts, United States|Alkermes Investigational Site, Berlin, New Jersey, United States|Alkermes Investigational Site, Brooklyn, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, Canton, Ohio, United States|Alkermes Investigational Site, Dayton, Ohio, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, United States|Alkermes Investigational Site, Charleston, South Carolina, United States|Alkermes Investigational Site, Austin, Texas, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, Houston, Texas, United States|Alkermes Investigational Site, San Antonio, Texas, United States|Alkermes Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01500200"
254,"NCT01650740","Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Drug: Duloxetine|Drug: placebo|Other: Study visits only",">= 50% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (MADRS Response)|MADRS remission|Credibility and Expectancy Scale (CES)","Sunnybrook Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","081-2012","August 2012","August 2014","November 2014","July 26, 2012",,"December 23, 2014","Sunnybook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01650740"
255,"NCT00839423","Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine (Lu AA21004)|Drug: Venlafaxine XL","Change From Baseline in MADRS Total Score After 6 Weeks of Treatment|Change From Baseline in MADRS Total Score After 1 Week of Treatment|Change From Baseline in HAM-D 24 Total Score After 6 Weeks of Treatment|Change From Baseline in HAM-A Total Score After 6 Weeks of Treatment|Change From Baseline in CGI-S Score After 6 Weeks of Treatment|Change in Clinical Status Using CGI-I Score at Week 6|Proportion of Responders at Week 6 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)|Proportion of Remitters at Week 6 (Remission is Defined as a MADRS Total Score <=10)","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","426","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11492A|2006-001515-29","August 2006","August 2007","September 2007","February 9, 2009","December 17, 2013","May 13, 2014",,,"https://ClinicalTrials.gov/show/NCT00839423"
256,"NCT03642964","A Study in Patients With Major Depressive Disorder",,"Active, not recruiting","No Results Available","Major Depressive Disorder (MDD)","Drug: CTC-501","Tolerability will be assessed by the determination of a Maximum Tolerated Dose of pramipexole|Safety will be assessed by Incidence of Treatment-Emergent Adverse Events|The Montgomery-Åsberg Depression Rating Scale|Clinical Global Impression - Severity scale|Clinical Global Impression - Improvement scale|Pharmacokinetics will measure plasma concentrations of pramipexole and ondansetron","Chase Therapeutics Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CTC-003","September 10, 2018","May 30, 2021","May 30, 2021","August 22, 2018",,"January 27, 2021","Collaborative Neuroscience Network, Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03642964"
257,"NCT01149889","Transcranial Direct Current Stimulation to Treat Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Procedure: transcranial direct current stimulation","Treatment Response|Treatment response","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USP-HU-002","June 2010","September 2011","December 2011","June 24, 2010",,"December 6, 2011","University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01149889"
258,"NCT01601210","Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Creatine monohydrate or placebo","Brain PCr concentrations","Perry Renshaw|University of Utah","Female","13 Years to 21 Years   (Child, Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00055231","June 2012","May 2014","May 2014","May 17, 2012",,"October 25, 2016","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01601210"
259,"NCT01464229","Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability",,"Completed","Has Results","Major Depressive Disorder","Drug: Iloperidone|Drug: Placebo","SQ Anger/Hostility Scale","Maurizio Fava, MD|Novartis Pharmaceuticals|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011P002043","April 2012","December 2014","December 2014","November 3, 2011","April 11, 2017","April 11, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01464229"
260,"NCT01370733","Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder","NEST-MDD","Completed","Has Results","Major Depressive Disorder","Device: NEST-1 (NeoSync EEG Synchronized TMS)|Device: SHAM","Mean HAM-D17 Total Score Change (Intent to Treat - All)|Mean HAM-D17 Total Score Change (Per Protocol - All)|Mean HAM-D17 Total Score Change (Per Protocol - Non-Naive Subjects)|Number of Subjects Who Demonstrate Clinical Response at Week 6 or Early Termination (Intent to Treat)|Number of Subjects Who Demonstrate Clinical Response at Week 6 (Per Protocol - All)|Number of Subjects Who Demonstrate Clinical Response at Week 6 (Per Protocol - Non-Naive Subjects)|Number of Subjects Who Demonstrate Clinical Remission at Week 6 or Early Termination (Intent to Treat)|Number of Subjects Who Demonstrate Clinical Remission at Week 6 (Per Protocol - All)|Number of Subjects Who Demonstrate Clinical Remission at Week 6 or Early Termination (Per Protocol - Non-Naive Subjects)","Wave Neuroscience","All","22 Years to 65 Years   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NND3001","May 2012","August 2013","September 2013","June 10, 2011","July 14, 2015","October 26, 2015","UCLA Depression Research & Clinic Program, Los Angeles, California, United States|UCSD Medical Center, San Diego, California, United States|UCLA-Harbor, Torrance, California, United States|Hartford Hospital Institute of Living, Hartford, Connecticut, United States|TMS Specialists Chicago, Chicago, Illinois, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Center for Mood Disorders and Neuromodulation Therapies, UMDNJ-SOM, Cherry Hill, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University Brain Stimulation and Neurophysiology Center, Durham, North Carolina, United States|Wake Forest University Medical Center, Winston Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Mood Disorders Treatment Research Program University of Pittsburgh-Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Butler Hospital Mood Disorders Research Program, Brown Department of Psychiatry and Human Behavior, Providence, Rhode Island, United States|MUSC Institute of Psychiatry, Brain Stimulation Lab, Charleston, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|R/D Clinical Research, Lake Jackson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01370733"
261,"NCT01395147","Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Lu AA21004","Number of Participants Reporting One or More Treatment-emergent Adverse Events|Number of Participants With Markedly Abnormal Laboratory Values|Significant Change from Baseline in Body Weight|Change from Baseline in Vital Signs|Change from Baseline in Electrocardiograms|Clinically Significant Change From Baseline in Physical Examination Findings|Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at each time point|Change from Baseline in the Clinical Global Impression Scale-Severity (CGI-S) score at each time point|Change from Baseline in the Clinical Global Impression - Improvement (CGI-I) score at each time point","Takeda","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","119","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LuAA21004/OCT-001|JapicCTI-111530|U1111-1122-3910","July 2011","May 2013","May 2013","July 15, 2011",,"November 5, 2013","Inzai-shi, Chiba, Japan|Noda-City, Chiba, Japan|Fukuoka-city, Fukuoka, Japan|Kitakyushu-shi, Fukuoka, Japan|Annaka-shi, Gunma, Japan|Fujioka-shi, Gunma, Japan|Takasaki-shi, Gunma, Japan|Hatsukaichi-shi, Hiroshima, Japan|Hiroshima-shi, Hiroshima, Japan|Sapporo-Shi, Hokkaido, Japan|Amagasaki-shi, Hyogo, Japan|Kobe-shi, Hyogo, Japan|Fujisawa-shi, Kanagawa, Japan|Kawasaki-shi, Kanagawa, Japan|Sagamihara-shi, Kanagawa, Japan|Yokohama-shi, Kanagawa, Japan|Osaka-shi, Kita-ku, Japan|Kumamoto-shi, Kumamoto, Japan|Kyoto-shi, Kyoto, Japan|Kurashiki-shi, Okayama, Japan|Osaka-shi, Osaka, Japan|Fukaya-shi, Saitama, Japan|Saitama-city, Saitama, Japan|Utsunomiya-shi, Tochigi, Japan|Anan-shi, Tokushima, Japan|Tokushisma-shi, Tokushima, Japan|Hachioji-shi, Tokyo, Japan|Katsushika-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Nanyo-shi, Yamagata, Japan|Ibaraki, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01395147"
262,"NCT01148472","Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Duloxetine","To compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) as assessed by change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of 24 weeks|To compare the efficacy of escitalopram with that of duloxetine per visit over the 24-week study period in outpatients with MDD.|To compare the tolerability and safety of escitalopram with that of duloxetine over the 24-week study period in outpatients with MDD.|To evaluate the discontinuation emergent signs and symptoms during and after taper-down treatment with escitalopram or duloxetine after 24 weeks of treatment assessed by the Discontinuation Emergent Signs and Symptoms Scale (DESS).","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10990|2004-005069-39","September 2005","September 2006","November 2006","June 22, 2010",,"November 8, 2016",,,"https://ClinicalTrials.gov/show/NCT01148472"
263,"NCT00633399","Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs",,"Completed","Has Results","Major Depressive Disorder","Drug: Ziprasidone|Drug: Placebo","The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2|Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.|Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8","Massachusetts General Hospital|University of Alabama at Birmingham","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","458","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-P-002361","July 2008","March 2014","March 2014","March 12, 2008","July 3, 2014","July 3, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Massachusetts General Hospital- Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00633399"
264,"NCT01557712","Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks","KETADEP","Completed","No Results Available","Major Depressive Disorder","Drug: ketamine venlafaxine|Drug: Venlafaxine","Depressive state","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)","Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1129","March 2012","January 2017","January 2017","March 19, 2012",,"February 24, 2017","Centre hospitalier universitaire, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT01557712"
265,"NCT02209142","Blood Biomarkers in Major Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Other: blood prelevement|Other: psychometric data collection","describe a transcriptional signature of the Major Depressive Episode.|evaluate the role played by confounding factors as genetic polymorphisms,","Assistance Publique Hopitaux De Marseille","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","275","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2010-19","February 2012","November 2015","October 2016","August 5, 2014",,"July 27, 2016","Assistance Publique Hopitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT02209142"
266,"NCT01613820","Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: Ketamine|Drug: Scopolamine","Hamilton Depression Rating Scale - 28 items|Systematic Assessment for Treatment Emergent Events (SAFTEE)","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-P-000624","September 2015","February 2017","February 2017","June 7, 2012",,"February 19, 2018","Depression Clinical and Reseach Program - MGH, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01613820"
267,"NCT01355081","Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine|Drug: Placebo","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment|Percentage of Patients With MADRS Response After 8 Weeks of Treatment|Percentage of Patients With MADRS Remission After 8 Weeks of Treatment|Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment|Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment|Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment","Takeda","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","366","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004/CCT-003|U1111-1120-9277|JapicCTI-111492","May 2011","December 2012","December 2012","May 17, 2011","November 11, 2014","November 11, 2014","Inzai-shi, Chiba, Japan|Noda-City, Chiba, Japan|Fukuoka-city, Fukuoka, Japan|Kitakyushu-shi, Fukuoka, Japan|Annaka-shi, Gunma, Japan|Fujioka-shi, Gunma, Japan|Takasaki-shi, Gunma, Japan|Hatsukaichi-shi, Hiroshima, Japan|Hiroshima-shi, Hiroshima, Japan|Sapporo-Shi, Hokkaido, Japan|Amagasaki-shi, Hyogo, Japan|Kobe-shi, Hyogo, Japan|Fujisawa-shi, Kanagawa, Japan|Kawasaki-shi, Kanagawa, Japan|Sagamihara-shi, Kanagawa, Japan|Yokohama-shi, Kanagawa, Japan|Osaka-shi, Kita-ku, Japan|Kumamoto-shi, Kumamoto, Japan|Kyoto-shi, Kyoto, Japan|Kurashiki-shi, Okayama, Japan|Osaka-shi, Osaka, Japan|Fukaya-shi, Saitama, Japan|Saitama-city, Saitama, Japan|Utsunomiya-shi, Tochigi, Japan|Anan-shi, Tokushima, Japan|Tokushisma-shi, Tokushima, Japan|Hachioji-shi, Tokyo, Japan|Katsushika-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Nanyo-shi, Yamagata, Japan|Ibaraki, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01355081"
268,"NCT01189318","Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: Quetiapine Fumarate Extended Release","change from baseline Pittsburgh Quality Index total scores at 4 weeks|change from baseline Pittsburgh Quality Index total scores at 2 weeks|change from baseline Pittsburgh Quality Index total scores at 4 days|change from baseline in sleep architecture measured using polysomnography at 4 weeks|number of participants with adverse events","Ewha Womans University","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443C00042","March 2012","February 2014","February 2014","August 26, 2010",,"August 7, 2015","Ewha Womans University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01189318"
269,"NCT01397903","Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response","MADDRE","Completed","No Results Available","Major Depressive Disorder",,"To assess the response of additional therapy by assessment of percentage of patients with CGI-I score ≤ 2|Number of consecutive treatments administered for the management of the current MDD episode until the commencement of adjunctive (add-on) medication.|Percentage of patients (n, %) with MADRS score ≤ 10 at week 4 following the onset of adjunctive medication|Percentage of patients (n,%) with a change (decrease) in MADRS score be ≥ 50%","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)",,"545","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","NIS-NGR-XXX-2011/1","September 2011","March 2012","March 2012","July 20, 2011",,"June 25, 2012","Research Site, Arta, Artas, Greece|Research Site, Athens, Attika, Greece|Research Site, Chaidari, Attika, Greece|Research Site, Dafni, Attika, Greece|Research Site, Glyfada, Attika, Greece|Research Site, Kifisia, Attika, Greece|Research Site, Koropi, Attika, Greece|Research Site, Maroussi, Attika, Greece|Research Site, Nea Makri, Attika, Greece|Research Site, Peristeri, Attika, Greece|Research Site, Petroupoli, Attika, Greece|Research Site, Rodos, Dodekanese, Greece|Research Site, Agrinio, Etoloacarnania, Greece|Research Site, Lamia, Fhiotida, Greece|Research Site, Ioannina, Ioanninon, Greece|Research Site, Larisa, Larissa, Greece|Research Site, Ag. Nikolaos, Lasithiou, Greece|Research Site, Patra, Patras, Greece|Research Site, Egaleo, Piraeus, Greece|Research Site, Thiva, Viotia, Greece|Research Site, Heraklio, Greece|Research Site, Kalamata, Greece|Research Site, Karditsa, Greece|Research Site, Kavala, Greece|Research Site, Serres, Greece|Research Site, Thessaloniki, Greece|Research Site, Trikala, Greece",,"https://ClinicalTrials.gov/show/NCT01397903"
270,"NCT01309776","Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder","CAMPION","Completed","No Results Available","Major Depressive Disorder","Drug: Tianeptine|Drug: Escitalopram","Changes in Hamilton Rating Scale for Depression(HAM-D)score from baseline|Changes in Korean version-California Verbal Learnign Test(K-CVLT) total score from baseline|Changes in Visual Continuous Performance Test(CPT) total score from baseline|Changes in Raven Progressive Matrices(RPM) total score from baseline|Changes in Hamilton Rating Scale for Anxiety(HAM-A) score from baseline|Changes in Clinical Clinical Global Impression- improvement(CGI-I)|Change in Response Rate from baseline|Change in Mini-Mental status examination(MMSE) total score from baseline|Change in Sexual Function Scale|Change in Clinical Global Impression- severity(CGI-S)|Change in Remission Rate from baseline","Samsung Medical Center","All","40 Years and older   (Adult, Older Adult)","Phase 4","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-11-029","March 2011","September 2012","September 2012","March 7, 2011",,"January 25, 2013","Inje University Paik Hospital, Goyang, Korea, Republic of|Inje University Seoul Paik Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Eulji Medical College Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01309776"
271,"NCT01838681","Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Brexpiprazole|Drug: ADT","Full Remission During the Randomised Treatment Period|Full Functional Remission During the Randomised Treatment Period|Full Global Score Remission During the Randomised Treatment Period|Total Time in Remission During the Randomised Treatment Period|Time to Full Remission During the Randomised Treatment Period|Full Remission Sustained During the Randomised Treatment Period|Change From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period|Change From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period|Response at Week 6 During the Randomised Treatment Period|Response at Week 24 During the Randomised Treatment Period|Remission at Week 6 During the Randomised Treatment Period|Remission at Week 24 in the Randomised Treatment Period|Change From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period|Change From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period|Change From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period|Change From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period|Change From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period|Change From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period","H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1986","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14570A|2012-001380-76","June 2013","June 2016","June 2016","April 24, 2013","August 9, 2017","August 9, 2017","US041, Little Rock, Arkansas, United States|US043, Cerritos, California, United States|US042, Temecula, California, United States|US053, Flowood, Mississippi, United States|US040, Brooklyn, New York, United States|US046, Houston, Texas, United States|US052, Houston, Texas, United States|US047, Milwaukee, Wisconsin, United States|BG007, Kardjali, Bulgaria|BG002, Pazardzhik, Bulgaria|BG003, Ruse, Bulgaria|BG001, Sofia, Bulgaria|BG004, Sofia, Bulgaria|BG005, Varna, Bulgaria|BG006, Varna, Bulgaria|CA003, Burlington, Canada|CA004, Edmonton, Alberta, Canada|CA001, Kingston, Canada|CA002, Montral, Canada|CA005, Montreal, Canada|EE002, Tallinn, Estonia|EE003, Tallinn, Estonia|EE006, Tallinn, Estonia|EE001, Tartu, Estonia|EE005, Tartu, Estonia|EE004, Voru, Estonia|FI002, Helsinki, Finland|FI003, Helsinki, Finland|FI006, Helsinki, Finland|FI001, Kuopio, Finland|FI007, Pori, Finland|FI009, Tampere, Finland|DE007, Berlin, Germany|DE014, Berlin, Germany|DE015, Berlin, Germany|DE006, Bielefeld, Germany|DE010, Bochum, Germany|DE012, Gelsenkirchen, Germany|DE009, Hannover, Germany|DE022, Hattingen, Germany|DE008, Heidelberg, Germany|DE017, Leipzig, Germany|DE001, Nuernberg, Germany|DE004, Nuernberg, Germany|DE002, Schwerin, Germany|DE016, Wiesbaden, Germany|KR001, Seoul, Korea, Republic of|KR004, Seoul, Korea, Republic of|LV004, Daugavpils, Latvia|LV005, Jelgava, Latvia|LV002, Liepaja, Latvia|LV003, Riga, Latvia|LV001, Strenci, Latvia|LT006, Kaunas Region, Lithuania|LT003, Kaunas, Lithuania|LT001, Palanga, Lithuania|LT005, Silute, Lithuania|LT002, Vilnius, Lithuania|LT004, Vilnius, Lithuania|MX009, Guadalajara, Mexico|MX008, Leon, Mexico|MX003, Monterrey, Nuevo Len, Mexico|MX002, Monterrey, Mexico|PL010, Bialystok, Poland|PL016, Bialystok, Poland|PL017, Bydgoszcz, Poland|PL007, Chelmno, Poland|PL002, Gdansk, Poland|PL011, Gorlice, Poland|PL018, Kielce, Poland|PL013, Leszno, Poland|PL001, Lublin, Poland|PL006, Lublin, Poland|PL014, Szczecin, Poland|PL012, Torun, Poland|PL019, Torun, Poland|RO003, Bucuresti, Romania|RO006, Bucuresti, Romania|RO001, Iasi, Romania|RO004, Timisoara, Romania|RU002, Moscow, Russian Federation|RU004, Moscow, Russian Federation|RU003, Saint-Petersburg, Russian Federation|RU006, Saint-Petersburg, Russian Federation|RU007, Saint-Petersburg, Russian Federation|RU010, Saint-Petersburg, Russian Federation|RU014, Saint-Petersburg, Russian Federation|RU012, Saratov, Russian Federation|RU005, Stavropol, Russian Federation|SE008, Halmstad, Sweden|SE006, Malmo, Sweden|SE009, Skovde, Sweden|SE001, Stockholm, Sweden|UA006, Kharkiv, Ukraine|UA007, Kherson,Vil. Stepanivka, Ukraine|UA003, Kiev, Ukraine|UA014, Kiev, Ukraine|UA002, Kyiv, Ukraine|UA005, Lviv, Ukraine|UA012, Ternopil, Ukraine|UA009, Vinnytsya, Ukraine|GB003, Blackpool, United Kingdom|GB005, Bognor Regis, United Kingdom|GB002, Bradford, United Kingdom|GB004, Cannock, United Kingdom|GB001, Leeds, United Kingdom|GB006, Winwick, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01838681"
272,"NCT04403373","Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Behavioral: Waitlist control|Behavioral: Moderate-intensity walking exercise|Behavioral: Vigorous-intensity walking exercise","Depressive symptoms-Beck Depression Inventory (BDI)|Antidepressants Usage-Medication History|Anxiety-Generalized Anxiety Disorder 7-item (GAD-7) scale|Sleep quality-Pittsburgh Sleep Quality Index (PSQI)|Quality of life-12-item short form health survey (SF-12)|Cardiorespiratory fitness-VO2max Test|Resting heart rate|Body Mass Index|Daily physical activity-International Physical Activity Questionnaire (IPAQ)","The University of Hong Kong","All","50 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RF-9835-MDD-007","November 1, 2019","December 31, 2020","December 31, 2020","May 27, 2020",,"May 4, 2021","Li Kai Shing Faculty of Medicine, Hong Kong, Southern District, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04403373"
273,"NCT04853407","A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: LY03005 extended-release tablet|Drug: Placebo","Montgomery- Åsberg Depression Rating Scale(MADRS)|17 items Hamilton Depression Scales (HAM-D17)","Luye Pharma Group Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","588","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LY03005/CT-CHN-305","December 5, 2018","December 24, 2020","December 24, 2020","April 21, 2021",,"April 23, 2021","The Sixth Hospital of Peking University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04853407"
274,"NCT01436175","SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study",,"Terminated","Has Results","Major Depressive Disorder","Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant","Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Baseline in Systolic Blood Pressure at Week 52|Change From Baseline in Diastolic Blood Pressure at Week 52|Change From Baseline in Pulse Rate at Week 52|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET|Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)|Short Form-12 Health Survey Version 2 (SF-12V2)|EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility|EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care|EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities|EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort|EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression|EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale|Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)|Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)|Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET|Amphetamine Cessation Symptom Assessment (ACSA) Total Score|Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)|PRUQ-MDD - Number of Days of Resource Utilization|PRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)|PRUQ-MDD - Number of Hours|PRUQ-MDD - Effect of Depressive Symptoms","Shire|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1570","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPD489-329|2011-003019-47","February 27, 2012","March 27, 2014","March 27, 2014","September 19, 2011","February 23, 2015","June 14, 2021","Birmingham Research Group, Birmingham, Alabama, United States|ResearchOne, Inc., Scottsdale, Arizona, United States|Arkansas Psychiatric Clinical Research Trials, P.A., Little Rock, Arkansas, United States|South Coast Clinical Trials, Inc., Anaheim, California, United States|American Neuropsychiatric Research, Inc., Carson, California, United States|Catalina Research Institute, LLC, Chino, California, United States|Shanti Clinical Trials, Colton, California, United States|ATP Clinical Research, Costa Mesa, California, United States|Clinical Innovation, Inc., Costa Mesa, California, United States|Diligent Clinical Trials, Downey, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|UC, Irvine Child Development Center, Irvine, California, United States|Irvine Center For Clinical Research, Irvine, California, United States|Omega Clinical Trials, LLC, La Habra, California, United States|Semel Institute for Neuroscience & Human Behavior at UCLA, Los Angeles, California, United States|Pacific Research Partners, Oakland, California, United States|North County Clinical Research, Oceanside, California, United States|Pasadena Research Institute, LLC, Pasadena, California, United States|Anderson Clinical Research, Redlands, California, United States|BreakThrough Clinical Trials, LLC, San Bernardino, California, United States|Affiliated Research Institute, San Diego, California, United States|PCSD - Feighner Research, San Diego, California, United States|Clinical Innovations, Inc., San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Neuropsychiatric Center of Orange County, Santa Ana, California, United States|Caliifornia Neuroscience Research Medical Group, Sherman Oaks, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Geriatric and Adult Psychiatry, LLC, Hamden, Connecticut, United States|Institute of Living - Hartford Hospital, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|CNS Clinical Research Group, Coral Springs, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA, Fort Walton Beach, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Amit Vijapura MD, Jacksonville, Florida, United States|Psychiatric Associates, Lake City, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Fidelity Clinical Research Inc, North Miami, Florida, United States|Scientific Clinical Research Inc., North Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Ali A. Kashfi, MD, PA, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Comprehensive Clinical Development, Inc., Saint Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Kolin Research Group, Winter Park, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine & Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|American Medical Research, Inc., Oakbrook Terrace, Illinois, United States|Psyichiatric Medicine Associates, LLC, Skokie, Illinois, United States|Sleep and Behavior Medicine Institute, Vernon Hills, Illinois, United States|Davis Clinic, Indianapolis, Indiana, United States|Pedia Research, LLC, Newburgh, Indiana, United States|Northwest Indiana Center for Clinical Research, Valparaiso, Indiana, United States|Clinical Trials Technology, Inc., Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|MCM Clinical Research LLC, Florence, Kentucky, United States|Pedia Research, LLC, Owensboro, Kentucky, United States|Louisiana Clinical Research LLC, Shreveport, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Potomac Grove Clinical Research Center, Gaithersburg, Maryland, United States|Office of Marc Hertzman, MD, Rockville, Maryland, United States|Adams Clinical Trials, LLC, Watertown, Massachusetts, United States|Comprehensive Psyichatric Associates, Gladstone, Missouri, United States|The Center for Pharmaceutical Research PC, Kansas City, Missouri, United States|Private Practice - Howard J. Ilivicky, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Mid-America Clinical Research, Saint Louis, Missouri, United States|Mercy Health Research, Saint Louis, Missouri, United States|Premier Psychiatric Research Institute, Lincoln, Nebraska, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Center For Emotional Fitness, Cherry Hill, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|CRI Worldwide, LLC, Willingboro, New Jersey, United States|Albuquerque Neuroscience Inc., Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Brooklyn Medical Institutes, Brooklyn, New York, United States|Comprehensive Clinical Development, Inc., Fresh Meadows, New York, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Clinilabs, Inc., New York, New York, United States|Medical & Behavioral Health Research, PC, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Sleep Medicine Centers of Western New York, West Seneca, New York, United States|Triangle Neuropsyhiatry, Durham, North Carolina, United States|Clinical Trials of America, Hickory, North Carolina, United States|Dr. Richard Weisler, Raleigh, North Carolina, United States|Northcoast Clinical Trials, Beachwood, Ohio, United States|Community Research, Inc., Cincinnati, Ohio, United States|Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Lindner Center for Hope, Mason, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|SP Research, PPC dba Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|CRI Worldwide LLC, Philadelphia, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|University Services, West Chester, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Medical University of South Carolina, Anxiety Disorders Program, North Charleston, South Carolina, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|FutureSearch Clinical Trials, LP, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|Future Search Trials of Dallas, LP, Dallas, Texas, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Bay Area Clinical Services, Friendswood, Texas, United States|Houston Clinical Trials, LLC, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Wharton Research Center, Inc., Wharton, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Alliance Research Group, Richmond, Virginia, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Dean Foundation for Health, Research, and Education, Middleton, Wisconsin, United States|Independent Physician Consultants (dba IPC Research), Waukesha, Wisconsin, United States|Dr. Alexander McIntyre Inc, Penticton, British Columbia, Canada|Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc., Vancouver, British Columbia, Canada|Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada|Anxiety and Mood Disorder Center, Mississauga, Ontario, Canada|Dr. Sunny Johnson Medical Corporation, Medican Research Associates, Mississauga, Ontario, Canada|A. K. Karan Holdings, Ltd., Oakville, Ontario, Canada|International Sleep Clinic, West Parry Sound Health Centre, Parry Sound, Ontario, Canada|START Clinic for Mood and Anxiety Disorders, Toronto, Ontario, Canada|Sleep & Alertness Clinic, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Recherches Neuro-Hippocampe, Gatineau, Quebec, Canada|l'Hopital Louis H. Lafontaine, Montreal, Quebec, Canada|Kells Medical Research Group Inc., Pointe Claire, Quebec, Canada|Q & T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Especialidades Medicas L y S, Las Condes, Santiagio, Chile|Centro de Estudios Clinicos (CEC), Providencia, Santiago, Chile|Biomedica Research Group, Providencia, Santiego, Chile|Psicomed Estudio Medicos, Antofagasta, Chile|Psychiatrie Ricany, Ricany, Praha Vychod, Czechia|Saint Anne s.r.o., Psychiatricka ambulance, Brno, Czechia|Psychiatricka ambulance, Brno, Czechia|Medicana s.r.o., Horovice, Czechia|Supervize s.r.o., Kutna Hora, Czechia|Bialbi s.r.o., Litomerice, Czechia|Clintrial s.r.o., Prague 10, Czechia|Psychiatry Trial, s.r.o, Prague, Czechia|Medical Services Prague s.r.o., Prague, Czechia|Marienthal Psychiatry & Psychology Center of Mustamae, Tallinn, Estonia|North Estonia Medical Centre Foundation, Tallinn, Estonia|Jaanson & Laane Ou, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|ARTES Psykiatrinen Palvelukeskus Oy, Helsinki, Finland|Satucon Oy / Privater, Kuopio, Finland|Puutonin Psykiatripalvelu, Turku, Finland|Facharzt fur Neurologie und Psychiatrie, Berlin, Germany|Emovis GmbH, Berlin, Germany|Complete Facharzt fur Neurologie und Psychiatrie, Berlin, Germany|Private Practice Drs. Bitter/Schumann, Bochum, Germany|ZSL Zentrum fuer medizinische Studien in Leipzig, Leipzig, Germany|Complete Karlstr, Munchen, Germany|Studienzentrum Klinikum Nuernberg, Nuernberg, Germany|Somni bene GmbH, Schwerin, Germany|Gemeinschaftspraxis fur Neurologie und Psychiatrie, Westerstede, Germany|Medizinisches Studienzentrum Wuerzburg, Wuerzburg, Germany|Semmelweis Egyetem Pszichiatrial es Pszichoterapias Klinkia, Budapest, Hungary|Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum, Debrecen, Hungary|B&B Investigaciones Medicas, SC, Sinaloa, Mazatian, Mexico|CRI Centro Regiomontano de Investigacion Clinica S.C, Nuevo Leon, Monterrey, Mexico|Prywatne Gabinety Lekarskie ""Promedicus"" Anna Agnieszka Tomczak, Bialystok, Poland|Zespol Opleki Zdrowotnej w Chelmole, Chelmno, Poland|Centrum Badan Klinicznych PI-House sp. z o. o., Gdansk, Poland|Centrum Badan Klinicznych Pl-House, Gdansk, Poland|Klinika Chorob Psychicznych i Zaburzen Nerwicowych Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Klinika Chorob Psychicznych i Zaburzen Nerwicowych, Gdansk, Poland|Centrum Psychiatrii i Psychoterapi, Gorlice, Poland|NZOZ Syntonia, Kielce, Poland|Samodzieiny Publiczny Zespol Zakladow Opieki Zdrowotnej w Zurominie, Zuromin, Poland|Dharma Institute and Research Center, San Juan, Puerto Rico|INSPIRA Clinical Research, San Juan, Puerto Rico|Spitalul Clinic de Psihiatrie ""Prof. Dr. Alexandru Obregia"" Sectia Clinica Psihiatrie I, Bucuresti, Romania|Lorentina 2102 SRL, Targoviste, Romania|Spitalui Clinic Judetean Mures, Targu Mures, Romania|Cape Trial Centre, Bellville, Cape Town, South Africa|Somerset West Clinical Research Unit, Somerset West, Western Cape, South Africa|Flexivest Fourteen Research Centre, Cape Town, South Africa|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Fundacion de Alcorcon, Madrid, Spain|Centro de Salud Mental II la Corredoria, Oviedo, Spain|Centro de Salud Alamedilla Unidad de Salud Mental, Salamanca, Spain|Complejo hospitalario de Zamora, Zamora, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01436175"
275,"NCT01447576","Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: ADT|Drug: OPC-34712","Participants With Adverse Events (AEs).|Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Scale Score.|Mean Clinical Global Impression - Improvement (CGI-I) Scale Score.","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1036","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-08-212","September 2009","December 2012","December 2012","October 6, 2011","November 6, 2015","November 6, 2015","Pacific Clinical Research Medical Group, Arcadia, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Florida Clinical Research Center, Maitland, Florida, United States|Clinical Neurosciences Solutions, Orlando, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Carman Research, Smyrna, Georgia, United States|Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States|Pharmasite Research, Baltimore, Maryland, United States|Clinical Insights, Glen Burnie, Maryland, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Medical & Behavioral Health Research, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States|Oregon Center for Clinical Investigations, Salem, Oregon, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Radiant Research, Murray, Utah, United States|Psychiatric Alliance of the Blue Ridge, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01447576"
276,"NCT00635219","Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine (Lu AA21004)|Drug: Duloxetine","Change From Baseline in MADRS Total Score After 8 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment|Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)|Change in Clinical Status Using CGI-I Score at Week 8|Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score >=20|Change From Baseline in SDS Total Score After 8 Weeks of Treatment|Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)|Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment|Change From Baseline in CGI-S Score After 8 Weeks of Treatment|Change From Baseline in ASEX Total Score After 8 Weeks of Treatment","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","766","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11984A|EudraCT 2007-001870-95","February 2008","April 2009","April 2009","March 13, 2008","February 11, 2014","February 11, 2014",,,"https://ClinicalTrials.gov/show/NCT00635219"
277,"NCT01483053","Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)",,"Unknown status","No Results Available","Major Depressive Disorder (MDD)","Drug: Agomelatine|Drug: Escitalopram","Change from baseline in markers of sympathetic nervous system activity.|Change from baseline in the magnitude of morning surge in blood pressure.|To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.|Change from baseline in insulin resistance.|Change from baseline on markers of cardiac risk.","Baker Heart and Diabetes Institute|Servier Laboratories (Australia) Pty Ltd|The Alfred|Monash Medical Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","498/11","January 2014","February 2015","February 2015","December 1, 2011",,"December 18, 2013","Monash Medical Centre - Monash Health, Clayton, Victoria, Australia|Alfred and Baker Medical Unit - Alfred Hospital, Melbourne, Victoria, Australia|Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01483053"
278,"NCT01837797","Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",,"Terminated","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Brexpiprazole 1 mg|Drug: Brexpiprazole 3 mg","Change From Randomisation in Depressive Symptoms During the Randomised Treatment|Number of Adverse Events|Change From Randomisation in Clinical Global Impression During the Randomised Treatment|Change From Randomisation in Functionality Assessed by SDS During the Randomised Treatment|Change From Randomisation in Social Adaptation During the Randomised Treatment|Response During the Randomised Treatment|Sustained Response During the Randomised Treatment|Remission During the Randomised Treatment|Sustained Remission During the Randomised Treatment|Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)","H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.","All","65 Years and older   (Older Adult)","Phase 3","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14571A|2012-001361-32","April 2013","May 2014","May 2014","April 23, 2013","March 3, 2016","October 17, 2018","US001, National City, California, United States|US008, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01837797"
279,"NCT01606384","Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder","NAPA","Completed","No Results Available","Major Depressive Disorder","Drug: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Drug: Placebo","Cortisol plasma concentration response to Corticotropin releasing factor (CRF) administration before and after 27 days of dosing|Adrenocorticotropic hormone (ACTH) plasma concentration response to CRF administration before and after 27 days of dosing|Number of patients with adverse events|Changes in Hamilton Depression Rating Scale (HAM-D) depressed mood, factor and core items scores|Changes Clinical Global Impression (CGI) Severity and Improvement scores","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PDY5467","December 2006","August 2007","August 2007","May 25, 2012",,"May 25, 2012","Sanofi-Aventis, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01606384"
280,"NCT01263223","A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo","Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 1|Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 4|Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 1|Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Heart Rate During Treatment With 36-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Systolic and Diastolic Blood Pressure During Treatment With 36-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Heart Rate During Treatment With 18-mg LY2216684 or 36-mg LY2216684 on Day 4|Maximum and Mean Change From Baseline in ABPM Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or 36-mg LY2216684 on Day 4","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12607|H9P-EW-LNCP","December 2010","March 2011","March 2011","December 20, 2010","October 23, 2018","October 23, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01263223"
281,"NCT00816322","The Effect of Fish Oil in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Dietary Supplement: Omega-3 fatty acids|Dietary Supplement: Placebo","HAMD|BDI|Adverse effects|Recurrence rate","National Science Council, Taiwan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DMR93-IRB-87","January 2005","January 2014","December 2014","January 1, 2009",,"April 14, 2015","China Medical University, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00816322"
282,"NCT03685942","Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder","LUMIDEP","Recruiting","No Results Available","Major Depressive Disorder|Unipolar Depression","Device: active light therapy (LUMINETTE®)|Device: placebo light therapy","Montgomery-Åsberg depression rating scale (MADRS)|Pittsburgh Sleep Quality Index (PSQI)|Epworth Sleepiness Scale (ESS)|Hamilton Anxiety Rating Scale (HAM-A)","Centre Psychothérapique de Nancy|LUCIMED","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIPH 2017-02","January 16, 2019","August 2023","September 2023","September 26, 2018",,"May 27, 2021","Centre Psychothérapique de Nancy, Laxou, France",,"https://ClinicalTrials.gov/show/NCT03685942"
283,"NCT00781742","AZD6765 Severe Major Depressive Disorder (MDD) IV",,"Completed","No Results Available","Major Depressive Disorder","Drug: AZD6765|Drug: Placebo","To give evidence of an antidepressant effect versus placebo, given together with another antidepressant confirmed by change in the MADRS total score|To determine if the antidepressant effect can be achieved at week 3 with AZD6765 (100 or 150 mg/infusion) versus placebo by assessing a change from baseline to week 3 in the MADRS total score.|To evaluate the rapid antidepressant efficacy of AZD6765 at 1 day after a first infusion, as assessed by a change in the Quick Inventory of Depressive Symptomology Self-Report 16-item scale (QIDS-SR-16) total score.|• To assess the safety and tolerability of multiple infusions when administered concomitantly with other anti-depressants by incidence of AEs.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D6702C00009","October 2008","March 2010","March 2010","October 29, 2008",,"July 25, 2012","Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Overland Park, Kansas, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, St. Louis, Missouri, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Rochester, New York, United States|Research Site, East Stroudsburg, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00781742"
284,"NCT03353493","Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder, Recurrent","Behavioral: MBCT|Other: TAU","Change in neural connectivity|Change in mindfulness skills|Change in decentering|Change in rumination|Change in emotional processing bias|Change in interoceptive awareness|Change in perceived stress|Time to relapse or recurrence of depression|Change in depressive symptoms|Change in interleukin gene expression|Change in interleukin protein expression|Change in gene expression of norepinephrine transporter|Change in gene expression of glutamate receptor|Change in gene expression of TNF|Change in protein expression of tumor necrosis factor|cRP expression|Change in NF-kB gene expression|Change in NF-kB protein expression|Change in INFG gene expression|Change in Interferon gamma protein expression|Mitochondrial DNA Copy Number","University of Aarhus|University of Oxford|VIA University College|University of York|Harvard Medical School","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","314 #2016-051-000001","February 15, 2017","June 1, 2018","June 1, 2019","November 27, 2017",,"June 5, 2019","Aarhus University, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT03353493"
285,"NCT01435759","SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Drug: Antidepressant + Placebo","Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)|Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16|Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16|Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16","Shire|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD489-209|2011-003615-28","May 31, 2011","January 17, 2014","January 17, 2014","September 19, 2011","February 19, 2015","June 9, 2021","Arkansas Psychiatric Clinic Clinical Research Trials, Little Rock, Arkansas, United States|South Coast Clinical Trials, Anaheim, California, United States|Catalina Research Institute, LLC, Chino, California, United States|Shanti Clinical Trials, Colton, California, United States|Clinical Innovation, Inc., Costa Mesa, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Omega Clinical Trials, La Habra, California, United States|Provate Practice of Andrew Leuchter, MD, Los Angeles, California, United States|PCSD - Feighner Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Institute of Living, Hartford, Connecticut, United States|The Hospital of Central Connecticut, Psychiatry & Behavioral Health Research, New Britain, Connecticut, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Private Practice - Amit Vijapura MD, Jacksonville, Florida, United States|Psychiatric Associates, Lake City, Florida, United States|Comprehensive Neuroscience, Inc., Miramar, Florida, United States|Fideltiy Clinical Research, Inc., North Miami, Florida, United States|Ali A. Kashfi, MD, PA, Orlando, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Kolin Research Group, Winter Park, Florida, United States|Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States|Treatment Research Center, Rush University Medical Center, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Psychiatric Medicine Associates, LLC, Skokie, Illinois, United States|Sleep and Behavior Medicine Institute, Vernon Hills, Illinois, United States|Clinical Trials Technology, Inc., Prairie Village, Kansas, United States|Pedia Research, LLC, Owensboro, Kentucky, United States|Psyichatric Care and Research Center, O'Fallon, Missouri, United States|Mid-America Clinical Research, LLC, Saint Louis, Missouri, United States|Premier Psychiatric Research Institute, LLC., Lincoln, Nebraska, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|CRI Worldwide LLC, Willingboro, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Clinlabs, Inc., New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Private Practice - Daniel I. Rifkin MD PC, West Seneca, New York, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|North Coast Clinical Trials, Inc., Beachwood, Ohio, United States|Ohio State University, Dept. of Psychiatry, Columbus, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University Services, West Chester, Pennsylvania, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Bay Area Clinical Services, Friendswood, Texas, United States|Houston Clinical Trials, LLC, Houston, Texas, United States|Wharton Research Center, Inc., Wharton, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Alliance Research Group, Richmond, Virginia, United States|Dean Foundation for Health, Research and Education, Inc., Middleton, Wisconsin, United States|Independent Psychiatric Consultants, SC, dba, IPC Research, Waukesha, Wisconsin, United States|Instituto Nacional de Psicopatologia, Buenos Aires, Argentina|Cervino, Buenos Aires, Argentina|Centro Medico de Medicina Familiar Mind Out Research, Caba, Argentina|BA Psychiatric Research Center, Caba, Argentina|Instituto Medico SAMIC, Cordoba, Argentina|Peninsula Health Mental Health Services, Frankston, Victoria, Australia|Neurotherapy Victoria, Malvern, Victoria, Australia|The Alfred, Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia|The Melbourne Clinic, Richmond, Victoria, Australia|Lyell McEwin Hospital, Mental Health Clinical Trials Unit, Elizabeth Vale, Australia|Psocomed Estudios Medicos, Antofagasta, Il Region, Chile|Especialidades Medicas L y S, Las Condes, Santiago, Chile|Centro de Estudios y Tratemiento de Enfermedades Psiquiatricas, Las Condes, Santiago, Chile|Biomedica Research Group, Providencia, Santiago, Chile|Centro de Estudios Clinicos, Providencia, Santiago, Chile|Unidad de Salud Mental y Psiquietriea Hospital y CRS El Pino, San Bernardo, Santiago, Chile|Hospital Barros Luco Trudsau, San Miguel, Santiago, Chile|Hollins Park Hospital, Winwick, Warrington Cheshire, United Kingdom|Radbourne Unit, Derby, United Kingdom|ADHD Mental Health Research Unit, Horsham, United Kingdom|Newcastle University, Wolfson Research Centre, Newcastle upon Tyne, United Kingdom|Rushcliffe Mental Health Team, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01435759"
286,"NCT01312922","Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Drug: PNB01 fixed dose combination of pipamperone and citalopram|Drug: Citalopram|Drug: Pipamperone","Early and Sustained (antidepressant) Response (ESR) rate|Change from baseline in total MADRS score at Week 6|Change from baseline in total SDS score at Week 6","PharmaNeuroBoost N.V.","All","18 Years and older   (Adult, Older Adult)","Phase 3","555","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PNB01-C301|2011-001190-11","September 2011","November 2012","December 2012","March 11, 2011",,"November 19, 2014","Site 103, Glendale, California, United States|Site 101, National City, California, United States|Site 113, Riverside, California, United States|Site 106, San Diego, California, United States|Site 116, San Diego, California, United States|Site 112, Fort Meyers, Florida, United States|Site 135, Miami, Florida, United States|Site 108, Winter Park, Florida, United States|Site 133, Atlanta, Georgia, United States|Site 128, Smyrna, Georgia, United States|Site 132, Libertyville, Illinois, United States|Site 117, Schaumburg, Illinois, United States|Site 110, Baltimore, Maryland, United States|Site 109, Flowood, Mississippi, United States|Site 115, New York, New York, United States|Site 126, Beachwood, Ohio, United States|Site 127, Cincinnati, Ohio, United States|Site 124, Middleburg Heights, Ohio, United States|Site 105, Allentown, Pennsylvania, United States|Site 123, Media, Pennsylvania, United States|Site 122, Philadelphia, Pennsylvania, United States|Site 119, Austin, Texas, United States|Site 104, Dallas, Texas, United States|Site 102, Wichita Falls, Texas, United States|Site 107, Kirkland, Washington, United States|Site 134, Seattle, Washington, United States|Site 201, Kelowna, British Columbia, Canada|Site 202, Penticton, British Columbia, Canada|Site 205, Chatham, Ontario, Canada|Site 203, Mississauga, Ontario, Canada|Site 204, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01312922"
287,"NCT01903200","Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder Patients","Drug: FK949E","Maximum plasma concentration (Cmax) of unchanged quetiapine|AUC (area under the curve) of unchanged quetiapine|tmax of plasma concentration of unchanged quetiapine|t1/2 of plasma concentration of unchanged quetiapine|Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam","Astellas Pharma Inc","All","65 Years to 80 Years   (Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","6949-CL-0002","February 2010","September 2011","September 2011","July 19, 2013",,"February 16, 2017","Kansai, Japan|Kantou, Japan",,"https://ClinicalTrials.gov/show/NCT01903200"
288,"NCT01323478","Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine (Lu AA21004)","Number of Patients With Adverse Events (AEs)|Percentage of Patients Who Withdrew Due to Intolerance to Treatment|Change From Baseline in MADRS Total Score After 52 Weeks of Treatment|Change From Baseline in CGI-S Score After 52 Weeks of Treatment|Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment|Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)|Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)|SDS Total Score After 52 Weeks of Treatment|ASEX Total Score After 52 Weeks of Treatment|Risk of Suicidality Using C-SSRS Scores","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","71","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13267B|2010-024198-38","April 2011","September 2012","October 2012","March 25, 2011","February 11, 2014","February 11, 2014",,,"https://ClinicalTrials.gov/show/NCT01323478"
289,"NCT00926835","Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients",,"Terminated","No Results Available","Major Depressive Disorder","Drug: paroxetine|Drug: Escitalopram|Drug: Venlafaxine XR|Drug: Paroxetine+Bupropion|Drug: Paroxetine+Lamotrigine|Drug: Paroxetine+Lithium|Drug: Escitalopram+Mirtazapine|Drug: Escitalopram+Aripiprazole|Drug: Paroxetine + Venlafaxine XR","Hamilton Depression Rating Scale","Ministry of Health & Welfare, Korea","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","692","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MIHWAF-CRCD-K-01","May 2009","May 2015","July 2015","June 24, 2009",,"September 2, 2015","Clinical research center for depression, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00926835"
290,"NCT04103892","CLE-100 as an Oral Therapy in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study",,"Recruiting","No Results Available","Adjunctive Treatment of Major Depressive Disorder","Drug: CLE-100|Drug: placebo","Part A - Frequency of adverse events|Part A - Self-Administered Karolinska Sleepiness Scale|Part A - Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S)|Part A - Clinician-Administered Dissociative Symptoms Scale (CADSS)|Part A - Columbia Suicide Severity Rating Scale (C-SSRS)|Part A - Four-items positive subscale from the Brief Psychiatric Rating Scale (BPRS)|Part A - 20-item Physician Withdrawal Checklist (PWC-20)|Part A - Cognitive function evaluated by Cogstate battery|Part A - Digit Symbol Substitution Test (DSST)|Part A - Pharmacokinetics of CLE-100 (Cmax)|Part A - Pharmacokinetics of CLE-100 (Tmax)|Part A - Pharmacokinetics of CLE-100 (AUC)|Part B - Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score|Part B - Change from baseline in Symptoms of Depression Questionnaire (SDQ) score|Part B - Change from baseline in Sheehan Disability Scale (SDS)|Part B - Change from baseline in Clinical Global Impression - Severity (CGI-S) score","Clexio Biosciences Ltd.","All","18 Years to 60 Years   (Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLE100-MDD-201","September 5, 2019","June 30, 2022","July 31, 2022","September 26, 2019",,"July 23, 2021","Clinical Site 126, Bentonville, Arkansas, United States|Clinical Site 120, Little Rock, Arkansas, United States|Clinical Site 129, Little Rock, Arkansas, United States|Clinical Site 115, Bellflower, California, United States|Clinical Site 117, Oakland, California, United States|Clinical Site 113, Oceanside, California, United States|Clinical Site 123, Riverside, California, United States|Clinical Site 124, Santa Ana, California, United States|Clinical Site 112, Torrance, California, United States|Clinical Site 107, Hialeah, Florida, United States|Clinical Site 108, Miami Gardens, Florida, United States|Clinical Site 116, Miami, Florida, United States|Clinical Site 105, Orlando, Florida, United States|Clinical Site 104, Decatur, Georgia, United States|Clinical Site 122, Marietta, Georgia, United States|Clinical Site 103, Boston, Massachusetts, United States|Clinical Site 121, Boston, Massachusetts, United States|Clinical Site 125, Lincoln, Nebraska, United States|Clinical Site 110, Las Vegas, Nevada, United States|Clinical Site 101, Marlton, New Jersey, United States|Clinical Site 128, New York, New York, United States|Clinical Site 102, Staten Island, New York, United States|Clinical Site 111, Hickory, North Carolina, United States|Clinical Site 106, Media, Pennsylvania, United States|Clinical Site 118, Philadelphia, Pennsylvania, United States|Clinical Site 114, Fort Worth, Texas, United States|Clinical Site 109, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04103892"
291,"NCT01432457","Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: desvenlafaxine succinate sustained-release 50 mg/day|Drug: desvenlafaxine succinate sustained-release 100 mg/day|Drug: placebo","Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8|Change From Baseline on the Clinical Global Impression Scale-Improvement (CGI-I)|Change From Baseline on the Clinical Global Impression-Severity Score (CGI-S)|Change From Baseline on the Clinical Global Impression-Severity (CGI-S) Score|Hamilton Rating Scale for Depression, 17-item (HAM-D17) Response Rate|Hamilton Rating Scale for Depression, 17-item (HAM-D17) Remission Rate|Change From Baseline on the Arizona Sexual Experiences (ASEX) Scale Total Score","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","924","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2061028|3151A1-4420","October 2011","July 2012","August 2012","September 13, 2011","January 20, 2014","January 20, 2014","Dedicated Clinical Research, Phoenix, Arizona, United States|Deidcated Clinical Research, Phoenix, Arizona, United States|Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|Pacific Clinical Research Medical Group, Arcadia, California, United States|Southwestern Research, Incorporated, Beverly Hills, California, United States|Clinical Innovations, Inc., Costa Mesa, California, United States|Synergy Clinical Research of Escondido, Escondido, California, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Research Partners, Oakland, California, United States|Pasadena Research Institute, LLC, Pasadena, California, United States|Clinical Innovations, Inc., Riverside, California, United States|Affiliated Research Institute, San Diego, California, United States|Clinical Innovations, Inc., San Diego, California, United States|California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States|Viking Clinical Research Center, Temecula, California, United States|Collaborative Neuroscience Network, Inc. South Bay, Torrance, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Clinical Neuroscience Solutions Incorporated, Jacksonville, Florida, United States|Accurate Clinical Trials, Inc., Kissimmee, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Comprehensive NeuroScience, Incorporated, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Joliet Center for Clinical Research, Joliet, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|American Medical Research, Inc., Oak Brook, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Via Christi Research, Wichita, Kansas, United States|Pharmasite Research Inc, Baltimore, Maryland, United States|Midwest Research Group, St. Charles, Missouri, United States|Heartland Pharma Development, North Platte, Nebraska, United States|CRI Worldwide, LLC, Marlton, New Jersey, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Neurobehavioral Research, Inc, Cedarhurst, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Medical and Behavioral Health Research Pc, New York, New York, United States|Prairie St. Johns Clinic - Fargo, Fargo, North Dakota, United States|Odyssey Research, Fargo, North Dakota, United States|Plains Medical Clinic, Fargo, North Dakota, United States|NorthCoast Clinical Trials Inc., Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|FutureSearch Trials, Austin, Texas, United States|KRK Medical Research, Dallas, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Radiant Research, Inc., Murray, Utah, United States|Eastside Therapeutic Resource, Kirkland, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01432457"
292,"NCT01871974","Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder Patients","Drug: FK949E","Maximum plasma concentration (Cmax) of unchanged quetiapine|AUC (area under the curve) of unchanged quetiapine|tmax of plasma concentration of unchanged quetiapine|t1/2 of plasma concentration of unchanged quetiapine|Safety assessed by the incidence of adverse events, clinical lab tests, vital signs, 12-lead ECGs and physical exam","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","6949-CL-0001","May 2009","March 2010","March 2010","June 7, 2013",,"February 16, 2017","Kansai, Japan|Kantou, Japan",,"https://ClinicalTrials.gov/show/NCT01871974"
293,"NCT00464711","Brain GABA Levels and Treatment Response in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram","Response and Remitter Status at Endpoint, Based on Change in Depression Severity Rating Scores","Massachusetts General Hospital|Mclean Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-P-001295","September 2006","September 2009","September 2009","April 24, 2007","January 4, 2017","January 4, 2017","Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00464711"
294,"NCT01422213","Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder","FOCUS","Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine (Lu AA21004)","Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores|Change From Baseline to Week 8 in DSST (Number of Correct Symbols)|Change From Baseline to Week 8 in RAVLT (Acquisition)|Change From Baseline to Week 8 in RAVLT (Delayed Recall)|Change From Baseline to Week 8 in the TMT A (Speed of Processing)|Change From Baseline to Week 8 in the TMT B (Executive Function)|Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)|Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)|Change From Baseline to Week 8 in the SRT (Speed of Processing)|Change From Baseline to Week 8 in the CRT (Attention)|Change From Baseline to Week 8 in MADRS Total Score|Change From Baseline to Week 8 in CGI-S Score|Clinical Status Using CGI-I Score at Week 8|Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline|Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)|Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score|Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score|Risk of Suicidality Using C-SSRS Scores","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","598","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14122A|2011-001572-19","December 2011","May 2013",,"August 23, 2011","August 5, 2014","August 5, 2014",,,"https://ClinicalTrials.gov/show/NCT01422213"
295,"NCT01457677","ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment",,"Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: RO4995819","Mean change in Montgomery Asberg Depression Rating Scale (MADRS) scores|Safety (incidence of a adverse events)|Proportion of patients exhibiting remission based on the Montgomery Asberg Depression Rating Scale (MADRS) (score of </=10)|Proportion of patients exhibiting response based on the Montgomery Asberg Depression Rating Scale (MADRS) (reduction in score of >/= 50% of the baseline score)","Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","357","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP25712","December 2011","June 2014","June 2014","October 24, 2011",,"November 2, 2016","Phoenix, Arizona, United States|Oakland, California, United States|Redlands, California, United States|San Diego, California, United States|Stanford, California, United States|Torrance, California, United States|Victorville, California, United States|Denver, Colorado, United States|Coral Springs, Florida, United States|Gainsville, Florida, United States|Jacksonville, Florida, United States|Lauderhill, Florida, United States|North Miami, Florida, United States|Ocala, Florida, United States|Atlanta, Georgia, United States|Roswell, Georgia, United States|Smyrna, Georgia, United States|Chicago, Illinois, United States|Prairie Village, Kansas, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Watertown, Massachusetts, United States|Flowood, Mississippi, United States|O'Fallon, Missouri, United States|Albuquerque, New Mexico, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Beachwood, Ohio, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Jenkintown, Pennsylvania, United States|Media, Pennsylvania, United States|Columbia, South Carolina, United States|Arlington, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Innsbruck, Austria|Wien, Vienna, Austria|Wien, Austria|Kentville,, Nova Scotia, Canada|Kingston, Ontario, Canada|Ottowa, Ontario, Canada|Gatineau, Quebec, Canada|Sherbrooke, Quebec, Canada|Verdun, Quebec, Canada|Ellwangen, Germany|Leipzig, Germany|Mannheim, Germany|Nürnberg, Germany|Oranienburg, Germany|Ostfildern, Germany|Schwerin, Mecklenburg-Vorpommern, Germany|Ekaterinburg, Russian Federation|Ekaterinburg, Russian Federation|Lipetsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Talagi, Russian Federation|Tomsk, Russian Federation|Yaroslavl, Russian Federation|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Rimavska Sobota, Slovakia|Trencin, Slovakia|Bellville, Cape Town, South Africa|Cape Town, Western Cape, South Africa|Cape Town, WESTERN CAPE, South Africa|Centurion, Pretoria, South Africa|Nieu Muckleneuk, Pretoria, South Africa|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kherson,Vil. Stepanivka, Ukraine|Kiev, Ukraine|Odessa, Ukraine|Simferopol, Crimea, Ukraine|Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01457677"
296,"NCT01185340","A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo|Drug: SSRI","Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score|Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score|Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8|Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement|Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score|Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8|Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score|Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items|Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)|Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score|Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items|Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)|Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)|Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale|Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|Change From Randomization to Week 8 in Blood Pressure|Change From Randomization to Week 8 in Pulse Rate","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1056","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12183|H9P-MC-LNBR","March 2011","April 2013","April 2013","August 19, 2010","April 27, 2018","April 27, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garden Grove, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakland, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Temecula, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Bay Village, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakland Park, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marlton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herndon, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Everton Park, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Hill, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malvern, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Diest, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mont-Godinne, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Saarow, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cham, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prien, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Schwerin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goteborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bexhill-On-Sea, East Sussex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01185340"
297,"NCT01145755","6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: AZD2066|Drug: Placebo|Drug: Duloxetine","MADRS Total Score Change From Baseline to Week 6|MADRS Response|MADRS Remission","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D0475C00020","May 2010","November 2010","November 2010","June 17, 2010","September 27, 2012","October 3, 2012","Research Site, Garden Grove, California, United States|Research Site, San Diego, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Rockville, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cedarhurst, New York, United States|Research Site, Rochester, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Memphis, Tennessee, United States|Research Site, Friendswood, Texas, United States|Research Site, Bellevue, Washington, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01145755"
298,"NCT00855530","Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorders","Drug: amibegron (SR58611A)","Clinical monitoring of adverse events (AEs), laboratory parameters, vital signs, physical examinations, and physician withdrawal checklists|17-item Hamilton Depression rating Scale, Clinical Global Impression, Sheehan Disability Scale, Qol Enjoyment and satisfaction Questionnaire - Short Form,Medical Outcomes Study Short Form, Endicott Work Productivity Scale.","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","527","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS4848","September 2005","July 2007","July 2007","March 4, 2009",,"March 25, 2009","Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Causeway Bay, Hong Kong|Sanofi-Aventis Administrative Office, Casablanca, Morocco|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Megrine, Tunisia",,"https://ClinicalTrials.gov/show/NCT00855530"
299,"NCT01437657","MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy",,"Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: RO4917523 0.5 mg|Drug: RO4917523 1.5 mg","Change in Montgomery Asberg Depression Rating Scale (MADRS)|Change in Clinical Global Impression Score - Severity (CGI-S)|Change in Clinical Global Impression Score - Improvement (CGI-I)|Safety: Incidence of adverse events|Proportion of patients exhibiting remission (MADRS </= 10) after 6 weeks of treatment|Proportion of patients exhibiting response (reduction in MADRS >/= 50% of baseline score) after 6 weeks of treatment","Hoffmann-La Roche","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","319","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NP25620|2011-001436-33","October 2011","September 2013","September 2013","September 21, 2011",,"November 2, 2016","Little Rock, Arkansas, United States|Costa Mesa, California, United States|Garden Grove, California, United States|Oceanside, California, United States|Orange, California, United States|Riverside, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Wildomar, California, United States|Atlanta, Georgia, United States|Libertyville, Illinois, United States|Naperville, Illinois, United States|Oak Brook, Illinois, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|Oklahoma City, Oklahoma, United States|Norristown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Memphis, Tennessee, United States|Kirkland, Washington, United States|Santiago, Chile|Santiago, Chile|Temuco, Chile|Berlin, Germany|Berlin, Germany|Freiburg, Germany|Hannover, Germany|Mainz, Germany|Wiesbaden, Germany|Chuo-ku, Japan|Hokkaido, Japan|Hyogo, Japan|Kanagawa, Japan|Kanagawa, Japan|Kita-Ku, Japan|Kurayoshi-shi, Japan|Kyoto, Japan|Osaka, Japan|Shinjuku-ku, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Aguascalientes, Mexico|Leon, Mexico|Monterrey, Mexico|Belchatow, Poland|Bialystok, Poland|Bialystok, Poland|Choroszcz, Poland|Kielce, Poland|Lodz, Poland|Tuszyn, Poland|Bucuresti, Romania|Bucuresti, Romania|Constanta, Romania|Craiova, Romania|Targouiste, Romania|Targu Mures, Romania|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Keelung, Taiwan|Taichung, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01437657"
300,"NCT01436162","Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Drug: Antidepressant + Placebo","Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks|Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks|Percentage of Participants Achieving a 25% Response on the MADRS|Percentage of Participants Achieving a 50% Response on the MADRS|Percent of Participants Achieving Remission on the MADRS|Mean Change From Baseline Over Time in MADRS Total Score|Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores|Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)|Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male|Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female|Clinical Global Impressions - Global Improvement (CGI-I)|Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)|Columbia Suicide Severity Rating Scale (C-SSRS)|Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score","Shire|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD489-323|2011-003006-25","October 19, 2011","December 10, 2013","December 10, 2013","September 19, 2011","November 7, 2014","June 9, 2021","ResearchOne, Inc., Scottsdale, Arizona, United States|K&S Professional Research Services, LLC, Little Rock, Arkansas, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Diligent Clinical Trials, Downey, California, United States|Synergy Clinical Reserach Center of Escondido, Escondido, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|Anderson Clinical Research, Redlands, California, United States|BreakThrough Clinical Trials, LLC, San Bernardino, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Comprehensive NeuroScience, Inc., Saint Petersburg, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine & Research, Atlanta, Georgia, United States|Pedia Research, Newburgh, Indiana, United States|Heartland Research Associates, Wichita, Kansas, United States|Louisiana Clinical Research, LLC, Shreveport, Louisiana, United States|Comprehensive Psychiatric Associates, Gladstone, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Mercy Health Research, Saint Louis, Missouri, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Medical & Behavioral Health Research, PC, New York, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|Medical University South Carolina Anxiety Disorder Program, North Charleston, South Carolina, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|KRK Medical Research, Dallas, Texas, United States|Future Search Trials of Dallas, LP, Dallas, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Dr Lieven De Weirdt, Sint Niklaas, Belgium|Saint Anne s.r.o., Brno, Czechia|Psychiatricka ambulance, Brno, Czechia|Medicana s.r.o., Horovice, Czechia|Psychiatrie s.r.o., Kutna Hora, Czechia|Bialbi s.r.o., Litomerice, Czechia|Clintrial s.r.o., Prague 10, Czechia|Psychiatry Trial s.r.o., Prague 5, Czechia|Prague Medical Services s.r.o., Prague 6, Czechia|Ricany s.r.o., Ricany, Czechia|Parnu Hospital, Psychiatric Clinic, Parnu, Estonia|North Estonia Medical Centre Foundation Psychiatry Clinic, Tallinn, Estonia|Marienthal Psychiatry and Psychology Center, Tallinn, Estonia|Jaanson & Laane OU, Tartu, Estonia|Tartu University Hospital Psychiatric Clinic, Tartu, Estonia|ARTES Psykiatrinen Palvelukeskus Oy, Helsinki, Finland|Satucon Oy, Kuopio, Finland|Satakunnan Psykiatripalveiu Oy at Mentoria Oy, Tampere, Finland|Puutorin Psykiatripalvelu, Turku, Finland|Gemeinschafstpraxis für Neurologie und Psychiatrie, Psychotherapie, Achim, Germany|Private Praxis Dr. Jana Thomsen, Berlin, Germany|emovis GmbH, Berlin, Germany|Alexander Schulze, MD, Berlin, Germany|Private Practice Drs. Bitter/Schumann, Bochum, Germany|University Hospital Carl Gustav Carus, Dresden, Germany|ZSL Zentrum fuer medizinische Studien in Leipzig, Leipzig, Germany|Studienzentrum Muenchen, Muenchen, Germany|Universitaetsklinikum Munster, Muenster, Germany|Studienzentrum Klinikum Nuernberg, Nuernberg, Germany|Somni bene GmbH, Schwerin, Germany|Private Practice: Eugen Schlegel, Siegen, Germany|Studiezentrum Nord-West, Westerstede, Germany|Medizinisches Studienzentrum Wuerzburg, Wuerzburg, Germany|Semmelweis Univ. Dept.of Psychiatry, Budapest, Hungary|Debrecent Egyetem Orvos es Egeszsegtudomanyl Centrum Pszichiatrai, Debrecen, Hungary|Santha Kalman Mentalis Egeszsegkozpont es Szakkorhaz, Nagykallo, Hungary|Josa Andras Teaching Hospital, Nyiregyhaza, Hungary|Pecsi Tudomanyegyeiem Pszichiatriai es Pszichoterapias Klinika, Sziget, Hungary|Prywatne Gabinety Lekarskie ""Promedicus"", Bialystok, Poland|NZOZ Centrum Kultury, Higieny i Zdrowia Psychicznego, Bydgoszcz, Poland|Zespol Opieki Zdrowotnej w Chelmnie, Chelmno, Poland|Centrum Badan Klinicznuch Pl-House sp. z.o.o., Gdansk, Poland|Klinika Chorob Psychicznych i Zaburzen Nerwicowych, Gdansk, Poland|Centrum Psychiatrii i Psychoterapli, Gorlice, Poland|NZOZ Syntonia, Poradnia Zdrowia Psychicznego, Kielce, Poland|Osrodek Badafi Klinicznych Prof dr hab n med Meszek Szczepanski Prywatna Praktyka Lekarska, Lublin, Poland|Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej w Zurominie, Zuromin, Poland|Spitatul Clinic Judetean de Urgenta Arad, Clinica de Psihiatrie, Arad, Romania|Stefi-Dent SRL, Botosani, Romania|Spitalui Clinic de Psihiatrie ""Prof. Dr. Alexandru Obregia"" Sectia Clinica Psihiatrie I, Bucharest, Romania|Crucea Alba, Oradea, Romania|Lorentina 2201 SRL, Targoviste, Romania|Spitalul Clinic Judetean Mures, Targu Mures, Romania|Cape Trial Centre, Bellville, Cape Town, South Africa|Flexivest Fourteen Research Centre, Bellville, Cape Town, South Africa|Private Practice - Gerta Brink, Johannesburg, Gauten, South Africa|Somerset West Clinical Research, Somerset West, Western Cape, South Africa|Vista Clinic, Centurion, South Africa|George Medi Clinic Extension, George, South Africa|SU/ Affektiva 1, Göteborg, Sweden|ProbarE i Lund AB, Lund, Sweden|Ekdahl Medical AB, Malmo, Sweden|INM Psykiatrisk Mottagning, Malmo, Sweden|Medinstructor Lippitz AB, Stockholm, Sweden|Dr. Wahlstedts mottagning, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01436162"
301,"NCT01436149","Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: SPD489 (Lisdexamfetamine dimesylate )|Drug: Placebo","Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks|Percentage of Participants Achieving a 25% Response on the MADRS|Percentage of Participants Achieving a 50% Response on the MADRS|Percentage of Participants Achieving Remission on the MADRS|Mean Change From Baseline Over Time in MADRS Total Score|Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)|Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)|Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)|Clinical Global Impressions - Global Improvement (CGI-I)|Columbia Suicide Severity Rating Scale (C-SSRS)|Amphetamine Cessation Symptom Assessment (ACSA)","Shire|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD489-322|2011-003018-17","October 27, 2011","December 23, 2013","December 23, 2013","September 19, 2011","November 19, 2014","June 9, 2021","Birmingham Research Group, Birmingham, Alabama, United States|AV Institue, Inc., Carson, California, United States|University of California, Irvine Child Development Center, Irvine, California, United States|South Coast Clinicals, Norwalk, California, United States|North County Clinical Research, Oceanside, California, United States|Pasadena Research Institute, LLC, Pasadena, California, United States|Affiliated Research Institute, San Diego, California, United States|Clinical Innovations, Inc., San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Geriatric and Adult Psychiatry, LLC, Hamden, Connecticut, United States|Middlexex Hospital Center for Behavioral Health, Middletown, Connecticut, United States|CNS Clinical Research Group, Coral Springs, Florida, United States|Emerald Coast Mood & Memory, PA, Fort Walton Beach, Florida, United States|Florida Clinical Research Center, LLC., Maitland, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Carman Research, Smyrna, Georgia, United States|American Medical Research, Inc., Oak Brook, Illinois, United States|The Davis Clinic, Indianapolis, Indiana, United States|Northwest Indiana Center for Clinical Research, Valparaiso, Indiana, United States|MCM Clinical Research LLC, Florence, Kentucky, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Potomac Grove Clinical Research Center, Gaithersburg, Maryland, United States|Office of Marc Hertzman, MD, Rockville, Maryland, United States|Adams Clinical Trials, LLC, Watertown, Massachusetts, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Bioscience Research, LLC, Mount Kisco, New York, United States|Fieve Clinical Research, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Triangle Neuropsychiatry, Durham, North Carolina, United States|Rcihard H. Weisler, MD, PA & Associates, Raleigh, North Carolina, United States|Community Research, Cincinnati, Ohio, United States|Lindner Center of HOPE, Mason, Ohio, United States|SP Research, PLLC, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|CRI Worldwide LLC, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Clinical Research Associates, Nashville, Tennessee, United States|FutureSearch Clinical Trials, LP, Austin, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Dr. Alexander McIntyre Inc, Penticton, British Columbia, Canada|Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc., Vancouver, British Columbia, Canada|Aggarwal & Associates Ltd., Brampton, Ontario, Canada|Depression, Mood Disorders and Schizophrenia Treatment Centre, Burlington, Ontario, Canada|Chatham-Kent Clinical Trials Research Center, Chatham, Ontario, Canada|Regional Mental Health Care, London, Ontario, Canada|Anxiety and Mood Disorder Center, Mississauga, Ontario, Canada|Medical Research Associates, Mississauga, Ontario, Canada|A.K. Karan Holdings, Oakville, Ontario, Canada|International Sleep Clinic, West Parry Sound Health Centre, Parry Sound, Ontario, Canada|START Clinic for Mood and Anxiety Disorders, Toronto, Ontario, Canada|Univ Health Network, Toronto Western Hospital, Toronto, Ontario, Canada|Sleep & Alertness Clinic (Sleep & Alertness Research, Inc.), Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Windsor Regional Hospital-Tayfour Campus, Windsor, Ontario, Canada|Pierre-Janet Hospital, Gatineau, Quebec, Canada|l'Hopital Louis H. Lafontaine, Montreal, Quebec, Canada|Kells Medical Research Group Inc., Pointe-Claire, Quebec, Canada|Q&T Research Sherbrooke, Sherbrooke, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Poliklinika Neuron, Zagreb, Croatia|Psychiatric Clinic Vrapoe, Zagreb, Croatia|Centro Regiomontano de Investigacion S.C. (CRI), Monterrey, Nuevo Leon, Mexico|Hospital Aranda de la Parra, Leon Guanajuato, Mexico|Instituto de Infromacion e Investigación en Salud Mental (INFOSAME), Nuevo Leon, Mexico|Consultorio Especializado en Psiquiatria Infantil y Adolescentes, San Luis Potosi, Mexico|B & B Investigaciones Medicas S.C., Sinaloa, Mexico|Dharma Institute & Research Center, San Juan, Puerto Rico|INSPIRA Clinical Research, San Juan, Puerto Rico|Hospital de la Santa Creo l Sant Pau, Barcelona, Spain|Hospital Universitari de Bellvitge, Servicio de Psiquiatria, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Fundacion de Alcorcon, Madrid, Spain|Hospital Universitario de Henares, Madrid, Spain|Centro de Salud Mental Il la Corredoria, Oviedo, Spain|Centro Salud Alamedilla Unidad de Salud Mental, Salamanca, Spain|Complejo hospitalario de Zamora, Zamora, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01436149"
302,"NCT00849901","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: duloxetine|Drug: Placebo|Drug: fluoxetine","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint|Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint|Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint|Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint|Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint|Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint|Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10|Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36|Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10|Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36|Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10|Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36","Eli Lilly and Company","All","7 Years to 17 Years   (Child)","Phase 3","337","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6223|F1J-MC-HMCK","March 2009","March 2011","October 2011","February 24, 2009","March 6, 2012","September 11, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palo Alto, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Altamonte Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smyrna, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coeur d'Alene, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester Hills, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Charles, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willingboro, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilmington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleburg Heights, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bartlett, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clinton, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orem, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elancourt, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouffach, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koeln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tubingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nizhniy Novgorod, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Novosibirsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smolensk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tomsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kosice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Martin, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloemfontein, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Centurion, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Johannesburg, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vereeniging, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Cape, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Donetsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kharkiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lugansk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odesa, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poltava, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ternopil, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uzhorod, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00849901"
303,"NCT00849693","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: fluoxetine|Drug: duloxetine","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint|Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint|Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint|Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint|Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint|Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint|Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10|Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36|Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10|Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36|Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10|Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36","Eli Lilly and Company","All","7 Years to 17 Years   (Child)","Phase 3","463","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7109|F1J-MC-HMCL","March 2009","February 2011","September 2011","February 24, 2009","April 19, 2012","April 19, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dothan, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Imperial, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riverside, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middletown, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hialeah, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winter Park, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oak Brook, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terre Haute, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Charles, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Burnie, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clinton Twp, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salem, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dalllas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wharton, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Allis, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parry Sound, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalnepantla, Mexico",,"https://ClinicalTrials.gov/show/NCT00849693"
304,"NCT01000805","A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine|Drug: Placebo","Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-week Treatment Period|Change From Baseline in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 8|Change From Baseline in the Sheehan Disability Scale (SDS) Total and Item Scores at Week 8|Change From Baseline in the Percentage of Participants Achieving Remission up to Week 8|Percentage of Participants Achieving Remission up to Week 8|Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 4|Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Week 2|Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 8|Patient's Global Impressions of Improvement Scale (PGI-I) at Week 8|Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Double-blind Treatment Phase|Change From Baseline in Pulse Rate up to Week 8|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Up to Week 8|Change From Baseline in Weight up to Week 8","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","528","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13399|F1J-US-HMGR","November 2009","October 2010","October 2010","October 23, 2009","January 13, 2012","January 13, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cedarhurst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcachon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elancourt, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alzenau, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ellwangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Craiova, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Targoviste, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lulea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01000805"
305,"NCT00882362","Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: OPC-14597 (Aripiprazole)","Montgomery-Asberg Depression Rating Scale (MADRS)","Otsuka Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Older Adult)","Phase 3","155","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","031-08-002|JapinCTI-090725","March 2009","July 2012","July 2012","April 16, 2009","February 10, 2014","February 10, 2014","Chubu Region, Japan|Chugoku Region, Japan|Hokkaido Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan|Shikoku Region, Japan|Tohoku Region, Japan",,"https://ClinicalTrials.gov/show/NCT00882362"
306,"NCT00876343","Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Aripiprazole (Fixed dose)|Drug: Aripiprazole (Titrated dose)|Drug: Placebo","Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|MADRS Response Rate|Mean Change in Sheehan Disability Scale (SDISS)","Otsuka Pharmaceutical Co., Ltd.","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 3","586","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","031-08-001|JapicCTI-090724","March 2009","July 2012","July 2012","April 6, 2009","February 10, 2014","February 10, 2014","Chubu Region, Japan|Chugoku Region, Japan|Hokkaido Region, Japan|Kanto region, Japan|Kinki Region, Japan|Kyushu Region, Japan|Shikoku Region, Japan|Tohoku Region, Japan",,"https://ClinicalTrials.gov/show/NCT00876343"
307,"NCT01173601","A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo|Drug: SSRI","Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Scale|Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score|Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal 10 up to Week 8|Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement|Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score|Percentage of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization up to Week 8|Change From Randomization to Week 8 in Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score|Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items|Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)|Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score|Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items|Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)|Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)|Percentage of Treatment Emergent (TE) Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale|Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|The Percentage of Participants Experiencing Treatment-Emergent Adverse Events as a Function of CYP2D6 Phenotype|Change From Randomization to Week 8 in Blood Pressure (BP)|Change From Randomization to Week 8 in Pulse Rate|Pharmacokinetics: Plasma Concentrations of LY2216684","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1416","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11316|H9P-MC-LNBM","November 2010","October 2013","October 2013","August 2, 2010","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Habra, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redlands, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jamaica, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleburg Heights, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allentown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murray, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagano, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saga, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daugavpils, Latvia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jelgava, Latvia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liepaja, Latvia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sigulda, Latvia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strenci, Latvia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., ?Uromin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelmno, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gorlice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leszno, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuszyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellville, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Centurion, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., George, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Cape, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chernihiv District, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Donetsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kherson, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lugansk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odesa, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poltava, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Simferopol, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uzhorod, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01173601"
308,"NCT00822744","An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients","FIDELIO","Completed","No Results Available","Major Depressive Disorder","Drug: SSR411298|Drug: Escitalopram|Drug: Placebo (for SSR411298)","17-item Hamilton Depression Rating Scale (HAM-D) total score|Montgomery-Asberg Depression Rating Scale (MADRS) total score|Clinical Global Impression (CGI) scores|HAM-D depressed mood item score, factor scores and core item score|Geriatric Depression Scale (GDS) total score|Sheehan Disability Scale (SDS) total score|Hamilton Anxiety Rating scale (HAM-A) total score|Overview of Adverse Events (AE)|SSR411298 plasma concentration","Sanofi","All","60 Years and older   (Adult, Older Adult)","Phase 2","527","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DFI10560|2008-001718-26","December 2008","February 2010","February 2010","January 14, 2009",,"March 15, 2013","Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Brastislava, Slovakia|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT00822744"
309,"NCT00659347","Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Drug: DOV 21, 947|Drug: Placebo","The primary outcome measure will be the change in tot al score of MADRS scale.","DOV Pharmaceutical, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DOV 947-010","March 2008","December 2008","December 2008","April 16, 2008",,"December 5, 2008","Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Future Care Studies, Springfield, Massachusetts, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|CRI Worldwide, LLC, Clementon, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|Richmond Behavorial Associates, Staten Island, New York, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Scranton Medical Institutes, Scranton, Pennsylvania, United States|Spitalul Judetean Arges, Pitesti, Arges, Romania|Spitalul Clinic de Neurologie si Psihiatrie Oradea, Oradea, Bihor, Romania|Cabinetul Medical Lorentina 2102 S.R.L., Targoviste, Dambovita, Romania|SC Corpores Sana Medical SRL, Bucharest, Romania|Spitalul Clinic ""Colentina"", Ambulator Specialitate, Sectia Psihiatrie, Bucharest, Romania|Spitalul Clinic de Psihiatrie ""Prof. Dr. Alexandru Obregia"", pavilion III, Bucharest, Romania|Spitalul Clinic de Psihiatrie ""Prof. Dr. Alexandru Obregia"", Pavilion IV, Bucharest, Romania|Spitalul Clinic de Psihiatrie ""Prof. Dr. Alexandru Obregia"", Pavilion X, Bucharest, Romania|Spitalul Clinic de Psihiatrie ""Socola"", Lasi, Romania|Spitalul Universitar de Psihiatrie ""Socola"", Lasi, Romania|Spitalul Judetean de Urgenta Piatra Neamt, Piatra Neamt, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania|Institut za mentalno zdravlje Palmoticeva 37, Belgrade, Serbia|Institut za psihijatriju KCS, Belgrade, Serbia|Klinika za neurologiju i psihijatriju, Kragujevac, Serbia|Klinika za psihijatriju Vojnomedicinske Akademije, Velgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT00659347"
310,"NCT00442481","Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Procedure: A baseline overnight polysomnography (oPSG)","Change in latency of the first REM episode of the night.|Density of rapid eye movements|Changes of total percentage of REM sleep|Changes in deep slow wave sleep (SWS)|Number of night awakenings","Sheba Medical Center|Lundbeck Israel","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-06-4205-JL-CTIL","February 2007",,,"March 2, 2007",,"March 2, 2007","Sheba Medical Center, Department of psychiatry, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT00442481"
311,"NCT00599911","Dose-finding Study With Lu AA24530 in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Lu AA24530|Drug: Duloxetine|Drug: Placebo","The difference in change from baseline to end of treatment on the Montgomery-Åsberg Depression Rating Scale total score|Response rate, remission rate, and safety","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","652","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11918A|2007-001071-11","October 2007","March 2009","April 2009","January 24, 2008",,"November 8, 2016","AU002, Brisbane, Australia|AU001, Brisbane, Australia|AU003, Dandenc, Australia|AU004, Epping, Australia|AU006, Malvern, Australia|AT001, Vienna, Austria|AT002, Vienna, Austria|AT003, Vienna, Austria|BE003, Diest, Belgium|BE002, Sint-Niklaas, Belgium|CA006, Mississauga, Canada|CA004, Oakville, Canada|CA003, Penticton, Canada|CA005, Toronto, Canada|CA001, Vancouver, Canada|CZ002, Brno, Czech Republic|CZ005, Praha 2, Czech Republic|CZ001, Praha 5, Czech Republic|CZ004, Praha 5, Czech Republic|CZ003, Praha 6, Czech Republic|CZ006, Sternberk, Czech Republic|FI001, Helsinki, Finland|FI003, Helsinki, Finland|FI006, Järvenpää, Finland|FI004, Seinäjoki, Finland|FI005, Tampere, Finland|FI002, Turku, Finland|FR007, Angouleme, France|FR002, Dole, France|FR003, Montpellier, France|FR001, Orvault, France|FR008, Rouen, France|FR004, Savigny sur Orge, France|FR005, Wattigny, France|IN001, Ahmedabab, India|IN009, Ahmedabad, India|IN007, Chennai, India|IN006, Hyderabaad, India|IN003, Mangalore, India|IN002, Pune, India|KR003, Gwangju, Korea, Republic of|KR002, Seoul, Korea, Republic of|KR001, Seoul, Korea, Republic of|LT002, Kaunas, Lithuania|LT003, Klaipeda, Lithuania|LT001, Vilnius, Lithuania|MY002, Kuala Lumpur, Malaysia|MY003, Kuala Lumpur, Malaysia|NO004, Fredrikstad, Norway|NO001, Hamar, Norway|NO003, Skien, Norway|PH002, Las Pinas, Philippines|PH003, Mandaluyong City, Philippines|PH001, Mandaue City, Philippines|RU005, Arkhangelsk, Russian Federation|RU002, Nikolskoe, Russian Federation|RU004, Saratov, Russian Federation|RU003, St-Petersburg, Russian Federation|RU001, Tomsk, Russian Federation|RS004, Belgrade, Serbia|RS002, Kragujevac, Serbia|SE006, Halmstad, Sweden|SE001, Linköping, Sweden|SE002, Lund, Sweden|SE003, Malmö, Sweden|SE005, Stockholm, Sweden|SE004, Uppsala, Sweden|UA003, Dnepropetrovsk, Ukraine|UA005, Kharkov, Ukraine|UA002, Kyiv, Ukraine|UA004, Lviv, Ukraine|UA001, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00599911"
312,"NCT00731653","Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: Combination Product: BCI-024 + BCI-049","The Primary Safety and Tolerability Outcome Measure is Reported Adverse Events.","Massachusetts General Hospital|BrainCells Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","81","Other|Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBM-IT-01-EXT","July 2008","December 2008","January 2009","August 11, 2008","December 17, 2013","December 17, 2013","Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Synergy Research Centers, San Diego, California, United States|Atlanta Institute of Medicine & Research, Inc., Altanta, Georgia, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|NorthCoast Clinical Trials, Beachwood, Ohio, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|FutureSearch Clinical Trials, L.P., Austin, Texas, United States|FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00731653"
313,"NCT01121484","Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)",,"Completed","Has Results","Major Depressive Disorder","Drug: desvenlafaxine succinate sustained-release|Drug: placebo","Change From Baseline in Hamilton Depression Scale (HAM-D17) at Week 8|Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)|Change From Baseline in Clinical Global Impression - Severity (CGI-S) at Week 8|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score at Week 8|Change From Baseline in Quick Inventory of Depressive Symptoms, 16 Question Self-report (QIDS-SR)|Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) at Week 8","Pfizer","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","439","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-3364|B2061029","June 2010","June 2011","June 2011","May 12, 2010","March 30, 2012","April 4, 2012","Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham, Alabama, United States|Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|Pacific Clinical Research Medical Group, Arcadia, California, United States|Southwestern Research, Inc., Beverly Hills, California, United States|Catalina Research Institute LLC, Chino, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Radiant Research, Inc., Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Emory University Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Roswell, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Deaconess Clinic Gateway Health Center Research Institute, Newburgh, Indiana, United States|Via Christi Research, Witchita, Kansas, United States|Westside Family Medical Center, P.C., Kalamazoo, Michigan, United States|Radiant Research, Inc., Las Vegas, Nevada, United States|Center For Emotional Fitness, Cherry Hill, New Jersey, United States|Robert Wood Johnson Medical School, Piscataway, New Jersey, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Medical & Behavioral Health Research PC, New York, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Horizon Medical Services, PC, Bismarck, North Dakota, United States|Legacy Pharma Research, Bismark, North Dakota, United States|North Coast Clinical Trials, Inc., Beechwood, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Research Services, LLC, Columbia, South Carolina, United States|Holston Medical Group, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Bayou City Research, Ltd., Houston, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|University of Virginia Health System Center for Psychiatric Clinical Research, Charlottesville, Virginia, United States|Nelson Clinic, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Independent Psychiatric Consultants, SC dba IPC Research, Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01121484"
314,"NCT00705003","Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|Drug: BCI-024 (Buspirone)|Drug: Matching placebo","The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6|The Change From Baseline in the CGI-S at Week 6|The Change From Baseline in the IDS-C30 at Week 6|The Change From Baseline in the Quick Inventory of Depressive Symptomatology - 16 Item Self-Report (QIDS-SR16) at Week 6|The Change From Baseline on the HAM-A at Week 6","Massachusetts General Hospital|BrainCells Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","142","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBM-IT-01","May 2008","December 2008","December 2008","June 25, 2008","June 18, 2014","June 18, 2014","Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Synergy Research Centers, San Diego, California, United States|Atlanta Institute of Medicine & Research, Inc., Altanta, Georgia, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|NorthCoast Clinical Trials, Beachwood, Ohio, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|FutureSearch Clinical Trials, L.P., Austin, Texas, United States|FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00705003"
315,"NCT00807248","Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram placebo|Drug: Gaboxadol placebo|Drug: Escitalopram 20 mg|Drug: Gaboxadol 5 mg|Drug: Gaboxadol 10 mg","Montgomery and Åsberg Depression Rating Scale (MADRS)|MADRS|Hospital Anxiety and Depression Scale (HADS)|Insomnia Severity Index (ISI)|Sheehan Disability Scale (SDS): Family Subscale|SDS: Work Subscale|SDS: Social Subscale|Clinical Global Impression - Severity of Illness (CGI-S)|Clinical Global Impression - Global Improvement (CGI-I)","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","490","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12213A|2008-000506-36","November 2008","December 2009","February 2010","December 11, 2008","August 11, 2011","December 17, 2012","AT001, Vienna, Austria|RU019, Barnaul, Russian Federation|RU018, Ekaterinburg, Russian Federation|RU029, Izhevsk, Russian Federation|RU020, Kemerovo, Russian Federation|RU012, Krasnodar, Russian Federation|RU010, Krasnodar, Russian Federation|RU022, Kursk, Russian Federation|RU015, Moscow, Russian Federation|RU026, Moscow, Russian Federation|RU001, Moscow, Russian Federation|RU002, Moscow, Russian Federation|RU028, Moscow, Russian Federation|RU003, Moscow, Russian Federation|RU007, Moscow, Russian Federation|RU027, Saransk, Russian Federation|RU024, Saratov, Russian Federation|RU013, Saratov, Russian Federation|RU021, Tomsk, Russian Federation|RU016, Tver, Russian Federation|RU014, Volgograd, Russian Federation|RU011, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00807248"
316,"NCT00057239","An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: Radafaxine","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score after 8 weeks of treatment|Change in the MADRS score at other timepoints; change in Clinical Global Impression; percentage of remitters and responders based on the MADRS; change in disability, motivation, energy and pain;incidence of adverse events over course of study.","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","OHB20001","March 2003","May 2004","May 2004","March 28, 2003",,"October 4, 2010","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Farmington, Connecticut, United States|GSK Investigational Site, Largo, Florida, United States|GSK Investigational Site, Maitland, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, North Miami, Florida, United States|GSK Investigational Site, Edwardsville, Illinois, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, Farmington Hills, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Clementon, New Jersey, United States|GSK Investigational Site, Kenilworth, New Jersey, United States|GSK Investigational Site, Lawrence, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Conshohocken, Pennsylvania, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Irving, Texas, United States|GSK Investigational Site, Woodstock, Vermont, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00057239"
317,"NCT00931775","Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder","CIT-PIN","Completed","No Results Available","Major Depressive Disorder|Antidepressant Treatment Response","Drug: Pindolol","Scores on Hamilton Depression Rating Scale","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIT-PIN_01-0C3","December 2002","March 2005","November 2005","July 2, 2009",,"July 2, 2009","Outpatients Service of Psychiatry Department. Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT00931775"
318,"NCT00531622","An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: saredutant (SR48968)|Drug: escitalopram|Drug: placebo","Change from baseline to Day 56 in Hamilton depression rating scale (HAM-D) total score|Change from Baseline to Day 56 in the CGI-S Severity of Illness score|Change from baseline to Day 56 in the Clinical Global Impression (CGI) severity of illness score|Change from baseline to Day 56 in HAM-D depressed mood item scores.|Percentage of patients demonstrating a treatment response","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","643","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10290|EudraCT 2007-003159-36","September 2007","January 2009","January 2009","September 19, 2007",,"May 24, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Bromma, Sweden",,"https://ClinicalTrials.gov/show/NCT00531622"
319,"NCT00831415","Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: desvenlafaxine succinate sustained release tablets","Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score|Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Categorical Scores on Clinical Global Impression-Improvement (CGI-I)|Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score","Pfizer","All","20 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-3350|B2061002","March 2009","March 2011","March 2011","January 29, 2009","January 30, 2012","December 7, 2018","Pfizer Investigational Site, Aichi, Japan|Pfizer Investigational Site, Chiba, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Fukushima, Japan|Pfizer Investigational Site, Gunma, Japan|Pfizer Investigational Site, Hiroshima, Japan|Pfizer Investigational Site, Hokkaido, Japan|Pfizer Investigational Site, Hyogo, Japan|Pfizer Investigational Site, Ishikawa, Japan|Pfizer Investigational Site, Kanagawa, Japan|Pfizer Investigational Site, Kumamoto, Japan|Pfizer Investigational Site, Kyoto, Japan|Pfizer Investigational Site, Osaka, Japan|Pfizer Investigational Site, Saga, Japan|Pfizer Investigational Site, Saitama, Japan|Pfizer Investigational Site, Shiga, Japan|Pfizer Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00831415"
320,"NCT00905424","Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant",,"Completed","Has Results","Major Depressive Disorder","Drug: Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Drug: Antidepressant + placebo","Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF)|Change From Augmentation Baseline for Non-Remitters in the Hamilton Depression Scale (HAM-D) Total Score at Week 6 - LOCF|Change From Augmentation Baseline for Non-Remitters in the Sheehan Disability Scale (SDS) Total Score at Week 6|Percentage of Non-Remitters With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 6 - LOCF|Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline|Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Week 6|Change From Augmentation Baseline for Non-Remitters in the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Scale Total Score at Week 6|Change From Augmentation Baseline for Non-Remitters in the Multidimensional Assessment of Fatigue (MAF) Scale Total Score at Week 6|Change From Augmentation Baseline for Non-Remitters in the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) Scale Total Score at Week 6|Change From Augmentation Baseline for Remitters in MADRS Total Score at Week 6 - LOCF|Change From Augmentation Baseline for Remitters in the HAM-D Total Score at Week 6 - LOCF|Change From Augmentation Baseline for Remitters in the SDS Total Score at Week 6|Percentage of Remitters With Improvement on CGI-I at Week 6 - LOCF|Assessment in Remitters of CGI-S at Augmentation Baseline|Assessment in Remitters of CGI-S at Week 6|Change From Augmentation Baseline for Remitters in the BRIEF-A Scale Total Score at Week 6|Change From Augmentation Baseline for Remitters in the MAF Scale Total Score at Week 6|Change From Augmentation Baseline for Remitters in the QIDS-SR Scale Total Score at Week 6","Shire|Takeda","All","18 Years to 55 Years   (Adult)","Phase 2","246","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPD489-203","July 30, 2009","August 4, 2010","August 4, 2010","May 20, 2009","July 14, 2011","June 14, 2021","Pharmacology Research Institute (PRI), Newport Beach, California, United States|Affiliated Research Institute, San Diego, California, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Atlanta Institute of Medicine & Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Vince & Associates Clinical Research, Overland Park, Kansas, United States|Duke University Medical Center, Durham, North Carolina, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|FutureSearch Clinical Trials, LP, Austin, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle), LLC, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00905424"
321,"NCT00735709","Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine|Drug: Placebo","Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8|Clinical Global Impression Scale-Global Improvement at Week 8|Percentage of Responders in HAM-D24 Total Score at Week 8|Change From Baseline in HAM-D24 Total Score at Week 8 in Participants With Baseline HAM-A Score ≥20|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed|Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed|Percentage of Responders in HAM-D24 Total Score at Other Weeks Assessed|Change From Baseline in HAM-D24 Total Score at Other Weeks Assessed in Participants With a Baseline HAM-A Score ≥20|Percentage of Participants in MADRS Remission at Other Weeks Assessed|Percentage of Participants With a Sustained Response in HAM-D24 Total Score|Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Each Week|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Each Week Assessed|Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed|Change From Baseline in Hospital Anxiety and Depression (HAD) Scales at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at All Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at All Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at All Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at All Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at All Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at All Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at All Weeks Assessed|Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire.","Takeda|H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","560","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LuAA21004_305|2008-001580-11|U1111-1114-0326","August 2008","July 2009","August 2009","August 15, 2008","December 18, 2013","December 18, 2013","Elizabeth Vale, Australia|Southport, Australia|Litomerice, Czech Republic|Lnare, Czech Republic|Prague, Czech Republic|Praha, Czech Republic|Bully les Mines, France|Marseille, France|Strasbourg, France|Bochum, Germany|Chemnitz, Germany|Dillingen, Germany|Huettenberg, Germany|Leipzig, Germany|Munchen, Germany|München, Germany|Nuernberg, Germany|Osnabrueck, Germany|Rodgau, Germany|Westerstede, Germany|Bucheon-si, Korea, Republic of|Namdong-gu, Korea, Republic of|Seoul, Korea, Republic of|Leipaja, Latvia|Riga, Latvia|Sigulda, Latvia|Strenci, Latvia|Vilnius, Lithuania|Kuala Lumpur, Malaysia|Wildervank, Netherlands|Białystok, Poland|Leszno, Poland|Skórzewo, Poland|Toruń, Poland|Tuszyn, Poland|Moscow, Russian Federation|Novgorod, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Tomsk, Russian Federation|Durban, South Africa|Noordheuwel, South Africa|Pretoria, South Africa|Lin-Yan District, Taiwan|Dnepropetrovsk, Ukraine|Kharkiv, Ukraine|Lugansk, Ukraine|Simferopol, Ukraine|Bath, United Kingdom|Bolton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00735709"
322,"NCT00644358","A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: vilazodone","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Change Form Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score|Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score|Clinical Global Impression - Improvement (CGI-I) Score","Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","616","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLDA-07-DP-04","December 31, 2007","May 31, 2009","May 31, 2009","March 26, 2008","September 25, 2017","September 25, 2017","Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Affiliated Research Institute, San Diego, California, United States|Collaborative Neuroscience Network, Inc, Torrance, California, United States|Pacific Clinical Research, Upland, California, United States|Radiant Research, Denver, Colorado, United States|CNS Clinical Research Group, Coral Springs, Florida, United States|Gulfcoast Clinical Research, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Florida Clinical Research Center, LLC, Lady Lake, Florida, United States|Clinical Neuroscience Solutions, PA, Orlando, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Carman Research, Smyrna, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Davis Clinic, Indianapolis, Indiana, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|Summit Research Network, Farmington, Michigan, United States|Radiant Research, Saint Louis, Missouri, United States|Radiant Research, Las Vegas, Nevada, United States|Bioscience Research, LLC, Mount Kisco, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|North Coast Clinical Trials, Beachwood, Ohio, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Paramount Clinical Research, Bridgeville, Pennsylvania, United States|Introspect of Buxmont, Colmar, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|FutureSearch Trials, Dallas, Texas, United States|Croft Group Research Center, San Antonio, Texas, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States|Neuroscience, Inc., Herndon, Virginia, United States|Dominion Clinical Research, Midlothian, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00644358"
323,"NCT00452595","Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR (desvenlafaxine sustained release )","HAM-D17|MADRS, CGI-S, CGI-I, Covi Anxiety Scale, SDS, VAS-PI, and WHO-5","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-318","January 2004",,"May 2005","March 27, 2007",,"March 27, 2007",,,"https://ClinicalTrials.gov/show/NCT00452595"
324,"NCT00715559","Cysteamine Therapy for Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: cysteamine bitartrate","Montgomery-Åsberg Depression Rating Scale (MADRS)|Clinical Global Impression Scales for Severity (CGI-S) and Improvement (CGI-I)|Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16)|Systematic Assessment for Treatment Emergent Effects (SAFTEE)","Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO # 07-0478","July 2008","May 2009","May 2009","July 15, 2008","June 16, 2011","April 7, 2017","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00715559"
325,"NCT00511810","Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Low Dose Fish Oil|Drug: High Dose Fish Oil","Mood Symptoms Ratings","University of Cincinnati|The Inflammation Research Foundation","All","12 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","McNamara Omega3 MDD","August 2007","March 2011","March 2011","August 6, 2007","December 4, 2014","May 27, 2016","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00511810"
326,"NCT00536471","A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine hydrochloride|Drug: Placebo","Change From Baseline to 8 Weeks in 24-Item Hamilton Depression Rating Scale (HAMD-24) Item 7 (Work and Activities)|Change From Baseline to 12 Week and 9 Month Endpoints in the 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score and HAMD-24 Subscales (8 Week Endpoint for Maier Subscale)|Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Total Score|Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Item 1:Depressed Mood|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 2:Feelings of Guilt|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 3:Suicide|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 4:Insomnia Early|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 5:Insomnia Middle|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 6:Insomnia Late|Change From Baseline to 9 Month Endpoint in HAMD-24 - Item 7:Work and Activities|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 8:Retardation|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 9:Agitation|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 10:Anxiety (Psychic)|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 11:Anxiety (Somatic)|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 12:Somatic Symptoms/Gastrointestinal|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 13:Somatic Symptoms/General|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 14:Genital Symptoms|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 15:Hypochondriasis|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 16:Loss of Weight|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 17:Insight|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18A:Diurnal Variation|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18B:Diurnal Variation-Severity|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 19: Depersonalization and Derealization|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 20:Paranoid Symptoms|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 21:Obsessional and Compulsive Symptoms|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 22B:Helplessness|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 23B:Hopelessness|Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 24B:Worthlessness|Change From Baseline to 12 Week Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment).|Change From Baseline to 9 Month Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment)|Change From Baseline to 12 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores|Change From Baseline to 9 Month Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores|Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7|Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7 - Percent of Total Effect|Path Analysis of BPOMS Total Score to Overall Improvement in Sheehan Disability Scale (SDS) Total Score|Path Analysis of BPOMS Total Score to Overall Improvement in SDS Total Score - Percent of Total Effect|Change From Baseline to 12 Week and 9 Month Endpoints in 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) Total Score|Probability of Remission at 12 Week Endpoint and Sustained Remission at 9 Month Endpoint|Probability of Response at 12 Week Endpoint|Change From Baseline to 12 Week and 9 Month Endpoints in Pain Numerical Rating Scale (NRS)|Change From Baseline to 12 Week and 9 Month Endpoint in the Clinical Global Impression-Severity Scale (CGI-S)|Change From Baseline to 12 Week and 9 Month Endpoints in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ)|Change From Baseline to 12 Week and 9 Month Endpoints in the Social Adaptation Self-evaluation Scale (SASS) Total Score|Change From Baseline to 12 Week and 9 Month Endpoints in Blood Pressure|Change From Baseline to 12 Week and 9 Month Endpoints in Pulse Rate|Change From Baseline to 12 Week and 9 Month Endpoints in Weight|Abnormal Vital Signs at Anytime Over 12 Weeks|Abnormal Vital Signs at Anytime Over 9 Months|Abnormal Vital Signs at 12 Week Endpoint|Abnormal Vital Signs at 9 Month Endpoint|Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid|Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Hematocrit|Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Mean Cell Volume (MCV)|Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium|Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Platelet Count|Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Alkaline Phosphatase|Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Hemoglobin|Statistically Significant Abnormal Laboratory Values at Anytime/12 Week Endpoint|Statistically Significant Abnormal Laboratory Values at Anytime During 9 Months|Statistically Significant Abnormal Laboratory Values at 9 Month Endpoint|Summary of Adverse Events Leading to Discontinuation","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","776","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11669|F1J-US-HMFS","September 2007","May 2008","December 2008","September 27, 2007","July 17, 2009","November 20, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., National City, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Britain, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New London, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilmington, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maitland, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edwardsville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoffman Estates, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Naperville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oak Brook, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terre Haute, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Burnie, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsfield, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Peters, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clementon, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cedarhurst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olean, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allentown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arlington, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlottesville, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Allis, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arecibo, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caguas, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00536471"
327,"NCT00361218","Biological Markers of Response to Treatment in Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: open-label selective serotonin reuptake inhibitor (SSRI)","Serum Brain-derived Neurotrophic Factor (BDNF) Levels|Quantitative Electroencephalogram (QEEG) Parameters as Predictors of Response","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","72","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005P000413","October 2005","December 2008","December 2008","August 8, 2006","September 26, 2013","May 11, 2018",,,"https://ClinicalTrials.gov/show/NCT00361218"
328,"NCT00733668","Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder","UNIQUE","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine fumarate (Seroquel)","The Montgomery-Asberg Depression Scale (MADRS) score|The Brief psychiatric Rating Scale (BPRS) scoreThe Clinical Global impression (CGI) scorePatient reported outcomes (PROs)|Sheehan Disability Scale (SDS) score|The Symptom Checklist 90 Revisred (SCL-90-R) score","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1449C00009","March 2006","November 2007","November 2007","August 13, 2008",,"March 25, 2009","Research Site, Brugge, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Sint-Truiden, Belgium",,"https://ClinicalTrials.gov/show/NCT00733668"
329,"NCT03786731","A Transdiagnostic Sleep and Circadian Treatment for Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Sleep Disturbance","Behavioral: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)","Change in the Patient Health Questionnaire (PHQ-9)|Change in Hospital Anxiety and Depression Scale (HADS)|Change in Insomnia Severity Index (ISI)|Change in 7-Day Sleep Diary|Change in Multidimensional Fatigue Inventory (MFI)|Change in Short Form (Six-Dimension) Health Survey - The Chinese (Hong Kong) Version (SF-6D)|Change in Sheehan Disability Scale (SDS)|Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD)|Patient-Reported Outcomes Measurement Information System-Sleep-Related Impairment (PROMIS-SRI)","Chinese University of Hong Kong|University of California, Berkeley","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PSY004","January 1, 2019","December 2020","June 2021","December 26, 2018",,"March 11, 2020","The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03786731"
330,"NCT00262665","Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: ORG 24448|Drug: Placebo","mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) from baseline to 8 weeks|change in neuropsychological function from baseline to 7 weeks","Dennis Charney|National Institutes of Health (NIH)|Icahn School of Medicine at Mount Sinai","All","21 Years to 55 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GCO # 05-0384","March 2005","March 2005","March 2005","December 7, 2005",,"December 11, 2012",,,"https://ClinicalTrials.gov/show/NCT00262665"
331,"NCT04722666","Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent",,"Recruiting","No Results Available","Major Depressive Disorder With Suicidal Ideation With Intent","Drug: MIJ821 Intravenous Injection|Drug: Placebo Intravenous Injection","Change from baseline in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS)|Number and severity of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI)|Pharmacokinetics (PK) of MIJ821 in plasma|Percentage of participants meeting response criteria of ≥50% reduction|Percentage of participants meeting criteria for sustained response of ≥50% reduction|Percentage of participants meeting remission criteria of MADRS total score of ≤12|Percentage of participants meeting sustained remission criteria of MADRS total score of ≤12|Percentage of participants meeting criteria for relapse in the Extension Period|Percentage of relapsing participants meeting response criteria or remission criteria after the first infusion","Novartis Pharmaceuticals|Novartis","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMIJ821A12201","May 30, 2021","December 5, 2023","December 5, 2023","January 25, 2021",,"June 8, 2021","Novartis Investigative Site, Oakland Park, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04722666"
332,"NCT00775203","A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.",,"Completed","Has Results","Major Depressive Disorder","Drug: Trazodone Hydrochloride (HCl) Extended-Release Tablets|Drug: Placebo","Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline|HAMD-17 Responders at Each Visit|HAMD-17 Remitters at Each Visit|Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit|Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline|Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit|Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit|Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit|Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit|Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit|Overall Quality of Sleep at Each Visit|Trouble Falling Asleep at Each Visit|Awakening During the Night at Each Visit|Discontinuation Due to Lack of Efficacy","Labopharm Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04ACL3-001","June 2007","November 2007","November 2007","October 20, 2008","April 7, 2010","April 27, 2012","Birmingham, Alabama, United States|Mesa, Arizona, United States|Beverly Hills, California, United States|Burbank, California, United States|San Diego, California, United States|Denver, Colorado, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Smyrna, Georgia, United States|Libertyville, Illinois, United States|Indianapolis, Indiana, United States|Overland Park, Kansas, United States|Clementon, New Jersey, United States|Brooklyn, New York, United States|New York, New York, United States|New-York, New York, United States|Beachwood, Ohio, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Bellaire, Texas, United States|San Antonio, Texas, United States|Woodstock, Vermont, United States|Kelowna, British Columbia, Canada|Penticton, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|Oakville, Ontario, Canada|Gatineau, Quebec, Canada|Saint-Leonard, Quebec, Canada|Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00775203"
333,"NCT01318434","A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)",,"Completed","No Results Available","Major Depressive Disorder","Drug: EB-1010 25mg BID|Drug: SSRI Active|Drug: EB-1010 50mg BID|Drug: Placebo","Change from baseline in MADRS Score|Change in Clinical Global Severity Scale","Euthymics BioScience, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","342","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EB-1010-301","February 2011","February 2013","February 2013","March 18, 2011",,"December 4, 2015","Pacific Clinical Research Medical Group, Arcadia, California, United States|Southwest Research, Inc., Beverly Hills, California, United States|Synergy Clinical Research Center, National City, California, United States|Clinical Innovations, Inc., Santa Ana, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Sanitas Research, Coral Gables, Florida, United States|Clinical Neuroscience Solution, Inc., Jacksonville, Florida, United States|Florida Clinical Research Center, Maitland, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|AMR Baber Research, Naperville, Illinois, United States|Psychiatric Medicine Associates, Stokie, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Clinical Insights, Glen Burnie, Maryland, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|AccelRx Research, Fall River, Massachusetts, United States|St Charles Psychiatric Associates, St. Charles, Missouri, United States|Global Medical Institutes, Princeton, New Jersey, United States|CRI Worldwide, LLC, Willingboro, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Community Research, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|North Star Medical Research, Middleburg Heights, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|SP Research, PLLC, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Southeastern PA Medical Institute, Broomall, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|Scranton Counseling Center, Scranton, Pennsylvania, United States|Radiant Research, Greer, South Carolina, United States|Clinical NeuroScience Solutions, Inc., Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Radiant Research, Inc., Murray, Utah, United States|Aspen Clinical Research, Orem, Utah, United States|VCU, Richmond, Virginia, United States|Dean Foundation for Health, Research & Education, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01318434"
334,"NCT00529789","Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: duloxetine","Number of Participants With Emergence of Suicidal Ideation During Period II/III|Number of Participants With Emergence of Suicidal Ideation During Period IV|Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) During Period II/III|Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) During Period IV|Number of Participants Meeting Criteria for Potentially Clinically Significant Vital Sign Values at Any Time During Period II/III|Number of Participants Meeting Criteria for Potentially Clinically Significant Vital Sign Values at Any Time During Period IV|Number of Participants Meeting Criteria for Potentially Clinically Significant (PCS) Laboratory Analyte Values at Any Time During Period II/III|Number of Participants Meeting Criteria for Potentially Clinically Significant (PCS) Laboratory Analyte Values at Any Time During Period IV|Number of Participants Meeting Criteria for Potentially Clinically Significant Electrocardiograms at Any Time in Period II/III|Number of Participants With Potentially Clinically Significant Electrocardiograms at Any Time in Period IV|Pharmacokinetics: Summary of Observed Duloxetine Plasma Concentrations Stratified by Duloxetine Dose|Change From Baseline to 18 Weeks and 30 Weeks in Clinical Global Impressions of Severity Scale (CGI-S)|Change From Baseline to 18 Weeks and 30 Weeks in Children's Depression Rating Scale-Revised (CDRS-R) Total Score","Eli Lilly and Company","All","7 Years to 17 Years   (Child)","Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11664|F1J-MC-HMFN","August 2007","September 2008","September 2008","September 14, 2007","December 9, 2009","October 24, 2011","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dothan, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chandler, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., El Centro, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eagle, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terre Haute, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Overland Park, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baton Rouge, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Kisco, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herndon, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midlothian, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00529789"
335,"NCT00811252","Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine (Lu AA21004)|Drug: Duloxetine","Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment|Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment|Change From Baseline in MADRS Total Score After 8 Weeks of Treatment|Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment|Change From Baseline in CGI-S Score After 8 Weeks of Treatment|Change in Clinical Status Using CGI-I Score at Week 8|Change From Baseline in GDS Total Score After 8 Weeks of Treatment|Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)|Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)|Risk of Suicidality Using C-SSRS Scores","H. Lundbeck A/S","All","65 Years and older   (Older Adult)","Phase 3","453","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12541A|2008-002901-38","January 2009","February 2010","March 2010","December 18, 2008","December 18, 2013","January 29, 2014",,,"https://ClinicalTrials.gov/show/NCT00811252"
336,"NCT00242229","Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR","To evaluate the long-term safety and tolerability of DVS SR in elderly outpatients with MDD.|To evaluate the long-term response of subjects receiving DVS SR for the clinical global evaluation, functionality, general well-being, pain and absence of depressive symptoms (Hamilton Psychiatric Rating Scale for Depression 17-item score < or = 7).","Wyeth is now a wholly owned subsidiary of Pfizer","All","65 Years and older   (Older Adult)","Not Applicable","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","3151A1-307","October 2004","October 2005","October 2005","October 19, 2005",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00242229"
337,"NCT00239954","Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Montgomery Asberg Depression Rating Scale (MADRS)|Hamilton Depression Rating Scale (HAMD)","Pharmacology Research Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PRI#591 & #592","March 2005",,,"October 17, 2005",,"May 9, 2012","Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|Pharmacology Research Institute, Riverside, California, United States",,"https://ClinicalTrials.gov/show/NCT00239954"
338,"NCT00683592","Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: vilazodone|Drug: placebo","Change From Baseline to Week 8 in the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score.|Change From Baseline to Week 8 in the HAM-D 17 (17-Item Hamilton Rating Scale for Depression) Total Score|The CGI-I (Clinician's Global Impression of Improvement) Score at Week 8|Change From Baseline to Week 8 in the HAM-A ( Hamilton Anxiety Rating Scale) Total Score|MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate at Week 8|MADRS (Montgomery-Asberg Depression Rating Scale) Remission Rate at Week 8","Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","481","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLDA-07-DP-02","March 2008","February 2009","March 2009","May 23, 2008","October 27, 2010","October 27, 2010","Pharmacology Research Institute, Newport Beach, California, United States|Florida Clinical Research Center, Bradenton, Florida, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|Summit Research Network, Portland, Oregon, United States|University of Pennsylvania Department of Psychiatry Mood and Anxiety Disorders, Philadelphia, Pennsylvania, United States|Mood Disorders Research Program and Clinic Exchange Park, Dallas, Texas, United States|University of Utah Health Sciences Ctr, Dept of Psychiatry Mood Disorders Clinic, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00683592"
339,"NCT02149836","Study to Treat Major Depressive Disorder (MDD) With a New Medication",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: ezogabine","Montgomery-Asberg Depression Rating Scale Comparison to Baseline|Patient Rated Inventory of Side Effects (PRISE)|Columbia-Suicide Severity Rating Scale (C-SSRS)|Changes in Reward System Activation After Treatment With Ezogabine","Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 14-0597","August 2014","December 2016","December 2016","May 29, 2014","April 16, 2019","April 16, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02149836"
340,"NCT00464048","A Controlled Study to Assess the Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Procedure: controlled physical exercise","response of depressive symptoms- reduction in HAM-D score at the end of the follow-up period|reduction in pretreatment BDI score|remission according to HAM-D score|remission according to BDI score|changes in plasmatic measurements before and after the first and last exercise|length of hospitalization","Hadassah Medical Organization","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","bhmi55-hmo-ctil","May 2007",,"May 2009","April 20, 2007",,"April 20, 2007","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00464048"
341,"NCT00432614","Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder","ALBERIO","Completed","No Results Available","Major Depressive Disorder","Drug: SR58611A|Drug: escitalopram|Drug: placebo","Change from baseline in Hamilton Depression Rating scale (HAM-D) total score|Speed of response based on HAM-D and change in Clinical Global Impression (CGI) severity score","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","510","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC6224|EudraCT 2006-004146-16","January 2007","February 2008","February 2008","February 8, 2007",,"March 25, 2009","Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Tatari, Estonia|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Casablanca, Morocco|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Megrine, Tunisia|Sanofi-Aventis Administrative Office, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00432614"
342,"NCT00095758","A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Antidepressant + Placebo|Drug: Antidepressant + Aripiprazole","Change in a depression rating scale at endpoint|Change in a disability scale and Clinical Global Impression scale at endpoint","Bristol-Myers Squibb|Otsuka America Pharmaceutical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-163","September 2004","December 2006","December 2006","November 9, 2004",,"November 25, 2013","Local Institution, Beverly Hills, California, United States|Local Institution, Burbank, California, United States|Local Institution, National City, California, United States|Local Institution, Orange, California, United States|Local Institution, Pasadena, California, United States|Local Institution, Denver, Colorado, United States|Local Institution, Farmington, Connecticut, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Orlando, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Rockville, Maryland, United States|Local Institution, Albuquerque, New Mexico, United States|Local Institution, Brooklyn, New York, United States|Local Institution, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Local Institution, Toledo, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Memphis, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Arlington, Virginia, United States|Local Institution, Herndon, Virginia, United States|Local Institution, Richmond, Virginia, United States|Local Institution, Bellevue, Washington, United States|Local Institution, Seattle, Washington, United States|Local Institution, Brown Deer, Wisconsin, United States|Local Institution, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00095758"
343,"NCT02741791","A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder","STRIDE-1","Completed","No Results Available","Treatment Resistant Major Depressive Disorder","Drug: AXS-05|Drug: Bupropion","Montgomery-Åsberg Depression Rating Scale (MADRS) total score|Clinical Global Impressions-Severity (CGI-S)|Hamilton Depression Rating Scale - 17 items (HAMD-17)","Axsome Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AXS-05-301","March 2016","March 20, 2020","March 20, 2020","April 18, 2016",,"March 24, 2021","Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Garden Grove, California, United States|Oakland, California, United States|Oceanside, California, United States|Panorama City, California, United States|Redlands, California, United States|Riverside, California, United States|San Diego, California, United States|San Francisco, California, United States|Sherman Oaks, California, United States|Temecula, California, United States|Upland, California, United States|Colorado Springs, Colorado, United States|Cromwell, Connecticut, United States|Washington, District of Columbia, United States|Coral Springs, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|North Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Saint Petersburg, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Skokie, Illinois, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Saint Charles, Missouri, United States|Saint Louis, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Nashua, New Hampshire, United States|Berlin, New Jersey, United States|Cherry Hill, New Jersey, United States|Marlton, New Jersey, United States|Princeton, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Jamaica, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Canton, Ohio, United States|Dayton, Ohio, United States|Middleburg Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Allentown, Pennsylvania, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Lincoln, Rhode Island, United States|Charleston, South Carolina, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Orem, Utah, United States|Charlottesville, Virginia, United States|Herndon, Virginia, United States|Bellevue, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02741791"
344,"NCT00168376","A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation","The outcome measure used is the MADRS (Montgomery-Asberg Depression Rating Scale). This is administered at baseline and on a fortnightly basis.|Other outcome measures administered fortnightly are: BPRS (Brief Psychiatric Rating Scale), CORE (measure of melancholic symptoms), BDI (Beck Depression Inventory), CGI (Clinical Global Impression Scale), GAF (Global Assessment of Functioning Scale).","The Alfred","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Educational/Counseling/Training","57/04","July 2004",,"April 2006","September 15, 2005",,"April 16, 2007","Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00168376"
345,"NCT00321152","A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder","Other: 6(S)-5-MTHF (a Medical Food)","HAM-D|QIDS-SR","Massachusetts General Hospital|Pamlab, L.L.C.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006P000604","November 2006","August 2008","June 2010","May 3, 2006",,"June 8, 2010","University of California San Diego School of Medicine, San Diego, California, United States|Rush University Medical Center, Psychiatric Medicine Associates, LLC, Chicago, Illinois, United States|Lousiana State University Health Sciences Center, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Burlington Medical Associates, Burlington, Massachusetts, United States|Waltham Family Practice, Waltham, Massachusetts, United States|Charles River Medical Associates, Westborough, Massachusetts, United States|Univeristy of Cincinnati, College of Medicine, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Southeast Health Consultants, LLC, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00321152"
346,"NCT01733654","Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder",,"Withdrawn","No Results Available","Depression|Major Depressive Disorder","Biological: RO4995819","Montgomery Asberg Depression Rating Scale","Stanford University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","23708","September 2012","December 2013","May 2014","November 27, 2012",,"October 4, 2019",,,"https://ClinicalTrials.gov/show/NCT01733654"
347,"NCT03580967","Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes",,"Not yet recruiting","No Results Available","Type2 Diabetes|Major Depressive Disorder","Drug: Vortioxetine","Change in depressive symptoms measured by Hamilton Depression Rating Scale (HAM-D)","Todd Doyle|Takeda|Loyola University","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","210161","December 1, 2019","August 1, 2020","August 1, 2023","July 10, 2018",,"October 24, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03580967"
348,"NCT00135421","Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Pexacerfont|Drug: Escitalopram|Drug: Placebo","Mean change from baseline to endpoint (Week 8) on the total score of the Hamilton Depression Rating Scale (HAMD-17)|Compare safety and tolerability of BMS-562086 to placebo by assessing adverse events, vital signs, electrocardiograms (ECGs), physical examinations and clinical lab tests|Compare efficacy of escitalopram to placebo","Bristol-Myers Squibb","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN148-007","November 2005","October 2007","October 2007","August 26, 2005",,"March 2, 2010","Apc Clinical Research Trials Nw, Pa, Springdale, Arkansas, United States|Pacific Clinical Research Medical Group, Orange, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Front Range Clinical Research, Wheatridge, Colorado, United States|University Of Connecticut Health Center, Farmington, Connecticut, United States|University Of Florida, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Cunningham Clinical Research, Llc, Edwardsville, Illinois, United States|Alexian Center For Psychiatric Research, Hoffman Estates, Illinois, United States|American Medical Research, Inc., Oakbrook, Illinois, United States|Alpine Clinic, Lafayette, Indiana, United States|J. Gary Booker, Md, Shreveport, Louisiana, United States|Dupont Clinical Research, Rockville, Maryland, United States|Summit Research Network, Farmington Hills, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Bioscience Research, Llc, New York, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|Behavioral Medical Research Of Staten Island, Staten Island, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Richard H. Weisler, Md, Raleigh, North Carolina, United States|Community Research, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Oregon Center For Clinical Investigations, Inc. (Occi, Inc), Portland, Oregon, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Usc School Of Medicine, Columbia, South Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Futuresearch Trials, Austin, Texas, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|Insite Clinical Research, Desoto, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Croft, Harry A., San Antonio, Texas, United States|Radiant Research, Salt Lake City, Salt Lake City, Utah, United States|University Of Utah School Of Medicine, Salt Lake City, Utah, United States|Psychiatric Alliance Of The Blue Ridge, Charlottesville, Virginia, United States|Dominion Clinical Research, Midlothian, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle), Inc., Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00135421"
349,"NCT00326144","Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders","OPAL","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine fumarate","To evaluate the efficacy of Quetiapine SR compared with placebo in the treatment of patients with MDD as assessed by change from randomization to Week 8 in the MADRS total score|To evaluate if Quetiapine SR improves the health-related quality of life of patients with MDD, compared to placebo|To evaluate if quetiapine SR reduces anxiety symptoms in patients with MDD, compared to placebo","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D1448C00003|OPAL","April 2006",,"May 2007","May 16, 2006",,"March 25, 2009","Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, El Centro, California, United States|Research Site, Garden Grove, California, United States|Research Site, National City, California, United States|Research Site, Riverside, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Naperville, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lafayette, Indiana, United States|Research Site, Owensboro, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Braintree, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research SIte, Staten Island, New York, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, DeSoto, Texas, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00326144"
350,"NCT00063206","Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","247","Industry","Interventional","Primary Purpose: Treatment","3151A1-304",,"May 2004","May 2004","June 25, 2003",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00063206"
351,"NCT00277823","Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-SR 50 mg|Drug: DVS-SR 100 mg|Drug: Placebo","The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.|Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-332","February 2006",,"January 2007","January 16, 2006",,"December 28, 2007","Beverly Hills, California, United States|Northridge, California, United States|Farmington, Connecticut, United States|Washington, District of Columbia, United States|Miami, Florida, United States|St. Petersburg, Florida, United States|Marietta, Georgia, United States|Smyrna, Georgia, United States|Libertyville, Illinois, United States|New Orleans, Louisiana, United States|Farmington Hills, Michigan, United States|Clementon, New Jersey, United States|Moorestown, New Jersey, United States|New York, New York, United States|New York, New York, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00277823"
352,"NCT01344733","A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)","Improve","Completed","No Results Available","Major Depressive Disorder|MDD",,"To define the potential bipolarity status in treatment resistant MDD patient population|Hypomanic condition will be defined if the patient will give positive answer to at least 12 items of HCL32. HCL-32-positive patients is expected to be ranged between 4.3% and 21.3%. The difference between the means in the two groups will be estimated.|To collect patient characteristics by evaluation of demographic information|To collect disease characteristics by evaluation of the number of previous episodes, and the duration of current episode|To collect information on the ongoing treatment","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)",,"660","Industry","Observational","Time Perspective: Prospective","NIS-NIT-DUM-2010/1","May 2011","March 2012","March 2012","April 29, 2011",,"March 23, 2012","Research Site, Agrigento, AG, Italy|Research Site, Sciacca, AG, Italy|Research Site, Ancona, AN, Italy|Research Site, Corato, BA, Italy|Research Site, Putignano, BA, Italy|Research Site, Triggiano, BA, Italy|Research Site, Fasano, BR, Italy|Research Site, Bolzano, BZ, Italy|Research Site, Cagliari, CA, Italy|Research Site, Ortona, CH, Italy|Research Site, Cantu, CO, Italy|Research Site, Rogliano, CS, Italy|Research Site, Adrano-Bronte, CT, Italy|Research Site, Lamezia, CZ, Italy|Research Site, Foggia, FG, Italy|Research Site, Firenze- ASL di Firenze, FI, Italy|Research Site, Genova, GE, Italy|Research Site, Latina, LT, Italy|Research Site, Messina, ME, Italy|Research Site, Rho, MI, Italy|Research Site, Corleone, PA, Italy|Research Site, Palermo, PA, Italy|Research Site, Guidonia, RM, Italy|Research Site, Roma, RM, Italy|Research Site, Capaccio, SA, Italy|Research Site, Savona, SA, Italy|Research Site, Montecchio Maggiore, VI, Italy|Research Site, Castellammare di Stabia, Italy|Research Site, Novara, Italy",,"https://ClinicalTrials.gov/show/NCT01344733"
353,"NCT00095745","A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Antidepressant + Aripiprazole","Safety assessments","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","18 Years and older   (Adult, Older Adult)","Phase 3","1002","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN138-164","September 2004","November 2007","November 2007","November 9, 2004",,"November 8, 2013","Local Institution, Mesa, Arizona, United States|Local Institution, Peoria, Arizona, United States|Local Institution, Beverly Hills, California, United States|Local Institution, Burbank, California, United States|Local Institution, Encino, California, United States|Local Institution, Garden Grove, California, United States|Local Institution, National City, California, United States|Local Institution, Orange, California, United States|Local Institution, Pasadena, California, United States|Local Institution, Riverside, California, United States|Local Institution, San Diego, California, United States|Local Institution, Denver, Colorado, United States|Local Institution, Farmington, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Gainesville, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Orlando, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Smyrna, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Edwardsville, Illinois, United States|Local Institution, Oakbrook Terrace, Illinois, United States|Local Institution, Terre Haute, Indiana, United States|Local Institution, Overland Park, Kansas, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Rockville, Maryland, United States|Local Institution, Springfield, Massachusetts, United States|Local Institution, Farmington Hills, Michigan, United States|Local Institution, Okemos, Michigan, United States|Local Institution, Albuquerque, New Mexico, United States|Local Institution, Brooklyn, New York, United States|Local Institution, New York, New York, United States|Local Institution, Staten Island, New York, United States|Local Institution, Chapel Hill, North Carolina, United States|Local Institution, Raleigh, North Carolina, United States|Local Institution, Cincinnati, Ohio, United States|Local Institution, Toledo, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, East Providence, Rhode Island, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Memphis, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Woodstock, Vermont, United States|Local Institution, Arlington, Virginia, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Herndon, Virginia, United States|Local Institution, Richmond, Virginia, United States|Local Institution, Bellevue, Washington, United States|Local Institution, Seattle, Washington, United States|Local Institution, Morgantown, West Virginia, United States|Local Institution, Brown Deer, Wisconsin, United States|Local Institution, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00095745"
354,"NCT01421134","Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose","RESOLVE 1","Completed","Has Results","Major Depressive Disorder With Mixed Features","Drug: Lurasidone|Drug: Placebo","Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores|Mean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score|Mean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score|Mean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score|Mean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score|Percentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF).|Percentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF)","Sunovion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1050304","September 2011","October 2014","October 2014","August 22, 2011","October 9, 2015","July 15, 2016","Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham, Alabama, United States|Synergy Clinical Research Center, Escondido, California, United States|Collaborative Neuroscience Network Inc., Garden Grove, California, United States|Stanford -VA Palo Alto Health Care System, Palo Alto, California, United States|Clinical Innovations Inc., Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Florida Clinical Research Center, LLC, Sarasota, Florida, United States|Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders, Boston, Massachusetts, United States|St. Charles Psychiatric Associates/Midwest Research Group, St. Charles, Missouri, United States|Social Psychiatric Research Inst. (SPRI) Clinical Trials, Brooklyn, New York, United States|Village Clinical Research Inc., New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Psychiatry and Behavioral Sciences, Duke, Durham, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|CRI Worldwide - Kirkbride, Philadelphia, Pennsylvania, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Dept. of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Municipal Healthcare Institution""City Clinical Hospital #2, n.a. V.I. Razumovsky"" of Healthcare Committee of Administration of Municipal Entity ""City of Saratov"", Saratov, Russian Federation|State Healthcare Institution, Saratov Regional Psychiatric Hospital of St.Sophia,, Saratov, Russian Federation|Saint Nicholas Psychiatric Hospital., St. Petersburg, Russian Federation|City Psychiatry Hospital 4 (Saint Petersburg Psychiatric Admitting Unit), St. Petersburg, Russian Federation|Federal State Institution ""Saint-Petersburg Research psychoneurogical Institute named after V.M. Bekhtereva"", St. Petersburg, Russian Federation|Limited Liability Company ""Research-And-Educational Centre of Psychotherapy ""Podderzhka"", Stavropol, Russian Federation|Institute of Mental Health, Belgrade, Serbia|Psychiatric Clinic, Clinical Hospital Center""Dr. Dragisa Misovic-Dedinje"", Belgrade, Serbia|Health Centre Cacak Department of Psychiatry, Cacak, Serbia|Clinical Center Nis, Psychiatric Clinic, Gornja Toponica, Serbia|Clinical Center Kragujevac, Psychiatric Clinic, Kragujevac, Serbia|Clinic for Mental Health, Clinical Center Nis, Nis, Serbia|Special Hospital for Psychiatric Diseases ""Sveti Vracevi"", Vojvodina, Serbia|Special Hospital for Psychiatric Diseases ""Dr Slavoljub Bakalovic"", Vrsac, Serbia|General Hospital ""Djordje Joanovic"" Psychiatric Dept., Zrenjanin, Serbia|Dnipropetrovsk Regional Clinical Hospital named Mechnikov, Dnipropetrovsk, Ukraine|State Institution ""Institute of Neurology, Psychiatry and Narcology NAMS of Ukraine"", Dep. of Clinical, Social and Child Psychiatry, Kharkiv, Ukraine|Communal Institution of Kyiv Regional Council ""Regional Psychiatric and Narcological Medical Association ""Psychiatric Dept. #10 and Psychiatric Dept. #2, Kyiv, Ukraine|""Lugansk State Medical University""Chair of Psychiatry, Narcology and Medical Psychology; Lugansk Regional Clinical Psychoneurological Hospital, Dispensary Dept. for adults, Lugansk, Ukraine|Municipal Institution ""Lviv Regional State Clinical Psychiatric Hospital, Department #20, Lviv, Ukraine|Odesa Regional Psychoneurological Dispensary, Outpatient Dept., Odesa, Ukraine|Vinnytsya National Medical University n.a. M.I. Pyrogov, Dept. of Psychiatry and Narcology, Vinnytsya Regional Psychoneurological Hospital n.a. O.I. Yushchenko, Dept. no. 14, Dept. no 15, Vinnytsya, Ukraine|MAC Clinical Research Limited, Cannock, United Kingdom|MAC Clinical Research Limited, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01421134"
355,"NCT00095823","A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Antidepressant + Placebo|Drug: Antidepressant + Aripiprazole","Change in a depression rating scale at endpoint|Change in a disability scale and Clinical Global Impression scale at endpoint","Bristol-Myers Squibb|Otsuka America Pharmaceutical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-139","June 2004","August 2006","August 2006","November 9, 2004",,"November 25, 2013","Local Institution, Garden Grove, California, United States|Local Institution, Northridge, California, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Edwardsville, Illinois, United States|Local Institution, Rockville, Maryland, United States|Local Institution, Springfield, Massachusetts, United States|Local Institution, Farmington Hills, Michigan, United States|Local Institution, Okemos, Michigan, United States|Local Institution, Staten Island, New York, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Austin, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Woodstock, Vermont, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Bellevue, Washington, United States|Local Institution, Seattle, Washington, United States|Local Institution, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00095823"
356,"NCT04507243","Transcranial Direct Current Stimulation (tDCS) Therapy in Major Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Active - HD tDCS|Device: Sham - HD tDCS","Measured joint longitudinal change in rCBF and mood scores over the tDCS trial|Measured joint longitudinal change in regional brain activation and mood scores over the tDCS trial|Measured magnetic fields and rCBF at baseline and change in mood scores over the tDCS trial","University of California, Los Angeles|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","20-001544|R33MH110526","December 1, 2020","April 1, 2023","April 1, 2023","August 11, 2020",,"May 4, 2021","University of California, Los Angeles (UCLA), Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04507243"
357,"NCT04000009","Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment",,"Terminated","No Results Available","Adjunctive Treatment of Major Depressive Disorder","Drug: Pimavanserin","Treatment-emergent adverse events (TEAEs)","ACADIA Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","236","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACP-103-055|2018-003252-20","June 3, 2019","February 22, 2021","February 22, 2021","June 27, 2019",,"March 26, 2021","CNS Network, Garden Grove, California, United States|Behavioral Research Specialists, Glendale, California, United States|Irvine Clinical Research, Irvine, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|NRC Research Institute, Orange, California, United States|MCB Clinical Research centers, LLC, Colorado Springs, Colorado, United States|Clinical Neuroscience Solutions ( CNS Healthcare)-Jacksonville, Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|CNS Health Care (Orlando), Orlando, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Synexus Clinical Research, Atlanta, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Collective Medical Research, LLC, Prairie Village, Kansas, United States|Adams Clinical, Watertown, Massachusetts, United States|Integrative Clinical Trials, Brooklyn, New York, United States|Social Psychiatry Research Institute (SPRI), Brooklyn, New York, United States|Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Future Search Trials of Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Grayline Research Center, Wichita Falls, Texas, United States|IPC Research, Waukesha, Wisconsin, United States|ARTES Psykiatrinen Palvelukeskus Oy (Mederon Ltd.), Helsinki, Finland|Savon Psykiatripalvelu Oy, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Satakunnan Psykiatripalvelu Oy at Mehiläinen Pori, Pori, Finland|Psykiatri- ja psykologikeskus Mentoria, Tampere, Finland|Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski, Belchatow, Poland|Przychodnia Śródmieście Sp. Z o.o., Bydgoszcz, Poland|Indywidualna Specijalistyczna Praktyka Lekarska Wiesław Jerzy Cubała, Gdańsk, Poland|Nzop Mentis, Leszno, Poland|Zachodniopomorski Instytut Psychoterapii, Szczecin, Poland|Mental Health Research Center, Department #6, Moscow, Russian Federation|St. Nicholas the Wonder Worker Psychiatric Hospital, Saint Petersburg, Russian Federation|City Narcology Hospital, Saint Petersburg, Russian Federation|Samara Psychiatric Hospital, Samara, Russian Federation|Saratov City Clinical Hospital #2 n.a. V.I. Razumovsky, Saratov, Russian Federation|Regional Clinical Psychiatric Hospital of St. Sofia, Saratov, Russian Federation|Psychoneurological Dispensary # 5, St. Petersburg, Russian Federation|LION-MED, Voronezh, Russian Federation|Clinical Center of Serbia, Clinic for psychiatry, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic, Belgrade, Serbia|Clinical Centre Nis, Clinic for Psychiatry, Gornja Toponica, Serbia|Special hospital for psychiatric diseases ""Kovin, Kovin, Serbia|Clinical Center Kragujevac , Clinic for Psychiatry, Kragujevac, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Centre for Mental Health Protecton, Clinical Center Nis, Nis, Serbia|EPAMED s r.o., Kosice, Slovakia|Liptovska nemocnice s poliklinikou MUDr. Ivana Stodolu, Psychiatricke oddelenie, Liptovsky Mikulas, Slovakia|Centrum Zdravia R.B.K., s.r.o., Svidnik, Slovakia|Flexivest Fourteen Research Centre, Unit 1, Durbanville Health Center, Durbanville,, South Africa|Regional Centre of Psychosomatic Disorders based on Psychoneurology Department, Communal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnykov, Dnipro, Ukraine|Institute of neurology, Psychiatry and Narcology of NAMS of Ukraine, MC ""Neuron"", Kharkiv, Ukraine|Kyiv Railway Clinical Hospital № 1 of Branch ""Health Center"" of the Public joint stock company ""Ukrainian Railway"", Kyiv, Ukraine|Kherson Regional Psychiatric Hospital Department # 3 and # 10 Kherson region,, Stepanivka, Ukraine|Ternopil Regional Communal Clinical Psychoneurological Hospital, psychiatric department # 2 (men), psychiatric department # 6 (women), Ternopil State Medical University n.a. I.Y. Gorbachevskyy, Chair of Psychiatry, Narcology and Medical Psychology, Ternopil, Ukraine|Municipal Institution ""Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko"", Male Department #14, Female Department #15, Vinnytsya National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeutic, Vinnytsya, Ukraine|MAC Clinical Research- Blackpool, Blackpool, United Kingdom|MAC Clinical Research Ltd.-Liverpool, Liverpool, United Kingdom|MAC Clinical Research- Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04000009"
358,"NCT00072774","Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-306",,"November 2004","November 2004","November 13, 2003",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00072774"
359,"NCT00095134","Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy",,"Completed","No Results Available","Major Depressive Disorder","Drug: risperidone","Difference in therapeutic effect of risperidone and placebo as measured by change in depression rating scale (HAM-D) at end of week 4 of the double-blind phase.|Safety will be assessed through reported adverse events and vital signs (weight, blood pressure, pulse, and temperature).","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","630","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR004726","October 2004",,"November 2005","November 1, 2004",,"December 6, 2011","Innovative Clinical Trials, LLC, Birmingham, Alabama, United States|Greystone Medical Research, Birmingham, Alabama, United States|Scottsdale Family Health, Scottsdale, Arizona, United States|Sun Valley Medical, Sun City, Arizona, United States|Southwest Biomedical Research Foundation, Tucson, Arizona, United States|Southwestern Research Institute, Burbank, California, United States|Chrishard Clinical Research, Inglewood, California, United States|Optimum Health Services, La Mesa, California, United States|Pacific Insititute for Medical Research, Los Angeles, California, United States|Optimum Health Services, Oceanside, California, United States|Behavioral Health 2000, LLC, Riverside, California, United States|nTouch Research, San Diego, California, United States|Psychiatric Medicine Center, New London, Connecticut, United States|Glasgow Family Practice, Newark, Delaware, United States|Leonard Bass, MD, PA, Ft. Lauderdale, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Roger Miller, MD, Jacksonville, Florida, United States|BioQuan Research Group, Inc., North Miami, Florida, United States|Family Practice - St. Cloud, St. Cloud, Florida, United States|Allan B. Aven, MD, Arlington Heights, Illinois, United States|nTouch Research - Chicago, Naperville, Illinois, United States|nTouch Research - Peoria, Peoria, Illinois, United States|Balanced Health Research Center, Peoria, Illinois, United States|American Health Network, Avon, Indiana, United States|Research Solutions - Evansville, Evansville, Indiana, United States|Amy Kaissar, MD, Indianapolis, Indiana, United States|Clinco, Terre Haute, Indiana, United States|Hartford Research Group, Florence, Kentucky, United States|New Orleans Medical Institute, Metairie, Louisiana, United States|Brentwood Research Institute, Shreveport, Louisiana, United States|Professional Clinical Research at Great Lakes Family Care, Cadillac, Michigan, United States|Sam Hawatmeh, MD, PC, St. Louis, Missouri, United States|Alliance Medical Center, PC, Alliance, Nebraska, United States|Clinical Trial Associates, Glendora, New Jersey, United States|Partners in Primary Care, Turnersville, New Jersey, United States|ABQ Med., P.C., Albuquerque, New Mexico, United States|Eastside Comprehensive Medical Services, LLC, New York, New York, United States|Raleigh Medical Group, Raleigh, North Carolina, United States|Salem Research Group, Winston Salem, North Carolina, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Community Research Management Associates, Inc., Cincinnati, Ohio, United States|Hightop Medical Research Center, Cincinnati, Ohio, United States|CFP Research, Inc., Cincinnati, Ohio, United States|Martin Schear, MD, Dayton, Ohio, United States|Family Practice Center of Wadsworth, Wadsworth, Ohio, United States|Sooner Clinical Research, Edmond, Oklahoma, United States|Med-line Research, Moore, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Advanced Clinical Trials, Eugene, Oregon, United States|Clinical Research Consultants/Providence Medical, Medford, Oregon, United States|Medford Medical Clinic, LLP, Medford, Oregon, United States|Gateway Medical, Downingtown, Pennsylvania, United States|Feasterville Family Health Care, Feasterville, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice, Lansdale, Pennsylvania, United States|Woodburne Family Practice, Levittown, Pennsylvania, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Joseph Rybicki, MD, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|Consolidated Clinical Trials, Inc., Pittsburgh, Pennsylvania, United States|Charles Buttz, MD, Pottstown, Pennsylvania, United States|Research Across America, Reading, Pennsylvania, United States|The Family Practice, Greer, South Carolina, United States|Harmony Clinical Research, Johnson City, Tennessee, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|South Texas Applied Research, Corpus Christi, Texas, United States|International Clinical Research Associates, LLC, Richmond, Virginia, United States|International Clinical Research Associates, Virgina Beach, Virginia, United States|Richard Neiman, MD, Kirkland, Washington, United States|Daniel Blizzard, MD, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00095134"
360,"NCT01554176","Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)",,"Terminated","Has Results","Major Depressive Disorder, Recurrent","Drug: Filorexant|Drug: Placebo","Change From Baseline to Week 6 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Number of Participants With an Adverse Event (AE) During Treatment Phase|Number of Participants Who Discontinued Study Drug Due to an AE During Treatment Phase|Number of Participants With an AE During Run-out Phase|Number of Participants Who Discontinued Study Drug Due to an AE During Run-out Phase|Change From Baseline to Week 6 in MADRS Total Score Excluding the Sleep Item|Change From Baseline to Week 6 in the Hamilton Depression Rating Scale, 17-item Version (HAM-D17) Bech Subscale Score|Percentage of Participants With HAM-D17 Remission (HAM-D17 Total Score ≤7) at Week 6","Merck Sharp & Dohme Corp.","All","21 Years to 64 Years   (Adult)","Phase 2","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6096-022|2011-005200-15","May 18, 2012","September 3, 2013","September 3, 2013","March 14, 2012","November 6, 2016","November 7, 2018",,,"https://ClinicalTrials.gov/show/NCT01554176"
361,"NCT00090649","Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-309",,"March 2005","March 2005","September 1, 2004",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00090649"
362,"NCT00326105","Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders","PEARL","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine fumarate","To evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in MDD patients with inadequate response to an antidepressant treatment as assessed by the change from randomization to week 6 in the MADRS|To evaluate if quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone|To evaluate if quetiapine SR in combination with an antidepressant reduces anxiety symptoms in patients with MDD, compared to an antidepressant alone","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00006|PEARL","April 2006",,"July 2007","May 16, 2006",,"March 25, 2009","Research Site, Phoenix, Arizona, United States|Research Site, El Centro, California, United States|Research Site, Irvine, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, Pueblo, Colorado, United States|Research Site, Coral Springs, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Naperville, Illinois, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lafayette, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research SIte, Glen Burnie, Maryland, United States|Research Site, Braintree, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, St Charles, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Clementon, New Jersey, United States|Research Site, Cedarhurst, New York, United States|Research Site, New York, New York, United States|Research Site, Olean, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Beechwood, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Friendswood, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research SIte, Wichita Falls, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Arlington, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00326105"
363,"NCT00087737","Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR|Drug: Venlafaxine ER",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-317",,"May 2005","May 2005","July 16, 2004",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00087737"
364,"NCT00839176","Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: RX-10100","Change from baseline at 8 weeks on the Montgomery-Asberg Depression Rating Scale (MADRS)|Changes from baseline on the HAM-D|Changes from baseline on the QIDS-SR|CGI-I scale at the end of treatment,|Side effects during and immediately following the treatment period","Rexahn Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RX-10100-P2A-002","January 2009","September 2009","October 2009","February 9, 2009",,"November 19, 2013","Denver, Colorado, United States|Atlanta, Georgia, United States|Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00839176"
365,"NCT00042029","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)",,"Completed","No Results Available","Major Depressive Disorder","Drug: MK0869, aprepitant|Drug: Comparator: placebo","HAMD-17 total score; Tolerability|CGI-I Scale score; Sheehan Disability Scale","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","324","Industry","Interventional","Primary Purpose: Treatment","0869-073|Formally-8DL718|MK0869-073|2006_409","June 18, 2002","October 3, 2003","October 3, 2003","July 23, 2002",,"May 5, 2017",,,"https://ClinicalTrials.gov/show/NCT00042029"
366,"NCT00075257","Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","603","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-302",,"August 2005","August 2005","January 9, 2004",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00075257"
367,"NCT00073762","Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: DVS-233 SR",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-308?",,"September 2004","September 2004","December 8, 2003",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00073762"
368,"NCT00073203","A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: R228060|Drug: Placebo and Paroxetine",,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","488","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR004339",,,"May 2004","November 19, 2003",,"August 28, 2009","JJ PRD Research Center, Titusville, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00073203"
369,"NCT03556124","Transcranial Direct Current Stimulation in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Active - HD tDCS|Device: Sham - HD tDCS|Device: Active - Conventional tDCS|Device: Sham - Conventional tDCS","Changes in non-invasive MRI measures of cerebral blood flow between baseline and end of treatment|Change in non-invasive MRI measures of current flow","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Not Applicable","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","17-000779|R61MH110526","February 2, 2018","May 31, 2020","May 31, 2020","June 14, 2018",,"July 31, 2020","University of California, Los Angeles (UCLA), Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03556124"
370,"NCT00669110","Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)","Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs)|Number of Participants for Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories","Wyeth is now a wholly owned subsidiary of Pfizer","All","7 Years to 18 Years   (Child, Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A6-2001|B2061013","May 2008","May 2010","May 2010","April 29, 2008","May 16, 2011","May 16, 2011","Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, North Miami, Florida, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00669110"
371,"NCT00048607","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)",,"Completed","No Results Available","Major Depressive Disorder","Drug: aprepitant|Drug: Comparator: paroxetine HCL|Drug: Comparator: Placebo (Unspecified)","HAMD-17 total score at week 8. Tolerability.|CGI-I Scale score at week 8 and Sheehan Disability Scale at week 8","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-062|Formally-65MBS4W|MK0869-062|2006_408","July 30, 2002","December 31, 2003","December 31, 2003","November 5, 2002",,"May 5, 2017",,,"https://ClinicalTrials.gov/show/NCT00048607"
372,"NCT00034944","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)",,"Completed","No Results Available","Major Depressive Disorder","Drug: MK0869, aprepitant|Drug: Comparator: placebo","HAMD-17 total score at week 8. Tolerability.|CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","495","Industry","Interventional","Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-063|2006_403","January 24, 2002","December 17, 2003","December 17, 2003","May 3, 2002",,"May 5, 2017",,,"https://ClinicalTrials.gov/show/NCT00034944"
373,"NCT00621270","Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety",,"Completed","No Results Available","Major Depressive Disorder|Anxiety","Drug: BCI-540","Co-primary outcome measures will be the change from Baseline to Week 6 on the total score of the Inventory of Depressive Symptomatology-Clinician Version (IDS-C30) and the Hamilton Rating Scale for Anxiety (HAM-A).|The safety, tolerability and side effect profile of BCI-540 will also be measured by adverse events, clinical laboratory values, electrocardiograms, vital signs, and the Physician Withdrawal Checklist (PWC).","BrainCells Inc.","All","21 Years to 60 Years   (Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCI-540-CL-001","January 2008","October 2009","October 2009","February 22, 2008",,"October 24, 2011","Grey Nuns Hospital, Clinical Research, Edmonton, Alberta, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Dr. Alexander McIntyre, Inc, Penticton, British Columbia, Canada|University of British Columbia Mood Disorders Centre, Vancouver, British Columbia, Canada|Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc., Vancouver, British Columbia, Canada|Eden Mental Health Centre, Winkler, Manitoba, Canada|Sanjay Siddhartha, MD, Miramichi, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Autar K. Munshi, MD, Sydney, Nova Scotia, Canada|Robert Fairbairn, MD, Chatham, Ontario, Canada|Providence Care Mental Health Services, Kingston, Ontario, Canada|Robert G. Luton, MD, London, Ontario, Canada|Anxiety and Mood Disorder Center, Mississauga, Ontario, Canada|Ottawa Psychopharmacology Clinic, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Dept. of Psychiatry, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00621270"
374,"NCT00035295","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)",,"Completed","No Results Available","Major Depressive Disorder","Drug: MK0869, aprepitant|Drug: Comparator: placebo","HAMD-17 total score at week 8. Tolerability.|CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","584","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-061|2006_404","November 8, 2001","December 5, 2003","December 5, 2003","May 3, 2002",,"April 18, 2017",,,"https://ClinicalTrials.gov/show/NCT00035295"
375,"NCT00035282","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)",,"Completed","No Results Available","Major Depressive Disorder","Drug: aprepitant|Drug: Comparator: placebo (unspecified)","HAMD-17 total score at week 8. Tolerability.|CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-060|Formally-103|2006_401","September 2001","December 2003","December 2003","May 3, 2002",,"February 9, 2015",,,"https://ClinicalTrials.gov/show/NCT00035282"
376,"NCT00034983","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)",,"Completed","No Results Available","Major Depressive Disorder","Drug: aprepitant|Drug: Comparator: paroxetine HCL","Long-term safety and tolerability.|Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-066|Formally-497B|MK0869-066|2006_407","October 29, 2001","December 29, 2003","December 29, 2003","May 3, 2002",,"April 26, 2017",,,"https://ClinicalTrials.gov/show/NCT00034983"
377,"NCT03999918","Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment",,"Completed","No Results Available","Adjunctive Treatment of Major Depressive Disorder","Drug: Pimavanserin|Drug: Placebo","Change from Baseline in the Hamilton Depression Scale (17 items) (HAMD-17) total score|Change from Baseline in Sheehan Disability Scale (SDS) score|Change from Baseline in Clinical Global Impression-Severity (CGI-S) score for depressive symptoms|Clinical Global Impression-Improvement (CGI-I) score for depressive symptoms|Change from Baseline in the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14)|Change from Baseline in Karolinska Sleepiness Scale (KSS) score|• Treatment responder rates. Treatment response is defined as a reduction from Baseline in HAMD-17 total score of 50% or more.|• Treatment remission rates. Treatment remission is defined as a HAMD-17 total score ≤7.|Change from Baseline in the Hamilton Depression (HAMD) Anxiety/Somatization factor score|Change from Baseline in the Barratt Impulsiveness Scale (BIS-11)|Change from Baseline to Week 1 in the HAMD-17 total score","ACADIA Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-054|2018-003251-37","July 8, 2019","April 27, 2020","May 29, 2020","June 27, 2019",,"June 26, 2020","ARTES Psykiatrinen Palvelukeskus Oy (Mederon Ltd.), Helsinki, Finland|Savon Psykiatripalvelu Oy, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Satakunnan Psykiatripalvelu Oy at Mehiläinen Pori, Pori, Finland|Psykiatri- ja psykologikeskus Mentoria, Tampere, Finland|Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski, Bełchatów, Poland|Przychodnia Śródmieście Sp. z o.o., Bydgoszcz, Poland|Indywidualna Specijalistyczna Praktyka Lekarska Wiesław Jerzy Cubała, Gdańsk, Poland|Nzop Mentis, Leszno, Poland|Zachodniopomorski Instytut Psychoterapii, Szczecin, Poland|Mental Health Research Center, Department #6, Moscow, Russian Federation|St. Nicholas the Wonder Worker Psychiatric Hospital, Saint Petersburg, Russian Federation|Samara Psychiatric Hospital, Samara, Russian Federation|Saratov City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|Regional Clinical Psychiatric Hospital of St. Sofia, Saratov, Russian Federation|St. Nicholas the Wonder Worker Psychiatric Hospital, St. Petersburg, Russian Federation|Psychoneurological Dispensary # 5, St. Petersburg, Russian Federation|City Narcology Hospital, St. Petersburg, Russian Federation|LION-MED, Voronezh, Russian Federation|Clinical Center of Serbia, Clinic for psychiatry, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic, Belgrade, Serbia|Special hospital for psychiatric diseases ""Kovin"", Kovin, Serbia|Clinical Center Kragujevac , Clinic for Psychiatry, Kragujevac, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Centre for Mental Health Protecton, Clinical Center Nis, Nis, Serbia|Clinical Centre Nis, Clinic for Psychiatry Gornja, Toponica, Serbia|EPAMED s r.o., Kosice, Slovakia|Liptovska nemocnice s poliklinikou MUDr. Ivana Stodolu, Psychiatricke oddelenie, Liptovský Mikuláš, Slovakia|Centrum Zdravia R.B.K., s.r.o., Svidník, Slovakia|Cape Trial Centre, Cape Town, South Africa|Dr DG Dennis Incorporated Knighton Surgery, Cape Town, South Africa|Flexivest Fourteen Research Centre, Unit 1, Durbanville Health Center, Durbanville, South Africa|Dr GP Bosch Clinical Research, Pretoria, South Africa|Regional Centre of Psychosomatic Disorders based on Psychoneurology Department, Communal Institution ""Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnykov, Dnipro, Ukraine|Institute of neurology, Psychiatry and Narcology of NAMS of Ukraine, MC ""Neuron"", Kharkiv, Ukraine|Kyiv Railway Clinical Hospital № 1 of Branch ""Health Center"" of the Public joint stock company ""Ukrainian Railway"", Kyiv, Ukraine|Odesa Regional Medical Centre of Mental Health, Odesa, Ukraine|Kherson Regional Psychiatric Hospital Department # 3 and # 10 Kherson region,, Stepanivka, Ukraine|Ternopil Regional Communal Clinical Psychoneurological Hospital, psychiatric department # 2 (men), psychiatric department # 6 (women), Ternopil State Medical University n.a. I.Y. Gorbachevskyy, Chair of Psychiatry, Narcology and Medical Psychology, Ternopil, Ukraine|Communal Institution ""Vinnytsia Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko"", Department #7 (male), Department #10 (female),Vinnytsia National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeuti, Vinnytsya, Ukraine|Municipal Institution ""Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko"", Male Department #14, Female Department #15, Vinnytsya National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeutic, Vinnytsya, Ukraine|MAC Clinical Research - Blackpool, Blackpool, United Kingdom|MAC Clinical Research Ltd - Liverpool, Liverpool, United Kingdom|MAC Clinical Research - Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03999918"
378,"NCT00035009","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)",,"Completed","No Results Available","Major Depressive Disorder","Drug: MK0869, aprepitant|Drug: Comparator: paroxetine HCL","Change from baseline in HAMD-17 total score at week 8. Mk-0869 will be generally well tolerated|Actual CGI-I score at week 8, improving social disability by change from baseline in Sheehan Disability Score at Week 8, change from baseline in the HAMA score at week 8, change from baseline in depressed mood of the HAMD-17 at week 8","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","468","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-059|Formally-1A407|MK0869-059|2006_402","September 20, 2001","December 22, 2003","March 24, 2004","May 3, 2002",,"April 18, 2017",,,"https://ClinicalTrials.gov/show/NCT00035009"
379,"NCT03968159","Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)",,"Completed","No Results Available","Adjunctive Treatment of Major Depressive Disorder","Drug: Pimavanserin|Drug: Placebo","Change from Baseline in the Hamilton Depression Scale (17 items) (HAMD-17) total score|Change from Baseline in Sheehan Disability Scale (SDS) score|Change from Baseline in Clinical Global Impression-Severity (CGI-S) score for depressive symptoms|Clinical Global Impression-Improvement (CGI-I) score for depressive symptoms|Change from Baseline in the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14)|Change from Baseline in Karolinska Sleepiness Scale (KSS) score|Treatment responder rates. Treatment response is defined as a reduction from Baseline in HAMD-17 total score of 50% or more|Treatment remission rates. Treatment remission is defined as a HAMD-17 total score ≤7|Change from Baseline in the Hamilton Depression (HAMD) Anxiety/Somatization factor score|Change from Baseline in the Barratt Impulsiveness Scale (BIS-11)|Change from Baseline to Week 1 in the HAMD-17 total score","ACADIA Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-059","April 25, 2019","April 30, 2020","May 21, 2020","May 30, 2019",,"June 26, 2020","University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States|CNS Network, Garden Grove, California, United States|Behavioral Research Specialists, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Clinical Research, Irvine, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|NRC Research Institute, Orange, California, United States|MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States|Mountain View Clinical Research, Inc., Denver, Colorado, United States|CT Clinical Research, Cromwell, Connecticut, United States|Clinical Neuroscience Solutions ( CNS Healthcare)-Jacksonville, Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|CNS Health Care (Orlando), Orlando, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Synexus Clinical Research, Atlanta, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Collective Medical Research, LLC, Prairie Village, Kansas, United States|Clinical Trials of America (Monroe, LA), Monroe, Louisiana, United States|Adams Clinical, Watertown, Massachusetts, United States|St. Charles Psychiatric Associates-Midwest Research Group, Saint Charles, Missouri, United States|Integrative Clinical Trials, Brooklyn, New York, United States|Social Psychiatry Research Institute (SPRI), Brooklyn, New York, United States|Mount Sinai Hospital, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lake Clinical Research, Rochester, New York, United States|Clinical Trial of America, LLC, Hickory, North Carolina, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Future Search Trials of Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Grayline Research Center, Wichita Falls, Texas, United States|IPC Research, Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03968159"
380,"NCT00048594","Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)",,"Completed","No Results Available","Major Depressive Disorder","Drug: aprepitant|Drug: Comparator: placebo (unspecified)","Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months|CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; an HAMA total score change from week 10 at Month 6.","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-065|Formally-35MRB2|MK0869-065|2006_405","January 3, 2002","December 18, 2003","December 22, 2003","November 5, 2002",,"May 5, 2017",,,"https://ClinicalTrials.gov/show/NCT00048594"
381,"NCT01912196","Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: MSI-195|Drug: Placebo","Change in the total Hamilton Depression Rating Scale (HAM-D17) between randomization and end of study.|change in the total score of the Montgomery-Asberg Depression Rating Scale (MADRS)|change in total score of the Clinical Global Impression Improvement Scale (CGI-S)|change from randomization to each study visit in the total score of the Inventory of Depressive Symptomatology-Self Rated (IDS-SR30)|Adverse events|Columbia Suicide Severity Rating Scale (C-SSRS)","MSI Methylation Sciences, Inc.","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MSI-CP.002","October 2013","September 2015","September 2015","July 31, 2013",,"March 18, 2016","MSI Investigational Site, Birmingham, Alabama, United States|MSI Investigational Site, Encino, California, United States|MSI Investigational Site, Escondido, California, United States|MSI Investigational Site, Garden Grove, California, United States|MSI Investigational Site, Los Alamitos, California, United States|MSI Investigational Site, Los Angeles, California, United States|MSI Investigational Site, National City, California, United States|MSI Investigational Site, Newport Beach, California, United States|MSI Investigational Site, Oakland, California, United States|MSI Investigational Site, Oceanside, California, United States|MSI Investigational Site, Torrance, California, United States|MSI Investigational Site, Jacksonville, Florida, United States|MSI INvestigational Site, Kissimmee, Florida, United States|MSI Investigational Site, Lauderhill, Florida, United States|MSI Investigational Site, Orlando, Florida, United States|MSI Investigational Site, Atlanta, Georgia, United States|MSI Investigational Site, Hoffman Estates, Illinois, United States|MSI Investigational Site, Towson, Maryland, United States|MSI Investigational Site, Flowood, Mississippi, United States|MSI Investigational Site, Las Vegas, Nevada, United States|MSI Investigational Site, Marlton, New Jersey, United States|MSI Investigational Site, Albuquerque, New Mexico, United States|MSI Investigational Site, New York, New York, United States|MSI Investigational Site, Rochester, New York, United States|MSI Investigational Site, Canton, Ohio, United States|MSI Investigational Site, Dayton, Ohio, United States|MSI Investigational Site, Portland, Oregon, United States|MSI Investigational Site, Memphis, Tennessee, United States|MSI Investigational Site, Austin, Texas, United States|MSI Investigational Site, Austin, Texas, United States|MSI Investigational Site, Dallas, Texas, United States|MSI Investigational Site, Houston, Texas, United States|MSI Investigational Site, Houston, Texas, United States|MSI Investigational Site, Murray, Utah, United States|MSI Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01912196"
382,"NCT00035048","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)",,"Completed","No Results Available","Major Depressive Disorder","Drug: aprepitant|Drug: Comparator: placebo (unspecified)","HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability|CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; MADRS total score change at Month 6, HAMA total score change at Month 6","Merck Sharp & Dohme Corp.","All","65 Years and older   (Older Adult)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0869-068|Formally-3N25|MK0869-068|2006_406","November 21, 2001","December 29, 2003","December 31, 2003","May 3, 2002",,"May 5, 2017",,,"https://ClinicalTrials.gov/show/NCT00035048"
383,"NCT02078258","Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents",,"Completed","No Results Available","Major Depressive Disorder, Single Episode, Unspecified","Behavioral: ABMT","Changes in depressive symptom number|Changes in depressive severity|Change of Self-report symptoms|Diagnostic status of major depressive disorder","Hunan Normal University","All","11 Years to 19 Years   (Child, Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1","September 2012","January 2014","July 2015","March 5, 2014",,"March 28, 2019","Department of Psychology, Hunan Normal University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT02078258"
384,"NCT02433093","A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Major Depressive Disorder, Healthy Volunteer","Drug: Basimglurant|Drug: Placebo","Safety: Incidence of adverse events (AEs)|Safety: Suicidality as assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)|Safety: Sleep habits as assessed using a participant-recorded sleep diary|Pharmacokinetics: Maximum plasma concentration (Cmax)|Pharmacokinetics: Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24)|Pharmacokinetics: Area under the plasma concentration-time curve over the dosing interval (AUC0-tau)|Pharmacokinetics: Time to maximum plasma concentration (Tmax)|Pharmacokinetics: Trough plasma concentration (Ctrough)|Pharmacokinetics: Apparent terminal elimination half-life (t1/2)|Safety: QT interval corrected using the Fridericia method (QTcF)","Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","NP29583","April 2015","September 2015","September 2015","May 4, 2015",,"November 2, 2016","Garden Grove, California, United States",,"https://ClinicalTrials.gov/show/NCT02433093"
385,"NCT03018340","Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)",,"Completed","Has Results","Adjunctive Treatment of Major Depressive Disorder","Drug: Pimavanserin|Other: Placebo","Change From Baseline to Week 5 in the HAMD-17 Total Score|Change From Baseline to Week 5 in the SDS Total Score|Treatment Response and Remission Rates at the End of 5-week Treatment Period|Change From Baseline to Week 5 in CGI-S Total Score|CGI-I Score at Week 5|Change From Baseline to Week 5 in SF-12 Score|Change From Baseline to Week 5 in DAI-10 Score|Change From Baseline to Week 5 in KSS Score|Change From Baseline to Week 5 in MGH-SFI Score|Change From Baseline to Week 5 in BIS-11 Score|Change From Baseline to Week 5 in SIS Score","ACADIA Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACP-103-042","December 2016","September 2018","October 2018","January 12, 2017","November 14, 2019","November 14, 2019","UAB, Birmingham, Alabama, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Synergy San Diego, National City, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Collaborative Neuroscience Network, LLC, Torrance, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Meridien Research, Bradenton, Florida, United States|CNS Health care (Jacksonville), Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|CNS Health care (Orlando), Orlando, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Alam Medical Research, INC, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|KUMC, Wichita, Kansas, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|Altea Research, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Neuro-Behavioral Clinical Research, Canton, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Rivus Wellness & Research Institute, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon), Portland, Oregon, United States|UPenn, Philadelphia, Pennsylvania, United States|BTC of Lincoln, Lincoln, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States|UTSW, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Pillar Clinical Research, Richardson, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|IPC Research, Waukesha, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03018340/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03018340/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03018340"
386,"NCT03122158","Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders",,"Unknown status","No Results Available","Major Depressive Disorder|Anxiety Disorders","Drug: Escitalopram","Clinical Global Impression Scale (CGI)|The Hamilton Rating Scale for Depression|The Hamilton Anxiety Rating Scale","Erzurum Regional Training & Research Hospital","All","12 Years to 18 Years   (Child, Adult)","Phase 4","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ErzurumRTRH","April 8, 2017","September 15, 2018","December 15, 2018","April 20, 2017",,"April 20, 2017","ErzurumRTRH, Erzurum, Palandöken, Turkey",,"https://ClinicalTrials.gov/show/NCT03122158"
387,"NCT00548964","Continuation Ketamine in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Lithium|Drug: Ketamine","Montgomery Asberg Depression Rating Scale|Hamilton Anxiety Rating Scale|Quick Inventory of Depressive Symptoms|Systematic Assessment for Treatment Emergent Events (SAFT)|Clinical Global Impression","James Murrough|Icahn School of Medicine at Mount Sinai","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-1225 (002)","October 2007","July 2013","July 2013","October 25, 2007",,"May 23, 2014","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00548964"
388,"NCT00960986","A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder (MDD)","Drug: Duloxetine hydrochloride","Mean Maximum Nausea Severity, Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)|Mean Change From Baseline to 8-Week Endpoint in Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea)|Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Gastric Events Score|Mean Change From Baseline to 1-Week and 8-Week Endpoints in Association for Methodology and Documentation in Psychiatry (AMDP-5) Measure: Common Adverse Events (AEs) Score|Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score|Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale|Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Core Mood Subscale|Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Anxiety/Somatization Subscale|Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Retardation/Somatization Subscale|Mean Change From Baseline to 1-Week and 8-Week Endpoints in 17-Item Hamilton Depression Rating Scale (HAMD-17) Sleep Subscale|Mean Change From Baseline to 1-Week and 8-Week Endpoints in Clinical Global Impressions of Severity (CGI-S)|Patient Global Impression of Improvement (PGI-I) at 1 Week and 8 Weeks|Time to Onset of Nausea|Time to Resolve Nausea|Percentage of Participants Achieving Response|Percentage of Patients Achieving Remission","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9884|F1J-MC-HMFL","August 2009","February 2011","April 2011","August 18, 2009","April 17, 2012","December 31, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cheong Ju-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sungnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00960986"
389,"NCT02004145","Trial of a Positive Psychology Intervention in Major Depressive Disorder","HOPE","Completed","No Results Available","Major Depressive Disorder","Behavioral: Positive Psychology|Behavioral: Control Condition","Change in BHS Scores|Change in CHRT Scores|Change in QIDS-SR Scores","Massachusetts General Hospital|American Foundation for Suicide Prevention","All","18 Years and older   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2013P001234|SRG-2-019-12","October 2013","September 2015","September 2015","December 6, 2013",,"April 19, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02004145"
390,"NCT03078322","AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression","ELEVATE","Completed","No Results Available","Major Depressive Disorder","Drug: AV-101|Drug: Placebo","Montgomery Åsberg Depression Rating Scale 10-item version (MADRS-10)|Time course of improvement including response rates|Safety and tolerability will be assessed by incidence of adverse events (AEs)","VistaGen Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VSG-CL 003","March 5, 2018","October 1, 2019","October 1, 2019","March 13, 2017",,"October 9, 2019","VistaGen Investigational Site, Garden Grove, California, United States|VistaGen Investigational Site, Los Angeles, California, United States|VistaGen Investigational Site, National City, California, United States|VistaGen Investigational Site, Oakland, California, United States|VistaGen Investigational Site, San Diego, California, United States|VistaGen Investigational Site, Temecula, California, United States|VistaGen Investigational Site, Fort Myers, Florida, United States|VistaGen Investigational Site, Jacksonville, Florida, United States|VistaGen Investigational Site, Atlanta, Georgia, United States|VistaGen Investigational Site, Augusta, Georgia, United States|VistaGen Investigational Site, Hoffman Estates, Illinois, United States|VistaGen Investigational Site, Lake Charles, Louisiana, United States|VistaGen Investigational Site, Gaithersburg, Maryland, United States|VistaGen Investigational Site, Saint Louis, Missouri, United States|VistaGen Investigational Site, New York, New York, United States|VistaGen Investigational Site, Rochester, New York, United States|VistaGen Investigational Site, Dayton, Ohio, United States|VistaGen Investigational Site, Oklahoma City, Oklahoma, United States|VistaGen Investigational Site, Media, Pennsylvania, United States|VistaGen Investigational Site, Houston, Texas, United States|VistaGen Investigational Site, Houston, Texas, United States|VistaGen Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03078322"
391,"NCT01734291","Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Family psychoeducation","The change of total score of K6 of family members|The change of total score of Family Attitude Scale(FAS) of family members","Nagoya City University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCUPsychiatricNursing001|ID24593499","October 1, 2012","June 20, 2016","October 9, 2016","November 27, 2012",,"April 5, 2017","Fujika Katsuki, Nagoya, Aichi, Japan",,"https://ClinicalTrials.gov/show/NCT01734291"
392,"NCT01667926","Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Ketamine|Drug: Placebo","Hamilton Depression Rating Scale - Suicidal Ideation (HDRS-SI)|HDRS-28 Total","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-P-001042","January 2013","October 2015","November 2015","August 17, 2012","April 20, 2017","April 20, 2017","Depression Clinical and Reseach Program - MGH, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01667926"
393,"NCT03230682","Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: antidepressant","Early improvement|Response","Huashan Hospital","All","16 Years to 55 Years   (Child, Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KY2017-01","July 25, 2017","June 11, 2018","July 11, 2018","July 26, 2017",,"July 26, 2017","Dept. of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03230682"
394,"NCT00234195","Wellbutrin XL, Major Depressive Disorder and Breast Cancer",,"Completed","No Results Available","Breast Cancer|Major Depressive Disorder","Drug: bupropion extended release (Wellbutrin XL)","To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer.|To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients|To evaluate the effect of bupropion extended-release (Wellbutrin XL™) on fatigue, sexual functioning, and pain in these patients.","Thomas Jefferson University|GlaxoSmithKline","Female","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Prot105042|29000-J08101","September 2005",,"January 2007","October 6, 2005",,"April 17, 2007","Thomas Jefferson University, Department of Psychiatry, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00234195"
395,"NCT00104611","Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: Repetitive Transcranial Magnetic Stimulation","• Evaluate the antidepressant effect of a specified treatment course of rTMS compared to sham treatment given under the same experimental conditions|Safety and tolerability of rTMS|Change in depressive symptomatology with rTMS|Short term durability of rTMS efficacy","Neuronetics","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","286","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","44-01101-000","January 2004","November 2005","November 2005","March 3, 2005",,"September 20, 2013","PsyCare, Poway, California, United States|Stanford University School of Medicine, Stanford, California, United States|Northwestern University School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|UVA Center for Psychiatric Clinical Research, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00104611"
396,"NCT01187407","A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment",,"Completed","Has Results","Major Depressive Disorder (MDD)","Drug: LY2216684|Drug: Placebo|Drug: SSRI","Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Randomization to Week 8 in the Sheehan Disability Scale (SDS) Global Functional Impairment Score|Change From Randomization to Week 8 in the Fatigue Associated With Depression (FAsD) Impact Subscale Score|Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 up to Week 8|Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement|Change From Randomization to Week 8 in the Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score|Percentage of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization up to Week 8|Change From Randomization to Week 8 in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score|Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items|Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)|Change From Randomization to Week 8 in The Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score|Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items|Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)|Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)|Percentage of Participants With Treatment-emergent (TE) Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Randomization to Week 8 in the Arizona Sexual Experiences (ASEX) Scale|Change From Randomization to Week 8 in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|Change From Randomization to Week 8 in Blood Pressure|Change From Randomization to Week 8 in Pulse Rate|Pharmacokinetics: Plasma Concentrations of LY2216684","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12182|H9P-MC-LNBQ","March 2011","August 2013","August 2013","August 24, 2010","April 24, 2018","April 24, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chino, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Imperial, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., National City, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Colorado Springs, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clearwater, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Gables, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoffman Estates, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haverhill, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Weymouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flowood, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., O'Fallon, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rab, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zagreb, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Horovice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hostivice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kladno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olomouc, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strakonice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Usti Nad Labem, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joensuu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kosice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Michalovce, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rimavska Sobota, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roznava, Slovakia",,"https://ClinicalTrials.gov/show/NCT01187407"
397,"NCT04847245","Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder",,"Not yet recruiting","No Results Available","Chronic Visceral Pain|Major Depressive Disorder","Drug: Pregabalin 75mg tid + Duloxetine|Drug: Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Drug: Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Drug: Intravenous administration of esketamine 0.50 mg/kg+Duloxetine","Visual Analogue Scale (VAS)|Hamilton Depression Rating Scale (HAMD)|Short Form 12 Health Survey (SF-12)|Hamilton Anxiety Scale (HAMA)|Changes in serum inflammatory factors|Electroencephalogram (EEG)|Functional magnetic resonance imaging (fMRI)","Peking University","All","18 Years to 55 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Esketamine20210221","May 1, 2021","December 31, 2022","March 1, 2023","April 19, 2021",,"April 19, 2021",,,"https://ClinicalTrials.gov/show/NCT04847245"
398,"NCT04556890","Pain and Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Chronic Pain","Device: Active rTMS/Active iTBS DFPLC/Sham Pain M1|Device: Sham rTMS/ Active iTBS Pain|Device: Active rTMS/Active iTBS","Percent change in depression scores|Percent change in pain score|Levels of inflammatory markers and transcription factors","University of California, Los Angeles","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","69","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","20-000530","September 30, 2021","September 30, 2022","September 30, 2022","September 21, 2020",,"July 27, 2021","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04556890"
399,"NCT01370499","A Study of LY2216684 in Participants With Major Depression Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: SSRI","Number of Participants With Clinically Significant Events|Percentage of Participants With Suicidal Behaviors and Ideations Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Baseline to 52 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Items|Change From Baseline to 52 Week Endpoint in Clinical Global Impression - Severity (CGI-S)|Change From Baseline to 52 Week Endpoint in Fatigue Associated With Depression (FAsD) Average Score and Subscale Scores|Change From Baseline to 52 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety Subscale Scores|Change From Baseline to 52 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores|Change From Baseline to 52 Week Endpoint in EuroQol Questionnaire - 5 Dimension (EQ-5D)|Change From Baseline to 52 Week Endpoint in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)|Change From Baseline to 52 Week Endpoint in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|Change From Baseline to 52 Week Endpoint in Arizona Sexual Experiences (ASEX) Scale|Change From Baseline to 52 Week Endpoint in Blood Pressure|Change From Baseline to 52 Week Endpoint in Pulse Rate","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","288","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12849|H9P-JE-LNDJ","August 2011","January 2014","January 2014","June 10, 2011","October 25, 2018","October 25, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagano, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saga, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01370499"
400,"NCT03732378","Role of Omega-3 Polyunsaturated Fatty Acid in the Management of Major Depressive Disorder.",,"Completed","No Results Available","Role of Omega-3 Polyunsaturated Fatty Acid in the Management of Major Depressive Disorder: A Randomized Controlled Trial","Dietary Supplement: Omega-3 capsule","Beck depression inventory scale","Allama Iqbal Open University Islamabad|King Edward Medical University","All","20 Years to 40 Years   (Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","561/17","April 27, 2017","August 16, 2017","November 10, 2017","November 6, 2018",,"November 6, 2018","Zaheer Ahmad, Islamabad, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT03732378"
401,"NCT02051413","Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)","DEPARRESTCLIN","Unknown status","No Results Available","Major Depressive Disorder|Major Depressive Episode","Drug: Venlafaxine extended release","Change from baseline in depressive symptoms on the Hamilton Depression Rating Scale-17 items","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C13-25|2013-004326-29","February 2014","February 2016","February 2017","January 31, 2014",,"February 25, 2016","CHU de Bicetre, Le Kremlin Bicetre, France",,"https://ClinicalTrials.gov/show/NCT02051413"
402,"NCT01175616","Creatine Augmentation in Veterans With SSRI-Resistant Major Depression",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: Creatine","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score|Changes in 3T 31Phosphorus Magnetic Resonance Spectroscopy metabolites","University of Utah","All","18 Years to 55 Years   (Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00041936","September 2012","April 2014","April 2014","August 5, 2010",,"August 15, 2016",,,"https://ClinicalTrials.gov/show/NCT01175616"
403,"NCT02339285","Transcranial Alternating Current Stimulation for Major Depressive Disorder","MDD","Completed","Has Results","Major Depressive Disorder|MDD","Device: tACS (alpha)|Device: tACS (gamma)","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score|Change in Alpha Oscillation Power From Resting State EEG Recordings on the First and Last Day of Stimulation|Change in Alpha Oscillation Power From Resting State EEG Recordings on the First of Stimulation to 4 Weeks After Completion of Intervention","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-1622|5R01MH101547-02","May 7, 2015","June 19, 2017","June 19, 2017","January 15, 2015","August 20, 2018","August 20, 2018","UNC Chapel Hill Medical School Wing C, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02339285/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02339285"
404,"NCT01465165","Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression",,"Terminated","No Results Available","Major Depressive Disorder",,"high energy phosphate metabolites (Phosphocreatine (PCr)) as measured by magnetic resonance spectroscopy|regional cerebral glucose metabolism, as measured by Positron Emission Tomography (PET)|N-Acetyl-Aspartate (NAA) metabolite intensity, as measured by proton Magnetic Resonance Spectroscopy (MRS)|severity of depressive symptoms, as scored on the Montgomery-Asberg Depression Rating Scale (MADRS)","Paul Carlson|Western Institute for Biomedical Research|University of Utah|Molecular Imaging Program, Huntsman Cancer Institute","All","18 Years to 55 Years   (Adult)",,"12","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","WIBR08-PJC","May 15, 2011","June 24, 2012","June 24, 2012","November 4, 2011",,"May 19, 2017","University of Utah Dept of Psychiatry, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01465165"
405,"NCT02165449","Biomarkers of Fast Acting Therapies in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Ketamine","Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions|Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up|Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions|Change in gene expression measured between the last ketamine infusion treatment and 5 week follow-up|Change in non-invasive Magnetic Resonance Imaging measures of structural connectivity measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions|Change in non-invasive Magnetic Resonance Imaging measures of structural connectivity measured between the last ketamine infusion treatment and at 5 weeks|Change in non-invasive Magnetic Resonance Imaging measures of functional connectivity measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions|Change in non-invasive Magnetic Resonance Imaging measures of functional connectivity measured between the last ketamine infusion treatment and at 5 weeks|Change in non-invasive Magnetic Resonance Imaging measures of neurochemistry measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions|Change in non-invasive Magnetic Resonance Imaging measures of neurochemistry measured between the last ketamine infusion treatment and at 5 weeks","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","18 Years to 64 Years   (Adult)","Phase 1","60","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS001796|K24MH102743|U01MH110008","June 2014","August 2019","August 2019","June 17, 2014",,"August 28, 2019","Geffen School of Medicine, UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02165449"
406,"NCT01488071","A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication","REVIVE","Completed","Has Results","Major Depressive Disorder","Drug: Vortioxetine (Lu AA21004)|Drug: Agomelatine","Change From Baseline in MADRS Total Score at Week 8|Change From Baseline in MADRS Total Score at Week 12|Change From Baseline in HAM-A Total Score at Week 8|Change From Baseline in HAM-A Total Score at Week 12|Change From Baseline in CGI-S Score at Week 8|Change From Baseline in CGI-S Score at Week 12|Change in Clinical Status Using CGI-I Score at Week 8|Change in Clinical Status Using CGI-I Score at Week 12|Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)|Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)|Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)|Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)|Change From Baseline in SDS Total Score at Week 8|Change From Baseline in SDS Total Score at Week 12","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","495","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14178A|2011-002362-21","January 2012","December 2012",,"December 8, 2011","March 26, 2014","March 26, 2014",,,"https://ClinicalTrials.gov/show/NCT01488071"
407,"NCT01579942","Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression",,"Terminated","No Results Available","Major Depressive Disorder",,"Brain Network Analysis group patterns|Identify possible predictors of treatment response","Massachusetts General Hospital|ElMindA Ltd","All","18 Years to 55 Years   (Adult)",,"70","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2011P000200","April 2012",,,"April 18, 2012",,"March 6, 2017","Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01579942"
408,"NCT02427789","Therapeutic Effectiveness of Exercise Associated to the Pharmacotherapy in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Other: Physical Exercise","Physical exercise evaluation|Biomarkers level comparison","University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCLim27/FAPESP2012/20002-5","March 2012","April 2014","July 2014","April 28, 2015",,"April 29, 2015","University of São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02427789"
409,"NCT04000022","Repetitive Transcranial Magnetic Stimulation in Pharmaco-naïve Patients With Major Depression","NAIV","Unknown status","No Results Available","Major Depressive Disorder","Device: intermittent theta burst stimulation (iTBS)","Change in depression severity as measured by the Hamilton Depression Rating Scale (HDRS-17) over 7 timepoints","University Hospital, Bonn|Maximilian Kiebs, M.S.|Clemens Mielacher, M.S.","All","18 Years to 70 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NAIV","January 1, 2019","December 29, 2020","May 1, 2021","June 27, 2019",,"June 28, 2019","Klinik und Poliklinik für Psychiatrie und Psychotherapie, Bonn, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT04000022"
410,"NCT04355650","Augmented Human Intelligence in Major Depressive Disorder",,"Enrolling by invitation","No Results Available","Depression|Major Depressive Disorder","Other: Clinical decision support tool","Observed clinical outcomes compared to predicted outcome at 2 week follow up|Observed clinical outcomes compared to predicted outcome at 4 week follow up","Mayo Clinic","All","18 Years to 64 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","19-005341","January 27, 2020","January 27, 2022","July 27, 2022","April 21, 2020",,"April 21, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04355650/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04355650/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04355650"
411,"NCT03716869","Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder|Major Depressive Episode","Other: Universal Screening Arm","MDD composite: Adolescents MDD screen positive by PHQ-9 (universal arm) or with concern for MDD prompting Student Assistance Program (SAP) triage request, identified with MDD by SAP, and who engage with at least one SAP recommended service or treatment|MDD screen positive/concern: Adolescents who screen positive for MDD either by PHQ-9 (universal screening arm only) or by concern for MDD prompting a request for SAP triage|Suicidal Adolescent|MDD identification: Adolescents who are identified as having MDD based on triage by the school SAP team|MDD treatment engagement: Successful engagement with at least one SAP recommendation|Standardized test scores: Keystone exams mathematics (school district). This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.|Standardized test scores: Keystone exams English language arts (ELA; school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.|Standardized test scores: Keystone exams science (school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.|Preliminary Scholastic Aptitude Test (PSAT)/Plan (school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.|Scholastic Aptitude Test (SAT)/ American College Testing (ACT) performance (school district) This information may no longer be available due to COVID-19 school closures and cancellation of state standardized testing.|Student school policy violations and suspensions based on school district data|Missed school days|Grade point average|Grade advancement: This measure represents the percent of students promoted in each grade for the school (grades 9-11, school district data)|Graduation: This measure represents the percent of students who graduate 12th grade with a high school diploma (school district data)","Milton S. Hershey Medical Center|Health Resources and Services Administration (HRSA)|Patient-Centered Outcomes Research Institute","All","Child, Adult, Older Adult","Not Applicable","12909","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","STUDY00010090|R40MC31765","November 6, 2018","November 20, 2020","February 3, 2021","October 23, 2018",,"April 28, 2021","The Pennsylvania State University, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03716869"
412,"NCT03957850","Cognitive Reappraisal in Adolescents With Major Depression","KONNI","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Reappraisal Training|Behavioral: Control Training","Change in negative and positive affect via the Positive and Negative Affect Schedule for Children-Short Form (PANAS-C-SF)|Change in perceived stress via the Perceived Stress Scale (PSS-10)|Change in rumination as assessed via the German adaptation of the Response Style Questionnaire (RSQ-D)|Change in depressive Symptoms via the Beck Depression Inventory - Second Edition (BDI-II)|Changes in the downregulation of affective behavioral responses to negative pictures via CR based on the self-assessment manikin scale|Changes in the downregulation of the LPP (late positive potential) to negative pictures via CR|Changes in the percent gaze fixations in emotional areas of interest within negative pictures","Ludwig-Maximilians - University of Munich|German Research Foundation|RWTH Aachen University|University of Amsterdam","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","399482529","May 27, 2019","April 30, 2021","April 30, 2021","May 21, 2019",,"February 18, 2021","Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Munich, Munich, Germany, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT03957850"
413,"NCT00435279","A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia",,"Completed","No Results Available","Major Depressive Disorder|Insomnia","Drug: Eszopiclone|Drug: Placebo|Drug: Venlafaxine","The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.|The key secondary endpoint is the change from baseline in the mean subjective Total Sleep Time (TST) during Week 1.","Sunovion","All","18 Years to 64 Years   (Adult)","Phase 3","678","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","190-062","June 2007","July 2009","July 2009","February 14, 2007",,"February 22, 2012","Salzburg, Austria|Wien, Austria|Wien, Austria|Split, Croatia|Zagreb, Croatia|Zagreb, Croatia|Arcachon, France|Caen, France|Elancourt, France|Le Pecq, France|Rennes, France|Savigny sur Orge, France|Strasbourg, France|Toulouse, France|Toulouse, France|Toulouse, France|Verasailles, France|Balassagyarmat, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Cegled, Hungary|Nyiregyhaza, Hungary|Belchatow, Poland|Bydgoszcz, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Torun, Poland|Tuszyn, Poland|Bucuresti, Romania|Lasi, Romania|Oradea, Romania|Arkhangelsk, Russian Federation|Belchatow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Beograd, Serbia|Beograd, Serbia|Kragujevac, Serbia|NIS, Serbia|NIS, Serbia|Novi Sad, Serbia|Donetsk, Pobeda District, Ukraine|Crimea, Ukraine|Dnepropetrovsk, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Vinnitsa, Ukraine|Avon, Bath, United Kingdom|Glasgow, Scotland, United Kingdom|Coventry, United Kingdom|Fowey, United Kingdom|Glasgow, United Kingdom|Harrow, United Kingdom|Haywards Heath, United Kingdom|Plymouth, United Kingdom|Warks, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00435279"
414,"NCT04990687","Vagal Nerve Stimulation for Treatment Resistant Major Depression",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Device: gammaCore™","Antidepressant effects of nVNS in humans|Incidence of gammaCore™ Adverse Events","University of Alabama at Birmingham","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300007636","September 1, 2021","September 1, 2023","September 1, 2023","August 4, 2021",,"August 4, 2021",,,"https://ClinicalTrials.gov/show/NCT04990687"
415,"NCT04620759","Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","PsiloMDDAUD","Recruiting","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: Psilocybin|Drug: Placebo","Change from baseline in grid-version of the Hamilton Depression Rating Scale (GRID-HAMD) score|Change from baseline in percentage of days abstinent as measured by the Time Line Follow Back (TLFB) assessment|Change from baseline in percentage of days of heavy drinking as measured by the TLFB assessment|Change from baseline in gamma-glutamyl transferase (GGT)|Change from baseline in the percentage of carbohydrate deficient transferrin relative to total transferrin concentration (%CDT)|Change from baseline in the ratio of aspartate transaminase to alanine transaminase (AST/ALT)|Change from baseline in Quick Inventory of Depressive Symptomatology - Self Rated (QIDS-SR) score|Change from baseline in State Trait Anxiety Index (STAI) score|Change from baseline in percentage of days abstinent as measured by the TLFB assessment|Change from baseline in GGT|Change from baseline in %CDT|Change from baseline in AST/ALT ratio","Johns Hopkins University","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00233684","April 14, 2021","August 31, 2025","August 31, 2026","November 9, 2020",,"April 15, 2021","Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04620759"
416,"NCT04727229","Stellate Ganglion Block for Major Depressive Disorder.",,"Recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Drug: Bupivacaine Hydrochloride|Drug: Normal Saline","Feasibility, Recruitment, Acceptability, Safety,|Change in the symptoms of depression","Karim Ladha|Unity Health Toronto","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","20-301","July 2021","July 2022","October 2022","January 27, 2021",,"July 14, 2021","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04727229"
417,"NCT00927173","Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: Brainsway H-Coil Deep TMS System|Device: Brainsway H-Coil Deep TMS System (Sham treatment)","HDRS-21|Response rate|Remission rates|Quality of Life","Brainsway","All","22 Years to 68 Years   (Adult, Older Adult)","Not Applicable","233","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTP-0001-00|IL-MOH-HTA-4860","September 2009","March 2012","June 2012","June 24, 2009",,"July 15, 2020","University of California (UCLA), Los Angeles, California, United States|UC Davis Center for Mind & Brain, Sacramento And Davis, California, United States|Smart Brain and Health, Santa Monica, California, United States|Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States|Advanced Mental Health Care Inc. - Royal Palm Beach, Royal Palm Beach, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|McLean Hospital - TMS Services, Belmont, Massachusetts, United States|Greater Nashua Mental Health Center, Nashua, New Hampshire, United States|Neuropharmacology Services, New York, New York, United States|Columbia University / New York State Psychiatric Institute, New York, New York, United States|Duke Medical Center Department of Psychiatry & Behavioral Sciences, Durham, North Carolina, United States|Medical Uni. Of South Carolina (MUSC), Charleston, South Carolina, United States|Senior Adults Specialty Research, Austin, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Center for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|EPS Ville-Evrard, Neuilly Sur Marne, France|Universitätsklinikum Bonn, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Bonn, Germany|Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität, Munich, Germany|Beer Yaacov Mental Health Center, Beer Yaacov, Israel|Shalvata Mental Health Center, Hod Hasharon, Israel|Hadasah Ein-Karem Medical Center, Jerusalem, Israel|Kfar Shaul Mental Health Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00927173"
418,"NCT00714779","Fluoxetine vs. Brief Psychotherapy for Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Fluoxetine|Behavioral: Short-term psychodynamic psychotherapy","HAM-D","University of Turku|KELA|Finnish State Grant","All","20 Years to 60 Years   (Adult)","Not Applicable","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HK123","January 2000","December 2004","December 2004","July 14, 2008",,"July 14, 2008",,,"https://ClinicalTrials.gov/show/NCT00714779"
419,"NCT04832178","Sumor as Adjuvant Therapy in Treatment-resistant Major Depression","SUSCA","Not yet recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: SUMOR|Other: Placebo","Hamilton Rating Scale for Depression (HAM-D)|Hamilton Anxiety Scale (HAM-A)|SIDE|Depressive symptoms remission","Azienda Ospedaliero-Universitaria Careggi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14976","June 1, 2021","June 1, 2023","June 1, 2023","April 5, 2021",,"April 5, 2021","Azienda Ospedaliero Universitaria Careggi, Florence, Italy",,"https://ClinicalTrials.gov/show/NCT04832178"
420,"NCT04619121","Near-infrared Radiation-transcranial Photobiomodulation for Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Oxidative Stress","Device: NIR-tPBM|Device: Sham device","Change in depressive symptoms (subjective)|Change in depressive symptoms (objective)|Change in circadian rhythm|Change in sleep quality","China Medical University Hospital|Ministry of Science and Technology, Taiwan","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMUH109-REC3-054","December 21, 2020","August 2021","October 2021","November 6, 2020",,"July 7, 2021","China Medical University Beigang Hospital, Beigang, Yunlin County, Taiwan",,"https://ClinicalTrials.gov/show/NCT04619121"
421,"NCT03748446","Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Bipolar Depression","Drug: Xenon|Drug: Nitrogen gas","Depressive Symptoms","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018P002500","December 5, 2019","December 1, 2022","December 1, 2024","November 20, 2018",,"February 20, 2020","Dauten Family Center for Bipolar Treatment Innovation, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03748446"
422,"NCT03869736","Nitrous Oxide for the Treatment of Major Depressive Disorder",,"Recruiting","No Results Available","Depression|Major Depressive Disorder","Drug: Nitrous Oxide|Drug: Placebo","Change in HDRS-21 score|Treatment response and remission|Pattern of treatment response|Sustainability of treatment response - change in HDRS-21 scores|Sustainability of treatment response - response and remission rates|Treatment compliance rate|Dose effect of nitrous oxide using treatment-by-dose interaction term in a logistic regression model|Computerized Adaptive Test-Depression Inventory (CAT-DI)|Computerized Adaptive Test-Suicide Scale (CAT-SS)","Bayside Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","438/19","January 22, 2019","December 10, 2020","December 10, 2020","March 11, 2019",,"April 22, 2020","University of Chicago Medicine, Chicago, Illinois, United States|Alfred Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03869736"
423,"NCT01685294","Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Group IPT for Depression + TAU","Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months|Change from Baseline in Suicidality at 3 Months|Change from Baseline in In-Prison Functioning at 3 Months|Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 6 Months|Change from Baseline in Suicidality at 6 Months|Change from Baseline in In-Prison Functioning at 6 Months|Cost-effectiveness","Brown University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","181","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R01MH095230-01|R01MH095230","December 2011","October 2014","October 2014","September 14, 2012",,"January 13, 2016","Massachusetts Correctional Institute - Old Colony Correctional Center, Bridgewater, Massachusetts, United States|Massachusetts Correctional Institution - Framingham, Framingham, Massachusetts, United States|South Middlesex Correctional Center, Framingham, Massachusetts, United States|Massachusetts Correctional Institution - Norfolk, Norfolk, Massachusetts, United States|Adult Correctional Institution - Men's & Women's Medium & Minimum Security Facilities, Cranston, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01685294"
424,"NCT01182103","Epigenetic Regulation of BDNF in Major Depression",,"Completed","Has Results","Major Depressive Disorder",,"Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls|Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls|BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls","Chang Gung Memorial Hospital","All","18 Years to 60 Years   (Adult)",,"110","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","NSC99-2628-B-182-002-MY2","August 2010","July 2012","May 2013","August 16, 2010","August 15, 2014","August 15, 2014","Department of Psychiatry, Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01182103"
425,"NCT04124276","Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Depression|Depressive Disorder","Dietary Supplement: Lycium barbarum polysaccharide|Dietary Supplement: Placebo","Reduction rate of Hamilton Depression Scale (HDRS)|Changes in depressive severity measured by Beck Depression Inventory (BDI) scale and Kessler Scale(K10)|Changes in sleep quality|Changes in cognitive function|Changes in social adaptive levels|Changes in serum brain-derived neurotrophic factor (BDNF) levels|Changes in serum triglyceride levels|Changes in serum total cholesterol levels","Guangzhou Psychiatric Hospital|The Fifth Affiliated Hospital of Guangzhou Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","284","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangzhou Brain LBPMD","November 1, 2019","December 30, 2020","June 1, 2021","October 11, 2019",,"October 30, 2020","Guangzhou Brain Hospital (Guangzhou Huiai Hospital), Guanzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04124276"
426,"NCT04607226","Effects of Respiratory-Gated Transcutaneous Vagal Nerve Stimulation in Major Depression (Phase 1)",,"Recruiting","No Results Available","Major Depressive Disorder","Other: Active transcutaneous vagus nerve stimulation|Other: Sham transcutaneous vagus nerve stimulation","Cardiac autonomic function|Change in depressive symptoms assessed by the Beck Depression Inventory|Change in serum levels of pro-inflammatory cytokines","Massachusetts General Hospital|Brain & Behavior Research Foundation","Female","24 Years to 45 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","2019P003698|26236","November 2, 2020","January 14, 2022","January 14, 2022","October 29, 2020",,"November 19, 2020","Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04607226"
427,"NCT02176408","Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression",,"Completed","Has Results","Major Depressive Disorder","Behavioral: Behavioral Activation|Behavioral: Exercise Intervention|Behavioral: Stretching Intervention","Montgomery-Asberg Depression Rating Scale (MADRS)|Beck Depression Inventory-II (BDI-II)|Work and Social Adjustment Scale (WSAS)|Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Logical Memory|Continuous Performance Test- Identical Pairs|7 Day Physical Activity Recall (PAR)|Brain-derived Neurotrophic Factor (BDNF)","Boston University Charles River Campus|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","38","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","F31MH100773-01A1","June 2014","August 2016","August 2016","June 27, 2014","September 10, 2019","September 10, 2019","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02176408"
428,"NCT01999010","Mental Health Telemetry for Self-Management in Major Depression","MHTV","Completed","No Results Available","Major Depressive Disorder","Device: MHT","Change in self-management ratings|Change in Quality-of-life (QoL) ratings","Sunnybrook Health Sciences Centre|Canadian Institutes of Health Research (CIHR)","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","186-2013","November 2014","April 2016","April 2016","December 3, 2013",,"January 5, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01999010"
429,"NCT04116528","Opiate Suicide Study in Patients With Major Depression","AFSP","Recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine|Drug: Buprenorphine|Drug: Placebo oral tablet","Change in Beck Suicidal Ideation Scale total scores will be analyzed as the primary outcome measure using analysis of variance model for repeated measures.|The investigators will assess opioid activity of ketamine as well as buprenorphine","Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","51536","August 1, 2020","October 1, 2022","December 1, 2022","October 4, 2019",,"August 31, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04116528"
430,"NCT02562677","TNS for Treating Major Depressive Disorder in the Elderly",,"Unknown status","No Results Available","Major Depressive Disorder|Elderly","Device: Transcutaneous Trigeminal Nerve Stimulation","Hamilton Depressive Rating Scale version 17 items (HDRS-17)","Santa Casa Medical School","All","65 Years to 99 Years   (Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TNS for Elderly","October 2015","December 2015","February 2016","September 29, 2015",,"September 29, 2015",,,"https://ClinicalTrials.gov/show/NCT02562677"
431,"NCT04448327","Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression","tVNS_MDD_Sex","Recruiting","No Results Available","Major Depressive Disorder","Device: active tVNS|Device: Sham tVNS","Brain activity during functional magnetic resonance imaging (fMRI)|Cardiac autonomic function during functional magnetic resonance imaging (fMRI)|Change in serum cortisol levels|Change in serum levels of pro-inflammatory cytokines|Change in depressive symptoms assessed by the Beck Depression Inventory","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","2020P001212|1U54MH118919-01A1","March 1, 2021","July 15, 2024","November 15, 2024","June 25, 2020",,"March 15, 2021","Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04448327"
432,"NCT03866252","LSD Therapy for Persons Suffering From Major Depression","LAD","Recruiting","No Results Available","Major Depressive Disorder","Drug: LSD","Change in depressive symptomatology assessed by questionnaire compared with active placebo","University Hospital, Basel, Switzerland|Department of Psychiatry Basel (UPK Basel; Prof. Dr. med. Stefan Borgwardt)","All","25 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BASEC 2018-02370","November 1, 2019","December 31, 2023","December 31, 2023","March 7, 2019",,"February 9, 2021","Universitäre Psychiatrische Kliniken, Basel, Basel-Stadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT03866252"
433,"NCT03012724","Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)",,"Recruiting","No Results Available","Major Depressive Disorder (MDD)","Device: H7-Coil|Device: H1-Coil","HDRS-21 Score Change From Baseline|Response Rate in HDRS-21|Remission Rate","Brainsway","All","22 Years to 68 Years   (Adult, Older Adult)","Not Applicable","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTP-0001-01","March 30, 2017","December 2020","December 2020","January 6, 2017",,"July 15, 2020","Kadima Neuropsychiatry, La Jolla, California, United States|CalNeuro Research Group, Los Angeles, California, United States|Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States|Advanced Mental Health Care Inc. - Palm Beach, Palm Beach, Florida, United States|Advanced Mental Health Care Inc. - Royal Palm Beach, Royal Palm Beach, Florida, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenbrook TMS NeuroHealth Centers, McLean, Virginia, United States|Center for Addiction & Mental Health (CAMH), Toronto, Ontario, Canada|Dr. Hadar Shalev, Be'er Sheva', Israel",,"https://ClinicalTrials.gov/show/NCT03012724"
434,"NCT01185977","Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)",,"Completed","No Results Available","Major Depressive Disorder","Drug: Fluoxetine|Drug: Placebo","Score on Children's Depression Rating Scale-Revised|Score on Hamilton Depression Rating Scale (HAM-D)","University of California, Los Angeles","All","14 Years to 18 Years   (Child, Adult)","Phase 4","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","090713201","April 2010","October 2011",,"August 20, 2010",,"July 3, 2014","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01185977"
435,"NCT01450150","Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Device: Transcranial Direct Current Stimulation","Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C)|21-item Hamilton Depression Rating Scale (HAM-D21)|Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)","Douglas Mental Health University Institute","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","tDCS-ERB08/04-2011","January 2016","October 2018","October 2018","October 12, 2011",,"January 20, 2016","Douglas Mental Health University Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01450150"
436,"NCT03254017","Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial",,"Terminated","No Results Available","Treatment Resistant Major Depressive Disorder","Procedure: Bilateral surgical implantation of DBS system to Habeluna|Other: Follow-up Period","Change in the Montgomery-Asberg Depression Rating Scale|Change in the Hamilton Depression Scale|Change in the Hamilton Anxiety Scale|Change in the Quality of Life Assessment (SF-36)|Neuropsychological measures(Scores of cogstate battery)|Change in the WHO-BREF|Change in Young Manic Rating Scale|Chang in Pittsburgh Sleep Quality Index","Ruijin Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Habenula DBS","July 24, 2017","November 30, 2018","August 30, 2019","August 18, 2017",,"November 29, 2019","Shanghai Ruijin Hospital Functional Neurosurgery, Shanghai, Shanghai, China|Shanghai Ruijin Hospital Functional Neurosurgery, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03254017"
437,"NCT00102492","Study Of GW679769 In Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major|Major Depressive Disorder (MDD)","Drug: GW679769","Change from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D) total score at week 8, Last Observation Carried Forward.|CGI, HAM-A, QUIDS, SDS, MOS-12 Sleep Module, LSEQ, Safety and Tolerability, PK/PD","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","356","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","NKF100092","October 2004","September 2006","September 2006","January 31, 2005",,"April 16, 2015","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, North Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Smyrna, Georgia, United States|GSK Investigational Site, Oakbrook Terrace, Illinois, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Farmington Hills, Michigan, United States|GSK Investigational Site, St. Charles, Missouri, United States|GSK Investigational Site, Clementon, New Jersey, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Beachwood, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Irving, Texas, United States|GSK Investigational Site, Lake Jackson, Texas, United States|GSK Investigational Site, Bellevue, Washington, United States|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Miramichi, New Brunswick, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00102492"
438,"NCT01944657","Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study",,"Withdrawn","No Results Available","1. Major Depressive Disorder","Device: Supplemental TMS|Drug: Standard Medication Monotherapy","Montgomery-Åsberg Depression Rating Scale (MADRS)|Hamilton Rating Scale for Depression (HRSD)","Sheppard Pratt Health System|Central Michigan University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPHS IRB [354612-3]","September 2013","December 2015","December 2015","September 18, 2013",,"April 25, 2017","Sheppard Pratt Health System, Towson, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01944657"
439,"NCT02470026","Noradrenergic Activity, Cognition and Major Depressive Disorder","YohCog","Completed","No Results Available","Major Depressive Disorder|Early Life Trauma","Drug: yohimbine|Drug: placebo","behavioral responses in two different conditions of noradrenergic stimulation|physiological responses in two different conditions of noradrenergic stimulation","Charite University, Berlin, Germany","All","18 Years to 60 Years   (Adult)","Not Applicable","131","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","KU3106/2-1","June 2014","November 2017","October 2018","June 12, 2015",,"May 23, 2019","Charite University, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02470026"
440,"NCT01180400","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","295","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00003","September 2010","September 2011","September 2011","August 12, 2010","November 20, 2012","April 11, 2014","Research Site, Brno, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 10 - Strasnice, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Praha 9, Czech Republic|Research Site, Dublin, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallin, Estonia|Research Site, Tartu, Estonia|Research Site, Voru, Estonia|Research Site, Dublin, Finland|Research Site, Espoo, Finland|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Mikkeli, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Toulon, La Seyne Sur Mer, France|Research Site, Douai, France|Research Site, Dublin, France|Research Site, Elancourt, France|Research Site, Jarnac, France|Research Site, La Seyne Sur Mer, France|Research Site, Nimes Cedex 9, France|Research Site, Rennes, France|Research Site, Toulon, France|Research Site, Villejuif, France|Research Site, Mainz, Rp, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dublin, Germany|Research Site, Siegen, Germany|Research Site, Dublin, Hungary|Research Site, Dublin, Latvia|Research Site, Jelgava, Latvia|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Sigulda, Latvia|Research Site, Strenci, Latvia|Research Site, Ziegzdrai, Kaunas, Lithuania|Research Site, Dublin, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Palanga, Lithuania|Research Site, Silute, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Belchatow, Poland|Research Site, Bialystok, Poland|Research Site, Bydgoszczy, Poland|Research Site, Dublin, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Leszno, Poland|Research Site, Lublin, Poland|Research Site, Sosnowiec, Poland|Research Site, Torun, Poland|Research Site, Toru, Poland|Research Site, Zuromin, Poland|Research Site, Dublin, Sweden|Research Site, Goteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01180400"
441,"NCT03632434","Transcranial Direct Current Stimulation Therapy for Major Depression",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Device: transcranial direct current stimulation","Clinical response","University of East London|Rosetrees Trust|King's College London|University College, London|University of Oxford","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A1950","October 14, 2019","June 2021","November 2021","August 15, 2018",,"April 30, 2021","University of East London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03632434"
442,"NCT01153347","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in Hamilton Anxiety Scale (HAM-A) Total Score From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form(Q LES-Q-SF)Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)|Change in Irritability Symptoms as Measured by the Sheehan Irritability Scale (SIS) Total Score From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00004","June 2010","January 2012","January 2012","June 30, 2010","November 20, 2012","April 11, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Conway, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Arcadia, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Garden Grove, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oakland, California, United States|Research Site, Oceanside, California, United States|Research Site, Pico Rivera, California, United States|Research Site, Santa Ana, California, United States|Research Site, Upland, California, United States|Research Site, Denver, Colorado, United States|Research Site, Cromwell, Connecticut, United States|Research Site, New London, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bradenton, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Ft Walton Beach, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Florence, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Gaithersburg, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Weymouth, Massachusetts, United States|Research Site, Flowood, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, North Platte, Nebraska, United States|Research Site, Toms River, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Beachwood, Ohio, United States|Research Site, Beechwood, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Mason, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersvillle, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Irving, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Bellevue, Washington, United States|Research Site, Bothell, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, South Kirkland, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Guntur, Andhra Pradesh, India|Research Site, Vijayawada, Andhra Pradesh, India|Research Site, Vishakhapatnam, Andhra Pradesh, India|Research Site, Anand, Gujarat, India|Research Site, Junagadh, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Rajkot, Gujrat, India|Research Site, Bangalore, Karnataka, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Nashik, Mahara, India|Research Site, Durham, NC, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Madurai, Tamilnadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kanpur, India|Research Site, Karnataka, India|Research Site, Mysore, India|Research Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01153347"
443,"NCT01157078","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in Irritability Symptoms as Measured by the Sheehan Irritability Scale (SIS) Total Score From Randomization (Week 8) to End of Treatment (Week 16)|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","319","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00002","June 2010","November 2011","November 2011","July 5, 2010","November 20, 2012","April 11, 2014","Research Site, Tuscaloosa, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Chino, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Oceanside, California, United States|Research Site, Pico Rivera, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Coral Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Florence, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, St. Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Woodstock, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, Visakhapatnam, Andh Prad, India|Research Site, Guntur, Andhra Pradesh, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Rajkot, Gujrat, India|Research Site, Mangalore, Karnataka, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Nashik, Mahara, India|Research Site, Jaipur, Rajasthan, India|Research Site, Khatipura, Rajasthan, India|Research Site, Madurai, Tamilnadu, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kanpur, India|Research Site, Mysore, India",,"https://ClinicalTrials.gov/show/NCT01157078"
444,"NCT03658330","Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder",,"Completed","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: Ketamine + Naltrexone","Response in symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS)|Obsessive Compulsive Drinking Scale (OCDS)","VA Connecticut Healthcare System","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","5","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GY0004","May 2016","October 2016","June 2018","September 5, 2018",,"September 7, 2018",,,"https://ClinicalTrials.gov/show/NCT03658330"
445,"NCT03421574","Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Device: MR-guided Focused Ultrasound","Incidence of Treatment-Emergent Adverse Events|Quality of Life will be measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)|Clinical efficacy will be measured using the Hamilton Rating Scale for Depression (HAMD)|Clinical efficacy will be measured using the Montgomery Asberg Depression Rating Scale (MADRS)|Clinical efficacy will be measured using the Beck Depression Inventory (BDI)|Clinical efficacy will be measured using the Columbia-Suicide Severity Rating Scale (C-SSRS)","Sunnybrook Health Sciences Centre","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","344-2017","January 19, 2018","December 7, 2021","December 7, 2021","February 5, 2018",,"March 16, 2021","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03421574"
446,"NCT02579343","Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture",,"Unknown status","No Results Available","Major Depressive Disorder","Device: Auricular Acupuncture|Drug: Sham Auricular Acupuncture + Lexapro","Change from baseline score of the Behavioral Health Measure-20 through 6 weeks|Change from baseline score of the Sheehan Disability Scale through 6 weeks","Florida Gulf Coast University","All","18 Years to 24 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","FloridaGCU","August 2015","May 2016","May 2016","October 19, 2015",,"October 19, 2015","Counseling and Psychological Services, Fort Myers, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02579343"
447,"NCT02013531","Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms",,"Completed","Has Results","Major Depressive Disorder|Anxiety","Drug: Brexpiprazole","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Mean Change in Clinical Global Impression-Severity (CGI-S) Total Score|Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 6.|Percentage of Participants With CGI-I Response Rate|Percentage of Participants With a MADRS Response|Percentage of Participants With a MADRS Remission|Mean Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score|Mean Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score|Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score|Mean Change From Baseline in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score|Mean Change From Baseline in Kellner Symptom Questionnaire (KSQ)|Mean Change From Baseline in Go/No-Go Task for P-inhibition Failures|Mean Change From Baseline in Go/No-Go Task for Mean Reaction Time|Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Score|Mean Change From Baseline in Delay and Probability Discounting Task (DPDT) Scores|Mean Change From Baseline to Week 6 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)|Mean Change From Baseline in Food Delay Discounting Task|Mean Change From Baseline in Money Delay Discounting Task|Mean Change From Baseline in Barratt Impulsiveness Scale 11-item (BIS-11) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","37","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-13-002","November 2013","May 2014","June 2014","December 17, 2013","March 29, 2016","March 29, 2016","Tuscon, Arizona, United States|Garden Grove, California, United States|Oceanside, California, United States|Temecula, California, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Lafayette, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Haverhill, Massachusetts, United States|Rochester Hills, Michigan, United States|New York, New York, United States|Staten Island, New York, United States|Salem, Oregon, United States|Allentown, Pennsylvania, United States|Arlington, Texas, United States|Austin, Texas, United States|Woodstock, Vermont, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02013531"
448,"NCT01594866","Lexapro®'s Efficacy After Dose Escalation in Remission Study","LEADERS","Completed","No Results Available","Major Depressive Disorder","Drug: escitalopram","Montgomery-Åsberg Depression Rating Scale (MADRS)|Hamilton Depression Rating Scale-17 items (HAM-D)|Hamilton Anxiety Rating Scale (HAM-A)|Clinical Global Impression-severity (CGI-S)|Clinical Global Impression-Improvement (CGI-I)|Beck's Depression Inventory(BDI)|WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF)|Clinically Useful Depression Outcome Scale (CUDOS)|Short From-36 Health survey (SF-36 Health survey)","Seoul National University Hospital|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AYM-LEADERS","May 2012","June 2016","December 2016","May 9, 2012",,"September 7, 2018","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01594866"
449,"NCT04019704","A Trial of AXS-05 in Patients With Major Depressive Disorder","GEMINI","Completed","No Results Available","Depression|Major Depressive Disorder","Drug: AXS-05|Drug: Placebo","Types and rates of adverse events|Montgomery-Åsberg Depression Rating Scale (MADRS)","Axsome Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","327","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AXS-05-MDD-301","June 20, 2019","November 26, 2019","December 5, 2019","July 15, 2019",,"March 18, 2021","Clinical Research Site, Phoenix, Arizona, United States|Clinical Research Site, Phoenix, Arizona, United States|Clinical Research Site, Little Rock, Arkansas, United States|Clinical Research Site, Bellflower, California, United States|Clinical Research Site, Beverly Hills, California, United States|Clinical Research Site, Garden Grove, California, United States|Clinical Research Site, Oakland, California, United States|Clinical Research Site, Oceanside, California, United States|Clinical Research Site, Panorama City, California, United States|Clinical Research Site, Redlands, California, United States|Clinical Research Site, Riverside, California, United States|Clinical Research Site, San Diego, California, United States|Clinical Research Site, Sherman Oaks, California, United States|Clinical Research Site, Upland, California, United States|Clinical Research Site, Coral Springs, Florida, United States|Clinical Research Site, Hollywood, Florida, United States|Clinical Research Site, Jacksonville, Florida, United States|Clinical Research Site, Lauderhill, Florida, United States|Clinical Research Site, North Miami, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Atlanta, Georgia, United States|Clinical Research Site, Boise, Idaho, United States|Clinical Research Site, Chicago, Illinois, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, Las Vegas, Nevada, United States|Clinical Research Site, Berlin, New Jersey, United States|Clinical Research Site, Cherry Hill, New Jersey, United States|Clinical Research Site, Toms River, New Jersey, United States|Clinical Research Site, Jamaica, New York, United States|Clinical Research Site, Rochester, New York, United States|Clinical Research Site, Staten Island, New York, United States|Clinical Research Site, Hickory, North Carolina, United States|Clinical Research Site, Cincinnati, Ohio, United States|Clinical Research Site, Middleburg Heights, Ohio, United States|Clinical Research Site, Oklahoma City, Oklahoma, United States|Clinical Research Site, Media, Pennsylvania, United States|Clinical Research Site, Philadelphia, Pennsylvania, United States|Clinical Research Site, Memphis, Tennessee, United States|Clinical Research Site, Dallas, Texas, United States|Clinical Research Site, Fort Worth, Texas, United States|Clinical Research Site, Houston, Texas, United States|Clinical Research Site, Wichita Falls, Texas, United States|Clinical Research Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04019704"
450,"NCT03468686","The Study of Effectiveness of rTMS on Rumination and Anhedonia in Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Bipolar Depression","Device: Bilateral rTMS|Device: Sham rTMS|Device: Unilateral rTMS (High frequency)","Rumination Symptoms|changes in default mode network|Anhedonia Symptoms|Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale|Depressive symptoms measured by the 21-item Beck Depression Inventory-II","University of Tehran|Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","4748","December 21, 2016","September 30, 2020","October 30, 2020","March 16, 2018",,"August 20, 2020","Atieh Clinical Neuroscience Center (ACNC), Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03468686"
451,"NCT03072823","Omega-3 Polyunsaturated Fatty Acids on Major Depressive Disorder in Patients With Cardiovascular Diseases",,"Completed","No Results Available","Cardiovascular Diseases|Major Depressive Disorder","Dietary Supplement: n-3 Polyunsaturated fatty acid|Dietary Supplement: placebo","Change in Hamilton Depression Scale(HAM-D) score at 3 months|Change in Beck's Depression Inventory(BDI) score at 3 months|Electrocardiogram (EKG)|mini nutritional assessment (MNA) score|Adverse effects|plasma level of n-3 polyunsaturated fatty acids|plasma cytokine/chemokine","China Medical University Hospital|National Science Council, Taiwan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMUH104-REC2-059","January 27, 2016","March 31, 2017","June 30, 2017","March 7, 2017",,"July 23, 2019","China Medical University, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03072823"
452,"NCT02793258","Impact of tDCS on Emotional Processing in Major Depression","EmoStim","Recruiting","No Results Available","Major Depressive Disorder","Device: transcranial direct current stimulation","Number of correct responses at a facial expression recognition task|Evolution of the depressive symptoms measured by MADRS|Performance on an attentional dot-probe task|tests of executive functions|Beck depression inventory scale|Clinical global impression scale|Eye movements during facial emotion recognition task and attentional task|Skin conductance measured in speed per microseconds|Heart rate measured in number of heart pulses per milliseconds|Respiratory frequency measured in number of respiratory cycles per minute","Hôpital le Vinatier","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-A00415-46","July 22, 2016","June 30, 2021","February 2022","June 8, 2016",,"October 5, 2020","Ch Le Vinatier, Lyon, Rhone Alpes, France",,"https://ClinicalTrials.gov/show/NCT02793258"
453,"NCT02454426","Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease",,"Withdrawn","No Results Available","Major Depressive Disorder|Coronary Artery Disease","Drug: Vortioxetine","Severity of depressive episodes measured using the Montgomery-Asberg Depression Rating Scale (MADRS)","Thomas Jefferson University|Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TakedaHRV","April 2016","June 2016","June 2016","May 27, 2015",,"August 25, 2016","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02454426"
454,"NCT03771664","A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia",,"Suspended","No Results Available","Major Depressive Disorder|Insomnia","Drug: SAGE-217|Drug: Placebo","Change from baseline in sleep efficiency (SE) as assessed by polysomnography (PSG)|Change from baseline of wake after sleep onset (WASO).|Change from baseline in total sleep time (TST).|Change from baseline in Latency to Persistent Sleep (LPS)|Change from baseline in Number of Awakenings (NAW).|Change from baseline in Insomnia Severity Index (ISI)|Change from baseline in Consensus Sleep Diary - Core (CSD-C)|Change from baseline in Clinical Global Impression - Severity (CGI-S).|Change from baseline in the Clinical Global Impression - Improvement (CGI-I).|Change from baseline in the 17-item HAM-D total score.|Change from baseline in the 9-item subject-rated Patient Health Questionnaire (PHQ).|Incidence and severity of adverse events/serious adverse events.|Change from baseline in rapid eye movement (REM) and non-REM sleep.","Sage Therapeutics","All","18 Years to 64 Years   (Adult)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-MDD-304","February 20, 2019","May 2020","May 2020","December 11, 2018",,"January 13, 2020","Sage Investigational Site, Little Rock, Arkansas, United States|Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Garden Grove, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, San Diego, California, United States|Sage Investigational Site, Temecula, California, United States|Sage Investigational Site, Fort Myers, Florida, United States|Sage Investigational Site, Hollywood, Florida, United States|Sage Investigational Site, Miami Lakes, Florida, United States|Sage Investigational Site, North Miami, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Lake Charles, Louisiana, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Saint Louis, Missouri, United States|Sage Investigational Site, Las Vegas, Nevada, United States|Sage Investigational Site, Berlin, New Jersey, United States|Sage Investigational Site, Albuquerque, New Mexico, United States|Sage Investigational Site, Brooklyn, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Salem, Oregon, United States|Sage Investigational Site, Charleston, South Carolina, United States|Sage Investigational Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03771664"
455,"NCT04825535","Non-Inferiority RCT Comparing Online and On-Site CBT in MDDi",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Behavioral: Standard psychiatry and cognitive behavioral online intervention|Behavioral: Standard psychiatry and cognitive behavioural in-person intervention","Change in Beck Depression Inventory - 2 (0 to 63 - higher score indicates worse outcome)|Change in Beck Anxiety Inventory (0 to 63 - higher score indicates worse outcome)|Change in Quick Inventory of Depressive Symptoms (0 to 48 - higher score indicates worse outcome)|Change in Hamilton Depression Rating Scale - 24-item version (0 to 72) Hamilton Depression Rating Scale - 24 item (0 - 96 - higher score indicates worse outcome)|Change in 5-Facet Mindfulness Questionnaire - 39-item version (39 to 195 - higher score indicates better outcome) Five-Facet Mindfulness Questionnaire|Change in Brief Pain Inventory - 11 item (0 - 176 - high score indicates worse outcome)|Change in EQ-5D Quality of Life Instrument - 5 items - 0 - 25 - high score - worse outcome)","York University","All","18 Years to 60 Years   (Adult)","Not Applicable","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","08-2020","April 2021","April 2025","April 2025","April 1, 2021",,"April 1, 2021","York University, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04825535"
456,"NCT04285515","Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder",,"Recruiting","No Results Available","Bipolar Depression|Major Depressive Disorder","Drug: Lumateperone|Drug: Placebos","Montgomery-Åsberg Depression Rating Scale|Clinical Global Impression Scale - Severity","Intra-Cellular Therapies, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ITI-007-403","February 27, 2020","December 2022","December 2022","February 26, 2020",,"January 19, 2021","Clinical Site, Garden Grove, California, United States|Clinical Site, Oceanside, California, United States|Clinical Site, Sherman Oaks, California, United States|Clinical Site, Lauderhill, Florida, United States|Clinical Site, Miami, Florida, United States|Clinical Site, Orange City, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Decatur, Georgia, United States|Clinical Site, O'Fallon, Missouri, United States|Clinical Site, Cedarhurst, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04285515"
457,"NCT02530164","Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression","DepressionDC","Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial direct current stimulation (tDCS)","Change from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) scores at week 6 post-randomization compared to baseline.","Ludwig-Maximilians - University of Munich","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DEP-1483-0152-I","September 2015","August 2020","January 2021","August 20, 2015",,"September 9, 2020","Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT02530164"
458,"NCT01416220","Lithium Versus Paroxetine in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Lithium|Drug: Paroxetine","Montgomery Asberg Depression Rating Scale (MADRS)|The Young Mania Rating Scale (YMRS)|The Clinical Global Impression (CGI)|The Columbia Suicide Classification Scale|Barnes Akathisia Rating Scale (BARS)|Treatment -emergent symptom checklist and questionnaire","Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Phase 4","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MoodDig-001","September 2011","February 2013","February 2013","August 12, 2011",,"July 16, 2020","Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT01416220"
459,"NCT02125799","Accelerated rTMS for Treatment-Resistant Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Accelerated HF-rTMS (Magstim Rapid 2 stimulator)","Quick Inventory of Depressive Symptomatology - Clinician Version","Douglas Mental Health University Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ERB12/38|IRB12/38","October 2012","December 2013","December 2013","April 29, 2014",,"October 6, 2014","Douglas Mental Health University Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02125799"
460,"NCT04041284","A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder",,"Recruiting","No Results Available","Migraine|Major Depressive Disorder","Drug: Fremanezumab|Drug: Placebo","Mean change in the monthly average number of migraine days|Mean change in depression symptoms|Number of participants with 50% or more reduction of migraine days|Mean change in quality of life|Mean change in disability score for overall impact as measured by Clinical Global Impression-Severity (CGI-S)|Mean change in disability score for overall impact as measured by Headache Impact Test (HIT-6)|Number of participants reporting adverse events|Number of participants who use concomitant medication for adverse events|Percentage of participants who do not complete the study due to adverse events|Change in eC-SSRS (electronic Columbia-Suicide Severity Rating Scale) scores","Teva Branded Pharmaceutical Products R&D, Inc.|Teva Pharmaceutical Industries","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TV48125-MH-40142|2019-001989-15","September 13, 2019","May 17, 2022","May 17, 2022","August 1, 2019",,"April 14, 2021","Teva Investigational Site 14330, Little Rock, Arkansas, United States|Teva Investigational Site 14337, San Diego, California, United States|Teva Investigational Site 14332, Stamford, Connecticut, United States|Teva Investigational Site 14329, Hialeah, Florida, United States|Teva Investigational Site 14334, Jacksonville, Florida, United States|Teva Investigational Site 14341, Orlando, Florida, United States|Teva Investigational Site 14411, Tampa, Florida, United States|Teva Investigational Site 14336, Pikesville, Maryland, United States|Teva Investigational Site 14331, Waltham, Massachusetts, United States|Teva Investigational Site 14343, Bolivar, Missouri, United States|Teva Investigational Site 14345, Bronx, New York, United States|Teva Investigational Site 14335, Brooklyn, New York, United States|Teva Investigational Site 14340, Portland, Oregon, United States|Teva Investigational Site 14338, Philadelphia, Pennsylvania, United States|Teva Investigational Site 14333, Memphis, Tennessee, United States|Teva Investigational Site 14339, Nashville, Tennessee, United States|Teva Investigational Site 54190, Chocen, Czechia|Teva Investigational Site 54183, Prague 4, Czechia|Teva Investigational Site 54184, Prague 6, Czechia|Teva Investigational Site 54185, Praha 8, Czechia|Teva Investigational Site 54186, Rychnov nad Kneznou, Czechia|Teva Investigational Site 40058, Kuopio, Finland|Teva Investigational Site 40057, Oulu, Finland|Teva Investigational Site 40056, Tampere, Finland|Teva Investigational Site 40055, Turku, Finland|Teva Investigational Site 35265, Bron, France|Teva Investigational Site 35267, Saint Priest en Jarez, France|Teva Investigational Site 32736, Dresden, Germany|Teva Investigational Site 32731, Essen, Germany|Teva Investigational Site 32737, Essen, Germany|Teva Investigational Site 32734, Leipzig, Germany|Teva Investigational Site 32732, Mittweida, Germany|Teva Investigational Site 32733, Westerstede, Germany|Teva Investigational Site 63076, Glyfada, Greece|Teva Investigational Site 63077, Marousi, Greece|Teva Investigational Site 80172, Hadera, Israel|Teva Investigational Site 80173, Holon, Israel|Teva Investigational Site 80177, Jerusalem, Israel|Teva Investigational Site 80178, Petah Tikva, Israel|Teva Investigational Site 80175, Rehovot, Israel|Teva Investigational Site 30242, Catanzaro, Italy|Teva Investigational Site 30236, Firenze, Italy|Teva Investigational Site 30237, Milano, Italy|Teva Investigational Site 30232, Rome, Italy|Teva Investigational Site 30234, Rome, Italy|Teva Investigational Site 53447, Krakow, Poland|Teva Investigational Site 53445, Poznan, Poland|Teva Investigational Site 53446, Warszawa, Poland|Teva Investigational Site 53448, Wroclaw, Poland|Teva Investigational Site 50482, Moscow, Russian Federation|Teva Investigational Site 50483, Moscow, Russian Federation|Teva Investigational Site 50480, Moscow, Russian Federation|Teva Investigational Site 50481, Nizhnij Novgorod, Russian Federation|Teva Investigational Site 31276, Sevilla, Spain|Teva Investigational Site 31274, Valencia, Spain|Teva Investigational Site 31272, Valladolid, Spain|Teva Investigational Site 31273, Zaragoza, Spain|Teva Investigational Site 58319, Kyiv, Ukraine|Teva Investigational Site 58321, Odesa, Ukraine|Teva Investigational Site 58320, Vinnytsya, Ukraine|Teva Investigational Site 34254, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04041284"
461,"NCT00531947","Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Selegiline Transdermal System|Drug: Placebo","CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12|CGI-S - Week 12 (mITT w/LOCF Population)|CGI-C - Week 12 (mITT w/LOCF Population)|CGI-C Percent Responders (mITT w/LOCF Population)|CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)|CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)|CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)|CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)|CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)|Physical Examination (Screening vs. EOS)|Urinalysis (Change From Baseline)|Vital Signs-Heart Rate (Change From Baseline)|Vital Signs-Blood Pressure (Change From Baseline)|12 Lead ECG (Change From Baseline)|12 Lead ECG (Change From Baseline)Ventricular Heart Rate|Hematology - White Blood Cell (WBC) (Change From Baseline)|Hematology - Hematocrit (Change From Baseline)|Hematology - Hemoglobin (Change From Baseline)|Hematology - Red Blood Cell (Change From Baseline)","Somerset Pharmaceuticals","All","12 Years to 17 Years   (Child)","Phase 4","308","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S9303-P0605","July 2007","October 2010","October 2010","September 19, 2007","June 26, 2013","January 15, 2014","Dr. Nelson Handal, Dothan, Alabama, United States|Dr. Mohammed Bari, National City, California, United States|Dr. Michael McManus, SanDiego, California, United States|Dr. Elias Sarkis, Gainesville, Florida, United States|Dr. Scott Segal, North Miami, Florida, United States|Dr. Mary Stedman, Tampa, Florida, United States|Dr. Irving Kolin, Winter Park, Florida, United States|Dr. Rory Murphy, Overland Park, Kansas, United States|Dr. Andrew Sediloo, Owensboro, Kentucky, United States|Dr. Bruce Waslick, Springfield, Massachusetts, United States|Dr. Christopher Kratochvil, Omaha, Nebraska, United States|Dr. Ann Childress, Las Vegas, Nevada, United States|Dr. Melissa DelBello, Cincinnati, Ohio, United States|Dr. Leland Dennis, Oklahoma City, Oklahoma, United States|Dr. David Brown, Austin, Texas, United States|Dr. Alain Katic, Bellaire, Texas, United States|Dr. Graham Emslie, Dallas, Texas, United States|Dr. Mary Shemo, Charlottesville, Virginia, United States|Dr. John Gilliam, Richmond, Virginia, United States|Dr. Arifulla Khan, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00531947"
462,"NCT02132286","Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine XR (extended release)","Changes in amygdala responses to negative emotional faces from the pre-treatment baseline to 8 weeks post treatment.|Changes in depression symptom severity as measured by Hamilton Depression Rating Scale from the pre-treatment baseline to week 8 post-treatment","University of Calgary|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","57","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","D1443L00037","December 2008","April 2012","April 2012","May 7, 2014",,"May 7, 2014","University of Calgary: Foothills medical centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02132286"
463,"NCT01409317","Neural Predictors and Longitudinal Neural Correlates of Deep Transcranial Magnetic Stimulation for Treating Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Deep Transcranial Magnetic Stimulation|Device: Repetitive Transcranial Magnetic Stimulation","21-item Hamilton Depression Rating Scale (HAM-D21)|Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)","Douglas Mental Health University Institute|Brainsway","All","25 Years to 50 Years   (Adult)","Phase 2|Phase 3","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DTMS-ERB11/28-2011","April 2013","January 2015","January 2015","August 4, 2011",,"May 28, 2015","Neuromodulation Research Clinic, Douglas Mental Health University Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01409317"
464,"NCT02268487","Integral Assessment in Unipolar Depression","AIUNI","Unknown status","No Results Available","Major Depressive Disorder","Drug: Sertraline","Early Improvement|Response|Remission","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","795996","January 2014","January 2017","January 2017","October 20, 2014",,"December 11, 2015","Insitute of Psychiatry of the University of São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02268487"
465,"NCT02669082","The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy",,"Completed","Has Results","Insomnia|Major Depressive Disorder","Drug: Ramelteon","Change From Baseline in Actigraphy-Measured Sleep Latency at the End of the Treatment Period|Change From Baseline in Diary-Measured Sleep Latency at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Total Nocturnal Sleep Time at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Nocturnal Wake Time at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Number of Nocturnal Awakenings at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Sleep Efficiency at the End of the Treatment Period|Change From Baseline in Diary-Measured Total Nocturnal Sleep Time at the End of the Treatment Period|Change From Baseline in Diary-Measured Number of Nocturnal Awakenings at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Daytime Activity Level, as Evaluated by the Number of Footsteps, at the End of the Treatment Period","Takeda","All","20 Years to 64 Years   (Adult)","Phase 4","26","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ramelteon-4002|JapicCTI-163143|U1111-1177-4116","May 9, 2017","January 31, 2018","January 31, 2018","January 29, 2016","July 22, 2019","July 22, 2019","You Ariyoshi Sleep Clinic, Kitakyushu, Fukuoka, Japan|Ishikawa Mental Clinic, Sapporo, Hokkaido, Japan|Minami 1jo Mental Clinic, Sapporo, Hokkaido, Japan|Senzoku Psychosomatic Clinic, Meguro, Tokyo, Japan|Sangenjaya Neurology and Psychosomatic Clinic, Setagaya, Tokyo, Japan|Himorogi Kokorono Clinic, Shinjuku, Tokyo, Japan|Seiwa Hospital, Shinjuku, Tokyo, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02669082/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02669082/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02669082"
466,"NCT02484456","Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder",,"Completed","No Results Available","Major Depression","Drug: AV 101 (4-Chlorokynurenine)|Other: Placebo Comparator","Change from baseline in the Hamilton Depression Rating scale total score.|Change from baseline in BPRS, CADSS, C-SSRS, HAM-A, HDRS, MADRS, PANAS, SHAPS, SSI, TEPS, YMRS total scores.|Change from baseline in the C-SSRS total score.|Proportion of subjects with response (defined as greater than or equal to 50% reduction from baseline in HDRS total score)|Proportion of subjects in remission (defined as HDRS total score less than or equal to 7|Incidence and nature of adverse events; vital signs; weight and body mass index (BMI) changes; physical examination changes; clinical laboratory evaluations; ECG.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","22","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","150151|15-M-0151","October 14, 2015","February 21, 2019","December 3, 2019","June 29, 2015",,"December 6, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02484456"
467,"NCT02948036","A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety",,"Recruiting","No Results Available","Major Depressive Disorder","Other: Mobile-device, plasticity-based adaptive cognitive treatment","Change in total score for depressive symptoms using Beck Depression Scale (BDI-II)|Change in total score for depressive symptoms using Patient Health Questionnaire (PHQ-9)|Change in total score for anxiety symptoms using Generalized Anxiety Disorder (GAD-7)|Change in total score for mood symptoms using Immediate Mood Scaler (IMS)|Change in total score for quality of life using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)","Posit Science Corporation|National Institute of Mental Health (NIMH)|University of Minnesota","All","18 Years to 60 Years   (Adult)","Not Applicable","30","Industry|NIH|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSC-1011-16|1R43MH111325","October 1, 2017","May 31, 2022","May 31, 2022","October 28, 2016",,"May 11, 2021","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02948036"
468,"NCT01119430","Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder",,"Terminated","No Results Available","Major Depression","Drug: DU125530|Drug: Placebo","Scores on Hamilton Depression Rating Scale","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSP-2003-01","May 2004","November 2007","November 2007","May 7, 2010",,"May 7, 2010","Hospital de Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01119430"
469,"NCT00125554","Metyrapone as Additive Treatment in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Metyrapone","Two psychometric criteria defined by the number of responders and time to onset-of-action. The number of responders was considered twice after 3 and 5 weeks by defining the treatment response as a 30% and 50% reduction|the course of concentrations of ACTH, cortisol, 11-deoxycortisol and DHEA.|Other psychometric scores, demographic parameters and side effects were considered as secondary variables.","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","HH-PSY-ja-007","May 1998",,"July 2001","August 1, 2005",,"August 12, 2005","Dept. of Psychiatry and Psychotherapy, UKE, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00125554"
470,"NCT01942785","Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy",,"Completed","Has Results","Major Depressive Disorder|Irritability","Drug: Brexpiprazole","Change From Baseline to Week 6 in SIS Total Score|Change From Baseline to Week 6 in SIS Item 1 Score|Change From Baseline to Week 6 in IDS-C30 Item 6 Score|Change From Baseline to Week 6 in Delay Discounting - Log-transformed MCQ Scores|Change From Baseline to Week 6 in BIS-11 Total Score|Change From Baseline to Week 6 in KSQ Anger-hostility Subscore|Shift From Baseline to Week 6 in Anger Attacks (AAQ)|Change From Baseline to Week 6 in IDS-C30 Total Score|Change From Baseline to Week 6 in KSQ Depression Subscore|Change From Baseline to Week 6 in MADRS Total Score|Change From Baseline to Week 6 in CPFQ Total Score|Change From Baseline to Week 6 in CGI-S Score|CGI-I Score at Week 6|Change From Baseline to Week 6 in KSQ Total Score|Change From Baseline to Week 6 in Delay Discounting - Log-transformed EDT DPDT Scores|Change From Baseline to Week 6 in Delay Discounting - EDT DRT Score|Change From Week 6 to Week 10 in SIS Total Score|Change From Week 6 to Week 10 in SIS Item 1 Score|Change From Week 6 to Week 10 in Delay Discounting - MCQ Scores|Change From Week 6 to Week 10 in BIS-11 Total Score|Change From Week 6 to Week 10 in KSQ Anger-hostility Subscore|Change From Week 6 to Week 10 in KSQ Depression Subscore|Change From Week 6 to Week 10 in CGI-S Score|Change From Baseline to Week 6 in MADRS Total Score in Patients With a Pre-defined Baseline BIS-11 Total Score|Change From Baseline to Week 6 in CGI-S Score in Patients With a Pre-defined Baseline BIS-11 Total Score|CGI-I Score at Week 6 Patients With a Pre-defined Baseline BIS-11 Total Score","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","55","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15353A","October 2013","July 2014",,"September 16, 2013","March 15, 2016","March 15, 2016","US015, Tucson, Arizona, United States|US019, Glendale, California, United States|US016, Oakland, California, United States|US014, San Diego, California, United States|US011, Denver, Colorado, United States|US018, Hallandale Beach, Florida, United States|US009, Jacksonville, Florida, United States|US005, Orlando, Florida, United States|US006, Gaithersburg, Maryland, United States|US012, Weymouth, Massachusetts, United States|US003, Jamaica, New York, United States|US001, Dayton, Ohio, United States|US007, Portland, Oregon, United States|US004, Memphis, Tennessee, United States|US002, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01942785"
471,"NCT00400088","Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide",,"Terminated","No Results Available","Major Depressive Disorder","Drug: paroxetine|Drug: lithium","Response will be defined as 50% reduction in MADRS score.|Remission will be defined as MADRS ≤ 12.|The MADRS will be done at week 0,1,2,3,4,5,6.|The Hamilton Depression Rating Scale (HAM -D)-17 item scale, at weeks 0 and 6.|Hamilton Anxiety Rating Scale (HAM-A),at weeks 0 and 6.|The Young Mania Rating Scale (YMRS), at weeks 0,1,2,3,4,5,6.|The Bipolar Depression Rating Scale (BDRS) (42),at weeks 0,1,2,3,4,5,6.|Checklist of DSM IV symptoms of mania/ hypomania, with additional questions assessing the presence of mood lability, abnormally high energy, abnormally high libido, and rage. Done at weeks 0,1,2,3,4,5,6.|The Beck Suicide Scale (BSS), at weeks 0, 1, 2,3,4,5, 6.","Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CDHA012|CDHA-RS/2006-076","June 2007","January 2013","January 2013","November 16, 2006",,"January 29, 2021","Capital District Health Authority - Dept. of Psychiatry, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT00400088"
472,"NCT00787501","Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression","ssrifMRI","Completed","No Results Available","Major Depressive Disorder","Drug: SSRI|Behavioral: CBT","Treatment outcome will be assessed on a variety of dimensions including change in symptoms, self-reported rumination, behavioral performance on cognitive tasks, and physiological reactivity to emotional information processing tasks.","University of Pittsburgh|The Pittsburgh Foundation|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Phase 1","98","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO07100326|M2007-0114|R01MH074807","June 2008","July 2011","July 2011","November 7, 2008",,"January 28, 2019","Mood Disorders Treatment and Research Program - UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00787501"
473,"NCT04217837","Treatment of Major Depressive Disorder in the UK Using TMS Therapy",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulator","Clinical Global Impression - Severity Scale|Patient Health Questionnaire - 9-item Self Report|Inventory of Depressive Symptomatology - Self Report (IDS-SR)|EuroQol 5 Dimensions|Health Resource Utilization Questionnaire (HRU)|Short Form 36-item Questionnaire","Neuronetics","All","22 Years to 70 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","44-50011-000","March 2020","February 2022","February 2022","January 3, 2020",,"January 7, 2020","St Pancras Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04217837"
474,"NCT00888862","Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women","DVS","Unknown status","No Results Available","Major Depressive Disorder|Menopausal Staging and Vasomotor Symptoms (for Females)","Drug: Desvenlafaxine Succinate","Effects of desvenlafaxine succinate (DVS) on brain structure and activation in midlife men and women with MDD.|Changes in brain activity|Changes in menopause-related symptoms among females","Hamilton Health Sciences Corporation|Wyeth is now a wholly owned subsidiary of Pfizer|St. Joseph's Healthcare Hamilton|McMaster University","All","40 Years to 60 Years   (Adult)","Phase 3","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WHCC2008-3","June 2009","June 2012","October 2012","April 28, 2009",,"February 8, 2012","Women's Health Concerns Clinic, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00888862"
475,"NCT00146523","An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Mifepristone|Drug: placebo","The change in a measure of psychosis|The change in a measure of depression","Corcept Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","247","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C-1073-09","May 2005","July 2006","July 2006","September 7, 2005",,"February 15, 2012","Georgy Koychev M.D., Sofia, Bulgaria|Luchezar G Hranov M.D., Sofia, Bulgaria|Svetlozar H Haralanov Ph.D., Sofia, Bulgaria|Vihra Milanova M.D., Sofia, Bulgaria|Georgi Popov M.D., Varna, Bulgaria|Pavo Filakovic M.D./Ph.D., Osijek, Croatia|Ljiljana Moro M.D./Ph.D., Rijeka, Croatia|Goran Dodig M.D./Ph.D., Split, Croatia|Dubravka Kocijan-Hercigonja M.D., Zagreb, Croatia|Miro Jakovljevic M.D., Zagreb, Croatia|Vera Folnegovic-Smalc M.D./Ph.D., Zagreb, Croatia|Ivana Timotijevic M.D., Belgrade, Former Serbia and Montenegro|Jelena Martinovic M.D., Belgrade, Former Serbia and Montenegro|Vladimir Diligenski M.D., Belgrade, Former Serbia and Montenegro|Vladimir Paunovic M.D., Belgrade, Former Serbia and Montenegro|Dragana Ignjatovic-Ristic M.D., Kragujevac, Former Serbia and Montenegro|Ratomir Lisulov M.D., Novi Sad, Former Serbia and Montenegro|Mihai Dumitru Gheorge, Bucharest, Romania|Aurel Nirestean M.D./Ph.D., Targu Mures, Romania",,"https://ClinicalTrials.gov/show/NCT00146523"
476,"NCT00489775","Duloxetine Versus Paroxetine for Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine|Drug: Paroxetine","To assess hypothesis that efficacy of duloxetine 60mg QD is non-inferior to paroxetine 20mg QD in treating major depressive disorder as defined by DSM-IV. Primary efficacy evaluated by mean change of HAMD17 total scores from baseline to endpoint.|To compare the efficacy of duloxetine 60 mg QD and paroxetine 20 mg QD on anxiety symptoms associated with depression as measured by mean changes in Hamilton Anxiety Rating Scale (HAMA) total scores|To compare efficacy of treatment with duloxetine 60 mg QD and paroxetine 20 mg QD on symptoms of depression measured by mean endpoint scale on the Clinical Global Impression of Severity Scale (CGI-S) scale and the endpoint score|To compare efficacy of treatment with duloxetine 60 mg QD and paroxetine 20 mg QD on symptoms of depression measured by the endpoint score on the Patient Global Impression of Improvement (PGI-I) scale|To compare the efficacy of treatment with duloxetine 60 mg QD and paroxetine 20 mg QD on somatic complaints of pain as measured by the Somatic Symptom Inventory Scale (SSI) and Visual Analog Scales for pain (VAS)|To compare the efficacy of duloxetine 60 mg QD and paroxetine 20 mg QD as measured by response and remission rates|To compare the safety of duloxetine 60 mg QD and paroxetine 20 mg QD using information on treatment-emergent adverse events and other safety measures - e.g. electrocardiograms (ECGs) and laboratory tests","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6937|F1J-AA-HMCV","January 2004",,"June 2005","June 21, 2007",,"June 21, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China",,"https://ClinicalTrials.gov/show/NCT00489775"
477,"NCT01085812","Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder",,"Completed","Has Results","Depression|Major Depressive Disorder","Drug: Levomilnacipran ER|Drug: Placebo","Time to Relapse (Days)","Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","734","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-05","March 2010","October 2011","October 2011","March 12, 2010","January 13, 2020","January 13, 2020","Forest Investigative Site #023, Beverly Hills, California, United States|Forest Investigative Site #017, Encino, California, United States|Forest Investigative Site #021, Garden Grove, California, United States|Forest Investigative Site #025, Newport Beach, California, United States|Forest Investigative Site #030, Orange, California, United States|Forest Investigative Site #002, San Diego, California, United States|Forest Investigative Site #003, Sherman Oaks, California, United States|Forest Research Institute #001, Bonita Springs, Florida, United States|Forest Investigative Site #015, Fort Myers, Florida, United States|Forest Investigative Site #029, Maitland, Florida, United States|Forest Investigative Site #005, North Miami, Florida, United States|Forest Investigative Site #016, Orlando, Florida, United States|Forest Investigative Site #004, South Miami, Florida, United States|Forest Investigative Site #014, Atlanta, Georgia, United States|Forest Investigative Site #022, Chicago, Illinois, United States|Forest Investigative Site #006, Chicago, Illinois, United States|Forest Investigative Site #009, Prairie Village, Kansas, United States|Forest Investigative Site #013, Baltimore, Maryland, United States|Forest Investigative Site #010, Boston, Massachusetts, United States|Forest Investigative Site #012, Saint Louis, Missouri, United States|Forest Investigative Site #011, Staten Island, New York, United States|Forest Investigative Site #026, Portland, Oregon, United States|Forest Investigative Site #008, Bridgeville, Pennsylvania, United States|Forest Investigative Site #028, Norristown, Pennsylvania, United States|Forest Investigative Site #020, Philadelphia, Pennsylvania, United States|Forest Investigative Site #024, Memphis, Tennessee, United States|Forest Investigative Site #007, Dallas, Texas, United States|Forest Investigative Site #019, San Antonio, Texas, United States|Forest Investigative Site #018, Bellevue, Washington, United States|Forest Investigative Site #027, Seattle, Washington, United States|Forest Investigative Site #050, Kelowna, British Columbia, Canada|Forest Investigative Site #051, Vancouver, British Columbia, Canada|Forest Investigative Site #052, Sydney, Nova Scotia, Canada|Forest Investigative Site #055, Chatham, Ontario, Canada|Forest Investigative Site #053, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01085812"
478,"NCT01851356","Brain Inflammation in Major Depressive Disorder Background",,"Completed","No Results Available","Major Depression",,"Comparison of VT values obtained in MDD subject with those from healthy controls.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"61","NIH","Observational","Time Perspective: Prospective","130100|13-M-0100","May 8, 2013","July 27, 2017","March 22, 2018","May 10, 2013",,"December 16, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01851356"
479,"NCT02330679","Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Desvenlafaxine|Drug: Placebo","The resting state and emotional task related brain activity pattern at the pretreatment baseline and two weeks post treatment as measured by functional MRI and analyzed by machine learning techniques|The clinical response to antidepressant treatment as measured by Montgomery-Asberg Depression Rating (MADRS) scale.","University of Calgary|University of Alberta","All","20 Years to 55 Years   (Adult)","Phase 4","61","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","REB 14-0194","December 2014","December 2016","December 2016","January 5, 2015",,"January 5, 2015","University of Calgary, TRW Building, Foothills Hospital Campus, Calgary, Alberta, Canada|University of Calgary: Foothills Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02330679"
480,"NCT01337609","Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder|Irritable Bowel Syndrome","Drug: Ganeden BC30|Other: Placebo (sugar pill)|Other: Ganeden BC30, Placebo (sugar pill)","Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)|IBS Severity Scoring System (IBS-SSS)|Visual Analog Scale (VAS)|Adequate Relief of IBS Pain (AR-IBS)|Patient Global Impression of Change (PGI-C) - IBS Symptoms","Massachusetts General Hospital|Ganeden Biotech, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","5","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008P002387","June 2011","February 2012","February 2012","April 19, 2011","August 9, 2013","August 9, 2013","Burlington Medical Associates, Burlington, Massachusetts, United States|Charles River Medical Associates, Westborough, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01337609"
481,"NCT00385307","Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)",,"Completed","No Results Available","Major Depressive Disorder","Drug: amibegron (SR58611A)","Change from baseline in total score of a depression rating scale at 8 weeks|Safety assessments","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","680","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC6607","September 2006","November 2007","November 2007","October 9, 2006",,"March 25, 2009","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00385307"
482,"NCT00889369","Duloxetine for Major Depression in Peri-/Postmenopausal Women",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Duloxetine","The effects of response to treatment with duloxetine on brain structure and activation in subjects (peri- and postmenopausal women with MDD).|Changes in brain activation in remitters versus non-remitters after treatment with duloxetine (remission of depression defined MADRS total score <10 at study end).|Correlations between changes in brain activation and changes from baseline to study end and menopausal symptoms, depressive symptoms, cognition, quality of life, and clinical global impression (improvement and severity).","Hamilton Health Sciences Corporation|Eli Lilly and Company|St. Joseph's Healthcare Hamilton|McMaster University","Female","40 Years to 60 Years   (Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WHCC2008-2","May 2009","February 2012","June 2012","April 28, 2009",,"February 8, 2012","Women's Health Concerns Clinic, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00889369"
483,"NCT01098240","A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression",,"Terminated","Has Results","Major Depressive Disorder","Drug: CP-601,927|Other: Placebo","Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score at Week 14|Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score at Weeks 9 Through 13|Change From Double-blind Baseline in Hamilton Depression Scale 25-item (HAM-D25) - Total Score at Weeks 9 Through 14|Change From Double-blind Baseline in Bech Melancholia Subscale Score at Weeks 9 Through 14|Change From Double-blind Baseline in Clinical Global Impression - Severity (CGI-S) at Weeks 9, 10, 12, and 14|Change From Double-blind Baseline in Sheehan Irritability Scale (SIS) Total Score at Weeks 11 and 14|Change From Double-blind Baseline in Sheehan Disability Scale (SDS) Total Score at Weeks 11 and 14|Change From Double-blind Baseline in Sheehan Disability Scale (SDS) Subscale Score at Weeks 11 and 14|Clinical Global Impression - Improvement (CGI-I) Total Score at Weeks 9, 10, 12 and 14|Number of Participants With Remission at Weeks 9, 10, 12 and 14|Number of Participants With Response at Weeks 9 Through 14|Population Pharmacokinetics|Plasma CP-601,927 Concentration","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","297","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A3331017","June 14, 2010","September 12, 2011","September 12, 2011","April 2, 2010","June 26, 2013","May 3, 2021","Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|Southwestern Research Incorporated, Beverly Hills, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Synergy Clinical Research Center, National City, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|William B. Backus Hospital Satellite Blood Draw, Norwich, Connecticut, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Comprehensive NeuroScience, Inc., Saint Petersburg, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Psychiatric Medicine Associates, LLC., Skokie, Illinois, United States|Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States|Clinco, Terre Haute, Indiana, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Louisiana Clinical Research, LLC, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|AccelRx Research, Fall River, Massachusetts, United States|Detroit Bio-Medical Laboratories, Inc., Rochester Hills, Michigan, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Erie County Medical Center / State University of New York at Buffalo affiliate, Buffalo, New York, United States|Comprehensive NeuroScience, Inc., Fresh Meadows, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Kettlie Joseph Daniels, MD, Inc., Toledo, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|City Line Family Medicine, Bala-Cynwyd, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|University of Pennsylvania / Department of Psychiatry, Philadelphia, Pennsylvania, United States|Frankford Avenue Family Practice, PC, Philadelphia, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Carolina Clinical Research Service LLC, Columbia, South Carolina, United States|FutureSearch Trials, Austin, Texas, United States|FutureSearch Trials of Dallas, L.P., Dallas, Texas, United States|University of Texas (UT) Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas (UT) Southwestern Medical Center at Dallas, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Radiant Research, Inc, Salt Lake City, Utah, United States|University of Utah School of Medicine Department of Psychiatry Mood Disorders Clinic, Salt Lake City, Utah, United States|University of Virginia Health System / Department of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Mcguire Hall Annex, Richmond, Virginia, United States|Nelson Clinic, Richmond, Virginia, United States|Virginia Commonwealth University (VCU) Medical Center, Richmond, Virginia, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation for Health, Research and Education, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01098240"
484,"NCT00973934","Magnetic Seizure Therapy (MST) for the Treatment of Major Depression","MST-2","Completed","No Results Available","Major Depressive Disorder","Device: Magstim Theta|Device: Thymatron System IV","Hamilton Rating Scale for Depression (HRSD), 24 item|Beck Depression Inventory|Neuropsychological testings to assess the acute, short term, long term memory effects of the treatments","Sarah Lisanby|University of Texas|Stanley Medical Research Institute|Duke University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","4371|01-069","April 2002","January 2006","December 2009","September 9, 2009",,"June 10, 2014","Duke Universtiy Medical Center, Durham, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00973934"
485,"NCT00873795","Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: aripiprazole , sertraline","score change of Hamilton Rating Scale For Depression (HAM-D17 )|score change of Brief Psychiatric Rating Scale (BPRS-50)","Chimei Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB 09603-001","April 2007","March 2009","March 2009","April 2, 2009",,"April 2, 2009","Psychiatry Department, Chimei Medical Center, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00873795"
486,"NCT00296920","Deep Brain Stimulation for Refractory Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Deep Brain Stimulation","Hamilton Rating Scale for Depression, 24-item version (HRSD-24)|Clinical Global Impression (CGI) of Severity/Improvement|Psychiatric assessments will be performed every two weeks in the clinic. Once final stimulation parameters are established, psychiatric symptoms will be monitored monthly.","University Health Network, Toronto|National Alliance for Research on Schizophrenia and Depression","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-0118-B","June 2002","November 2007",,"February 27, 2006",,"February 17, 2009","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00296920"
487,"NCT01310140","Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features",,"Terminated","No Results Available","Major Depressive Disorder|Major Depressive Disorder w/ Psychotic Features|Metabolic Syndrome",,"The primary measure is any change in fasting insulin from admission to discharge while subjects are inpatient.|The first secondary measure is a fasting lipid panel, including fasting total cholesterol, fasting LDL, fasting HDL, and fasting triglycerides; we want to measure a change in data from admission to discharge|Fasting glucose will be a separate secondary outcome measure; we want to measure a change in data from admission to discharge|Waist Circumference; we want to measure a change in data from admission to discharge|Urine microalbumin; we want to measure a change in data from admission to discharge|C-reactive Protein; we want to measure a change in data from admission to discharge|Homocysteine; we want to measure a change in data from admission to discharge|Blood pressure (supine & standing as available)|Cortisol; we want to measure a change in data from admission to discharge","Massachusetts General Hospital|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 85 Years   (Adult, Older Adult)",,"14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009-P-002723","January 2011","September 2012","September 2012","March 8, 2011",,"February 13, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01310140"
488,"NCT00420004","A Study for Participants With Major Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo|Drug: Escitalopram","Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score|Change From Baseline to Week 8 in Maier-Philipp Subscale of the 17-item Hamilton Depression Rating Scale (HAMD-17)|Response and Remission Rates|Clinical Global Impression of Improvement Score at Week 8|Change From Baseline in Hamilton Anxiety Rating Scale (HAMA) Total Score up to Week 8 Endpoint|Change From Baseline on the 36-item Short-Form (SF-36) Health Status Survey Mental and Physical Components up to Week 8 Endpoint|Change From Baseline in Quick Inventory of Depressive Symptomatology Total Score up to Week 8 Endpoint|Change From Baseline in Beck Scale for Suicide Ideation up to Week 8 Endpoint|Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint|Change From Baseline in Arizona Sexual Experiences Scale up to Week 8 Endpoint|Change From Baseline in Insomnia Severity Index up to Week 8 Endpoint|Change From Baseline to Week 8 in Fatigue Severity Scale|Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint|Number of Participants With at Least 1 Serious Adverse Event (Safety and Tolerability)|Change From Baseline to Week 8 in the 21-item Hamilton Depression Rating Scale (HAM-21) Total Score|Cognitive Assessment Battery: Change From Baseline in Word List Learning and Delayed Recall Test (WLDRT) up to Week 8 Endpoint|Cognitive Assessment Battery: Change From Baseline in Symbol Digit Substitution Test (SDST) up to Week 8 Endpoint|Cognitive Assessment Battery: Change From Baseline in Two Digit Cancellation Test up to Week 8 Endpoint|Cognitive Assessment Battery: Change From Baseline in Trail Making A up to Week 8 Endpoint","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","469","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11174|H9P-MC-LNBD","December 2006","March 2008","March 2008","January 9, 2007","April 27, 2018","April 27, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allentown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lasi, Romania",,"https://ClinicalTrials.gov/show/NCT00420004"
489,"NCT00868374","Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder","MDD/GAD","Terminated","Has Results","Major Depressive Disorder|Generalized Anxiety Disorder","Drug: Quetiapine XR|Drug: Placebo","Change in 17 Item Hamilton Rating Scale for Depression (HAM-D-17)","Keming Gao|AstraZeneca|University Hospitals Cleveland Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-07-29","June 2008","October 2011","October 2011","March 25, 2009","February 11, 2014","December 29, 2016","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00868374"
490,"NCT00168272","Priming rTMS In Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation","The primary outcome measure used is the MADRS (Montgomery-Asberg Depression Rating Scale). At study end response criteria is defined as a 50% reduction in total MADRS score and remission defined as less or equal to 10.|Other outcome measures administered fortnightly are: BPRS (Brief Psychiatric Rating Scale), CORE (measure of melancholic symptoms), BDI (Beck Depression Inventory), CGI (Clinical Global Impression Scale), GAF (Global Assessment of Functioning Scale).","The Alfred","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","5/04","June 2004",,"March 2007","September 15, 2005",,"April 16, 2007","Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00168272"
491,"NCT00402220","A Double-blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: TMS|Device: Sham TMS","The 17- item Hamilton Rating Scale for Depression (HAM-D)","Bayside Health|National Health and Medical Research Council, Australia","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","fitzgeraldp","March 2007","January 2011","January 2011","November 22, 2006",,"October 19, 2020","Alfred Psychiatry Research Centre, Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00402220"
492,"NCT03000530","A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder",,"Completed","Has Results","Major Depression","Drug: SAGE-217|Drug: Placebo","Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A|Percentage of Participants With TEAEs, Graded by Severity - Part A|Change From Baseline in Basophils - Part A|Change From Baseline in Basophils to Leukocytes Ratio [Percentage (%)] - Part A|Change From Baseline in Eosinophils - Part A|Change From Baseline in Eosinophils to Leukocytes Ratio (%) - Part A|Change From Baseline in Hematocrit - Part A|Change From Baseline in Hemoglobin - Part A|Change From Baseline in Lymphocytes - Part A|Change From Baseline in Lymphocytes to Leukocytes Ratio (%) - Part A|Change From Baseline in Monocytes - Part A|Change From Baseline in Monocytes to Leukocytes Ratio (%) - Part A|Change From Baseline in Neutrophils - Part A|Change From Baseline in Neutrophils to Leukocytes Ratio (%) - Part A|Change From Baseline in Platelets - Part A|Change From Baseline in Erythrocytes - Part A|Change From Baseline in Reticulocytes - Part A|Change From Baseline in Leukocytes - Part A|Change From Baseline in Albumin - Part A|Change From Baseline in Alkaline Phosphatase - Part A|Change From Baseline in Alanine Aminotransferase - Part A|Change From Baseline in Aspartate Aminotransferase - Part A|Change From Baseline in Bilirubin - Part A|Change From Baseline in Chloride - Part A|Change From Baseline in Carbon Dioxide - Part A|Change From Baseline in Creatinine - Part A|Change From Baseline in Potassium - Part A|Change From Baseline in Protein - Part A|Change From Baseline in Sodium - Part A|Change From Baseline in Urea Nitrogen - Part A|Change From Baseline in Activated Partial Thromboplastin Time - Part A|Change From Baseline in Prothrombin International Normalized Ratio (%) - Part A|Change From Baseline in Prothrombin Time - Part A|Change From Baseline in pH - Part A|Change From Baseline in Specific Gravity - Part A|Change From Baseline (CFB) in Supine Systolic Blood Pressure - Part A|Change From Baseline (CFB) in Supine Diastolic Blood Pressure - Part A|Change From Baseline (CFB) in Standing Systolic Blood Pressure - Part A|Change From Baseline (CFB) in Standing Diastolic Blood Pressure - Part A|Change From Baseline (CFB) in Heart Rate - Part A|Change From Baseline (CFB) in Respiratory Rate - Part A|Change From Baseline (CFB) in Oral Temperature - Part A|Change From Baseline (CFB) in Oxygen Saturation - Part A|Change From Baseline in QT Interval - Part A|Change From Baseline in QTcF Interval - Part A|Change From Baseline in ECG Mean Heart Rate - Part A|Change From Baseline in RR Interval - Part A|Change From Baseline in PR Interval - Part A|Change From Baseline in QRS Interval - Part A|Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item - Part A|Change From Baseline in Stanford Sleepiness Scale (SSS) Score at Day 15 - Part A|Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 - Part B|Change From Baseline in the HAM-D Total Score at Day 15 and All Other Time Points - Part A|Percentage of Participants With TEAEs - Part B|Percentage of Participants With AEs During Post-TEAE Period|Percentage of Participants With TEAEs, Graded by Severity - Part B|Change From Baseline in Basophils - Part B|Change From Baseline in Basophils to Leukocytes Ratio (%) - Part B|Change From Baseline in Eosinophils - Part B|Change From Baseline in Eosinophils to Leukocytes Ratio (%) - Part B|Change From Baseline in Hematocrit - Part B|Change From Baseline in Hemoglobin - Part B|Change From Baseline in Lymphocytes - Part B|Change From Baseline in Lymphocytes to Leukocytes Ratio (%) - Part B|Change From Baseline in Monocytes - Part B|Change From Baseline in Monocytes to Leukocytes Ratio (%) - Part B|Change From Baseline in Neutrophils - Part B|Change From Baseline in Neutrophils to Leukocytes Ratio (%) - Part B|Change From Baseline in Platelets - Part B|Change From Baseline in Erythrocytes - Part B|Change From Baseline in Reticulocytes - Part B|Change From Baseline in Reticulocytes to Erythrocytes Ratio (%) - Part B|Change From Baseline in Leukocytes - Part B|Change From Baseline in Albumin - Part B|Change From Baseline in Alkaline Phosphatase - Part B|Change From Baseline in Alanine Aminotransferase - Part B|Change From Baseline in Aspartate Aminotransferase - Part B|Change From Baseline in Bilirubin - Part B|Change From Baseline in Calcium - Part B|Change From Baseline in Chloride - Part B|Change From Baseline in Carbon Dioxide - Part B|Change From Baseline in Creatinine - Part B|Change From Baseline in Glucose - Part B|Change From Baseline in Potassium - Part B|Change From Baseline in Magnesium - Part B|Change From Baseline in Phosphate - Part B|Change From Baseline in Protein - Part B|Change From Baseline in Sodium - Part B|Change From Baseline in Thyrotropin - Part B|Change From Baseline in Urea Nitrogen - Part B|Change From Baseline in Activated Partial Thromboplastin Time - Part B|Change From Baseline in Prothrombin International Normalized Ratio (%) - Part B|Change From Baseline in Prothrombin Time - Part B|Change From Baseline in pH - Part B|Change From Baseline in Specific Gravity - Part B|Change From Baseline (CFB) in Supine Systolic Blood Pressure - Part B|Change From Baseline (CFB) in Supine Diastolic Blood Pressure - Part B|Change From Baseline (CFB) in Standing Systolic Blood Pressure - Part B|Change From Baseline (CFB) in Standing Diastolic Blood Pressure - Part B|Change From Baseline (CFB) in Heart Rate - Part B|Change From Baseline (CFB) in Respiratory Rate - Part B|Change From Baseline (CFB) in Oral Temperature - Part B|Change From Baseline (CFB) in Oxygen Saturation - Part B|Change From Baseline in QT Interval - Part B|Change From Baseline in QTcF Interval - Part B|Change From Baseline in ECG Mean Heart Rate - Part B|Change From Baseline in RR Interval - Part B|Change From Baseline in PR Interval - Part B|Change From Baseline in QRS Duration - Part B|Percentage of Participants With a Response of ""Yes"" to Any C-SSRS Suicidal Ideation (SI) Item - Part B|Percentage of Participants With HAM-D Response - Part A|Percentage of Participants With HAM-D Remission - Part A|Change From Baseline in the Montgomery and Åsberg Depression Rating Scale (MADRS) Total Score at Day 15 and All Other Time Points - Part A|Change From Baseline in HAM-D Subscale Scores at Day 15 and All Other Time Points - Part A|Change From Baseline (CFB) in HAM-D Individual Item Scores at Day 15 and All Other Time Points - Part A|Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at All Time Points - Part A|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response - Part A|Change From Baseline (CFB) in the SSS Score - Part B|Change From Baseline in the 17-item HAM-D Total Score at All Time Points - Part B|Percentage of Participants With HAM-D Response - Part B|Percentage of Participants With HAM-D Remission - Part B|Change From Baseline in the MADRS Total Score at Day 15 and All Other Time Points - Part B|Change From Baseline in HAM-D Subscale Scores at All Time Points - Part B|Change From Baseline (CFB) in HAM-D Individual Item Scores at All Time Points - Part B|Change From Baseline in HAM-A Total Score at Day 15 and All Other Time Points - Part B|Percentage of Participants With CGI-I Response - Part B","Sage Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-MDD-201","December 7, 2016","October 4, 2017","November 8, 2017","December 22, 2016","December 2, 2020","December 2, 2020","Sage Investigational Site, Garden Grove, California, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Lake Charles, Louisiana, United States|Sage Investigational Site, Berlin, New Jersey, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Charlottesville, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03000530/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03000530/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03000530"
493,"NCT02191124","The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial",,"Completed","No Results Available","Major Depressive Disorder","Drug: Paroxetine|Drug: Mirtazapine","The estimated time from randomization to response and remission according to Hamilton Rating Scale for Depression (HAMD) total score.|The changes of Hamilton Rating Scale for Depression (HAMD) total score|The incidence and nature of overall adverse events|The incidence and nature of drug-related adverse events|The number of subject withdrawal due to adverse events during double-blind phase|The changes of Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) total score|The changes of Frequency, Intensity, and Burden of Side Effects-Rating (FIBSER)","Capital Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","164","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2009-1051","June 2011","November 2012","May 2013","July 16, 2014",,"July 16, 2014","Beijing Anding Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02191124"
494,"NCT01538199","Transcranial Laser Therapy for Major Depressive Disorder","ELATED","Completed","Has Results","Major Depressive Disorder","Device: Near-infrared radiation via Transcranial LED Therapy|Device: Sham device","Change in Hamilton Depression Rating Scale (HAM-D 17) Score|Systematic Assessment for Treatment Emergent Events-systematic Inquiry (SAFTEE-SI)|Number of Participants With Adverse Events","Paolo Cassano|Mclean Hospital|North Suffolk Mental Health Association|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010P002718|2010A050442","February 2012","August 2015","August 2015","February 24, 2012","November 29, 2017","November 29, 2017","Massachusetts General Hospital- Depression Clinical and Research Program, Boston, Massachusetts, United States|Chelsea Counseling Center- North Suffolk Mental Health Association, Chelsea, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01538199"
495,"NCT02212613","Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability",,"Withdrawn","No Results Available","Major Depressive Disorder and Irritability","Drug: Brexpiprazole","Change from Phase B baseline to Phase B Week 6 in functional magnetic resonance imaging (fMRI) BOLD activation score in the ventromedial prefrontal cortex and amygdala, scanned by fMRI during performance of the Emotion-induction Task|Change from Phase B baseline to Phase B Week 6 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Change from Phase B baseline to Phase B Week 6 in Spielberger State Trait Anger Expression Inventory (STAXI-2) Part 1|Change from Phase B baseline to Phase B Week 6 in Visual Analog Scale (VAS)|Change from Phase B baseline to Phase B Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) score|Clinical Global Impression - Improvement Scale (CGI-I) score at Phase B Week 6|MADRS response rate, where response is defined as ≥ 50% reduction in respective total scores from Phase B baseline to Phase B Week 6|MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Phase B baseline to Phase B Week 6|Change from Phase B baseline to Phase B Week 6 in Sheehan Disability Scale (SDS) 3-item mean score|Change from Phase B baseline to Phase B Week 6 in Anger Attacks Questionnaire (AAQ) score|Change from Phase B baseline to Phase B Week 6 in Symptoms of Depression Questionnaire (SDQ)|Change from Phase B baseline to Phase B Week 6 in Kellner Symptom Questionnaire (KSQ)|Change from Phase B baseline to Phase B Week 6 in Barratt Impulsiveness Scale 11 item (BIS-11) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","331-13-004","September 2014","November 2015","November 2015","August 8, 2014",,"July 7, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02212613"
496,"NCT00361374","Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression",,"Completed","Has Results","Major Depressive Disorder","Dietary Supplement: eicosapentaenoic acid|Dietary Supplement: docosahexaenoic acid|Drug: Placebo","Score on a Depression Severity Rating Scale Over Eight Weeks","Massachusetts General Hospital|Cedars-Sinai Medical Center|National Institute of Mental Health (NIMH)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","196","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2005P002337|5R01MH074085","July 2006","February 2013","March 2013","August 8, 2006","July 18, 2014","July 18, 2014","Depression Clinical Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00361374"
497,"NCT00619619","Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder",,"Completed","Has Results","Depression|Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)","Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)|Area Under the Curve From Time Zero to Infinity (AUC0-∞)|Population Pharmacokinetics Dose Normalized AUC (AUC/D): First Method, Second Method|Population Pharmacokinetics Dose Normalized AUC (AUC/D): Third Method","Wyeth is now a wholly owned subsidiary of Pfizer","All","7 Years to 17 Years   (Child)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","3151A6-2000|B2061012|3151A6-2000-US","February 2008","November 2009","November 2009","February 21, 2008","February 21, 2011","February 23, 2011","Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, North Miami, Florida, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00619619"
498,"NCT04352621","Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: intranasal ketamine|Device: rTMS treatment","Inventory for Depressive Symptomatology - Self-Rated","University of Cincinnati","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nelson Ketamine IIT","May 1, 2020","May 1, 2022","May 1, 2022","April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04352621"
499,"NCT01371734","A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD",,"Completed","Has Results","Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release|Drug: Placebo","Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106)|Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score (n=102, 105, 106)|Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8|Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'","Pfizer","All","7 Years to 17 Years   (Child)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","B2061032|3151A6-3343|2008-001875-32","August 2011","September 2015","September 2015","June 13, 2011","March 20, 2017","March 20, 2017","Children's Hospital of Alabama Laboratory, Birmingham, Alabama, United States|The University of Alabama at Birmingham, Office of Psychiatric Research, Birmingham, Alabama, United States|Center for Advanced Improvement, Tucson, Arizona, United States|Sun Valley Research Center, Imperial, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Bliss Basement Pharmacy - Hartford Hospital, Hartford, Connecticut, United States|Institute of Living/Hartford Hospital, Hartford, Connecticut, United States|Institute of Living, Hartford, Connecticut, United States|SJS Clinical Research, Inc., Destin, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Millenia Psychiatry & Research, Inc., Orlando, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Clinco, Terre Haute, Indiana, United States|Louisiana State University Health Sciences Center-Psychopharmacology Research Clinic, Shreveport, Louisiana, United States|Drug:University Health Shreveport Outpatient, Shreveport, Louisiana, United States|Pharmasite Research Inc, Baltimore, Maryland, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Erie County Medical Center / State University of New York at Buffalo affiliate, Buffalo, New York, United States|The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, New York, United States|Bioscience Research, LLC., Mount Kisco, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Stony Brook University Medical Center, Child And Adolescent Psychiatry, Stony Brook, New York, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Discovery and Wellness Center for Children/University Hospitals Case Medical Center, Cleveland, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Research Strategies of Memphis, LLC., Memphis, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Alliance Research Group, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Treatment Center, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Eastside Therapeutic Resource, Kirkland, Washington, United States|Biomedica Research Group, Santiago, Region Metropolitana, Chile|Optima Salud, Santiago, Region Metropolitana, Chile|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Departamento de Psiquiatria, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT01371734"
500,"NCT01371721","A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD",,"Completed","Has Results","Major Depressive Disorder","Drug: DVS SR","Percentage of Participants Experiencing a Treatment Emergent Adverse Event|Change From Baseline at Week 26 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score Based on Observed Cases|Change From Baseline at Week 26 in the Clinical Global Impression of Severity (CGI-S) Score Based on Observed Cases|Percentage of Participants With a Clinical Global Impression, Improvement (CGI-I) Response Defined as a Score of 'Very Much Improved' or 'Much Improved' at Week 26|Percentage of Participants With Remission as Determined by a CDRS-R Score of ≤28 at Week 26 Based on Observed Cases|Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Week 26 Based on Observed Cases","Pfizer","All","7 Years to 17 Years   (Child)","Phase 3","269","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","B2061031|3151A6-3357|2008-002064-34","February 2012","October 2015","October 2015","June 13, 2011","February 8, 2017","February 8, 2017","Harmonex Neuroscience Research, Inc., Dothan, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|University of Arizona Clinical and Translational Science Center (CATS), Tucson, Arizona, United States|University of Arizona College of Medicine Dept of Psychiatry, Tucson, Arizona, United States|Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|ATP Clinical Research, Incorporated, Costa Mesa, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Synergy Clinical Research Center, National City, California, United States|Neuropsychiatric Research Center of Orange County, Orange, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|Elite Clinical Trials, Incorporated, Wildomar, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Amedica Research Institute, Incorporated, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Kolin Research Group, Winter Park, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|Lake Charles Clinical Trials,, Lake Charles, Louisiana, United States|Precise Research Centers, Flowood, Mississippi, United States|St. Charles Psychiatric Associates - Midwest Research Group, St. Charles, Missouri, United States|Center for Psychiatry and Behavioral Medicine, Incorporated, Las Vegas, Nevada, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, LLC, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon), Incorporated, Portland, Oregon, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Focus & Balance, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Witchita Falls, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Rogers Center for Research and Training, Incorporated, Milwaukee, Wisconsin, United States|Hospital Aranda de la Parra, S.A. de C.V., Leon, Guanajuato, Mexico|CIT-Neuropsique, S.C., Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT01371721"
501,"NCT01371708","A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD",,"Completed","Has Results","Major Depressive Disorder","Drug: DVS SR","Percentage of Participants With a Treatment-emergent Adverse Event (TEAE)|Percentage of Participants With a Treatment-emergent Adverse Event (TEAE) (Combination Group)|Change From Baseline to Week 26 in Total Score on the Children's Depression Rating Scale, Revised (CDRS-R), Based on Observed Cases|Change From Baseline to Week 26 in Total Score on the Children's Depression Rating Scale, Revised (CDRS-R), Based on Observed Cases (Combination Group)|Change in Score From Baseline to Week 26 on the Clinical Global Impression-Severity (CGI-S) Scale, Based on Observed Cases|Change in Score From Baseline to Week 26 on the Clinical Global Impression-Severity (CGI-S) Scale, Based on Observed Cases (Combination Group)|Percentage of Participants With a Response of Very Much Improved or Much Improved on the Clinical Global Impression-Improvement (CGI-I) Scale at Week 26, Based on Observed Cases|Percentage of Participants With a Response of Very Much Improved or Much Improved on the Clinical Global Impression-Improvement (CGI-I) Scale at Week 26, Based on Observed Cases (Combination Group)|Percentage of Participants by Score on the Clinical Global Impression-Improvement (CGI-I) Scale, Based on Observed Cases|Percentage of Participants by Score on the Clinical Global Impression-Improvement (CGI-I) Scale, Based on Observed Cases (Combination Group)|Percentage of Participants With Remission at Week 26, Based on Score on the Children's Depression Rating Scale, Revised (CDRS-R), <=28 and on Observed Cases|Percentage of Participants With Remission at Week 26, Based on a Score on the Children's Depression Rating Scale, Revised (CDRS-R), <=28 and on Observed Cases (Combination Group)","Pfizer","All","7 Years to 17 Years   (Child)","Phase 3","283","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2061030|3151A6-3344|2008-001876-67","February 2, 2012","April 22, 2016","April 22, 2016","June 13, 2011","December 8, 2016","July 27, 2017","The University Of Alabama At Birmingham, Office Of Psychiatric Research, Birmingham, Alabama, United States|Center for Advanced Improvement, Tucson, Arizona, United States|Sun Valley Research Center, Imperial, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Institute of Living/Hartford Hospital, Hartford, Connecticut, United States|SJS Clinical Research, Inc., Destin, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Millenia Psychiatry & Research, Inc., Orlando, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|Clinco, Terre Haute, Indiana, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Erie County Medical Center/State University of New York (SUNY) at Buffalo Affiliate, Buffalo, New York, United States|The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, New York, United States|Bioscience Research, LLC., Mount Kisco, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Stony Brook University Medical Center, child and Adolescent Psychiatry, Stony Brook, New York, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Discovery and Wellness Center for Children/University Hospitals Case Medical Center, Cleveland, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Research Strategies of Memphis, LLC., Memphis, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Clinical Trials of Texas, INC, San Antonio, Texas, United States|Allance Research Group, Richmond, Virginia, United States|Alliance Research Group, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Treatment Center for Children, Richmond, Virginia, United States|Eastside Therapeutic Resource, Kirkland, Washington, United States|Biomedica Research Group, Santiago, Region Metropolitana, Chile",,"https://ClinicalTrials.gov/show/NCT01371708"
502,"NCT01268137","DBS in Treatment Resistant Major Depression",,"Unknown status","No Results Available","Resistant Major Depressive Disorder","Procedure: Deep Brain Stimulation","Hamilton Rating Scale for Depression, 17-item version (HRSD-17)|Montgomery-Asberg Depression Rating scale (MADRS) Clinical Global Impression (CGI) of Severity/Improvement Neuropsychological variables","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Fondo de Investigacion Sanitaria","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DEP-012004","January 2008","June 2011","June 2011","December 29, 2010",,"December 29, 2010","Hospital Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01268137"
503,"NCT01372150","A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD",,"Completed","Has Results","Major Depressive Disorder","Drug: desvenlafaxine succinate sustained release|Drug: fluoxetine|Drug: placebo","Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score|Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score|Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8|Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'","Pfizer","All","7 Years to 17 Years   (Child)","Phase 3","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","B2061014|3151A6-3356|2008-002063-13","November 17, 2011","March 20, 2015","March 20, 2015","June 13, 2011","November 20, 2015","January 15, 2019","Harmonex Neuroscience Research, Inc., Dothan, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|University of Arizona Clinical and Translational Science Center (CATS), Tucson, Arizona, United States|University of Arizona College of Medicine Dept of Psychiatry, Tucson, Arizona, United States|Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|ATP Clinical Research, Inc. 1, Costa Mesa, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Synergy Clinical Research Center, National City, California, United States|Neuropsychiatric Research Center of Orange County, Orange, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Elite Clinical Trials, Incorporated, Wildomar, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Amedica Research Institute, Incorporated, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Kolin Research Group, Winter Park, Florida, United States|Winter Park Memorial Hospital, Winter Park, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|Lake Charles Clinical Trials,, Lake Charles, Louisiana, United States|Neuroscientific Insights, Rockville, Maryland, United States|Precise Research Centers, Flowood, Mississippi, United States|Midwest Research Group, Saint Charles, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Heartland Pharma Developments, North Platte, Nebraska, United States|Creighton University, Omaha, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Incorporated, Las Vegas, Nevada, United States|Cincinnati Children's Hospital Medical Center (New), Cincinnati, Ohio, United States|Nina F. Wimpie, MD Pediatrics, Middleburg Heights, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, LLC, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon), Incorporated, Portland, Oregon, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Focus & Balance, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States|Rogers Center For Research And Training, Milwaukee, Wisconsin, United States|Hospital Aranda de la Parra S.A. de C.V., Leon, Guanajuato, Mexico|CIT - Neuropsique, S.C., Monterrey, Nuevo LEON, Mexico",,"https://ClinicalTrials.gov/show/NCT01372150"
504,"NCT00252356","Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder","ORION","Completed","No Results Available","Major Depressive Disorder","Drug: SR58611A","17-item Hamilton Depression Rating Scale (HAM-D) total score|Change from baseline in Clinical Global Impression (CGI) and MADRS Severity of Illness score|Safety assessments","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","468","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5041","September 2005","January 2007","May 2007","November 11, 2005",,"March 12, 2009","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Laval, Canada",,"https://ClinicalTrials.gov/show/NCT00252356"
505,"NCT00252330","Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder","PHOENIX","Completed","No Results Available","Major Depressive Disorder","Drug: SR58611A","17-item Hamilton Depression Rating Scale (HAM-D) total score|Change from baseline in Clinical Global Impression (CGI) and MADRS Severity of Illness score|Safety assessments","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","476","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5116","September 2005","January 2007","January 2007","November 11, 2005",,"March 12, 2009","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Laval, Canada",,"https://ClinicalTrials.gov/show/NCT00252330"
506,"NCT01921543","Deep Brain Stimulation in Treatment Refractory Depression","DBSTRD","Terminated","No Results Available","Major Depressive Disorder","Device: ITP Stimulation|Device: CI/BNST stimulation|Device: No stimulation","Change from baseline in depressive symptoms as measured by the 17-item Hamilton Depression Rating Scale|Montgomery- Asberg Depression Rating Scale (MADRS)|Inventory for Depressive Symptoms, Self-Report (IDS-SR)|Global measures of illness severity and improvement:the clinician-rated Clinical Global Impressions - Severity (CGI-S) and Clinical Global Impressions - Improvement (CGI-I) scales, and the patient-rated Patient Global Impressions (PGI-S and PGI-I)|Global Assessment of Function (GAF)|patient-rated Symptom CheckList (SCL-90)|Cognitive function: Rey Auditory Verbal Learning Test; Trailmaking A & B, Stroop Test, Rey-Osterrieth complex figure test ; Wisconsin Card Sorting Test; Standard Progressive Matrices of Raven; Digit Span Test; Word Fluency Test|Hopelessness: using the Beck Hopelessness scale|Hamilton Anxiety Rating Scale (HARS)|Young Mania Rating Scale (YMRS)|Side Effects Questionnaire (SEQ)","Universitaire Ziekenhuizen Leuven|Medtronic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","s28650","January 2005","October 2013","October 2013","August 13, 2013",,"July 16, 2015","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT01921543"
507,"NCT02400346","Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment",,"Completed","Has Results","Major Depression Disorder","Drug: Adjunct brexpiprazole|Drug: ADT","Number of Patients With Treatment-Emergent Adverse Events","H. Lundbeck A/S","All","65 Years and older   (Older Adult)","Phase 3","132","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16160A|2014-003547-35","March 2015","June 2016","June 2016","March 27, 2015","June 26, 2017","August 10, 2017","US012, Arcadia, California, United States|US004, Miami, Florida, United States|US007, Orlando, Florida, United States|US006, Smyrna, Georgia, United States|US002, O'Fallon, Missouri, United States|US010, Toms River, New Jersey, United States|US005, New York, New York, United States|US008, New York, New York, United States|US003, Staten Island, New York, United States|US014, Oklahoma City, Oklahoma, United States|US009, Allentown, Pennsylvania, United States|US001, Memphis, Tennessee, United States|US011, San Antonio, Texas, United States|EE002, Tallinn, Estonia|EE001, Tartu, Estonia|EE004, Tartu, Estonia|EE003, Voru, Estonia|FI001, Helsinki, Finland|FI002, Kuopio, Finland|FI003, Oulu, Finland|FI004, Tampere, Finland|DE002, Berlin, Germany|DE008, Berlin, Germany|DE003, Frankfurt, Germany|DE007, Hannover, Germany|DE006, Mittweida, Germany|DE001, Schwerin, Germany|DE005, Wiesbaden, Germany|PL006, Bialystok, Poland|PL003, Bydgoszcz, Poland|PL001, Chelmno, Poland|PL005, Gdansk, Poland|PL004, Lublin, Poland|PL002, Pruszcz Gdanski, Poland",,"https://ClinicalTrials.gov/show/NCT02400346"
508,"NCT00781677","Using Neuroimaging to Investigate Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder|Depression|Anxiety",,"Treatment response-the Quick Inventory of Depressive Symptomatology: Clinician Rated (QIDS-SR)|Degree of comorbid anxiety-a subset of the Hamilton Rating Scale for Depression will be used to determine the anxiety/somatization factor scores","University of Texas Southwestern Medical Center","All","18 Years to 50 Years   (Adult)",,"14","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Anx_Dep","May 2008","October 20, 2009","January 20, 2011","October 29, 2008",,"February 6, 2019","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00781677"
509,"NCT01070134","Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial","Mipsy","Unknown status","No Results Available","Major Depressive Disorder|Personality Disorder","Behavioral: Mindfulness-based Behavioural Therapy (MIBT)|Behavioral: PT (psychodynamic therapy)","17 item Hamilton rating scale for depression (score at the end of 18 weeks of day- treatment)|SCL-90-R (GSI score at the end of 18 weeks of day- treatment)|The proportion of patients who achieve remission (Hamilton score < 8).","Psychiatry Roskilde","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Mipsy trial","February 2010","August 2011","August 2011","February 17, 2010",,"June 8, 2011","The day clinic for treatment of non-psychotic disorders (Roskilde Psychiatry), Roskilde, Zeeland, Denmark",,"https://ClinicalTrials.gov/show/NCT01070134"
510,"NCT00071123","Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder",,"Completed","No Results Available","Current Major Depressive Disorder|Healthy|Remitted Major Depressive Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)",,"172","NIH","Observational",,"040002|04-M-0002","October 9, 2003",,"November 15, 2010","October 13, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00071123"
511,"NCT01582815","A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms",,"Completed","No Results Available","Major Depressive Disorder","Drug: JNJ-40411813|Drug: Placebo","The change from baseline to endpoint on the Hamilton Anxiety Rating scale (HAM-A6) score|The change from baseline to endpoint on the Hamilton Depression Rating Scale (HDRS17) total score|The change from baseline to endpoint on the SIGH-A (Structured Interview Guide of the Hamilton Anxiety Scale 14-item HAM-A) total score|The change from baseline to endpoint in the Clinical Global Impression - Improvement (CGI-I) scale|The change from baseline to endpoint in the Hamilton Depression Rating Scale (HDRS17) anxiety/somatization factor total score|The change from baseline to endpoint in the HAM-D6 score|The change from baseline to endpoint in the Inventory of Depressive Symptomatolgy -Clinician rated (IDS-C30) total score|The change from baseline to endpoint in the Inventory of Depressive Symptomatology - Clinician-Rated (IDS-C30) anxiety subscale|The change from baseline to Week 4 in the Work Limitations Questionnaire (WLQ)|The change from baseline to endpoint on the Perceived Stress Scale (PSS)|The change from baseline to endpoint in the Profile of Moods Scale-Brief Form (POMS-BF)|The change from baseline to endpoint on the Medical Outcomes Study- 12-item Sleep Scale Acute - Revised (MOS Sleep-R)|The number of patients with a Hamilton Depression Rating Scale (HDRS17) anxiety/somatization factor score ≥7 at Week 4|The number and percentage of patients with either ≥50% or ≥30% improvement on the HDRS17 total score at Week 4, and number and percentage of patients with HDRS 17 total score ≤ 7 at week 4|The number of patients at Week 4 with ≥ 50% improvement on the SIGH-A (Structured Interview Guide of the Hamilton Anxiety Scale 14-item HAM-A) total score","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR100851|40411813DAX2001|2011-006121-26","September 2012","November 2013","November 2013","April 23, 2012",,"June 16, 2015","Bourgas, Bulgaria|Kazanlak, Bulgaria|Rousse, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Baja, Hungary|Budapest, Hungary|Gyõr, Hungary|Kalocsa, Hungary|Chisinau, Moldova, Republic of|Arad, Romania|Iasi, Romania|Nizny Novgorod, Russian Federation|Saratov, Russian Federation|St Petersburg, Russian Federation|St-Peterburg, Russian Federation|St-Petersburg, Russian Federation|Tomsk, Russian Federation|Donetsk, Ukraine|Glevakha, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Smela, Ukraine|Uzhgorod, Ukraine|Village Stepanovka Kherson, Ukraine",,"https://ClinicalTrials.gov/show/NCT01582815"
512,"NCT01426997","Phenotype Depression Study",,"Completed","No Results Available","Major Depressive Disorder",,"We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.|We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.","Emory University|National Institute of Mental Health (NIMH)","All","21 Years to 65 Years   (Adult, Older Adult)",,"279","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IRB00039107|1R01MH087604-01A1","July 2010","May 2016","May 2016","September 1, 2011",,"June 22, 2016","Emory University Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01426997"
513,"NCT00042562","Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: duloxetine",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6476|F1J-US-HMBZ","December 2002",,"December 2003","August 5, 2002",,"July 19, 2006","Carlsbad, California, United States|Los Angeles, California, United States|Stanford, California, United States|Cromwell, Connecticut, United States|Coral Springs, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Bangor, Maine, United States|Boston, Massachusetts, United States|New York, New York, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Falls Church, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00042562"
514,"NCT00042575","Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6475|F1J-US-HMBY","June 2002",,"August 2002","August 5, 2002",,"July 19, 2006","Trumbull, Connecticut, United States|Lafayette, Indiana, United States|Gaithersburg, Maryland, United States|Belmont, Massachusetts, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|Staten Island, New York, United States|Salt Lake City, Utah, United States|Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00042575"
515,"NCT04181567","Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients",,"Completed","No Results Available","Major Depressive Disorder","Other: electroconvulsive therapy|Drug: agomelatine|Drug: Placebo","17-item Hamilton Rating Scale for Depression (HAMD-17)|Clinical severity by Clinical Global Impression-Severity (CGI-S)|Work and Social Adjustment Scale (WSAS)|UKU side effects rating scale|Electroencephalograph (EEG)|Medical Outcomes Study Short-Form 36 (SF-36)|Mini Mental State Examination (MMSE)|Arizona Sexual Experiences Scale (ASEX)|Depression and Somatic Symptoms Scale (DSSS)|The Wechsler Memory Scale (WMS).","Kaohsiung Kai-Suan Psychiatric Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan)|Ministry of Science and Technology, Taiwan","All","18 Years and older   (Adult, Older Adult)","Phase 4","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MOST-103-2314-B-280-001-MY3|KSPH-2013-36","March 3, 2014","October 8, 2019","November 22, 2019","November 29, 2019",,"November 29, 2019","Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04181567"
516,"NCT03237078","Lactobacillus Plantarum PS128 in Patients With Major Depressive Disorder and High Level of Inflammation",,"Unknown status","No Results Available","Major Depressive Disorder|Inflammation|Probiotics","Dietary Supplement: Lactobacillus plantarum PS128","Changes of serum hs-CRP|Changes of serum TNF-alpha|Changes of serum IL-6|Changes of serum IL-10|Changes of HAMD-17|Changes of DSSS|Change of Microbiota|Change of zonulin|Change of calprotectin|Changes of expression of Toll-like proteins","Taipei Medical University WanFang Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N201702049","August 1, 2017","July 31, 2018","July 31, 2019","August 2, 2017",,"July 2, 2018","Taipei Medical University - WanFang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03237078"
517,"NCT02461927","Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: Ketamine + Naltrexone|Drug: Ketamine + Placebo|Drug: Placebo (psychoactive placebo midazolam) + Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Time Line Follow Back (TLFB)","VA Office of Research and Development","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","65","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MHBB-009-16F|GY 0002","January 1, 2015","December 31, 2022","December 31, 2022","June 3, 2015",,"July 14, 2021","VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02461927"
518,"NCT04615234","Clinical Validation of a Combinatorial PharmAcogeNomic Approach in Major Depressive Disorder: an Observational Prospective RAndomized, Single-blind Controlled Trial","PANDORA","Recruiting","No Results Available","Major Depressive Disorder","Device: Pharmacogenomics test (PGx)","Clinical response|Clinical response and remission","Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","All","18 Years to 65 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RF-2016-02361697","February 1, 2020","September 1, 2022","March 1, 2023","November 4, 2020",,"November 4, 2020","Department of Mental Health and Addiction, Brescia, BS, Italy",,"https://ClinicalTrials.gov/show/NCT04615234"
519,"NCT03595579","Assessing Symptomatic Clinical Episodes in Depression","ASCEND","Completed","No Results Available","Major Depressive Disorder","Drug: AXS-05|Drug: Bupropion","Safety outcomes: types and rates of adverse events; discontinuations due to adverse events.","Axsome Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AXS-05-MDD-201","May 30, 2018","January 7, 2019","January 7, 2019","July 23, 2018",,"April 2, 2021","Clinical Research Site, Beverly Hills, California, United States|Clinical Research Site, Jacksonville, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03595579"
520,"NCT01034995","A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder","AGATE","Completed","No Results Available","Major Depression","Drug: SSR125543|Drug: escitalopram|Drug: placebo","Change from baseline (Day -1) to Day 56 in the 17-item HAM-D total score|Change from baseline in HAM-D depressed mood item|Change from baseline in HAM-D responders (50% improvement)|Changes from baseline in the HAM-D core and factor scores|Changes from baseline in the Montgomery-Asberg depression rating scale (MADRS) total score|Changes from baseline in the Clinical Global Impression (CGI) Severity of Illness score","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","580","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI5687|2009-010339-42","February 2010","March 2011","March 2011","December 18, 2009",,"April 14, 2011","Sanofi-Aventis Investigational Site Number 056002, Asse, Belgium|Sanofi-Aventis Investigational Site Number 056003, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056001, Liège, Belgium|Sanofi-Aventis Investigational Site Number 124011, Burlington, Canada|Sanofi-Aventis Investigational Site Number 124012, Chatham, Canada|Sanofi-Aventis Investigational Site Number 124004, Edmonton, Canada|Sanofi-Aventis Investigational Site Number 124003, Gatineau, Canada|Sanofi-Aventis Investigational Site Number 124001, Kelowna, Canada|Sanofi-Aventis Investigational Site Number 124006, Mississauga, Canada|Sanofi-Aventis Investigational Site Number 124008, Penticton, Canada|Sanofi-Aventis Investigational Site Number 124007, Sherbrooke, Canada|Sanofi-Aventis Investigational Site Number 124009, Toronto, Canada|Sanofi-Aventis Investigational Site Number 152001, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152002, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152003, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152005, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152006, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152004, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152007, Valparaiso, Chile|Sanofi-Aventis Investigational Site Number 152008, Vina Del Mar, Chile|Sanofi-Aventis Investigational Site Number 233001, Tallinn, Estonia|Sanofi-Aventis Investigational Site Number 233002, Tallinn, Estonia|Sanofi-Aventis Investigational Site Number 233004, Tallinn, Estonia|Sanofi-Aventis Investigational Site Number 233003, Tartu, Estonia|Sanofi-Aventis Investigational Site Number 246001, Helsinki, Finland|Sanofi-Aventis Investigational Site Number 246003, Helsinki, Finland|Sanofi-Aventis Investigational Site Number 246005, Järvenpää, Finland|Sanofi-Aventis Investigational Site Number 246002, Tampere, Finland|Sanofi-Aventis Investigational Site Number 246004, Turku, Finland|Sanofi-Aventis Investigational Site Number 250008, Arcachon, France|Sanofi-Aventis Investigational Site Number 250007, Dole, France|Sanofi-Aventis Investigational Site Number 250006, Elancourt, France|Sanofi-Aventis Investigational Site Number 250001, Grenoble, France|Sanofi-Aventis Investigational Site Number 250003, Montpellier Cedex 05, France|Sanofi-Aventis Investigational Site Number 250005, Nimes Cedex 9, France|Sanofi-Aventis Investigational Site Number 250004, Orvault, France|Sanofi-Aventis Investigational Site Number 250002, Toulouse, France|Sanofi-Aventis Investigational Site Number 276008, Achim, Germany|Sanofi-Aventis Investigational Site Number 276002, Berlin, Germany|Sanofi-Aventis Investigational Site Number 276004, Dresden, Germany|Sanofi-Aventis Investigational Site Number 276005, Leipzig, Germany|Sanofi-Aventis Investigational Site Number 276006, Mannheim, Germany|Sanofi-Aventis Investigational Site Number 276007, München, Germany|Sanofi-Aventis Investigational Site Number 276001, Schwerin, Germany|Sanofi-Aventis Investigational Site Number 276003, Würzburg, Germany|Sanofi-Aventis Investigational Site Number 528001, Den Haag, Netherlands|Sanofi-Aventis Investigational Site Number 643006, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643005, Nizhny Novgorod, Russian Federation|Sanofi-Aventis Investigational Site Number 643008, Rostov-Na-Donu, Russian Federation|Sanofi-Aventis Investigational Site Number 643010, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643004, Samara, Russian Federation|Sanofi-Aventis Investigational Site Number 643007, Smolensk, Russian Federation|Sanofi-Aventis Investigational Site Number 643009, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643011, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643003, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643002, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643001, St.-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 703101, Bratislava 2, Slovakia|Sanofi-Aventis Investigational Site Number 703102, Bratislava, Slovakia|Sanofi-Aventis Investigational Site Number 703104, Michalovce, Slovakia|Sanofi-Aventis Investigational Site Number 703105, Rimavska Sobota, Slovakia|Sanofi-Aventis Investigational Site Number 703103, Roznava, Slovakia|Sanofi-Aventis Investigational Site Number 710005, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710001, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710006, Centurion, South Africa|Sanofi-Aventis Investigational Site Number 710002, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710003, Pretoria, South Africa|Sanofi-Aventis Investigational Site Number 710004, Somerset West, South Africa|Sanofi-Aventis Investigational Site Number 752004, Linköping, Sweden|Sanofi-Aventis Investigational Site Number 752002, Lund, Sweden|Sanofi-Aventis Investigational Site Number 752003, Malmö, Sweden|Sanofi-Aventis Investigational Site Number 752005, Stockholm, Sweden|Sanofi-Aventis Investigational Site Number 752001, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01034995"
521,"NCT04388189","Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion","LEAP-DB","Withdrawn","No Results Available","Major Depressive Disorder","Drug: Duloxetine|Drug: Bupropion","Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score|Percentage decrease in depressive symptoms on the QIDS-SR at the week 8 endpoint as a function of biomarker score|Absolute score decrease from baseline to the week 8 endpoint on the QIDS-SR as a function of biomarker score","Alto Neuroscience","All","22 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LEAP-DB","October 15, 2020","May 30, 2023","May 30, 2023","May 14, 2020",,"October 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04388189"
522,"NCT04388202","Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram","LEAP-SE","Withdrawn","No Results Available","Major Depressive Disorder","Drug: Sertraline|Drug: Escitalopram","Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score|Percentage decrease in depressive symptoms on the patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score|Absolute score decrease from baseline to the week 8 endpoint on the QIDS-SR as a function of biomarker score","Alto Neuroscience|National Institute of Mental Health (NIMH)","All","22 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LEAP-SE|1R44MH123373-01","October 15, 2020","May 30, 2023","May 30, 2023","May 14, 2020",,"October 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04388202"
523,"NCT04471818","Ketamine or Placebo in Patients With Major Depression and Advanced Cancer","KODIAC","Recruiting","No Results Available","Major Depressive Disorder|Advanced Cancer","Drug: Ketamine|Other: Placebo","Brief Edinburg Depression Scale (BEDS) score","Instituto Nacional de Cancerologia de Mexico","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","(019/024/CPI) /CEI/1332/18)","November 19, 2019","December 19, 2021","February 19, 2022","July 15, 2020",,"July 15, 2020","Instituto Nacional de Cancerología (INCan), Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04471818"
524,"NCT01683019","Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression",,"Completed","Has Results","Major Depressive Disorder (MDD)","Device: NeoSync EEG Synchronization Therapy|Device: Sham NeoSync EEG Synchronization Therapy","Percent Change in Hamilton Depression Rating Scale (HAMD-17) at Baseline and the End of Week 4 of Treatment.","Wave Neuroscience","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NST#002","June 2008","November 2008","December 2008","September 11, 2012","May 5, 2014","December 7, 2018","Amen Clinic, Newport Beach, California, United States|Institute of Mental Health, Peking University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01683019"
525,"NCT03191994","Impact of an Eight Week Exercise Intervention in Treating Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Exercise","Brain function during an associative memory task|Depression scores|Biochemical markers|Sleep quality|Anxiety|Memory performance","University of Ontario Institute of Technology","All","18 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UOntarioIT","January 2, 2014","December 2017","June 2018","June 19, 2017",,"June 20, 2017","University of Ontario Institute of Technology, Oshawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03191994"
526,"NCT00566202","A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: Escitalopram|Drug: JNJ-18038683","Explore the effectiveness of JNJ-18038683 in patients with moderate to severe depression as determined by accepted clinical assessments done throughout the study.|Explore the safety and tolerability of JNJ-18038683 in patients with moderate to severe depression by assessing adverse events, vital signs, laboratory test results, ECGs and physical exams.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years to 60 Years   (Adult)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR014617|C-2007-007","December 2007","December 2008","December 2008","December 3, 2007",,"August 6, 2014","Little Rock, Arkansas, United States|Beverly Hills, California, United States|Glendale, California, United States|San Diego, California, United States|Bradenton, Florida, United States|Maitland, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Eagle, Idaho, United States|Chicago, Illinois, United States|Prairie Village, Kansas, United States|Topeka, Kansas, United States|Baton Rouge, Louisiana, United States|Shreveport, Louisiana, United States|Nutley, New Jersey, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|Fresh Meadows, New York, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Norristown, Pennsylvania, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Irving, Texas, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00566202"
527,"NCT01075529","Early Prediction of Fluoxetine Response",,"Completed","No Results Available","Major Depressive Disorder","Drug: fluoxetine","Stable response was defined as a reduction of 50% or more of the HAMD-17 score at week 4 and week 6 of treatment|CGI, GAF, Zung's Depression Scale, Short-Form 36, auditory evoked potential, psychomotor speed","Kaohsiung Kai-Suan Psychiatric Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSPH-2007-16","March 2007","February 2010","February 2010","February 25, 2010",,"February 25, 2010","Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01075529"
528,"NCT02752724","Ketamine Anesthesia for Improvement of Depression in ECT","KAID","Completed","No Results Available","Major Depressive Disorder","Drug: Ketamine|Drug: Methohexital","Change in Depression Patient Health Questionnaire 9 (PHQ9) Scoring|Soluble Amino Acid Metabolomic Biomarkers|ECT Seizure Duration|Change in Montreal Cognitive Assessment (MoCA) Scoring","VA Puget Sound Health Care System","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","52","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","00850","March 2016","April 2017","April 30, 2018","April 27, 2016",,"June 6, 2018","VA Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02752724"
529,"NCT02934035","Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Antidepressant","Response|Remission","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Time Perspective: Prospective","1575","September 2016","September 2017","September 2017","October 14, 2016",,"October 17, 2016",,,"https://ClinicalTrials.gov/show/NCT02934035"
530,"NCT02443584","Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis","PGX-AMG","Completed","No Results Available","Major Depressive Disorder","Other: pharmacogenetic testing","Clinical outcomes (response to medication following medication recommendation guided by pharmacogenetic testing)|Clinical utility (Utilization by physicians in following medication recommendations guided by pharmacogenetic testing)","Avera McKennan Hospital & University Health Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","AIHG-1430-PGxAMG","February 1, 2015","April 1, 2017","April 1, 2017","May 14, 2015",,"May 3, 2017","Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02443584"
531,"NCT01824433","Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression",,"Completed","No Results Available","Major Depression","Drug: venlafaxine|Drug: fluoxetine","Overall Improvement|Improvement of individual symptoms","Capital Medical University","Female","50 Years to 80 Years   (Adult, Older Adult)","Phase 4","189","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","VFPWMDD","March 7, 2013","March 16, 2017","March 16, 2017","April 4, 2013",,"September 14, 2017","Beijing Anding Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01824433"
532,"NCT01682785","Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder|Metabolic Syndrome|Thyroid Dysfunction",,,"ChaingMai University","All","18 Years and older   (Adult, Older Adult)",,"140","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MDD-Met","September 2012",,,"September 11, 2012",,"September 11, 2012",,,"https://ClinicalTrials.gov/show/NCT01682785"
533,"NCT03065335","Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder",,"Recruiting","No Results Available","Healthy Volunteer|Major Depressive Disorder|Depression","Drug: Ketamine|Other: Placebo|Device: Cobot TS MV robotic arm for TMS","To demonstrate more robust neuropharmacodynamic effects measured by neuropharmacodynamic imaging (fMRI+EEG and MEG) of ketamine 0.5 mg/kg as compared to placebo administered over 40 minutes.|Ketamine Metabolites Substudy: To determine if ketamine metabolites cross the blood brain barrier and enter the brain during ketamine IV administration.|To determine if increases in synaptic plasticity, using electrophysiological measures in response to TMS and in association with sleep (i.e. slow wave sleep EEG activity) are associated with better antidepressant response to 0.5 mg/kg ketamine.|To demonstrate enhanced efficacy, as measured by the MADRS, of IV ketamine 0.5 mg/kg in participants with MDD using a psychophysiological technique (i.e. NPU-threat test).|To identify baseline peripheral measures associated with response to the administration of ketamine 0.5 mg/kg, as potential biomarkers of acute (24 hour) treatment response.|Ketamine Metabolites Substudy: To correlate metabolite levels in periphery and CSF with changes in clinical rating scales.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","150","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","170060|17-M-0060","May 25, 2017","January 1, 2025","January 1, 2028","February 27, 2017",,"July 12, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03065335"
534,"NCT01263236","A Study of LY2940094 in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: LY2940094|Drug: Placebo","Number of participants with clinically significant effects|Pharmacokinetics of LY2940094, maximal concentration (Cmax)- single dose|Pharmacokinetics of LY2940094, area under the concentration-time curve (AUC)- single dose|Pharmacokinetics of LY2940094, maximal concentration (Cmax) - multiple dose|Pharmacokinetics of LY2940094, area under the concentration-time curve (AUC)- multiple dose","BlackThorn Therapeutics, Inc.","Male","18 Years to 45 Years   (Adult)","Phase 1","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","14095|I5J-MC-NOAA","December 2010","September 2011","September 2011","December 20, 2010",,"February 3, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01263236"
535,"NCT00621946","Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder",,"Completed","Has Results","Severe Asthma|Moderate or Severe Major Depressive Disorder","Drug: Placebo|Drug: Escitalopram","HAM-D (Hamilton Rating Scale for Depression)|ACQ (Asthma Control Questionnaire)|IDS-SR (Inventory of Depressive Symptomatology - Self-Report)","University of Texas Southwestern Medical Center|Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","092007-057","March 2008","March 2010","March 2010","February 22, 2008","December 27, 2013","February 4, 2014","The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00621946"
536,"NCT03163940","Laughter Yoga Intervention for People With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder|Mood Disorder|Depression","Behavioral: Laughter Yoga","Change in Depression, Anxiety and Stress Scale (DASS-21) scores from baseline|Change in Short form 12 item Health Survey (SF12v2) scores from baseline","The Hong Kong Polytechnic University|Community Psychiatric Service, Castle Peak Hospital, Tuen Mun, Hong Kong.","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","G-UAB6","June 1, 2017","August 1, 2018","August 1, 2018","May 23, 2017",,"February 22, 2019","The Castle Peak Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03163940"
537,"NCT01413932","Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder",,"Completed","No Results Available","Healthy Volunteers (Part 1)|Major Depressive Disorder (Part 2)","Drug: HT-2157|Drug: Placebo","7-day plasma PK profile of HT-2157|To assess the brain penetration of HT-2157|PD profile (CSF and peripheral biomarkers, exploratory biologic and pharmacodynamic markers of potential efficacy) of multiple (21-day) doses of HT-2157 patients with MDD|Safety and tolerability of multiple (7-day) doses of HT-2157|Safety and tolerability of multiple (21-day) ascending-doses of HT 2157|21-day ascending-dose plasma PK profile of HT-2157","Dart NeuroScience, LLC","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HT-2157-107","July 2011","December 2012","December 2012","August 10, 2011",,"December 16, 2015","Clinical Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01413932"
538,"NCT01573741","Study of Ketamine as an Antidepressant in Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Ketamine","all cause remission","Shi Jinyun|Jinling Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","nju-030614","February 2012","December 2012","February 2013","April 9, 2012",,"May 4, 2012","The PLA 102nd Hospital and mental health center of military, Changzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01573741"
539,"NCT04288895","Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Vortioxetine","Number of participants with Treatment-Emergent Adverse Events|Change in Patient Health Questionnaire-9 (PHQ-9) total score|Change in Clinical Global Impression-severity of illness (CGI-S) score|Clinical Global Impression-improvement (CGI-I)","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","400","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17775A","February 10, 2020","February 18, 2022","March 18, 2022","February 28, 2020",,"June 24, 2021","Ratandeep Multispecialty Hospital (IN1002), Ahmedabad, Gujarat, India|MITR Foundation 1 (IN1013), Ahmedabad, Gujarat, India|BJ Medical College and Civil Hospital (IN028), Ahmedabad, Gujarat, India|Shree Hatkesh Health Foundation (IN1016), Junagadh, Gujarat, India|Nagecha Hospital, Creative Chamber (IN1015), Rajkot, Gujarat, India|Divyam Clinic (IN1025), Surat, Gujarat, India|GMERS Medical College and Hospital,Department of Psychiatry (IN1004), Vadodara, Gujarat, India|People Tree Hospitals (IN1027), Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre (IN1007), Mangalore, Karnataka, India|Mangala Hospital & Mangala Kidney Foundation (IN1006), Mangalore, Karnataka, India|K. S. Hegde Medical Academy (IN1003), Mangalore, Karnataka, India|Department of Psychiatry K R Hospital Mysore Medical College and Research Institute (IN1020), Mysuru, Karnataka, India|IQRAA International Hospital & Research Centre (IN030), Kozhikode, Kerala, India|Society for Psychiatric Update and Research, Shanti Nursing Home (IN1008), Aurangabad, Maharashtra, India|Arneja Heart and Multispeciality Hospital (IN1022), Nagpur, Maharashtra, India|Central Institute of Behavioural Sciences (IN1019), Nagpur, Maharashtra, India|Chopda Medicare & Research Centre (IN023), Nashik, Maharashtra, India|Lata Mangeshkar Medical Foundation's (IN1001), Pune, Maharashtra, India|Oyster and Pearl Hospital (IN1014), Pune, Maharashtra, India|Dayanand Medical College and Hospital (IN024), Ludhiana, Punjab, India|ASHA hospital (IN1018), Hyderabad, Telangana, India|Deva Institute of Healthcare and Research PVT ltd. (IN1005), Varanasi, Uttar Pradesh, India|Institute of Post Graduate Medical Education and Research (IN1026), Kolkata, West Bengal, India|Maharaja Agarsen Hospital (IN1021), Delhi, India",,"https://ClinicalTrials.gov/show/NCT04288895"
540,"NCT01995422","Effect of Physical Activity on Depressive Symptoms With a 5 Month Follow-up","2DPAP","Completed","No Results Available","Major Depressive Disorder","Other: Physical activity program","Effect of physical activity on depression|Distraction, self-efficacy and social support scores on 7-point Likert scales and balance on force platform","Laboratory Motricité, Interactions, Performance|Nantes University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2011-A00934-37","December 2011","May 2014","June 2014","November 26, 2013",,"April 1, 2015","University of Nantes, Nantes, Pays de la Loire, France",,"https://ClinicalTrials.gov/show/NCT01995422"
541,"NCT00130676","A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression",,"Completed","No Results Available","Major Depressive Disorder|Psychotic Disorders","Drug: Mifepristone|Drug: matching placebo","The change in a measure of psychosis|The change in a measure of depression","Corcept Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","257","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C-1073-07","September 2004","June 2006","June 2006","August 16, 2005",,"February 15, 2012","CNRI-LA, Pico Rivera, California, United States|Behavioral Health 2000, LLC, Riverside, California, United States|Cnri, Llc, San Diego, California, United States|University of Florida Clinical Trials, Jacksonville, Florida, United States|Quantum Laboratories/Memory Disorder Center, Pompano Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|American Medical Research, Inc., Oak Brook, Illinois, United States|Valle Vista Health System, Greenwood, Indiana, United States|Psychopharmacology Research, Farmington Hills, Michigan, United States|Robert Horne, MD, Las Vegas, Nevada, United States|CNS Research Institute, Clementon, New Jersey, United States|NMDNJ, Newark, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Zucker Hillside Hospital, Glen Oaks, New York, United States|Neurobehavioral Research Company, Lawrence, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Rakesh Ranjan, MD and Associates, Inc, Lyndhurst, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|CNS Research Institute, Philadelphia, Pennsylvania, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|International Clinical Research Associates, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00130676"
542,"NCT03142919","Lipopolysaccharide (LPS) Challenge in Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Biological: Lipopolysaccharide|Biological: Placebo","Snaith-Hamilton Pleasure Scale (SHAPS)|Interleukin 6 (IL-6) protein levels|Blood Oxygenation Level Dependent signal (BOLD) Ventral Striatum|Blood Oxygenation Level Dependent signal (BOLD) Insula|Tumor Necrosis Factor (TNF) protein levels","Laureate Institute for Brain Research, Inc.","All","18 Years to 55 Years   (Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","2016-002-00","September 7, 2017","May 31, 2022","May 31, 2023","May 8, 2017",,"July 7, 2020","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03142919"
543,"NCT00128505","An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression",,"Completed","No Results Available","Major Depressive Disorder|Psychotic Disorders","Drug: Mifepristone","To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-09|To assess the frequency of retreatment with Corlux in patients with PMD and qualitatively describe the psychotic symptoms for which retreatment is clinically indicated","Corcept Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-1073-13","August 2005","November 2006","November 2006","August 10, 2005",,"February 15, 2012","Georgy Koychev M.D., Sofia, Bulgaria|Luchezar G Hranov M.D., Sofia, Bulgaria|Svetlozar H Haralanov Ph.D., Sofia, Bulgaria|Vihra Milanova M.D., Sofia, Bulgaria|Georgi Popov M.D., Varna, Bulgaria|Pavo Filakovic M.D./Ph.D., Osijek, Croatia|Ljiljana Moro M.D./Ph.D., Rijeka, Croatia|Goran Dodig M.D./Ph.D., Split, Croatia|Dubravka Kocijan-Hercigonja M.D., Zagreb, Croatia|Miro Jakovljevic M.D., Zagreb, Croatia|Vera Folnegovic-Smalc M.D/Ph.D, Zagreb, Croatia|Mihai Dumitru Gheorge, Bucharest, Romania|Aurel Nirestean M.D./Ph.D, Targu Mures, Romania|Ivana Timotijevic M.D., Belgrade, Serbia|Jelena Martinovic M.D., Belgrade, Serbia|Vladimir Diligenski M.D., Belgrade, Serbia|Vladimir Paunovic M.D., Belgrade, Serbia|Dragana Ignjatovic-Ristic M.D., Kragujevac, Serbia|Ratomir Lisulov M.D., Novi Sad, Serbia",,"https://ClinicalTrials.gov/show/NCT00128505"
544,"NCT04509882","Bear Bile Pill as add-on the Treatment of MDD",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: bear bile pill|Drug: placebo","Change in the total Montgomery-Asberg Depression Rating Scale (MADRS) score between randomization and end of study.|Effective treatment|Clinical remission rate|The Montgomery-Asberg Depression Rating Scale (MADRS) reduction ratio|The Hamilton Depression Rating Scale (HAM-D17) reduction ratio|change in the total score of the Hamilton Anxiety Scale(HAMA)|change in total score of the Clinical Global Impression-Severity (CGI-S) scale.|change in total score of the Clinical Global Impression-Improvement (CGI-I) scale.","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCTNCT04002259","October 30, 2020","March 31, 2022","March 31, 2022","August 12, 2020",,"August 12, 2020","Jing jing Huang, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04509882"
545,"NCT01488266","Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Aripiprazole|Drug: switching to different class of antidepressant","Change of total score of MADRS|Response rate|Remission rate|Change of total score of HDRS-17|Change of total score of CGI-S|Change of total score of IFS|Change of total score of SDS|Patients' ratio who have have scored 1 or 2 in the score of CGI-Improvement","Korea University|Korea OIAA|Taiwan Otsuka Pharm. Co., Ltd","All","20 Years and older   (Adult, Older Adult)","Not Applicable","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CASCADE","November 2011","January 2013","March 2013","December 8, 2011",,"December 8, 2011","Korean Univ Ansan Hospital; Bucheon St.Mary Hospital; DonggukUniv Gyeongju Hospital; Catholic University of Korea St. Paul's Hospital, Seoul, Korea, Republic of|Chang Gung Memorial Hospital; Kaohsiung Medical University Chung-ho Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01488266"
546,"NCT00763594","Linköping University Relational and Interpersonal Psychotherapy Project","LURIPP","Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Brief Relational Therapy|Behavioral: Interpersonal Psychotherapy","Hamilton Depression Rating Scale, 17 item version|Patient Health Questionnaire - 9|Inventory of Interpersonal Problems|Quality of Life Inventory|Depressive Experiences Questionnaire|Outcome Questionnaire - 45","Linkoeping University|Swedish Council for Working Life and Social Research","All","17 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","M59-08","September 2008","May 2016","December 2017","October 1, 2008",,"September 1, 2015","Linköping University, Linköping, Sweden",,"https://ClinicalTrials.gov/show/NCT00763594"
547,"NCT04679753","Brainsway DTMS for Treatment of MDD Using iTBS",,"Completed","No Results Available","Major Depressive Disorder","Device: Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Device: Brainsway DTMS with High Frequency (HF) Stimulation","The primary outcome measure was the change from baseline in HDRS-21 scores at the 5 week visit.|HDRS-21 Response and Remission rates|Change in CGI-S score from baseline at the 6 week visit|CGI-S Response and Remission rates","Brainsway","All","18 Years and older   (Adult, Older Adult)","Phase 4","177","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTP-0001-03","January 1, 2019","July 1, 2020","July 1, 2020","December 22, 2020",,"December 23, 2020","SynapseTMS, Yorkton, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT04679753"
548,"NCT02890212","Selenium as Augmentation Treatment for Sertraline Resistant Major Depression",,"Suspended","No Results Available","Major Depression","Dietary Supplement: selenium supplementation|Dietary Supplement: placebo","Hamilton Depressive Rating Scale|Montgomery-Asberg Depression Rating Scale|Clinical Global Impression Scale","University of Sao Paulo General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Selen-2015","August 2005","December 2021","December 2021","September 7, 2016",,"April 30, 2021","Instituto de Psiquiatria - Hcfmusp, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02890212"
549,"NCT00188942","A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Fluoxetine+Olanzapine|Drug: Olanzapine|Procedure: Functional Magnetic Resonance Imaging","MRI Data - Acquired before and 1- 3- and 6- weeks after beginning pharmacotherapy.|17 Item - Hamilton Depression Rating Scale - Weekly|Clinical Global Impression - Improvement/Severity - Weekly|Young Mania Rating Scale - Weekly|Positive Affect Negative Affect Scale|Beck Depression Inventory|State Trait Anxiety Index|Behavioural Activation/Inhibition Scale|SexFX Scale|AMDP-5 Symptom Questionnaire","University Health Network, Toronto|Eli Lilly and Company","All","18 Years to 55 Years   (Adult)","Phase 4","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UHN REB 04-0204-B|CTA Control #095694","February 2005","June 2009","June 2009","September 16, 2005",,"February 8, 2013","University Health Network - Toronto General Division, Toronto, Ontario, Canada|University Health Network - Toronto Western Division, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00188942"
550,"NCT00223197","Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse",,"Completed","No Results Available","Bipolar Disorder|Major Depressive Disorder|Substance Abuse","Drug: Pregnenolone","For the primary outcome measure, we will analyze both between group differences in change from baseline but also response rates.|Paired T tests will be used to compare outcome measures of HRSD, IDS-SR, HRSA, YMRS, RAVLT, Stroop, Trails B, and PRD III from baseline to exit.|All participants returning for at least one post baseline assessment will be used.|In the case of early withdrawal from the study, the last visit will be used for the exit scores (last observation carried forward).","University of Texas Southwestern Medical Center|Stanley Medical Research Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1103-714","February 2004",,"April 2006","September 22, 2005",,"April 3, 2012","The University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00223197"
551,"NCT04166864","Spectral Correlation Coefficient-determine TMS for Depression","SCC-TMS","Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial magnetic Stimulation","Change in Inventory of Depressive Symptoms-Self-report scores","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-000758","June 16, 2019","June 16, 2022","June 16, 2022","November 18, 2019",,"July 27, 2021","UCLA Depression Research and Clinic Program, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04166864"
552,"NCT04268316","Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|MDD|Depression","Device: Virtual Reality Behavioral Activation|Behavioral: Behavioral Activation in real-life","Participant's Desire to Continue Using VR After the Study Ends|Number of Participants Who Dropped Out of Each Study Arm|Participant's Satisfaction With the VR-BA Treatment|Participant's Use of the VR Headset|Participant's Acceptance of VR-BA Treatment|How Well Can Participants Tolerate the VR-BA Treatment?|How Present Did Individuals in the VR-BA Treatment Feel?|Change in Depression Scores on the PHQ-9 From Baseline to Session 4, Compared Across Three Study Arms","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","53483","May 18, 2020","January 15, 2021","January 15, 2021","February 13, 2020","May 10, 2021","June 2, 2021","Stanford University, Palo Alto, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04268316/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04268316/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04268316"
553,"NCT04395183","5-HTP and Creatine for Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: 5-Hydroxytryptophan 100 MG|Drug: Creatine monohydrate|Drug: placebo matched to 5-HTP|Drug: Placebo","17-Item Hamilton Depression Rating Scale|Montgomery Asberg Depression Rating Scale","University of Utah","All","25 Years to 40 Years   (Adult)","Phase 2","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB_00132830","March 1, 2021","July 31, 2025","July 31, 2025","May 20, 2020",,"April 29, 2021","University of Utah Department of Psychiatry, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04395183"
554,"NCT00289523","EEG Biomarkers for Predicting Response to Antidepressant Therapy",,"Completed","No Results Available","Major Depressive Disorder",,"1. To confirm prospectively the accuracy of an EEG biomarker as a leading indicator of SSRI antidepressant treatment response;|1. To confirm prospectively the accuracy of an EEG biomarker as a leading indicator of remission;","Medtronic - MITG","All","21 Years to 75 Years   (Adult, Older Adult)",,"375","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","227","January 2006","July 2007","July 2007","February 10, 2006",,"March 7, 2012","University of California, Los Angeles-Westwood, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|University of California, Los Angeles-Harbor, Torrance, California, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Southwestern, Dallas, Texas, United States|Baylor University College of Medicine, Houston, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00289523"
555,"NCT04448431","Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression","VIVRE","Recruiting","No Results Available","Major Depressive Disorder","Drug: Vortioxetine|Drug: Desvenlafaxine","Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score|Remission (defined as a MADRS total score =<10)|Response (defined as a => 50% decrease from baseline in MADRS total score)|Change in MADRS anhedonia factor score|Change in Digital Symbol Substitution Test (DSST) total score|The proportion number of Hard Choice/number of High Reward trials and number of Low choice/number of Low Reward trials when performing the Effort- Expenditure for Rewards Task (EEfRT)|Change in Clinical Global Impression - Severity of Illness (CGI-S) score|Clinical Global Impression Scale- Global Improvement (CGI-I) score|Change in Functioning Assessment Short Test (FAST) total score|Change in FAST sub-domain scores|Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total score|Change in Q-LES-Q work subscale|Change in Q-LES-Q household duties subscale|Change in Q-LES-Q school/course subscale|Change in Q-LES-Q leisure time activities subscale|Change in Q-LES-Q social relations subscale","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18498A","June 18, 2020","May 31, 2022","June 30, 2022","June 25, 2020",,"June 21, 2021","Clinica Privada Banfield S.A. (AR1010), Banfield, Buenos Aires, Argentina|INAPsi (Instituto Nacional de Psicopatologia) (AR1005), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Clinica Privada De Salud Mental Santa Teresa De Avila (AR1004), La Plata, Buenos Aires, Argentina|Sanatorio Prof. Leon S. Morra S.A. (AR1003), Córdoba, Providencia De Cordo, Argentina|CINME (Centro de Investigaciones Metabolicas de Buenos Aires) (AR1014), Ciudad Autonoma de Buenos Aire, Argentina|Cenydet-Centro Neurobiologico Y De Estres Traumatico-Biopsychomedical Research Group Srl (AR1008), Ciudad Autonoma de Buenos Aire, Argentina|Fundacion Para Estudios Y Tratamientos De Las Enfermedades Mentales (AR1006), Ciudad Autonoma de Buenos Aire, Argentina|CEN (Centro Especializado Neurociencias) (AR1012), Córdoba, Argentina|Instituto Modelo de Neurologia Fundacion Lennox (AR1011), Córdoba, Argentina|Instituto Damic / Fundacion Rusculleda (AR1007), Córdoba, Argentina|Instituto De Neurociencias San Agustin SA (AR1001), La Plata, Argentina|Centro De Asistencia E Investigacion En Neurociencias CENAIN (AR1002), Mendoza, Argentina|Resolution Psicopharmacology Research Institute (AR1009), Mendoza, Argentina|CIAP (Centro de Investigacion y Asistencia en Psiquiatria) (AR1013), Rosario, Argentina|Algemeen Ziekenhuis St. Lucas-St. Jozef (BE1002), Brugge, Belgium|SINAPS - University Antwerpe- Psychiatrisch Ziekenhuis Duffel (BE1006), Duffel, Belgium|Cliniques De Mont-Godinne (BE1004), Yvoir, Belgium|MHAT Dr. Hristo Stambolski (BG1005), Kazanlak, Bulgaria|UMHAT Sv.Georgi (BG1003), Plovdiv, Bulgaria|Center For Mental Health-Rousse (BG1001), Rousse, Bulgaria|MC Complete Medical Solutions (BG1007), Samokov, Bulgaria|Centre for Mental Health - Sofia (BG1006), Sofia, Bulgaria|MC Avicena EOOD (BG1002), Sofia, Bulgaria|DCC Mladost-M Varna (BG1004), Varna, Bulgaria|Dr.Jan Holan MD, Office of (CZ1004), Brno, Czechia|Meditrine s.r.o. - Psychiatricka Ambulance, Lecebne Centrum (CZ1005), Havířov, Czechia|Clinline services s.r.o. (CZ1008), Hostivice, Czechia|Neuropsychiatrie HK, s.r.o. (CZ1003), Hradec Kralove, Czechia|National Institute of Mental Health (CZ1011), Klecany, Czechia|SUPERVIZE, s.r.o. (CZ1002), Kutná Hora, Czechia|A-Shine s.r.o. (CZ1006), Plzen, Czechia|Clintrial s.r.o. (CZ1001), Prague, Czechia|Psychiatricka ordinace (CZ1013), Praha 10, Czechia|Institut neuropsychiatricke pece (CZ1007), Praha 8, Czechia|North Estonia Medical Centre (North Estonia Regional Hospital) (EE1001), Tallinn, Estonia|Marienthali Kliinik (EE1003), Tallinn, Estonia|Daugavpils Psychoneurosis Hospital (LV1004), Daugavpils, Latvia|Psihiatrijas Centrs (LV1002), Liepāja, Latvia|Riga Centre Of Psychiatry And Addiction Disorders (LV1003), Riga, Latvia|Sigulda Hospital Outpatient Clinic (LV1001), Sigulda, Latvia|Arkhangelsk Regional Clinical Mental Hospital (RU1013), Arkhangelsk, Russian Federation|GUZ Engels Psychiatric Hospital (RU1009), Engel's, Russian Federation|Moscow Scientific Research Institute of Psychiatry (RU1015), Moscow, Russian Federation|Clinic named after professor Yu. N. Kasatkin FGBOU DPO RMANPO Minzdrava Rossii (RU1011), Moscow, Russian Federation|Nizhny Novgorod Region State Institution Of Healthcare Clinical Psychiatric Hospital 1 Of Nizhny Novgorod (RU1012), Nizhny Novgorod, Russian Federation|Rostov State Medical University of the Minzdravsotsrazvitiya of Russia (RU1002), Rostov-on-Don, Russian Federation|LLC Medical Center Nova Vita (RU1007), Rostov-on-Don, Russian Federation|St. Nicolas State Psychiatric Hospital (RU1008), Saint Petersburg, Russian Federation|Leningrad Regional Psychoneurological Dispensary (RU1003), Saint Petersburg, Russian Federation|Hospital OrKli, LLC (RU1004), Saint Petersburg, Russian Federation|Astarta LLC (RU1016), Saint Petersburg, Russian Federation|Saratov State Medical University (RU1005), Saratov, Russian Federation|State Budgetery Educational Institution Of Higher Professional Education Smolensk State Medical University Of Ministry Of Healthcare Of Russian Federation (RU1006), Smolensk, Russian Federation|Region Specialized Psychiatric Hospital #2 (RU1001), Stavropol, Russian Federation|Yaroslavl Regional Clinical Psychiatry Hospital (RU1010), Yaroslavl, Russian Federation|Psychiatricka ambulancia, MENTUM, s.r.o. (SK1009), Bratislava, Slovakia|Epamed, S.R.O (SK1001), Košice, Slovakia|Psycholine S.R.O. (SK1002), Rimavská Sobota, Slovakia|Crystal Comfort, s.r.o. (SK1003), Vranov Nad Topľou, Slovakia|BONA MEDIC s.r.o. (SK1007), Zlaté Moravce, Slovakia|Psychiatricka Ambulancia (SK1005), Zlaté Moravce, Slovakia|Hospital De La Santa Creu I Sant Pau (ES1006), Barcelona, Spain|Consultoria i Projectes Sanitaris. Hestia Palau Unidad de Investigacion (ES1002), Barcelona, Spain|Hospital Universitario Fundacion Alcorcon (ES1003), Madrid, Spain|Centro De Salud Mental La Corredoria (ES1004), Oviedo, Spain|Ambulatorio Creu Roja (ES1001), Palma de Mallorca, Spain|Hospital Alvaro Cunqueiro (ES1005), Vigo, Spain|Affecta Psyikiatri AB (SE1001), Halmstad, Sweden|ProbarE i Lund (SE1003), Lund, Sweden|Smaert & Psykiatricentrum Malmoe (SE1006), Malmö, Sweden|ONE LIFETIME Lakarmottagning (SE1007), Skövde, Sweden|ProbarE (SE1005), Stockholm, Sweden|CI of KRC Regional psychiatric and narcological medical association (UA1002), Hlevakha, Ukraine|Academy of Medical Sciences of Ukraine - Institute of Neurology, Psychiatry and Narcology (UA1010), Kharkiv, Ukraine|Si Inpn Namsu (Ua1003), Kharkiv, Ukraine|Lviv Regional State Clinical Psychiatric Hospital, Lviv Danylo Galytsky National Medical University (UA1012), Lviv, Ukraine|Odessa Regional Medical Centre of Mental Health (UA1005), Odessa, Ukraine|Municipal Non-profit Enterprise Odesa Regional Psychiatric Hospital No.2 of Odesa Regional Council (UA1008), Odessa, Ukraine|Ukrainian Medical Stomatological Academy, Chair Of Psychiatry, Narcology And Medical Psychology Based On Poltava Regional Clinical Psychiatric Hospital Named After O.F. Maltsev (UA1001), Poltava, Ukraine|""Communal Non-commercial Enterprise """"Cherkasy regional psychiatric hospital of Cherkasy regional council¿"" (UA1007), Smila, Ukraine|Vinnitsa National Medical University (UA1006), Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT04448431"
556,"NCT03711123","Group Metacognitive Therapy vs Clinical Management for Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Group metacognitive therapy|Behavioral: Clinical management","Change in depression|Change in diagnosis|Change in rumination|Change in positive beliefs|Change in Negative beliefs|Change in metacognitions|Change in personality|Change in dysfunctional attitudes and beliefs|Change in resilience|Change in anxiety|Change in sleep|change in report of executive function|change in personality diagnoses","University of Oslo","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015/673-1","November 1, 2018","April 2021","June 2025","October 18, 2018",,"October 18, 2018","Specialist practice Dr Toril Dammen, Drammen, Buskerud, Norway",,"https://ClinicalTrials.gov/show/NCT03711123"
557,"NCT02837887","Computerized Cognitive Behavior Therapy in Treating Depression in Patients With Cancer",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Computerized Cognitive Behavior Therapy","Change in Hamilton Rating Scale for Depression (HRSD)|Change in the Beck Depression Inventory (BDI-II)|Change in Patient Health Questionnaire-9 (PHQ-9)|Change in Generalized Anxiety Disorder-7 (GAD7)","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","OSU-16008|NCI-2016-00954","July 15, 2016","December 31, 2017","March 29, 2018","July 20, 2016",,"June 22, 2020","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02837887"
558,"NCT03060967","Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS)","MOODDIS","Unknown status","No Results Available","Major Depression","Behavioral: Computer-based tasks","Point of subjective equality (PSE)|Percentage of subjective discrimination (PSD)","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 60 Years   (Adult)","Not Applicable","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","C15-88","June 2017","September 2020","September 2020","February 23, 2017",,"May 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03060967"
559,"NCT04543123","Effect of Self-administered tDCS in Patients With MDD",,"Completed","No Results Available","Major Depressive Disorder","Device: tDCS treatment|Drug: Antidepressant Drug(escitalopram)","Hamilton Depression Scale (HAM-D)|Beck Depression Inventory (BDI)|Montgomery-Asberg Depression Rating Scale|Beck Anxiety Inventory","Jeong-Ho Chae|Ybrain Inc.|Seoul St. Mary's Hospital","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 4","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","tDCS in MDD","November 16, 2017","May 2, 2019","May 2, 2019","September 9, 2020",,"September 9, 2020","Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04543123"
560,"NCT03835715","Study With Vortioxetine on Emotional Functioning in Patients With Depression","COMPLETE","Completed","No Results Available","Major Depressive Disorder","Drug: Vortioxetine","Change from baseline to Week 8 in Oxford Depression Questionnaire (ODQ) total score|Change from baseline to Week 8 in MEI total score.|Change from baseline to Week 8 in DSST total score|Change from baseline to Week 8 in ODQ domain scores (NC, ED, PR, GR, and AC)|Change from baseline to Week 8 in MADRS total score|Change from baseline to Week 8 in SDS individual item scores (family, work, and social life)|Change from baseline to Week 8 in SDS total scores|Change from baseline to Week 8 in CGI-S score|CGI-I score at Week 8","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17797A","February 5, 2019","February 21, 2020","February 21, 2020","February 8, 2019",,"March 24, 2020","Office of Dr. Patrick Bourgoin (FR0011), Angoulême, France|Cabinet Psyche (FR0012), Douai, France|Dr. David Modavi Md, Office Of (FR0001), Toulouse, France|Private Practice Dr. Paule Khalifa (FR0010), Toulouse, France|GHS De Nancy - CPN Laxou (FR0006), Vandœuvre-lès-Nancy, France|Dr Karim Boutayeb MD, Office of (FR0009), Viersat, France|Centre Medical Ambroise Pare (FR0007), Élancourt, France|DSM Giulianova c/o ospedale di Giulianova (IT0004), Giulianova, Italy|Dipartimento Salute Mentale ASL Lecce (IT0006), Lecce, Italy|Universita degli Studi di Roma La Sapienza - Azienda Ospedaliera Sant Andrea (IT0013), Rome, Italy|JSC Romuvos Klinika (LT0002), Kaunas, Lithuania|Mental Health Centre Kaunas Outpatient Clinic (LT0005), Kaunas, Lithuania|JSC Nefridos klinika (LT0006), Klaipėda, Lithuania|Jsc Silutes Mental Health And Psychotherapy Center (LT0001), Silute, Lithuania|Antakalnis Psychiatric Consultation Centre (LT0003), Vilnius, Lithuania|PI Mental Health Center of Zirmunai (LT0004), Vilnius, Lithuania|Hospital Universitario Fundacion Alcorcon (ES0009), Alcorcón, Spain|Instituto Internacional de Neurociencias Aplicadas (ES0004), Barcelona, Spain|Centro De Salud Mental De Foios (ES0002), Foios, Spain|University of Oviedo (ES0011), Oviedo, Spain|Francesca Canellas Dols (ES0005), Palma De Mallorca, Spain|Hospital Clínico Universiatrio de Salamanca (ES0001), Salamanca, Spain|Centro De Especialidades A Doblada (ES0006), Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT03835715"
561,"NCT02332954","Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine","AtWoRC","Completed","No Results Available","Major Depressive Disorder","Drug: vortioxetine","the association/correlation between changes in patient-reported cognitive symptoms and work productivity. (Perceived Deficit Questionnaire-Depression)|Cognitive function (PDQ-D-20)|Cognitive function (Digit Symbol Substitution Test (DSST)|Work productivity (WLQ)|Work productivity (Work Productivity and Activity Impairment (WPAI) questionnaire)|Work productivity (World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12)|Work productivity (Sheehan Disability Scale (SDS)|Depressive symptoms (Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR)|Depressive symptoms (Clinical Global Impression-Improvement (CGI-I) score)|Depressive symptoms (Clinical Global Impression-Severity (CGI-S)","Lundbeck Canada Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","226","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15913A","February 2015","July 6, 2017","July 6, 2017","January 7, 2015",,"January 30, 2018","CA004, Edmonton, Alberta, Canada|CA005, Kelowna, British Columbia, Canada|CA006, St. John's, Newfoundland and Labrador, Canada|CA007, Halifax, Nova Scotia, Canada|CA016, Burlington, Ontario, Canada|CA013, Chatham, Ontario, Canada|CA010, Corunna, Ontario, Canada|CA012, Fort Erie, Ontario, Canada|CA017, Hamilton, Ontario, Canada|CA026, Hamilton, Ontario, Canada|CA011, London, Ontario, Canada|CA003, Mississauga, Ontario, Canada|CA008, Sarnia, Ontario, Canada|CA009, Sarnia, Ontario, Canada|CA015, St. Catharines, Ontario, Canada|CA022, Montreal, Quebec, Canada|CA020, Montreal, Quebec, Canada|CA023, Montreal, Quebec, Canada|CA018, Pointe-Claire, Quebec, Canada|CA024, St-Jean-sur-Richelieu, Quebec, Canada|CA030, Victoriaville, Quebec, Canada|CA027, Westmount, Quebec, Canada|CA028, Saskatoon, Saskatchewan, Canada|CA019, Quebec, Canada|CA021, Quebec, Canada|CA029, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02332954"
562,"NCT01056289","Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|Drug: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|Drug: Placebo","Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase|Percentage of Participants With Taper Adverse Events (AEs) in the Double-blind Phase|Percentage of Participants Who Were Unable to Successfully Complete Tapering of the Study Drug Because of the Number and/or Severity of Their Discontinuation Symptoms","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-4437|B2061010","March 2010","February 2011","February 2011","January 26, 2010","February 17, 2012","February 28, 2012",,,"https://ClinicalTrials.gov/show/NCT01056289"
563,"NCT00878748","Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: Effexor XR|Other: Effexor XR discontinue","time from entering maintenance phase to recurrence of major depression|Patient Health Questionnaire(PHQ-15),Clinical Global Impressions(CGI),Visual Analogue Scale(VAS),Short Form Health Survey(SF-36)","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0600X1-4434","April 2009","October 2011","October 2011","April 9, 2009",,"September 22, 2010",,,"https://ClinicalTrials.gov/show/NCT00878748"
564,"NCT04673383","SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: SPL026|Drug: Placebo","Safety and tolerability in healthy volunteers|Efficacy of SPL026 in MDD patients with moderate to severe depression","Small Pharma Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT026_001","February 4, 2021","October 1, 2022","February 1, 2023","December 17, 2020",,"March 19, 2021","Hammersmith Medicines Research, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04673383"
565,"NCT01203683","Testing the Effectiveness of a Computer-based Program for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Active computer-based training|Behavioral: Inert computer training","Beck Depression Inventory-II|Structured Clinical Interview for DSM-IV diagnoses|Neural processing of emotion stimuli","University of Texas at Austin","All","18 Years to 55 Years   (Adult)","Phase 3","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-09-0004","January 2011","October 2013","October 2013","September 16, 2010",,"October 10, 2013","University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01203683"
566,"NCT04210973","Comparison of Anyu Peibo With Placebo in Treatment of MDD in China",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Anyu Peibo|Drug: Placebo","The change of total score from baseline in Montgomery Asberg Depression Rating Scale （MADRS）|Clinical Remission Rate according to total score of MADRS at the end of study|Clinical Remission Rate according to 17-items Hamilton Depression Scale (HAMD17) total score at the end of study|The change of total score of MADRS by time|The change of total score from baseline in HAMD17|The change of total score from baseline in Hamilton Anxiety Scale (HAMA)|The change of score from baseline in Clinical Global Impression-Severity of Illness (CGI-S)|Clinical Global Impression-Severity of Illness (CGI-I) score|The change of total score from baseline in Discriminative Scale Space Tracker (DSST)|The change of total score from baseline in Trail Making Test (TMT) A&B|The change of total score from baseline in Sheehan Disability Scale (SDS)|Proportion of subjects who withdrew from clinical trial due to poor efficacy|Proportion of subjects who combined medication to treat insomnia|Incidence rate of AE|Breath Rate|Pulse Rate|Heartbeat Rate|Diastolic blood pressure|Systolic blood pressure|Electrocardiogram(ECG)|Assessment of Arizona Sexual Experience Scale (ASES)|Number of Participants with AE result in early withdrawal from clinical trials|Number of Participants with Serious Adverse Event (SAE) result in early withdrawal from clinical trials|Number of Emerging AE during drug withdrawal period","Shanghai Mental Health Center|Su Zhou YiHua Biotechnology Co. LTD","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","266","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AYPB-MDD-Ⅲ-201901|2018ZX09734-005","January 23, 2020","December 2020","May 2021","December 26, 2019",,"May 12, 2020","Beijing Anding Hospital，Capital Medical University, Beijing, Beijing, China|Beijing HuiLongGuan Hospital, Beijing, Beijing, China|Peking University Sixth Hospital, Beijing, Beijing, China|Chongqing Mental Health Center, Chongqing, Chongqing, China|Guangzhou Brain Hospital, Guangzhou, Guangdong, China|The Sixth People's Hospital of Hebei Province, Baoding, Hebei, China|The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China|Zhumadian mental Hospital, Zhumadian, Henan, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|Jiangxi Mental Hospital, Nanchang, Jiangxi, China|Brain Hospital of Jilin Province, Siping, Jilin, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|XI'AN Mental Health Center, Xi'an, Shanxi, China|Ningbo Kangning Hospital, Ningbo, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04210973"
567,"NCT00770289","Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)","B2411003","Completed","Has Results","Major Depressive Disorder","Other: Cohort","Percentage of Participants With Remission Based on Hamilton Depression Scale (HAM-D)|Percentage of Participants With Remission Based on Beck Depression Inventory (BDI)|Hamilton Depression Scale 17 (HAM-D17), HAM-D7 and Beck Depression Inventory (BDI)|Number of Participants With Residual Symptoms in Case of Non Remission","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)",,"851","Industry","Observational","Observational Model: Cohort","0600B-102374|B2411003","May 2008","December 2009","December 2009","October 9, 2008","August 31, 2012","August 31, 2012","Pfizer Investigational Site, Haidari, Athens, Greece|Pfizer Investigational Site, Haidari, Athens, Greece|Pfizer Investigational Site, Ilissia, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT00770289"
568,"NCT03555136","Real-life Effectiveness of Vortioxetine in Depression","RELIEVE","Completed","No Results Available","Major Depressive Disorder","Drug: Vortioxetine","Sheehan Disability Scale (SDS)|The Patient Health Questionnaire - nine items (PHQ-9)|Perceived Deficits Questionnaire - Depression - five items (PDQ-D-5)","H. Lundbeck A/S","All","18 Years and older   (Adult, Older Adult)",,"992","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17354N","November 17, 2017","January 31, 2021","January 31, 2021","June 13, 2018",,"May 27, 2021","Harmonex Neuroscience Research Inc (US0072), Dothan, Alabama, United States|Center For Advanced Improvement (US0011), Tucson, Arizona, United States|Pharmacology Research Institute (US0045), Newport Beach, California, United States|North County Clinical Research (Nccr) (US0071), Oceanside, California, United States|Breakthrough Clinical Trials (US0074), San Bernardino, California, United States|Viking Clinical Research Center LLC (US0033), Temecula, California, United States|Da Vinci Research Institute (US0063), Boca Raton, Florida, United States|Sarkis Clinical Trials (US0066), Gainesville, Florida, United States|Maxblue Institute (US0038), Hialeah, Florida, United States|Office Of Amit Vijapura, Md (US0057), Jacksonville, Florida, United States|International Research Associates LLC (US0060), Miami, Florida, United States|Millenia Psychiatry and Research, Inc. (US0015), Orlando, Florida, United States|Professional Health Care of Pinellas (US0050), Saint Petersburg, Florida, United States|Northwest Behavioral Research Center (US0007), Marietta, Georgia, United States|Pearl Health Clinic (US0001), Ammon, Idaho, United States|Southern Illinois Associates LLC (US0079), Glen Carbon, Illinois, United States|AMR- Baber Research, Inc. (US0006), Naperville, Illinois, United States|University Of Kansas Cancer Center (US0078), Kansas City, Kansas, United States|Neuroscientific Insights (US0029), Rockville, Maryland, United States|Rochester Center For Behavioral Medicine (US0059), Rochester Hills, Michigan, United States|St. Charles Psychiatric Associates - Midwest Research Group (US0039), Saint Charles, Missouri, United States|Alivation Research, LLC (US0020), Lincoln, Nebraska, United States|Meridian Clinical Research (US0027), Norfolk, Nebraska, United States|Finger Lakes Clinical Research (US0005), Rochester, New York, United States|Quest Therapeutics Of Avon Lake (US0002), Avon Lake, Ohio, United States|Psychiatric Consultants, Pc (US0028), Franklin, Tennessee, United States|Bay Pointe Behavioral Health (US0030), Friendswood, Texas, United States|Biopharma Informatic, LLC (US0031), Houston, Texas, United States|Biopharma Informatic, LLC, Houston, Texas, United States|West park Springs (US0073), Richmond, Texas, United States|Core Clinical Research (US0067), Everett, Washington, United States|Chokka Center For Integrative Health (CA0001), Edmonton, Alberta, Canada|Chatham-Kent Clinical Trials Research Centre (CA0007), Chatham, Ontario, Canada|Queen's University-Hotel Dieu Hospital (CA0011), Kingston, Ontario, Canada|St. Joseph's Health Care London - Parkwood Institute (Regional Mental Health Care London and Parkwood Hospital) (CA0004), London, Ontario, Canada|Start Clinic For Mood And Anxiety Disorders (CA0006), Toronto, Ontario, Canada|Jodha Tishon Inc (CA0008), Toronto, Ontario, Canada|GCP Research (CA0013), Montreal, Quebec, Canada|Mana Research Inc (CA0012), Point Claire, Quebec, Canada|Alpha Recherche Clinique (CA0009), Quebec City, Quebec, Canada|Alpha Recherche Clinique (CA0017), Quebec, Canada|Centre Hospitalier Bp29 (FR0015), Rouffach, Alsace, France|Dr Philippe Marmor, MD, Office of (FR0035), Strasbourg, Alsace, France|CHU de Nantes (FR0023), Nantes, Cedex 1, France|CHS Le Vinatier (FR0013), Bron Cedex, Cedex, France|Cmpi (FR0004), Le Vesinet, Yvelines, France|Chru Houtel Dieu (FR0020), Angers Cedex, France|Dr. Philippe Remaud MD, Office of (FR0010), Angers, France|Clinique Villa Bleue (FR0008), Angouleme, France|Clinique Clinea orgemont (FR0061), Argenteuil, France|Centre Hospitalier De Blois (FR0011), Blois, France|CH De Novillars (FR0025), Chalezeule, France|CHU Clermont-Ferrand, Hopital Gabriel Montpied (FR0037), Clermont Ferrand Cedex 1, France|Chs Philippe Pinel (Fr0017), Dury, France|Centre Medical Ambroise Pare (FR0005), Elancourt, France|Hopital Albert Michallon- CHU Grenoble Alpes (FR0021), Grenoble cedex 9, France|Clinique Korian La Crau (FR0063), La Crau, France|Dr. Norbert Rigaud Md, Office Of (FR0028), Lamagistere, France|Centre Hospitalier Esquirol (FR0038), Limoges, France|Clinique Mon Repos (FR0057), Marseille, France|Centre Hospitalier De Martigues (FR0064), Martigues Cedex, France|Hopital de la Colombiere (FR0026), Montpellier Cedex, France|Cabinet Medical (FR0043), Mulhouse, France|Maison Des Addictions (FR0006), Nancy, France|Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur - Clinique de Psychiatrie et de Psychologie Medicale (FR0041), Nice, France|Centre Hospitalier Universitaire de Nimes (FR0018), Nimes, France|Centre Hospitalier Sainte Anne (FR0029), Paris, France|Camp Antonin Artaud (FR0001), Quimper, France|Dr. Dominique Januel, MD Office of (FR0044), Rueil-Malmaison, France|Unites De Soins Romain Rolland (FR0012), St Denis, France|Hopital Nord (FR0042), St Priest En Jarez Cedex, France|Dr Lousqui Charles MD, Office of (FR0033), Strasbourg, France|Hopital civil (FR0039), Strasbourg, France|Cabinet Du Dr D Bonneau (FR0036), Thouars, France|Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer - Hôpital Sainte Musse (FR0019), Toulon, France|Hopital De Psychiatrie (FR0009), Toulouse, France|Dr. David Modavi Md, Office Of (FR0034), Toulouse, France|Dr. Joel Pon MD, Office of (FR0027), Toulouse, France|Ospedale Versilia (IT0002), Lucca, LU, Italy|Casa di Cura Villa San Benedetto Menni, Suore Ospedaliere (IT0025), Albese con Cassano, Milano, Italy|Asl Roma G (IT0005), Colleferro, Roma, Italy|Ospedale Sant'Andrea Hospital (IT0003), Rome, Roma, Italy|Insituto Di Ricovero E Cura A Carattere Scientifico San Raffaele Pisana (IT0035), Roma, Rome, Italy|DSM Giulianova - ospedale di Giulianova (IT0019), Giulianova, Teramo, Italy|Azienda Ospedaliero-Universitaria San Luigi Gonzaga (IT0004), Orbassano, Torino, Italy|Istituto di Neuroscienze (INS) (IT0028), Firenze, Toscana, Italy|Azienda Ospedaliera di Perugia - Policlinico Monteluce (IT0034), Perugia, Umbria, Italy|ASST Papa Giovanni XXIII (IT0016), Bergamo, Italy|Università degli Studi di Brescia (IT0029), Brescia, Italy|Universita Degli Studi Di Catania - Azienda Policlinico (IT0030), Catania, Italy|Universita Degli Studi Magna Graecia Di Catanzaro (IT0006), Catanzaro, Italy|DSM Cosenza (IT0015), Cosenza, Italy|Psichiatria Ospedale Oglio Po (IT0023), Cremona, Italy|Ospedali Riuniti Foggia (IT0007), Foggia, Italy|Dipartimento Salute Mentale ASL Lecce (IT0009), Lecce, Italy|ASST Lodi (IT0042), Lodi, Italy|Azienda Toscana nord ovest zona Apuane (IT0039), Massa, Italy|Policlinico Universitario Di Messina (IT0031), Messina, Italy|Azienda Ospedaliera San Paolo - Universita Degli Studi Di Milano (IT0014), Milano, Italy|Disturbi Depressivi Ospedale Luigi Sacco Polo Universitario Psichiatria 2 - CTDD (IT0033), Milano, Italy|Pneumology Clinic - AO San Gerardo (IT0017), Monza, Italy|Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma (IT0032), Roma, Italy|Villa Von Siebenthal (IT0008), Roma, Italy|Universita Cattolica del Sacro Cuore (University of Sacred Heart Policlinico A. Gemelli) (IT0018), Rome, Italy|Ospedale Alfredo Fiorini (IT0026), Terracina, Italy|University Of Turin (IT0001), Turin, Italy",,"https://ClinicalTrials.gov/show/NCT03555136"
569,"NCT03766867","Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Vortioxetine infusion 25 mg|Drug: Vortioxetine tablets 10 mg/day|Drug: Placebo infusion|Drug: Placebo tablets","Change from baseline (Day 0) to Day 1 (24 h post-infusion) in MADRS-6 subscale score|Change from baseline (Day 0) to Day 3 in MADRS-6 subscale score|Change from baseline (Day 0) to Day 7 in MADRS-6 subscale score|Change in MADRS total score from baseline to Day 1, Day 3, Day 7|≥50% decrease in MADRS total score from baseline on Day 1 and Day 3|CGI-I score at Day 1, Day 3, Day 7|CGI-I response (defined as CGI-I score ≤2) on Day 1 and 3|Change from baseline in CGI-S score to Day 1, Day 3, Day 7|CL/F of vortioxetine|Cav","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17915A","December 3, 2018","July 31, 2019","August 28, 2019","December 6, 2018",,"August 29, 2019","Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD (BG1004), Burgas, Bulgaria|SPH - Kardzhali, EOOD (BG1005), Kardzhali, Bulgaria|MHAT ""Dr. Hristo Stambolski"", EOOD (BG1001), Kazanlak, Bulgaria|State Psychiatric Hospital ""Sv. Ivan Rilski"" (BG1009), Novi Iskar, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD (BG1006), Pleven, Bulgaria|MHC - Ruse, EOOD (BG1007), Ruse, Bulgaria|State Psychiatric Hospital (BG1008), Tsarev Brod, Bulgaria|Mental Health Center-Vratsa EOOD (BG1002), Vratsa, Bulgaria|Marienthali Kliinik (EE2001), Tallinn, Estonia|Tartu University Hospital (EE2002), Tartu, Estonia|Psychoneurological Hospital of Daugavpils (LV3003), Daugavpils, Latvia|Riga Centre of Psychiatry and Narcology (LV3002), Riga, Latvia|Psychoneurological Hospital of Strenci (LV3001), Strenči, Latvia",,"https://ClinicalTrials.gov/show/NCT03766867"
570,"NCT03511599","Cycloserine rTMS Plasticity Augmentation in Depression",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Cycloserine|Device: Transcranial Magnetic Stimulation|Drug: Placebo Oral Tablet","Motor evoked potential amplitude|Motor evoked potential dose-response curve","University of Calgary","All","18 Years to 60 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","REB18-0604","September 3, 2018","December 8, 2020","September 1, 2021","April 30, 2018",,"January 15, 2021","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03511599"
571,"NCT01934491","Cognitive Training for Depression II",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Training A|Behavioral: Cognitive Training B","Hamilton Depression Rating Scale (Ham-D)|Negative Affective Bias|Working Memory","Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Not Applicable","51","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 12-0266|1K23MH099223-01","August 2013","May 16, 2017","May 16, 2017","September 4, 2013",,"July 21, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01934491"
572,"NCT02024620","Mobile Apps for the Treatment of Depression",,"Withdrawn","No Results Available","Major Depressive Disorder","Behavioral: Behavioral activation plus mobile app|Behavioral: Standard behavioral activation","Change in Behavioral Activation for Depression Scale-Short Form|Change in Depression Anxiety Stress Scales-21","Central Arkansas Veterans Healthcare System|National Center for PTSD","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","529128","March 2014","October 2014","October 2014","December 31, 2013",,"December 15, 2015","Central Arkansas Veterans Healthcare System, North Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02024620"
573,"NCT04040062","Spectral Correlation Coefficient-based TMS",,"Enrolling by invitation","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation","Inventory of Depressive Symptoms- Self report","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-005605","June 25, 2019","October 2022","October 2022","July 31, 2019",,"April 15, 2021","University of California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04040062"
574,"NCT00128479","A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression",,"Completed","No Results Available","Major Depressive Disorder|Psychotic Disorders","Drug: mifepristone|Drug: mifepristone matched placebo|Drug: mifepristone 600 mg|Drug: mifepristone 1200 mg","The change in a measure of psychosis|The change in a measure of depression","Corcept Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","443","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C-1073-06","September 2004","January 2007","January 2007","August 10, 2005",,"February 15, 2012","K&S Research Services, Little Rock, Arkansas, United States|Center for Emotional Fitness, Cerritos, California, United States|Harbor Medical Associates, Inc., Fountain Valley, California, United States|Synergy Clinical Research Center, National City, California, United States|Excell Research, Oceanside, California, United States|Pacific Clinical Research Medical Group, Riverside, California, United States|AV Institute, Inc., Torrance, California, United States|Neuropsychiatric Institute of Orange County, Westminster, California, United States|Geriatric and Adult Psych, Hamden, Connecticut, United States|Comprehensive NeuroScience, Inc., Washington, District of Columbia, United States|Professional Clinical Research Inc., Ft. Lauderdale, Florida, United States|Amit Vijapura, MD, Jacksonville, Florida, United States|Tukoi Inst for Clinical Research, Miami, Florida, United States|Bioquan Research Group, Inc., North Miami, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Mark Ashby, MD, Sebring, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Hawaii Clinical Research Center, Honolulu, Hawaii, United States|Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace, Illinois, United States|Peryam and Kroll Health Care Research, Schaumburg, Illinois, United States|Clintell, Inc., Skokie, Illinois, United States|CTT Research, Prairie Village, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates, Inc, New Orleans, Louisiana, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|Saaid Khojasteh & Assoc, Inc, St. Charles, Missouri, United States|Medex Healthcare Research, St. Louis, Missouri, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Anxiety and Depression Clinic at Montefiore Medical Center, Bronx, New York, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Advanced Bio-Behavioral Science, Inc, Elmsford, New York, United States|Saint Vincent Catholic Medical Centers of New York, Staten Island, New York, United States|Lutheran Hospital, Cleveland, Ohio, United States|Southwest Cleveland Sleep Center, Inc., Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Crossroads Counseling & Consulting Associates, Moon Township, Pennsylvania, United States|CNS Research Institute (CRI), Philadelphia, Pennsylvania, United States|Segal Institute, Charleston, South Carolina, United States|Harmony Research, Johnson City, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Cedars Hospital, InSite Clinical Research, Desoto, Texas, United States|Felin-Jennings Clinic, Houston, Texas, United States|R&D Clinical Research, Inc., Lake Jackson, Texas, United States|America's Doctor/Essential Doctor, Inc, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00128479"
575,"NCT03965858","Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Esketamine DPI - low dose|Drug: Esketamine DPI - medium dose|Drug: Esketamine DPI - high dose|Drug: Placebo DPI","Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Day 14|Change from baseline in MADRS total score at each other than Day 14 timepoint|Number of participants with clinical response (>= 50% decrease in MADRS baseline score)|Onset of clinical response that was sustained through the end of the 2-week, double-blind, treatment phase|Change from baseline in depression severity, measured by Hamilton Depression Rating Scale (HDRS) at every timepoint|Number of participants with clinical remission (MADRS total score <= 10)|Time to relapse|Change from baseline in Clinical Global Impression - Severity (CGI-S) score at Day 14 and every other timepoint|Change from baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14 and every other timepoint|Change from baseline in the Clinician Administered Dissociative States Scale (CADSS) at each day of administration|Change from baseline in the Brief Psychiatric Rating Scale (BPRS) at each day of administration|Potential withdrawal symptoms after Esketamine treatment, as measured by the 20-item Physician Withdrawal Checklist (PWC-20)|Potential Esketamine effect on cognition as measured by Montreal Cognitive Assessment (MoCA)|Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Esketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h|Esketamine Cmax - maximum plasma concentration|Esketamine AUC0-inf - area under the plasma concentration - time curve from time 0 to infinity|Esketamine Kel - terminal elimination rate constant|Esketamine t1/2 - plasma elimination half-life|Esketamine Tmax - time to reach maximum concentration in plasma|Esnorketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h|Esnorketamine Cmax - maximum plasma concentration|Esnorketamine Tmax - time to reach maximum concentration in plasma|Changes between predose and postdose values for each administration in hematology and biochemistry|Changes between predose and postdose values for each administration in vital signs (heart rate, blood pressure, respiratory rate) and urinalysis|Changes between predose and postdose values for each administration in SpO2 (blood oxygen saturation)","Celon Pharma SA|National Center for Research and Development, Poland","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","88","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","02KET2018","February 25, 2019","March 15, 2020","April 24, 2020","May 29, 2019",,"April 28, 2020","Wojewodzki Szpital im. Jana Pawła II, Belchatow, Poland|Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych, Boleslawiec, Poland|Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej, Choroszcz, Poland|Szpital Miejski, Elblag, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Gornoslaskie Centrum Medyczne, Katowice, Poland|Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej, Lodz, Poland|Pabianickie Centrum Medyczne, Pabianice, Poland|Mazowieckie Specalistyczne Centrum Zdrowia, Pruszkow, Poland|Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych, Swiecie, Poland|Mazowiecki Szpital i Centrum Diagnostyczne Allenort, Warsaw, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT03965858"
576,"NCT04114565","Prevalence of Major Depression Among Immigrants in Santiago, Chile","STRING","Completed","No Results Available","Major Depressive Disorder",,"Major Depressive Disorder|Any affective/mood disorder|Suicidal ideation, plans and attempts|Depressive symptoms|Anxiety symptoms|Mental wellbeing|Mental health service use|Hazardous/harmful drinking","Pontificia Universidad Catolica de Chile|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile","All","18 Years and older   (Adult, Older Adult)",,"1092","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","17051004|96875479","July 29, 2019","November 30, 2019","June 30, 2020","October 3, 2019",,"July 31, 2020","Pontificia Universidad Catolica de Chile, Santiago, RM, Chile",,"https://ClinicalTrials.gov/show/NCT04114565"
577,"NCT00174590","Treatment of Major Depressive Disorder With Psychotic Features.",,"Terminated","No Results Available","Major Depression With Psychotic Features","Drug: risperidone","Hamilton Depression Rating Scale|Positive and Negative Symptom Scale","Rush University Medical Center|Janssen, LP","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","RIS-USA-248","September 2001",,"August 2007","September 15, 2005",,"January 10, 2008","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00174590"
578,"NCT00209066","Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy",,"Completed","No Results Available","Major Depressive Disorder",,,"Emory University|The Dana Foundation","All","18 Years to 90 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0422-1998|98052113","November 1998",,"April 2005","September 21, 2005",,"November 19, 2013","Emory University School of Medicine, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00209066"
579,"NCT01768052","Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression",,"Unknown status","No Results Available","Major Depression","Device: functional Near Infrared Spectroscopy","Change in the connectivity strength in the CCN as assessed by fMRI|Change in brain activation in DLPFC as assessed by fNIRS monitoring","Mclean Hospital|National Alliance for Research on Schizophrenia and Depression","All","21 Years to 45 Years   (Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2012P002394","June 2013","January 2016","January 2016","January 15, 2013",,"May 4, 2015","McLean Hospital, Belmont, Massachusetts, United States|McLean Imaging Center/McLean TMS Service, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01768052"
580,"NCT04031157","Controlled Study to Evaluate the Safety and Efficacy of the Predictix Antidepressant Clinician Support Tool",,"Unknown status","No Results Available","Major Depressive Disorder","Device: Predictix Antidepressant","Overall Response rate in the PGT and SOC groups|Change from baseline in Quick Inventory of Depressive Symptomatology( QIDS 16) self reported score|Usability and satisfaction of the Predictix tool|Economic burden* and social impact on patients, employers, the health system and payers","Taliaz Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CL-02-PRT-02","January 1, 2018","December 2020","December 2020","July 24, 2019",,"July 24, 2019","Maccabi healthcare services, Tel Aviv, Israel|Maccabi healthcare services, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT04031157"
581,"NCT04425278","tDCS Intervention on Motivational Anhedonia of Major Depressive Disorder",,"Recruiting","No Results Available","Transcranial Direct Current Stimulation|Major Depressive Disorder|Event-Related Potentials","Device: transcranial direct current stimulation with real current|Device: transcranial direct current stimulation with sham current","Change from baseline in Hamilton Depression Scale|Change from baseline in Motivation and Pleasure Scale|The change from baseline in behavioral results of Monetary Incentive Delay task|The change from baseline in event-related brain potentials during the monetary incentive delay task","Anhui Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Yu","March 1, 2018","December 31, 2021","December 31, 2021","June 11, 2020",,"June 11, 2020","Anhui Medical University, Hefei, Anhui, China",,"https://ClinicalTrials.gov/show/NCT04425278"
582,"NCT03624621","Integral Remediation for Major Depression (""Rehabilitación Integral Para la Depresión Mayor"", RIDEM)","RIDEM","Unknown status","No Results Available","Major Depressive Disorder|Cognitive Symptom","Behavioral: Functional Remediation|Device: Computerized Cognitive Training (CCT)|Behavioral: Psychoeducation|Device: Online games","Change from baseline Functioning Assessment Short Test (FAST) score at 6 and 15 months|Change from baseline perceived cognitive deficits (PDQ)","Hospital de Sant Pau|Instituto de Salud Carlos III","All","18 Years to 60 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIBSP-rid-2017-107","March 15, 2018","October 31, 2019","December 31, 2020","August 10, 2018",,"August 24, 2018","Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT03624621"
583,"NCT01152554","A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|MDD|Depression","Drug: TC-5214|Drug: Placebo","Frequency of Patients Experiencing at Least One Adverse Event (AE)|Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)|Frequency of Patients Experiencing Serious Adverse Events (SAEs)|Sustained Efficacy at 3 Months, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤12 at Week 12 and All Visits up to and Including Week 24|Sustained Efficacy at 9 Months, Defined as a MADRS Total Score of ≤12 at Week 12 and at All Visits up to and Including Week 52|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 0) to End of Treatment (Week 52)|Change in Functional Impairment From Randomization (Week 0) to End of Treatment (Week 52) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 0) to End of Treatment (Week 52) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 0) to End of Treatment (Week 52)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","813","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00007","June 2010","February 2012","February 2012","June 29, 2010","October 29, 2012","April 11, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Arcadia, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Carson, California, United States|Research Site, Cerritos, California, United States|Research Site, Chino, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Garden Grove, California, United States|Research Site, Irvine, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Pico Rivera, California, United States|Research Site, Riverside, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Roswell, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Florence, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Gaithersburg, Maryland, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Weymouth, Massachusetts, United States|Research Site, Flowood, Mississippi, United States|Research Site, Creve Coeur, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Toms River, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Beechwood, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dublin, Ohio, United States|Research Site, Mason, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Lake Jackson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Woodstock, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, South Kirkland, Washington, United States|Research Site, Middleton, Wisconsin, United States|Research Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01152554"
584,"NCT03739632","Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets",,"Completed","No Results Available","Major Depressive Disorder","Drug: Hypidone Hydrochloride tablets|Other: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Hamilton Depression Scale 17 items(HAMD17)|Hamilton Anxiety Rating Scale (HAM-A)|Clinical Global Impression of Severity Scale(CGI-S)|Clinical Global Impression of Improvement Scale(CGI-I)|Change in Digit Symbol Substitution Test (DSST)|Change in Trail Making Test Parts A&B (TMT)","Zhejiang Huahai Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HYP202-CTP","November 30, 2018","December 18, 2019","December 23, 2019","November 14, 2018",,"October 30, 2020","Beijing Anding Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Huilongguan Hospital, Beijing, Beijing, China|Peking University Sixth Hospital, Beijing, Beijing, China|Guangzhou Hui'ai Hospital, Guangzhou, Guangdong, China|Hebei Mental Health Center, Baoding, Hebei, China|Henan Psychiatric Hospital, Xinxiang, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Wuhan Mental Health Center, Wuhan, Hubei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|Jiangxi Mental Hospital, Nanchang, Jiangxi, China|Jilin Neuropsychiatric Hospital, Siping, Jilin, China|Shandong Mental Health Center, Jinan, Shandong, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Xi'an Mental Health Center, Xi'an, Shanxi, China|The 7th People's Hospital of Hangzhou, Hangzhou, Zhejiang, China|the First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|The Third People's Hospital of Huzhou, Huzhou, Zhejiang, China|Ningbo Kangning Hospital, Ningbo, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03739632"
585,"NCT03310281","Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)",,"Completed","No Results Available","Major Depressive Disorder","Device: HOLD: Videogame","Change in reaction time to rare target stimuli, from the Test of Variables of Attention (TOVA)|Change in the cognitive component sub-score (items 4-7) of the Cognitive and Physical Functioning Questionnaire (CPFQ)|Change in Patient Deficit Questionnaire (PDQ) score|Change in Letter Number Span (LNS) working memory test score|Change in Stroop color and words test score|Change in Trail-making tests A and B scores|Change in BAC Symbol Coding Test score|Change in Trait Adjective Task score","Akili Interactive Labs, Inc.","All","25 Years to 55 Years   (Adult)","Not Applicable","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Akili-035","December 4, 2017","November 14, 2018","November 14, 2018","October 16, 2017",,"November 21, 2018","CNS Network, Inc., Garden Grove, California, United States|Behavioral Clinical Research, Inc., North Miami, Florida, United States|Innovative Clinical Research, Inc., North Miami, Florida, United States|Segal Trials, Charleston, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03310281"
586,"NCT02371291","Memory Flexibility Training for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Memory Flexibility Training|Behavioral: Psychoeducation","Depressive Status|Change in score on the Beck Depression Inventory (Beck, Steer, & Brown, 1996) from baseline|Depression free days|Change in memory flexibility from baseline, Score on the alternating instructions autobiographical memory task (Dritschel et al., 2013)","Medical Research Council Cognition and Brain Sciences Unit","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Mrccbu","January 2015","December 2016","January 2017","February 25, 2015",,"September 11, 2017","MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom|Cambridge and Peterborough NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02371291"
587,"NCT02480400","The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Sheehan Disability Scale|Montgomery Åsberg Depression Rating Scale","Abarbanel Mental Health Center|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","Lu-Pl-001","June 2010","June 2012","October 2012","June 24, 2015",,"June 24, 2015","Abarbanel MHC, Bat-Yam, Israel",,"https://ClinicalTrials.gov/show/NCT02480400"
588,"NCT04889976","App-based Psychological Interventions and Home-use Brain Stimulation for Depression","PSYLECT","Recruiting","No Results Available","Major Depressive Disorder|Unipolar Depression","Device: Double Active: Active home-use transcranial direct current stimulation (tDCS) and active app-based behavioral therapy (BT)|Device: tDCS-only: Active home-use transcranial direct current stimulation (tDCS) and sham app-based behavioral therapy (BT)|Device: Double sham: Sham home-use transcranial direct current stimulation (tDCS) and sham app-based behavioral therapy (BT)","Change in Hamilton Depression Rating Scale scores (17-item version)|Change in Montgomery-Asberg Depression Rating Scale scores (MADRS)|Change in Beck Depression Inventory - II scores (BDI - II)|Change in Hamilton Anxiety Rating Scale scores (HAM-A)|Change in Clinical Global Impression Rating Scale (Severity of Illness) scores (CGI-S)|Clinical Global Impression Rating Scale (Global Improvement) score (CGI-I)|Change in Young Mania Rating Scale (YMRS) scores|Change in Positive and Negative Affect Schedule scores (PANAS)|Change in State-Trait Anxiety Inventory scores (STAI-T and STAI-S)|Change in Device usability Likert scale scores|Change in tDCS Adverse Event Questionnaire scores","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years to 59 Years   (Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13922419.1.0000.0076|19/06009-6","May 22, 2021","July 22, 2024","January 22, 2025","May 17, 2021",,"May 25, 2021","Institute of Psychiatry, HC-FMUSP, São Paulo, SP, Brazil|Hospital Universitário - USP, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04889976"
589,"NCT03131050","Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD","SCE","Completed","No Results Available","Major Depressive Disorder","Drug: Scopolamine|Drug: Escitalopram|Drug: Saline","The time of early onset|Response rate of patients receiving scopolamine|The proportion of subjects at endpoint with HAMD-17≤7|Change in 17-item Hamilton Depression Scale (HAMD-17) scores|Change in Montgomery-Asberg Depression Rating Scale(MADRS)|Change in QIDS-SR16 score|Change in GAD7 score|Change in YMRS score|Change in CGI-S score","Capital Medical University","All","18 Years to 45 Years   (Adult)","Phase 4","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Scopolamine i.m.","March 15, 2017","February 8, 2018","March 8, 2018","April 27, 2017",,"December 26, 2018","Beijing Anding Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03131050"
590,"NCT01659814","Dopamine Neurotransmission in Major Depression",,"Completed","No Results Available","Major Depressive Disorder|Anhedonia",,"Event-Related Potentials (ERPs) during PSST task|[11C]raclopride binding potential|Behavioral Performance in Monetary Incentive Delay task|Behavioral Performance in Probabilistic Stimulus Selection Task (PSST)|Questionnaire Data","Mclean Hospital","All","18 Years to 45 Years   (Adult)",,"71","Other","Observational","Observational Model: Case-Control","2009P000038","March 2011","December 2012","December 2012","August 8, 2012",,"April 23, 2014","McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01659814"
591,"NCT01260649","N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression",,"Terminated","Has Results","Major Depressive Disorder","Drug: ketamine|Other: IV Saline|Procedure: ECT|Drug: Muscle Relaxant|Drug: Anesthetic Agents","Change in Hamilton Depression Rating Scale - 28|Number of Participants With Cognitive Side Effects","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2010P001672","November 1, 2010","October 26, 2012","November 1, 2012","December 15, 2010","April 14, 2017","May 22, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01260649"
592,"NCT00585585","Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features",,"Terminated","Has Results","Recurrent Major Depressive Disorder With Atypical Features","Drug: betahistine dihydrochloride","Maximum Tolerable Dose of Betahistine Dihydrochloride in mg","University of Cincinnati","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nelson #1","July 2007","January 2011","January 2011","January 3, 2008","July 25, 2017","July 25, 2017","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00585585"
593,"NCT03404466","To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD",,"Completed","No Results Available","Major Depressive Disorder","Drug: Hypidone Hydrochloride tablets","Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Hamilton Depression Scale 17 items(HAMD17)|Change in Hamilton Anxiety Rating Scale (HAM-A)|Change in Clinical Global Impression of Severity Scale(CGI-S)|Change in Clinical Global Impression of Improvement Scale(CGI-I)|Columbia-Suicide Severity Rating Scale (C-SSRS)","Zhejiang Huahai Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYP201-CTP","February 24, 2018","July 10, 2018","July 17, 2018","January 19, 2018",,"October 30, 2020","Shanghai mental health center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03404466"
594,"NCT02029963","Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?",,"Suspended","No Results Available","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation (rTMS)|Behavioral: Treatment as Usual","Change in depressive symptom severity","University of Manitoba|Manitoba Medical Service Foundation","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2013:178","February 2014","December 2017","July 2021","January 8, 2014",,"November 4, 2020","St. Boniface Hospital, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT02029963"
595,"NCT03183505","Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb",,"Completed","No Results Available","Major Depressive Disorder","Drug: Anyu Peibo|Drug: Placebo","The change of total score from baseline in MADRS scale|Clinical Response Rate according to MADRS|Clinical Remission Rate according to MADRS|Clinical Response Rate according to HAMD-17|Clinical Remission Rate according to HAMD-17|the Change of CGI (CGI-S, CGI-I) from baseline|the Change of total score from baseline in HAMA","Shanghai Mental Health Center|Su Zhou YiHua Biotechnology Co. LTD","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AYPB-MDD-Ⅱb-1701|2017ZX09304-020","June 30, 2017","October 5, 2018","November 29, 2018","June 12, 2017",,"January 23, 2019","Beijing Anding Hospital，Capital Medical University, Beijing, Beijing, China|Beijing HuiLongGuan Hospital, Beijing, Beijing, China|Wuhan Mental Health Center, Wuhan, Hubei, China|Jiangxi Mental Hospital, Nanchang, Jiangxi, China|Brain Hospital of Jilin Province, Siping, Jilin, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|XI'AN Mental Health Center, Xi'an, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03183505"
596,"NCT00320268","Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder","MOONSTONE","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine fumarate","Change from randomization to Week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score|Change from randomization to each assessment in the MADRS total score|MADRS response, defined as a ≥50% reduction from randomization in the MADRS total score at Week 6","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00001|Moonstone","April 2006",,"May 2007","May 3, 2006",,"March 25, 2009","Research Site, Little Rock, Arkansas, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Oceanside, California, United States|Research Site, Santa Ana, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, St. Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Clementon, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York City, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bellevue, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00320268"
597,"NCT04004169","Closed-Loop Deep Brain Stimulation for Major Depression","PReSiDio","Recruiting","No Results Available","Major Depressive Disorder","Device: Stimulation-ON|Device: Stimulation-OFF","The change in Montgomery Asberg Depression Rating Scale (MADRS) score|The change in Montgomery Asberg Depression Rating Scale (MADRS) score after 1 year|The difference in Hamilton Depression Rating Scale (HAMD-17) score|The difference in Hamilton Depression Rating Scale (HAMD-17) score after 1 year|The difference in the Inventory of Depressive Symptomatology Self-Report (IDS-SR) score|The difference in Inventory of Depressive Symptomatology Self-Report (IDS-SR) score after 1 year","University of California, San Francisco","All","22 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","17-23724","July 18, 2019","June 28, 2030","June 28, 2035","July 1, 2019",,"January 15, 2021","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04004169"
598,"NCT02506127","Intermittent Theta Burst Stimulation for MDD","iTBS","Not yet recruiting","No Results Available","Major Depressive Disorder","Device: Neuronetics XPLOR system","Percent change in Hamilton Depression Scale (HamD17)","University of California, Los Angeles","All","22 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15-000701","December 9, 2021","December 8, 2023","December 8, 2023","July 22, 2015",,"July 27, 2021",,,"https://ClinicalTrials.gov/show/NCT02506127"
599,"NCT03187093","Cognitive Dysfunction in MDD Patients",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Vortioxetine|Drug: Escitalopram","Change from baseline to week 8 in Sheehan Disability Scale|Change from baseline to week 8 in MADRS|Change from baseline to week 8 in PHQ-9|Change from baseline to week 8 in CGI-S|Change from baseline to week 8 in PDQ-5-D|Change from baseline to week 8 in RAVLT|Change from baseline to week 8 in TMT-B|Change from baseline to week 8 in DSST|Change from baseline to week 8 in plasma levels of IGF-1|Change from baseline to week 8 in plasma levels of BDNF|Change from baseline to week 8 in plasma levels of CRP|Change from baseline to week 8 in plasma levels of cortisol|Change from baseline to week 8 in plasma levels of ACTH","Oleg Levada|State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11031215","October 2016","April 2019","April 2019","June 14, 2017",,"January 10, 2019","State Institution ""Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine"", Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03187093"
600,"NCT00321490","Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder","DIAMOND","Completed","No Results Available","Major Depressive Disorder","Drug: Quetiapine fumarate|Drug: Duloxetine","Change from randomization to Week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score|Change from randomization to each assessment in the MADRS total score|MADRS response, defined as a ≥50% reduction from randomization in the MADRS total score at Week 6","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00002|Diamond","April 2006",,"May 2007","May 3, 2006",,"March 25, 2009","Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Beverly Hills, California, United States|Research Site, San Diego, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Wildomar, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Edwardsville, Illinois, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Okemos, Michigan, United States|Research Site, St. Paul, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Princeton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York City, New York, United States|Research Site, Dayton, Ohio, United States|Research Site, Mayfield Village, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Salem, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Kirkland, Washington, United States|Research Site, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00321490"
601,"NCT02153281","Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer","DETB","Completed","No Results Available","Major Depressive Disorder","Other: phenelzine treatment","MAO-B VT levels measured with PET in MDE secondary to MDD","Centre for Addiction and Mental Health","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DETB-071-13","June 2014","May 2019","May 2019","June 3, 2014",,"May 24, 2019","Center for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02153281"
602,"NCT02456948","Adjunct Minocyline in Treatment-resistant Depression","Mino-TRD","Completed","No Results Available","Major Depressive Disorder","Drug: Minocycline|Drug: Placebo","Response as per MADRS (Montgomery-Åsberg Depression Rating Scale)|Remission as per MADRS (Montgomery-Åsberg Depression Rating Scale)|HAM-D-17-Scale (17-item Hamilton Depression Rating Scale)|BDI-Scale (Beck Depression Inventory, Self Rating Scale)|CGI-Scale (Clinical Global Impressions Scale)|SCL-90-R (Symptom Checklist 90-R, Self Rating Scale)|Transcriptomic changes in patient-specific peripheral blood-derived monocytic cells|Protein levels of various inflammation-associated markers in patient sera","Charite University, Berlin, Germany","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","01EE1401F","January 2015","August 7, 2020","August 7, 2020","May 29, 2015",,"October 19, 2020","Heidelberg University Hospital, Department of Psychiatry, Heidelberg, Baden-Württemberg, Germany|Department of Psychiatry, Universitiy Hospital, Erlangen, Bavaria, Germany|Department of Psychiatry, LMU Munich, Munich, Bavaria, Germany|Max Planck Institute of Psychiatry, Munich, Bavaria, Germany|Department of Psychiatry, Universitiy Hospital, Regensburg, Bavaria, Germany|Department of Psychiatry, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany|Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen, Aachen, Germany|Department of Psychiatry, Charité - Campus Benjamin Franklin, Berlin, Germany|Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany",,"https://ClinicalTrials.gov/show/NCT02456948"
603,"NCT02548949","Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ","PMS","Completed","Has Results","Major Depressive Disorder",,"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants in Each Category of Clinical Global Impression-Improvement (CGI-I) Scale|Number of Participants With Final Effectiveness Evaluation","Pfizer","All","19 Years and older   (Adult, Older Adult)",,"700","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","B2061143","April 25, 2016","February 12, 2020","February 12, 2020","September 14, 2015","February 9, 2021","February 9, 2021","Chungbuk National University Hospital, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Konkuk University Chungju Hospital / Department of Psychiatry, Chungju-si, Chungcheongbuk-do, Korea, Republic of|Hallym University Dongtan Sacred Heart Hospital/Department of Neuropsychiatry, Hwaseong-si, Gyeonggi Province, Korea, Republic of|Hallym University Sacred Heart Hospital, Anyang-Si, Gyeonggi-do, Korea, Republic of|Roa Neurology Clinic/Neurology, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Bundang Cha Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of|Bong Seng Memorial Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chuncheon Sacred Heart Hospital-Hallym University, Gangwon-do, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Presbyterian Medical Center, Jeonju, Korea, Republic of|Nowon Eulji Medical Center, Eulji University, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong Department of Psychiatry, Seoul, Korea, Republic of","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02548949/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02548949/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02548949"
604,"NCT01431001","Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)","Remission from depression|Safety and tolerability of rTMS","Cervel Neurotech, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NS-CPS-TRMD-1","October 2011","October 2013","October 2013","September 9, 2011",,"May 19, 2014","Emory University, Atlanta, Georgia, United States|Rush Medical College, Chicago, Illinois, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01431001"
605,"NCT02720198","Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD",,"Completed","Has Results","Major Depressive Disorder","Drug: Levomilnacipran|Drug: Quetiapine","Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Response Rate|Remission Rate|Changes in Neurocognition by Changes in Scores on Reyes Verbal Learning Test|Changes in Neurocognition by Changes in Scores on Scores on Digit Symbol Substitution Test (DSST)|Number of Subjects With Global Improvement in Scores on Clinical Global Impression Scale- Severity (CGI-S)|Number of Subjects With General Improvement in Scores on Clinical Global Impression Scale- Improvement (CGI-I)|Changes of Anxiety Symptoms in Scores on Hamilton Anxiety Rating Scale (HAM-A)|Changes of Quality of Life in Scores on Sheehan Disability Scale (SDS) Total|Changes in Scores on Apathy Evaluation Scale (AES).|Changes in Sexual Dysfunction by Changes in Scores on Arizona Sexual Experience Scale (ASEX)","Duke University|Forest Laboratories|Institute for Advanced Medical Research, Alpharetta, GA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00064983","January 23, 2017","June 12, 2018","June 12, 2018","March 25, 2016","July 2, 2019","August 14, 2019","Institute for Advanced Medical Research, Alpharetta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02720198/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02720198"
606,"NCT02805439","Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment",,"Completed","No Results Available","Major Depressive Disorder","Drug: S47445 15mg|Drug: S47445 50mg|Drug: Placebo","Hamilton Depression Rating Scale (HAM-D) total score expressed as change from baseline value|HAM-D total score|Response to treatment defined by HAM-D total score decrease from baseline ≥ 50%|Clinical Global Impression scale (CGI), item 1 (Severity of depression) and item 2 (global Improvement) scores, response to treatment (CGI item 2 = 1 or 2)|Hospital Anxiety and Depression Scale (HAD), Anxiety and Depression sub-scores|Sheehan Disability Scale (SDS) scores (Work, social and family life)|Adverse Events|Body Weight|BMI|Laboratory tests (haematology and biochemistry)|12-lead ECG|Vital signs (standing and supine Systolic and Diastolic Blood Pressure, heart rate)|Columbia-Suicide Severity Rating Scale (C-SSRS)","Institut de Recherches Internationales Servier|ADIR Association|Servier","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL2-47445-014|2015-003867-13","March 2016","April 2017","April 2017","June 20, 2016",,"January 3, 2020","Mental Health Centre - Plovdiv, Plovdiv, Bulgaria|Mental Health Centre - Sofia district, Sofia, Bulgaria|Military Medical Academy, MHAT - Sofia, Sofia, Bulgaria|Diagnostic Consultative center ""Tchaika"", Varna, Bulgaria|Medical center ""City clinic"", Varna, Bulgaria|Mental health centre - Vratsa, Vratsa, Bulgaria|Saint Anne s.r.o., Brno, Czechia|Soukroma psychiatricka ambulance, Brno, Czechia|Neuropsychiatrie HK, s.r.o., Hradec Kralove, Czechia|Bialbi s.r.o., Litomerice, Czechia|CLINTRIAL s.r.o., Praha, Czechia|AD71 s.r.o., Praha, Czechia|Pragtis s.r.o., Praha, Czechia|Medical services Prague s.r.o., Praha, Czechia|Psychiatricka ambulance Strakonice, Strakonice, Czechia|Laakarikeskus Mehilainen Psychiatric, Helsinki, Finland|Private Practice, Kuopio, Finland|Oulu Mentalcare Oy, Research Unit, Oulu, Finland|Mentoria Oy, Tampere, Finland|Bajai Szent Rokus Korhaz, Neurologia/Pszichiátria, Baja, Hungary|Dr. Kenessey Albert Korhaz-Rendelointezet 1-es Pszihiatriai Osztaly, Balassagyarmat, Hungary|Forras Outpatient Clinic, Budapest, Hungary|Semmelweis Orvostudomanyi Egyetem, Pszichiatriai es Pszichoterapias Klinika, Budapest, Hungary|Nyiro Gyula Korhaz, Pszihiatriai Osztaly, Budapest, Hungary|Processus Kft., Városkapu Rendelo, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Pszihiatriai, Mentalhygienes es Addiktologiai Osztaly, Gyor, Hungary|Bekes Megyei Pandy Kalman Korhaz, Pszihiatriai Osztaly, Gyula, Hungary|Pecsi Tudomanyegyetem, Klinikai Kozpont, Pszich. es Pszichoter. Klinika, Pecs, Hungary|Szent-Gyorgyi Albert Klinikai Kozpont, Pszichiatriai Klinika, Szeged, Hungary|Psychiatric Hospital N 13, Moscow, Russian Federation|Scientific Center of Mental Health, Dpt of Psychiatry N 1, Moscow, Russian Federation|State Budgetary lnstitution of Healthcare Leningrad RPND, In-patient psychiatry department, Roshchino, Russian Federation|Scientific Center for Treatment and Rehabilitation Phoenix, Research department, Rostov on don, Russian Federation|Psychoneuropathology Dispensary N 10, Psychiatry dpt, St Petersburg, Russian Federation|City Psychiatric Hospital N 4, Psychiatric department, St Petersburg, Russian Federation|V.M.Bekhterev Research Institute of Psychoneurology, Department of the neuroses and psychotherapy, St Petersburg, Russian Federation|Psychiatricka ambulancia Mentum, s.r.o., Bratislava, Slovakia|VAVRUSOVA CONSULTING s.r.o., Nestatna psychiatricka ambulancia, Bratislava, Slovakia|INVESTA, spol. s r.o., Psychiatricka ambulancia, Kosice, Slovakia|Private practice, Kysucke Nove Mesto, Slovakia|PsychoLine psychiatricka ambulancia s.r.o., Rimavska Sobota, Slovakia|NsP Svatej Barbory, Psychiatricke oddelenie, Roznava, Slovakia|Centrum zdravia R.B.K. s.r.o., Svidnik, Slovakia|Institute of Neurology, Psychiatry and Narcology, Department of Borderline and Neurotic Disorders, Kharkiv, Ukraine|Kherson Regional Psychiatric Hospital, Psychiatry department, Kherson, Ukraine|Kyiv Municipal Psychiatric Hospital #2, Department of psychiatry, Kyiv, Ukraine|Railway Clinic Hospital #1, Psychoneurological dpt, Kyiv, Ukraine|Kyiv Regional Medical Incorporation ""Psychiatry"", Center of Novel Treatment Rehabilitation Psychotic disorders, Kyiv, Ukraine|Ukrainian Research Institut of Social, Forensic Psyshiatry, Department of Therapy, Kyiv, Ukraine|Lviv District Psychiatric hospital, Lviv, Ukraine|Regional Clinic of Psychiatry, Lviv, Ukraine|ODESA REGIONAL MEDICAL CENTRE OF MENTAL HEALTHE DAY CARE department, Odesa, Ukraine|Odesa Regional Medical Centre of Mental Health Child-adolescens, Odesa, Ukraine",,"https://ClinicalTrials.gov/show/NCT02805439"
607,"NCT02634177","Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD",,"Completed","Has Results","Major Depressive Disorder","Genetic: Assay-guided treatment (AGT)|Other: Treatment-as-usual (TAU)","Mean Change From Baseline in SIGH-D-17 Score at 8 Weeks.|Mean Change From Baseline in QIDS-SR16 Score at 8 Weeks.|Percentage of Treatment Responders at Week 8 Based on ≥ 50% Reduction of SIGH-D-17 Score From Baseline.|Percentage of Treatment Responders at Week 8 Based on ≥ 50% Reduction of QIDS-SR16 Score From Baseline.|Percentage of Treatment Responders at Week 8 Based on ≤ 3 Score on the CGI-I.|Percentage of Remitters at Week 8 Based on ≤ 7 Score on the SIGH-D-17.|Percentage of Remitters at Week 8 Based on ≤ 5 Score on the QIDS-SR16.|Safety Outcomes Based on Frequency, Intensity and Burden of Side Effects Rating (FIBSER).|Safety Outcomes Based on Frequency and Severity of Reported Adverse Events.","Genomind, LLC|Medpace, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GNM-PROT MDD-01","January 2016","July 25, 2017","July 25, 2017","December 17, 2015","August 28, 2020","August 28, 2020","University of Alabama - Birmingham, Birmingham, Alabama, United States|Noesis Pharma, Phoenix, Arizona, United States|Woodland Research Northwest, Springdale, Arkansas, United States|Collaborative Neuroscience Network, Inc. - Garden Grove, Garden Grove, California, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Collaborative Neuroscience Network, Inc. - Torrance, Torrance, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Florida Clinical Research Center, LLC - Bradenton, Bradenton, Florida, United States|Clinical Neuroscience Solutions Inc. - Jacksonville, Jacksonville, Florida, United States|Florida Clinical Research Center, LLC - Maitland, Maitland, Florida, United States|Clinical Neuroscience Solutions Inc. - Orlando, Orlando, Florida, United States|Chicago Research Center, Inc., Chicago, Illinois, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Richard H Weisler MD, PA and Associates, Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Thomas Jefferson University Mood Disorder Program, Philadelphia, Pennsylvania, United States|Clinical Neuroscience Solutions Inc. - Memphis, Memphis, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|University of Virginia Center for Psychiatric Research, Charlottesville, Virginia, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02634177/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02634177/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02634177"
608,"NCT00290914","Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Vilazodone",,"Pharmacology Research Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2",,"Other","Interventional","Primary Purpose: Treatment","PRI #608",,,,"February 13, 2006",,"May 9, 2012",,,"https://ClinicalTrials.gov/show/NCT00290914"
609,"NCT03347487","DBS of the Habenula for Treatment- Resistant Major Depression",,"Terminated","No Results Available","Treatment Resistant Major Depression Disorder","Procedure: Deep brain stimuation system implantation","changes in the Hamilton Depression Scale(HAMD-17) score from baseline to 9 months|changes in the Montgomery-Asberg Depression Rating Scale from baseline to 9 months|changes in the brain activity|Side Effects|Young Mania Rating Scale (YMRS)|Changes in Hamilton Anxiety Scales(HAMA)|Global Assessment of Functioning Scale(GAF)|Columbia Suicide Severity Rating Scale (C-SSRS)|Changes in Beck Depression Inventory|Chang in Pittsburgh Sleep Quality Index|World Health Organization Quality of Life-BREF(WHO-BREF)|the MOS item short from health survey (SF-36)|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form|Sheehan Disability Scale|Changes in Neuropsychological measures(Scores of CANTAB tasks)","Ruijin Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018 DBS-Hb MDD","November 13, 2017","May 30, 2021","May 30, 2021","November 20, 2017",,"June 9, 2021","Shanghai Ruijin Hospital Functional Neurosurgery, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03347487"
610,"NCT01594996","European Drug Utilization Study","EUDUS","Completed","No Results Available","Major Depressive Disorder (MDD)",,"Patient age (mean and range)|Patient gender (%)|Diagnosis for which Seroquel XR was prescribed (% of Major Depressive Disorder- MDD)|Patients hospitalized for any psychiatric condition (n, %)|Daily dose of Seroquel XR (mode and range)|Patient referral pathway (%)|Participating psychiatrist practice setting (%)|Percent of patients experiencing psychotic symptoms at initiation of Seroquel XR (n, %)","AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)",,"814","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","D1443C00057","April 24, 2012","March 27, 2014","March 27, 2014","May 9, 2012",,"November 1, 2017","Research Site, Dortmund, Germany",,"https://ClinicalTrials.gov/show/NCT01594996"
611,"NCT01887782","Randomized Controlled Trial of Conventional vs Theta Burst rTMS","HFL vs TBS","Completed","No Results Available","Major Depressive Disorder","Device: HFL rTMS|Device: iTBS","HAM-D17 score","Centre for Addiction and Mental Health|University Health Network, Toronto","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","414","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","179/2012","September 2013","July 2016","October 2016","June 27, 2013",,"January 30, 2017","Non-Invasive Neurostimulation Therapies Centre, University of British Columbia, Vancouver, British Columbia, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01887782"
612,"NCT01920490","Blame Rebalance fMRI Feedback Proof-of-concept","GUIMRINFB1","Completed","No Results Available","Major Depressive Disorder","Device: GUILT-INCREASE-CORRELATION|Device: GUILT-STABILIZE-CORRELATION","Increase in correlation between anterior temporal and subgenual frontal fMRI signal for guilt relative to indignation|Beck Depression Inventory|Interpersonal Guilt Questionnaire - Self-hate subscale|Rosenberg Self-Esteem Scale","D'Or Institute for Research and Education","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IDOR","May 2013","October 2014","October 2014","August 12, 2013",,"July 23, 2015","Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT01920490"
613,"NCT00505518","Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home",,"Completed","Has Results","Major Depressive Disorder","Drug: Psychotropic medication (at discretion of psychiatrist)|Behavioral: Collaborative psychiatric and primary medical care","Change in Mean Scores on Clinical Global Impressions|Patient/Family Telepsychiatry Service Satisfaction Survey|Nurse Telepsychiatry Services Satisfaction Questionnaire","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-P-001508","September 2006","November 2007","November 2007","July 23, 2007","September 17, 2013","September 17, 2013","Depression and Clinical Research Program at Massachusetts General Hospital, Boston, Massachusetts, United States|South Cove Manor, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00505518"
614,"NCT00208702","Thyroid Medication and Antidepressants for Treating Major Depression",,"Completed","No Results Available","Major Depression","Drug: Triiodothyronine|Other: Placebo|Drug: Sertraline","MADRS score|CGI","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 60 Years   (Adult)","Phase 4","153","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0431-1996|R01MH056946|431-1996|DSIR AT-SO","September 1996","July 2003","July 2003","September 21, 2005",,"November 17, 2015","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00208702"
615,"NCT01299272","A Study in Prevention of Re-emergence of Depression Symptoms",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo|Drug: SSRI","Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period)|Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety Subscale Scores at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Clinical Global Impression of Severity (CGI-S) Scores at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Fatigue Associated With Depression (FAsD) Average Score, Experience Subscale Score, and Impact Subscale Score at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Sheehan Disability Scale (SDS) Items at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Randomization in the EuroQol Questionnaire-5 Dimension (EQ-5D) Index Scores, Visual Analog Scale up to Week 44 (Double-blind Randomized Withdrawal Period)|Number of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Arizona Sexual Experiences (ASEX) Questionnaire at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Randomization in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores up to Week 8 (Acute Open-label Period)|Change From Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores up to Week 20 (Stabilization Open-label Period)|Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety Subscale Scores up to Week 8 (Acute Open-label Period)|Change From Week 8 in the Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety Subscale Scores up to Week 20 (Stabilization Open-label Period)|Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Scores up to Week 8 (Acute Open-label Period)|Change From Week 8 in the Clinical Global Impression of Severity (CGI-S) Scores up to Week 20 (Stabilization Open-label Period)|Change From Baseline in the Fatigue Associated With Depression (FAsD) Average Score, Experience Subscale Score, and Impact Subscale Score up to Week 8 (Acute Open-label Period)|Change From Week 8 in the Fatigue Associated With Depression (FAsD) Average Score, Experience Subscale Score, and Impact Subscale Score up to Week 20 (Stabilization Open-label Period)|Change From Baseline in the Sheehan Disability Scale (SDS) Items up to Week 8 (Acute Open-label Period)|Change From Week 8 in the Sheehan Disability Scale (SDS) Items up to Week 20 (Stabilization Open-label Period)|Change From Baseline in the EuroQol Questionnaire-5 Dimension (EQ-5D) Index Scores, Visual Analog Scale up to Week 20 (Open-label Period)|Number of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Open-label Period)|Change From Baseline in the Arizona Sexual Experiences (ASEX) Questionnaire up to Week 20 (Open-label Period)|Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score at Week 20 (Open-label Period)|Change From Randomization in Blood Pressure at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Baseline in Blood Pressure up to Week 20 (Open-label Period)|Change From Randomization in Pulse Rate at Week 44 (Double-blind Randomized Withdrawal Period)|Change From Baseline in Pulse Rate up to Week 20 (Open-label Period)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11317|H9P-MC-LNBN","May 2011","November 2013","November 2013","February 18, 2011","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redlands, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wildomar, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Gables, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terre Haute, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherry Hill, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greensboro, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clinton, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heusden-Zolder, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Split, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zagreb, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcachon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dole, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Douai, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elancourt, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fains, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oranienburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haidari, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tripoli, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camaiore-Viareggio, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Colleferro, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ferrara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gwangju, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fracc. Bosques Del Prado Norte, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Focsani, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Targu Mures, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smolensk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tomsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Banska Bystrica, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Svidnik, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zvolen, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palma De Mallorca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salamanca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adapazari, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Diyarbakir, Turkey",,"https://ClinicalTrials.gov/show/NCT01299272"
616,"NCT02192099","Open Label Extension for GLYX13-C-202, NCT01684163",,"Terminated","Has Results","Major Depressive Disorder","Drug: Rapastinel (225 mg/450 mg IV administration)","The Number of Participants Who Experience an Adverse Event Over the Course of the Study.","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GLYX13-C-203","September 8, 2014","November 8, 2018","November 8, 2018","July 16, 2014","November 27, 2019","November 27, 2019","Office of Psychiatric Research, Birmingham, Alabama, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Chicago Research Center, Chicago, Illinois, United States|University of Kansas School of Medicine Clinical Trial Unit, Wichita, Kansas, United States|PharmaSite Research, Inc., Baltimore, Maryland, United States|Boston Clinical Trials Inc., Roslindale, Massachusetts, United States|Woodlands Professional Princeton Medical Institute Building, Princeton, New Jersey, United States|Finger Lake Clinical Research, Rochester, New York, United States|Lindner Center of HOPE, Mason, Ohio, United States|PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02192099/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02192099/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02192099"
617,"NCT01717508","Neural Components Underlying the Treatment of Adolescent Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy","EEG Activity","Mclean Hospital|National Institute of Mental Health (NIMH)","Female","13 Years to 18 Years   (Child, Adult)","Not Applicable","112","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012P001844|2011A053424|2011A051965|2010A054978|K23MH097786","October 2012","June 1, 2019","June 30, 2019","October 30, 2012",,"February 24, 2020","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01717508"
618,"NCT02141399","A Long-Term Safety Study of ALKS 5461",,"Completed","Has Results","Major Depressive Disorder","Drug: ALKS 5461","Incidence of Adverse Events (AEs)","Alkermes, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1485","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALK5461-208","May 2014","November 20, 2017","November 20, 2017","May 19, 2014","December 14, 2018","December 14, 2018","Alkermes Investigational Site, Birmingham, Alabama, United States|Alkermes Investigational Site, Birmingham, Alabama, United States|Alkermes Investigational Site, Tucson, Arizona, United States|Alkermes Investigational Site, Little Rock, Arkansas, United States|Alkermes Investigational Site, Bellflower, California, United States|Alkermes Investigational Site, Beverly Hills, California, United States|Alkermes Investigational Site, Carson, California, United States|Alkermes Investigational Site, Garden Grove, California, United States|Alkermes Investigational Site, Glendale, California, United States|Alkermes Investigational Site, Los Alamitos, California, United States|Alkermes Investigational Site, Los Angeles, California, United States|Alkermes Investigational Site, National City, California, United States|Alkermes Investigational Site, Oakland, California, United States|Alkermes Investigational Site, Oceanside, California, United States|Alkermes Investigational Site, Orange, California, United States|Alkermes Investigational Site, Pico Rivera, California, United States|Alkermes Investigational Site, Redlands, California, United States|Alkermes Investigational Site, San Gabriel, California, United States|Alkermes Investigational Site, Sherman Oaks, California, United States|Alkermes Investigational Site, Temecula, California, United States|Alkermes Investigational Site, Torrance, California, United States|Alkermes Investigational Site, Upland, California, United States|Alkermes Investigational Site, Colorado Springs, Colorado, United States|Alkermes Investigational Site, Denver, Colorado, United States|Alkermes Investigational Site, Hartford, Connecticut, United States|Alkermes Investigational Site, Norwich, Connecticut, United States|Alkermes Investigational Site, Bradenton, Florida, United States|Alkermes Investigational Site, Coral Springs, Florida, United States|Alkermes Investigational Site, Fort Myers, Florida, United States|Alkermes Investigational Site, Gainesville, Florida, United States|Alkermes Investigational Site, Hallandale Beach, Florida, United States|Alkermes Investigational Site, Hialeah, Florida, United States|Alkermes Investigational Site, Jacksonville, Florida, United States|Alkermes Investigational Site, Lauderhill, Florida, United States|Alkermes Investigational Site, Maitland, Florida, United States|Alkermes Investigational Site, Melbourne, Florida, United States|Alkermes Investigational Site, North Miami, Florida, United States|Alkermes Investigational Site, Oakland Park, Florida, United States|Alkermes Investigational Site, Orlando, Florida, United States|Alkermes Investigational Site, Tampa, Florida, United States|Alkermes Investigational Site, The Villages, Florida, United States|Alkermes Investigational Site, West Palm Beach, Florida, United States|Alkermes Investigational Site, Winter Haven, Florida, United States|Alkermes Investigational Site, Alpharetta, Georgia, United States|Alkermes Investigational Site, Atlanta, Georgia, United States|Alkermes Investigational Site, Decatur, Georgia, United States|Alkermes Investigational Site, Smyrna, Georgia, United States|Alkermes Investigational Site, Chicago, Illinois, United States|Alkermes Investigational Site, Chicago, Illinois, United States|Alkermes Investigational Site, Deerfield, Illinois, United States|Alkermes Investigational Site, Hoffman Estates, Illinois, United States|Alkermes Investigational Site, Joliet, Illinois, United States|Alkermes Investigational Site, Oak Brook, Illinois, United States|Alkermes Investigational Site, Skokie, Illinois, United States|Alkermes Investigational Site, Indianapolis, Indiana, United States|Alkermes Investigational Site, Lafayette, Indiana, United States|Alkermes Investigational Site, Newburgh, Indiana, United States|Alkermes Investigational Site, Valparaiso, Indiana, United States|Alkermes Investigational Site, Edgewood, Kentucky, United States|Alkermes Investigational Site, Owensboro, Kentucky, United States|Alkermes Investigational Site, Baltimore, Maryland, United States|Alkermes Investigational Site, Baltimore, Maryland, United States|Alkermes Investigational Site, Washington D.C., Maryland, United States|Alkermes Investigational Site, Belmont, Massachusetts, United States|Alkermes Investigational Site, Brockton, Massachusetts, United States|Alkermes Investigational Site, Watertown, Massachusetts, United States|Alkermes Investigational Site, Worcester, Massachusetts, United States|Alkermes Investigational Site, Flowood, Mississippi, United States|Alkermes Investigational Site, O'Fallon, Missouri, United States|Alkermes Investigational Site, Saint Charles, Missouri, United States|Alkermes Investigational Site, Saint Louis, Missouri, United States|Alkermes Investigational Site, Saint Louis, Missouri, United States|Alkermes Investigational Site, Berlin, New Jersey, United States|Alkermes Investigational Site, Cherry Hill, New Jersey, United States|Alkermes Investigational Site, Princeton, New Jersey, United States|Alkermes Investigational Site, Albuquerque, New Mexico, United States|Alkermes Investigational Site, Brooklyn, New York, United States|Alkermes Investigational Site, Jamaica, New York, United States|Alkermes Investigational Site, Mount Kisco, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, New York, New York, United States|Alkermes Investigational Site, Staten Island, New York, United States|Alkermes Investigational Site, Staten Island, New York, United States|Alkermes Investigational Site, Charlotte, North Carolina, United States|Alkermes Investigational Site, High Point, North Carolina, United States|Alkermes Investigational Site, Beachwood, Ohio, United States|Alkermes Investigational Site, Canton, Ohio, United States|Alkermes Investigational Site, Cincinnati, Ohio, United States|Alkermes Investigational Site, Cincinnati, Ohio, United States|Alkermes Investigational Site, Dayton, Ohio, United States|Alkermes Investigational Site, Mason, Ohio, United States|Alkermes Investigational Site, Middleburg Heights, Ohio, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Oklahoma City, Oklahoma, United States|Alkermes Investigational Site, Portland, Oregon, United States|Alkermes Investigational Site, Portland, Oregon, United States|Alkermes Investigational Site, Salem, Oregon, United States|Alkermes Investigational Site, Allentown, Pennsylvania, United States|Alkermes Investigational Site, Media, Pennsylvania, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, United States|Alkermes Investigational Site, Philadelphia, Pennsylvania, United States|Alkermes Investigational Site, Lincoln, Rhode Island, United States|Alkermes Investigational Site, Charleston, South Carolina, United States|Alkermes Investigational Site, Memphis, Tennessee, United States|Alkermes Investigational Site, Austin, Texas, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, Dallas, Texas, United States|Alkermes Investigational Site, DeSoto, Texas, United States|Alkermes Investigational Site, Houston, Texas, United States|Alkermes Investigational Site, Houston, Texas, United States|Alkermes Investigational Site, San Antonio, Texas, United States|Alkermes Investigational Site, Sugar Land, Texas, United States|Alkermes Investigational Site, Wichita Falls, Texas, United States|Alkermes Investigational Site, Clinton, Utah, United States|Alkermes Investigational Site, Woodstock, Vermont, United States|Alkermes Investigational Site, Bellevue, Washington, United States|Alkermes Investigational Site, Seattle, Washington, United States|Alkermes Investigational Site, Spokane, Washington, United States|Alkermes Investigational Site, Middleton, Wisconsin, United States|Alkermes Investigational Site, Waukesha, Wisconsin, United States|Alkermes Investigational Site, Towong, Queensland, Australia|Alkermes Investigational Site, Frankston, Victoria, Australia|Alkermes Investigational Site, Melbourne, Victoria, Australia|Alkermes Investigational Site, Bourgas, Bulgaria|Alkermes Investigational Site, Kazanlak, Bulgaria|Alkermes Investigational Site, Sofia, Bulgaria|Alkermes Investigational Site, Sofia, Bulgaria|Alkermes Investigational Site, Sofia, Bulgaria|Alkermes Investigational Site, Varna, Bulgaria|Alkermes Investigational Site, Veliko Turnovo, Bulgaria|Alkermes Investigational Site, Vratza, Bulgaria|Alkermes Investigational Site, Penticton, British Columbia, Canada|Alkermes Investigational Site, Halifax, Nova Scotia, Canada|Alkermes Investigational Site, Gatineau, Quebec, Canada|Alkermes Investigational Site, Quebec, Canada|Alkermes Investigational Site, Oranienburg, Brandenburg, Germany|Alkermes Investigational Site, Achim, Germany|Alkermes Investigational Site, Berlin, Germany|Alkermes Investigational Site, Berlin, Germany|Alkermes Investigational Site, Berlin, Germany|Alkermes Investigational Site, Ellwangen, Germany|Alkermes Investigational Site, Freiburg, Germany|Alkermes Investigational Site, Hannover, Germany|Alkermes Investigational Site, Mainz, Germany|Alkermes Investigational Site, Schwerin, Germany|Alkermes Investigational Site, Stralsund, Germany|Alkermes Investigational Site, Budapest, Hungary|Alkermes Investigational Site, Budapest, Hungary|Alkermes Investigational Site, Budapest, Hungary|Alkermes Investigational Site, Bialystok, Poland|Alkermes Investigational Site, Gdansk, Poland|Alkermes Investigational Site, Gdansk, Poland|Alkermes Investigational Site, Gorlice, Poland|Alkermes Investigational Site, San Juan, Puerto Rico|Alkermes Investigational Site, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02141399/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02141399/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02141399"
619,"NCT01882829","Nuedexta in Treatment-Resistant Major Depression",,"Completed","Has Results","Major Depressive Disorder|Treatment Resistant","Drug: dextromethorphan/quinidine","Montgomery-Asberg Depression Rating Scale|Quality of Life Enjoyment and Satisfaction Questionnaire Short Form|Range of Impaired Functioning Tool|Sheehan Disability Scale|Patient Rated Inventory of Side Effects (PRISE)|Columbia-Suicide Severity Rating Scale (C-SSRS)|Quick Inventory of Depressive Symptomatology, Self Report (QIDS-SR)|Clinical Global Impression (CGI) Scale|Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|HAM-A|Beck Scale for Suicidal Ideation (BSI)","James Murrough|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 13-0389|IF1463152","July 2013","March 2016","March 2016","June 20, 2013","June 11, 2018","June 11, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01882829"
620,"NCT01189591","Slow-wave Sleep Deprivation in Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Slow-wave deprivation","Hamilton Depression Scale|Inventory of Depressive Symptomology","University of Wisconsin, Madison|National Institutes of Health (NIH)","All","18 Years to 35 Years   (Adult)","Not Applicable","25","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Basic Science","2013-0019|P20MH077967 NIH grant number|H-2007-0150|P20MH077967","June 2009","August 2011","August 2011","August 26, 2010",,"November 8, 2017","Wisconsin Center for Sleep Medicine and Research, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01189591"
621,"NCT02058693","Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT)",,"Completed","No Results Available","Major Depressive Disorder","Drug: mixed salts amphetamine","Change in scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionaire|Change in scores on the Montgomery Asberg Depression Rating Scale|Change in scores on the Quick Inventory of Depressive Symptomatology Self Report 16","Rush University Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTHF-1","December 2010","December 2014","December 2014","February 10, 2014",,"December 19, 2014","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02058693"
622,"NCT01070329","A Study in Depression and Associated Painful Physical Symptoms",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine|Drug: Placebo","Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-Week Treatment Period|Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8|Change From Baseline in the Sheehan Disability Scale (SDS) Total and Item Scores at Week 8|Change From Baseline in the Percentage of Participants Achieving Remission up to Week 8|Percentage of Participants Achieving Remission up to Week 8|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 4|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 2|Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 8|Patient Global Impression of Improvement (PGI-I) Score at Week 8|Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on the Columbia Suicide Severity Rating Scale (C-SSRS) During the Double-Blind Treatment Phase","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","527","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13630|F1J-US-HMGU","March 2010","March 2011","March 2011","February 18, 2010","February 13, 2012","February 13, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cromwell, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoffman Estates, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Florence, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Charles, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Troy, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willingboro, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salem, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allentown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caguas, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01070329"
623,"NCT02214511","Biomarkers of Social Sensitivity in Major Depression","SENSO","Unknown status","No Results Available","Major Depressive Disorder","Behavioral: emotional facial stimuli|Behavioral: Cyberball game","Rapid facial reactions : milliVolts amplitude of electromyographic signal of zygomaticus, corrugator, depressor & frontalis muscles|Implicit pro-social behavior : invested money during a 4-round trust game|Explicit pro-social behavior : affiliation desire measured by a questionnaire|Self esteem assessed by questionnaires mediates social pain after rejection and pro-social behavior|Systemic inflammation mediates social pain after rejection and pro-social behavior","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 60 Years   (Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C13-31|2013-A01484-41","July 2014","October 2015",,"August 12, 2014",,"August 12, 2014","ICM, Pitié Salpêtrière Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02214511"
624,"NCT01162382","Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study",,"Terminated","Has Results","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation","Hamilton Depression Rating Scale-24 Point Version (HDRS-24)|fCMRI Results","Washington University School of Medicine","All","18 Years to 50 Years   (Adult)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","WUSM3621222-201110079","January 2010","September 2013","September 2013","July 14, 2010","February 18, 2019","February 18, 2019","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01162382"
625,"NCT02959307","Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)","ELATED-3","Completed","Has Results","Depression|Major Depressive Disorder","Device: Transcranial Light Therapy|Device: Sham Transcranial Light Therapy","Quick Inventory of Depressive Symptomatology-Phase 1|Quick Inventory of Depressive Symptomatology(QIDS)-Phase 2|Hamilton Depression Rating Scale - 17 Items(Phase 1)|Hamilton Depression Rating Scale - 17 Items(Phase 2)","Massachusetts General Hospital|LiteCure LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","49","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2016P001490","November 2016","November 2018","November 2018","November 9, 2016","September 21, 2020","September 21, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02959307/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02959307/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02959307/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02959307"
626,"NCT01234558","Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: GLYX-13","Change in depression score|Change in BPRS+","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GLYX13-C201","May 2011","June 2012","July 2012","November 4, 2010",,"September 12, 2012","Mulitple, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01234558"
627,"NCT02273063","rTMS for PTSD Comorbid With Major Depressive Disorder",,"Completed","Has Results","Posttraumatic Stress Disorder|Major Depressive Disorder|Transcranial Magnetic Stimulation, Repetitive","Device: Transcranial Magnetic Stimulation (TMS)","Total Score on PTSD Checklist for DSM-5 (PCL-5)|Total Score on Inventory of Depressive Symptomatology, Self-Report (IDS-SR) Scale","Butler Hospital|Providence VA Medical Center|Neuronetics","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1404-005","October 2014","April 22, 2016","April 22, 2016","October 23, 2014","October 4, 2018","October 4, 2018","Butler Hospital, Providence, Rhode Island, United States|Providence VA Medical Center, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02273063"
628,"NCT01684163","Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants",,"Completed","No Results Available","Major Depressive Disorder","Drug: GLYX-13 5 mg/kg|Drug: GLYX-13 10 mg/kg|Drug: Placebo","Change in Hamilton Depression Rating Scale Score|Clinical Global Impression of Change","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GLYX13-C-202","November 2012","April 2014","June 2014","September 12, 2012",,"March 17, 2016","University of Alabama Office of Psychiatric Clinical Research, Birmingham, Alabama, United States|Pharmacology Research Institute, Encino, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Evanston Premier Healthcare Research, LLC, Northbrook, Illinois, United States|Indiana University Health Neuroscience Center, Indianapolis, Indiana, United States|University of Kansas, Wichita, Kansas, United States|PharmaSite Research , Inc., Baltimore, Maryland, United States|Bostin Clinical Trials, Inc., Roslindale, Massachusetts, United States|CRI Lifetree, Marlton, New Jersey, United States|Global Medical Institutes LLC, Princeton, New Jersey, United States|Clinilabs, Inc., New York, New York, United States|Michael R Liebowitz MD, New York, New York, United States|Finger Lake Clinical Research, Rochester, New York, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|CRI Lifetree, Phildadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center of Dallas, Dallas, Texas, United States|CRI Lifetree, Salt Lake City, Utah, United States|Summit Research Network, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01684163"
629,"NCT00419003","Research Study for Major Depressive Disorder: Investigation of Glutamate Medications",,"Completed","Has Results","Major Depression","Drug: Lamotrigine|Drug: Ketamine|Drug: Riluzole","Montgomery-Asberg Depression Rating Scale (MARDS) Score (Acute Response to IV Ketamine in Patients With Treatment Resistant Major Depression)","Baylor College of Medicine|National Alliance for Research on Schizophrenia and Depression|National Center for Research Resources (NCRR)","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 4","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","05-0850|5M01RR000071-46","December 2006","July 2008","September 2008","January 5, 2007","March 21, 2016","July 31, 2019","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00419003"
630,"NCT01429831","Aripiprazole for the Augmentation of Antidepressant Therapy",,"Completed","No Results Available","Major Depressive Disorder","Drug: Aripiprazole","17-Item Hamilton Depression Rating Scale (HAM-D17) score|Clinical Global Impression of Severity (CGI-S) score|Sheehan Disability Scale (SDS) total score|World Health Organization Quality of Life (WHOQOL-BREF) score","Taiwan Otsuka Pharm. Co., Ltd","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","300","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","031-TWB-1101i","September 2011","May 2013","May 2013","September 7, 2011",,"May 21, 2014","Chung Shan Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01429831"
631,"NCT00851006","Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram",,"Completed","Has Results","Major Depressive Disorder","Drug: Creatine Monohydrate","Mean Children's Depression Rating Scale (CDRS-R) [Reference: Poznanski EO et al. Preliminary Studies of the Reliability and Validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7.]|31-phosphorus Magnetic Resonance Spectroscopy Phosphocreatine Metabolite","University of Utah|AlzChem, LLC","Female","13 Years to 18 Years   (Child, Adult)","Phase 2","13","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","33465","April 2009","December 2012","December 2012","February 25, 2009","January 13, 2015","May 12, 2017","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00851006"
632,"NCT04602715","The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Anxiety","Drug: MET-2|Drug: Placebo","Change in Major Depression Symptoms|Change in Anxiety Symptoms","NuBiyota","All","18 Years to 45 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MET-2 301-2","April 1, 2021","June 2021","June 2021","October 26, 2020",,"May 11, 2021","Providence Care Hospital, Kingston, Ontario, Canada|CAMH, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04602715"
633,"NCT01381107","ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD",,"Completed","No Results Available","Major Depressive Disorder","Drug: ALKS 5461|Drug: Placebo","The number and percent of subjects with treatment-emergent adverse events following sublingual administration of ALKS 33 and buprenorphine co-formulation (ALKS 5461)","Alkermes, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","ALK33BUP-201","May 2011","July 2011","July 2011","June 27, 2011",,"August 23, 2011","Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01381107"
634,"NCT00000375","Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Nortriptyline-lithium (NOR-Li)|Procedure: Bilateral electroconvulsive therapy (ECT)|Drug: Continuation therapy|Behavioral: Continuation ECT",,"National Institute of Mental Health (NIMH)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4",,"NIH","Interventional","Allocation: Randomized|Masking: Single|Primary Purpose: Treatment","MH55495","February 1997",,,"November 3, 1999",,"December 20, 2005","New Jersey Medical School, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00000375"
635,"NCT00675896","A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome",,"Completed","No Results Available","Major Depression","Drug: Quetiapine Fumarate Sustained Release|Drug: Placebo","last observation carried forward (LOCF) mean change from baseline to week 8 on the Hamilton Depression Scale (HAM-D) total score.|Change from baseline to week 8 in: Brief Pain Inventory,HAM-A,CGI-S,FIQ, Sleep Scale from the Medical Outcome Study,SDS,QLES- Short Form,PHQ-15,Global Assessment Scale,Improvement (CGI-I) score from randomisation to Week 8","Dr Alexander McIntyre Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D1443C00007","April 2007","June 2011","July 2011","May 12, 2008",,"July 6, 2011","Dr. A McIntyre Inc, Penticton, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00675896"
636,"NCT00596817","Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Vortioxetine (Lu AA21004)","Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator|Relapse During the Entire Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator|Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment|Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment|Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment|Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment|Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a >=50% Reduction in MADRS Total Score From Open-label Baseline)|Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score <=10)|Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period","H. Lundbeck A/S","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","639","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11985A|2007-001871-13","December 2007","September 2009","October 2009","January 17, 2008","March 31, 2014","March 31, 2014",,,"https://ClinicalTrials.gov/show/NCT00596817"
637,"NCT00286546","Testosterone and Major Depression",,"Completed","No Results Available","Major Depression",,,"University Health Network, Toronto","Male","40 Years to 65 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Defined Population|Time Perspective: Other","002","January 2001",,"August 2005","February 3, 2006",,"September 11, 2006","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00286546"
638,"NCT01020799","AZD7268 Safety and Tolerability Study",,"Completed","Has Results","Major Depressive Disorder","Drug: AZD7268|Drug: Escitalopram|Drug: Placebo capsules|Drug: Placebo tablets","Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score Change From Baseline to Week 4.|Montgomery-Åsberg Depression Rating Scale (MADRS) Response|Montgomery-Åsberg Depression Rating Scale (MADRS) Remission|Hamilton Rating Scale for Depression (HAM-D) Total Score Change From Baseline to Week 4.|Clinical Global Impression - Severity (CGI-S) Score Change From Baseline|Hamilton Rating Scale for Anxiety (HAM-A) Total Score Change From Baseline","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","247","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1151C00005","November 2009","April 2010","April 2010","November 26, 2009","April 10, 2012","April 17, 2012","Research Site, Birmingham, Alabama, United States|Research Site, Garden Grove, California, United States|Research Site, San Diego, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Rockville, Maryland, United States|Research Site, Cedarhurst, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Dayton, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Memphis, Tennessee, United States|Research Site, Friendswood, Texas, United States|Research Site, Bellevue, Washington, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01020799"
639,"NCT00445237","Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression",,"Completed","No Results Available","Major Depression","Device: H1 and H2 deep TMS coils",,"Shalvata Mental Health Center|Brainsway","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1",,"Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SH-505","May 2006",,"March 2008","March 8, 2007",,"February 5, 2009","Shalvata MHC, Hod Hasharon, Israel",,"https://ClinicalTrials.gov/show/NCT00445237"
640,"NCT00739908","A Study of CX157 (TriRima) for the Treatment of Depression","CX157-200","Completed","Has Results","Major Depressive Disorder","Drug: CX157 (TriRima)|Drug: Placebo","Change From Randomization in Montgomery and Asberg Depression Rating Scale (MADRS)|Montgomery and Asberg Depression Rating Scale (MADRS) Response Rate|Montgomery and Asberg Depression Rating Scale (MADRS) Remitter Rate|The Hospital Anxiety and Depression Scale (HADS)|Inventory of Depressive Symptomatology 30 Item -Self Report (IDS -SR 30 Items)|Clinical Global Impression - Improvement of Illness (CGI-I)|Clinical Global Impression - Severity of Illness (CGI-S)","CeNeRx BioPharma Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CX157-200","September 2008","July 2009","July 2009","August 22, 2008","June 27, 2012","June 27, 2012","Birmingham Research Group, Birmingham, Alabama, United States|Southwestern Research, Inc., Beverly Hills, California, United States|The George Washington University, Washington, District of Columbia, United States|Irving S. Kolin, M.D., Winter Park, Florida, United States|Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace, Illinois, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|CRI Worldwide, LLC, Clementon, New Jersey, United States|Fieve Clinical Services, New York, New York, United States|Richard H. Weisler, M.D., P.A., Raleigh, North Carolina, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|FutureSearch Trials, Austin, Texas, United States|Summit Research Network (Seattle), LLC, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00739908"
641,"NCT00157547","Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Selective serotonin reuptake inhibitors (SSRI)","Ham-D-17","Massachusetts General Hospital|Medtronic - MITG","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","95","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2002-P-001784","April 2003","August 2006","August 2006","September 12, 2005",,"May 28, 2008",,,"https://ClinicalTrials.gov/show/NCT00157547"
642,"NCT00683852","A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",,"Completed","Has Results","Major Depressive Disorder","Drug: Aripiprazole 5mg|Drug: Aripiprazole 2mg|Drug: Placebo","MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate|MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate|Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up|Mean Change in Clinical Global Impression of Severity (CGI-S)|Mean Change in Symptom Questionnaire (SQ)","Massachusetts General Hospital|Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","225","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BMS - 2008A053242","September 2008","September 2009","September 2009","May 26, 2008","July 19, 2017","July 19, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00683852"
643,"NCT00785434","Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD",,"Completed","No Results Available","Major Depressive Disorder","Drug: escitalopram","The number of patients achieving remission (MADRS<9).","Community Pharmacology Services Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPS/04/2008","October 2008","December 2009","December 2009","November 5, 2008",,"January 13, 2010","CPS Research, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00785434"
644,"NCT02109939","Genomics Used to Improve DEpression Decisions","GUIDED","Completed","Has Results","Major Depressive Disorder (MDD)","Genetic: GeneSight Psychotropic","Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks|Percent Change in the 16-item Quick Inventory of Depression Symptomology (QIDS-C16) Score From Baseline to 8 Weeks|Percentage of Responders at Week 8 for HAM-D17|Percentage of Responders at Week 12 for HAM-D17|Percentage of Remitters at Week 12 Defined as HAM-D17 ≤7|Percentage of Remitters at Week 8 Defined as HAM-D17 ≤7 Each Treatment Group;|Time to Response/Remission of Depressive Symptoms Over 8 Weeks;|Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 24 Weeks|Percentage of Responders at Week 8 for QIDS-C16|Percentage of Responders at Week 8 for PHQ-9|Percentage of Remitters at Week 12 Defined as QIDS-C16 ≤5|Percentage of Remitters at Week 12 Defined as PHQ-9 <5|Percentage of Remitters at Week 12 Defined as CGI-S ≤1|Percentage of Responders at Week 12 for QIDS-C16|Percentage of Responders at Week 12 for PHQ-9|Percentage of Responders at Week 12 for CGI-S|Percentage of Responders at Week 12 for CGI-I|Percentage of Responders at Week 12 for CGI-EI|Percentage of Remitters at Week 8 Defined as QIDS-C16 ≤ 5 in Each Treatment Group|Percentage of Remitters at Week 8 Defined as PHQ-9 <5 in Each Treatment Group|Time to Response/Remission of Depressive Symptoms Over 12 Weeks;|Percentage of Responders at Week 24 for HAM-D17 in the GeneSight Psychotropic Tested Treatment Group|Percentage of Remitters at Week 24 Defined as HAM-D17 ≤7 in the GeneSight Psychotropic Tested Treatment Group","Assurex Health Inc.|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1398","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ARX1006","April 2014","April 20, 2017","July 31, 2017","April 10, 2014","January 14, 2020","January 14, 2020","Birmingham Psychiatry Pharmaceutical Studies, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|CiTrials, Bellflower, California, United States|Catalina Research Institute, Chino, California, United States|CiTrials, Costa Mesa, California, United States|Synergy Research Center, Escondido, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|North County Research, Oceanside, California, United States|CiTrials, Riverside, California, United States|Stanford School of Medicine, Stanford, California, United States|Viking Clinical Research, Temecula, California, United States|Elite Clinical Trials, Inc, Wildomar, California, United States|MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States|Howard University Hospital Mental Health Clinic, Washington, District of Columbia, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions Healthcare, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Janus Center For Psychiatric Research, West Palm Beach, Florida, United States|Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States|Mood and Anxiety Program at Emory University, Atlanta, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Behavioral Healthcare Associates, Schaumburg, Illinois, United States|The Institute of Psychiatric Research, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kansas University Medical Center- Clinical Trials Unit, Wichita, Kansas, United States|Pharmasite Research, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Geriatric Outpatient Unit- McLean Hospital, Belmont, Massachusetts, United States|Boston Clinical Trials, Boston, Massachusetts, United States|UMASS Center for Psychopharmacologic Research and Treatment, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Meridian Clinical Research, Bellevue, Nebraska, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|United Medical Research Associates, Binghamton, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Mood and Anxiety Disorders Treatment and Research, Philadelphia, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Alliance Research Group, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network, Seattle, Washington, United States|Frontier Institute, Spokane, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02109939/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02109939/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02109939"
645,"NCT01409304","Effectiveness of Deep Transcranial Magnetic Stimulation in Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Deep Transcranial Magnetic Stimulation (DTMS)","21-item Hamilton Depression Rating Scale (HAM-D21)|Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)","Douglas Mental Health University Institute|Brainsway","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","18","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DTMS-ERB10/18-2011","October 2011","December 2012","December 2012","August 4, 2011",,"January 18, 2013","Neuromodulation Research Clinic, Douglas Mental Health University Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01409304"
646,"NCT00149071","Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression",,"Completed","No Results Available","Major Depression","Device: rTMS|Device: TMS","depression scores","Hillerod Hospital, Denmark|Medicon Valley Academy","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","61","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1,2","March 2004",,"January 2006","September 8, 2005",,"November 4, 2007","Psychiatric research unit, Hilleroed Hospital,, Hillerod, Denmark",,"https://ClinicalTrials.gov/show/NCT00149071"
647,"NCT03643159","A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder",,"Terminated","Has Results","Schizophrenia|Bipolar 1 Disorder|Major Depressive Disorder","Combination Product: Abilify MyCite - Digital Medicine System|Drug: Aripiprazole or other oral antipsychotics","Difference In The Number Of Participants With All-cause Hospitalizations For Participants Using Abilify MyCite Versus Virtual Matched Controls From Baseline To Day 180|Difference In The Number Of Participants With At Least 80% Proportion Of Days Covered (PDC) (With Antipsychotic Medication) For Participants Using Abilify MyCite Versus Virtual Matched Controls From Baseline To Day 180","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 63 Years   (Adult)","Phase 4","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","316-13-217","June 28, 2018","October 17, 2018","October 17, 2018","August 22, 2018","November 8, 2019","November 8, 2019","Siyan Clinical Research, Santa Rosa, California, United States|Psychiatric Addiction Curative/PACT Atlanta LLC, Decatur, Georgia, United States|Georgia Psychiatry and Sleep, Smyrna, Georgia, United States|Kolade Research Institute, Las Vegas, Nevada, United States|Signature Research Associates, Inc., Fairlawn, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03643159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03643159/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03643159"
648,"NCT00628914","Brain Mechanisms and Targeting Insomnia in Major Depression",,"Unknown status","No Results Available","Major Depressive Disorder|Insomnia","Drug: escitalopram and eszopiclone|Drug: Escitalopram, eszopiclone, and placebo|Drug: Escitalopram","Change in cordance value|Depression symptom severity|Serum BDNF|Cognitive testing","University of California, Los Angeles","All","18 Years to 64 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ESRC973|07-11-013","May 2008","November 2009","February 2010","March 5, 2008",,"August 20, 2010","Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00628914"
649,"NCT03265808","Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.","Alaunus","Recruiting","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)|Drug: Placebo","Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI","Joshua M Hare|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Miami","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170674|1R01AA024933-01A1","March 18, 2018","October 23, 2022","April 2025","August 29, 2017",,"June 30, 2021","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03265808"
650,"NCT00330616","Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan",,"Completed","Has Results","Major Depressive Disorder (MDD)","Drug: 323U66 SR","Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 8|Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4|Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)Total Score at Week 8|Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4|Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8|Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4|Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8|Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) of Each Question's Score at Week 4|Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8|Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)for Each Question's Score at Week 4|Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8|Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 and Week 8|Percentage of Responders Based on the Clinical Global Impression - Global Improvement Score (CGI-I)at Week 4 and Week 8|Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score at Weeks 1, 2, 3, 4, 8|Adverse Events (>=5% Incidence)|Serious Adverse Events","GlaxoSmithKline","All","65 Years and older   (Older Adult)","Phase 2","35","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","AK1102369","May 2006","November 2007","November 2007","May 29, 2006","March 20, 2009","May 4, 2015","GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukushima, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00330616"
651,"NCT00782964","Antidepressant Incomplete Response Depression","DRIA","Completed","No Results Available","Major Depressive Disorder",,"Profile of use of 3 group of strategies: 1 - Change to another antidepressive agent (Quetiapine, Lamotrigine, antidepressant…) 2- Association with another antidepressant 3- Association with any other treatment (antipsychotics, lithium…)|Clinical assessment|Visits to nurse, psychiatrics: Hospitalization, social support: Productivity assessment","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)",,"364","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIS-NES-DUM-2007/4","October 2008",,"November 2009","October 31, 2008",,"December 24, 2009","Research Site, Alcoy, Alicante, Spain|Research Site, Benidorm, Alicante, Spain|Research Site, Villajoyosa, Alicante, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Merida, Badajoz, Spain|Research Site, Inca, Baleares, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, El Hospitalet de Llobregat, Barcelona, Spain|Research Site, Martorell, Barcelona, Spain|Research Site, Vic, Barcelona, Spain|Research Site, San Fernando, Cadiz, Spain|Research Site, Villamartin, Cadiz, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Murcia, Caravaca, Spain|Research Site, Villarreal, Castellon, Spain|Research Site, Guadix, Granada, Spain|Research Site, Mondragon, Guipuzcoa, Spain|Research Site, Las Palmas de Gran Canaria, Las Palmas, Spain|Research Site, Lleida, Lerida, Spain|Research Site, Alcala de Henares, Madrid, Spain|Research Site, Alcobendas, Madrid, Spain|Research Site, Colmenar Viejo, Madrid, Spain|Research Site, Torrejon de Ardoz, Madrid, Spain|Research Site, Cartagena, Murcia, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Valls, Tarragona, Spain|Research Site, La Cuesta de Arguijon, Tenerife, Spain|Research Site, Santa Cruz de Tenerife, Tenerife, Spain|Research Site, Talavera de La Reina, Toledo, Spain|Research Site, Gandia, Valencia, Spain|Research Site, Bilbao, Vizcaya, Spain|Research Site, Getxo, Vizcaya, Spain|Research Site, Zalla, Vizcaya, Spain|Research Site, Benavente, Zamora, Spain|Research Site, Albacete, Spain|Research Site, Almeria, Spain|Research Site, Barcelona, Spain|Research Site, Burgos, Spain|Research Site, Ceuta, Spain|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Tarragona, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00782964"
652,"NCT00561509","Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months",,"Completed","No Results Available","Major Depressive Disorder","Drug: SSRIs|Drug: Dual antidepressants","Frequency of sexual dysfunction due to treatment with either SSRIs or Dual antidepressants|Frequency of sexual dysfunction along treatment with SSRIs or Dual antidepressants|Disease severity|Resource Utilization|Quality of Life|Treatment Compliance|Identify factors related to sexual dysfunction","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,"1626","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","11539|F1J-MC-B019","November 2007",,"June 2009","November 21, 2007",,"July 15, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jenbach, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spital/Drau, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Steyr, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wels, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolfsberg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harbin, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hong Kong, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jinan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuhan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pokfulam, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bat Yam, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herzliya, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hod Hasharon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ramat Gan, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beirut, Lebanon|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuala Lumpur, Malaysia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cancun, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexicali, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puebla, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tijuana, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torreon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villahermosa, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lucena, Philippines|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Makati, Philippines|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pasig City, Philippines|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quezon City, Philippines|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dammam, Saudi Arabia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jeddah, Saudi Arabia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Khamis Mushayt, Saudi Arabia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madina, Saudi Arabia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Makkah, Saudi Arabia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riyadh, Saudi Arabia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hualien, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neihu Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abu Dhabi, United Arab Emirates|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT00561509"
653,"NCT01931995","Investigation of Brain Network Dynamics in Depression",,"Completed","Has Results","Major Depressive Disorder, Recurrent","Device: TMS positively correlated DLPFC|Procedure: TMS to negatively correlated DLPFC","Relative Changes in Corticolimbic Functional Connectivity as a Result of TMS|Changes in Local Glucose Metabolism at Corticolimbic Network Nodes","Massachusetts General Hospital","All","18 Years to 50 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2012p001784","February 2013","June 2018","July 2018","August 30, 2013","July 7, 2021","July 7, 2021","Martinos Center for Biomedical Imaging/Massachusetts General Hospital, Charlestown, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01931995/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01931995/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01931995"
654,"NCT01916824","Effects of Treatment on Decision-making in Major Depression",,"Completed","Has Results","Major Depressive Disorder|Healthy Controls","Drug: Any FDA Approved Antidepressant","Money Earned","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00066705","August 2013","December 2015","December 2015","August 6, 2013","October 20, 2017","November 21, 2017","Emory Mood and Anxiety Disorders Program, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01916824"
655,"NCT00179283","Sertraline vs. Venlafaxine XR",,"Completed","No Results Available","Major Depressive Disorder","Drug: sertraline|Drug: venlafaxine XR","Ham-D (Hamilton Depression Rating Scale for Depression) 17-item|Clinical Global Impression - Severity Scale|Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Treatment Emergent Symptom Scale-Revised (TESS-R)|Brief Symptom Inventory (BSI)|NEO-5 factor Inventory (NEO-FFI)|Anxiety Sensitivity Inventory (ASI)|Mood Disorder Questionnaire (MDQ)|Ham-A (Hamilton Rating Scale for Anxiety)|Arizona Sexual Functioning Inventory (A-SEX)|Atypical Features Inventory","Vanderbilt University|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","Sert-Ven","April 2002",,"April 2003","September 15, 2005",,"June 2, 2015","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00179283"
656,"NCT00368303","A Local Register Study For Major Depression Of Paroxetine Controlled Release",,"Completed","No Results Available","Depressive Disorder, Major|Major Depressive Disorder (MDD)","Drug: Paroxetine CR|Drug: Paroxetine IR","Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.|Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","362","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PCR103124","December 2006",,,"August 24, 2006",,"June 4, 2012","GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Baoding, Hebei, China|GSK Investigational Site, Changsha, Hunan, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Xi'an, Shaanxi, China|GSK Investigational Site, Xi'an, Shaanxi, China|GSK Investigational Site, Chengdu, Sichuan, China|GSK Investigational Site, Kunming, Yunnan, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China",,"https://ClinicalTrials.gov/show/NCT00368303"
657,"NCT04629599","Healing After Loss Trial","HeAL","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Interpersonal psychotherapy for major depression following perinatal loss|Behavioral: Coping with Depression","Time to Major Depressive Disorder recovery|Depressive symptoms|PTSD symptoms|Time to PTSD recovery|Overall perceived social support|Dyadic social support (from partner or another important person)|Social role functioning (including parental functioning)|Well-being|Grief symptoms|Complicated grief symptoms|Perceived deservingness of loss and guilt over loss|Fear of subsequent pregnancies","Michigan State University|Women and Infants Hospital of Rhode Island","Female","18 Years to 50 Years   (Adult)","Phase 2|Phase 3","274","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD100471","August 2, 2021","January 15, 2025","August 31, 2025","November 16, 2020",,"July 23, 2021","Multiple locations across Genesee, Wayne, Oakland, and surrounding counties, Flint, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04629599"
658,"NCT02139540","Nitrous Oxide as Treatment for Major Depression - a Pilot Study",,"Completed","Has Results","Depression|Major Depressive Disorder","Drug: Nitrous Oxide|Drug: Placebo","Change in Hamilton Depression Rating Scale HDRS-21|Change in Quick Inventory of Depressive Symptomatology - Self Report - QIDS -SR","Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201204023","November 2012","April 2015","April 2015","May 15, 2014","January 27, 2020","January 27, 2020","Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02139540"
659,"NCT01542957","Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention",,"Completed","Has Results","Major Depressive Disorder|Dysthymic Disorder","Behavioral: Combined Cognitive Behavioral and Dilemma-Focused Therapy|Behavioral: Cognitive Behavioral Therapy for Depression","Change From Baseline in Beck Depression Inventory-Second Edition (BDI-II) at the End of Therapy, 3 and 12-month Follow-up|Change From Baseline in Hamilton-Depression Rating Scale-17 Items|Change From Baseline in Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) at the End of Therapy, 3 and12 Month Follow-up","University of Barcelona|National Distance Education University (UNED)|University of Minho|University of Hertfordshire|University of Bern|University Ramon Llull|Institut Trastorn Límit|Hospital de Mataró|Fundació Institut de Recerca de l|Associació Centre de Salut Mental Nou Barris|Fundacion IMIM|EAP Poble Sec|Associació Catalana de Terapies Cognitives|Sant Pere Claver Fundació Sanitaria","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","dilemma2012|PSI2011-23246","November 2011","November 2014","May 2015","March 2, 2012","December 19, 2016","March 22, 2017","Hospital de Mataro (Consorci Sanitari del Maresme), Mataro, Barcelona, Spain|CAP Les Hortes, Barcelona, Catalonia, Spain|Fundació Sanitària Sant Pere Claver, Barcelona, Catalonia, Spain|Associació Catalana de Teràpies Cognitives, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT01542957"
660,"NCT00345098","A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder","CALYPSO","Completed","No Results Available","Depressive Disorder|Major Depression","Drug: SR58611A","The primary outcome measure is the time to relapse of depressive symptoms (in days) during the double-blind study phase.|Change in Clinical Global Impression Severity score. Change in MADRS total score. Change in HAM-A total score","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","704","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LTE5376|EudraCT 2005-004006-81","May 2006","February 2008","February 2008","June 27, 2006",,"March 12, 2009","Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Belgrade, Serbia|Sanofi-Aventis Administrative Office, Bratislava, Slovakia|Sanofi-Aventis Administrative Office, Midrand, South Africa",,"https://ClinicalTrials.gov/show/NCT00345098"
661,"NCT00844974","Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms",,"Completed","No Results Available","Major Depression|Bipolar Disorder","Other: Prevalence","To examine the relationship between severity and type of depression with cognitive deficits","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","2007-p-001665","December 2007","December 2012","December 2012","February 16, 2009",,"November 18, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00844974"
662,"NCT00744406","Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression",,"Completed","No Results Available","Depression|Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy|Behavioral: Interpersonal Therapy|Drug: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)","Hamilton Depression Rating Scale","Centre for Addiction and Mental Health|Ontario Mental Health Foundation","All","18 Years to 60 Years   (Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160/2001","July 2003","September 2006",,"September 1, 2008",,"September 1, 2008","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00744406"
663,"NCT02980484","fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI",,"Terminated","No Results Available","Major Depressive Disorder|Traumatic Brain Injury","Procedure: Active|Procedure: Sham","Improvement in depressive symptoms|Changes in resting-state fMRI and DTI findings|Changes in NIH Toolbox Cognitive, Emotional, and Quality of Life batteries|Changes in temperament and character|Response and remission rates in depressive symptoms|Changes in headache scales|Changes in tinnitus score","Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201603051","August 2016","August 2017","August 2017","December 2, 2016",,"March 29, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02980484"
664,"NCT01851915","Cognitive Behavioral Therapy and Interpersonal Psychotherapy as Treatment for Major Depressive Disorder","CIPPS","Unknown status","No Results Available","Short Term Therapy for Outpatients Diagnosed With Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy|Behavioral: Interpersonal Psychotherapy (IPT)","Montgomery Asberg Depression Rating Scale (MADRS) ( Montgomery SA & Åsberg M. Br J Psychiatry 1979; 134:382-9)|Return to Work","Linkoeping University|REHSAM|Västernorrland County Council, Sweden|Psychiatric clinic, Hospital of Sundsvall, Sweden","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RS2010/013","January 2011","December 2013","December 2014","May 13, 2013",,"May 13, 2013","Psychiatric clinic, Hospital of Sundsvall, Sundsvall, Sweden",,"https://ClinicalTrials.gov/show/NCT01851915"
665,"NCT03670823","Prediction of SSRI Treatment in Major Depression.",,"Unknown status","No Results Available","Major Depression","Device: SIEMENS PRISMA MRI","EEG responses to cognitive tasks in combination with the Eye-tracker Device.|Resting state connectivity analysis|Examine correlations between the different methods|EEG brain activation to cognitive tasks|Eye-tracking tasks|Examine MRI structural changes|Cognitive scores on CANTAB (computerized cognitive assessments)","ElMindA Ltd|Sheba Medical Center|Hebrew University of Jerusalem","All","18 Years to 65 Years   (Adult, Older Adult)",,"100","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ELM-55 5323-18-SMC","March 1, 2019","October 1, 2020","October 1, 2020","September 14, 2018",,"June 7, 2019","Sheba Medical CENTER, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03670823"
666,"NCT04120285","Appalachian Mind Health Initiative","AMHI","Not yet recruiting","No Results Available","Major Depressive Disorder","Behavioral: remote internet-based cognitive behavior therapy (eCBT)","RDQ-7|PROMIS Short Form v1.0 - Severity of Substance Use (past 30 days)|Compliance with Antidepressant Medication Treatment|SDM-Q-9","West Virginia University|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCS-2017C3-9252","March 31, 2020","June 1, 2023","July 1, 2023","October 9, 2019",,"October 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04120285"
667,"NCT04080752","A Study of JNJ-61393215 in the Treatment of Depression",,"Recruiting","No Results Available","Major Depressive Disorder With Anxious Distress","Drug: JNJ-61393215|Drug: Placebo","Change From Baseline in Hamilton Depression Rating Scale-17 (HDRS-17) Total Score at Week 6|Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 6|Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 2 and 4|Change from Baseline in HDRS-17 Total Score in Participants with a Baseline HAM-A Score Greater than or Equal to (>=) 20 at Week 6|Change from Baseline in HAM-A Total Score in Participants with a Baseline HAM-A Score >=20 at Week 6|Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Total Score at Week 6|Change from Baseline in Patient Health Questionnaire (PHQ-9) Total Score at Weeks 2, 4 and 6|Change from Baseline in HDRS-17 Total Score at Weeks 2 and 4|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Plasma Concentration-time Curve (AUC) of JNJ-61393215|Trough Plasma Concentration (Ctrough) of JNJ-61393215|Maximum Observed Plasma Concentration (Cmax) of JNJ-61393215|Plasma Protein Binding (PPB) of JNJ-61393215","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108655|2019-001683-29|61393215MDD2001","September 17, 2019","October 6, 2021","October 6, 2021","September 6, 2019",,"July 23, 2021","Collaborative NeuroScience Network, Garden Grove, California, United States|Hartford Hospital - Institute of Living, Hartford, Connecticut, United States|Atlanta Institute, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|The Medical Research Network, LLC, New York, New York, United States|Richmond Behavioural Associates, Staten Island, New York, United States|Ohio State University, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|ARENSIA, Chisinau, Moldova, Republic of|City Clinical Psychiatric Hopsital 3, Moscow, Russian Federation|St-Petersburg State Budget Institution Of Public Health Psychiatric Hospital #1 n.a. p.p. Kaschenko, Nikolskoe, Russian Federation|Nizny Novgorod clinical psychiatric hospital 1, Nizny Novgorod, Russian Federation|Orenburg Regional Clinical Psychiatric Hospital #1, Orenburg, Russian Federation|Medical and Rehabilitation Research Center Phoenix, Rostov-on-Don, Russian Federation|Engels psychiatric hospital, Saratov Region, Russian Federation|SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky, Saratov, Russian Federation|Saratov Regional Psychiatric hospital named after St. Sofia, Saratov, Russian Federation|Psychoneurological dispensary 10, St-Petersburg, Russian Federation|City Psychiatric hospital 7 named after I.P.Pavlov, St-Petersburg, Russian Federation|Psychoneurological dispensary 1, St-Petersburg, Russian Federation|Psychoneurological Dispensary #4, St.Peterburg, Russian Federation|Stavropol Region Psychiatric Hospital #2, Stavropol, Russian Federation|Research Institute of Mental Health, Tomsk, Russian Federation|MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association, Glevakha, Ukraine|CNCE'Precarpathian Regional Clinical Mental Health Center Ivano-Frankivsk RC', Ivano-Frankivsk, Ukraine|Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3', Kharkiv, Ukraine|CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council, Kherson, Ukraine|Kyiv Railway Station Clinical Hospital #2, Kyiv, Ukraine|Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa), Kyiv, Ukraine|Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council', Nove, Kropyvnytskiy, Ukraine|CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council', Smila, Ukraine|CNCE 'Vinnytsya RC Psychoneurological Hospital n.a. O.I. Yushchenko Vinnytsya RC', Vinnytsia, Ukraine|MAC Clinical Research, Barnsley, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|Kings College London, London, United Kingdom|MAC Clinical Research, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04080752"
668,"NCT00427128","Prozac Treatment of Major Depression: Discontinuation Study",,"Completed","No Results Available","Major Depression","Drug: fluoxetine|Drug: placebo","MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)|Ham-D|CGI","New York State Psychiatric Institute|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","627","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","4099R|RO1 MH56058","November 1995",,"March 2003","January 26, 2007",,"December 15, 2011","Massachusetts General Hospital, Boston, Massachusetts, United States|New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00427128"
669,"NCT00005013","Treatment of Major Depression With St. John's Wort (Hypericum)",,"Completed","No Results Available","Major Depression","Drug: Sertraline|Drug: Hypericum perforatum (St. John's wort)",,"National Institute of Mental Health (NIMH)|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","N01 MH70007|DSIR CT","December 1998",,"July 2001","April 3, 2000",,"April 8, 2014","Feighner Research Institute, San Diego, California, United States|Stanford Univ School of Medicine, Stanford, California, United States|Harbor-UCLA Rsch and Education Inst, Torrance, California, United States|Univ of South Florida College of Med, Tampa, Florida, United States|Emory Mood and Anxiety Disorders Clinical Trials Program, Atlanta, Georgia, United States|McLean Hospital, Belmont, Massachusetts, United States|Eastside Comprehensive Medical Services, New York, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of Cincinnati Medical Ctr, Cincinnati, Ohio, United States|Univ of Texas Southwestern Med Ctr, Dallas, Texas, United States|Seattle Clinical Research Center, Seattle, Washington, United States|Dean Foundation for Hlth Rsch and Education, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00005013"
670,"NCT04255784","High Dose Accelerated iTBS for Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Active iTBS|Device: Sham iTBS","Change on the 17-item Hamilton Rating Scale for Depression (HRSD-17)|Proportion of participants achieving response (50% reduction in HRSD-17) and remission (HRSD-17 <8)|Change on the Beck Depression Inventory-II (BDI-II)|Change on the Generalized Anxiety Disorder 7-Item (GAD-7)","Centre for Addiction and Mental Health|University Health Network, Toronto|University of British Columbia","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","109-2019","February 6, 2020","February 2022","February 2023","February 5, 2020",,"February 15, 2021","University of British Columbia, Vancouver, British Columbia, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|CAMH, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04255784"
671,"NCT03203954","Testing the Neuroscience of Guided Learning in Depression",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Behavioral: Standard Learning|Behavioral: Guided Learning: Instructed statistics|Behavioral: Guided Learning: Changing statistics","Task performance|Neuroimaging measures|Symptoms","Virginia Polytechnic Institute and State University|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Not Applicable","216","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","MDDLEARNING|R01MH106756","May 1, 2016","June 2021","June 2021","June 29, 2017",,"April 5, 2021","Virginia Tech Carilion Research Institute, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03203954"
672,"NCT00092911","Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Depression|Depressive Disorder|Major Depressive Disorder","Drug: DVS-233 SR",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","244","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-320",,"May 2005","May 2005","September 28, 2004",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00092911"
673,"NCT02395263","Comparison of Yuxintine With Placebo in Treatment of MDD",,"Unknown status","No Results Available","Major Depressive Disorder (MDD)","Drug: Yuxintine","The change of total score from baseline in MADRS scale|clinical response rate according to MADRS|clinical remission rate according to MADRS|CGI(CGI-S,CGI-I)|The change of total score from baseline in HAMD scale|decreasing rate from baseline in HAMD scale|clinical remission rate according to HAMD|change from baseline in HAMA|Traditional Chinese Medicine Syndrome Scale","Shanghai Mental Health Center|Shanghai Innovative Research Center of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Yuxintine Capsule-MDD-Ⅱb|2012ZX09303-003","March 2015","March 2016","April 2016","March 23, 2015",,"March 24, 2015","Peking University Sixth Hospital, Beijing, Beijing, China|Beijing HuiLongGuan Hospital, Beijing, Beijing, China|the First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Shenzhen Mental Health Center, Shenzhen, Guangdong, China|the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China|Hebei Mental Health Center, Shijiazhuang, Hebei, China|Hunan Brain Hospital, Changsha, Hunan, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Tianjin Anding Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02395263"
674,"NCT02380066","Comparison of Anyu Peibo With Placebo in Treatment of MDD",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: Anyu Peibo","The change of total score from baseline in MADRS scale|clinical response rate according to MADRS|clinical remission rate according to MADRS|CGI(CGI-S,CGI-I)|The change of total score from baseline in HAMD scale|decreasing rate from baseline in HAMD scale|clinical response rate according to HAMD|clinical remission rate according to HAMD|change from baseline in HAMA","Shanghai Mental Health Center|Su Zhou YiHua Biotechnology Co. LTD","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AYPB-MDD-Ⅱa-1401|2012ZX09303-003","March 2015","March 2016","January 2017","March 5, 2015",,"January 2, 2020","Anhui province hospital of TCM, Hefei, Anhui, China|Guang'anmen Hospital, Beijing, Beijing, China|Peking University Sixth Hospital, Beijing, Beijing, China|Guangzhou Huiai Hospital, Guangzhou, Guangdong, China|Jiangsu province hospital of TCM, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02380066"
675,"NCT02191384","Comparison of Orcinoside With Placebo in Treatment of MDD",,"Unknown status","No Results Available","Major Depressive Disorder (MDD)","Drug: Orcinoside","The change of total score from baseline in MADRS and HAMD scale|response rate and remission rate|decreasing rate from baseline in MADRS|decreasing rate from baseline in HAMD scale|change from baseline in HAMA|CGI(CGI-S,CGI-I)|sleep VAS scale.","Shanghai Mental Health Center|Kun Ming KingBio Biotechnology Co. LTD","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASLST-MDD-Ⅱa-1401|2012ZX09303-003","July 2014","May 2015",,"July 16, 2014",,"March 6, 2015","Peking University Sixth Hospital, Beijing, Beijing, China|Guangzhou Brain Hospital, Guangzhou, Guangdong, China|Hebei Province Mental Health Center, Baoding, Hebei, China|Wuhan Mental Health Center, Wuhan, Hubei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|the first affiliated hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Xi'an Mental Health Center, Xi'an, Shanxi, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT02191384"
676,"NCT03068247","Neurobiology of Treatment Responses in MDD",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Duloxetine|Drug: Placebo","mu-opioid receptor binding capacity|depression score","University of Utah","All","18 Years to 55 Years   (Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","MH108534","November 2021","May 2023","May 2023","March 1, 2017",,"April 23, 2021","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03068247"
677,"NCT03460574","Targeting Cognitive Immunization in Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: INFORMATION|Behavioral: SALIENCE|Behavioral: ATTENTION|Behavioral: CONTROL","Performance Expectations Scale - generalized|Performance Expectations Scale - task-specific","Philipps University Marburg Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2017-39k","October 14, 2017","April 30, 2018","August 21, 2018","March 9, 2018",,"August 23, 2018","Schoen Klinik Bad Arolsen, Bad Arolsen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT03460574"
678,"NCT03432221","Switching From SSRI to Desvenlafaxine on Cognitive Functioning",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Desvenlafaxine","Composite cognitive measure|Subjective cognitive function|Attention|Processing speed|Verbal Memory|Executive Functions|Hot cognition|Intelligence quotient|Depressive symptoms|Anxiety symptoms|Severity and improvement of depression|Self-perceived remission status|Disability|Functioning|Sexual dysfunction|Side effect rating scale for psychotropic drugs","Corporacion Parc Tauli|Pfizer","All","18 Years to 60 Years   (Adult)",,"36","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017.116","April 3, 2018","June 3, 2019","June 3, 2019","February 14, 2018",,"April 18, 2019","Corporació Sanitària Parc Taulí, Sabadell, Spain",,"https://ClinicalTrials.gov/show/NCT03432221"
679,"NCT00521352","Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression","rTMS","Completed","Has Results","Panic Disorder|Major Depressive Disorder","Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)","Panic Disorder Severity Scale (PDSS)|Hamilton Depression Rating Scale (HDRS), 28 Item Version|Clinical Improvement (CGI-S)","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","5517","October 2007","June 2011","June 2011","August 27, 2007","September 22, 2014","September 22, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00521352"
680,"NCT02047968","Wake and Light Therapy to In-patients With Major Depression: Efficacy, Predictors and Patient Experiences",,"Completed","No Results Available","Major Depression","Behavioral: wake therapy","Response|Remission|Length of admission|Percentage of patients with response|Percentage of patients with remission","University of Aarhus","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","VT12","February 2014","May 2016","May 2016","January 29, 2014",,"October 31, 2016","Mette Kragh, Risskov, Central Denmark Region, Denmark",,"https://ClinicalTrials.gov/show/NCT02047968"
681,"NCT01670019","Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression",,"Completed","Has Results","Major Depressive Disorder Without Psychotic Features","Drug: Asenapine 5-20 mg daily|Drug: Placebo 1-4 tablets daily","Change in MADRS Total Score|Study Completion Rate|Clinical Response Rate|Clinical Remission Rate|Rates of Sustained Remission","Duke University|Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00037462","October 2012","May 2014","June 2014","August 21, 2012","October 1, 2015","October 1, 2015","Georgia Health Sciences University, Augusta, Georgia, United States|Carolina Behavioral Care, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|North Carolina Psychiatric Research Center, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01670019"
682,"NCT00159146","Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression",,"Terminated","No Results Available","Major Depression","Drug: Pindolol and venlafaxin","Hamilton Depression Rating Scale scores|Preskorn scores","Hillerod Hospital, Denmark|Wyeth is now a wholly owned subsidiary of Pfizer|Tvergaards Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","version 5","August 2002",,"September 2007","September 12, 2005",,"December 27, 2007","Psychiatric Research Unit, Hillerod Hospital, Hillerod, Denmark",,"https://ClinicalTrials.gov/show/NCT00159146"
683,"NCT01001559","Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis",,"Completed","Has Results","Major Depressive Disorder","Drug: L-methylfolate|Drug: Selective serotonin reuptake inhibitor (SSRI)|Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI)","Improvement as Measured by Change in Clinical Global Impression of Severity (CGI-S) Rating From Baseline|Length of Time to Peak Response, as Determined by the Clinical Global Impression of Severity (CGI-S) Scale|Number of Hospitalizations Due to MDD|Absolute Count of Alterations in Therapy Required, Such as Dose Increases, Antidepressant Substitutions, or Addition of Augmentation Medications","Pamlab, Inc.|Red Oak Psychiatry Associates, PA|Baylor Health Care System","All","18 Years to 70 Years   (Adult, Older Adult)",,"242","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Pamlab D-005","August 2009","December 2010","June 2011","October 26, 2009","December 19, 2013","December 19, 2013","Red Oak Psychiatry Associates, PA, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01001559"
684,"NCT00229398","Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder",,"Completed","No Results Available","Major Depressive Disorder",,,"Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)",,,"Other","Observational","Time Perspective: Retrospective","SHEBA-99-1744-JZ-CTIL","November 1998","December 2004","December 2004","September 29, 2005",,"January 31, 2008",,,"https://ClinicalTrials.gov/show/NCT00229398"
685,"NCT04388748","Stress Management and Resiliency Training for Depression vs Treatment as Usual in the Treatment of Major Depression",,"Recruiting","No Results Available","Major Depression","Behavioral: Stress Management and Resiliency Training for Depression (SMART-D) Therapy","Change in patient health questionnaire depression assessment|Change in severity of depression|Change in measures of resilience|Changed in perceived stress scale","Mayo Clinic","All","25 Years to 80 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","19-009475","December 18, 2020","December 30, 2021","September 30, 2022","May 14, 2020",,"February 8, 2021","Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04388748"
686,"NCT02375308","Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: HDT|Behavioral: ACDT","Montgomery-Åsberg Depression Rating Scale (MADRS)|QIDS: Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C16)|Patient Health Questionnaire (PHQ-9)","University Hospital Tuebingen","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UTubingen","April 2015","July 2017","June 28, 2018","March 2, 2015",,"September 25, 2018","Prof. Dr. A. Batra/ Dr. Kristina Fuhr, University Department for Psychiatry and Psychotherapie, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT02375308"
687,"NCT01894815","Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial","ELECT-TDCS","Completed","No Results Available","Major Depressive Disorder|Major Depressive Disorder, Recurrent, Unspecified|Major Depressive Disorder, Single Episode, Unspecified","Drug: Escitalopram oxalate|Device: transcranial direct current stimulation|Other: Sham tDCS + Placebo Pill","Changes in Hamilton Rating Scale for Depression, 17 items (HAMD17)|Change in HDRS|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Beck Depression Inventory (BDI)|Change in Positive and Negative Affect Scale (PANAS)|Change in State-Trait Anxiety Inventory (STAI)|Hamilton Rating Scale for Depression, 17 items (HAMD17)|Adverse events|Serious adverse events|Young Manic Rating Scale (YMRS)|Predictor of response","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo|Brain & Behavior Research Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","245","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELECT-TDCS|FAPESP 2012/20911-5","October 2013","July 2016","November 2016","July 10, 2013",,"December 5, 2016","Institute of Psychiatry, HC-FMUSP, São Paulo, SP, Brazil|Hospital Universitário, Universidade de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01894815"
688,"NCT01589315","Focal Electroconvulsive Therapy for Depression","FEAST","Completed","Has Results","Major Depressive Disorder","Device: focal ECT","Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item.","Medical University of South Carolina","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FEAST for depression","January 2007","August 2015","August 2016","May 1, 2012","August 20, 2019","August 20, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01589315"
689,"NCT00220623","Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression",,"Unknown status","No Results Available","Major Depression","Drug: antidepressant medications, flexible drug choice|Behavioral: CBT, Psychodynamic or Supportive Psychotherapy","Time to recovery of major depressive episode|Time to recurrence of major depression, once recovered|improvement in depressive defenses|proportion of time with depressive symptoms|improvement on other specified psychological measures related to depression|cost-effectiveness measures","Sir Mortimer B. Davis - Jewish General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","#04-013","August 2004",,,"September 22, 2005",,"September 22, 2005","Institute of Community and Family Psychiatry, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00220623"
690,"NCT00059579","Brain Regulation of Emotions in People With Depression and Anhedonia",,"Completed","No Results Available","Major Depressive Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"163","NIH","Observational",,"030149|03-M-0149","April 24, 2003",,"November 12, 2010","April 29, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00059579"
691,"NCT00472576","Antidepressant Effects of NR2B in Major Depression",,"Completed","Has Results","Major Depression","Drug: MK-0657|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Hamilton Depression Rating Scale (HDRS)","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 1","5","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","070152|07-M-0152","May 2007","August 2009","August 2009","May 11, 2007","April 7, 2011","August 3, 2012","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00472576"
692,"NCT00702598","The WORKER Study: Escitalopram and Telephone-based Cognitive Behaviour Therapy (CBT) for Depressed Working People",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Behavioral: Telephone-based Cognitive Behaviour Therapy (CBT)|Behavioral: Telephone reminder calls","Change in adjusted HAM-D and MADRS scores at 3 month followup|At 3 and 6 month followup: clinical response and remission rates, absenteeism and work productivity, adverse events, quality of life, and cost-effectiveness.","University of British Columbia","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H07-03029","June 2008","April 2011","December 2011","June 20, 2008",,"May 9, 2012","UBC Hospital Mood Disorders Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00702598"
693,"NCT00944996","Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression",,"Completed","No Results Available","Major Depression","Drug: SSRI; SNRI; TCA","Measurements of PACAP and BDNF serum levels|Analysis of genetic variants of PACAP and PAC1 coding and regulatory regions","Tirat Carmel Mental Health Center|University of Michigan|Ariel University|The Nazareth Hospital, Israel","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","akparl08|920080174|040-2008","June 2009","June 2010","July 2012","July 23, 2009",,"July 26, 2012","Tirat Carmel Mental Health Center, Tirat Hacarmel, Israel",,"https://ClinicalTrials.gov/show/NCT00944996"
694,"NCT01740726","Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression",,"Terminated","Has Results","Major Depressive Disorder","Behavioral: Behavioral Activation|Drug: Fluoxetine","Change in Depressive Symptoms From Baseline Based on Beck Depression Inventory, 2nd Edition (BDI-II)|Change in Depressive Symptoms From Baseline Based on Children's Depression Rating Scale - Revised (CDRS-R)|Overall Improvement and Change in Symptom Severity From Baseline Based on Clinical Global Impression - Improvement and Severity (CGI-I, CGI-S)|Change in Behaviors From Baseline Based on Behavioral Activation for Depression Scale (BADS)|Change in Anxiety From Baseline Based on Multidimensional Anxiety Scale for Children (MASC)|Change in Suicidal Ideation Based on Suicidal Ideation Questionnaire (SIQ)|Change in Hope Based on Children's Hope Scale (CHS)","Emory University","All","13 Years to 17 Years   (Child)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00061525|CAMP-61525","January 2013","March 2014","March 2014","December 4, 2012","April 7, 2015","December 20, 2017","Emory Executive Park, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01740726"
695,"NCT01887639","Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial","PANTHER","Completed","No Results Available","Non-psychotic Unipolar Major Depression",,"Percentage of patients with unipolar major depression that do not achieve remission after one antidepressant treatment.|Clinical, therapeutic and socio-demographic characteristics of resistant depression patients and comparisson of them with the characteristics of the sample of depressed patients in remission.|Comparison of the depression severity change assessed by the physician with the evaluation done by the patient","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIS-NAR-XXX-2013/1","September 2013","September 2014","September 2014","June 27, 2013",,"July 30, 2015","Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Chaco, Argentina|Research Site, Cordoba, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Santa Fe, Argentina|Research Site, Tucuman, Argentina",,"https://ClinicalTrials.gov/show/NCT01887639"
696,"NCT00260468","Brain Abnormalities in Late-Onset Major Depression",,"Completed","No Results Available","Major Depression","Other: Clinical examination program",,"University of Aarhus|The Danish Medical Research Council|Bayer","All","50 Years and older   (Adult, Older Adult)",,"44","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","20051050","November 2005",,"December 2008","December 1, 2005",,"October 22, 2009","Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark",,"https://ClinicalTrials.gov/show/NCT00260468"
697,"NCT04093960","Escitalopram Plus PS128 vs. Escitalopram",,"Terminated","No Results Available","Major Depression","Dietary Supplement: Lactobacillus plantarum PS128","Depression severity by the change of 17-item Hamilton Rating Scale for Depression (HAMD-17) total scores|Clinical severity by Clinical Global Impression-Severity (CGI-S)|Assessments of safety for general adverse events|Change of body weights|Change of body mass index (BMI)|Change of pulse rate|Change of blood pressure|Change of ECG QT Interval|change of fasting glucose.|change of liver function|change of renal function|change of lipid profiles.|Assessments of quality of life|Assessments of heart rate variability|depression and somatic symptoms evaluation|Gastrointestinal Symptoms evaluation|Sleep Quality evaluation: The Pittsburgh Sleep Quality Index (PSQI)|Function evaluation|change of work and social adjustment","Kaohsiung Kai-Suan Psychiatric Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KSPH-2016-02","November 18, 2016","March 4, 2019","September 1, 2019","September 18, 2019",,"September 18, 2019","Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04093960"
698,"NCT00988663","The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?","ECTAug","Withdrawn","No Results Available","Major Depressive Disorder","Drug: memantine|Drug: Placebo","Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.|Whether memantine will improve response of Depression to Electroconvulsive therapy.","Jerrry L Lewis|University of Iowa","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Memantine ECT trial","November 2009","November 2009","November 2009","October 2, 2009",,"March 24, 2017","University of Iowa hosptitals and clinic, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT00988663"
699,"NCT04156425","The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Escitalopram+golimumab|Dietary Supplement: Escitalopram+Calcium Tablet|Drug: Escitalopram","remission of acute phase","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","81930033","July 1, 2020","December 31, 2024","December 31, 2024","November 7, 2019",,"May 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04156425"
700,"NCT01391221","Inflammatory Markers and Cognitive Function in Major Depression",,"Unknown status","No Results Available","Major Depression","Drug: Duloxetine","Cognitive function measured by CANTAB|pain inhibition|Allostatic load","Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal|Eli Lilly and Company","All","20 Years to 50 Years   (Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2011005","July 2011","August 2013","August 2013","July 11, 2011",,"July 19, 2012","Centre de Recherche Fernand Seguin, Montreal, Quebec, Canada|Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01391221"
701,"NCT00406848","A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients",,"Completed","Has Results","Major Depressive Disorder","Drug: duloxetine hydrochloride|Drug: placebo","Change From Baseline to 13 Weeks in Hamilton Depression Rating Scale (HAMD-17) Maier Subscale|Change From Baseline on the 30-item Geriatric Depression Scale (GDS)|Change From Baseline in the HAMD-17 Total Score, Subscales, and Individual Items|Change From Baseline in the Brief Pain Inventory (BPI) Severity and Interference Scores|Change From Baseline in the Numeric Rating Scales (NRS) for Pain Item Scores|Patient's Global Impression of Improvement (PGI-I) at 13 Weeks and 25 Weeks|Change From Baseline in the Clinical Global Impression-Severity (CGI-S)|Change From Baseline in the Mini-Mental State Exam (MMSE)|Change From Baseline in the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q-SF)|Probability of Remission as Measured by the HAMD-17 Total Score ≤7 and ≤10|Probability of Response at Endpoint as Measured by ≥50% Improvement in the HAMD-17 Total Score|Probability of Remission as Measured by the HAMD-17 Total Score ≤7 and ≤10 by Medical Comorbidity Severity as Assessed by the Cumulative Illness Rating Scale-Geriatric Version (CIRS-G)|Probability of Efficacy Onset as Measured by at Least 20% Sustained Reduction From Baseline in the HAMD-17 Maier Subscale at Week 3|Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate|Change From Baseline in Weight|Number of Participants With Abnormal Vital Signs and Weight at Any Time During the Study|Number of Participants Experiencing Sustained Hypertension (SH) or Orthostatic Hypotension (OH)|Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation|Change From Baseline in Laboratory Values - Platelet Count|Change From Baseline in Laboratory Values - Uric Acid|Change From Baseline in Laboratory Values - Erythrocyte Count|Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)|Change From Baseline in Laboratory Values - Chloride and Fasting Glucose|Number of Participants With Abnormal Laboratory Values - Low Leukocyte Count|Change From Baseline in Electrocardiograms|Number of Participants With Successful Treatment Outcome|Change From Baseline on Cognitive Test Scores: Verbal Learning and Recall Test (VLRT), Symbol Digit Substitution Test (SDST), Trail Making Test (Part B), 2-Digit Cancellation Test (2DCT), and the Composite Cognitive Score Derived From the Above Scores","Eli Lilly and Company|Boehringer Ingelheim","All","65 Years and older   (Older Adult)","Phase 4","370","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10815|F1J-US-HMFA","November 2006","July 2009","November 2009","December 4, 2006","September 29, 2010","September 29, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pasadena, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoffman Estates, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Charles, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaithersburg, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Burnie, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fall River, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olean, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bartlett, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcachon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Douai, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Limoges, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metz, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valence, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00406848"
702,"NCT02746367","Bipolar Proteomic Assay Validation Study",,"Completed","No Results Available","Major Depressive Disorder, Bipolar I and Bipolar II","Other: Diagnostic test (LDT)","Agreement between the model derived diagnosis (based on panel of serum proteomic markers) and the clinical diagnosis (confirmed by the SCID DSM-5)|Self-report clinical rating scales (IDS-SR30, PHQ-9, MDQ, HCL-32 and TEMPS-A)|Changes in proteomic markers at Week 2 and Week 8","Myriad Genetic Laboratories, Inc.|University of Minnesota","All","18 Years to 70 Years   (Adult, Older Adult)",,"261","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EP-001","March 2016","November 8, 2018","November 8, 2018","April 21, 2016",,"May 14, 2020","University of Iowa Health Care, Department of Psychiatry, Iowa City, Iowa, United States|University of Minnesota (UMN) Department of Psychiatry, Minneapolis, Minnesota, United States|Lindner Center of HOPE/University of Cincinnati College of Medicine, Mason, Ohio, United States|University of Pittsburgh Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|University of Texas Health Science Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02746367"
703,"NCT00955474","Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms","Seroquel","Terminated","Has Results","Major Depressive Disorder With Psychotic Features","Drug: Quetiapine|Drug: escitalopram|Drug: Sertraline|Drug: Citalopram","Depression|Psychosis|Fasting Blood Glucose|CPFQ (Cognitive and Psychological Functioning Questionnaire)|RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Total Score|RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Immediate Memory Sub-scale Score|RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Visuospatial/Constructional Sub-scale.|RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Language Sub-scale Score.|RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Attention Sub-scale Scores at Baseline and Week 8.|RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Delayed Memory Subscale Scores at Baseline and Week 8.|Blood Level of Total Cholesterol Levels Were Collected at Baseline and Week 8.|Blood Level of Triglycerides at Baseline and Week 8.|HDL Blood Levels at Baseline and Week 8.|LDL Blood Levels at Baseline and Week 8.|Blood Hemoglobin A1C at Baseline and Week 8.","Massachusetts General Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2008P001022","September 2008","January 2013","January 2013","August 10, 2009","March 28, 2016","April 20, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00955474"
704,"NCT00229645","A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety",,"Completed","No Results Available","Major Depression With Comorbid Anxiety Symptoms","Drug: Quetiapine Fumarate (Seroquel®)","To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the|1. Hamilton Depression Scale (HAM-D) total score,|2. Hamilton Anxiety Scale (HAM-A) total score","Dr Alexander McIntyre Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1441C00017","November 2003",,"April 2005","September 30, 2005",,"July 13, 2016","Dr. A. McIntyre, Penticton, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00229645"
705,"NCT00384436","Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients",,"Completed","No Results Available","Major Depressive Disorder","Drug: escitalopram","Time to premature discontinuation|Montgomery Asberg Depression Rating Scale (MADRS)","Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","580","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SCT-MD-39","October 2006","October 2007",,"October 6, 2006",,"January 7, 2008","For information regarding investigative sites, contact Forest Professional Affairs, St Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00384436"
706,"NCT01867749","Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss",,"Completed","No Results Available","Major Depressive Disorder|Miscarriage|Stillbirth|Neonatal Death","Behavioral: Group Interpersonal Psychotherapy (IPT-G)|Behavioral: Coping with Depression (CWD)","Treatment Acceptability|Reduced time to remission from major depressive disorder (exploratory in this underpowered feasibility/acceptability study)|Reduction in depressive symptoms (exploratory in this underpowered feasibility/acceptability study)|Perceived Social Support|Couple Distress|Grief","Brown University|National Institute of Mental Health (NIMH)","Female","18 Years to 50 Years   (Adult)","Not Applicable","62","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","5R34MH086682-03","June 2010","June 2014","June 2014","June 4, 2013",,"January 13, 2016","Brown University, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01867749"
707,"NCT03994081","Mechanism of Action of tACS for the Treatment of MDD","GLADIATOR2","Recruiting","No Results Available","Major Depressive Disorder|MDD","Device: tACS|Device: Sham tACS","Change in the amplitude of left frontal alpha oscillations measured in eyes-open resting-state EEG recordings from baseline to day 5 of stimulation.|Change in the amplitude of left frontal alpha oscillations measured in eyes-open resting-state EEG recordings from baseline to two-week follow-up of stimulation.|Correlation between changes in the amplitude of left frontal alpha oscillations from baseline to day 5 of intervention and changes in symptoms of depression from baseline to two-week follow-up|Correlation between changes in the amplitude of left frontal alpha oscillations from baseline to two-week follow-up|Correlation between changes in the amplitude of left frontal alpha oscillations and changes in symptoms of depression from baseline to two-week follow-up","University of North Carolina, Chapel Hill|Foundation of Hope for Research and Treatment of Mental Illness|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-1822","June 9, 2021","July 2023","July 2024","June 21, 2019",,"June 28, 2021","UNC at Vilcom Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03994081"
708,"NCT01313403","Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depression|Unipolar Depression|Depression|Anxiety Disorder","Other: Antidepressant (SSRI)",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Not Applicable","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","110097|11-M-0097","February 10, 2011","April 25, 2012","April 25, 2012","March 11, 2011",,"July 2, 2017",,,"https://ClinicalTrials.gov/show/NCT01313403"
709,"NCT03973268","Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression",,"Recruiting","No Results Available","Depression|Major Depressive Disorder|Major Depression","Drug: Ketamine|Drug: Perampanel|Other: Placebo|Device: MagPro 100 TMS Therapy System","Acute Antidepressant Efficacy: Change from baseline Montgomery Asberg Depression Rating Scale (MADRS) score post ketamine infusion|Continued Antidepressant Efficacy: Change from baseline MADRS score post treatment with ketamine with perampanel versus placebo.|Acute Antidepressant Efficacy: Change in slow wave activity /slope post ketamine infusion|Acute Antidepressant Efficacy: Change in synaptic plasticity post ketamine infusion|Continued Antidepressant Efficacy: Gamma power change from baseline post treatment with ketamine with perampanel versus placebo|Continued Antidepressant Efficacy: Change in slow wave activity/slope from baseline post treatment with ketamine with perampanel versus placebo|Continued Antidepressant Efficacy: Change in synaptic plasticity from baseline post treatment with ketamine with perampanel versus placebo|Acute Antidepressant Efficacy: Gamma power change from baseline post ketamine infusion|Acute Antidepressant Efficacy: Change in peripheral measures associated with the administration of ketamine","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","190107|19-M-0107","January 21, 2020","February 1, 2022","February 1, 2022","June 4, 2019",,"March 11, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03973268"
710,"NCT00909155","Brain Imaging Techniques That Predict Antidepressant Responsiveness","WyethKolden","Completed","Has Results","Major Depressive Disorder","Drug: Venlafaxine ERT|Drug: Fluoxetine","Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales|Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.","University of Wisconsin, Madison|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","0600B-100953|2001-294","July 2002","December 2009","December 2009","May 27, 2009","December 15, 2014","August 3, 2018","University of Wisconsin Madison Psychiatry Department, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00909155"
711,"NCT02346682","Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder","NMNTDM","Unknown status","No Results Available","Severe Major Depression Disorder","Drug: venlafaxine","Brain neuroimaging|Biochemical tests","Zhejiang Provincial Tongde Hospital|The University of Hong Kong","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","zjsltdyy2014009|8140151401","February 2015","June 2017","December 2017","January 27, 2015",,"April 27, 2015","Tongde hospital of zhejiang province, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02346682"
712,"NCT01778790","Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression","FORESEEII","Completed","No Results Available","Major Depression","Device: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator","Depression Severity assessed with Montgomery Asberg Depression Scale (MADRS)|Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)","University Hospital, Bonn","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","16","Other","Interventional","Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BSG-13-2319DBS","July 2013","February 2016","January 2018","January 29, 2013",,"August 7, 2018","University Hospital Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT01778790"
713,"NCT02294305","Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder",,"Unknown status","No Results Available","Social Anxiety Disorder|Major Depressive Disorder","Drug: Vortioxetine|Drug: Placebo","Clinical Global Impression of Improvement (CGI-I) Responder Rate|Change in total Montgomery Asberg Depression Rating Scale (MADRS) score|Change in total Liebowitz Social Anxiety Scale (LSAS) score","The Medical Research Network","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-S001560","December 2014","November 2016","November 2016","November 19, 2014",,"August 24, 2016","The Medical Research Network, LLC, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02294305"
714,"NCT02802293","Treatment of Depression With Connectivity Guided Robotically Delivered rTMS",,"Terminated","No Results Available","Major Depressive Disorder","Device: repetitive transcranial magnetic stimulation|Device: robotic arm","Change in depression severity (MADRS)|Clinically significant response (MADRS)|Remission from depression (MADRS)|Functional connectivity changes of the targeted brain network(s) following rTMS treatment|Incidence of treatment-emergent adverse events and serious adverse events","The University of Texas Health Science Center at San Antonio|IKARE Mood, Trauma, Recovery Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CE-MDD-LRTC|HSC20160129H","August 17, 2017","March 23, 2021","March 23, 2021","June 16, 2016",,"May 18, 2021","Ikare, Mood, Trauma, Recovery Clinic, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02802293"
715,"NCT01095263","Effects of Deep Brain Stimulation in Treatment Resistant Major Depression","FORESEE","Completed","No Results Available","Major Depression","Device: DBS|Device: No Stimulation (Sham)","Depression Severity assessed with Montgomery Asberg Depression Scale (MADRS)|Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)|Adverse Event Schedule|Comprehensive neuropsychological test battery","University Hospital, Bonn","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BSG-10-4711DBS","April 2011","August 2012","January 2013","March 30, 2010",,"August 6, 2018","University Hospital Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT01095263"
716,"NCT00770783","Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression",,"Completed","No Results Available","Major Depression","Device: Thymatron|Device: Tonica MagPro MST","Clinical improvement (Hamilton Rating Scale for Depression)|Clinical improvement (Montgomery- Åsberg Rating Scale for Depression)","University Hospital, Bonn","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","BSG-05-001","February 2005","September 2013","May 2014","October 10, 2008",,"August 6, 2018","Department of Psychiatry and Psychotherapy - University Hospital, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT00770783"
717,"NCT02213016","Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients",,"Unknown status","No Results Available","Major Depression","Device: Transcranial Magnetic Stimulation|Device: Sham Transcranial Magnetic Stimulation","Total scores on the Hamilton depression scale depression|Performance on the Wisconsin card sorting test","Universidad Nacional Autonoma de Mexico","All","18 Years to 35 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","141-2011","September 2013","September 2016","February 2017","August 11, 2014",,"August 11, 2014","Department of Psychiatry and Mental Health, Faculty of Medicine, UNAM, Mexico, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT02213016"
718,"NCT00067301","PUFA Augmentation in Treatment of Major Depression",,"Completed","No Results Available","Major Depression","Drug: Polyunsaturated Fatty Acids (PUFA)|Drug: Citalopram",,"National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R21AT001077|GertsikL","September 2003","April 2007","April 2007","August 15, 2003",,"January 25, 2008","Cedars-Sinai Medical Center Dept. of Psychiatry, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00067301"
719,"NCT00510822","Cimicoxib for the Treatment of Major Depression (SECIM)",,"Completed","No Results Available","Major Depression","Drug: Cimicoxib|Drug: Placebo","• Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).|• Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of","Affectis Pharmaceuticals AG|FGK Clinical Research GmbH","All","18 Years to 60 Years   (Adult)","Phase 2","169","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AFX-01|EudraCT-No. 2007-001335-54","October 2007","February 2010","February 2010","August 2, 2007",,"November 13, 2013","Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie, Klagenfurt, Austria|Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH, Salzburg, Austria|Faculty Hospital Brno, Brno, Czech Republic|Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic|Pardubice Regional Hospital, Pardubice, Czech Republic|1st Medical Faculty Prague, Prague, Czech Republic|Prague Psychiatric Centrum, Praha, Czech Republic|Masaryk Hospital, Ústí nad Labem, Czech Republic|Charite - Center for Psychiatry and Psychotherapy, Berlin, Germany|LWL-Universitätsklinik Bochum, Bochum, Germany|University Bonn, Center for Psychiatry and Psychotherapy, Bonn, Germany|Carl Gustav Carus University Dresden, Center for Psychiatry and Psychotherapy, Dresden, Germany|Georg-August-University Goettingen, Department of Psychiatry and Psychotherapy, Goettingen, Germany|Hospital Guenzburg, Center for Psychosomatic Medicine, Guenzburg, Germany|University Jena, Center for Psychiatry and Psychotherapy, Jena, Germany|Klinik für Psychiatrie und Psychotherapie der Universität zu Köln, Köln, Germany|Fachklinik Katzenelnbogen, Limburg an der Lahn (Katzenelnbogen), Germany|Otto-von-Guericke University Magdeburg, Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Magdeburg, Germany|Klinikum der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie, Mannheim, Germany|Center for Psychiatry and Psychotherapy, University of Muenster, Muenster, Germany|Ludwig-Maximilians University Munich, Munich, Germany|Max Planck Institute of Psychiatry, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Ernst Moritz Arndt University of Greifswald, Center for Psychiatry and Psychotherapy, Stralsund, Germany",,"https://ClinicalTrials.gov/show/NCT00510822"
720,"NCT03571412","Antidepressive Effect on 5 Herz (Hz) rTMS Over Dorsomedial Prefrontal Cortex and Left Dorsolateral Prefrontal Cortex",,"Completed","No Results Available","Major Depressive Disorder","Device: repetitive Transcranial Magnetic Stimulation","Changes in depressive symptoms evaluated by Hamilton Depressive Rating Scale (HADRS)|Changes in depressive symptoms evaluated by Montgomery-Asberg Depressive Rating Scale (MADRS)","Universidad Autonoma de Queretaro","All","18 Years to 45 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","01-05/05/2016","August 8, 2016","July 31, 2017","September 1, 2017","June 27, 2018",,"April 16, 2019",,,"https://ClinicalTrials.gov/show/NCT03571412"
721,"NCT00461279","Attachment Security as Mediator and Moderator of Outcome in Major Depression",,"Completed","No Results Available","Major Depression","Behavioral: Cognitive Behavior Therapy|Behavioral: Interpersonal Psychotherapy","HAMD|BDI","Centre for Addiction and Mental Health|Ontario Mental Health Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","165/2006","August 2006","February 2010","March 2010","April 17, 2007",,"December 6, 2011","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00461279"
722,"NCT00285766","Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression",,"Completed","No Results Available","Major Depression","Drug: Selegiline Transdermal System",,"Somerset Pharmaceuticals","All","65 Years and older   (Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S9303-P0204","August 2002",,"July 2005","February 2, 2006",,"April 22, 2008","Mohammed Bari, M.D., Chula Vista, California, United States|Charles Meredith, M.D., San Diego, California, United States|Daniel Zimbroff, M.D., Upland, California, United States|Kathleen Toups, M.D., Walnut Creek, California, United States|Abbey Strauss, M.D., Boynton Beach, Florida, United States|Barry Baumel, M.D., Miami Beach, Florida, United States|Margarita Nunez, M.D., St. Petersburg, Florida, United States|Mildred Farmer, M.D., St. Petersburg, Florida, United States|Larry Eisner, M.D., Tamarack, Florida, United States|Andrew Cutler, M.D., Winter Park, Florida, United States|Robert Riesenberg, M.D., Atlanta, Georgia, United States|James Hartford, M.D., Florence, Kentucky, United States|Mitchel Kling, M.D., Baltimore, Maryland, United States|Louise Beckett, M.D., Oklahoma City, Oklahoma, United States|Penny Barnhart, M.D., Wichita Falls, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00285766"
723,"NCT00377299","A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence",,"Completed","Has Results","Amphetamine Abuse|Amphetamine Dependence|Bipolar Disorder|Major Depressive Disorder","Drug: Citicoline|Drug: Placebo","Depression Symptoms|Amphetamine Craving|Amphetamine Use|Hopkins Auditory Verbal Learning Test (HVLT)|Stroop Color Word Test","University of Texas Southwestern Medical Center|Stanley Medical Research Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","052006-27","October 2006","May 2009","May 2009","September 18, 2006","August 8, 2013","August 8, 2013","Psychoneuroendocrine Research Program, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00377299"
724,"NCT03289923","Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes",,"Recruiting","No Results Available","Major Depressive Disorder","Other: sham TMS|Device: TMS|Behavioral: Self-System Therapy|Behavioral: Mindfulness exercises|Other: TMS+SST","Change in magnitude of Bold signal|Electrophysiological changes using MEG and EEG measures|Clinical Rating Scales: BSL, C-SSRS, CTQ, HAM-A, NIH-BFI, PANAS, RBANS, RRS, SHAPS, and TLEQ","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","170147|17-M-0147","May 17, 2018","March 1, 2029","March 1, 2029","September 21, 2017",,"June 30, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03289923"
725,"NCT00289484","A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression",,"Unknown status","No Results Available","Major Depression","Drug: Omega-3 Polyunsaturated Fatty Acids","Change form pretreatment score on Depression Rating scale at 4 weeks|Daily mood rating|Weekly measure of depression|Weekly measure of anxiety|Weekly measure of functional status","The University of New South Wales|Your Health Inc.|Sphere Healthcare|Ocean Nutrition","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","05156","February 2006",,,"February 9, 2006",,"September 13, 2006","The University of New South Wales/Black Dog Institute, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT00289484"
726,"NCT01774045","A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: PDC-1421|Drug: Placebo","Number of Dose Limiting Toxicity of Physical Examination|Number of Dose Limiting Toxicity of Electrocardiograph|Number of Dose Limiting Toxicity of Vital Sign|Number of Dose Limiting Toxicity of Laboratory Values|Number of Dose Limiting Toxicity of Columbia-Suicide Severity Rating Scale (C-SSRS)","BioLite, Inc.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Phase I study of PDC-1421","November 2012","July 2013","July 2013","January 23, 2013","September 22, 2014","August 13, 2020","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01774045"
727,"NCT00320372","Treatment-Resistant Depression Registry",,"Completed","Has Results","Major Depressive Disorder",,"Montgomery Asberg Depression Rating Scale (MADRS)% Responders (>/= 50% Improvement From Baseline)|Time Until Recurrence (TUR) for Patients That Achieved Remission, Based on Montgomery Asberg Depression Rating Scale (MADRS)|Montgomery Asberg Depression Rating Scale (MADRS)% Remitters (MADRS Total Score ≤9 at Visit Month Assessment Post-Baseline)|Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Baseline MADRS Item 10 Suicidal Ideation|Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Medical Threat to Life of Most Recent Suicidal Gesture|Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Intent of Most Recent Suicidal Gesture|Predictors of Suicidality Based on Montgomery Asberg Depression Rating Scale (MADRS) Item 10 Score - Primary Diagnosis of MDE","Cyberonics, Inc.","All","18 Years and older   (Adult, Older Adult)",,"795","Industry","Observational","Time Perspective: Prospective","TRD Registry","January 2006","March 2015","May 2015","May 3, 2006","December 23, 2015","December 23, 2015","University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Hospital, Beverly Hills, California, United States|Mark Zetin, MD - Private Practice, Garden Grove, California, United States|Loma Linda University, Loma Linda, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Fair Oaks Psychiatric Associates, Sacramento, California, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Florida Atlantic University, Boca Raton, Florida, United States|University of Florida, Gainesville, Florida, United States|MG Martelli, MD, PC and Associates, Brunswick, Georgia, United States|Arthur Holt, Private Practice, Columbus, Georgia, United States|Pact Atlanta, LLC, Decatur, Georgia, United States|Private Practice, Macon, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Valdosta Psychiatric Associates LLC, Valdosta, Georgia, United States|Northshore University Health System, Evanston, Illinois, United States|McGrath Clinic, Evergreen Park, Illinois, United States|Alexian Brothers Behavioral Health Hospital, Hoffman Estates, Illinois, United States|Psychiatric Medicine Associates, LLC, Skokie, Illinois, United States|Dupage Mental Health Services, Wheaton, Illinois, United States|3c Methodist Hospital, Indianapolis, Indiana, United States|Clinical Research Institute, Wichita, Kansas, United States|Louisiana Clinical Research, LLC, Shreveport, Louisiana, United States|Pharmasite Research Inc., Baltimore, Maryland, United States|Sheppard Pratt Health Systems, Inc., Baltimore, Maryland, United States|Clinical Insights, Glen Burnie, Maryland, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|Psychiatric Recovery, St. Paul, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|Washington University in St. Louis, St. Louis, Missouri, United States|Psych Care Consultants Research, St. Louis, Missouri, United States|Dent Neurologic Institute, Amherst, New York, United States|Suburban Psychiatric Associates, Amherst, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Columbia University, New York, New York, United States|SUNY UMU at Syracuse, Syracuse, New York, United States|Wake Forest University - Health Sciences, Winston Salem, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Century Health, Findlay, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute & Clinic (WPIC), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Claghorn-Lesem Reserach Clinic, Ltd., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|The Mech Center, Plano, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Alamo Superior Research, San Antonio, Texas, United States|Psychiatric & Behavioral Solutions, Salt Lake City, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Center for Anxiety and Depression, Mercer Island, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00320372"
728,"NCT04864353","Internet-delivered Intervention Targeting Residual Cognitive Symptoms After Major Depressive Disorder","RestDep","Recruiting","No Results Available","Cognitive Remediation|Cognitive Impairment|Major Depression in Remission","Behavioral: RestDep: Internet-delivered intervention targeting residual cognitive symptoms","Behaviour Rating Inventory Of Executive Function-Adult|Perceived Deficit Questionnaire 5|Rumination Response Scale|Montgomery Aasberg Depression Rating Scale|Patient Health Questionaire 9 and 2|The Satisfaction With Life Scale|The Credibility/Expectancy Questionnaire|Log-ins|Session length|Days in treatment","Haukeland University Hospital|University of Bergen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","204287","April 26, 2021","December 22, 2023","January 15, 2024","April 28, 2021",,"April 28, 2021","Haukeland University Hospital, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT04864353"
729,"NCT00825799","Serum Markers as a Bioassay for Unipolar Depression",,"Completed","No Results Available","Major Depression",,"Protein biomarker MDDScore.|Score on Hamilton Depression Rating Scale (HDRS).","Steward St. Elizabeth's Medical Center of Boston, Inc.|Ridge Diagnostics Inc.","All","18 Years to 60 Years   (Adult)",,"160","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","00435","November 2007","May 2011","May 2011","January 21, 2009",,"January 3, 2014","Steward St. Elizabeth's Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00825799"
730,"NCT00291239","Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression",,"Unknown status","No Results Available","Major Depression","Behavioral: partial sleep deprivation","cognition|cytokine concentration|clinical improvement","Zentrum für Integrative Psychiatrie|German Research Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WADE|DFG-SFB 654, C5 ""IL-6-MDE""","February 2006","December 2008","July 2009","February 13, 2006",,"April 3, 2009","Zentrum für Integrative Psychiatrie, Kiel, Germany",,"https://ClinicalTrials.gov/show/NCT00291239"
731,"NCT04972136","rTMS for Depression in Young Adults With Autism","rTMS-MDD","Recruiting","No Results Available","Autism Spectrum Disorder|Major Depressive Disorder","Device: Active Bilateral Theta Burst Stimulation|Device: Sham Bilateral Theta Burst Stimulation","Change in scores on the 17-item Hamilton Rating Scale for Depression (HRSD-17)|Change in scores on the Beck Scale for Suicide Ideation (BSI)","Centre for Addiction and Mental Health","All","16 Years to 29 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","141/2019","January 14, 2021","January 14, 2024","January 14, 2024","July 22, 2021",,"July 22, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04972136"
732,"NCT01198561","Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Device: repetitive Transcranial Magnetic Stimulation","Hamilton depression rating scale (HAM-D 17)","Samsung Medical Center","All","Child, Adult, Older Adult",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2005-08-072","February 2006","December 2016","December 2016","September 10, 2010",,"December 31, 2015","Samsung Medical Center, Seoul, Kangnam-Ku, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01198561"
733,"NCT00313417","Creatine as a New Therapeutic Strategy in Depression",,"Terminated","No Results Available","Major Depressive Disorder","Dietary Supplement: Creatine monohydrate|Other: Placebo","Hamilton Depression Rating Scale, CGI","Herzog Hospital|Beersheva Mental Health Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shapira1CTIL","January 2007","December 2010","December 2010","April 12, 2006",,"April 5, 2013","Beer Sheva Mental Health Center, Beer Sheva, Israel",,"https://ClinicalTrials.gov/show/NCT00313417"
734,"NCT03537547","Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder|Depression|Depressive Disorder|Depressive Episode|Depression, Unipolar","Other: GeneSight Psychotropic test|Drug: FDA-approved antidepressant or antipsychotic treatment","Hamilton Rating Scale for Depression change score- Week 8|Hamilton Rating Scale for Depression change score- Week 4|Hamilton Rating Scale for Depression change score- Week 12|Hamilton Rating Scale for Depression change score- Week 24","Washington University School of Medicine|AssureRx Health, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201609109","May 4, 2018","August 19, 2019","August 19, 2019","May 25, 2018",,"June 5, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03537547"
735,"NCT02669030","A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia",,"Unknown status","No Results Available","Depression|Major Depressive Disorder|MDD|Insomnia","Drug: suvorexant|Drug: Placebo","Total Sleep Time|Insomnia Severity Index (ISI)|Hamilton Depression Rating Scale|Sheehan Disability Scale|Wake After Sleep Onset (WASO)|Sleep Latency (SL)|Perceived Deficits Questionnaire (PDQ)","Institute for Advanced Medical Research, Alpharetta, GA|Augusta University, Dept. of Psychiatry","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SVX-IIT2016-001","March 1, 2017","December 2019","December 2019","January 29, 2016",,"February 27, 2019","Institute for Advanced Medical Research @ Mercer Univeristy, Atlanta, Georgia, United States|Medical College of GA at Augusta Univeristy, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02669030"
736,"NCT00067444","Depression Study In Elderly Patients",,"Completed","No Results Available","Depressive Disorder, Major|Major Depressive Disorder (MDD)","Drug: Paroxetine CR","Change from baseline to the week 10 last observation carried forward endpoint in the 17-item HAM-D total score.|Mean change from baseline in HAM-D item 1; Mean change from baseline in the CGI severity of illness score at study endpoint; Percentage of patients with HAM-D total score less than or equal to 7.","GlaxoSmithKline","All","60 Years and older   (Adult, Older Adult)","Phase 3","560","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","29060/874","June 2003","January 2005","January 2005","August 21, 2003",,"September 1, 2016","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, El Centro, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Redlands, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Norwich, Connecticut, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Leesburg, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Sebring, Florida, United States|GSK Investigational Site, St. Petersburg, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Boise, Idaho, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Prairie Village, Kansas, United States|GSK Investigational Site, Gaithersburg, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Braintree, Massachusetts, United States|GSK Investigational Site, Nashua, New Hampshire, United States|GSK Investigational Site, Clementon, New Jersey, United States|GSK Investigational Site, Princeton, New Jersey, United States|GSK Investigational Site, Mount Kisco, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Conshohocken, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, East Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00067444"
737,"NCT00209807","Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Major Depression|Pain|Abdominal Pain","Drug: escitalopram|Drug: Reboxetine|Other: No intervention","rectal distension Transcutaneous Electrical Neuro-Stimulation","Hospital Universitari Vall d'Hebron Research Institute","All","18 Years to 64 Years   (Adult)","Phase 4","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PFD-ESC","September 2005","June 2009","April 2011","September 21, 2005",,"May 27, 2010","Hospital Universitari vall d'Hebron, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT00209807"
738,"NCT01814085","A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Percentage of Participants With Remission Based on Montgomery-Asberg Depression Rating Scale (MADRS)|Percentage of Participants With Clinical Response Based on Montgomery-Asberg Depression Rating Scale (MADRS)|Percentage of Participants With Clinical Onset Based on Montgomery-Asberg Depression Rating Scale (MADRS)|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 1, 2, 4 and 8|Change From Baseline in Hamilton Depression Rating Scale (HAM-D-17) Score at Week 1, 2, 4 and 8|Change From Baseline in Hamilton Anxiety Scale (HAMA) Score at Week 1, 2, 4 and 8|Change From Baseline in Brain-Derived Neurotrophic Factor (BDNF) at Week 8|Change From Baseline in Short Form-12 (SF-12) Score at Week 8|Change from Baseline in Plasma Drug Concentration at Week 1 and 8|Number of Participants with Structural and Functional Changes in Magnetic Resonance Imaging (MRI) at Week 8","Xian-Janssen Pharmaceutical Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","225","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR016300|ESCITALDEP4001","February 2010","February 2012","March 2012","March 19, 2013",,"January 3, 2014","Beijing, China|Huzhou, China|Nanjing, China|Qingdao, China|Shanghai, China|Wuhan, China",,"https://ClinicalTrials.gov/show/NCT01814085"
739,"NCT00692445","TC-5214 as add-on the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder|Depression","Drug: TC-5214 + citalopram|Drug: Placebo + citalopram","Mean change between TC-5214 and placebo from DB baseline (Week 8) of the HAMD-17 score, at Week 16.|Number of Participants with Adverse Events","Targacept Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","574","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TC-5214-23-CRD-001","June 2008","May 2009","July 2009","June 6, 2008",,"June 21, 2013","Aurora Clinical Trials, Miami, Florida, United States|Community Research, Cincinnati, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Sravani Poly Clinic and Mental Health, Guntur, Andhra Pradesh, India|Asha Hospital, Hyderabaad, Andhra Pradesh, India|Brain Mind Behaviour Neuroscience Research Institute, Maharanipet, Andhra Pradesh, India|VIMHANS, Vijaywada, Andhra Pradesh, India|Government Hospital for Mental Care, Dept. of Psychiatry, Visakhapatnam, Andhra Pradesh, India|SV Medical College, Tirupati, Chittoor District, Andhra Pradesh, India|AIIMS, New Dehli, Dehli, India|GB pant Hospital, Indraprastha, Delhi, India|Bhora Nuro Psychiatric Centre, New Delhi, Delhi, India|Sri Kishna Prasad Psychiatric Nursing Home, Ahmedabad, Gujarat, India|Victoria Hospital, Dept. of Psychiatry, Bangalore, Karnataka, India|St. John's Hospital, Bangalore, Karnataka, India|Adhit Kiran Neuro Psychiatric Centre, Mangalore, Karnataka, India|JSS Medical College Hospital, Dept. of Psychiatry, Mysore, Karnataka, India|Bhopal Memorial Hospital & Research Centre, Dept. of Psychiatry, Bhopal, Madhya Pradesh, India|Holy Family Hospital, Mumbai, Maharashtra, India|Deenanath Maneshkas Hospital, Pune, Maharashtra, India|Sanjeevan Hospital, Pune, Maharashtra, India|Poona Hospital & Research Centre, Pune, Maharashtra, India|Gautam Hospital & Research Center, Jaipur, Rajasthan, India|Madras Medical College, Chennai, Tamilnadu, India|M.S. Chellamuthu Trust & Research Foundation, Madurai, Tamilnadu, India|Mahendru Psychiatric Centre, Kanpur, Uttar Pradesh, India|C.S.M. Medical University, Department of Psychiatry, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT00692445"
740,"NCT03749629","Comparative Effectiveness of Pharmacogenomics for Treatment of Depression","CEPIO-D","Recruiting","No Results Available","Major Depressive Disorder","Other: GeneSight Psychotropic test|Other: Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines","Well-being as assessed by the World Health Organization Well-Being Index (WHO-5)|Depression severity|Necessary medication adjustments|Functioning","Massachusetts General Hospital|Genetic Alliance|Patient-Centered Outcomes Research Institute|Vanderbilt University|Montefiore Medical Center|Louisiana State University Health Sciences Center in New Orleans|Duke University|University of North Carolina, Chapel Hill","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P002499","May 1, 2019","July 31, 2021","February 28, 2022","November 21, 2018",,"February 20, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03749629"
741,"NCT00824291","Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: desvenlafaxine succinate sustained release|Genetic: Genotyping","Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 12|Clinical Global Impression Scale - Improvement (CGI- I) Score at Week 12|Clinical Global Impressions Scale - Severity of Illness (CGI-S) at Week 12|Change From Baseline on Work and Activities Item of HAM-D17 at Week 12|Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS) at Week 12|Change From Baseline on Worry Anxiety Tension Scale (WATS) at Week 12|Change From Baseline on Stress and Social Support Scales at Week 12","Wyeth is now a wholly owned subsidiary of Pfizer","All","19 Years to 74 Years   (Adult, Older Adult)","Phase 3","437","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-4415|B2061006","February 2009","October 2009","November 2009","January 16, 2009","November 25, 2010","March 10, 2011",,,"https://ClinicalTrials.gov/show/NCT00824291"
742,"NCT04944758","Feasibility of Adherence to Light Therapy",,"Not yet recruiting","No Results Available","Major Depression in Remission","Device: Light therapy","Adherence|Relapse rate|Change in clinician-rated depressive symptoms|Change in patient-rated depressive symptoms|Discontinuation symptoms","University of British Columbia|Michael Smith Foundation for Health Research","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V2.0_May-17-2021","July 15, 2021","December 31, 2021","June 30, 2022","June 30, 2021",,"June 30, 2021","UBC Mood Disorders Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04944758"
743,"NCT03452384","Acupuncture in Depression: From the Clinical Trial, Biomarkers to Molecular Biology",,"Completed","No Results Available","Major Depressive Disorder","Other: Acupuncture","The Change from Baseline Hamilton depression rating scale at 12 weeks|The Change from Baseline Pittsburgh sleep Quality Inventory rating scale at 12 weeks","National Science Council, Taiwan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMUH103-REC2-074","November 6, 2014","October 31, 2016","October 31, 2016","March 2, 2018",,"March 5, 2018","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03452384"
744,"NCT02874131","Behavioral Activation + Cognitive Processing Therapy for PTSD and Comorbid MDD",,"Recruiting","No Results Available","Posttraumatic Stress Disorder|Major Depressive Disorder","Behavioral: Behavioral Activation|Behavioral: Cognitive Processing Therapy","Montgomery-Asberg Depression Rating Scale (MADRS)|Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5)|Patient Health Questionnaire (PHQ-9)","United States Naval Medical Center, San Diego|Naval Health Research Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NMCSD.2015.0039","April 1, 2015","June 2021","September 2021","August 22, 2016",,"September 17, 2020","Naval Medical Center San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02874131"
745,"NCT00519428","Does Dual Therapy Hasten Antidepressant Response?",,"Completed","Has Results","Major Depressive Disorder","Drug: escitalopram|Drug: bupropion extra long (XL)|Drug: escitalopram + bupropion","Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7|Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) <= 7, With no HAM-D 17 >7 Through Week 12|Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)|Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score|Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)","New York State Psychiatric Institute|University of Ottawa|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","245","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","5476|5R01MH076961-04","August 2007","July 2011","March 2012","August 22, 2007","October 4, 2017","October 4, 2017","New York State Psychiatric Institute, New York, New York, United States|University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00519428"
746,"NCT01217645","Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration","AZD6765","Completed","No Results Available","Major Depressive Disorder","Radiation: 150 mg [14C] AZD6765","The change in distribution, metabolism, and elimination of AZD6765 and total radioactivity after single-dose (150 mg) intravenous administration of [14C]-labelled AZD6765|The change in excretion of 14C (mass balance) in urine and faeces after a single intravenous dose of 150 mg [14C] AZD6765|To identify and profile the metabolites in selected samples of urine, faeces and plasma following a single intravenous dose of 150 mg [14C] AZD6765|Safety and tolerability after a single IV administration of [14C] AZD6765 by assessing a panel of measures: adverse events, blood pressure and pulse, blood samples, urinalysis, hematology, clinical chem, physical exam, ECG and symptoms of suicidality.","AstraZeneca","Male","18 Years to 60 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D6702C00030","September 2010","October 2010","October 2010","October 8, 2010",,"October 13, 2014","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01217645"
747,"NCT03932825","Nitrous Oxide for Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder|Major Depressive Disorder|Treatment Resistant Depression|Depressive Disorder, Major|Depression","Drug: Nitrous Oxide|Drug: Placebo","Change in Hamilton Depression Rating Scale-17 item (HDRS-17)|Change in QIDS-16-SR (Quick Inventory of Depressive Symptomatology-16 Self Report)|Change in Visual Analog Scale-Depression (VAS-D)|Chang in Event Related Potentials (ERPs)|Change in voxel-based morphometry of grey matter, white matter as assessed by structural magnetic resonancce imaging.|Change in Functional connectivity|Change in peripheral blood cytokines|Change in feces bacterial flora|Change in the TMT/A and B (Executive Function)|Change in Congruent STROOP Time to Complete (Executive Function)|Digit-Span Test|Change in DSST (Number of Correct Symbols)|Improvement on Snaith-Hamilton Pleasure Scale (SHAPS)|Change in Hamilton Anxiety Rating Scale (HAM-A)","Lingjiang Li|Central South University","All","18 Years to 60 Years   (Adult)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18-05-04-XY-0001","April 1, 2019","March 31, 2021","March 31, 2021","May 1, 2019",,"April 8, 2021","Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03932825"
748,"NCT04295941","Long-term Study With Trazodone Once-a-Day",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: TraZODone Hydrochloride 300 MG","Clinical Global Impression-improvement scale responders percentage|Sheehan Disability Scale score|EQ-5D-5L Quality of life scale","Aziende Chimiche Riunite Angelini Francesco S.p.A","All","18 Years and older   (Adult, Older Adult)",,"233","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","039(C)WO19201","June 23, 2020","September 30, 2021","September 30, 2021","March 5, 2020",,"July 27, 2020","Medical Center Hera EOOD - Clinic/Outpatient Facility, Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT04295941"
749,"NCT01027559","fMRI Study of Treatment Changes in Major Depression",,"Completed","Has Results","Major Depression|Treatment","Drug: Sertraline|Behavioral: Cognitive Behavioral Therapy","Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.|Hamilton Depression Rating Scale Score at Baseline and 12 Weeks","Washington University School of Medicine|National Institute of Mental Health (NIMH)","All","18 Years to 50 Years   (Adult)","Not Applicable","97","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","081348|R01MH064821|2R01MH064821-05A2|DDTR A3-NSI","February 2009","January 2014","January 2014","December 8, 2009","June 13, 2018","July 17, 2018","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01027559"
750,"NCT04986124","Quality of Life in Chinese Working and School Age Population With MDD",,"Recruiting","No Results Available","Major Depressive Disorder|Remission","Other: treatment as usual","The Sheehan disability scale (SDS)|Quality of Life, short form 6 (QOL-6)|The Psychosocial Function Questionnaire in Patients with Depression (PFQ)|The Lam Employment Absence and Productivity Scale (LEAPS)|The Hamilton Depression Scale-17 items (HAMD)|Patient Health Questionnaire-9 (PHQ-9)|The Hamilton Anxiety Scale (HAMA)|Pittsburgh Sleep Quality Index (PSQI)|The Snaith-Hamilton Pleasure Scale (SHAPS)|THINC-it toolkit","Shanghai Mental Health Center|Beijing HuiLongGuan Hospital|Huaxi Hospital|Second Xiangya Hospital, Central South University|Nanjing Brain Hospital, Nanjing Medical University|Guangzhou Psychiatric Hospital|The First Affiliated Hospital of Medical College, Xi'an Jiaotong University","All","16 Years to 50 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2020-76","April 1, 2021","August 30, 2021","August 30, 2021","August 2, 2021",,"August 2, 2021","Shanghai Mental Health Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04986124"
751,"NCT02026622","Comparative Study of Physiological and Cerebrovascular Reactivity in Depression, at the Three Phases of Emotion","EMPHILINE","Completed","No Results Available","Major Depressive Disorder","Behavioral: psychometric tests|Device: MRI|Device: transcranial doppler and TPI|Behavioral: explicitative interview","amplitude variations of heart and respiratory rate, cerebral pulsatility, galvanic skin response and startle as measure of physiological reactivity|MRI data as measure of cerebral perfusion, volume of leukoaraiosis and default network (fMRI at rest)|ultrasound data of doppler as measure of cerebral pulstility|score of psychometric tests as measure of emotional state|spontaneous verbal production to emotional pictures and explicitative interviews","University Hospital, Tours","Female","18 Years to 55 Years   (Adult)","Not Applicable","76","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PHAO 2012 - TD / EMPHILINE","February 2013","May 2015","August 2015","January 3, 2014",,"September 1, 2015","University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02026622"
752,"NCT01109030","Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: Pioglitazone+Citalopram+Chlordiazepoxide|Drug: Placebo+ Citalopram+ Chlordiazepoxide","Scores of Hamilton Depression Rating Scale (17 items) at the end|Number of Adverse events in each group|Scores of Hamilton Depression Rating Scale (17 items)","Tehran University of Medical Sciences","All","18 Years to 50 Years   (Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","94976","April 2010","October 2011","October 2011","April 22, 2010",,"May 9, 2012","Department of psychiatry, Roozbeh psychiatric hospital, Tehran University of medical sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01109030"
753,"NCT00232700","Investigation of a Combination Treatment of Escitalopram and rTMS",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Evaluation of efficacy and response speed of an Escitalopram-rTMS-combination in the acute treatment of Major Depression.|To determine the changes of hippocampal metabolites measured by MRS|To assess the changes of parameters of motor cortical inhibition measured by MEP|To assess the changes of NGF and BDNF|To determine the changes of event related potentials measured by electroencephalography","Charite University, Berlin, Germany|H. Lundbeck A/S","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20050041","September 2005","December 2008","December 2008","October 5, 2005",,"June 23, 2011","Department of Psychiatry, Charité - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00232700"
754,"NCT02209597","Clinical Study of Generic and Brand Bupropion in Depression","BALANCE","Completed","Has Results","Major Depressive Disorder","Drug: Bupropion XL 300","Area Under the Curve (AUC0-24) Ratio for Racemic Bupropion","Washington University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","201312021","June 25, 2014","August 14, 2016","August 14, 2016","August 6, 2014","April 24, 2020","April 24, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02209597/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02209597"
755,"NCT00143091","Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: CP-316,311|Drug: Placebo|Drug: Sertraline","Change from baseline in HAM-D (17) at the week 6 visit|Change from baseline in MADRS, HAM-A, CGI-S and CGI-I at the week 6 visit.","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A2211002","April 2005",,"April 2006","September 2, 2005",,"March 24, 2008","Pfizer Investigational Site, Bellevue, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Belgrade, Serbia, Former Serbia and Montenegro|Pfizer Investigational Site, Kragujevac, Serbia, Former Serbia and Montenegro|Pfizer Investigational Site, Novi Sad, Serbia, Former Serbia and Montenegro|Pfizer Investigational Site, Belgrade, Former Serbia and Montenegro|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Rostov On Don, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St.-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00143091"
756,"NCT01496248","Efficacy Study of Korean Red Ginseng to Treat Depression",,"Completed","Has Results","Major Depressive Disorder","Dietary Supplement: Korean Red Ginseng","Depression Residual Symptom Scale|Visual Analogue Scale|Montgomery Asberg Depression Rating Scale|Clinical Global Index","Korea University|The Korean Society of Ginseng","Female","18 Years to 55 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1105721","August 2011","July 2012","December 2012","December 21, 2011","October 10, 2014","October 10, 2014","Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01496248"
757,"NCT03378570","rTMS for MDD: 5.5cm Rule vs. F3 Targeting",,"Recruiting","No Results Available","Major Depressive Disorder|Depression","Device: Repetitive transcranial magnetic stimulation","Percentage change in MADRS score|Response and remission rates on MADRS|Personality measures|Clinical Global Impression Scale|PHQ9 changes|Montreal Cognitive Assessment (MOCA) score changes|Cognitive measures|Emotion measures|Functional MRI changes|Structural MRI changes|Neurobehavioral battery changes","Nicholas Trapp|University of Iowa","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201709834","May 1, 2018","October 2021","October 2021","December 20, 2017",,"November 20, 2020","University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03378570"
758,"NCT04294654","Vortioxetine in Patients With Depression and Early Dementia","MEMORY","Recruiting","No Results Available","Major Depressive Disorder|Dementia","Drug: Vortioxetine","Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score|Change in Digit-Symbol Substitution Test (DSST) Substitution Test (DSST) score|Change in Rey Auditory Verbal Learning Test (RAVLT) score|Change in Instrumental Activities of Daily Living (IADL) score|Change in Clinical Global Impression - Severity (CGI-S) score|Clinical Global Impression - Improvement (CGI-I) score|Response defined by decrease in MADRS total score|Remission defined by MADRS score|Change in Bath Assessment of Subjective Quality of Life in Dementia (BASQID) score","H. Lundbeck A/S|ICON plc","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18315A","February 29, 2020","March 5, 2022","April 2, 2022","March 4, 2020",,"June 16, 2021","Marienthali Kliinik (EE0001), Tallinn, Estonia|Centre Hospitalier Esquirol (FR0005), Limoges, France|Cabinet du Docteur Karim Boutayeb (FR0001), Viersat, France|Hospices Civils de Lyon-Hopital des Charpennes (FR0006), Villeurbanne, France|Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia (IT0001), Brescia, Province Of Brescia, Italy|Azienda Ospedaliera di Perugia - Policlinico Monteluce (IT0003), Perugia, Umbria, Italy|Fondazione Universitaria G.D'Annunzio Ce.S.I. Centro Ricerca (Centro Scienze del l'Invecchiamento) Centro di Ricerca Clinica (IT0009), Chieti, Italy|Fondazione Santa Lucia IRCCS (IT0002), Rome, Italy|Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k. (PL0007), Poznań, Wielkopolskie, Poland|MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk (PL0009), Bialystok, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o. (PL0003), Bydgoszcz, Poland|CareClinic (PL0005), Katowice, Poland|Centrum Zdrowia Psychicznego Biomed (PL0001), Kielce, Poland|Niepubliczny Zaklad Opieki Psychiatrycznej Mentis (PL0004), Leszno, Poland|Centrum Medyczne Luxmed Sp.Z O.O. (PL0006), Lublin, Poland|Nzoz Syntonia (PL0010), Pruszcz Gdanski, Poland|Hospital Clinic de Barcelona (ES0003), Barcelona, Spain|University Clinical Hospital of Valladolid (ES0004), Valladolid, Spain|Hospital Rio Hortega (ES0005), Valladolid, Spain|Centro de Saude de Lavadores (ES0006), Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT04294654"
759,"NCT02752542","Personalized Indications for CBT and Antidepressants in Treating Depression","CANBIND6","Unknown status","No Results Available","Major Depressive Disorder|Persistent Depressive Disorder","Behavioral: Cognitive Behavioral Therapy|Drug: Pharmacotherapy","Total score on the Montgomery Asberg Depression Rating Scale (MADRS)|Global-Clinical Impression scale (GCI)|Quick Inventory of Depressive Symptoms (QIDS-SR)","Nova Scotia Health Authority|University Health Network, Toronto|Queen's University|Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Phase 4","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1021193","October 31, 2016","May 2020","May 2021","April 27, 2016",,"July 23, 2019","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT02752542"
760,"NCT02709161","Effects of Amygdala Neurofeedback on Depressive Symptoms",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: real-time fMRI neurofeedback: Amygdala|Behavioral: real-time fMRI neurofeedback: HIPS","Beck Depression Inventory (BDI-II)|PROMIS Item Bank v1.0 - Depression","University of Pittsburgh","All","18 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO16010381","October 2016","April 1, 2020","April 1, 2020","March 15, 2016",,"February 3, 2021","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02709161"
761,"NCT02999269","ECT Pulse Amplitude and Medial Temporal Lobe Engagement",,"Completed","No Results Available","Major Depressive Disorder","Device: MECTA Spectrum 5000Q Amplitude","Efficacy assessed with the Hamilton Depression Rating Scale - 24 item|Cognition assessed with the Hopkins Verbal Learning Trial-Revised (percent retention score)|Structural magnetic resonance imaging (MRI): Medial temporal lobe volumes|Resting state functional MRI","University of New Mexico|The Mind Research Network|University of Texas|National Institute of Mental Health (NIMH)","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 4","62","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R01MH111826|1R01MH111826-01","October 2016","March 23, 2020","March 23, 2020","December 21, 2016",,"March 25, 2020","Chris Abbott, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT02999269"
762,"NCT01627782","A Study of Ketamine in Patients With Treatment-resistant Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Placebo|Drug: Ketamine","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15|Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 29|Number of Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Number of Remitters Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Number of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change in Clinical Global Impression-Severity (CGI-S) Score From Baseline to Endpoint (Day 29)|Clinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase|Change in Patient Global Impression-Severity (PGI-S) Score From Baseline to Endpoint (Day 29)|Patient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase|Maximum Observed Plasma Concentration (Cmax) of Ketamine|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ketamine|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC[0-last])|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])|Total Systemic Clearance (CL) of Ketamine|Volume of Distribution at Steady-State (Vss) of Ketamine|Elimination Half-Life (t1/2)","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR100886|KETIVTRD2002","August 6, 2012","September 12, 2013","September 12, 2013","June 26, 2012","August 5, 2016","June 2, 2020","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Centennial, Colorado, United States|Hartford, Connecticut, United States|New Haven, Connecticut, United States|Atlanta, Georgia, United States|Rockville, Maryland, United States|Marlton, New Jersey, United States|New York, New York, United States|Allentown, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01627782"
763,"NCT01101373","Treatment of Severe Depressive Illness by Targeted Brain Surgery",,"Completed","No Results Available","Major Depressive Disorder",,,"University of British Columbia","All","18 Years to 75 Years   (Adult, Older Adult)",,,"Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","H10-00851","October 2000","November 2009","April 2010","April 9, 2010",,"November 19, 2019","UBC Hospital, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01101373"
764,"NCT00986479","This is a Study to Determine the Antidepressant Effects of AZD6765",,"Completed","Has Results","Treatment Resistant Major Depressive Disorder","Drug: AZD6765|Drug: Placebo to AZD6765","Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.|The Number of Participants With Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than 10 (MADRS Remission).|The Number of Participants With at Least 50% Reduction in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (MADRS Response).|Scale for Suicide Ideation (SSI) Total Score.|Hamilton Anxiety Rating Scale (HAM-A) Total Score.|Hamilton Depression Rating Scale-17 Item (HDRS) Total Score|Visual Analogue Scale (VAS) Depressed Score|Clinician-Administered Dissociative States Scale (CADSS) Score.|Brief Psychiatric Rating Scale (BPRS) Score.|Beck Depression Inventory (BDI) Score.|Young Mania Rating Scale (YMRS) Score.|Visual Analogue Scale (VAS) Anxious Score.|Brief Psychiatric Rating Scale (BPRS) Positive Score.","AstraZeneca|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","22","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D6702C00015","December 2009","December 2011","December 2011","September 30, 2009","October 21, 2014","October 21, 2014","Research Site, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00986479"
765,"NCT01082237","Biomarkers for Outcomes In Late-life Depression (BOLD)","BOLD","Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram","Score on Hamilton Depression Rating Scale (HAM-D)|Score on Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30)","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","62 Years and older   (Adult, Older Adult)","Phase 4","80","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1RC1MH088438","October 2009","October 2012","October 2012","March 8, 2010",,"April 16, 2013","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01082237"
766,"NCT02479464","Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting","HAMM","Completed","No Results Available","Major Depressive Disorder","Genetic: Genotyping results","Percentage of patients approached who consent to use of pharmacogenomic algorithm|Amount of time from ordering test to receipt of results|Proportion of time that the physician prescribed a medication that was recommended by the algorithm|Time to remission of depressive symptoms|Measured side effect burden|Number of participants who change their initial medication regimen|Health care clinical cost|Physician satisfaction with delivery of clinical care|Patient satisfaction with clinical care","Mayo Clinic|AssureRx Health, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","09-002523","October 2009","September 2010","August 2014","June 24, 2015",,"May 21, 2019",,,"https://ClinicalTrials.gov/show/NCT02479464"
767,"NCT02843373","Brain-Based Biomarkers in Response to TMS in MDD",,"Recruiting","No Results Available","Major Depressive Disorder|Depression","Device: TMS","TMS-EEG","Stanford University","All","18 Years to 60 Years   (Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-25948","July 2016","July 2022","December 2022","July 25, 2016",,"February 28, 2020","Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02843373"
768,"NCT04061148","Near Infrared Spectroscopy (NIRS) for Assessment of Depression","NIRSIT","Recruiting","No Results Available","Major Depressive Disorder","Device: NIRSIT","Change in Frontal Oxyhemoglobin concentration before initiation of treatment for MDD|Change in Frontal Oxyhemoglobin concentration 3 weeks after initiation of treatment for MDD|Change in Frontal Oxyhemoglobin concentration 6 weeks after initiation of treatment for MDD|Change in Frontal Deoxyhemoglobin concentration before initiation of treatment for MDD|Change in Frontal Deoxyhemoglobin concentration 3 weeks after initiation of treatment for MDD|Change in Frontal Deoxyhemoglobin concentration 6 weeks after initiation of treatment for MDD|Hamilton Depression Rating Scale (HAM-D) Score|Beck's Depression Inventory - II (BDI-II) Scores|Patient Health Questionnaire-9 (PHQ-9) Scores","University of California, San Francisco|Obelab Inc.|San Francisco Veterans Affairs Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-22188","January 4, 2019","December 30, 2021","June 30, 2022","August 19, 2019",,"August 12, 2020","San Francisco Veterans Affairs Medical Center, San Francisco, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04061148/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT04061148"
769,"NCT03062332","The Gut Microbiota of Bipolar and Depression",,"Recruiting","No Results Available","Bipolar Disorder|Major Depressive Disorder","Genetic: Faecal genome","Composition of the gut microbiota|metabolon","First Affiliated Hospital Xi'an Jiaotong University","All","up to 65 Years   (Child, Adult, Older Adult)",,"240","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TGMOBAD2017","January 16, 2020","November 2022","November 2022","February 23, 2017",,"July 23, 2020","Xiancang Ma, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03062332"
770,"NCT02593643","Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.",,"Completed","No Results Available","Major Depressive Disorder|Bipolar I Disorder|Bipolar II Disorder|Bipolar Depression|Suicidal Ideation","Drug: Ketamine|Drug: Midazolam|Other: Treatment as usual (TAU)","Montgomery-Aspberg Depression Rating Scale (MADRS)|Clinical Global Impression of Severity/Improvement (CGI-S, CGI-I)|Scale of Suicidal Ideation (SSI)|Columbia-Suicide Severity Rating Scale (CSSRS)","Sunnybrook Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","361-2013","January 2016","April 2017","April 2017","November 1, 2015",,"July 26, 2017","Sunnybook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02593643"
771,"NCT00051272","Effects Of Antidepressants On Sexual Functioning In Adults",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: Extended-release Bupropion Hydrochloride","Percent of subjects with orgasm dysfunction. Change from baseline in HAMD-17 total score.|Percent of subjects in remission, HAMD-17. Changes in Sexual functioning Questionnaire. CGI-I and CGI-S. Percent of responders, HAMD-17.","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","425","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AK130927","January 2003","June 2004","June 2004","January 8, 2003",,"March 29, 2011","GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Berkeley, California, United States|GSK Investigational Site, Middletown, Connecticut, United States|GSK Investigational Site, Wilmington, Delaware, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Smyrna, Georgia, United States|GSK Investigational Site, Boise, Idaho, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Braintree, Massachusetts, United States|GSK Investigational Site, Piscataway, New Jersey, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Bellaire, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00051272"
772,"NCT00531895","An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache",,"Completed","No Results Available","Major Depression|Chronic Primary Headache","Drug: duloxetine","Montgomery-Äsberg Depression Scale (MADRS)|Visual Analog Scale for pain (VAS)|WHO Quality of Life Scale (WHOQOL BREF)","Kraepelin Psiquiatria Clinica|Eli Lilly and Company","All","18 Years to 55 Years   (Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","O021","April 2006",,"March 2007","September 19, 2007",,"September 19, 2007","Hospital SOCOR, Belo Horizonte, MG, Brazil",,"https://ClinicalTrials.gov/show/NCT00531895"
773,"NCT03053362","THINC-it Vortioxetine - Sensitivity to Change",,"Completed","No Results Available","Major Depressive Disorder|Cognitive Change","Drug: Vortioxetine|Other: THINC-it Tool","Cognition measured using the THINC-it tool|Early changes in mood as measured by the Montgomery Åsberg Depression Rating Scale|Early changes in cognition using Sheehan Disability Scale|Early changes in cognition using Endicott Work Productivity Scale|Early changes in cognition using the 5-Item World Health Organization Wellbeing Index","Brain and Cognition Discovery Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00020418","May 24, 2017","August 8, 2018","August 8, 2018","February 15, 2017",,"January 22, 2019","Toronto Sleep Clinic, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03053362"
774,"NCT00759122","Electroencephalography (EEG) Biomarkers of Response in Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: venlafaxine (Effexor)|Drug: placebo",,"University of California, Los Angeles|Medtronic - MITG|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","44","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Biomarkers in MDD","November 2002","November 2005","December 2005","September 25, 2008",,"September 25, 2008","UCLA Laboratory of Brain, Behavior, and Pharmacology, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00759122"
775,"NCT04701840","Accelerated TBS for Adolescent Suicidal Ideation",,"Not yet recruiting","No Results Available","Suicidal Ideation|Major Depressive Disorder","Device: MagVenture TMS Therapy System w/Theta Burst Stimulation|Device: Sham MagVenture TMS Therapy System w/Theta Burst Stimulation","Change in Suicidal Ideation|Change in Number of Hospitalizations|Change in Number of Emergency Department Visits","Paul E. Croarkin|National Institute of Mental Health (NIMH)|Mayo Clinic","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-009630|R01MH124655-01","August 1, 2021","April 1, 2026","April 1, 2027","January 8, 2021",,"May 3, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04701840"
776,"NCT00051259","Effects of Antidepressants on Sexual Functioning",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Drug: Extended-Release Bupropion Hydrochloride","Percentage of subjects with orgasm dysfunction. Change in HAMD-17 total score.|Percent of subjects in remission, HAMD-17. Changes in Sexual Functioning Questionnaire. Percent of responders, HAMD-17 CGI-I and CGI-S.","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AK130926","January 2003","June 2004","June 2004","January 8, 2003",,"October 4, 2010","GSK Investigational Site, Berkeley, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Oceanside, California, United States|GSK Investigational Site, Coral Springs, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Terre Haute, Indiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Lincoln, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Bellaire, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00051259"
777,"NCT01754493","Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression","IBS-MDD","Completed","Has Results","Major Depression|Irritable Bowel Syndrome","Drug: Duloxetine","Montgomery-Asberg Depression Rating Scale (MADRS)|Gastrointestinal Symptoms Rating Scale (GSRS)|Clinician-Rated Global Impression Scales (CGI)|Visual Analogue Scales (VAS)|Somatization Module of the Patient's Health Questionnaire (PHQ-15)","New York State Psychiatric Institute|Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","17","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#6479R|F1J-US-X037","December 2008","December 2014","December 2014","December 21, 2012","November 25, 2016","May 19, 2021","New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01754493"
778,"NCT01515215","Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Device: Repetitive Transcranial Magnetic Stimulation","Degree of Change in HAM-D17 Scores|Degree of Change in Montgomery-Asberg Depression Rating Scale Scores|Degree of Change in Beck Depression Inventory Scores|Degree of Change in Brief Psychiatric Ratings Scale Scores|Changes in Cortical Excitability","Centre for Addiction and Mental Health|Ontario Mental Health Foundation","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","107","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","040 / 2008","July 2008","October 2016","October 2016","January 24, 2012",,"November 1, 2016","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01515215"
779,"NCT04032301","Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans",,"Recruiting","No Results Available","Post-Traumatic Stress Disorders|Major Depressive Disorder","Drug: Ketamine|Other: Normal Saline","Montgomery-Asberg Depression Rating Scale (MADRS)|PTSD Symptom Scale-Interview for DSM-5 (PSS-I-5)","University of Minnesota|Minneapolis Veterans Affairs Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","108","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","PSYCH-2019-28086","September 30, 2019","September 1, 2024","September 1, 2024","July 25, 2019",,"May 10, 2021","Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04032301"
780,"NCT00742573","Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics",,"Completed","Has Results","Major Depressive Disorder","Drug: Antidepressants through Texas Medication Algorithm (TMA)|Behavioral: Brief Interpersonal Psychotherapy (IPT-B)","Mean Time of Retention|Hamilton Depression Scale (HAMD-17)","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","170","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","#5692|R01MH076051|DSIR 83-ATSO","August 2008","January 10, 2014","January 10, 2014","August 27, 2008","March 3, 2020","March 3, 2020","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00742573"
781,"NCT01360307","Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale","CUDOS","Completed","No Results Available","Unipolar Depression",,"Clinically Useful Depression Outcome Scale|Hamilton Depression Rating Scale|SF 36|Patient Global Impression Scale|Social Occupational Functioning Scale|Clinically Global Impression Scale","AstraZeneca","All","18 Years and older   (Adult, Older Adult)",,"330","Industry","Observational","Time Perspective: Cross-Sectional","NIS-NES-XXX-2011/1","June 2011","November 2011","November 2011","May 25, 2011",,"December 6, 2011","Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Cadiz, Spain|Research Site, Cordoba, Spain|Research Site, El Vendrell, Spain|Research Site, Granada, Spain|Research Site, Huelva, Spain|Research Site, Lugo, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Malaga, Spain|Research Site, Nigran, Spain|Research Site, Palma Mallorca, Spain|Research Site, Salamanca, Spain|Research Site, Terrasa, Spain|Research Site, Tudela, Spain|Research Site, Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT01360307"
782,"NCT04721678","Internet-administered Interpersonal Psychotherapy for Depressive Symptoms",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Behavioral: Interpersonal psychotherapy","Change on Montgomery Åsberg Depression Rating Scale (MADRS-S)|Change on Beck Depression Inventory-II (BDI-II)|Change on Brunnsviken Brief Quality of Life Inventory (BBQ)|Change on Generalized Anxiety Disorder 7-Item Scale (GAD-7)|Change on Reflective Functioning Questionnaire-8 item version (RFQ-8)","Linkoeping University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","113","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INDIGO","January 22, 2021","February 15, 2022","February 15, 2022","January 25, 2021",,"February 11, 2021","Department of Behavioral Sciences and Learning, Linköping University, Linköping, Östergötland, Sweden",,"https://ClinicalTrials.gov/show/NCT04721678"
783,"NCT02983838","Research on Pathophysiology and Treatment in Depression Using Brain Derived Neurotrophic Factor and Amyloid Neuroimaging",,"Unknown status","No Results Available","Major Depressive Disorder",,"The change of Psychiatric symptom profile scores|The change of subjective Cognitive decline assessment profiles","Samsung Medical Center|Sungkyunkwan University|Korea University","All","65 Years and older   (Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2015-12-009","April 2016","December 2017","December 2017","December 6, 2016",,"December 6, 2016","Samsung Medical Center, Seoul, Irwon-dong, Gangnam-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02983838"
784,"NCT00998959","Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Mindfulness Based Stress Reduction and Psychoeducation|Behavioral: Psychoeducation","Feasibility (rate of enrollment, attrition)|Perceived stress","Trina E. Chang, MD|Dupont-Warren|Massachusetts General Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008p001576","August 2008","January 2012","January 2012","October 21, 2009",,"April 30, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00998959"
785,"NCT02624102","Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Trial based cognitive therapy|Behavioral: Behavioral Activation|Drug: Antidepressants","Severity of Depression|Quality of Life|Cognitive Distortions|Disability|Severity of Depression (BDI)|Severity of Depression (HRSD)","Hemanny, Curt, M.D.|Federal University of Bahia","All","18 Years to 60 Years   (Adult)","Phase 3","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CAAE 44663315.4.0000.5662","September 2015","December 2016","December 2017","December 8, 2015",,"December 17, 2015","Curt Hemanny, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT02624102"
786,"NCT00977353","N-methylglycine (Sarcosine) Treatment for Depression",,"Completed","No Results Available","Major Depressive Disorder|Depression|Major Depression","Drug: citalopram|Drug: sarcosine","17-item Hamilton Depression Rating Scale|Remission rate|GAF(Global Assessment of Function)|dropout rate|CGI(clinical global impression)|Response Rate|Factors of 17-item Hamilton Depression Rating Scale","China Medical University Hospital|National Science Council, Taiwan","All","18 Years to 55 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DOH95-TD-B-111-TM002","April 2009","July 2011","July 2011","September 15, 2009",,"July 12, 2011","Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT00977353"
787,"NCT01718730","Cortical Excitability and Inhibition in MDD",,"Completed","No Results Available","Major Depressive Disorder, Recurrent, Mild|Depressive Disorder, Major","Device: Transcranial Magnetic Stimulation (TMS)|Device: Magnetic Resonance Spectroscopy and Imaging","Cortical Excitability and Inhibition at Motor Cortex|Glutamate Concentrations in the Motor Cortex and Anterior Cingulate Cortex","Mayo Clinic|Neuronetics","All","13 Years to 21 Years   (Child, Adult)",,"23","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","12-000335","October 2012","August 2019","August 2019","October 31, 2012",,"October 22, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01718730"
788,"NCT04621708","Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS",,"Recruiting","No Results Available","Multiple Sclerosis|Major Depressive Disorder","Device: Repetitive transcranial magnetic stimulation","Change in depressive symptoms|Change in anxiety and depressive symptoms|Change in fatigue, severity and impact|Change in Neuropsychological function","Sunnybrook Health Sciences Centre","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1563","April 30, 2020","April 30, 2021","April 30, 2021","November 9, 2020",,"November 9, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04621708"
789,"NCT01051466","A Study of the Neurobiology of Depression",,"Completed","Has Results","Major Depressive Disorder|Healthy Participants","Drug: Duloxetine","Change From Baseline to 12-Week Endpoint in the Functional Magnetic Resonance Imaging (fMRI) Mean Blood Oxygenation-Level-Dependent (BOLD) Response in the Amygdalae|Change From Baseline to 12-Week Endpoint in Activation [Blood Oxygenation-Level-Dependent (BOLD) Response to Implicit Processing of Sad Faces] for Each of the 3 Brain Regions|Change From Baseline to 12-Week Endpoint in Volume of Subgenual Anterior Cingulate, Amygdalae, and Hippocampus|Translocation of Gs Alpha (Gsα) From Lipid Rafts in the Cell Membranes of Red Blood Cells (RBCs), White Blood Cells (WBCs) and Platelets Compared With Baseline|Gs Alpha (Gsα)-Activated Adenylyl Cyclase|Change From Baseline to 12-Week Endpoint in Brain-Derived Neurotrophic Factor (BDNF) and the Precursor of BDNF (proBDNF)|Change From Baseline to 12-Week Endpoint in Brain-Derived Neurotrophic Factor (BDNF) and the Precursor of BDNF (proBDNF) Receptors|Change From Baseline to 12-Week Endpoint in Proinflammatory Cytokines [Tumor Necrosis Factor Alpha (TNFα), Interleukin 1 (IL-1), and Interleukin 6 (IL-6)]|17-Item Hamilton Depression Rating Scale (HAMD17)|Percentage of Participants With 17-Item Hamilton Depression Rating Scale (HAMD17) Response|Percentage of Participants With 17-Item Hamilton Depression Rating Scale (HAMD17) Remission|Sheehan Disability Scale (SDS)|Clinical Global Impressions of Severity Scale (CGI-S)|Patient's Global Impressions of Improvement (PGI-I) Scale|Hamilton Anxiety Rating Scale (HAMA)|Incidence of Suicidal Behavior and Suicidal Ideation as Measured by the Columbia Suicide Severity Rating Scale (C-SSRS)","Eli Lilly and Company","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12875|F1J-US-HMGO","January 2010","March 2013","March 2013","January 18, 2010","April 2, 2014","October 10, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01051466"
790,"NCT01574742","Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression",,"Unknown status","No Results Available","Unipolar Depression","Drug: Minocycline","Depression symptoms|Depression symptoms - CGI|depression symptoms - (QIDS-SR)|depression symptoms - HDRS-21|Safety","Shalvata Mental Health Center","All","18 Years to 68 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0007-12-SHA","June 2012","June 2014","June 2014","April 10, 2012",,"July 4, 2012","Shalvata Medical Health Center, Hod-HaSharon, Israel",,"https://ClinicalTrials.gov/show/NCT01574742"
791,"NCT01492309","Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation","TMS","Completed","Has Results","Major Depressive Disorder","Device: Active Transcranial Magnetic Simulation|Device: Sham Transcranial Magnetic Stimulation","Change in Hamilton Rating Scale for Depression (HDRS-17) Scores Pre- and Post- Treatment|Change in Brain Derived Neurotrophic Factor (BDNF) With Active Transcranial Magnetic Simulation (TMS)","University of Pennsylvania|National Institute of Mental Health (NIMH)","Female","18 Years to 39 Years   (Adult)","Not Applicable","22","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","812494|K23MH092399","November 2011","July 2016","January 2017","December 14, 2011","April 10, 2018","April 10, 2018","Penn Center for Women's Behavioral Wellness, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01492309"
792,"NCT03628027","The Antidepressant Advisor Study","ADeSS","Recruiting","No Results Available","Major Depressive Disorder","Device: Computerised decision support algorithm","Self-Rated Quick Inventory of Depressive Symptomatology (QIDS-SR16)|Montgomery Asberg Depression Rating Scale (MADRS)|Clinical Global Impression|Generalised Anxiety Disorder (GAD-7)|Body Mass Index (BMI)","King's College London|NHS Lambeth Clinical Commissioning Group|EMIS PLC|D'Or Institute for Research and Education","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","PB-PG-0416-20039","August 1, 2018","April 2021","July 2021","August 14, 2018",,"July 30, 2020","King's College London, IoPPN, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03628027"
793,"NCT04476030","A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: SAGE-217|Drug: Matching Placebo|Drug: Sertraline|Drug: Escitalopram|Drug: Citalopram|Drug: Duloxetine|Drug: Desvenlafaxine","Change from Baseline in 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15|Change from Baseline in Clinical Global Impression - Severity (CGI-S) Score|Change from Baseline in 17-item HAM-D Total Score|Percentage of Participants with HAM-D Response|Percentage of Participants with HAM-D Remission|Percentage of Participants with Clinical Global Impression - Improvement (CGI-I) Response|Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score|Time to First HAM-D Response|Change from Baseline in Depressive Symptoms Assessed by 9-item Patient Health Questionnaire (PHQ-9)|Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)|Percentage of Participants with TEAEs, Graded by Severity","Sage Therapeutics","All","18 Years to 64 Years   (Adult)","Phase 3","424","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-MDD-305","November 16, 2020","December 2021","December 2021","July 17, 2020",,"March 29, 2021","Sage Investigational Site, Dothan, Alabama, United States|Sage Investigational Site, Phoenix, Arizona, United States|Sage Investigational Site, Anaheim, California, United States|Sage Investigational Site, Costa Mesa, California, United States|Sage Investigational Site, Glendale, California, United States|Sage Investigational Site, Irvine, California, United States|Sage Investigational Site, Los Alamitos, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Riverside, California, United States|Sage Investigational Site, San Diego, California, United States|Sage Investigational Site, Stanford, California, United States|Sage Investigational Site, Temecula, California, United States|Sage Investigational Site, Colorado Springs, Colorado, United States|Sage Investigational Site, Cromwell, Connecticut, United States|Sage Investigational Site, Norwich, Connecticut, United States|Sage Investigational Site, Coral Springs, Florida, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Alpharetta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Marietta, Georgia, United States|Sage Investigational Site, Savannah, Georgia, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Towson, Maryland, United States|Sage Investigational Site, Watertown, Massachusetts, United States|Sage Investigational Site, Ann Arbor, Michigan, United States|Sage Investigational Site, Saint Charles, Missouri, United States|Sage Investigational Site, Lincoln, Nebraska, United States|Sage Investigational Site, Cherry Hill, New Jersey, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Princeton, New Jersey, United States|Sage Investigational Site, Albuquerque, New Mexico, United States|Sage Investigational Site, Brooklyn, New York, United States|Sage Investigational Site, Brooklyn, New York, United States|Sage Investigational Site, Mount Kisco, New York, United States|Sage Investigational Site, Beachwood, Ohio, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational Site, North Canton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Norristown, Pennsylvania, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Dallas, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Wichita Falls, Texas, United States|Sage Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04476030"
794,"NCT00036309","Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder","Drug: Duloxetine Hydrochloride",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Primary Purpose: Treatment","4445|F1J-MC-HMBC","May 2002",,"July 2003","May 9, 2002",,"July 19, 2006","For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559), Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00036309"
795,"NCT01743716","Genetic and Neural Predictors of Adolescent Depression",,"Active, not recruiting","No Results Available","Major Depressive Disorder",,"Neurobiological Activity in Frontostriatal and Mesolimbic Regions|Depressive Symptoms","Mclean Hospital|The Klingenstein Third Generation Foundation|The Dana Foundation","Female","12 Years and older   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2012P002351","April 2013","December 2020","December 2020","December 6, 2012",,"February 25, 2020","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01743716"
796,"NCT04478058","Feasibility and Effectiveness of Delivering CBT Through OPTT for Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Live CBT|Behavioral: e-CBT","Change in symptoms - Patient Health Questionnaire - 9 Item|Change in symptoms (Quick Inventory of Depressive Symptomatology)|Change in quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire)|Qualitative Analysis - Healthcare Provider Experience|Qualitative Analysis - Participant Experience","Queen's University|Online PsychoTherapy Clinic","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSIY-563-17","June 1, 2019","September 30, 2021","September 30, 2021","July 20, 2020",,"April 14, 2021","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04478058"
797,"NCT02021149","Enhancing Psychotherapy for Mood Disorders With Whole Body Hyperthermia",,"Terminated","No Results Available","Major Depressive Disorder","Device: High intensity whole-body infrared heating|Behavioral: Psychotherapy|Other: Questionnaires|Device: Low intensity whole-body infrared heating","Change in depression scores over time [Inventory of Depressive Symptomatology-Self Report (IDS-SR)]|Change in Therapeutic bond / alliance|Change in depression scores over time (OQ-45 Measurement)|Change in Vitality|Change in Positive and Negative Affect|Change in relationship with psychotherapist","Charles (Chuck) Raison|University of Arizona","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13-0614","July 2014","November 2015","November 2015","December 27, 2013",,"July 27, 2015","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02021149"
798,"NCT02015546","Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone",,"Completed","Has Results","Major Depressive Disorder (MDD)","Drug: Vilazodone","Change in Total MADRS Scores From Baseline to Week 8|Change in the Discontinuation Emergent Signs and Symptoms Check List (DESS)|Change in Safety as Assessed by the Arizona Sexual Experience Scale (ASEX)|Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores|Change in Sheehan Disability Scale (SDS)|Change in Clinical Global Impression-Improvement (CGI-I) Scale|Change in Clinical Global Impression-Severity (CGI-S) Scale|MADRS Response|MADRS Remission","Duke University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Pro00036210","December 2012","December 2013","December 2013","December 19, 2013","February 9, 2015","April 16, 2015","Duke University Medical Center / Civitan Building, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02015546"
799,"NCT00226356","Natural Supplements for Unipolar Depression",,"Completed","No Results Available","Unipolar Depression","Drug: Supplements of L-methionine, betaine and folate","Depressive symptoms","Cambridge Health Alliance|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 64 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHA-IRB-0048/04/04","December 2004","June 2007","September 17, 2008","September 27, 2005",,"April 18, 2017","Cambridge Health Alliance, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00226356"
800,"NCT04575285","Using EEG to Predict Depression Treatment Response to Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Major Depression",,"Not yet recruiting","No Results Available","Major Depression|Repetitive Transcranial Magnetic Stimulation","Diagnostic Test: Electroencephalogram (EEG)","Change in Hamilton Depression Rating Scale score|Electroencephalograph (EEG) scalp signal changes over time","Baptist Health South Florida|Florida International University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMS Depression","December 1, 2021","December 1, 2030","December 1, 2031","October 5, 2020",,"July 15, 2021",,,"https://ClinicalTrials.gov/show/NCT04575285"
801,"NCT02033369","Imaging Dopamine Release in Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Pramipexole","Change in Hamilton Rating Scale for Depression|Change in Snaith Hamilton Pleasure Scale|Change in Temporal Experience of Pleasure Scale - Anticipatory Subscale|Change in Mood and Anxiety Symptom Questionnaire, Short Form|Change in the Apathy Evaluation Rating Scale|Change in Clinical Global Improvement - Severity Scale|Change in Temporal Experiences of Pleasure Scale -- Consummatory Subscale","New York State Psychiatric Institute|Columbia University|Research Foundation for Mental Hygiene, Inc.|Mclean Hospital|Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)","All","18 Years to 50 Years   (Adult)","Phase 4","52","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","#6853|1R01MH099322-01A1","February 2014","December 2016","July 2017","January 10, 2014","November 21, 2017","November 1, 2019","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02033369"
802,"NCT03288714","Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder|Depression|Depressive Disorder, Major|Depressive Episode|Major Depressive Disorder","Device: Synchronized Transcranial Magnetic Stimulation (sTMS)|Device: Sham Stimulation","Clinical Response","Wave Neuroscience","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NND-3002","November 27, 2017","March 1, 2019","June 1, 2019","September 20, 2017",,"August 29, 2019","Kadima Neuropsychiatry Institute, La Jolla, California, United States|UCLA Westwood - Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|New York University, New York, New York, United States|Laureate Institute for Brain Research, Tulsa, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Brain Health Consultants, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03288714"
803,"NCT00368030","A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder",,"Completed","No Results Available","Insomnia|Depressive Disorder, Major","Drug: Eszopiclone|Other: Placebo","Mean subjective wake time after sleep onset (WASO)|Time to onset of 30% antidepressant response using the HAM-D-6 (Bech)|Mean WASO|Mean subjective total sleep time (TST)|Mean subjective sleep latency (SL)|Mean number of awakenings|Quality and depth of sleep|Daytime alertness|Ability to concentrate|Physical well-being|Ability to function|average rebound and withdrawal effects will be analyzed for each of the subjective sleep endpoints|Time to onset of 50% antidepressant response using the HAM-D-6 (Bech)|Time to onset of 50% and 30% antidepressant responses using the HAM-D-6 (Maier)|Change in the HAM-D-6 (Bech) and HAM-D-6 (Maier) from baseline to each visit|Change in the HAM-D-17 from baseline|Symptom Questionnaire (SQ) Score (Depression Subscale)|Daily Telephone Assessment (DTA) Score|Change in HAM-D-6 (Bech), HAM-D-6 (Maier), HAM-D-17, SQ, and DTA during the wash-out phase until end of study|SF-36 Score|Work Limitations Questionnaire (WLQ) Score|Epworth Sleepiness Scale (ESS)|Insomnia Severity Index (ISI) score|Clinical Global Impression|Safety will be assessed by physical examinations, a standard 12-lead ECG, vital signs, clinical laboratory assessments and AE reporting","Sunovion","All","21 Years to 64 Years   (Adult)","Phase 3","545","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","190-052","January 2004","October 2004","October 2004","August 24, 2006",,"February 22, 2012","Birmingham, Alabama, United States|Peoria, Arizona, United States|Tucson, Arizona, United States|Fayetteville, Arkansas, United States|Garden Grove, California, United States|Irvine, California, United States|Northridge, California, United States|Riverside, California, United States|San Diego, California, United States|Wheat Ridge, Colorado, United States|New Britian, Connecticut, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|St. Petersburg, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Smyrna, Georgia, United States|Boise, Idaho, United States|Overland Park, Kansas, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Braintree, Massachusetts, United States|Brighton, Massachusetts, United States|Brockton, Massachusetts, United States|Cambridge, Massachusetts, United States|Watertown, Massachusetts, United States|Farmington Hills, Michigan, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Clementon, New Jersey, United States|Morestown, New Jersey, United States|Bronx, New York, United States|Lawerence, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Bismarck, North Dakota, United States|Beachwood, Ohio, United States|Cincinatti, Ohio, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Springfield, Oregon, United States|Conshohocken, Pennsylvania, United States|Emmaus, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Scotland, Pennsylvania, United States|Anderson, South Carolina, United States|Madison, Tennessee, United States|Memphis, Tennessee, United States|Selmer, Tennessee, United States|Austin, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Lakewood, Washington, United States|Seatle, Washington, United States|Spokane, Washington, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00368030"
804,"NCT02998762","Long-Term Follow Up Study","CAN-BIND LTFU","Completed","No Results Available","Major Depressive Disorder",,"Change in Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg 1979) scores from CAN-BIND baseline|Longitudinal Interval Follow-up Evaluation (LIFE) (Keller et al., 1978)|Life Events and Difficulties Schedule (LEDS) (Brown & Harris, 1978)","Sidney Kennedy|Queen's University|McMaster University|University of Calgary|University of British Columbia|University Health Network, Toronto","All","18 Years to 60 Years   (Adult)",,"96","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","15-9055-AE","February 3, 2016","July 29, 2019","July 29, 2019","December 20, 2016",,"November 3, 2020","University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|McMaster University, Hamilton, Ontario, Canada|Queen's University, Kingston, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02998762"
805,"NCT01424111","Exploring Biomarkers for Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Other: Healthy Control","Objective Biomarkers","Wyss Institute at Harvard University|Massachusetts General Hospital|Martinos Center for Biomedical Imaging|Massachusetts Institute of Technology","All","18 Years to 65 Years   (Adult, Older Adult)",,"51","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AMD-CS-0007","August 2011","October 14, 2017","October 14, 2017","August 26, 2011",,"May 1, 2018","Depression Clinical and Research Program, MGH, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01424111"
806,"NCT04842929","Magnetic Randomized Trial in Elderly Depressed","MrTED","Recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial magnetic stimulation","Changes in Hamilton Rating Scale for Depression, 17 items (HDRS-17)|Change in HDRS-17|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Global Clinical Impression Scale (CGI)|Change in Cumulative Illness Rating Scale (CIRS)|Change in Geriatric Depression Scale (GDS)|Change in Positive and Negative Affect Scale (PANAS)|Change in serum BDNF concentrations|HDRS 17|Young Manic Rating Scale (YMRS)|Serious adverse events","University of Sao Paulo|Brain & Behavior Research Foundation","All","60 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2.643.551","January 16, 2019","December 17, 2021","February 20, 2022","April 13, 2021",,"April 13, 2021","University of Sao Paulo, Sao Paulo, SP, Brazil","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04842929/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04842929/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04842929"
807,"NCT00617045","Duloxetine for the Treatment of Postpartum Depression","DuloxPPD","Withdrawn","No Results Available","Postpartum Depression|Major Depressive Disorder","Drug: duloxetine","Change in depression severity compared to baseline scores on the IDS-C between the two subject groups.","Yale University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIC0609001827-Lilly-Duloxetine|F1J-US-X043","July 2007","December 2012","May 2013","February 15, 2008",,"June 17, 2016","Perinatal & Postpartum Research Program 142 Temple ST Suite 301, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00617045"
808,"NCT00186784","Transcranial Magnetic Treatment (TMS) in Unipolar Depression",,"Completed","No Results Available","Unipolar Depression","Procedure: Transcranial Magnetic Stimulation (TMS)","Hamilton Depression Rating Scale|Beck Depression Rating Scale|Quantitive Electroencephalographic(QEEG)activity and measures of regional cerebral blood flow","St. Joseph's Healthcare Hamilton|Queen's University, Kingston, Ontario","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TMS1871","December 2000","July 2011","July 2011","September 16, 2005",,"August 3, 2011","St.Joseph's Healthcare, rTMS Laboratory, Mood Disorders Program, 100 West Fifth Street, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00186784"
809,"NCT01640080","A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Esketamine|Drug: Placebo","Change from Day 1 (baseline) to Day 2 in the Montgomery Asberg Depression Rating Scale (MADRS) total score in the double-blind treatment phase|Change from Day 1 (baseline) to Day 4 in Major Depressive Disorder (MDD) symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) total score in the double-blind treatment phase|Change from Day 1 (baseline) to Day 35 in Major Depressive Disorder (MDD) symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) total score during the posttreatment phase|The number of patients who have a reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score of >50% versus baseline on Day 2|Change from Day 1 (baseline) to Day 4 in Major Depressive Disorder (MDD) symptoms using the Quick Inventory of Depressive Symptomatology-Self Report- 14-Item (QIDS-SR14)|Change from Day 1 (baseline) to Day 14 in Major Depressive Disorder (MDD) symptoms using the Quick Inventory of Depressive Symptomatology-Self Report-16-item (QIDS-SR16)|Change from Day 1 (baseline) to Day 7 in severity of illness using the Clinical Global Impression- Severity (CGI-S) for esketamine compared to placebo|Change from Day 1 (baseline) to Day 7 of global change in Major Depressive Disorder (MDD) since start of study treatment, as measured by the Clinical Global Impression- Improvement (CGI-I)|Change from Day 1 (baseline) to Day 7 in severity of illness using the Patient Global Impression - Severity (PGI-S) for esketamine compared to placebo|Change from Day 1 (baseline) to Day 7 in patient perspective of global change in Major Depressive Disorder (MDD) since start of study treatment, as measured by the Patient Global Impression of Change (PGI-C)|Change from Day 4 to Day 7 in Major Depressive Disorder (MDD) symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) total score in the double-blind treatment phase|The number of patients who have a reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score of >50% versus baseline on Day 3|The number of patients who have a reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score of >50% versus baseline on Day 4|Change from Day 4 to Day 7 in Major Depressive Disorder (MDD) symptoms using the Quick Inventory of Depressive Symptomatology-Self Report- 14-Item (QIDS-SR14)","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR100843|ESKETIVTRD2001|2011-005992-17","June 27, 2012","June 3, 2013","June 3, 2013","July 13, 2012",,"June 2, 2020","Dave, Belgium|Gent, Belgium|Kortenberg, Belgium|Lede, Belgium|Berlin, Germany|Freiburg, Germany|Mainz, Germany|Munchen, Germany|Gdansk, Poland",,"https://ClinicalTrials.gov/show/NCT01640080"
810,"NCT04342299","The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression","ADeSS_S3","Recruiting","No Results Available","Major Depressive Disorder",,"Baseline functional connectivity of the right superior anterior temporal lobe (RSATL) during self- vs. other-blame|Baseline functional connectivity of the subgenual cingulate cortex (SCC) during resting state fMRI|Baseline pregenual anterior cingulate cortex (pgACC) activity in response to implicit facial emotions|Baseline amygdala activation in response to implicit facial emotions","King's College London|NHS Lambeth Clinical Commissioning Group","All","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADeSS_S3|PB-PG-0416-20039|2064430|M816","August 1, 2018","April 30, 2021","July 31, 2021","April 13, 2020",,"April 21, 2020","King's College London, IoPPN, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04342299"
811,"NCT01469663","Event Related Potentials in Borderline Personality Disorder and Major Depression",,"Terminated","No Results Available","Borderline Personality Disorder|Major Depression",,"Error related negativity amplitude|N2 amplitude","State University of New York - Upstate Medical University|Syracuse University","Female","18 Years to 45 Years   (Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","5910","July 2011","March 2015","March 2015","November 10, 2011",,"May 18, 2021","Syracuse University - CNY Medical Center, Syracuse, New York, United States|Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT01469663"
812,"NCT01353963","Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients",,"Terminated","Has Results","Major Depressive Disorder|Vasomotor Symptoms","Drug: desvenlafaxine succinate","Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs)|Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 4.|Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 8.|Change From Baseline in Heart Rate at Week 4.|Change From Baseline in Heart Rate at Week 8.|Change From Baseline in Weight at Week 4.|Change From Baseline in Weight at Week 8.","Pfizer","All","18 Years and older   (Adult, Older Adult)",,"13","Industry","Observational","Time Perspective: Prospective","B2061038","March 2012","August 2012","August 2012","May 16, 2011","January 18, 2016","January 18, 2016","Private Clinic, Las Pinas, Philippines|Private Clinic, Manila, Philippines|Private Clinic, Pasay City, Philippines",,"https://ClinicalTrials.gov/show/NCT01353963"
813,"NCT01244724","Lexapro for Major Depression in Patients With Epilepsy",,"Terminated","Has Results","Major Depression|Epilepsy","Drug: Lexapro","Hamilton Depression Scale|National Hospital Seizure Severity Scale","Weill Medical College of Cornell University|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LXP-MD-109","October 2007","December 2011","March 2012","November 19, 2010","August 3, 2015","July 11, 2018","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01244724"
814,"NCT00517387","The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression",,"Completed","No Results Available","Unipolar Depression","Drug: Quetiapine XR","Primary outcome will be measurements of cognitive function, determined both prior to treatment and after 8 weeks of treatment.|To evaluate Quetiapine XR compared to placebo, in SSRI-nonresponsive unipolar patients, in treatment of anxiety and depressive symptoms and biomarkers, improving patient's overall quality of life, and to evaluate its safety and tolerability.","University of British Columbia|AstraZeneca","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 3","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H07-00629","September 2007","September 2010","September 2010","August 16, 2007",,"November 16, 2010","University of British Columbia Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00517387"
815,"NCT01558063","Ketamine in the Treatment of Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Ketamine|Drug: Saline|Procedure: Magnetic Resonance Imaging (MRI)","Number of Responders 24-hours Post-ketamine Infusion|Change in Glutamate Levels|Change in Gamma-Amino Butyric Acid (GABA) Levels","Columbia University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","38","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NYSPI 6460|5R01MH093637-03","February 2012","May 2015","October 2019","March 20, 2012","July 16, 2019","December 10, 2019","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01558063"
816,"NCT02366364","Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers","NRX-1074","Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: NRX-1074 375 mg|Drug: NRX-1074 500 mg|Drug: NRX-1074 750 mg","Number of participants with adverse events as a measure of safety and tolerability|Plasma pharmacokinetics Cmax|Plasma pharmacokinetics - Tmax","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX1074-C-102","February 2015","April 2015","April 2015","February 19, 2015",,"February 22, 2016","Chicago Research Center, Inc., Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02366364"
817,"NCT01851967","Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans",,"Completed","No Results Available","Major Depressive Disorder","Other: MoodGYM","Change in Center for Epidemiologic Studies Depression Scale (CES-D)","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","112","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-P-002340","September 2014","December 2015","November 2016","May 13, 2013",,"December 1, 2016","Massachusetts General Hospital Depression Clinical and Research Program, Boston, Massachusetts, United States|Ying Wang, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01851967"
818,"NCT03430869","Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: F-18 AV-45|Drug: F-18-THK-5351","The standard uptake value ratio (SUVR) of 18F-florbetapir|The standard uptake value ratio (SUVR) of 18F-THK-5351","Chang Gung Memorial Hospital","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201601655A0","March 23, 2018","December 31, 2021","December 31, 2021","February 13, 2018",,"July 20, 2020","Chang Gung Memorial Hospital, Taoyuan, Guishan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03430869"
819,"NCT04162522","Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Brexpiprazole","Change in Montgomery Asberg Depression Rating Scale (MADRS) scores from baseline","University Health Network, Toronto|Unity Health Toronto|Baycrest|Centre for Addiction and Mental Health|McMaster University|Queen's University|University of Ottawa|University of British Columbia|University of Calgary|McGill University|Dalhousie University|University of Michigan|Simon Fraser University","All","18 Years to 60 Years   (Adult)","Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","19-5371","December 23, 2019","August 1, 2022","August 1, 2022","November 14, 2019",,"April 27, 2021","University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|McMaster University, Hamilton, Ontario, Canada|Queen's University, Kingston, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04162522"
820,"NCT02460666","Brain Connectivity and Response to Tai Chi in Geriatric Depression",,"Completed","Has Results","Major Depressive Disorder","Behavioral: Tai-Chi-Chih (TCC)|Behavioral: Health Education and Wellness Classes (HEW)","Change in Hamilton Depression Rating Scale (HDRS) Scores|Change in Delayed Recall Cognitive Domain Scores|Change in Attention/Executive Function Cognitive Domain Scores|Change in Language Cognitive Domain Scores","University of California, Los Angeles","All","60 Years and older   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","R01AT008383-01A1","January 2016","November 18, 2020","December 1, 2020","June 2, 2015","July 9, 2021","July 16, 2021","UCLA Semel Institute, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02460666/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02460666/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02460666"
821,"NCT01557946","Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression",,"Completed","Has Results","MDD|Citalopram|Major Depressive Disorder","Drug: citalopram","Mean Difference From Baseline to Day 3 in Glutamine/Glutamate (Gln/Glu) Ratio Within Depressed Group|Mean Difference From Baseline to Day 7 in Glutamine/Glutamate (Gln/Glu) Ratio Within Depressed Group","Mclean Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-P-001192","March 2012","September 2015","September 2015","March 20, 2012","September 12, 2017","September 12, 2017","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01557946"
822,"NCT00824044","Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression",,"Completed","Has Results","Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy (CBT)|Drug: Escitalopram","Hamilton Depression Rating Scale (HAM-D-17) Scores|Change in Absolute Beta Power in Channel 4|Change in Absolute Theta Power From Channel 1|Change in Relative Theta Power Channel 3|Change in Relative Theta Power From Channel 4|Change in Relative Beta Power From Channel 4|Change in Absolute Beta Power From the Ear Channel|Change in Relative Theta Power From Temporal Channel|Change in Relative Theta Power From Ear Channel|Percent Change in Relative Theta Power From Week 1 of the Ear Channel","Massachusetts General Hospital|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","2008-P-000838","July 2008","March 2011","March 2011","January 16, 2009","January 8, 2013","January 5, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT00824044/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT00824044/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00824044"
823,"NCT02066077","The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy",,"Completed","No Results Available","Major Depressive Disorder","Drug: Etomidate|Drug: Propofol|Device: Bilateral temporal MECT|Device: The right temporal MECT|Device: Bilateral frontal MECT","Change in Hamilton Depression Scale(HAMD) Scores|Change in Wechsler Memory Scale (WMS) Scores as a Measure of Safety|Young Manic Rating Scale(MMSE) as a Measure for Evaluation of Mania State|Resting-state/Task-state functional magnetic resonance imaging (fMRI)|Change in Hamilton Anxiety Scale(HAMA) Scores|Change in Clinical Global Impression-severity of illness(CGI-SI) Scores as a Measure of Efficacy|Change in Wisconsin Card Sorting Test(WCST) Scores as a Measure of Safety|Change in P300/P50 Event-Related Potentials(ERP)","Shanghai Mental Health Center|Tongji Hospital|Huashan Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHDC12012109","January 1, 2013","December 31, 2017","December 31, 2017","February 19, 2014",,"April 23, 2018","Shanghai Mental Health Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02066077"
824,"NCT03688139","Reward Function and Therapy for Late-Life Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Engage Therapy|Behavioral: Supportive Therapy","Change in neural response to rewarding stimuli|Change in behavioral activation","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1803019076|K23MH116105","March 14, 2019","June 2023","June 2023","September 28, 2018",,"February 15, 2021","Weill Cornell Medicine, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT03688139"
825,"NCT04979910","Targeting IL-17A for Treatment-Resistant Depression",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Ixekizumab|Drug: Placebo","Change in Montgomery-Åsberg Depression Rating Scale Score|Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score|Change in Snaith-Hamilton Pleasure Scale (SHAPS)|Change in Temporal Experience of Pleasure Scale|Change in Clinical Global Impression Scale|Change in The Columbia-Suicide Severity Rating Scale (C-SSRS)|Change in The Hamilton Anxiety Rating Scale (HAM-A)","Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 20-1909","August 2021","October 2023","October 2023","July 28, 2021",,"July 28, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04979910"
826,"NCT02449447","Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet","E-compared","Completed","No Results Available","Major Depressive Disorders","Behavioral: Cognitive behavioral therapy|Other: Treatment as usual","Quick Inventory of Depressive Symptomatology Self-Report (QIDS|EuroQol-5D (EQ-5D-5L)|Client Satisfaction Questionnaire (CSQ-8)|Credibility and Expectancy Questionnaire (CEQ)|System Usability Scale (SUS)|Patient Health Questionnaire (PHQ-9)|Working Alliance Inventory (WAI-SF)|Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P)","Linkoeping University|European Commission","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-compared","February 2015","June 2016","June 2017","May 20, 2015",,"September 20, 2017","Department of Behavioral Sciences and Learning, Linköping University, Linköping, Östergötland, Sweden",,"https://ClinicalTrials.gov/show/NCT02449447"
827,"NCT02845349","Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)",,"Withdrawn","No Results Available","TBI|Major Depression","Drug: Vortioxetine|Drug: Placebo","Reduction of depressive symptoms at 12 weeks as assessed by the Hamilton Depression Scale 17 items (HAMD-17)|Reduction of depressive symptoms at 12 weeks as assessed by the Clinical Global Impression Improvement (CGI-I) scale|Comparison of rates and severity of side-effects and adverse effects in subjects in the treatment arm versus placebo at week 1-12|Change from baseline at week 12 on the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change from baseline at week 12 on the Arizona Sexual Experience (ASEX) scale","Johns Hopkins University|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00105196","October 2016","October 2018","October 2018","July 27, 2016",,"September 2, 2016",,,"https://ClinicalTrials.gov/show/NCT02845349"
828,"NCT00812227","Neural Correlates of Psychodynamic Psychotherapy for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Psychodynamic Psychotherapy","Correlation between changes in HAMD-17 and changes in QEEG measurements (theta cordance) from treatment initiation to two weeks after starting treatment|PET: Treatment-related change in FDG metabolism within regions-of-interest identified at baseline as related to depression severity.","Massachusetts General Hospital|Hope for Depression Research Foundation","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-P-001181","August 2008","February 2013","February 2013","December 22, 2008",,"May 13, 2013","Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00812227"
829,"NCT04526002","The Utility of Concurrent TBS/fNIRS for Antidepressant Treatment Optimization",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Device: Theta-burst stimulation (TBS)","Response rate after treatment (MADRS≤50% of baseline)|Oxygenated hemoglobin (HbO) change compared to baseline|Remission rate after treatment (MADRS≤8); Absolute reduction of mean MADRS, HAMD17, IDS-C30|Response and remission rates defined using the Hamilton scale (HAMD17), as well as mentioned clinical outcomes 2 at follow-up|Hb change compared to baseline","Dr Georg Kranz|Chinese University of Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Kowloon Hospital, Hong Kong|The Hong Kong Polytechnic University","All","18 Years to 60 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15100120","January 2021","June 2023","December 2023","August 25, 2020",,"August 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04526002"
830,"NCT01179516","Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Vortioxetine|Drug: Placebo","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With a MADRS Response at Week 8|Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8|Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥ 20|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score","Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","469","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_317|U1111-1116-3223|SU-06032011-7846","August 2010","May 2012","June 2012","August 11, 2010","December 18, 2013","December 18, 2013","Little Rock, Arkansas, United States|Carson, California, United States|Cerritos, California, United States|El Centro, California, United States|Fresno, California, United States|Glendale, California, United States|Los Angeles, California, United States|Oakland, California, United States|Oceanside, California, United States|San Diego, California, United States|Santa Ana, California, United States|Sherman Oaks, California, United States|Stanford, California, United States|Upland, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Hockessin, Delaware, United States|Fort Walton Beach, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Pompano Beach, Florida, United States|Atlanta, Georgia, United States|Hoffman Estates, Illinois, United States|Naperville, Illinois, United States|Oak Brook, Illinois, United States|Indianapolis, Indiana, United States|Lafayette, Indiana, United States|Newburgh, Indiana, United States|Prarie Ridge, Kansas, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Fall River, Massachusetts, United States|Watertown, Massachusetts, United States|Clinton Township, Michigan, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Nashua, New Hampshire, United States|Albuquerque, New Mexico, United States|Staten Island, New York, United States|Avon Lake, Ohio, United States|Beachwood, Ohio, United States|Canton, Ohio, United States|Garfield Heights, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Salem, Oregon, United States|Allentown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Franklin, Tennessee, United States|Dallas, Texas, United States|Desoto, Texas, United States|Houston, Texas, United States|Lake Jackson, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Salt Lake City, Utah, United States|Roanoke, Virginia, United States|Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01179516"
831,"NCT01478113","Stimulant Enhancement of Well-Being Therapy for Depression",,"Terminated","Has Results","Major Depressive Disorder","Drug: Amphetamine/dextroamphetamine|Drug: Placebo|Behavioral: Well-being therapy","Change in Hamilton-Depression Rating Scale(SIGH-D)-17 Items|Change in Hamilton-Depression Rating Scale(SIGH-D)-31 Item|Change in Psychological Well-being Scale (PWB)|Change in the Snaith-Hamilton Pleasure Scale (SHAPS)|Change in Behavioral Inhibition/Activation Scale (BIS/BAS)|Change in Positive and Negative Affective Scale (PANAS)|Change in Functioning on Short Form-12(SF-12)","Massachusetts General Hospital|Harvard Medical School","All","18 Years to 60 Years   (Adult)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011P002148|2011D002171","February 2012","July 2014","July 2015","November 23, 2011","April 26, 2017","April 26, 2017","Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01478113"
832,"NCT00933439","Assessment of Cognitive Functioning Before and After Treatment With Duloxetine","DULOX","Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine","Cognitive function|Psychosocial function","University of Texas Southwestern Medical Center|Eli Lilly and Company","All","18 Years to 45 Years   (Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Duloxetine","February 2005","September 2007","September 2007","July 7, 2009",,"August 13, 2013","Mood Disorders Research Program and Clinic - UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00933439"
833,"NCT00637494","A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features",,"Terminated","Has Results","Psychotic Depression|Severe Major Depression With Psychotic Features|Psychosis","Drug: mifepristone|Drug: placebo","Proportion of Mifepristone vs. Placebo Treated Patients With at Least a 50% Reduction From Baseline in Brief Psychiatric Rating Scale-Positive Symptom Subscale (BPRS-PSS) at Days 7 and 56|Proportion of Mifepristone Treated Patients With Plasma Drug Concentrations Equal to or Above 1637 ng/mL vs. Placebo Treated Patients Who Achieve a ≤ 50% Reduction in BPRS-PSS at Days 7 and 56","Corcept Therapeutics","All","22 Years and older   (Adult, Older Adult)","Phase 3","292","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-1073-14","March 2008","June 2014","June 2014","March 18, 2008","February 16, 2017","June 5, 2017","K&S Professional Research Services, LLC, Little Rock, Arkansas, United States|Woodland International Research Group, Inc., Little Rock, Arkansas, United States|South Coast Clinical Trials, Inc, Anaheim, California, United States|Diligent Clinical Trials, Downey, California, United States|Synergy Clinical Research Center, Escondido, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Pacific Research Partners, Oakland, California, United States|North County Clinical Research, Oceanside, California, United States|Breakthrough Clinical Trials, San Bernardino, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Cnri, Llc, San Diego, California, United States|Professional Clinical Research, Inc., Aventura, Florida, United States|University of Florida, Gainesville, Florida, United States|Segal Institute for Clinical Research, Hollywood, Florida, United States|Accurate Clinical Trials, Kissimmee, Florida, United States|AMB Research Center, Miami, Florida, United States|Lakeside Behavioral Health, Orlando, Florida, United States|University of South Florida Dept of Psychiatry and Neurosciences, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associate, Creve Coeur, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|CRI Lifetree, Marlton, New Jersey, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|The Zucker Hillside Hospital, Glen Oaks, New York, United States|Inquest Clinical Group/ Global Research Associates, Hope Mills, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|FutureSearch Clinical Trials, L.P., Austin, Texas, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|InSite Clinical Research, LLC, DeSoto, Texas, United States|Claghorn-Lesem Research Clinic, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Fein-Jennings Clinic, Inc., Houston, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00637494"
834,"NCT01703039","Riluzole Augmentation Pilot in Depression (RAPID) Trial","RAPID","Terminated","Has Results","Major Depressive Disorder","Drug: Riluzole|Drug: Sertraline|Other: placebo","Mean Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline (0 Weeks) to Endpoint at 8 Weeks|Number of Patients Experiencing an Antidepressant Response (>50% Reduction in HDRS) at Endpoint of 8 Weeks|Number of Patients Experiencing Remission From Depression (HDRS<7) at Endpoint of 8 Weeks|Mean Change in Hamilton Anxiety Rating Scale (HARS) Score From Baseline (0 Weeks) to Endpoint at 8 Weeks|Mean Change in Clinical Global Impression (CGI) Scale From Baseline (0 Weeks) to Endpoint at 8 Weeks","Brigham and Women's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012P001841","January 2013","June 2018","June 2018","October 10, 2012","August 28, 2019","August 28, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01703039/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01703039"
835,"NCT01477931","Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features","WellbutrinXL","Completed","No Results Available","Depressive Disorder, Major","Drug: Bupropion extended release","HAM-D-29 scores(Hamilton Depression Rating Scale 29)|8-atypical items on the HAM-D-29|Tolerability|CGI-I score(Clinical Global Impression Improvement score)|SDS(Zung Self-Rating Depression Scale)|C-SSRS(The Columbia-Suicide Severity Rating Scale, changes in behaviours and ideation)|ESQ(Epworth Sleepiness Questionnaire)|Response|Remission","Chi-Un Pae|GlaxoSmithKline|The Catholic University of Korea","All","20 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","114003","November 2010","July 2011","September 2011","November 23, 2011",,"November 23, 2011","Korea University Ansan Hospital, Ansan, Gyeonggi-Do, Korea, Republic of|Bucheon St.Mary's Hospital, Bucheon, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, St.Vincent Hospital, Suwon, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Uijeongbu St. Mary'S Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of|dongguk university MEDICAL CENTER, Kyungju, Kyoung-Book, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01477931"
836,"NCT00892463","Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Quetiapine (Seroquel) XR","The QIDS-SR16 (Quick Inventory of Depressive Symptomatology - Self-report)|HADS (Hamilton Anxiety Depression Scale) VADIS","Sunnybrook Health Sciences Centre|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00072","May 2009","December 2010","December 2010","May 4, 2009",,"July 28, 2011","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00892463"
837,"NCT02037503","The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression",,"Recruiting","No Results Available","Suicidal Ideation|Major Depressive Disorder|Healthy Participants","Drug: Ketamine|Drug: Saline","Resolution of suicidal ideation|Improvement in depression indices","Tel-Aviv Sourasky Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TASMC-13-TH-0270-CTIL","January 2014","May 2020","May 2020","January 16, 2014",,"April 2, 2020","Tel Aviv Sourasky Medical Center, Tel Aviv, N/A = Not Applicable, Israel",,"https://ClinicalTrials.gov/show/NCT02037503"
838,"NCT02440815","Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression","PRS","Completed","No Results Available","Major Depressive Disorder","Behavioral: Problem Solving Therapy","Rate of change in Cerebral Blood Flow (CBF) as measured by cortical surface-based analysis|Rate of change in Cortical Gray Matter (GM) Atrophy as measured by the FreeSurfer image analysis suite|Rate of change in Subcortical White Matter Lesion as measured by WML-T2 FLAIR|Rate of change in Depression Severity as measured by the Hamilton Depression Rating Scale (24 item).|Rate of change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct|Rate of change in expressive language as measured by the Boston Naming Test using total correct.|Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.","University of California, San Francisco|San Francisco Veterans Affairs Medical Center","All","65 Years and older   (Older Adult)","Not Applicable","108","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ROI MH101472","November 2015","July 28, 2021","July 28, 2021","May 12, 2015",,"August 4, 2021","University of California, San Francisco, Langley Porter Psychiatric Institute, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02440815"
839,"NCT03403881","Movement for Depression - An RCT Assessing the Effects of Physical Activity Promotion for People With MDD","MOVEDEP","Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Physical activity promotion + TAU|Behavioral: Control","Depressive symptoms (blinded assessment)|Physical activity - self-report|Physical activity levels - objective measure|Quality of life|Depressive symptoms (self-reported)|Melancholia|Weight","Hospital de Clinicas de Porto Alegre","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","15-0532","March 2016","December 2018","May 2019","January 19, 2018",,"February 7, 2018","Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT03403881"
840,"NCT03437928","Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Directional Deep Brain Stimulation","Changes in depressive symptoms","Baylor College of Medicine|University of California, Los Angeles","All","22 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-43036","August 20, 2019","August 19, 2023","August 19, 2024","February 19, 2018",,"May 21, 2021","University of California, Los Angeles, Los Angeles, California, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03437928"
841,"NCT00158990","Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.",,"Completed","No Results Available","Major Depression|Bipolar Disorder|Unipolar Depression","Drug: triiodothyronine|Drug: sertraline","Response - HAM-D-21 improvement >50% at 8 weeks|Remission - final HAM-D-21 total <7 at 8 weeks|Rate of change in HAM-D-21 scores over 8 week treatment period","Hadassah Medical Organization|Stanley Medical Research Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BPL-0100-HMO-CTIL","October 2002",,"July 2007","September 12, 2005",,"January 4, 2007","Global Medical Institutes, Princeton, New Jersey, United States|Hadassah Medical Organisation, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00158990"
842,"NCT00238758","A Study of Omega-3 as a Treatment for Major Depression",,"Unknown status","No Results Available","Major Depression|Dysthymia","Drug: Omega-3 Polyunsaturated Fatty Acids","Change from pretreatment score on Depression Rating Scale at 6 weeks.|Weekly measure of depressive symptoms|Weekly measure of anxiety symptoms|Weekly measure of functional status","The University of New South Wales|Your Health Inc.|Sphere Healthcare|Ocean Nutrition","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","128","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","05157","October 2005",,,"October 13, 2005",,"September 13, 2006","The University of New South Wales/ Black Dog Institute, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT00238758"
843,"NCT01655706","Canadian Biomarker Integration Network for Depression Study","CAN-BIND-1","Completed","No Results Available","Major Depressive Disorder","Drug: escitalopram|Drug: aripiprazole","Change in MADRS (Montgomery-Asberg Depression Rating Scale) scores from baseline","University Health Network, Toronto|University of Toronto|University of Calgary|University of British Columbia|McGill University|Queen's University|Centre for Addiction and Mental Health|McMaster University","All","18 Years to 60 Years   (Adult)","Phase 3","211","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11-0917-A","April 23, 2012","January 2017","January 2017","August 2, 2012",,"May 11, 2018","University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|McMaster University, Hamilton, Ontario, Canada|Queen's University, Kingston, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01655706"
844,"NCT01031810","PET Biomarkers in Treatment Resistant Depression",,"Terminated","Has Results","Major Depressive Disorder","Drug: tranylcypromine","Hamilton Depression Rating Scale Scores 17 at Baseline|Hamilton Depression Rating Scale Scores 17 at week12|Quick Inventory of Depression- Self Report 16","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","13","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6025|RC1MH088405-01","November 2009","March 2013","March 2013","December 15, 2009","September 18, 2014","September 18, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01031810"
845,"NCT00413023","Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major","Drug: GW679769","Change in score on a Depression rating scale following 8 weeks of treatment.|Change in score on a number of rating scales following 8 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","NKF100096","June 2005","September 2006","September 2006","December 19, 2006",,"October 28, 2016","GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Alken, Belgium|GSK Investigational Site, Kortrijk, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Mont-Godinne, Belgium|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, San José, Costa Rica|GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Guardiagrele (CH), Abruzzo, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Chelmno, Poland|GSK Investigational Site, Kościan, Poland|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Levoca, Slovakia|GSK Investigational Site, Liptovsky Mikulas, Slovakia|GSK Investigational Site, Rimavska Sobota, Slovakia|GSK Investigational Site, Trencin, Slovakia|GSK Investigational Site, Oviedo, Spain|GSK Investigational Site, Solna, Sweden",,"https://ClinicalTrials.gov/show/NCT00413023"
846,"NCT03889756","Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy","SAD-KIDS","Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine infusion|Drug: Midazolam infusion","Evaluate the efficacy of a multiple-dosing ketamine infusion paradigm (2 infusions per week for 3 weeks) compared to midazolam in adolescents with treatment resistant depression|Evaluate the tolerability of a multiple-dosing ketamine infusion paradigm (2 infusions per week for 3 weeks) compared to midazolam in adolescents with treatment resistant depression","Yale University","All","13 Years to 17 Years   (Child)","Phase 2|Phase 3","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2000023857","July 17, 2019","September 2022","November 2022","March 26, 2019",,"February 23, 2021","Yale Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03889756"
847,"NCT00526383","Do Antidepressants Induce Metabolic Syndromes METADAP Study","METADAP","Completed","No Results Available","Major Depressive Disorder","Drug: Tricyclic antidepressants","Definition criteria of the metabolic syndromes: Weight and waist circumference Systolic and diastolic blood pressure Glycemia Triglyceridemia Cholesterolemia Insulinemia|Antidepressant efficacy (HAM-D, quickIDS-C, quickIDS-SR, CGI)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","624","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P060219","November 2007","April 2013","April 2013","September 10, 2007",,"April 17, 2014","Assistance Publique hopital Bicêtre, Paris, France",,"https://ClinicalTrials.gov/show/NCT00526383"
848,"NCT00517985","Duloxetine for Perimenopausal Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine","Reduction of the initial HAM-D by 50% or more at week 9 of the trial|Reduction of the HAM-D score to less than or equal to 7 at week 9|Change of CGI score achievement to ""very much improved"" or ""much improved"" at week 9|A 50% decrease in the GCS at week 9.","University of Arizona|Eli Lilly and Company","Female","40 Years and older   (Adult, Older Adult)","Phase 4","7","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F1JUSX026","February 2007","June 2008","June 2008","August 17, 2007",,"July 9, 2012","Women's Mental Health Program; University of Arizona; Department of Psychiatry, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00517985"
849,"NCT01114477","NeuroStar TMS Therapy System: Utilization and Outcomes",,"Completed","No Results Available","Major Depressive Disorder",,"Total Score on the Patient Health Questionnaire 9-Item (PHQ-9)|Total score for the Clinical Global Impressions-Severity (CGI-S)|Total score for the Inventory of Depressive Symptoms-Self Report (IDS-SR)|Total Score for the EuroQol Questionnaire (EQ-5D)|Health Resource Utilization Questionnaire (HRU)|Short Form 36-Item Questionnaire(SF-36) Individual Factor Scores and General Medical and Mental Health Composite Scores","Neuronetics","All","Child, Adult, Older Adult",,"307","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","19-50001-000","March 2010","September 2012","September 2012","May 3, 2010",,"November 13, 2015","Lee Ann Kelley, M.D., PC, Phoenix, Arizona, United States|Bay Psychiatric Associates, Berkeley, California, United States|TMS Center of Beverly Hills, Beverly Hills, California, United States|Clinical Training & Research Institute, Burlingame, California, United States|Sacramento TMS, El Dorado Hills, California, United States|Martha Koo, MD, Hermosa Beach, California, United States|Orange County TMS Center, Laguna Hills, California, United States|Depression Research Center and Clinic-Semel Institute for Neuroscience & Human Behavior at UCLA, Los Angeles, California, United States|Kevin Kinback, MD, Mission Viejo, California, United States|Todd Hutton, MD & Associates, Pasadena, California, United States|The Botkiss Center for TMS Therapy, San Diego, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Arjun Reyes, MD, Woodland Hills, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Christiana Care Health Services, Wilmington, Delaware, United States|Health Sciences America, LLC, Boca Raton, Florida, United States|Curtis Cassidy, MD, Lakeland, Florida, United States|Brian Teliho, MD, Atlanta, Georgia, United States|Carl M. Wahlstrom, Jr. MD Limited, Chicago, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Brain Stimulation Chicago North Shore, Northbrook, Illinois, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|University Psychiatric Foundation, Louisville, Kentucky, United States|Integrative Psychiatry, Louisville, Kentucky, United States|Spectrum Behavioral Health, Annapolis, Maryland, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Anthony Drobnick, MD, St. Michaels, Maryland, United States|Newton-Wellesley Psychiatry, Newton, Massachusetts, United States|Central Psychiatry, Las Vegas, Nevada, United States|TMS Center of New England, Portsmouth, New Hampshire, United States|Santa Fe TMS Therapy Center, Santa Fe, New Mexico, United States|Dent Neurosciences Research Center, Inc., Amherst, New York, United States|The TMS Institute of Pennsylvania-Advanced Neuropsychiatric Solutions, West Chester, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|W. Scott West, M.D., Nashville, Tennessee, United States|Texas Neuropsychiatric Institute, Amarillo, Texas, United States|Texas TMS Center at Senior Adults Specialty Healthcare (SASH), Austin, Texas, United States|Houston TMS, Houston, Texas, United States|Agape Mind Services/The Costello Clinic, Lewisville, Texas, United States|Serenity Center for Depression, P.A., Sugar Land, Texas, United States|University Neuropsychiatric Institute, Salt Lake City, Utah, United States|Center for Anxiety and Depression, Mercer Island, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01114477"
850,"NCT04555408","Efficacy of Blue Light Treatment in Patients With Nonseasonal Major Depressive Disorder",,"Not yet recruiting","No Results Available","Depression","Device: blue light|Device: bright light|Device: dim light","Change in 17-item Hamilton Depression Rating Scale (HAMD17)|Change in Quick Inventory of Depressive Symptoms, Self-Rated version (QIDS-SR)|Change in 14-item Hamilton Anxiety Rating Scale (HAMA14)|Change in Pittsburgh sleep quality index (PSQI)|Change in Clinical Global Impression scale(CGI)|Change in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Change in Morningness-Eveningness Questionnaire (MEQ)|Change in Repeatable Battery for the Assessment of Neuropsychological Status(RBANS)|Change in subjective fatigue symptom scale|Change in semantic differential scale","Shanghai Zhongshan Hospital|Shanghai Mental Health Center, Jingan District|Shanghai Mental Health Center, Yangpu District|Fudan University","All","18 Years to 60 Years   (Adult)","Not Applicable","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2019ZSQN44","October 1, 2020","October 2022","December 2022","September 18, 2020",,"September 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04555408"
851,"NCT02935647","Burst Suppression Anesthesia for Treatment of Severe Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Diprivan","Hamilton Rating Scale for Depression|Quick Inventory of Depressive Symptoms","University of Utah","All","18 Years to 55 Years   (Adult)","Phase 1","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00090838","October 1, 2016","September 2018","September 2018","October 17, 2016",,"June 2, 2021","University Neuropsychiatric Institute, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02935647/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02935647"
852,"NCT01325831","Changes of Functional Connectivity After rTMS in Depression",,"Completed","No Results Available","Major Depression","Device: repetitive transcranial magnetic stimulation(rTMS)|Device: Sham repetitive transcranial magnetic stimulation(rTMS)","change of functional connectivity between pre/post rTMS","Yonsei University","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 4","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","4-2008-0525","May 2009","June 2011","June 2011","March 30, 2011",,"February 2, 2012","Department of Psychiatry, Severance Hospital, Seoul,, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01325831"
853,"NCT03121573","Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine","Change in Depression severity|Change in Brain cortical activity","Taichung Veterans General Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","SF14216","December 15, 2014","September 26, 2016","January 17, 2017","April 20, 2017",,"April 20, 2017",,,"https://ClinicalTrials.gov/show/NCT03121573"
854,"NCT00384033","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: Placebo|Drug: Duloxetine 60 mg/day","Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation|Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) Score at Week 8 or FOT Evaluation|Change From Baseline in Mean CGI-S Score at Week 8 or FOT Evaluation|Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or FOT Evaluation|Change From Baseline in the Lassitude Item of the MADRS Scale at Week 8 or FOT Evaluation|Change From Baseline in HAM-D6 Total Score at Week 8 or FOT Evaluation|Change From Baseline in the HAM-D Energy Subscale Score at Week 8 or FOT Evaluation|Change From Baseline in Covi Anxiety Scale at Week 8 or FOT Evaluation|Change From Baseline in Visual Analog Scale-Pain Intensity (VAS-PI) Overall and Subcomponent Score at Week 8 or FOT Evaluation","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","638","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-335","September 2006","September 2007","September 2007","October 4, 2006","March 15, 2012","March 15, 2012","Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Burbank, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Los Alamitos, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Northridge, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, Edwardsville, Illinois, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, Flint, Michigan, United States|Pfizer Investigational Site, Okemos, Michigan, United States|Pfizer Investigational Site, Clementon, New Jersey, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00384033"
855,"NCT00568672","Optimal Duration of Olanzapine Add-on Therapy in Major Depression","OLA-D","Withdrawn","No Results Available","Relapse Rate of a Major Depressive Episode|Safety of Olanzapine in Subjects With Major Depression","Drug: Olanzapine","Relapse Rate, Hamilton Depression Rating Scale (17 item version)|Safety and side effect scales (SWN Scale, CGI), Beck Depression Inventory","Charite University, Berlin, Germany|Eli Lilly and Company","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-000512-82|Franziska Jakob, MD|Ion Anghelescu, MD","October 2007",,"April 2008","December 6, 2007",,"April 25, 2008","Departement of Psychiatry and Psychotherapy, Charite, University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00568672"
856,"NCT00595699","Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy",,"Completed","No Results Available","Major Depression|Temporal Lobe Epilepsy","Drug: escitalopram|Drug: placebo","Montgomery And Asberg Depression Rating Scale|Clinician's Global Impression Severity and Improvement subscales","Conrad, Erich J., M.D.|Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LXP-MD-116|LSUHSC IRB #6653","November 2006","December 2009","December 2009","January 16, 2008",,"July 18, 2011","LSU Anxiety and Mood Disorders Clinic, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00595699"
857,"NCT01556971","Efficacy Study of Botox for Depression",,"Unknown status","No Results Available","Major Depression","Drug: Botox|Drug: Saline Solution","MADRS|Beck Depression Inventory|CGI-I","Capital Clinical Research Associates, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Botox 5515","February 2011","June 2012","June 2012","March 19, 2012",,"March 19, 2012","Chevy Chase Cosmetic Center, Chevy Chase, Maryland, United States|Capital Clinical Research Associates, LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01556971"
858,"NCT02546024","Predictors of Treatment Response in Late-onset Major Depressive Disorder",,"Suspended","No Results Available","Depressive Disorder, Major","Drug: Standard care","Resting Functional brain MRI|Neuropsychological test battery|Structural brain MRI|Functional assessment","King's College London|South London and Maudsley NHS Foundation Trust","All","60 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","178116/813302/14/153","September 2015","November 2017","November 2017","September 10, 2015",,"August 31, 2016",,,"https://ClinicalTrials.gov/show/NCT02546024"
859,"NCT01922219","Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression",,"Completed","Has Results","Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy","Remitters as Assessed by Post-treatment Beck Depression Inventory Less Than or Equal to 10|Post-Treatment Beck Depression Inventory|Final Score on the Hamilton Depression Rating Scale","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#6127|5K08MH085061","December 2009","August 2015","August 2015","August 14, 2013","March 1, 2017","September 19, 2017","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01922219"
860,"NCT00246233","CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.",,"Completed","No Results Available","Depressive Disorder, Major","Drug: methylphenidate","Change in total Montgomery Asberg Depression Rating Scale (MADRS) score between the two groups from baseline to the final visit.|Safety and tolerability of study drug based on adverse events and clinical laboratory tests, ECG, vital signs and physical examination, finding changes from baseline to the final visit.","Janssen-Ortho Inc., Canada","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR006073","June 2005",,"April 2006","October 30, 2005",,"May 17, 2011",,,"https://ClinicalTrials.gov/show/NCT00246233"
861,"NCT03287362","Effects of Schema Therapy vs. Cognitive Behavioral Therapy vs. Individual Supportive Therapy",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Behavioral: schema therapy|Behavioral: cognitive behavioral therapy|Behavioral: individualized supportive therapy","BDI-II (Beck-Depression-Inventory-II)|MADRS (Montgomery-Åsberg Depression Rating Scale)|CIDI (Composite International Diagnostic Interview)|BSI (Brief Symptom Inventory)|WHOQOL (WHO - Quality of Life)|Neuropsychological testing (including sections on episodic memory, working memory, inhibition, cognitive flexibility, word fluency, sensitivity to interference, and attention)|Decreased need for psychopharmacological medication|Dropout rate from therapeutic treatment|WHODAS (WHO-Disability Assessment Schedule)","Max-Planck-Institute of Psychiatry|Ludwig-Maximilians - University of Munich","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-395","September 13, 2017","August 2022","August 2025","September 19, 2017",,"March 23, 2021","Max Planck Institute of Psychiatry, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT03287362"
862,"NCT02586688","Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents",,"Unknown status","No Results Available","Major Depressive Disorder","Device: Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Device: Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Device: Open Label Active NeuroStar® TMS","Hamilton Depression Rating Scale-24(HAMD24) total score change from baseline value.","Neuronetics","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","44-02219-000","October 2015","January 2018","December 2018","October 26, 2015",,"February 5, 2018","Dothan Behavioral Medicine, Dothan, Alabama, United States|UCLA, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Rocky Mountain TMS, Grand Junction, Colorado, United States|Florida Clinical Practice Association, Inc., Gainesville, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Beacon Medical Group, South Bend, Indiana, United States|Integrative Psychiatry, Louisville, Kentucky, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Cincinnati College of Medicine, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02586688"
863,"NCT01608295","Vilazodone for Treatment of Geriatric Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Vilazodone; Viibryd|Drug: Paroxetine; Paxil","Hamilton Depression Rating Scale (HDRS)|UKU Side-effect Profile|Neurocognitive Measure: The Rey-Osterrieth Complex Figure Test|Changes in Proinflammatory Gene Expression From Baseline to Final Visit (up to 12 Weeks)","University of California, Los Angeles|Forest Laboratories","All","60 Years and older   (Adult, Older Adult)","Phase 4","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VII-IT-02","July 2012","September 2015","September 2015","May 31, 2012","May 9, 2017","May 11, 2018","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01608295"
864,"NCT03429075","Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","Psilodep-RCT","Active, not recruiting","No Results Available","Depressive Disorder, Major","Drug: Psilocybin + Placebo|Drug: Psilocybin + Escitalopram","functional magnetic resonance imaging (fMRI)|Quick Inventory of Depressive Symptomatology (QIDS-SR16)","Imperial College London|Alexander Mosely Charitable Trust","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17HH3790|2017-000219-18","January 7, 2019","April 17, 2020","October 2020","February 12, 2018",,"July 31, 2020","Imperial College Hammersmith campus, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03429075"
865,"NCT01428804","Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression","DEPRESCO","Completed","No Results Available","Resistant Major Depression","Device: transcranial Direct Current Stimulation (tDCS)","MADRS [time frame: baseline, 1 wk, 2 wk, 4wk, 12 wk, 24 wk]|HDRS-21|BDI-13|subscores for anxiety depression scale from HRDS-21|STAI","Centre Hospitalier Universitaire de Besancon|H. Lundbeck A/S","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DEPRESCO","June 2011","July 2013","July 2013","September 5, 2011",,"August 23, 2016","CHU Besancon - Clinical Psychaitric Department, Besancon, France",,"https://ClinicalTrials.gov/show/NCT01428804"
866,"NCT00057226","An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Radafaxine","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score after 8 weeks of treatment|Change in the MADRS score at other timepoints; change in the Global Impression; percentage of remitters and responders based on the MADRS; change in anxiety, disability, motivation, energy, fatigue and pain; incidence of adverse events during the study","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","OHB20003","March 2003","April 2004","April 2004","March 28, 2003",,"April 16, 2015","GSK Investigational Site, Cerritos, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Boynton Beach, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Libertyville, Illinois, United States|GSK Investigational Site, Oakbrook Terrace, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, St. Charles, Missouri, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00057226"
867,"NCT04972474","Exploring Engagement With Remote Symptom Tracking for Depression (RADAR: Engage)",,"Recruiting","No Results Available","Major Depressive Disorder","Other: Smartphone app in-app components","Behavioural engagement|Experiential engagement (1)|Experiential engagement (2)|System Usability|Passive monitoring adherence","King's College London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","RESCM-20/21-21083","April 7, 2021","July 2021","July 2021","July 22, 2021",,"July 22, 2021","Department of Psychological Medicine, King's College London, London, United Kingdom","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT04972474/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04972474"
868,"NCT00048204","A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: GW597599B|Drug: paroxetine","Hamilton Depression Rating Scale|Hamilton Depression Rating Scale Clinical Global Impression-Global Improvement Clinical Global Impression-Severity of Illness Hospital Anxiety and Depression Scale","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","372","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","NKD20006","November 4, 2002","September 30, 2003","September 30, 2003","October 30, 2002",,"October 9, 2017",,,"https://ClinicalTrials.gov/show/NCT00048204"
869,"NCT04977856","Efficacy and Cost-effectiveness of Internet-delivered CBT for Adolescents With Depression","IDA","Not yet recruiting","No Results Available","Major Depressive Disorder","Behavioral: Behavioral activation (BA)|Other: Regular care within primary or secondary mental health care for children","Change from baseline in clinician-rated depressive scores on Children's Depression Rating Scale - Revised (CDRS-R)|Clinical Global Impression Scale - Severity (CGI-S)|Clinical Global Impression - Improvement (CGI-I)|Children's global assessment scale (CGAS)|Internet Intervention Patient Adherence Scale (iiPAS)|Anhedonia Scale for Adolescents (ASA)|Affective Reactivity Index (ARI)|Behavioral activation of Depression Scale - short form (BADS-S)|Concomitant interventions|The Client Satisfaction Questionnaire-8 (CSQ-8) - adolescent and parent version|Insomnia Severity Index (ISI)|Kidscreen-10 Index - adolescent and parent version|Need for further treatment - adolescent and parent version|Negative Effects Questionnaire (NEQ-20) - adolescent and parent version|The Revised Children's Anxiety and Depression Scale, short (RCADS-S) -adolescent and parent version|Quick Inventory of Depressive Symptomatology 17 items (QIDS-17) - adolescent and parent version|Work and Social Adjustment Scale, youth version (WSAS-Y) - adolescent and parent version|The Expressed Emotion Adjective Checklist (EEAC)|Trimbos Questionnaire for Costs associated with Psychiatric Illness (TiC-P)|Treatment credibility and expectancy scale - adolescent and parent version","Region Stockholm|Karolinska Institutet","All","13 Years to 17 Years   (Child)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2021-0859","September 1, 2021","September 1, 2023","June 1, 2024","July 27, 2021",,"July 27, 2021",,,"https://ClinicalTrials.gov/show/NCT04977856"
870,"NCT04953208","Remotely Non-invasive Brain Stimulation and Videogame to Alleviate Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Device: active tDCS|Device: sham tDCS|Behavioral: cognitive and emotional control video game|Behavioral: sham video game","Feasibility of treatment|Efficacy-Improvement on the MADRS scores compared to baseline.","Mor Nahum|Hadassah Medical Organization|Ludwig-Maximilians - University of Munich|Riga Stradins University|Hebrew University of Jerusalem","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","388-20-HMO","June 22, 2021","June 30, 2023","December 31, 2023","July 7, 2021",,"July 7, 2021","Ludwig-Maximilian University, Munich, Germany|Hadassah University Hospital, Jerusalem, Israel|Riga Stradins University (RSU), Riga, Latvia",,"https://ClinicalTrials.gov/show/NCT04953208"
871,"NCT04838262","Stress and the Sympathetic Nervous System in Adults With Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Other: Acute Stressors","total number of daily stressors|change in negative affect in response to daily stressors|increase in muscle sympathetic nerve activity in response to acute stress (compared to resting baseline activity)","The University of Texas at Arlington|Penn State University","All","18 Years to 30 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MH123928","April 1, 2021","March 2023","March 2023","April 9, 2021",,"April 9, 2021","The University of Texas at Arlington, Arlington, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04838262"
872,"NCT04891224","Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression",,"Enrolling by invitation","No Results Available","Major Depressive Disorder","Other: Pathway Platform mobile app","Determine if there is a change in adherence to measurement based care practices following the implementation of the Pathway Platform in a primary care setting.|Process Outcome: Measurement-based care.|Process Outcome: Shared-decision making|Process Outcome: Referrals to behavioral health|Process Outcome: Follow-up after hospitalization for mental illness|Process Outcome: Follow-up after emergency department visit for mental illness|Process Outcome: Healthcare resource utilization, hospital admissions|Process Outcome: Healthcare resource utilization, length of stay|Process Outcome: Healthcare resource utilization, emergency room admissions|Process Outcome: Healthcare resource utilization, outpatient visits|Process Outcome: Healthcare resource utilization, financials|Patient Clinical Outcomes: remission of major depressive disorder|Patient Clinical Outcomes: response to treatment for major depressive disorder","Advocate Health Care|Takeda|Lundbeck LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","9050020","February 19, 2021","March 31, 2022","March 31, 2022","May 18, 2021",,"May 18, 2021","Advocate Christ Medical Center, Oak Lawn, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04891224"
873,"NCT04721249","D-serine Supplementation for Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: D-serine|Dietary Supplement: Placebo","Depression Severity|Anxiety|Anhedonia|Neurocognition|Prefrontal glutamate concentration|Stress level|Inflammation","André Schmidt|Psychiatric Hospital of the University of Basel","All","18 Years to 60 Years   (Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AS-2124","July 1, 2021","April 1, 2023","September 1, 2023","January 22, 2021",,"July 28, 2021","University of Basel, Department of Psychiatry (UPK), Basel, Baselstadt, Switzerland",,"https://ClinicalTrials.gov/show/NCT04721249"
874,"NCT02945735","Gaze Contingent Feedback in Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depression, Unipolar|Depressive Disorder|Depressive Disorder, Major","Behavioral: Attention Modification","Change from baseline - Structured Interview for the Montgomery-Asberg Depression Rating Scale (SIGMA)|Change from baseline - BDI-II - Beck Depression Inventory","Tel Aviv University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAUDEPI","November 6, 2016","January 7, 2019","January 7, 2019","October 26, 2016",,"December 18, 2019","Tel-Aviv University, Tel-Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT02945735"
875,"NCT01392287","Treatment Resistant Geriatric Depression in Primary Care",,"Completed","No Results Available","Major Depressive Disorder","Drug: Memantine","Mean Differences in NAAG Levels between Subject Groups at Baseline and Week 8|Relationship of NAAG Levels and MADRS Scores between Subject Groups at Baseline and Week 8|Cognitive Impairment between Subject Groups at Baseline and Week 8","Mclean Hospital|Cambridge Health Alliance|Harvard University","All","55 Years to 89 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010-P-001094","May 2010","April 2012","April 2012","July 12, 2011",,"February 1, 2017","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01392287"
876,"NCT03666390","Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine|Drug: Midazolam","Reduction rate of suicide symptom|Reduction rate of depression symptom","Taipei Veterans General Hospital, Taiwan","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","107-2314-B-075-063-MY3","September 10, 2018","December 31, 2021","December 31, 2021","September 11, 2018",,"September 19, 2018","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03666390"
877,"NCT04724447","ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Valganciclovir|Drug: Placebo","White matter integrity of the inferior fronto-occipital fasciculus (IFOF)|Volume of the medial temporal gyrus (MTG)","Laureate Institute for Brain Research, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2021-001","July 2021","March 2023","March 2024","January 26, 2021",,"June 10, 2021","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04724447"
878,"NCT01326793","Internet-Based Depression Screening for College Students",,"Completed","No Results Available","Major Depressive Disorder","Other: Skype Consultation","9-item Patient Health Questionnaire","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1900","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2008P001438","September 2008","December 2014","December 2014","March 31, 2011",,"April 28, 2015","Depression Clinical and Research Program at Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01326793"
879,"NCT01253421","The Effects of Dopamine on Reward Processing",,"Completed","Has Results","Major Depressive Disorder (MDD)","Drug: amisulpride|Drug: placebo","Effect on PST Reward Learning|Effect on PST Penalty Learning|Effect on Caudate Response to Cues|Effect on NAcc Response to Cues|Putamen Response to Cues|Effect on Caudate Response to Reward|Effect on NAcc Response to Reward|Effect on Putamen Response to Reward|Effect on Caudate-dACC Connectivity After Reward|Effect on NAcc-MCC Connectivity After Reward","Mclean Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 45 Years   (Adult)","Phase 1","159","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2010-P001568|R01MH068376","February 2012","May 2016","May 2016","December 3, 2010","January 18, 2018","April 27, 2018","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01253421"
880,"NCT04541563","Fisher Wallace Neurostimulation & Depression Study",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Fisher Wallace Cranial Electrotherapy Stimulator Device","Change in Beck Depression Inventory Score Baseline vs week 4|Systematic Assessment for Treatment Emergent Events (SAFTEE) at week 8|Change in Patient Health Questionnaire - 8 (PHQ-8) Score Baseline vs week 4|Change in Patient Health Questionnaire - 8 (PHQ-8) Score Baseline vs week 2|Change in Beck Depression Inventory Score Delay Arm Week 4 to Week 8|Change in Hamilton Depression Score Baseline vs week 4|Change in Hamilton Depression Score Baseline vs week 2","ProofPilot|Fisher Wallace","All","21 Years and older   (Adult, Older Adult)","Not Applicable","175","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2518","August 24, 2020","March 30, 2021","November 30, 2021","September 9, 2020",,"February 11, 2021","ProofPilot (Remote Virtual Trial), New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT04541563/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT04541563/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04541563"
881,"NCT04531423","PKC as Serum Biomarkers for Depression",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: SSRI + golimumab|Other: SSRI + placebo","remission of acute phase","Shanghai Mental Health Center","All","18 Years to 45 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","smhcgxy","October 1, 2020","September 30, 2022","September 30, 2022","August 28, 2020",,"August 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04531423"
882,"NCT01831882","Identifying Biological Markers for Severe Depression",,"Completed","No Results Available","Major Depressive Disorder",,"Genetics","Stanford University|Cornell University|University of California, Irvine|Pritzker Consortium","All","18 Years to 70 Years   (Adult, Older Adult)",,"210","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","26529","July 2013","August 2020","August 2020","April 15, 2013",,"August 21, 2020","University of California, Irvine, Irvine, California, United States|Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, California, United States|Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01831882"
883,"NCT04576182","Supportive-Expressive and Emotion-Focused Treatment for Depression","SETEFT","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Supportive-expressive treatment|Behavioral: Emotions-Focused treatment","Weekly change in Hamilton rating scale for depression (HRSD)|Weekly change in Beck Depression Inventory (BDI)|Weekly change in Outcome Questionnaire (OQ)|Trajectories of change in Inventory of Interpersonal Problems (IIP-32)|trajectories of change in Quality of Life Enjoyment and Satisfaction- Short Version (Q-LES-Q)","University of Haifa|Israel Science Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISF 395/19","November 29, 2020","December 31, 2025","December 31, 2025","October 6, 2020",,"December 1, 2020","University of Haifa, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT04576182"
884,"NCT04529694","Patient Characteristics and Cognitive vs. Behavioral Therapies for Depression",,"Completed","No Results Available","Major Depressive Disorder","Other: Psychotherapy","Change in Hamilton Rating Scale for Depression at week 8 and week 16|Change in Beck Depression Inventory-II at week 8 and week 16","Ohio State University|Social Sciences and Humanities Research Council (Canada)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011B0342","October 20, 2011","June 26, 2012",,"August 28, 2020",,"August 28, 2020","Department of Psychology, The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04529694"
885,"NCT01255787","Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Vortioxetine|Drug: Placebo","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With a MADRS Response at Week 8|Percentage of Participants in MADRS Remission at Week 8|Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8","Takeda","All","20 Years to 64 Years   (Adult)","Phase 2|Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004/CCT-002|2010-022257-41|U1111-1117-6595|JapicCTI-101344|CTRI/2011/08/001963","November 2010","March 2012","April 2012","December 7, 2010","December 18, 2013","December 18, 2013","Split, Croatia|Zagreb, Croatia|Helsinki, Finland|Kuopio, Finland|Oulu, Finland|Tampere, Finland|Berlin, Germany|Bochum, Germany|Chemnitz, Germany|Hannover, Germany|Leipzig, Germany|Munchen, Germany|Nuernberg, Germany|Schwerin, Germany|Westerstede, Germany|Wiesbaden, Germany|Hong Kong, Hong Kong|Hyderabad, Andhra Pradesh, India|Ahmedabad, Gujarat, India|Lucknow, Uttar Pradesh, India|Varanasi, Uttar Pradesh, India|Kanpur, UttarPradesh, India|Tokoname-shi, Aichi, Japan|Fukuoka-shi, Fukuoka, Japan|Kitakyushu-shi, Fukuoka, Japan|Omuta-shi, Fukuoka, Japan|Shirakawa-shi, Fukushima, Japan|Sapporo-shi, Hokkaido, Japan|Yokohama-shi, Kanagawa, Japan|Kumamoto-shi, Kumamoto, Japan|Tokyo, Japan|Sungnam-si, Gyeonggi-do, Korea, Republic of|Incheon, Korea, Korea, Republic of|Seoul, Korea, Korea, Republic of|Yangsan-si, Korea, Korea, Republic of|Liepaja, Latvia|Riga, Latvia|Sigulda, Latvia|Johor Bahru, Malaysia|Kuala Lumpur, Malaysia|Makati City, NCR, Philippines|Mandaluyong City, NCR, Philippines|Manila, NCR, Philippines|Quezon City, NCR, Philippines|Bialystok, Poland|Gorlice, Poland|Leszno, Poland|Torun, Poland|Zuromin, Poland|Iasi, Lasi, Romania|Targu Mures, Mures, Romania|Bucharest, Romania|Bucuresti, Romania|Ekaterinburg, Russia, Russian Federation|Nizhny Novgorod, Russia, Russian Federation|Rostov on Don, Russia, Russian Federation|Saint-Petersburg, Russia, Russian Federation|Smolensk, Russia, Russian Federation|St. Petersburg, Russia, Russian Federation|Stavropol, Russia, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|Senta, Serbia|Changhua, Taiwan|Kaohsiung City, Taiwan|Taipei City, Taiwan|Taipei, Taiwan|Taoyuan Hsien, Taiwan|Chernigiv region, Ukraine|Dnipropetrovsk, Ukraine|Kharkiv,, Ukraine|Kiev, Ukraine|Lugansk, Ukraine",,"https://ClinicalTrials.gov/show/NCT01255787"
886,"NCT04528628","Optimization of Diagnosis and Treatment of Depression Based on Multidimensional Clinical Assessment Classification",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Drug: Treatment as Usual|Combination Product: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations","remission of acute phase","Shanghai Mental Health Center|RenJi Hospital|Shanghai 10th People's Hospital|Huashan Hospital|Shanghai Jiao Tong University School of Medicine|Nanjing Medical University|Zhejiang University","All","18 Years to 60 Years   (Adult)","Not Applicable","960","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SHZD2020PDH","October 2020","September 2022","September 2022","August 27, 2020",,"August 27, 2020","Huashan Hospital, Fudan University, Shanghai, Shanghai, China|Med-X Research Institute of Shanghai Jiao Tong University, Shanghai, Shanghai, China|Renji Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Shanghai Tenth People's Hospital, Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04528628"
887,"NCT01971203","Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat",,"Completed","Has Results","Major Depressive Disorder|Generalized Anxiety Disorder","Drug: seroquel xr|Behavioral: CBT","MADRS|HAM-A|Clinical Global Impression Scales for Severity and Improvement|Changes in Sexual Functioning Questionnaire (CSFQ)","Icahn School of Medicine at Mount Sinai|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","62","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 09-0807","September 2009","June 2013","June 2013","October 29, 2013","February 15, 2018","February 15, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01971203"
888,"NCT04518592","Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module in Multidimensional Omics for Peripheral Biomarkers.",,"Not yet recruiting","No Results Available","Major Depressive Disorder",,"reductive ratio of HAMD-17|Montgomery-Asberg Depression Rating Scale (MADRS).|HAMILTON ANXIETY SCALE (HAMA)|Clinical Global Impression scale - Severity of Illness (CGI-S)|The Pittsburgh Sleep Quality Index (PSQI)|The Montreal Cognitive Assessment (MoCA), score|The Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report) (QIDS-SR16)","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MDSDOT","September 1, 2020","August 31, 2022","August 31, 2022","August 19, 2020",,"August 19, 2020","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04518592"
889,"NCT02273154","Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder",,"Unknown status","No Results Available","Major Depression Disorder","Drug: Buspirone|Drug: Paroxetine","Rate of onset of effect|clinical response rate|remission rate|Changes of HAMD scores at week 4 and week 8 compared with baseline|Changes of HAMA scores at week 4 and week 8 compared with baseline","Si Tianmei|Peking University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BUS-IV-01","August 2014","December 2015","December 2015","October 23, 2014",,"October 23, 2014","Institute of mental health, Peking University, Beijing, Beijing, China|Henan mental health center, Xinxiang, Henan, China|Wuhan mental health center, Wuhan, Hubei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|Dalian No.7 People's Hospital, Dalian, Liaoning, China|Shanxi Dayi Hospital, Taiyuan, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT02273154"
890,"NCT04345471","A Study of MD-120 in Patients With Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Desvenlafaxine 100 mg|Drug: Desvenlafaxine 50 mg|Drug: Placebo","Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Number of Participants With Adverse Events (AEs)|Change from Baseline in Hamilton Depression Rating Scale-17 (HAM-D17) Total Score|Number of Participants With Adverse Drug Reactions (ADRs)|Plasma Concentration of desvenlafaxine","Mochida Pharmaceutical Company, Ltd.|Pfizer","All","20 Years and older   (Adult, Older Adult)","Phase 3","594","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MD120101|JapicCTI-205252","May 18, 2020","December 2022","December 2022","April 14, 2020",,"June 7, 2021","Mochida Investigational sites, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04345471"
891,"NCT04366258","Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression","TRIADE","Recruiting","No Results Available","Major Depressive Disorder","Device: Transcranial photobiomodulator|Device: Sham","Change of t-PBM effects on Blood Oxygen Level Dependent (BOLD) signal|Changes in the frequency of suicidal ideation experienced|Change in overall depression severity|Change in overall clinical improvement|Effectiveness of Blinding Process|Change in the frequency of side effects experienced|Changes in frequency of self reported side effects of t-PBM","NYU Langone Health|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","20-00217|1R61MH122647-01","August 1, 2020","April 2022","May 2022","April 28, 2020",,"November 5, 2020","Massachusetts General Hospital, Charlestown, Massachusetts, United States|New York University, New York, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States",,"https://ClinicalTrials.gov/show/NCT04366258"
892,"NCT04328103","Mechanisms of Emotion Regulation Underlying Successful CBT in Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Behavior Therapy (CBT)|Behavioral: Nonspecific Supportive Therapy (PBO)","HRSD week 0|HRSD week 3|HRSD week 6|HRSD week 9|HRSD week 12|BDI week 0|BDI week 1|BDI week 2|BDI week 3|BDI week 4|BDI week 5|BDI week 6|BDI week 7|BDI week 8|BDI week 9|BDI week 10|BDI week 11|BDI week 12|HRSD slope|BDI slope|N2 sink week 0|N2 sink week 12|P3 source week 0|P3 source week 12|CP source week 0|CP source week 12|LEA ERT week 0|LEA ERT week 12|Responder Yes/No|Remitter Yes/No|SRIS week 0|SRIS week 6|SRIS week 12|PMS week 0|PMS week 6|PMS week 12|MAAS week 0|MAAS week 6|MAAS week 12|FFMQ week 0|FFMQ week 6|FFMQ week 12|ERQ week 0|ERQ week 6|ERQ week 12|REA Fused Words week 0|REA Fused Words week 12|TAS week 0|TAS week 6|TAS week 12","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","6559R|R21MH121915-01A1","November 25, 2020","February 28, 2023","February 28, 2023","March 31, 2020",,"June 18, 2021","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04328103"
893,"NCT04181736","The BIomarker Guided Study for Depression","BIG","Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Guanfacine Pill|Drug: Placebo","Change in dorsolateral prefrontal cortex (DLPFC) activity|Change in digit span task performance|Change in maze task performance|Change in verbal memory recognition task performance","Stanford University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","49147","October 15, 2021","December 31, 2024","December 31, 2024","November 29, 2019",,"March 16, 2021","Stanford Psychiatry, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT04181736"
894,"NCT04142320","Closed-loop Optimized rTMS for Depression",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Device: closed-loop rTMS|Device: open-loop rTMS|Device: sham rTMS","Transcranial Magnetic Stimulation (TMS) / Electroencephalography (EEG) change","Stanford University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","138408","August 1, 2021","February 1, 2024","February 1, 2024","October 29, 2019",,"April 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04142320"
895,"NCT04138680","Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression","Biofeedback","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Active Biofeedback|Behavioral: Sham Biofeedback","Percent Increase in VTA Activation during MOTIVATE trials","Icahn School of Medicine at Mount Sinai","All","18 Years to 45 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 19-0616","October 9, 2019","December 2022","December 2022","October 24, 2019",,"May 28, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04138680"
896,"NCT04091971","Ketamine Treatment Effects on Synaptic Plasticity in Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine","Synaptic Density|17-item Hamilton Depression Rating Scale","New York State Psychiatric Institute","All","18 Years to 55 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","7847","October 9, 2020","March 1, 2022","March 1, 2022","September 17, 2019",,"May 7, 2021","New York State Psychiatric Institute/Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04091971"
897,"NCT04117789","Feasibility of Internet-delivered CBT for Adolescents With Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Behavioral: Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Other: Treatment as usual","Children's Depression Rating Scale - Revised (CDRS-R)|Treatment credibility and expectancy scale - adolescent and parent version|The Client Satisfaction Questionnaire-8 (CSQ-8) - adolescent and parent version|Need for further treatment - adolescent and parent version|Negative Effects Questionnaire (NEQ-20) - adolescent and parent version|Treatment completion|Therapist time|Clinical Global Impression Scale - Severity (CGI-S)|Clinical Global Impression - Improvement (CGI-I)|Children's global assessment scale (CGAS)|Short Mood and Feeling Questionnaire (SMFQ) - adolescent and parent version|The Revised Children's Anxiety and Depression Scale, short (RCADS-S) -adolescent and parent version|Affective Reactivity Index (ARI) - adolescent and parent version|Insomnia Severity Index (ISI)|Work and Social Adjustment Scale, youth version (WSAS-Y) - adolescent and parent version|Working Alliance Inventory, Short (WAI-S) - adolescent and parent version|Kidscreen-10 Index - adolescent and parent version","Karolinska Institutet|Region Stockholm","All","13 Years to 17 Years   (Child)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2019-03235","October 14, 2019","October 15, 2020","October 21, 2020","October 7, 2019",,"October 28, 2020","Child and Adolescent Psychiatry Research Center, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04117789"
898,"NCT03998748","Electrophysiological Correlates of Cognition in Depression",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Other: Sham Genetic Feedback","Default Mode Network Connectivity|Error Positivity (Pe)|Treatment Credibility and Expectancy Questionnaire","Mclean Hospital","All","18 Years to 45 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2019P001081","October 8, 2019","August 1, 2021","August 1, 2022","June 26, 2019",,"August 4, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03998748"
899,"NCT04032015","rTMS Study in Depression to Evaluate the Relationship Between Brain Plasticity and Clinical Outcome",,"Withdrawn","No Results Available","Major Depressive Disorder","Device: TMS","TMS-EEG change|Hamilton Depression Rating Scale (HamD)","Stanford University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","133611","January 1, 2020","June 1, 2023","June 1, 2023","July 25, 2019",,"April 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04032015"
900,"NCT03979040","Comparing Group Therapies for Veterans With Depression and PTSD",,"Recruiting","No Results Available","Major Depressive Disorder|Posttraumatic Stress Disorder","Behavioral: Group Transdiagnostic Behavior Therapy|Behavioral: Group Disorder-Specific Therapy (G-DSTs)","Depression Anxiety Stress Scale (DASS-Depression)|Illness Intrusiveness Ratings Scale (IIRS)|PTSD Checklist for DSM-5 (PCL-5)","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","208","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D2910-R","February 3, 2021","June 30, 2023","September 30, 2023","June 7, 2019",,"February 5, 2021","Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03979040"
901,"NCT03327974","Evolution of Dark Ideas When Introducing or Switching an Antidepressant","DEPASSE","Terminated","No Results Available","Current Major Depressive Disorder","Other: DEPASSE Apllication","Values of dark ideas assessed with a Likert type scale [1;5]|Values of the actual mood assessed with a Lickert type scale [1;5]|Values of the actual motivation assessed with a Lickert type scale [1;5]|Values of the ability to feel pleasure as usual assessed with a Lickert type scale [1;5]|Values of the energy assessed with a Lickert type scale [1;5]|Values of the social activities assessed with a Lickert type scale [1;5]|Values of the concentration assessed with a Lickert type scale [1;5]|Values of the stress assessed with a Lickert type scale [1;5]|Values of the libido assessed with a Lickert type scale [1;5]|Values of sleep assessed with a Lickert type scale [1;5]|Score at the Montgomery-Åsberg Depression Rating Scale (MADRS)|Score at the Columbia Suicide Severity Rating Scale (CSSRS)|Number of emergency room visits|Number of hospitalizations|Satisfaction score on the Lickert type scale [1;5]","University Hospital, Montpellier","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","UF9829","November 24, 2017","December 14, 2018","April 9, 2019","November 1, 2017",,"December 31, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT03327974"
902,"NCT03833206","A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: PDC-1421 Capsule","Montgomery-Åsberg Depression Rating Scale (MADRS)","BioLite, Inc.","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABV-1601-001","December 1, 2021","March 31, 2022","March 31, 2022","February 6, 2019",,"July 21, 2021","Cedars-Sinai Health System, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03833206"
903,"NCT00057213","An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Radafaxine","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) after 8 weeks of treatment|Change in the MADRS score at other timepoints; change in Clinical Global Impression; percentage of remitters and responders based on the MADRS; change in disability, motivation, energy, fatigue and pain;incidence of adverse events over course of study;","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","367","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","OHB20002","March 2003","April 2007","April 2007","March 28, 2003",,"April 16, 2015","GSK Investigational Site, Peoria, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Garden Grove, California, United States|GSK Investigational Site, Irvine, California, United States|GSK Investigational Site, National City, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Terre Haute, Indiana, United States|GSK Investigational Site, Florence, Kentucky, United States|GSK Investigational Site, Brockton, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Lyndhurst, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Galveston, Texas, United States|GSK Investigational Site, Lake Jackson, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00057213"
904,"NCT03742960","Sleep Subtypes in Adolescent Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Behavioral Sleep Restriction","Change in self-reported sleep efficiency (defined as total sleep time divided by time in bed and thus expressed as a percentage) as assessed via sleep diary|Change in self-reported mood assessed via the Multidimensional Mood Questionnaire|Change in Repetitive Negative Thinking (focus on problems) assessed by one question from the Response Style Questionnaire|Change in Repetitive Negative Thinking (focus on feelings) assessed by one question from the Response Style Questionnaire|Change in depressive symptoms from 1 to 3 days prior to the sleep manipulation and the end of the manipulation (second to last or last day of sleep manipulation)|Change in anxiety symptoms from 1 to 3 days prior to the sleep manipulation and the end of the manipulation (second to last or last day of sleep manipulation)","University of Bern|University Hospital for Child and Adolescent Psychiatry and Psychotherapy Bern","All","14 Years to 17 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sleep Subtypes","April 24, 2019","January 1, 2022","January 1, 2022","November 15, 2018",,"April 28, 2021","Leila Tarokh, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03742960"
905,"NCT01163266","Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Vortioxetine|Drug: Placebo","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With a MADRS Response at Week 8|Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 8|Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8","Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","462","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_316|U1111-1115-8770","July 2010","January 2012","January 2012","July 15, 2010","December 18, 2013","December 18, 2013","Anaheim, California, United States|Cerritos, California, United States|Costa Mesa, California, United States|Encino, California, United States|Garden Grove, California, United States|Irvine, California, United States|Pico Rivera, California, United States|Riverside, California, United States|Colorado Springs, Colorado, United States|Norwich, Connecticut, United States|Maitland, Florida, United States|North Miami, Florida, United States|Orange City, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|Smyrna, Georgia, United States|Chicago, Illinois, United States|Joliet, Illinois, United States|Skokie, Illinois, United States|Wichita, Kansas, United States|Lake Charles, Louisiana, United States|Worcester, Massachusetts, United States|St. Charles, Missouri, United States|St. Louis, Missouri, United States|Willingboro, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Rochester, New York, United States|Cinti, Ohio, United States|Dayton, Ohio, United States|Middleburg Heights, Ohio, United States|Portland, Oregon, United States|Norristown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Irving, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01163266"
906,"NCT03731728","Group CBT and Exercise in Management of Depression",,"Terminated","No Results Available","Major Depressive Disorder","Behavioral: Group CBT|Behavioral: Group exercise","Measuring changes in depressive symptoms scores using Beck Depression Inventory [Symptom Variable - Severity of Depression]|Evaluating change in symptoms using CORE 34 OM [Symptom variable - Symptoms Sub-scale - Psychological Health ]|Evaluating change in risk level using CORE 34 OM [Symptom variable - Risk Sub-scale - Psychological Health ]|Evaluating change in interpersonal functioning using CORE 34 OM [Functional variable - Functioning Sub-scale - Social Relationship ]|Evaluating change in well-being using CORE 34 OM [Functional variable - Well-being sub-scale - Psychological Health ]|Evaluating change in symptoms, risk level, interpersonal functioning, and well-being using CORE 10 OM [Symptom and Functional Variable - Psychological Health]|Change in the level of physical activity using the International Physical Activity Questionnaire [Functional Variable - Physical Activity]|Evaluating patients satisfaction with the service using Addiction and Mental Health Client Experience Survey [Service variables - Satisfaction with service]|Evaluating patients satisfaction with the care and treatment they received using Addiction and Mental Health Client Experience Survey [Service variables - Satisfaction with care and treatment]|Number of emergency department presentations in the past 6 months - [Service Variable - Service Utilization]|Number of EMS use in the past 6 months - [Service Variable - Service Utilization]|Number of community Addiction and Mental Health services appointments completed in the past 6 months - [Service Variable - Service Utilization]|Number of days stayed in inpatient services in the past 6 months - [Service Variable - Service Utilization]|Number of calls to Crisis and urgent services in the past 6 months - [Service Variable - Service Utilization]|Social Return on Investment (SROI) of the initiative to the system in the past 6 months - [Service Variable - Service Utilization]","University of Alberta|Alberta Health Services","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00080975","April 15, 2019","March 1, 2020","March 1, 2020","November 6, 2018",,"November 12, 2020","Royal Alexander Hospital, Edmonton, Alberta, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03731728/Prot_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03731728/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT03731728"
907,"NCT00300404","Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression",,"Completed","No Results Available","Schizophrenia|Major Depression","Drug: daraprim|Drug: pyrimethamine|Drug: folinic acid","Psychopathology ratings|TG infection parameters","Zentrum für Integrative Psychiatrie|Stanley Medical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","TOXO-KI-TT|SMRI grant # 01T-404","January 2002",,"September 2005","March 8, 2006",,"May 22, 2006",,,"https://ClinicalTrials.gov/show/NCT00300404"
908,"NCT01153009","Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With a MADRS Response at Week 8|Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8|Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8","Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_315|U1111-1114-8191","June 2010","March 2012","March 2012","June 29, 2010","December 18, 2013","December 18, 2013","Beverly Hills, California, United States|Chino, California, United States|Garden Grove, California, United States|Irvine, California, United States|Los Alamitos, California, United States|Oceanside, California, United States|Pasadena, California, United States|Pico Rivera, California, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|Norwalk, Connecticut, United States|Boca Raton, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Lauderhill, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Libertyville, Illinois, United States|Oakbrook Ter, Illinois, United States|Valparaiso, Indiana, United States|Shreveport, Louisiana, United States|Boston, Massachusetts, United States|Weymouth, Massachusetts, United States|Rochester Hills, Michigan, United States|Flowood, Mississippi, United States|Toms River, New Jersey, United States|Cedarhurst, New York, United States|Fresh Meadows, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|North Charleston, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|San Antonio, Texas, United States|Orem, Utah, United States|Woodstock, Vermont, United States|Richmond, Virginia, United States|Middleton, Wisconsin, United States|Waukesha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01153009"
909,"NCT00316160","Sexual Functioning Study With Antidepressants",,"Completed","No Results Available","Depressive Disorder, Major|Major Depressive Disorder (MDD)","Drug: Bupropion Hydrochloride Extended-release|Drug: Extended-release Venlafaxine","To compare the effects of bupropion XL and venlafaxine XR on overall sexual functioning in outpatients with MDD as measured by mean changes in CSFQ-S total scores across Weeks 5, 6, 9 and 12.|Efficacy, Safety, Tolerability, Health Outcome","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","347","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","100368","September 2004","May 2005","May 2005","April 20, 2006",,"May 30, 2017","GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Temecula, California, United States|GSK Investigational Site, Upland, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Coral Springs, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Smyrna, Georgia, United States|GSK Investigational Site, Oak Brook, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Braintree, Massachusetts, United States|GSK Investigational Site, Greenfield, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Lincoln, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bellaire, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Yakima, Washington, United States|GSK Investigational Site, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00316160"
910,"NCT02120729","Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT","CYP-GUIDES","Unknown status","No Results Available","Major Depressive Disorder","Other: Genotype-guided care","Length of Hospitalization Stay|Readmission to Psychiatric Hospital within 30 days","Hartford Hospital|Agency for Healthcare Research and Quality (AHRQ)","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","1500","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","RUAN004090HE","March 2014","August 2018","October 2019","April 23, 2014",,"February 12, 2019","Institute of Living at Hartford Hospital, Hartford Healthcare, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02120729"
911,"NCT01360190","Neurophysiologic Monitoring of Antidepressant Treatment","Lilly","Completed","No Results Available","Major Depressive Disorder","Drug: fluoxetine","Change in Hamilton Rating Scale For Depression Score","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","94-08-273-13","August 1994","August 1996","August 1996","May 25, 2011",,"May 25, 2011",,,"https://ClinicalTrials.gov/show/NCT01360190"
912,"NCT04788524","Neural Correlates of Stress and Perceived Control in Adolescent Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Computer Task Manipulation","Blood-Oxygen-Level-Dependent Imaging (BOLD) activation of the ventral striatum and ventral medial prefrontal cortex|Cortisol Rating|Mood Rating|Stress Reactivity Score|Stress Reactive Rumination Score|Positive Affect Score","Mclean Hospital","Female","14 Years to 18 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","K23MH122668","April 21, 2021","April 30, 2025","April 30, 2025","March 9, 2021",,"July 12, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04788524"
913,"NCT04621786","Electroconvulsive Therapy Amplitude Titration",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface","Inventory of Depressive Symptomatology - Clinician (IDS-C)|Delis-Kaplan Executive Function System verbal fluency (DKEFS) test score","University of New Mexico|The Zucker Hillside Hospital|National Institute of Mental Health (NIMH)|The Mind Research Network|University of Texas Southwestern Medical Center","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MH125126","March 1, 2021","December 1, 2022","December 30, 2022","November 9, 2020",,"May 3, 2021","University of New Mexico, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT04621786"
914,"NCT03363919","Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Device: NeuroStar TMS Therapy® System|Device: NeuroStar XPLOR®","Total Children's Depression Rating Scale, Revised (CDRS-R) score|Intracortical Facilitation ICF","Mayo Clinic|National Institute of Mental Health (NIMH)|Neuronetics","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","17-004958|1R01MH113700-01","September 24, 2018","December 2021","December 2022","December 6, 2017",,"October 22, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03363919"
915,"NCT02715128","Disorder-tailored Transcranial Direct Current Stimulation (tDCS) of the Prefrontal Cortex","MRSDC1","Recruiting","No Results Available","Major Depressive Disorder|Schizophrenia","Device: Transcranial direct current stimulation (tDCS)","FMRI modulations|GABA and Glutamate modulations|Clinical trajectories","Ludwig-Maximilians - University of Munich","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","493-14","March 2016","January 2021","January 2022","March 22, 2016",,"June 2, 2020","Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT02715128"
916,"NCT04543773","Individualized Targeting and Neuromodulation of Late-Life Depression","TMS-LLD","Recruiting","No Results Available","Major Depressive Disorder","Device: rTMS","Anterior Cingulate Cortex (ACC) Connectivity|Depression Severity","University of New Mexico|The Mind Research Network","All","60 Years to 79 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-531","October 1, 2020","October 30, 2021","October 30, 2021","September 10, 2020",,"April 19, 2021","University of New Mexico HSC, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04543773/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04543773"
917,"NCT03281044","Fecal Microbiota Transplantation in Depression",,"Terminated","No Results Available","Major Depressive Disorder","Drug: Fecal microbiota capsules|Drug: Placebo oral capsule","Depressive symptoms as measured with the Hamilton Rating Scale for Depression|Gut microbiota composition as assessed by 16-S-rRNA sequencing of stool samples|Cerebral blood flow (measured with arterial spin labeling, mL/100 g/min^10)|Brain structure (measured with structural magnetic resonance imaging to assess gray matter volume in mm^3, and diffusion tensor imaging to assess fractional anisotropy (dimensionless) and mean diffusivity (m2/s))|Brain function (measured Blood-oxygen-level dependent contrast imaging)|HPA axis function (measured with salivary cortisol awakening responses).|Neurogenesis (measured with blood levels of BDNF).|Appetite-regulating hormones (measured with blood levels of ghrelin and leptin).|Immunoregulation and inflammation (measured with blood levels of macrophage migration inhibitory factor and interleukin 1 beta).|Cognition (measured with the Trail Making Test)|Physical activity (measured with a portable wristwatch).|Sleep quality (measured with 28-channel electroencephalography)","Psychiatric Hospital of the University of Basel","All","18 Years to 60 Years   (Adult)","Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017-01050","October 24, 2018","March 16, 2020","March 16, 2020","September 13, 2017",,"April 16, 2020","University Psychiatric Clinics (UPK), Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT03281044"
918,"NCT00961454","Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression",,"Completed","No Results Available","Major Depression|Anxiety Disorder|Post-Traumatic Stress Disorder|Substance Abuse Disorder","Device: Photobiomodulation with a super-luminous light emitting diode","Hamilton Depression Rating Scale|Hamilton Anxiety Rating Scale","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008P-000937","January 2009","June 2009","June 2009","August 19, 2009",,"August 19, 2009","Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00961454"
919,"NCT03242213","Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Mobile App","Patient activation|Patient-provider engagement|Depression symptoms|Cognitive dysfunction|Medication changes|Quality of Life|Health care utilization","Advocate Health Care|Takeda","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","6680","July 20, 2017","January 18, 2019","September 9, 2019","August 8, 2017",,"January 22, 2021","Advocate Christ Medical Center, Oak Lawn, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03242213"
920,"NCT04952532","A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic","CogRemVet","Not yet recruiting","No Results Available","Major Depressive Disorder","Other: Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score: pre- minus post-treatment intervention","VA Office of Research and Development","All","18 Years to 60 Years   (Adult)","Not Applicable","36","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D3738-P|1I21RX003738-01A1","October 1, 2021","September 30, 2023","September 30, 2023","July 7, 2021",,"July 12, 2021","James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04952532"
921,"NCT04487730","Social Reward and Its Effect on Brain Functions in Psychotherapies for Mid- and Late-Life Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: ""Engage & Connect"" Psychotherapy|Behavioral: Symptom Review and Psychoeducation (SRP)","Change in Resting State fMRI Connectivity of the Positive Valence System|Change in Montgomery Asberg Depression Rating Scale (MADRS)|Change in Behavioral Activation for Depression Scale (BADS)","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-04021860|K23MH123864-01","October 15, 2020","April 1, 2025","April 1, 2025","July 27, 2020",,"May 14, 2021","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04487730"
922,"NCT04239963","Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression",,"Recruiting","No Results Available","Major Depressive Disorder",,"Feedback-related positivity (FRP) amplitudes over frontocentral scalp regions in response to rewarded trials versus no-reward trials|Event-related negativity (ERN) amplitudes over frontocentral scalp regions in response to correct trials versus incorrect trials.|Behavioral Performance on the Probabilistic Reward Task (PRT)|Behavioral Performance on the Flanker Task|Rumination","Mclean Hospital","All","18 Years to 64 Years   (Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2019P003371","August 17, 2020","August 2022","August 2023","January 27, 2020",,"August 4, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04239963"
923,"NCT04337242","Blended Care Versus Face-to-Face Therapy for Depression","BLENDED","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: B-DIT|Behavioral: B-CBT|Behavioral: DIT|Behavioral: Cognitive Behavioral Therapy","Changes in depressive symptoms assessed by the Beck Depression Inventory (BDI-II) at 6-month follow-up (12 months after the start of treatment)|Partial and full recovery|Quality of Life|Treatment Expectancy|Satisfaction with treatment|Cost-effectiveness","Universitaire Ziekenhuizen Leuven|Belgium Health Care Knowledge Centre|Erasmus University Rotterdam","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S59765","March 22, 2019","September 30, 2021","March 31, 2023","April 7, 2020",,"April 7, 2020","CGG Andante, Berchem, Belgium|CGG Vagga, Berchem, Belgium|CGG Mandel & Leie, Kortrijk, Belgium|CGG VBO, Leuven, Belgium|CGG De Pont, Mechelen, Belgium|CGG Kempen, Turnhout, Belgium",,"https://ClinicalTrials.gov/show/NCT04337242"
924,"NCT04623034","Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine",,"Completed","No Results Available","Major Depressive Disorder","Drug: Ademetionine","Incidence and severity of treatment-related adverse events (safety and tolerability) as measured by vital signs, ECG, laboratory tests, neurological function tests, and the occurance of adverse events|Pharmacokinetics was evaluated by measuring the systemic plasma concentration of ademetionine","MSI Methylation Sciences, Inc.|Algorithme Pharma Inc","All","21 Years to 55 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MSI-CP.001.02","April 17, 2013","June 8, 2013","June 8, 2013","November 10, 2020",,"November 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04623034"
925,"NCT00075296","FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression",,"Completed","No Results Available","Major Depressive Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"100","NIH","Observational",,"040075|04-M-0075","January 5, 2004",,"April 21, 2008","January 9, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00075296"
926,"NCT02191397","Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Bupropion|Drug: Bupropion Matching Placebo|Drug: Escitalopram|Drug: Escitalopram Matching Placebo","Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)|Response Rate Based on HAMD-17 Total Score|Remission Rate Based on HAMD-17 Total Score|Sustained Response Rate Based on HAMD-17 Total Score|Sustained Remission Rate Based on HAMD-17 Total Score|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 1, 2, 4, 6 and 8|Change From Baseline in HAMD-17 Depressed Mood Subscale Score (Score of Item 1) at Weeks 1, 2, 4, 6 and 8|Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score (Sum of Scores of Items 10, 11, 12, 13, 15 and 17) at Weeks 1, 2, 4, 6 and 8|Change From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8|Change From Baseline in HAMD-17 Sleep Disorder Subscale Score (Sum of Scores of Items 4, 5 and 6) at Weeks 1, 2, 4, 6 and 8|Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Weeks 1, 2, 4, 6 and 8|Percentage of Participants With a Clinical Global Impression Global Improvement (CGI-I) Score of 1 (""Very Much Improved"") or 2 (""Much Improved"") at Weeks 1, 2, 4, 6 and 8|Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious AE (SAE)|Change From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points|Change From Baseline in Hematocrit at the Indicated Time Points|Change From Baseline in White Blood Cell (WBC) Count, Total Neutrophil, Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Points|Change From Baseline in Total Bilirubin, Direct Bilirubin and Creatinine at the Indicated Time Points|Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT) and Lactose Dehydrogenase (LD) at the Indicated Time Points|Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at the Indicated Time Points|Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points|Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points|Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points|Number of Participants With Urinalysis Data Outside the Normal Range|Number of Participants With Vital Sign Parameters Outside the Clinical Concern Range|Number of Participants With Electrocardiogram (ECG) Data Outside the Clinical Concern Range|Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ)|Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","534","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","114589","February 10, 2015","October 10, 2016","October 25, 2016","July 16, 2014","February 18, 2019","February 25, 2020","GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Nanning, Guangxi, China|GSK Investigational Site, Guiyang, Guizhou, China|GSK Investigational Site, Baoding, Hebei, China|GSK Investigational Site, Harbin, Heilongjiang, China|GSK Investigational Site, Changsha, Henan, China|GSK Investigational Site, Changsha, Hunan, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Xian, Shaanxi, China|GSK Investigational Site, Taiyuan, Shanxi, China|GSK Investigational Site, Xi'an, Shanxi, China|GSK Investigational Site, Kunming, Yunnan, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Guangzhou, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Wuhan, China",,"https://ClinicalTrials.gov/show/NCT02191397"
927,"NCT03779789","Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment","VESPA","Unknown status","No Results Available","Major Depressive Disorder","Drug: Vortioxetine|Drug: Sertraline|Drug: citalopram|Drug: Escitalopram|Drug: Paroxetine|Drug: Fluoxetine|Drug: Fluvoxamine","Number of participants withdrawing from treatment due to adverse events (tolerability)|Number of participants withdrawing from treatment due to any cause (acceptability)|Overall mortality|Number of participants with at least one episode of self-harm|Number of participants died by suicide|Treatment-related adverse events as assessed by the ASEC|Number of participants with a reduction of at least 50% of the baseline score of the MADRS (responders)|Efficacy on depressive symptoms as assessed by the MADRS|Quality of life as assessed by the EQ-5D|Cognitive performance as assessed by the SBT","Azienda Ospedaliera Universitaria Integrata Verona|University of Catania","All","65 Years and older   (Older Adult)","Phase 4","358","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016-0234923|2018-001444-66","February 1, 2019","July 30, 2019","January 31, 2020","December 19, 2018",,"January 9, 2019",,,"https://ClinicalTrials.gov/show/NCT03779789"
928,"NCT04031937","Sensory and Psychomotor Profile in Depression","DEPCOR","Completed","No Results Available","Major Depressive Disorder","Other: Psychomotor assessment","% of patients with a distinctive feature at the sensory profile questionnaire from the AASP|% of patients with a failure at the muscle tone test from the NP-MOT battery|% of patients with a failure at the gross motor test from the NP-MOT battery","Centre Hospitalier Esquirol","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2018-A02055-50","October 23, 2018","March 23, 2019","October 15, 2019","July 24, 2019",,"July 20, 2021","Centre Hospitalier Esquirol, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04031937"
929,"NCT04317001","Treatment for Cognitive Impairment in Depression","T-CID","Withdrawn","No Results Available","Major Depressive Disorder","Drug: Modafinil|Drug: Placebo","Change in Depression, Anxiety and Stress Scale (DASS)","Stanford University","All","18 Years to 50 Years   (Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","46217","December 1, 2018","November 30, 2022","November 30, 2024","March 20, 2020",,"March 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04317001"
930,"NCT01941043","A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment",,"Completed","No Results Available","Major Depressive Disorder","Drug: CERC-301|Other: Placebo","HDRS-17 after 7 days of dosing with study drug|HDRS-17 Averaged between 7 and 28 days of treatment with study drug|HDRS-17 after 28 days of dosing with study drug","Cerecor Inc","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","1357","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clin301-201","November 2013","September 2014","October 2014","September 13, 2013",,"December 21, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona TMS Therapy Center, Phoenix, Arizona, United States|ProScience Research Group, Culver City, California, United States|Collaborative NeuroScience Network, Inc., Garden Grove, California, United States|Behavioral Research Specialists, Glendale, California, United States|Synergy Clinical Research Center, National City, California, United States|Pacific Clinical Trials, LLC, Oakland, California, United States|Southern CA Psychiatrists, Oceanside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Scientific Clinical Research, Inc., North Miami, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Chicago Psychiatry Associates, Chicago, Illinois, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|PCRC, O'Fallon, Missouri, United States|Bioscience Research, Mount Kisco, New York, United States|The Medical Research Network, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Suburban Research Associates, Media, Pennsylvania, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01941043"
931,"NCT00984087","rTMS for Adolescents and Young Adults","JHU","Withdrawn","No Results Available","Major Depressive Disorder","Device: TMS with Neurostar TMS Therapy System","Change in depressive level after 4 weeks of rTMS compared with baseline scores. The Hamilton Depression Rating Scale (HDRS) will be used to measure changes in adolescents and young adults.|Change in depressive level using the CDRS (if adolescent) and HDRS (if young adult) at 1-week follow-up compared with baseline scores.|Rates of remission (CDRS≤20; HDRS ≤10) and response (≥40% reduction in CDRS; ≥50% reduction in HDRS) at end of treatment and at follow-up.|Measure across the 4 weeks of rTMS and at 1-week follow-up and compare with baseline scores the following: depressive symptoms, suicidal ideation, anxiety, and Clinical Global Impression-Severity Score (CGI-S).|Safety of rTMS, as defined by maintained participant baseline pretreatment physical and neurological status.","Johns Hopkins University","All","15 Years to 24 Years   (Child, Adult)","Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21284|NA_00021284","October 2009","October 2011","October 2011","September 24, 2009",,"April 4, 2013","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00984087"
932,"NCT03780881","EXperimental Paradigm to Investigate Expectation Change in Depression 4","EXPECD4","Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Expectation confirmation|Behavioral: Expectation disconfirmation","2-Item Performance Expectations Scale - generalized|2-Item Performance Expectations Scale - task-specific","Philipps University Marburg Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","171","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","2018-37k","November 11, 2018","March 30, 2019","August 31, 2019","December 19, 2018",,"May 14, 2019","Schoen Klinik Bad Arolsen, Bad Arolsen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT03780881"
933,"NCT02801513","Maintaining Mechanisms of Chronic Depression and Their Changeability","GetWell","Completed","No Results Available","Major Depressive Disorder","Behavioral: Brief Mindfulness Training|Behavioral: Resting Control Training","Error-related negativity|Long-range temporal correlations of theta oscillations in resting EEG|Late positive potentials|Levels of state mindfulness|Interoceptive awareness|Levels of depressive symptoms|Ruminative tendencies","Freie Universität Berlin|Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","BA2255/3-1","September 2013","March 2015","March 2015","June 16, 2016",,"June 16, 2016",,,"https://ClinicalTrials.gov/show/NCT02801513"
934,"NCT04711005","Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: (2R,6R)-Hydroxynorketamine hydrochloride|Drug: Placebo","Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, maximum plasma concentration (Cmax)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, time taken to reach maximum plasma concentration (tmax)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, minimum plasma concentration at the end of the dosing interval after each dose in the MAD study (Cmin)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, area under the curve concentration (AUC)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, plasma drug clearance (CL)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, renal drug clearance (CLr)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, apparent volume of distribution during terminal phase (Vz)|Pharmacokinetics of (2R,6R)-Hydroxynorketamine, half-life (t1/2)|Pharmacodynamics of (2R,6R)-Hydroxynorketamine, quantitative electroencephalography (qEEG) relative spectral power|Pharmacodynamics of (2R,6R)-Hydroxynorketamine, quantitative electroencephalography (qEEG) visual evoked time-locked data|Pharmacodynamics of (2R,6R)-Hydroxynorketamine, quantitative electroencephalography (qEEG) source localization","National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HNK-378227-01|18-01","January 11, 2021","November 2021","November 2021","January 15, 2021",,"February 2, 2021","Duke Early Phase Clinical Research, Durham, North Carolina, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04711005/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04711005"
935,"NCT00285935","Cellular Aging and Neurobiology of Depression Study","CAN-D","Completed","No Results Available","Major Depressive Disorder","Other: Standard Clinical Care with an SRRI","Depression ratings at baseline and Week 8|Serum levels of steroids and neurosteroids at baseline and Week 8|Serum levels of oxidative stress markers at baseline and Week 8|Serum levels of cytokines and immune markers at baseline and Week 8","University of California, San Francisco|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)","All","21 Years to 60 Years   (Adult)","Not Applicable","228","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","10-00825|R01MH083784","December 2010","March 2020","March 2020","February 2, 2006",,"December 17, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00285935"
936,"NCT03708159","Maintenance of Response After rTMS for Depression Using tDCS","START","Recruiting","No Results Available","Major Depressive Disorder","Device: active tDCS + mindfulness meditation|Other: sham tDCS + mindfulness meditation","Proportion of patients maintaining remission of depressive symptoms or response to rTMS treatments as measured by the Hamilton Rating Scale for Depression - 17 Hamilton Rating Scale for Depression (17-item version)|Proportion of responders and remitters who relapse","Centre for Addiction and Mental Health|University Health Network, Toronto","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","063-2018","September 24, 2018","December 2021","July 2022","October 17, 2018",,"February 15, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03708159"
937,"NCT02942251","Relapse Predicting Model for First Episode Depression","RPM-FED","Unknown status","No Results Available","Major Depressive Disorders","Other: Clinical features and medication|Other: Psycho-social|Other: immunology|Other: Laboratory abnormality|Other: Comorbidity|Other: Treatment as usual","HAM-D total score|Time to relapse","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pending","December 2016","December 2018","December 2019","October 24, 2016",,"October 26, 2016",,,"https://ClinicalTrials.gov/show/NCT02942251"
938,"NCT03645096","Development of Pregnenolone as a Treatment for Depression R61",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Pregnenolone 500 mg|Drug: Pregnenolone 800 mg|Drug: Placebo","Functional connectivity.|GABA concentration.|Systematic Assessment for Treatment Emergent Events (SAFTEE).|Serum pregnenolone level.|Pregnenolone dose.","University of Texas Southwestern Medical Center|National Center for Complementary and Integrative Health (NCCIH)","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STU 052018-030","September 1, 2019","September 30, 2021","October 31, 2021","August 24, 2018",,"July 2, 2021","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03645096"
939,"NCT03652597","Neuro-Cardiac-Guided Transcranial Magnetic Stimulation: Replication and Dose-response.",,"Completed","No Results Available","Major Depressive Disorder","Device: Transcranial magnetic stimulation (TMS)","Heart rate during stimulation, converted to RR intervals","Utrecht University|Research institute Brainclinics","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NL63092.041.17","March 6, 2018","May 2, 2019","May 2, 2019","August 29, 2018",,"May 15, 2019","Research institute Brainclinics, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03652597"
940,"NCT04981561","Safety and Tolerability of GATE-251 in Normal Human Volunteers",,"Completed","No Results Available","Major Depressive Disorder","Drug: GATE-251|Drug: Placebo","Treatment emergent adverse events|Pharmacokinetics, maximum plasma concentration|Pharmacokinetics, time to maximum plasma concentration|Pharmacokinetics, area under the curve for plasma concentration","Ronald M Burch MD PhD|Gate Neurosciences, Inc","All","18 Years to 45 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3125-101-009","December 9, 2016","December 21, 2017","December 21, 2017","July 29, 2021",,"July 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04981561"
941,"NCT02459236","A Study of Intermittent Doses of CERC-301 in MDD",,"Completed","No Results Available","Major Depressive Disorder","Drug: CERC-301|Drug: Placebo","Change in Bech-6 from baseline|Change from baseline in Santen-7|Change from baseline in HDRS-17|Change from baseline in Bech-6|Change from baseline in CUDOS-A|Change from baseline in SHAPS-SR|Change from baseline in QIDS-SR|Change from baseline in CGI-I|Change from baseline in CGI-S","Cerecor Inc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Clin301-203","June 2015","September 2016","December 2016","June 2, 2015",,"September 28, 2017","Pharmacology Research Institute (PRI), Newport Beach, California, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Chicago Research Center, Inc., Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|Bioscience Research LLC, Mount Kisco, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Fingerlakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02459236"
942,"NCT04933630","Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study","TRAIT-RS","Recruiting","No Results Available","Major Depressive Disorder","Drug: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)","Stability of treatment response as defined as change in self-report PHQ-9 total scores during the observational period from Baseline/Day 0 to End of Study (EOS)/Day 365.|The number of participants who meet MDD relapse criteria as defined as the higher of a) PHQ-9 score ≥ 10, or b) ≥ 50% increase in PHQ-9 score from Baseline/Day 0, and verified by clinician-rated assessment as indicated by a HAM-D score ≥ 14 and CGI ≥ 4.|The number of participants who maintain ADT compliance as defined as ≥ 80% average monthly adherence during the observational period.","Adams Clinical","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TRAIT-MDD-401","June 1, 2021","December 31, 2023","December 31, 2023","June 22, 2021",,"June 22, 2021","Adams Clinical, Watertown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04933630"
943,"NCT03388177","Yoga for Young Women With Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Yoga-based therapy|Other: Treatment as usual","Change in Hamilton Depression Rating Scales (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Depression scale of Depression Anxiety Stress Scales (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Structured clinical interview for DSM-IV|Change in Anxiety scale of Depression Anxiety Stress Scales (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Stress scale of Depression Anxiety Stress Scales (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Healthcare use with healthcare consumption scale (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Health-related quality of life with EQ-5D-5L (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Perseverative thinking Questionnaire (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Exogenous cuing task (from baseline to 10-15 weeks post baseline)|Change in Self-Compassion Scales (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Implicit Association Test (of depression self-concept) (from baseline to 10-15 weeks post baseline)|Change in Intolerance of Uncertainty Scale-short form (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Five-Facet Mindfulness Questionnaire-short form (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Awareness scale of the Scale of Body Connection (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Work and Social Adjustment Scale (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in World Health Organization Quality of Life Questionnaire-brief (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)|Change in Scales of Psychological Well-being-short form (from baseline to 10-15 weeks post baseline, 6-month follow-up and 12-month follow-up)","University of Groningen|Lentis Psychiatric Institute|ZonMw: The Netherlands Organisation for Health Research and Development|Triodos Foundation","Female","18 Years to 34 Years   (Adult)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","60-63600-98-127","December 16, 2016","December 16, 2018","December 16, 2019","January 2, 2018",,"February 5, 2018","Lentis Psychiatric Institute, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03388177"
944,"NCT04384965","Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic",,"Recruiting","No Results Available","Major Depressive Disorder","Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil","Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)|Change in HRSD-24|Response on HRSD-24|Remission on Patient Health Questionnaire (PHQ-9)|Response on PHQ-9|Change in PHQ-9|Remission on General Anxiety Disorder 7 item (GAD-7)|Response on GAD-7|Change in GAD-7|Remission on Beck Depression Inventory (BDI-II)|Response on BDI-II|Change on BDI-II|Remission on Beck Scale for Suicidal Ideation (SSI)|Change on SSI|Change in WHO Disability Assessment Schedule (WHODAS)|Proportion of Patients Maintaining Response During Relapse Prevention","Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","059/2020","May 12, 2020","May 1, 2022","November 1, 2022","May 12, 2020",,"February 15, 2021","CAMH, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04384965"
945,"NCT03564067","MARt-Depression Trial",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Behavioral: Computerized CBT (cCBT)","Maintained remission of depressive symptoms as measured by the Hamilton Rating Scale for Depression - 24","Centre for Addiction and Mental Health","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","126-2016","July 5, 2018","July 31, 2021","December 30, 2021","June 20, 2018",,"February 16, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03564067"
946,"NCT00243425","Patient-Centered Depression Care for African Americans",,"Unknown status","No Results Available","Major Depressive Disorder","Procedure: Standard Quality Improvement|Procedure: Patient-centered Intervention","Compare the effectiveness of a culturally tailored intervention with the effectiveness of a standard intervention by evaluating its impact on patient outcomes (remission of depression, depression symptom level, functional status) at 6 and 12 months.|Evaluating intervention impact on processes of care (satisfaction of care, guideline concordant care, patient involvement in participatory decision making, communication skills) rated by patients and providers at 6 and 12 months.","Agency for Healthcare Research and Quality (AHRQ)|Aetna, Inc.|National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","250","U.S. Fed|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01HS013645","March 2004",,"March 2007","October 24, 2005",,"October 24, 2005","Christiana Care Health Services, Wilmington, Delaware, United States|Johns Hopkins Community Phsyicians, Baltimore, Maryland, United States|Sinai Hospital, Baltimore, Maryland, United States|Baltimore Medical Systems, Middlesex Health Center, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00243425"
947,"NCT04467164","Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation","tVNS-MDD","Completed","No Results Available","Major Depressive Disorder","Device: exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Device: Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)","Brain activity changes [percent blood oxygenation level dependent signal change] evaluated using functional magnetic resonance imaging during a visual stress challenge|Change in depressive symptoms assessed by the Beck Depression Inventory|Changes in cardiac autonomic function during functional magnetic resonance imaging","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","Female","25 Years to 40 Years   (Adult)","Not Applicable","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2013P001259|R21MH103468","April 15, 2015","September 15, 2018","September 22, 2018","July 10, 2020",,"July 10, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04467164"
948,"NCT04748276","Tracking Response to Antidepressants in Advance of Investigational Trials","TRAIT","Recruiting","No Results Available","Major Depressive Disorder","Drug: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)","Change in Hamilton Depression Inventory - 17 item (HAM-D) total score in response to a treatment cycle from Baseline/Day 0 to the end of a 6-week treatment cycle.|Failure to respond to 1, 2, or 3+ ADT treatment cycles, as defined as < 25% change in HAM-D total score from study Baseline/Day 0 to Day 42 of the participant's 1st, 2nd, or 3rd+ treatment cycles.|Partial response to 1, 2, or 3+ ADT treatment cycles, as defined as ≥ 25% to < 50% change in HAM-D total score from study Baseline/Day 0 to Day 42 of the participant's 1st, 2nd, or 3rd+ treatment cycles.|Total number of treatment cycles required to reach ADT response, as defined as ≥ 50% reduction in HAM-D score from Baseline/Day 0 to Day 42 of each treatment cycle.","Adams Clinical","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TRAIT-MDD-107","January 2, 2019","December 31, 2022","December 31, 2022","February 10, 2021",,"March 10, 2021","Adams Clinical, Watertown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04748276"
949,"NCT02376257","Improving Therapeutic Learning in Depression: Proof of Concept",,"Completed","Has Results","Major Depressive Disorder","Drug: 250 mg DCS|Drug: 100 mg Modafinil|Drug: Placebo","Recall of Cognitive Therapy Content|1 Week Delayed Recall of Emotional Story Items|1 Week Delayed Recall Logical Memory|Logical Memory Immediate Recall|Immediate Memory Measured by the Hopkins Verbal Learning Task|Immediate Recall of Emotional Story Items|Skills of Cognitive Therapy|Digits Backward","Boston University Charles River Campus","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R21MH102646","September 16, 2014","April 21, 2017","May 2017","March 3, 2015","September 19, 2018","September 19, 2018","Boston University, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02376257/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02376257/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02376257"
950,"NCT03871088","N-3 Fatty Acids as the First-line Antidepressant Therapy: From Biomarkers to Clinical Subtypes",,"Completed","No Results Available","Major Depressive Disorder","Dietary Supplement: Omega-3 fatty acids","Hamilton Rating Scale for Depression (HAMD) Changes|Response rate|Remission rate","National Science Council, Taiwan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","NHRI-EX105-10528NI","July 2015","June 2018","December 2018","March 12, 2019",,"March 12, 2019","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03871088"
951,"NCT00629551","An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder","COMPASS","Completed","No Results Available","Depressive Disorder, Major","Drug: saredutant (SR48968)|Drug: paroxetine|Drug: placebo","Change from baseline in the Hamilton Depression Rating Scale (HAM-D) total score|Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ) total score|Change from baseline in the Clinical Global Impression severity of illness score|Change from baseline in the HAM-D depressed mood item scores","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","825","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10438|EudraCT 2007-003863-31","February 2008","February 2009","February 2009","March 6, 2008",,"May 26, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Midrand, South Africa",,"https://ClinicalTrials.gov/show/NCT00629551"
952,"NCT04657575","Optimisation of ECT Based on ASTI vs Narcotrend",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Procedure: Narcotrend","Convulsion Quality","Medical University Innsbruck","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","ECT: ASTI vs Narcotrend","March 1, 2021","December 31, 2022","December 31, 2023","December 8, 2020",,"March 2, 2021",,,"https://ClinicalTrials.gov/show/NCT04657575"
953,"NCT02330744","The Neurobiology of Approach Avoidance Training in Depression","ACTIV8","Completed","No Results Available","Major Depressive Disorder","Behavioral: Approach-positive AAT|Behavioral: Control AAT","Change from pre-training in blood oxygen level dependent (BOLD) response in the striatum, amygdala, and medial prefrontal cortex, as measured with functional magnetic resonance imaging (fMRI) during reward trials on the Social Incentive Delay (SID) task.|Response bias to rewards on the Probabilistic Reward Task (PRT)|Response to social interaction task","University of California, San Diego|Brain & Behavior Research Foundation","All","18 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","21695","July 2014","April 2017","July 2017","January 5, 2015",,"September 1, 2017","University of California, San Diego; Psychiatry Clinical Research, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02330744"
954,"NCT04623814","the Safety, Tolerability, and Pharmacokinetics Study of HEC113995",,"Completed","No Results Available","Major Depressive Disorder","Other: Food|Drug: HEC113995|Drug: placebo","Adverse event|Area under the concentration versus time curve (AUC) from time zero to infinity(AUC0-∞ )|Maximum Plasma Concentration （ Cmax）|Time to peak（tmax）|Apparent terminal elimination half-life（t½）|Apparent volume of distribution（Vz/F）|The Mean Residence Time（ MRT）|The Apparent Clearance （CL/F）|The Accumulation Ratio（R）|Food Effect on the Cmax|Food Effect on the AUC","Sunshine Lake Pharma Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HEC113995-P-04/CRC-C2006","March 30, 2020","August 12, 2020","August 12, 2020","November 10, 2020",,"November 25, 2020","Shanghai Xuhui Central Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04623814"
955,"NCT04014959","Mini Theta Burst TMS in MDD Patients","NARSAD","Completed","No Results Available","Major Depressive Disorder","Combination Product: TMS/ fMRI Stimulation","Evoked response (change in functional brain activity) to TMS measured using fMRI|Changes in evoked functional brain activity after the 3 day ""mini-TMS"" stimulation regimen|Correlation of changes in MDD symptoms and evoked brain response to TMS","University of Pennsylvania","All","18 Years to 60 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","825761","July 14, 2017","June 30, 2020","June 30, 2021","July 10, 2019",,"July 12, 2021","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04014959"
956,"NCT04609267","Interactive Voice-Based Administration of the PHQ-9",,"Recruiting","No Results Available","Major Depressive Disorder","Diagnostic Test: PHQ-9 - Mirror format","PHQ-9 Total Scores|User Experience Survey","Oklahoma State University Center for Health Sciences|Oral Roberts University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020039","November 3, 2020","June 18, 2021","July 31, 2021","October 30, 2020",,"July 8, 2021","OSU Behavioral Health Clinic, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04609267"
957,"NCT04598607","Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects",,"Completed","No Results Available","Major Depressive Disorder","Drug: Hypidone Hydrochloride tablets|Drug: Placebo","Cmax|Tmax|AUC|T1/2|Percentage of subjects with treatment-emergent adverse events(TEAE)|Percentage of subjects with abnormal Laboratory values|Percentage of subjects with abnormal Physical examinations results|Percentage of subjects with abnormal Vital signs results|Percentage of subjects with abnormal ECG(12-lead Electrocardiogram) results","Zhejiang Huahai Pharmaceutical Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HYP104-CTP|2017ZX09309012","October 30, 2020","January 11, 2021","January 15, 2021","October 22, 2020",,"April 21, 2021","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04598607"
958,"NCT04591301","The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects",,"Completed","No Results Available","Major Depressive Disorder","Drug: HEC113995 PA•H2O tablets|Drug: Placebo tablets","Safety and Tolerability of HEC113995 PA•H2O by Assessment of the Number of Adverse Events (AEs) Following Administration in Single Ascending Dose|PK parameters - AUC0-∞|PK parameters - Cmax|PK parameters -tmax|PK parameters -t½|PK parameters -Vz/F|PK parameters - MRT|PK parameters -CL/F","Sunshine Lake Pharma Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEC113995PA•H2O-P-01/CRC-C1910","July 4, 2019","December 6, 2019","December 6, 2019","October 19, 2020",,"October 28, 2020","Shanghai Xuhui Central Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04591301"
959,"NCT04587778","Imaging Neural Correlates of Ketamine Using PET/MR","RSKet","Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: Ketamine Hydrochloride|Drug: Esketamine|Drug: Placebo","Change in Cerebral metabolic rate of glucose (CMRGlu)|Change in cerebral blood flow (CBF)|Change in Positive and Negative Syndrome Scale|Change in Brief Psychiatric Rating Scale|Change in Clinician Administered Dissociative States Scale","Medical University of Vienna","All","18 Years to 55 Years   (Adult)","Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","v1.7_21.02.2020","October 2020","September 30, 2023","September 30, 2023","October 14, 2020",,"October 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04587778"
960,"NCT03822065","A Relative Bioavailability Food Effect Study of LY03005",,"Completed","No Results Available","Major Depressive Disorder","Drug: LY03005","Pharmacokinetic Parameters","Luye Pharma Group Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY03005/CT-USA-105","January 16, 2019","February 16, 2019","February 16, 2019","January 30, 2019",,"August 6, 2019","Pharmaron CPC, Inc., Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03822065"
961,"NCT03733574","A Study of LY03005 vs Pristiq",,"Completed","No Results Available","Major Depressive Disorder","Drug: LY03005|Drug: Pristiq","concentration-time curve (AUC)","Luye Pharma Group Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY03005/CT-USA-106","June 19, 2018","July 17, 2018","July 26, 2018","November 7, 2018",,"November 9, 2018","Pharmaron CPC, Inc., Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03733574"
962,"NCT04461327","Psychophysiological Study of Pain Perception in Depressed Patients With Suicidal Risk","R2D2","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Painful stimulations of major depressive patients|Biological: Blood sample|Diagnostic Test: Clinical assessment|Behavioral: Social touch","Effectiveness of the conditioned pain modulation|Effectiveness of the Wind-up mechanism|Aδ and C fibers thresholds|Pleasantness associated with social touch|Emotional Reactivity Score|Emotional Regulation Score|Dissociative experiences score|Body investment score|Acquired Capability of Suicide Scale","University Hospital, Montpellier|Clinea psychiatrie France","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","153","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RECHMPL20_0157","November 25, 2020","November 2022","March 2023","July 8, 2020",,"December 2, 2020","University Hospital of Montpellier, Montpellier, Occitanie, France|Clinic La Lironde, Saint Gély du Fesc, Occitanie, France",,"https://ClinicalTrials.gov/show/NCT04461327"
963,"NCT03009448","The Experience of Older Adults Facing Depression for the First Time in Old Age",,"Unknown status","No Results Available","MAjor Depressive Disorder","Other: Interview","Data analysis","Shalvata Mental Health Center","All","62 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","shalvataMHC","March 2017","October 2017",,"January 4, 2017",,"January 4, 2017","Shalvata MHC, Hod HaSharon, Israel",,"https://ClinicalTrials.gov/show/NCT03009448"
964,"NCT02871141","Multimodal Imaging of ECT Effects",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Procedure: electroconvulsive therapy|Drug: Antidepressant","Changes in functional connectivity between medial and lateral prefrontal regions|Changes in functional activity in medial and lateral prefrontal regions|Changes in neurotransmitter concentrations in medial and lateral prefrontal regions|Changes in levels of cytokines, cortisol and BDNF","Charite University, Berlin, Germany","All","25 Years to 60 Years   (Adult)",,"68","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BA 3578_ECT","September 1, 2017","May 31, 2021","December 31, 2021","August 18, 2016",,"August 3, 2021","Charité, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02871141"
965,"NCT03026036","Neuroimaging Studies of Reward Processing in Depression",,"Completed","No Results Available","Major Depressive Disorder","Radiation: PET Scan with Raclopride","Behavioral Performance on the Probabilistic Stimulus Selection Task|MRI Data|PET scan with raclopride|Salivary Cortisol|Four Blood Samples (6ml)|Follow-up Clinical Interviews|Behavioral Performance on the Instrumental Learning Task","Mclean Hospital","All","18 Years to 45 Years   (Adult)",,"123","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2015P002520","April 2016","March 2021","March 2021","January 20, 2017",,"August 4, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03026036"
966,"NCT02666989","Open-Label Placebo for the Treatment of Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: placebo","v. HAM-D-17 (Hamilton, 1960)","Shalvata Mental Health Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Yehuda04","February 2016","February 2017",,"January 28, 2016",,"January 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02666989"
967,"NCT04311619","Does rTMS Induce Synaptic Plasticity?",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Drug: [11C]UCB-J radiotracer|Device: PET-MR","Change in Synaptic Density Quantified by Regional Binding Potential (BP_ND)","Davidzon, Guido, M.D.|Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","54574","December 30, 2020","December 2022","December 2023","March 17, 2020",,"November 6, 2020","VA Palo Alto Health Care System, Palo Alto, California, United States|Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04311619"
968,"NCT03893162","Gut Feeling: Understanding the Mechanisms Underlying the Antidepressant Properties of Probiotics","PROMEX","Recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: Multi-strain probiotic|Other: Placebo","gut microbiota in MDD|differences in gut microbiota between MDD and healthy volunteers|gut microbiota changes in MDD following probiotic intervention and their correlation to change in depressive symptoms|Neurotransmitters|Blood|Brain activity","King's College London","All","18 Years to 55 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","PROMEX","July 1, 2019","March 2022","March 2022","March 28, 2019",,"March 22, 2021","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03893162"
969,"NCT03523767","Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study",,"Recruiting","No Results Available","Major Depressive Disorder","Biological: S.typhi Injection|Biological: Normal Saline Injection","Change in Inflammation as indicated by cytokines|Change in depressed mood as indicated by Hamilton Depression Rating Scale (HAM-D) score|Level of prefrontal, limbic and striatal cortex activation as indicated by fMRI","The University of Texas Health Science Center, Houston","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","HSC-MS-16-0496","February 7, 2018","August 2021","August 2021","May 14, 2018",,"August 17, 2020","Sudhakar Selvaraj, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03523767"
970,"NCT02415166","Influenza Challenge in Mood Disorders",,"Terminated","Has Results","MAJOR DEPRESSIVE DISORDER","Biological: INFLUENZA VACCINE|Other: NaCl-saline placebo","THE TITER OF INFLUENZA ANTIBODIES|THE INFLUENZA VIRUS-INDUCED PROLIFERATION OF CD4+ MEMORY T-CELLS","Laureate Institute for Brain Research, Inc.","Female","18 Years to 55 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","LIBR # 2015-001-00","July 2015","March 2016","March 2016","April 14, 2015","December 26, 2017","January 23, 2018","Laureate Institute for Brian Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02415166"
971,"NCT03128021","Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)","NEMO","Recruiting","No Results Available","Major Depressive Disorder","Drug: Escitalopram Pill|Other: Placebo|Drug: Levomilnacipran Pill","Change in Montgomery Asberg Depression Rating Scale Score|Change in Functional Connectivity|Response Styles Questionnaire- Rumination (RSQ-Rumination)|Hamilton Anxiety Rating Scale (HARS)|Neuropsychological evaluations|Antidepressant Treatment History Questionnaire (ATHF)|Medication Plasma Levels|Age of Onset|Duration of Illness","Howard Aizenstein|Weill Cornell Institute of Geriatric Psychiatry|National Institute of Mental Health (NIMH)|University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)","Phase 4","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY19120137|R01MH076079","May 24, 2017","April 2022","July 2022","April 25, 2017",,"November 3, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03128021/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03128021"
972,"NCT00421369","Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.",,"Completed","No Results Available","Major Depressive Disorder","Drug: sertraline|Drug: triiodothyronine (T3)|Drug: reboxetine","treatment outcome defined categorically as Remission: A Hamilton Depression Scale (HAM-D) less or equal to 6.|RESPONSE: Based on Hamilton Depression Scale (HAM-D)reduction of >50% from baseline to endpoint..|REMISSION: Based on the other rating scales applied in this project.|RESPONSE: Based on the other rating scales applied in this project.","Hadassah Medical Organization","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","t3rbx-HMO-CTIL","September 2007",,"August 2011","January 12, 2007",,"March 22, 2013","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00421369"
973,"NCT04137367","A Personalized Approach to Effects of Affective Bias Modification on Symptom Change and Rumination",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Affective bias modification|Behavioral: Sham Affective bias modification","Self-reported depressive symptoms: Becks Depression Inventory-II|State rumination: Brief State Rumination Inventory|Affective bias: Dot-probe task|Symptom network change: experience sampling of depressive symptoms|Symptom network: experience sampling of depressive symptoms","University of Oslo|Extrastiftelsen|Diakonhjemmet Hospital|University of Oxford","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019/FO249225","November 19, 2019","November 1, 2021","November 1, 2021","October 24, 2019",,"November 6, 2020","Department of Psychology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04137367"
974,"NCT02922725","Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females",,"Terminated","No Results Available","Major Depressive Disorder","Drug: 5-hydroxytryptophan and Creatine|Other: Placebo control","Change from Baseline in Hamilton Depression Rating Scale","Brent Michael Kious, MD, PhD|University of Utah","Female","25 Years to 40 Years   (Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","94176","November 2016","May 2020","May 2020","October 4, 2016",,"May 3, 2021","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02922725"
975,"NCT03551288","Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects","SUVN-911","Completed","No Results Available","Major Depressive Disorder","Drug: SUVN-911","Area under concentration (AUC)|Vital signs","Suven Life Sciences Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTP1S2911A4B2","May 22, 2018","July 10, 2018","July 16, 2018","June 11, 2018",,"August 9, 2018","IQVIA Phase One Services, LLC, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03551288"
976,"NCT01990053","Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Beating the Blues","Change in Hamilton Rating Scale for Depression (HRSD) from 0 to 8 weeks|Change in Patient Health Questionnaire-9 (PHQ9) over 8 weeks","Ohio State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013B0307","April 14, 2014","May 3, 2016","May 1, 2017","November 21, 2013",,"March 25, 2019","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01990053"
977,"NCT02747134","Combining Emotion Regulation and Mindfulness Skills for Preventing Depression Relapse",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Emotion Regulation and Mindfulness skills","Hamilton Depression Rating Scale","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","EC/07/178/2678","September 2008","September 2011",,"April 21, 2016",,"April 21, 2016",,,"https://ClinicalTrials.gov/show/NCT02747134"
978,"NCT02728557","Supportive and Supportive-Expressive Treatment for Depression","SSETD","Active, not recruiting","No Results Available","Major Depressive Disorder","Behavioral: Supportive-Expressive Therapy|Behavioral: Supportive Therapy","Hamilton rating scale for depression (HRSD)|Beck Depression Inventory (BDI)|Outcome Questionnaire (OQ)","University of Haifa","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ISF 186.15","March 2016","September 2021","November 2022","April 5, 2016",,"April 28, 2021","University of Haifa, Haifa, Mount Carmel, Israel",,"https://ClinicalTrials.gov/show/NCT02728557"
979,"NCT03357796","Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®",,"Completed","No Results Available","Major Depressive Disorder","Drug: LY03005|Drug: Pristiq","Area under the concentration-time curve (AUC) Assessment|Maximum concentration (Cmax) Assessment|Adverse Events Assessment","Luye Pharma Group Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY03005/CT-USA-104","November 27, 2017","December 22, 2017","December 22, 2017","November 30, 2017",,"January 4, 2018","Clinilabs, Inc., Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03357796"
980,"NCT00422162","A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine hydrochloride|Drug: Placebo","Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change in 6-Item Hamilton Depression Scale (HAMD-6) Total Scores From Baseline|Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline|Evaluation of Rescue Options Based on Changes in the Montgomery-Asberg Depression Rating Scale (MADRS) and the 6-Item Hamilton Depression Scale (HAMD-6)|Clinical Global Impression of Severity (CGI-S) Scores at Each Visit|Clinical Global Impression of Improvement (CGI-I) at Each Visit|Patient Global Impression of Improvement (PGI-I) Score at Each Visit|Hamilton Anxiety Scale (HAMA) Score at Baseline and Weeks 4 and 8|Percentage of Responders|Patients Reaching Remission|Reason for Living (RFL) Questionnaire Mean Scores at Baseline and Week 8|Utilization of Allowed Hypnotic and/or Anxiolytic Co-Medication|Number of Patients With Potentially Clinically Significant Laboratory Findings|Discontinuations Due to Adverse Events (AE)|Number of Participants Experiencing High Values for Vital Signs at Any Time During the Study|Change From Baseline to Week 4 and Week 8 in Weight","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","339","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10614|F1J-BI-HMES","February 2007","August 2008","August 2008","January 15, 2007","October 2, 2009","July 26, 2011","For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Besancon, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Bordeaux, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Bully les Mines, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Chateau-Gontier, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Dijon, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Dole, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Fains Veel, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Jarnac, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, La Charite sur Loire, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, La Rochelle, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Limoges, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Marseille, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Montberon, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Montpellier, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Nimes, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Paris, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Saint-Dizier, France|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Firenze, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Foggia, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Messina, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Milano, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Pisa, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Roma, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Siena, Italy|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Kazan, Russian Federation|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Lipetsk, Russian Federation|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Moscow, Russian Federation|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Nizhny Novgorod, Russian Federation|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Saratov, Russian Federation|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, St. Petersburg, Russian Federation|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Bryanston, South Africa|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Cape Town, South Africa|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, George, South Africa|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Krugersdorp, South Africa|For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT00422162"
981,"NCT03872492","Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale","REDRESS","Active, not recruiting","No Results Available","Depressive Disorder, Major","Other: Digital Assessment on mobile","Show that responders and non-responders in phase 1, have a different early profile on some of the items assessed by REDRESS at week 2 (or before) and identify the predictor item(s).|Show that responders and non-responders in phase 1 have a different profile on some of the items assessed by REDRESS at week 6 and identify the discriminating item(s).|Reproducibility: show that responders and non-responders in phase 2 have a different profile on some of the items assessed by REDRESS at week 8 and identify the same predictor item(s) found in phase 1.|Reproducibility: show that responders and non-responders in phase 2 have a different profile on some of the items assessed by REDRESS at week 12 and identify the same discriminating item(s) found in phase 1.|Intra-patient comparison phase 1 / phase 2: show that patients non-responding in phase 1 and responding in phase 2 have a different profile on some of the items assessed by REDRESS|Build up a composite score (the REDRESS digital score), from the item(s) identified in the previous objectives.|Evaluate patients' adherence to the mobile application|Evaluate the adverse events of the mobile application use.|Collect patients and investigators feedback (usability, satisfaction) on the REDRESS mobile application|Evaluate patient's social relationship|Evaluate patient's quality of life|Evaluate the patient's quality of life evolution|Evaluate patient's social relationship evolution|Explore correlation between patient's quality of life and REDRESS score","Ad scientiam","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","REDRESS","October 17, 2019","September 30, 2021","September 30, 2021","March 13, 2019",,"July 20, 2021","CHU Nantes - CAPPA Jacques Prévet, Nantes, France|Centre Hospitalier Saint-Anne, Paris, France|Centre hospitalier Saint-Antoine, Paris, France|Hôpital de la Pitié Salpêtrière, Paris, France|Centre hospitalier Henri Laborit, Poitiers, France|Centre Hospitalier Guillaume Régnier, Rennes, France",,"https://ClinicalTrials.gov/show/NCT03872492"
982,"NCT01931202","Mechanisms of Antidepressant Non-Response in Late-Life Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo oral tablet","Hamilton Rating Scale for Depression (HRSD)|Quick Inventory of Depressive Symptoms (QIDS-SR)|Credibility and Expectancy Scale-Better (CES)|Credibility and Expectancy Scale-Depression|Quick Inventory of Depression Scale (QIDS-SR): Expectancy|Executive Dysfunction: Stroop Color Word|Executive Dysfunction: Stroop Interference|White Matter Hyperintensity (WMH) Outcome- Total WMH","New York State Psychiatric Institute","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6836","February 19, 2014","January 17, 2019","January 17, 2020","August 29, 2013","April 8, 2020","July 2, 2020","New York State Psychiatric Institute, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01931202/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01931202/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01931202"
983,"NCT03977675","The Role of HNKs in the Antidepressant Effect of Ketamine",,"Terminated","No Results Available","Major Depressive Disorder","Drug: Ketamine","Change in HNK Plasma Concentration|Change in DHNK Plasma Concentration","Columbia University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","NYSPI 7558","May 15, 2019","July 2, 2020","July 2, 2020","June 6, 2019",,"January 22, 2021","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03977675"
984,"NCT02800226","Pilot Study Comparing 10hz vs Theta Burst Stimulation",,"Completed","No Results Available","Major Depressive Disorder","Device: 10Hz|Device: iTBS","Change in the Hamilton Depression Rating scale 17-item (HDRS-17) score","University of British Columbia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H13-02340","March 2014","May 2015","May 2015","June 15, 2016",,"August 10, 2018","Non-Invasive Neurostimulation Therapies lab, University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02800226"
985,"NCT00380042","Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder","PROSPECT","Terminated","No Results Available","Depression|Depressive Disorder","Device: Cortical Stimulation|Device: Sham","Hamilton Depression Rating Scale (HDRS28)|10-item Montgomery-Asberg Depression Rating Scale (MADRS)","Northstar Neuroscience","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","V0479","September 2006","October 2007","March 2009","September 25, 2006",,"December 31, 2009","Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00380042"
986,"NCT01919216","Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms",,"Completed","Has Results","Major Depressive Disorder","Drug: Citalopram","Hamilton Rating Scale for Depression","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","Female","24 Years to 75 Years   (Adult, Older Adult)","Phase 4","65","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6038/6996R|K23MH085236","January 2010","June 2016","June 2016","August 8, 2013","January 5, 2018","March 9, 2020","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01919216"
987,"NCT00943033","Study of Mindfulness-Based Cognitive Therapy","MBCT","Completed","No Results Available","Major Depressive Disorder","Behavioral: Mindfulness-Based Cognitive Therapy","Sustained Attention to Response Task|Five Facet Mindfulness Questionnaire","Binghamton University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MLI-FJVRF-08-SMB","August 2009","July 2010","July 2010","July 21, 2009",,"September 21, 2012",,,"https://ClinicalTrials.gov/show/NCT00943033"
988,"NCT02612142","Physical EXercise as an Adjunct Treatment for Depression","PEXAT","Completed","No Results Available","Major Depressive Disorder","Behavioral: physical exercise","Score change on the 21-item Beck depression inventory (BDI-II). Each item has a set of severity-graded self-evaluative statements that are rated 0 (neutral) to 3 (maximum severity).","Université de Reims Champagne-Ardenne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPSMM-2011","June 2011","July 2015","July 2015","November 23, 2015",,"November 24, 2015",,,"https://ClinicalTrials.gov/show/NCT02612142"
989,"NCT02615405","Phospholipid Hypothesis of Depression: From Molecular Biology, Neuroimaging to Behaviour",,"Completed","No Results Available","Major Depressive Disorder","Dietary Supplement: EPA|Dietary Supplement: DHA|Dietary Supplement: Placebo","Changes from Baseline Hamilton Depression Rating Scale (HDRS) at 12 weeks|Remission rate|Response rate|Changes in Beck Depression Inventory (BDI)|Changes in Neurotoxicity Rating Scale (NRS)","National Science Council, Taiwan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NSC101-2628-B-039-001-MY3","August 2012","January 2015","January 2015","November 26, 2015",,"November 26, 2015","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02615405"
990,"NCT02525978","Heart Rate Variability in Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Video Task|Other: Imaginal Task","Change in heart rate variability (HRV, also called RSA)|Mean values of positive emotional expressions|Mean values of negative emotional expressions|Mean activation of muscle action units|Change in heart rate|Change in skin conductance response (SCR)|Change in respiration rate|Change in pulse rate","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00082047","July 2015","April 12, 2017","April 12, 2017","August 18, 2015",,"September 20, 2019","Emory University Hospital, Atlanta, Georgia, United States|12 Executive Park Drive, Atlanta, Georgia, United States|Emory University at Wesley Woods Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02525978"
991,"NCT03821506","ROOM-LIGHT: Effect of a Dynamic Lighting System in Depressed Inpatients",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Dynamic Light|Device: Usual care","Hamilton Depression Rating Scale 6 item version|Score on the SIDAS scale|Hamilton Depression Rating Scale 17 item version|WHOQOL-BREF","Mental Health Centre Copenhagen|Mental Health Services in the Capital Region, Denmark|Toyota-Fonden|Grosserer L. F. Foghts Fond Denmark|ELFORSK Danish Energy|Technical University of Denmark","All","17 Years and older   (Child, Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Version 1.7","May 15, 2019","June 2021","December 2021","January 29, 2019",,"June 13, 2019","Psychiatic Hospital Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03821506"
992,"NCT03812588","Contact: Developing New Clinical Management Strategies",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo","Change from Baseline Hamilton Rating Scale for Depression at Study Completion (8 or 20 Weeks)|Hamilton Anxiety Rating Scale 14-item scale","New York State Psychiatric Institute|University of Haifa","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7738","January 30, 2019","October 31, 2021","October 31, 2022","January 23, 2019",,"November 18, 2020","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03812588"
993,"NCT01514435","Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)",,"Completed","No Results Available","Major Depressive Disorder","Device: Electroconvulsive therapy|Device: 18-Fluoro-desoxy-glucose positron emission tomography","Brain glucose metabolism measured by FDG-PET","Medical University of Graz","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRECT-2006-PET","May 2006","May 2009","July 2011","January 23, 2012",,"January 23, 2012","Medical University Graz; Department for Psychiatry, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT01514435"
994,"NCT03718013","Efficacy and Safety of Accelerated Transcranial Magnetic Stimulation With H1-coil (dTMS)",,"Completed","No Results Available","Major Depressive Disorder","Device: accelerated deep TMS|Device: standard deep TMS","Percentage improvement in the Hamilton Rating Scale for Depression (HAM-D) scores|Treatment response|The proportion of patients who experienced complete remission of the disease|Percentage improvement in BDI-II scores|Change in perceived quality of life (EQ-5D-5L scale)|Change in cognitive functions (MoCA test)","Sveti Ivan Psychiatric Hospital","All","18 Years to 68 Years   (Adult, Older Adult)","Not Applicable","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","acceleratedDTMS","December 1, 2018","July 31, 2019","November 1, 2019","October 24, 2018",,"February 12, 2020","PB Sveti Ivan, Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT03718013"
995,"NCT01731678","Transcranial Magnetic Stimulation for Adolescent Depression","TMSAD","Completed","Has Results","Major Depressive Disorder","Procedure: Transcranial Magnetic Stimulation","Hamilton Depression Rating Scale","University of Calgary","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","39","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-24656","November 2012","April 2018","December 2018","November 22, 2012","November 15, 2019","September 25, 2020","Alberta Children's Hospital, Calgary, Alberta, Canada","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT01731678/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT01731678/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01731678"
996,"NCT02311725","Storytelling Video Intervention for Depressed Primary Care Patients - Pilot Trial","sTVi-RCT","Completed","No Results Available","Major Depressive Disorder","Behavioral: aTAU + sTVi|Behavioral: aTAU + Attention Control Videos","Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C)|Client Satisfaction Questionnaire-8 (CSQ-8)|Acceptance and Action Questionnaire-II (AAQ-II)|WHO-Quality of Life-BREF (WHO-QOL-BREF)|WHO-Disability Assessment Schedule-II (WHO-DAS-II)","Butler Hospital|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","sTVi-2|R34MH103568","May 1, 2017","March 1, 2019","March 1, 2019","December 8, 2014",,"June 4, 2019","Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02311725"
997,"NCT02309060","Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial","sTVi-Open","Completed","No Results Available","Major Depressive Disorder","Behavioral: Storytelling Video Intervention (sTVi)","Client Satisfaction Questionnaire-8 (CSQ-8)|Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-C)|Acceptance and Action Questionnaire-II (AAQ-II)","Butler Hospital|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sTVi-1|R34MH103568","September 2016","February 2017","March 1, 2017","December 5, 2014",,"June 25, 2019","Family Care Center of Memorial Hospital, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02309060"
998,"NCT03609190","A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine",,"Completed","No Results Available","Major Depressive Disorder","Drug: Ketamine|Drug: Placebo","Change in functional reactivity to emotional stimuli|Change in glutamate concentrations in prefrontal cortex|Change in resting-state functional connectivity","Psychiatric University Hospital, Zurich","All","20 Years to 60 Years   (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","E-31/2008","January 2015","December 2018","December 2018","August 1, 2018",,"March 20, 2019",,,"https://ClinicalTrials.gov/show/NCT03609190"
999,"NCT03606850","Transcranial Magnetic Stimulation Study of Cortical Excitability as Marker of Antidepressant Response: EXCIPSY Study","EXCIPSY","Unknown status","No Results Available","Major Depressive Disorder","Device: Measurements of markers of cortical excitability by TMS","Variation of the CSP between day 1 and day 28|Variation of the RMT between day 1 and day 28|Variation of the MEP between day 1 and day 28|Variation of the ICI between day 1 and day 28|Variation of the ICF between day 1 and day 28|Variation of the markers of cortical excitability at other times|Variation in HAMD-21 between day 1 and day 60 for the responders at day 28|Variations in UKU (Udvalg pour Kliniske Undersøgelser Side Effect Rating Scale) at different times|Variations in Morisky compliance scale","Centre Hospitalier du Rouvray|Centre hospitalier de Ville-Evrard, France|University Hospital Caen, France","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-A00157-48","July 30, 2018","August 30, 2020","August 30, 2020","July 31, 2018",,"July 31, 2018","Rouvray Hospital, Sotteville-lès-Rouen, France",,"https://ClinicalTrials.gov/show/NCT03606850"
1000,"NCT03594773","Modeling Multi-level Dyadic Behavior to Transform the Science and Practice of Psychotherapy Process and Outcome.","DAPPeR","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy|Behavioral: Interpersonal Psychotherapy","Depression severity|Working Alliance Inventory--Short Revised Client Version (WAI-SR-C)|Working Alliance Inventory--Short Revised Therapist Version (WAI-SR-T)","University of Pittsburgh|Carnegie Mellon University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PRO17110528|171722822","July 8, 2018","June 30, 2021","August 2021","July 20, 2018",,"February 2, 2021","WPIC/ Bellefield Towers/Depression and Manic Depression Prevention Program, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03594773"
1001,"NCT02229188","Games to Overcome Late Life Depression","GOLD","Completed","No Results Available","Major Depressive Disorder","Behavioral: Problem Solving Therapy|Behavioral: Evolution|Behavioral: Words","Change in depression over time","University of Washington","All","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","STUDY00001751","December 2013","August 2018","August 31, 2018","September 1, 2014",,"September 19, 2018","University of Washington Department of Psychiatry and Behavioral Sciences, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02229188"
1002,"NCT02466958","Trial of Levomilnacipran in Geriatric Depression","LMIL","Completed","Has Results","Major Depressive Disorder","Drug: levomilnacipran|Drug: Placebo","Hamilton Depression Rating Scale (HDRS) Scores 24|Clinical Global Impression Scale (CGI) Scores|Geriatric Depression (GDS) Scores","University of California, Los Angeles","All","60 Years and older   (Adult, Older Adult)","Phase 4","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IIT-USA-000620","June 2016","December 9, 2018","December 9, 2018","June 9, 2015","April 26, 2019","August 14, 2019","UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02466958/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02466958"
1003,"NCT02429011","MRI Studies of Emotion in Depression",,"Completed","No Results Available","Major Depressive Disorder",,"Change in Montgomery-Asberg Depression Rating Scale|Change in Clinician-Rated Inventory of Depressive Symptomatology (IDS-C30)|Change in Brief Psychiatric Rating Scale and the Clinician-Administered Dissociative States Scale (CADSS)","Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)","All","18 Years to 70 Years   (Adult, Older Adult)",,"135","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GCO 10-1385|5K23MH094707","July 15, 2011","May 31, 2016","May 31, 2016","April 29, 2015",,"April 6, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02429011"
1004,"NCT00064467","Lethargic Depression Study",,"Completed","No Results Available","Epilepsy|Major Depressive Disorder (MDD)","Drug: Extended-release bupropion (HCl)","Change from randomization on the Inventory of Depressive Symptomatology, self report and clinician rated.|Percent of responders. Percent of remitters. Quality of Life Enjoyment and Satisfaction Questionnaire.","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","268","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AK130931","June 2003","May 2005","May 2005","July 10, 2003",,"May 30, 2017","GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Sherman Oaks, California, United States|GSK Investigational Site, Temecula, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Cromwell, Connecticut, United States|GSK Investigational Site, Hamden, Connecticut, United States|GSK Investigational Site, Middletown, Connecticut, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Oak Brook, Illinois, United States|GSK Investigational Site, Cedar Rapids, Iowa, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Farmington Hills, Michigan, United States|GSK Investigational Site, Ridgeland, Mississippi, United States|GSK Investigational Site, Moorestown, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Beachwood, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Lincoln, Rhode Island, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Lake Jackson, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00064467"
1005,"NCT02283541","Gait, Depression, and Mind-body Therapy in Seniors",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Automatic self-transcending meditation","Change from baseline in mean stride length at 4 weeks|Change from baseline in mean stride length at 8 weeks|Change from baseline in mean stride length at 12 weeks|Change from baseline in mean stride length at 24 weeks|Change from baseline in gait velocity at 4 weeks|Change from baseline in gait velocity at 8 weeks|Change from baseline in gait velocity at 12 weeks|Change from baseline in gait velocity at 24 weeks","Lawson Health Research Institute","All","65 Years to 85 Years   (Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSREB 105915","June 2015","January 2017","January 2017","November 5, 2014",,"August 23, 2017","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02283541"
1006,"NCT00825058","Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine",,"Completed","No Results Available","Major Depressive Disorders","Drug: amibegron (SR58611A)|Drug: placebo|Drug: paroxetine","change from baseline of the total score of the HAM-D 17 items.|HAM-D subscores|HAM-D responders and remitters|HAM-A total score and subscores|MADRS total score|clinical global impression (CGI) severity and improvement scores|patient global impression (PGI) improvement score|social and occupational functioning assessment scale (SOFAS) score|clinical monitoring of adverse events (AEs)|laboratory parameters|electrocardiogram (ECG) parameters, change in vital signs and body weight","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","317","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5374","November 2003","May 2004","October 2004","January 19, 2009",,"March 25, 2009","Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Montenegro, Montenegro|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Belgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT00825058"
1007,"NCT00825019","Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine",,"Completed","No Results Available","Major Depressive Disorders","Drug: amibegron (SR58611A)|Drug: placebo|Drug: paroxetine","change from baseline of the total score of the HAM-D 17 items|HAM-D subscores, HAMD responders and remitters, HAM-A total score and subscores|Montgomery-Asberg Depression Rating Scale (MADRS) total score|clinical global impression (CGI) severity and improvement scores|patient global impression (PGI) improvement score|social and occupational functioning assessment scale (SOFAS) score|AEs, Arizona Sexual Experience Scale (ASEX),|laboratory parameters, physical examination findings, ECG parameters, change of vital signs, body weight","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5379","September 2003","October 2004","December 2004","January 19, 2009",,"March 25, 2009","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00825019"
1008,"NCT02385786","Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Mindfulness-Based Cognitive Therapy","Hamilton Depression Rating Scale Change with MBCT treatment|C-Reactive Protein (Blood) Change with MBCT treatment","University of California, San Francisco","All","18 Years to 60 Years   (Adult)","Not Applicable","43","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-07162","November 2011","August 2012","August 2012","March 11, 2015",,"March 11, 2015","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02385786"
1009,"NCT03079297","Rapid Antidepressant Effects of Leucine",,"Suspended","No Results Available","Major Depressive Disorder","Drug: L-Leucine|Other: Maltodextrin","Comparison of reduction in QIDS-SR after 14 days of treatment with L-leucine (LEU) and placebo (PBO) in MDD patients.|Percentage of MDD patients with 50% or greater reduction in depression severity after 14 days of LEU and PBO treatments.|Percentage of MDD patients with QIDS-SR score less than or equal to 5 at 14 days of LEU and PBO treatments.|Rates of adverse effects after 3 days, 7 days and 14 days of LEU and PBO treatments.|Change in fatigue symptoms from baseline after 3, 7, and 14 days of LEU and PBO treatments measured with Multidimensional fatigue inventory.|Change in psychosocial function from baseline after 3, 7, and 14 days of LEU and PBO treatments measured using Work and Social Adjustment Scale.|Change in anhedonia from baseline after 3, 7, and 14 days of LEU and PBO treatments measured using Snaith-Hamilton Pleasure Scale (SHAPS)","University of Texas Southwestern Medical Center","All","18 Years to 64 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STU 082016-037","March 9, 2017","March 1, 2022","June 30, 2022","March 14, 2017",,"March 9, 2021","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03079297"
1010,"NCT02361684","e-Compared-S: Comparative Effectiveness Research on Internet-based Depression Treatment - Spanish Trial","E-COMPARED_S","Completed","No Results Available","Major Depressive Disorder","Behavioral: Blended CBT treatment|Other: Treatment as usual","Change in Patient Health Questionnaire-9|Change in Quick Inventory of Depressive Symptomatology Self-Report (QIDS-16-SR) US Translation|Change in the MINI International Neuropsychiatric Interview (M.I.N.I) version 5.0|Change in the EQ-5D-5L (EuroQol)|Change in the Questionnaires on Costs Associated with Psychiatric Illness (TiC-P; Hakkaart-van Rooijen, van Straten, Donker, Tiemens, 2002)|Change in the Working Alliance Inventory (WAI-SF)|Change in the credibility and expectancy questionnaire (CEQ; Devilly and Borkovec, 2000)|Change in the Satisfaction Questionnaire (CSQ-8; Nguyen, Attkinson, & Stegner, 1983)|Change in the system usability scale (SUS; Brooke, 1996)","Universitat Jaume I|University of Valencia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","UJaumeI07","February 2015","June 2019","September 2019","February 12, 2015",,"September 20, 2019","University Jaume I, Castelló de la Plana, Castellón, Spain|University of Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02361684"
1011,"NCT02900092","Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone",,"Completed","Has Results","Major Depressive Disorder","Drug: Ganaxolone","Montgomery-Asberg Depression Rating Scale (MADRS)","Massachusetts General Hospital","Female","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P001182","November 2016","January 12, 2018","January 12, 2018","September 14, 2016","February 18, 2019","February 18, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02900092/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02900092/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02900092"
1012,"NCT02369393","Efficacy of Two Internet Delivered Intervention Programs for Depression: Behavioral Activation vs Physical Activity","PROMETEOII","Recruiting","No Results Available","Major Depressive Disorder","Behavioral: Behavioral Activation|Behavioral: Physical Activity","Change in Patient Health Questionnaire-9|Change in the Beck Depression Inventory|Change in the EQ-5D-5L (EuroQol)|Change in the Quality of Life (QLI)|Change in the Overall Anxiety Severity and Impairment Scale (OASIS)|Change in the Positive and Negative Affect Scale (PANAS)|Change in the Happiness Scale (Fordyce)|Change in the Satisfaction with Life Scale (SWLS, Diener)|Change in the Ryff Scale of Psychological Wellbeing|Change in the Behavioral Activation for Depression Scale - Short Form (BADS-SF)|Change in the Environmental Reward Observation Scale (EROS)|Change in Beck Depression Inventory (BDI-II)","Universitat Jaume I|University of Valencia|Universitat Politècnica de València","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","UJaimeI06","November 2, 2021","April 2022","February 2023","February 23, 2015",,"May 10, 2021","University Jaume I, Castelló de la Plana, Spain",,"https://ClinicalTrials.gov/show/NCT02369393"
1013,"NCT00451516","St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety",,"Completed","No Results Available","Depressive Disorder, Major|Anxiety Disorders","Drug: Herbal medicine (St. John's wort and Kava)","BDI II|BAI|DASS|WHOQOL|Daily Mood Monitoring Form","The University of Queensland","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","2006000925","March 2007","October 2007","October 2007","March 23, 2007",,"May 19, 2008","RBWH, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT00451516"
1014,"NCT02474680","Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes","PGx-TIME","Completed","No Results Available","Major Depressive Disorder 1","Genetic: Pharmacogenetic testing","Depression scores|Economic impact of pharmacogenetic testing","Avera McKennan Hospital & University Health Center","All","18 Years and older   (Adult, Older Adult)",,"84","Other","Observational","Observational Model: Cohort|Time Perspective: Other","AIHG-1420-PGxTIME","November 1, 2015","January 1, 2017","January 1, 2017","June 18, 2015",,"May 3, 2017","Avera Institute for Human Genetics, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02474680"
1015,"NCT01936506","Cognitive Training for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Training A|Behavioral: Cognitive Training B","change in Hamilton Depression Rating Scale (Ham-D)|change in Self-referential Information Processing Task|change in Working Memory","Icahn School of Medicine at Mount Sinai","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 10-0645","July 2010","October 2012","October 2012","September 6, 2013",,"September 6, 2013","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01936506"
1016,"NCT02940769","Neurobiological Effects of Light on MDD",,"Suspended","No Results Available","Major Depressive Disorder","Device: light glasses|Device: sham glasses (placebo)","salivary cortisol levels|salivary melatonin levels","University of Michigan","All","18 Years to 60 Years   (Adult)","Early Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","PRITZ1","September 4, 2014","October 2022","October 2022","October 21, 2016",,"February 15, 2021","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02940769"
1017,"NCT03202095","Creatine for Treatment of Depression Associated With Type 2 Diabetes",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Creatine Monohydrate","Change from Baseline in Hamilton Depression Rating Scale","University of Utah","Female","20 Years to 64 Years   (Adult)","Phase 4","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00101803","August 1, 2017","November 1, 2022","November 1, 2022","June 28, 2017",,"April 26, 2021","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03202095"
1018,"NCT03138681","Rapid Antidepressant Effects of ATP and Phosphocreatine",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: ATP|Drug: Phosphocreatine","Changes in Hamilton depression rating scale during the first six weeks|Changes in Patient Health Questionnaire (PHQ-9) during the first six weeks|Changes in Clinical global impression scale during the study|Side effects assessment during the first six weeks","Zhujiang Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017-SJNK-001","May 3, 2017","April 30, 2019","April 30, 2019","May 3, 2017",,"May 8, 2017","Zhujiang Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03138681"
1019,"NCT02141776","Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Transcranial direct current stimulation (t-DCS)|Other: Sham Controlled Arm","Montgomery Asberg depression rating scale score","University of Florida","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","95-2013|IRB201501014","May 2014","January 8, 2018","January 8, 2018","May 19, 2014",,"January 12, 2018","Univ of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02141776"
1020,"NCT02078817","Ketamine in Adolescents With Treatment-Resistant Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Ketamine","Number of Responders Measured by Clinical Global Impression (CGI)|Children's Depression Rating Scale-Revised|Montgomery-Åsberg Depression Rating Scale (MADRS)|Beck Depression Inventory-II (BDI-II)|Change in Clinician Administered Dissociative States Scale (CADSS)|Maximum Change in Systolic Blood Pressure|Maximum Change in Diastolic Blood Pressure|Maximum Change in Heart Rate|Maximum Decrease in Pulse Oximetry","University of Minnesota","All","12 Years to 18 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22225","September 2014","March 2018","March 2018","March 5, 2014","January 27, 2020","January 27, 2020","University of Minnesota, Minneapolis, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02078817/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02078817/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02078817"
1021,"NCT02829671","Loneliness and Occurrence of Suicide Attemps and Suicidal Ideas","SOLSTIS","Unknown status","No Results Available","Major Depressive Disorders","Other: Clinical and biological assessment","frequency of suicide attempts at one year|frequency of suicide attempts during the follow up|comorbid psychiatric disorders of Axis I|intensity of the depression|intensity of suicidal ideation|features of suicidal behavior|personal history of childhood abuse|intensity of psychological pain|inflammatory markers|thyroïd function|lipid profile","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","UF 9702|2016- -A00276-45","July 2016","July 2020","January 2021","July 12, 2016",,"July 12, 2016",,,"https://ClinicalTrials.gov/show/NCT02829671"
1022,"NCT02149810","Automatic Self Transcending Meditation Versus Treatment as Usual",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Automatic Self Transcending Meditation","change in heart rate variability from baseline to end of study|change in depression severity|change in comorbid anxiety|physical activity|quality of life","Lawson Health Research Institute|University of Western Ontario, Canada","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSREB","May 2014","January 2017","January 2017","May 29, 2014",,"May 14, 2021","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02149810"
1023,"NCT02830399","Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression","STIMAGNECT","Completed","No Results Available","Major Depressive Disorder","Device: active rTMS-ECT|Device: sham rTMS-ECT","Relative improvement of the Hamilton Rating Scale for Depression 21-items score","Centre Hospitalier du Rouvray|University Hospital, Rouen|Centre Hospitalier Henri Laborit|University Hospital, Caen","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2015-A01810-49","July 15, 2016","July 12, 2019","July 12, 2019","July 12, 2016",,"February 18, 2021","Centre Esquirol- CHU de Caen, Caen, France|Centre Hospitalier Laborit, Poitiers, France|Centre Hospitalier du Rouvray, Sotteville-lès-Rouen, France",,"https://ClinicalTrials.gov/show/NCT02830399"
1024,"NCT03414931","NMDA Modulation in Major Depressive Disorder in Late- Life",,"Completed","No Results Available","Depressive Disorder, Major","Drug: NMDA|Drug: Sertraline|Drug: Placebo - Cap","Change from baseline of 17-item Hamilton Rating Scale for Depression|Change from baseline of Perceived Stress Scale|Drop out rate|Change from baseline of Geriatric Depression Scale|Clinical Global Impression|Cognitive function|Change from baseline of Beck's Suicide Scale","Chang Gung Memorial Hospital","All","55 Years and older   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","101-0365A3","January 2016","November 2020","November 2020","January 30, 2018",,"December 1, 2020","Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03414931"
1025,"NCT03051945","Endogenous Opioid Modulation by Ketamine",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: Ketamine Hydrochloride|Other: Normal saline","Hamilton Depression Rating Scale at 24 hours, change from baseline","University of Utah","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","00087544","August 2019","August 1, 2019","August 1, 2019","February 14, 2017",,"January 28, 2020","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03051945"
1026,"NCT00807105","Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive Episode",,"Completed","No Results Available","Major Depressive Disorder","Device: H-coil dTMS","response in HAMDS","Shalvata Mental Health Center|Brainsway","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0013-07 SHA","June 2008","May 2010","May 2010","December 11, 2008",,"January 5, 2012","ShalvataMHC, Hod Hasharon, Israel",,"https://ClinicalTrials.gov/show/NCT00807105"
1027,"NCT03031665","Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression",,"Recruiting","No Results Available","Major Depressive Disorder",,"Blood oxygen level-dependent (BOLD) activation in response to stress|Network-specific effective connectivity|GABA concentration","Mclean Hospital|Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years to 25 Years   (Adult)",,"144","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2016P000693","October 1, 2017","April 30, 2022","April 30, 2022","January 25, 2017",,"January 20, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03031665"
1028,"NCT02674529","Study of Neural Responses Induced by Antidepressant Effects","SONRISA","Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo","Montgomery-Åsberg Depression Rating Scale (MADRS)|Quick Inventory of Depressive Symptomatology (QIDS)|Neural Responses (Blood oxygen dependent level response to neurofeedback signal).","Marta Peciña, MD PhD|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STUDY19070392/PRO16050131","September 2016","May 2021","May 2021","February 4, 2016",,"June 7, 2021","WPIC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02674529"
1029,"NCT02992158","Feasibility of a Behavioral Activation Trial",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: behavioral activation|Behavioral: treatment-as-usual","percent of eligible patients who refuse randomization|percent of patients who complete 9 sessions of BA treatment|percent of BA homework assignments that are completed|percent of monthly assessments obtained|Opinions About Treatment questionnaire|Brief Alliance Inventory|Behavioral Activation for Depression Scale|Reward Probability Index|Hamilton Rating Scale for Depression|Short Form Health Survey (SF-36)|Inventory of Depressive Symptomatology|Behavior and Symptom Identification Scale (BASIS-24)|Dysfunctional Attitudes Scale|Quality of Life Index (questionnaire)|Beck Anxiety Inventory|Effort Expenditure for Rewards Task (EEfRT)","University of Pennsylvania|Merakey Behavioral Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R34MH108818","March 2016","November 2019","November 2019","December 14, 2016",,"March 25, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02992158"
1030,"NCT02095639","Inflammation and Electroconvulsive Therapy",,"Terminated","No Results Available","Major Depressive Disorder",,"Change in translocator protein distribution volume (TSPO Vt) measured by [18F]FEPPA PET|17-item Hamilton Depression Rating Scale (HDRS)|Neurocognitive Battery|Peripheral Inflammatory Markers","Centre for Addiction and Mental Health","All","18 Years to 80 Years   (Adult, Older Adult)",,"5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","074-2012","August 2012","March 2017","May 2017","March 26, 2014",,"February 14, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02095639"
1031,"NCT01860157","Deep rTMS for Treatment-Resistant Late-life Depression","rTMS","Completed","No Results Available","Major Depressive Disorder","Device: Brainsway H1-Coil Deep TMS System (Sham treatment)|Device: Brainsway H1-Coil Deep TMS System","HDRS-24|Mean change in HDRS-24","Centre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR)|Brainsway","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","107/2011","June 2013","November 2016","December 2016","May 22, 2013",,"May 31, 2017","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01860157"
1032,"NCT03101527","Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy",,"Terminated","No Results Available","Major Depressive Disorder in Pregnancy","Drug: Omega-3 PUFA supplementation","The Hamilton Rating Scale for Depression (HAM-D)|Montgomery-Asberg Depression Scale (MADRS)|Edinburgh Postnatal Depression Scale (EPDS)|Beck Depression Scale (BDI)","William Coryell|University of Iowa","Female","18 Years to 50 Years   (Adult)","Early Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201002781","May 2011","February 2012","February 2012","April 5, 2017",,"April 28, 2017",,,"https://ClinicalTrials.gov/show/NCT03101527"
1033,"NCT01896934","Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Sertraline","Remission of Depression|Change in Clinician-rated Depression Severity|Change in Patient-rated Depression Severity","Vanderbilt University|National Institute of Mental Health (NIMH)|Vanderbilt University Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 4","31","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","130360|R21MH099218-01A1","July 2013","June 2016","June 2016","July 11, 2013","July 21, 2017","July 21, 2017","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01896934"
1034,"NCT00226278","Safety Study of ORG 34517 for Major Depression With Psychotic Features",,"Completed","No Results Available","Major Depressive Disorder|Psychotic Disorders","Drug: ORG 34517",,"Weill Medical College of Cornell University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","28130","September 2004","November 2005","November 2005","September 26, 2005",,"March 31, 2008","Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00226278"
1035,"NCT01706731","Effectiveness of Buddhist Monks in Providing Cognitive Behavior Therapy","Add-CBT","Unknown status","No Results Available","Major Depressive Disorder","Behavioral: Treatment as usual|Behavioral: Cognitive-behavioral therapy","Evidence of clinically depression confirmed by clinician|Depression- self report|Dimensional psychological distress (anxiety, depression,and somatization)|Dimensional psychological distress ( perception of stress)","Chiang Mai University","All","60 Years to 95 Years   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","918","October 2012","October 2013","October 2013","October 15, 2012",,"October 15, 2012","Geriatric clinic, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT01706731"
1036,"NCT00415142","An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder","Drug: saredutant (SR48968)|Drug: placebo|Drug: escitalopram","Change from baseline to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score.|Change from baseline to Day 56 in the Clinical Global Impression (CGI) Severity of Illness score.|Change from baseline to Day 56 in the HAM-D depressed mood item score|Change from baseline to Day 56 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score","Sanofi","All","60 Years to 64 Years   (Adult)","Phase 3","393","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5574","December 2006","February 2008","February 2008","December 22, 2006",,"May 24, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00415142"
1037,"NCT02715778","Translational Investigation of Gestational Environment on Neurobehavioral Function in Children",,"Completed","No Results Available","Major Depressive Disorder",,"neuropsychological functioning as assessed by CANTAB research battery","Massachusetts General Hospital|Boston Children's Hospital","All","6 Years and older   (Child, Adult, Older Adult)",,"95","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","2015P001326","February 2016","September 2017","June 2019","March 22, 2016",,"March 16, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02715778"
1038,"NCT02711215","Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)",,"Unknown status","No Results Available","Major Depressive Disorder","Diagnostic Test: PET/MR [11C]DASB|Drug: Citalopram|Drug: Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|Drug: Placebo","Hamilton Depression Scale (HDRS)","Medical University of Vienna","All","18 Years to 55 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1.6_20180316","May 2015","January 2020","January 2020","March 17, 2016",,"September 3, 2019","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02711215"
1039,"NCT01421342","VA Augmentation and Switching Treatments for Improving Depression Outcomes","VAST-D","Completed","Has Results","Major Depressive Disorder","Drug: Switching: Bupropion-SR|Drug: Augmenting: Antidepressant + Bupropion-SR|Drug: Augmenting: Antidepressant + Aripiprazole","Rate of Protocol Remission of Symptoms of Major Depressive Disorder|Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase|Rate of Protocol Response as Reduction in Symptoms of Major Depression (>= 50% Reduction in QIDS-C)|Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 3","1522","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","576","December 2012","August 2015","June 2016","August 22, 2011","May 29, 2018","May 29, 2018","Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Tucson, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|VA Eastern Colorado Health Care System, Denver, CO, Denver, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States|Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States|New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States|Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Philadelphia VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|Central Texas Veterans Health Care System, Temple, TX, Temple, Texas, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States|VA Puget Sound Health Care System American Lake Division, Tacoma, WA, Tacoma, Washington, United States|Clarksburg Louis A. Johnson VA Medical Center, Clarksburg, WV, Clarksburg, West Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States|Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01421342"
1040,"NCT02644629","Intra-nasal vs. Intra-venous Ketamine Administration",,"Completed","No Results Available","Major Depressive Disorder","Drug: Placebo|Drug: Ketamine (1st phase)|Drug: Ketamine (2st phase)","MADRS (Montgomery-Åsberg Depression Rating Scale) score improvement from baseline|Ratio of subjects achieving remission|Ratio of subjects achieving Response|Durability of anti-depressant effect according to MADRS Score|Tolerability of Route, based on side effects questionnaire","Shalvata Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHA-15-0019","April 2016","May 2020","May 2020","January 1, 2016",,"October 28, 2020","Shalvata MHC, Hod Hasharon, Israel",,"https://ClinicalTrials.gov/show/NCT02644629"
1041,"NCT02614326","MemFlex to Prevent Depressive Relapse",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Autobiographical Memory Flexibility (MemFlex) training|Behavioral: Psychoeducation","Time to depressive relapse|Number of depression free days at 12 month follow-up|Depressive status at 12 month follow-up|Depression symptoms at 12 month follow-up|Autobiographical memory retrieval","Medical Research Council Cognition and Brain Sciences Unit","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","MemFlex to prevent relapse","January 2016","August 2020","December 2020","November 25, 2015",,"May 26, 2021","MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom|Cambridge and Peterborough NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02614326"
1042,"NCT02418195","miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Drug: ketamine","Beck Scale for Suicide Ideation (BSS)|Montgomery Asberg Depression Rating Scale (MADRS)|Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Beck Hopelessness Scale (BHS)|4-item Brief Psychiatric Rating Scale (BPRS)|Clinician-Administered Dissociative States Scale (CADSS)|Young Mania Rating Scale (YMRS)|Systematic Assessment for Treatment Emergent Events (SAFTEE)","University of Alabama at Birmingham|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","247","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","F141029007|1R01MH107183-01","April 20, 2015","December 31, 2020","August 31, 2021","April 16, 2015",,"July 2, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02418195"
1043,"NCT01671124","The Study of Antidepressant Properties and Safety of Fer-01(Soline®) on the Patients With Depression",,"Unknown status","No Results Available","Major Depressive Disorder","Other: Soline capsule","DSM-IV|analysis of inflammation cytokine|analysis of basic biochemical|Fatty acid composition","Taipei Medical University Hospital|Taipei Medical University Shuang Ho Hospital","All","20 Years to 60 Years   (Adult)",,"1","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Fer-01","September 2012","July 2013","November 2013","August 23, 2012",,"September 11, 2012","Taipei Mecical University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01671124"
1044,"NCT01426516","Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)","PAGE-1_AG1","Terminated","Has Results","Major Depressive Disorder","Device: Genecept Assay","Efficacy Measured by Change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), Adjusted for Baseline Severity, at 6 Months|Clinician Behavior as Measured by Change in Recorded Treatment Choice Before and After the Assay Results Are Made Available.|Quality of Life as Measured by Self Reported Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)|Cost|Acceptability of the Use of AGT for Subjects and Clinicians as Measured by Satisfaction Survey","Genomind, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","AG1-0001/2","September 2011","June 2014","June 2014","August 31, 2011","November 30, 2015","August 28, 2020","Centerstone, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01426516"
1045,"NCT04272476","The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy","ACUfNIRS","Completed","No Results Available","Depressive Disorder, Major","Other: acupuncture and moxibustion|Drug: Fluoxetine","The Hamilton score as a measure of depressive degree|The fNIRS score as a measure of prefrontal oxyhemoglobin","Chengdu University of Traditional Chinese Medicine|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ChengduUTCM","January 2014","December 2019","December 2019","February 17, 2020",,"February 17, 2020","Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04272476"
1046,"NCT02383693","Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study","TMS/DEP","Unknown status","No Results Available","Major Depressive Disorder","Device: Repetitive Transcranial Magnetic Stimulation","'Hamilton depression rating scale (HDRS)","Centre hospitalier de Ville-Evrard, France","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-A00244-49","January 2007","December 2015","December 2015","March 9, 2015",,"March 9, 2015","Unité de Recherche Clinique, Neuilly Sur Marne, Île de France, France",,"https://ClinicalTrials.gov/show/NCT02383693"
1047,"NCT02332291","Connectivity Affecting the Antidepressant REsponse Study","CAARE","Completed","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Bupropion XL","Remission of depression|Change in depression severity, clinician rated|Change in depression severity, self rated","Vanderbilt University Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","141137","April 2015","August 2020","August 2020","January 6, 2015",,"August 21, 2020","Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02332291"
1048,"NCT02507219","Study of Ibuprofen Effects on Brain Function",,"Completed","Has Results","Major Depressive Disorder","Drug: Ibuprofen","Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala","Laureate Institute for Brain Research, Inc.|University of Oklahoma","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2015-007-00","July 2015","October 2015","October 2015","July 23, 2015","February 23, 2018","February 23, 2018","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02507219"
1049,"NCT00086307","Lexapro and Pramipexole and to Treat Major Depression",,"Completed","Has Results","Major Depression","Drug: Pramipexole|Drug: Escitalopram","Montgomery Asberg Depression Rating Scale (MADRS)","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","39","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","040227|04-M-0227","June 2004","March 2010","March 2010","June 30, 2004","July 12, 2012","January 28, 2013","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00086307"
1050,"NCT02590185","MetAbolism vaRiability of VEnLafaxine","MARVEL","Unknown status","No Results Available","Major Depressive Disorders","Drug: cocktail probe drugs","The CYP2C19 activity|The CYP2D6 activity|The CYP3A4 activity|The P-gp activity|Tobacco use|Mood disorder|Anxiety scale Tyrer|QIDS-SR16|Criteria for rating medication trials for antidepressant failure and level of resistance|MARS Score|PRISE-M score|FISBER score","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","205","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AOM14562","December 2015","December 2019","April 2020","October 28, 2015",,"February 19, 2019","Fernand Widal hospital, Paris, France|Lariboisiere hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02590185"
1051,"NCT01342536","African American Depression Intervention Trial (AADI)","AADI","Completed","No Results Available","Major Depressive Disorder","Behavioral: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)","Center for Epidemiologic Studies Depression Scale (CES-D)|Quick Inventory of Depressive Symptomatology (QIDS)","University of Wisconsin, Madison|National Institute on Minority Health and Health Disparities (NIMHD)","All","30 Years to 60 Years   (Adult)","Phase 3","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0109, 2011-0234|R01MD005905-01A1","December 14, 2011","June 2018","June 2018","April 27, 2011",,"May 8, 2019","Mental Health Center of Dane County, Madison, Wisconsin, United States|Milwaukee Health Services, INC, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01342536"
1052,"NCT02356107","5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females",,"Completed","Has Results","Major Depressive Disorder","Drug: 5-hydroxytryptophan and Creatine monohydrate","Change From Baseline in Hamilton Depression Rating Scale","Perry Renshaw|University of Utah","Female","18 Years to 64 Years   (Adult)","Phase 4","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5HTP/Creatine","April 2015","August 2016","August 2016","February 5, 2015","January 4, 2018","January 29, 2018","University of Utah/The Brain Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02356107"
1053,"NCT01582581","Study of Technology-assisted Treatment of Adolescent Depression","iTAD","Completed","No Results Available","Major Depressive Disorder","Behavioral: Telephonic CBT|Behavioral: Wait List Control","Changes in measures of depression over the course of treatment among teens with Major Depressive Disorder.|Evidence of program efficacy as indicate by changes in subjects' knowledge of depression.|Evidence of program efficacy as indicated by development of self-efficacy skills.|Evidence of program efficacy as indicated by the establishment of therapeutic alliance.|Evidence of program efficacy as indicated by fidelity and treatment quality.|Evidence of program efficacy as indicated by program acceptance.","iHope Network, Inc.|Woburn Pediatric Associates|UConn Health","All","12 Years to 17 Years   (Child)","Not Applicable","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VHS 85350-02","March 2012","December 2014","December 2014","April 20, 2012",,"April 30, 2015","University of Connecticut Health Center, Farmington, Connecticut, United States|Woburn Pediatric Associates, Woburn, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01582581"
1054,"NCT01438242","An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression",,"Withdrawn","No Results Available","Major Depressive Disorder","Device: Genecept Assay","Efficacy|Medication Adherence|Resource Utilization|Impact of Specific Genetic Variants|Side Effects","Genomind, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AT1","January 2015","January 2016","January 2016","September 22, 2011",,"March 23, 2015","Genomind, LLC, Chalfont, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01438242"
1055,"NCT01207271","A Comparison of Cognitive and Dynamic Therapy for Depression in Community Settings",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Therapy|Behavioral: Supportive-Expressive Psychodynamic Therapy","Hamilton Rating Scale for Depression (HAM-D)|BASIS-24|Beck Depression Inventory - II (BDI-II)|Medical Outcomes Study 36-Item Short Form (SF-36)|Quality of Life Inventory (QOLI)|Ways of Responding (WOR)|Dysfunctional Attitudes Scale (DAS)|Psychological Distance Scaling Task (PDST)|Self-Understanding of Interpersonal Patterns Scale-Revised (SUIP-R)","University of Pennsylvania","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","237","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01HS018440","November 2010","December 9, 2014","December 9, 2014","September 22, 2010",,"May 2, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01207271"
1056,"NCT01975948","Evaluation of a Mental Health Physician Support Program in Nova Scotia",,"Completed","Has Results","Major Depressive Disorder","Other: Mental Health Practice Support Program|Other: Treatment as Usual","Depression Severity (Change in Patient Health Questionnaire-9 (PHQ-9) Score From Baseline|Between Group Changes in Total Score on the Opening Minds Scale for Health Care Providers (OMS-HC)|Between Group Changes in Occupational Functioning From Baseline to 6 Months|Economic Impact","Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Not Applicable","285","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","CDHA-RS/2014-150","November 2013","December 2015","December 2015","November 5, 2013","June 26, 2017","August 14, 2018","Dalhousie University Department of Psychiatry, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT01975948"
1057,"NCT01601002","LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Mirtazapine","increase in weight as measured in the clinic|Proportion of population achieving clinical response as measured by rate of fall in HAM-D 24 item scores|Proportion of patients achieving remission at end of study on HAM-D 24 (<11)|Frequency of adverse events|Percentage adhering to medication","Lawson Health Research Institute","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","HSREB-102574","June 2012","October 2015","December 2015","May 17, 2012",,"April 21, 2016","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01601002"
1058,"NCT02099630","Functional and Metabolic Changes in the Course of Antidepressive Treatment",,"Completed","No Results Available","Major Depressive Disorder",,"Change in neurotransmitter concentrations (glutamate, glutamine, gamma-aminobutyric acid) from baseline to response to antidepressive intervention|Change in neuronal activation patterns from baseline to response to antidepressive intervention","Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMOKET-103/13","March 2014","November 2019","February 2020","March 31, 2014",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT02099630"
1059,"NCT02082392","Developing New Clinical Management Strategies",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Placebo","Hamilton Rating Scale for Depression|Hamilton Anxiety Rating Scale (HARS) 14-item Scale|CGI Severity and Improvement|Treatment Emergent Symptom Scale|California Pharmacotherapy Alliance Scale (CALPAS)-Clinician Version|Blind Assessment-Clinician Version|Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR) 16 Item Scale|Treatment Credibility and Expectancy Scale (CES)|Client Satisfaction Questionnaire 8 (CSQ 8)|Cornell Treatment Preference Index|Revised Life Orientation Test (LOT-R)|Schedule for Adaptive and Nonadaptive Personality (SNAP)|California Pharmacotherapy Alliance Scale (CALPAS)-Patient Version|Blind Assessment-Patient Version","New York State Psychiatric Institute","All","18 Years to 60 Years   (Adult)","Phase 4","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#6652","September 2012","August 2015","August 4, 2015","March 10, 2014","July 7, 2017","March 3, 2020","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02082392"
1060,"NCT01492621","Effect of Antidepressants on White Matter Structure",,"Unknown status","No Results Available","Major Depression","Drug: Desvenlafaxine","Anisotropy|cognitive measures|Pain threshold","Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal|Pfizer","All","18 Years to 55 Years   (Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DTI","November 2011","September 2013","November 2013","December 15, 2011",,"December 15, 2011","Centre de Recherche Fernand-Seguin, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01492621"
1061,"NCT02067299","A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants",,"Completed","No Results Available","Depressive Disorder, Major","Drug: JNJ-42847922|Other: Placebo","Latency to Persistent Sleep (LPS) on Day 1|Number of participants with adverse events|Maximum Observed Plasma Concentration (Cmax) of JNJ-42847922|Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-42847922|Area Under the Plasma Concentration-Time Curve From Time Zero to Time 12 (AUC[12])|Total amount of JNJ-42847922 excreted in urine (Ae12)|Renal clearance (CLR)|Number of participants with suicidal ideation or behavior measured using Columbia Suicide Severity Rating Scale (C-SSRS)|Total sleep time in participants|Sleep efficiency in participants|Next-day residual effect of JNJ-42847922 measured using visual analogue scale (VAS) for sleepiness|Next-day residual effect of JNJ-42847922 measured using the Bond and Lader visual analogue scale (VAS) to rate subjective feelings|Next-day residual effect of JNJ-42847922 on body movements measured using a pot string meter and a stabilometric platform|Next-day residual effect of JNJ-42847922 on saccadic eye movements|Number of participants with depressive symptoms measured using Quick Inventory of Depressive Symptomatology - Self Report 14-item (QIDS-SR14)|Concentration of cortisol in saliva|Time spent awake by the participants|Total time spent deep sleep by the participants","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR103409|42847922EDI1002","February 2014","December 2014","December 2014","February 20, 2014",,"February 4, 2016","Berlin, Germany|Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02067299"
1062,"NCT02055300","Safety, Tolerability and Pharmacokinetics Study of LY03005","LY03005SAD","Completed","No Results Available","Major Depressive Disorder","Drug: LY03005|Drug: Placebo|Other: Meal|Drug: Pristiq","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|PK parameters of: Cmax,","Luye Pharma Group Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LY03005","February 2014","August 2014","August 2014","February 5, 2014",,"November 10, 2014","Medpace, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02055300"
1063,"NCT02048423","An Open Prospective Trial of IV Ketamine in Suicidal Adolescents",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: Ketamine","Change in Quick Inventory of Depression Clinician (QIDS-C) total scores from baseline to endpoint and Clinical Global Improvement Score.|Clinical Global Assessment Scale","Nationwide Children's Hospital","All","12 Years to 17 Years   (Child)","Phase 2|Phase 3","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB12-00445","June 2013","June 2015","June 2015","January 29, 2014",,"January 29, 2014","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02048423"
1064,"NCT02816138","Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)",,"Completed","Has Results","Major Depressive Disorder","Drug: Nicotine","Change in Total MADRS (Montgomery Asberg Depression Rating Scale) Score|Change in Continuous Performance Task (CPT) Performance|Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score|Change in Penn State Worry Questionnaire (PSWQ)|Change in Ruminative Response Scale Total Score|Change in Apathy Evaluation Scale (AES)|Change in MFQ (Memory Frequency Questionnaire) Score|Change in Choice Reaction Time (CRT) Performance|Change in One-back Test Performance|Change in NYU (New York University) Paragraph Recall Performance","Vanderbilt University Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 4","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DepMIND","October 2016","August 23, 2017","September 12, 2017","June 28, 2016","September 27, 2018","September 27, 2018","Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02816138/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02816138"
1065,"NCT01804296","rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Repetitive transcranial magnetic stimulation (rTMS)","Mean change from Baseline in Children's Depression Rating Scale-Revised (CDRS-R) post Treatment 30 or Last Treatment (in the case of early withdrawal)|Mean change from Baseline in Clinical Global Impression - Severity (CGI-S) post Treatment 30 or Last Treatment (in the case of early withdrawal)|Mean Clinical Global Impression - Improvement (CGI-I) Score post Treatment 30 or Last Treatment (in the case of early withdrawal)","Paul E. Croarkin|Mayo Clinic","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-003248 Part 2","March 2013","December 2021","December 2021","March 5, 2013",,"January 22, 2021","Mayo Clinic, Rochester, Minnesota, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01804296"
1066,"NCT01804270","rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1",,"Active, not recruiting","No Results Available","Major Depressive Disorder","Device: Repetitive transcranial magnetic stimulation (rTMS)","Mean change from Baseline in Children's Depression Rating Scale-Revised (CDRS-R) post Treatment 30 or Last Treatment (in the case of early withdrawal)|Mean change from Baseline in Clinical Global Impression - Severity (CGI-S) post Treatment 30 or Last Treatment (in the case of early withdrawal)|Mean Clinical Global Impression - Improvement (CGI-I) Score post Treatment 30 or Last Treatment (in the case of early withdrawal)","Paul E. Croarkin|Mayo Clinic","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-003248 Part 1","April 2013","December 2021","December 2021","March 5, 2013",,"January 22, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01804270"
1067,"NCT01598922","Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function","iCBT","Completed","Has Results","Major Depressive Disorder","Behavioral: Internet Cognitive Behavioral Therapy","Change From Pre-treatment to Post-treatment (10 Weeks), Measured by the Hamilton Rating Scale for Depression, 17 Item Version (HRSD-17).|Weekly Patient Health Questionnaire (PHQ-9) Score|Weekly Kessler Psychological Distress Scale (K-10) Score|Improvement From Baseline in Brain Functioning on the Emotional Interference Task (EIT) and the Monetary Incentive Delay Task (MID)|Change From Baseline in Positive and Negative Affect Scale (PANAS) Score|Change From Baseline in Connor Davidson Resilience Scale (CD-RISC) Score|Change From Baseline in Modified Erikson Flanker Test|Change From Baseline in Implicit Association Test (IAT)","Mclean Hospital","All","18 Years to 45 Years   (Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W81XWH-12-1-0109","October 2012","August 2015","August 2015","May 15, 2012","December 7, 2020","May 25, 2021","Isabelle Rosso, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01598922"
1068,"NCT00939718","Comparison of Vitamin B12 Supplementation to Selective Serotonin Reuptake Inhibitor (SSRI) Versus SSRI Antidepressant Treatment Alone",,"Unknown status","No Results Available","Major Depressive Disorder","Dietary Supplement: Vitamin B12","Decline in HAM-D score of 20% or more from baseline indicating improvement in Depression.","Aga Khan University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","081011PSY","April 2009","June 2010","September 2010","July 15, 2009",,"May 31, 2010","Aga Khan University, Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT00939718"
1069,"NCT03143075","Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?",,"Recruiting","No Results Available","Major Depressive Disorder","Dietary Supplement: Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day","Reduction in depressive symptoms|Response|Change in depressed mood|Absolute change in ""inflammatory depressive symptoms""|Improvement in functioning and quality of life.|Absolute change in general Anxiety symptoms|Absolute change in IL-6 and TNF-alpha|Absolute change in CRP, leptin, adiponectin|Absolute change in oxidative stress marker F2 Isoprostanes|Absolute change in oxidative stress marker 8-OHdG|Absolute change in oxidative stress marker glutathione|Absolute change in metabolic markers|Absolute change in antioxidant glutathione peroxidase|Absolute change in vascular cell adhesion molecule (VCAM) and intracellular adhesion molecule (ICAM)|Absolute change in leukocyte telomerase activity|Absolute change in leukocyte telomere length|Absolute change in circulating cell-free mitochondrial DNA (ccf mtDNA)|Number of dropouts (due to side effects)|Remission in depressive symptoms","Region Skane|University of California, San Francisco","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017150","August 1, 2017","May 2021","May 2021","May 8, 2017",,"April 7, 2020","Lund University, Dept of Psychiatry, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT03143075"
1070,"NCT01022632","Effect of Curcumin as Nutraceutical in Patients of Depression",,"Completed","No Results Available","Major Depressive Disorder","Dietary Supplement: Curcumin|Drug: Fluoxetine|Dietary Supplement: Curcumin and Fluoxetine","Response rate according to HAM-D17 scale|Mean change in HAM-D17 score|Clinical global impression assessment|Global efficacy at the end of study|Change in laboratory parameters (routine hematology and urine)","Government Medical College, Bhavnagar|Health and Family Welfare Department, Government of Gujarat, India|Arjuna Natural Extracts Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pharmacol no.01 /2008 Research","March 2009","January 2010","January 2010","December 1, 2009",,"January 28, 2010","Sir Takthasinhji General Hospital, Bhavnagar, Gujarat, India",,"https://ClinicalTrials.gov/show/NCT01022632"
1071,"NCT01502033","Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens",,"Completed","Has Results","Major Depressive Disorder","Device: Transcranial Magnetic Stimulation","Children's Depression Rating Scale-Revised (CDRS-R) Post Treatment 30 or Last Treatment (in Cases of Early Withdrawal)|Clinical Global Impression - Severity (CGI-S) Post Treatment 30 or Last Treatment (in Cases of Early Withdrawal)|The Clinical Global Impression - Improvement (CGI-I)","Paul E. Croarkin|Mayo Clinic","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-004500","December 2011","May 2013","December 2013","December 30, 2011","February 17, 2016","April 22, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01502033"
1072,"NCT01633437","Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers","CX157-112","Completed","No Results Available","Major Depressive Disorder","Drug: CX157|Other: Placebo","Systolic Blood Pressure (SBP)|Number of subjects with adverse events as a measure of safety and tolerability of CX157.|Cmax, Cmin, Tmax","CeNeRx BioPharma Inc.","Male","18 Years to 50 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CX157-112","September 2010","October 2010","October 2010","July 4, 2012",,"July 4, 2012","Comprehensive Phase One, Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01633437"
1073,"NCT00479726","Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)","LEAPS","Completed","No Results Available","Major Depressive Disorder","Drug: duloxetine hydrochloride","Clinical Global Impression of Severity|Somatic Symptom Inventory|Depressive Symptomatology-Self Report|Patient Global Impression of Improvement|Mood and Physical Symptoms in Depression|Quality of Life Enjoyment Satisfaction Questionnaire-Short form","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","8000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8300|F1J-MC-HMCY","August 2004",,"January 2005","May 28, 2007",,"May 28, 2007","For additional information regarding investigative sites for this trial,contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00479726"
1074,"NCT00871299","Practicing Alternative Techniques to Heal From Depression: The PATH-D Study","PATH-D","Completed","No Results Available","Major Depressive Disorder","Behavioral: Mindfulness Based Cognitive Therapy|Behavioral: Health Enhancement Program and medication management","Hamilton Depression Rating Scale (HAMD-17)|Quick Inventory of Depressive Symptomatology(Self-Rated)-16 items(QIDS-SR16)|Short Form Health Survey-36|Clinical Global Improvement Scale (CGI)|Work and Social Activity Scale (WSAS)|Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (QLESQ-SF)","University of California, San Francisco|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","173","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01 AT004572-O1A1|R01AT004572-01A1|3063975","September 2009","June 2014","June 2014","March 30, 2009",,"December 2, 2014","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00871299"
1075,"NCT03866174","A Study of Psilocybin for Major Depressive Disorder (MDD)",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Psilocybin|Drug: Niacin","Change in central rater Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to post-dose Day 8|Change in central rater MADRS score from Baseline to post-dose Day 43|Change in on-site rater administered Sheehan Disability Scale (SDS) score from Baseline to post-dose Day 43|Sustained depressive symptom response defined as a ≥ 50% reduction from Baseline central rater MADRS score at all post-dose assessments|Sustained depressive symptom remission defined as a central rater MADRS total score ≤ 10 at all post-dose assessments","Usona Institute|Signant Health|The Emmes Company, LLC","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PSIL201","October 15, 2019","February 2021","February 2021","March 7, 2019",,"January 7, 2021","University of California, San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Segal Trials, Lauderhill, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|New York University School of Medicine, New York, New York, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03866174"
1076,"NCT02079610","Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases",,"Completed","Has Results","Major Depressive Disorder","Behavioral: real-time fMRI neurofeedback: Amygdala|Behavioral: real-time fMRI neurofeedback: HIPS","Change From Baseline in Montgomery Asberg Depression Rating Scale at 2 Weeks|Change From Baseline Beck Depression Inventory at 2 Weeks|Change From Baseline Hamilton Rating Scale for Depression at 2 Weeks","Laureate Institute for Brain Research, Inc.|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013-013-00|4R00MH101235-03","April 2014","April 2016","April 2016","March 6, 2014","September 25, 2017","September 25, 2017","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02079610"
1077,"NCT01369290","Electroencephalography (EEG) Signal Processing","EEG-SP","Unknown status","No Results Available","Major Depressive Disorder","Drug: Venlafaxine|Drug: bupropion|Drug: escitalopram|Other: Psychotherapy|Drug: Duloxetine","Machine learning","St. Joseph's Healthcare Hamilton","All","18 Years to 70 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ESP-3152|EEG Signal Processing","October 2009","October 2012","October 2013","June 8, 2011",,"November 30, 2011","St. Joseph's Healthcare, Centre for Mountain Health Services, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01369290"
1078,"NCT00452543","Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism",,"Completed","Has Results","Major Depressive Disorder|Alcohol Abuse|Alcohol Dependence","Drug: acamprosate|Drug: escitalopram|Behavioral: Medical management|Drug: Placebo","Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)|Total Drinking Days on the Alcohol Timeline Followback (TLFB)|Total Drinks Consumed Per Week on the TLFB|Total Drinks Consumed Per Drinking Day on the TLFB","Massachusetts General Hospital|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 64 Years   (Adult)","Phase 4","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006-P-001592/1","March 2007","May 2010","May 2010","March 27, 2007","July 9, 2012","July 9, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00452543"
1079,"NCT00784199","Validating PROMIS Instruments in Depression",,"Completed","No Results Available","Major Depressive Disorder",,"PROMIS computerized adaptive tests (CATs) for pain, fatigue, social functioning, depression, anxiety, anger, sleep, wake, and physical functioning, and non-PROMIS measures (conventional instruments) also administered by computer|Judgments of clinically significant change (via diagnostic interviews) and comparison of these changes with the changes reflected in the PROMIS measures","University of Pittsburgh|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Duke University|NorthShore University HealthSystem|University of North Carolina, Chapel Hill|Stanford University|Stony Brook University|University of Washington","All","18 Years and older   (Adult, Older Adult)",,"115","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","07-04a|5U01AR052155-02|2U01AR052155-06","June 2008","July 2010","July 2010","November 2, 2008",,"May 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00784199"
1080,"NCT02498392","An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress",,"Completed","No Results Available","Depressive Disorder|Anxiety","Drug: JNJ-42165279|Other: Placebo","Change from Baseline to Endpoint on the Hamilton Depression Rating Scale (HDRS17) Total Score|Change from Baseline to Endpoint on the Hamilton Anxiety Rating scale (HAM-A6) Score|Change from Baseline to Endpoint on the SIGH-A (Structured Interview Guide of the Hamilton Anxiety Scale 14-item HAM-A) Total Score|Change from Baseline to Endpoint on the Hamilton Anxiety Rating scale (HAM-D6) Score|Change from Baseline to Endpoint in the Hamilton Depression Rating Scale (HDRS17) Anxiety/Somatization Factor Total Score|Number of Participants with a Hamilton Depression Rating Scale (HDRS17) Anxiety/Somatization Factor Score Greater than or equal to 7 at Week 6|Maximum Plasma Concentration (Cmax) of JNJ-42165279|Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-42165279|Area Under the Plasma Concentration-time Curve From Time Zero to Dosing Interval [AUC(0-t)]","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107733|2015-002007-29|42165279MDD2001","October 7, 2015","February 4, 2019","February 4, 2019","July 15, 2015",,"February 10, 2020","Costa Mesa, California, United States|Oceanside, California, United States|Miami, Florida, United States|Natick, Massachusetts, United States|Cedarhurst, New York, United States|Raleigh, North Carolina, United States|Allentown, Pennsylvania, United States|Salt Lake City, Utah, United States|Chisinau, Moldova, Republic of|Ekaterinburg, Russian Federation|Orenburg, Russian Federation|Saratov, Russian Federation|St-Petersburg, Russian Federation|Tomsk, Russian Federation|Alicante, Spain|Barcelona, Spain|Bilbao, Spain|Sant Boi de Llobregat, Spain|Zamora, Spain|Glevakha, Ukraine|Kharkiv, Ukraine|Kherson, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Smila, Ukraine|Uzhgorod, Ukraine|Barnsley, United Kingdom|Blackpool, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|South Staffordshire, United Kingdom|Stourton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02498392"
1081,"NCT04405791","Efficacy of Clinical Application of Transcranial Low Intensity Focused Ultrasonic Stimulation for Patients With Major Deperessive Disorder - Exploratory Clinical Trial",,"Recruiting","No Results Available","Major Depressive Disorder(MDD)","Procedure: Active stimulation group Sham stimluation group","Change in Montogmery-Asberg Depression Rating Scale, MADRS","Gangnam Severance Hospital","All","19 Years to 60 Years   (Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","3-2018-0352","June 12, 2019","July 31, 2021","August 11, 2021","May 28, 2020",,"February 4, 2021","GangnamSeverance Hospital, Seoul, Gangnam, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04405791"
1082,"NCT00523081","Study of Adolescence and Depression","STAND","Completed","No Results Available","Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy (CBT)|Behavioral: Active control","The two Primary outcomes are (a) recovery of response from the index episode of major depression and (b) improvements in continuous depression symptomatology .|Secondary outcomes include depression response; rates of new, recurrent episodes of MDD during follow-up; improvement in psychosocial function; clinical improvements; and reduction in depression-related dysfunction.","Kaiser Permanente|National Institute of Mental Health (NIMH)","All","12 Years to 18 Years   (Child, Adult)","Phase 3","212","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH073918-01A1","October 2006","March 2012","January 2014","August 30, 2007",,"February 3, 2014","Kaiser Permanente Center for Health Research, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00523081"
1083,"NCT01357967","The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope",,"Unknown status","No Results Available","Major Depressive Disorder","Drug: SSRI monotherapy|Drug: Seroquel XR adjunctive","Change from baseline in HDRS scale|Change from baseline in CGI, BDI, and YMRS scales","Inje University","All","18 Years to 55 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Seroquel ISS D1443C00053","May 2011","December 2012","April 2013","May 23, 2011",,"November 1, 2012","Psychiatry Department, Inje University Ilsan Paik Hospital, Goyang, Geyonggi, Korea, Republic of|Inje University Ilsanpaik Hospital, Goyang, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01357967"
1084,"NCT01188135","Antidepressant Adherence Via AD_IVR","AD_IVR","Completed","No Results Available","Major Depressive Disorder","Behavioral: Interactive voice messaging or Interactive voice messaging + psycho ed materials","Participants in the IVR study arm will have a significantly higher rate of AD persistence (ELPT) than those in the TAU control condition|cost-effectiveness analyses","Kaiser Permanente|National Institute of Mental Health (NIMH)","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 3","6058","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R01MH090160","February 2011","February 2013","November 2014","August 25, 2010",,"March 17, 2015","Kaiser Permanente Center for Health Research, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01188135"
1085,"NCT01369030","Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)",,"Completed","Has Results","Major Depressive Disorder","Other: Deplin®","Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)|Proportion of Patients Reporting Difficulty in Daily Functioning Due to Depressive Symptoms|Change in Overall Patient Satisfaction With Deplin® Using a 9-point Satisfaction Scale","Pamlab, Inc.|InfoMedics, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)",,"554","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","D-009","November 2010","April 2012","April 2012","June 8, 2011","June 3, 2014","June 3, 2014","Moses Cone Family Practice Center, Greensboro, North Carolina, United States|Vanderbilt University School of Medicine, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01369030"
1086,"NCT01305889","The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders",,"Recruiting","No Results Available","Major Depressive Disorder","Behavioral: problem solving therapy|Drug: Sertraline","change in cerebral perfusion|Change in cognitive measures of memory, learning, and executive dysfunction|Change in BDNF","University of California, San Francisco|Leon J. Epstein Endowment","All","65 Years and older   (Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-02704","March 2011","January 16, 2021","January 16, 2021","March 1, 2011",,"May 4, 2020","Langley Porter Psychiatric Institute, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01305889"
1087,"NCT01304147","Intranasal Ketamine in Treatment-Resistant Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Ketamine|Drug: placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Systematic Assessment for Treatment Emergent Effects (SAFTEE)","James Murrough|Icahn School of Medicine at Mount Sinai","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 11-0492|INKET-001","October 2011","October 2014","October 2014","February 25, 2011","February 8, 2017","February 8, 2017","Icahn School of Medicine at Mount Sinai, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT01304147"
1088,"NCT01443208","Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet",,"Completed","No Results Available","Major Depressive Disorder","Drug: desvenlafaxine","For single dose: maximum concentration (Cmax)|For single dose: time to first occurence of Cmax (Tmax)|For single dose: area under curve (0-time for last quantifiable concentration) (AUClast)|For multiple dose: maximum concentration (Cmax)|For multiple dose: time to first occurence of Cmax (Tmax)|For multiple dose: trough concentration (Ctrough)|For multiple dose: area under curve (0-24hours) (AUC0-24)|For single dose if data permit: terminal elimination half life (t1/2)|For single dose if data permit: area under curve (0-infinity) (AUCinf)|For single dose if data permit: oral clearance (CL/F)|For single dose if data permit: apparent volume of distribution (Vz/F)|For multiple dose if data permit: accumulation factor (Rac)|For multiple dose if data permit: terminal elimination half life (t1/2)|For multiple dose if data permit: oral clearance (CL/F)|For multiple dose if data permit: apparent volume of distribution (Vz/F)","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","B2061137","November 2011","December 2011","December 2011","September 29, 2011",,"January 2, 2012","Pfizer Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01443208"
1089,"NCT00590863","Combining Medications to Enhance Depression Outcomes","CO-MED","Completed","Has Results","Major Depressive Disorder","Drug: SSRI + placebo|Drug: Escitalopram + Bupropion SR|Drug: Venlafaxine XR + Mirtazapine","Quick Inventory of Depressive Symptoms|Quality of Life Inventory","National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","665","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","N01 MH090003-02|DSIR AT","March 2008","September 2009","September 2009","January 11, 2008","April 23, 2014","April 23, 2014","Tuscalossa VA Mental Health Clinic, Tuscaloosa, Alabama, United States|Harbor UCLA Family Health Care Center, Harbor City, California, United States|UCLA Internal Medicine Clinic, Los Angeles, California, United States|Veterans Affairs Medical Center/FIRM Primary Care Clinic, San Diego, California, United States|Northwestern Psychiatric Outpatient Treatment Care Center, Chicago, Illinois, United States|Clinical Research Institute, Wichita, Kansas, United States|MGH/Northshore Medical Center (Salem Psychiatric Facility), Salem, Massachusetts, United States|General Psychiatric Ambulatory Clinic, Ann Arbor, Michigan, United States|Irving Goldman Primary Care at North Shore Hospital, New York, New York, United States|UNC Chapel Hill Adult Diagnostic & Treatment Clinic, Chapel Hill, North Carolina, United States|Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, United States|Bellefield Clinic of WPIC, Pittsburgh, Pennsylvania, United States|Vine Hill Community Clinic, Nashville, Tennessee, United States|UT Southwestern Family Medicine Clinic, Dallas, Texas, United States|VCU Outpatient Psychiatry Clinic, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00590863"
1090,"NCT00952653","Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam",,"Completed","Has Results","Major Depressive Disorder","Drug: Desvenlafaxine Succinate Sustained Release|Drug: Midazolam","Midazolam Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Midazolam Alone and When Coadministered With DVS SR|Midazolam Maximum Observed Plasma Concentration (Cmax) Following Midazolam Alone and When Coadministered With DVS SR|1-Hydroxy-Midazolam (Analyte) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Midazolam Alone and When Coadministered With DVS SR|1-Hydroxy-Midazolam (Analyte) Maximum Observed Plasma Concentration (Cmax) Following Midazolam Alone and When Coadministered With DVS SR|Midazolam Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) Following Midazolam Alone and When Coadministered With DVS SR|Midazolam Time to Cmax (Tmax) Following Midazolam Alone and When Coadministered With DVS SR|Midazolam Terminal Half-life (t 1/2) Following Midazolam Alone and When Coadministered With DVS SR|1-Hydroxy-Midazolam (Analyte) Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) Following Midazolam Alone and When Coadministered With DVS SR|1-Hydroxy-Midazolam (Analyte) Time to Cmax (Tmax) Following Midazolam Alone and When Coadministered With DVS SR|1-Hydroxy-Midazolam (Analyte) Terminal Half-life (t 1/2) Following Midazolam Alone and When Coadministered With DVS SR","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 4","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-1205|B2061001","June 2010","August 2010","August 2010","August 6, 2009","August 2, 2011","August 15, 2011","Pfizer Investigational Site, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00952653"
1091,"NCT01380691","A Study of LY2216684 in Healthy Participants",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo-matching LY2216684|Drug: Placebo-matching alcoholic beverage|Drug: Alcoholic beverage","Change From Baseline to 10 Hours in Power of Attention Composite Score|Change From Baseline to 10 Hours in Continuity of Attention Composite Score|Change From Baseline to 10 Hours in Postural Stability|Change From Baseline to 10 Hours in Self-Rated Alertness|Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax) of LY2216684|Pharmacokinetics: Observed Cmax of Alcohol|Pharmacokinetics: Observed Time to Maximum Plasma Concentration (Tmax) of LY2216684|Pharmacokinetics: Observed Tmax of Alcohol|Pharmacokinetics: Area Under the Concentration Time Curve Over a Dosing Interval (AUCt) of LY2216684|Pharmacokinetics: Area Under the Concentration Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Alcohol|Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Working Memory|Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Episodic Memory|Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Speed of Retrieval of Information From Memory|Change From Baseline to 1, 2, 3, 4.5, 6, 8, and 10 Hours in Self-Ratings of Calmness and Contentment","Eli Lilly and Company","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12613|H9P-EW-LNCV","June 2011","September 2011","September 2011","June 27, 2011","June 26, 2019","June 26, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01380691"
1092,"NCT00693849","International Study to Predict Optimised Treatment - in Depression","iSPOT-D","Unknown status","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Sertraline|Drug: Venlafaxine-XR","To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDD|To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months.","BRC Operations Pty. Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","2688","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","iSPOT-D","September 2008","December 2019","December 2019","June 9, 2008",,"July 11, 2018","Shanti Clinical Trials, Colton, California, United States|A.D.D. Treatment Center, Mission Viejo, California, United States|Stanford University, Stanford, California, United States|Veteran Affairs/Stanford University, Stanford, California, United States|Center for Healing the Human Spirit, Tarzana, California, United States|University of Miami, Miami, Florida, United States|University of Missouri - St. Louis, Saint Louis, Missouri, United States|Brain Resource Center, Englewood Cliffs, New Jersey, United States|Brain Resource Center, New York, New York, United States|Weill Cornell Medical College, White Plains, New York, United States|Skyland Behavioral Health Associates , P.A., Asheville, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|NeuroDevelopment Center, Providence, Rhode Island, United States|Brain Dynamics Centre, Westmead, New South Wales, Australia|Flinders University, Adelaide, South Australia, Australia|Swinburne University, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Brainclinics Diagnostics B.V., Nijmegen, Gelderland, Netherlands|University of Auckland, Auckland, New Zealand|Brain Health Lab, Johannesburg, Guatang, South Africa",,"https://ClinicalTrials.gov/show/NCT00693849"
1093,"NCT01559324","Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression",,"Completed","No Results Available","Major Depression","Device: ECT","Depression|Cognitive function|Blood-tests","Diakonhjemmet Hospital|MD Tor Magne Bjølseth|MD Torfinn Lødøen Gaarden","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 4","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","6.2009.06 2011/02/0009","August 2009","July 2013","November 2013","March 21, 2012",,"July 9, 2015","Diakonhjemmet Hospital, Department of Old Age Psychiatry, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01559324"
1094,"NCT00533832","Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)",,"Completed","No Results Available","Major Depressive Disorder","Device: vagus nerve stimulation (VNS)",,"Cyberonics, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D02","July 2000",,"July 2005","September 24, 2007",,"September 24, 2007","Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00533832"
1095,"NCT01275144","A Study of the Effect of LY2216684 on Lorazepam",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo|Drug: Lorazepam","Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax)|Pharmacokinetics of Lorazepam, Time to Maximum Plasma Concentration (Tmax)|Pharmacokinetics of Lorazepam, Area Under the Plasma Concentration Curve (AUC) From Time 0 to Infinity (∞)|Change From Baseline in Cognitive Function-Simple Reaction Time|Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected|Change From Baseline in Cognitive Function-Digit Vigilance Speed|Change From Baseline in Cognitive Function-Digit False Alarms|Change From Baseline in Cognitive Function-Choice Reaction Time|Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy|Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI)|Change From Baseline in Cognitive Function-Numeric Working Memory Speed|Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy|Change From Baseline in Cognitive Function-Immediate Word Recall Errors|Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy|Change From Baseline in Cognitive Function-Delayed Word Recall Errors|Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI)|Change From Baseline in Cognitive Function-Word Recognition Speed|Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI)|Change From Baseline in Cognitive Function-Picture Recognition Speed|Change From Baseline in Cognitive Function-Tracking Average Distance From Target|Change From Baseline in Cognitive Function-Postural Stability|Change From Baseline in Cognitive Function-Self-rated Alertness|Change From Baseline in Cognitive Function-Self-rated Contentment|Change From Baseline in Cognitive Function-Self-rated Calmness","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12596|H9P-EW-LNCG","December 2010","February 2011","February 2011","January 12, 2011","March 11, 2019","March 11, 2019","For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01275144"
1096,"NCT01266590","A Study of LY2216684 and Digoxin in Healthy Subjects",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Digoxin","Pharmacokinetics of Digoxin: Maximum Plasma Concentration (Cmax)|Pharmacokinetics of Digoxin: Time to Maximum Plasma Concentration (Tmax)|Pharmacokinetics of Digoxin: Area Under the Concentration Time Curve at Steady State Over the Dosing Interval (AUCt)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12600|H9P-EW-LNCK","December 2010","February 2011","February 2011","December 24, 2010","October 22, 2018","October 22, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01266590"
1097,"NCT01263730","Tai Chi Training for Treating Depressed Chinese Americans",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Tai Chi","Depressive Symptoms|Psychological questionnaires, specifically the Quality of Life Enjoyment questionnaire.","Massachusetts General Hospital|Centers for Disease Control and Prevention","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","38","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2008P000262","February 2008","August 2010","August 2010","December 21, 2010",,"April 19, 2012","South Cove, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01263730"
1098,"NCT01263197","A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: albuterol|Drug: propranolol|Drug: placebo for LY2216684|Drug: placebo for albuterol|Drug: placebo for propranolol","Maximum, Minimum and Average Changes in Heart Rate|Maximum, Minimum and Average Changes in Systolic Blood Pressure|Maximum, Minimum and Average Changes in Diastolic Blood Pressure","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12598|H9P-EW-LNCI","December 2010","March 2011","March 2011","December 20, 2010","October 22, 2018","January 29, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01263197"
1099,"NCT01263119","A Study of LY2216684 and Warfarin in Healthy Subjects",,"Completed","Has Results","Major Depressive Disorder","Drug: Warfarin|Drug: LY2216684","Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of S-Warfarin|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of S-Warfarin|Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of S-Warfarin|Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of R-Warfarin|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of R-Warfarin|Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-Warfarin|Pharmacodynamics: Area Under the Curve of the International Normalized Ratio (AUCINR) of Warfarin|Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12595|H9P-EW-LNCF","December 2010","February 2011","February 2011","December 20, 2010","October 19, 2018","January 22, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01263119"
1100,"NCT01263106","A Study of LY2216684 and Theophylline in Healthy Subjects",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Theophylline","Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Theophylline|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Theophylline|Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of Theophylline|Mean Change From Baseline in Heart Rate: 200 mg Theophylline|Mean Change From Baseline in Heart Rate: 18 mg LY221684 + 200 mg Theophylline","Eli Lilly and Company","All","18 Years to 45 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12594|H9P-EW-LNCE","December 2010","January 2011","January 2011","December 20, 2010","July 8, 2019","July 8, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01263106"
1101,"NCT01263093","A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel",,"Completed","Has Results","Major Depressive Disorder","Drug: Clopidogrel|Drug: LY2216684","Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)|Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)|Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)|Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)|Percentage Inhibition of Platelet Aggregation","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12593|H9P-EW-LNBY","December 2010","March 2011","March 2011","December 20, 2010","October 22, 2018","October 22, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01263093"
1102,"NCT01250873","A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Sertraline","Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684|Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of LY2216684|Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of LY2216684|Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of Sertraline|Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Sertraline|Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of Sertraline","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12611|H9P-EW-LNCT","November 2010","January 2011","January 2011","December 1, 2010","October 19, 2018","January 4, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01250873"
1103,"NCT01243957","A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Fluoxetine","Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684|Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of LY2216684|Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of LY2216684|Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time-Curve Over a 24-Hour Dosing Interval (AUCτ) of Fluoxetine and Norfluoxetine|Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Fluoxetine and Norfluoxetine|Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of Fluoxetine and Norfluoxetine","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12597|H9P-EW-LNCH","October 2010","January 2011","January 2011","November 19, 2010","October 22, 2018","January 29, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01243957"
1104,"NCT01226238","Online Self-help for Depressed Patients Awaiting Psychotherapy",,"Terminated","No Results Available","Major Depressive Disorder","Other: Online self-help","Depressive Symptomatology","University of Luebeck","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Deprexis-HH-HL-WL","October 2010","June 2011",,"October 22, 2010",,"June 26, 2014","MVZ Falkenried, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01226238"
1105,"NCT00953745","Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Aripiprazole|Drug: Placebo Capsule|Drug: Placebo Tablet","Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders|Depression Symptom Change on The Montgomery-Åsberg Depression Rating (MADRS) Scale Between ARP Responders and Non-responders.","Washington University School of Medicine|Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Not Applicable","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","201101790-2","May 2009","June 2012","December 2012","August 6, 2009","April 19, 2018","April 19, 2018","Washington University in St. Louis, School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00953745"
1106,"NCT03586427","AGN-241751 in the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: AGN-241751|Drug: Placebo","Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change from Baseline in MADRS Total Score at Week 3","Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","251","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3125-201-002","June 13, 2018","July 22, 2019","August 21, 2019","July 13, 2018",,"July 24, 2020","Health Initiatives Research PLLC, Fayetteville, Arkansas, United States|Synexus US - Cerritos, Cerritos, California, United States|Wake Research - Pharmacology Research Institute, Encino, California, United States|Wake Research - Pharmacology Research Institute, Newport Beach, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|North County Clinical Research, Inc., Oceanside, California, United States|Collaborative Neuroscience Network, Torrance, California, United States|Elite Clinical Trials, Inc., Wildomar, California, United States|Synexus US - Atlanta, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Pillar Clinical Research, Lincolnwood, Illinois, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Hassman Research Institute, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Neurobehavioral Research, Inc, Cedarhurst, New York, United States|Synexus US - Queens, Jamaica, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Clinical Neuroscience Solutions, Inc - Memphis, TN, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03586427"
1107,"NCT00609453","Brain Imaging of Psychotherapy for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Brief Behavioral Activation Treatment for Depression","Hamilton Depression Inventory|Functional Magnetic Resonance Imaging","University of North Carolina, Chapel Hill","All","21 Years to 55 Years   (Adult)","Not Applicable","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","05-2605|NIMH R03 MH078145","October 2006","January 2008","January 2008","February 7, 2008",,"October 8, 2012","Duke-UNC Brain Imaging and Analysis Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00609453"
1108,"NCT01138007","A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)",,"Completed","Has Results","Depressive Disorder, Major","Drug: 323U66 SR 150 mg tablet|Drug: 323U66 SR 150 mg placebo tablet","Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal|Change From Baseline in the MADRS Total Score at Weeks 1, 2, 4, and 6|Change From Baseline in the MADRS Individual Item Scores at Weeks 1, 2, 4, 6, and 8|Number of MADRS Responders at Week 8|Number of MADRS Remitters at Week 8|Number of Clinical Global Impression-Global Improvement (CGI-GI) Responders at Week 8|Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-SI) Scores at Weeks 1, 2, 4, 6, and 8|Change From Baseline in the Inventory of Depressive Symptomatology-Self Report (IDS-SR) Total Score at Weeks 1, 2, 4, 6, and 8|Change From Baseline in the IDS-SR Subscores for Energy, Pleasure, and Interest at Weeks 1, 2, 4, 6, and 8","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 3","572","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","113351","June 17, 2010","August 1, 2012","August 7, 2012","June 7, 2010","May 6, 2013","August 10, 2018","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukushima, Japan|GSK Investigational Site, Fukushima, Japan|GSK Investigational Site, Fukushima, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Nara, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saga, Japan|GSK Investigational Site, Saga, Japan|GSK Investigational Site, Saga, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Shizuoka, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01138007"
1109,"NCT00367341","Imaging Predictors of Treatment Response in Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: escitalopram|Behavioral: Cognitive Behavioral Therapy (CBT)","Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks|Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks","Emory University|National Institute of Mental Health (NIMH)","All","21 Years to 60 Years   (Adult)","Not Applicable","82","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00026176","August 2006","August 2011","July 2013","August 22, 2006","January 9, 2014","January 9, 2014","Emory University School of Medicine, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00367341"
1110,"NCT00209105","Characterizing Psychological Consequences of Childhood Trauma",,"Completed","No Results Available","Major Depressive Disorder","Drug: DEX-CRF stimulation test|Behavioral: Psychosocial stress induction|Procedure: Brain imaging of sad mood , self-reference, reward|Behavioral: Acoustic startle","Pathophysiological pathways (e.g., blood chemicals, physiological measures, brain images, behavioral measures), as assessed by diagnostic tests","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 45 Years   (Adult)",,"113","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00021800|P50MH058922|572-2004|DATR A3-NSC","January 2005","December 2009","March 2011","September 21, 2005",,"November 13, 2013","General Clinical Research Center at Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00209105"
1111,"NCT03406052","Smartphone-enabled Health Coaching Intervention for Youth Diagnosed With Major Depressive Disorders",,"Suspended","No Results Available","Disorder, Major Depressive","Behavioral: Smartphone-Assisted MB-CBT","Beck Depression Inventory II|Beck Anxiety Scale|Quick Inventory of Depressive Symptomatology|Hamilton Depression Rating Scale (HRDS-24)|Five-Facet Mindfulness Questionnaire|Brief Pain Inventory","York University|Centre for Addiction and Mental Health","All","18 Years to 30 Years   (Adult)","Not Applicable","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Yorku|2016-115|2017-154","January 19, 2018","March 31, 2019","May 30, 2019","January 23, 2018",,"April 23, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03406052"
1112,"NCT00353028","Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents",,"Completed","No Results Available","Major Depressive Disorder","Drug: Fluvoxamine maleate|Drug: Placebo","the time of onset of 50% decrease from baseline in the Japanese Version of the Structured Interview Guide for the Hamilton Depression Rating Scale (JSIGH-D) 17-item total score|The Clinical Global Impression(CGI) improvement at Week 8","Solvay Pharmaceuticals","All","8 Years to 18 Years   (Child, Adult)","Phase 4","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","S114.3.117","October 2006","July 2009","July 2009","July 17, 2006",,"March 4, 2010","S114.3.117 Kohnodai Hospital, National Center of N, Chiba prefecture, Japan|S114.3.117 Fukuoka University Hospital, Fukuoka prefecture, Japan|S114.3.117 Hatakeyama Clinic, Fukuoka prefecture, Japan|S114.3.117 Kaname Clinic, Fukuoka prefecture, Japan|S114.3.117 Kashi shinryo Clinic, Fukuoka prefecture, Japan|S114.3.117 Kashii Sanatorium, Fukuoka prefecture, Japan|S114.3.117 Kyushu University Hospital, Fukuoka prefecture, Japan|S114.3.117 Shiranui Hospital, Fukuoka prefecture, Japan|S114.3.117 Sugahara Tenjin Hospital, Fukuoka prefecture, Japan|S114.3.117 Hiroshima-city Funairi Hospital, Hiroshima prefecture, Japan|S114.3.117 Goryokai Hospital, Hokkaido prefecture, Japan|S114.3.117 Kobe University Hospital, Hyogo prefecture, Japan|S114.3.117 National Hospital Organization Kagawa C, Kagawa prefecture, Japan|S114.3.117 Yokohama City University Hospital, Kanagawa Prefecture, Japan|S114.3.117 National Hospital Organization Kikuti N, Kumamoto prefecture, Japan|S114.3.117 Kyoto University Hospital, Kyoto prefecture, Japan|S114.3.117 National Hospital Organization Sakakiba, Mie prefecuture, Japan|S114.3.117 Shinshu University Hospital, Nagano prefecture, Japan|S114.3.117 Aichi Children's Health and Medical Cen, Nagoya prefecture, Japan|S114.3.117 Nagoya Mental Clinic, Nagoya prefecture, Japan|S114.3.117 Nara Medical University Hospital, Nara prefecture, Japan|S114.3.117 Kansai Medical University Takii Hospita, Osaka prefecture, Japan|S114.3.117 Kusube Clinic, Osaka prefecture, Japan|S114.3.117 Yasuhara Children's Clinic, Osaka prefecture, Japan|S114.3.117 Tokushima University Hospital, Tokushima prefecture, Japan",,"https://ClinicalTrials.gov/show/NCT00353028"
1113,"NCT00373477","A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients",,"Completed","No Results Available","Major Depressive Disorder","Procedure: Generalist Care Manager vs Usual Care","Baseline, 3 and 6-month Patient Health Questionnaire (PHQ9) scores|Baseline and 6-month Short Form (SF)-12 scores, Medicaid claims data; patient perception of treatment by self-report; review of GCM case notes, physician and office staff time study; physician and office staff focus groups","University of North Carolina|Robert Wood Johnson Foundation|University of North Carolina, Chapel Hill","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-fam/med-161|RWJF ID number: 048128","July 2003",,"February 2005","September 8, 2006",,"September 8, 2006","Mountain Area Health Education Center (MAHEC), Asheville, North Carolina, United States|Hot Springs Health Program, Marshall, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00373477"
1114,"NCT04939649","Ketamine as an Adjunctive Therapy for Major Depression (2)","KARMA-Dep2","Recruiting","No Results Available","Major Depressive Episode|Unipolar Depression|Bipolar Depression","Drug: Ketamine|Drug: Midazolam","Montgomery Asberg Depression Rating Scale-10 item version (MADRS)|The Clinician-Administered Dissociative States Scale (CADSS)|The Brief Psychiatric Rating Scale (BPRS)|Young Mania Rating Scale (YMRS; mood item)|Observer's Assessment of Alertness/Sedation; responsiveness subscale (OAA/S-R)|20-item Physician Withdrawal Checklist (PWC-20)|The Quick Inventory of Depressive Symptoms, self-report version (QIDS-SR)|Patient-Rated Inventory of Side Effects (PRISE)|The Montreal Cognitive Assessment (MoCA)|EuroQol-5 dimensions-5 level scale for health status (EQ-5D-5L)|Client Service Receipt Inventory (CSRI)|Adverse events (AE) and serious adverse events (SAE) review|Concomitant Medication","University of Dublin, Trinity College","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRFSPN004|2019-003109-92","June 28, 2021","October 1, 2023","April 1, 2024","June 25, 2021",,"June 25, 2021","St Patrick's Univeristy Hospital, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT04939649"
1115,"NCT00963196","Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response","SADFAT","Withdrawn","No Results Available","Major Depressive Disorder","Dietary Supplement: Omega-3 fatty acid|Drug: Bovine gelatin capsules","Improvement in MADRS and PHQ-9 scores occurs in a shorter period of time in the intervention group versus the placebo group.|Subjects in the intervention group experience greater reduction of scores in MADRS and PHQ-9 than the placebo group.","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","14503","September 2009","May 2010","May 2010","August 21, 2009",,"June 4, 2010","UVA Psychiatry Outpatient Clinic, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00963196"
1116,"NCT00166114","Depression, Epinephrine, and Platelet Function",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Desipramine","Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 55 Years   (Adult)","Phase 4","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0473-2002|1R01HL065523-01A2","February 2002","January 2009","January 2009","September 14, 2005","July 23, 2015","July 23, 2015","Emory University School of Medicine, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00166114"
1117,"NCT00204152","Treatment for Chronic Depression",,"Terminated","No Results Available","Major Depressive Disorder","Behavioral: (Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation","severity of depression, measured by Longitudinal Interval Follow-up Evaluation (LIFE; Keller et al., 1982; Keller et al., 1987), Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996a), and Hamilton Rating Scale for Depression.|Cognitive functioning, social/behavioral functioning, and stress regulation.","University of Chicago","All","18 Years to 58 Years   (Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","13166B","June 2004","June 2006","June 2006","September 20, 2005",,"September 5, 2013","The University of Chicago, Department of Psychiatry, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00204152"
1118,"NCT03675776","Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)",,"Terminated","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at End of Double-blind Treatment (End of Week 6).|Change From Baseline in MADRS Total Score at 1 Day After First Dose of Treatment","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-30|2018-000060-29","October 30, 2018","July 11, 2019","July 11, 2019","September 18, 2018","July 28, 2020","July 28, 2020","Bugát Pál Hospital, Clinexpert, Gyongyos, Hungary|Himorogi Psychiatric Institute, Ichigayatamachi, Japan|Kishiro Mental Clinic, Kawasaki-shi, Japan|Tatsuta Clinic, Kobe-shi, Japan|Medical corporation Sato-Kai Yuge Hospital, Kumamoto-shi, Japan|Sagaarashiyama-Tanaka Clinic, Kyoto-shi, Japan|Senzoku psychosomatic Medicine Clinic, Meguro-ku, Japan|Higashi Sapporo Mental Clinic, Sapporo-shi, Japan|Sangenjaya Neurology- Psychosomatic Clinic, Setagaya-ku, Japan|Yoyogi Mental Clinic, Shibuya-ku, Japan|Maynds Tower Mental Clinic, Shibuya-ku, Japan|Himeno Tomomi Clinic, Shinagawa-ku, Japan|Shinjuku Research Park Clinic, Shinjuku-ku, Japan|Ohwa Mental Clinic, Toshima-ku, Japan|Okehazama Hospital Fujita Kokoro Care Center, Toyoake-city, Japan|Yokohama Onoecho Clinic, Yokohama-shi, Japan|Centrum Medyczne Luxmed Sp.z o.o., Lublin, Poland|Federal State Budgetary Research Institution ""Mental Health Science Center"", Moscow, Russian Federation|Yaroslavl Regional Psychiatric Hospital, Yaroslavl, Russian Federation|MENTUM, s.r.o., Bratislava, Slovakia|Vavrusova Consulting s.r.o. Neštátna Psychiatrická ambulancia, Bratislava, Slovakia|Liptovská nemocnica s poliklinikou MUDr. Ivana Stodolu Liptovský Mikuláš, Liptovsky Mikulas, Slovakia|Psycholine s.r.o., Rimavska Sobota, Slovakia","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03675776/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03675776/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03675776"
1119,"NCT00870805","Ultrabrief Pulsewidth Electroconvulsive Therapy (ECT)","UB ECT","Completed","No Results Available","Major Depressive Disorder","Procedure: bilateral ultrabrief ECT|Procedure: bilateral standard ECT|Procedure: right-unilateral ultrabrief ECT|Procedure: right-unilateral standard ECT","Change in scores on Memory Tests|Change in scores on Depression Rating Scale","The University of New South Wales|Northside Clinic, Australia|The Melbourne Clinic, Australia|St George Hospital, Australia|Wandene Private Hospital, Australia","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UNSW HREC 08322","January 2009","January 2013","January 2013","March 27, 2009",,"February 27, 2013","St George Hospital, Kogarah, New South Wales, Australia|Wandene Private Hospital, Kogarah, New South Wales, Australia|The Melbourne Clinic, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00870805"
1120,"NCT03855865","Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)",,"Withdrawn","No Results Available","Depressive Disorder, Major","Drug: Rapastinel|Drug: Vortioxetine|Drug: Placebo","Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at the End of the Double Blind Treatment Period (DBTP) (end of Week 6)|Change from Baseline in MADRS Total Score at Day 1 Post-first Dose of Treatment","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-31|2018-000063-88","July 1, 2019","December 31, 2020","December 31, 2020","February 27, 2019",,"July 19, 2019",,,"https://ClinicalTrials.gov/show/NCT03855865"
1121,"NCT00332670","Light Therapy for Elderly Depression",,"Terminated","No Results Available","Major Depressive Disorder","Procedure: 10.000lux blue 1 hour every day during three weeks|Procedure: 50lux dim red 1 hour every day during three weeks","Hamilton Depression Rating Scale (HADRS-17)|Actimetry|24-hour urinary cortisol measurements|saliva cortisol daytime curve|Social Rhythm Metric|Groningen Activity Restriction Scale (GARS)|Algemene Competentieverwachtingen Schaal (ALCOS)|Social Support List interactions, discrepancies and negative (SSL-i, SSL-d, SSL-n)|MOS-short form General Health Survey (SF-20)|Pittsburgh Sleep Quality Inventory (PSQI)|Neuropsychological test battery|fMRI (encoding task, recognition task, N-Back)|structural MRI scanning (brain and volumetry of adrenals)|MADRS|Adverse effects inventarisation","GGZ Buitenamstel|Netherlands Institute for Brain Research, Amsterdam, The Netherlands.","All","60 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","89","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SOW 014-91-049|ZonMw SOW nr 014-91-049|ZonMw AGIKO nr 940-37-033","January 2003","June 2007","June 2007","June 2, 2006",,"August 15, 2008","GGZ Buitenamstel, Amsterdam, Noord-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT00332670"
1122,"NCT01191333","The Effectiveness of rTMS in Depressed VA Patients",,"Completed","Has Results","Major Depressive Disorder","Device: rTMS|Device: Sham Device","The Proportion of Participants Achieving Remission From Depression as Assessed by Hamilton Rating Scale for Depression|Mean Suicidal Ideation Score as Assessed by Beck Scale for Suicide Ideation (BSS)|Mean Depression Score as Assessed by Beck Depression Inventory (BDI)|Mean Mental Component Score as Assessed by VR-36 Mental Component Summary (MCS)|Mean Physical Component Score as Assessed by VR-36 Physical Component Summary (PCS)|Mean Depression Score as Assessed by the Montgomery Asberg Depression Rating Scale (MADRS)","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","164","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","556","July 2, 2012","February 15, 2017","March 31, 2017","August 30, 2010","February 7, 2018","March 9, 2018","VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Philadelphia VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Central Texas Veterans Health Care System, Temple, TX, Temple, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01191333/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01191333/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01191333"
1123,"NCT00215228","Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: duloxetine vs. escitalopram","Effect of treatment on heart rate variability|Effect of treatment on affective variables (depression, anxiety, stress reactivity)|Effect of treatment on neurotransmitter transporter occupancy","Duke University|Forest Laboratories","All","20 Years to 60 Years   (Adult)","Phase 2|Phase 3","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","Pro00007159|6957-05-3R0","July 2005",,"August 2007","September 22, 2005",,"July 21, 2014","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00215228"
1124,"NCT00245557","Magnetic Resonance Imaging Study of Geriatric Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Sertraline","HAM-D 17 (Hamilton Depression Rating Scale)|Geriatric Depression Scale|Phosphorus Magnetic Resonance Spectroscopy (31P-MRS)","Mclean Hospital|Pfizer|National Alliance for Research on Schizophrenia and Depression","All","55 Years to 89 Years   (Adult, Older Adult)","Not Applicable","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004P-002540","November 2004","August 2008","August 2008","October 28, 2005","February 26, 2010","March 30, 2017","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00245557"
1125,"NCT00608543","Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Aripiprazole","Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems|Stockings of Cambridge (SOC) Mean Initial Thinking Time for 5-move Problems|Spatial Working Memory (SWM) Between Errors for 6-move Problems|Spatial Working Memory (SWM) Strategy Score|Quality of Life Enjoyment and Satisfaction Questionnaire|Change in Hamilton Rating Scale for Depression (HRSD - 17-item)","University of Texas Southwestern Medical Center|Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","17","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","042004-011","October 2005","January 2009","January 2009","February 6, 2008","October 26, 2012","October 26, 2012","University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00608543"
1126,"NCT00367003","Deep Brain Stimulation for Treatment Resistant Depression",,"Active, not recruiting","Has Results","Major Depressive Disorder","Device: Deep Brain Stimulation","Change in Hamilton Depression Rating Scale-17 Score","Emory University|The Dana Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00024883","September 2006","January 2, 2014","January 2024","August 22, 2006","July 14, 2020","July 14, 2021","Emory University School of Medicine, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT00367003/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00367003"
1127,"NCT00562367","Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones",,"Completed","No Results Available","Major Depressive Disorder","Drug: Cytomel (liothyronine)","change in depression (as measured by Ham-D-17) over the 4 weeks study|change in bioenergetic metabolism (e.g., NTP and PCr) as measured by phosphorus magnetic resonance spectroscopy (P31-MRS)","Massachusetts General Hospital|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2001-P-000836","October 2001",,"September 2004","November 22, 2007",,"November 22, 2007","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00562367"
1128,"NCT00360256","Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants",,"Completed","No Results Available","Major Depressive Disorder",,"Cytochrome P450 2D6 and 2C19 genotype|Drug tolerability","Augusta University|Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)",,"46","Other|Industry","Observational","Time Perspective: Retrospective","CYP450 Antidepressant study|HAC File #: 06-04-278","June 2006","December 2007","December 2007","August 4, 2006",,"April 19, 2012","Medical College of Georgia, Dept. of Psychiatry and Health Behavior, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00360256"
1129,"NCT03101540","Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD",,"Terminated","No Results Available","Major Depressive Disorder in Pregnancy","Drug: Omega-3 PUFA supplementation","Hamilton Rating Scale for Depression (HAM-D)|Montgomery-Asberg Depression Scale (MADRS)|Edinburgh Postnatal Depression Scale (EPDS)|Beck Depression Scale (BDI)","William Coryell|University of Iowa","Female","18 Years to 50 Years   (Adult)","Early Phase 1","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201102756","August 2011","May 2014","May 2014","April 5, 2017",,"April 28, 2017",,,"https://ClinicalTrials.gov/show/NCT03101540"
1130,"NCT00331799","Pilot Study of Duloxetine in Psychological Resilience",,"Completed","Has Results","Major Depressive Disorder","Drug: Duloxetine","Change in Connor Davidson Resilience Scale (CD-RISC) From Baseline to 8 Weeks","Duke University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00008715","April 2007","May 2008","July 2008","May 31, 2006","August 2, 2013","August 2, 2013","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00331799"
1131,"NCT03668600","Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)",,"Terminated","Has Results","Depressive Disorder, Major","Drug: Rapastinel","Count of Participants Experiencing One or More Treatment Emergent Adverse Events (TEAEs)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAP-MD-99","August 23, 2018","July 3, 2019","July 3, 2019","September 12, 2018","July 17, 2020","July 17, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Pharmacology Research Institute, Encino, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|CITrials, Riverside, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|David A. Medina, MD, Orlando, Florida, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|University of Kansas School of Medicine Clinical Trial Unit, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|Coastal Research Associates, South Weymouth, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Patient Priority Clinical Sites, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network LLC, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Austin, Texas, United States|Houston Clinical Trials, Bellaire, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Inc, Charlottesville, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03668600/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03668600/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03668600"
1132,"NCT00474708","Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients",,"Completed","Has Results","Major Depressive Disorder","Drug: Effexor|Drug: SSRI","Number of Patients Achieving Remission|Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status)","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","1151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0600B2-4418","April 2007","March 2008","March 2008","May 17, 2007","April 30, 2010","March 5, 2012","Beijing, Beijing, China|Beijing, Beijing, China|Beijing, Beijing, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhengzhou, Henan, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Shenyang, Liaoning, China|Jinan, Shandong, China|Shanghai, Shanghai, China|Shanghai, Shanghai, China|Shanghai, Shanghai, China|Shanghai, Shanghai, China|Shanghai, Shanghai, China|Shanghai, Shanghai, China|Shanghai, Shanghai, China|Xian, Shanxi, China|Tianjin, Tianjin, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Huzhou, Zhejiang, China|Suzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT00474708"
1133,"NCT00451490","The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder",,"Withdrawn","No Results Available","Depressive Disorder, Major","Drug: Agomelatine|Drug: Fluoxentine","the Pittsburgh Sleep Quality Index|the Leeds Sleep Evaluation Questionnaire|heart rate variability","National Taiwan University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Health Services Research","200610027R","October 2006",,"December 2007","March 23, 2007",,"January 8, 2008","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00451490"
1134,"NCT01153139","Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression","TheBuS_D","Completed","No Results Available","Major Depression","Device: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)","Number of responders (response = decrease of the Montgomery-Åsberg Depression Rating Scale for at least 50%)|Change of the Hamilton rating scale for depression (HAMD 17)|Change of the Beck Depression Inventory (BDI)|Change of the Montgomery-Asberg rating scale for depression (MADRS) score","University Hospital Tuebingen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","124/2009BO1","April 2010","December 2012","July 2013","June 29, 2010",,"July 16, 2013","University of Tübingen, Department of Psychiatry and Psychotherapy, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT01153139"
1135,"NCT00414323","Evaluation of the Effects of Duloxetine on Norepinephrine",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine|Drug: Escitalopram|Drug: Placebo","Concentrations of DHPG and NE in plasma (in sitting and standing positions), urine, and CSF after multiple daily doses (steady state).|Effect of duloxetine versus escitalopram on ex vivo reuptake inhibition of NE and F-hydroxytryptamine (5-HT) in serum and relationship to exposure.|Effect of duloxetine versus escitalopram on heart rate variability.|Ratio of duloxetine exposure in plasma to CSF at steady state.|Relationship between DHPG and NE concentrations and duloxetine exposure in CSF and plasma.","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment","9547|F1J-MC-HMEU","November 2006",,"May 2007","December 21, 2006",,"June 12, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00414323"
1136,"NCT03614156","Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)",,"Terminated","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Time to First Relapse During the 52 Weeks of the Double-Blind Treatment Period (DBTP)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-33|2018-000064-28","August 2, 2018","July 11, 2019","July 11, 2019","August 3, 2018","October 9, 2020","October 9, 2020","Alea Research, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|California Pharmaceutical Research Institute, Anaheim, California, United States|Synergy Research San Diego, National City, California, United States|Excell Research Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|California Neuroscience Research Medical Group,Inc., Sherman Oaks, California, United States|Viking Clinical Research Ltd., Temecula, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Research Centers of America, Hollywood, Florida, United States|Clinical NeuroscienceSolutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Iris Research, Inc., Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|CBH Health, Gaithersburg, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Bugát Pál Hospital, Clinexpert, Gyongyos, Hungary|Medical corporation Sato-Kai Yuge Hospital, Kumamoto-shi, Japan|Sagaarashiyama-Tanaka Clinic, Kyoto-shi, Japan|Sangenjaya Neurology- Psychosomatic Clinic, Setagaya-ku, Japan|Yoyogi Mental Clinic, Shibuya-ku, Japan|Maynds Tower Mental Clinic, Shibuya-ku, Japan|Ohwa Mental Clinic, Toshima-ku, Japan|Centrum Medyczne Luxmed Sp.z o.o., Lublin, Poland|MENTUM, s.r.o., Bratislava Mestská Časť Ružinov, Slovakia|VAVRUŠOVÁ CONSULTING s.r.o., Psychiatrická ambulancia, Bratislava, Slovakia|Liptovská nemocnica s poliklinikou MUDr. Ivana Stodolu Liptovský Mikuláš, Liptovský Mikuláš, Slovakia|PsychoLine s.r.o., Psychiatrická ambulancia, Rimavská Sobota, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03614156/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03614156/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03614156"
1137,"NCT02473289","An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Sirukumab 50 mg|Drug: Placebo","Change From Baseline in Hamilton Depression Rating Scale (HDRS-17) Total Score at Week 12|Change From Baseline in HDRS-17 Total Score at Weeks 1, 4 and 8|Percentage of Participants With Remission as Assessed by HDRS-17 Total Score at Week 12|Percentage of Participants With Response as Assessed by HDRS-17 Total Score at Week 12|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Patient Health Questionnaire (PHQ-9) Total Score at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Snaith Hamilton Pleasure Scale (SHAPS) Total Score (Definition 1) at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Snaith Hamilton Pleasure Scale (SHAPS) Total Score (Definition 2) at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score at Weeks 1, 4, 8, 12, 16, and 22","Janssen Research & Development, LLC","All","21 Years to 64 Years   (Adult)","Phase 2","193","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107171|CNTO136MDD2001|2014-005206-37","July 23, 2015","May 22, 2018","May 22, 2018","June 16, 2015","June 11, 2019","June 11, 2019","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Bellflower, California, United States|Glendale, California, United States|Lemon Grove, California, United States|Orange, California, United States|Santa Ana, California, United States|Torrance, California, United States|Wildomar, California, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Edgewood, Kentucky, United States|Baltimore, Maryland, United States|Grand Rapids, Michigan, United States|Lebanon, New Hampshire, United States|Brooklyn, New York, United States|New York, New York, United States|Staten Island, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Houston, Texas, United States|Plano, Texas, United States|Salt Lake City, Utah, United States|Edmonton, Alberta, Canada|Chatham, Ontario, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Belchatow, Poland|Bydgoszcz, Poland|Chelmno, Poland|Gorlice, Poland|Lublin, Poland|Karelia, Russian Federation|Moscow, Russian Federation|Nizny Novgorod, Russian Federation|Rostov-on-Don, Russian Federation|Saratov Region, Russian Federation|Saratov, Russian Federation|St-Petersburg, Russian Federation|Tomsk, Russian Federation|Yaroslavl, Russian Federation|Edinburgh, United Kingdom|Glasgow, United Kingdom|Oxford, United Kingdom|Redruth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02473289/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02473289/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02473289"
1138,"NCT04352101","Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits",,"Recruiting","No Results Available","Major Depression","Drug: Bupropion XL|Drug: Escitalopram","Change in Targeted Ventromedial Prefrontal Cortex-Ventral Striatal (vmPFC-VS) Functional Connectivity (FC)|Change in Effort-Expenditure for Rewards Task (EEfRT) Score|Change in Snaith-Hamilton Pleasure Scale (SHAPS-C) Score|Change in Motivation and Pleasure Scale-Self-Report (MAP-SR) Score|Change in Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)","Emory University|National Institute of Mental Health (NIMH)","All","25 Years to 55 Years   (Adult)","Phase 4","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00117673|1R21MH121891","September 23, 2020","May 2022","May 2022","April 20, 2020",,"January 11, 2021","Emory Clinic, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04352101"
1139,"NCT02659085","Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Ketamine IV Infusion|Procedure: ECT","Proportion of patients in remission in each treatment arm assessed by Montgomery-Asberg Depression Rating Scale (MADRS)|Time to remission compared between the two treatments.|Time to response compared between the two treatments.|Ketamine treatment is associated with a smaller decrease in the performance in a CANTAB cognitive test battery compared to ECT.|Remission from severe depression is associated with improved performance in the performance in a CANTAB cognitive test battery.|The antidepressant effect of ketamine is longer lasting than that of ECT, assessed by the proportion of patients in remission (defined by a maximum score of 9 in the Montgomery-Asberg Depression Rating Scale (MADRS)).|Ketamine treatment is associated with a smaller decrease in the performance in Rey Auditory Verbal Learning Test (RAVLT) compared to ECT.|Remission from severe depression is associated with improved performance in the performance in Rey Auditory Verbal Learning Test (RAVLT).","Pouya Movahed Rad|Region Skane","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-001520-37","February 2015","August 2019","August 2019","January 20, 2016",,"December 19, 2019","Department of Psychiatry, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT02659085"
1140,"NCT00896363","Safety and Efficacy Study in Patients With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder","Drug: GSK163090 1 mg|Drug: GSK163090 Placebo|Drug: GSK163090 3 mg","Change From Baseline in the Hamilton Depression Rating Scale (HAMD17), on Day 14 and 42|Change From Baseline in Bech Melancholia Subscale (BECH 6) Scale, on Day 14 and 42|Change From Baseline in Quick Inventory of Depressive Symtomatology - Self Rated (QIDS-SR) Scale, on Day 14 and 42|Number of Participants With Suicidal Behavior and Suicidal Ideation Subscales of the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Abnormal Hematology Values of Clinical Concern Range (CCR).|Number of Participants With Abnormal Chemistry Values of CCR|Change From Baseline in Liver Chemistry -Alkaline Phosphatase (ALP), ALT, AST and GGT|Change From Baseline in Liver Chemistry- Direct Bilirubin and Total Bilirubin|Number of Participant of Urinanalysis Assessment Over Period|Change From Baseline in Electrocardiogram (ECG) Values -PR Interval, QRS Duration, QT Interval, QTcB, QTcF, RR Interval|Mean of Change From Baseline in Systolic and Diastolic Blood Pressure (BP)|Mean of Change From Baseline in Heart Rate|Number of Participants With All Adverse Events (AEs), and Serious Adverse Events (SAEs)|Mean Last Observed Quantifiable Concentration (Ct) of GSK163090 Over the Period|Area Under Concentration-time Curve (AUC) at Steady State|Average Concentration (Cave) at Steady State|Preliminary Pharmacokinetic/ Pharmacodynamic (PK/PD)Relationships for GSK163090 in Participants With MDD.","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","109035","April 23, 2009","February 9, 2010","February 9, 2010","May 11, 2009","March 19, 2018","March 19, 2018","GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Lipetsk Region, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhny Novgorod, Russian Federation|GSK Investigational Site, Saint Petersburg, Russian Federation|GSK Investigational Site, Saint Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saratov, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St.Petersburg, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00896363"
1141,"NCT04442490","A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major","Drug: SAGE-217|Drug: Placebo","Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15|Clinical Global Impression - Severity (CGI-S) Score|HAM-D Total Score|Percentage of Participants With HAM-D Response|Percentage of Participants With HAM-D Remission|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response|Montgomery Åsberg Depression Rating Scale (MADRS) Total Score|Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Time to First HAM-D Response|Change From Baseline in PRO Measures of Health-Related Quality of Life, as Assessed by the 36-item Short Form version 2 (SF-36v2) Score|Change From Baseline in PRO Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score","Sage Therapeutics","All","18 Years to 64 Years   (Adult)","Phase 3","543","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-MDD-301B","May 7, 2020","March 26, 2021","April 21, 2021","June 22, 2020",,"May 25, 2021","Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Bellflower, California, United States|Sage Investigational Site, Garden Grove, California, United States|Sage Investigational Site, Glendale, California, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Pico Rivera, California, United States|Sage Investigational Site, Redlands, California, United States|Sage Investigational Site, San Diego, California, United States|Sage Investigational Site, Sherman Oaks, California, United States|Sage Investigational Site, Temecula, California, United States|Sage Investigational Site, Coral Springs, Florida, United States|Sage Investigational Site, Hollywood, Florida, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Lauderhill, Florida, United States|Sage Investigational Site, Orange City, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Alpharetta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Skokie, Illinois, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, O'Fallon, Missouri, United States|Sage Investigational Site, Las Vegas, Nevada, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Charlotte, North Carolina, United States|Sage Investigational Site, Cincinnati, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, North Canton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Portland, Oregon, United States|Sage Investigational Site, Allentown, Pennsylvania, United States|Sage Investigational Site, Memphis, Tennessee, United States|Sage Investigational Site, DeSoto, Texas, United States|Sage Investigational Site, Wichita Falls, Texas, United States|Sage Investigational Site, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04442490"
1142,"NCT00294944","The Effectiveness of Idazoxan in Treating TRD",,"Withdrawn","No Results Available","Major Depressive Disorder","Drug: Idazoxan",,"Sheba Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","SHEBA-05-3911-JZ-CTIL",,,,"February 22, 2006",,"January 29, 2008","Chaim Sheba Medical Center, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT00294944"
1143,"NCT03256162","Ketamine as an Adjunctive Therapy for Major Depression","KARMA-dep","Completed","Has Results","Major Depressive Episode|Unipolar Depression|Bipolar Depression","Drug: Ketamine|Drug: Midazolam","The Hamilton Rating Scale for Depression-24 Item Version (HRSD-24)|The Quick Inventory of Depressive Symptoms, Self-report Version (QIDS-SR16)|The Clinician-Administered Dissociative States Scale (CADSS)|The Brief Psychiatric Rating Scale (BPRS)|Young Mania Rating Scale (YMRS; Mood Item)|The Patient-Rated Inventory of Side Effects (PRISE)|The Montreal Cognitive Assessment (MoCA)","St Patrick's Hospital, Ireland","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","01/17|2016-004764-18","September 7, 2017","September 21, 2018","September 21, 2018","August 21, 2017","January 18, 2020","January 18, 2020","St Patrick's University Hospital, Dublin, Ireland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03256162/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03256162"
1144,"NCT00460902","Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication",,"Completed","No Results Available","Major Depression","Device: Transcranial Magnetic Stimulation (TMS)","HAMILTON RATING SCALE FOR DEPRESSION 24 items","Hadassah Medical Organization","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","395/3.11.06(HMO)","April 2007","August 2009","August 2009","April 17, 2007",,"March 20, 2015","Beer Yaacov Medical Center, Beer Yaacov, Israel|Biological psychiatry unit, Psychiatric ward, Hadassah Medical organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00460902"
1145,"NCT02943577","A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study|Change From Baseline in MADRS Total Score|Change From Baseline to Day 21 in MADRS Total Score for the Placebo Non-responders of mITT Population|Change From Baseline to Day 8 in MADRS Total Score for the Placebo Non-responders of mITT Population","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","429","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-03","November 2, 2016","October 26, 2018","November 21, 2018","October 24, 2016","November 13, 2019","November 13, 2019","Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Innova Clinical Trials Inc., Miami, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|The University of South Florida Board of Trustees, A public Body Corporate, for University of South Florida, Tampa, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, Inc, Brooklyn, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Houston Clinical Trials, LLC, Bellaire, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States|Psychiatric Alliance of the Blue Ridge, Inc., Charlottesville, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02943577/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02943577/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02943577"
1146,"NCT02943564","A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study|Change From Baseline in MADRS Total Score","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","658","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-02","November 1, 2016","December 12, 2018","December 18, 2018","October 24, 2016","December 27, 2019","December 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Department of Psychiatry, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|ProScience Research Group, Culver City, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Pacific Research Partners; LLC., Oakland, California, United States|CITrials, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|PCSD Feighner Research, San Diego, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Sarkis Clinical Trials, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Millenia Psychiatry & Research, Inc, Orlando, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|IRIS Research, Smyrna, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|J Gary Booker, MD APMC, Shreveport, Louisiana, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|CBH Health, Rockville, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, Olivette, Missouri, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Pharmaceutical Research Associates Inc, Marlton, New Jersey, United States|The Medical Research Network, LLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Patient Priority Clinical Site, LLC, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Lindner Center of Hope, Mason, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|Community Clinical Research, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Family Psychiatry of The Wood, The Woodlands, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Eastside Therapeutic Resource, Everett, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02943564/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02943564/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02943564"
1147,"NCT00610259","Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: brief behavioral therapy for insomnia (bBT-I)|Other: Treatment as usual (TAU)","Changes in the total Insomnia Severity Index (ISI) score between the baseline and the 8-week assessment|""No clinically significant insomnia"" at the 8-week assessment, which is defined as 7 or less on the total ISI score|""No clinically significant insomnia"" at the 4-week assessment, which is defined as 7 or less on the total ISI score|Changes in the total ISI score between the baseline and the 4-week assessment|Changes in the total score of the modified Pittsburgh Sleep Quality Index (PSQI) between the baseline and the 8-week assessment|Changes in the total score of the modified PSQI between the baseline and the 4-week assessment|Changes in the 17-item Hamilton Rating Scale for Depression (HAMD) between the baseline and the 8-week assessment|Changes in the 17- HAMD between the baseline and the 4-week assessment|Changes in the Short Form 36 (SF-36) scores between the baseline and the 8-week assessment|Changes in the SF-36 scores between the baseline and the 4-week assessment","Nagoya City University|Kochi University","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NCUPsychiatry001|HLSRG (Ministry of Health)","January 2008","July 2009","August 2009","February 7, 2008",,"September 18, 2009","Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan",,"https://ClinicalTrials.gov/show/NCT00610259"
1148,"NCT02932943","A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial|Change From Baseline in MADRS Total Score|Change From Baseline to Day 21 in MADRS Total Score for the Placebo Non-responders of mITT Population|Change From Baseline to Day 8 in MADRS Total Score for the Placebo Non-responders of mITT Population","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-01","October 15, 2016","September 21, 2018","November 8, 2018","October 13, 2016","October 11, 2019","October 11, 2019","Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Excell Research, Oceanside, California, United States|Anderson Clinical Research, Redlands, California, United States|Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc.,, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Altea Research, Las Vegas, Nevada, United States|Bioscience Research, Mount Kisco, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|NorthWest Clinical Research Center, Bellevue, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02932943/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02932943/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02932943"
1149,"NCT00093288","Major Depressive Disorder In The Elderly",,"Completed","No Results Available","Depressive Disorder, Major","Drug: bupropion XL","Montgomery-Asberg Depression Rating Scale|Montgomery-Asberg Depression Rating Scale Clinical Global Impression Improvement Scale Clinical Global Impression Severity Scale Hamilton Anxiety Rating Scale","GlaxoSmithKline","All","65 Years and older   (Older Adult)","Phase 3","364","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","AK130940","June 2004","October 2005","October 2005","October 7, 2004",,"September 2, 2013","GSK Investigational Site, Caboolture, Queensland, Australia|GSK Investigational Site, Everton Park, Queensland, Australia|GSK Investigational Site, New Farm, Queensland, Australia|GSK Investigational Site, St. Albans, Victoria, Australia|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Mont-Godinne, Belgium|GSK Investigational Site, Montignies-sur-Sambre, Belgium|GSK Investigational Site, Mikkeli, Finland|GSK Investigational Site, Amersfoort, Netherlands|GSK Investigational Site, Grubbenvorst, Netherlands|GSK Investigational Site, Hilversum, Netherlands|GSK Investigational Site, Hoogvliet, Netherlands|GSK Investigational Site, Wildervank, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00093288"
1150,"NCT00208897","Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?",,"Completed","No Results Available","Major Depressive Disorder","Drug: Fluoxetine","Plasma ACTH and cortisol concentrations before and after administration of 1 microgram per kg ovine CRF|Symptom Rating Scales for Depression, Anxiety and PTSD as well as general well-being","Emory University|Eli Lilly and Company","Female","18 Years to 45 Years   (Adult)","Not Applicable","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00001850|B1Y-MC-X176","December 1997","November 2007","November 2007","September 21, 2005",,"November 11, 2013","Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00208897"
1151,"NCT00205946","The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity",,"Completed","No Results Available","Major Depressive Disorder","Drug: Bupropion|Drug: Placebo","Whether an acute dose of bupropion vs. placebo differentially affects the neurobiology and behavior of reward processing in depressed participants.","Affective Neuroscience Laboratory|Massachusetts General Hospital","All","18 Years to 64 Years   (Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2004-P-002234-1|2004-P002234-1","April 2005",,"July 2007","September 21, 2005",,"December 6, 2007","The Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States|Affective Neuroscience Laboratory, Department of Psychology, Harvard University, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00205946"
1152,"NCT00191932","Switching to Duloxetine From Other Antidepressants",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine","To test the hypothesis that the efficacy associated with direct switch from SSRI to duloxetine is non-inferior to start-taper switch|To compare the efficacy, health outcomes, safety and tolerability associated with the above two switching methods, as measured by HAMD17, CGI-S, PGI-I, SF-36, spontaneously reported adverse events , vital signs and other measures.","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8604|F1J-MC-HMDG","August 2004",,"March 2006","September 19, 2005",,"July 25, 2006","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Cherbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Palaiseau, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Paris Cedex 14, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Belfast, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ourense, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Salamanca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Zamora, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Haywards Heath, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Horsham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wythenshawe, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00191932"
1153,"NCT00191594","Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials",,"Completed","No Results Available","Major Depressive Disorder","Drug: Duloxetine Hydrochloride","Adverse events|Vital signs","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","105","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9548|F1J-XM-HMED","March 2005",,"August 2006","September 19, 2005",,"January 26, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orense, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salamanca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago De Composte, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zamora, Spain",,"https://ClinicalTrials.gov/show/NCT00191594"
1154,"NCT00179257","The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram",,"Completed","No Results Available","Major Depressive Disorder","Drug: sertraline (Zoloft)","Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q)|Hamilton Rating Scale for Depression (21-item) total score|Clinical Global Impressions - Improvement Scale|Hamilton Anxiety Scale Total score|Clinical Global Impressions - Severity Scale","Vanderbilt University|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lexapro Failure Study","June 2004",,"March 2005","September 15, 2005",,"June 2, 2015",,,"https://ClinicalTrials.gov/show/NCT00179257"
1155,"NCT03002077","Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel","The Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Change From Baseline in Brief Psychiatric Rating Scale Positive Symptoms Subscale (BPRS+)|Change From Baseline in the Clinician Administered Dissociative States Scale (CADSS)","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","617","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAP-MD-06","February 3, 2017","December 6, 2018","December 6, 2018","December 23, 2016","June 22, 2020","June 22, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex, Inc., Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Research Partners; LLC., Oakland, California, United States|Excell Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Anderson Clinical Research, Redlands, California, United States|CITrials, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|PCSD Feighner Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc.,, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|Innova Clinical Trials Inc., Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Millenia Psychiatry & Research, Inc, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|University of South Florida, Psychiatry and Behavioral Neurosciences, Tampa, Florida, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Iris Research, Smyrna, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|J Gary Booker, MD APMC, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|CBH Health, Gaithersburg, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|Coastal Research Associates, South Weymouth, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Millennium Psychiatric Associates, Saint Louis, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Altea Research, Las Vegas, Nevada, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Pharmaceutical Research Associates Inc, Marlton, New Jersey, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, Inc, Brooklyn, New York, United States|Bioscience Research, Mount Kisco, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Carolina Clinical Trials, Inc., Charleston, North Carolina, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|Patient Priority Clinical Site, LLC, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Lindner Center of Hope, Mason, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, LLC, Bellaire, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Wood, The Woodlands, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|Pharmaceutical Research Associates, Inc, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Inc., Charlottesville, Virginia, United States|NorthWest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03002077/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03002077/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03002077"
1156,"NCT00035321","The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression",,"Completed","No Results Available","Major Depressive Disorder","Drug: Olanzapine|Drug: Fluoxetine","To assess the efficacy of up to 8 weeks of treatment with OFC versus olanzapine and fluoxetine monotherapies, in patients with recurrent MDD without psychotic features|who meet study criteria for TRD, as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the MADRS total score|Treatment-resistant depression will be defined as:historic failure to achieve satisfactory response to an antidepressant (other than fluoxetine) during the current MDD episode|when treated with an acceptable antidepressant drug and dose for at least 6 weeks|prospective failure to achieve a satisfactory response to fluoxetine monotherapy during the 8 week study lead-in phase|To compare the efficacy, safety, and quality of life results of up to 8 weeks of OFC therapy(treatment phase) with fluoxetine and olanzapine monotherapies using the following assessments:|Onset of action as measured by time to achieve and initial response (greater than or equal to 25% reduction from baseline in MADRS total score|Efficacy in the treatment of co-morbid anxiety symptoms as measured by LOCF mean change from baseline to endpoint in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A)total score|Study-defined response and remission rates including time to achieve a full response (defined as greater than or equal to 50% reduction in MADRS total score)|and time to achieve remission (defined as MADRS total score less than or equal to 10 at endpoint)|LOCF mean change from baseline to endpoint in Clinical Global Impression - Severity of Depression score|(CGI-Severity of Depression), individual MADRS questions,and HAM-A item scores|Repeated measures analyses of post-baseline MADRS and HAM-A total scores|The incidence and severity of treatment-emergent adverse events and EPS. The Barnes Akathisia Scale,Simpson-Angus Scale, and the Abnormal Involuntary Movement Scale (AIMS) will be used to assess EPS|The Brief Psychiatric Rating Scale (BPRS) to evaluate the emergence of psychosis|Changes in vital signs and weight, laboratory analytes, and electrocardiograms (ECG)),Quality of life as measured by the LOCF mean change from baseline to endpoint on the Sheehan Disability Scale (SDS) score and the Short Form 36 Health Survey|Additional secondary objectives are to assess the efficacy, safety, and quality of life results of up to 8 additional weeks of open-label OFC therapy (after the treatment phase)using the following measures:|LOCF mean change from baseline to endpoint in MADRS, HAM-A, and CGI-Severity of Depression scores and study-defined rates of response and remission|Safety as measured by the incidence and severity of treatment-emergent adverse events, and EPS using the Barnes Akithisia Scale, Simpson Angus Scale and the AIM|The BPRS to examine the emergence of psychosis|Changes in vital signs and weight, laboratory analytes, and ECG","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6272|H6P-MC-HDAO","April 2002",,"July 2005","May 3, 2002",,"July 24, 2006","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oceanside, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Marcos, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrance, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New London, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oak Brook, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Burnie, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Westminster, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsfield, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clementon, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moorestown, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medford, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salem, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sellersville, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waukesha, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St John's, Newfoundland and Labrador, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingston, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. John, Canada",,"https://ClinicalTrials.gov/show/NCT00035321"
1157,"NCT00256412","Essential Fatty Acids for Major Depression",,"Completed","No Results Available","Major Depression","Drug: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS) scores","University of Iowa","All","18 Years to 55 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-01 200408033","October 2005","October 2007","October 2007","November 21, 2005",,"June 5, 2008","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT00256412"
1158,"NCT02116361","OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females",,"Completed","Has Results","Depressive Disorder, Major","Biological: onabotulinumtoxinA|Drug: Normal Saline","Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline Values in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Baseline Values for the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score|Change From Baseline Values in the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score|Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)|Change From Baseline Values in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D17)","Allergan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","191622-135","April 22, 2014","August 25, 2016","December 22, 2016","April 16, 2014","December 19, 2017","December 19, 2017","Woodland International Research Group, Little Rock, Alaska, United States|CITrials, Bellflower, California, United States|Radiant Research/Comprehensive Clinical Development, Inc., Cerritos, California, United States|Collaborative Neuroscience Network Inc., Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Excell Research, Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Compass Research LLC-North Clinic, Leesburg, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Uptown Research Institute, LLC, Chicago, Illinois, United States|Psychiatric Medicine Associates, LLC, Skokie, Illinois, United States|St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States|Integrative Clinical Trials, Brooklyn, New York, United States|SPRI Clinical Trials, Brooklyn, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Clinical Neuroscience Solutions, INC, Memphis, Tennessee, United States|KRK Medical Research, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Virginia Commonwealth University Clinical Research Services Unit, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Zain Research LLC, Richland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02116361"
1159,"NCT00174603","Treatment of Depression With Quetiapine",,"Terminated","No Results Available","Major Depression With Psychotic Features","Drug: quetiapine","Hamilton Rating Scale for Depression|Positive and Negative Syndrome Scale|Young Mania Rating Scale|Barnes Akathisia Scale|Simpson Angus Scale|Clinical Global Impressions","Rush University Medical Center|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","IRUSQUET305","August 2005",,"January 2007","September 15, 2005",,"January 10, 2008","Rush University Medical Center, Chicago,, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00174603"
1160,"NCT01640483","Differential Efficacy of Supportive and Interpretative Psychodynamic Techniques for Dependent and Self-critical Depressive Patients","PsychodynDep","Unknown status","No Results Available","Major Depressive Disorder.","Other: psychodynamic techniques.","Reduction in depressive symptoms at 25 weeks (50 sessions, 2 sessions/week).|improvement in relational capacities|improvement in insight|improvement in quality of life, a broad range of physical and psychological symptoms.","University Ghent|Funding by BOF (Bijzonder Onderzoeksfonds)","All","18 Years to 60 Years   (Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EC/2012/455","December 2012","December 2015","December 2015","July 13, 2012",,"June 4, 2015","Ghent University, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT01640483"
1161,"NCT00429689","Hormonal Levels in Men With Major Depressive Disorder",,"Withdrawn","No Results Available","Depression","Procedure: Saliva sample",,"Sheba Medical Center","Male","18 Years to 65 Years   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SHEBA-06-4480-RA-CTIL",,,,"February 1, 2007",,"August 30, 2011",,,"https://ClinicalTrials.gov/show/NCT00429689"
1162,"NCT04984512","The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder",,"Not yet recruiting","No Results Available","Depressive Disorder, Major","Drug: Mitizodone Phosphate tablets|Drug: Placebo-matching tablets","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 8|Percentage of subjects With a MADRS Response at Week 8|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 1、week 2 、week 4、week 6.|Change From Baseline in the Clinical Global Impression - Severity of illness (CGI-S) Total Score at week 1、week 2 、week 4、week 6、week 8.|Clinical Global Impression - Improvement (CGI-I) Score at week 1、week 2 、week 4、week 6、Week 8|Change From Baseline in the hamilton anxiety rating scale （HAM-A）Total Score at week 1、week 2 、week 4、week 6、week 8.","Sunshine Lake Pharma Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEC113995-P-5","August 2021","April 2024","May 2024","July 30, 2021",,"July 30, 2021",,,"https://ClinicalTrials.gov/show/NCT04984512"
1163,"NCT03096886","Novel Neural Circuit Biomarkers of Major Depression Response to CCBT",,"Recruiting","No Results Available","Depression|Major Depressive Disorder|Depressive Disorder|Depression, Unipolar","Behavioral: Computer-Augmented Cognitive Behavioral Therapy","Resting State Functional Connectivity: MDD vs Controls|Resting state functional connectivity: Immediate CCBT vs Waitlist followed by CCBT","University of Pennsylvania","All","18 Years to 60 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH110939-01A1","June 5, 2017","March 31, 2022","March 31, 2022","March 30, 2017",,"March 18, 2021","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03096886"
1164,"NCT04829318","A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","ESCAPE-LTE","Recruiting","No Results Available","Depressive Disorder, Major","Drug: Esketamine|Drug: SSRI/SNRI","Percentage of Participants with Intervention-emergent Adverse Events (AEs)|Percentage of Participants with Intervention-emergent AEs of special interest (AESI)|Suicidal Ideation and Behavior as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) Score|Percentage of Participants with no Relapse Until the end of the Prospective Observation Period at Week 104|Change from Baseline in Study 54135419TRD3013 with Clinician-rated MADRS Scale Score|Change from Baseline in Study 54135419TRD3013 with Clinical Global Impression -severity (CGI-S) Scale Score|Change from Baseline in Study 54135419TRD3013 with Patient Health Questionnaire (PHQ) 9-item Total Score|Change from Baseline in Study 54135419TRD3013 with European Quality of Life (EuroQol) Group, 5 Dimension, 5-Level (EQ-5D-5L) Questionnaire Score","Janssen-Cilag Ltd.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108992|2020-004291-18|54135419TRD4010","April 20, 2021","August 5, 2024","August 30, 2024","April 2, 2021",,"July 23, 2021","Anima, Alken, Belgium|Mental Health Center - Rousse, Rousse, Bulgaria|MHC - Sofia, EOOD, Sofia, Bulgaria|Centre for Mental Health Prof.N.Shipkovenski EOOD, Sofia, Bulgaria|Psychiatricka ambulance Saint Anne s.r.o., Brno, Czechia|Psychiatricka ambulance, MUDr. Marta Holanova, Brno, Czechia|NeuropsychiatrieHK, s.r.o., Hradec Kralove-Vekose, Czechia|A-Shine s.r.o., Plzen, Czechia|Institut Neuropsychiatricke pece, Prague, Czechia|AD71 s.r.o., Praha 10, Czechia|Medical Services Prague s.r.o., Praha 6, Czechia|Universitaetsklinikum der RWTH Aachen, Aachen, Germany|Emovis GmbH, Berlin, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Medizinisches Versorgungszentrum LiO GmbH, Berlin, Germany|Alexander Schulze - Germany, Berlin, Germany|Praxis Dr. med. Kirsten Hahn, Berlin, Germany|Vivantes Klinikum Spandau, Berlin, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Chemnitz, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Klinische Forschung Hamburg, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena, Jena, Germany|Panakeia - Arzneimittelforschung GmbH, Leipzig, Germany|Universitaetsklinikum Magdeburg A.oe.R, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Münster, Munster, Germany|Praxis Prof. Steinwachs, Nurnberg, Germany|Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik, Pfaffenhofen, Germany|Somni Bene GmbH, Schwerin, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Semmelweis Egyetem, Budapest, Hungary|Észak-Közép-budai Centrum, Új Szent János Kórház és Szakrendelő Budai Családközpontú, Budapest, Hungary|Nyírő Gyula Kórház, Budapest, Hungary|Debreceni Egyetem, Kenézy Gyula Egyetemi Oktatókórház, Debrecen, Hungary|Bugat Pal Korhaz, Gyongyos, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, Kalocsa, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk, Bialystok, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Bydgoszcz, Poland|Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Centrum Medyczne Care Clinic Katowice, Katowice, Poland|Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS, Leszno, Poland|Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej w Lodzi Szpital im. J. Babinskiego, Lodz, Poland|Centrum Medyczne Luxmed Sp z o o, Lublin, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Torun, Poland|Ankara Sehir Hastanesi, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04829318"
1165,"NCT00723970","Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression",,"Completed","No Results Available","Major Depressive Disorder|Insomnia|Hot Flashes","Drug: Quetiapine Extended Release","Changes in depressive scores (MADRS) from baseline (after a 2-week lead-in phase) to study end|Changes in Menopause-related scores, based on the Greene Climacteric Scale (GCS) and Hot Flash Related daily interference Scale (HFRDIS)","McMaster University","Female","40 Years to 60 Years   (Adult)","Phase 4","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D1443C00008","June 2007","May 2009","May 2009","July 29, 2008",,"February 8, 2012","Women's Health Concerns Clinic (WHCC), Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00723970"
1166,"NCT01875419","Non-invasive Brain Stimulation and Cognitive Processing in Depression",,"Completed","No Results Available","Unipolar Major Depressive Disorder","Device: Transcranial direct current stimulation (tDCS)|Behavioral: Cognitive Behavioural Therapy","Beck Depression Inventory (BDI) score|Hamilton Depression Rating Scale (HAMD)|Cognitive Control Performance|Functional Magnetic Resonance Imaging (fMRI) data","University College, London","All","18 Years to 60 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13/0256","July 22, 2014","March 7, 2017","September 20, 2017","June 11, 2013",,"May 9, 2018","UCL Institute of Cognitive Neuroscience, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01875419"
1167,"NCT01033084","Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder","SELECT-TDCS","Completed","No Results Available","Depressive Disorder, Major","Device: transcranial direct current stimulation|Drug: Sertraline|Other: double placebo","MADRS score|HDRS-17 score at week 6.|Remission rate (MADRS<=10)","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","USP-HU-001|FAPESP2009/05728-7","December 2009","December 2011","December 2011","December 16, 2009",,"December 6, 2011","University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01033084"
1168,"NCT02553915","Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach",,"Active, not recruiting","Has Results","Major Depressive Disorder|Overweight|Inflammation","Other: Placebo|Drug: EPA 1 g/day|Drug: EPA 2 g/day|Drug: EPA 4 g/day","Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL)|Mean Change in Depression Severity Score (IDS-C30) After 12 Weeks of Treatment|Percent Change in IDS-C Score After 12 Weeks of Treatment|Percent Change in Plasma Concentrations of Mitogen-stimulated PBMC IL-6 (pg/mL) and Plasma Tumor Necrosis Factor (TNF)-α (pg/mL)|Percent Changes in Levels of Expression of Inflammation-related Genes for Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-α (in ΔΔCt Units)|Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) in mg/L","Massachusetts General Hospital|Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01AT008857-01","December 2015","July 13, 2018","December 31, 2021","September 18, 2015","November 18, 2019","March 19, 2021","Emory University School of Medicine, Atlanta, Georgia, United States|Depression Clinical and Research Program at Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02553915/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02553915/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02553915"
1169,"NCT01360866","Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","Orion","Completed","Has Results","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders","Drug: OPC-34712|Drug: Escitalopram|Drug: Fluoxetine|Drug: Paroxetine CR|Drug: Sertraline|Drug: Duloxetine|Drug: Venlafaxine XR","Adverse Events (AEs) - All Participants|Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score|Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score|Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score|Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2944","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-10-238","October 2011","April 18, 2017","May 18, 2017","May 26, 2011","September 17, 2018","September 17, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Glendale, California, United States|Research Site, Irvine, California, United States|Research Site, Oceanside, California, United States|Research Site, Redlands, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Ana, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Temecula, California, United States|Research Site, Upland, California, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Oakland Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, The Villages, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Alpharetta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lafayette, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Belmont, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Weymouth, Massachusetts, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Creve Coeur, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Tom River, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Jamaica, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Beachwood, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Bala-Cynwyd, Pennsylvania, United States|Research Site, Bridgeville, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Woodstock, Vermont, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Herndon, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Brown Deer, Wisconsin, United States|Research Site, Middleton, Wisconsin, United States|Research Site, Gatineau, Canada|Research Site, Penticton, Canada|Research Site, Pointe-Claire, Canada|Research Site, Sherbrooke, Canada|Research Site, Toronto, Canada|Research Site, Arcachon, France|Research Site, Douai, France|Research Site, Elancourt, France|Research Site, Jarnac, France|Research Site, Orvault, France|Research Site, Palaiseau, France|Research Site, Toulouse, France|Research Site, Achim, Germany|Research Site, Bochum, Germany|Research Site, Mittweida, Germany|Research Site, Stralsund, Germany|Research Site, Wurzburg, Germany|Research Site, Budapest, Hungary|Research Site, Belchatow, Poland|Research Site, Bydgoszcz, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Lublin, Poland|Research Site, Poznań, Poland|Research Site, Pruszcz Gdanski, Poland|Research Site, Tuszyn, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Bucharest, Romania|Research Site, Iași, Romania|Research Site, Târgu-Mureş, Romania|Research Site, Arkhangelsk Region, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Roshchino, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Saint Petersberg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tonnel'nyy, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Knezevac, Serbia|Research Site, Bratislava, Slovakia|Research Site, Košice, Slovakia|Research Site, Michalovce, Slovakia|Research Site, Chernihiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Poltava, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01360866/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01360866/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01360866"
1170,"NCT01814098","An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms","Lexapro","Completed","No Results Available","Depressive Disorder, Major","Drug: Escitalopram","Percentage of Participants With Remission According to Montgomery-Asbery Depression Rating Scale (MADRS) and Hamilton Anxiety Scale (HAM-A)|Percentage of Participants Showing Response|Change From Baseline in MADRS Total Score at Week 24|Change From Baseline of Single Rating Item in MADRS Total Score at Week 24|Change From Baseline in Hamilton Depression Rating Scale (HAMD)-17 Score at Week 24|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24|Change From Baseline of Single Rating Item in HAM-A at Week 24|Change From Baseline in Clinical Global Impression Score (CGI-S) at Week 24|Change From Baseline in Short Form-12 (SF-12) Score at Week 24","Xian-Janssen Pharmaceutical Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","318","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR016381|ESCITALDEP4002","July 7, 2009","May 31, 2011","November 30, 2011","March 19, 2013",,"October 2, 2017","Beijng, China|Changsha, China|Hangzhou, China|Nanjing, China|Shanghai, China|Shenyang, China|Shijiazhuang, China|Tianjin, China|Wenzhou, China|Wuhan, China",,"https://ClinicalTrials.gov/show/NCT01814098"
1171,"NCT03062150","Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression","MISO","Completed","No Results Available","Major Depression","Drug: Placebo|Drug: Fludrocortisone|Drug: D-Cycloserine","Emotional dot probe|Facial recognition task|Multifaceted Empathy Test (MET)|Virtual Water Maze","Charite University, Berlin, Germany|NeuroCure Clinical Research Center, Charite, Berlin","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","232","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","OT 209/7-1|2014-005239-15","September 27, 2016","February 11, 2019","February 11, 2019","February 23, 2017",,"June 23, 2020","Charité Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03062150"
1172,"NCT02667041","NeuroQore rTMS (Monophasic vs. Biphasic) for Major Depressive Disorder: A Randomized Controlled Pilot Trial",,"Completed","No Results Available","Depressive Disorder, Major","Device: NeuroQore rTMS Device","Montgomery-Åsberg Depression Rating Scale (MADRS) scores","University of Ottawa|NeuroQore Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2015014","May 2015","March 2018","March 2018","January 28, 2016",,"November 16, 2018","Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02667041"
1173,"NCT02633449","Psychotherapy Plus: Combining Cognitive Behavioral Therapy With tDCS",,"Active, not recruiting","No Results Available","Major Depression","Behavioral: cognitive behavioral therapy|Device: tDCS|Device: sham-tDCS","Change in depression severity as measured by Montgomery Asberg Depression Rating Scale (MADRS)","Charite University, Berlin, Germany|University of München|University Hospital Tuebingen|University of Freiburg|University of Leipzig|Central Institute of Mental Health, Mannheim","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01EE1403F","February 2016","November 15, 2019","January 2021","December 17, 2015",,"December 20, 2019","Charité University Medicine Berlin, Department of Psychiatry and Psychotherapy, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02633449"
1174,"NCT03352453","A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder",,"Terminated","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in Sheehan - Suicidality Tracking Scale (S-STS) Total Score","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-20","December 15, 2017","June 21, 2019","June 21, 2019","November 24, 2017","August 14, 2020","August 14, 2020","The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, Birmingham, Alabama, United States|Collaborative NeuroScience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Asclepes Research Centers, Panorama City, California, United States|Institute of Living, Hartford, Connecticut, United States|Innovative Clinical Research, Inc, Hialeah, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Atlanta Center for Medical Research (ACMR), Atlanta, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|CBH Health, Gaithersburg, Maryland, United States|Altea Research Institute, Las Vegas, Nevada, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States|Carilion Medical Center, a Virginia Nonprofit Corporation, Roanoke, Virginia, United States|Department of Veterans Affairs Salem VA Medical Center, Salem, Virginia, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03352453/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03352453/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03352453"
1175,"NCT01727726","A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial",,"Completed","Has Results","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders","Drug: Brexpiprazole|Drug: Seroquel XR|Drug: Placebo","Montgomery Asberg Depression Rating Scale (MADRS)|Sheehan Disability Scale (SDS)|Change From End of Phase A in MADRS Total Score for Trial Week 2 and Week 4.|Clinical Global Impression Score|MADRS Response at Week 6|Number of Participants With MADRS|CGI-I Response Rate|Number of Participants With Adverse Events|Sheehan Disability Scale (SDS) Individual Item Scores.","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-12-282","December 2012","October 17, 2016","November 10, 2016","November 16, 2012","June 8, 2018","June 8, 2018","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Bellflower, California, United States|Beverly Hills, California, United States|Costa Mesa, California, United States|Glendale, California, United States|Irvine, California, United States|Redlands, California, United States|San Diego, California, United States|Upland, California, United States|Gainesville, Florida, United States|Jacksonville Beach, Florida, United States|Jacksonville, Florida, United States|Leesburg, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Oakland Park, Florida, United States|Orange City, Florida, United States|Orlando, Florida, United States|Decatur, Georgia, United States|Lake Charles, Louisiana, United States|Baltimore, Maryland, United States|Belmont, Massachusetts, United States|Roslindale, Massachusetts, United States|Watertown, Massachusetts, United States|Creve Coeur, Missouri, United States|Lebanon, New Hampshire, United States|New York, New York, United States|New York, New York, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Edmond, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Dallas, Texas, United States|Murray, Utah, United States|Herndon, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Kirkland, Washington, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States|Penticton, British Columbia, Canada|Dijon, France|Douai, France|Elancourt, France|Jarnac, France|Montepellier, France|Orvault, France|Achim, Germany|Mittweida, Germany|Stralsund, Germany|Wuerzburg, Germany|Belchatow, Poland|Bydgoszcz, Poland|Gdynia, Poland|Kielce, Poland|Lublin, Poland|Tuszyn, Poland|Wroclaw, Poland|Arkhangelsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Smolensk, Russian Federation|Tonnelniy, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Knezevac, Serbia",,"https://ClinicalTrials.gov/show/NCT01727726"
1176,"NCT02489305","Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major",,"Number of Participants With Near Term Relapse","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)",,"330","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR105160|OBSERVEMDD0001","December 15, 2014","May 1, 2018","May 1, 2018","July 3, 2015",,"October 26, 2018","Birmingham, Alabama, United States|Glendale, California, United States|Oceanside, California, United States|San Diego, California, United States|Sherman Oaks, California, United States|Stanford, California, United States|Hartford, Connecticut, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Skokie, Illinois, United States|Springfield, Illinois, United States|Iowa City, Iowa, United States|Wichita, Kansas, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02489305"
1177,"NCT02847741","Predictive Nature of Total Cholesterol Threshold: Possible Link to Suicidal Behavior",,"Unknown status","No Results Available","Current Major Depressive Disorder","Other: patient's routine care","frequency of suicide attempts|number of past SB|moral pain|physical pain|suicidal ideation|depression (Quick Inventory of Depressive Symptomatology)|history of childhood abuse|National Adult Reading Test score|scores to California Verbal Learning Test|scores to Iowa Gambling Task Time frame: 18 months|score to the brixton test|scores to verbal fluency|scores to Reversal Learning Task|scores to the Attentional Stroop test|relation between inflammatory markers and the occurrence of SB|relation between thyroid function and the occurrence of SB|relation between lipid profile and the occurrence of SB|relation between pharmacological assays and the occurrence of SB|relation between the characteristic of the mood depressive disorder (unipolar or bipolar depression) and the predictive or vulnerability factors of SB|the characteristic of past SB|depression level (Inventory of Depressive Symptomatology)|National Adult Reading Test score ( NART)|scores to Iowa Gambling Task|verbal fluency|relation between inflammatory markers and the response to antidepressant treatment|relation between thyroid function and the response to antidepressant treatment|relation between lipid profile and the response to antidepressant treatment|relation between pharmacological assays and the response to antidepressant treatment|lethality of past SB|Depression (Inventory of Depressive Symptomatology)|Depression (Beck Depression Inventory)|depression level (Beck depression Inventory)|depression level (Quick Inventory of Depressive Symptomatology)","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)","Not Applicable","555","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","UF 8921|2011-A01657-34","June 2012","December 2016","April 2017","July 28, 2016",,"July 28, 2016","Montpelleir University Hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02847741"
1178,"NCT02951988","A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo-matching Rapastinel","Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period|Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales|Time to First Relapse During the Entire Double-Blind Treatment Period","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-MD-04","November 13, 2016","February 22, 2019","February 22, 2019","November 1, 2016","March 9, 2020","March 9, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience Research, Dothan, Alabama, United States|NoesisPharma, Phoenix, Arizona, United States|University of Arizona Department of Psychiatry, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|California Pharmaceutical Research Institute, Inc, Anaheim, California, United States|Southern California Research LLC., Beverly Hills, California, United States|ATP Clinical Research Inc., Costa Mesa, California, United States|ProScience Research Group, Culver City, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Center for Clinical Research, Inc, Irvine, California, United States|Synergy Clinical Research Center of Escondido, Lemon Grove, California, United States|Synergy San Diego, Lemon Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Research Partners; LLC., Oakland, California, United States|Excell Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Centers, Panorama City, California, United States|Anderson Clinical Research, Redlands, California, United States|CITrials, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|PCSD Feighner Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Thomas M. Shiovitz, M.D., Inc., DBA California Neuroscience Research Medical Group, Inc.,, Sherman Oaks, California, United States|Viking Clinical Research, Temecula, California, United States|Pacific Clinical Research Medical, Upland, California, United States|MCB Clinical Research Center, Colorado Springs, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Reliable Clinical Research, Hialeah, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Innovative Clinical Research, Inc, Lauderhill, Florida, United States|Innova Clinical Trials Inc., Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|Sarkis Clinical Trials, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Millenia Psychiatry & Research, Inc, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|The University of South Florida Board of Trustees, A public Body Corporate, for University of South Florida, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|IRIS Research, Smyrna, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|AMR - Baber Research, Inc., Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|J Gary Booker, MD APMC, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|CBH Health, Rockville, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Adams Clinical Trials, Watertown, Massachusetts, United States|Coastal Research Associates, Weymouth, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Alivation Research, Lincoln, Nebraska, United States|Altea Research, Las Vegas, Nevada, United States|Healthy Perspectives - Innovative Mental Health Services. PLLC, Nashua, New Hampshire, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Pharmaceutical Research Associates Inc, Marlton, New Jersey, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc, Albuquerque, New Mexico, United States|SPRI Clinical Trials, Inc, Brooklyn, New York, United States|Bioscience Research, Mount Kisco, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Fieve Clinical Research, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Richard H. Weisler, MD, PA, Raleigh, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|Patient Priority Clinical Site, LLC, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Department of Psychiatry, Columbus, Ohio, United States|Midwest Clinical Research Center LLC, Dayton, Ohio, United States|Charak Clinical Research Center, Garfield Heights, Ohio, United States|Lindner Center of Hope, Mason, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|IPS Research, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Inc, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Dr. Cherian Verghese, Norristown, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|BioBehavioral Research of Austin, Austin, Texas, United States|Houston Clinical Trials, LLC, Bellaire, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|El Campo Clinical Trials, El Campo, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Earle Research, Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Family Psychiatry of The Wood, The Woodlands, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Psychiatric and Behavioral Solutions, Salt Lake City, Utah, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, United States|Psychiatric Alliance of the Blue Ridge, Inc, Charlottesville, Virginia, United States|NorthWest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Eastside Therapeutic Resource, Everett, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02951988/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02951988/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02951988"
1179,"NCT03374475","A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: JNJ-42847922 20mg|Drug: JNJ-42847922 40mg|Drug: Placebo","Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Total Score|Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Sleep Item-Adjusted Total Score|Change From Baseline in Hamilton Rating Scale for Depression-17 (HDRS17) Anxiety/Somatization Factor Score|Change From Baseline in 6 Item Subscale From HDRS17 (HAM-D6) Score|Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|Association Between Major Depressive Disorder (MDD) Symptoms and Signals of Hyper-Arousal|Performance Score on a Cognitive Test Battery Evaluated by Symbol Digit Matching Test (SDMaT)|Performance Score on a Cognitive Test Battery Evaluated by Word List Recall Test (WLRT)|Performance Score on a Cognitive Test Battery Evaluated by Trail Making Test Form B (TMT-B)|Change From Baseline in Bond & Lader (B&L) Visual Analogue Scale (VAS)|Change From Baseline in Profile of Mood States (POMS)|Plasma Concentration of JNJ- 42847922 and its Metabolites|Percent Change From Baseline in Biomarker Levels|Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Janssen Research & Development, LLC","All","18 Years to 55 Years   (Adult)","Phase 1","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108382|2017-002633-28|42847922MDD1009","January 5, 2018","April 29, 2019","April 29, 2019","December 15, 2017",,"May 20, 2019","Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Qps-Mra, Llc, Miami, Florida, United States|SGS Phase 1 Unit AZ St-Maarten, Mechelen, Belgium|Clinical Pharmacology Unit, Merksem, Belgium|Charité Research Organisation GmbH, Berlin, Germany|Emovis GmbH, Berlin, Germany|Fraunhofer-Institut für Toxikologie und Experimentelle Medizin, Hannover, Germany|Somni Bene GmbH, Schwerin, Germany|Centre for Human Drug Research, Leiden, Netherlands|MAC Clinical Research, Blackpool, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|Hammersmith Medicines Research, London, United Kingdom|MAC Clinical Research, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03374475"
1180,"NCT00618865","Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy",,"Completed","No Results Available","Depressive Disorder","Dietary Supplement: Omega-3 fatty acids",,"National Science Council, Taiwan","Female","18 Years to 40 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NSC 93-2320-B-039-001","June 2004","June 2004","June 2004","February 20, 2008",,"February 20, 2008",,,"https://ClinicalTrials.gov/show/NCT00618865"
1181,"NCT03108625","Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Vortioxetine","Incidence of Treatment-Emergent Adverse Events (Safety)|Change in CDRS-R total score|Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)|Loss of remission (CDRS-R <28 with a history of 2 weeks of clinical deterioration)|Change in CGI-S score|CGI-I score|Children (7-11 years): change in BRIEF using the Global Executive Composite score|Children (7-11 years): change in BRIEF using the Megacognition Index|Adolescents (12-17 years): change in BRIEF-SR using the Global Executive Composite score|Adolescents (12-17 years): change in BRIEF-SR using the Megacognition Index|Change in CGAS score|Change in PedsQL VAS score","H. Lundbeck A/S","All","7 Years to 17 Years   (Child)","Phase 3","94","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12712B|2015-002658-11","March 1, 2017","April 16, 2020","April 16, 2020","April 11, 2017",,"June 24, 2021","MHAT ""Targovishte"" AD, Targovishte, Bulgaria|DCC Mladost-M, Varna, Bulgaria|Marienthal Center of Psychiatry and Psychology, Tallinn, Estonia|CHU de Nantes - Hopital Hotel Dieu, Nantes, France|Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri, Mainz, Germany|Vadaskert Alapitvany, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Scientific Institute Fondazione Stella Maris, Calambrone, Italy|Universita degli Studi di Messina - Facolta di Medicina e Chirurgia, Messina, Italy|Linda Keruze's Psychiatric Center, LLC, Liepāja, Latvia|Prywatne Gabinety Lekarskie ¿Promedicus¿ Anna Agnieszka Tomczak, Białystok, Poland|Centrum Badan Klinicznych PI-House Sp. z o.o., Gdańsk, Poland|Przychodnia Syntonia Poradnia Zdrowia Psychicznego, Kielce, Poland|SPECTRUM Centrum Neurologii i Psychiatrii, Lublin, Poland|Filip Rybakowski Specjalistyczna Praktyka Lekarska, Poznań, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej (SPZOZ) - Centrum Neuropsychiatrii ""NEUROMED"", Wrocław, Poland|State Budgetary Healthcare Institution of Sverdlovsk Region, Ekaterinburg, Russian Federation|Specialized Clinical Psychiatric Hospital 1 of the Ministry of Health, Krasnodar, Russian Federation|Lipetsk Regional Psychoneurological Hospital, Lipetsk, Russian Federation|Nizhny Novgorod Region State Institution Of Healthcare, Nizhny Novgorod, Russian Federation|Medicorehabilitation Research Center ""Phoenix"", Rostov-on-Don, Russian Federation|Rostov State Medical University of the Minzdravsotsrazvitiya of Russia, Rostov-on-Don, Russian Federation|Guz ""Saratov Regional Psychiatric Hospital St. Sofii"", Saratov, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|State Budgetary Healthcare Institution, Tonnel'nyy, Russian Federation|Clinic of Neurology and Psychiatry for Children and Adolescents, Belgrade, Serbia|Clinical Center of Vojvodina - Clinic of Psychiatry, Novi Sad, Serbia|Cape Trial Centre, Bellville, South Africa|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo, Torremolinos, Spain|Alder Hey Childrens Hospital, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03108625"
1182,"NCT00149110","Chronos: the Use of Chronobiological Treatment in Depression",,"Completed","No Results Available","Major Depression","Procedure: Sleep deprivation|Procedure: Light therapy|Procedure: Diurnal rhythms|Behavioral: Exercise|Drug: duloxetine","Hamilton score during the 29 weeks trial|Cortisol measurements|Depression self rating by the Preskorn scale","Hillerod Hospital, Denmark|Eli Lilly and Company|The County of Frederiksborg","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2005-001855-39 Eudra CT number","September 2005","March 2009","March 2009","September 8, 2005",,"August 6, 2009","Psychiatric Research Unit, Hilleroed Hospital, Hilleroed, Denmark",,"https://ClinicalTrials.gov/show/NCT00149110"
1183,"NCT01284218","Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major",,"All cause health care costs|Health care costs: MDD related, mental health related|Health care resource utilization: All cause, MDD related, mental health related|Duration of index therapies|Medication possession ratio to evaluate adherence|Discontinuation of index therapies|Therapy switches to a non-index antidepressant or non-index augmentation therapy","Otsuka Pharmaceutical Development & Commercialization, Inc.|i3 Innovus","All","18 Years and older   (Adult, Older Adult)",,"23514","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CN138-609","January 2011","December 2011","December 2011","January 26, 2011",,"November 8, 2013",,,"https://ClinicalTrials.gov/show/NCT01284218"
1184,"NCT01798407","DBS of the Lateral Habenula in Treatment-Resistant Depression",,"Active, not recruiting","No Results Available","Treatment Resistant Major Depressive Disorder","Device: Activa Tremor Control Sys (DBS Implant)|Other: Randomized, staggered withdrawal phase","Change in HDRS^17 score from baseline to 6 months after the commencement of stimulation|MADRS (Montgomery and Asberg Depression Rating Scale)|Clinical Global Impression of Severity (CGI-S)|Clinical Global Impression of Improvement (CGI-I)|Young Mania Rating Scale (YMRS)|Columbia Suicide Severity Rating Scale (C-SSRS)|Neuropsychological Battery|QIDS-SR (Quick Inventory of Depressive Symptomatology)|Generalized Anxiety Disorder 7-item Scale (GAD-7)|Sheehan Disability Scale|PRISE (The Patient Rated Inventory of Side Effects)","Wayne Goodman MD|Baylor College of Medicine","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H40307|49593|277909|HSM#12-00467|GCO 12-1815","February 2013","August 2021","August 2021","February 25, 2013",,"November 12, 2020","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01798407"
1185,"NCT01360645","Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)","Pyxis","Completed","Has Results","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders","Drug: OPC-34712 + ADT|Drug: Placebo + ADT","Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol.|Mean Change From Baseline (End of Phase A [Week 8]) to Week 14 in Sheehan Disability Scale (SDS) Score for the Efficacy Sample.|Mean Change From Baseline (End of Phase A [Week 8]) to Week 14 in SDS Score for the Efficacy Sample Per the Final Protocol|Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score by Trial Week for the Efficacy Sample.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score by Trial Week for the Efficacy Sample Per the Final Protocol.|Mean Clinical Global Impression-Improvement (CGI-I) Scale Score (End of Phase A [Week 8]) to Week 14 by Trial Week for the Efficacy Sample.|Mean CGI-I Scale Score (End of Phase A [Week 8]) to Week 14 by Trial Week for the Efficacy Sample Per the Final Protocol.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in Clinical Global Impression - Severity of Illness (CGI-S) Scale Score for the Efficacy Sample.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in CGI-S Scale Score for the Efficacy Sample Per the Final Protocol.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in the Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score for the Efficacy Sample.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in the IDS-SR Total Score for the Efficacy Sample Per the Final Protocol.|Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample.|Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Per the Final Protocol.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in Hamilton Depression (HAM-D) Rating Scale Total Score for the Efficacy Sample.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in HAM-D Rating Scale Total Score for the Efficacy Sample Per the Final Protocol.|Change From Baseline (End of Phase A [Week 8]) to Week 14 in Hamilton Anxiety (HAM-A) Rating Scale Total Score for the Efficacy Sample|Change From Baseline (End of Phase A [Week 8]) to Week 14 in HAM-A Rating Scale Total Score for the Efficacy Sample Per the Final Protocol.|Percentage of Participants With MADRS Response at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample.|Percentage of Participants With MADRS Response at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol.|Percentage of Participants With MADRS Remission at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample.|Percentage of Participants With MADRS Remission at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol.|Percentage of Participants With CGI-I Scale Response Rate at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample.|Percentage of Participants With CGI-I Scale Response Rate at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol.","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","826","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","331-10-228","July 2011","May 2013","June 2013","May 25, 2011","November 26, 2015","November 26, 2015","Research Site, Arcadia, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Fresno, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Coral Springs, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Belmont, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Lincoln, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Dayton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Salem, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Bala Cynwyd, Pennsylvania, United States|Research Site, Bridgeville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, San Antonio, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Woodstock, Vermont, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Penticton, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Arcachon, France|Research Site, Elancourt, France|Research Site, Orvault, France|Research Site, Palaiseau, France|Research Site, Toulouse, France|Research Site, Katowice, Upper Silesia, Poland|Research Site, Poznan, Woj. Wielkopolskie, Poland|Research Site, Belchatow, Poland|Research Site, Gdynia, Poland|Research Site, Kielce, Poland|Research Site, Lublin, Poland|Research Site, Tuszyn, Poland|Research Site, Warszawa, Poland|Research Site, Bratislava, Slovakia|Research Site, Kosice-Barca, Slovakia|Research Site, Levice, Slovakia|Research Site, Michalovce, Slovakia",,"https://ClinicalTrials.gov/show/NCT01360645"
1186,"NCT00385437","Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder",,"Completed","No Results Available","Depression|Excessive Daytime Sleepiness","Behavioral: Driving Simulator Testing|Drug: Mirtazapine Treatment","Driving performance on the driving simulator|Ability to maintain wakefulness","University Health Network, Toronto|Organon","All","25 Years to 50 Years   (Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","REB-03-0255-A","April 2003",,"June 2004","October 9, 2006",,"October 9, 2006","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00385437"
1187,"NCT04451187","A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Seltorexant Dose 1|Drug: Seltorexant Dose 2|Drug: Placebo|Drug: Zopiclone","Driving Performance as Assessed by the Mean Difference of SDLP From an on-road Driving Test|Participant Driving Performance as Assessed by Visual Analog Scale|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Janssen Research & Development, LLC","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CR108762|42847922MDD1005|2019-004913-15","July 16, 2020","March 31, 2022","September 30, 2022","June 30, 2020",,"May 3, 2021","Anima, Alken, Belgium|Universitaetsklinikum der RWTH Aachen, Aachen, Germany",,"https://ClinicalTrials.gov/show/NCT04451187"
1188,"NCT02902601","A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: JNJ-54175446, 600 mg|Drug: JNJ-54175446, 150 mg|Other: Placebo","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Effect of JNJ-54175446 Versus Placebo on Total Sleep Deprivation (TSD)-Induced Changes in Depressive Symptoms by HDRS17/IDS-C30 Rating Scale|Effect of JNJ-54175446 Versus Placebo on Total Sleep Deprivation (TSD)-Induced Changes in Depressive Symptoms by QIDS-SR16/QIDS-SR10 Rating Scale|Effect of JNJ-54175446 Versus Placebo on TSD-Induced Changes in Biomarker Profiles (interleukin [IL]-1 beta, cortisol)|Effect of JNJ-54175446 Versus Placebo on Latency to Persistent Sleep (LPS)|Effect of JNJ-54175446 Versus Placebo on Total Sleep Time (TST)|Effect of JNJ-54175446 Versus Placebo on Wake After Sleep Onset (WASO)|Effect of JNJ-54175446 Versus Placebo on Sleep Efficiency (SE)|Effect of JNJ-54175446 Versus Placebo on Snaith-Hamilton Pleasure Scale [SHAPS])|Effect of JNJ-54175446 Versus Placebo on Profile of Mood States brief form (POMS)|Effect of JNJ-54175446 Versus Placebo on Emotional Faces Recognition Test|Effect of JNJ-54175446 Versus Placebo on Soluble Biomarkers (Inclusive Ex-vivo Lipopolysaccharide [LPS]/Benzoylated(Bz) Adenosine Triphosphate [ATP]-Induced IL-1 Beta Release)|Effect of JNJ-54175446 Versus Placebo on Central Pharmacodynamic (PD) by Motor Learning by Adaptive Tracking Test|Effect of JNJ-54175446 Versus Placebo on Sustained Attention by the Three Choice Vigilance Task (3CVT) With EEG|Maximum Observed Plasma Concentration (Cmax) of JNJ-54175446|Minimum Observed Plasma Concentration (Cmin) of JNJ-54175446|Trough Plasma Concentration (Ctrough) of JNJ-54175446|Average Plasma Concentration at Steady State (Cavg) of JNJ-54175446|Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-54175446|Area Under the Plasma ConcentrationTime Curve During a Dosing Interval (tau) [AUCtau] of JNJ-54175446|Area Under the Plasma ConcentrationTime Curve From Time Zero to Time 't' (AUC[0t]) of JNJ-54175446|Apparent Elimination HalfLife (t1/2) of JNJ-54175446|Ratio of the Maximum Plasma Concentration (Peak) to Trough Observed Concentration of JNJ-54175446|Accumulation Ratio Based on AUC of JNJ-54175446|Effect of JNJ-54175446 Versus Placebo on a Reward Test","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108204|54175446MDD1001|2016-001929-14","October 17, 2016","June 2, 2017","June 7, 2017","September 16, 2016",,"April 29, 2020","Berlin, Germany|Hamburg, Germany|Schwerin, Germany|Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02902601"
1189,"NCT00970437","A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression",,"Completed","No Results Available","Chronic Major Depressive Disorder","Behavioral: Cognitive Behavioral Analysis System of Psychotherapy|Behavioral: System of Supportive Psychotherapy","Depressive symptoms as measured by the HRSD (24-item Hamilton Rating Scale of Depression)","University Hospital Freiburg","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UKF001906","April 2010","October 2013","December 2014","September 2, 2009",,"July 5, 2017","University Medical Center Freiburg, Department of Psychiatry and Psychotherapy, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT00970437"
1190,"NCT01360632","Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)","Polaris","Completed","Has Results","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders","Drug: OPC-34712 + ADT|Drug: Placebo + ADT","Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set|Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol|Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Set|Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Per Final Protocol|Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Scores for the Efficacy Sample Set|Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in SDS Mean Scores for the Efficacy Sample Per Final Protocol|Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set|Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set Per Final Protocol|Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression Severity of Illness (CGI-S) for the Efficacy Sample Set|Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical CGI-S for the Efficacy Sample Per Final Protocol|Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) IDS-SR Total Score for the Efficacy Sample Set|Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in IDS-SR Total Score for the Efficacy Sample Per Final Protocol|Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set|Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol|Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set|Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol|Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Set|Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Per Final Protocol|Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set|Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol|Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Set|Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Per Final Protocol|Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set|Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1539","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","331-10-227","June 2011","August 2013","September 2013","May 25, 2011","January 1, 2016","January 1, 2016","Research Site, Birmingham, Alabama, United States|Research Site, Costa Mesa, California, United States|Research Site, Glendale, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Temecula, California, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Weymouth, Massachusetts, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Creve Coeur, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, New York, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Beachwood, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Salem, Oregon, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Witchita Falls, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Herndon, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Brown Deer, Wisconsin, United States|Research Site, Middleton, Wisconsin, United States|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Wurzburg, Bavaria, Germany|Research Site, Stralsund, Mecklenburg-Vorpommern, Germany|Research Site, Bochum, NRW, Germany|Research Site, Achim, Germany|Research Site, Nyiregyhaza, Szabolcs Szatmar Bereg, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Bucharest, Romania|Research Site, Lasi, Romania|Research Site, Targu Mures, Romania|Research Site, Moscow, Russian Federation|Research Site, Rostov on Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Chenigiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01360632"
1191,"NCT02232555","Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Duloxetine|Drug: Placebo","Change of 24-hour average pain rated on Brief Pain Inventory-Short Form (BPI-SF) score|Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score|Time to sustained clinical response for Painful Physical Symptoms (PPS) according BPI-SF score|Change of patient symptoms rated on Symptom Checklist 90 Revised (SCL-90-R) scale|Patients Global Impression (PGI) rated on PGI-improvement scale|Clinical Global Impressions (CGIs) by investigator rated on CGI-severity score|Clinical Global Impressions (CGIs) by investigator rated on CGI-improvement scale|Time to sustained clinical response for overall depression symptoms|Number of patients with adverse events|Number of patients withdrawing due to adverse event|Number of patients with clinical significant findings in vital signs|Number of patients with clinical significant findings in weight|Number of patients with clinical significant findings in laboratory values","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","327","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1208.10","May 2005","May 2006",,"September 5, 2014",,"September 5, 2014",,,"https://ClinicalTrials.gov/show/NCT02232555"
1192,"NCT04951609","A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy",,"Not yet recruiting","No Results Available","Depressive Disorder, Major","Drug: Seltorexant|Drug: Placebo","Number of Participants with Treatment Emergent Adverse Events (TEAEs)|Number of Participants with Adverse Event of Special Interest (AESIs)|Pediatric Adverse Event Rating Scale (PAERS)|Number of Participants with Abnormalities in Clinical Laboratory Values|Number of Participants with Abnormalities in Electrocardiogram (ECG)|Number of Participants with Abnormalities in Vital Signs|Number of Participants with Abnormalities in Physical Examination|Suicidality Assessment Using the Columbia Suicide Severity Rating Scale (C-SSRS) Score|Withdrawal Symptoms Assessment Using the Physician Withdrawal Checklist (PWC-20)|Number of Participants with Menstrual Cycle Tracking|Change from Baseline to Week 6/End of Treatment (EOT) in the Children's Depression Rating Scale (CDRS) Total Score|Change from Baseline to Week 6 in Montgomery Asberg Depression Rating Scale (MADRS) Score|Change from Baseline in Clinical Global Impression- severity (CGI-S) Score Over Time|Change from Baseline to Week 6/EOT on Subjective Sleep Assessment (Patient Reported Outcome Measurement Information System-Pediatric-Sleep Disturbance [PROMIS-Pediatric-SD] [Short Form 8a])|Change from Baseline to Week 6/EOT on Objective Sleep Assessment Actigraphy|Cognitive Performance on a Neurocognitive Battery at Baseline and Week 6/EOT|Change in Subjective Sleep Related Impairment (PROMIS-Pediatric- Sleep-Related Impairment [SRI])|Plasma Concentration of Seltorexant","Janssen Research & Development, LLC","All","12 Years to 17 Years   (Child)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR109041|2021-000567-77|42847922MDD1016","July 16, 2021","May 4, 2023","May 4, 2023","July 7, 2021",,"July 23, 2021","Children's National Medical Center, Washington, District of Columbia, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Segal Trials, Lauderhill, Florida, United States|Baber Research Group, Naperville, Illinois, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Professional Psychiatric Services, West Chester, Ohio, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|G.Gaslini Institute, Genova, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, Spain|Corporacio Sanitari Parc Tauli, Sabadell, Spain",,"https://ClinicalTrials.gov/show/NCT04951609"
1193,"NCT00813735","Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder",,"Completed","No Results Available","Insomnia","Drug: Eszopiclone|Drug: Placebo|Drug: Escitalopram","Change in total sleep time from baseline to final visit|change in sleep latency from baseline to final visit|Change in HAMD from baseline to final visit|Change in ISI from baseline to final visit|Change in CGI-S, CGI-I from baseline to final visit|labs (CBC,urinalysis,TSH,Chemprofile,drugscreen),height|vitals: BP,pulse,temperature,weight,assess AE's/SAE's","Lehigh Center for Clinical Research|Sunovion","All","65 Years to 85 Years   (Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ESRCO66","September 2006","March 2009","April 2009","December 23, 2008",,"October 3, 2012","Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00813735"
1194,"NCT02871297","Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age",,"Enrolling by invitation","No Results Available","Depressive Disorder, Major","Drug: Vortioxetine","Number of participants with Treatment-Emergent Adverse Events|Change in CDRS-R total score|Time to first relapse (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)|Time to first loss of remission (CDRS-R <28 with a history of 2 weeks of clinical deterioration)|Change in Clinical Global Impression - Severity of Illness (CGI-S) score|Clinical Global Impression - Global Improvement (CGI-I) score|Children (7-11 years): Change in Behaviour Rating Inventory of Executive Function (BRIEF) using the Global Executive Composite score|Children (7-11 years): Change in BRIEF using the Metacognition Index|Adolescents (12-18 years): Change in BRIEF-Self-report (SR) using the Global Executive Composite score|Adolescents (12-18 years): Change in BRIEF-SR using the Metacognition Index|Change in Children's Global Assessment Scale (CGAS) score|Change in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales (PedsQL VAS) score|Absolute value of palatability scores|Absolute value of acceptability item scores in number of percentage","H. Lundbeck A/S","All","7 Years to 18 Years   (Child, Adult)","Phase 3","850","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12712A|2008-005356-25","August 2016","February 2023","February 2023","August 18, 2016",,"January 6, 2021","US1333, Tucson, Arizona, United States|US1386, Wichita, Kansas, United States|US1015, Baltimore, Maryland, United States|US1051, Cincinnati, Ohio, United States|US1054, Cleveland, Ohio, United States|BG1023, Targovishte, Bulgaria|BG1025, Varna, Bulgaria|CA1038, Toronto, Canada|CO1003, Barranquilla, Colombia|CO1001, Bello, Colombia|CO1004, Bogotá, Colombia|CO1002, Pereira, Colombia|EE1007, Tallinn, Estonia|FR1041, Douai, France|FR1017, Elancourt, France|FR1009, Nantes, France|DE1078, Freiburg, Germany|DE1034, Mainz, Germany|DE1081, Maulbronn, Germany|DE1076, Tuebingen, Germany|HU1023, Budapest, Hungary|HU1020, Gyula, Hungary|IL1008, Tel Aviv, Israel|IT1075, Cagliari, Italy|IT1073, Genova, Italy|IT1029, Messina, Italy|IT1068, Napoli, Italy|IT1074, Padova, Italy|IT1070, Pisa, Italy|KR1035, Cheonan, Korea, Republic of|KR1032, Seoul, Korea, Republic of|LV1002, Jelgava, Latvia|LV1008, Liepaja, Latvia|LV1009, Riga, Latvia|LT1007, Sigulda, Latvia|MX1014, Culiacán, Mexico|MX1011, Guadalajara, Mexico|MX1022, Guadalajara, Mexico|MX1023, Mazatlán, Mexico|MX1003, Mexico City, Mexico|MX1001, Monterrey, Mexico|MX1017, San Luis Potosi, Mexico|MX 1017 Centro de Atencion e Investigacion Cardiovascular del Potosi S.C., San Luis Potosí, Mexico|PL1002, Bialystok, Poland|PL1050, Gdańsk, Poland|PL1068, Kielce, Poland|PL1057, Lublin, Poland|PL1052, Poznań, Poland|PL1054, Wałbrzych, Poland|PL1051, Wroclaw, Poland|RU1009, Arkhangel'sk, Russian Federation|RU1059, Engel's, Russian Federation|RU1046, Krasnodar, Russian Federation|RU1011, Lipetsk, Russian Federation|RU1004, Nizhny Novgorod, Russian Federation|RU1010, Novosibirsk, Russian Federation|RU1012, Rostov-on-Don, Russian Federation|RU1044, Rostov-on-Don, Russian Federation|RU1031, Saint Petersburg, Russian Federation|RU1013, Saratov, Russian Federation|RU1038, Saratov, Russian Federation|RU1057, Tomsk, Russian Federation|RU1048, Tonnel'nyy, Russian Federation|RU1058, Yaroslavl, Russian Federation|RU1016, Yekaterinburg, Russian Federation|RS1006, Belgrade, Serbia|RS1010, Belgrade, Serbia|RS1011, Kragujevac, Serbia|RS1003, Niš, Serbia|RS1007, Novi Sad, Serbia|ZA1019, Belville, South Africa|ES1041, Alcorcón, Spain|ES1044, Madrid, Spain|ES1040, Torremolinos, Spain|UA1002, Kiev, Ukraine|UA1019, Odessa, Ukraine|UA1001, Poltava, Ukraine|UA1004, Ternopil', Ukraine|GB1051, Glasgow, United Kingdom|GB1047, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02871297"
1195,"NCT00795821","A Study in Adult Patients With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684|Drug: Placebo","Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10|Mean Change From Baseline (Week 10) in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 62|Mean Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 10|Mean Change From Baseline (Week 10) in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 62|Mean Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10|Mean Change From Baseline (Week 10) in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 62|Mean Change From Baseline in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 10|Mean Change From Baseline (Week 10) in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 62|Mean Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 10|Mean Change From Baseline (Week 10) in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 62|Mean Change From Baseline in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 10|Mean Change From Baseline (Week 10) in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 62|Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 10|Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 62|Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 10|Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 62|Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 10|Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 62|Mean Change From Baseline in the Brief Fatigue Inventory (BFI) Global Total Score at Week 10|Mean Change From Baseline (Week 10) in Brief Fatigue Inventory (BFI) Global Total Score at Week 62|Mean Change From Baseline in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 10|Mean Change From Baseline (Week 10) in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 62|Percentage of Participants Reporting Resource Utilization at Week 10|Percentage of Participants Reporting Resource Utilization at Week 62|Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 10|Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 62|Mean Change From Baseline in Supine Systolic and Diastolic Blood Pressure at Week 10|Mean Change From Baseline (Week 10) in Supine Systolic and Diastolic Blood Pressure at Week 62|Mean Change From Baseline in Supine Pulse at Week 10|Mean Change From Baseline (Week 10) in Supine Pulse at Week 62|Pharmacokinetic (PK) Parameter: Plasma Concentration of LY2216684","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","495","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11313|H9P-MC-LNBI","December 2008","February 2010","March 2011","November 21, 2008","March 20, 2018","March 20, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cerritos, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smyrna, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Overland Park, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willingboro, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belchatow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gorlice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leszno, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torun, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuszyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00795821"
1196,"NCT02709655","Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Vortioxetine 10 mg/day|Drug: Vortioxetine 20 mg/day|Drug: Fluoxetine 20mg/day|Other: Placebo","Change in CDRS-R total score after treatment|Change in CDRS-R total score during treatment|CDRS-R response (defined as >50% reduction in the CDRS-R total score (subtracted 17 points))|Remission (defined as CDRS-R≤28), at each visit assessed|Change in General Behaviour Inventory (GBI), using the 10-item depression subscale|Change in PGA score|Change in CGI-S score|Change in CGI-I score|Remission in the CGI-S score (defined as a CGI-S score of 1or 2), at each visit assessed|Response in the CGI-I score (defined as a CGI-I score of 1or 2)|Change in CGAS score|Change in PedsQL VAS score|Change in PQ-LES-Q score","H. Lundbeck A/S|Takeda","All","7 Years to 11 Years   (Child)","Phase 3","770","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12709A|2008-005353-38","May 19, 2016","March 31, 2022","April 30, 2022","March 16, 2016",,"July 9, 2021","Woodland International Research Group, Little Rock, Arkansas, United States|Sun Valley Research Center, Imperial, California, United States|Synergy Clinical Research Center, Lemon Grove, California, United States|Alliance for Wellness dba Alliance for Research, Long Beach, California, United States|NRC Research Institute, Orange, California, United States|Asclepes Research Center, Panorama City, California, United States|Children's National Medical Center Merge, Washington, District of Columbia, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|American Medical Research, Inc., Chicago, Illinois, United States|AMR Conventions Research, Naperville, Illinois, United States|AMR- Baber Research, Inc., Naperville, Illinois, United States|Kansas University School of Medicine-Wichita, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Manhattan Behavioral Medicine, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, LLC, Oklahoma City, Oklahoma, United States|Research Strategies Of Memphis, Llc, Memphis, Tennessee, United States|BioBehavioral Research of Austin, Austin, Texas, United States|AIM Trials, LLC, Plano, Texas, United States|Research Across America, Plano, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Westside Medical, Clinton, Utah, United States|Aspen Clinical Research, LLC, Orem, Utah, United States|MHAT Targovishte AD, Targovisthe, Bulgaria|Diagnostic Consultative Center Mladost-M Varna OOD, Varna, Bulgaria|Paediatric Sleep Research Inc., Toronto, Ontario, Canada|E.S.E. Hospital Mental de Antioquia HOMO, Bello, Antioquia, Colombia|Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS., Barranquilla, Atlantico, Colombia|Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS, Bogota, DC, Colombia|Psynapsis Salud Mental S.A., Pereira, Risaralda, Colombia|Marienthali Kliinik, Tallinn, Estonia|Cabinet Psyche, Douai, Nord, France|Centre Medical Ambroise Pare, Elancourt, France|CHU de Nantes - Hopital Hotel Dieu, Nantes Cedex 1, France|Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri, Mainz, Germany|Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri, Mainz, Germany|Vadaskert Alapitvany, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Shalvata Mental Health Center, Hod Hasharon, Israel|Ramat Chen - Mental Health Clinic, Tel Aviv, Israel|The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital, Tel Hashomer, Israel|Scientific Institute Fondazione Stella Maris, Calambrone Pisa, Pisa, Italy|Sciaf Ulss 16 Padova, Padova, Regione Veneto, Italy|University Federico II Of Naples, Napoli, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Linda Keruze's Psychiatric Center, LLC, Liepaja, Latvia|Children Hospilal -Gailezers, Riga, Latvia|Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics), Ciudad de Mexico, Distrito Federal, Mexico|Centro Investigacion Medico Biologica Y Terapia Avanzada, Guadalajara, Jalisco, Mexico|Clinica Cemelli, Guadalajara, Jalisco, Mexico|Roberto Zepeda Sanchez, Guadalajara, Jalisco, Mexico|CRI Centro Regiomontano de Investigacion SC, Monterrey, Nuevo Leon, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C, Culiacan De Rosales, Sinaloa, Mexico|B & B Investigaciones Medicas, SC, Mazatlan, Sinaloa, Mexico|ICARO Investigaciones en Medicina S.A. de C.V., Chihuahua, Mexico|BIND Investigaciones S.C, San Luis Potosi, Mexico|Prywatne Gabinety Lekarskie Promedicus, Bialystok, Podlaskie, Poland|Centrum Badan Klinicznych PI-House Sp. z o.o., Gdansk, Poland|Przychodnia Syntonia Poradnia Zdrowia Psychicznego, Kielce, Poland|Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny, Lublin, Poland|Filip Rybakowski Specjalistyczna Praktyka Lekarska, Poznan, Poland|Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu, Walbrzych, Poland|Medicorehabilitation Research Center Phoenix, Rostov-On-Don, Rostov State, Russian Federation|Stavropol Region Psychiatric Hospital #2, Stavropol, Stavropol Region, Russian Federation|Arkhangelsk Regional Clinical Mental Hospital, Arkhangelsk, Russian Federation|State Budgetary Healthcare Institution of Sverdlovsk Region Â¿Sverdlovsk Regional Clinical Psychi..., Ekaterinburg, Russian Federation|GUZ Engels Psychiatric Hospital, Engels, Russian Federation|State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ..., Krasnodar, Russian Federation|LLC City Neurological Center Sibneuromed, Novosibirsk, Russian Federation|Rostov State Medical University of the Minzdravsotsrazvitiya of Russia, Rostov-on-Don, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Guz Saratov Regional Psychiatric Hospital St. Sofii, Saratov, Russian Federation|City Psychiatric Hospital # 3 named after I.I. Skvortsov-Stepanov, St-Petersburg, Russian Federation|Nebbiolo LLC, Tomsk, Russian Federation|Yaroslavl Regional Clinical Psychiatry Hospital, Yaroslavl, Russian Federation|Child and Adolescent Neurology and Psychiatry Clinic, Belgrade, Serbia|Institute of Mental Health, Belgrade, Serbia|University Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center of Vojvodina - Clinic of Psychiatry, Novi Sad, Serbia|Daily Hospital for Children and Adolescents, Pantelej-Nis, Serbia|Cape Trial Centre, Bellville, Cape Town, South Africa|Tara Hospital, Sandhurst, Gauteng, South Africa|Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Spain|Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo, Torremolinos, Malaga, Spain|Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro..., Kyiv, Ukraine|Odessa Regional Medical Centre of Mental Health, Odessa, Ukraine|Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U..., Poltava, Ukraine|Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers..., Ternopil, Ukraine",,"https://ClinicalTrials.gov/show/NCT02709655"
1197,"NCT02709746","Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)",,"Completed","Has Results","Depressive Disorder, Major","Drug: Vortioxetine 10 mg/day|Drug: Vortioxetine 20 mg/day|Drug: Fluoxetine 20 mg/day|Other: Placebo","Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment|Change in CDRS-R Total Score During Treatment (at Week 2)|Change in CDRS-R Total Score During Treatment (at Week 4)|Change in CDRS-R Total Score During Treatment (at Week 6)|Change in CDRS-R Mood Score|Change in CDRS-R Somatic Score|Change in CDRS-R Subjective Score|Change in CDRS-R Behaviour Score|CDRS-R Response|CDRS-R Remission|Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents|Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child|Parent Global Assessment-Global Improvement (PGA) Score|Change in Symbol Digit Modalities Test (SDMT)|Change in Clinical Global Impression Severity of Illness (CGI-S) Score|Clinical Global Impression - Global Improvement (CGI-I) Score|CGI-S Remission|Change in Children's Global Assessment Scale (CGAS) Score|Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score|Change in PedsQL VAS: Sad or Blue (Sadness) Score|Change in PedsQL VAS: Angry Score|Change in PedsQL VAS: Worry Score|Change in PedsQL VAS: Tired (Fatigue) Score|Change in PedsQL VAS: Pain or Hurt Score|Change in PedsQL VAS Total Average Score|Change in PedsQL Emotional Distress Summary Average Score|Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores|Change in PQ-LES-Q Overall Score","H. Lundbeck A/S|Takeda","All","12 Years to 17 Years   (Child)","Phase 3","784","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12710A|2008-005354-20","May 2016","July 2, 2019","July 30, 2019","March 16, 2016","August 19, 2020","August 19, 2020","US1369, Dothan, Alabama, United States|US1333, Tucson, Arizona, United States|US1310, Little Rock, Arkansas, United States|US1062, Costa Mesa, California, United States|US1387, Downey, California, United States|US1114, Escondido, California, United States|US1118, Glendale, California, United States|US1123, Imperial, California, United States|US1160 Renew Behavioral Health, Inc., Long Beach, California, United States|US1368, Orange, California, United States|US1370, Panorama City, California, United States|US1351, Wildomar, California, United States|US1133, Washington, District of Columbia, United States|US1217, Gainesville, Florida, United States|US1229, Orange City, Florida, United States|US1009, Atlanta, Georgia, United States|US1313, Marietta, Georgia, United States|US1311, Naperville, Illinois, United States|US1315, Naperville, Illinois, United States|US1103, Oak Brook, Illinois, United States|US1386, Wichita, Kansas, United States|US1261, Lake Charles, Louisiana, United States|US1015, Baltimore, Maryland, United States|US1385 Ericksen Research And Development, Clinton, Mississippi, United States|US1064, Creve Coeur, Missouri, United States|US1314, O'Fallon, Missouri, United States|US1266, Saint Charles, Missouri, United States|US1312, Berlin, New Jersey, United States|US1222, Princeton, New Jersey, United States|US1317, New York, New York, United States|US1171, Rochester, New York, United States|US1190, Staten Island, New York, United States|US1051, Cincinnati, Ohio, United States|US1054, Cleveland, Ohio, United States|US1334, Middleburg Heights, Ohio, United States|US1323, Oklahoma City, Oklahoma, United States|US1329, Oklahoma City, Oklahoma, United States|US1328, Austin, Texas, United States|US1320, Plano, Texas, United States|US1162, San Antonio, Texas, United States|US1308, Orem, Utah, United States|US1309, Richmond, Virginia, United States|BG1023, Targovishte, Bulgaria|BG1025, Varna, Bulgaria|CA1036 University of Calgary, Calgary, Canada|CA1038, Toronto, Canada|CO1003, Barranquilla, Colombia|CO1001, Bello, Colombia|CO1004, Bogotá, Colombia|CO1002, Pereira, Colombia|EE1007, Tallinn, Estonia|EE1015, Viljandi, Estonia|FR1041, Douai, France|FR1017, Elancourt, France|FR1009, Nantes, France|DE1078, Freiburg, Germany|DE1034, Mainz, Germany|DE1077, Mannheim, Germany|DE1081, Maulbronn, Germany|DE1076, Tübingen, Germany|HU1023, Budapest, Hungary|HU1020, Gyula, Hungary|IT1075, Cagliari, Italy|IT1073, Genova, Italy|IT1029, Messina, Italy|IT1068, Napoli, Italy|IT1074, Padova, Italy|IT1070, Pisa, Italy|IT1072 Osppedale Bambin gesu, Rome, Italy|KR1035, Cheonan, Korea, Republic of|UA1037, Gyeongsang, Korea, Republic of|KR1032, Seoul, Korea, Republic of|KR1038, Seoul, Korea, Republic of|LV1002, Jelgava, Latvia|LV1008, Liepaja, Latvia|LV1009, Riga, Latvia|LV1007, Sigulda, Latvia|MX1003, Ciudad de mexico, Mexico|MX1014, Culiacán, Mexico|MX1011, Guadalajara, Mexico|MX1013, Guadalajara, Mexico|MX1022, Guadalajara, Mexico|MX1023, Mazatlán, Mexico|MX1001, Nuevo León, Mexico|PL1002, Bialystok, Poland|PL1050, Gdansk, Poland|PL1068, Kielce, Poland|PL1057, Lublin, Poland|PL1052, Poznan, Poland|PL1051, Wroclaw, Poland|PL1054, Wąbrzeźno, Poland|RU1009, Arkhangel'sk, Russian Federation|RU1016, Ekaterinburg, Russian Federation|RU1059, Engel's, Russian Federation|RU1046, Krasnodar, Russian Federation|RU1011, Lipetsk, Russian Federation|RU1004, Nizhniy Novgorod, Russian Federation|RU1010, Novosibirsk, Russian Federation|RU1012, Rostov on Don, Russian Federation|RU1044, Rostov-na-Donu, Russian Federation|RU1013, Saratov, Russian Federation|RU1038, Saratov, Russian Federation|RU1030, St.Petersburg, Russian Federation|RU1057, Tomsk, Russian Federation|RU1048, Tonnel'nyy, Russian Federation|RS1006 Clinic of Neurology and Psychiatry for Children and Adolescents, Belgrade, Serbia|RS1010, Belgrad, Serbia|RS1011, Kragujevac, Serbia|RS1003, Niš, Serbia|RS1007, Novi Sad, Serbia|ZA1019, Cape Town, South Africa|ZA1022, Randburg, South Africa|ZA1023, Sandton, South Africa|ES1041, Alcorcon, Spain|ES1044, Madrid, Spain|ES1043, Pamplona, Spain|ES1018 Hospital de Sabadell, Sabadell, Spain|ES1040, Torremolinos, Spain|UA1002, Kyiv, Ukraine|UA1019, Odessa, Ukraine|UA1001, Poltava, Ukraine|UA1004, Ternopil', Ukraine|GB1051, Glasgow, United Kingdom|GB1047, Liverpool, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02709746/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02709746/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02709746"
1198,"NCT04805879","The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder",,"Recruiting","No Results Available","Depression|Treatment Resistant Depression","Biological: FMT oral Capsules|Biological: Placebo Capsules","Change in the MADRS total score|Side effects as reported on the Toronto Side Effect Scale (TSES)|GI tolerability of patients with Irritable Bowel Syndrome (IBS)","University of Calgary|Cumming school of medicine|The W. Garfield Westin Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","REB#19-0016","March 4, 2021","March 4, 2023","March 4, 2024","March 18, 2021",,"March 18, 2021","Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04805879"
1199,"NCT01399671","Study of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in Major Depression",,"Completed","No Results Available","Depression|Major Depression|Vestibular Disorders","Other: vestibular stimulation","Hamilton depression rating score","Fuerza Aérea de Chile|Pontificia Universidad Catolica de Chile","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","SA10I220044","March 2011","January 2012","January 2012","July 22, 2011",,"March 5, 2012","Centro de Medicina Aeroespacial, Santiago, Región Metropolitana, Chile",,"https://ClinicalTrials.gov/show/NCT01399671"
1200,"NCT01153867","Schema Focused Therapy for Chronic Depression",,"Completed","No Results Available","Chronic Major Depressive Disorder","Behavioral: Schema Focused Therapy","Depressive symptom improvement|Depressive relapse/recurrence","Maastricht University Medical Center|Academic Community Mental Health Centre (RIAGG)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEC 10-3-048","January 2011","January 2016","January 2016","June 30, 2010",,"March 16, 2016","Academic Community Mental Health Center, Riagg, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT01153867"
1201,"NCT03014544","Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major","Device: Computer- administered test battery|Device: Examiner- administered test battery","Performance Score on a Cognitive Test Battery Evaluated by Symbol Sorting Test (SST)|Performance Score on a Cognitive Test Battery Evaluated by Digit Span Forward Test (DSFT)|Performance Score on a Cognitive Test Battery Evaluated by Digit Span Backward Test (DSBT)|Performance Score on a Cognitive Test Battery Evaluated by Word List Recall Test (WLRT)|Performance Score on a Cognitive Test Battery Evaluated by Visuospatial Block Recall Test (VBRT)|Performance Score on a Cognitive Test Battery Evaluated by Symbol Digit Matching Test (SDMaT)|Performance Score on a Cognitive Test Battery Evaluated by Trail Making Test Form B (TMT-B)|Performance Score on a Cognitive Test Battery Evaluated by Block Maze Test (BMT)|Performance Score on a Cognitive Test Battery Evaluated by Rey Auditory Verbal Learning Test (RAVLT)|Performance Score on a Cognitive Test Battery Evaluated by Brief Visuospatial Memory Test-Revised (BVMT-R)|Performance Score on a Cognitive Test Battery Evaluated by Symbol Digit Modalities Test (SDMT)|Performance Score on a Cognitive Test Battery Evaluated by Neuropsychological Assessment Battery - Maze Test (NAB-MT)|Performance Score on a Cognitive Test Battery Evaluated by Wisconsin Card Sorting Test (WCST)","Janssen Research & Development, LLC","All","18 Years to 59 Years   (Adult)",,"585","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR108211|NOPRODMDD0003","October 26, 2016","April 8, 2019","April 8, 2019","January 9, 2017",,"June 25, 2019","Birmingham, Alabama, United States|Anaheim, California, United States|Beverly Hills, California, United States|Glendale, California, United States|Long Beach, California, United States|Temecula, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Jacksonville, Florida, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Saint Charles, Missouri, United States|Lincoln, Nebraska, United States|Buffalo, New York, United States|Mount Kisco, New York, United States|New York, New York, United States|Allentown, Pennsylvania, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03014544"
1202,"NCT02919579","A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder","DriveSaFe2","Completed","No Results Available","Depressive Disorder, Major","Drug: Placebo (Intranasal)|Drug: Esketamine|Other: Alcohol|Drug: Placebo (Oral)","The Effect of a Single 84-Milligram (mg) Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance|The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance|Effect on Subjective Driving Ability Scale|Karolinska Sleepiness Scale (KSS) Score|Efficacy Measured by the Montgomery Asberg Depression Rating Scale (MADRS)|Effects on Suicidal Ideation/Behavior Measured by the Columbia Suicide Severity Rating Scale (C-SSRS)|Effects on Dissociative Symptoms Using the Clinician-Administered Dissociative State Scale (CADSS)|Potential Relationship Between Changes in SDLP and the Plasma Concentration of Esketamine and Noresketamine|Effect on Subjective Mental Effort Scale|Potential Relationship Between Changes in Mean Lateral Position (MLP) and the Plasma Concentration of Esketamine and Noresketamine|Potential Relationship Between Changes in Mean Speed and the Plasma Concentration of Esketamine and Noresketamine","Janssen Research & Development, LLC","All","22 Years to 60 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR108228|2016-002424-86|54135419TRD1019","October 7, 2016","June 29, 2018","June 29, 2018","September 29, 2016",,"April 24, 2019","Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02919579"
1203,"NCT01155661","A Safety Study in Participants With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684 (edivoxetine)|Drug: SSRI","The Number of Participants Experiencing Clinically Significant Effects|Percent of Participants With Suicidal Ideation and Behavior Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Baseline to 54 Week Endpoint in the Arizona Sexual Experiences (ASEX) Scale|Change From Baseline to 54 Week Endpoint in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|Change From Baseline to 54 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Items|Change From Baseline to 54 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score|Change From Baseline to 54 Week Endpoint in Clinical Global Impression - Severity (CGI-S)|Change From Baseline to 54 Week Endpoint in Fatigue Associated With Depression (FAsD) Average Score and Subscale Scores|Probability of Meeting the Response Criteria for Depressive Symptoms at Week 54 Endpoint|Probability of Meeting the Remission Criteria for Depressive Symptoms at Week 54 Endpoint|Percentage of Participants Who Meet Response Criteria of Depressive Symptoms by Week 8|Change From Baseline to 54 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score|Change From Baseline to 54 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores|Change From Baseline to 54 Week Endpoint in EuroQol Questionnaire - 5 Dimension (EQ-5D)|Change From Baseline to 54 Week Endpoint in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)|Percentage of Participants Who Reported Resource Utilization (RU) at Baseline and at the Week 54 Endpoint|Percentage of Participants With Discontinuation-Emergent Adverse Events (DEAEs)|Percentage of Participants Who Meet Remission Criteria of Depressive Symptoms by Week 8|Plasma Concentration of LY2216684|The Number of Participants Experiencing Clinically Significant Effects as a Function of CYP2D6 Predicted Phenotype at Week 54 Endpoint|Change From Baseline to 54 Week Endpoint in Blood Pressure|Change From Baseline to Week 54 Endpoint in Pulse Rate","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","608","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11318|H9P-MC-LNBO","October 2010","December 2012","December 2012","July 2, 2010","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cerritos, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Alamitos, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redlands, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riverside, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Upland, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Walton Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Princeton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Kisco, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aparecida De Goiania, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belo Horizonte, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Botucatu, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pelotas, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ribeirão Preto, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antofagasta, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaunas, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Klaipeda, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mazatlan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villahermosa, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zapopan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heerde, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wildervank, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcala De Henares, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zamora, Spain",,"https://ClinicalTrials.gov/show/NCT01155661"
1204,"NCT02466477","Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major|Depression|Depressive Disorder","Genetic: GeneSight Psychotropic (GEN)|Genetic: Enhanced-GeneSight Psychotropic (E-GEN)|Other: Treatment as Usual (TAU)","Change in depressive symptoms as assessed by the 17-item Hamilton Depression (HAM-D17) score|Change in depressive symptoms as assessed by the 16-Item Clinician Quick Inventory of Depressive Symptomatology (QIDS-SR16)|Change in depressive symptoms as assessed by the 9-Item Patient Health Questionnaire (PHQ-9)|Change in anxiety symptoms as assessed by theGeneralized Anxiety Disorder 7-Item (GAD-7) Scale|Change in severity of illness as assessed by the Clinical Global Impression of Severity (CGI-S)|Change in global improvement as assessed by the Clinical Global Impression of Improvement (CGI-I)|Change in global therapeutic benefit and global severity of side effects as assessed by the Clinical Global Impression Efficacy Index|Changes to initial prescribing based on availability of pharmacogenomic data|Response rates to psychotropic medication|Remission rates|Time to response|Time to remission|Change in psychotropic medication side effects as assessed by the Udvalg for Kliniske Undersogeler (UKU) Side Effect Rating Scale|Change in global measure of side effects (frequency, intensity, and burden domains) as assessed by the Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)|Weight gain|Waist-to-hip ratio|Change in health related quality of life as assessed by the EuroQol (EQ-5D-5L)|Change in health related quality of life as assessed by the Short Form (36) Health Survey (SF-36)|Pharmacogenetics in Psychiatry Follow-up Questionnaire (PIPFQ)|Healthcare resource utilization (Composite measure of healthcare costs): physician visits, hospital utilization, emergency department visits, medication use, and laboratory tests|Productivity losses (measured as economic costs)","Assurex Health Inc.|Programs for Assessment of Technology in Health Research Institute|Centre for Addiction and Mental Health|Genome Canada|Assurex Health Ltd.|Mars Excellence in Clinical Innovation and Technology Evaluation","All","18 Years and older   (Adult, Older Adult)","Phase 4","542","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","EXCITE-013304-ARX1009.PTL","June 2015","November 2018","September 2019","June 9, 2015",,"April 30, 2020","Chatham-Kent Clinical Trials Research Center, Chatham, Ontario, Canada|Hamilton Community Health Centre Family Health Organization, Hamilton, Ontario, Canada|Hamilton Medical Research Group, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada|Milestone Research, London, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Parkwood Institute, London, London, Ontario, Canada|Hopital Montfort, Ottawa, Ontario, Canada|Thornhill Medical Centre, Thornhill, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02466477/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02466477/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02466477"
1205,"NCT00733980","A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: GSK561679|Other: Placebo","Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for Depression (HamD17).|Change From Randomization to Weeks 1, 2, and 4 in the Bech Melancholia Scale Score.|Change From Randomization to Weeks 1, 2, 4, and 6 in the Hamilton Anxiety Scale (HAM A)|Change From Randomization to Weeks 1, 2, 3, 4, and 6 in the Inventory of Depressive Symptomatology-Self- Report (IDS-SR) Total Score.|Change From Randomization to Weeks 1, 2, 4, and 6 in the Hamilton Rating Scale for Depression (HAMD-17)|Percentage HAMD-17 Responders at Weeks 1, 2, 4, and 6.|Time to Maintained Antidepressant Response at the End of Treatment Phase (Week 6)|Change From Randomization in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 4, and 6.|Percentage of Clinical Global Impression - Global Improvement (CGI-I) Responders at Weeks 1, 2, 4, and 6.|Change From Randomization in the Medical Outcomes Study 12-item Sleep Module (MOS 12) at Week 6|Change From Randomization in the Cohen Perceived Stress Scale (PSS) at Week 6.|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Vital Sign of Potential Clinical Importance (PCI)|Number of Participants With Abnormal Urinalysis Data|Number of Participants With Abnormal Electrocardiograph (ECG) Values|Number of Participants With Abnormal Hematology Values of PCI-Platelet|Number of Participants With Clinical Chemistry Laboratory Data Outside Reference Range|Number of Participants With Hormonal Data of PCI|Discontinuation-Emergent Signs and Symptoms","GlaxoSmithKline","Female","18 Years to 64 Years   (Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","106139","October 2, 2008","June 18, 2010","June 18, 2010","August 13, 2008","November 17, 2017","November 17, 2017","GSK Investigational Site, Cerritos, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Skokie, Illinois, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Brown Deer, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00733980"
1206,"NCT04532749","A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Seltorexant|Drug: Placebo","Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 43|Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score to Day 43|Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score to Day 43|Change from Baseline in the MADRS-6 Total Score to Day 43|Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to Day 43|Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score to Day 43","Janssen Research & Development, LLC","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 3","386","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108805|42847922MDD3002|2020-000338-16","September 15, 2020","January 6, 2023","January 25, 2023","August 31, 2020",,"July 23, 2021","Altea Research Institute, Phoenix, Arizona, United States|Preferred Research Partners, Little Rock, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Sun Valley Research Center, Imperial, California, United States|Alliance for Research, Long Beach, California, United States|Excell Research Inc, Oceanside, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Pharmax Research Clinic Inc, Miami, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Harmony Clinical Research Inc, North Miami Beach, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Synexus Research Orlando, Orlando, Florida, United States|Stedman Medical Trials, Tampa, Florida, United States|Compass Research LLC-Bioclinica Research, The Villages, Florida, United States|Synexus Clinical Research US, Inc, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Uptown Research Institute, LLC, Chicago, Illinois, United States|Phoenix Medical Research, Inc., Prairie Village, Kansas, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Michigan Clinical Research Institute, Ann Arbor, Michigan, United States|Eastside Comprehensive Medical Services, New York, New York, United States|Community Research Management Associates, Inc., Cincinnati, Ohio, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|Intend Research, Norman, Oklahoma, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|InSite Clinical Research, LLC, DeSoto, Texas, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States|Clínica Privada Banfield S.A, Banfield, Argentina|NOVAIN Neurociencias Group, Ciudad Autonoma de Buenos Aires, Argentina|Fundación para el Estudio y Tratamiento de las Enfermedades Mentales, Ciudad Autonoma de Buenos Aires, Argentina|CEN-Consultorios Especializados en Neurociencias, Cordoba, Argentina|Instituto Médico DAMIC, Cordoba, Argentina|Sanatorio Prof. Leon S. Morra, Cordoba, Argentina|INSA Instituto de Neurociencias San Agustín, La Plata, Argentina|C.I.A.P. (Centro de investigación y Asistencia en Psiquiatría), Rosario, Argentina|Clinica Mayo de UMCB, San Miguel de Tucuman, Argentina|Psicomed Estudios Medicos, Antofagasta, Chile|BioMedica Research Group, Santiago, Chile|CeCim - Centro de Estudios Clinicos e Investigacion Medica, Santiago, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Psykiatriskt Center Glostrup, Glostrup, Denmark|Psykiatrisk Center Nordsjaelland, Hillerod, Denmark|Psykiatriskt Center Kopenhavn, Kobenhavn, Denmark|Ålborg Universitetshospital, Ålborg, Denmark|Eira Hospital, Helsinki, Finland|Mederon LTD at ARTES, Helsinki, Finland|Savon Psykiatripalvelu, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Satakunnan Psykiatripalvelu, Rauma, Finland|Korea University Ansan Hospital, Ansan-si, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Eulji General Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Sunway Medical Centre, Bandar Sunway, Malaysia|Hospital Kuala Lumpur, Jalan Pahang, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Sibu, Sibu, Malaysia|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Synexus Polska Sp. z o.o. Oddzial w Czestochowie, Czestochowa, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS, Leszno, Poland|Synexus Polska Sp. z o.o., Lodz, Poland|Centrum Medyczne Luxmed Sp z o o, Lublin, Poland|Psychiatricka Ambulancia Mentum S.R.O., Bratislava, Slovakia|Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O., Svidník, Slovakia|Crystal Comfort s.r.o., Vranov nad Toplou, Slovakia|BONA MEDIC, s.r.o., Zlate Moravce, Slovakia|Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3', Kharkiv, Ukraine|CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council, Kherson,Vil. Stepanivka, Ukraine|Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa), Kyiv, Ukraine|Main Military Clinical Hospital of MDU, Kyiv, Ukraine|Kyiv Clinical Railway Hospital #2 of the Branch Health Care Center of the PJSC Ukrainian Railway, Kyiv, Ukraine|CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital', Lviv, Ukraine|CI Odesa Regional Medical Center of Mental Health, Odesa, Ukraine|CNCE Odesa regional psychiatric hospital #2 Odesa regional council, Oleksandrivka, Ukraine|Poltava O.F. Maltsev RC Psychiatric Hospital Dept #9 (Ad-P Dept) HSEIU Ukrainian MSA, Poltava, Ukraine|CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council', Smila, Ukraine|CI O.I. Yuschenko VRPsH Depts #7 & #10 M.I. Pyrogov VNMU, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT04532749"
1207,"NCT01145313","Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major",,"Pre/post-augmentation healthcare costs and resource utilization among patients diagnosed with MDD who augment antidepressant therapy with an atypical antipsychotic.|A secondary post-hoc analysis may be conducted to determine differences in outcomes among patients during a longer treatment period, ie 6 month pre- and 6 month post-augmentation.","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 64 Years   (Adult)",,"501","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CN138-582","October 2007","June 2010","June 2010","June 16, 2010",,"November 8, 2013",,,"https://ClinicalTrials.gov/show/NCT01145313"
1208,"NCT03436823","Does Nurse Semi Structured Interview Added to a rTMS Improve Patients With Major Depressive Disorder?","DESTIMCARE","Recruiting","No Results Available","Depressive Disorder, Major","Other: nurse semi-structured interview|Other: Music & Relaxation with eyes closed","score of the Montgomery-Asberg Depression Rating Scale","Rennes University Hospital|Ministry of Health, France","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","35RC14_9783_DESTIMCARE","March 19, 2018","December 31, 2023","December 31, 2023","February 19, 2018",,"April 28, 2021","CHGR, Rennes, France",,"https://ClinicalTrials.gov/show/NCT03436823"
1209,"NCT04761757","Antidepressant Decision Aid for Major Depressive Disorder Patients","ADAM","Completed","No Results Available","Depression|Depressive Symptoms|Depressive Disorder, Major|Mood Disorders","Other: Booklet of Scripts of Doctors|Other: Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)","Shared Decision Making_Patient Perspective|Shared Decision Making_Physician Perspective|Preparation for Decision Making_Patient Perspective|Preparation for Decision Making_Physician Perspective","University of Malaya|Ministry of Education, Malaysia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","752","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","ADAM","December 1, 2019","October 30, 2020","October 30, 2020","February 21, 2021",,"February 21, 2021","Hospital Permai, Johor Bahru, Johor, Malaysia|Sultanah Aminah Hospital, Johor Bahru, Johor, Malaysia|Columbia Asia Hospital, Nusajaya, Johor, Malaysia|KPJ Ampang Puteri Specialist Hospital, Ampang, Kuala Lumpur, Malaysia|Dr Seed Specialist Clinic, Kepong, Kuala Lumpur, Malaysia|Hospital Pengajar Universiti Putra Malaysia, Serdang, Kuala Lumpur, Malaysia|Hospital Sultan Haji Ahmad Shah, Temerloh, Pahang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Pulau Pinang, George Town, Pulau Pinang, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia|A. H. Lee Specialist Clinic, Petaling Jaya, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Hospital Pusrawi, Kuala Lumpur, Malaysia|Klinik Pakar Dr Yeoh & Dr Hazli Mental Health Specialist, Kuala Lumpur, Malaysia|Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia|University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Putrajaya, Putrajaya, Malaysia",,"https://ClinicalTrials.gov/show/NCT04761757"
1210,"NCT01870843","A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom",,"Completed","Has Results","Depressive Disorder, Major","Drug: Escitalopram","Change in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF) From Baseline up to Day 56|Change in Sheehan Disability Scale (SDS) From Baseline up to Day 56|Remission Rate Based on Montgomery-Asberg Depression Rating Scale (MADRS) up to Day 56|Treatment Improvement Rate at the End of Week 1 and Week 2|Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores From Baseline up to Day 56|Change in Hamilton Anxiety Scale (HAM-A) Total Scores From Baseline up to Day 56|Change in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Total Scores From Baseline up to Day 56|Depression Response Rate Based on Montgomery-Asberg Depression Rating Scale (MADRS) up to Day 56|Remission Rate Based on Hamilton Anxiety Scale (HAM-A) up to Day 56|Remission Rate Based on Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) up to Day 56","Xian-Janssen Pharmaceutical Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","261","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100826|ESCITALDEP4005|ESC-C-11-CN-002-V04","March 2014","May 2015","May 2015","June 6, 2013","July 11, 2016","July 11, 2016","Beijing, China|Guangzhou, China|Hangzhou, China|Hohhot, China|Jinan, China|Kunming, China|Nanjing, China|Shijiazhuang, China|Urumqi, China|Xiamen, China",,"https://ClinicalTrials.gov/show/NCT01870843"
1211,"NCT04039022","Open-Label Safety Study of AXS-05 in Subjects With Depression",,"Completed","No Results Available","Major Depressive Disorder|Treatment Resistant Depression|Depression","Drug: AXS-05","Types and rates of adverse events","Axsome Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","876","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AXS-05-303","July 8, 2019","October 23, 2020","October 23, 2020","July 31, 2019",,"December 17, 2020","Clinical Research Site, Phoenix, Arizona, United States|Clinical Research Site, Little Rock, Arkansas, United States|Clinical Research Site, Bellflower, California, United States|Clinical Research Site, Beverly Hills, California, United States|Clinical Research Site, Culver City, California, United States|Clinical Research Site, Garden Grove, California, United States|Clinical Research Site, Oakland, California, United States|Clinical Research Site, Oceanside, California, United States|Clinical Research Site, Panorama City, California, United States|Clinical Research Site, Redlands, California, United States|Clinical Research Site, San Diego, California, United States|Clinical Research Site, Sherman Oaks, California, United States|Clinical Research Site, Upland, California, United States|Clinical Research Site, Cromwell, Connecticut, United States|Clinical Research Site, Coral Springs, Florida, United States|Clinical Research Site, Hialeah, Florida, United States|Clinical Research Site, Hollywood, Florida, United States|Clinical Research Site, Jacksonville, Florida, United States|Clinical Research Site, Lauderhill, Florida, United States|Clinical Research Site, Miami, Florida, United States|Clinical Research Site, North Miami, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Atlanta, Georgia, United States|Clinical Research Site, Atlanta, Georgia, United States|Clinical Research Site, Boise, Idaho, United States|Clinical Research Site, Chicago, Illinois, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, Las Vegas, Nevada, United States|Clinical Research Site, Berlin, New Jersey, United States|Clinical Research Site, Cherry Hill, New Jersey, United States|Clinical Research Site, Toms River, New Jersey, United States|Clinical Research Site, Jamaica, New York, United States|Clinical Research Site, Rochester, New York, United States|Clinical Research Site, Staten Island, New York, United States|Clinical Research Site, Hickory, North Carolina, United States|Clinical Research Site, Raleigh, North Carolina, United States|Clinical Research Site, Cincinnati, Ohio, United States|Clinical Research Site, Cincinnati, Ohio, United States|Clinical Research Site, Middleburg Heights, Ohio, United States|Clinical Research Site, Oklahoma City, Oklahoma, United States|Clinical Research Site, Media, Pennsylvania, United States|Clinical Research Site, Philadelphia, Pennsylvania, United States|Clinical Research Site, Memphis, Tennessee, United States|Clinical Research Site, Austin, Texas, United States|Clinical Research Site, Dallas, Texas, United States|Clinical Research Site, Fort Worth, Texas, United States|Clinical Research Site, Houston, Texas, United States|Clinical Research Site, San Antonio, Texas, United States|Clinical Research Site, Wichita Falls, Texas, United States|Clinical Research Site, Bellevue, Washington, United States|Clinical Research Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04039022"
1212,"NCT02919501","Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Vortioxetine (IV)|Other: Placebo (IV)|Drug: Vortioxetine (tablet)","Change from baseline to Week 1 in MADRS total score|Change from baseline to Week 2 in MADRS total score|Change from baseline to Day 3 in MADRS total score|Change from baseline to Day 1 in MADRS total score|Response (defined as a ≥ 50% decrease in MADRS total score from baseline) at Week 1|Remission at Week 1 (defined as a MADRS total score ≤ 10)|Change from baseline to Week 1 in HADS depression subscale|Global clinical impression -Global Improvement|Change from baseline in Global clinical impression -Severity|Oral clearance (CL/F)|Average Plasma Concentration (Cav)|Change from baseline to Week 1 in HADS anxiety subscale","H. Lundbeck A/S|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16903A|2015-005081-30","September 27, 2016","April 27, 2017","April 27, 2017","September 29, 2016",,"June 20, 2018","EE1019, Tallinn, Estonia|EE1020, Tallinn, Estonia|FI1040, Helsinki, Finland|FI1041, Helsinki, Finland|FI1030, Kuopio, Finland|FI1009, Pori, Finland|FI1027, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT02919501"
1213,"NCT01168674","Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder",,"Completed","Has Results","Depression|Bipolar Disorder","Drug: ziprasidone|Drug: Sugar pill","MADRS Improvement Over 6 Weeks|Predictors of Bipolarity to Define the Study Population","Tufts Medical Center|Duke University|University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","49","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","9238","February 2010","December 2011","December 2011","July 23, 2010","February 13, 2017","February 24, 2017",,,"https://ClinicalTrials.gov/show/NCT01168674"
1214,"NCT02288325","A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Levomilnacipran ER|Drug: Placebo","Time to First Relapse During the Double-Blind Treatment Period (DBTP)","Forest Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","644","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVM-MD-15","November 18, 2014","September 16, 2016","September 16, 2016","November 11, 2014","October 29, 2018","October 29, 2018","Forest Investigative Site 053, Birmingham, Alabama, United States|Forest Investigative Site 050, Dothan, Alabama, United States|Forest Investigative Site 039, Phoenix, Arizona, United States|Forest Investigative Site 048, Beverly Hills, California, United States|Forest Investigative Site 047, Chino, California, United States|Forest Investigative Site 028, Costa Mesa, California, United States|Forest Investigative Site 021, Encino, California, United States|Forest Investigative Site 052, Lemon Grove, California, United States|Forest Investigative Site 042, Oceanside, California, United States|Forest Investigative Site 016, Sherman Oaks, California, United States|Forest Investigative Site 037, Sherman Oaks, California, United States|Forest Investigative Site 043, Simi Valley, California, United States|Forest Investigative Site 040, Cromwell, Connecticut, United States|Forest Investigative Site 038, Norwich, Connecticut, United States|Forest Investigative Site 023, Bradenton, Florida, United States|Forest Investigative Site 018, Fort Myers, Florida, United States|Forest Investigative Site 008, Jacksonville Beach, Florida, United States|Forest Investigative Site 001, Jacksonville, Florida, United States|Forest Investigative Site 057, Kissimmee, Florida, United States|Forest Investigative Site 009, Orlando, Florida, United States|Forest Investigative Site 045, West Palm Beach, Florida, United States|Forest Investigative Site 034, Alpharetta, Georgia, United States|Forest Investigative Site 049, Smyrna, Georgia, United States|Forest Investigative Site 019, Schaumburg, Illinois, United States|Forest Investigative Site 020, Methuen, Massachusetts, United States|Forest Investigative Site 051, Watertown, Massachusetts, United States|Forest Investigative Site 044, Cherry Hill, New Jersey, United States|Forest Investigative Site 031, Brooklyn, New York, United States|Forest Investigative Site 036, Cedarhurst, New York, United States|Forest Investigative Site 013, Mount Kisco, New York, United States|Forest Investigative Site 003, New York, New York, United States|Forest Investigative Site 005, New York, New York, United States|Forest Investigative Site 055, Rochester, New York, United States|Forest Investigative Site 058, Charlotte, North Carolina, United States|Forest Investigative Site 011, Dayton, Ohio, United States|Forest Investigative Site 035, Tulsa, Oklahoma, United States|Forest Investigative Site 046, Portland, Oregon, United States|Forest Investigative Site 041, Salem, Oregon, United States|Forest Investigative Site 012, Media, Pennsylvania, United States|Forest Investigative Site 030, Memphis, Tennessee, United States|Forest Investigative Site 033, Memphis, Tennessee, United States|Forest Investigative Site 054, Dallas, Texas, United States|Forest Investigative Site 059, Houston, Texas, United States|Forest Investigative Site 014, Murray, Utah, United States|Forest Investigative Site 010, Charlottesville, Virginia, United States|Forest Investigative Site 056, Roanoke, Virginia, United States|Forest Investigative Site 026, Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02288325"
1215,"NCT03881449","DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole","DIMES","Active, not recruiting","No Results Available","Schizophrenia|Major Depressive Disorder|Bi-Polar Disorder|Schizo Affective Disorder","Combination Product: ABILIFY MYCITE","Aripiprazole refills|Population Proportion of Days Covered (PDC)|Days in acute care settings","Durham VA Medical Center|Otsuka Pharmaceutical Development and Commercialization, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","46","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02188","April 4, 2019","January 2021","November 2021","March 19, 2019",,"June 18, 2020","Durham VA Medical Center, Durham, North Carolina, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03881449"
1216,"NCT01725048","Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer","NRR","Completed","No Results Available","Major Depressive Disorder|Neoplasms","Drug: Mirtazapine|Drug: Citalopram","Feasibility|Depression Score","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LCCC 1021","January 2011","May 2012","October 2013","November 12, 2012",,"March 13, 2017","University of North Carolina Hospital, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01725048"
1217,"NCT04513912","A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Seltorexant|Drug: Matching placebo to Seltorexant|Drug: Quetiapine XR|Drug: Matching placebo to Quetiapine XR","Percentage of Participants with Response (>=50 Percent improvement in MADRS total score from baseline) at Week 26|Change from baseline in Weight up to Week 26|Time to Study Drug Discontinuation for Potentially Treatment Related Reasons|Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change from Baseline in MADRS-6 Total Score|Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score|Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score|Percentage of Participants with Remission (MADRS Total Score less than or equal to (<=) 12) at Week 26|Percentage of Participants with a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26|Percentage of Participants with Weight Increase >=7 Percent from Baseline at Week 26","Janssen Research & Development, LLC","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108810|42847922MDD3005|2020-000341-14","September 15, 2020","December 26, 2022","March 31, 2023","August 14, 2020",,"July 27, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|SW Biomedical Research, LLC, Tucson, Arizona, United States|Proscience Research Group, Culver City, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative NeuroScience Network, Garden Grove, California, United States|Collaborative NeuroScience Network, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|NRC Research Institute, Orange, California, United States|CNRI-Los Angeles, LLC, Pico Rivera, California, United States|Prospective Research Innovations, Inc., Rancho Cucamonga, California, United States|Anderson Clinical Research, Redlands, California, United States|University of California at San Diego, San Diego, California, United States|National Research Institute, Santa Ana, California, United States|CMB Clinical Trials, Santee, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Moonshine Research Center, Inc, Doral, Florida, United States|Velocity Clinical Research, Hallandale Beach, Hallandale Beach, Florida, United States|Meridien Research, Lakeland, Florida, United States|Premier Clinical Research, Miami, Florida, United States|Miami Jewish Health System, Miami, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Synexus Research Orlando, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Compass Research LLC-Bioclinica Research, The Villages, Florida, United States|Synexus Clinical Research US, Inc, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Psych Atlanta, P.C., Marietta, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Alexian Brothers Health System, Lisle, Illinois, United States|Lemah Creek Clinical Research, Oakbrook Terrace, Illinois, United States|Heartland Research Associates, an AMR Company, Wichita, Kansas, United States|Ascension via Christi Research, Wichita, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Riverstar Research, New Orleans, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Boston Clinical Trials & Medical Research, Roslindale, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Rochester Center for Behavioral Medicine (RCBM), Rochester Hills, Michigan, United States|Bio Behavioral Health, Toms River, New Jersey, United States|The Medical Research Network, LLC, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Velocity Clinical Research, Inc., Durham, North Carolina, United States|University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neuro-Behavioral Clinical Research, North Canton, Ohio, United States|Paradigm Research Professionals, LLC, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States|Suburban Research Associates, Pine Hill, Pennsylvania, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Clinical NeuroScience Solutions, Inc, Memphis, Tennessee, United States|West Houston Clinical Research Service, Bellaire, Texas, United States|Future Search Trials of Dallas, Dallas, Texas, United States|North Texas Clinical Trials, Fort Worth, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Alpine Research Organization, Layton, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Cary J. Kohlenberg, MD, SC, dba, IPC Research., Waukesha, Wisconsin, United States|Hospital Fleni, Ciudad Autonoma Buenos Aires, Argentina|Hospital Italiano, Ciudad Autonoma de Buenos Aires, Argentina|FunDaMos, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Lennox, Cordoba, Argentina|Centro Medico Luquez, Cordoba, Argentina|CENPIA, La Plata, Argentina|Clinica Mayo de UMCB, San Miguel de Tucuman, Argentina|Clinica El Jardin, Santiago del Estero, Argentina|Albert Road Clinic, Melbourne, Australia|Neuro Trials Victoria, Noble Park, Australia|Medizinische Universität Innsbruck, Innsbruck, Austria|AZ Sint-Lucas, Brugge, Belgium|Clinique Psychiatrique des Frères Alexiens, Henri-Chapelle, Belgium|CHU de Liège, Liège, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|CHU UCL Namur - Site Godinne, Yvoir, Belgium|MC 'Hipokrat - N', EOOD, Plovdiv, Bulgaria|Mental Health Center - Rousse, Ruse, Bulgaria|Medical Center Intermedica, OOD, Sofia, Bulgaria|MC 'Synexus Sofia' EOOD, Sofia, Bulgaria|MC 'Synexus Sofia' EOOD, Stara Zagora, Bulgaria|State Psychiatric Hospital - Tzarev Brod, Tzarev Brod, Bulgaria|Diagnostic Consulting Center Mladost - M Varna, Varna, Bulgaria|Mental Health Center - Veliko Tarnovo EOOD, Veliko Tarnovo, Bulgaria|A.K. Munshi Medical Inc., Sydney, Nova Scotia, Canada|Recherches Neuro-Hippocampe Inc., Ottawa, Ontario, Canada|Canadian Phase Onward, Toronto, Ontario, Canada|Clinique Force Medic (GCP Trials), Montreal, Quebec, Canada|DIEX Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Psychiatricka ambulance Saint Anne s.r.o., Brno, Czechia|NeuropsychiatrieHK, s.r.o., Hradec Kralove, Czechia|AD71 s.r.o., Praha 10, Czechia|NeuropsychiatrieHK, s.r.o., Praha 6, Czechia|Institut Neuropsychiatricke pece, Praha 8, Czechia|Marienthali Kliinik, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|The Mental Hospital of Jelgava Ģintermuiža - Psychiatry, Jelgava, Latvia|L. Keruze Practice in Psychiatry, Liepaja, Latvia|Hospital of Rezekne, Outpatient Centre Of Psychiatry, Latvia|Riga Centre of Psychiatry and Narcology, Riga, Latvia|Kaunas Silainiu Outpatient Clinic, Public Institution, Kaunas, Lithuania|Neuromeda, JSC, Kaunas, Lithuania|Republic Kaunas Hospital, Kaunas, Lithuania|Romuvos Klinika, JSC, Kaunas, Lithuania|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Silutes Mental health and psychotherapy center, JSC, Silute, Lithuania|Zirmunai Mental Health Center, Public Institution, Vilnius, Lithuania|Antakalnis Psychiatric Consultation Centre, Public Institution, Vilnius, Lithuania|Vilnius Mental Health Center, Vilnius, Lithuania|Hospital Raja Permaisuri Bainun, Ipoh, Malaysia|Hospital Permai, Johor Bahru, Malaysia|Hospital Pulau Pinang, Pulau Pinang, Malaysia|Hospital Tuanku Jaafar, Seremban, Malaysia|Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski, Bialystok, Poland|Przychodnia Srodmiescie SP. z o.o., Bydgoszcz, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Bydgoszcz, Poland|Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, Poland|SPSK nr 7 SUM w Katowicach Gornoslaskie Centrum Medyczne im. Prof. Leszka Gieca, Katowice, Poland|Specjalistyczna Indywidualna Praktyka Lekarska, Lodz, Poland|CCBR - Lodz - PL, Lodz, Poland|Synexus Polska Sp. z.o.o. Oddzial w Poznaniu, Poznan, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o., Warszawa, Poland|Instytut Psychiatrii I Neurologii, Warszawa, Poland|Sverdlov Regional Psychiatric Clinical Hospital, Ekaterinburg, Russian Federation|Engels psychiatric hospital, Engels, Saratov Region, Russian Federation|Kemerovo Regional Clinical Psychiatric Hospital, Kemerovo, Russian Federation|GUZ Lipetsk Regional psychoneurological Hospital #1, Lipetsk Region, Russian Federation|JSC Scientific Centre of Personalized Medicine, Moscow, Russian Federation|FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia, Moscow, Russian Federation|Moscow Scientific Research Institute of Psychiatry, Moscow, Russian Federation|Clinical Psychiatry Hospital n.a. N.N. Solodovnikov, Omsk, Russian Federation|St-Petersburg Bekhterev Psychoneurological Research Institute, St. Petersburg, Russian Federation|St-Petersburg Bekhterev Psychoneurological Research Institute, St. Petersburg, Russian Federation|Klinika StoLet Ltd, Tomsk, Russian Federation|Bel Medic General Hospital, Belgrade, Serbia|General Hospital Euromedik, Belgrade, Serbia|Institute of Mental Health Serbia, Belgrade, Serbia|University Clinical Center of Serbia, Belgrade, Serbia|University Clinical Hospital Center Dr Dragisa Misovic- Dedi, Belgrade, Serbia|Special Neuropsychiatric Hospital Kovin, Kovin, Serbia|University Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|Specialized Hospital for Neuropsychiatric Diseases 'Sveti Vracevi', Novi Knezevac, Serbia|Psychomed-Svatosavsky, s.r.o., Banska Bystrica, Slovakia|Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach, Bojnice, Slovakia|Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu, Liptovsky Mikulas, Slovakia|Psychiatricka Ambulancia Psycholine S.R.O., Rimavska Sobota, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|FN Trencin, Trencin, Slovakia|Pro mente sana s.r.o., Trencin, Slovakia|Fakultna nemocnica Trnava, Trnava, Slovakia|Fakultna nemocnica s poliklinikou v Ziline, Zilina, Slovakia|MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association, Glevakha, Ukraine|Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3', Kharkiv, Ukraine|Kyiv Territorial Medical Incorporation 'Psychiatry', Kyiv, Ukraine|Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway', Kyiv, Ukraine|Medical Center Health and Happy, Kyiv, Ukraine|Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council', Nove, Kropyvnytskiy, Ukraine|Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU, Ternopil, Ukraine|Transcarpathian Regional Narcological Dispensary, Uzhgorod, Ukraine|Zaporizhzhia Regional Clinical Hospital, Zaporizhzhia, Ukraine|Kingsway Hospital, Derby, United Kingdom|Synexus, Greater Manchester, United Kingdom|Garden Valleys Resource Centre, Harrogate, United Kingdom|Kings College Hospital NHS Trust, London, United Kingdom|Barnes Hospital, London, United Kingdom|Cornwall Partnership Foundation Trust, Redruth, United Kingdom|Cherry Knowle Hospital, Sunderland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04513912"
1218,"NCT00446719","Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder",,"Completed","No Results Available","Depression","Drug: Rellidep","50% improvement on Hamilton Depression Rating Scale-17 at 8 weeks|Clinical Global Impression-Severity and Improvement|Montgomery Asberg Depression Rating Scale (MADRS) at 8 weeks|Medical Outcomes Study Short-Form 36 (SF-36)at 8 weeks|Beck Depression Inventory Scale (BDI) a t 8 weeks|Hamilton rating scale for Anxiety (HAM-A)at 8 weeks|UKU","Mount Sinai Hospital, Canada","All","18 Years to 64 Years   (Adult)","Phase 2|Phase 3","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSH 06-0307-A","August 2007","December 2008","December 2008","March 13, 2007",,"January 5, 2011","Mount Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00446719"
1219,"NCT02646449","Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial","YAAD-P","Completed","Has Results","Major Depressive Disorder|Alcohol Use Disorder","Drug: Mirtazapine|Drug: Placebo","Drinks Per Drinking Day|Level of Depressive Symptoms","University of Pittsburgh","All","18 Years to 30 Years   (Adult)","Phase 2","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R21AA022863-01A1","June 2015","December 2016","December 2016","January 5, 2016","April 27, 2017","April 27, 2017","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02646449"
1220,"NCT00551109","SA4503 8-Week Study in Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major","Drug: placebo|Drug: SA4503 Low|Drug: SA4503 High","Montgomery-Åsberg Depression Rating Scale (MADRS)","M's Science Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ME1-1|EudraCT number: 2007-002740-16","November 2007",,"September 2008","October 30, 2007",,"December 18, 2008","Helsinki, Finland|Jyväskylä, Finland|Kuopio, Finland|Tampere, Finland|Turku, Finland",,"https://ClinicalTrials.gov/show/NCT00551109"
1221,"NCT01564862","Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: vortioxetine (Lu AA21004)|Drug: Duloxetine|Drug: Placebo","Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)|Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore|Clinical Global Impressions-Improvement (CGI-I) Score at Week 8|Change From Baseline to Week 8 in the Trail Making Test (TMT-A)|Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)|Change in Time From Baseline to Week 8 in the Stroop Test|Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)|Change From Baseline to Week 8 in the Detection Task (DT)|Change From Baseline to Week 8 in the Identification Task (IT)|Change From Baseline to Week 8 in the One-Back Task|Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression|Change From Baseline to Week 8 in the MADRS Total Score|Percentage of Participants With MADRS Response at Week 8|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score","Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","602","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_202|2011-005298-22|U1111-1126-0091","April 2012","February 2014","February 2014","March 28, 2012","February 5, 2015","February 5, 2015","Tucson, Arizona, United States|Little Rock, Arkansas, United States|Bellflower, California, United States|Carson, California, United States|Cerritos, California, United States|Glendale, California, United States|Imperial, California, United States|Los Angeles, California, United States|Norwalk, California, United States|Oakland, California, United States|Paramount, California, United States|San Bernardino, California, United States|Santa Ana, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Norwalk, Connecticut, United States|Lauderhill, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Sanford, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Chicago, Illinois, United States|Hoffman Estates, Illinois, United States|Naperville, Illinois, United States|Oak Brook, Illinois, United States|Skokie, Illinois, United States|Indianapolis, Indiana, United States|Prairie Village, Kansas, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Haverhill, Massachusetts, United States|St. Louis, Missouri, United States|North Platte, Nebraska, United States|Las Vegas, Nevada, United States|Buffalo, New York, United States|New York, New York, United States|Staten Island, New York, United States|Avon lake, Ohio, United States|Beachwood, Ohio, United States|Garfield Heights, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Franklin, Tennessee, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|Kirkland, Washington, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States|Milwaukee, Wisconsin, United States|Kazanlak, Bulgaria|Novi Iskar, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Tzerova Koria, Bulgaria|Helsinki, Finland|Kuopio, Finland|Turku, Finland|Berlin, Germany|Bochum, Germany|Chemnitz, Germany|Hannover, Germany|Munchen, Germany|Schwerin, Germany|Westerstede, Germany|Wiesbaden, Germany|Bialystok, Poland|Leszno, Poland|Lodz, Poland|Torun, Poland|Ekaterinburg, Russian Federation|Nizhny Novgorod, Russian Federation|Saint-Petersburg, Russian Federation|Smolensk, Russian Federation|Stavropol, Russian Federation|Kharkiv, Ukraine|Kyiv, Ukraine|Luhansk, Ukraine|Ternopil, Ukraine",,"https://ClinicalTrials.gov/show/NCT01564862"
1222,"NCT01114698","A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder",,"Terminated","No Results Available","Depression","Drug: Venlafaxine XR|Drug: Placebo|Drug: JNJ26489112","Change from baseline in Montgomery-Asberg Depression Rating Scale (10 item diagnostic questionnaire measuring the severity of depression)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Mean Change in Inventory of Depressive Symptoms (IDS) and Clinical Global Impression (CGI)|Findings from ophthalmologic examinations","Janssen Research & Development, LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CR016579|26489112MDD2001","March 2011","January 2012","February 2012","May 3, 2010",,"February 13, 2013","Arcadia, California, United States|Escondido, California, United States|San Diego, California, United States|Hartford, Connecticut, United States|Atlanta, Georgia, United States|Naperville, Illinois, United States|Brooklyn, New York, United States|Garfield Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Dallas, Texas, United States|Houston, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01114698"
1223,"NCT00840034","A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684|Drug: Placebo","Change From Baseline to 8 Weeks in Montgomery-Asberg Depression Rating Scale (MADRS)|Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Total Score|Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Individual Items|Change From Baseline to 8 Weeks in Hospital Anxiety and Depression Scale (HADS)|Change From Baseline to 8 Weeks in Clinical Global Impression of Severity (CGI-S)|Change From Baseline to 8 Weeks in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)|Change From Baseline to 8 Weeks in Fatigue Associated With Depression Participant-Reported Outcome (FAsD PRO)|Change From Baseline to 8 Weeks in Visual Analog Scale for Fatigue (VAS-F)|Change From Baseline to 8 Weeks in Visual Analog Scale for Pain (VAS-P)|Change From Baseline to 8 Weeks in Sheehan Disability Scale (SDS)|Change From Baseline to 8 Weeks in Quality of Life Enjoyment and Satisfaction Survey-Short Form (Q-LES-Q-SF)|Change From Baseline to 8 Weeks Massachusetts General Hospital Sexual Functioning Questionnaire (MGH-SFQ)|Colombia-Suicide Severity Rating Scale (C-SSRS)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","227","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12850|H9P-MC-LNDK","February 2009","January 2010","January 2010","February 10, 2009","April 24, 2018","April 24, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Ana, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrance, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smyrna, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oak Brook, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Charles, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willingboro, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresh Meadows, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00840034"
1224,"NCT00956514","Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder",,"Completed","No Results Available","Depression","Device: Transcranial Magnetic Stimulation","Change in HAM-D17 scale score|Change in MADRS scale score|Change in IDS-SR30 scale score","University of California, Los Angeles","All","18 Years to 64 Years   (Adult)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-02-045|IRB# 09-02-045","July 2009","September 2011","October 2011","August 11, 2009",,"February 6, 2013","UCLA Depression Research and Clinic Program, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00956514"
1225,"NCT03227224","A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Placebo|Drug: JNJ-42847922","Primary Efficacy Parameter: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Primary Safety Parameter: Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Primary Safety Parameter: Suicidal Ideation Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)|Primary Safety Parameter: Sexual Functioning Measured by the Arizona Sexual Experiences Scale (ASEX)|Primary Safety Parameter: Potential Withdrawal Effects Measured By the Physician Withdrawal Checklist (PWC)|Change From Baseline Through Week 6 in the MADRS Total Score in Participants With Baseline Insomnia Severity Index (ISI) Score Greater Than or Equal to (>=)15 Versus Participants With Baseline ISI Score Less Than (<)15|Change From Baseline in ISI Score Category at Week 6|Percentage of Participants With Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS)|Percentage of Participants With Remission of Depressive Symptoms Based on Montgomery-Asberg Depression Rating Scale (MADRS)|Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 6|Percentage of Participants With Response on Anxiety Symptoms Scale Based on Hamilton Anxiety Rating scale (HAM-A)|Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 6|Change From Baseline in the Sheehan Disability Scale (SDS) at Week 6|Change From Baseline in the MADRS Total Score at Week 6 in Participants With Major Depressive Disorder (MDD) With Anxious Distress Versus Participants With MDD Without Anxious Distress|Change From Baseline in Salivary Cortisol Levels, Measured Upon Awakening at Weeks 2, 4, and 6|Area Under the Plasma Concentration-Time Curve (AUC)|Maximum Observed Plasma Concentration (Cmax)|Change From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at Week 6|Change From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) at Week 6|Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at Week 6|Change From Baseline in Fatigue Using the PROMIS-Fatigue Short Form at Week 6|Change From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) at Week 6|Change From Baseline in Health Related Quality of Life and Utility Using the European Quality of Life (EuroQol) Group, 5 Dimension, 5 Level (EQ-5D-5L) Questionnaire at Week 6|Change From Baseline in Work Productivity and Limitations Using the Work Limitations Questionnaire (WLQ) Short Form at Week 6","Janssen Research & Development, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108281|42847922MDD2001|2015-005282-22","August 16, 2017","January 12, 2019","January 19, 2019","July 24, 2017",,"August 18, 2020","California Pharmaceutical Research Institute, Inc., Anaheim, California, United States|Catalina Research Institute, Chino, California, United States|Synergy Clinical Research Center Of Escondido, Lemon Grove, California, United States|Asclepes Research, Panorama City, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|SF-Care, Inc, San Rafael, California, United States|Collaborative NeuroScience Network, Torrance, California, United States|Elite Clinical Trials, Wildomar, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Clinical NeuroScience Solutions, Inc, Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Qps-Mra, Llc, Miami, Florida, United States|Behavioral Clinical Research , Inc, North Miami, Florida, United States|Clinical NeuroScience Solutions, Inc, Orlando, Florida, United States|Compass Research LLC, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Radiant Research, Inc., Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Joliet Center for Clinical Research, Joliet, Illinois, United States|Clinilabs, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Clinical Trials of America, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Neuro-Behavioral Clinical Research, Canton, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Suburban Research Associates, Media, Pennsylvania, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Core Clinical Research, Everett, Washington, United States|Mental Health Center Prof. Dr. Ivan Temkov, Burgas, Bulgaria|State Psychiatric Hospital Kardzhali, Kardzhali, Bulgaria|State Psychiatric Hospital - Lovech, Lovech, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|MC 'Hipokrat - N', EOOD, Plovdiv, Bulgaria|Mental Health Center - Rousse, Rousse, Bulgaria|MHC - Sofia, EOOD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD, Sofia, Bulgaria|Medical Center 'Doverie', Sofia, Bulgaria|Medical Center Intermedica, OOD, Sofia, Bulgaria|MHAT-Targovishte, AD, Targovishte, Bulgaria|State Psychiatric Hospital - Tzarev Brod, Tzarev Brod, Bulgaria|Diagnostic Consulting Center Mladost - M Varna, Varna, Bulgaria|Mental Health Center - Veliko Tarnovo EOOD, Veliko Tarnovo, Bulgaria|Mederon Oy, Helsinki, Finland|Savon Psykiatripalvelu, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Satakunnan Psykiatripalvelu, Rauma, Finland|CHU Clermont-Ferrand - Hopital Gabriel Montpied, Clermont Ferrand, France|Cabinet Medical des Drs Prizac-Desbonnet Scottez, Douai, France|CHU Nimes - Hôpital Carémeau, Nimes Cedex, France|Hopital Sainte Anne, Paris, France|Centre Hospitalier Guillaume Regnier, Rennes Cedex, France|Neurologische Praxis Dr. Schoell & Kollegen, Bad Homburg, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Somni Bene GmbH, Schwerin, Germany|Hongo Todaimae Mental Clinic, Bunkyo-ku, Japan|Kuramitsu Hospital, Fukuoka-shi, Japan|National Center for Global Health and Medicine, Kohnodai hospital, Ichikawa-shi, Japan|National Hospital Organization Hizen Psychiatric Center, Kanzaki-gun, Japan|Nara Medical University Hospital, Kashihara-shi, Japan|Senzoku Psychosomatic Clinic, Meguro-ku, Japan|Heart Care Ginga Clinic, Nakano-ku, Japan|Shiranui Hospital, Omuta-shi, Japan|Seiwakai Yutaka Clinic, Sagamihara-shi, Japan|Sangenjaya Nakamura Mental Clinic, Setagaya-ku, Japan|Yoyogi Mental Clinic, Shibuya-ku, Japan|Eto Mental Clinic, Shinagawa-ku, Japan|Nishi-Shinjuku Concieria Clinic, Shinjuku-ku, Japan|Tamaki Clinic, Shinjuku-ku, Japan|Shinjuku Research Park Clinic, Shinjuku-ku, Japan|Ohwa Mental Clinic, Toshima-ku, Japan|Sekino Hospital, Toshima-ku, Japan|Jisenkai Hozumi Himorogi Clinic, Toshima-ku, Japan|SHI Arkhangelsk Regional Clinical Psychiatric Hospital, Arkhangelsk, Russian Federation|Sverdlov Regional Psychiatric Clinical Hospital, Ekaterinburg, Russian Federation|City Clinical Psychiatric Hopsital 3, Moscow, Russian Federation|FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia, Moscow, Russian Federation|Closed corporation 'Scientific Center of Personalized Psychiatry', Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Clinical Psychiatry Hospital n.a. N.N. Solodovnikov, Omsk, Russian Federation|Medical and Rehabilitation Research Center Phoenix, Rostov-on-Don, Russian Federation|City Psychiatric Hospital of St. Nikolay Chudotvorets, Saint-Petersburg, Russian Federation|Engels psychiatric hospital, Saratov Region, Russian Federation|SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky, Saratov, Russian Federation|St-Petersburg Bekhterev Psychoneurological Research Institute, St. Petersburg, Russian Federation|Research Institute of Mental Health, Tomsk, Russian Federation|CNCE'Precarpathian Regional Clinical Mental Health Center Ivano-Frankivsk RC', Ivano-Frankivsk, Ukraine|SI Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, Ukraine|Kyiv Psychiatry Hospital #2, Kyiv, Ukraine|CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital', Lviv, Ukraine|CI Odesa Regional Medical Center of Mental Health, Odesa, Ukraine|CNCE Odesa regional psychiatric hospital #2 Odesa regional council, Oleksandrivka, Ukraine|Poltava O.F. Maltsev RC Psychiatric Hospital Dept #9 (Ad-P Dept) HSEIU Ukrainian MSA, Poltava, Ukraine|Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU, Ternopil, Ukraine|CI O.I. Yuschenko VRPsH Depts #7 & #10 M.I. Pyrogov VNMU, Vinnytsia, Ukraine|CNCE 'Vinnytsya RC Psychoneurological Hospital n.a. O.I. Yushchenko Vinnytsya RC', Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03227224"
1226,"NCT04533529","A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Seltorexant|Drug: Placebo","Double-blind (DB) Treatment Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Open-Label (OL) Treatment Phase: Number of Participants with Adverse Events (AEs) including AEs of Special Interest (AESI) as a Measure of Safety and Tolerability|OL Treatment Phase: Change From Baseline in Blood Pressure|OL Treatment Phase: Change From Baseline in Pulse Rate|OL Treatment Phase: Change From Baseline in Weight|OL Treatment Phase: Change From Baseline in Body Mass Index (BMI)|OL Treatment Phase: Change From Baseline in Suicidality Assessment Using the Columbia Suicide Severity Rating Scale (C-SSRS)|OL Treatment Phase: Physician Withdrawal Checklist (PWC-20) Scores|OL Treatment Phase: Number of Participants with Laboratory Abnormalities|OL Treatment Phase: Change From Baseline in QTc Interval|OL Treatment Phase: Change from Baseline in Heart Rate (HR)|OL Treatment Phase: Change from Baseline in QRS Interval|OL Treatment Phase: Change from Baseline in PR Interval|OL Treatment Phase: Change From Baseline in QT Interval|OL Treatment Phase: Participant-reported Sexual Functioning Using Arizona Sexual Experiences Scale (ASEX) Score|DB Treatment Phase: Change From Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score|DB Treatment Phase: Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score|DB Treatment Phase: Change From Baseline in the MADRS-6 Total Score|DB Treatment Phase: Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS)|DB Treatment Phase: Change From Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score|DB Treatment Phase: Number of Participants with Adverse Events (AEs) including AEs of Special Interest (AESI) as a Measure of Safety and Tolerability|OL Treatment Phase: Change From Baseline Over Time in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|OL Treatment Phase: Change From Baseline Over Time in the Clinical Global Impression-Severity (CGI S) Score|OL Treatment Phase: Change from Baseline Over Time in the MADRS-WOSI Total Score|OL Treatment Phase: Change From Baseline Over Time in Sleep Disturbance Using the PROMIS SD Short Form 8a T-score","Janssen Research & Development, LLC","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108804|2020-000337-40|42847922MDD3001","September 16, 2020","June 29, 2022","June 22, 2023","August 31, 2020",,"July 23, 2021","Advanced Research Center Inc, Anaheim, California, United States|Synexus, Cerritos, California, United States|Irvine Clinical Research, Irvine, California, United States|Synergy East, Lemon Grove, California, United States|Catalina Research Institute, Montclair, California, United States|Pacific Research Partners, Oakland, California, United States|North County Clinical Research, Oceanside, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical NeuroScience Solutions, Inc, Jacksonville, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Phoenix Medical Research, Inc., Miami, Florida, United States|APG Research, LLC, Orlando, Florida, United States|Joliet Center for Clinical Research, Joliet, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|American Medical Research, Inc., Oak Brook, Illinois, United States|Adams Clinical, Watertown, Massachusetts, United States|Midwest Research Group - St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Mid-America Clinical Research, LLC, Saint Louis, Missouri, United States|Premier Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, LLC., Berlin, New Jersey, United States|Synexus Clinical Research US, Inc, Jamaica, New York, United States|Lindner Center of Hope, Mason, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|CPN - Centro de Pesquisa em Neurociências Ltda, Belo Horizonte, Brazil|CCBR Brasilia, Brasilia, Brazil|Instituto de Neurologia de Curitiba, Curitiba, Brazil|Instituto Mederi de Pesquisa e Saude, Passo Fundo, Brazil|Centro de Psiquiatria e Pesquisas Sandra Ruschel, Rio de Janeiro, Brazil|Hospital Universitario Walter Cantidio - Hwc, Rodolfo Teofilo, Brazil|Universidade Federal da Bahia - Hospital Universitario Prof. Edgard Santos, Salvador, Brazil|Instituto Bairral de Psiquiatria, Sao Paulo, Brazil|Mental Health Center Prof. Dr. Ivan Temkov, Bourgas, Bulgaria|State Psychiatric Hospital Kardzhali, Kardzhali, Bulgaria|State Psychiatric Hospital Pazardzhik, Pazardzhik, Bulgaria|Medical center Spectar - Plovdiv EOOD, Plovdiv, Bulgaria|UMHAT 'Sv. Georgi' EAD, Plovdiv, Bulgaria|Medical Center St. Naum, Sofia, Bulgaria|DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD, Sofia, Bulgaria|Medical center - VAS OOD, Targovishte, Bulgaria|Mental Health Center - Vratsa EOOD, Vratsa, Bulgaria|Psicomed Estudios Medicos, Antofagasta, Chile|BioMedica Research Group, Santiago, Chile|CeCim - Centro de Estudios Clinicos e Investigacion Medica, Santiago, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|HOMO - ESE Hospital Mental de Antioquia, Bello, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda., Bogotá, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Psynapsis Salud Mental S.A., Pereira, Colombia|BRAIN-SOULTHERAPY s.r.o., Kladno, Czechia|Neuroterapie KH, s.r.o., Kutna Hora, Czechia|A-Shine s.r.o., Plzen, Czechia|Clintrial s.r.o., Praha 10, Czechia|Medical Services Prague s.r.o., Praha 6, Czechia|Clinica Cemelli, Guadalajara, Mexico|Centro de Investigación Clínica Acelerada, SC, Mexico, Mexico|Iecsi S.C., Monterrey, Mexico|CRI Centro Regiomontano de Investigacion SC, Nuevo Leon, Mexico|Bind Investigaciones S.C., San Luis Potosi, Mexico|LLC City Neurological Center-Sibneuromed, Novosibirsk, Russian Federation|Psychoneurological dispensary 1, Saint Petersburg, Russian Federation|City Psychiatric Hospital of St. Nikolay Chudotvorets, Saint-Petersburg, Russian Federation|Bekhterev Psychoneurological Research Institute, St Petersburg, Russian Federation|Psychoneurological Dispensary of Frunzensky District, St-Petersburg, Russian Federation|SPb SBIH 'City Psychoneurological Dispensary # 7 (With Inpatient Facilities)', St. Petersburg, Russian Federation|St-Petersburg Bekhterev Psychoneurological Research Institute, St. Petersburg, Russian Federation|Stavropol Region Psychiatric Hospital #2, Stavropol, Russian Federation|Yaroslavl Region Clinical Psychiatric Hospital, Yaroslavl, Russian Federation|Farmovs Pty Ltd, Bloemfontein, South Africa|Iatros International, Bloemfontein, South Africa|Cape Town Clinical Research Centre, Cape Town, South Africa|Flexivest 14 Research, Cape Town, South Africa|David Dennis - Western Cape South Africa, Cape Town, South Africa|DJW Research, Krugersdorp, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Synexus Watermeyer, Pretoria, South Africa|Somerset West Clinical Research Unit, Strand, South Africa|Institucion Hosp Hestia Palau, Barcelona, Spain|Hosp. Univ. de Basurto, Bilbao, Spain|Hosp. Univ. Vall D Hebron, Edificio Antigua Escuela De Enfermería, Planta 5, Spain|Hosp. Valle Del Nalon, Langreo, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Centro Salud Mental La Corredoria, Oviedo, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Centro de salud San Juan - IBSAL, Salamanca, Spain|Hosp. Prov. de Zamora, Zamora, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Affecta Pskyiatrimottagning, Halmstad, Sweden|PharmaSite Helsingborg, Helsingborg, Sweden|ProbarE i Lund AB, Lund, Sweden|PharmaSite, Malmo, Sweden|Läkarmottagningen, Skovde, Sweden|ProbarE i Solna, Stockholm, Sweden|Sophiahemmet, Stockholm, Sweden|Chang-Gung Memorial Hospital-Keelung, Keelung, Taiwan|Taipei Medical University, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital- Linkou, Taoyuan County, Taiwan",,"https://ClinicalTrials.gov/show/NCT04533529"
1227,"NCT02185131","Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.","PT-MAD","Completed","Has Results","Major Depressive Disorder|Alcohol Use Disorder","Drug: Mirtazapine|Drug: Placebo","Drinks Per Drinking Day|Level of Depressive Symptoms","University of Pittsburgh|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 55 Years   (Adult)","Phase 2","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R21AA022123|5R21AA022123-02","September 2013","July 2016","July 2016","July 9, 2014","May 5, 2017","May 5, 2017","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02185131"
1228,"NCT04669665","A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide",,"Recruiting","No Results Available","Depressive Disorder, Major|Suicidal","Drug: SLS-002|Drug: Placebo|Other: Standard of care|Device: Intranasal device","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose|Change From Baseline in Clinical Global Impression of Severity for Suicidal Ideation and Behavior (CGIS-SI/B) Scale at 24 Hours Post First Dose|Change from Baseline in Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure (S-STS CMCM) Total Score at 24 hours post first dose (Day 2)|Change From Baseline in Patient Global Impression of Severity for Suicidal Ideation and Behavior (PGIS-SI/B) Scale at 24 Hours Post First Dose|Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 16|Change From Baseline in Clinical Global Impression of Severity for Suicidal Ideation and Behavior (CGIS-SI/B) Scale at Day 16|Change from Baseline in Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure (S-STS CMCM) Total Score at Day 16|Change From Baseline in Patient Global Impression of Severity for Suicidal Ideation and Behavior (PGIS-SI/B) Scale at Day 16","Seelos Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SLS-002-201","December 17, 2020","December 2022","December 2022","December 17, 2020",,"January 22, 2021","Seelos Investigational Site, Culver City, California, United States|Seelos Investigational Site, Glendale, California, United States|Seelos Investigational Site, Orange, California, United States|Seelos Investigational Site, Miami Lakes, Florida, United States|Seelos Investigational Site, Atlanta, Georgia, United States|Seelos Investigational Site, Decatur, Georgia, United States|Seelos Investigational Site, Gaithersburg, Maryland, United States|Seelos Investigational Site, North Canton, Ohio, United States|Seelos Investigational Site, Richardson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04669665"
1229,"NCT03874130","Scopolamine in Healthy Volunteers",,"Recruiting","No Results Available","Major Depressive Disorder (MDD)","Drug: Scopolamine","Describe the safety of Scopolamine HBr","Repurposed Therapeutics, Inc.","All","18 Years to 40 Years   (Adult)","Phase 1","130","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DPI-386-DE-10","August 1, 2018","May 2020","May 2020","March 14, 2019",,"February 17, 2020","Collaborative Neuroscience Network, LLC, Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03874130"
1230,"NCT04350567","Sleep/Wake Cycle and Depression: An Imaging and Treatment Study",,"Recruiting","No Results Available","Depression; Major Depressive Disorder","Other: Sleep Deprivation","Measure circadian phase in depressed and non-depressed individuals using the following outcome measure: phase angle difference (DLMO - sleep midpoint, units: hours)|Measure mGluR5 expression (outcome measure: volume of distribution divided by free fraction) at the time of DLMO, peak and nadir of melatonin secretion.|Measure the effect of acute sleep deprivation on circadian rhythms (outcome measure: shift of the concentration of melatonin over time curve).|To determine whether reliable estimates of [11C]ABP688 in plasma can be obtained using a miniPET scanner.","Stony Brook University","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1218123","September 1, 2020","August 2025","August 2025","April 17, 2020",,"June 9, 2021","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04350567"
1231,"NCT04338321","A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","ESCAPE-TRD","Recruiting","No Results Available","Depressive Disorder, Major","Drug: Esketamine 28 mg|Drug: Esketamine 56 mg|Drug: Esketamine 84 mg|Drug: Quetiapine XR 50 mg|Drug: Quetiapine XR 100 mg|Drug: Quetiapine XR 150 mg|Drug: SSRI/SNRI","Percentage of Participants with Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)|Percentage of Participants with Remission at Week 8 Without Relapse Until Week 32|Change from Baseline in Clinician-rated MADRS Scale Score|Change from Baseline in Clinical Global Impression - Severity (CGI-S) Scale Score|Clinical Global Impression - Change (CGI-C) Scale Score|Change from Baseline in Patient Health Questionnaire (PHQ) 9-item Total Score|Change from Baseline in Sheehan Disability Scale (SDS) Total Score|Change from Baseline in Health-Related Quality of life Status as Assessed by 36-item Short-Form Health Survey (SF-36) Domain Scores|Change from Baseline in Quality of Life in Depression Scale (QLDS) Total Score|Change from Baseline in European Quality of Life (EuroQol) Group, 5 Dimension, 5-Level (EQ-5D-5L)|Change from Baseline in Work Productivity and Activity Impairment (WPAI): Depression Questionnaire|Number of Participants with Intervention-Emergent Adverse Events|Suicidal ideation and behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score","Janssen-Cilag International NV","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 3","622","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108787|2019-002992-33|54135419TRD3013","August 21, 2020","December 19, 2021","December 15, 2022","April 8, 2020",,"July 23, 2021","FunDaMos, Ciudad Autonoma de Buenos Aires, Argentina|Fundación para el Estudio y Tratamiento de las Enfermedades Mentales, Ciudad Autónoma De Buenos Aires, Argentina|CEN-Consultorios Especializados en Neurociencias, Cordoba, Argentina|Fundacion Lennox, Cordoba, Argentina|Instituto Médico DAMIC, Cordoba, Argentina|Sanatorio Prof. Leon S. Morra S.A, Cordoba, Argentina|Instituto de Neurociencias San Agustín, La Plata, Argentina|C.I.A.P. (Centro de investigación y Asistencia en Psiquiatría), Rosario, Argentina|Medical University Graz, Graz, Austria|Schmitz and Schmitz, Vienna, Austria|Medical University Vienna, MUV, Vienna, Austria|Anima, Alken, Belgium|AZ St.-Jan Brugge-Oostende AV, Brugge, Belgium|Pz Duffel, Duffel, Belgium|Clinique Psychiatrique des Frères Alexiens, Henri-Chapelle, Belgium|Sint-Franciskusziekenhuis, Heusden-Zolder, Belgium|ARIADNE, Lede, Belgium|CHU de Liège, Liege, Belgium|Psychiatrisch Centrum O.L.V.-van Vrede, Menen, Belgium|CPN Centro De Pesquisas EM Neurociencia, Belo Horizonte, Brazil|Hospital São José, Criciúma, Brazil|Trial Tech Tecnologia em Pesquisas com Medicamentos, Curitiba, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Centro de Psiquiatria e Pesquisas Sandra Ruschel, Rio de Janeiro, Brazil|BR Trials, Sao Paulo, Brazil|C.J.S. Carvalho & Carvalho LTDA (Viver - Centro De Desospitalizacao Humana), São Paulo, Brazil|State Psychiatric Hospital Kardzhali, Kardzhali, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|Mental Health Center - Plovdiv, Plovdiv, Bulgaria|Mental Health Center - Rousse, Rousse, Bulgaria|Medical Center St. Naum, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Nuam, Sofia, Bulgaria|MHC - Sofia, EOOD, Sofia, Bulgaria|Centre for Mental Health Prof.N.Shipkovenski EOOD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD, Sofia, Bulgaria|Diagnostic Consulting Center Mladost - M Varna, Varna, Bulgaria|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda., Bogotá, Colombia|Instituto Colombiano del Sistema Nervioso, Bogotá, Colombia|HOMO - ESE Hospital Mental de Antioquia, Medellin, Colombia|Psynapsis Salud Mental S.A., Pereira, Colombia|Psychiatricka ambulance Saint Anne s.r.o., Brno, Czechia|Psychiatricka ambulance, MUDr. Marta Holanova, Brno, Czechia|Psychoporadna s.r.o., Dolany, Czechia|NeuropsychiatrieHK, s.r.o., Hradec Kralove-Vekose, Czechia|Psychiatrie - MUDr. Olga Hromková, Ivancice, Czechia|Supervize s.r.o., Kutna Hora, Czechia|A-Shine s.r.o., Plzen, Czechia|Institut Neuropsychiatricke pece, Prague, Czechia|Clintrial s.r.o., Praha 10, Czechia|AD71 s.r.o., Praha 10, Czechia|Medical Services Prague s.r.o., Praha 6, Czechia|Aalborg University Hospital, Aalborg, Denmark|Psykiatrien i Region Syddanmark, Esbjerg N, Denmark|Odense Universitets Hospital, Odense, Denmark|Mederon LTD at ARTES, Helsinki, Finland|Psykiatrinen Palvelukeskus Solvum Oy, Helsinki, Finland|Eira Hospital, Helsinki, Finland|Savon Psykiatripalvelu, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Satakunnan Psykiatripalvelu Oy at Mehilainen Oy, Tampere, Finland|Alexianer Aachen GmbH, Aachen, Germany|Universitaetsklinikum der RWTH Aachen, Aachen, Germany|Rheinhessen Fachklinik Alzey, Alzey, Germany|Praxis Dr. med. Jana Thomsen, Berlin, Germany|Emovis GmbH, Berlin, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Medizinisches Versorgungszentrum LiO GmbH, Berlin, Germany|Alexander Schulze - Germany, Berlin, Germany|Praxis Dr. med. Kirsten Hahn, Berlin, Germany|Vivantes Klinikum Spandau, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Universitatsklinikum Frankfurt, Frankfurt Am Main, Germany|Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik, Freiburg, Germany|Gemeinschaftspraxis Sallach/Leonhardt, Gelsenkirchen, Germany|SRH Waldklinikum Gera GmbH, Gera, Germany|Georg-August Universität, Universitätsmedizin Göttingen, Gottingen, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Evangelisches Krankenhaus Bethanien gGmbH, Greifswald, Germany|Universitaetsklinik Hamburg-Eppendorf, Hamburg, Germany|Klinische Forschung Hamburg, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universität Heidelberg, Heidelberg, Germany|Oberhavel Kliniken GmbH, Hennigsdorf, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena, Jena, Germany|Universitaetsklinikum Koeln, Köln, Germany|Panakeia - Arzneimittelforschung GmbH, Leipzig, Germany|Universitaetsklinikum Magdeburg A.oe.R, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida, Germany|Universitätsklinikum Münster, Munster, Germany|Ruppiner Kliniken, Neuruppin, Germany|Praxis Prof. Steinwachs, Nurnberg, Germany|Johanniter Krankenhaus Oberhausen, Oberhausen, Germany|Praxis Dr. med. Frank Kühn, Oranienburg, Germany|Gerhard D. Roth - Private Practice, Ostfildern, Germany|Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik, Pfaffenhofen, Germany|Universitaetsmedizin Rostock, Rostock, Germany|Somni Bene GmbH, Schwerin, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Klinikum der Hansestadt Stralsund GmbH-Ambulanz-Klinik für Psychiatrie und Psychotherapie - Germany, Stralsund, Germany|Aiginition Hospital of Athens, Athens, Greece|'Dafni' Psychiatric Hospital of Attica, Athens, Greece|414 Military Hospital Special Diseases, Athens, Greece|Venizeleio General Hospital, Crete, Greece|Psychiatric Clinic 'Agios Charalampos', Heraklion, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Rio Patras, Patra, Greece|424 Military Hospital of Thessaloniki, Thessaloniki, Greece|Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece|'G. Papanikolaou' Hospital of Thessaloniki, Thessaloniki, Greece|Semmelweis Egyetem, Budapest, Hungary|Észak-Közép-budai Centrum, Új Szent János Kórház és Szakrendelő Budai Családközpontú, Budapest, Hungary|Nyírő Gyula Kórház, Budapest, Hungary|Processus Kft., Budapest, Hungary|Debreceni Egyetem, Kenézy Gyula Egyetemi Oktatókórház, Debrecen, Hungary|Bugat Pal Korhaz, Gyongyos, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, Kalocsa, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Rambam Medical Center, Haifa, Israel|Shalvata Mental Health Center, Hod Hasharon, Israel|Jerusalem Mental Health Center, Jerusalem, Israel|Beer Yaakov Mental Health Center, Lod, Israel|Geha Mental Health Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Telaviv, Israel|Republican Scientific and Practical Center of Mental Health, Almaty, Kazakhstan|Medical Center for Psychological Healt SME, Nur-Sultan, Kazakhstan|East-Kazakhstan Regional Centre of Mental Health, Ust'-Kamenogorsk, Kazakhstan|Chonnam National University Hospital, Gwangju-si, Korea, Republic of|Wonkwang University Hospital, Iksan, Korea, Republic of|Kyung Hee University Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Raja Permaisuri Bainun, Ipoh, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Pengajar Universiti Putra Malaysia, Serdang, Malaysia|Hospital Tuanku Jaafar, Seremban, Malaysia|Brain Research Center, Amsterdam, Netherlands|AMC, Amsterdam, Netherlands|LUMC, Leiden, Netherlands|Haukeland University Hospital, Hordaland, Norway|Sykehuset Ostfold, Moss, Norway|St Olav University Hospital, Trondheim, Norway|Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk, Bialystok, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Bydgoszcz, Poland|Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Centrum Medyczne Care Clinic Katowice, Katowice, Poland|Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS, Leszno, Poland|Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej w Lodzi Szpital im. J. Babinskiego, Lodz, Poland|SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych, Lodz, Poland|Centrum Medyczne Luxmed Sp z o o, Lublin, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Torun, Poland|Hospital de Braga, Braga, Portugal|Centro Hospitalar do Tâmega e Sousa, EPE - Hospital Padre Americo, Vale do Sousa, Guilhufe - Penafiel, Portugal|Fundação Champalimaud, Lisboa, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal|Hospital CUF Tejo, Lisbon, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Cape Town Clinical Research Centre, Cape Town, South Africa|Flexivest 14 Research, Cape Town, South Africa|Gert Bosch - Pretoria South Africa, Garsfontein, South Africa|Psykiatriska kliniken, Goteborg, Sweden|Affecta Pskyiatrimottagning, Halmstad, Sweden|Psykiatriska kliniken, Lulea, Sweden|Vuxenpsykiatriska kliniken i Lund, Lund, Sweden|ProbarE i Lund AB, Lund, Sweden|ONE LIFETIME Läkarmottagning, Skovde, Sweden|ProbarE i Stockholm AB, Stockholm, Sweden|Changhua Christian Hospital, ChangHua, Taiwan|Hualien Tzu Chi Hospital, Hualien, Taiwan|Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Medical University, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan|Hacettepe University Medical Faculty, Ankara, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Ankara Sehir Hastanesi, Ankara, Turkey|Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey|Uludag University Medical Faculty, Bursa, Turkey|Bakirkoy Mental Health Training and Research Hospital, Istanbul, Turkey|Erenkoy Mental Health Hospital, Istanbul, Turkey|Uskudar University Neuropsychiatry Hospital, Istanbul, Turkey|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Selcuk University Medical Faculty, Konya, Turkey|Liv Hospital, Samsun, Turkey|Namik Kemal University, Tekirdag, Turkey|American Center for Psychiatry and Neurology, Abu Dhabi, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT04338321"
1232,"NCT03321526","A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy",,"Completed","No Results Available","Depressive Disorder, Major","Drug: JNJ-42847922|Drug: Placebo Matching to JNJ-42847922|Drug: Quetiapine XR|Drug: Placebo Matching to Quetiapine XR|Drug: Selective Serotonin Reuptake Inhibitor (SSRI)|Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)","Time to All-Cause Discontinuation of Study Drug|Percentage of Participants Achieving Remission at Week 12 and Sustaining Remission at Weeks 18 and 24|Percentage of Participants Achieving Response at Week 12 and Sustaining Response at Weeks 18 and 24|Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (baseline Insomnia Severity Index [ISI] score >=15) Versus Those Without Significant Insomnia (baseline ISI score <15) at Weeks 12, 18, and 24|Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24|Percentage of Participants With Weight Gain >=7% of Baseline Body Weight at End-of-Study Assessment|Percentage of Participants With Shifts in Triglycerides From Normal to High|Percentage of Participants With Shifts in Triglycerides From Borderline to High|Percentage of Participants With Shifts in Triglycerides From Normal to Very High|Percentage of Participants With Shifts in Triglycerides From Borderline to Very High|Percentage of Participants With Shifts in Triglycerides From High to Very High|Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline|Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High|Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High|Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Weeks 12 and 24|Change From Baseline in the Patient Global Impression Severity (PGI-S) Score at Weeks 12 and 24|Change From Baseline in Quality of Life in Depression Scale (QLDS) at Weeks 12 and 24|Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD Short Form 8a) at Weeks 12 and 24|Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI Short Form 8a) at Weeks 12 and 24|Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) at Weeks 12 and 24|Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24|Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24|Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24|Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and at Home During the Evening at Weeks 6 and 24|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Percentage of Participants With all Serious Adverse Events (SAEs) and Events of Special Interest|Number of Participants With Clinically Significant Vital Sign Findings as a Measure of Safety and Tolerability|Number of Participants With Clinically Significant Physical Examination Findings as a Measure of Safety and Tolerability|Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings as a Measure of Safety and Tolerability|Number of Participants With Clinically Significant Laboratory Findings as a Measure of Safety and Tolerability|Participant's Sexual Functioning Measured by the Arizona Sexual Experiences Scale (ASEX)|Participant's Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A)|Participant's Suicidality Ideation Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS)|Participant's Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)","Janssen Research & Development, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108394|42847922MDD2002","December 12, 2017","June 13, 2019","June 27, 2019","October 25, 2017",,"June 26, 2020","NoesisPharma Research, Phoenix, Arizona, United States|Clinical Research Consortium Arizona, Tempe, Arizona, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Collaborative NeuroScience Network, Garden Grove, California, United States|Pacific Institute of Medical Sciences, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Excell Research Inc, Oceanside, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Anderson Clinical Research, Redlands, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|SIH Research, Kissimmee, Florida, United States|Premier Clinical Research, Miami, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Arocha Research Center Inc, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Stedman Medical Trials, Tampa, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Suburban Clinical Research Group, Inc, Bolingbrook, Illinois, United States|RxClinicals, Crystal Lake, Illinois, United States|Alexian Brothers Health System, Hoffman Estates, Illinois, United States|Psychiatric Medicine Associates LLC, Skokie, Illinois, United States|American Research, LLC, Jeffersonville, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Phoenix Medical Research, Inc., Prairie Village, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Boston Clinical Trials & Medical Research, Roslindale, Massachusetts, United States|Rochester Center for Behavioral Medicine (RCBM), Rochester Hills, Michigan, United States|Midwest Research Group, Saint Charles, Missouri, United States|PsychCare Consultants Research, Saint Louis, Missouri, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|CNS Research Science, Inc., Jamaica, New York, United States|Hapworth Psychiatric Medical PLLC, New York, New York, United States|Carolina Partners c/o Tripha Life Sciences, Raleigh, North Carolina, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|Intend Research, Norman, Oklahoma, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|BTC Network, Lincoln, Rhode Island, United States|Hawkins Psychiatry, PC, Arlington, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03321526"
1233,"NCT01790919","Improving Depression Outcome by Enhancing Memory for Cognitive Therapy",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Behavioral: Cognitive therapy for depression","Inventory of Depressive Symptomatology, Self Report (IDS-SR)|Global Assessment of Functioning (GAF)|Structured Clinical Interview for DSM-IV (SCID)|Longitudinal Interval Follow-up Evaluation (LIFE)|ACNP defined Response, Remission, Relapse, Recurrence using the IDS, SCID and LIFE","University of California, Berkeley|National Institute of Mental Health (NIMH)|Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R34MH094535-01A1","February 2013","March 2015","March 2015","February 13, 2013",,"September 17, 2015","University of California, Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT01790919"
1234,"NCT00105989","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Duloxetine|Drug: placebo","Percentage of Participants With Depressive Recurrence After Time (t) in Days|Recurrence Count|Percentage of Participants With Greater Than or Equal to 50% Worsening After Time (t) in Days|Loss of Response at Any Time|Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Acute and Continuation Phases|Change From Baseline to Endpoint in 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score - Maintenance Phase|Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Acute and Continuation Phases|Change From Baseline to Endpoint in Clinical Global Impressions (CGI) Severity Scale - Maintenance Phase|Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Acute and Continuation Phases|Mean Values at Endpoint in Patient's Global Impressions of Improvement (PGI-I) - Maintenance Phase|Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Acute and Continuation Phases|Change From Baseline to Endpoint in Hamilton Depression Rating Scale Subscales, Including the Core, Maier, Anxiety/Somatization, Retardation/Somatization, and Sleep Subscales, and the Depressed Mood Item - Maintenance Phase|Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Acute and Continuation Phase|Change From Baseline to Endpoint in Visual Analog Scales (VAS) for Pain - Maintenance Phase|Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Acute and Continuation Phases|Change From Baseline to Endpoint in Symptom Questionnaire-Somatic Subscale (SQ-SS) - Maintenance Phase|Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Acute and Continuation Phases|Change From Baseline to Endpoint in Sheehan Disability Scale (SDS) - Maintenance Phase|Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Acute and Continuation Phase|Change From Baseline to Endpoint in 36-item Short-Form Health Survey (SF-36) - Maintenance Phase|Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Acute and Continuation Phases|Resource Utilization and Hospitalization Module - Visits to Health Care Providers - Maintenance Phase|Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Acute and Continuation Phases|Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Average Number of Hours Worked in a Week - Maintenance Phase|Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Acute and Continuation Phase|Resource Utilization and Hospitalization Module - Change From Baseline to Endpoint in Number of Missed Paid Work Hours - Maintenance Phase|Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Males)|Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Acute and Continuation Phases (Females)|Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Males)|Change From Baseline to Endpoint in Arizona Sexual Experience Scale (ASEX) - Maintenance Phase (Females)|Vital Signs - Change From Baseline to Endpoint in Weight - Acute and Continuation Phases|Vital Signs - Change From Baseline to Endpoint in Weight - Maintenance Phase|Vital Signs - Change From Baseline to Endpoint in Pulse - Acute and Continuation Phases|Vital Signs - Change From Baseline to Endpoint in Pulse - Maintenance Phase|Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Acute and Continuation Phases|Vital Signs - Change From Baseline to Endpoint in Blood Pressure - Maintenance Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Chloride - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Eosinophils - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Platelet Count - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Sodium - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Uric Acid - Acute Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Albumin - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bicarbonate, HCO3 - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Direct - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Bilirubin, Total - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Erythrocyte Count - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Gamma-Glutamyl Transferase - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hematocrit - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Hemoglobin - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Leukocyte Count - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Low Density Lipoprotein (LDL) Cholesterol (Direct) - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Hemoglobin - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Mean Cell Volume (MCV) - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Monocytes - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Total Protein - Continuation Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Alanine Aminotransferase (ALT) - Maintenance Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Calcium - Maintenance Phase|Statistically Significant Laboratory Measurements - Change From Baseline to Endpoint in Glucose - Maintenance Phase|Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Participants -- Open-Label Acute Therapy Phase|Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of the Participants -- Open-Label Continuation Phase","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","514","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8606|F1J-MC-HMDI","March 2005","January 2008","January 2008","March 21, 2005","July 17, 2009","July 28, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaithersburg, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Angouleme, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Douai, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fains, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roubaix, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ellwangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hildesheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wurzburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ferrara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Village Nikolskoe, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halmstad, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sundsvall, Sweden",,"https://ClinicalTrials.gov/show/NCT00105989"
1235,"NCT03623711","A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Depression, Unipolar","Drug: Escitalopram|Drug: Duloxetine|Drug: Bupropion|Other: Healthy control","change of functional magnetic resonance imaging (fMRI) after medication","Yuqi Cheng|Kunming Medical University","All","18 Years to 60 Years   (Adult)","Early Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81660237","August 1, 2018","December 31, 2022","December 31, 2022","August 9, 2018",,"September 17, 2019","The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT03623711"
1236,"NCT04712968","Efficacy of Daylight as Adjunctive Treatment in Patients With Depression",,"Not yet recruiting","No Results Available","Unipolar Depression","Behavioral: Regular exposure to morning daylight","Change in depressive symptoms|Change in sleep quality|Change in insomnia severity|Change in well-being","University of Aarhus","All","18 Years to 50 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Aarhus universitet","April 2021","April 2023","December 2024","January 19, 2021",,"March 4, 2021",,,"https://ClinicalTrials.gov/show/NCT04712968"
1237,"NCT03156504","The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","Bio-K","Active, not recruiting","No Results Available","Major Depression|Bipolar I Disorder|Bipolar II Disorder|Unipolar Depression","Drug: Ketamine Hydrochloride","Change in MÅDRS total score.","Mayo Clinic|National Network of Depression Centers","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-009737","June 1, 2017","December 31, 2020","January 1, 2022","May 17, 2017",,"April 6, 2021","Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03156504"
1238,"NCT02340351","Auricular Acupuncture vs. Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.",,"Completed","No Results Available","Anxiety Disorders|Depressive Disorder, Major","Device: Auricular acupuncture|Procedure: Progressive muscle relaxation","Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 1.|Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 2.|Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 3.|Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 4.","Universitätsklinikum Hamburg-Eppendorf","All","Child, Adult, Older Adult","Not Applicable","136","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UKE-Psych-Aku-08-14","July 2007","March 2009","August 2013","January 16, 2015",,"January 16, 2015",,,"https://ClinicalTrials.gov/show/NCT02340351"
1239,"NCT02196506","Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress",,"Completed","Has Results","Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders","Drug: Placebo + ADT|Drug: Brexpiprazole +ADT","Change in the Montgomery-Asberg Depression|Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment|Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score|Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","837","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","331-13-214","July 2014","April 2016","May 2016","July 22, 2014","August 21, 2018","August 21, 2018","Birmingham, Alabama, United States|Beverly Hills, California, United States|Denver, Colorado, United States|Hialeah, Florida, United States|Orlando, Florida, United States|Alpharetta, Georgia, United States|Smyrna, Georgia, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester Hills, Michigan, United States|Cherry Hill, New Jersey, United States|Jamaica, New York, United States|New York, New York, United States|Staten Island, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Philadelphia, Pennsylvania, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Memphis, Tennessee, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Woodstock, Vermont, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Achim, Germany|Berlin, Germany|Dusseldorf, Germany|Frankfurt, Germany|Freiburg, Germany|Oranienburg, Germany|Stralsund, Germany|Wurzburg, Germany|Budapest, Hungary|Gyor, Hungary|Gdansk, Poland|Lubin, Poland|Sosnowiec, Poland|Warszawa, Poland|Bratislava, Slovakia|Kosice-Barca, Slovakia|Liptovsky Mikulas, Slovakia",,"https://ClinicalTrials.gov/show/NCT02196506"
1240,"NCT04081519","Stimulation of Parieto-hippocampal Connectivity in Patients With Major Depressive Disorder",,"Completed","No Results Available","Depression|Depressive Disorder|Depressive Episode|Depressive Disorder, Major","Device: active rTMS over DLPFC|Device: Add-on active rTMS over DLPFC|Device: Add-on active rTMS over LPC|Device: Add-on sham rTMS","Change in depression severity as measured by the Hamilton Depression Rating Scale (HAMD-17)|Change in functional connectivity coefficients based on resting-state fMRI|Change in task-based fMRI activation during associative memory paradigm|Change in depression severity as measured by the Beck's Depression Inventory (BDI-II)|Change in visual memory as assessed by the Delayed Matching to Sample test (DMS)|Change in spatial planning as assessed by the One Touch Stockings of Cambridge (OTS)|Change in visual sustained attention as assessed by the Rapid Visual Information Processing (RVP)|Change in working memory as assessed by the Spatial Working Memory (SWM)|Change in task-based fMRI activation during social touch paradigm|Change in task-based fMRI activation during emotional processing paradigm","University Hospital, Bonn|Clemens Mielacher, University Hospital, Bonn","All","18 Years to 60 Years   (Adult)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","SHIP","August 2, 2016","March 31, 2018","June 22, 2018","September 9, 2019",,"August 4, 2021","Klinik und Poliklinik für Psychiatrie und Psychotherapie, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT04081519"
1241,"NCT00880399","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder","orvepitant MDD","Terminated","Has Results","Depressive Disorder, Major","Drug: orvepitant|Other: placebo","Change From Baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) Total Score|Percentage of Participants With a >= 50 Percent (%) Reduction From Baseline in HAM-D Total Score|Number of Participants With (Maintained) Clinical Response|Change From Baseline in the Bech Melancholia Scale Total Score (Sum of Items 1, 2, 7, 8, 10, and 13 of the 17-item HAMD Scale)|Change From Baseline in the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR 16) Total Score|Change From Baseline in the HAM-D Anxiety Factor Score (Sum of Items 10, 11, 12, 13, 15 and 17)|Percentage of Participants With Clinical Global Impression- Global Improvement (CGI-I) Score of 1 (Very Much Improved) or 2 (Much Improved)|Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) Score|Change From Baseline in the Cognitive and Physical Function Questionnaire (CPFQ) Total Score|Change From Baseline in Morning Sleep Questionnaire (MSQ) Values for Total Sleep Time (TST), Sleep Onset Latency (SOL) and Wake Time After Sleep Onset (WTSO)|Change From Baseline in MSQ Values for Number of Nocturnal Awakenings|Change From Baseline in MSQ Values for Sleep Quality (SQ) and Refreshing Value of Sleep (RVS)|Number of Participants Who Remit (Have an Endpoint HAM-D Total Score <= 7) Who Continue to Show Symptoms on the HAM-D Sleep Items|Number of Participants With Suicidal Behavior, Ideation, and Most Common Ideation Using the Columbia Suicidality Severity Rating Scale (C-SSRS)|Number of Discontinuation-emergent Signs and Symptoms Using the Discontinuation-Emergent Signs and Symptoms (DESS)|Change From Baseline in the Massachusetts Sexual Function Questionnaire (MSFQ)-Males|Change From Baseline in the MSFQ Total Score-Females","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","111733","March 1, 2009","June 1, 2010","June 16, 2010","April 13, 2009","September 12, 2017","September 12, 2017","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Arcadia, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, National City, California, United States|GSK Investigational Site, Upland, California, United States|GSK Investigational Site, Bradenton, Florida, United States|GSK Investigational Site, Maitland, Florida, United States|GSK Investigational Site, North Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, The Bronx, New York, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Lincoln, Rhode Island, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Middleton, Wisconsin, United States|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00880399"
1242,"NCT01662817","Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depression","Behavioral: Intervention|Behavioral: Control","Percentage of Patient Participants with Under-Recognized Major Depressive Disorder (MDD) Episodes at 24 Weeks|Percentage of Patient Participants with Under-Treatment of MDD Episodes at 24 Weeks|Change from Baseline in Primary Care Physician (PCP) Adherence to Intervention Questionnaire at 24 Weeks|Change from Baseline in PCP Feasibility of Intervention Questionnaire at 24 Weeks|Change from Baseline in PCP Acceptance of Intervention Questionnaire at 24 Weeks|Mean Duration of Depressive Episodes in Patient Participants|Clinical Global Impressions: Severity (CGI-S) Score in Patient Participants|Sheehan Disability Scale (SDS) Score in Patient Participants|Mean Duration of Sick Leave Due to Depression in Patient Participants|Percentage of Patient Participants with Sick Leave Due to Depression","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,"525","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13487|H6U-XM-S007","September 2009","July 2010","July 2010","August 10, 2012",,"August 10, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01662817"
1243,"NCT00532480","Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine",,"Completed","Has Results","Major Depression","Drug: Duloxetine","17-item Hamilton Depression Rating Scale","Indiana University School of Medicine|Eli Lilly and Company|Indiana University","All","18 Years to 60 Years   (Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0607-22","September 2007","April 2009","April 2009","September 20, 2007","October 3, 2016","October 3, 2016","Indiana University Adult Psychiatric Clinic, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00532480"
1244,"NCT04496505","Neuromodulation Device Use in Patients With Major Depressive Disorder",,"Withdrawn","No Results Available","Clinical Depression","Device: Device|Device: Sham Device","Depression","Medical Center of Aurora","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EUF1076","August 17, 2020","September 17, 2020","September 17, 2020","August 3, 2020",,"May 20, 2021",,,"https://ClinicalTrials.gov/show/NCT04496505"
1245,"NCT00671515","Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome",,"Completed","Has Results","Depressive Disorder, Major|Metabolic Syndrome X","Drug: Pioglitazone","Change in Depression Symptom Severity From Baseline to Study Endpoint|Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) From Baseline to Study Endpoint","Joseph Calabrese, MD|Takeda Pharmaceuticals North America, Inc.|University Hospitals Cleveland Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-07-20","April 2008","August 2011","November 2011","May 5, 2008","October 17, 2014","January 26, 2017","University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00671515"
1246,"NCT03877393","The Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet","SANGUT","Unknown status","No Results Available","Depressive Disorder, Major|Depression","Combination Product: Probiotic supplementation + gluten-free diet|Combination Product: Placebo supplementation + gluten-free diet|Combination Product: Probiotic supplementation + gluten-containing diet|Combination Product: Placebo supplementation + gluten-containing diet","The changes in Montgomery-Åsberg Depression Rating Scale(MADRS) total score to measure the severity of depression symptoms|The changes in Beck Depression Inventory (BDI) total score to measure the severity of depression symptoms|The changes in Symptom Checklist-90 (SCL-90) total score to measure the severity of psychopathological impairment|The changes in the 36-Item Short Form Survey (SF-36) total score to measure the quality of life|The changes in the Perceived Stress Scale (PSS-10) total score to measure the stress levels|Changes in serum levels of high-specific C-reactive protein (hs-CRP)|Changes in serum levels of interleukin 6 (Il-6)|Changes in serum levels of interleukin 1beta (Il-1beta)|Changes in serum levels of tumor necrosis factor alpha (TNF-alpha)|Changes in serum levels of anti-tissue transglutaminase (anti-TG2) IgG antibodies|Changes in serum levels of anti-gliadin (anti-AGA) IgG antibodies|Changes in serum levels of anti-gliadin (anti-AGA) IgA antibodies|Changes in serum levels of intestinal fatty acid-binding protein (I-FABP/FABP-2)|Changes in serum levels of lipopolysaccharide biding protein (LBP)|Changes in serum levels of total cholesterol|Changes in serum levels of low-density lipoprotein (LDL) cholesterol|Changes in serum levels of high-density lipoprotein (HDL) cholesterol|Changes in serum levels of triglycerides (TG)|Changes in serum levels of glucose|Changes in serum levels of insulin|Changes in serum levels of cortisol|Changes in serum levels of alanine aminotransferase (ALT)|Changes in serum levels of aspartate aminotransferase (AST)|Changes in diversity in microbial community in a single sample (alpha-diversity)|Changes in diversity in microbial community between samples (beta-diversity)|Changes in stool short-chain fatty acids (SCFAs) levels|Changes in electroencephalography (EEG) analysis to assess the functional connectivity (FC)|Changes in Gastrointestinal Symptom Rating Scale (GSRS) total score to measure intensity of experienced gastrointestinal symptoms|Changes in Trail Making Test (TMT) to measure the cognitive abilities","Medical University of Lublin|Sanprobi Sp. z o.o., Sp. k., Szczecin, Poland","All","18 Years to 60 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DS192/2019","April 2019","July 2020","February 2021","March 15, 2019",,"March 15, 2019","1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Lublin, Poland",,"https://ClinicalTrials.gov/show/NCT03877393"
1247,"NCT04015206","Effectiveness of IPT-G in Major Depression","IPT-GinMD","Terminated","No Results Available","Depressive Disorder, Major","Other: Group Interpersonal Psychotherapy","Rate of Depression symptoms|Rate of Anxiety symptoms|Rate of Quality of life domains|Rate of Social support|Rate of Resilience|Style of Attachment","Hospital de Clinicas de Porto Alegre","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2018-0547","August 25, 2019","April 20, 2020","March 20, 2021","July 10, 2019",,"March 25, 2021","Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT04015206"
1248,"NCT03626181","Biomarkers of Theta Burst Stimulation in Major Depressive Disorder",,"Unknown status","No Results Available","Depressive Disorder, Treatment-Resistant","Device: Theta Burst Stimulation ( Transcranial Magnetic Stimulation)","Hamilton Depression Rating Scale|1. Montgomery-Åsberg Depression Rating Scale (MADRS)|2. Hamilton Anxiety rating Scale (HAM-A)|2. Columbia Suicide Severity Rating Scale ( CSSRS)|MGH Rumination questionnaire|Snaith-Hamilton Pleasure scale-Clinician administered (SHAP-C)|36 item short form survey (SF-36)|Global Assessment of Functioning (GAF)|Resting state functional connectivity-Functional magnetic resonance imaging (rsfMRI)|Magnetic resonance spectroscopy (MRS)|Electroencephalogram","University of Calgary","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10001858|RT # 10016954","July 6, 2018","July 1, 2019","July 1, 2019","August 10, 2018",,"August 10, 2018","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03626181"
1249,"NCT00300378","Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: desvenlafaxine 50 mg|Drug: desvenlafaxine 100 mg","The primary efficacy variable will be the change from baseline on the 17-item of the Hamilton Depression rating scale (HAM-D17 score) at the final on therapy evaluation|The Global Clinical Improvement will be the key secondary efficacy variable.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","3151A1-333","March 2006",,"January 2007","March 8, 2006",,"December 5, 2007","Rijeka, Croatia|Split, Croatia|Zagreb, Croatia|Tallinn, Estonia|Tartu, Estonia|Tartu, Estonia|Espoo, Finland|Helsinki, Finland|Helsinki, Finland|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Oulu, Finland|Rauma, Finland|Salo, Finland|Turku, Finland|Caen, France|Dole, France|Douai, France|Mulhouse, France|Orvault, France|Rennes, France|Tours, France|Jelgava, Latvia|Liepaja, Latvia|Riga, Latvia|Strenci, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Lubiaz, Poland|Tuszyn, Poland|Zuromin, Poland|Bucuresti, Romania|Bucuresti, Romania|Craiova, Romania|Bojnice, Slovakia|Bratislava, Slovakia|Rimavska Sobota, Slovakia|Bloemfontein, South Africa|Cape Town, South Africa|Durban, South Africa|Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT00300378"
1250,"NCT01135758","Study of Depression-Ketamine-Brain Function",,"Terminated","No Results Available","Major Depression","Drug: Ketamine","Difference of the MADRS score at baseline and after ketamine injection","Markus KOSEL|University Hospital, Geneva","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE09-144/Psy 09-22","June 2010","June 2015","September 2015","June 3, 2010",,"December 7, 2015","Service de Psychiatrie Adulte, Programme dépression, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT01135758"
1251,"NCT01098318","Rhodiola Rosea Therapy of Major Depressive Disorder",,"Completed","Has Results","Depression","Dietary Supplement: Herbal extract|Drug: Sertraline|Other: Lactose monohydrate","Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12.|The Clinical Global Impression (CGI) Severity and Change|Change in Depressive Symptoms as Measured by the Beck Depression Inventory|Change in Sexual Function|Number of Participants With Suicide Ideation as Determined by the Columbia Suicide Form|Number of Participants With Treatment Emergent Side Effects","University of Pennsylvania|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","58","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT005230|R21AT005230","June 2010","July 2013","July 2013","April 2, 2010","May 18, 2016","February 22, 2018","Depression Research Unit, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01098318"
1252,"NCT01049347","Amitriptyline and Paroxetine Treatment of Major Depression",,"Completed","No Results Available","Unipolar Depression","Drug: amitriptyline|Drug: paroxetine","Hamilton Depression Rating Scale (21-item version)|cortisol in saliva (8.00, 16.00, 22.00) during wash-out (6 days) and 35 days of treatment","Central Institute of Mental Health, Mannheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","127","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AmiPar|DFG De 660/1-1","October 1997","May 2000","May 2000","January 14, 2010",,"January 14, 2010","Central Institute of Mental Health, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT01049347"
1253,"NCT00247195","Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder",,"Completed","No Results Available","Depression","Behavioral: Culturally Congruent Assessment and Treatment","Entry into specialty mental health care from primary care|Entry into treatment for major depressive disorder after evaluation|Dropout from stepped care|Score on the Hamilton Depression Scale (17-item)|Score on the Clinical Global Impression Scale|Score on the Working Alliance Inventory|Score on the Client Satisfaction Questionnaire|Score on the Side Effects Checklist|Score on the Quality of Life Index|Score on the Social Adjustment Scale - Self-report version|Score on the Nervios Treatment Scale|Score on the Clinical Global Impression Scale - Patient version","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","113","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#4985|R34MH073087|DSIR 82-SESC","November 2005","August 2010","August 2010","November 1, 2005",,"October 25, 2012","New York State Psychiatric Institute - Hispanic Treatment Program, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00247195"
1254,"NCT02977299","Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","ASCERTAINTRD","Recruiting","No Results Available","Treatment Resistant Major Depressive Disorder","Drug: Aripiprazole|Device: Repetitive transcranial magnetic stimulation (rTMS)|Drug: Venlafaxine XR","Montgomery-Asberg Depression Rating Scale (MADRS)|Quality of Life, Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)","Massachusetts General Hospital|Patient-Centered Outcomes Research Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","639","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2015P002430","May 1, 2017","October 2021","January 2022","November 30, 2016",,"September 2, 2020","The University of Alabama School of Medicine, Birmingham, Alabama, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|Stanford University, Stanford, California, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Kansas University School of Medicine, Wichita, Kansas, United States|Shepperd Pratt Health System, University of Maryland School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States|New York University, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Virginia School of Medicine, Charlottesville, Virginia, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba St. Boniface Hospital, Winnipeg, Manitoba, Canada|University Health Network Toronto, Toronto, Ontario, Canada|Foundation Santa Lucia, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT02977299"
1255,"NCT00429169","Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression",,"Terminated","Has Results","Depression","Drug: Paroxetine|Drug: Bupropion","Go-No go Test|Scale for Suicidal Ideation|Occurrence of Suicidal Ideation or Acts Necessitating a Change in Treatment|Brain Activity Measured by BOLD Signal With fMRI During a Reward Processing Task.","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","101","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#5933R|K23MH076049|DSIR 8KRT-AT","June 2004","January 2010","January 2013","January 31, 2007","January 24, 2013","October 30, 2018","Columbia University/New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00429169"
1256,"NCT02286024","Study of Morphological and Perfusion Imaging Predictors of Pejorative Outcome in Major Depressive Disorder","LONGIDEP","Active, not recruiting","No Results Available","Depressive Disorder",,"Cortical thickness|Cerebral Blood Flow (after treatment of ASL data)","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)",,"178","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2013-A01733-42|829","November 3, 2014","September 30, 2018","September 4, 2021","November 7, 2014",,"January 6, 2021","Centre Hospitalier Guillaume Regnier, Rennes, Britanny, France",,"https://ClinicalTrials.gov/show/NCT02286024"
1257,"NCT00693680","Zinc Supplementation of Imipramine Therapy",,"Completed","No Results Available","Major Depression","Dietary Supplement: Zincas Forte|Dietary Supplement: Placebo","To compare the effect of zinc vs placebo in imipramine treated depressed patients (CGI, BDI, HADRS, MADRS)|To assess unwanted side effects in both groups","Polish Academy of Sciences|Jagiellonian University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZnIMI/2004","January 2005","April 2006","April 2006","June 9, 2008",,"June 13, 2008","Department of Psychiatry, Collegium Medicum, Jagiellonian University, Krakow, Poland",,"https://ClinicalTrials.gov/show/NCT00693680"
1258,"NCT02690324","The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders",,"Unknown status","No Results Available","Major Depressive Disorder, Anxiety Disorder","Behavioral: cognitive stress (serial 7)","Electrodermal activity(EDA)|Heart rate variability|Brain-derived neurotrophic factor(BDNF) genotyping: Val66Met|Cytokines|Leptin|Adiponectin|Epinephrine|Norepinephrine|C reactive protein|BDNF|MINI plus|MINI Suicidality Module|Hamilton Depression Rating Scale-17(HAMD-17)|Hamilton Anxiety Rating Scale(HAMA)|Anxiety Sensitivity Index(ASI)|APPQ(Albany Panic and Phobia Questionnaire)|PSWQ(Penn state worry questionnaire)|SRI(Stress response Inventory)|Perceived Stress Scale(PSS)|Barratt Impulsivity Scale|Panic disorder severity scale(PDSS)","Samsung Medical Center","All","20 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015-07-151","November 2015","February 2018",,"February 24, 2016",,"February 24, 2016","Samsung Medical Center, Seoul, Irwon-dong, Gangnam-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02690324"
1259,"NCT04582916","PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)",,"Recruiting","No Results Available","Depression","Drug: 11C-MCI|Drug: 11CPS13","Measure the concentration of radioligands|measure peripheral markers of inflammation and COX binding|measure clinical rating scales and COX binding","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","64","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","200157|20-M-0157","July 20, 2021","May 29, 2023","August 29, 2023","October 12, 2020",,"July 22, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04582916"
1260,"NCT00958204","Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression",,"Completed","No Results Available","Major Depressive Disorder (MDD)","Procedure: Light treatment|Procedure: Negative ion therapy|Drug: Placebo|Drug: Fluoxetine","Change in adjusted HAM-D scores at 2-month follow-up.|At 2-month follow-up: clinical response and remission rates, absenteeism and work productivity, adverse events, quality of life, and health services.","University of British Columbia|Canadian Institutes of Health Research (CIHR)","All","19 Years to 60 Years   (Adult)","Phase 3","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","H09-01015","October 2009","February 2014","May 2014","August 13, 2009",,"June 6, 2014","UBC Hospital Mood Disorders Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00958204"
1261,"NCT03666494","Ketamine Co-induction for Patients With Major Depressive Disorder",,"Unknown status","No Results Available","Ketamine|Depression|Anesthesia","Drug: Ketamine Hydrochloride|Drug: Propofol|Drug: Fentanyl","Depression Severity|Pain Score|Analgesia use","University of Saskatchewan","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bio 18-19","December 2018","December 2019","December 2019","September 11, 2018",,"September 13, 2018",,,"https://ClinicalTrials.gov/show/NCT03666494"
1262,"NCT00056472","Study of Pharmacotherapy of Psychotic Depression","STOP-PD","Completed","Has Results","Major Depressive Disorder With Psychotic Features","Drug: Olanzapine|Drug: Sertraline|Other: placebo","Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial|Scores on CGI-S Compared to Baseline Over the Course of the Trial","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","259","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U01MH062624|U01MH062565|U01MH062518|U01MH062446","January 2003","June 2008","June 2008","March 17, 2003","August 2, 2013","August 2, 2013","University of Massachusetts Medical School, Worcester, Massachusetts, United States|Cornell University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00056472"
1263,"NCT01190514","Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)",,"Completed","Has Results","Depression - Major Depressive Disorder","Drug: desvenlafaxine succinate sustained release","Area Under the Plasma Concentration-time Profile From Time 0 to 48 Hours (AUC48)|Maximum Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Terminal Elimination Half-life (t 1/2)|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf)|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUClast)","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B2061035","September 2010","November 2010","November 2010","August 27, 2010","January 27, 2012","January 27, 2012","Pfizer Investigational Site, Bruxelles, Belgium",,"https://ClinicalTrials.gov/show/NCT01190514"
1264,"NCT00275197","A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Sertraline and Elzasonan Combination|Drug: Sertraline|Drug: Placebo","The estimated treatment difference (elzasonan plus sertraline - sertraline monotherapy) in MADRS (Montgomery-Asberg Depression Rating Scale) remission rates at Week 8 in patients with MDD.|Change from baseline in: MADRS, CGI-I, CGI-S, HAMA, HAMD17, CSFQ, SOS-10 and PGID-D total scores at Week 8. Treatment differences in MADRS response rates at Week 8.","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A7571001","December 2005",,"July 2007","January 11, 2006",,"November 2, 2008","Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Norwich, Connecticut, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Beachwood, Ohio, United States|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Viljandi, Viljandi mk., Estonia|Pfizer Investigational Site, Pärnu, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Gatchina, Leningrad region, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Rostov On Don, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00275197"
1265,"NCT04814355","The Effect of Celecoxib on Neuroinflammation in MDD",,"Recruiting","No Results Available","Major Depressive Disorder|Neuroinflammation","Drug: Celecoxib 400 mg","Change in neuroinflammation as measured by [18F]FEPPA PET.|Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score.","Stony Brook University|Brain & Behavior Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","42","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81741","August 1, 2018","July 31, 2022","July 31, 2023","March 24, 2021",,"June 1, 2021","Psychiatry Department at Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04814355"
1266,"NCT02499094","Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder","Other: Behavioral-data driven support","Change in depression symptom severity|Change in patient activation","Ginger.io","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1004","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","GIO-001","December 2014","July 2015",,"July 15, 2015",,"July 15, 2015",,,"https://ClinicalTrials.gov/show/NCT02499094"
1267,"NCT03185819","Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Intranasal Placebo|Drug: Midazolam Placebo Solution|Drug: Midazolam|Drug: Esketamine","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose","Janssen Research & Development, LLC","All","9 Years to 17 Years   (Child)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108323|2016-004422-42|ESKETINSUI2002","October 5, 2017","June 13, 2022","June 13, 2022","June 14, 2017",,"July 23, 2021","Asclepes Research, Panorama City, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Institute of Living/ Hartford Hospital, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|Neuroscience Research Institute, Winfield, Illinois, United States|Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|University of Iowa, Carver College of Medicine, Iowa City, Iowa, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|Johns Hopkins Hospital, Child and Adolescent Psychiatry, Baltimore, Maryland, United States|State University of New York at Buffalo, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|University North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Hospital, Cincinnati, Ohio, United States|University Hospital of Cleveland, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Tennessee State University, Johnson City, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Hopital Erasme, Brussels, Belgium|Hospital Universitario Professor Edgar Santos, Bahia, Brazil|Trial Tech Tecnologia em Pesquisas com Medicamentos, Curitiba, Brazil|Hospital Infantil Pequeno Príncipe - Associação Hospitalar de Proteção à Infância Dr. Raul Carneiro, Curitiba, Brazil|Bioserv SMO - HSVP ( Hospital São Vicente de Paulo), Passo Fundo, Brazil|Hospital de Clínicas de Porto Alegre/ HCPA / UFRGS, Porto Alegre, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, Brazil|Hospital São Sebastião, Turvo, Brazil|Mental Health Center - Rousse, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment - MHAT Sveta Marina EAD, Varna, Bulgaria|Hospices Civils de Lyon HCL, Bron, France|CHRU Lille - Hôpital Fontan 1, Lille, France|CHU Nantes, Nantes, France|Hôpital Universitaire Pitié-Salpêtrière, Paris, France|Hopital Sainte Anne, Paris, France|Hôpital Robert Debré, Paris, France|CHU Saint-etienne, Saint-Priest-En-Jarez, France|Vadaskert Gyermek- és Ifjúságpszichiátriai Kórház és Szakambulancia, Budapest, Hungary|Szegedi Tudomanyegyetem, Szeged, Hungary|Azienda Ospedaliera G. Brotzu, Cagliari, Italy|OSP RIUNITI-DIP Donna- Bambino, Foggia, Italy|Ospedale di Merano, Merano, Italy|Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|IRCCS C. Mondino, Istituto Neurologico Nazionale, Fondazione, Pavia, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|Irccs Burlo-Garofalo, Trieste, Italy|Klinika Psychiatrii Dzieci i Mlodziezy, CM UJ, Krakow, Poland|Dzieciecy Szpital Kliniczny im. Jozefa Polikarpa Brudzinskiego, Warszawa, Poland|Instytut Psychiatrii i Neurologii Klinika Psychiatrii Dzieci i Mlodziezy, Warszawa, Poland|Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego, Oddział Psychiatryczny Dzieci i Młodzieży, Wroclaw, Poland|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Infantil Univ. Niño Jesus, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, Spain|Hosp. Univ. Central de Asturias, Oviedo, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Corporacio Sanitari Parc Tauli, Sabadell, Spain",,"https://ClinicalTrials.gov/show/NCT03185819"
1268,"NCT00646087","Ketamine Frequency Treatment for Major Depressive Disorder",,"Withdrawn","No Results Available","Treatment Resistant Depression","Drug: Ketamine|Drug: Ketamine/Saline","The primary efficacy measure is the change in scores in the 21-item Hamilton Depression Rating Scale.|Proportion of patients with remission (HDRS score < 18) at the end of the 2-week treatment and each follow-up contact.","Essentia Health","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04-07-04","March 2008",,,"March 28, 2008",,"June 6, 2011","St. Mary's Duluth Clinic Health System, Duluth, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00646087"
1269,"NCT00697268","p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram",,"Completed","No Results Available","Depression",,"We will study whether blood cell levels of p11 differ between healthy individuals and patients with depression. Moreover, we will study whether the levels of p11 are affected by treatment with the selective serotonin reuptake inhibitor, citalopr...|Complementary work will continue at other laboratories to better characterize the role of p11 in the pathophysiology of depression (e.g., animal studies, post-mortem studies).","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"38","NIH","Observational",,"080150|08-M-0150","June 3, 2008",,"July 28, 2016","June 13, 2008",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00697268"
1270,"NCT01882452","A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression","MEST","Completed","No Results Available","Major Depressive Disorder|Depressive Symptoms","Behavioral: Memory Specificity Training|Behavioral: Education and Support","Change from baseline in depressive symptoms on the Beck Depression Inventory II (BDI-II)|Change in depressive status according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders - IV (SCID-IV)|Change from baseline in autobiographical memory specificity on Autobiographical Memory Test (AMT)|Change from baseline in depressive symptoms as measured on the BDI-II|Depression free days following treatment according to the Longitudinal Follow-up Evaluation on the SCID-IV","Medical Research Council|KU Leuven","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MEST-UK","July 2013","August 2016","October 2016","June 20, 2013",,"March 22, 2018","Aliza Werner-Seidler, Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT01882452"
1271,"NCT04720040","The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder",,"Completed","No Results Available","Depression","Device: Mind STIM","Korean-Beck Depression Inventory-II|Korean-Beck Anxiety Depression Inventory|Hamilton Rating Scale for Depression","Ybrain Inc.|The Catholic University of Korea|Inje University|Korea University|Seoul National University Bundang Hospital|Hallym University Medical Center|Soonchunhyang University Hospital","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","65","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YB_ST_SIT1902","December 23, 2019","August 31, 2020","October 15, 2020","January 22, 2021",,"January 22, 2021","YBrain Inc., Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04720040"
1272,"NCT04101474","Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality",,"Not yet recruiting","No Results Available","Treatment Resistant Depression","Drug: Ketamine","Role of Ketamine as Antidepressant|Effect of Ketamine on Suicidality","Assiut University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ketamine with TRD","December 1, 2019","December 1, 2020","February 1, 2021","September 24, 2019",,"September 27, 2019",,,"https://ClinicalTrials.gov/show/NCT04101474"
1273,"NCT04618263","Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers",,"Recruiting","No Results Available","Major Depressive Disorder|Excessive Sleepiness","Drug: GATE-101","Number of Participants with Treatment-Emergent Adverse Events Through Study Completion, 28 days|Pharmacokinetics - maximum plasma concentration - following a single intravenous dose|Pharmacokinetics - maximum plasma concentration - following 5 daily intravenous doses|Pharmacokinetics - area under the curve - following a single intravenous dose|Pharmacokinetics - area under the curve - following 5 daily intravenous doses","Gate Neurosciences, Inc","All","18 Years to 40 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GATE-101-C-101","October 26, 2020","October 1, 2021","December 1, 2021","November 5, 2020",,"July 27, 2021","Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04618263"
1274,"NCT03219008","Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics","STEP-MDD","Unknown status","No Results Available","Depressive Disorder","Drug: Fluoxetine|Combination Product: fluoxetine + cognitive-behavioral treatment（CBT）|Drug: fluoxetine + Amfebutamone|Combination Product: physical treatment+fluoxetine+amfebutamone|Drug: Fluvoxamine|Drug: Lithium+fluvoxamine|Combination Product: fluvoxamine + lithium + physical therapy|Combination Product: Cognitive behavior treatment +fluvoxamine|Drug: Mirtazapine/SNRIs|Combination Product: mirtazapine+ Cognitive behavior treatment|Drug: mirtazapine + SNRIs|Combination Product: mirtazapine + SNRIs + physical therapy|Other: TAU(treat as usual)","Change from baseline in levels of microRNA，apolipoproteins, meta ion (Composite measure)|Hamilton Depression Scale(HADA) scores,reductive ratio|Patient health questionnaire(PHQ-9):the clinical remission ratio|life event scale(LES)|social support scale(SSS)|dysfunctional attitudes scales(DAS)|the gray matter volume,|fractional amplitudes of low-frequency fluctuation(fLAFF)|Neuroelectrophysiological examination: electroencephalogram(EEG)|Neuroelectrophysiological examination:electrocardiograph(ECG)","Shanghai Mental Health Center|Shanghai Jiao Tong University School of Medicine|Chinese Academy of Sciences|Shanxi Medical University|Central South University|Second Military Medical University|Peking University Sixth Hospital|First Affiliated Hospital Xi'an Jiaotong University|The First Affiliated Hospital of Kunming Medical College|Air Force Military Medical University, China|Zhejiang University|Wuhan Mental Health Centre|Corning Hospital, Shenzhen City|the First Specialized Subject Hospital of Harbin|Renmin Hospital of Wuhan University|Seventh People's Hospital of Hangzhou|Shandong Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2016YFC1307100","August 1, 2017","December 2019","December 2020","July 17, 2017",,"October 10, 2017","ShanghaiMHC, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03219008"
1275,"NCT01625546","Whole Body Hyperthermia and Major Depression (MDD)",,"Completed","No Results Available","Depressive Disorder, Major","Device: Whole Body Hyperthermia system","17-item Hamilton Rating Scale for Depression (HAM-D; derived from the 31-item instrument)|Change in QIDS (Quick Inventory of Depressive Symptoms) Score from baseline response|Core body temperature monitoring|Skin conductance level|Heart Rate Variability|EAR Assessment|Sleep assessment|Plasma Concentrations of Biological Predictors of Response and Mechanism of Action for WBH.|QIDS = Quick Inventory of Depressive Symptoms","University of Arizona|Dr. med. h.c. Erwin Braun Foundation|The Depressive and Bipolar Disorder Alternative Treatment Foundation|Brain & Behavior Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","12-0147-01","July 2012","May 2015","May 2015","June 21, 2012",,"August 10, 2015","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01625546"
1276,"NCT02222012","Neuromarkers Identification in Major Depressive Disorder Based on Monitoring Measures",,"Unknown status","No Results Available","Depression","Device: single channel ""Multiway Coil®""|Device: Two channels ""Multiway stimulator coil®"" (Brainsway Ltd.)","Clinical antidepressant response as defined by decline of HDRS-21 score over time|Symptomatic improvement|Clinical antidepressant remission as defined by decline of HDRS-21 score over time","Shalvata Mental Health Center|Beer Yaakov Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","sha-04-14","August 2014","September 2014","September 2017","August 21, 2014",,"August 21, 2014","Shalvata Mental Health Center, Hod-HaSharon, Israel",,"https://ClinicalTrials.gov/show/NCT02222012"
1277,"NCT01473615","Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression",,"Unknown status","No Results Available","Major Depressive Disorder|Dysthymic Disorder|Depressive Disorder NOS|Chronic Pain","Behavioral: Mindfulness Based Cognitive Therapy","Change from Baseline on the combined Quick Inventory of Depressive Symptomatology-clinician rated and the Hamilton Rating Scale for Depression (QIDS-C16/HRDS17), at week 8.|Response according to the Beck Anxiety Inventory, 21 items (BAI).|Response according to Short Form Health Survey, 36 items (SF-36).|Response according to Brief Pain Inventory (BPI-sf).","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2011P001699","November 2011","June 2013","June 2014","November 17, 2011",,"May 7, 2013","MGH Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01473615"
1278,"NCT01467804","Randomized Double Blinding Controlled Study on"" Jia Wei Xiao Yao Jiaonang"" Treating Mild to Moderate Major Depressive Disorder",,"Unknown status","No Results Available","Depressive Disorder","Drug: Sertraline plus placebo of JWXYJN|Drug: JWXYJN plus placebo of Sertraline","HAMD scale","Su Rui|China Academy of Chinese Medical Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","y00741015-zjx","November 2011","November 2012","December 2012","November 9, 2011",,"November 10, 2011","China Academy of Chinese Medicine Science, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01467804"
1279,"NCT04076644","Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder",,"Recruiting","No Results Available","MDD","Device: TMS treatment","Depression Severity changes scored from Patient Health Questionnaire (PHQ9)|Depression Severity changes scored from Quick Inventory of Depression Symptom Questionnaire (QIDS)","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013884","September 1, 2019","September 2021","September 2021","September 3, 2019",,"March 10, 2021","University of Missouri Neuromodulation Center, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04076644"
1280,"NCT00993876","Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment","Decoflex","Completed","No Results Available","Cognitive Performance in Major Depression","Drug: citalopram|Drug: reboxetine|Behavioral: interpersonal psychotherapy","cognitive performance with respect to cognitive flexibility, memory and attention|CREB-phosphorylation in T-Lymphocytes","Zentrum für Integrative Psychiatrie|German Research Foundation","All","20 Years to 45 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","KO 2067","August 2005","August 2008","August 2008","October 14, 2009",,"October 14, 2009","Zentrum für Integrative Psychiatrie, Kiel, Germany",,"https://ClinicalTrials.gov/show/NCT00993876"
1281,"NCT00976560","Clinical Study to Test a New Drug to Treat Major Depression","PKI113009","Completed","Has Results","Depressive Disorder, Major","Drug: GW856553|Other: Placebo","Change From Randomization (Week 0) Associated With GW856553 Versus Placebo at Week 6 in the Bech (6-item HAMD-17 [Hamilton Depression Rating Scale]) Score.|Number of Participants With Adverse Events|Number of Participants With Suicidality as Assessed by the Columbia Suicidality Severity Rating Scale Score|Number of Participants With Abnormal Haematology and Clinical Chemistry Values|Number of Participants With Abnormal Vital Signs (Blood Pressure, Heart Rate)|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Changes From Randomization (Week 0)in IL-6 and TNF-alpha Associated With GW856553 Versus Placebo at Week 1 and Week 6 in the Morning Plasma Levels|Change From Randomisation Bech Total Score: Bech Score|Mean HAMD-17 Total Score|Mean Inventory of Depressive Symptomatology Clinician (IDS-C) Total Score|Mean IDS-SR Total Score|Mean Quick Inventory of Depressive Symptomatology Self Report-16 Item (QIDS-SR16) Total Score Derived From the IDS-SR (Only at Weeks 0, 2, 4 and 6)|Percentage of IDS-C Responders (Participants With a Reduction in Total Score of ≥50% From Randomization at Week 6/Study Exit).|Percentage of IDS-C Remitters (Participants Whose Total Score Was ≤ 15 at Week 6/Study Exit).|Percentage of IDS-SR Responders (Participants With a Reduction in Total Score of ≥ 50% From Randomization at Week 6/Study Exit).|Percentage of IDS-SR Remitters (Participants Whose Total Score Was ≤ 15 at Week 6/Study Exit).|Percentage of QIDS-SR16 Responders (Participants With a Reduction in Total Score of ≥ 50% From Randomization at Week 6/Study Exit).|Percentage of QIDS-SR16 Remitters (Subjects Whose Total Score Was ≤ 5 at Week 6/Study Exit).|Percentage of Bech Responders (Participants With a Reduction in Total Score of ≥ 50% From Randomization at Week 6/Study Exit).|Percentage of Bech Remitters (Participants Whose Total Score Was ≤ 4 at Week 6/Study Exit).|Percentage of Participants With a Clinicians Global Impression of Improvement (CGI-I) Score of 1 (""Very Much Improved"") or 2 (""Much Improved"") at Weeks 1, 2, 3, 4, 5 and 6.|Assessment of Clinical Global Impression-Severity of Illness (CGI-S) up to 6 Weeks","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Phase 2","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","113009","September 25, 2009","July 7, 2010","July 7, 2010","September 14, 2009","November 14, 2017","November 14, 2017","GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Park Ridge, Illinois, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Pazardzhik, Bulgaria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Ruse, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Samara, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00976560"
1282,"NCT00167154","Risperidone and Suicidality in Major Depressive Disorder",,"Completed","No Results Available","Depression","Drug: Risperidone and placebo comparator","CGI|MADRS","University of Alabama at Birmingham|Janssen Pharmaceuticals","All","19 Years to 60 Years   (Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F030929002|RIS-DED-402","June 2004","April 2007","August 2008","September 14, 2005",,"June 10, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00167154"
1283,"NCT00866294","Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)",,"Completed","Has Results","Depressive Disorder","Drug: paroxetine IR 10mg tablet|Drug: paroxetine IR 20mg tablet|Drug: matched placebo to paroxetine IR 10mg or 20mg|Drug: Paroxetine CR 12.5mg tablet|Drug: Paroxetine CR 25mg tablet|Drug: matched placebo to paroxetine CR 12.5mg or 25mg","Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8|Mean Change From Baseline in the HAM-D Total Score at Weeks 1, 2, 3, 4, 6, and 8|Percentage of HAM-D Responders at Weeks 4 and 8|Percentage of HAM-D Remitters at Weeks 4 and 8|Mean Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-SI) Scores at Weeks 1, 2, 3, 4, 6, and 8|Percentage of Responders Based on the Clinical Global Impression-Global Improvement (CGI-GI) Scores at Weeks 4 and 8","GlaxoSmithKline","All","20 Years and older   (Adult, Older Adult)","Phase 3","416","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","112810","April 2009","February 2010","February 2010","March 20, 2009","November 15, 2010","January 30, 2017","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Gunma, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saga, Japan|GSK Investigational Site, Saga, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tottori, Japan|GSK Investigational Site, Gwangju, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00866294"
1284,"NCT04482296","Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients",,"Completed","No Results Available","MDD","Drug: SSRI with Zinc Sulfate","To measure the serum zinc level in SSRI-treated MDD patients pre and post supplementation of zinc.","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","18 Years to 55 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BSMMU/2019/8875","September 15, 2019","July 15, 2020","August 20, 2020","July 22, 2020",,"January 27, 2021","BSMMU, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT04482296"
1285,"NCT04719663","The Modulatory Role of Communicated Treatment Rationale on Treatment Expectation Effects in Depression.",,"Not yet recruiting","No Results Available","Condition: Major Depressive Disorder (MDD)","Behavioral: Biological illness and treatment rationale|Behavioral: Psychological illness and treatment rationale|Drug: Active pharmacological placebo|Behavioral: Active psychological placebo","Change in depression severity scores after 4 weeks of treatment - 'Montgomery Asberg Depression Scale' (MADRS)|Change in depressive symptom scores after 4 weeks of treatment- 'Beck Depression Inventory' (BDI-II)|Change in subjective disability scores after 4 weeks of treatment - adaptation of 'Pain Disability Index' (PDI)|Change in 'Generic Assessment of Side-Effects' scores (GASE) after 4 weeks of treatment|Change in treatment expectations at the start of treatment - 'Treatment Expectation Questionnaire' (TEX-Q)|Change in subjective stress scores after 4 weeks of treatment - 'Perceived Stress Scale' (PSS-10)|Change in anxiety scores after 4 weeks of treatment - 'State-Trait-Anxiety- Depression-Inventory' (STADI)","Philipps University Marburg Medical Center|Psychotherapie-Ambulanz Marburg e.V.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","CRC 289 Project A16","February 10, 2021","November 30, 2023","June 30, 2024","January 22, 2021",,"February 9, 2021","Department of Clinical Psychology and Psychotherapy, Philipps-University Marburg, Marburg, Germany",,"https://ClinicalTrials.gov/show/NCT04719663"
1286,"NCT01916200","Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients",,"Withdrawn","No Results Available","Depressive Disorder","Drug: Paroxetine CR","HDRS-17|HDRS-17 item 10|CGI-I|CGI-S|WHOQOL|IBSSS","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117049","January 2014","September 2014","September 2014","August 5, 2013",,"July 16, 2014",,,"https://ClinicalTrials.gov/show/NCT01916200"
1287,"NCT04226352","Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder",,"Recruiting","No Results Available","MDD|Treatment Resistant Depression|Smoking Cessation|Smoking","Drug: Dextromethorphan","Time to All-Cause Discontinuation of Dextromethorphan","Johns Hopkins University","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00192193","March 15, 2020","December 31, 2021","December 31, 2021","January 13, 2020",,"December 10, 2020","Johns Hopkins Department of Psychiatry, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04226352"
1288,"NCT02722967","Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System",,"Completed","Has Results","Schizophrenia|Major Depressive Disorder|Bipolar I Disorder","Drug: Aripiprazole + IEM (Ingestible Event Marker)","Assessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole.","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","316-13-215","March 2016","September 2016","September 2016","March 30, 2016","May 23, 2018","May 23, 2018","Granada Hills, California, United States|Rochester, New York, United States|Durham, North Carolina, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02722967"
1289,"NCT02898233","Augmenting Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder With Low-Level Light Therapy","CBT/LLLT","Completed","No Results Available","Depression","Other: Deprexis|Device: Active low-level light therapy|Device: Sham low-level light therapy","Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)|Deprexis usage|Inventory of Depression and Anxiety Symptoms (IDAS)|Tridimensional Personality Questionnaire (TPQ)|Massachusetts General Hospital Antidepressant Treatment Questionnaire (ATRQ)|Sheehan Disability Scale (SDS)|Perseverative Thinking Questionnaire (PTQ)|Questionnaire about daily activities and mood|Colombia Suicide Severity Rating Scale","University of Texas at Austin","All","18 Years to 45 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015-09-0100","February 2016","November 2020","November 30, 2020","September 13, 2016",,"April 28, 2021","The University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02898233"
1290,"NCT01769859","Systematic Genetic Analysis of Phenomenology and Treatment Response in Mood Disorders",,"Terminated","No Results Available","Bipolar Disorder|Major Depressive Disorder",,"Identify genetic variations contributing to inter-patient variability in disease susceptibility","University Hospitals Cleveland Medical Center|National Institutes of Health (NIH)|The Cleveland Foundation","All","7 Years and older   (Child, Adult, Older Adult)",,"396","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Fan General|KL2TR000440","January 2013","May 2016","May 2016","January 17, 2013",,"October 4, 2016",,,"https://ClinicalTrials.gov/show/NCT01769859"
1291,"NCT02013609","Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",,"Completed","Has Results","MDD","Drug: Brexpiprazole","Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Mean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score|Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 12|Number of Participants With CGI-I Response|Percentage of Participants With MADRS Response|Percentage of Participants With MADRS Remission|Mean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score|Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score|Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) Single Item Sub-scores|Mean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score|Mean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score|Mean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score|Mean Change From Baseline to Week 12 in Go/No-Go Task (P-inhibition Failure)|Mean Change From Baseline to Week 12 in Go/No-Go Task (Mean Reaction Time)|Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value|Mean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)|Mean Change From Baseline to Week 12 in Delay and Probability Discounting Task (DPDT)|Mean Change From Baseline in Food Delay Discounting Task (DDT)|Mean Change From Baseline in Money Delay Discounting Task|Mean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 35 Years   (Adult)","Phase 3","48","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-13-003","November 2013","September 2014","October 2014","December 17, 2013","March 29, 2016","March 29, 2016","Cerritos, California, United States|Costa Mesa, California, United States|Garden Grove, California, United States|Glendale, California, United States|Orange, California, United States|Riverside, California, United States|San Diego, California, United States|Norwich, Connecticut, United States|Fort Myers, Florida, United States|Hialeah, Florida, United States|Melbourne, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Prairie Village, Kansas, United States|Weymouth, Massachusetts, United States|Las Vegas, Nevada, United States|Brooklyn, New York, United States|Jamaica, New York, United States|Staten Island, New York, United States|Portland, Oregon, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02013609"
1292,"NCT00885222","Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients",,"Completed","No Results Available","Parkinson's Disease|Major Depressive Disorder","Device: DBS parameters setting","The primary outcome measure of the study will be the stimulation parameters of patients who fulfill criteria for MDD at the inception of trial and manifest remission (HAM-D21 score <7) after 4 months (or less) of DBS treatment.|Secondary outcome measures will be the relationship between improvement in mental status (as measured by HAM-21, BDI, CGI, HAM-A, BPRS and PDQ39) and change in PD symptoms (as measured by UPDRS).","Hadassah Medical Organization","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Eitan-DBS-PD-MDD-HMO-CTIL","May 2009","May 2010","May 2010","April 21, 2009",,"June 3, 2010","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00885222"
1293,"NCT02271412","Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005",,"Completed","No Results Available","Major Depressive Disorder, Recurrent, Unspecified","Drug: LY03005|Drug: Placebo","Number of Participants With Adverse Events","Luye Pharma Group Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","LY03005 MAD|LY03005/CT-USA-102","October 2014","March 2015","March 2015","October 22, 2014",,"October 21, 2015","PRA Health Sciences, Marlton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02271412"
1294,"NCT00880048","A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder","Orvepitant MDD","Terminated","Has Results","Depressive Disorder","Drug: orvepitant|Other: Placebo","Change From Baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) Total Score|Percentage of Participants With a >=50% Reduction From Baseline in HAM-D Total Score|Number of Participants Who Maintained Clinical Response by Week 6|Change From Baseline in the Bech Melancholia Scale Total Score (Sum of Items 1, 2, 7, 8, 10, and 13 of the 17-item HAM-D Scale)|Change From Baseline in the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR 16) Total Score|Change From Baseline in the HAM-D Anxiety Factor Score (Sum of Items 10, 11, 12, 13, 15 and 17)|Percentage of Participants With Clinical Global Impression- Global Improvement (CGI-I) Score|Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) Score|Change From Baseline in the Cognitive and Physical Function Questionnaire (CPFQ) Total Score|Change From Baseline in Morning Sleep Questionnaire (MSQ) Total Sleep Time, Sleep Onset Latency and Wake Time After Sleep Onset|Change From Baseline in the MSQ Number of Nocturnal Awakenings|Change From Baseline in the MSQ Sleep Quality and Refreshing Value of Sleep|Number of HAM-D Remitters|Number of Participants With Suicide-Related Events Based on the Columbia Suicidality Severity Rating Scale (CSSRS)|Number of Incidences of Discontinuation Emergent Signs and Symptoms Using the Discontinuation-Emergent Signs and Symptoms (DESS)|Change From Baseline in the Massachusetts Sexual Function Questionnaire (MSFQ) Total Score in Males|Change From Baseline in the MSFQ Total Score in Females","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110833","March 11, 2009","June 21, 2010","June 21, 2010","April 13, 2009","October 13, 2017","October 13, 2017","GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Norwich, Connecticut, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Weymouth, Massachusetts, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Willingboro, New Jersey, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Garfield Heights, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Salem, Oregon, United States|GSK Investigational Site, Emmaus, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Penticton, British Columbia, Canada|GSK Investigational Site, Miramichi, New Brunswick, Canada|GSK Investigational Site, Sydney, Nova Scotia, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Gatineau, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00880048"
1295,"NCT03754712","Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder",,"Unknown status","No Results Available","MDD","Dietary Supplement: Vitamin D3","Severity of depression","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","18 Years to 60 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","No. BSMMU /2018/2964","March 10, 2018","January 10, 2019","February 28, 2019","November 27, 2018",,"November 28, 2018","BSMMU, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03754712"
1296,"NCT02330068","Microbiome of Depression & Treatment Response to Citalopram",,"Completed","No Results Available","Major Depressive Disorder, Bipolar I and Bipolar II","Drug: citalopram","The potential differences in the microbiome between depressed patients and healthy controls|Microbiome change in treatment response vs. non-response to citalopram|Inflammatory markers of depression and their relationship to the microbiome","Mayo Clinic","All","18 Years to 55 Years   (Adult)",,"34","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","14-002154","December 2014","December 2017","December 2017","January 1, 2015",,"March 21, 2018","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02330068"
1297,"NCT03097133","54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide","Aspire II","Completed","Has Results","Depressive Disorder, Major","Drug: Esketamine|Drug: Placebo|Other: Standard of Care","Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase|Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase|Number of Participants With Remission of Major Depressive Disorder (MADRS Total Score Less Than or Equal to [<=] 12): DB Treatment Phase|Change From Baseline in MADRS Total Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase|Change From Baseline in CGI-SS-R Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase|Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1): DB Treatment Phase|Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase|Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 in DB Treatment Phase|Change From Baseline in European Quality of Life Group, 5-Dimension, 5-Level (EQ-5D-5L) Sum Score at Days 2, 11 and 25 of the DB Treatment Phase|Change From Baseline in European Quality of Life Group, Visual Analogue Scale (EQ-VAS) Score at Days 2, 11 and 25 of the DB Treatment Phase|Change From Baseline in EQ-5D-5L Health Status Index at Days 2, 11 and 25 of the DB Treatment Phase|Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 of the DB Treatment Phase|Treatment Satisfaction Questionnaire for Medication (TSQM-9) Domain Score at Days 15 and 25: DB Treatment Phase|Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Participant-Reported Frequency of Suicidal Thinking) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase|Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase|Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase|Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase|Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase|Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase|Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase|Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase|Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase|Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108285|2016-003992-23|54135419SUI3002","June 15, 2017","April 11, 2019","April 11, 2019","March 31, 2017","September 25, 2020","September 25, 2020","University of California San Diego/Psychiatry, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|University of Conneticut School of Medicine, Farmington, Connecticut, United States|University of Miami Health System, Miami, Florida, United States|Innovative Clinical Research, Inc., North Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States|Memorial Medical Center, Springfield, Illinois, United States|Neuroscience Research Institute, Winfield, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Altea Research Institute, Las Vegas, Nevada, United States|The Zucker Hillside Hospital, Glen Oaks, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|East Tennessee State University, Johnson City, Tennessee, United States|University of Wisconsin Medical Center, Madison, Wisconsin, United States|Clínica Privada Banfield S.A, Banfield, Argentina|Hospital Fleni, Ciudad de Buenos Aires, Argentina|Sanatorio Prof. Leon S. Morra, Cordoba, Argentina|Clinica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Argentina|Medical University Vienna, MUV, Vienna, Austria|Klinikum Wels-Grieskirchen, Wels, Austria|AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium|UZ Gent, Gent, Belgium|ARIADNE, Lede, Belgium|Hospital Universitario Professor Edgar Santos, Bahia, Brazil|Hospital Das Clinicas Da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil|Universidade Federal Do Ceara, Fortaleza, Brazil|Instituto Bairral de Psiquiatria, Itapira, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, Santo Andre, Brazil|Instituto de Psiquiatria - Hcfmusp, Sao Paulo, Brazil|St. Michael's Hospital, Toronto, Ontario, Canada|Institut universitaire en sante mentale de Montreal, Montréal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Nemocnice s pol. Havirov, p.o., Havirov, Czechia|Narodni ustav dusevniho zdravi, Klecany, Czechia|Vseobecna Fakultní Nemocnice, Praha, Czechia|Úst?ední vojenské nemocnice Praha, Praha, Czechia|Hôpital de Bohars, Bohars, France|CHRU Montpellier - Hôpital Lapeyronie, Montpellier, France|CHU Caremeau, Nimes, France|Hopital Sainte Anne, Paris, France|CHU Saint-Etienne - Hôpital Nord, Saint-Priest en Jarez, France|CHU Toulouse, Toulouse, France|Republic Kaunas Hospital, Kaunas County, Lithuania|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Vilnius Mental Health Center, Vilnius, Lithuania|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpital Specjalistyczny im. H. Klimontowicza, Oddzial Psychiatryczny, Gorlice, Poland|SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych, Lodz, Poland|Klinika Psychiatryczna WUM Mazowieckie Specjalistyczne Centrum Zdrowia im prof Jana Mazurkiewicza, Pruszkow, Poland|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Inst. Internac. Neurociencias Aplicadas, Barcelona, Spain|Hosp. Univ. de Basurto, Bilbao, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Bursa Sevket Yilmaz Research and Training Hospital, Bursa, Turkey|Uludag University Medical Faculty, Bursa, Turkey|Şişli Etfal Research Training Hospital, Istanbul, Turkey|Samsun Psychiatric Hospital, Samsun, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03097133/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03097133/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03097133"
1298,"NCT02105376","TNS for Major Depressive Disorder: a Phase II Randomized Controlled Trial",,"Unknown status","No Results Available","Depressive Symptoms","Device: Trigeminal Nerve Stimulation (TNS)","Hamilton Depressive Rating Scale version 17 items (HDRS-17)|Montreal Cognitive Assessment (MOCA)","Santa Casa Medical School|Faculdade de Ciências Médicas da Santa Casa de São Paulo","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TNS_depression","May 2014","June 2015",,"April 7, 2014",,"May 5, 2015","Centro de Atencao Integrada à Saúde Mental, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02105376"
1299,"NCT03039192","54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide","Aspire I","Completed","Has Results","Depressive Disorder, Major","Drug: Esketamine|Other: Placebo|Other: Standard of Care","Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF] Data) During Double-blind Phase|Change From Baseline in Clinical Global Impression of Severity of Suicidality- Revised (CGI-SS-R) Score at 24 Hours After the First Dose (Day 2) (LOCF Data) During Double-blind Phase|Number of Participants Who Achieved Remission (MADRS Total Score Less Than or Equal to [<=] 12) Through the Double-blind Phase|Change From Baseline in Montgomery Asberg Depression Rating Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase|Change From Baseline in Clinical Global Impression- Severity of Suicidality-Revised (CGI-SS-R) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase|Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1) Through Double-blind Phase|Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase|Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 During Double-blind Phase|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Health Status Index|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: EQ-Visual Analogue Scale (EQ-VAS)|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Sum Score|Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 During Double-blind Phase|Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score at Days 15 and 25 During Double-blind Phase|Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Patient-reported FoST) Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase|Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 - Clinician-rated FoST Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase|Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase|Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase|Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase|Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase|Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase|Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase|Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase|Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 3","226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108284|2016-003990-17|54135419SUI3001","June 9, 2017","December 18, 2018","December 18, 2018","February 1, 2017","October 29, 2020","October 29, 2020","UAB Department of Psychiatry and Behavioral Neurobiology, Birmingham, Alabama, United States|Metropolitan Neuro Behavioral Institute, Chandler, Arizona, United States|Collaborative NeuroScience Network, Garden Grove, California, United States|Yale University, New Haven, Connecticut, United States|Rush University, Chicago, Illinois, United States|Alexian Behavioral Health Hospital, Hoffman Estates, Illinois, United States|University of Louisville, Department of Psychiatry, Louisville, Kentucky, United States|LSU Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Louisiana Clinical Research, Shreveport, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|CBH Health, Gaithersburg, Maryland, United States|State University of New York, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|Clinical Trials of America, Hickory, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Mental Health Center Prof. Dr. Ivan Temkov, Bourgas, Bulgaria|Regional Psychiatric Dispansery, Bulgaria, Bulgaria|State Psychiatric Hospital - Lovech, Lovech, Bulgaria|UMHAT 'Sveti Georgi'-Plovdiv, Plovdiv, Bulgaria|Military Medical Academy, Multiprofile Hospital for Active Treatment -Sofia, Sofia, Bulgaria|North Estonian Medical Centre Foundation, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Vivantes Humboldt Klinikum, Berlin, Germany|Universitatsklinikum Frankfurt, Frankfurt Am Main, Germany|Klinik für Psychiatrie und Psychotherapie, Freiburg, Germany|Semmelweis Egyetem Kútvölgyi Klinikai Tömb, Budapest, Hungary|Szent János Kórház és Észak-budai Egyesített Kórházak, Budapest, Hungary|Nyírő Gyula Kórház, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Korea University Ansan Hospital, Ansan-si, Korea, Republic of|Chonnam National University Hospital, Gwangju-si, Korea, Republic of|Kyung Hee University Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University Kebangsaan Malaysia Medical Centre, Cheras, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tuanku Jaafar, Seremban, Malaysia|Fakultna nemocnica s poliklinikou v Ziline, Zilina, Slovakia|Flexivest 14 Research, Cape Town, South Africa|Juan Schrönen - Western Cape South Africa, Welgemoed, South Africa|Hosp. Univ. Fundacion Alcorcon, Alcorcón, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Inst. Internac. Neurociencias Aplicadas, Barcelona, Spain|Hosp. Univ. de Basurto, Bilbao, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Benito Menni Comp. Asist. Salut Mental, Sant Boi de Llobregat, Spain|Tri-Service Genaral Hospital, Neihu District, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03039192/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03039192/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03039192"
1300,"NCT02859103","Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment",,"Completed","No Results Available","Depression|Anhedonia","Drug: Desvenlafaxine","Measuring Reward association and valuation using the Reward Association Task|Measuring Expectation using a prediction error task, to measure learning and choosing, during functional Magnetic Resonance Imaging (fMRI)|Anticipation of reward using the monetary incentive delay during fMRI|Motivation/effort using the Cued-Reinforcement Reaction Time Task and the EEfRT task.|Pleasure/Liking using the monetary incentive delay task in an fMRI|Feedback integration using the Probabilistic Reversal Learning task during fMRI","Unity Health Toronto","All","18 Years to 60 Years   (Adult)","Phase 4","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","DVS-01","June 1, 2017","November 4, 2019","November 4, 2019","August 8, 2016",,"November 2, 2020","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02859103"
1301,"NCT04880460","Assess the Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients",,"Recruiting","No Results Available","MDD","Dietary Supplement: Magnesium Glycinate tablet 200mg|Dietary Supplement: Placebo tablet 200mg","Depression severity score assessment|Biochemical assessment","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","18 Years to 60 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BSMMU/2021/257","January 9, 2021","July 2021","July 2021","May 10, 2021",,"May 21, 2021","Basic Science and Paraclinical Science of BSMMU, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT04880460"
1302,"NCT02122068","Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers",,"Completed","No Results Available","Mentalizing Imagery Therapy|Relaxation Recording","Behavioral: Mentalizing Imagery Therapy|Behavioral: Relaxation cd","Hamilton Depression Rating Scale|Quick Inventory of Depression Symptoms - Self Report","University of California, San Francisco|Friends of Semel Institute|Morris A. Hazan Memorial Foundation","All","45 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CMIT003","April 2014","September 2015","September 2015","April 24, 2014",,"January 22, 2021","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02122068"
1303,"NCT01598324","Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder",,"Terminated","No Results Available","Treatment-Resistant Depression",,"Glutamate level in antidepressant non-responders|Glutamine level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment.|Glutamine level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment|GABA level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment|Glutamine level in antidepressant non-responders|GABA level in antidepressant non-responders|Functional connectivity in default mode network measured by functional magnetic resonance imaging (fMRI) in treatment-resistant individuals receiving adjunctive treatment|Functional connectivity in default mode network measured by functional magnetic resonance imaging (fMRI) in treatment-resistant individuals receiving adjunctive treatment and treatment-responders receiving an antidepressant","Mclean Hospital|Pfizer|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"1","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WS2058787","July 2012","April 2013",,"May 15, 2012",,"August 13, 2013","McLean Hospital - McLean Imaging Center, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01598324"
1304,"NCT00672659","Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)",,"Completed","No Results Available","Depression","Drug: Citalopram + Pipamperone|Drug: Citalopram","Change in Montgomery-Asberg Depression Rating Scale score|The number of patients showing evidence of onset of action defined as a 20% improvement from baseline MADRS","PharmaNeuroBoost N.V.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PNB/CPS 02 2007","February 2008","January 2009","January 2009","May 6, 2008",,"May 2, 2011","CPSResearch, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00672659"
1305,"NCT02376491","Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study","THETA-DEP","Completed","No Results Available","DEPRESSION","Device: Transcranial magnetic stimulation","Therapeutic response rate|Relapse rate|Quality of life|Measures of cortical excitability","Nantes University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RC14_0375","June 2015","March 2019","March 2019","March 3, 2015",,"July 5, 2019","CHU de Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT02376491"
1306,"NCT00358631","An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder","Drug: SSR149415","The primary efficacy endpoint is the change from baseline to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score.|The main secondary endpoints are the changes from baseline to Day 56 in the HAM-D depressed mood item, Montgomery-Asberg Depression Rating Scale (MADRS) total, and Clinical Global Impression (CGI) Severity of Illness scores.","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","319","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DFI5878","July 2006","December 2007","December 2007","August 1, 2006",,"April 13, 2009","Sanofi-Aventis, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00358631"
1307,"NCT00922064","Effects of Electroconvulsive Therapy (ECT) on Serotonin-1A Receptor Binding",,"Completed","No Results Available","Unipolar Depression","Procedure: ECT","serotonin-1A receptor binding potential","Medical University of Vienna","All","18 Years to 60 Years   (Adult)","Phase 4","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EKT-20090219 Version 1.3|MUW EC No. 556/2008","June 2009","September 2011","September 2011","June 17, 2009",,"November 16, 2011","Medical University of Vienna, Dept. of Psychiatry and Psychotherapy, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00922064"
1308,"NCT02153502","Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",,"Completed","No Results Available","Depressive Disorder, Treatment-Resistant","Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|Drug: Placebo","Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score|17-item Hamilton Rating Scale for Depression (HAM-D17)|Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ)|16-item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)|Sheehan Disability Scale (SDS)|Clinical Global Impression of Severity of Illness (CGI-S)|Clinical Global Impression of Change (CGI-C)|EuroQOL 5 Dimension 5 Level (EQ-5D-5L)|Patient Global Impression of Change (PGIC)|7-item Generalized Anxiety Disorder (GAD-7)","Avanir Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-AVP-786-201","July 2014","February 2016","February 2016","June 3, 2014",,"May 15, 2017","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Bellflower, California, United States|Costa Mesa, California, United States|Garden Grove, California, United States|Lomita, California, United States|Oceanside, California, United States|Riverside, California, United States|Santa Ana, California, United States|Sherman Oaks, California, United States|Denver, Colorado, United States|Bradenton, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orange City, Florida, United States|Orlando, Florida, United States|Decatur, Georgia, United States|Hoffman Estates, Illinois, United States|Valparaiso, Indiana, United States|Baltimore, Maryland, United States|Glen Burnie, Maryland, United States|Boston, Massachusetts, United States|Brooklyn, New York, United States|New York, New York, United States|Staten Island, New York, United States|Garfield Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02153502"
1309,"NCT00062673","Study of Duloxetine in Elderly Patients With Major Depressive Disorder",,"Completed","No Results Available","Depression|Cognition","Drug: Duloxetine|Drug: Placebo","To compare the efficacy of duloxetine 60 mg QD & placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from the Verbal Learning & Recall Test (VLRT)|To compare the efficacy of duloxetine 60 mg QD & placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from the Symbol Digit Substitution Test (SDST)|To compare the efficacy of duloxetine 60 mg QD & placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from 2-Digit Cancellation Test (2DCT)|To compare the efficacy of duloxetine 60 mg QD & placebo on cognition during acute treatment phase in elderly patients using a composite cognitive score derived from the Letter-Number Sequencing Test (LNST)|To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by the Geriatric Depression Scale (GDS)|To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by the 17-item Hamilton Depression Rating Scale (HAMD17) total score|To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by response and remission rates|To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on depression as measured by the Clinical Global Impressions of Severity Scale (CGI Severity) and the HAMD17 subscale scores|To compare the efficacy of treatment with duloxetine 60 mg QD and placebo on the painful physical symptoms of depression, as measured by the Visual Analog Scale for pain (VAS)|To compare the safety of duloxetine 60 mg QD and placebo using information on vital signs, electrocardiograms (ECGs), treatment-emergent adverse events, discontinuation-emergent adverse events, discontinuation rates and laboratory analyses|To assess the impact of treatment with duloxetine 60 mg QD and placebo on quality of life as measured by the Short-Form (SF-36) Health Survey","Eli Lilly and Company","All","65 Years and older   (Older Adult)","Phase 3","311","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6091|F1J-MC-HMBV","March 2003",,"July 2004","June 12, 2003",,"May 21, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00062673"
1310,"NCT01707706","Acupuncture for Persistent Insomnia Associated With Major Depressive Disorder",,"Completed","No Results Available","Insomnia|Depression","Other: Acupuncture","Self-rated sleep quality score changes from baseline to 5-week posttreatment measured by Insomnia Severity Index questionnaire|Self-rated sleep quality score measured by the Pittsburgh Sleep Quality Index (PSQI) questionnaire|Depression state measured by Hamilton Depression Rating Scale (HAMD)|Depression state measured by Hamilton Anxiety Rating Scale (HAMA)|Subjective report of painful and non-painful somatic symptoms measured by Somatic Symptom Inventory (SSI)|Subjects' functioning regarding work/study, social life and family measured by Sheehan Disability Scale (SDS)|Self-rated severity of depressive and anxiety symptoms measured by Hospital Anxiety and Depression Scale (HADS)|Self-rated assessment regarding the degree of catastrophic thoughts about pain measured by Pain Catastrophizing Scale (PCS)|Subjects' general health and quality of life regarding physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, bodily pain, and general health perception measured by Short form -36 (SF-36)|Self-rated fatigue score measured by Multidimensional Fatigue Inventory (MFI)|Subjects' credibility to the treatment measured by Credibility of treatment rating scale|Serious adverse events measured by Serious Adverse Event (SAE)|Potential adverse events related to acupuncture measured by Adverse Events Report Related to Acupuncture|Sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) changes from baseline to 5-week posttreatment by objective measure - wrist actigraphy|Sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) changes from baseline to 5-week posttreatment by subjective measures using sleep log.","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACUP-004","January 2011","December 2013","December 2013","October 16, 2012",,"December 13, 2013","Western Psychiatry Centre, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT01707706"
1311,"NCT00616889","Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder",,"Completed","No Results Available","Bipolar Disorder","Drug: Seroquel","Sleep quality as measured by overnight PSG.","Queen's University|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)",,"15","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PSIY-206-05|D1449C00011","May 2006","January 2009","January 2009","February 15, 2008",,"December 16, 2015","Pccc, Mhs, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00616889"
1312,"NCT03449394","Effect of 4-session Metacognitive Training in Chinese Adult Outpatients With Schizophrenia Spectrum Disorders and Major Depressive Disorder",,"Completed","No Results Available","Delusions|Depression","Other: Metacognitive Training","Attributional style as measured by the Internal, Personal and Situational Attributions Questionnaire (IPSAQ)|Psychotic symptomatology as measured by Positive and Negative Syndrome Scale (PANSS)|Depressive symptomatology as measured by Beck Depression Inventory - II (BDI-II) and Calgary Depression Scale (CDS)|Conviction of beliefs as measured by the Psychotic Symptom Rating Scale (PSYRATS)|Belief flexibility as measured by Maudsley Assessment of Delusions Schedule (MADS) and the BADE task|State-trait personality as measured by the State-Trait Personality Inventory (STPI)|Cognitive capacity as measured by the Chinese version of the Wechsler Adult Intelligence Scale - III (WAIS-III)|Severity of generalized anxiety disorder as measured by Generalised Anxiety Disorder 7 (GAD-7)","Chinese University of Hong Kong","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","113","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MCT2.0","April 2015","November 2019","November 2019","February 28, 2018",,"January 23, 2020","Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03449394"
1313,"NCT00361491","An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder","LENA","Completed","No Results Available","Depressive Disorder","Drug: SSR149415","The primary efficacy endpoint is the change from baseline to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score|The main secondary endpoints are the changes from baseline to Day 56 in the HAM-D depressed mood item, Montgomery-Asberg Depression Rating Scale (MADRS) total, and Clinical Global Impression (CGI) Severity of Illness scores.","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","324","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DFI5879","August 2006","September 2007","September 2007","August 8, 2006",,"January 16, 2009","Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago de Chile, Chile|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00361491"
1314,"NCT01644747","tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients","STICODEP","Unknown status","No Results Available","Resistant Depression|Moods Disorders|Unipolar Depression|Bipolar Disorder","Device: transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)","change from baseline in HDRS-21 scale|Change from baseline in MADRS, BDI, HAMA, STAI, YMRS|Change from baseline in COT, TMT, IST and Cardebat fluency task","Centre Hospitalier Universitaire de Besancon|Clinical Investigation Centre for Innovative Technology Network|University Hospital, Grenoble|CH Le Vinatier - Service de Psychiatrie (Dr Emmanuel POULET)|Rennes University Hospital|EPS Ville-Evrard - Unité de Recherche Clinique (Dr Dominique JANUEL)|Hôpital Civil de Strasbourg - Service de Psychiatrie (Pr G.Bertschy)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","N/2011/60","July 2012","December 2017","December 2017","July 19, 2012",,"August 23, 2016","CHRU Besancon - Service de Psychiatrie - Centre Investigation Clinique Innovation Technologique (CIC-IT808), Besancon, France|CHU Grenoble - Clinique de Psychiatrie de l'Adulte, Grenoble, France|CH Le Vinatier - Service de Psychiatrie, Lyon, France|Centre Hospitalier Guillaume Régnier - Rennes - Service Hospitalo-Universitaire de Psychiatrie, Rennes, France|Hôpital Civil de Strasbourg - Service de Psychiatrie, Strasbourg, France|Etablissement Public de Santé Mentale - Unité de Recherche Clinique, Ville Evrard, France",,"https://ClinicalTrials.gov/show/NCT01644747"
1315,"NCT00616915","Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?",,"Completed","No Results Available","Mood Disorder","Drug: Wellbutrin XL","This study is looking at the effect of Wellbutrin SR versus Wellbutrin XL on sleep quality","Queen's University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSIY-219-05","January 2007","January 2009","January 2010","February 15, 2008",,"December 16, 2015","Providence Care Mental Health Services, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00616915"
1316,"NCT01568684","Brain Imaging, Genetics and Treatment for Major Depression",,"Withdrawn","No Results Available","Depressive Disorder|Depressive Disorder, Major|Depression","Other: Citalopram","Changes in prefrontal glutamate concentration after citalopram treatment.|Changes in depressive symptoms after citalopram treatment.|Association between glutamate changes and genetic variation.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","25 Years to 55 Years   (Adult)","Phase 1","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120099|12-M-0099","March 12, 2012","December 11, 2012","December 11, 2012","April 2, 2012",,"December 17, 2019",,,"https://ClinicalTrials.gov/show/NCT01568684"
1317,"NCT00285818","Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT",,"Completed","Has Results","Depression","Drug: Mifepristone|Drug: Placebo Oral Capsule","Hamilton Depression Rating Scale Score","Stanford University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2HSE450|Oberndorf Family Fund","January 2003","January 2009","April 2009","February 2, 2006","February 16, 2017","February 16, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00285818"
1318,"NCT00838994","Acupuncture for Residual Insomnia Associated With Major Depressive Disorder",,"Completed","No Results Available","Insomnia|Depression","Other: Acupuncture","Self-rated sleep quality score measured by Insomnia Severity Index questionnaire|Sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) by objective measure - wrist actigraphy|Sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) by subjective measures using sleep log.|Self-rated sleep quality score measured by the Pittsburgh Sleep Quality Index (PSQI) questionnaire|Depression state measured by Hamilton Depression Rating Scale (HAMD)|Subjects' functioning regarding work/study, social life and family measured by Sheehan Disability Scale|Subjects' credibility to the treatment measured by Credibility of treatment rating scale","The University of Hong Kong|Hong Kong Baptist University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACUP-002","October 2007","April 2009","April 2009","February 9, 2009",,"January 14, 2010","Western Psychiatry Centre, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00838994"
1319,"NCT01842542","Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset",,"Completed","No Results Available","Depression, Postpartum","Device: NeuroStar Transcranial Magnetic Stimulation (TMS)","Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in patients with MDD with postpartum onset|Determine the safety of NeuroStar TMS Therapy.","Neuronetics","Female","18 Years to 50 Years   (Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","44-03014-000","December 2013","July 2015","August 2015","April 29, 2013",,"October 27, 2015","Hartford Hospital Institute of Living, Hartford, Connecticut, United States|UF Health Adult Psychiatry - Springhill, Gainesville, Florida, United States|Harmonex Neuroscience and Research of Pensacola, Pensacola, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Integrative Psychiatry, Louisville, Kentucky, United States|TMS Medical Associates of NY, New York, New York, United States|TMS Center of Lehigh Valley, Allentown, Pennsylvania, United States|University of Utah - Neuropsychiatric Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01842542"
1320,"NCT02236702","Kappa Opioid Receptor Imaging in Depression (KOR Depression)",,"Terminated","No Results Available","Major Depressive Disorder|Anhedonia","Other: Positron Emission Tomography (PET) imaging","[11C]LY2795050 volume of distribution (VT) values in specific brain regions of asymptomatic vs mildly symptomatic vs moderately symptomatic vs severely symptomatic individuals","NYU Langone Health|Yale University","All","18 Years to 55 Years   (Adult)",,"15","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","S14-00643","August 2014","March 2015","February 2016","September 10, 2014",,"August 17, 2016","NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02236702"
1321,"NCT01361815","Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)",,"Completed","No Results Available","Major Depressive Disorder, Recurrent, Unspecified|Major Depressive Disorder, Single Episode, Unspecified","Device: H-Coil Deep TMS in combination with SSRIs","The tolerability and safety of H-coil deep rTMS treatment in combination with SSRI medications","Brainsway","All","22 Years to 68 Years   (Adult, Older Adult)","Not Applicable","75","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTP-0002-00","July 2011","December 2014","December 2014","May 27, 2011",,"July 15, 2020","UC Davis Center for Mind & Brain, Davis, California, United States|University of California (UCLA), Los Angeles, California, United States|Smart Brain and Health, Santa Monica, California, United States|Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States|Advanced Mental Health Care Inc. - Royal Palm Beach, Royal Palm Beach, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|McLean Hospital - TMS Services, Belmont, Massachusetts, United States|Greater Nashua Mental Health Center, Nashua, New Hampshire, United States|Neuropharmacology Services, New York, New York, United States|Columbia University / New York State Psychiatric Institute, New York, New York, United States|Medical Uni. Of South Carolina (MUSC), Charleston, South Carolina, United States|Senior Adults Specialty Research, Austin, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Center for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|Universitätsklinikum Bonn, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Bonn, Germany|Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität, Munich, Germany|Beer Yaacov Mental Health Center, Be'er Ya'aqov, Israel|Shalvata Mental Health Center, Hod Hasharon, Israel|Hadasah Ein-Karem Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01361815"
1322,"NCT00844194","Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder",,"Completed","Has Results","Diabetic Neuropathies|Depressive Disorder, Major","Drug: Duloxetine 60 mg QD|Drug: Duloxetine 30 mg QD|Drug: Duloxetine 90 mg QD|Drug: Duloxetine 120 mg QD","Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12|Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 6|Change in BPI Worst Pain During Treatment From Baseline to Week 2|Change in Worst Pain (BPI) From Baseline to Week 6|Change in Worst Pain (BPI) From Baseline to Week 12|Change in Least Pain (BPI) From Baseline to Week 2|Change in Least Pain During Treatment (BPI) From Baseline to Week 6|Change in Least Pain (BPI) From Baseline to Week 12|Change in Average Pain (BPI) From Baseline to Week 2|Change in Average Pain During Treatment (BPI) From Baseline to Week 6|Change in Average Pain (BPI) From Baseline to Week 12|Number of Patients With a Reduction in BPI Average Pain at Week 2|Number of Patients With a Reduction in BPI Average Pain at Week 6|Number of Patients With a Reduction in BPI Average Pain at Week 12|Change in Pain During Treatment (BPI) From Baseline to Week 2|Change in Pain (BPI) From Baseline to Week 6|Change in Pain During Treatment (BPI) From Baseline to Week 12|Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 2|Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 6|Change in Relief of Pain (BPI) From the Week Before Baseline to the Week Before Week 12|Change in Interference of Pain With General Activity (BPI) From Baseline to Week 2|Change in Interference of Pain With General Activity (BPI) From Baseline to Week 6|Change in Interference of Pain With General Activity (BPI) From Baseline to Week 12|Change in Interference of Pain With Mood (BPI) From Baseline to Week 2|Change in Interference of Pain With Mood (BPI) From Baseline to Week 6|Change in Interference of Pain With Mood (BPI) From Baseline to Week 12|Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 2|Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 6|Change in Interference of Pain With Walking Ability (BPI) From Baseline to Week 12|Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 2|Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 6|Change in Interference of Pain With Normal Work (BPI) From Baseline to Week 12|Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 2|Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 6|Change in Interference of Pain With Relations to Other People (BPI) From Baseline to Week 12|Change in Interference of Pain With Sleep (BPI) From Baseline to Week 2|Change in Interference of Pain With Sleep (BPI) From Baseline to Week 6|Change in Interference of Pain With Sleep (BPI) From Baseline to Week 12|Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 2|Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 6|Change in Interference of Pain With Enjoyment of Life (BPI) From Baseline to Week 12|Patient Global Impression - Improvement (PGI-I) at Week 2|Patient Global Impression - Improvement (PGI-I) at Week 6|Patient Global Impression - Improvement (PGI-I) at Week 12|Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 2|Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 6|Change in Beck Depression Inventory Total Score (BDI-II) From Baseline to Week 12|Change in Hospital Anxiety and Depression Scale (HADS) Anxiety Total Score From Baseline to Week 2|Change in HADS Anxiety Total Score From Baseline to Week 6|Change in HADS Anxiety Total Score From Baseline to Week 12|Change in HADS Depression Total Score From Baseline to Week 2|Change in HADS Depression Total Score From Baseline to Week 6|Change in HADS Depression Total Score From Baseline to Week 12|Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 6|Change in Short Form Health Survey (SF-12) - Physical Component Summary From Baseline to Week 12|Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 6|Change in Short Form Health Survey (SF-12) - Mental Component Summary From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Interference of Pain (With Subjective Well-being) From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Interference of Pain From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Support From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Support Which the Patient Received From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Pain Severity From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Life Control From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Affective Distress From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Negative Responses From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Solicitous Responses From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Degree to Which Significant Others Display Distracting Responses to the Patient's Pain Behaviors and Complaints From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Household Chores From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Outdoor Work From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): Social Activities From Baseline to Week 12|Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 6|Change in Multidimensional Pain Inventory (MPI): General Activities From Baseline to Week 12|Change in Clinical Global Impression - Severity Pain From Baseline to Week 2|Change in Clinical Global Impression - Severity Pain From Baseline to Week 6|Change in Clinical Global Impression - Severity Pain From Baseline to Week 12|Change in Hamilton Depression Score From Baseline to Week 2|Change in Hamilton Depression Score From Baseline to Week 6|Change in Hamilton Depression Score From Baseline to Week 12|Suicidal Thoughts by BDI-II at Week 2|Suicidal Thoughts by BDI-II at Week 6|Suicidal Thoughts by BDI-II at Week 12|Suicidal Thoughts or Behaviours by HAMD-17 at Week 2|Suicidal Thoughts or Behaviours by HAMD-17 at Week 6|Suicidal Thoughts or Behaviours by HAMD-17 at Week 12|Change of Fasting Blood Glucose From Baseline at Week 12|Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline at Week 12|Change of Systolic Blood Pressure From Baseline at Week 12|Change of Diastolic Blood Pressure From Baseline at Week 12|Change of Pulse Rate From Baseline at Week 12","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","108","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1208.34|2008-002731-32","February 2009","June 2010",,"February 16, 2009","October 31, 2011","May 15, 2014","1208.34.49008 Boehringer Ingelheim Investigational Site, Achim bei Bremen, Germany|1208.34.49025 Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|1208.34.49001 Boehringer Ingelheim Investigational Site, Bad Mergentheim, Germany|1208.34.49018 Boehringer Ingelheim Investigational Site, Baesweiler, Germany|1208.34.49007 Boehringer Ingelheim Investigational Site, Berlin-Steglitz, Germany|1208.34.49002 Boehringer Ingelheim Investigational Site, Berlin, Germany|1208.34.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany|1208.34.49009 Boehringer Ingelheim Investigational Site, Berlin, Germany|1208.34.49021 Boehringer Ingelheim Investigational Site, Bremen, Germany|1208.34.49028 Boehringer Ingelheim Investigational Site, Frankfurt am Main, Germany|1208.34.49012 Boehringer Ingelheim Investigational Site, Gera, Germany|1208.34.49004 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1208.34.49020 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1208.34.49023 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1208.34.49015 Boehringer Ingelheim Investigational Site, Hattingen, Germany|1208.34.49027 Boehringer Ingelheim Investigational Site, Heidenheim, Germany|1208.34.49016 Boehringer Ingelheim Investigational Site, Kelkheim, Germany|1208.34.49006 Boehringer Ingelheim Investigational Site, Limburgerhof, Germany|1208.34.49022 Boehringer Ingelheim Investigational Site, Münster, Germany|1208.34.49019 Boehringer Ingelheim Investigational Site, Neuwied, Germany|1208.34.49024 Boehringer Ingelheim Investigational Site, St. Ingberg, Germany|1208.34.49010 Boehringer Ingelheim Investigational Site, Stuhr, Germany|1208.34.49013 Boehringer Ingelheim Investigational Site, Unterhaching, Germany|1208.34.49029 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany|1208.34.49026 Boehringer Ingelheim Investigational Site, Wuppertal, Germany",,"https://ClinicalTrials.gov/show/NCT00844194"
1323,"NCT04055181","Influence of rTMS on Symptoms and Cognitive Function in Patients With Psychiatric Disorders",,"Completed","No Results Available","Schizophrenia|Major Depressive Disorder","Device: rTMS in schizophrenia Controls|Device: rTMS in schizophrenia patients|Device: rTMS in major depressive disorders controls|Device: rTMS in major depressive disorders patients","symptoms assessed on PANSS|cognitive functioning assessed on RBANS|major depressive disorders assessed on Diagnostic and Statistical Manual of Mental Disorders (DSM-V)|Side effect assessed on UKU","Beijing HuiLongGuan Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CASPsy2","December 1, 2018","December 30, 2019","January 30, 2020","August 13, 2019",,"June 9, 2021","Chaohu Hospital of Anhui medical unviersity, Chaohu, Anhui, China|Zhongshan Third People's Hospital, Zhongshan, Guangdong, China|Wuhan Mental Health Center, Wuhan, Hubei, China|Ganzhou Third Hospital, Ganzhou, Jiangxi, China|Ningxia Mental Health Center, Ning'an, Ningxia, China|Xi'an Mental Health Center, Xi'an, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT04055181"
1324,"NCT01134731","Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation","AFSP","Completed","Has Results","Major Depressive Disorder|Suicidal Ideation","Drug: paliperidone|Drug: lithium|Drug: Placebo","Mean Score of Beck Scale for Suicidal Ideation of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment|Mean Score of Montgomery-Asberg Depression Scale of Three Treatment Groups (Paliperidone, Lithium and Placebo) After 3 Months of Treatment","University of Alabama at Birmingham|American Foundation for Suicide Prevention|Ortho-McNeil Janssen Scientific Affairs, LLC","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 4","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F100329001","May 2010","February 2014","February 2014","June 2, 2010","January 29, 2016","March 3, 2016","UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01134731"
1325,"NCT00610649","Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)",,"Completed","Has Results","Depression","Drug: MK-8777|Drug: Placebo","Part 1: Number of Participants With Moderate Intensity Adverse Events (AEs)|Part 1: Number of Participants With Serious Adverse Events (SAEs)|Part 1: Number of Participants With AEs Leading to Discontinuation of Study Drug|Part 2: Number of Participants With AEs|Part 2: Number of Participants With AEs Leading to Discontinuation of Study Drug|Part 1: Change From Baseline in the Montgomery-Ashberg Depression Rating Scale (MADRS)|Part 2: Change From Baseline in the MADRS","Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05704|174001","September 20, 2007","November 18, 2008","December 10, 2008","February 8, 2008","July 2, 2014","November 6, 2018",,,"https://ClinicalTrials.gov/show/NCT00610649"
1326,"NCT04430556","Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients",,"Active, not recruiting","No Results Available","Major Depressive Disorder|Anxiety Disorders","Drug: Sertraline","Response on Hamilton Anxiety Rating Scale|Response on Clinical Global Impression-Improvement|Response on Hamilton Depression Rating Scale|Response on Montgomery-Asberg Scale for Depression|Response on Columbia Scale for Suicidality|Response on State-Trait Depression Inventory|Response on Beck Anxiety Inventory|Response on EQ-5D","Hospital Universitario Dr. Jose E. Gonzalez|Instituto de Información e Investigación en Salud Mental A. C.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PS18-00016","July 1, 2018","December 2020","December 2020","June 12, 2020",,"June 12, 2020","Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04430556"
1327,"NCT04315597","Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes",,"Completed","No Results Available","Moderate Depressive Episodes (Major Depression)","Drug: Laif® 900, BAY98-7108|Drug: Placebo","Relapse rate|Time between baseline and occurrence of relaps measured by: Total score of HAMD-17|Time between baseline and occurrence of relaps measured by: Beck Depression Inventory (BDI)|Time between baseline and occurrence of relaps measured by: Clinical Global Impressions (CGI)|Global assessment of efficacy by investigators and patients|Safety and Tolerability: Number of Adverse Events","Bayer|Steigerwald Arzneimittelwerk GmbH","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","398","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20997|2008-001417-26","March 3, 2009","November 22, 2011","November 22, 2011","March 19, 2020",,"March 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04315597"
1328,"NCT01364649","Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction",,"Completed","Has Results","Treatment Outcome","Drug: Vortioxetine|Drug: Escitalopram|Drug: Placebo","Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8|Change From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed|Number of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed","Takeda","All","18 Years to 55 Years   (Adult)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LuAA21004_318|U1111-1120-3483","June 2011","December 2013","December 2013","June 2, 2011","October 9, 2014","October 9, 2014","Birmingham, Alabama, United States|Tucson, Arizona, United States|Anaheim, California, United States|Chino, California, United States|Costa Mesa, California, United States|Encino, California, United States|Escondido, California, United States|Irvine, California, United States|Newport Beach, California, United States|Oceanside, California, United States|San Diego, California, United States|Norwich, Connecticut, United States|Washington, District of Columbia, United States|Coral Springs, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Lauderhill, Florida, United States|North Miami, Florida, United States|Orlando, Florida, United States|Sanford, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Joliet, Illinois, United States|Lake Charles, Louisiana, United States|Shreveport, Louisiana, United States|Gaithersburg, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Weymouth, Massachusetts, United States|Flowood, Mississippi, United States|Creve Coeur, Missouri, United States|St. Louis, Missouri, United States|Toms River, New Jersey, United States|Willingboro, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Cincinatti, Ohio, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Waukesha, Wisconsin, United States|Medicine Hat, Alberta, Canada|Kelowna, British Columbia, Canada|Penticton, British Columbia, Canada|Sydney, Nova Scotia, Canada|Burlington, Ontario, Canada|Chatham, Ontario, Canada|Kingston, Ontario, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01364649"
1329,"NCT00695552","The Effect of Exercise on Depressive Symptoms in Unmedicated Patients","DEMOII","Unknown status","No Results Available","Major Depression","Behavioral: Aerobic exercise|Behavioral: Low impact exercise","HAM-D17|Remission from depression (not fulfilling the DSM-IV criteria for depression and a hamilton rating below 8)","University of Copenhagen","All","18 Years to 60 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DEMOII","September 2008","January 2011","April 2011","June 12, 2008",,"March 18, 2010","Psychiatric Center Bispebjerg, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00695552"
1330,"NCT04423471","Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis","INPSYDER","Recruiting","No Results Available","Psoriasis|Neuroinflammation|Major Depressive Disorder|Cognitive Symptom|Immunological Abnormality","Diagnostic Test: Sociodemographic variables","Correlation between immunological markers and affective and cognitive symptoms at baseline.|Changes in immunological markers and affective and cognitive symptoms between baseline and after 4 months of treatment.|Correlation between immunological markers and the course of psychiatric comorbidity in relation to anti-inflammatory treatments|Correlation between the course of major depression with antidepressant treatment and biomarkers of inflammation","Germans Trias i Pujol Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"123","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI-16-150","February 1, 2021","March 2022","December 2022","June 9, 2020",,"February 3, 2021","Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT04423471"
1331,"NCT00901407","Lamotrigine Augmentation in Resistant Depression",,"Completed","No Results Available","Unipolar Depression","Drug: lamotrigine|Drug: placebo|Drug: paroxetine","MADRS score|Ham-D score|CGI-S and CGI-I","Louisiana State University Health Sciences Center in New Orleans|GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","138","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LMC-R93","December 2003","July 2006","April 2007","May 13, 2009",,"May 13, 2009","LSUHSC- New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00901407"
1332,"NCT01774747","A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder","MAD","Terminated","No Results Available","Healthy","Drug: DSP-1053|Drug: Placebo","To reach minimumally intolerable dose based on stopping criteria|Characterize the pharmacodynamic relationship based on serotonin transporter occupancy of DSP-1053 following multiple oral doses of DSP-1053 in healthy subjects and major depressive disorder subjects|To characterize exposure of DSP-1053 and its metabolites (AUC, Cmax and Tmax) after multiple ascending dose of DSP-1053","Sunovion","All","18 Years to 50 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D7750090","December 2012","April 2014","April 2014","January 24, 2013",,"June 18, 2014","California Clinical Trials Medical Group, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01774747"
1333,"NCT01942733","Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder",,"Completed","Has Results","Sleep Disturbances","Drug: Brexpiprazole","Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Parameters|Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Number of Awakenings (PSG NAW)|Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Sleep Efficiency (PSG SE)|Changes From Baseline to Week 8 on Sleep Quality as Assessed by the Consensus Sleep Diary for Morning (CSD-M) Sleep Efficiency (SE)|Changes From Baseline to Week 8 on Sleep Quality as Assessed by the Consensus Sleep Diary for Morning (CSD-M)|Changes From Baseline to Week 8 on Sleep Quality as Assessed by the Consensus Sleep Diary for Morning (CSD-M) Number of Awakenings (NAW)|Changes From Baseline to Week 8 in Sleep Architecture as Assessed With Polysomnography|Changes From Baseline to Week 8 in Sleep Architecture as Assessed With Polysomnography (Continued)|Change From Baseline to Week 8 in ISI Total Score|Change From Baseline to Week 8 on ESS Total Score|Changes From Baseline to Week 8 in Response Speed as Assessed Using a PVT Device|Changes From Baseline to Week 8 in Number of Lapses as Assessed Using a PVT Device|Change From Baseline to Week 8 on BL-VAS-s (Evening) Score|Change From Baseline to Week 8 on BL-VAS-s (Morning) Score|Change From Baseline to Week 8 on BL-VAS-s Scores (Noon)|Change From Baseline to Week 8 in CPFQ Total Score|Changes From Baseline to Week 8 in Circadian and Biological Rhythm|Change From Baseline to Week 8 in MADRS Total Score|Change From Baseline to Week 8 in CGI-S Score|Percentage of MADRS Responders at Week 8|Percentage of MADRS Remitters at Week 8|Changes From Baseline to Week 8 on Sleep Quality as Assessed by Actigraphy (ACT) Parameters|Changes From Baseline to Week 8 on Sleep Efficiency (SE) as Assessed by Actigraphy (ACT)|Changes From Baseline to Week 8 on Number of Awakenings (NAW) as Assessed by Actigraphy (ACT)|Change From Baseline to Week 8 in BRIAN Total Score|CGI-I Score at Week 8","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","44","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15352A","September 2013","August 2014","August 2014","September 16, 2013","March 1, 2016","March 20, 2019",,,"https://ClinicalTrials.gov/show/NCT01942733"
1334,"NCT02502604","Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder",,"Completed","No Results Available","Major Depressive Disorder|Post-traumatic Stress Disorder","Behavioral: Goal Management Training","Verbal and Phonemic Fluency on the Controlled Oral Word Association Task|Processing speed and response inhibition on the Stoop Colour and Word Test|Attention alternation on the Trail Making Test Part B|Forming and shifting concepts on the Wisconsin Card Sorting Task|Processing speed on the Weschler Adult Intelligence Scale IV - Symbol Coding subtest|Inattentiveness, impulsivity, sustained attention and vigilance on Connors Continuous Performance Task|Working memory on the N-back Task|Immediate and delayed memory, interference learning and recognition on the California Verbal Learning Test II|Contextually based memory on the Weschler Memory Scale III - Logical Memory|Nonverbal visuospatial memory on the Brief Visuospatial Memory Test - Revised|Current intellectual functioning on the Weschler Abbreviated Scale of Intelligence - II|Pre-morbid intellectual functioning on the National Adult Reading Test|Self-reported executive difficulties on the Dysexecutive Questionnaire|Self reported daily errors in distractibility, blunders, and memory on the Cognitive Failures Questionnaire|Self reported work, education, and residential functioning on the Multidimensional Scale of Independent Functioning|Disability in work, social relationships, and family life on the Sheehan Disability Scale|Functional competence on the Canadian Objective Assessment of Life Skills - Brief Version|Current PTSD symptomatology on the Clinician Administered PTSD Scale for DSM 5|Exposure ot childhood trauma on the Childhood Trauma Questionnaire|Dissociative symptoms on the Multiscale Dissociation Inventory|Current depressive symptomatology on the Beck Depression Inventory - II|Current anxiety symptomatology on the Beck Anxiety Inventory","St. Joseph's Healthcare Hamilton","All","18 Years to 60 Years   (Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0416","September 2015","August 2018","August 2018","July 20, 2015",,"February 11, 2021","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02502604"
1335,"NCT00955955","Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder","TRD-2","Completed","Has Results","Depression","Other: 6(S)-5-MTHF(Deplin)|Other: Placebo","The 17-item Hamilton Depression Scale (HAM-D-17)|The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)","George I. Papakostas|Pamlab, L.L.C.|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006P000604 (2)","July 2009","April 2011","April 2011","August 10, 2009","January 18, 2013","April 28, 2017","University of California San Diego School of Medicine, San Diego, California, United States|Rush University Medical Center, Psychiatric Medicine Associates, LLC, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Cincinnati, College of Medicine, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00955955"
1336,"NCT04106466","DBS for TRD With the Medtronic Summit RC+S",,"Recruiting","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Device: Medtronic Summit RC+S DBS system","Change in Hamilton Depression Rating Scale (HDRS) score|Change in Montgomery-Asberg Depression Rating Scale (MADRS)","Helen Mayberg, MD|Emory University|Georgia Institute of Technology|National Institute of Neurological Disorders and Stroke (NINDS)|Icahn School of Medicine at Mount Sinai","All","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","GCO 17-2763|5UH3NS103550","January 21, 2020","December 31, 2023","December 31, 2030","September 27, 2019",,"August 31, 2020","Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04106466"
1337,"NCT00208156","A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Mifepristone","To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-07|To assess the frequency of retreatment with Corlux in patients with PMD and qualitatively describe the psychotic symptoms for which retreatment is clinically indicated","Corcept Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","87","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-1073-10","May 2005","November 2006","November 2006","September 21, 2005",,"February 15, 2012","Cnri, Llc, San Diego, California, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Robert Horne M.D., Las Vegas, Nevada, United States|CNS Research Institute (CRI), Clementon, New Jersey, United States|New Jersey Medical School - UMDNJ, Newark, New Jersey, United States|BioBehavioral Health, Toms River, New Jersey, United States|Zucker Hillside Hospital, Glen Oaks, New York, United States|Neurobehavioral Research, Inc., Lawrence, New York, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|CNS Research Institute (CRI), Philadelphia, Pennsylvania, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|International Clinical Research Associates, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00208156"
1338,"NCT00853346","Psychosocial Treatment of Depression in Parkinson's Disease",,"Unknown status","No Results Available","Major Depressive Disorder|Parkinson's Disease","Behavioral: Cognitive Behavioral Therapy","Response according to the Hamilton Rating Scale for Depression, 17 items (HAM-D 17).","Amy Farabaugh, PhD|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MH076037-01","April 2007","April 2013","April 2013","March 2, 2009",,"November 16, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00853346"
1339,"NCT00319540","RCT of Psychoeducational Program of Depression",,"Completed","No Results Available","Unipolar Depression","Behavioral: Control with depression course (CWD)","BeckDepression Inventory : A questionnaire with 23 items to measure symptoms of depression","Norwegian Institute of Public Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","155","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2906","March 2001",,"March 2002","April 27, 2006",,"April 27, 2006","Norwegian Institute of Public Health, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00319540"
1340,"NCT01244711","Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines",,"Terminated","Has Results","Major Depression|Generalized Anxiety Disorder","Drug: quetiapine","Montgomery Asberg Depression Rating Scale (MADRS)","Weill Medical College of Cornell University|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","1","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRUSQUET0483","September 2008","September 2011","September 2011","November 19, 2010","March 6, 2015","April 3, 2015","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01244711"
1341,"NCT00650897","Efficacy Study of Escitalopram for Depression in Patients With Diabetes","EFDID","Unknown status","No Results Available","Major Depression|Diabetes Mellitus","Drug: Escitalopram","Depressive symptoms|Diabetes self-care","Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-06-4426-RG-CTIL","April 2008","June 2009","October 2009","April 2, 2008",,"April 2, 2008","Sheba Medical Center, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT00650897"
1342,"NCT00626340","Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder",,"Completed","Has Results","Menopause|Depression","Drug: MDD diagnosis and Estrogen treatment|Drug: MDD diagnosis and Fluoxetine treatment|Drug: MDD diagnosis with both Estrogen and Fluoxetine treatment|Drug: No depression and estrogen treatment","Comparison of Cortical GABA Levels in 4 Groups of Subjects Using Estrogen Alone, Fluoxetine Alone, Estrogen and Fluoxetine Combined in Pre and Post 4.0T Magnetic Resonance Spectroscopy Sessions.","University of Pennsylvania","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9907010780","July 1999","July 2008","July 2008","February 29, 2008","June 1, 2017","June 1, 2017","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00626340"
1343,"NCT00704860","Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism",,"Completed","No Results Available","Major Depression","Other: Open label pharmacotherapy","Sustained Remission from Depression and Hippocampal Atrophy|5-HT1a Genetic Markers","University of Ottawa","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REB- 200506","February 2005","November 2009","December 2010","June 25, 2008",,"January 19, 2011","University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00704860"
1344,"NCT00149825","Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome",,"Completed","Has Results","Major Depressive Disorder|Insomnia","Drug: Escitalopram|Behavioral: CBTI|Behavioral: CTRL","Remission of Depression (%)|Remission of Insomnia","Stanford University|National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R21MH066131|DSIR 83-ATAS","June 2004","August 2007","August 2007","September 8, 2005","October 14, 2009","May 20, 2014","Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00149825"
1345,"NCT00269334","Clinical Pharmacogenomics of Antidepressant Response",,"Unknown status","No Results Available","Major Depression","Drug: Using Citalopram(drug) or Paroxetine(drug)","Using the following assessment instruments:|Structured Clinical Interview for DSM-IV Disorders (SCID) at week baseline.|Hamilton Depression Rating Scale (HAM-D) at week 1,2,4,6,8.|Beck Depression Inventory (BDI) at week 1,2,4,6,8.|Clinical Global Impression Scale (CGI) at week 1,2,4,6,8.|Patient's Global Improvement Scale (PGI) at week 1,2,4,6,8.|Treatment Emergent Symptoms Scale (TESS) at week 1,2,4,6,8.|Arizona Sexual Experience Scale (ASEX) at week 1,2,4,6,8.","National Health Research Institutes, Taiwan|National Science Council, Taiwan|Taipei Medical University WanFang Hospital|Chang Gung Memorial Hospital|Jing-Ho Mental Hospital, Taiwan|Tsyr-Huey Mental Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC0931204|NSC 94-2314-B-400 -001 -","December 2005",,"November 2007","December 23, 2005",,"December 23, 2005","Jing-Ho Mental Hospital, Kaohsiung, Taiwan|TSYR-HUEY(LOVING) Mental Hospital, Kaohsiung, Taiwan|Taipei Municipal Wang-Feng Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00269334"
1346,"NCT00168493","The Neurobiology of Depressive Illness",,"Unknown status","No Results Available","Major Depression","Drug: antidepressants primarily selective serotonin reuptake inhibitors","level of sympathetic nervous system activity and its response to treatment|clinical response to treatment","Baker Heart Research Institute|National Health and Medical Research Council, Australia","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NHMRC D-01","June 2000","December 2008","December 2009","September 15, 2005",,"May 20, 2008","Baker Heart Research Institute, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00168493"
1347,"NCT00696293","Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults","ACHIEVE2","Completed","Has Results","Major Depressive Disorder|Back Pain|Aged","Drug: Duloxetine","Change in Montgomery Asberg Depression Rating Scale(MADRS) Score From Baseline and 12 Weeks|Change in McGill Pain Questionaire, Short Form, Score From Baseline and 12 Weeks","University of Pittsburgh|National Institutes of Health (NIH)|Eli Lilly and Company","All","60 Years and older   (Adult, Older Adult)","Phase 4","30","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KL2RR024154","May 2007","March 2010","April 2010","June 12, 2008","May 26, 2016","February 1, 2017","University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00696293"
1348,"NCT00541957","Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients",,"Completed","No Results Available","Major Depression","Behavioral: behavior therapy|Drug: Medication prescribed by PCP","Depression symptoms|Psychosocial functioning","Butler Hospital|Memorial Hospital of Rhode Island","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","K23MH067779","April 2007","September 2009","January 2010","October 10, 2007",,"July 8, 2011","Memorial Hospital of RI, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00541957"
1349,"NCT01483391","Early Intervention for Youth at Risk for Bipolar Disorder",,"Unknown status","No Results Available","Bipolar Disorder|Major Depressive Disorder","Behavioral: Enhanced Care|Behavioral: Family-Focused Treatment","Changes in symptom severity|Delaying onset of a first (hypo)manic or mixed episode|Psychosocial functioning|Mental health service use","University of California, Los Angeles|Stanford University|University of Colorado, Boulder","All","9 Years to 17 Years   (Child)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R01MH093676","October 2011","December 30, 2019","July 1, 2020","December 1, 2011",,"April 18, 2019","UCLA Child and Adolescent Mood Disorders Program, UCLA School of Medicine, Los Angeles, California, United States|Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, California, United States|University of Colorado, Boulder, Boulder, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01483391"
1350,"NCT02872454","Psychotherapeutic Text Messaging for Depression Pilot Study","TEXT4U","Completed","No Results Available","Major Depression","Behavioral: Text Messaging","Intervention Feasibility|Perceived Helpfulness of Messages|Change in Depression Symptoms","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","190","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HUM00090058","April 2015","April 2016","April 2016","August 19, 2016",,"August 19, 2016","University of Michigan Inpatient Psychiatry Unit, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02872454"
1351,"NCT02307617","Glutamate Probes in Adolescent Depression","GPII","Completed","No Results Available","Major Depressive Disorder|Major Depressive Disorder, Recurrent|Major Depressive Disorder, Remitted",,"Concentrations of GABA and glutamate in the brains of adolescents with MDD.|The change of GABA and glutamate concentrations in adolescents with MDD after 6 weeks of SSRI treatment.|The effect of glutamatergic and GABAergic functioning on human development in adolescents with MDD|The effect of glutamatergic and GABAergic functioning on human development in adolescents with MDD after 6 weeks of SSRI treatment.","Mayo Clinic","All","13 Years to 21 Years   (Child, Adult)",,"57","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","14-004662","August 1, 2014","April 17, 2017","April 17, 2017","December 4, 2014",,"April 23, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02307617"
1352,"NCT02122562","Ketamine Alcohol (in Treatment-Resistant Depression)",,"Recruiting","No Results Available","Magnetic Resonance Imaging|Major Depression|Alcoholism","Drug: Ketamine|Other: Alcohol Infusion","Montgomery-Åsberg Depression Rating Scale (MADRS)|Biphasic Alcohol Effects Scale (BAES)|Drug Effects Questionnaire (DEQ)|Profile of Mood States (POMS)|Number of Drinks Questionnaire (NODQ)|Self Rating of the Effects of Alcohol (SRE) scale|Heart Rate Variability|Grooved Pegboard (GPB)|Body Sway|Balloon Analogue Risk Task (BART)|Risk Taking Task|Concentration of Glutamate and Other Neurometabolites|Resting State Functional Connectivity|Hamilton Depression Rating Scale (HDRS)|Beck Depression Inventory (BDI)|Hamilton Psychiatric Rating Scale for Anxiety (HAM-A)|Young Mania Rating Scale (YMRS)|Snaith-Hamilton Pleasure Scale (SHAPS)|Temporal Experience of Pleasure Scale (TEPS)|Scale for Suicidal Ideation (SSI)|Columbia-Suicide Severity Rating Scale (C-SSRS)|Alcohol Urge Questionnaire (AUQ)|Obsessive Compulsive Drinking Scale (OCDS)|Brief Psychiatric Rating Scale (BPRS)|Visual Analog Scale (VAS)|Clinician-Administered Dissociative States Scale (CADSS)|Clinical Global Impression/Severity (CGI)|Modified Version of the NIMH Data Safety Event Codes (NIMH-DSEC)|The Positive and Negative Affect Schedule (PANAS)","Mark Niciu|National Institute of Mental Health (NIMH)|University of Iowa","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140085|14-M-0085","April 23, 2014","September 2021","September 2021","April 24, 2014",,"July 7, 2020","University of Iowa Health Care, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT02122562"
1353,"NCT03548545","tDCS as add-on Treatment to Cognitive-Behavior Therapy in People With MDD","ESAP","Unknown status","No Results Available","Major Depressive Disorder|CBT|Transcranial Direct Current Stimulation","Device: tDCS","Mood improvement|EEG activity","University of Minho|Fundação para a Ciência e a Tecnologia","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","SECVS 174/2017","March 28, 2018","December 31, 2019","December 31, 2020","June 7, 2018",,"June 15, 2018","School of Psychology, University of Minho, Braga, Portugal",,"https://ClinicalTrials.gov/show/NCT03548545"
1354,"NCT02579928","Ketamine Infusion for Adolescent Depression and Anxiety",,"Completed","Has Results","Major Depressive Disorder|Anxiety Disorder","Drug: Ketamine|Drug: Midazolam","Montgomery-Asberg Depression Rating Scale Score 1 Day After Infusion","Yale University|American Academy of Child Adolescent Psychiatry.","All","13 Years to 17 Years   (Child)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1506016041","October 2015","September 28, 2018","September 2019","October 20, 2015","March 16, 2020","July 14, 2020","Hospital Research Unit at the Yale New Haven Hospital, New Haven, Connecticut, United States|Yale Child Study Center, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02579928/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02579928"
1355,"NCT00818506","Associations Between Depression and Cardiovascular Disease - a Study of Patients With Late Onset Depression",,"Completed","No Results Available","Depression|Major Depressive Disorder|Cardiovascular Disease|Coronary Artery Disease",,,"University of Aarhus|The Ministry of Science, Technology and Innovation, Denmark|Vejle Hospital|Danish National Research Foundation|Aarhus University Hospital|Augustinus Fonden","All","50 Years to 70 Years   (Adult, Older Adult)",,"55","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CPF-TAD-1","March 2009",,"June 2012","January 7, 2009",,"November 21, 2012","Center of Psychiatric Research, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT00818506"
1356,"NCT04731454","Feasibility and Acceptability of a Healthy Nordic Diet Intervention in Depressed and Non-depressed Adults",,"Completed","No Results Available","Depression|Major Depressive Disorder","Other: Control Diet (CD)|Other: Healthy Nordic Diet (ND)","Median rating of the liking of all meals as assessed by a Likert item (the Hedonic scale)|Median rating of the appearance of all meals as assessed by an original Likert item|Median rating of the smell of all meals as assessed by an original Likert item|Median rating of the extent to which the smell matches the appearance of the meals as assessed by an original Likert item|Median rating of the taste intensity of all meals as assessed by a Just About Right (JAR) scale|Median rating of the portion size of all meals as assessed by a Just About Right (JAR) scale|Median rating of feelings of fullness after the meals as assessed by an original visual analog scale (VAS)|Median perception of healthiness of all meals as assessed by an original visual analog scale (VAS)|Total amount of non-study foods consumed as assessed by self-report on a questionnaire every evening|Total amount of non-study drinks consumed as assessed by self-report on a questionnaire every evening|Total amount of provided juice drink not consumed as assessed by self-report on a questionnaire every evening.|Rating of how easy it was to follow the protocol, as assessed by an original Likert item on the final questionnaire|Rating of how easy it would be to participate in such a study, with meals recurring every 8 days for 8 weeks (but not having to fill out a questionnaire for the meals)|Change in work impairment after 8 days, as calculated from questions of the Work Productivity and Activity Impairment (WPAI) questionnaire|Change in activity impairment after 8 days, as calculated from questions of the Work Productivity and Activity Impairment (WPAI) questionnaire|Change in gastrointestinal symptom severity after 8 days, as assessed by the total mean score of the Gastrointestinal Symptoms Rating Scale (GSRS) questionnaire|Change in indigestion symptom severity after 8 days, as assessed by the indigestion sub-score of the Gastrointestinal Symptoms Rating Scale (GSRS) questionnaire|Change in physical activity level after 8 days, as assessed by the Frändin-Grimby Physical Activity Scale|Change in depression severity after 8 days, as assessed by the total score of the Montgomery-Åsberg Depression Rating Scale, self-rated (MADRS-S) questionnaire|Change in perceived general health status after 8 days, as assessed by the visual analog scale (VAS) question of the EuroQol Health-Related Quality of Life (EQ-5D-5L) questionnaire|Change in general health after 8 days, as assessed by the summary index value calculated from the questions of the EuroQol Health-Related Quality of Life (EQ-5D-5L) questionnaire|Self-reported change in health after 8 days, as assessed by a written open-ended response on the final questionnaire|Change in body weight after 8 days, as assessed by self-measurement or approximation","Örebro University, Sweden","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","2020-03735","September 15, 2020","October 2, 2020","October 2, 2020","February 1, 2021",,"February 1, 2021","Örebro University, Örebro, Närke, Sweden",,"https://ClinicalTrials.gov/show/NCT04731454"
1357,"NCT04898725","Effects of Vitamin D Supplementation on Depression and Inflammatory Markers",,"Recruiting","No Results Available","Major Depression|Vitamin D Deficiency","Dietary Supplement: Vitamin D3","Change of total score of 17-item Hamilton Depression Rating Scale (HDRS-17)|17-item Hamilton Depression Rating Scale (HDRS-17)|Response rate of 17-item Hamilton Depression Rating Scale (HDRS-17)|Remission rate of 17-item Hamilton Depression Rating Scale (HDRS-17)|End of intervention remission rate in17-item Hamilton Depression Rating Scale (HDRS-17)|Change of total score of Beck Depression Inventory-Second Edition|Significant change (mean±SD) in vitamin D status","Mackay Memorial Hospital","All","10 Years to 24 Years   (Child, Adult)","Not Applicable","460","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","109-2314-B-195 -017 -MY3","May 28, 2021","April 28, 2024","June 28, 2024","May 24, 2021",,"May 26, 2021","MacKay Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04898725"
1358,"NCT00592384","Project to Improve Symptoms and Mood in People With Spinal Cord Injury","PRISMS","Completed","Has Results","Major Depressive Disorder|Dysthymia|Spinal Cord Injuries","Drug: venlafaxine XR|Drug: placebo","Hamilton Depression Rating Scale-17|Hamilton Depression Rating Scale-Maier Subscale|Symptom Checklist-20 Depression Subscale|Modified Brief Pain Inventory|Modified Ashworth Spasticity Scale|Structured Clinical Interview for DSM IV Depression Module|SF-12|Side Effects Checklist|Craig Handicap and Reporting Technique|Satisfaction With Life|Sheehan Disability Scale|Clinical Global Impression|Patient Global Impression|Hamilton Rating Scale for Anxiety","University of Washington|University of Michigan|Shirley Ryan AbilityLab|University of Alabama at Birmingham|Baylor Health Care System|University of Miami|New York University","All","18 Years to 64 Years   (Adult)","Phase 4","133","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","31665-D|H133A060107;","July 2007","September 2012","September 2012","January 14, 2008","January 1, 2015","January 1, 2015","University of Alabama, Birmingham, Alabama, United States|University of Miami, Miami, Florida, United States|Rehabilitation Institute of Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Baylor Institute for Rehabilitation, Dallas, Texas, United States|University of Washington/Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00592384"
1359,"NCT04009135","The Internet Therapy for Depression Trial","INTEREST","Recruiting","No Results Available","Chronic Pain|Major Depressive Disorder","Behavioral: internet delivered cognitive behavioural therapy (iCBT)|Behavioral: online delivered acceptance and commitment therapy (iACT)|Other: Attention Control (AC)","Screening and Consent Rates|Change in symptoms of depression measured using the Patient Health Questionnaire - 9 (PHQ-9)|Adherence to intervention measured as frequency of visits to online modules.|Perceived acceptability of treatment measured using qualitative interviews|Change in physical function measured using the pain interference subscale of the Brief Pain Inventory - Short Form (BPI-SF)|Change in emotion function measured using the Depression, Anxiety Stress Scale - 21 (DASS-21).|Change in pain severity will be measured using the pain severity composite scale of the Brief Pain Inventory - Short Form (BPI-SF)|Change in psychological flexibility measured using the Multidimensional Psychological Flexibility Inventory (MPFI).|Mediators of change for cognitive behavioural therapy measured using change in the cognitive behavioural therapy skills questionnaire.|Mediators of change for acceptance and commitment therapy measured using change in the acceptance and action questionnaire.","Memorial University of Newfoundland","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HREB2018.275","June 10, 2019","December 31, 2021","December 31, 2021","July 5, 2019",,"October 22, 2020","Memorial University of Newfoundland, Saint John's, Newfoundland and Labrador, Canada",,"https://ClinicalTrials.gov/show/NCT04009135"
1360,"NCT00122031","Deep Brain Stimulation for Treatment-Refractory Major Depression",,"Completed","No Results Available","Depression","Device: Deep Brain Stimulation with Medtronic Activa Neurostimulator","Hamilton Depression Rating Scale (HDRS)|Montgomery-Asberg Depression Rating Scale (MADRS)","University Hospital, Bonn|Medtronic","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","13","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BSG-04-006","July 2005","April 2009","January 2011","July 21, 2005",,"June 14, 2012","Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT00122031"
1361,"NCT02046330","Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Device: Deep Brain Stimulation Model 3387 Model 3389","Changes in patients MADRS scores|Accuracy of Electrode placement|Frequency and Charge of Stimulation|Determine Feasibility of a Double Blind Study|Decrease in Neurocognitive scores on CSTC|Assess maintenance of treatment response (or remission) associated with chronic DBS:|Number of Adverse Events","The University of Texas Health Science Center, Houston|Medtronic","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-13-0004","November 2013","November 2022","November 2022","January 27, 2014",,"June 21, 2021","UT Center of Excellence on Mood Disorders, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02046330"
1362,"NCT02176226","IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)",,"Completed","Has Results","Major Depressive Disorder|Anxiety Disorders","Behavioral: IntelliCare","Patient Health Questionnaire - 9 (PHQ-9) - Depression Severity Module|GAD-7 (Generalized Anxiety Disorder Scale-7)|Mean Number of Treatment App Use Sessions by Study Week","Northwestern University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","105","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH100482-01FTIC","March 2015","June 2016","June 2016","June 27, 2014","October 29, 2018","October 29, 2018","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02176226"
1363,"NCT00188396","Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response",,"Completed","No Results Available","Major Depressive Disorder|Depression","Drug: Citalopram","Hamilton Depression Rating Scale (HAM-D)|Clinical Global Impression (CGI)|Trimodal Anxiety Questionnaire (TAQ)|Women's Health Questionnaire|Prism calender|Biological measures (β-estradiol, estrogen, progesterone, follicle-stimulating hormone [FSH], luteinizing hormone [LH], and testosterone)","University Health Network, Toronto|Ontario Mental Health Foundation","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-0225-AE","April 2004","October 2008","October 2008","September 16, 2005",,"March 13, 2009","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00188396"
1364,"NCT02181231","Buprenorphine Used With Treatment Resistant Depression in Older Adults","IRLGreyB","Completed","Has Results","Major Depressive Disorder|Depression","Drug: venlafaxine XR|Drug: buprenorphine|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)|Antidepressant Side Effect Checklist (ASEC)|Suicide Ideation Scale (SIS)|Brief Symptom Inventory-Anxiety Subscale (BSI)|Numeric Scale of Pain (NRS-P)","Washington University School of Medicine|Reckitt Benckiser LLC","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201406016|IND 123020|IND 130774","June 1, 2016","April 30, 2018","April 30, 2018","July 3, 2014","June 4, 2019","June 4, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02181231/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02181231"
1365,"NCT01458626","Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement",,"Completed","No Results Available","Major Depression","Drug: mirtazapine|Drug: paroxetine 20mg QD","Symptoms Improvement by HAMD-17|Self-reported improvement by QIDS-SR|Remission rate by HAMD-17|Remission rate by QIDS-SR|Response rate HAMD-17|Response rate by QIDS-SR|Clinical Global Impression-improvement|Clinical Global Impression- severity|Safety outcome 1|Safety outcome 2|Drop-off rate due to adverse events","Capital Medical University","All","18 Years to 60 Years   (Adult)","Phase 4","525","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MISP # 39888","November 14, 2012","August 24, 2016","August 24, 2016","October 25, 2011",,"August 31, 2017","Beijing Anding Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01458626"
1366,"NCT03595020","Probing Prefrontal Cortex Hemodynamic Alterations for Major Depression Disorder","MDD","Unknown status","No Results Available","Depressive Disorder, Major",,"Hamilton Depression Scale-17(HAMD-17) score alterations|facial emotion recognition|Pittsburgh Sleep Quality Index（PSQI）","Xijing Hospital|Health Science Center of Xi'an Jiaotong University","All","18 Years to 35 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","KY20172012-1","February 16, 2017","August 31, 2018","December 31, 2018","July 23, 2018",,"July 23, 2018","Department of psychiatry, Xijing Hospital; Research Institute of Biomedical Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03595020"
1367,"NCT01700829","Ketamine in the Treatment of Suicidal Depression",,"Completed","Has Results","Major Depressive Disorder|Suicidal Ideation","Drug: Ketamine|Drug: Midazolam","Change in Scale for Suicidal Ideation|Saliva Cortisol Awakening Response (CAR).|Neuropsychological Effects","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","82","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#6598|R01MH096784","June 2012","January 12, 2017","July 31, 2017","October 4, 2012","March 11, 2020","March 11, 2020","Columbia University/New York State Psychiatric Institute, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01700829/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT01700829"
1368,"NCT00517036","Omega-3 Fatty Acids for Treating Adults With Major Depression",,"Completed","No Results Available","Depression","Dietary Supplement: EPA omega-3 fatty acid|Dietary Supplement: DHA omega-3 fatty acid|Dietary Supplement: Placebo comparator","Depression rating scale score on HAM-D 17, SCID Mood Module","Cedars-Sinai Medical Center|National Institute of Mental Health (NIMH)|Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","196","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R01MH073765|DATR A5-ETMA","July 2006","January 2011","January 2011","August 16, 2007",,"April 4, 2013","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00517036"
1369,"NCT01035073","Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome",,"Completed","Has Results","Major Depressive Disorder|Soft Tissue Discomfort Syndrome|Pain","Drug: Duloxetine","24-hour Activity Level|Functional Symptom Questionnaire","University of Pennsylvania|Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F1J-US-X018","April 2006","May 2009","May 2009","December 18, 2009","April 16, 2020","April 16, 2020","Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01035073"
1370,"NCT01701141","Depression and Dopamine Transporter Function Study Using C-11 Altropane",,"Completed","No Results Available","Major Depressive Disorder|Anhedonia",,"11C-Altropane Binding|Behavioral Performance in Probabilistic Reward Task|Brain Activity during Instrumental Learning Task|Behavioral Performance in Instrumental Learning Task|Behavioral Performance in the Social Reinforcement Learning Task|Questionnaire Data|Behavioral Performance in Implicit Learning Serial Reaction Time Task","Mclean Hospital","All","18 Years to 45 Years   (Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2009-P-001360","January 2012","July 2014","July 2014","October 4, 2012",,"May 21, 2018","McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01701141"
1371,"NCT01976975","Brain Mechanisms of Human Motivation",,"Completed","Has Results","Major Depressive Disorder|Bipolar Disorder",,"Change in Response Bias|Mean Accuracy on Gain Trials During an Instrumental Learning Task|Symptom Severity at 6 Month Follow-up","Mclean Hospital","All","18 Years to 50 Years   (Adult)",,"270","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2013-P-001352","October 2013","January 2018","January 2018","November 6, 2013","April 23, 2019","August 4, 2021","McLean Hospital, Belmont, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01976975/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01976975"
1372,"NCT00644982","A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: sertraline|Drug: venlafaxine XR","Change from baseline in QOL, measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).|Change from baseline in the 17-item Hamilton-Depression Rating Scale (HAM-D) including response (≥50% reduction in HAM-D total score from baseline) and remission (HAM-D total score ≤7) rates.|The 17-item Hamilton-Depression Rating Scale response rates at endpoint (week 8).|CGI response rate at endpoint (week 8).|Change from baseline in the CGI-Severity Scale (CGI-S).|Change from baseline in the Hamilton Anxiety Scale (HAM-A).|Change from baseline in the Endicott Work Productivity Scale (EWPS).|Change from baseline in the Visual Analogue Scale (VAS) for Depression.|Change from baseline in the Visual Analogue Scale (VAS) for Overall Assessment of Pain.|Hamilton-Depression Rating Scale remission rates at endpoint (week 8).|Change from baseline in the Clinical Global Impression-Improvement Scale.","Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A0501066","October 2002",,"September 2003","March 27, 2008",,"January 27, 2021","Pfizer Investigational Site, Cairns, Queensland, Australia|Pfizer Investigational Site, Everton Park, Queensland, Australia|Pfizer Investigational Site, North Cairns, Queensland, Australia|Pfizer Investigational Site, Box Hill, Victoria, Australia|Pfizer Investigational Site, Heidelberg, Victoria, Australia|Pfizer Investigational Site, WEST Heidelberg, Victoria, Australia|Pfizer Investigational Site, West Perth, Western Australia, Australia|Pfizer Investigational Site, Adana, Turkey|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Diyarbakir, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Izmir, Turkey|Pfizer Investigational Site, Izmit, Turkey|Pfizer Investigational Site, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT00644982"
1373,"NCT04678232","Positive Processes and Transition to Health","PATH","Not yet recruiting","No Results Available","Major Depressive Disorder|Post Traumatic Stress Disorder","Behavioral: Positive Processes and Transition to Health (PATH)","Affective Updating Task (Pe et al., 2013; Pe, Raes, et al., 2013)|Idiographic Behavioral Approach Task|Probabilistic Reward Task (Pizzagalli et al., 2005)|Posttraumatic Cognitions Inventory (Foa et al., 1999)|Behavioral Activation for Depression Scale (Kanter et al., 2006)|Snaith-Hamilton Pleasure Scale (Snaith et al., 1995)","Case Western Reserve University|University of Washington|University of Delaware","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R61MH113646","October 1, 2021","June 30, 2023","June 30, 2023","December 21, 2020",,"May 10, 2021",,,"https://ClinicalTrials.gov/show/NCT04678232"
1374,"NCT00304746","AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment",,"Completed","Has Results","Depressive Disorder, Major","Drug: Testosterone gel|Drug: Placebo","21-item Hamilton Depression Rating Scale Score (HAM-D)|Montgomery Asberg Depression Rating Scale (MADRS)","Mclean Hospital|Solvay Pharmaceuticals","Male","30 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2005P-001667","April 2006","December 2008","April 2009","March 20, 2006","November 17, 2010","November 24, 2010","McLean Hospital, Belmont, Massachusetts, United States|The Chaim Sheba Medical Center, Tel-Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT00304746"
1375,"NCT00667680","Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression",,"Completed","No Results Available","Therapy Resistant Major Depression","Device: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator","Hamilton Psychiatric Rating Scale for Depression (HRSD-24)|Beck depression Inventory (BDI) Clinical Global Impression (CGI) Mini-Mental-Status-Test (MMST) Verbal Learning and Memory Test (VLMT) Regensburger Word Fluency Test (RWT)","Ludwig-Maximilians - University of Munich","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01/2007","March 2007","September 2008","November 2008","April 28, 2008",,"November 16, 2009","Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00667680"
1376,"NCT00745017","Stress Generation and Recurrent Depression: The Role of Differential Treatment Response",,"Completed","No Results Available","Depression|Major Depressive Disorder","Behavioral: Cognitive Behavioral Therapy|Behavioral: Interpersonal Therapy|Drug: Antidepressant medication","Hamilton Rating Scale for Depression","Centre for Addiction and Mental Health|Ontario Mental Health Foundation","All","18 Years to 60 Years   (Adult)","Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","091/2003","July 2001","July 2006",,"September 1, 2008",,"September 1, 2008","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00745017"
1377,"NCT04634669","Open-Label Safety Study of AXS-05 in Subjects With TRD",,"Enrolling by invitation","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Drug: AXS-05 (dextromethorphan-bupropion)","Incidence of treatment-emergent AEs (TEAEs) following dosing with AXS-05","Axsome Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AXS-05-TRD-202","September 23, 2020","May 2022","May 2022","November 18, 2020",,"July 30, 2021","Clinical Research Site, Little Rock, Arkansas, United States|Clinical Research Site, Redlands, California, United States|Clinical Research Site, Sherman Oaks, California, United States|Clinical Research Site, Upland, California, United States|Clinical Research Site, Miami, Florida, United States|Clinical Research Site, North Miami, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Chicago, Illinois, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, Berlin, New Jersey, United States|Clinical Research Site, Rochester, New York, United States|Clinical Research Site, Staten Island, New York, United States|Clinical Research Site, Hickory, North Carolina, United States|Clinical Research Site, Raleigh, North Carolina, United States|Clinical Research Site, Cincinnati, Ohio, United States|Clinical Research Site, Middleburg Heights, Ohio, United States|Clinical Research Site, Media, Pennsylvania, United States|Clinical Research Site, Dallas, Texas, United States|Clinical Research Site, Houston, Texas, United States|Clinical Research Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04634669"
1378,"NCT04608396","Mechanistic Evaluation of Response in TRD (MERIT)","MERIT","Recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Drug: AXS-05|Drug: Placebo","Relapse","Axsome Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AXS-05-TRD-201","August 13, 2020","September 2021","September 2021","October 29, 2020",,"March 26, 2021","Clinical Research Site, Little Rock, Arkansas, United States|Clinical Research Site, Redlands, California, United States|Clinical Research Site, Sherman Oaks, California, United States|Clinical Research Site, Upland, California, United States|Clinical Research Site, Miami, Florida, United States|Clinical Research Site, North Miami, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Chicago, Illinois, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, Berlin, New Jersey, United States|Clinical Research Site, Rochester, New York, United States|Clinical Research Site, Staten Island, New York, United States|Clinical Research Site, Hickory, North Carolina, United States|Clinical Research Site, Raleigh, North Carolina, United States|Clinical Research Site, Cincinnati, Ohio, United States|Clinical Research Site, Middleburg Heights, Ohio, United States|Clinical Research Site, Media, Pennsylvania, United States|Clinical Research Site, Dallas, Texas, United States|Clinical Research Site, Houston, Texas, United States|Clinical Research Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04608396"
1379,"NCT03999736","Biomarkers of Response to Treatment With Frontal Cortex Stimulation for Anxious Depression",,"Terminated","No Results Available","Major Depressive Disorder|Anxiety","Device: transcranial direct current stimulation using a Soterix mini-CT device","Number of participants with a reduction in depressive symptoms of 50% or more","Mclean Hospital","All","18 Years to 28 Years   (Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019P000167","February 13, 2020","February 9, 2021","February 9, 2021","June 27, 2019",,"February 12, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03999736"
1380,"NCT04037111","Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms",,"Recruiting","No Results Available","Major Depressive Disorder|Rheumatoid Arthritis","Device: Transcutaneous electrical vagus nerve stimulation|Device: Sham vagus nerve stimulation|Drug: drug treatment","Changes of Hamd-17 Scale Scores From Baseline to Week 8|Changes of Hamd-17 Scale Scores from Baseline to Week 4|Changes of MADRS Scale and SDS Scale Score from Baseline to Week 4 and Week 8|The Clinical Improvement Rate at Week 4 and Week 8|The Remission Rate after 8 Weeks' Treatment|Changes of Cytokines from Baseline to Week 4 and Week 8","Xijing Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","82554333","July 23, 2019","January 2021","December 2021","July 30, 2019",,"August 20, 2019","Xijing Hospital, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT04037111"
1381,"NCT01890083","A Health Intervention to Prevent Depression Hepatitis C Patients",,"Terminated","No Results Available","Hepatitis C|Major Depressive Disorder","Behavioral: Exercise|Behavioral: Health Education","Change in Depressive Symptoms over 6 months|Change in Sleep Quality over 6 months|Change in blood biomarkers over 6 months","University of Texas Southwestern Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","K01MH097847","June 2013","October 2015","October 2015","July 1, 2013",,"December 29, 2016","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01890083"
1382,"NCT00636246","A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.",,"Completed","No Results Available","Depressive Disorder, Major","Drug: sertraline/[S,S]-reboxetine|Drug: sertraline|Drug: Placebo|Drug: [S,S]-reboxetine monotherapy","The change from Baseline up to Week 8 (Visit 9) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score as measured by a mixed concentration, suicidal ideation and restlessness.|Change from Baseline in HAM-D (17-item) total score|Change from Baseline in the Hamilton Anxiety Rating Scale (HAM-A) and Apathy Evaluation Scale (AES)|The frequency and severity of treatment-emergent adverse events, ECG changes, laboratory and vital signs changes by treatment group using descriptive statistics.|Change from Baseline in MADRS total score","Pfizer's Upjohn has merged with Mylan to form Viatris Inc.|Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","510","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A0501075","June 2004",,"August 2005","March 14, 2008",,"January 28, 2021","Pfizer Investigational Site, Viljandi, Viljandi Mk., Estonia|Pfizer Investigational Site, Pärnu, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Kazan, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Rostov On Don, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00636246"
1383,"NCT01979289","Computerized Cognitive Remediation for Geriatric Depression",,"Unknown status","No Results Available","Major Depressive Disorder|Major Depressive Episode","Other: computerized cognitive remediation|Other: computerized cognitive remediation:Control","Montgomery-Asberg Depression Rating Scale","Weill Medical College of Cornell University","All","60 Years to 89 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","K23MH095830","August 2012","July 2017","July 2017","November 8, 2013",,"February 3, 2017","Weill Cornell Medical College, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT01979289"
1384,"NCT00642694","Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon","TAKEDA","Terminated","Has Results","Major Depressive Disorder|Insomnia","Drug: Escitalopram|Drug: Ramelteon|Other: Placebo","Percentage of Remitters on IDS-C30 at Week 12|Sleep Latency|Short-Form Health Survey - Version 2 (SF-36)|Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Social Adjustment Scale - Self-Report (SAS-SR)|Work and Social Adjustment Scale (WSAS)|Work Productivity and Activity Impairment Questionnaire (WPAI)|Patient Perception of Benefits of Care (PPBC)|Hamilton Rating Scale for Depression 17-item","University of Texas Southwestern Medical Center|Takeda Pharmaceuticals North America, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","29","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","06-031R|112006-017","May 2007","May 2010","May 2010","March 25, 2008","October 26, 2012","July 26, 2019","University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00642694"
1385,"NCT02378714","Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers",,"Completed","Has Results","Nicotine Dependence|Major Depressive Disorder","Drug: Varenicline|Behavioral: BASC|Behavioral: Standard treatment","Bioverified Point-prevalence Abstinence at 27 Weeks|Adverse Event and Serious Adverse Event Rates|Bioverified Point-prevalence Abstinence at 14 Weeks (End of Treatment)|Prolonged Abstinence|Continuous Abstinence|Time to 7-day Relapse","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STU00100303|1R01CA184211-01A1","July 24, 2015","March 13, 2020","March 13, 2020","March 4, 2015","May 27, 2021","July 29, 2021","Northwestern University, Chicago, Illinois, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02378714/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02378714/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02378714"
1386,"NCT00006286","Treatment for Adolescents With Depression Study (TADS)",,"Completed","No Results Available","Major Depressive Disorder|Depression","Drug: Fluoxetine|Behavioral: Psychotherapy",,"National Institute of Mental Health (NIMH)","All","12 Years to 17 Years   (Child)","Phase 3","432","NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","N01 MH80008|DSIR CT","September 1998",,"March 2004","September 15, 2000",,"April 17, 2014","Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Wayne State University, Detroit, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|New York University Medical Center, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States|Behavioral Health Center, Charlotte, North Carolina, United States|Children's Hospital Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|University of Oregon, Eugene, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00006286"
1387,"NCT00369798","Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients",,"Completed","No Results Available","Major Depressive Disorder|Healthy","Procedure: PET scan|Drug: Rolipram","PET measurement of PDE4 levels.|Correlation between PDE4 levels and depression symptoms","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 1","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","060215|06-M-0215","August 2, 2006","June 16, 2016","October 12, 2016","August 29, 2006",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00369798"
1388,"NCT00166296","Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients",,"Completed","Has Results","Major Depressive Disorder|Hepatitis C, Chronic","Drug: Escitalopram|Drug: Placebo","Number of Participants Who Developed a Major Depressive Episode According to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria During the First 12 Weeks of Antiviral Treatment.|Number of Participants With Sustained Hepatitis C Viral Response (Negativization of Serum Hepatitis C Virus Ribonucleic Acid).|Total Score in the Montgomery-Asberg Depression Rating Scale|Total Score in the Depression Subscale of the Hospital Anxiety and Depression Scale.","Germans Trias i Pujol Hospital|Hoffmann-La Roche|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","133","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PSQHEPGTP1|EudraCT number: 2004-002982-19","March 2005","October 2007","October 2007","September 14, 2005","March 30, 2011","August 17, 2020","Fundacion Hospital Alcorcon, Alcorcon, Spain|Hospital Nuestra Señora de Sonsoles, Avila, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Parc Tauli, Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Consorci Sanitari de Terrassa, Tarrasa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital General Universitario, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00166296"
1389,"NCT03307070","Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury",,"Recruiting","No Results Available","Major Depressive Disorder|Traumatic Brain Injury","Behavioral: Cognitive Behavioral Therapy for individuals with TBI|Other: Waitlist Control","QIDS-C","Massachusetts General Hospital|Spaulding Rehabilitation Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016P002823","September 23, 2017","June 1, 2021","June 1, 2021","October 11, 2017",,"September 1, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03307070/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03307070/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03307070"
1390,"NCT00322777","Spirituality Teaching Program for Depressed Adults",,"Completed","Has Results","Major Depression","Behavioral: Spirituality Teaching Program","Hamilton Depression Rating Scale - Depression Severity|Response Rate|Remission","Canadian Institute of Natural and Integrative Medicine|University of Calgary, Dept. of Psychiatry & Dept. of Community Health Sciences|Southwest Behavioral Health Sciences|Alberta Health Services|Arizona School of Health Sciences|The Center for Mind-Body Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Spirit II","January 2005","December 2006","December 2008","May 8, 2006","March 3, 2016","March 3, 2016","Canadian Institute of Natural and Integrative Medicine, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00322777"
1391,"NCT04780542","Internet-delivered Cognitive Behavioral Treatment of Depression and Anxiety in Latin American College Students",,"Recruiting","No Results Available","Major Depressive Disorder|Generalized Anxiety Disorder","Behavioral: Yo Puedo Sentirme Bien- Clinician-Guided version|Behavioral: Yo Puedo Sentirme Bien- Self-Guided version|Behavioral: Treatment as usual","Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7)|Sheehan Disability Scale (SDS)","Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|National Institute of Mental Health (NIMH)|Harvard Medical School","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EP20142|R01MH120648-01A1","March 1, 2021","May 2025","June 2025","March 3, 2021",,"April 27, 2021","Universidad Cooperativa de Colombia, Medellín, Colombia|Universidad Nacional Autonoma de México, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04780542"
1392,"NCT00149643","Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence","CADY","Completed","Has Results","Depressive Disorder, Major|Cannabis Abuse","Drug: Fluoxetine|Other: Placebo","Days Per Week of Cannabis Use.|Depression Symptoms at Week 12|Number of Cannabis Use Disorder Criterion Met at a Particular Time Point.","University of Pittsburgh|National Institute on Drug Abuse (NIDA)","All","14 Years to 25 Years   (Child, Adult)","Phase 2","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIDA-19142-1|R01DA019142|DPMC","September 2004","August 2009","December 2012","September 8, 2005","September 3, 2012","June 24, 2013","Department of Psychiatry, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00149643"
1393,"NCT04785456","rTMS for Suicidality in Opioid Use Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Opioid-use Disorder","Device: Active TBS|Device: Sham TBS","Change in Scale for Suicidal Ideation Remission|Change in Scale for Suicidal Ideation Change|Change in Columbia - Suicide Severity Rating Scale Change|17-item Hamilton Rating Scale for Depression (HRSD-17) Change|Visual Analogue Scale for Opioid Cravings Change|Timeline Followback Change","Centre for Addiction and Mental Health|The Physicians' Services Incorporated Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","131/2020","August 1, 2021","January 31, 2022","March 31, 2022","March 8, 2021",,"July 28, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04785456"
1394,"NCT04253678","Vortioxetine for Cancer Patients With Depression: An Observational Study",,"Recruiting","No Results Available","Major Depressive Disorder|Cancer","Drug: Vortioxetine","Changes in Montgomery-Asberg Depression Rating Scale (MADRS)|Changes in Perceived Deficits Questionnaire - 5 items (PDQ-5)|Changes in Clinical Global Impression (CGI)|Changes in EORTC-QLQ-C30","University of Malaya","All","18 Years and older   (Adult, Older Adult)",,"140","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","VOR001","December 12, 2019","July 2020","July 2020","February 5, 2020",,"February 5, 2020","Hospital Raja Permaisuri Bainun, Ipoh, Ipoh, Perak, Malaysia|Hospital Tengku Ampuan Rahimah Klang, Klang, Selangor, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|National Cancer Institute, Kuala Lumpur, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Putrajaya, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04253678"
1395,"NCT04469608","Establishing TCM Daycare Model and Teaching Mechanism of Depression Patients",,"Enrolling by invitation","No Results Available","Traditional Chinese Medicine|Major Depressive Disorder","Behavioral: acupuncture","Hamilton Depression Rating Scale, HAM-D|Beck Depression Inventory(BDI)|Pittsburgh Sleep Quality Inventory|WHOQOL-Taiwan","China Medical University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMUH109-REC3-041","May 11, 2020","December 31, 2021","December 31, 2021","July 14, 2020",,"July 14, 2020","Department of Acupuncture, China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04469608"
1396,"NCT04711915","Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans",,"Recruiting","No Results Available","Major Depressive Disorder|Depression","Drug: 0.1 mg/kg Dimethyltryptamine (DMT)|Drug: 0.3 mg/kg Dimethyltryptamine (DMT)","Change in Blood Pressure|Change in Heart Rate|Change in Psychedelic Effects|Change in Anxiety|Drug Reinforcing Effects|Overall Tolerability assessed by the VAS","Yale University","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2000027720","March 17, 2021","December 1, 2021","June 1, 2022","January 15, 2021",,"May 17, 2021","Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04711915"
1397,"NCT04630964","The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density","PSIPET","Not yet recruiting","No Results Available","Major Depressive Disorder|Depression","Drug: Psilocybin|Drug: Niacin","Montgomery Åsberg Depression Rating Scale (MADRS)|[11C]UCB-J","Section for Affective Disorders; Northern Stockholm Psychiatry|Karolinska Institutet","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-002790-94","January 2021","December 2021","December 2022","November 16, 2020",,"December 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04630964"
1398,"NCT03329287","Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression",,"Unknown status","No Results Available","Generalized Anxiety Disorder|Major Depressive Disorder","Behavioral: SCBT|Drug: SSRIs and/or SNRIs|Behavioral: Psychological Placebo","changes of The Hamilton Depression Scale (HAMD-17)|changes of The Hamilton Anxiety Scale (HAMA-14)|changes of The Patient Health Questionnaire (PHQ-9)|changes of The GAD-7|changes of The Mos 36-item Short Form Health Survey (SF-36)|changes of Treatment Emergent Symptom Scale (TESS)|changes of Clinical Global Impression (CGI)","Shanghai Mental Health Center|Changhai Hospital|Shanghai 10th People's Hospital|Tongji Hospital|Fudan University|Second Hospital of Shanxi Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","15411950201","July 1, 2017","March 30, 2018","June 30, 2018","November 1, 2017",,"November 1, 2017","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03329287"
1399,"NCT04278521","Mechanism of Action of Transcranial Magnetic Stimulation",,"Recruiting","No Results Available","Major Depressive Disorder|Depression","Device: Transcranial Magnetic Stimulation","Changes in Functional Connectivity of Key Nodes in Depression","Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014P001835","November 2011","November 2023","November 2023","February 20, 2020",,"April 1, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04278521"
1400,"NCT04276259","Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","RAISE","Recruiting","No Results Available","Major Depressive Disorder|Depression","Drug: Buprenorphine|Drug: Naltrexone|Drug: Oral Placebo|Drug: IM Placebo|Device: Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.","BOLD Responses in the vmPFC-VS circuit|TBS Effects of BOLD Response|Opioid Modulation Effects on BOLD Responses in the vmPFC-VS circuit","Marta Peciña, MD PhD|University of Pittsburgh","All","18 Years to 55 Years   (Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","STUDY19050307","October 19, 2020","March 31, 2025","March 31, 2025","February 19, 2020",,"February 5, 2021","Bellefield Tower, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04276259"
1401,"NCT04887350","SSIPP vs. PST vs. WLC",,"Not yet recruiting","No Results Available","Major Depressive Disorder|Late Life Depression","Behavioral: Student-Senior Isolation Prevention Partnership (SSIPP)|Behavioral: Problem Solving Therapy (PST).","Rate of participant recruitment|Rate of retention|Completeness of data entry|Cost of interventions|Unexpected costs|Depression|Anxiety|Resilience","Lawson Health Research Institute","All","65 Years and older   (Older Adult)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11336","June 1, 2021","June 1, 2022","June 1, 2022","May 14, 2021",,"May 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04887350"
1402,"NCT00296933","Memory Functioning and Antidepressant Treatment",,"Completed","No Results Available","Depression|Major Depressive Disorder","Drug: Escitalopram|Drug: Bupropion XL","General Verbal Memory-California Verbal Learning Test® -2nd ed (CVLT® -II)|Hamilton Rating Scale for Depression - 17-Item|Clinical Global Impression Severity and Improvement Ratings|Short Term & Working Memory: Wechsler Memory Scales III|Nonverbal Memory - Faces|WMS III Logical Memory (Prose Recall)|Nonverbal Memory - Spatial Memory|Shipley Institute of Living Scale|Prospective Memory","University Health Network, Toronto|GlaxoSmithKline|H. Lundbeck A/S","All","18 Years to 50 Years   (Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","UHN REB #05-0464-A","December 2005",,,"February 27, 2006",,"February 17, 2009","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00296933"
1403,"NCT02924090","Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression",,"Unknown status","No Results Available","Depression","Drug: Etomidate|Drug: Ketamine|Procedure: Hyperventilation|Procedure: Electroconvulsive therapy (ECT)","EEG seizure duration (seconds)|ECT-induced seizure duration (seconds)|Changes in cerebral metabolism assessed by cerebral saturation (%)|Remission of depressive symptoms assessed by HAM-D|Remission of depressive symptoms assessed by MADRS|Effect on blood pressure|Effect on heart rate|Duration of stay in post-anesthesia care unit (hours)|Incidence of nausea in post-anesthesia care unit (%)|Incidence of vomiting in post-anesthesia care unit (%)","University of Manitoba","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","B2015050","September 2016","December 2017","December 2018","October 5, 2016",,"October 21, 2016","Health Sciences Centre, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT02924090"
1404,"NCT04530942","The Effecay and Prediction of Deep Brain Stimulation for Treatment-resistant Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Deep Brain Stimulation","Device: Deep brain stimulation(Active)|Device: Deep brain stimulation(sham)","changes in the Hamilton Depression Scale(HAMD-17) score|changes in the Montgomery-Asberg Depression Rating Scale(MADRS)|changes in the Quick Inventory of Depression Scale(QIDS-SR16)|changes in the Depression and Somatic Symptoms Scale(DSSS)|changes in the Dimensional Anhedonia Rating Scale(DARS)|changes in Hamilton Anxiety Scales(HAMA)|changes in World Health Organization Quality of Life-BREF(WHO-BREF)|changes in the MOS item short from health survey (SF-36)|changes in Sheehan Disability Scale|changes in Neuropsychological measures(Scores of Thinc-it tasks)","Ruijin Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020 DBS for TRD","March 29, 2021","February 1, 2024","December 30, 2024","August 28, 2020",,"April 27, 2021","Functional neurosurgery of Shanghai Jiaotong University affiliated Ruijin Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04530942"
1405,"NCT04441008","Accelerated iTBS for Depression and Suicidality","RAPID","Not yet recruiting","No Results Available","Major Depressive Disorder|Suicide","Device: Accelerated Intermittent Theta Burst (aiTBS)|Device: Electroconvulsive therapy (ECT)","Retention rate at completion of aiTBS vs the ECT group","University of Iowa","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","202002608","July 2021","July 2023","July 2024","June 22, 2020",,"June 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04441008"
1406,"NCT04633096","The Efficacy of Automated Feedback After Internet-based Depression Screening","DISCOVER","Recruiting","No Results Available","Depression|Major Depressive Disorder","Behavioral: tailored feedback of depression screening results|Behavioral: standardized feedback of depression screening results","Depression severity (Questionnaire: Patient Health Questionnaire-9)|Guideline-based depression care|Depression-related help-seeking behaviour|Health economic Evaluation (Questionnaire: Client Sociodemographic and Service Receipt Inventory)|Health-related quality of life (Questionnaire: EuroQol-5D)|Anxiety (Questionnaire: Generalized Anxiety Disorder-7)|Somatic symptom severity (Questionnaire: Somatic Symptom Scale-8)|Intervention acceptance (Questionnaire: Usefulness scale for patient information material)|Adverse events","Universitätsklinikum Hamburg-Eppendorf|German Research Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1074","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening","PV7039","January 12, 2021","July 2022","July 2022","November 18, 2020",,"April 1, 2021","University Medical Center Hamburg, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT04633096"
1407,"NCT03623724","iCare4Depression: Effectiveness of a Blended Cognitive-Behavioral Therapy in Routine Practice","iCare4Dep","Unknown status","No Results Available","Major Depression","Behavioral: blended Cognitive-behavioral Therapy|Other: Treatment-As-Usual","Change in depressive symptoms from baseline to 52 weeks after baseline|Change in the diagnosis of major depression disorder from baseline to 52 weeks after baseline|Change in the general clinical outcome from baseline to 52 weeks after baseline|Change in anxiety symptoms from baseline to 52 weeks after baseline|Evolution of the working alliance between therapist and patient during therapeutic sessions and follow-up assessments|Usability of the Moodbuster system (web platform and smartphone application) for patients and therapists|Patients' treatment credibility and expectancy|Patients' treatment satisfaction|Change in patients' quality of life from baseline to 52 weeks after baseline|Assessment of treatment's cost-effectiveness|Ecological Momentary Assessments","University Institute of Maia|INESC TEC|University of Limerick|VU University of Amsterdam|Center of Psychology at University of Porto|ARS - Norte","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PTDC/MHC-PCL/1991/2014","December 2, 2017","September 30, 2018","June 30, 2019","August 9, 2018",,"August 9, 2018","University Institute of Maia, Maia, Porto, Portugal",,"https://ClinicalTrials.gov/show/NCT03623724"
1408,"NCT00113022","Org 24448 to Treat Major Depression",,"Terminated","Has Results","Depression","Drug: Org 24448|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","9","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","050161|05-M-0161","May 2005","February 2007","February 2007","June 3, 2005","July 6, 2012","July 13, 2012","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Mt. Sinai Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00113022"
1409,"NCT03795688","The Role of Sex Steroids and Serotonin Brain Dynamics in Perinatal Mental Health",,"Completed","No Results Available","Major Depressive Disorder|Perinatal Depression","Other: Pregnancy","Depressive symptoms|Gene transcript and DNA methylation markers of estrogen sensitivity|Cerebral serotonin 4 receptor binding postpartum|CSF levels of GABA|CSF levels of serotonin metabolite (5-HIAA)|Cortisol awakening response|Hair cortisol level mothers|Hair cortisol level newborns|Hippocampal volumes|functional MRI response to reward|Resting state functional connectivity MRI|Change in epigenetic SERT status|Concentration of inflammatory markers, i.e hsCRP and immunoactive cytokines, in peripheral blood|functional MRI response to emotional faces|CSF levels of serotonin|CSF levels of dopamine metabolites|CSF levels of noradrenaline metabolites|CSF levels of inflammatory markers|Estradiol level|Change in estradiol level|Progesterone level|Change in progesterone level|Allopregnanolone level|Change in allopregnanolone level|Change in cortisol level|Change in cortisol awakening response|DNA methylation of the SERT gene|DNA methylation of the FK506-binding protein 51 (FKBP5) gene|Change in DNA methylation of the FK506-binding protein 51 (FKBP5) gene|DNA methylation of the glucocorticoid receptor gene|Change in DNA methylation of the glucocorticoid receptor gene|DNA methylation of the COMT gene|Change in DNA methylation of the COMT gene|DNA methylation of the MAO-A gene|Change in DNA methylation of the MAO-A gene|DNA methylation of the oxytocin receptor gene|Change in DNA methylation of the oxytocin receptor gene|DNA methylation of the oxytocin gene|Change in DNA methylation of the oxytocin gene|Systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Change in systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Self reported family history of mood disorders|Self reported impulsiveness score|Self reported Neuroticism score from NEO personality questionnaire|Self reported parental bonding quality|Self-reported perceived stress|Change in self-reported perceived stress|Self-reported anhedonia|Change in self-reported anhedonia|Self-reported rumination|Change in elf-reported rumination|Self-reported mood|Change in self-reported mood|Self-reported sleep quality|Change in self-reported sleep quality|Self-reported psychiatric symptoms|Change in self-reported psychiatric symptoms|Self-reported well-being|Change in self-reported well-being|Self-reported anxiety|Change in self-reported anxiety|Self-reported obsessive and compulsive symptoms|Change in self-reported obsessive and compulsive symptoms|Performance on Simple Reaction Time|Gray matter brain volume prefrontal cortex and anterior cingulate cortex|Serotonergic turnover in placenta|11-beta-hydroxysteroid dehydrogenase type 2 activity in placenta|Methylation status of genes relevant for stress-hormone regulation in placenta|Methylation status of genes related to serotonergic signaling in placenta|Methylation status and gene transcript profiles of relevance for early brain development and stress regulation in newborn infants","Vibe G Frøkjær, MD, PhD|Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak|Mental Health Centre Copenhagen|University of Copenhagen|Rigshospitalet, Denmark","Female","18 Years to 40 Years   (Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PND1|H-18029563","January 24, 2019","December 1, 2020","December 1, 2020","January 8, 2019",,"December 17, 2020","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03795688"
1410,"NCT03977038","Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression",,"Unknown status","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Device: repetitive transcranial magnetic stimulation","Change in cold cognition|Change in hot cognition|depressive symptoms (physician-rated)|depressive symptoms (self-report)","Sunnybrook Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","096-2019","July 2019","April 2020","May 2020","June 6, 2019",,"July 25, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03977038"
1411,"NCT03642522","Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI",,"Completed","No Results Available","Major Depressive Disorder|Depression","Device: repetitive transcranial magnetic stimulation","Inventory of Depressive Symptomatology (IDS-30)|Quick Inventory of Depressive Symptomatology (QIDS-SR)","University of British Columbia|University of Victoria","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H14-02819","November 1, 2018","March 30, 2020","August 1, 2020","August 22, 2018",,"January 12, 2021","Non-Invasive Neurostimulation Therapies lab, University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03642522"
1412,"NCT03573349","Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:",,"Enrolling by invitation","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Drug: Ketamine","To evaluate percent change in the anterior cingulate cortex (ACC) GABA and Glutamate (baseline to peak) during a 40-minute IV ketamine infusion and remission (MADRS ≤9) at 24 hour|To evaluate a correlation between percent change in ACC GABA and Glutamate/Glx levels (baseline to peak) with a change in MADRS (baseline to 24 hours).|To compare the percent change in peripheral GABA/Glutamate levels between remitters and non-remitters|To evaluate the correlation between percent change in peripheral GABA and glutamate levels with a change in MADRS scores.","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-011373","January 3, 2019","August 2021","December 2021","June 29, 2018",,"October 22, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03573349"
1413,"NCT04510519","Scaling Mental Healthcare in COVID-19 With Voice Biomarkers",,"Not yet recruiting","No Results Available","Major Depressive Disorder|Generalized Anxiety",,"Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder (GAD-7)","Kintsugi Mindful Wellness, Inc.","All","18 Years to 100 Years   (Adult, Older Adult)",,"50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV-1","September 1, 2020","June 30, 2021","June 30, 2021","August 12, 2020",,"August 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04510519"
1414,"NCT02263248","Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine","(IRLGREY-B)","Completed","No Results Available","Major Depressive Disorder|Depression","Drug: venlafaxine|Drug: buprenorphine|Drug: placebo","The Montgomery-Asberg Depression Rating Scale|Suicidal Ideation Scale ( SIS)|Brief Symptom Inventory for Anxiety|Numeric Scale of Pain ( NRS-P)|Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)|Antidepressant Side Effect Checklist (ASEC)","Centre for Addiction and Mental Health|Reckitt Benckiser LLC","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","035/2014","December 2014","January 19, 2017","May 1, 2018","October 13, 2014",,"July 26, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02263248"
1415,"NCT03084042","Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety",,"Unknown status","No Results Available","Major Depressive Disorder|General Anxiety Disorder","Device: fMRI","Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI|Behavioral performance during the fMRI: face processing|Behavioral performance during the fMRI: empathy reactivity|Behavioral performance during the fMRI: working memory|Cognitive performance at study inclusion|Symptom improvement after 3 months: depression|Symptom improvement after 3 months: anxiety","University of Electronic Science and Technology of China|Sichuan Provincial People's Hospital|The Fourth People's Hospital of Chengdu","All","18 Years to 55 Years   (Adult)",,"105","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","UESTC-neuSCAN-23","July 2016","December 2018","June 2019","March 20, 2017",,"October 29, 2018","School of Life Science and Technology, University of Electronic Science and Technology of China, Chendu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03084042"
1416,"NCT03859297","Mechanisms of Rumination Change in Adolescent Depression","RuMeChange","Recruiting","No Results Available","Major Depressive Disorder|Mood Disorders","Behavioral: Rumination-Focused CBT|Behavioral: Relaxation-based Therapy","Rumination Responsiveness Scale (RRS)|Resting state functional magnetic resonance imaging (fMRI) connectivity of Default mode network to cognitive control network.","University of Utah|University of Exeter|National Institute of Mental Health (NIMH)","All","14 Years to 17 Years   (Child)","Not Applicable","183","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","IRB_00113733|R61MH116080","May 1, 2019","March 2024","March 2026","March 1, 2019",,"November 12, 2019","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03859297"
1417,"NCT04841798","MAO-B Occupancy in Depressed Patients","MOCP","Not yet recruiting","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Other: [11C]SL25.1188 PET radiotracer","MAO-B occupancy of tranylcypromine at standard treating dose|MAO-B occupancy of rasagiline at standard treating dosse|Duloxetine effect on MAO-B distribution volumen (VT) in the prefrontal cortex","Centre for Addiction and Mental Health","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","REB#094/2018","April 15, 2021","June 1, 2024","December 1, 2024","April 12, 2021",,"April 12, 2021","CAMH, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04841798"
1418,"NCT04971291","An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients","TARGET","Enrolling by invitation","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Drug: AXS-05|Drug: Bupropion SR","Montgomery-Åsberg Depression Rating Scale (MADRS) total score","Axsome Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AXS-05-TRD-203","April 14, 2021","July 2021","July 2021","July 21, 2021",,"July 26, 2021","Axsome Research Site, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04971291"
1419,"NCT03429361","Testing the Value of Smartphone Assessments of People With Mood Disorders",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder","Other: Health by Mindstrong","Hamilton Depression Rating Scale (HAM-D)|Cognitive Battery|Hamilton Anxiety Rating Scale (HAM-A)|Patient Health Questionnaire (PHQ-9)","Mindstrong|Kadima Neuropsychiatry Institute","All","18 Years to 65 Years   (Adult, Older Adult)",,"23","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-01","August 8, 2017","May 30, 2019","May 30, 2019","February 12, 2018",,"August 22, 2019","Kadima Neuropsychiatry Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT03429361"
1420,"NCT03620253","Modafinil's Effects on Cognition in Remitted MDD",,"Terminated","No Results Available","Major Depressive Disorder|Cognitive Impairment","Drug: Modafinil|Drug: Placebo","Cognition|Composite Memory|Psychomotor Speed|Reaction Time|Complex Attention|Cognitive Flexibility|Processing Speed|Subjective Cognitive Improvement|Functional Disability|Work Productivity|Motivation and Energy","Unity Health Toronto|Ontario Ministry of Health and Long Term Care|The Canadian Biomarker Integration Network in Depression","All","18 Years to 55 Years   (Adult)","Phase 3","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MOCOG-01","October 15, 2018","August 6, 2019","August 6, 2019","August 8, 2018",,"August 8, 2019","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03620253"
1421,"NCT04685148","Maternal Mental Health Trial","MAMA","Recruiting","No Results Available","Major Depressive Disorder|Postpartum Depression","Drug: Transdermal patch estradiol|Drug: Transdermal patch placebo","Number of participants with Major Depression Disorder|EPDS Depressive symptoms|HamD6 Depressive symptoms|Maternal mental wellbeing|Parental stress|Parental reflective capacity|Parental competences|Proportion of women who exclusively breastfeed their infants|Predictive value of composite gene transcription and DNA methylation marker for estrogen sensitivity|Maternal sleep quality|Maternal attachment to unborn child|Cold cognitive function|Hot cognitive function|Socio-emotional infant development|Infant development (Bayley-III)|Cortisol dynamics Cortisol dynamics|Hair cortisol level Cortisol dynamics|Epigenetic markers relevant for infant HPA axis|Estradiol level|Change in estradiol level|Progesterone level|Change in progesterone level|Allopregnanolone level|Change in allopregnanolone level|Negative bias in responses to infant vocalisations and video","Vibe G Frøkjær, MD, PhD|Herlev Hospital|Hvidovre University Hospital|Rigshospitalet, Denmark","Female","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2020-001592-33","February 3, 2021","December 31, 2026","December 31, 2030","December 28, 2020",,"February 23, 2021","Neurobiology Researc hUnit, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04685148"
1422,"NCT01829165","Brain Imaging of rTMS Treatment for Depression",,"Completed","Has Results","Major Depressive Disorder|Depression","Device: rTMS Treatment|Device: Sham rTMS Treatment","Clinician Administered HAM-D","Stanford University|The Dana Foundation|National Institute of Mental Health (NIMH)","All","18 Years to 50 Years   (Adult)","Not Applicable","85","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","21206|P30MH089888-01","September 2012","January 20, 2017","January 20, 2017","April 11, 2013","April 10, 2018","April 10, 2018","Stanford University, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01829165/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01829165"
1423,"NCT01358487","Healthy Mood Internet Intervention Research Project",,"Completed","No Results Available","Major Depression","Behavioral: Online self-help course plus live follow-up if needed|Behavioral: Online + incentives Follow-up Group","PHQ-9","University of California, San Francisco|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","116","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CHR10-00059|1R34MH091231-01","July 2011","January 2013","January 2013","May 23, 2011",,"November 15, 2018","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01358487"
1424,"NCT02086201","Comparing Engage to PST for Late Life Depression","Engage","Completed","No Results Available","Major Depression","Behavioral: Problem Solving Therapy|Behavioral: Engage","Depression","University of Washington|Weill Medical College of Cornell University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","262","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001739","May 2014","March 31, 2020","March 31, 2020","March 13, 2014",,"June 29, 2021","Weill Medical College of Cornell University, White Plains, New York, United States|University of Washington Department of Psychiatry and Behavioral Sciences, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02086201"
1425,"NCT01147913","Computerized Information-Processing Bias Retraining in Depressed Adolescents",,"Completed","No Results Available","Major Depression","Behavioral: Computerized Information-Processing Bias Retraining|Behavioral: Attention Control Training","Test of Interpretation Bias (TIB)|Test of Interpretation Bias|Kiddie-Schedule of Affective Disorders and Schizophrenia-Epidemiologic Version (K-SADS-E; Orvaschek & Puig-Antich, 1987)|Beck Depression Inventory, 2nd Version|State-Trait Anxiety Scale (STAI)|Structured Clinical Interview for DSM-IV (SCID-IV; First et al, 1997), Mood Disorder Modules only|Dysfunctional Attitudes Scale (DAS)|CANTAB Affective Go-No Go Task (AGN)","Massachusetts General Hospital","All","14 Years to 21 Years   (Child, Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F32MH088065-01","March 2010","April 2012","April 2012","June 22, 2010",,"May 3, 2012","Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01147913"
1426,"NCT01874951","Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence",,"Completed","Has Results","Major Depressive Disorder|Depression, Unipolar|Recurrence|Relapse","Drug: Naltrexone|Drug: Placebo","Change in HAM-D-17 Total Score|Change in HAM-D28 Total Score|Change in MADRS-10 Total Score|Change in MADRS-15 Total Score|Change in CGI-S Total Score|Final CGI-I Score|Response Rate|Remission Rate","Massachusetts General Hospital|Boston Clinical Trials (BCT)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013P000371","June 2013","June 2015","June 2015","June 11, 2013","February 24, 2017","February 24, 2017","Massachusetts General Hospital; Depression Research and Clinical Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01874951"
1427,"NCT04322526","Study of Naltrexone-Induced Blockade of Antidepressant Effects","SONRISA2","Completed","Has Results","Depression|Major Depressive Disorder","Drug: Naltrexone 50 Mg Oral Tablet|Drug: Placebo oral tablet","BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Baseline (Post-placebo)|Naltrexone-induced Changes in BOLD Responses in the rACC Cortex During the Processing of Contextual Cues (Placebo vs. Naltrexone)","Marta Peciña, MD PhD|Brain & Behavior Research Foundation|University of Pittsburgh","All","18 Years to 55 Years   (Adult)","Phase 4","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PRO16050133","July 1, 2017","July 15, 2018","July 15, 2018","March 26, 2020","April 21, 2020","April 21, 2020","Bellefield Towers, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04322526/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04322526"
1428,"NCT03113890","McLean and Genomind Prospective Study","GPS","Completed","No Results Available","Major Depressive Disorder|PTSD","Genetic: Phlebotomy - Folate|Genetic: Cheek Swab|Other: Self-report surveys","Does Inpatient Genetic Testing Improve Symptoms at Follow-up:|Does Inpatient Genetic Testing Improve Readmission:","Mclean Hospital|Genomind, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017P000380","September 22, 2017","July 12, 2019","July 31, 2020","April 14, 2017",,"February 23, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03113890"
1429,"NCT02734602","Imaging SV2A in Mood Disorders",,"Recruiting","No Results Available","Major Depressive Disorder|Post-Traumatic Stress Disorder","Drug: Ketamine|Behavioral: Cognitive Testing|Radiation: PET|Device: MRI","Evidence of synaptic changes in psychiatric disorders confirmed by PET data.|Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data.","Yale University|VA Office of Research and Development","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1511016789","April 2016","January 2024","March 2024","April 12, 2016",,"March 3, 2021","PET Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02734602"
1430,"NCT03895658","Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)",,"Recruiting","No Results Available","Unipolar Depression","Device: MRI|Device: MagPro TMS stimulator and coil|Device: MECTA paired with the 4X1 HD-ECT","Successful seizure induction as measured by topographical EEG and motor manifestations, vital signs, ECG, subjective side effect scale, and adverse events/significant adverse events|Neurocognitive battery known to be sensitive to the cognitive effects of ECT, with alternative versions to avoid practice effects; and, Amplitude- titrated seizure threshold (STa), measured electrical motor threshold (MT), and simulated MT","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","22 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","NIH","Interventional","Allocation: N/A|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","190073|19-M-0073","August 9, 2021","December 31, 2025","December 31, 2025","March 29, 2019",,"August 4, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03895658"
1431,"NCT04159207","A Longitudinal Study of Inflammatory Pathways in Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Suicide, Attempted",,"Suicidal behavior of participants|Establish metabolic biomarkers that indicate risk for suicidal behavior|Establish inflammatory biomarkers that indicate risk for suicidal behavior|Determine epigenetic marks in blood cells from patients with suicidal behavior|Functional validation of the significant methylation changes","Van Andel Research Institute|Pine Rest Christian Mental Health Services|Columbia University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)",,"160","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","19010|1R01MH118211-01A1","October 1, 2019","June 30, 2024","June 30, 2024","November 12, 2019",,"March 30, 2021","Pine Rest Christian Mental Health Services, Grand Rapids, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04159207"
1432,"NCT00917059","Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)",,"Completed","No Results Available","Depression","Drug: Escitalopram|Drug: Bupropion XL","Score on Hamilton Depression Rating Scale (HAM-D)|Score on Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30)","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 4","172","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R01MH085925|09-03-022-01|DSIR 84-CT","May 2009","May 2012","May 2012","June 10, 2009",,"February 6, 2013","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00917059"
1433,"NCT04843462","Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray","Esketamin+","Recruiting","No Results Available","Major Depressive Disorder|Therapy Resistant Depression","Device: edupression.com®|Drug: Esketamine nasal spray","Therapy response (observer-rated)|Percentage of received esketamine treatments in relation to scheduled ones|Therapy response (self-rated)","Lukas Pezawas|Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2467/2020","April 29, 2021","April 11, 2022","April 11, 2022","April 13, 2021",,"April 28, 2021","Medical University Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04843462"
1434,"NCT02943096","Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression","Flavanol","Terminated","Has Results","Depression|Major Depressive Disorder","Dietary Supplement: CocoaVia|Other: Placebo","Hamilton Rating Scale of Depression (HRSD)|Mnemonic Similarity Task (MST)|Modified-Benton Task (ModBent)","New York State Psychiatric Institute|Columbia University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7368","November 2016","February 6, 2018","February 6, 2018","October 24, 2016","September 6, 2019","September 6, 2019","New York State Psychiatric Institute, New York, New York, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02943096/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02943096"
1435,"NCT01479920","A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture",,"Completed","No Results Available","Major Depressive Disorder|Depression","Drug: Fluoxetine|Procedure: DCEAS (Hwato®/ Dongbang®)|Procedure: n-CEA (Strietberger®)","HAMD-17|SDS|PET scanning|Clinical response|Remission|Latency|Adverse events","The University of Hong Kong|Queen Mary Hospital, Hong Kong|Kowloon Hospital, Hong Kong|Southern Medical University, China","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UW 09-091","June 2012","May 2015","May 2015","November 28, 2011",,"December 7, 2015","School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China|Department of Psychiatry, Queen Mary Hospital, Hong Kong, China|Department of Psychiatry, Kowloon Hospital, Kowloon, China|Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT01479920"
1436,"NCT04422652","Combination of Novel Therapies for CKD Comorbid Depression","CONCORD","Recruiting","No Results Available","Chronic Kidney Diseases|Major Depressive Disorder","Drug: Bupropion|Behavioral: Behavioral activation therapy|Drug: Placebo|Other: Clinical Management","Quick Inventory of Depressive Symptomatology-Clinician Rated scale (QIDS-C)|Serious adverse events|Serious adverse events with monotherapy|High sensitivity C-reactive protein|Adherence to medications by Pill Count|Fatigue assessed by the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scale|Sleep assessed by the Insomnia Severity Index (ISI)|Overall functioning assessed by the Sheehan Disability Scale (SDS)","University of Texas Southwestern Medical Center|University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 2","201","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STU-2020-0046|R01DK124379","September 24, 2020","April 1, 2025","April 1, 2026","June 9, 2020",,"May 17, 2021","Parkland Health and Hospital System, Dallas, Texas, United States|UT Southwestern and Affiliates, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04422652"
1437,"NCT02285608","Partnership in Medication Management (PIMM) in Patients With Mood Disorders","PIMM","Unknown status","No Results Available","Major Depressive Disorder|Bipolar Disorder","Other: PIMM/SAM","Medication adherence measured by the Medication Adherence Rating Scale (MARS).|Time to re-hospitalization|Costs of re-hospitalization","St. Joseph's Healthcare Hamilton","All","18 Years and older   (Adult, Older Adult)","Not Applicable","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PIMM MDP|PIMM Mood Disorders Program","January 2015","November 2016","May 2017","November 7, 2014",,"November 18, 2015","Mood Disorders Program, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02285608"
1438,"NCT02405715","Therapy With an Oxytocin Adjunct for Major Depression","TOAD2015","Completed","No Results Available","Depressive Disorder","Drug: Oxytocin nasal spray or placebo","Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]|Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D)[Change Score]|Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]|Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]|Patient dropout rate [Number of sessions missed]|Depressive Symptoms (patient-rated) (Beck Depression Inventory-II (BDI-II) [Change Score]|Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D) [Change Score]|Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score]|Biological stress reactivity (Daily Diurnal Cortisol) [Change Score]|Working alliance (clinician-rated) (Working Alliance Inventory (WAI) [Change Score]|Social functioning (patient-rated) (Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS) COMPOSITE SCORE [Change Score]|Stress (patient-rated) (Perceived Stress Scale (PSS) [Change Score]|Anxiety (patient-rated) (Beck Anxiety Inventory (BAI) [Change Score]|Therapeutic Alliance (patient-rated) (Working Alliance Inventory (WAI)|Usefulness of Therapy (patient-rated); COMPOSITE SCORE","Concordia University, Montreal","All","18 Years to 50 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIHR-12678","February 2015","August 2016","August 2016","April 1, 2015",,"July 27, 2021","Concordia University, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02405715"
1439,"NCT04041479","Biomarker-guided rTMS for Treatment Resistant Depression","BioTMS","Not yet recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Device: Repetitive Transcranial Magnetic Stimulation","Change in depression, as measured by the Hamilton Depression Rating Scale (HAMD17)|Change in depression, as measured by the Quick Inventory of Depressive Symptomology (QIDS)|Change in depression, as measured by the Beck Depression Inventory (BDI-21)|Change in Resting State fMRI Connectivity","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","464","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1810019638|R01MH118388","August 1, 2021","April 2026","August 2026","August 1, 2019",,"May 5, 2021","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04041479"
1440,"NCT04923685","MicroRNA Correlates of Childhood Maltreatment and Suicidality",,"Recruiting","No Results Available","Major Depressive Disorder|Suicidal Ideation","Other: Trier Social Stress Test","MicroRNA response to stress","University of Alabama at Birmingham|National Institute of Mental Health (NIMH)","All","18 Years to 60 Years   (Adult)",,"450","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Other","IRB-300006024","February 26, 2021","September 2025","September 2025","June 11, 2021",,"July 2, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|UAB Huntsville Regional Medical Campus, Huntsville, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04923685"
1441,"NCT01219686","EScitalopram PIndolol ONset of Action","ESPION","Terminated","No Results Available","Unipolar Depression","Drug: escitalopram, pindolol|Drug: escitalopram","MADRS score change between baseline and 2 weeks of treatment|Response/remission (MADRS) at 6 weeks|Adverse events|Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups","Markus KOSEL|University Hospital, Geneva|University of Lausanne Hospitals|University Hospital, Basel, Switzerland|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CER 09-054, Psy 09-004","October 2010","April 2013","June 2013","October 13, 2010",,"May 27, 2015","Centre de Thérapies Breves (CTB), Secteur Jonction, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT01219686"
1442,"NCT02583867","Predictors of Depression Treatment Response to Exercise",,"Completed","No Results Available","Depression|Major Depressive Disorder","Behavioral: Exercise","Depressive Symptoms","University of Texas Southwestern Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 052015-018","December 2015","February 2019","February 2019","October 22, 2015",,"April 1, 2019","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02583867"
1443,"NCT02568865","Noninvasive Physiologic Sensors to Assess Depression",,"Completed","No Results Available","Depression|Major Depressive Disorder","Other: Physiological Sensors|Other: Sleep Monitoring Device|Other: Vocal Monitoring|Other: Mobile Phone","Physiologic Biorhythms (heart rate)|Phone Usage|Voice Characteristics|Physiologic Biorhythms (Skin conductance)","Massachusetts General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015P001913","January 15, 2016","July 1, 2018","January 3, 2020","October 6, 2015",,"February 25, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02568865"
1444,"NCT01430767","Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder",,"Completed","No Results Available","Major Depressive Disorder|Attention-deficit Hyperactivity Disorder (ADHD)",,"Adherence to Standard-of-Care Medication for Depression or ADHD","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)",,"33","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WFBMC-Psych-17564","September 2011","December 2014","December 2014","September 8, 2011",,"April 20, 2017","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01430767"
1445,"NCT02637466","Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers",,"Withdrawn","No Results Available","Unipolar Major Depression|Stage I, II or III Breast Cancer","Drug: Vortioxetine","Antidepressant efficacy","University of Miami|Takeda","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20150753","July 2016","July 2018","July 2019","December 22, 2015",,"September 30, 2016",,,"https://ClinicalTrials.gov/show/NCT02637466"
1446,"NCT02150681","Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders","MBCT","Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder","Behavioral: Mindfulness-based cognitive therapy","Change in Self-Rated Depression from Pretreatment to Post-treatment to 1- and 6- months post-treatment|Change in Observer-Rated Depression from Pretreatment to Post-treatment to 1- and 6 months post-treatment|Changes in Anxiety Symptoms|Changes in mania symptoms","University of California, Los Angeles|University of Colorado, Boulder","Female","18 Years and older   (Adult, Older Adult)","Phase 1","39","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-003212","October 2012","October 2013","October 2013","May 30, 2014",,"May 30, 2014","University of California, Los Angeles, Los Angeles, California, United States|University of Colorado, Boulder, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02150681"
1447,"NCT00515658","Antidepressant Effect of Theta-Burst rTMS",,"Unknown status","No Results Available","Major Depression","Device: theta-burst rTMS",,"Rambam Health Care Campus","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rambam2141_CTIL","March 2007",,,"August 14, 2007",,"August 14, 2007","Rambam Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT00515658"
1448,"NCT01443715","A Stepped Care Model of Adolescent Depression Treatment in Primary Care","SCIPT-A","Completed","No Results Available","Major Depressive Disorder|Dysthymia","Behavioral: Stepped Care IPT-A (SCIPT-A)|Behavioral: Treatment as Usual","Feasibility based on proportionality|The proportion of adolescents who agree to be randomized and enrolled in the study protocol","New York State Psychiatric Institute","All","13 Years to 20 Years   (Child, Adult)","Phase 2|Phase 3","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","6432|1R34MH091320-01A1","September 2011","June 2014","July 2014","September 30, 2011",,"September 4, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01443715"
1449,"NCT01818453","Can Genetics Predict Treatment Response to a Computerized Self-help Program for Depression?",,"Completed","No Results Available","Major Depressive Disorder|Mood Disorders","Behavioral: Computerized self-help program for depression","Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16)|Hamilton Depression Rating Scale (HAM-D)|Inventory of Depression and Anxiety Symptoms (IDAS)|Psychiatric Diagnostic Screening Questionnaire (PDSQ)|Risky Families Questionnaire (RFQ)|Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)|Sheehan Disability Scale (SDS)","University of Texas at Austin|Brown University","All","18 Years to 55 Years   (Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-01-0025","March 2013","November 2015","November 2015","March 26, 2013",,"November 9, 2015","The University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01818453"
1450,"NCT03435744","Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.","DepSTAT","Unknown status","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Drug: Simvastatin 20 mg|Other: Placebo Oral Tablet","Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery Asberg, 1979)","Pakistan Institute of Living and Learning|King's College London","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PILL-DepSTAT-001","January 1, 2019","December 2020","December 2020","February 19, 2018",,"August 5, 2019","Civil Hospital, Hyderabad, Pakistan|Civil Hospital, Karachi, Pakistan|Abbasi Shaheed Hospital, Karachi, Pakistan|Institute of Professional Psychology, Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT03435744"
1451,"NCT04957368","Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial","SMILE","Not yet recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Drug: Nitrous Oxide 99 %|Drug: Oxygen + Midazolam","Recruitment rate|Withdrawal rate|Adherence rate|Frequency of adverse events|Montgomery-Åsberg Depression Rating Scale (MADRAS) Score 0-60 (Higher scores represent higher depression). Measure changes in symptoms of depression|Toronto Side Effects Scale (TSES) - 32 items (each item has a score 1-25; higher score means higher intensity). Measure adverse side effects from antidepressant treatment","Karim Ladha|Unity Health Toronto","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","21-096","August 2021","August 2021","October 2023","July 12, 2021",,"July 16, 2021",,,"https://ClinicalTrials.gov/show/NCT04957368"
1452,"NCT02176291","Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine","IRLGREY-B","Completed","Has Results","Depression|Major Depressive Disorder","Drug: Buprenorphine|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Brief Symptom Inventory--Anxiety Subscale (BSI)","Jordan F. Karp|National Institute of Mental Health (NIMH)|University of Pittsburgh","All","50 Years and older   (Adult, Older Adult)","Phase 2","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO13120236|R34MH101371","August 2014","April 2017","February 2018","June 27, 2014","July 2, 2018","August 29, 2018","Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02176291/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02176291"
1453,"NCT01043289","Light Therapy for Depression During Pregnancy",,"Completed","No Results Available","Major Depressive Disorder|Pregnancy","Other: Light therapy","Change in depression ratings (HAMD, SIGH-ADS)|Effect of light therapy on circadian rhythms (e.g. melatonin, rest-activity cycle)","Psychiatric Hospital of the University of Basel|Basel Women's University Hospital|Columbia University|University of Pittsburgh|Velux Fonden","Female","18 Years to 45 Years   (Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UPK-2004|3100A0-102190/1, 320000-114110","October 2004","October 2008","October 2008","January 6, 2010",,"January 6, 2010","Psychiatric Policlinic of the University of Basel, Basel, BS, Switzerland",,"https://ClinicalTrials.gov/show/NCT01043289"
1454,"NCT04924257","ECT vs. Esketamine","ETES","Not yet recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder","Drug: Esketamine nasal spray|Procedure: Electroconvulsive therapy","MADRS score","Medical University Innsbruck","All","18 Years to 50 Years   (Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1417/2020","August 2021","August 2023","April 2024","June 11, 2021",,"June 18, 2021",,,"https://ClinicalTrials.gov/show/NCT04924257"
1455,"NCT02549547","Jump Step - A Participatory Approach to Physical Activity & Mental Wellness","JumpStep","Unknown status","No Results Available","Major Depressive Disorder|Bipolar, Depression","Behavioral: Group Medical Visits","'Jump Step Intervention Questionnaire'|Physical Activity|Patient Activation|Anxiety|Social Support|Depression","University of British Columbia|Vancouver Foundation|Mood Disorders Association of BC|YMCA","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID: H15-01932","August 2015","January 2016","June 2017","September 15, 2015",,"September 15, 2015","Centre for Hip Health & Mobility, Department of Family Practice, Vancouver, British Columbia, Canada|Mood Disorders Association of BC, Vancouver, British Columbia, Canada|Robert Lee YMCA, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02549547"
1456,"NCT01890356","Maintenance Transcranial Electrical Stimulation for Depression",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder","Device: Transcranial electrical stimulation","Montgomery Asberg Depression Rating Scale for Depression (MADRS)","The University of New South Wales","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC12499","June 2013","February 2018","February 2018","July 1, 2013",,"March 27, 2018","Black Dog Institute / University of New South Wales, Randwick, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01890356"
1457,"NCT01145872","The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse","MBCT","Completed","No Results Available","Major Depressive Disorder|Recurrent","Behavioral: Mindfulness Based Cognitive Therapy|Behavioral: Health Enhancement Program","Depression Relapse|Depressive Symptoms","University of Denver|Stanford University|University of Colorado, Boulder","All","18 Years to 55 Years   (Adult)","Phase 3","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","F32AT004879-01A2","July 2010","May 2012","April 2013","June 17, 2010",,"December 2, 2014","University of Denver, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01145872"
1458,"NCT01559857","Pioglitazone in Patients With Mood Disorders",,"Completed","Has Results","Major Depressive Disorder|Insulin Resistance","Drug: Pioglitazone|Drug: Sugar Pill","Hamilton Depression Rating Scale at Baseline|Fasting Insulin Measurements at Baseline|Change in HDRS-21: From Baseline to 12 Weeks","Stanford University|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R21MH093948-01A1","November 2011","January 2014","June 2014","March 21, 2012","May 10, 2017","May 10, 2017","Stanford University Department of Psychiatry & Behavioral Sciences, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT01559857"
1459,"NCT02809677","Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators",,"Completed","No Results Available","Asthma|Major Depressive Disorder","Drug: Escitalopram|Drug: Venlafaxine XR|Drug: Bupropion XR|Drug: Sertraline|Drug: Mirtazapine|Drug: Buspirone|Drug: Quetiapine|Drug: Aripiprazole|Drug: Lithium","Change from Baseline in the caregiver's depression scores, as assessed by Hamilton Rating Scale for Depression (HRS-D).|Change from Baseline in the child's asthma control scores, as indicated by increased Asthma Control Test (ACT) scores.|Change from Baseline in the child's asthma control scores, as indicated by decreased Composite Asthma Severity Index (CASI) scores.|Change from Baseline in the caregiver's depression scores, as assessed by Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR).|Change from Baseline in the number of unscheduled asthma-related service utilization visits for the child participant at 52 weeks.|Change from Baseline in child's quality of life scores on the Pediatric Asthma Quality of Life Questionnaire.|Relationship between caregiver's medication adherence and child depression scorers, as assessed by the Child Depression Inventory (CDI).|Relationship between caregiver's antidepressant medication adherence and child anxiety scorers, as assessed by the Screen for Child Anxiety Disorders (SCARED).","University of Texas Southwestern Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|University at Buffalo","All","7 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","205","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","022014-069|1R01HL123609-01A1","June 2016","October 2020","October 2020","June 22, 2016",,"December 2, 2020","University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02809677"
1460,"NCT01431573","Wake Therapy in the Treatment of Depression",,"Completed","Has Results","Major Depressive Disorder|Bipolar Disorder","Behavioral: Wake Therapy|Device: light box|Drug: Lithium","Structured Interview for the Hamilton Depression Scale With Atypical Depression Supplement(SIGH-ADS)|Morningness-Eveningness Questionnaire (MEQ),|Symptom Check List (SCL-90)|Quick Inventory of Depressive Symptoms, Self Rated (QIDS-SR 16)|Hypomania Interview Guide, Current Assessment Version (HIGH-C)|Clinical Global Improvement (CGI)","New York State Psychiatric Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5491/7316R|IRB 5491","July 2011","August 2016","August 2016","September 9, 2011","March 18, 2021","March 18, 2021","Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT01431573/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01431573"
1461,"NCT02156622","CID 0911 - Adaptation of A Depression Treatment Intervention for HIV Patients in Cameroon","ADEPT","Completed","No Results Available","HIV|Major Depressive Disorder",,"Mean CD4 count|Remission of depression","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)",,"55","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-0852|5R34MH084673-02","July 2009","November 2012","November 2012","June 5, 2014",,"June 5, 2014",,,"https://ClinicalTrials.gov/show/NCT02156622"
1462,"NCT02607514","Hyperthermic Yoga for Depressive Symptoms",,"Completed","No Results Available","Depression|Major Depressive Disorder","Behavioral: hyperthermic yoga","Depressive symptoms as measured by the Inventory of Depressive Symptomatology - Clinician Rated (IDS-CR)|Feasibility and tolerability measured by percent of the yoga group who complete a week 8 assessment","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016P000704","February 20, 2017","December 19, 2019","December 19, 2019","November 18, 2015",,"April 24, 2020","Depression Clinical and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02607514"
1463,"NCT04740879","The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms",,"Recruiting","No Results Available","Depressive Symptoms|Major Depressive Disorder, Recurrent, in Remission","Behavioral: Be Mindful","Mean Change in Depressive Symptoms from Baseline as Measured by the Patient Health Questionnaire 9 Post-Intervention|Mean Change in Depressive Symptoms from Baseline as Measured by the Patient Health Questionnaire 9 at 3-Month Follow-Up|Mean Change in Mindfulness from Baseline as Measured by the Five Factor Mindfulness Questionnaire Short Form|Mean Change in Decentering from Baseline as Measured by the Toronto Mindfulness Scale|Mean Change in Rumination from Baseline as Measured by the Ruminative Response Questionnaire|Mean Change in Worry from Baseline as Measured by the Penn State Worry Questionnaire|Mean Change in Self-Compassion from Baseline as Measured by the Self-Compassion Scale Short Form|Mean Change in Dysfunctional Attitudes from Baseline as Measured by the Dysfunctional Attitudes Scale (Short Form 1)|Mean Change in Dysfunctional Attitudes from Baseline as Measured by the Rosenberg Self-Esteem Scale|Mean Change in Dysfunctional Attitudes from Baseline as Measured by the Single-Item Self-Esteem Scale","State University of New York at Buffalo","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00005212|SU-20-01","March 30, 2021","January 2022","May 2022","February 5, 2021",,"May 6, 2021","State University of New York at Buffalo (SUNY at Buffalo), Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04740879"
1464,"NCT00191061","A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder","Drug: duloxetine hydrochloride","The primary objective in the acute phase of this study is to compare the incidence of treatment-emergent nausea|for patients initially dosed at duloxetine 30 mg QD|(once-daily), versus duloxetine 60 mg QD.|The primary objective in the extension phase of this study is to compare efficacy in patients not meeting response criteria during the acute phase for patients dosed at duloxetine 60 mg QD versus duloxetine 120 mg QD.|The secondary objective of greatest importance is to compare the incidence of treatment-emergent nausea|(as defined for the primary objective) for patients|initially dosed at duloxetine 30 mg QD, versus duloxetine 30 mg BID (twice-daily).|Additional secondary objectives include comparing the three initial dosing groups in regards to:Mean changes from baseline in the category total scores and individual items scores of the AMDP-5|The incidence and severity of adverse events using rates of spontaneously reported treatment-emergent adverse events, rates of discontinuations due to|adverse events, categorical changes in AMDP-5 items, mean changes and categorical changes in vital signs|as well as mean changes and rates of abnormal laboratory analytes|Mean changes from baseline in the HAMD17 total score, HAMD subscales, HAMD17 individual items, 30-item Inventory of Depressive Symptoms,|Clinician Rated (IDS-30) total score and individual items, Brief Pain Inventory items and interference|total score, Visual Analog Scales for pain, Clinical Global Impressions of Severity (CGI-Severity), Post-baseline means|on the Patient's Global Impression of Improvement (PGI-I), Remission rates (HAMD17 total score of less than 7),|and response rates (greater than 50% decrease from baseline on the HAMD17 total score).|- Sexual dysfunction, as measured by categorical changes (same, better, worse) and presence vs. absence, based on the patient global assessment of sexual functioning.|Time to onset of action in depression (30% improvement in Maier Subscale of HAMD) and painful physical symptoms (30% improvement in as measure by the BPI interference total score).","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","640","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","8950|F1D-US-HMDR","October 2004",,"January 2006","September 19, 2005",,"January 26, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Charlotte, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boise, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edwardsville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terre Haute, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Burnie, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clementon, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Princeton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olean, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlottesville, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midlothian, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00191061"
1465,"NCT00404755","Dichotic Listening as a Predictor of Medication Response in Depression",,"Completed","Has Results","Major Depressive Disorder|Dysthymia","Drug: escitalopram|Drug: bupropion|Drug: imipramine","Hamilton Depression Scale (HAM-D)|Clinical Global Impression Scale (CGI)","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#5294R|IRB 5294R","July 2006","August 2011","August 2011","November 29, 2006","March 15, 2018","April 30, 2018","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00404755"
1466,"NCT04641780","""Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program""","RAISE","Recruiting","No Results Available","Schizophrenia|Major Depressive Disorder","Drug: Brexpiprazole","Safety assessment of patients with Schizophrenia and Major Depressive Disorder|Efficacy assessment of patients with Schizophrenia and Major Depressive Disorder using Clinical Global Impression (CGI) Scale","Otsuka Pharmaceutical, Inc., Philippines","All","18 Years and older   (Adult, Older Adult)",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","331-414-00243","August 17, 2019","June 2023","March 2024","November 24, 2020",,"December 1, 2020","Otsuka (Philippines) Pharmaceutical Inc., Makati City, Metro Manila, Philippines","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04641780/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04641780"
1467,"NCT02422303","Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms",,"Terminated","Has Results","Depression|Major Depressive Disorder","Drug: ketamine","Depression Score Using Goldberg Depression Screening Test","The University of Texas Health Science Center at San Antonio","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HSC20150248H","December 2015","September 2016","September 2016","April 21, 2015","February 15, 2018","February 15, 2018","University Hospital, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02422303"
1468,"NCT01583569","Complex Dynamic Systems in Mood Disorders",,"Completed","No Results Available","Bipolar Disorder|Major Depressive Disorder",,,"Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)",,"20","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","3273723|1K18MH093939-01","November 2011","June 2014","December 2014","April 24, 2012",,"October 7, 2015","Bipolar Clinic and Research Program at Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01583569"
1469,"NCT00437125","Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease",,"Completed","Has Results","Major Depressive Disorder|Idiopathic Parkinson Disease","Drug: Duloxetine hydrochloride","Number of Participants Reporting Serious Adverse Events or Other Adverse Events Leading Either to Discontinuation or to Death|Change From Baseline to 12 Weeks on the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score|Change From Baseline to 12 Weeks on the UKU (Udvalg for Kliniske Undersogelser: Committee for Clinical Investigations) Side Effect Rating Scale|Change From Baseline on the Pittsburgh Sleep Quality Index (PSQI)|Change From Baseline to 12 Weeks on the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score|Change From Baseline to 12 Weeks on the Clinical Global Impression-Severity Scale|Patient's Global Impression-Improvement at Week 12|Change From Baseline to 12 Weeks in Beck Depression Inventory (BDI) Total Score|Change From Baseline to 12 Weeks in Visual Analog Scale (VAS)|Change From Baseline to 12 Weeks in Parkinson Disease Questionnaire - 39 Item Version (PDQ-39) Total Score|Average Change From Baseline to 12 Weeks in Blood Pressure|Average Change From Baseline to 12 Weeks in Heart Rate|Number of Participants With Abnormal Electrocardiograms (ECG) During the 12 Week Study|Laboratory Analytes|Number of Participants Who Responded to Treatment by 12 Weeks|Number of Participants Who Reached Remission by 12 Weeks","Eli Lilly and Company","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 4","151","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11127|F1J-IT-HMFQ","March 2007","July 2009","July 2009","February 19, 2007","August 16, 2010","September 8, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ancona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brescia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Messina, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozzilli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy",,"https://ClinicalTrials.gov/show/NCT00437125"
1470,"NCT02398877","HPA Axis Activity Due To Early Traumatic Stress and Metabolic Symptoms","Cort-Metab","Completed","No Results Available","Childhood Trauma|Major Depressive Disorder","Other: stress","Endocrine response to stress (salivary cortisol)|glucose to oral glucose tolerance test (plasma insulin)|insulin to oral glucose tolerance test (plasma insulin)|cortisol to corticotropin releasing factor (salivary cortisol)","Charite University, Berlin, Germany","Female","18 Years to 60 Years   (Adult)","Not Applicable","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","WI 3396/6-1","February 2013","February 2016","February 2016","March 26, 2015",,"March 7, 2016","Charite University, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02398877"
1471,"NCT01347138","Health Care Management for the Elderly in Community Through Screening",,"Completed","No Results Available","Major Depressive Disorders|Senile; Depression","Other: case management","Geriatric Depression Score|quality of life|treatment compliance|suicide ideation","National Clinical Research Coordination Center, Seoul, Korea","All","60 Years and older   (Adult, Older Adult)","Not Applicable","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","A102065","May 2011","April 2012","April 2012","May 4, 2011",,"March 11, 2016","City of Choongju public health center, Choongju, Choongchungbuk-Do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01347138"
1472,"NCT00612807","Treatment of Mood and Marriage Study (TOMMS)",,"Completed","Has Results","Major Depressive Disorder|Partner Relational Disorder (V61.10)","Behavioral: Weekly marital therapy|Drug: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.","Hamilton Depression Rating Scale (HDRS)|Dyadic Adjustment Scale (DAS)|Frequency & Acceptability of Partner Behavior|Conflict Tactics Scale|SCID Mood Disorders|Personal Assessment of Intimacy in Relationships|Beck Anxiety Inventory","Duke University|National Institutes of Health (NIH)","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00008099|R34MH073677-01A2","July 2006","June 2010","June 2010","February 12, 2008","April 26, 2011","June 24, 2013","Duke Child & Family Studies Center; Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00612807"
1473,"NCT00869765","Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder","Drug: D-Cycloserine|Device: tDCS (Eldith DC-Stimulator (CE certified))","Inventory of Depressive Symptomatology (IDS-C)|Montgomery Asberg Depression Rating Scale for Depression (MADRS)","The University of New South Wales","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09052","April 2009","September 2010","September 2010","March 26, 2009",,"September 10, 2010","Black Dog Institute, University of New South Wales, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT00869765"
1474,"NCT00369746","STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse",,"Completed","Has Results","Major Depressive Disorder|Alcohol Use Disorder","Drug: citalopram","Quick Inventory of Depression- Self Report 16|Timeline Follow Back (TLFB) Average Drinks Per Drinking Day|Quantitative Substance Use Inventory ((SUI)|Timeline Follow Back (TLFB) Drinking Days Per 30 Days|Timeline Follow Back (TLFB) Maximum Drinks Per Drinking Day","New York State Psychiatric Institute|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 65 Years   (Adult, Older Adult)",,"674","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","#5173|R01AA013303","September 2006","February 2009","February 2009","August 29, 2006","May 9, 2014","May 9, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00369746"
1475,"NCT01409096","Study Using Pregnenolone to Treat Bipolar Depression",,"Completed","Has Results","Bipolar Disorder|Major Depressive Disorder","Drug: Pregnenolone|Drug: Placebo","The 17-item Hamilton Rating Scale for Depression (HRSD17)|Inventory of Depressive Symptomatology-Self Report (IDS-SR)|Young Mania Rating Scale (YMRS)|Hamilton Rating Scale for Anxiety (HRSA)","University of Texas Southwestern Medical Center|Stanley Medical Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","122009-069","March 2010","November 2011","November 2011","August 3, 2011","March 31, 2016","March 31, 2016","The University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01409096"
1476,"NCT02507297","Sleep-Disordered Breathing and PAP in Perinatal Depression",,"Completed","Has Results","Sleep-disordered Breathing|Major Depressive Disorder","Device: Positive Airway Pressure (PAP)","Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item|Change in Edinburgh Postnatal Depression Scale Score|Change in Pittsburgh Sleep Quality Index Score|Change in Epworth Sleepiness Scale (ESS) Score|Change in Salivary Cortisol","University of Michigan","Female","18 Years to 45 Years   (Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1K23HL122461-01A1","January 2016","April 25, 2020","April 25, 2020","July 23, 2015","May 13, 2021","June 11, 2021","University of Michigan, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02507297/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02507297"
1477,"NCT01441258","Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression",,"Completed","No Results Available","Suicidal Ideation|Major Depressive Disorder","Behavioral: Dialectical Behavior Therapy Skills (DBT-S) Groups|Behavioral: Wait List-Treatment as Usual|Behavioral: No intervention-treatment as usual","Beck Scale for Suicidal Ideation (SSI)","Maurizio Fava, MD|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011P001088","October 2011","February 2015","February 2015","September 27, 2011",,"April 8, 2015","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01441258"
1478,"NCT01239888","Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study",,"Unknown status","No Results Available","Depression|Major Depressive Disorder","Drug: Oxytocin|Drug: Oxytocin and Tibolone|Drug: Placebo","Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)|Change from baseline in Hamilton Rating Scale for Depression (HAM-D)|Change from baseline in Beck Depression Inventory II (BDI-II)|Change from baseline in State Trait Anxiety Inventory (STAI)|Adverse Symptom Check List|Perceived stress scale|Pittsburgh sleep quality index|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)","The Alfred|Monash University","Female","18 Years to 45 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MAPRC 2010CK","January 2012","November 2012",,"November 15, 2010",,"January 18, 2012","Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01239888"
1479,"NCT01856127","Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?",,"Terminated","No Results Available","Sexual Dysfunction|Major Depressive Disorder","Drug: Vilazodone|Drug: Sertraline","Changes in Sexual Functioning Questionnaire (CSFQ (c))","Thomas Jefferson University|Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VII-IT-09","January 2013","June 2016","June 2016","May 17, 2013",,"August 25, 2016","University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01856127"
1480,"NCT00186446","Treatment of Nicotine Dependence and Acute Depression",,"Completed","Has Results","Major Depressive Disorder|Nicotine Dependence","Drug: bupropion and smoking cessation behavioral intervention","Hamilton Depression Scale Score|Cessation of Smoking|Can Depression and Smoking Cessation be Treated Simultaneously","Stanford University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GSK 103341","June 2004","September 2007","September 2007","September 16, 2005","April 4, 2017","April 4, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00186446"
1481,"NCT03175068","Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response",,"Recruiting","No Results Available","Major Depressive Disorder|Social Anxiety Disorder","Behavioral: CBT|Behavioral: ST","BOLD Effects Measured with Functional Magnetic Resonance Imaging (fMRI)","University of Illinois at Chicago|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","2017-0258|1R01MH112705-01A1","July 5, 2017","June 30, 2022","June 30, 2022","June 5, 2017",,"April 30, 2021","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03175068"
1482,"NCT00993629","Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans",,"Withdrawn","No Results Available","Post-traumatic Stress Disorder|Major Depressive Disorder","Drug: pregnenolone|Drug: placebo","Clinician Administered PTSD Scale (CAPS)","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 55 Years   (Adult)","Phase 2","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","B7064-W","January 2010","May 2010","May 2010","October 12, 2009",,"October 27, 2014","VA Medical Center, Durham, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00993629"
1483,"NCT00205933","Behavioral Processes Underlying Reward Processing in Depression",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder",,,"Affective Neuroscience Laboratory|Massachusetts General Hospital","All","18 Years to 64 Years   (Adult)",,"78","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2003-P-000994","April 2004",,"June 2007","September 21, 2005",,"December 6, 2007","The Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States|Affective Neuroscience Laboratory, Department of Psychology, Harvard University, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00205933"
1484,"NCT01211756","Oxytocin Add-on for Stable Depressed Patients",,"Terminated","Has Results","Major Depressive Disorder|Dysthymia Disorder","Drug: Oxytocin|Drug: Placebo","Total Score on Montgomery-Asberg Depression Rating Score (MADRS)|Global Assessment of Functioning (GAF)|Clinical Global Impression-Severity of Illness (CGI-S)|Clinical Global Impression-Global Improvement (CGI-I)|Young Mania Rating Scale (YMRS)|Hamilton-Anxiety Scale (HAM-A)|Reading Trust in the Mind's Eye Test|Profile of Mood States (POMS)|Arizona Sexual Experience Scale (ASEX)|Peabody Picture Vocabulary Test|California Verbal Learning Test|Letter Number Sequencing Memory Test|Continuous Performance Test (CPT)","David Feifel|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Oxytocin Depression","October 2010","February 2015","December 2015","September 29, 2010","September 25, 2019","September 25, 2019","UCSD Medical Center, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01211756"
1485,"NCT03811860","Lithium Therapeutic Drug Monitoring; Once Daily Vs Twice Daily Dosing and the Impact of Kidney Function",,"Unknown status","No Results Available","Bipolar Disorder|Major Depressive Disorder","Diagnostic Test: Lithium level|Diagnostic Test: Serum Creatinine","Difference in lithium levels between once and twice daily dosing|Correlation between renal function and difference in lithium level|Frequency of selected concurrent medication use","Mount Sinai Hospital, Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-0289-A","February 6, 2019","September 2019","December 2019","January 22, 2019",,"March 8, 2019","Mount Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03811860"
1486,"NCT02901249","Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder",,"Completed","Has Results","Depression","Drug: sertraline|Drug: Nortriptyline|Drug: Lithium","Number of Participants With Response to Treatment|Number of Participants With Remission to Treatment|Quality of Life -WHOQOL Intrument Scores","Federal University of Rio Grande do Sul","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","68","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","017/2009","May 2010","November 2014","September 2015","September 15, 2016","October 14, 2020","October 14, 2020",,,"https://ClinicalTrials.gov/show/NCT02901249"
1487,"NCT00789854","Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","RUBY","Completed","Has Results","Major Depressive Disorder|Treatment Resistant Depression","Drug: Quetiapine XR|Drug: Lithium carbonate|Drug: SSRI/Venlafaxine","Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)|Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)|Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12|Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients|Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure|Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure|Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients|Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure|Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure|Change in Clinical Global Impression Scale (CGI-S), All Patients|Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure|Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure|Change in Beck Depression Inventory (BDI)|Change in Pain, Measured by Visual Analog Scale (VAS)|Change in Anxiety Measured by Visual Analog Scale (VAS)|Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory|Change in Anxiety Measured by STAI, Trait Anxiety Inventory|Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4|Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)|Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component|Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component|Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility|Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)|Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients|Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure|Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","688","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00044","November 2008","August 2009","August 2009","November 13, 2008","May 23, 2012","May 23, 2012","Research Site, Garran, Australian Capital Territory, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Everton Park, Queensland, Australia|Research Site, Townsville, Queensland, Australia|Research Site, Gilberton, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Graz, Austria|Research Site, Klagenfurt, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wiener NEUSTADT, Austria|Research Site, Wien, Austria|Research Site, Assebroek, Belgium|Research Site, Diest, Belgium|Research Site, Liege, Belgium|Research Site, Tielt, Belgium|Research Site, Cerova Koria Village, Veliko Tarnovo, Bulgaria|Research Site, Kardjali, Bulgaria|Research Site, Pazardjik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Esbjerg N, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Odense, Denmark|Research Site, Aachen, Germany|Research Site, Achim, Germany|Research Site, Augsburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Honnef, Germany|Research Site, Bad Saarow, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Bochum, Germany|Research Site, Butzbach, Germany|Research Site, Chemnitz, Germany|Research Site, Dresden, Germany|Research Site, Duren, Germany|Research Site, Dusseldorf, Germany|Research Site, Ellwangen, Germany|Research Site, Erbach, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Gutersloh, Germany|Research Site, Halle, Germany|Research Site, Hattingen, Germany|Research Site, Herborn, Germany|Research Site, Kassel, Germany|Research Site, Kothen, Germany|Research Site, Neu-isenburg, Germany|Research Site, Neubrandenburg, Germany|Research Site, Nurnberg, Germany|Research Site, Oldenburg, Germany|Research Site, Ostfildern, Germany|Research Site, Schwerin, Germany|Research Site, Stuttgart, Germany|Research Site, Westerstede, Germany|Research Site, Wurzburg, Germany|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Bressanone, BZ, Italy|Research Site, Brunico, BZ, Italy|Research Site, Cagliari, CA, Italy|Research Site, Pisa, PI, Italy|Research Site, Roma, RM, Italy|Research Site, Bolzano, Italy|Research Site, Catania, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Santarem, Portugal|Research Site, Bucharest, Romania|Research Site, Craiova, Romania|Research Site, Galati, Romania|Research Site, Sibiu, Romania|Research Site, Bratislava, Slovakia|Research Site, Krupina, Slovakia|Research Site, Levice, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Michalovce Stranany, Slovakia|Research Site, Presov, Slovakia|Research Site, Roznava, Slovakia|Research Site, Zilina-bytcica, Slovakia|Research Site, Zlate Moravce, Slovakia|Research Site, Sama de Langreo, Asturias, Spain|Research Site, Salamanca, Castilla Leon, Spain|Research Site, Zamora, Castilla Leon, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Addlestone, Surrey, United Kingdom|Research Site, Winnick, Warrington, United Kingdom|Research Site, Horsham, West Sussex, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Winsford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00789854"
1488,"NCT00660062","Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)","DUAG-7","Terminated","No Results Available","Major Depression","Drug: escitalopram|Drug: nortriptyline","Hamilton depression rating scale|Drop out due to side-effects of drugs","Hillerod Hospital, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 4","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DUAG-7","August 2009","November 2014","November 2014","April 17, 2008",,"December 9, 2014","Mental Health Centre Copenhagen Department O, Copenhagenl, Denmark",,"https://ClinicalTrials.gov/show/NCT00660062"
1489,"NCT01710202","Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration","5-HTTLPR","Completed","No Results Available","Major Depressive Disorder|Anxiety Disorders","Drug: Hydrocortisone","Change in testosterone concentration","University of Texas at Austin","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control","2011-12-0017","October 2012","December 2013","November 2014","October 19, 2012",,"March 20, 2015","University of Texas at Austin Department of Psychology, Austin, Texas, United States|University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01710202"
1490,"NCT03971903","Attention Bias Modification Treatment for Young Adults With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Behavioral: Attention bias modification","Changes of attention bias score|Changes of depressive symptoms|Changes of severity of depression|Changes of self-reported depressive symptoms|Changes of self-reported trait anxiety|Changes of self-reported rumination","Hunan Normal University","All","16 Years to 20 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BBA130016","December 24, 2017","March 26, 2019","March 26, 2019","June 3, 2019",,"June 3, 2019","Department of Psychology, Hunan Normal University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03971903"
1491,"NCT03922581","Primary-Care Based Mindfulness Intervention",,"Recruiting","No Results Available","Post Traumatic Stress Disorder|Major Depressive Disorder","Behavioral: Mindfulness-Based Cognitive Therapy","Retention rate|Client Satisfaction Questionnaire (CSQ) Score|Perceived Barriers to Psychological Treatment (PBPT) Scale Score|Change in Difficulties in Emotion Regulation Scale (DERS) Score|Post-group Follow-up Questionnaire|Change in skin conductance|Change in Primary Care PTSD Screen (PC-PTSD) Determination|Change in Patient Health Questionnaire-9 (PHQ-9) Score|Change in PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (PCL-5) Score|Change in Beck Depression Inventory-II (BDI-II) Score|Change in Clinician Administered PTSD Scale PTSD Determination|Change in Mini International Neuropsychiatric Interview (MINI) MDD Determination|Change in Five Facet Mindfulness Questionnaire Score|Change in Self Compassion Scale, Short Form Score","Emory University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00104519|K23AT009713","September 14, 2018","June 2022","June 2022","April 22, 2019",,"November 13, 2020","Grady Health System, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03922581"
1492,"NCT00714090","Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression",,"Completed","No Results Available","Unipolar Depression","Other: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|Other: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|Other: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine","The primary outcome measure is remission. It will be evaluated using the Hamilton Depression Rating Scale (HDRS-17 < 8)and Montgomery Asberg Depression Rating Scale (MADRS)|Onset of action for remission and response (HDRS-17 diminution > 50%)|Anxiety will be assessed using the Covi Anxiety Scale.|Side effects will be assessed using the UKU Scale.|Evaluation of depression using 2 other scales : the Montgomery Asberg Depression Rating Scale (MADRS) and the Beck Depression Inventory scale (BDI-13)|Onset of action using the Clinical Global Impressions scale (CGI)","Club rTMS et Psychiatrie|Ministry of Health, France|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SAD-001","May 2008","July 2012","July 2013","July 14, 2008",,"July 19, 2013","C.H.U. Saint-Jacques - Service de Psychiatrie de l'Adulte, Besançon, France|C.H. Le Vinatier - EA 4166, UCB Lyon 1 - Department of Psychiatry - Service du Pr d'AMATO, Bron, France|C.H.U. Gabriel Montpied - Service de Psychiatrie et Psychologie Médicale - CMP A, Clermont Ferrand, France|Hôpital Louis Mourier, Colombes, France|C.H.U. Dijon, Hôpital Général - Service de Psychiatrie et d'Addictologie, Dijon, France|C.H.U. de Grenoble, Hôpital sud - Département de Psychiatrie, Grenoble, France|Hôpital Fontan - C.H.R.U. Lille, Lille, France|ASM Limoux, Lézignan-Corbières, France|C.H. Sainte Marguerite, Marseille, France|CHU - Hôpital La Colombière, Montpellier, France|Hôpital Pasteur - CHU Nice, Nice, France|Hôpital Sainte Anne - Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Paris, France|C.H.U. de POITIERS, Poitiers, France|C.H.U. - C.H. Guillaume Régnier, Rennes, France|C.H.U. Charles Nicolle - Service Hospitalo-Universitaire de Psychiatrie, Rouen, France|EPS de Ville Evrard - Unité de Saint-Denis, Saint-Denis, France|CHU St Etienne - Hôpital Nord, St Etienne cedex, France|Centre Hospitalier Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT00714090"
1493,"NCT04781127","Home-administered tDCS for Treatment of Depression",,"Recruiting","No Results Available","Unipolar Depression|Treatment Resistant Depression","Device: Soterix Medical mini-CT tDCS stimulator","Change in Mood|Self-Reported Mood Score|Quick Inventory of Depressive Symptomology (QIDS-SR)|Quality of Life Enjoyment and Satisfaction Questionnaire Form (Q-LES-Q-SF)|Columbia Suicide Severity Rating Scale (C-SSRS)|Self-report Columbia Suicide Severity Rating Scale (C-SSRS)|Adverse Effects: Pain|Adverse Effects: Suicidal Ideation","Soterix Medical|NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMI-F10","February 10, 2021","August 10, 2022","August 10, 2022","March 4, 2021",,"March 5, 2021","New York University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04781127"
1494,"NCT04697693","Antidepressant Response in Older Adults With Comorbid PTSD and MDD",,"Recruiting","No Results Available","Post Traumatic Stress Disorder|Major Depressive Disorder","Drug: Escitalopram|Drug: Duloxetine","Change in Hamilton Rating Score for Depression (HRSD) from baseline to week 8","New York State Psychiatric Institute","All","60 Years to 105 Years   (Adult, Older Adult)","Phase 4","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8111","March 3, 2021","March 1, 2025","March 1, 2026","January 6, 2021",,"March 24, 2021","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04697693"
1495,"NCT00485420","eCare for Moods: An Internet-based Management Program",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder","Other: Internet based disease management program","Reduction of severity of mania and depression symptoms and reduction in frequency of occurrence depression symptoms|Satisfaction with medical care","Kaiser Permanente|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Not Applicable","404","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CN-02EHunk-02-H","September 2002","September 2009","December 2009","June 13, 2007",,"April 19, 2012",,,"https://ClinicalTrials.gov/show/NCT00485420"
1496,"NCT00296686","Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression",,"Terminated","No Results Available","Major Depression","Drug: Tranylcypromine|Drug: Dextroamphetamine|Drug: Triiodothyronine","Hamilton Depression Scale (HAM-D)|Beck Depression Inventory (BDI)|Clinical Global Impression (CGI)|Patient Global Impression (PGI)","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#4213","September 2001","August 2006","August 2006","February 27, 2006",,"April 27, 2012","Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00296686"
1497,"NCT00998231","Major Depression and Messenger RNAs",,"Completed","No Results Available","Major Depressive Episode","Biological: blood sample","to compare gene expression difference for 21 candidate genes, of which 12 were already investigated, in 2 groups of subjects","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2009/15|2009-A00405-52","July 2009","September 2012",,"October 20, 2009",,"February 25, 2014","Assistance Publique-Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT00998231"
1498,"NCT02709668","B Vitamins in MTHFR Positive Patients With Major Depression: A Post Hoc Analysis of Findings","BVMD","Completed","No Results Available","Depression","Dietary Supplement: Enlyte|Other: placebo","Homocysteine levels|Montgomery Asberg Depression Rating Scale","High Point Regional Health Systems","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","AMBFDepression","August 2013","April 2014","April 2014","March 16, 2016",,"March 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02709668"
1499,"NCT00939250","A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care",,"Completed","No Results Available","Type 2 Diabetes|Major Depressive Disorder","Behavioral: Diabetes and depression intervention|Behavioral: Diabetes intervention","Glycosylated Hemoglobin|Quick Inventory of Depressive Symptoms - Self Report","University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 4","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 042009-010|R34DK081031","October 2009","December 2011","December 2011","July 14, 2009",,"September 2, 2020","Family and Community Medicine Clinic, University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00939250"
1500,"NCT02702154","High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Major Depression",,"Unknown status","No Results Available","Depression","Device: High-frequency rTMS|Device: Low-frequency rTMS|Device: Sham rTMS","HAM-D17 score|Beck Depression Inventory-II|Beck anxiety inventory","University Health Network, Toronto","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","15-9276-A","February 2016","April 2018","August 2018","March 8, 2016",,"March 30, 2018","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02702154"
1501,"NCT01691092","PET Imaging of mGLuR5 With Drug Challenge",,"Completed","Has Results","Major Depressive Disorder|Post-Traumatic Stress Disorder (PTSD)","Drug: Ketamine","Change in Glutamate Levels at Baseline and After Ketamine Administration as Confirmed by Positron Emission Tomography (PET) Imaging","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","79","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1111009365","June 2012","February 2016","February 2016","September 24, 2012","April 21, 2017","April 21, 2017","Connecticut Mental Health Center, New Haven, Connecticut, United States|Yale University Magnetic Resonance Research Center (MRRC), New Haven, Connecticut, United States|Yale University PET Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01691092"
1502,"NCT01342380","Pioglitazone and Quetiapine XR Pharmacogenetic Study",,"Completed","No Results Available","Bipolar Disorder|Major Depressive Disorder",,"Genetic markers associated with treatment response","Joseph Calabrese, MD|National Institutes of Health (NIH)|National Center for Research Resources (NCRR)|University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)",,"42","Other|NIH","Observational","Time Perspective: Retrospective","#10-10-25","February 2011","May 2015","May 2015","April 27, 2011",,"October 4, 2016","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01342380"
1503,"NCT00096798","Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression",,"Completed","No Results Available","Depressive Disorder|Depression","Drug: Ethyl-eicosapentanoic acid (ethyl-EPA)","Alleviation of depressive symptoms","National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","80","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","K23AT001129","September 2001","August 2007","August 2007","November 16, 2004",,"January 17, 2008","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00096798"
1504,"NCT03114891","Accelerated TMS to a Novel Brain Target in MDD and PTSD",,"Active, not recruiting","No Results Available","Post Traumatic Stress Disorder|Major Depressive Disorder","Procedure: Theta-burst stimulation","Change in depression and PTS symptoms from baseline to after TMS is performed at the standard brain target for 2 weeks|Change in depression and PTS symptoms from baseline to after TMS is performed at the fMRI-guided brain target for 2 weeks|Correlation between resting-state connectivity and degree of clinical change","University of Pennsylvania|Cures Within Reach","All","18 Years to 60 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","826007","April 20, 2017","December 2021","December 2021","April 14, 2017",,"June 28, 2021","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03114891"
1505,"NCT00096642","Cognitive Behavioral Therapy for Early-Onset Depression",,"Completed","No Results Available","Major Depressive Disorder|Dysthymic Disorder","Behavioral: Cognitive Behavioral Therapy","Diagnosis on structured interview|Children's Depression Inventory score|Multidimensional Anxiety Scale for Children|Children's Global Assessment Scale|Brief Family Assessment Measure|Perceived Competence Scale for Children","Centre for Addiction and Mental Health","All","10 Years to 17 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CBT DEP|Ethics # 138/2001","June 2002","June 2006","June 2006","November 15, 2004",,"August 5, 2011","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00096642"
1506,"NCT00572520","Effectiveness of Behavioral Treatments for Obesity and Major Depression in Women",,"Completed","No Results Available","Depression|Obesity","Behavioral: Weight loss treatment|Behavioral: Behavior therapy for depression|Behavioral: Health education counseling","Change in body weight and the trend in body weight over time|Change in depression, physical activity, diet (daily caloric intake), psychosocial variables (anhedonia, exercise self-efficacy, disinhibited eating, quality of life), and cardiovascular risk factors (blood pressure, serum lipids, C-reactive protein)|Effect of potential mediators (adherence, depression, general and physical activity, caloric intake) on weight change","University of Massachusetts, Worcester|National Institute of Mental Health (NIMH)","Female","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","161","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH078012|DAHBR 96-BHB","July 2007","April 2012","April 2012","December 13, 2007",,"July 5, 2018","University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00572520"
1507,"NCT02230592","PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX",,"Completed","No Results Available","Anxiety Disorder|Major Depressive Disorder",,"Ability to measure mGluR1 in brain","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)",,"19","NIH","Observational","Time Perspective: Prospective","140016|14-M-0016","November 8, 2013","June 16, 2016","June 16, 2016","September 3, 2014",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02230592"
1508,"NCT00620789","Behavioral Insomnia Therapy For Those With Insomnia and Depression",,"Unknown status","No Results Available","Insomnia|Major Depressive Disorder","Drug: Escitalopram + CBT-I|Behavioral: CBT-I plus placebo antidepressant medication|Drug: Escitalopram","Mean two-week sleep log estimate of post-treatment sleep continuity|Mean two-night polysomnographic post-treatment sleep continuity","Ryerson University","All","21 Years to 64 Years   (Adult)","Not Applicable","477","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00003416|1R01MH076856-01A2","March 2008","January 2014","January 2014","February 22, 2008",,"May 31, 2013","Ryerson University, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00620789"
1509,"NCT04158869","An Investigation of the Relationship Between Omega-3 Fatty Acid Nutrition and Mental Health in Children and Adolescents",,"Recruiting","No Results Available","Major Depressive Disorder|Depression|Child Mental Disorder",,"n-3 fatty acid intake|n-3 fatty acid status|Pediatric depressive symptoms|Fatty acid metabolism|Biomarkers related to brain health|Biomarkers related to systemic inflammation|Biomarkers related to gut microbiota|Biomarkers related to nutritional status","Swiss Federal Institute of Technology|Psychiatric University Hospital, Zurich","All","8 Years to 17 Years   (Child)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","n-3 case-control study","September 16, 2019","December 2020","June 2021","November 12, 2019",,"November 12, 2019","ETH Zürich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04158869"
1510,"NCT02049385","Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?",,"Terminated","Has Results","Depression","Drug: Diazoxide|Drug: Placebo","MADRS Change at Day 7","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","140041|14-M-0041","January 3, 2014","July 21, 2016","July 21, 2016","January 30, 2014","October 13, 2017","October 13, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02049385"
1511,"NCT00335205","A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.",,"Unknown status","No Results Available","Bipolar Disorder|Major Depressive Disorder","Drug: ropinirole","Hamilton Depression Rating Scale Score|Montgomery Asberg Depression Rating Scale Score","Sheba Medical Center|Jerusalem Mental Health Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SHEBA-02-2690-LG-CTIL","April 2003",,,"June 9, 2006",,"June 9, 2006","Jerusalem Mental Health Center, Jerusalem, Israel|Chaim Sheba Medical Center, Dept. of Psychiatry, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT00335205"
1512,"NCT02423824","Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists","COGDYS-GLP1","Completed","No Results Available","Bipolar Disorder|Major Depressive Disorder","Biological: Liraglutide","Executive function|Resting-state functional network connectivity","University Health Network, Toronto","All","18 Years to 45 Years   (Adult)","Phase 3","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-8561-A","May 2015","April 2016","May 2016","April 22, 2015",,"May 13, 2016","Mood Disorders Psychopharmacology Unit, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02423824"
1513,"NCT00433238","Screening for Mental Health Concerns for at-Risk Community Living Chinese Seniors",,"Unknown status","No Results Available","Major Depressive Disorder|Dementia","Behavioral: Participants will be screened for depression and cognitive impairment, then receive screening results.","Rate of help seeking in intervention group|Rate of confirmed psychiatric diagnoses in intervention group|Type of intervention received","Mount Sinai Hospital, Canada","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Screening","WCMSH","March 2007",,,"February 9, 2007",,"February 9, 2007","Wellness Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00433238"
1514,"NCT00518986","Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression",,"Completed","Has Results","Sleep Disorders|Obstructive Sleep Apnea|Major Depressive Disorder|Dysthymic Disorder","Drug: armodafinil|Drug: placebo","Change From Baseline on Maintenance of Wakefulness Test (MWT) to Endpoint (12 Weeks or Last Observation After Baseline)|Clinical Global Impression of Change (CGI-C) at Endpoint (12-weeks or Last Observation After Baseline)|Change From Baseline on the Epworth Sleepiness Scale (ESS) at Endpoint (12 Weeks or Last Measurement After Baseline)|Change From Baseline on Maintenance of Wakefulness Test (MWT) at 4 Weeks|Change From Baseline on Maintenance of Wakefulness Test (MWT) at 8 Weeks|Change From Baseline on Maintenance of Wakefulness Test (MWT) at 12 Weeks|Clinical Global Impression of Change (CGI-C) at 4 Weeks|Clinical Global Impression of Change (CGI-C) at 8 Weeks|Clinical Global Impression of Change (CGI-C) at 12 Weeks|Clinical Global Impression of Change (CGI C) at 4 Weeks - Full Scale|Clinical Global Impression of Change (CGI-C) at 8 Weeks - Full Scale|Clinical Global Impression of Change (CGI-C) at 12 Weeks - Full Scale|Change From Baseline on Epworth Sleepiness Scale (ESS) at 2 Weeks|Change From Baseline on Epworth Sleepiness Scale (ESS) at 4 Weeks|Change From Baseline on Epworth Sleepiness Scale (ESS) at 8 Weeks|Change From Baseline on Epworth Sleepiness Scale (ESS) at 12 Weeks|Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 2 Weeks|Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 4 Weeks|Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 8 Weeks|Number of Responders According to the Epworth Sleepiness Scale (ESS) Total Score at 12 Weeks|Change From Baseline to Endpoint (Week 12 or Last Observation After Baseline) in the Brief Fatigue Inventory (BFI) Total Score|Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 2 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 4 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 8 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Total Score at 12 Weeks|Change From Baseline on the Brief Fatigue Inventory (BFI) Worst Daily Fatigue Score at Endpoint (12 Weeks or Last Observation After Baseline)|Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 2 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 4 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 8 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Worse Daily Fatigue Score at 12 Weeks|Number of Responders According to Brief Fatigue Inventory (BFI) Worst Fatigue Score at Endpoint (12 Weeks or Last Observation After Baseline)|Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 2 Weeks|Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 4 Weeks|Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 8 Weeks|Number of Responders According to the Brief Fatigue Inventory (BFI) Worst Fatigue Score at 12 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at Endpoint (12 Weeks or Last Observation After Baseline)|Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 2 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 4 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 8 Weeks|Change From Baseline on Brief Fatigue Inventory (BFI) Interference Score at 12 Weeks (or Last Observation After Baseline)|Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at Endpoint (12 Weeks or Last Observation After Baseline)|Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 2 Weeks|Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 4 Weeks|Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 8 Weeks|Change From Baseline on Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 12 Weeks|Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at Endpoint (Week 12 or Last Observation After Baseline)|Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score at 2 Weeks|Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) at Week 4|Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) at Week 8|Number of Responders According to the Functional Outcomes of Sleep Questionnaire (FOSQ) at Week 12|Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at Endpoint (12 Weeks or Last Observation After Baseline)|Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 2 Weeks|Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 4 Weeks|Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 8 Weeks|Change From Baseline on Medical Outcomes Study 6 Item Cognitive Functioning (MOS-CF6) Scale at 12 Weeks|Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at Endpoint (12 Weeks or Last Observation After Baseline)|Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 2 Weeks|Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 4 Weeks|Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 8 Weeks|Change From Baseline in the Excessive Sleepiness (ES) Symptom Rating Form - Sleepiness Scores at 12 Weeks","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C10953/4024/ES/US","October 2007","March 2009","March 2009","August 21, 2007","March 29, 2011","July 19, 2013","Jasper Summit Research, LLC, Jasper, Alabama, United States|Pulmonary Associates, P.A., Phoenix, Arizona, United States|Psypharma Clinical Research, Phoenix, Arizona, United States|PsyPharm Clinical Research, Inc., Tucson, Arizona, United States|Behavioral Research Specialists, Glendale, California, United States|California Clinical Trials Medical Group, Inc., Glendale, California, United States|Pacific Sleep Medicine Services, Inc., Redlands, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Pacific Sleep Medicine Services, Inc., San Diego, California, United States|California Clinical Trials Medical Group, Inc., San Diego, California, United States|SDS Clinical Research, Santa Ana, California, United States|St. Johns Medical Plaza Sleep Disorders Center, Santa Monica, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Rocky Mountain Center for Clinical Research, Wheat Ridge, Colorado, United States|PAB Clinical Research, Brandon, Florida, United States|Florida Sleep Institute, Spring Hill, Florida, United States|Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States|SomnoMedics, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Florida Pulmonary Research Center, LLC, Winter Park, Florida, United States|The Sleep Disorders Center, Atlanta, Georgia, United States|Neurotrials Research, Inc, Atlanta, Georgia, United States|Sleep Disorders Center of Georgia, Atlanta, Georgia, United States|SleepMed, Inc, Macon, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Peoria Pulmonary Associates, Peoria, Illinois, United States|Sleep and Behavior Medicine, Vernon Hills, Illinois, United States|The Center for Sleep and Wake Disorders, Danville, Indiana, United States|Vince & Associates Clinical Research, Overland Park, Kansas, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Community Research, Crestview, Kentucky, United States|Clinical Trials of America, Shreveport, Louisiana, United States|The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States|Sleep Health Centers, Brighton, Massachusetts, United States|AccelRx Research, Fall River, Massachusetts, United States|The Center for Sleep Medicine, Hattiesburg, Mississippi, United States|Washington University, St. Louis, Missouri, United States|Somnos Sleep Center, Lincoln, Nebraska, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Clinilabs, Inc, New York City, New York, United States|Sleep Medicine Centers, West Seneca, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Hickory, North Carolina, United States|Tri-State Sleep Disorders Center, Cincinnati, Ohio, United States|Ohio Sleep Medicine Institute, Dublin, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Sleep Lab of Northeastern PA, Clarks Summit, Pennsylvania, United States|University of Pennsylvania Center for Sleep, Philadelphia, Pennsylvania, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|University Services, West Chester, Pennsylvania, United States|AccelRx Research, Lincoln, Rhode Island, United States|Lowcountry Lung and Critical Care, Charleston, South Carolina, United States|SleepMed of South Carolina, Columbia, South Carolina, United States|Sleep Medicine of Middle Tennessee, Nashville, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Sleep Medicine Associates of Texas, P.A., Dallas, Texas, United States|Baylor College of Medicine VAMC Sleep Research, Houston, Texas, United States|Houston Sleep Center, Houston, Texas, United States|Northwest Clinical Research, Bellevue, Washington, United States|Pacific Sleep Medicine Services, Inc., Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00518986"
1515,"NCT00581009","The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder","Other: chronobiological augmentation|Drug: sertraline, lithium|Radiation: one night of sleep deprivation and two FDG PET scans","Hamilton Rating Score for Depression","University of California, Irvine|University of California, San Diego","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS#2001-1616","May 30, 2001","December 9, 2011","December 9, 2011","December 27, 2007",,"January 25, 2021","University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT00581009"
1516,"NCT02253225","Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study",,"Unknown status","No Results Available","Bipolar Disorder|Major Depression|Rumination","Other: Functional Magnetic Resonance Imaging (fMRI)","Functional Magnetic Resonance Imaging (fMRI) to examine self processing and self focus","Massachusetts General Hospital|Brain & Behavior Research Foundation","All","18 Years to 64 Years   (Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2012P000714|19531","January 2013","August 2018","January 2019","October 1, 2014",,"August 29, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02253225"
1517,"NCT00745537","T- BOOM Teens--Building Options and Opportunities for Moms","T-BOOM","Completed","No Results Available","Postpartum Major Depression","Other: repeated mood measures and phone depression care management","Severity of PPD will be assessed with the Children's Depression Rating Scale (CDRS).|Edinburgh Postnatal Depression Scale|Center for Epidemiologic Studies of Depression instrument (CES-D)|A specific measure of functioning at school or work and with peers, the Children's Global Assessment of Functioning (C-GAS) will be obtained.|The Social Function-12 (SF-12; Ware et al., 1993) is the most widely used measure of health-related functioning.|The Inventory of Functional Status after Birth (IFSAC) was used in studies of postpartum women to measure the woman's readiness to assume infant care and resume usual activities (Fawcett et al., 1988).|To assess the mother-infant relational quality, the Gratification in the Maternal Role (GRAT) is a 14-item checklist in which women rate each item on a 5 point scale (Mercer, 1985).","University of Pittsburgh","Female","10 Years to 17 Years   (Child)","Not Applicable","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","B7473","April 2008","December 2010","December 2010","September 3, 2008",,"May 28, 2015","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00745537"
1518,"NCT01178424","My Depression Wellness Toolkit Study",,"Completed","No Results Available","Major Depression","Behavioral: Mindfulness Based Cognitive Therapy|Behavioral: Cognitive Behaviour Therapy","Rates of relapse/recurrence based on CMS and INS/FO configuration.|Changes in CMS and INSFO network imbalance following MBCT compared to CBT|Changes in attentional processing of dysphoric stimuli between the groups","Centre for Addiction and Mental Health|University of Toronto","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","093/2010","August 2010","August 2017","December 2017","August 10, 2010",,"March 13, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01178424"
1519,"NCT04446039","Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea",,"Not yet recruiting","No Results Available","Major Depression","Drug: Escitalopram|Drug: Paroxetine|Drug: Fluoxetine|Drug: Mirtazapine|Drug: Duloxetine|Drug: Sertraline|Drug: Venlafaxine|Drug: Tianeptine|Drug: Vortioxetine|Drug: Desvenlafaxine|Drug: Bupropion","Proportion of antidepressants|Dosage: Index date|Dosage: Acute treatment phase|Persistence: Average length of treatment|Discontinuation|Adherence|Recurrence|Adverse outcomes|Drug utilization pattern in acute phase|Drug utilization pattern in maintenance phase","Pfizer","All","18 Years to 100 Years   (Adult, Older Adult)",,"1","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","B2061147|CAR-BIG Study","February 2022","May 2022","May 2022","June 24, 2020",,"July 30, 2021",,,"https://ClinicalTrials.gov/show/NCT04446039"
1520,"NCT00613912","Advanced MRI in Major Depression",,"Completed","No Results Available","Depressive Disorder, Major","Other: Magnetic Resonance Imaging","Differences in morphological and functional cerebral MRI findings in patients suffering from major depression","University of Aarhus","All","20 Years to 65 Years   (Adult, Older Adult)",,"49","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AUFF-2005-740-004","March 2008","December 2009","June 2011","February 13, 2008",,"November 21, 2011","Aalborg Hospital / Aarhus University Hospital, Aalborg, Jutland, Denmark",,"https://ClinicalTrials.gov/show/NCT00613912"
1521,"NCT02219867","Ketamine Infusions for Major Depression Disorder","Ketamie","Unknown status","No Results Available","Depressive Disorder, Major","Drug: Ketamine","Montgomery Asberg Rating scale - MADRS|Side effects monitoring","Sheba Medical Center|Tel Aviv University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sheba- Ketamine","August 2014","January 2016","August 2017","August 19, 2014",,"August 29, 2014","Sheba MC, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT02219867"
1522,"NCT01506206","ON/OFF Stimulation and Impulsivity in Patients With Deep Brain Stimulators",,"Recruiting","No Results Available","Obsessive Compulsive Disorder|Major Depressive Disorder",,"Impulsive Action|Impulsive Choice","Massachusetts General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2011P002546","February 2012","December 2025","December 2025","January 9, 2012",,"April 6, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01506206"
1523,"NCT04106375","Neural Effects of Wellness Classes in Women With Vulnerability to Depression (""The Women's Wellness Study"")","WWS","Completed","No Results Available","Recurrent Major Depression","Behavioral: Online mindfulness based cognitive therapy intervention","Occurrence of mood episodes and post treatment relapse rate|Depression symptoms|Rumination|Cognitive Decentering|Self-Compassion|Mindfulness|Autobiographical Memory|Self concept|Brain activity during autobiographical memory recall|Brain activity in the absence of a task|Brain activity during processing of self-referential traits|Everyday thinking patterns|Lexical Associations|Worry|Fatigue|Physical pain|Expectations about treatment outcome|Client satisfaction about treatment outcome|Positive and negative emotion|Positive and negative affect|Emotion-induced attentional bias|Mind wandering|Well-being","University of Colorado, Boulder|Brain & Behavior Research Foundation|Mind and Life Institute, Hadley, Massachusetts|University of Arizona|University of Toronto|Children's Hospital Medical Center, Cincinnati","Female","18 Years to 55 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-0257","March 5, 2016","February 19, 2018","February 19, 2018","September 27, 2019",,"September 27, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04106375/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04106375"
1524,"NCT03927950","Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment",,"Completed","Has Results","Major Depression","Drug: escitalopram|Drug: bupropion","Montgomery-Asberg's Depression Rating Scale|Hamilton Rating Scale for Depression","University of Tartu","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","135","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-002649-19|7043|SF0180125s08","January 2007","January 2008","January 2008","April 25, 2019","April 25, 2019","April 25, 2019","Department of Psychiatry, University of Tartu, Tartu, Estonia",,"https://ClinicalTrials.gov/show/NCT03927950"
1525,"NCT00018057","Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes",,"Recruiting","No Results Available","Anxiety Disorders|Major Depressive Disorder","Behavioral: Attention Bias Modification Training|Drug: Fluoxetine","Pediatric Anxiety Rating Scale|Clinician Global Impression Scale","National Institute of Mental Health (NIMH)|University of Minnesota|University of Oregon|University of Maryland, College Park|National Institutes of Health Clinical Center (CC)","All","8 Years to 50 Years   (Child, Adult)","Phase 2","2530","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","010192|01-M-0192","October 2, 2001","January 1, 2029","January 1, 2029","July 2, 2001",,"July 28, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00018057"
1526,"NCT02855918","Blood Biomarkers in Suicidal Behaviour","2BSB","Unknown status","No Results Available","Major Depression","Other: Blood sample for genetic purpose","Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A)|Modification of the expression of ADAR1a enzymes|Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2)|Modification of the expression of ADAR1b enzymes|Modification of the expression of ADAR2 enzymes|Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)|Modification of the expression and RNA editing of Interleukins (ILs)|Modification of the expression and RNA editing of Chemokines (CXCLs)|Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF)|Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24)|Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1)|Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15)|Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha)|Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF)|Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A)|Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7)","University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France|Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","UF 9625|2015-A01978-41","September 2016","January 2019","July 2019","August 4, 2016",,"August 4, 2016","University Hospital, Montpêllier, France",,"https://ClinicalTrials.gov/show/NCT02855918"
1527,"NCT03287037","The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression",,"Completed","No Results Available","Depressive Disorder, Major|Depression, Bipolar|Electricity; Effects","Device: tDCS over DLPFC","Changes from baseline score of Hamilton Depression Rating Scale (HAM-D) at the timepoint immediately after tDCS, at one week and one month after tDCS|Changes from baseline score of Young Mania Rating Scale (YMRS) at the timepoint immediately after tDCS, at one week and one month after tDCS|Changes from baseline score of Hamilton Anxiety Rating Scale (HAM-A) at the timepoint immediately after tDCS, at one week and one month after tDCS|Changes from basline heart rate variability (HRV) at the timepoint immediately after tDCS, at one week and one month after tDCS|Changes from baseline results of continuous performance test (CPT) at the timepoint immediately after tDCS, at one week and one month after tDCS","Tri-Service General Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2-103-03-002-1","October 2016","September 6, 2019","September 6, 2019","September 19, 2017",,"September 30, 2019","Tri-service general hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03287037"
1528,"NCT00101452","Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression",,"Completed","Has Results","Depression","Drug: S-adenosyl-l-methionine|Drug: Escitalopram|Drug: Placebo","Hamilton Rating Scale for Depression (HAM-D)","Maurizio Fava, MD|National Center for Complementary and Integrative Health (NCCIH)|Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","199","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R01AT001638-01A1","April 2005","June 2010","June 2010","January 11, 2005","December 31, 2012","April 4, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00101452"
1529,"NCT00909220","Using Affective Differences to Predict Response to Behavioral Treatment for Major Depressive Disorder",,"Completed","Has Results","Depression","Behavioral: Behavioral Activation","Analyses of Covariance to Test for Group Differences (MDD vs. Healthy) on Clinician-rated Depression Severity After 16 Weeks of Behavioral Activation Psychotherapy, Controlling for Baseline Depression Severity.|Analyses of Covariance to Test for Group Differences (MDD vs. Healthy) on Patient-rated Depression Severity After 16 Weeks of Behavioral Activation Psychotherapy, Controlling for Baseline Depression Severity.|Pre-treatment Frontal EEG Asymmetry Score as a Predictor of Negative Affect at Post-treatment|A Two Level Hierarchical Model Testing the Association Between Negativity Bias Change During BA Treatment With Patient-reported Depression Severity (Week 16 IDS-SR).","Northwestern University|National Institute of Mental Health (NIMH)|University of Chicago|Dartmouth College","All","18 Years to 72 Years   (Adult, Older Adult)",,"77","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","R21MH082133","May 2009","April 2012","April 2012","May 27, 2009","January 16, 2018","April 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00909220"
1530,"NCT02988024","Pilot BA Study of New LY03005 vs Pristiq",,"Completed","No Results Available","Major Depression","Drug: LY03005|Drug: Pristiq","Area under curve (AUC) for the Pharmacokinetics (PK) of LY03005","Luye Pharma Group Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY03005/CT-USA-103","December 7, 2016","December 28, 2016","December 28, 2016","December 9, 2016",,"March 20, 2017","Clinilabs, Inc., Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02988024"
1531,"NCT02891564","ESTIA: Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults",,"Recruiting","No Results Available","Major Depression","Behavioral: Band Together|Other: Control Mobile 3D video game","CCN Function (Circuitry and Performance)|CCN Function (Self-Report- Disability)|CCN Function (Self-Report- Depressive Symptoms)","University of Washington|Weill Medical College of Cornell University|University of California, San Francisco","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","76","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001809","January 2, 2019","September 2021","January 2022","September 7, 2016",,"June 29, 2021","Weill-Cornell Medical Center, White Plains, New York, United States|University of Washington Department of Psychiatry and Behavioral Sciences, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02891564"
1532,"NCT03492203","Remote Cognitive Remediation for Depression","RECORD","Unknown status","No Results Available","Major Depression","Behavioral: Active Cognitive Remediation|Behavioral: Cognitive Remediation Control|Behavioral: Online computer exercises|Behavioral: Strategy monitoring|Behavioral: Bridging strategies","Changes in composite neurocognition scores from the CNS Vitals Signs battery|Virtual Reality Functional Capacity Test|Composite neurocognition score from the CNS Vitals Signs battery|World Health Organization Quality of Life|Bell-Lysaker Emotion Recognition Task|Montgomery-Asberg Depression Rating Scale|Sheehan Disability Scale|Lam Employment Absence and Productivity Scale|Need for Cognition Scale","Queen's University|Canadian Institutes of Health Research (CIHR)","All","18 Years to 60 Years   (Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PSYC-189-16","December 2016","July 2019","January 2020","April 10, 2018",,"August 29, 2018","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03492203"
1533,"NCT04872465","TBS Over DLPFC in Elderly Refractory Depression",,"Not yet recruiting","No Results Available","Major Depression","Device: TBS|Device: sham","Hamilton Depression Rating Scale, HAM-D|Beck depression inventory, BDI-II|Beck anxiety inventory, BAI","Kaohsiung Veterans General Hospital.","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Kaohsiung VGHKS","August 1, 2021","July 31, 2024","July 31, 2024","May 4, 2021",,"May 7, 2021",,,"https://ClinicalTrials.gov/show/NCT04872465"
1534,"NCT02653235","Impact of Immune Challenge on Triple Network Connectivity in Humans",,"Unknown status","No Results Available","Major Depression","Biological: Salmonella typhi vaccination|Biological: Placebo","Functional connectivity measured using resting state functional MRI BOLD time series cross correlations between the network nodes.|Correlation of functional connectivity measures with circulating serum cytokines and POMS/ BDI scores using multivariate general linear models","NHS Greater Glasgow and Clyde|University of Glasgow","Male","18 Years to 50 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","GN14NE490","January 2016","September 2016","January 2017","January 12, 2016",,"January 12, 2016",,,"https://ClinicalTrials.gov/show/NCT02653235"
1535,"NCT04717921","Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor",,"Enrolling by invitation","No Results Available","Unipolar Depression",,"Change in Retinal nerve fiber layer thickness|Choroid thickness","Mehmet Diyaddin Güleken|Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Mehmet Diyaddin Güleken","September 1, 2020","May 30, 2021","September 1, 2021","January 22, 2021",,"March 17, 2021","Sağlık Bilimleri Üniversitesi Gazi Yaşargil Tranining and Research Hospital, Diyarbakır, Turkey",,"https://ClinicalTrials.gov/show/NCT04717921"
1536,"NCT00325000","Interpersonal Psychotherapy for Severely Depressed Inpatients",,"Terminated","No Results Available","Major Depression","Behavioral: Interpersonal Psychotherapy|Drug: sertraline or amitriptyline","The 17-item version of the Hamilton Rating Scale for Depression (HAMD) served as the primary outcome measure|Beck Depression Inventory","German Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCHR443/4-1|SCHR443/4-2","November 2000",,"August 2004","May 11, 2006",,"December 20, 2006","University Clinic Freiburg , Dept. of Psychiatry and Psychotherapy, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT00325000"
1537,"NCT02998580","Conventional Bilateral rTMS vs. Bilateral Theta Burst Stimulation for Late-Life Depression",,"Active, not recruiting","No Results Available","Major Depression","Device: LFR followed by HFL|Device: cTBS followed by iTBS","Change on the Montgomery Asberg Depression Rating Scale (MADRS)|Remission on the MADRS","Centre for Addiction and Mental Health|University Health Network, Toronto","All","60 Years and older   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","076-2016","December 2016","December 2021","December 2021","December 20, 2016",,"February 15, 2021","CAMH, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02998580"
1538,"NCT02314767","A Finnish Community Randomized Psychotherapy Effectiveness Study for Major Depression",,"Completed","No Results Available","Depressive Disorder, Major","Behavioral: Interpersonal Psychotherapy|Behavioral: Psychoeducational Group Therapy","Change from baseline Hamilton Rating Scale for Depression at 12 months|Change from baseline Clinical Global Impression, severity and change at 12 months|Change from baseline Social and Occupational Functioning Assessment Scale at 12 months","Helsinki University Central Hospital","All","18 Years to 64 Years   (Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Lohja Depression Treatment","February 2004","April 2007","April 2007","December 11, 2014",,"December 11, 2014",,,"https://ClinicalTrials.gov/show/NCT02314767"
1539,"NCT00295347","Mineralocorticoid Receptor in the Treatment of Severe Depression",,"Completed","No Results Available","Major Depression","Drug: Spironolactone|Drug: fludrocortisone|Drug: escitalopram",,"Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","OT 209/3-1","December 2005","June 2008","June 2008","February 23, 2006",,"May 30, 2017","University Hospital Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT00295347"
1540,"NCT03484754","Infiltrations of OnaBotulinum Toxin A in Resistant Depression: Comparison of Two Facial Injection Sites.","OnaDEP","Recruiting","No Results Available","Major Depression","Biological: botulinum toxin","proportion of patients with improvement of depressive symptoms based on the evolution of the MADRS scale","Centre Hospitalier Esquirol","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-A0392-51","April 1, 2018","July 30, 2022","December 31, 2022","April 2, 2018",,"October 3, 2019","Centre Hospitalier esquirol, Limoges, France",,"https://ClinicalTrials.gov/show/NCT03484754"
1541,"NCT02914769","Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression",,"Completed","No Results Available","Major Depression","Drug: Ayahuasca|Drug: placebo","HAM-D effect at D7|MADRS effect at D1, D2 and D7|Response rate at D7 (HAM-D)|Response rate at D1, D2 and D7 (MADRS)|Remission rate at D7 (HAM-D)|Remission rate at D1, D2 and D7 (MADRS)","Universidade Federal do Rio Grande do Norte|University of Sao Paulo","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CNPq-466760/2014-0","February 2014","December 2016","December 2016","September 26, 2016",,"February 17, 2017","Draulio B de Araujo, Natal, Rio Grande do Norte, Brazil",,"https://ClinicalTrials.gov/show/NCT02914769"
1542,"NCT02916238","Measurement-based Care for Depression in Resource-Poor Settings","MBC","Completed","No Results Available","Major Depression","Drug: Fluoxetine|Behavioral: Enhanced Usual Care","Remission of Depression|ART adherence - viral suppression|ART adherence - immune functioning|Total treatment cost from the health center perspective","Florida International University","All","18 Years to 59 Years   (Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIU101503WIRB20132233","February 2014","November 2016","November 2016","September 27, 2016",,"December 1, 2016","GHESKIO Centers, Port-au-Prince, Haiti",,"https://ClinicalTrials.gov/show/NCT02916238"
1543,"NCT02171923","Multicenter Comparative Study of the Activity of the Medial Prefrontal Cortex in Vulnerability to Depression","CORVAD","Completed","No Results Available","Major Depression",,"BOLD signal in the medial prefrontal cortex|depression relapse","Assistance Publique - Hôpitaux de Paris","All","20 Years to 65 Years   (Adult, Older Adult)",,"77","Other","Observational","Observational Model: Case-Control","P110139","May 2013","July 2015","July 2015","June 24, 2014",,"October 6, 2015","URC - HEGP, 20 rue Leblanc, Paris, France",,"https://ClinicalTrials.gov/show/NCT02171923"
1544,"NCT02931487","Restoring Emotion Regulation Networks in Depression Vulnerability",,"Completed","No Results Available","Major Depression","Behavioral: Attentional Bias Modification|Behavioral: Sham Comparator","BOLD response in prefrontal cortical regions|BOLD response within the amygdala|DTI|RSFC|5-HTTLPR + A>G polymorphic variation divided by the triallelic functional ""high expressive"" versus ""low expressive"" genotype will moderate the impact from ABMT as measured by whole brain BOLD responses.|BDNF|Serotonergic cumulative genetic score and fMRI|Serotonergic cumulative genetic score and morphompetry|Serotonergic cumulative genetic score and fMRI and DTI","University of Oslo|Oslo University Hospital|University of Oxford","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HSØ-2015052","May 2015","December 2016","December 2016","October 13, 2016",,"April 30, 2019","University of Oslo, Department of Psychology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02931487"
1545,"NCT01652391","Modulation of Cognitive Control by Transcranial Direct Current Stimulation",,"Completed","No Results Available","Major Depression","Device: Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)","Correctness of response|Reaction time","University Hospital Tuebingen","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","211/2010BO1_1","July 2011","June 2012","December 2012","July 30, 2012",,"December 31, 2013","Universitiy Hospital Tübingen, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT01652391"
1546,"NCT02658682","Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure",,"Completed","No Results Available","Major Depression","Behavioral: Attention Bias Modification|Behavioral: Sham Attention Bias Modification","Change in residual symptoms of depression. Self report.|Change in residual symptoms of depression. Clinician rating|Recurrence of major depressive episodes|Changes in Emotion Regulation|Changes in Rumination|Changes in cortisol response.|Changes in symptoms of anxiety","University of Oslo|University of Oxford|Sorlandet Hospital HF|Diakonhjemmet Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NFR-229135","January 2015","October 2016","December 2017","January 20, 2016",,"April 26, 2019","Sørlandet Hospital, Department of Psychiatry, Arendal, Aust-Agder, Norway|University of Oslo, Department of Psychology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02658682"
1547,"NCT02622633","Epidural Stimulation for Resistant Depression Treatment",,"Unknown status","No Results Available","Major Depression","Device: Epidural Electrode","Change in Rating Scale Hamilton Depression|Change in Depression Scale Montgomery-Asberg Depression Rating Scale|Change in Scale of the SF-36|Frequency of Side Effects Scale - (UKU- Ugvalg is Kliniske Undersgelser)","University of Brasilia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","40803214.2.0000.0033","April 2016","December 2018","December 2019","December 4, 2015",,"May 23, 2017","Rivadavio Amorim, Brasília, Distrito Federal, Brazil",,"https://ClinicalTrials.gov/show/NCT02622633"
1548,"NCT01701258","An Investigation of Early Life Stress and Depression",,"Completed","Has Results","Major Depressive Disorder (MDD)|History of Childhood Sexual Abuse (CSA)","Drug: Amisulpride|Drug: Placebo","Dopamine Active Transporter Binding Potential|The Effects of CSA and Diagnosis on PRT Performance Under Acute Stress|The Effect of Major Depressive Disorder and Childhood Abuse History on a Reward-related EEG Component (Reward Positivity Component) While Under Stress|Cortisol Output in Response to a Stress Manipulation|Effects on Major Depressive Disorder and Childhood Sexual Abuse History on Striatal Activity in Response to Neutral and Reward Cues|Effects on Major Depressive Disorder and Childhood Sexual Abuse History on Striatal Activity in Response to Neutral and Reward Feedback|The Effect of Diagnosis on Cortisol Reactivity","Mclean Hospital|National Institute of Mental Health (NIMH)|Massachusetts General Hospital","Female","20 Years to 45 Years   (Adult)","Phase 1","153","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","2012P002593|5R01MH095809","August 2013","May 2017","May 2017","October 5, 2012","May 18, 2018","May 18, 2018","McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01701258/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01701258"
1549,"NCT02648165","Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure",,"Completed","No Results Available","Major Depression","Behavioral: Attention Bias Modification|Behavioral: Sham Attention Bias Modification|Behavioral: Acceptance and Commitment Therapy","Change in residual symptoms of depression - self report|Change in residual symptoms of depression - clinician rating|Recurrence of major depressive episodes|Changes in Cortisol response|Changes in symptoms of anxiety - self report|Changes in Quality of Life - self report|Changes in Acceptance - self report|Changes in Values - self report|Changes in Values and committed action - self report|Changes in Emotional, Psychological and Social Well-Being - self report|Changes in Present-moment awareness and acceptance - self report|Changes in Cognitive fusion - self report","Sorlandet Hospital HF|University of Oslo|University of Oxford|Karolinska Institutet|Wichita State University|The Hospital of Vestfold","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HSØ-2015056","April 2015","November 30, 2018","November 30, 2018","January 6, 2016",,"April 26, 2019","Sørlandet Hospital, Department of Psychiatry, Arendal, Aust-Agder, Norway|University of Oslo, Department of Psychology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02648165"
1550,"NCT02441387","Predictors of the Outcome of Late Life Depression",,"Unknown status","No Results Available","Major Depression","Drug: Antidepressant|Other: Psychoeducation|Other: Treatment as usual (only pharmacological treatment).","Change from Baseline Montgomery-Asberg Depression Scale (MADRS) below 8 during the initial 12 weeks of the study and remained below 8 until 18 months|Change from baseline Clinical Global Impression (CGI) up to 18 months|Change from baseline Hamilton-D Scale (HAM-D) up to 18 months|Change from baseline Mini Mental State Examination (MMSE) up to 18 months|Change from baseline Cognitive and self-contained part of the Cambridge Examination for Mental Disorders of the Elderly (CAMCOG) up to 18 months|Change from baseline Bayer Activities of Daily Living Scale (B-ADL) up to 18 months","University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","60 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PREDLLD10446","April 2015","March 2018","July 2019","May 12, 2015",,"May 24, 2018","University of São Paulo, Faculty of Medicine, Institute and Department of Psychiatry, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02441387"
1551,"NCT02143024","A Family-based Primary Care Intervention to Enhance Older Men's Depression Care",,"Completed","Has Results","Major Depression","Behavioral: Family-based depression intervention|Behavioral: Usual care plus educational materials","Depressive Symptoms","University of California, Davis|University of Washington|RAND","Male","50 Years and older   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","807849","November 1, 2015","December 31, 2016","December 31, 2016","May 20, 2014","January 18, 2020","January 18, 2020","San Joaquin General Hospital, Stockton, California, United States",,"https://ClinicalTrials.gov/show/NCT02143024"
1552,"NCT00965497","Escitalopram (Lexapro) for Depression MS or ALS",,"Completed","Has Results","Major Depression|Multiple Sclerosis|Amyotrophic Lateral Sclerosis","Drug: escitalopram","Hamilton Depression Scale (HAM-D 17).|McGill Quality of Life Scale (MQOL)","University of South Carolina","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00003013","July 2009","March 2010","March 2010","August 25, 2009","September 7, 2011","May 1, 2019","University of South Carolina School of Medicine, Columbia, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00965497"
1553,"NCT02379767","Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET",,"Completed","No Results Available","Major Depression","Device: Electroconvulsive therapy|Other: Positron emission tomography of the brain using [11C]harmine|Other: Structural magnetic resonance imaging","Monoamine oxidase A distribution volume in the brain|Grey matter volume","Medical University of Vienna","All","16 Years to 60 Years   (Child, Adult)",,"27","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","v1.2_201502","March 2015","May 25, 2018","May 25, 2018","March 5, 2015",,"August 28, 2019","Department of Psychiatry and Psychotherapy, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02379767"
1554,"NCT04142996","Comparing Uni- and Bi-lateral TBS in Major Depression",,"Recruiting","No Results Available","Major Depressive Episode","Device: Theta burst stimulation","Response - Treatment Phase (Hamilton Rating Scale for Depression-17 score)|Remission - Treatment Phase (Hamilton Rating Scale for Depression-17 Score)|Response - Maintenance Phase (Hamilton Rating Scale for Depression-17 score)|Remission - Maintenance Phase (Hamilton Rating Scale for Depression-17 Score)|Response - Treatment Phase (Quick Inventory of Depression Symptomology-Self Report)|Remission - Treatment Phase (Quick Inventory of Depression Symptomology-Self Report)|Response - Maintenance Phase (Quick Inventory of Depression Symptomology-Self Report)|Remission - Maintenance Phase Quick Inventory of Depression Symptomology-Self Report)","The Royal Ottawa Mental Health Centre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","256","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019017","December 12, 2019","September 2023","September 2023","October 29, 2019",,"October 28, 2020","The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04142996"
1555,"NCT03207438","Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression",,"Completed","Has Results","Depressive Disorder, Major","Drug: Quetiapine 50 MG Extended Release Oral Tablet|Drug: Quetiapine Fumarate XR 150-300 mg|Drug: Placebos","Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score Over Time for the Quetiapine XR 150-300mg and Placebo 2 Arms/Groups Stratified by Depression Type (Melancholic vs. Nonmelancholic)|Modified MADRS Response Rates|MADRS Response Rates|Modified MADRS Response Rate","University of Saskatchewan|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","1790","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","D1448C0001 (through ...0004)","April 2006","July 2007","October 2019","July 2, 2017","December 4, 2019","December 4, 2019",,,"https://ClinicalTrials.gov/show/NCT03207438"
1556,"NCT01328613","A Prospective Study of Postpartum Depression in Women With Major Depression",,"Terminated","No Results Available","Postpartum Depression",,,"National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","Female","18 Years and older   (Adult, Older Adult)",,"85","NIH","Observational","Time Perspective: Other","999908320|08-AG-N320","November 9, 2007",,"September 29, 2014","April 4, 2011",,"December 4, 2019","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01328613"
1557,"NCT01788657","iCBT for Depression - Standard Versus Condensed Treatment Material","KONRAD","Unknown status","No Results Available","Major Depression","Behavioral: Standard internet-based cognitive behavior therapy|Behavioral: Condensed internet-based cognitive behavior therapy","Change from baseline in depressive symptoms at post-treatment and after 12 months|Change from baseline in diagnostic status for Major depression|Change from baseline in symptoms of anxiety|Post-treatment treatment satisfaction|Therapist time|Alcohol use|Drug use|Treatment satisfaction at follow up","Örebro County Council|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Dnr 63:2012","March 2013","March 2015","March 2015","February 11, 2013",,"February 11, 2013","Örebro County Council, Örebro, Örebro County, Sweden",,"https://ClinicalTrials.gov/show/NCT01788657"
1558,"NCT01124344","Safety and Pharmacology Study of BMS-866949",,"Terminated","No Results Available","Major Depression","Drug: Placebo|Drug: BMS-866949","Assessment of safety by evaluating incidence of adverse events (AE)|Assessment of pharmacokinetics by evaluating plasma concentration versus time data|Assessment of pharmacodynamics by evaluating brain transporter occupancy","Bristol-Myers Squibb","All","21 Years to 55 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN166-002|2010-018461-38","May 2010","November 2011","November 2011","May 17, 2010",,"March 27, 2012","Local Institution, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01124344"
1559,"NCT01750359","Efficacy and Safety Curcumin in Depression",,"Completed","No Results Available","Major Depression","Drug: curcumin","Hamilton Depression Rating Scale|Montgomery-Asberg Depression Rating Scale|Clinical Global Impression","Vladimir Lerner|Tirat Carmel Mental Health Center|Beersheva Mental Health Center","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","LBM-2010|IsraelMHC","August 2010","May 2011","June 2011","December 17, 2012",,"February 7, 2013","Tirat Carmel Mental Health Center, Tirat Carmel, Israel",,"https://ClinicalTrials.gov/show/NCT01750359"
1560,"NCT01477203","Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders","MAN-BIOPSY","Completed","No Results Available","Major Depressive Disorder (MDD)|Anxiety Disorder","Drug: Escitalopram","SSRI induced changes in BOLD (blood oxygen level dependent) response over time|SSRI induced changes in ERPs (event-related potentials) over time|biochemical data","Medical University of Vienna","All","18 Years to 50 Years   (Adult)","Phase 4","289","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FA103FC001|2011-004860-31","November 2011","September 2016","September 2016","November 22, 2011",,"September 14, 2016","Medical University of Vienna, Department for Psychiatrie and Psychotherapie, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01477203"
1561,"NCT00953108","Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients",,"Completed","No Results Available","Major Depression","Drug: quetiapine|Drug: escitalopram","serial dexamethasone/CRH tests","Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QUE/09","September 2009","February 2012","February 2012","August 6, 2009",,"February 12, 2013","Department of Psychiatry, Ludwig-Maximilian-University, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT00953108"
1562,"NCT00768430","Optimization of IV Ketamine for Treatment Resistant Depression",,"Completed","Has Results","Major Depressive Disorder (MDD)|Treatment Resistant Depression (TRD)","Drug: Ketamine|Drug: Midazolam","MADRS","Baylor College of Medicine|Icahn School of Medicine at Mount Sinai","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 07-0114","November 2008","September 2012","November 2012","October 8, 2008","January 31, 2014","January 31, 2014","Mount Sinai School of Medicine, New York, New York, United States|Michael E. Dabakey VA Medical Center & Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00768430"
1563,"NCT00792168","Physiologic Monitoring of Antidepressant Treatment Response",,"Completed","No Results Available","Major Depression","Drug: venlafaxine (Effexor)|Other: placebo","quantitative electroencephalography (QEEG)|Clinical assessment measuresments: Ham-D, MADRS, Ham-A, SCL-90, Beck, LIFE, and CGI)","University of California, Los Angeles",,"Child, Adult, Older Adult","Phase 4","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","96-06-291","November 1996",,"December 1998","November 17, 2008",,"November 17, 2008","University of California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00792168"
1564,"NCT00707863","Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram",,"Completed","Has Results","Major Depression","Drug: Escitalopram","17-item Hamilton Depression Rating Scale (HAM-D)","Indiana University School of Medicine|National Alliance for Research on Schizophrenia and Depression|Indiana University","All","18 Years to 50 Years   (Adult)","Phase 4","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0711-14","May 2008","December 2012","December 2012","July 1, 2008","October 17, 2016","October 17, 2016","Indiana University Adult Psychiatric Clinic, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00707863"
1565,"NCT01178255","Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)","DEP-HOM","Terminated","No Results Available","Major Depression","Drug: homeopathic q-potencies|Drug: Placebo|Other: homeopathic case history taking type I|Other: homeopathic case history type II","primary endpoint is the mean total depression score post treatment|mean total depression score during the treatment|response and remission rates|Self-rated depression score|quality of life assessment|Safety","Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DEP-HOM10|2009-017458-11","August 2010","July 2011","July 2011","August 10, 2010",,"July 10, 2012","Institute for Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center Berlin, Germany, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01178255"
1566,"NCT01263275","Trial of Transcranial Direct Current Stimulation (tDCS) for Depression",,"Completed","No Results Available","Major Depression","Device: tDCS (Eldith DC-Stimulator (CE certified))","Montgomery Asberg Depression Rating Scale for Depression (MADRS).","The University of New South Wales","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10368","December 2010","July 2015","July 2015","December 20, 2010",,"September 17, 2015","Black Dog Institute, Randwick, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01263275"
1567,"NCT01208428","Cognitive Behavioral Treatments for Depression in Chronic Illness",,"Completed","No Results Available","Major Depression","Behavioral: Conventional cognitive behavioral therapy|Behavioral: Religious cognitive behavioral therapy","Beck Depression Inventory|Duke Social Support Index (abbreviated)|Duke Social Support Index","Duke University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00026533","April 2011","July 2014","August 2014","September 24, 2010",,"March 17, 2015","Glendale Adventist Medical Center, Glendale, California, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01208428"
1568,"NCT01201148","Open Pilot Trial of TES for Depression",,"Completed","No Results Available","Major Depression","Device: tDCS (Eldith DC-Stimulator (CE certified))","Montgomery Asberg Depression Rating Scale for Depression (MADRS)","The University of New South Wales","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10231","September 2010","September 2015","September 2015","September 14, 2010",,"December 2, 2015","Black Dog Institute, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01201148"
1569,"NCT04670081","Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","EPIsoDE","Recruiting","No Results Available","Treatment-resistant Depression","Drug: Psilocybin|Drug: Nicotinamide","Treatment Response (defined as a ≥ 50% drop in depressive symptom severity as measured by the Hamilton Rating Scale for Depression; HAM-D)|% change in HAM-D total score|Treatment response (≥ 50% drop) and % change in HAM-D total score|Treatment response (≥ 50% drop) and % change in the Beck Depression Inventory (BDI) - II","Central Institute of Mental Health, Mannheim|Charite University, Berlin, Germany|MIND Foundation gGmbH|German Federal Ministry of Education and Research|Usona Institute","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","EPIsoDE_01","June 10, 2021","March 1, 2023","March 1, 2024","December 17, 2020",,"July 29, 2021","Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin, Germany|Central Institute of Mental Health (CIMH), Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT04670081"
1570,"NCT01210651","Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial",,"Completed","Has Results","Depression, Unipolar","Behavioral: Hatha Yoga Practice Group|Behavioral: Attention Control Education Group","Intent-to-Treat Analysis of Adjusted Mean Beck Depression Inventory-II Scores Over Intervention Period|Total Change Scores on Beck Depression Inventory-II Among Study Completers|Number of Study Completers With Remitted Depression, Per Completers Analysis of BDI Scores at 8 Weeks|Total Change Scores on General Self-Efficacy Scale (GSES) Among Study Completers|Total Change Scores on Rosenberg Self-Esteem Scale (RSES) Among Study Completers","University of California, San Francisco|Mental Insight Foundation|Pritzker Family Foundation|Mount Zion Health Fund","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H49362-35940-01","May 2010","January 2011","January 2011","September 28, 2010","January 11, 2017","January 11, 2017","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01210651"
1571,"NCT04159662","Cognitive Rehabilitation in Schizophrenia and Depression",,"Recruiting","No Results Available","Schizophrenia / Schizoaffective Disorder|Depression / Major Depressive Disorder","Behavioral: Cognitive Intervention|Behavioral: Active Control Intervention","Change in verbal memory performance from baseline - Hopkins Verbal Learning Test-Revised (HVLT-R)|Change in emotion regulation performance from baseline - Mayer-Salovey-Caruso Emotional Intelligence Test (MSECIT)|Change in composite scores on cognitive assessments from baseline|Change in brain activity from baseline","The Royal Ottawa Mental Health Centre","All","18 Years to 45 Years   (Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018037","December 12, 2019","November 2022","November 2022","November 12, 2019",,"June 18, 2021","Royal Ottawa Mental Health Center, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04159662"
1572,"NCT00265291","Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group",,"Completed","No Results Available","Major Depressive Disorder|Major Depression|Unipolar Depression","Drug: fluoxetine or desipramine","The Hamilton Depression Rating Scale (HAM-D) on a weekly basis|The Hamilton Anxiety Rating Scales (HAM-A), the Global Assessment Scale (GAS), the Beck Depression Inventory (BDI), and the Center for Epidemiological Depression Rating Scale (CES-D) on a weekly basis","National Institute of General Medical Sciences (NIGMS)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","700","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","U01GM061394","November 1999","May 2006","October 2008","December 14, 2005",,"October 10, 2008","Center for Pharmacogenomics, University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00265291"
1573,"NCT01191580","Interpersonal Therapy for Depression in Breast Cancer",,"Completed","No Results Available","Major Depression","Behavioral: Interpersonal Psychotherapy|Behavioral: Problem-Solving Therapy|Behavioral: Brief Supportive Psychotherapy","Hamilton Depression Scale (HAMD-17)","New York State Psychiatric Institute","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","#5996/7033R","October 2009","April 2016","June 2017","August 31, 2010",,"July 18, 2017","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01191580"
1574,"NCT00806143","Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression",,"Completed","No Results Available","Major Depression","Device: repetitive transcranial stimulation (rTMS)|Device: unilateral stimulation","Hamilton Depression Scale (HAM-D)|Clinical Global Impression Scale (CGI)","Institute of Neuroscience, Florence, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMSDEP","September 2008","January 2009","January 2009","December 10, 2008",,"February 24, 2011","Institute of Neuroscience, Florence, Italy",,"https://ClinicalTrials.gov/show/NCT00806143"
1575,"NCT02894736","Home-Administered Trial of Direct Current Stimulation","HAT-DCS","Completed","No Results Available","Major Depression","Device: Soterix tDCS machine","Montgomery Asberg Depression Rating Scale for Depression (MADRS)","The University of New South Wales","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC15010","March 2016","March 2018","July 2018","September 9, 2016",,"August 2, 2018","Black Dog Institute, Randwick, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT02894736"
1576,"NCT00237666","Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression",,"Completed","Has Results","Bipolar II Disorder|Major Depressive Episode","Drug: Ziprasidone","The Primary Efficacy Endpoint is the Comparison of Baseline and Week 8 Endpoint in the 17-item HAM-D Total Scores|Mean Change From Baseline in the Hamilton Anxiety Scale (HAM-A)|Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale|Percentage of Subjects With Clinical Global Inventory (CGI) Global Improvement Score of 1 or 2|Mean Change From Baseline in the CGI-Severity of Illness (CGI-S) Score at Study Endpoint|Mean Change From Baseline in the Total Score of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Mean Change From Baseline in the Total Score of the Beck Depression Inventory (BDI)","The Medical Research Network|Liebowitz, Michael R., M.D.|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-3945-A 01","February 2005","February 2008","February 2008","October 12, 2005","June 19, 2013","June 19, 2013","Medical Research Network, L.L.C., New York, New York, United States|The Mech Center, Plano, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00237666"
1577,"NCT01114334","Motivational Interviews for Depression in Primary Care",,"Completed","Has Results","Major Depression","Behavioral: Guideline-Based Medical Management|Behavioral: Motivational Interviewing for Depression","Depression Remission|Adherence to Treatment With Antidepressant Medication|Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms","Denver Health and Hospital Authority","All","18 Years and older   (Adult, Older Adult)","Not Applicable","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","K23MH082997","April 2010","December 2012","December 2012","May 3, 2010","April 20, 2017","June 6, 2018","Denver Health and Hospital Authority, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01114334"
1578,"NCT00982345","Brain Imaging of Quetiapine Response in Anxious Depression",,"Completed","Has Results","Major Depression","Drug: quetiapine (Seroquel XR)","17-item Hamilton Depression Rating Scale (HDRS)","Indiana University School of Medicine|AstraZeneca|Indiana University","All","18 Years to 60 Years   (Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0901-13","March 2009","March 2012","March 2012","September 23, 2009","September 30, 2016","September 30, 2016","Indiana University Adult Psychiatry Clinic, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00982345"
1579,"NCT00249886","Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents",,"Withdrawn","No Results Available","Major Depression","Drug: Citalopram","Relapse - subject meets criteria for an episode of major depression for 2 weeks or more.","Sunnybrook Health Sciences Centre","All","13 Years to 18 Years   (Child, Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ISRCTN42386710","September 2002",,"November 2006","November 7, 2005",,"September 19, 2006","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00249886"
1580,"NCT03941301","Light Therapy on Major Depression Disorder",,"Unknown status","No Results Available","Depressive Disorder","Device: Light therapy","Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 1,2,4,8 weeks|Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 1,2,4,8 weeks|Change from Baseline Clinical Global Impression-Severity(CGI-S) at 1,2,4,8 weeks|Change from Baseline Patient Health Questionnaire(PHQ-9) at 1,2,4,8 weeks|functional MRI|Diffusion Tensor Imaging of MRI","Mackay Memorial Hospital|National Tsing Hua University,Taiwan|Ministry of Science and Technology, Taiwan","All","20 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","18MMHIS114e","May 1, 2019","December 2019","December 2019","May 7, 2019",,"July 9, 2019","Mackay Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03941301"
1581,"NCT00559299","Patient Tolerability Study of GSK163090",,"Completed","No Results Available","Depressive Disorder, Major|Major Depressive Disorder (MDD)","Drug: GSK163090","Safety and tolerability of GSK163090: Clinical laboratory, ECGs and vital signs assessments Questionnaire - DESS(Discontinuation Emergent Signs and symptoms)|•Questionnaires •Prolactin, cortisol •PK parameters for GSK163090","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment","HTP110333","November 2007","June 2008","June 2008","November 16, 2007",,"March 19, 2012","GSK Investigational Site, Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00559299"
1582,"NCT00174577","Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant",,"Unknown status","No Results Available","Major Depression","Drug: Risperidone","Depression symptoms,change score on MADRS scale at 4 weeks|Group differences on HRS-D scores|Group differences on remission and improvement|Between group differences on quality-of-life measures|Group differences of anxiety and psychosocial factors","Rhode Island Hospital|Janssen Pharmaceutica N.V., Belgium|Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","RIS-Dep-402","February 2003",,"February 2005","September 15, 2005",,"September 15, 2005","Emory University School of Medicine, Atlanta, Georgia, United States|Mood Disorders Program - Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00174577"
1583,"NCT04058080","Bikram Yoga and Aerobic Exercise for the Treatment of Major Depression",,"Completed","No Results Available","Depression","Other: Bikram Yoga|Other: Aerobic Exercise","Treatment Response|Depression remission|Hassles and Uplifts Scale (HUS)|Ruminative Responses Scale (RRS) of the Response Styles Questionnaire|Philadelphia Mindfulness Scale (PHLMS)|Heart Rate|Blood Pressure|Stress Sensitivity: Salivary Hormone and Trier Social Stress Test (TSST)|Submaximal Exercise Test","Queen's University|Canadian Institutes of Health Research (CIHR)|Queen's University Senate Advisory Research Committee","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSYC-132-13","March 12, 2013","March 13, 2016","March 13, 2016","August 15, 2019",,"August 21, 2019",,,"https://ClinicalTrials.gov/show/NCT04058080"
1584,"NCT00797901","Depression Treatment in General Medical Settings",,"Completed","No Results Available","Major Depression","Other: Collaborative Care","Depression|Health-Related Functional Impairment|Quality of Life|Satisfaction with Care|Barriers to Treatment","University of Puerto Rico|National Institute of General Medical Sciences (NIGMS)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","179","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","S06GM008224","August 2004","April 2008","April 2008","November 25, 2008",,"August 28, 2014","University of Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00797901"
1585,"NCT01792414","Transcranial Electrical Stimulation (TES) for the Treatment of Depression.",,"Completed","No Results Available","Major Depression","Device: Sham TES|Device: Active TES","Montgomery Asberg Depression Rating Scale for Depression (MADRS)|Beck Depression Inventory II","The University of New South Wales","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HC12143","January 2013","December 2016","December 2016","February 15, 2013",,"February 2, 2017","Black Dog Institute / University of New South Wales, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01792414"
1586,"NCT00576875","Duke Conte Center for the Neuroscience of Depression in Late Life",,"Completed","No Results Available","Major Depression",,"Each of the projects in the Duke Conte Center has its own aims and primary outcomes","Duke University|University of Mississippi Medical Center","All","60 Years and older   (Adult, Older Adult)",,"795","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Pro00007678","August 2006","July 2011","July 2011","December 19, 2007",,"February 22, 2012","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00576875"
1587,"NCT00781703","Evaluation of a Natural Experiment to Improve Statewide Depression Care in Minnesota (MN)","DIAMOND","Completed","No Results Available","Major Depression","Other: DIAMOND depression care model","Rates of best care processes|Improvement in depression symptoms, work productivity and total healthcare costs","HealthPartners Institute|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2631","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","PAR-06-039|R01MH080692","February 2008","June 2012","February 2014","October 29, 2008",,"July 15, 2014",,,"https://ClinicalTrials.gov/show/NCT00781703"
1588,"NCT00285727","Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Ropinirole CR","HamD|MADRS","Stanford University|Duke University|GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2969","January 2006",,"October 2007","February 2, 2006",,"May 19, 2008","Stanford University School of Medicine, Stanford, California, United States|Depression Research Clinic, Psychiatry Department, Stanford School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00285727"
1589,"NCT00026052","Riluzole to Treat Major Depression",,"Completed","No Results Available","Depression","Drug: riluzole",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","31","NIH","Interventional","Primary Purpose: Treatment","020034|02-M-0034","November 2001",,"April 2003","November 9, 2001",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00026052"
1590,"NCT03170362","PRIME Care (PRecision Medicine In MEntal Health Care)","PRIME Care","Active, not recruiting","No Results Available","Major Depression","Other: Pharmacogenetic Test","Depression Severity|Use of fewer medications that have potential gene-drug interactions|Self-reported antidepressant side effects|VR -12 - Quality of life measure|Provider attitudes","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","2000","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SDR 16-348","June 15, 2017","October 30, 2021","March 31, 2022","May 31, 2017",,"March 30, 2021","Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|Wilmington VA Medical Center, Wilmington, DE, Wilmington, Delaware, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States|VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03170362"
1591,"NCT00177996","Pharmacotherapy in Depression With Panic Spectrum",,"Completed","No Results Available","Major Depression","Drug: sertraline hydrochloride","Somatic Symptoms Scale (SSC)|Hamilton Rating Scale For Depression- 25 item (HRSD 25)|Global Assessment of Functioning (GAF)","University of Pittsburgh","All","18 Years to 60 Years   (Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","010403","October 2001","January 2007","January 2007","September 15, 2005",,"January 15, 2016","Western Psychiatric Insititue and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00177996"
1592,"NCT04116606","Antidepressant Trial With P2X7 Antagonist JNJ-54175446","ATP","Recruiting","No Results Available","Depressive Disorder, Major|Inflammation","Drug: Active JNJ-54175446|Drug: Placebo","Change from baseline in total score on the MADRS scale at week 8|Change from baseline in total score on the MADRS scale|Change in scores on Perceived Stress Scale|Change in scores on SHAPS|Change in scores on CFQ|Change in scores on QIDS-SR16|Change in scores on GAD-7|Change in score on participant self-reported depression scale|Change in scores in the cognitive function test ReVeRe-D|Change in scores in Continuous performance test|Change in scores in Emotional Test battery|Change in Brain structure and function|Change in heart rate variability","CCTU-Core|Janssen Pharmaceuticals|Cambridgeshire and Peterborough NHS Foundation Trust","All","18 Years to 60 Years   (Adult)","Phase 2","142","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCTU0251|2018-001884-21","September 12, 2019","April 30, 2022","June 30, 2022","October 4, 2019",,"July 28, 2021","Addenbroooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Cardiff University Brain Research Imaging Centre, Cardiff, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|The Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom|Warneford Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04116606"
1593,"NCT01571011","Chicago Urban Resiliency Building (CURB)","CURB","Completed","No Results Available","Major Depression","Behavioral: CURB","The Center for Epidemiological Studies of Depression (CES-D) Scale|Cost effective outcome measures|Vulnerability|Protective factors","Benjamin Van Voorhees, MD, MPH|University of Illinois at Chicago","All","13 Years to 17 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","RWJF 68177","March 2012","April 2014","April 2014","April 4, 2012",,"August 4, 2015","Mile Square Health Centers, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01571011"
1594,"NCT02237937","Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene",,"Unknown status","No Results Available","Major Depression","Drug: Paroxetine|Drug: Sertraline|Drug: Citalopram|Drug: Venlafaxine|Drug: Amitriptyline|Drug: Escitalopram|Drug: Amitriptylinoxide|Drug: Nortriptyline|Drug: Trimipramine","25% improvement in the HAM-D|side effects","HolsboerMaschmeyer NeuroChemie GmbH|Max-Planck-Institute of Psychiatry","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","80","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)","2011-003190-29","September 2011","December 2014","December 2014","September 12, 2014",,"September 12, 2014","Max Planck Institute of Psychiatry, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT02237937"
1595,"NCT00343070","Functional Neuroimaging in Depression",,"Completed","No Results Available","Major Depression","Drug: Oral administration of escitalopram during 8 weeks","Brain metabolism|Cognitive functions|Efficacy scales (mood, anxiety, anger and hopelessness)","University Hospital, Ghent|Fund for Scientific Research, Flanders, Belgium|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006/176","March 2007","October 2009","October 2009","June 22, 2006",,"August 31, 2010","University Hospital Ghent, Ghent, Belgium|AZ Groeninge campus Sint Maarten, Kortrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT00343070"
1596,"NCT00357045","Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine",,"Completed","No Results Available","Major Depression","Drug: Paroxetine",,"Portland VA Medical Center|GlaxoSmithKline|Schering-Plough","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","05-1002",,,,"July 27, 2006",,"July 27, 2006",,,"https://ClinicalTrials.gov/show/NCT00357045"
1597,"NCT00605358","Increasing Use of Mental Health Services","OpenDoor","Completed","Has Results","Major Depression","Behavioral: Open Door intervention","The Primary Outcome is Engagement Defined as at Least One Visit With a Mental Health Provider Who Can Offer Treatment of Depression.","Weill Medical College of Cornell University","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","R01MH079265-01A1","August 2007","January 2014","January 2015","January 31, 2008","March 3, 2017","March 3, 2017","Weill Cornell Medical College, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT00605358"
1598,"NCT00222820","Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study",,"Completed","No Results Available","Major Depression","Drug: escitalopram|Behavioral: Interpersonal Psychotherapy","Hamilton Rating Scale for Depression|Inventory of Depressive Symptoms","University of Pittsburgh|Mental Health Intervention Research Center (MHIRC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","011015","April 2002",,"September 2004","September 22, 2005",,"September 22, 2005","Western Psychaitric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00222820"
1599,"NCT00203723","Use of Risperidone in ECT for Treatment Resistant Depression",,"Terminated","No Results Available","Major Depression","Drug: Risperidone","Scores on depression scales after 6 ECT treatments|Scores on Clinical Global Impression Scales and Symptom Checklist","University of California, Los Angeles|Janssen, LP","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","UCLA IRB #03-10-049-01|RIS-DEP-405","March 2005",,"May 2006","September 20, 2005",,"May 18, 2006","UCLA Npi&H, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00203723"
1600,"NCT00517764","Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression",,"Completed","No Results Available","Depression","Drug: escitalopram","Hamilton Rating Scale for Depression (HRDS)","Centre for Addiction and Mental Health|Queen's University","All","16 Years to 29 Years   (Child, Adult)","Not Applicable","299","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","155/2006","December 2006","June 2013","June 2013","August 17, 2007",,"August 9, 2013","Queens University, Kingston, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00517764"
1601,"NCT01346306","Trial of Transcranial Direct Current Stimulation (tDCS)",,"Active, not recruiting","No Results Available","Major Depression","Device: Eldith Company - direct current stimulator","Montgomery Asberg Depression Rating Scale for Depression (MADRS).","The University of New South Wales|Singapore General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HC16360","April 2011","August 2021","August 2021","May 2, 2011",,"December 24, 2019","Black Dog Institute, Randwick, Sydney, New South Wales, Australia|Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01346306"
1602,"NCT00931619","GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression",,"Completed","No Results Available","Epilepsy|Epilepsy, Temporal Lobe|Depression|Depressive Disorder, Major",,"The primary outcome measures will include GABA(A) binding potential and regional glucose metabolic rate as measured by PET, and GABA and glutamate levels as measured by MRS.|Secondary outcome measures will include brain structure on MRI, blood oxygenation level dependent contrast in functional resting state scans, genetic data, and scores on depression rating scales.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)",,"29","NIH","Observational","Time Perspective: Prospective","090182|09-N-0182","June 29, 2009",,"April 2, 2013","July 2, 2009",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00931619"
1603,"NCT04301271","Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression","SIMCODE","Recruiting","No Results Available","Depressive Disorder, Major|Obesity","Drug: Simvastatin 40mg|Drug: Placebo oral tablet","Change score in MADRS (Montgomery-Asberg-Depression Rating Scale)|MADRS-response|MADRS-remission|MADRS-MCID|Change score in BDI-II (Beck Depression Inventory-II)|BDI-II-MCID|Change score in PGIC (Patients' Global Impression of Change Scale)|Change score in CGI-S (Clinicians' Global Impression of Severity of Illness)|CGI-I (Clinicians' Global Impression of Improvement )|EQ-5D-3L (EuroQol-5 Dimensions-3 Levels Questionnaire)|SOFAS (Social and Occupational Functioning Assessment Scale)","Charite University, Berlin, Germany|NeuroCure Clinical Research Center, Charite, Berlin|University Medical Center Goettingen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SIMCODE","August 13, 2020","June 2023","June 2023","March 10, 2020",,"September 22, 2020","Charité - Universitätsmedizin Berlin, Klinik für Psychiatrie und Psychotherapie, Berlin, Germany|Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Psychosomatik, Berlin, Germany|Universitätsklinikum Frankfurt, Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Frankfurt, Germany|Universitätsmedizin Greifswald, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Hamburg, Germany|Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Hannover, Germany|Universitätsklinikum Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Leipzig, Germany|Universitätsklinikum Schleswig-Holstein, Zentrum für Integrative Psychiatrie - Klinik für Psychiatrie und Psychotherapie, Lübeck, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04301271/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04301271"
1604,"NCT03257397","TBS in Major Depression",,"Unknown status","No Results Available","Treatment Resistant Depression","Device: theta-burst stimulation (TBS) using a MagPro X1000","HAMD|BDI-II|Regional white matter microstructure using DWI|Regional grey matter volume and using MRI","Rupert Lanzenberger|Medical University of Vienna","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PSY-NIL-0008","August 1, 2017","July 31, 2020","December 31, 2020","August 22, 2017",,"March 13, 2019","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03257397"
1605,"NCT00577070","Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression",,"Completed","No Results Available","Major Depression","Device: TMS","Treatment response defined as at least a 50% decrease in Hamilton Depression Rating Scale (HAM-D24). Remission is defined as below 8 in Hamilton Depression Rating Scale (HAM-D24)","BeerYaakov Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TMS-204CTIL","January 2008","October 2009","October 2009","December 19, 2007",,"October 6, 2009","Beer-Yaacov MHC, Beer Yaacov, Israel",,"https://ClinicalTrials.gov/show/NCT00577070"
1606,"NCT04463108","A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy","ARIANNA","Recruiting","No Results Available","Depressive Disorder, Major|Suicidal Ideation","Other: No Intervention","Type of Comprehensive Treatment for Major Depression Disorder (MDD) and Active Suicidal Ideation with Intent|Number of Psychiatric Drugs|Duration of Treatment|Sequence of Treatments in Participants with MDD and Suicidal Ideation with Intent|Care Setting|Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|European Quality of Life (EuroQol) 5-Dimension 5-Level Questionnaire (EQ-5D-5L) scores|Percentage of participants with AEs and SAEs|Healthcare Resource Utilization","Janssen-Cilag S.p.A.","All","18 Years to 74 Years   (Adult, Older Adult)",,"220","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR108760|54135419MDD4002","June 23, 2020","July 30, 2021","May 31, 2022","July 9, 2020",,"June 25, 2021","ASST Spedali Civili Brescia, Brescia, Italy|Ospedale Santissima Trinità, Cagliari, Italy|Ospedale Sant'Antonio Abate, Cantu', Italy|Ospedale Vittorio Emanuele, Catania, Italy|Ospedale Parodi Delfino, Colleferro, Italy|Ospedali Riuniti Foggia, Foggia, Italy|Ospedale San Giovanni di Dio, Frattamaggiore, Italy|Azienda Ospedaliera Universitaria San Martino di Genova, Genova, Italy|Az. USL 12 di Viareggio Ospedale Versilia, Lido Di Camaiore, Italy|H.U. Santa Lucía, Macerata, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|Ospedale Ca Granda - Niguarda, Milano, Italy|Dipartimento di Salute Mentale, Modena, Italy|Ospedale S. Francesco d'Assisi, Oliveto Citra, Italy|Aou San Luigi Gonzaga, Orbassano, Italy|Centro Salute Mentale, Padova, Italy|AOU Policlinico P.Giaccone, Palermo, Italy|P.O. Putignano, Putignano, Italy|Ospedale Infermi Rimini, Rimini, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Ospedale G. Mazzini, Teramo, Italy|A.O.U. Città della Salute e della Scienza, Torino, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Azienda Ulss 8 Berica- Ospedale Di Vicenza, Vicenza, Italy",,"https://ClinicalTrials.gov/show/NCT04463108"
1607,"NCT03328819","Therapeutic Effect and Mechanism of Acupuncture Treating Chronic Pain and Major Depression Comorbidity",,"Unknown status","No Results Available","Chronic Pain|Depression","Other: Acupuncture","The change of Hamilton Rating Scale for Depression (HAMD)|The change of Brief Pain Inventory (BPI)|The change of Beck Depressive Inventory (BDI-II)|The change of Neurotoxicity Rating Scale (NTRS)|The change of WHO Quality of Life Questionnaire (WHOQoL)|The change of Clinical Global Inventory (CGI)|change of tumor necrosis factor α in plasma|change of Interferon gamma in plasma|change of interleukin-1β in plasma|change of interleukin-6 in plasma|change of interleukin-12 in plasma|change of interleukin-17 in plasma|change of interleukin-23 in plasma|change of gene amount: Serotonin Transporter Gene-Linked Polymorphism Region in plasma|change of gene amount: Tryptophan Hydroxylase 2 Gene in plasma|brain-derived neurotrophic factor (BDNF) in serum","China Medical University Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CMUH106-REC1-077","August 1, 2017","July 31, 2019","July 31, 2020","November 1, 2017",,"February 26, 2019","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03328819"
1608,"NCT01786746","Adapting Cognitive Behavioral Therapy (CBT) for Chinese Americans",,"Completed","No Results Available","Major Depression","Behavioral: cognitive behavioral therapy|Behavioral: culturally adapted cognitive behavioral therapy","Hamilton Depression Rating Scale (Change is being assessed)","Claremont McKenna College|University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","61","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R34MH073545","June 2007","March 2011","March 2011","February 8, 2013",,"February 8, 2013","Claremont McKenna College, Claremont, California, United States",,"https://ClinicalTrials.gov/show/NCT01786746"
1609,"NCT00150839","Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy","COATS","Completed","No Results Available","Depressive Disorder, Major","Drug: Mirtazapine|Drug: Venlafaxine","Categorial response to the medication. Categorial response is defined on the basis of CGI Improvement scale and 50% reduction in MADR-S score|Tolerability of treatment as assessed using the DOTES scale|Cognitive deficits as judged by the SKT system|Self assessment of depression and anxiety using Beck's Depression/Anxiety Inventory (BDI/BAI)|Changes is blood levels of homocysteine, folate, vit B12, P11","University of Erlangen-Nürnberg Medical School","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COATS","March 2006","December 2009","December 2009","September 8, 2005",,"December 14, 2020","Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg, Erlangen, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT00150839"
1610,"NCT01957501","Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel",,"Terminated","No Results Available","Major Depressive Disorder|Bipolar Disorder|Serum Biomarkers","Other: MDDScoreTM","Biomarker for Major Depressive Disorder (MDD) and Bipolar Disorder in Adolescents","University of Utah","All","13 Years to 21 Years   (Child, Adult)",,"75","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Ridge II","July 2013","July 2015","March 2016","October 8, 2013",,"April 10, 2017","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01957501"
1611,"NCT04325529","Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation)",,"Recruiting","No Results Available","Major Depression in Remission","Device: Aversive stimuli","Clinical Interview|Behavioral Performance on the Probabilistic Reward Task (PRT)|MRI Data|Salivary Cortisol|Follow-up Clinical interviews","Mclean Hospital","All","18 Years to 45 Years   (Adult)",,"96","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020A000886","December 1, 2020","March 31, 2025","December 1, 2025","March 27, 2020",,"April 5, 2021","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04325529"
1612,"NCT00040261","Clinical Trial of Memantine for Major Depression",,"Completed","No Results Available","Depression","Drug: Memantine HCL",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 3","112","NIH","Interventional","Primary Purpose: Treatment","020231|02-M-0231","June 2002",,"March 2005","June 24, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00040261"
1613,"NCT04238039","Ketamine Long Therm Follow Up Study","ket_Fol_Up","Recruiting","No Results Available","Followin Ketamine Treatment",,"Time to relapse","The Chaim Sheba Medical Center","All","up to 90 Years   (Child, Adult, Older Adult)",,"16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5826-18-SMC","December 14, 2019","February 1, 2020","April 1, 2020","January 23, 2020",,"January 23, 2020","Revital Amiaz, Ramat Gan, RI, Israel",,"https://ClinicalTrials.gov/show/NCT04238039"
1614,"NCT01021709","Trial of Transcranial Direct Current Stimulation (tDCS) Using Alternative Electrode Montages",,"Completed","No Results Available","Major Depression","Device: tDCS (Eldith DC-Stimulator (CE certified))","Montgomery Asberg Depression Rating Scale for Depression (MADRS).|Inventory of Depressive Symptomatology (IDS-C).","The University of New South Wales","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09343","November 2009","November 2015","November 2015","November 30, 2009",,"May 24, 2016","Black Dog Institute, University of New South Wales, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01021709"
1615,"NCT00287703","Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression",,"Completed","No Results Available","Depression","Device: Pulsating Electro-Magnetic Fields|Device: Pulsating Electro-Magnetic Fields sham","Hamilton Depression Rating Scale score (depression)|AQT, measure of concentration","Hillerod Hospital, Denmark|The Lundbeckfoundation|Biofields","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Final version 26 Oktober 2005","March 2006","March 2009","March 2009","February 7, 2006",,"May 29, 2009","Speciallægerne Falkoner Allé, Municipality of Frederiksberg, Denmark",,"https://ClinicalTrials.gov/show/NCT00287703"
1616,"NCT00084162","Neurocardiac Control in Major Depression",,"Completed","No Results Available","Depression, Involutional",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"41","NIH","Observational",,"040136|04-M-0136","March 30, 2004",,"March 17, 2010","June 8, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00084162"
1617,"NCT00194948","Treatment Choices for Improving Adherence and Outcome",,"Completed","No Results Available","Major Depression","Drug: escitalopram|Behavioral: interpersonal psychotherapy","treatment initiation|treatment adherence|depressive symptomatology","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23MH069784|DSIR 8K-RTSE","September 2003","April 2007","May 2007","September 19, 2005",,"November 3, 2013","Cornell Internal Medicine Associates, New York, New York, United States|Weill Medical College of Cornell University, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT00194948"
1618,"NCT02752178","Peripheral Immunomarker Validation in Treatment-resistant Depression","BIODEP","Completed","No Results Available","Depressive Disorder, Major","Other: MA|Other: DEP","C-reactive protein (CRP) levels (mg/l)|Flow cytometric immunophenotype|Structural parameters of the brain|Response to stimulus|Microglial activation in the brain|Pro-inflammatory (M1-like) phenotype-producing cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α circulating in cerebrospinal fluid","University of Cambridge|University of Oxford|University of Glasgow|University of Sussex|King's College London|Janssen, LP|H. Lundbeck A/S|GlaxoSmithKline","All","25 Years to 50 Years   (Adult)",,"393","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","15/EE/0092","June 2015","September 2018","September 2018","April 26, 2016",,"September 25, 2018","University of Sussex, Brighton, United Kingdom|University of Cambridge, Cambridge, United Kingdom|University of Glasgow, Glasgow, United Kingdom|King's College London, London, United Kingdom|University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02752178"
1619,"NCT00616759","The Effect on Cognition of Terminating ECT Induced Seizures With Propofol",,"Completed","Has Results","Major Depression","Procedure: electroconvulsive therapy|Procedure: electroconvulsive therapy plus propofol|Drug: propofol","Wechsler Memory Scale-III (WMS-III) Auditory Delayed Index","Loma Linda University","All","45 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","56164","September 2006","March 24, 2010","March 24, 2010","February 15, 2008","February 4, 2013","June 8, 2021","Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT00616759"
1620,"NCT02190968","Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance",,"Completed","No Results Available","Major Depressive Disorder, Recurrent, in Remission|Depressive Symptoms","Behavioral: Usual Depression Care|Behavioral: Mindful Mood Balance","Patient Health Questionnaire-9|Ruminative Responses Scale|Five Facet Mindfulness Questionnaire|Five Facet Mindfulness Scale|Experiences Questionnaire","University of Toronto|University of Colorado, Boulder|Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","460","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH102229-01A1","March 2015","November 2018","November 2018","July 15, 2014",,"January 28, 2019","Kaiser Permanente Institute for Health Research, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02190968"
1621,"NCT00206765","Risperidone vs. Paroxetine for Panic Attacks",,"Terminated","No Results Available","Major Depressive Disorder With Panic Attacks|Panic Disorder","Drug: Risperidone|Drug: Paroxetine",,"Beth Israel Medical Center","All","21 Years to 55 Years   (Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","082-02","January 2003","July 2005","July 2005","September 21, 2005",,"October 22, 2012","Beth Israel Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00206765"
1622,"NCT00071110","Electroacupuncture for Major Depression",,"Completed","Has Results","Depression|Depressive Disorder","Procedure: Electroacupuncture|Procedure: Sham","Antidepressant Response, Defined as a Hamilton Depression Rating Scale Score Relative Decrease of 50 % or More and a Final Score < 10|Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Physical Component Score (MOSPCS)|Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Mental Component Score (MOSMCS)|Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Bodily Pain Index (MOSBPI)","National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","57","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","R21AT001218-01A1","March 2004","May 2007","May 2007","October 15, 2003","January 11, 2010","January 11, 2010","UPMC Shadyside, Center for Complementary Medicine, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00071110"
1623,"NCT00042380","Examination of a Soy-Based Supplement for Major Depression",,"Completed","No Results Available","Depression","Drug: Novasoy",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","120","NIH","Interventional","Primary Purpose: Treatment","020254|02-M-0254","July 2002",,"April 2005","July 29, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00042380"
1624,"NCT02062840","The Brain on Whole Body Hyperthermia: A Neuroimaging Study",,"Completed","No Results Available","Major Depression","Device: High intensity whole-body infrared heating|Device: Low intensity whole-body infrared heating|Device: Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|Other: Questionnaires","Change in acute brain effects of WBH on resting state brain connectivity and function|Degree of concordance of brain activity with autonomic nervous system function|Change in depression scores over time.|Change in Positive and Negative Affect|Change in ability to function in daily life|Change in quality of life","University of Arizona","All","18 Years to 30 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-121-670-10","February 2014","May 2015","May 2015","February 14, 2014",,"August 10, 2015","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02062840"
1625,"NCT03004430","Mantra Meditation in Major Depression","MAMED","Terminated","No Results Available","Depression","Behavioral: Mantra Meditation|Behavioral: Progressive Muscle Relaxation","MADRS / SIGMA|STAI-T|PTQ|RSQ|ASP|SpREUK|EEQ|ICPH|HRV","Diakonie Kliniken Zschadraß|University Hospital Dresden","All","18 Years and older   (Adult, Older Adult)","Not Applicable","123","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MAMED001","January 12, 2017","July 30, 2020","July 30, 2020","December 28, 2016",,"February 3, 2021","Diakoniekliniken Zschadraß, Colditz, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT03004430"
1626,"NCT01065311","Mindfulness-based Cognitive Therapy for Chronic Depression",,"Completed","No Results Available","Chronic Major Depression","Behavioral: Mindfulness-based Cognitive Therapy|Behavioral: The Cognitive Behavioral Analysis System of Psychotherapy|Biological: Standard psychiatric care","Hamilton Rating Scale for Depression|Beck Depression Inventory II|Social Adaption Self-evaluation Scale|Short Form (36) Health Survey|Global Assessment of Functioning Scale|Response Styles Questionnaire","Johannes Michalak|Ruhr University of Bochum","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DFG Mi 700/4","October 2010","March 2013","May 2013","February 9, 2010",,"May 15, 2014","University of Hildesheim, Hildesheim, Germany",,"https://ClinicalTrials.gov/show/NCT01065311"
1627,"NCT00611052","Prevention of Adolescent Major Depression","CWSA-Fin","Terminated","No Results Available","Depressive Disorder","Behavioral: the Adolescent Coping with Stress|Behavioral: Treatment as usual|Other: usual health education","Major depression (diagnostic interview) High level of depressive symptoms (self-report scale)|Suicidality (diagnostic interview, self-report scale)","Finnish Institute for Health and Welfare|University of Helsinki|University of Eastern Finland|Kuopio University Hospital|City of Vantaa|City of Kuopio|City of Turku","All","14 Years to 16 Years   (Child)","Not Applicable","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","KTL423-0","March 2008","December 2013","December 2013","February 8, 2008",,"April 20, 2016","Kuopio University Hospital and Kuopio University, Kuopio, Finland|Turku Primary Health care and Adolescent Psychiatric clinic, Turku, Finland|Vantaa Primary Health Care, Vantaa, Finland",,"https://ClinicalTrials.gov/show/NCT00611052"
1628,"NCT03944213","Resting-state Functional Connectivity Throughout a Course of iTBS in Major Depression",,"Unknown status","No Results Available","Depression|Depressive Disorder|Depressive Disorder, Major|Depressive Episode","Device: intermittent theta burst stimulation (iTBS)","Change in functional connectivity coefficients based on rs-fMRI over 7 timepoints.|Change in depression severity as measured by the Hamilton Depression Rating Scale (HDRS-17) over 7 timepoints.","University Hospital, Bonn|Clemens Mielacher, University Hospital, Bonn|Maximilian Kiebs, University Hospital, Bonn","All","18 Years to 60 Years   (Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","DepRest","July 23, 2018","February 1, 2020","June 1, 2020","May 9, 2019",,"May 9, 2019","Klinik und Poliklinik für Psychiatrie und Psychotherapie, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT03944213"
1629,"NCT01803711","Omega 3 FA Supplements as Augmentation in the Treatment of Depression",,"Terminated","Has Results","Major Depression|Cancer|Diabetes|Cardiovascular Diseases","Drug: Desvenlafaxine|Dietary Supplement: Omega 3 Fatty acids|Drug: Placebo (for Omega 3 fatty acid supplement)","Hospital Anxiety and Depression Scale|Montgomery-Asberg Depression Rating Scale (MADRS)|Short Form Health Survey (SF-12)|Visual Analog Scale for Energy (VAS-E)|Visual Analog Scale for Pain (VAS-P)|Leeds Sleep Evaluation Questionnaire (LSEQ)","UConn Health","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OmegaDVS","February 2013","June 2016","June 2016","March 4, 2013","December 27, 2017","December 27, 2017","University of Connecticut Health Center, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01803711"
1630,"NCT00463580","A Study of Infliximab for Treatment Resistant Major Depression","Infliximab","Completed","Has Results","Depression","Drug: Infliximab|Drug: Placebo","Hamilton Depression Rating Scale 17 (HDRS-17) Scores|Number of Participants With a 50% Reduction in Hamilton Depression Rating Scale (HDRS) Scores|Number of Remitted Patients During Treatment|Inventory of Depressive Symptomatology-Self-Report (IDS-SR) Scores|Plasma Concentrations of Interleukin-6 (IL-6)|Plasma Concentrations of CRP|Plasma Concentrations of Tumor Necrosis Factor (TNF)-Alpha|Sleep Efficiency|Sleep Efficiency in High (CRP>5mg/L) Versus Low (CRP < or =5mg/L) Infliximab-treated Patients|Change in Hamilton Depression Rating Scale 17 (HDRS-17) Scores Subgrouped by Baseline Hs-CRP.","Emory University|National Institute of Mental Health (NIMH)","All","25 Years to 60 Years   (Adult)","Phase 4","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00011734|1R21MH077172-01A2","December 2008","June 2011","June 2011","April 20, 2007","May 12, 2014","December 4, 2018","Emory Clinic, Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00463580"
1631,"NCT04031547","fMRI Study of tES in Major Depression",,"Active, not recruiting","No Results Available","Depression","Device: Transcranial Electrical Stimulation (tES)","Changes in brain function measured with blood-oxygenation-level-dependent (BOLD) functional MRI","Northwestern University|Brain & Behavior Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","STU00207022","February 1, 2019","July 31, 2021","July 31, 2022","July 24, 2019",,"February 24, 2021","Center for Translational Imaging at Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04031547"
1632,"NCT03915821","Memory Changes in Patients With Major Depression Disorder Treated With ECT",,"Recruiting","No Results Available","Depressive Disorder","Device: ECT","Evaluate the subjective memory changes present in a sample of patients with major depression disorder who admitted to psychiatry unit and evaluation of memory changes following ECT treatment .|Evaluate the subjective memory changes present in a sample of patients with major depression disorder who admitted to psychiatry unit and evaluation of memory changes following ECT treatment","Assiut University","All","20 Years to 50 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Memory Changes with ECT","December 15, 2020","June 15, 2021","October 15, 2021","April 16, 2019",,"June 3, 2021","Neuropsychiatry & Neurosurgery Hospital, Asyūţ, Asyut, Egypt",,"https://ClinicalTrials.gov/show/NCT03915821"
1633,"NCT03548519","Mouse-gaze Contingent Attention Training (MCAT)",,"Unknown status","No Results Available","Major Depression in Remission","Behavioral: MCAT-only|Behavioral: MCAT-sham|Behavioral: MCAT-combo","Change in depression, anxiety, and stress|Change in rumination|Change in attentional bias|Change in reappraisal|Change in negative emotions (after reappraisal)|Change in (mal-)adaptive cognitive emotion regulation strategies|Change in maladaptive cognitive emotion regulation strategies: State rumination|Change in general functioning: Quality of life|Change in general functioning: Remission from depression|Change in general functioning: Resilience|Treatment Credibility and Expectancy|Change in motivation-related variables","University Ghent","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","EC/2018/0509","May 7, 2018","June 2019","June 2019","June 7, 2018",,"June 7, 2018","Ghent University, Gent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT03548519"
1634,"NCT01832805","Theta Burst Study Ghent","TBS Ghent","Completed","No Results Available","Unipolar Major Depression","Other: Theta burst stimulation.","Depression severity in Theta burst treatment at baseline.|Depression severity of Theta burst treatment after 1 week of treatment.|Depression severity will be assessed at the end of the final second week of the stimulation protocol.|Depression severity will be assessed two weeks after stimulation.|Suicidal ideation will be assessed at baseline.|Suicidal ideation will be assessed after 1 week of treatment.|Suicidal ideation will be assessed at the end of the final second week of the stimulation protocol.|Suicidal ideation will be assessed two weeks after stimulation.|Resting state functional connectivity; diffusion MRI at baseline.|Resting state functional connectivity; diffusion MRI after 1 week of treatment.|Resting state functional connectivity; diffusion MRI at the end of the final second week of the stimulation protocol.","University Ghent|University Hospital, Ghent","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2013/392","April 2013","December 2015","December 2015","April 16, 2013",,"February 2, 2017","Ghent University Hospital, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT01832805"
1635,"NCT04104698","Cognitive, Psychological and Electrophysiological Attributes to Suicide Among Depressed Patients",,"Recruiting","No Results Available","Suicide|Major Depressive Disorder|Quantitative EEG (qEEG)","Diagnostic Test: Quantitative EEG","Electrophysiological attibutes to suicide among depressed patients","Mansoura University","All","16 Years to 65 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","MD.18.08.81","October 1, 2019","July 15, 2020","August 1, 2020","September 26, 2019",,"April 28, 2020","Mansoura University Hospital, Mansoura, Dakahlia, Egypt",,"https://ClinicalTrials.gov/show/NCT04104698"
1636,"NCT04071886","Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study",,"Unknown status","No Results Available","MDD","Behavioral: Mindfulness-Based Training|Behavioral: Relaxation Training","Mean Change from Baseline in Eye Movement Performance During Free-View Task at 2 Weeks|Mean Change from Baseline in the Symptoms of Major Depression as Measured by BDI-II at 2 Weeks|Mean Change from Baseline in the Symptoms of Major Depression as Measured by HAM-D at 2 Weeks|Mean Change from Baseline in State Mindfulness at 2 Weeks|Mean Change from Baseline in Tendency to Engage in Ruminative Responses at 2 Weeks","Central South University","All","18 Years to 40 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Second Xiangya hospital EMEN","September 1, 2019","January 2020","January 2020","August 28, 2019",,"August 28, 2019","Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT04071886"
1637,"NCT02091856","Internet-delivered Psychotherapy for Depression","PsiTOD","Terminated","Has Results","Mild - Major Depression","Behavioral: Cognitive Behavioral Therapy (CBT)","Beck Depression Inventory-II (BDI-II)|Beck Depression Inventory II (BDI-II)|Beck Anxiety Inventory (BAI)|Quality of Life Inventory (QOLI)|Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)","West University of Timisoara|Linkoeping University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WUTimisoara-PsiTOD","March 2014","September 2015","September 2015","March 19, 2014","March 28, 2016","June 28, 2018","West University of Timisoara, Timisoara, Timis, Romania",,"https://ClinicalTrials.gov/show/NCT02091856"
1638,"NCT04333277","Lactobacillus Helveticus in the Treatment of Major Depression",,"Recruiting","No Results Available","Depression","Other: Probiotic|Other: Maltodextrin","Change in the depressive symptoms severity|Change in microbiota composition|Changes in the serum levels of biomarkers|Change in perception of stress","Federal University of Minas Gerais","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAAE 83541717.0.0000.5149","April 1, 2020","April 2021","April 2021","April 3, 2020",,"February 5, 2021","Hospital das Clínicas, Belo Horizonte, Minas Gerais, Brazil",,"https://ClinicalTrials.gov/show/NCT04333277"
1639,"NCT04772651","Mediterranean Diet and the Microbiota Gut Brain Axis in Major Depression","MeDiVa","Not yet recruiting","No Results Available","Depression","Other: Mediterranean Diet|Other: Normal hospital diet|Other: dietary coaching|Other: Psychoeducation on depression","Change in Vagal function|Change of C-reactive protein (CRP)|Change in Interleukine-6|Change in Oxytocin|Change of Gut microbiome|Change of Body mass Index|Change in Hamilton Scale for Depression (HAMD)|Change in Beck Depression Inventory (BDI)|Change in Pittsburgh Sleep Quality Inventory (PSQI)|Change in Adult Attachment Scale|Change in Wiener Ernährungsprotokoll|Change in Mediterranean Diet Score|Change in International Physical Acitivity Questionnaire","Medical University of Graz","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EK 1087 ex 2021","August 1, 2021","September 1, 2022","September 30, 2022","February 26, 2021",,"March 3, 2021",,,"https://ClinicalTrials.gov/show/NCT04772651"
1640,"NCT03774641","A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women",,"Recruiting","No Results Available","Bipolar Disorder|Major Depressive Disorder|Schizo Affective Disorder","Drug: Lamictal","Change in Mood as assessed by The Edinburgh Postnatal Rating Scale|Change in Mood as assessed by The Young Mania Rating Scale|Side Effect as assessed by the Udvalg for Kliniske Undersøgelser Side Effects Rating Scale|Side Effect as assessed by the Frequency, Intensity, and Burden of Side Effects Rating Scale|Change in Infant Habituation as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Change in Infant Attention as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Change in Infant Self-Regulation as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Change in Infant Arousal as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Change in Infant Tonicity as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Change in Infant Reflexes as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Change in Infant Quality of Movement as assessed by the Neonatal Intensive Care Unit Network Neurobehavioral Scale|Gestational Age at Birth in Weeks assessed by Review of the Infant Delivery Chart|Birth Length in Inches assessed by Review of the Infant Delivery Chart|Birth Weight in pounds assessed by Review of the Infant Delivery Chart|APGAR Score at 1 Minute assessed by Review of the Infant Delivery Chart|APGAR Score at 5 Minutes assessed by Review of the Infant Delivery Chart|Assessment of Neonatal Intensive Care Unit Admission by Review of the Infant Delivery Chart","Johns Hopkins University","Female","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00162134","December 3, 2018","December 31, 2021","December 31, 2021","December 13, 2018",,"December 14, 2020","550 N Broadway, Baltimore, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03774641/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03774641"
1641,"NCT02407652","Cognitive Control Training for Remitted Depressed Patients",,"Completed","No Results Available","Major Depression in Remission","Behavioral: Cognitive Control Training|Behavioral: Low Cognitive Load Training","Change in depressive rumination from baseline to the post-training assessment and follow-up (RRS)|Change in depressive symptomatology from baseline to the post-training assessment and follow-up (BDI-II)|(mal-)Adaptive cognitive emotion regulation (CERQ)|Quality of Life (QLDS)|Disability (WHODAS 2.0)|Resilience (RS)|Remission from depression (RDQ)","University Ghent","All","23 Years to 65 Years   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","B/13808/01-CCT-003","December 2014","October 2015","October 2015","April 3, 2015",,"December 17, 2015","Ghent University, Ghent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT02407652"
1642,"NCT00445679","Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD",,"Completed","Has Results","Depressive Disorder, Major","Drug: DVS SR|Drug: Paroxetine","Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)|Clinical Global Impressions Scale-Improvement (CGI-I) Scores|Clinical Global Impressions Scale-Severity of Illness (CGI-S) Scores|Montgomery and Asberg Depression Rating Scale (MADRS) Total Score Mean Change From Baseline|Visual Analog Scale-pain Intensity (VAS-PI) Score Mean Change From Baseline|Hamilton Rating Scale for Depression, 6-item (HAM-D6) Score Mean Change From Baseline|Covi Anxiety Scale Score Mean Change From Baseline","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","807","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3151A1-336","July 2007","February 2009","February 2009","March 9, 2007","November 3, 2013","November 3, 2013","Beijing, China|Beijing, China|Guangdong Province, China|Hunan Province, China|Jiangsu Province, China|Shanghai, China|Shanghai, China|Shanxi Province, China|Sichuan Province, China|Yunnan Province, China|Zhejiang Province, China|Andhra Pradesh, India|Andhra Pradesh, India|Andhra Pradesh, India|Andhra Pradesh, India|Chandigarh, India|Gujarat, India|Gujarat, India|Karnataka, India|Karnataka, India|Maharashtra, India|Maharashtra, India|Maharashtra, India|Mumbai Maharashtra, India|New Delhi, India|Punjab, India|Uttar Pradesh, India|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Chang-Hua, Taiwan|KaoHsiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00445679"
1643,"NCT02386670","Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)","PACt-MD","Active, not recruiting","No Results Available","Mild Cognitive Impairment|Major Depressive Disorder, Recurrent, In Remission|Major Depressive Disorder, Single Episode, in Full Remission","Other: tDCS + CR|Other: sham tDCS + sham CR","Change in cognitive scores over time|Percentage of subjects who remain free of MCI or dementia over time","Centre for Addiction and Mental Health|Brain Canada|Applied Health Research Centre|Queen's University|Baycrest Centre for Geriatric Care|Unity Health Toronto|Sunnybrook Health Sciences Centre|University Health Network, Toronto","All","60 Years and older   (Adult, Older Adult)","Not Applicable","375","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","041-2014","January 2015","June 2022","December 2022","March 12, 2015",,"April 22, 2021","Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Heath Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada","""Study Protocol: Version 20"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02386670/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02386670"
1644,"NCT00326677","Primary Prevention of Major Depression in Later Life",,"Unknown status","No Results Available","Depression","Behavioral: Problem Solving Therapy|Behavioral: Dietary Education","BDI, Hamilton, FDI scores, SCID diagnosis of major depression|CES-D, ISEL,Folstein Mini-Mental, MOS-SF8,BSI, EXIT, Hopkins Verbal Learning Test, PTSD Checklist, Social Problem Solving Inventory, PSQI, CIRS-G, RAND 12","University of Pittsburgh","All","50 Years and older   (Adult, Older Adult)","Not Applicable","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","0601117","May 2006","June 2012","December 2013","May 17, 2006",,"February 18, 2011","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00326677"
1645,"NCT04428099","Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression",,"Recruiting","No Results Available","Depressive Disorder, Treatment-Resistant","Behavioral: Lifestyle change promotion program|Behavioral: Mindfullness based cognitive program|Behavioral: Written Information","Depression severity|Health-related quality of life","University of the Balearic Islands","All","18 Years and older   (Adult, Older Adult)","Not Applicable","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RMD01","January 13, 2020","January 12, 2022","July 12, 2022","June 11, 2020",,"June 11, 2020","Universitat Illes Balears, Palma de Mallorca, Illes Balears, Spain",,"https://ClinicalTrials.gov/show/NCT04428099"
1646,"NCT02226042","Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)",,"Completed","No Results Available","Major Depression (in Remission)","Behavioral: Mindfulness-based Cognitive Therapy","Changes in self-compassion following MBCT measured by both neuropsychological and self-report measures|Changes in levels of rumination following MBCT measured through both neuropsychological and self-report measures|Changes in attention regulation following MBCT|Changes in brain structure following MBCT","University of Manchester","All","18 Years to 60 Years   (Adult)","Not Applicable","112","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","MBCTMechanisms","October 2014","October 2016","October 2017","August 26, 2014",,"May 3, 2018","University of Manchester, Manchester, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02226042"
1647,"NCT00691535","Genetics of Symptomatology and Treatment Response in Psychotic Major Depression",,"Completed","No Results Available","Psychotic Disorders|Depressive Disorder|Depressive Disorder, Major",,,"Stanford University","All","Child, Adult, Older Adult",,"500","Other","Observational","Time Perspective: Other","SU-05132008-1160","October 2003","June 2012",,"June 5, 2008",,"June 19, 2019","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00691535"
1648,"NCT00641927","Antidepressant Therapy for Bipolar II Major Depression",,"Completed","No Results Available","Bipolar Type II Disorder","Drug: Venlafaxine|Drug: Lithium Carbonate","Reduction in Hamilton Depression Rating Scale score.|Change in Young Mania Rating Scale score.","Stanley Medical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-005","April 2002","October 2006","October 2006","March 24, 2008",,"March 24, 2008","Depression Research Unit, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00641927"
1649,"NCT00523302","A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia","TMS","Completed","Has Results","Major Depression|Fibromyalgia","Device: Active TMS|Device: Sham TMS","Average Pain|THE FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQ)-Modified|THE HAMILTON DEPRESSION RATING SCALE (HRDS)","Medical University of South Carolina|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HR#17365|AR049459","July 2007","October 2009","November 2009","August 31, 2007","July 11, 2018","July 11, 2018","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00523302"
1650,"NCT00260182","Genetics of Recurrent Early Onset Major Depression",,"Completed","No Results Available","Depression",,"Major depressive disorder diagnosis","Stanford University|National Institute of Mental Health (NIMH)","All","21 Years to 70 Years   (Adult, Older Adult)",,"2302","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","R01MH061686-02|R01MH059542|R01MH059552|R01MH075131|R01MH059541|R01MH060912|DNBBS 7G-GRR","October 2005","June 2009","June 2009","December 1, 2005",,"April 19, 2019","Stanford University, Palo Alto, California, United States|Howard University, Washington, District of Columbia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|Columbia University/New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00260182"
1651,"NCT02266693","Transdiagnostic iCBT for Depression and Anxiety",,"Completed","No Results Available","Major Depressive Disorder|Social Anxiety Disorder|Panic Disorder|Generalized Anxiety Disorder","Behavioral: iCBT","Change in Hamilton Depression Rating Scale (HAM-D) Total Score|Change in Hamilton Anxiety Rating Scale (HAM-A) Total Score|Change in Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) Total Score|Change in Liebowitz Social Anxiety Scale (LSAS) Total Score|Change in Panic Disorder Severity Scale Total Score|Change in Penn State Worry Questionnaire Total Score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score|Change in Sheehan Disability Scale (SDS) Total Score|Change in Clinical Global Impression (CGI)","Centre for Addiction and Mental Health","All","18 Years to 29 Years   (Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","057/2012","August 2014","August 2018","August 2018","October 17, 2014",,"February 15, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02266693"
1652,"NCT03278756","Online Cognitive Control Training for Remitted Depressed Patients",,"Completed","No Results Available","Major Depression in Remission","Behavioral: Cognitive control training|Behavioral: Active control training","Change in depressive symptomatology|Change in depressive rumination (brooding)|Change in cognitive emotion regulation strategies|Change in quality of life|Remission from depression|Resilience","University Ghent","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","B/14730/RMD","September 1, 2017","March 13, 2019","March 13, 2019","September 12, 2017",,"March 15, 2019","Ghent University, Gent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT03278756"
1653,"NCT04455646","Combining H1-Coil Deep Transcranial Magnetic Stimulation (dTMS) and App-guided CBT in Subjects With Major Depression Disorder (MDD)",,"Recruiting","No Results Available","Data Collection for Facilitation of Machine Learning Algorithm for Personalized Treatment","Behavioral: CBT-based, mobile-delivered, intervention platform","Patient Patient Health Questionnaire (PHQ) Patient Health Questionnaire (PHQ) Patient Health Questionnaire (PHQ) Health Questionnaire (PHQ)|Patient Patient Health Questionnaire (PHQ)","Brainsway","All","22 Years to 68 Years   (Adult, Older Adult)",,"540","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","101","August 26, 2019","August 26, 2021","August 26, 2021","July 2, 2020",,"July 9, 2020","Kadima Neuropsychiatry, San Diego, California, United States|Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States|Advanced Mental Health Care Inc. - Palm Beach, Palm Beach, Florida, United States|Advanced Mental Health Care Inc. - Royal Palm Beach, Royal Palm Beach, Florida, United States|Greenbrook - Annapolis, Annapolis, Maryland, United States|Greenbrook - Columbia, Columbia, Maryland, United States|Greenbrook - Frederick, Frederick, Maryland, United States|Greenbrook - Glen Burnie, Glen Burnie, Maryland, United States|Greenbrook - Greenbelt, Greenbelt, Maryland, United States|Greenbrook - Kensington, Kensington, Maryland, United States|Greenbrook - Olney, Olney, Maryland, United States|Greenbrook - Rockville, Rockville, Maryland, United States|Greenbrook - O'Fallon, O'Fallon, Missouri, United States|Greenbrook - Tesson Ferry, Saint Louis, Missouri, United States|Greenbrook - Creve Coeur, Saint Louis, Missouri, United States|Greenbrook - Chapel Hill, Chapel Hill, North Carolina, United States|Greenbrook - Greensboro, Greensboro, North Carolina, United States|Greenbrook - Matthews, Matthews, North Carolina, United States|Greenbrook - Raleigh, Raleigh, North Carolina, United States|Greenbrook - Glen Allen, Glen Allen, Virginia, United States|Greenbrook TMS NeuroHealth Centers, McLean, Virginia, United States|Greenbook - Newport News, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04455646"
1654,"NCT00125957","The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression",,"Completed","Has Results","Depression|Major Depressive Disorder|Unipolar Depression","Drug: Wellbutrin|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Hamilton Depression Rating Scale (HAM-D)","Mclean Hospital|National Association for Research on Schizophrenia and Affective Disorders.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2005P-000502","August 2005","January 2010","December 2011","August 2, 2005","August 6, 2014","August 6, 2014","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00125957"
1655,"NCT00037505","Major Depression and Inflammatory Risk Markers for Coronary Heart Disease",,"Completed","No Results Available","Depression",,,"National Center for Research Resources (NCRR)|American Heart Association","All","15 Years to 55 Years   (Child, Adult)",,,"NIH|Other","Observational","Observational Model: Defined Population|Time Perspective: Other","NCRR-M01RR00036-0849",,,,"May 20, 2002",,"June 24, 2005","Washington University, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00037505"
1656,"NCT01106313","Insulin Resistance in Patients With Major Depression",,"Completed","No Results Available","Depression|Bipolar Disorder|Mood Disorders|Insulin Resistance|Depressive Disorder, Major|Depressive Disorder",,"To quantify insulin-mediated glucose uptake as assessed by the SSPG concentration in patients with depression and compare the values to those previously obtained in a healthy age-matched control population|To examine the association between insulin resistance and cognitive performance and clinical course of depression in patients with depression","Stanford University|American Diabetes Association","All","20 Years to 65 Years   (Adult, Older Adult)",,"57","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","SU-02172010-5003|eProtocol 17089","July 2009","January 2016","January 2016","April 19, 2010",,"October 4, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01106313"
1657,"NCT00602537","Antidepressant Therapy in Treating Bipolar Type II Major Depression",,"Completed","Has Results","Bipolar Disorder|Depression","Drug: Venlafaxine|Drug: Lithium Carbonate","Depressive Relapse|Treatment-Emergent Mood Symptoms","University of Pennsylvania|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 4","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH060353-02|2R01MH060353-06A2","December 2007","June 2013","June 2013","January 28, 2008","April 25, 2017","April 25, 2017","Depression Research Unit - University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00602537"
1658,"NCT03421847","Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects.",,"Completed","No Results Available","Depression|Vestibular Disorder","Diagnostic Test: Rotatory vestibular test","Vestibular Activity","Vest Brain,Centro de Estudios Neurovestibulares|Centro de Medicina Aeroespacial.","All","18 Years and older   (Adult, Older Adult)",,"41","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","ROTDEPR01","July 1, 2005","December 15, 2006","December 15, 2006","February 5, 2018",,"February 6, 2018",,,"https://ClinicalTrials.gov/show/NCT03421847"
1659,"NCT03275961","Stress Management and Resiliency Training (SMART) Integrated Into Treatment of Major Depression",,"Completed","No Results Available","Depression","Behavioral: Stress Management and Resiliency Training","Change in Connor-Davidson Resilience Scale Score|Change in Hamilton Rating Scale for Depression Score|Change in Patient Health Questionnaire-9 Score|Change in Quick Inventory of Depressive Symptoms Score|Change in Generalized Anxiety Disorder-7 Score|Change in Perceived Stress Scale Score","Mayo Clinic","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-007944","November 29, 2016","July 1, 2018","October 15, 2018","September 8, 2017",,"November 14, 2018","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03275961"
1660,"NCT02469545","Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment",,"Completed","No Results Available","Depression|Anxiety Disorder","Drug: Lactobacillus Plantarum 299v|Drug: Crystalline cellulose powder|Drug: Escitalopram|Drug: Sertraline","Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study.|Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study.|Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study.|Cognitive functions evaluation - California Verbal Learning Test (CVLT)|Cognitive functions evaluation - Ruff Figural Fluency Test (RFFT)|Cognitive functions evaluation - Stroop Test (A and B)|Cognitive functions evaluation - Connecting Points Test (A and B)|Cognitive functions evaluation - Attention and Perceptivity Test|Biochemical analysis - morning cortisol level|Biochemical analysis - cytokines measurements profile|Biochemical analysis - kynurenic pathway metabolites measurements profile","Medical University of Bialystok","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","133-47818","June 2014","March 2016","March 2016","June 11, 2015",,"September 7, 2018","Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland",,"https://ClinicalTrials.gov/show/NCT02469545"
1661,"NCT03541707","Evaluation of the H1-Coil TMS- Double Blind Placebo Controlled Study in Adolescent Patients Suffering From Major Depression",,"Unknown status","No Results Available","Depression","Device: Deep TMS Brainsway's H coil","For efficacy, improvement in the CGI is the primary outcome measure.|For safety, severe side effects are the primary outcome measure.|cognitive changes in response to the treatment","Shalvata Mental Health Center","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0020-17 SHA","May 2018","May 2020","December 2020","May 30, 2018",,"May 30, 2018","Shalvata Mental health Center, Hod Hasharon, Israel",,"https://ClinicalTrials.gov/show/NCT03541707"
1662,"NCT03518749","Effects of tDCS-enhanced Cognitive Control Training on Depression",,"Unknown status","No Results Available","Depression Unipolar","Other: 1mA tDCS|Other: 2mA tDCS|Behavioral: Cognitive control training","Change of MADRS scores|BDI scores|Number of correct trials in the PASAT|RT in the DWM|Number of correct trials in the DWM|GAF score|Delta Mood ratings|Subjective performance ratings|Electroencephalography (EEG) measures|Prefrontal Brain activity (NIRS)|Course of MADRS scores|Prefrontal Brain activity (NIRS) as a predictor|Electroencephalography (EEG) measures as a predictor|Genetic factors as predictors","University Hospital Tuebingen|German Federal Ministry of Education and Research|Universität Tübingen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","01EE1403D-2","March 19, 2018","October 1, 2019","December 31, 2019","May 8, 2018",,"February 19, 2019","University Hospital Tuebingen, Tubingen, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03518749"
1663,"NCT03653858","Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression","FORESEE III","Recruiting","No Results Available","Treatment-resistant Depression","Device: Vercise GEVIA deep brain stimulation (DBS) system","Montgomery-Asberg Depression Rating Scale (MADRS) total score|Time to Montgomery-Asberg Depression Rating Scale (MADRS) augmentation of >5 points or clinical worsening in two consecutive visits after DBS termination|Assessment of (Serious) Adverse Events related to Investigational Medical Device and / or surgical procedures|Hamilton Depression Rating Scale (HDRS-28) total score|Clinical Global Impression Score (CGI) total score|Global Assessment of Functioning (GAF) total score|Beck Depression Inventory (BDI-II) total score|36-Item Short Form Health Survey (SF-36) total score|Change over time in HDRS total score after DBS surgery with DB stimulation OFF compared to stimulation ON|Change over time in CGI total score after DBS surgery with DB stimulation OFF compared to stimulation ON|Change over time in GAF total score after DBS surgery with DB stimulation OFF compared to stimulation ON|Change over time in BDI-II total score after DBS surgery with DB stimulation OFF compared to stimulation ON|Change over time in SF-36 total score after DBS surgery with DB stimulation OFF compared to stimulation ON|Neuropsychological Assessments: Rey Complex Figure Test (CFT)|Neuropsychological Assessments: d2 concentration test (d2)|Neuropsychological Assessments: 5-Point-Test|Neuropsychological Assessments: Wechsler Adult Intelligence Scale (WAIS) (vocabulary, similarities)|Neuropsychological Assessments: Mini-Mental-Status-Test (MMST)|Neuropsychological Assessments: Multiple-Choice Vocabulary Intelligence Test (MWT-B)|Neuropsychological Assessments: Rey Visual Design Learning Test (RVDLT)|Neuropsychological Assessments: Word Fluency Test|Neuropsychological Assessments: Stroop-Test|Neuropsychological Assessments: Test for Attentional Performance (TAP)|Neuropsychological Assessments: Trail-Making Test (TMT)|Neuropsychological Assessments: Verbal Memory and Learning Ability Test|Neuropsychological Assessments: Hopper Visual Organization Test (VOT)|Neuropsychological Assessments: Digit-Span and Block-Span Test|MADRS total score during long-term follow-up compared to baseline|HDRS total score during long-term follow-up compared to baseline|CGI total score|GAF total score|BDI-II total score|SF-36 total score|Incidence of relapse into clinical depression after tapering down of DBS|Pattern of metabolic activity as measured by FDG-PET at 1 week and 4 months after implantation compared to baseline","University Hospital Freiburg|Boston Scientific Corporation","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","47","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P000767|DRKS00014947|CIV-17-07-020746","September 3, 2018","June 2, 2022","June 2, 2023","August 31, 2018",,"November 2, 2020","University Hospital Freiburg, Freiburg, Baden-Württemberg, Germany|University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT03653858"
1664,"NCT00001969","Heart Disease Risk Factors in Major Depression",,"Completed","No Results Available","Adrenal Gland Hyperfunction|Cardiovascular Disease|Involutional Depression",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","21 Years to 55 Years   (Adult)",,"160","NIH","Observational",,"000049|00-M-0049","December 30, 1999",,"January 19, 2007","January 19, 2000",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001969"
1665,"NCT03268434","Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care",,"Completed","No Results Available","Unipolar Depression","Behavioral: D-MCT|Behavioral: Cognitive remediation","Quick Inventory of Depressive Symptomatology (QIDS)|Hamilton Depression Rating Scale|Self-assessed depression|Patient Health Questionnaire (PHQ-9)|Dysfunctional beliefs|Quality of life|Dysfunctional metacognitive beliefs|Rumination|Self-esteem|Remission rate|Information processing|Subjective appraisal of the training|Executive functioning|Verbal memory","Universitätsklinikum Hamburg-Eppendorf|Asklepios Kliniken Hamburg GmbH","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LJ05207","October 10, 2017","August 22, 2019","September 24, 2019","August 31, 2017",,"September 27, 2019","Asklepios Klinik Nord-Ochsenzoll, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03268434"
1666,"NCT03227133","Oral Fluency and the Response to Antidepressant Therapy in the Elderly With a Unipolar Depressive Episode","PREDICTage","Unknown status","No Results Available","Unipolar Depression","Other: Neuropsychological evaluations|Other: Psychiatric interview|Other: Cardiovascular risk assessment","Ability of the verbal fluency test score to predict the response to antidepressive treatment","Centre Hospitalier Universitaire de Besancon","All","60 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","P/2016/297","December 23, 2016","June 2019","June 23, 2019","July 24, 2017",,"July 24, 2017","Centre Hospitalier Universitaire de Besançon, Besançon, France",,"https://ClinicalTrials.gov/show/NCT03227133"
1667,"NCT00749125","fMRI Studies of Emotional Brain Circuitry in People With Major Depression",,"Completed","Has Results","Depression","Drug: Lexapro","Activations in Different Cortical Regions Caused by Emotionally Evocative Task","Washington University School of Medicine|National Institute of Mental Health (NIMH)","All","18 Years to 50 Years   (Adult)","Not Applicable","99","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","R01MH064821-04|R01MH064821|5R01 MH06482104|DATR A3-NSM","July 2001","January 2008","June 2008","September 9, 2008","July 17, 2018","July 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00749125"
1668,"NCT03386448","The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression",,"Completed","Has Results","Depression","Drug: Scopolamine and naltrexone|Drug: placebo arm","Response to Medications as Assessed by Change in Score on Modified MDRS Scale From Baseline to End of Study Period","The Taub Group","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","701","January 1, 2018","November 20, 2018","November 20, 2018","December 29, 2017","May 20, 2019","May 20, 2019","The Taub Group, Charlotte, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03386448/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03386448"
1669,"NCT02850341","Step Away From Depression - Evaluation of a Pedometer Intervention With Inpatients With Major Depression","SAD","Recruiting","No Results Available","Depression","Device: Pedometer","Change in average number of steps per day|Change in depressive symptoms - clinician rated|Change in physical activity - subjective|Change in physical activity - objective|Change in psychopathological symptoms|Change in health-related quality of life|Change in depressive symptoms|Change in anxiety symptoms|Change in self-efficacy for physical activity|Change in intention for physical activity|Change in self concordance of the motivation for physical activity|Change in outcome expectancies for physical activity|Change in planning and barrier planning for physical activity|Duration of inpatient treatment (Number of days)|Change in general self-efficacy","Charite University, Berlin, Germany|Robert-Enke-Stiftung","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SAD","July 2016","January 2020","December 2020","August 1, 2016",,"January 13, 2020","Paracelsus University Salzburg - Clinic for Psychiatry and Psychotherapy, Salzburg, Austria|Ludwig Maximilian University Munich - Clinic for Psychiatry and Psychotherapy, Munich, Bayern, Germany|Oberhavel Clinics GmbH - Clinic for Psychiatry, Psychosomatics and Psychotherapy, Hennigsdorf, Brandenburg, Germany|Health Center Odenwaldkreis GmbH - Center for Mental Health, Erbach, Hessen, Germany|University of Frankfurt/Main - Clinic for Psychiatry, Psychosomatic and Psychotherapy, Frankfurt am Main, Hessen, Germany|University of Göttingen - Clinic for Psychiatry and Psychotherapy, Göttingen, Niedersachsen, Germany|University RWTH Aachen, Clinic for Psychiatriy, Psychotherapy and Psychosomatic, Aachen, Nordrhein-Westfalen, Germany|Ev.Luth. Diakonissenanstalt Flensburg - Clinic for Psychiatry, Psychosomatic and Psychotherapy, Flensburg, Schleswig-Holstein, Germany|Charité Universitätsmedizin Berlin - Departement of Psychiatry, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02850341"
1670,"NCT01192685","Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring",,"Terminated","No Results Available","Depression","Procedure: Transcranial Magnetic Stimulation (TMS)|Device: near infrared spectroscopy (NIRS)","The correlations between EEG cordance or task-induced changes in frontal total Hb levels|Changes in MADRAS scores between baseline and the last treatment day","Boston University|Boston Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","H-29098","December 2012","December 2013","December 2013","September 1, 2010",,"April 20, 2017","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01192685"
1671,"NCT02771535","Long-term Efficacy of Metacognitive Training for Depression (D-MCT)",,"Completed","No Results Available","Unipolar Depression","Behavioral: D-MCT|Behavioral: Health Training","Hamilton Depression Rating Scale|Self-assessed depression|Dysfunctional beliefs|Dysfunctional metacognitive beliefs|Quality of life|Work status|Self-esteem|Remission rate","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1027/106","March 2016","May 2017","May 2017","May 13, 2016",,"August 3, 2017","University Medical Center Hamburg Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02771535"
1672,"NCT02750631","Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression","WakeTherapy","Completed","No Results Available","Unipolar Depression","Other: Triple Therapy","17-item Hamilton Rating Scale for Depression","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6938","April 2014","July 2017","July 2017","April 25, 2016",,"August 29, 2017","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02750631"
1673,"NCT02710279","Response to Social Rejection in Suicidal Behavior","SADS-CS","Unknown status","No Results Available","Unipolar Depression","Behavioral: Trier Social Stress Test (TSST)|Device: smartphone","Psychological pain response to Trier Social Stress Test (TSST) assessed by visual analogic sale|Inflammatory response to TTST|Impact of loneliness and childhood abuse on inflammatory markers|impact of neuropschychological function on psychological pain|Social rejection assessed by likert scale in real life condition with a smartphone","University Hospital, Montpellier","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","9615|2015-A01308-41","February 2016","February 2017","February 2017","March 16, 2016",,"March 23, 2016","University Hospital of Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02710279"
1674,"NCT01973478","Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression","STHYM","Completed","No Results Available","Major Depressive Disorder|Recurrent Depressive Disorder|Bipolar Disorder","Device: DBS|Device: SHAM","Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no)|Remission (yes/no)|CGI (Clinical global impressions) amelioration (yes/no)|GAF (Global assessment of functioning)|HDRS-17 (Hamilton depression rating scale, 17 items version)|MADRS (Montgomery-Asberg Depression Rating Scale)|BDI (Beck Depression Inventory)|CGI (Clinical global impressions)|LARS (Lille Apathy Rating scale)|Neuropsychological assessment|Cerebral metabolism (PET scans)|Adverse events","Rennes University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","35RC08_8902","June 3, 2014","July 3, 2017","November 27, 2018","October 31, 2013",,"December 27, 2019","APHM, Marseille, France|APHP Pitié Salpetriere, Paris, France|CHS, Poitiers, France|CHS, Rouen, France|CHU, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01973478"
1675,"NCT01611818","Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression",,"Completed","No Results Available","Depression","Other: Low Intensity Internet-delivered psychotherapy|Other: Self-guided Internet delivered psychotherapy|Other: Improved treatment as usual","Severity of depressive symptomatology measured by Beck Depression Inventory II|Socio-demographic variables.|Mini-International Neuropsychiatric Interview (MINI).|EuroQoL-5D questionnaire (EQ-5D - Spanish version)|Client Service Receipt Inventory - adapted (CSRI - Spanish version)|Overall Depression Severity and Impairment Scale|Positive and Negative Affect Scale (PANAS)|Credibility/expectancy questionnaire","Javier Garcia Campayo|Carlos III Health Institute|Hospital Miguel Servet","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PI10/01083","September 2012","December 2014","December 2016","June 5, 2012",,"August 10, 2017","Hospital Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain|Health Science Research Institute, University Balearic Islands, Palma de Mallorca, Mallorca, Spain|Psychiatric Service. Hospital Vall D'Hebrón, Barcelona, Spain|Psychiatric Service. University Hospital Carlos Haya, Málaga, Spain|Valencia University and CIBER Physiopathology of Obesity and Nutrition. Carlos III Health Institute, Valencia, Spain|Department of Psychiatry. Miguel Servet University Hospital, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01611818"
1676,"NCT02401139","Ketamine Trial for the Treatment of Depression",,"Unknown status","No Results Available","Unipolar Depression","Drug: Ketamine|Drug: Placebo","Montgomery Asberg Depression Rating Scale for Depression (MADRS)","The University of New South Wales|University of Sydney","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HREC 15009","March 2015","July 2015","September 2015","March 27, 2015",,"March 27, 2015","Brain & Mind Research Institute (BMRI), University of Sydney, Camperdown, New South Wales, Australia|Black Dog Institute, University of New South Wales, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT02401139"
1677,"NCT04052451","The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder",,"Completed","No Results Available","Depression, Anxiety","Biological: MET-2","Montgomery-Asberg Depression Rating Scale (MADRS)|Generalized Anxiety Disorder - 7 (GAD-7)","NuBiyota","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MET-2-301","May 16, 2019","May 1, 2020","May 1, 2020","August 9, 2019",,"August 11, 2020","Providence Care Hospital, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04052451"
1678,"NCT01460758","Effectiveness of rTMS With Double-Cone-Coil in Patients With Major Depression","ACDC","Completed","No Results Available","Depression","Device: Medial Frontal rTMS Double-Cone-Coil|Device: Left DLPFC Butterfly Coil|Device: Placebo Stimulation","Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)|Change in the Alertness (Baseline versus end of treatment/ day 19)|Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus end of treatment/ day 19)|Change in the Beck Depression Inventory (Baseline versus end of treatment/ day 19)|Change in the Clinical Global Impression Scale (Baseline versus end of treatment/ day 19)|Change in the Global Assessment of Functioning scale (Baseline versus end of treatment/ day 19)|Change in the Alertness (Baseline versus follow-up I/ day 47)|Change in the Alertness (Baseline versus follow-up II/ day 75)|Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus follow-up I/ day 47)|Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus follow-up II/ day 75)|Change in the Beck Depression Inventory (Baseline versus follow-up I/ day 47)|Change in the Beck Depression Inventory (Baseline versus follow-up II/ day 75)|Change in the Clinical Global Impression Scale (Baseline versus follow-up I/ day 47)|Change in the Clinical Global Impression Scale (Baseline versus follow-up II/ day 75)|Change in the Global Assessment of Functioning scale (Baseline versus follow-up I/ day 47)|Change in the Global Assessment of Functioning scale (Baseline versus follow-up II/ day 75)","University of Regensburg","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Uni-Reg-ACDC01","April 2011","September 2013","November 2013","October 27, 2011",,"April 28, 2014","University of Regensburg- Dept of Psychiatry, Regensburg, Germany",,"https://ClinicalTrials.gov/show/NCT01460758"
1679,"NCT01284751","The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients",,"Completed","No Results Available","Depression|Depressive Symptoms","Other: MDI - self-rating inventory","Depressive symptoms","Herlev Hospital","Female","30 Years to 70 Years   (Adult, Older Adult)",,"21","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","MVH-04|H-1-2010-FSP","January 2011","March 2011","March 2011","January 27, 2011",,"May 12, 2011","Herlev Hospital, Herlev, Denmark",,"https://ClinicalTrials.gov/show/NCT01284751"
1680,"NCT02777112","The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression in Canadian Working Men",,"Completed","No Results Available","Depression|Men","Other: e-mental health program|Other: e-mental health program and job coaching|Other: No intervention","Risk proportion of major depressive episode (MDE) over 12 months|Change in depression score|Change in presenteeism|Change in absenteeism|Return on investment|Change in anxiety score","University of Calgary|Movember Foundation","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","1133","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","#UCAL_01","September 2016","October 2018","December 2018","May 19, 2016",,"May 17, 2019","Mathison Centre for Mental Health Research and Education, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02777112"
1681,"NCT02111915","Thinking Healthy Program - Peer Delivered (Pakistan)","THPP-P","Completed","No Results Available","Unipolar Depression","Behavioral: THPP-P|Other: EUC","Remission (i.e. recovery from depression)|Maternal disability|Maternal support|Breastfeeding rates|Infant height","University of Liverpool|National Institute of Mental Health (NIMH)|London School of Hygiene and Tropical Medicine","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","560","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","THPP-P MH095687|1U19MH095687-01","October 2014","January 2017","February 2017","April 11, 2014",,"December 24, 2019","Human Development Research Foundation, Islamabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT02111915"
1682,"NCT02104232","Thinking Healthy Program - Peer Delivered, India (THPP-I)","THPP-I","Completed","No Results Available","Unipolar Depression","Behavioral: THPP-I|Behavioral: EUC","Remission (i.e. recovery from depression) and depressive symptoms, assessed by the PHQ-9|Depressive symptoms and remission (PHQ-9)|Maternal disability (measured with the WHO-DAS)|Breastfeeding rates of women|Infant weight|Infant height|Perceived social support (measured with MSPSS)","London School of Hygiene and Tropical Medicine|National Institute of Mental Health (NIMH)|University of Liverpool","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","280","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","THPP-I MH095687|1U19MH095687-01","October 2014","May 2017","May 2017","April 4, 2014",,"August 25, 2017","Sangath, Goa, India",,"https://ClinicalTrials.gov/show/NCT02104232"
1683,"NCT00655057","Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression",,"Completed","Has Results","Depression","Drug: S-citalopram|Behavioral: Cognitive behavioral therapy (CBT)|Procedure: TRODAT-1 single photon emission computed tomographic (SPECT) imaging","Change in Dopamine Transporter Binding","University of Pennsylvania|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","R34MH070753|DATR A3-NSS","October 2005","August 2009","December 2009","April 9, 2008","April 16, 2020","April 16, 2020","Depression Research Unit - University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00655057"
1684,"NCT00782405","Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine",,"Completed","No Results Available","Sleep","Drug: quetiapine|Drug: mirtazapine","sleep effiency","Technische Universität München","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D114432C00027","October 2008","April 2011",,"October 31, 2008",,"April 19, 2011","Sleep Disorders Center, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT00782405"
1685,"NCT02981225","Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.",,"Completed","No Results Available","Mild to Moderate Depression","Dietary Supplement: Phytostandard® Rhodiola-Saffron","Evolution of HAM-D scale|Evolution of HAD patient scale|Evolution of CGI|Evolution of PGI","PiLeJe","All","18 Years to 85 Years   (Adult, Older Adult)",,"59","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PiL-Obs-RSDep-015","November 8, 2016","May 30, 2017","May 31, 2017","December 5, 2016",,"July 17, 2018","Pileje, Paris, France",,"https://ClinicalTrials.gov/show/NCT02981225"
1686,"NCT02278224","Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression","RuCoD","Completed","No Results Available","Depression|Recurrent Depression","Behavioral: Group based rumination focused CBT|Behavioral: Group based CBT","Hamilton Depression Rating Scale 17","University of Copenhagen|University of Exeter|The University of Western Australia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","131","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RuCoD-CPH|RuCoD-UoC","November 2013","February 2016","February 2016","October 29, 2014",,"February 25, 2016","Psychiatric Outpatient Service, Hilleroed, Denmark",,"https://ClinicalTrials.gov/show/NCT02278224"
1687,"NCT00760097","Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression","aTDCS","Completed","No Results Available","Depression","Device: Transcranial direct stimulation","To test our hypotheses, assessments of cognition, mood, and brain activity will be performed on three occasions|ADVERSE EVENT REPORTS Subjects will be asked about adverse events at the end of each treatment session","University of California, Los Angeles","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","aTDCS in MDD","September 2007","May 2009","May 2009","September 25, 2008",,"February 6, 2013","UCLA Semel Institute for Neuroscience, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00760097"
1688,"NCT01151982","Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial","predictD-CCRT","Completed","No Results Available","Depression","Behavioral: Psychosocial Intervention","Accumulated incidence of major depression|Cost-effectiveness and cost-utility","The Mediterranean Institute for the Advance of Biotechnology and Health Research|Preventive Services and Health Promotion Research Network|Carlos III Health Institute|Andaluz Health Service","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","3326","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","PS09/00081","October 2010","July 2012","January 2013","June 29, 2010",,"November 19, 2014","Servicio Andaluz de Salud. Distrito Sanitario Málaga, Málaga, Spain|Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT01151982"
1689,"NCT01694030","Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study",,"Unknown status","No Results Available","Unipolar Depression","Other: Attachment security priming","Depressed Mood 1|Felt Security 1|Depressed Mood 2|Depressed Mood 3|Felt Security 2|Felt Security 3","University of Southampton","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","University of Southampton: LO6","November 2012","December 2014","December 2014","September 26, 2012",,"September 26, 2012","College Keep, Southampton, Hants, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01694030"
1690,"NCT01240083","Effectiveness of Theta-burst Stimulation (TBS) in Patients With Major Depression",,"Completed","No Results Available","Depression","Device: Thetaburst Stimulation|Device: High frequency rTMS|Device: Placebo Stimulation","Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (Baseline versus end of treatment/ day 19)|Change in the Beck Depression Inventar, the Clinical Global Impression Scale, the Global Assessment of Functioning scale, the Alertness (Baseline versus end of treatment/ day 19, follow-up I/ day 47, follow-up II/ day 75)|Number of responders (response = decrease of the Hamilton Depression rating scale for at least 50%) (Baseline versus end of treatment/ day 19, follow-up I/ day 47, follow-up II/ day 75)","University of Regensburg","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Uni-Reg-TB1","April 2010","September 2011","October 2011","November 15, 2010",,"October 16, 2013","University of Regensburg- Dept of Psychiatry, Regensburg, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT01240083"
1691,"NCT01544205","Neurofeedback as a Treatment Tool for Depression","NFD","Completed","No Results Available","Unipolar Depression","Other: fMRI-based neurofeedback","Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at the end of intervention (after 5th session)|Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at follow-up|Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at the end of intervention (after 5th session)|Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at follow-up|Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at the end of intervention (after 5th session)|Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at follow-up|Change from Baseline in the Quality of Life Scale (QOLS) at the end of intervention (after 5th session)|Change from Baseline in the Quality of Life Scale (QOLS) at follow-up|Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at the end of intervention (after 5th session)|Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at follow-up","Cardiff University|Medical Research Council|National Institute for Social Care and Health Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SPON927-11|G 1100629|HS/10/25|11/WA/0106","March 2012","September 2014","September 2014","March 5, 2012",,"December 15, 2016","CUBRIC, Cardiff, Wales, United Kingdom|School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01544205"
1692,"NCT00601055","Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease",,"Completed","No Results Available","Pulmonary Disease, Chronic Obstructive|Depression","Behavioral: Problem Solving-Rx Adherence (PSA)|Behavioral: PID-C","Depressive symptoms","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","50 Years to 95 Years   (Adult, Older Adult)","Not Applicable","101","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH076829|0511008253","February 2008","August 2015","August 2015","January 25, 2008",,"July 15, 2016","The Burke Rehabilitation Hospital, White Plains, New York, United States|Weill Medical College of Cornell University, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT00601055"
1693,"NCT04013464","Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Escitalopram","Clinical efficacy of MDD in the treatment of escitalopram|Sleep ratio of EEG power changes in MDD after 8 weeks treatment by escitalopram|The levels changes of plasma melatonin after 8 weeks treatment by escitalopram","Peking University Sixth Hospital|National Institute on Drug Dependence, China","Male","22 Years to 40 Years   (Adult)","Not Applicable","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-4-2113","May 1, 2016","May 31, 2018","December 30, 2018","July 9, 2019",,"July 9, 2019",,,"https://ClinicalTrials.gov/show/NCT04013464"
1694,"NCT00177528","Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression",,"Completed","No Results Available","Depression","Drug: venlafaxine-XR","The safety and tolerability of venlafaxine XR.|Rate of Major Depression remission to treatment.|Participant characteristics that influence safety and remission rate.","University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)","Phase 4","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","000918","October 2000","November 2004",,"September 15, 2005",,"October 9, 2008","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00177528"
1695,"NCT01464463","The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major Depression",,"Completed","No Results Available","Depression","Behavioral: CBT - active|Behavioral: CBT - euthymic|Behavioral: CBASP","Changes in severity of depressive symptoms from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up|Changes in immunological measures from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up|Changes in psychopathological variables from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up|Changes in perceived stress from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up|Changes in self-rated physical activity from baseline (beginning of therapy) to 4 weeks after baseline, to 8 weeks after baseline, to 16 weeks after baseline (end of therapy) to 6-month-follow up|Changes from baseline to 16 weeks after baseline (end of therapy)","Philipps University Marburg Medical Center|Universität Duisburg-Essen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFG RI 574/23-1","August 2011","April 2016",,"November 3, 2011",,"June 10, 2016","Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Marburg, Germany",,"https://ClinicalTrials.gov/show/NCT01464463"
1696,"NCT00610506","Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features",,"Completed","No Results Available","Atypical Depression","Drug: Escitalopram","changes in HAM-D-29 scores from baseline to end of treatment.|changes in 8-atypical items on the HAM-D-29, SDS and ESQ from baseline to end of treatment. Response will be defined as 50% or greater reduction in HAM-D-29 scores from baseline to end of treatment.","Duke University|Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","7842|IRB#7842","October 2005","May 2007","May 2007","February 8, 2008",,"May 31, 2013","Dept Psychiatry, Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00610506"
1697,"NCT04963907","Alpha-Stim AID and Major Depressive Disorder",,"Recruiting","No Results Available","Depressive Disorder, Major","Device: Active Alpha-Stim CES|Device: Sham Alpha-Stim CES","Change in depression|Cost effectiveness|Change in anxiety|Change in quality of life - work and social functioning|Change in quality of life - health related","Electromedical Products International, Inc.|University of Nottingham","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","230","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UK-MDDNHS","January 5, 2021","March 31, 2022","December 31, 2022","July 15, 2021",,"July 15, 2021","University of Nottingham, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04963907"
1698,"NCT04760652","Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","ENDURE","Recruiting","No Results Available","Depression and Suicide","Behavioral: Cognitive Behavioral Therapy CBT","To determine the feasibility of performing a larger study with similar design by measuring of recruitment rates.|To determine the feasibility of performing a larger study with similar design by measuring attrition.|Reasons for discontinuation|To determine the safety of performing a larger study with similar design.|Evaluate the appropriateness of the proposed tests of cognitive control measures in exploring the mechanisms of change.|Efficacy of esketamine/CBT combination compared to esketamine/TAU in reducing the risk of suicide.","Yale University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2000029473|1265736169","March 5, 2021","August 31, 2024","August 31, 2024","February 18, 2021",,"March 12, 2021","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04760652"
1699,"NCT01012856","Randomized Clinical Trial of an Exposure-based Cognitive Therapy for Depression",,"Unknown status","No Results Available","Unipolar Depression","Behavioral: Cognitive-Behavioral Therapy for Depression|Behavioral: Exposure-Based Cognitive Therapy for Depression","severity of depressive symptoms measured by the Beck-Depression-Inventory (BDI-II)|symptom impairment measured by the Brief Symptom Inventory (BSI)|quality of life measured by the WHO Quality of Life-BREF (WHOQOL-BREF)|interpersonal problems measured by the Inventory of Interpersonal Problems (IIP)|avoidance measured by the Cognitive-Behavioral Avoidance Scales (CBAS)|resources measured by the Bernese Inventory of Resources (RES-K)|explicit self-esteem measured by the Rosenberg self-esteem scale (RSES)|implicit self-esteem measured by the Self-Esteem Implicit Association Test (SE-IAT)|goal attainment measured by Goal Attainment Scaling (GAS)|avoidance motivation measured by the Inventory of Approach and Avoidance Motivation (IAAM)|motivational incongruence measured by The Incongruence Questionnaire (INC)","University of Zurich","All","18 Years and older   (Adult, Older Adult)","Phase 2","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PP00P1_ 123377","January 2010","December 2013","March 2014","November 13, 2009",,"October 31, 2012","University of Zurich, Department of Psychology, Zurich, ZH, Switzerland",,"https://ClinicalTrials.gov/show/NCT01012856"
1700,"NCT01447602","A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior","IPT-A-CSP","Completed","No Results Available","Unipolar Depression|Dysthymia","Behavioral: IPT-A","Score on Columbia Suicide Severity Rating Scale (C-SSRS)|Change in score on Children's Depression Rating Scale (CDRS)","New York State Psychiatric Institute","All","12 Years to 19 Years   (Child, Adult)","Phase 3","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6238","September 2011","June 2014","June 2014","October 6, 2011",,"September 4, 2014","New York Presbyterian Hospital, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01447602"
1701,"NCT01683214","Brain Network Activation Analysis to Diagnose/Assess Treatment of Unipolar Major Depression and Bipolar I Depression","BNA-Mood","Terminated","No Results Available","Depression",,"Correlation of changes in BNA with changes in mood symptoms","Rush University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","11122902","August 2012","August 21, 2015","August 21, 2015","September 11, 2012",,"November 24, 2020",,,"https://ClinicalTrials.gov/show/NCT01683214"
1702,"NCT00964054","Depression Outcomes Study of Exercise","DOSE","Completed","No Results Available","Unipolar Depression","Other: Public Health Dose of Exercise (PHD)|Other: Low Dose Exercise (LD)","Child Depression Rating Scale-Revised (CDRS-R)|Beck Depression Inventory (BDI)|The Multidimensional Anxiety Scale for Children (MASC)|Adolescent Stress Questionnaire (ASQ)","National Institute of Mental Health (NIMH)","All","12 Years to 21 Years   (Child, Adult)","Phase 1","9","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R34MH082153|MH082153|DSIR 84-CTS","September 2012","January 2013","February 2013","August 24, 2009",,"March 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00964054"
1703,"NCT01361555","Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression",,"Terminated","No Results Available","Depression","Drug: Placebo matching with BMS-820836|Drug: BMS-820836","Long-term effects of BMS-820836 on blood pressure in patients with depression|• Adverse Events (AEs), Serious Adverse Events, and Discontinuations Due to AEs","Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","789","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN162-010|2010-024371-12","August 2011","October 2013","October 2013","May 27, 2011",,"October 12, 2015","Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham, Alabama, United States|K & S Professional Research Services, Llc, Little Rock, Arkansas, United States|Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|Pacific Clinical Research Medical Group, Arcadia, California, United States|Catalina Research Institute, Llc, Chino, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Behavioral Research Specialists, Llc, Glendale, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Neuropsychiatric Research Center Of Orange County, Orange, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|Anderson Clinical Research, Redlands, California, United States|California Neuropsychopharmacology Clinical, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|Artemis Institute For Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Radiant Research, Inc., Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Amit Vijapura, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Comprehensive Clinical Development, Inc., Saint Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Janus Center For Psychiatric Research, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Institute Of Medicine & Research, Atlanta, Georgia, United States|Comprehensive Clinical Development, Inc, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|Alpine Clinic, Lafayette, Indiana, United States|Clinco, Terre Haute, Indiana, United States|Clinical Trials Technology, Inc, Prairie Village, Kansas, United States|James G. Barbee, Md, Llc, New Orleans, Louisiana, United States|J. Gary Booker, Md, Apmc, Shreveport, Louisiana, United States|Mclean Hospital, Belmont, Massachusetts, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Spri Clinical Trials, Llc, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Comprehensive Clinical Development, Inc, Jamaica, New York, United States|Village Clinical Research, Inc., New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Richard H. Weisler, Md, Pa & Assoc., Raleigh, North Carolina, United States|Northcoast Clinical Trials, Inc, Beachwood, Ohio, United States|Patient Priority Clinical Sites, Llc, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neurology & Neuroscience Center Of Ohio, Toledo, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Oregon Center For Clinical Investigations, Inc. (Occi, Inc), Portland, Oregon, United States|Summit Research Network (Oregon) Inc, Portland, Oregon, United States|Oregon Center For Clinical Investigations, Inc (Occi, Inc), Salem, Oregon, United States|Lehigh Center For Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, Llc, Norristown, Pennsylvania, United States|Univ Of Penn, Philadelphia, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Comprehensive Psychiatric Care, Pittsburgh, Pennsylvania, United States|Bioscience Research, Llc, Pittsburgh, Pennsylvania, United States|Insite Clinical Research, Pittsburgh, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|Psychiatric Consultants, Pc, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Futuresearch Trials, Austin, Texas, United States|Community Clinical Research, Inc., Austin, Texas, United States|Futuresearch Trials Of Dallas, Dallas, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Ut Health-Houston, Houston, Texas, United States|Red Oak Psychiatry Associates, Pa, Houston, Texas, United States|San Antonio Psychiatric Research Center, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Ericksen Research And Development, Clinton, Utah, United States|Radiant Research, Inc., Murray, Utah, United States|Psychiatric And Behavioral Solutions, Salt Lake City, Utah, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) Llc, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Independent Psychiatric Consultants, Sc, Dba, Ipc Research, Waukesha, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Mendoza, Argentina|Local Institution, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Helsinki, Finland|Local Institution, Helsinki, Finland|Local Institution, Jarvenpaa, Finland|Local Institution, Oulu, Finland|Local Institution, Seinajoki, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Dole, France|Local Institution, Douai, France|Local Institution, Elancourt, France|Local Institution, Jonzac, France|Local Institution, Limoges Cedex, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Paris, France|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Chennai, India|Local Institution, Pune, India|Local Institution, Varanasi, India|Local Institution, Vishakapattanam, India|Local Institution, Pisa, Italy|Local Institution, Siena, Italy|Local Institution, Ponce, Puerto Rico|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Arganda Del Rey, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Halmstad, Sweden|Local Institution, Kungens Kurva, Sweden|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01361555"
1704,"NCT01932931","Vitamin D, SSRIs and the Musculoskeletal System",,"Completed","No Results Available","Major Depression|Osteoporosis","Dietary Supplement: cholecalciferol (50ug)","Vitamin D|Bone Mineral Density (DXA)|muscle function|pain sensitivity|Quality of life|Degree of depression","Aalborg University|Aalborg University Hospital","Female","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","N-20130052","October 1, 2013","February 28, 2015","September 1, 2016","August 30, 2013",,"January 11, 2018","Aalborg University, Aalborg, North Jutland, Denmark|CCBR, Aalborg, North Jutland, Denmark",,"https://ClinicalTrials.gov/show/NCT01932931"
1705,"NCT01309945","Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression",,"Completed","No Results Available","Depression","Drug: Duloxetine|Drug: Placebo matching with BMS-820836|Drug: BMS-820836|Drug: Placebo matching with Duloxetine","Change in Montgomery Asberg Depression Rating Scale (MADRS) total score|Change in Sheehan Disability Scale (SDS) Total score|Change in the Montgomery Asberg Depression Rating Scale (MADRS) anhedonia factor score","Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","889","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN162-006|2010-022841-93","April 2011","January 2013","January 2013","March 7, 2011",,"October 12, 2015","K & S Professional Research Services, Llc, Little Rock, Arkansas, United States|Pacific Clinical Research Medical Group, Arcadia, California, United States|Pharmacology Research Institute, Encino, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|California Neuropsychopharmacology Clinical Research Inst., San Diego, California, United States|Pacific Research Network, Inc, San Diego, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Comprehensive Clinical Development, Inc., St Petersburg, Florida, United States|Atlanta Institute Of Medicine & Research, Atlanta, Georgia, United States|Comprehensive Clinical Development, Inc., Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Loyola University Health System, Maywood, Illinois, United States|Alpine Clinic, Lafayette, Indiana, United States|Clinical Trials Technology, Inc, Prairie Village, Kansas, United States|James G. Barbee, Md, Llc, New Orleans, Louisiana, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richard H. Weisler, Md, Pa & Assoc., Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Oregon Center For Clinical Investigations, Inc. (Occi, Inc), Portland, Oregon, United States|Summit Research Network (Oregon) Inc, Portland, Oregon, United States|Oregon Center For Clinical Investigations, Inc (Occi, Inc), Salem, Oregon, United States|Lehigh Center For Clinical Research, Allentown, Pennsylvania, United States|Univ Of Penn, Philadelphia, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Belmont Center For Comprehensive Treatment, Philadelphia, Pennsylvania, United States|University Of Pennsylvania, Philadephia, Pennsylvania, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|University Of South Carolina School Of Medicine, Columbia, South Carolina, United States|Psychiatric Consultants, Pc, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Community Clinical Research, Inc., Austin, Texas, United States|Uthealth - Houston, Houston, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|San Antonio Psychiatric Research Center, San Antonio, Texas, United States|Radiant Research, Inc., Murray, Utah, United States|Psychiatric And Behavioral Solutions, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) Llc, Seattle, Washington, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Independent Psychiatric Consultants, Sc, Dba, Ipc Research, Waukesha, Wisconsin, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Helsinki, Finland|Local Institution, Jarvenpaa, Finland|Local Institution, Oulu, Finland|Local Institution, Seinajoki, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Dole, France|Local Institution, Douai, France|Local Institution, Elancourt, France|Local Institution, Limoges Cedex, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Nimes, France|Local Institution, Paris, France|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Vereeniging, Gauteng, South Africa|Local Institution, Bellville, Western Cape, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Somerset West, Western Cape, South Africa|Local Institution, Halmstad, Sweden|Local Institution, Kungens Kurva, Sweden|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01309945"
1706,"NCT02522377","Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression",,"Completed","Has Results","Treatment Resistant Depression|Major Depressive Disorder|Severe Depression","Drug: Ketamine|Drug: Midazolam","Hamilton Depression Rating Scale (HAMD-17) at Last Infusion|Montgomery Asberg Depression Rating Scale (MADRS) at Last Infusion|Montreal Cognitive Assessment (MOCA) at Last Infusion|Hopkins Verbal Learning Test - Revised (HVLT-R) at Last Infusion|Controlled Oral Word Association Test (COWAT) at Last Infusion|Responder Rate on HAMD-17 by Last Infusion","The Cleveland Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ketamine ECT","August 2015","March 1, 2018","March 1, 2018","August 13, 2015","August 29, 2019","August 29, 2019","Cleveland Clinic Foundation Center for Behavioral Health, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02522377/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02522377"
1707,"NCT01369095","Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression",,"Completed","No Results Available","Depression","Drug: Duloxetine|Drug: Escitalopram|Drug: BMS-820836 Placebo|Drug: BMS-820836","Change from baseline to endpoint in the Montgomery Asberg Depression Rating Scale (MADRS) total score|Change from baseline to endpoint in mean Sheehan Disability Scale (SDS) score.","Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","976","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN162-007|2011-000778-71","July 2011","May 2013","May 2013","June 8, 2011",,"October 12, 2015","Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham, Alabama, United States|Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock, Arkansas, United States|Catalina Research Institute, Llc, Chino, California, United States|Behavioral Research Specialists, Llc, Glendale, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|Anderson Clinical Research, Redlands, California, United States|Affiliated Research Institute, San Diego, California, United States|Artemis Institute For Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Amit Vijapura, Jacksonville, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Janus Center For Psychiatric Research, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Uptown Research Institute, Llc, Chicago, Illinois, United States|Clinco, Terre Haute, Indiana, United States|Clinical Trials Technology, Inc, Prairie Village, Kansas, United States|Ert, Shreveport, Louisiana, United States|Mclean Hospital, Belmont, Massachusetts, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Comprehensive Clinical Development, Inc, Fresh Meadows, New York, United States|Bioscience Research, Llc, Mount Kisco, New York, United States|Village Clinical Research, Inc., New York, New York, United States|Northcoast Clinical Trials, Inc, Beachwood, Ohio, United States|Patient Priority Clinical Sites, Llc, Cincinnati, Ohio, United States|Neurology & Neuroscience Center Of Ohio, Toledo, Ohio, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, Llc, Norristown, Pennsylvania, United States|Ert, Pittsburgh, Pennsylvania, United States|Neuropsychiatric Research Center Of Orange County, Pittsburgh, Pennsylvania, United States|Northwest Clinical Research Center, Pittsburgh, Pennsylvania, United States|Lincoln Research, Lincoln, Rhode Island, United States|Future Search Trials, Austin, Texas, United States|Futuresearch Trials Of Dallas, Dallas, Texas, United States|Insite Clinical Research, Desoto, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Ericksen Research And Development, Clinton, Utah, United States|Clinical Methods Llc, Murray, Utah, United States|Neuropsychiatric Associates, Woodstock, Vermont, United States|Neuroscience, Inc, Herndon, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Summit Research Network (Seattle) Llc, Seattle, Washington, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Mendoza, Argentina|Local Institution, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Dole, France|Local Institution, Douai, France|Local Institution, Elancourt, France|Local Institution, Jonzac Cedex, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Tirupati, Andhra Pradesh, India|Local Institution, Visakhapatnam, Andhra Pradesh, India|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Lucknow, Uttar Pradesh, India|Local Institution, Chennai, India|Local Institution, Pune, India|Local Institution, Varanasi, India|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Ponce, Puerto Rico|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Edgware, Middlesex, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01369095"
1708,"NCT01282632","Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression",,"Completed","No Results Available","Subjects Had Unipolar, Non-psychotic Major Depression","Drug: Risperidone|Drug: Olanzapine","Change from Baseline in Hamilton Depression Rating Scale at 1 week|Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 1 week|Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 1 week|Change from Baseline in Hamilton Depression Rating Scale at 2 weeks|Change from Baseline in Hamilton Depression Rating Scale at 3 weeks|Change from Baseline in Hamilton Depression Rating Scale at 4 weeks|Change from Baseline in Hamilton Depression Rating Scale at 5 weeks|Change from Baseline in Hamilton Depression Rating Scale at 6 weeks|Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 2 weeks|Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 3 weeks|Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 4 weeks|Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 5 weeks|Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 6 weeks|Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 2 weeks|Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 3 weeks|Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 4 weeks|Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 5 weeks|Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 6 weeks|Clinical Global Improvement Scale - Improvement|Change from Baseline of Weight at 6 weeks","Sunnybrook Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ro123","August 2002","March 2004","March 2004","January 25, 2011",,"January 25, 2011","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01282632"
1709,"NCT00624858","A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression",,"Completed","No Results Available","Depression","Drug: naltrexone SR 32 mg/ bupropion SR 360 mg daily","To assess the change in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total score at 12 weeks|To assess the percentage change from baseline in total body weight at 12 and 24 weeks.","Orexigen Therapeutics, Inc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NB-402","January 2008","July 2009","July 2009","February 27, 2008",,"October 30, 2012","Lindner Center of HOPE, Mason, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00624858"
1710,"NCT00179244","Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression",,"Completed","No Results Available","Unipolar Depression","Drug: Rispridone (drug) and Bupropion ER (drug)","MADRS (Montgomery Asberg's Depression Rating Scale)|HAM-D(Hamilton Rating Scale for Depression ) 17-item|BDI (Beck Depression Inventory)|HAM-A (Hamilton Rating Scale for Anxiety)|Clinical Global Impression Scale and Severity and Improvement.","Vanderbilt University|Janssen Pharmaceutica","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","RIS vs. BUP Augmentation Depr.|040309","July 2004",,"April 2005","September 15, 2005",,"June 2, 2015","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00179244"
1711,"NCT00178100","Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression",,"Completed","No Results Available","Unipolar Depression","Behavioral: Interpersonal Psychotherapy|Drug: paroxetine","Combined treatment with paroxetine and interpersonal psychotherapy will be superior to either treatment alone (and to placebo)in preventing recurrence of major depressive episodes in patients aged 70 and above.|Cognitive status: Folstein Mini-Mental Status Exam, MATTIS Dementia Rating Scale, EXIT, and CDR|Quality of Life measures: Quality of Wellbeing Scale, CIDI Health Services Utilization, Older American Resources and Services Activities of Daily Living Scale, Global Assessment Scale, PSQI, SF-36, UKU, and CIRS-G|Social Support: Interpersonal Support Evaluation List, Luben Social Network Scale; and Life Events and Difficulties Schedule|Psychiatric status: SCID, Hamilton Depression Rating Scale, Suicidal History Questionnaire, Antidepressant Treatment History Form, Brief Psychiatric Rating Scale, and anxiety subscale of Brief Symptom Inventory|MRI","University of Pittsburgh","All","69 Years and older   (Older Adult)","Phase 4","225","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","R01MH043832-02|971156|DATR A4-GPS","March 1999",,"August 2005","September 15, 2005",,"August 2, 2013","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00178100"
1712,"NCT00178074","The Effects of Sleep Deprivation on Antidepressant Response",,"Completed","No Results Available","Unipolar Depression","Behavioral: total sleep deprivation|Procedure: PET imaging","To gain an understanding of the neurochemical processes that may lead to development of pharmacologic strategies that would accelerate antidepressant response or more directly to the development of antidepressant treatments.|PET study|Regional glucose metabolic rates and regional [18F]-altanserin binding|MRI scan|Beck Depression Inventory|Profile of Mood States|Serum anticholinergicity and paroxetine blood levels|SCID|Hamilton Depression Rating Scale|Folstein Mini-Mental State Exam","University of Pittsburgh","All","55 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R01MH037869-03|980753|DATR A4-GPS","February 1999",,"April 2003","September 15, 2005",,"August 2, 2013","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00178074"
1713,"NCT00556140","The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression","Abilify","Completed","Has Results","Psychotic Depression","Drug: Aripiprazole","Depression and Psychosis Response Rate|Depression and Psychosis Remission Rate","Massachusetts General Hospital|Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","16","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003-P-000990","June 2003","January 2008","January 2008","November 9, 2007","August 20, 2012","August 20, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00556140"
1714,"NCT00181896","Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder",,"Terminated","No Results Available","Depression|Bipolar Disorder","Drug: bupropion SR","reduction in depression symptoms assessed by|Children's Depression Rating Scale|Hamilton Depression Rating scale (HAM-D)","Massachusetts General Hospital","All","6 Years to 17 Years   (Child)","Phase 4","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-P-001727","January 2005","February 2007",,"September 16, 2005",,"July 15, 2011","Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00181896"
1715,"NCT00001413","Bone Mineral Density in Women With Major Depression",,"Completed","No Results Available","Healthy|Involutional Depression|Osteoporosis",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"585","NIH","Observational",,"940121|94-M-0121","April 6, 1994",,"January 19, 2007","November 4, 1999",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001413"
1716,"NCT00212797","A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)","Hermes","Completed","No Results Available","Depression|Depressive Disorders|Psychotic Disorders","Drug: Org 34517|Drug: Placebo","PANSS positive symptoms subscale.|Ham-D17, CGI, Cognition, spermatogenesis","Merck Sharp & Dohme Corp.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","273","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05845|Protocol 28130","July 2004","July 2006","July 2006","September 21, 2005",,"November 26, 2015",,,"https://ClinicalTrials.gov/show/NCT00212797"
1717,"NCT01121536","Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder",,"Terminated","Has Results","Depression","Drug: Armodafinil","Participants With Treatment-Emergent Adverse Events (TEAE)|Participants With Clinically Significant Abnormal Serum Chemistry Values|Participants With Clinically Significant Abnormal Hematology Values|Participants With Clinically Significant Abnormal Urinalysis Values|Participants With Clinically Significant Abnormal Vital Signs Values|Change From Baseline to Endpoint in Electrocardiogram (ECG) Values|Physical Examination Shifts From Baseline to Endpoint|Change From Baseline to Endpoint in Body Weight|Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total Score|Participants With Findings During the Open-Label Study on the Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV)|Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score|Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline to Week 1 and Months 1, 2, 4, 6 and Endpoint in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Change From Baseline to Week 1 and Months 1, 2, 4, 6 and Endpoint in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)|Change From Baseline to Week 1 and Months 1, 2, 4, 6 and Endpoint in the Clinical Global Impression of Severity (CGI-S) for Depression|Change From Baseline to Endpoint in the Global Assessment for Functioning (GAF) Scale","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","867","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C10953/3074|2009-016648-38","April 30, 2010","October 31, 2013","October 31, 2013","May 12, 2010","January 26, 2015","September 21, 2018","Teva Investigational Site 113, Birmingham, Alabama, United States|Teva Investigational Site 225, Birmingham, Alabama, United States|Teva Investigational Site 229, Anaheim, California, United States|Teva Investigational Site 217, Cerritos, California, United States|Teva Investigational Site 223, Cerritos, California, United States|Teva Investigational Site 115, Garden Grove, California, United States|Teva Investigational Site 121, Imperial, California, United States|Teva Investigational Site 303, Oceanside, California, United States|Teva Investigational Site 400, Oceanside, California, United States|Teva Investigational Site 200, Pico Rivera, California, United States|Teva Investigational Site 128, San Diego, California, United States|Teva Investigational Site 201, San Diego, California, United States|Teva Investigational Site 192, Santa Ana, California, United States|Teva Investigational Site 292, Santa Ana, California, United States|Teva Investigational Site 295, Sherman Oaks, California, United States|Teva Investigational Site 122, Temecula, California, United States|Teva Investigational Site 131, Gainesville, Florida, United States|Teva Investigational Site 606, Jacksonville Beach, Florida, United States|Teva Investigational Site 132, Jacksonville, Florida, United States|Teva Investigational Site 127, Lauderhill, Florida, United States|Teva Investigational Site 119, North Miami, Florida, United States|Teva Investigational Site 118, Tampa, Florida, United States|Teva Investigational Site 608, Tampa, Florida, United States|Teva Investigational Site 205, Atlanta, Georgia, United States|Teva Investigational Site 116, Atlanta, Georgia, United States|Teva Investigational Site 204, Smyrna, Georgia, United States|Teva Investigational Site 107, Naperville, Illinois, United States|Teva Investigational Site 301, Naperville, Illinois, United States|Teva Investigational Site 219, Oakbrook Terrace, Illinois, United States|Teva Investigational Site 195, Park Ridge, Illinois, United States|Teva Investigational Site 600, Lafayette, Indiana, United States|Teva Investigational Site 300, Pikesville, Maryland, United States|Teva Investigational Site 603, Watertown, Massachusetts, United States|Teva Investigational Site 290, Flowood, Mississippi, United States|Teva Investigational Site 133, Saint Louis, Missouri, United States|Teva Investigational Site 103, Mount Laurel, New Jersey, United States|Teva Investigational Site 212, Mount Laurel, New Jersey, United States|Teva Investigational Site 193, Albuquerque, New Mexico, United States|Teva Investigational Site 207, Brooklyn, New York, United States|Teva Investigational Site 104, Brooklyn, New York, United States|Teva Investigational Site 202, New York, New York, United States|Teva Investigational Site 129, Rochester, New York, United States|Teva Investigational Site 411, Staten Island, New York, United States|Teva Investigational Site 110, Staten Island, New York, United States|Teva Investigational Site 105, Raleigh, North Carolina, United States|Teva Investigational Site 190, Beachwood, Ohio, United States|Teva Investigational Site 213, Canton, Ohio, United States|Teva Investigational Site 610, Cincinnati, Ohio, United States|Teva Investigational Site 102, Dayton, Ohio, United States|Teva Investigational Site 401, Oklahoma City, Oklahoma, United States|Teva Investigational Site 609, Oklahoma City, Oklahoma, United States|Teva Investigational Site 616, Oklahoma City, Oklahoma, United States|Teva Investigational Site 406, Allentown, Pennsylvania, United States|Teva Investigational Site 117, Media, Pennsylvania, United States|Teva Investigational Site 106, Memphis, Tennessee, United States|Teva Investigational Site 111, Austin, Texas, United States|Teva Investigational Site 403, DeSoto, Texas, United States|Teva Investigational Site 612, Friendswood, Texas, United States|Teva Investigational Site 228, Houston, Texas, United States|Teva Investigational Site 224, Irving, Texas, United States|Teva Investigational Site 409, Orem, Utah, United States|Teva Investigational Site 408, Salt Lake City, Utah, United States|Teva Investigational Site 404, Richmond, Virginia, United States|Teva Investigational Site 100, Bellevue, Washington, United States|Teva Investigational Site 613, Kirkland, Washington, United States|Teva Investigational Site 605, Spokane, Washington, United States|Teva Investigational Site 237, Buenos Aires, Argentina|Teva Investigational Site 450, Buenos Aires, Argentina|Teva Investigational Site 881, Buenos Aires, Argentina|Teva Investigational Site 884, Buenos Aires, Argentina|Teva Investigational Site 136, Buenos Aires, Argentina|Teva Investigational Site 134, Buenos Aires, Argentina|Teva Investigational Site 235, Buenos Aires, Argentina|Teva Investigational Site 462, Buenos Aires, Argentina|Teva Investigational Site 135, Cordoba, Argentina|Teva Investigational Site 236, Cordoba, Argentina|Teva Investigational Site 138, La Plata, Buenos Aires, Argentina|Teva Investigational Site 371, La Plata, Argentina|Teva Investigational Site 238, Rosario, Argentina|Teva Investigational Site 141, Brisbane, Australia|Teva Investigational Site 240, Malvern, Australia|Teva Investigational Site 624, Rio de Janeiro, Brazil|Teva Investigational Site 248, Bourgas, Bulgaria|Teva Investigational Site 146, Kardzhali, Bulgaria|Teva Investigational Site 148, Kazanlak, Bulgaria|Teva Investigational Site 853, Pazardjik, Bulgaria|Teva Investigational Site 852, Pleven, Bulgaria|Teva Investigational Site 249, Plovdiv, Bulgaria|Teva Investigational Site 145, Plovdiv, Bulgaria|Teva Investigational Site 370, Ruse, Bulgaria|Teva Investigational Site 147, Sofia, Bulgaria|Teva Investigational Site 854, Sofia, Bulgaria|Teva Investigational Site 855, Sofia, Bulgaria|Teva Investigational Site 247, Sofia, Bulgaria|Teva Investigational Site 851, Varna, Bulgaria|Teva Investigational Site 245, Varna, Bulgaria|Teva Investigational Site 198, Kelowna, Canada|Teva Investigational Site 296, Mississauga, Canada|Teva Investigational Site 196, Mississauga, Canada|Teva Investigational Site 299, Penticton, Canada|Teva Investigational Site 635, Rijeka, Croatia|Teva Investigational Site 633, Zagreb, Croatia|Teva Investigational Site 634, Zagreb, Croatia|Teva Investigational Site 286, Dole, France|Teva Investigational Site 153, Nimes, France|Teva Investigational Site 655, Achim, Germany|Teva Investigational Site 651, Dresden, Germany|Teva Investigational Site 661, Budapest, Hungary|Teva Investigational Site 664, Budapest, Hungary|Teva Investigational Site 662, Budapest, Hungary|Teva Investigational Site 666, Nagykallo, Hungary|Teva Investigational Site 688, Catania, Italy|Teva Investigational Site 689, Firenze, Italy|Teva Investigational Site 687, Pisa, Italy|Teva Investigational Site 692, Rome, Italy|Teva Investigational Site 259, Bialystok, Poland|Teva Investigational Site 258, Gdansk, Poland|Teva Investigational Site 257, Gdansk, Poland|Teva Investigational Site 156, Kielce, Poland|Teva Investigational Site 155, Krakow, Poland|Teva Investigational Site 256, Leszno, Poland|Teva Investigational Site 255, Skorzewo, Poland|Teva Investigational Site 861, Szczecin, Poland|Teva Investigational Site 157, Tuszyn, Poland|Teva Investigational Site 832, Belgrade, Serbia|Teva Investigational Site 175, Belgrade, Serbia|Teva Investigational Site 177, Belgrade, Serbia|Teva Investigational Site 831, Belgrade, Serbia|Teva Investigational Site 833, Belgrade, Serbia|Teva Investigational Site 176, Kragujevac, Serbia|Teva Investigational Site 837, Nis, Serbia|Teva Investigational Site 834, Novi Knezevac, Serbia|Teva Investigational Site 699, Bratislava, Slovakia|Teva Investigational Site 697, Rimavska Sobota, Slovakia|Teva Investigational Site 696, Roznava, Slovakia|Teva Investigational Site 698, Trencin, Slovakia|Teva Investigational Site 712, Cape Town, South Africa|Teva Investigational Site 709, Cape Town, South Africa|Teva Investigational Site 708, Centurion, South Africa|Teva Investigational Site 710, Johannesburg, South Africa|Teva Investigational Site 711, Paarl, South Africa|Teva Investigational Site 706, Pretoria, South Africa|Teva Investigational Site 336, Alcoy, Spain|Teva Investigational Site 434, Coslada (Madrid), Spain|Teva Investigational Site 430, Vitoria-Gasteiz, Spain|Teva Investigational Site 433, Vitoria, Spain|Teva Investigational Site 181, Dnipropetrovsk, Ukraine|Teva Investigational Site 872, Donetsk, Ukraine|Teva Investigational Site 282, Kharkiv, Ukraine|Teva Investigational Site 281, Kiev, Ukraine|Teva Investigational Site 180, Lugansk, Ukraine|Teva Investigational Site 873, Lviv, Ukraine|Teva Investigational Site 280, Odessa, Ukraine|Teva Investigational Site 875, Odessa, Ukraine|Teva Investigational Site 183, Poltava, Ukraine|Teva Investigational Site 871, S. Oleksandrivka, Ukraine|Teva Investigational Site 184, Simferopol, Ukraine|Teva Investigational Site 182, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01121536"
1718,"NCT02245373","Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care.",,"Unknown status","No Results Available","Mild to Moderate Depression.","Drug: Antidepressants|Other: Active Monitoring","Compare the cost-effectiveness of active monitoring (standard treatment without antidepressants) vs antidepressants in mild major depression taking into account the severity and disability in Primary Care. The changes at Time Frame will be assessed.|1.Quality of life of patients with major depression who initiate treatment in Primary Care.|2. Cost-utility of an antidepressant vs no treatment in mild Depression in Primary.","Fundació Sant Joan de Déu","All","18 Years and older   (Adult, Older Adult)",,"263","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Infap","June 2013","July 2014","July 2015","September 19, 2014",,"September 19, 2014",,,"https://ClinicalTrials.gov/show/NCT02245373"
1719,"NCT01305408","Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder",,"Completed","Has Results","Depression","Drug: Armodafinil|Drug: Placebo","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Percentage of Responders At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score|Percentage of Participants in Remission At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score|Change From Baseline to Different Treatment Weeks in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Change From Baseline to Different Treatment Weeks in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)|Change From Baseline to Different Treatment Weeks in the Clinical Global Impression of Severity (CGI-S) for Depression|Change From Baseline to Weeks 4, 8 and Endpoint in the Global Assessment for Functioning (GAF) Scale|Participants With Treatment-Emergent Adverse Events (TEAE)|Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total Score|Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Actual Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Non-Suicidal Self-Injurious Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Interrupted Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Aborted Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Suicidal Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Preparatory Acts or Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Completed Suicide Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Wish to Be Dead Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Non-Specific Active Suicidal Thoughts Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Some Intent to Act Without a Specific Plan Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Specific Plan and Intent Question","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","399","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C10953/3073|2010-023623-26","March 2011","July 2013","July 2013","February 28, 2011","January 26, 2015","May 26, 2016","Teva Investigational Site 225, Birmingham, Alabama, United States|Teva Investigational Site 295, Sherman Oaks, California, United States|Teva Investigational Site 122, Temecula, California, United States|Teva Investigational Site 606, Jacksonville Beach, Florida, United States|Teva Investigational Site 127, Lauderhill, Florida, United States|Teva Investigational Site 608, Tampa, Florida, United States|Teva Investigational Site 116, Atlanta, Georgia, United States|Teva Investigational Site 205, Atlanta, Georgia, United States|Teva Investigational Site 195, Park Ridge, Illinois, United States|Teva Investigational Site 611, Indianapolis, Indiana, United States|Teva Investigational Site 600, Lafayette, Indiana, United States|Teva Investigational Site 603, Watertown, Massachusetts, United States|Teva Investigational Site 207, Brooklyn, New York, United States|Teva Investigational Site 202, New York, New York, United States|Teva Investigational Site 110, Staten Island, New York, United States|Teva Investigational Site 411, Staten Island, New York, United States|Teva Investigational Site 614, Wilmington, North Carolina, United States|Teva Investigational Site 610, Cincinnati, Ohio, United States|Teva Investigational Site 615, Toledo, Ohio, United States|Teva Investigational Site 401, Oklahoma City, Oklahoma, United States|Teva Investigational Site 609, Oklahoma City, Oklahoma, United States|Teva Investigational Site 616, Oklahoma City, Oklahoma, United States|Teva Investigational Site 406, Allentown, Pennsylvania, United States|Teva Investigational Site 403, Desoto, Texas, United States|Teva Investigational Site 612, Friendswood, Texas, United States|Teva Investigational Site 408, Salt Lake City, Utah, United States|Teva Investigational Site 613, Kirkland, Washington, United States|Teva Investigational Site 605, Spokane, Washington, United States|Teva Investigational Site 134, Buenos Aires, Argentina|Teva Investigational Site 136, Buenos Aires, Argentina|Teva Investigational Site 881, Buenos Aires, Argentina|Teva Investigational Site 884, Buenos Aires, Argentina|Teva Investigational Site 888, Buenos Aires, Argentina|Teva Investigational Site 135, Córdoba Capital, Argentina|Teva Investigational Site 236, Córdoba, Argentina|Teva Investigational Site 138, La Plata, Buenos Aires, Argentina|Teva Investigational Site 371, La Plata, Argentina|Teva Investigational Site 886, La Plata, Argentina|Teva Investigational Site 882, Mendoza, Argentina|Teva Investigational Site 883, Mendoza, Argentina|Teva Investigational Site 885, Mendoza, Argentina|Teva Investigational Site 887, Mendoza, Argentina|Teva Investigational Site 238, Rosario, Argentina|Teva Investigational Site 623, Belo Horizonte, Brazil|Teva Investigational Site 626, Curitiba-Parana, Brazil|Teva Investigational Site 621, Distrito de Rubiao Junior, Brazil|Teva Investigational Site 627, Itapira -Sao Paulo, Brazil|Teva Investigational Site 624, Rio de Janeiro, Brazil|Teva Investigational Site 622, Salvador, Brazil|Teva Investigational Site 628, Sao Paolo, Brazil|Teva Investigational Site 248, Bourgas, Bulgaria|Teva Investigational Site 146, Kardzhali, Bulgaria|Teva Investigational Site 148, Kazanlak, Bulgaria|Teva Investigational Site 853, Pazardjik, Bulgaria|Teva Investigational Site 852, Pleven, Bulgaria|Teva Investigational Site 145, Plovdiv, Bulgaria|Teva Investigational Site 370, Ruse, Bulgaria|Teva Investigational Site 147, Sofia, Bulgaria|Teva Investigational Site 149, Sofia, Bulgaria|Teva Investigational Site 244, Sofia, Bulgaria|Teva Investigational Site 247, Sofia, Bulgaria|Teva Investigational Site 854, Sofia, Bulgaria|Teva Investigational Site 855, Sofia, Bulgaria|Teva Investigational Site 245, Varna, Bulgaria|Teva Investigational Site 851, Varna, Bulgaria|Teva Investigational Site 856, Varna, Bulgaria|Teva Investigational Site 635, Rijeka, Croatia|Teva Investigational Site 631, Split, Croatia|Teva Investigational Site 632, Zagreb, Croatia|Teva Investigational Site 633, Zagreb, Croatia|Teva Investigational Site 634, Zagreb, Croatia|Teva Investigational Site 716, Helsinki, Finland|Teva Investigational Site 717, Helsinki, Finland|Teva Investigational Site 719, Kangasala, Finland|Teva Investigational Site 718, Turku, Finland|Teva Investigational Site 655, Achim, Germany|Teva Investigational Site 656, Berlin, Germany|Teva Investigational Site 653, Cologne, Germany|Teva Investigational Site 651, Dresden, Germany|Teva Investigational Site 654, Freiburg, Germany|Teva Investigational Site 652, Mittweida, Germany|Teva Investigational Site 661, Budapest, Hungary|Teva Investigational Site 662, Budapest, Hungary|Teva Investigational Site 664, Budapest, Hungary|Teva Investigational Site 665, Gyor, Hungary|Teva Investigational Site 666, Nagykallo, Hungary|Teva Investigational Site 688, Catania, Italy|Teva Investigational Site 689, Firenze, Italy|Teva Investigational Site 686, Genova, Italy|Teva Investigational Site 691, Lido di Camaiore(LU), Italy|Teva Investigational Site 690, Naples, Italy|Teva Investigational Site 687, Pisa, Italy|Teva Investigational Site 693, Pisa, Italy|Teva Investigational Site 692, Roma, Italy|Teva Investigational Site 259, Bialystok, Poland|Teva Investigational Site 257, Gdansk, Poland|Teva Investigational Site 258, Gdynia, Poland|Teva Investigational Site 155, Krakow, Poland|Teva Investigational Site 255, Skorzewo, Poland|Teva Investigational Site 861, Szczecin, Poland|Teva Investigational Site 157, Tuszyn, Poland|Teva Investigational Site 177, Belgrade, Serbia|Teva Investigational Site 831, Belgrade, Serbia|Teva Investigational Site 832, Belgrade, Serbia|Teva Investigational Site 835, Belgrade, Serbia|Teva Investigational Site 176, Kragujevac, Serbia|Teva Investigational Site 837, Nis, Serbia|Teva Investigational Site 834, Novi Knezevac, Serbia|Teva Investigational Site 700, Bojnice, Slovakia|Teva Investigational Site 699, Bratislava, Slovakia|Teva Investigational Site 697, Rimavska Sobota, Slovakia|Teva Investigational Site 696, Roznava, Slovakia|Teva Investigational Site 698, Trencin, Slovakia|Teva Investigational Site 707, Cape Town, South Africa|Teva Investigational Site 709, Cape Town, South Africa|Teva Investigational Site 712, Cape Town, South Africa|Teva Investigational Site 708, Centurion, South Africa|Teva Investigational Site 710, Johannesburg, South Africa|Teva Investigational Site 711, Paarl, South Africa|Teva Investigational Site 706, Pretoria, South Africa|Teva Investigational Site 181, Dnipropetrovsk, Ukraine|Teva Investigational Site 872, Donetsk, Ukraine|Teva Investigational Site 282, Kharkiv, Ukraine|Teva Investigational Site 281, Kiev, Ukraine|Teva Investigational Site 180, Lugansk, Ukraine|Teva Investigational Site 873, Lviv, Ukraine|Teva Investigational Site 875, Odessa, Ukraine|Teva Investigational Site 183, Poltava, Ukraine|Teva Investigational Site 871, s. Oleksandrivka, Ukraine|Teva Investigational Site 182, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01305408"
1720,"NCT01305707","Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression",,"Terminated","No Results Available","Depression","Device: C-ECT|Drug: PHARMACOTHERAPY","Hamilton Depression Rating Scale 21 items (HDRS-21)|Mini-Mental State Examination (MMSE 35)|UKU - Adverse effects rating scales|Demographical Data Memory (MEDABI-20)|Rey Figure|Trail Making Test A|Trail Making Test B|Stroop Test|Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).|Vocabulary WAIS (Weschler Adults Intelligence Scale)|Frequency Hospitalization Quotient|Hospital Day Quotient (HDQ)","Hospital Universitari de Bellvitge","All","18 Years and older   (Adult, Older Adult)","Phase 4","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","TECHUB2007","July 2009","July 2014","July 2014","March 1, 2011",,"August 31, 2015","Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Corporació Sanitària Parc Tauli, Sabadell, Barcelona, Spain|Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01305707"
1721,"NCT01072630","Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder",,"Completed","Has Results","Depression","Drug: Armodafinil|Drug: Placebo","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Percentage of Responders At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score|Percentage of Participants in Remission At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score|Change From Baseline to Different Treatment Weeks in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Change From Baseline to Different Treatment Weeks in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)|Change From Baseline to Different Treatment Weeks in the Clinical Global Impression of Severity (CGI-S) for Depression|Change From Baseline to Weeks 4, 8 and Endpoint in the Global Assessment for Functioning (GAF) Scale|Participants With Treatment-Emergent Adverse Events (TEAE)|Change From Baseline to Endpoint in the Young Mania Rating Scale Total Score|Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Actual Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Non-Suicidal Self-Injurious Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Interrupted Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Aborted Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Suicidal Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Preparatory Acts or Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Completed Suicide Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Wish to Be Dead Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Non-Specific Active Suicidal Thoughts Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Some Intent to Act Without a Specific Plan Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Specific Plan and Intent Question","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","492","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C10953/3072|2009-016634-27","March 2010","November 2012","November 2012","February 22, 2010","January 26, 2015","April 27, 2016","Birmingham Psychiatry Pharmaceutical Studies, Inc, Birmingham, Alabama, United States|South Coast Medical Associates/SC Clinical Trials, Inc., Anaheim, California, United States|Comprehensive NeuroScience, Cerritos, California, United States|Sun Valley Behavioral Medical, Imperial, California, United States|North County Clinical Research, Oceanside, California, United States|CNRI Los Angeles LLC, Pico Rivera, California, United States|CNRI-San Diego LLC, San Diego, California, United States|Clinical Innovations Inc., Santa Ana, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Stanford University Medical Center, Stanford, California, United States|Viking Clinical Research Center, Temecula, California, United States|Comprehensive NeuroScience, Washington DC, District of Columbia, United States|Scientific Clinical Research, Inc., Aventura, Florida, United States|Florida Clinical Research Center, Bradenton, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Fidelity Clinical Research, Lauderhill, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Hawaii Clinical Research Center, Honolulu, Hawaii, United States|Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace, Illinois, United States|CNS - Comprehensive Neuro Science, Park Ridge, Illinois, United States|Community Research, Crestview Hills, Kentucky, United States|AccelRx Research, Fall River, Massachusetts, United States|Mayo College of Medicine, Rochester, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|CRI Worldwide, LLC, Mount Laurel, New Jersey, United States|Behavioral Medical Research of Brooklyn, Brooklyn, New York, United States|Fieve Clinical Services, Inc., New York, New York, United States|Medical and Behavioral Health Research, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|North Coast Clinical Trials, Inc., Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigators, Inc. (OCCI, Inc.), Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Insite Clinical Research, Desoto, Texas, United States|Red Oak Psychiatry Associates, P.A., Houston, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Aspen Clinical Research, LLC, Orem, Utah, United States|Clinical Methods, Salt Lake City, Utah, United States|Alliance Research Group, Richmond, Virginia, United States|B.A. Psychiatric Research Cent, Buenos Aires, Argentina|Dr. Gregorio Hugo Sorin, Buenos Aires, Argentina|INECO, Buenos Aires, Argentina|Instituto FLENI, Buenos Aires, Argentina|Sanatorio Prof. León S. Morra SA, Córdoba, Argentina|Centro de Investigación y asistencia en Psiquiatria (CIAP), Rosario, Argentina|Neurotherapy Victoria Clinical Trials, Malvern, Victoria, Australia|Northern Area Mental Health Services Northern Psychiatric R, Melbourne, Victoria, Australia|District Department of Psychiatric Disorders With Stationary, Bourgas, Bulgaria|State Psychiatric Hospital - Pazardjik, Pazardjik, Bulgaria|Psychiatric clinic for women UMHAT ""Dr. Georgi Stranski"", Pleven, Bulgaria|ODPZS- EOOD, Plovdiv, Bulgaria, Plovdiv, Bulgaria|MHAT Doverie, Sofia, Bulgaria|Psychiatric clinic, University Hospital ""Alexandrovska"", Sofia, Bulgaria|Diagnostic Consultative Center ""Tchaika"", Varna, Bulgaria|MHAT - Sveta Marina, Varna, Bulgaria|Grey Nuns Hospital, Edmonton, Alberta, Canada|Dr. Alexander McIntyre, Inc., Penticton, British Columbia, Canada|Providence Care Mental Health Services, Kingston, Ontario, Canada|Medical Research Associates, Mississauga, Ontario, Canada|Hôpital Louis Hlafontaine, Montreal, Quebec, Canada|CMP/CHS du Jura, Dole, France|Centre Hospitalier de Jonzac, Jonzac, France|Hopital Universitaire Caremeau-Batiment Polyvalent, Service, Nîmes, France|Szpital Uniwersytecki im.dr.A.Jurasza w Bydgoszczy, Bydgoszcz, Poland|Klinika Chorob Psychicznych i Zaburzen Nerwicowych GUM, Gdansk, Poland|Wojewodzki Szpital Psychiatryczny im. prof. Tadeusza Bilikie, Gdansk, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Cape Trial Centre, Cape Town, South Africa|Flexivest Fourteen Research Centre, Cape Town, South Africa|Knighton Surgery, Cape Town, South Africa|Vista Clinic, Centurion, South Africa|Dr Magnus & Dr Brink, Johannesburg, South Africa|Paarl Medical Centre, Paarl, South Africa|Dey Clinic, Pretoria, South Africa|Hospital del Henares, Coslada (Madrid), Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Psiquiátrico de Álava, Vitoria-Gasteiz, Spain|Hospital Santiago Apostol, Vitoria, Spain|Odessa Regional Mental Hospital #2, s. Oleksandrivka, Odessa, Ukraine|Donetsk National Medical University n.a. M. Horkyy, Donetsk, Ukraine|Public Institution ""Institute of Neurology, Psychiatry and N, Kharkiv, Ukraine|Kiev City Psychoneurological Hospital N 1, CNTRP, Kiev, Ukraine|Danylo Galitsky Lviv State Medical University, Lviv, Ukraine|Odessa Regional Psychoneurology Dispensary, Odessa, Ukraine|Vinnytsa National Medical University named by M.I. Pirogov, Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT01072630"
1722,"NCT01072929","A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder",,"Completed","Has Results","Depression","Drug: Armodafinil|Drug: Placebo","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Percentage of Responders At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score|Percentage of Participants in Remission At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score|Change From Baseline to Different Treatment Weeks in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Change From Baseline to Different Treatment Weeks in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)|Change From Baseline to Different Treatment Weeks in the Clinical Global Impression of Severity (CGI-S) for Depression|Change From Baseline to Weeks 4, 8 and Endpoint in the Global Assessment for Functioning (GAF) Scale|Participants With Treatment-Emergent Adverse Events (TEAE)|Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total Score|Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Actual Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Non-Suicidal Self-Injurious Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Interrupted Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Aborted Attempt Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Suicidal Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Preparatory Acts or Behavior Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Completed Suicide Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Wish to Be Dead Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Non-Specific Active Suicidal Thoughts Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Some Intent to Act Without a Specific Plan Question|Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Specific Plan and Intent Question","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","433","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C10953/3071|2009-016667-11","January 2010","March 2012","March 2012","February 22, 2010","January 26, 2015","April 27, 2016","Birmingham Research Group, Birmingham, Alabama, United States|Southwestern Research, Beverly Hills, California, United States|Collaborative NeuroScience Network, Garden Grove, California, United States|Sun Valley Behavioral Medical, Imperial, California, United States|University of California Irvine, Irvine, California, United States|Excell Research, Oceanside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Clinical Innovations Inc., Santa Ana, California, United States|Viking Clinical Research Center, Temecula, California, United States|CNS Clinical Research Group - Florida Clinical Research Cent, Coral Springs, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Dr. Vijapura and Assoc., Jacksonville, Florida, United States|Fidelity Clinical Research, Lauderhill, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Comprehensive Neuroscience, Inc, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Roswell, Georgia, United States|AMR Baber Research Inc., Naperville, Illinois, United States|American Medical Research, Oak Brook, Illinois, United States|CNS - Comprehensive Neuro Science, Park Ridge, Illinois, United States|Pharmasite Research, Inc, Baltimore, Maryland, United States|AccelRx Research, Fall River, Massachusetts, United States|Mid-America Clinical Research, LLC, St. Louis, Missouri, United States|CRI Worldwide, LLC, Mount Laurel, New Jersey, United States|Albequerque Neuroscience, Albuquerque, New Mexico, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Richard Weisler, MD and Associates, Raleigh, North Carolina, United States|Charak Clinical Research Center, Beachwood, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Oregon Center for Clinical Investigations, Inc, Salem, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Scranton Counseling Center, Scranton, Pennsylvania, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Community Clinical Research, Austin, Texas, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01072929"
1723,"NCT00481195","Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder",,"Completed","Has Results","Bipolar I Depression","Drug: Armodafinil|Drug: Placebo","The Mean Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|The Mean Change From Baseline to Week 1 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|The Mean Change From Baseline to Week 2 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|The Mean Change From Baseline to Week 3 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|The Mean Change From Baseline to Week 4 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|The Mean Change From Baseline to Week 6 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|The Mean Change From Baseline to Week 8 in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)|Number of Patients Achieving Remission at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Number of Patients Achieving ""Response"" at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Number of Patients Achieving ""Sustained Remission"" at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Number of Patients Achieving ""Sustained Response"" at Endpoint According to the 30-item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)|Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) Combination of Items 1-3|Change From Baseline to Week 4 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) Combination of Items 1-3|Change From Baseline to Week 8 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) Combination of Items 1-3|Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) - Item 4|Change From Baseline to Week 4 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) - Item 4|Change From Baseline to Week 8 on 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30) - Item 4|Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline to Week 4 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Week 1 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Week 2 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Week 3 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Week 4 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Week 6 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Week 8 in the Quick Inventory of Depressive Symptomatology - 16 Items (QIDS-SR16)|Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)|Change From Baseline to Week 4 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)|Change From Baseline to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)|Change From Baseline to Endpoint (8 Weeks or Last Observation After Baseline) in Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline to 4 Weeks in the Hamilton Anxiety Scale (HAM A) Total Score|Change From Baseline to 8 Weeks in the Hamilton Anxiety Scale (HAM A) Total Score|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Endpoint (Week 8 or Last Observation After Baseline)|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 1|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 2|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 3|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 4|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 6|The Number of Responders According to the Clinical Global Impression of Change - Bipolar Version (CGI BP) Measure of Depression at Week 8","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","257","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C10953/2032/DP/US","June 2007","December 2008","December 2008","June 1, 2007","December 20, 2010","July 19, 2013","Birmingham Research Group, Birmingham, Alabama, United States|Birmingham Psychiatry Pharmaceutical Studies, Inc, Birmingham, Alabama, United States|Synergy Clinical Research Center, Escondido, California, United States|Bay Area Research Institute, Lafayette, California, United States|Synergy Clinical Research Center, National City, California, United States|Excell Research, Oceanside, California, United States|Pacific Clinical Research Medical Group, Orange, California, United States|CNRI Los Angeles LLC, Pico Rivera, California, United States|Pacific Clinical Research Medical Group, Riverside, California, United States|California Neuropsychopharmacology Clinical Research Inst, San Diego, California, United States|Stanford University, Stanford, California, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Fidelity Clinical Research, Lauderhill, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Atlanta Center for Clinical Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Psychiatric Medicine Associates, Skokie, Illinois, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|CNS Research Institute, Clementon, New Jersey, United States|Behavioral Medical Research of Brooklyn, Brooklyn, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|Medical & Behavioral Health Research, New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Richard Weisler, MD and Associates, Raleigh, North Carolina, United States|Piedmont Clinical Trials, Inc., Winston-Salem, North Carolina, United States|Mood Disorders Program, Cleveland, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|Dubois Regional Medical Center - Behavioral Health Services, Dubois, Pennsylvania, United States|Keystone Clinical Studies LLC, Norristown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Community Clinical Research, Austin, Texas, United States|Claghorn-Lesem Research Clinic, LTD, Bellaire, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Eastside Therapeutic Resource, Kirkland, Washington, United States|Call For Information, Burgas, Bulgaria|Call For Information - Center Site #2, Plovdiv, Bulgaria|Call For Information, Plovdiv, Bulgaria|Call For Information - Center Site #2, Sofia, Bulgaria|Call For Information, Sofia, Bulgaria|Call For Information, Budapest, Hungary|Call For Information, Nagykálló, Hungary|Call For Information, Bucuresti, Romania|Call For Information, Bucuresti, Romania|Call For Information - Center Site #2, Bucuresti, Romania|Call For Information, Bucuresti, Romania|Call For Information, Pitesti, Romania|Call For Information, Targoviste, Romania",,"https://ClinicalTrials.gov/show/NCT00481195"
1724,"NCT01594528","Behavior During Experimentally Induced Pain",,"Completed","Has Results","Schizophrenia|Major Depression","Other: pain tests","Indicators / Minute","Centre Hospitalier Esquirol","All","18 Years to 60 Years   (Adult)","Not Applicable","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2012-A00048-35","April 2012","December 2013","December 2013","May 9, 2012","March 22, 2019","March 22, 2019","Centre Hospitalier Esquirol, Limoges, France",,"https://ClinicalTrials.gov/show/NCT01594528"
1725,"NCT01575912","Past Pain Experience and Perception of Experimental Pain",,"Completed","Has Results","Schizophrenia|Major Depression","Other: experimental pain tests","Visual Analog Scale Evaluation for the Pre-fixed Pressure Test","Centre Hospitalier Esquirol","All","18 Years to 60 Years   (Adult)",,"92","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012-A00047-36","March 2012","January 2014","January 2014","April 12, 2012","May 3, 2017","June 12, 2017","Centre Hospitalier Esquirol, Limoges, France",,"https://ClinicalTrials.gov/show/NCT01575912"
1726,"NCT00406640","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women",,"Completed","Has Results","Depression|Depressive Disorder|Depressive Disorder, Major","Drug: Desvenlafaxine succinate sustained-release (DVS SR)|Drug: Escitalopram","Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8|Percentage of Patients Achieving Response to Treatment at Final On-therapy Evaluation (Acute Phase)|Percentage of Patients Achieving Remission at Final On-therapy Evaluation (Acute Phase)|Clinical Global Impression Improvement (CGI-I) Score at 8 Weeks|Change in Clinical Global Impression Severity (CGI-S) Score From Baseline to Week|Change in Hamilton Psychiatric Rating Scale for Anxiety From Baseline to Week 8 (HAM-A) Score|Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8|Percentage of Responders Maintaining Response to Treatment at Final On-therapy Evaluation (Double Blind Continuation Phase)|Percentage of Responders Achieving Remission at Final On-therapy Evaluation (Double Blind Continuation Phase)|Percentage of Responders Improving Response to Remission During 6-month Double Blind Continuation Phase|Percentage of Non-Responders Achieving Response at Final Evaluation of 6-month Open-Label (OL)Extension Phase|Percentage of Non-Responders Achieving Remission at Final Evaluation of 6-month Open-Label Extension Phase|Discontinuation-Emergent Signs and Symptoms (DESS) Total Score","Wyeth is now a wholly owned subsidiary of Pfizer","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 3","595","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3151A1-402","December 2006","February 2008","October 2008","December 4, 2006","June 29, 2010","June 29, 2010","Peoria, Arizona, United States|Pasadena, California, United States|San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Cromwell, Connecticut, United States|Farmington, Connecticut, United States|Waterbury, Connecticut, United States|Brooksville, Florida, United States|Coral Springs, Florida, United States|Fort Meyers, Florida, United States|Gainesville, Florida, United States|Maitland, Florida, United States|Atlanta, Georgia, United States|Roswell, Georgia, United States|Northfield, Illinois, United States|Oak Brook, Illinois, United States|Overland Park, Kansas, United States|Witchita, Kansas, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Fall River, Massachusetts, United States|St. Paul, Minnesota, United States|Las Vegas, Nevada, United States|Piscataway, New Jersey, United States|Elmsford, New York, United States|Holliswood, New York, United States|New York, New York, United States|New York, New York, United States|Syracuse, New York, United States|Raleigh, North Carolina, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|East Providence, Rhode Island, United States|Lincoln, Rhode Island, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Memphis, Tennessee, United States|Bellaire, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|Houston, Texas, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Morgantown, West Virginia, United States|Middleton, Wisconsin, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|La Plata, Argentina|Mendoza, Argentina|Santiago, Chile|Barranquilla, Colombia|Bogota, Colombia|Bucamaranga, Colombia|Mexico City, Mexico|Monterrey, Mexico|Tobasco, Mexico|Chiclayo, Peru|Lima, Peru",,"https://ClinicalTrials.gov/show/NCT00406640"
1727,"NCT00569062","A Study of GW856553X For the Treatment of Depression",,"Terminated","No Results Available","Depressive Disorder, Major","Drug: GW856553X|Other: Placebo","Change from Randomization at Week 6 in Bech subscale (6-item of 17-item Hamilton depression rating [HAMD-17] scale) score|Change from Randomization (Week 0) at Week 6 in Inventory for Depressive Symptomatology-Clinician rated (IDS-C) scale total score|Change from randomization (Week 0) at Week 6 in Quick Inventory of Depressive symptomatology 16 item self report (QIDS-SR16) scale total score|Change from Randomization (Week 0) at Week 6 in the morning serum levels of the pro-inflammatory biomarkers|Number of participants with any Adverse events (AEs), Serious adverse events (SAEs) or Death|Mean Suicidality Tracking Scale (STS) scores over period|Number of participants with abnormal chemistry values|Number of participants with abnormal hematology values|Number of participants with abnormal urinalysis results|Number of participants of vital signs outside range of Potential Clinical Importance (PCI)|Number of participants of abnormal electrocardiogram (ECG) values|Change from randomization (Week 0) at Week 1, 2, 3, 4 and 5 in Bech subscale (6-item of HAMD-17 scale) score|Change from Randomization (Week 0) at Week 1, 2, 3, 4 and 5 in IDS-C scale total score|Change from randomization (Week 0) at Week 2 and 4 in QIDS-SR16 scale total score|Change from randomization (Week 0) at Week 1, 2, 3, 4, 5 and 6 in HAMD-17 scale total score|Percentage of participants with Bech subscale (6-item HAMD-17) score responder and remitter at Week 6|Percentage of participants with IDS-C scale total score responder and remitter at Week 6|Percentage of participants with QIDS-SR16 scale total score responder and remitter at Week 6|Change from Randomization in Psychomotor Retardation subscale of the IDS-C scale over Week 6|Change from Randomization in Psychomotor Retardation subscale of the QIDS-SR16 scale over Week 6|Change from Randomization in Psychomotor Retardation-Psychomotor Slowing item 23 of the IDS-C scale over Week 6|Change from Randomization in Psychomotor Retardation-Psychomotor Slowing item 15 of QIDS-SR16 scale over Week 6|Functional assessment of Fatigue and Sleepiness over Week 6|Change from Randomization in Visual Analogue Scale (VAS) of Fatigue/Tiredness and Sleepiness (at time of cytokine sampling) over Week 6|Change from Randomization in Fatigue-Energy item 20 of the IDS-C scale over Week 6|Change from Randomization in Energy/Fatigue item 14 of the QIDS-SR16 scale over Week 6|Change from Randomization in plasma cortisol over Week 6|Change from Randomization in serum TNFα/IL-10 ratio over Week 6|Change from Randomization in high sensitivity C-reactive protein (hs-CRP) over Week 6|Change from Randomization in number of leukocytes over Week 6|Plasma concentration of GW856553X and GSK198602|Maximum plasma concentration (Cmax) of GW856553X and GSK198602|Median time to Cmax (tmax) and the terminal phase half-life (t1/2)|The area under the plasma concentration-time curve (AUC)","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKI108574","September 12, 2007","June 25, 2008","June 25, 2008","December 6, 2007",,"July 18, 2017","GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Manipal,, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhny Novgorod, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St.Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00569062"
1728,"NCT01292889","Study of Genes in Relation to Seasonal Affective Disorder and Major Depressive Disorder","Season605","Completed","No Results Available","Seasonal Affective Disorder",,,"University of Pittsburgh","All","18 Years to 65 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Seasonality605","October 2008","December 2011","December 2011","February 10, 2011",,"January 7, 2016","University of Pittsburgh Department of Psychology 605 Old Engineering Hall, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01292889"
1729,"NCT00036335","Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain",,"Completed","No Results Available","Depression|Pain","Drug: Duloxetine Hydrochloride",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6353|F1J-US-HMCB","March 2002",,"January 2003","May 10, 2002",,"July 19, 2006","Peoria, Arizona, United States|Burbank, California, United States|Fresno, California, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Oakbrook Terrace, Illinois, United States|Springfield, Illinois, United States|Glen Burnie, Maryland, United States|Farmington Hills, Michigan, United States|Nashua, New Hampshire, United States|Clementon, New Jersey, United States|Moorestown, New Jersey, United States|Albany, New York, United States|Olean, New York, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Lake Jackson, Texas, United States|San Antonio, Texas, United States|Woodstock, Vermont, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00036335"
1730,"NCT02678702","Cognitive Behavioral Therapy for Treatment of Insomnia in Patients With Major Depression",,"Unknown status","No Results Available","Insomnia","Behavioral: CBT-I|Behavioral: Treatment as usual","Patients Total sleep time (minutes).|Score on HamD17 (points)","University of Aarhus|TrygFonden, Denmark","All","18 Years to 67 Years   (Adult, Older Adult)","Not Applicable","47","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","109566","August 2015","December 2019","December 2020","February 10, 2016",,"August 1, 2019","Aarhus University Hospital, Aarhus, Region Midtjylland, Denmark",,"https://ClinicalTrials.gov/show/NCT02678702"
1731,"NCT04935619","Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression",,"Recruiting","No Results Available","Cannabis Use|Major Depressive Disorder|Cognitive Impairment","Behavioral: Contingency Reinforcement|Behavioral: Non-Contingency Reinforcement","Changes in Depressive Symptomology from Baseline to Week 4|Changes in Anxious Symptomology from Baseline to Week 4|Changes in Sleep Symptomology from Baseline to Week 4|Changes in Anhedonia from Baseline to Week 4|Changes in Verbal Learning and Memory|Changes in Attention and Visual Search|Changes in Working Memory|Changes in Sustained Attention","Centre for Addiction and Mental Health","All","18 Years to 55 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","125-2020","June 21, 2021","April 30, 2025","August 31, 2025","June 23, 2021",,"June 23, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04935619"
1732,"NCT02053649","Integrated Chronotherapy for Perinatal Depression",,"Completed","No Results Available","Depression|Major Depressive Disorder|Postpartum Depression","Behavioral: Triple Chronotherapy|Other: Usual Care","Change in Depression Score|Sleep/Circadian Behavior","Rhode Island Hospital|The Depressive and Bipolar Disorder Alternative Treatment Foundation|National Institute of Mental Health (NIMH)","Female","18 Years to 40 Years   (Adult)","Not Applicable","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","540053-2|1R34MH104377-01A1","January 2014","January 15, 2019","February 28, 2019","February 4, 2014",,"May 29, 2019","Miriam Hospital Women's Medicine Collaborative, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02053649"
1733,"NCT00200902","Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression",,"Completed","Has Results","Depression","Drug: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Other: Placebo|Behavioral: Interpersonal Clinical Interaction (ICI)","Response as Assessed by Participants' Change in Depression Rating|Average Change in 3 Weeks of Participant Treatment Expectations|Change in Hamilton Depression Assessment Score","University of California, Los Angeles|National Center for Complementary and Integrative Health (NCCIH)|Eli Lilly and Company|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","88","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R01AT002479-02|04-02-068","August 2005","June 2009","June 2009","September 20, 2005","April 10, 2019","July 28, 2021","UCLA Laboratory of Brain, Behavior, and Pharmacology, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00200902"
1734,"NCT00183755","Understanding Brain Reward Responses in Individuals With Major Depressive Disorder",,"Completed","No Results Available","Depression",,"Performance on Monetary Incentive Delay task|Signal detection reward task","Mclean Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 64 Years   (Adult)",,"87","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01MH068376|DATR A3-NSS","April 2005","April 2009","April 2009","September 16, 2005",,"April 21, 2014","The Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States|Affective Neuroscience Laboratory, Department of Psychology, Harvard University, Cambridge, Massachusetts, United States|Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00183755"
1735,"NCT04410575","Mental Health Assessment and Prescribing by Alberta Pharmacists","MAP-AP","Not yet recruiting","No Results Available","Major Depressive Disorder|Generalized Anxiety Disorder|Pharmacist-Patient Relations","Other: Patient Assessment|Other: Collaboration and discussion with the patient's physician|Other: Prescription dose adjustment and/or prescribing adjunctive therapy|Other: Communication update with physician after participant contact|Other: Medication Counselling and Educational Support|Other: Interim telephone follow-up|Other: Psychotherapy referral|Other: Standard Pharmacist Care","Mean score difference in Patient Health Questionnaire 9-item (PHQ-9) score|Mean score difference in Generalized Anxiety Disorder 7-item (GAD-7) score|Difference in proportion of participants achieving clinically significant treatment response in Patient Health Questionnaire 9-item (PHQ-9) score between pharmacist intervention vs. standard pharmacist care|Difference in proportion of participants achieving clinically significant treatment response in Generalized Anxiety Disorder 7-item (GAD-7) score between pharmacist intervention vs. standard pharmacist care|Difference in the proportion of participants with Major Depressive Disorder (MDD) to achieve Patient Health Questionnaire 9-item (PHQ-9) score <5|Difference in the proportion of participants with Generalized Anxiety Disorder (GAD) to achieve Generalized Anxiety Disorder 7-item (GAD-7) score <5|Difference in the proportion of participants with Major Depressive Disorder (MDD) and/or Generalized Anxiety Disorder (GAD) to achieve a British Columbia Cognitive Complaints Inventory (BC-CCI) score <5|Difference in the proportion of participants with Major Depressive Disorder (MDD) and/or Generalized Anxiety Disorder (GAD) to achieve Sheehan Disability Scale (SDS) score <5 on all subscales|Percentage difference in self-reported safety concerns disclosed by participant to pharmacist partner, between pharmacist intervention and standard pharmacist care groups, during the study period.","University of Alberta","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REB ID Pro00093776","September 1, 2020","March 31, 2022","June 30, 2022","June 1, 2020",,"June 1, 2020","University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04410575"
1736,"NCT00183677","Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram",,"Completed","Has Results","Depression","Drug: Escitalopram","Responder and Remission Status (%), Based on the Depression Rating Scale Score","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","97","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23MH067111","July 2003","June 2009","June 2009","September 16, 2005","January 4, 2017","January 4, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00183677"
1737,"NCT01731899","Agomelatine in Depressed Patients With Fibromyalgia",,"Completed","No Results Available","Major Depression|Fibromyalgia","Drug: agomelatine","change, from baseline to endpoint, in the Beck's depression inventory score|change, from baseline to endpoint, in the Pittsburgh Sleep Quality Inventory","Universidad de Granada","All","18 Years to 80 Years   (Adult, Older Adult)",,"27","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AGO-2010","June 2010","October 2012","November 2012","November 22, 2012",,"May 7, 2014","Instituto de Neurociencias, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT01731899"
1738,"NCT04829669","A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency","POWER","Not yet recruiting","No Results Available","Depressive Disorder, Major",,"Change From Baseline in Severity of Depression as Assessed by the Montgomery-asberg Depression Rating Scale (MADRS)|Change From Baseline in Severity of Suicidality as Assessed by Clinical Global Impression-Severity of Suicidality Revised (CGI-SS-R) Score|Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score|Change From Baseline in European Quality of Life (EuroQol) 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores|Number of Participants with Inpatient and Outpatient Care Across Specific Settings and Consultation With Different Healthcare Professionals (HCPs)|Number of Resources Used to Reduce the Risk for Suicide|Number of Participants who Used Psychopharmacological and Non-pharmacological Drug Therapies|Care Burden as Assessed by EQ-5D-5L Score|Care Burden as Assessed Work productivity and Activity Impairment Questionnaire (WPAI) Score","Janssen-Cilag Ltd.","All","18 Years to 64 Years   (Adult)",,"330","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR109009|54135419MDD4003","August 20, 2021","March 11, 2022","June 30, 2022","April 2, 2021",,"July 23, 2021","Greater Manchester Mental Health NHSFT, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04829669"
1739,"NCT04589143","Agomelatine Augmentation Added to SSRIs or SNRIs for Depression",,"Recruiting","No Results Available","MDD","Drug: Agomelatine|Drug: Placebos","Response rate|Remission rate","Central South University","All","18 Years to 60 Years   (Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Second Xiangya hospital","October 1, 2020","December 1, 2021","October 1, 2022","October 19, 2020",,"October 19, 2020","Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT04589143"
1740,"NCT03735576","Cognitive Behavioural Therapy for the Treatment of Late Life Depression","CBTlate","Active, not recruiting","No Results Available","Late-life Depression|Major Depressive Disorder|Major Depressive Episode|Major Depressive Disorder, Recurrent","Behavioral: Psychotherapy|Diagnostic Test: Questionnaires|Other: Magnetic Resonance Imaging|Other: Blood analysis","Change of Geriatric Depression Scale (GDS) Score|Change of Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C)|Change of Patient Reported Outcome for Major Depressive Disorder (PRO-MDD) Score|Longitudinal Interval Follow-up Evaluation (LIFE)|Change of Insomnia Severity Index (ISI) Score|Change of Epworth Sleepiness Scale (ESS) Score|Change of REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)Score|Change of Geriatric Anxiety Inventory (GAI) Score|Change in Quality of Life (WHOQOL)|Change in Short Form Health Survey (SF-36)|Change in Subjective Cognitive Functioning|Change in cognitive function (CERAD-Plus)|Change in executive function (NAB maze test)|Childhood Trauma Questionnaire (CTQ)|Big Five-Inventory 10 Item Short Version (BFI-10)","University of Cologne","All","60 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","01KG1716","October 1, 2017","September 30, 2021","September 30, 2021","November 8, 2018",,"April 28, 2021","Charité Berlin, Berlin, Germany|University of Bonn, Bonn, Germany|University of Cologne, Cologne, Germany|University of Freiburg, Freiburg, Germany|University of Leipzig, Leipzig, Germany|ZI Mannheim, Mannheim, Germany|University of Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT03735576"
1741,"NCT01909232","A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)",,"Completed","No Results Available","Depressive Disorder, Major","Device: Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|Device: Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator","Change in depression severity|Clinically significant response|Remission from depression|Change in quality of life|Incidence of treatment-emergent adverse events and serious adverse events","Cervel Neurotech, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN-CFS-TRMD-2","July 2013","June 2014","July 2014","July 26, 2013",,"July 28, 2016","Emory University, Atlanta, Georgia, United States|Sheppard-Pratt Health System, Baltimore, Maryland, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Kaiser Permanente Center for Health Research, Portland, Oregon, United States|Butler Hospital, Providence, Rhode Island, United States|CRI Lifetree, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01909232"
1742,"NCT03833063","Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression","BOTDEP","Unknown status","No Results Available","Major Depressive Disorder|Major Depressive Episode|Treatment Resistant Depression","Drug: botulinum toxin A|Drug: Placebos","Severity og depressive symptoms, response to treatment|remission|severity of depressive symptoms, self-rated Geriatric Depression Scale (GDS)|quality of life, as assessed with QOL-AD|safety/tolerability","Helse Stavanger HF","All","65 Years to 99 Years   (Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019BR","March 1, 2019","December 31, 2019","March 31, 2020","February 6, 2019",,"February 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03833063"
1743,"NCT04816617","The Effect of Exercise on Preventing Depression in Young People",,"Not yet recruiting","No Results Available","Subthreshold Depression|Exercise|Major Depression","Behavioral: Aerobic exercise intervention|Behavioral: Psycho-education","Onset of Major depressive Disorder (MDD)|Changes from baseline in CES-DC at month 6|Change in Cognitive function from baseline|Levels of inflammatory biomarkers from baseline|Brain structural and functional changes over time|Occurrence of Non-suicidal self-injury and suicidal behavior|Physical activity level|Electroencephalograph (EEG) scalp signal changes over time","Guangzhou Psychiatric Hospital|Shanghai Mental Health Center|King's College London","All","10 Years to 17 Years   (Child)","Not Applicable","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Exercise and MDD prevention","May 21, 2021","May 20, 2023","December 6, 2023","March 25, 2021",,"April 21, 2021",,,"https://ClinicalTrials.gov/show/NCT04816617"
1744,"NCT02501226","Effectiveness of the First French Psychoeducational Program on Unipolar Depression","PURE","Recruiting","No Results Available","Unipolar Depressed Outpatients|Mild Severity|Without Psychotic Features","Other: Treatment as usual|Behavioral: ENVIE psychoeducational program","Rate of remission of index episode at 15-months without relapse during follow-up|Variation of depressive intensity using Medication Adherence Rating Scale (MADRS)|Evolution of MADRS and BDI scores during follow-up;|Rate of response (decrease of MADRS score by 50%)|Rate of relapse (MADRS > 12 after remission of index episode)|Rate of hospitalisation during follow-up period|Variation of global functioning using the Functioning Assessment Short Test|Variation of quality of life using World Health Organization Quality Of Life measure-26|Variation of treatment adherence using MADRS|Variation of benzodiazepines doses (data collection, no modification treatment according to the protocol)|Discontinuation rate of the antidepressant treatment .|Variation of depressive intensity using Beck Depression Inventory (BDI) scores","University Hospital, Montpellier|Groupe Hospitalier de la Rochelle Ré Aunis|Centre Hospitalier Universitaire de Besancon|Centre Hospitalier Général de Béziers|University Hospital, Clermont-Ferrand|Centre Hospitalier Universitaire de Nice|Centre Hospitalier de l'Agglomération de Nevers|Centre Psychothérapique de Nancy|Hôpitaux à Bron|Assistance Publique - Hôpitaux de Paris|Centre Hospitalier Esquirol|Centre Hospitalier Sainte-Marie, Nice|Centre Hospitalier Universitaire de Nīmes","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","332","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","9532","December 2, 2015","June 2022","June 2023","July 17, 2015",,"October 19, 2020","University Hospital of Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02501226"
1745,"NCT03505905","A Neurosteroid Intervention for Menopausal and Perimenopausal Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Menopause|Perimenopause","Drug: Pregnenolone|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS)|Hamilton Anxiety Rating Scale (HRSA)|Pittsburgh Sleep Quality Index (PSQI)|Menopause Specific Quality of Life (MEN-QOL)|Greene Climacteric Scale (GCS)|Rey Auditory Verbal Learning Test (RAVLT)|Trail Making Test (TMT)","University of Texas Southwestern Medical Center|Massachusetts General Hospital","Female","40 Years to 67 Years   (Adult, Older Adult)","Phase 1|Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","102017-068","September 1, 2018","March 2022","March 2023","April 23, 2018",,"June 8, 2021","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03505905"
1746,"NCT04832750","Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep","DREAMS","Enrolling by invitation","No Results Available","Major Depressive Episode|Major Depressive Disorder|Borderline Personality Disorder","Device: intermittent theta burst stimulation (iTBS) or sham stimulation","Change in depression severity after the treatment phase|Change in BPD severity after the treatment phase|Changes in neural responses in an interoception task before the first and after the last treatment session|Changes in neural responses in a cognitive control task before the first and after the last treatment session|Changes in behavioral responses in an interoception task before the first and after the last treatment session|Changes in behavioral responses in a cognitive control task before the first and after the last treatment session|Changes in sleep staging over the treatment course|Changes in brain connectivity measures|Changes in vigilance over the treatment course|Changes in symptom severity over treatment course|Changes in self-reported symptom severity over treatment course and at follow-up|Changes in Cortisol Awakening Response (CAR) from saliva concentrations|Changes in blood parameters|Association between changes induced by the Forecaster session and treatment outcome|Changes in self-reported BPD symptom severity over treatment course and at follow-up|Changes in BPD symptom severity over treatment course and at follow-up|Changes in food craving","University of Oldenburg|Marc Onken, M.Sc.|Christina Mueller, M.Sc.","All","18 Years to 65 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DREAMS","May 3, 2021","October 2023","February 2024","April 6, 2021",,"May 20, 2021","Department of Psychiatry, University of Oldenburg, Bad Zwischenahn, Germany",,"https://ClinicalTrials.gov/show/NCT04832750"
1747,"NCT04632498","Investigating Biological Markers, Targets, and Intervention for Mood Disorders",,"Not yet recruiting","No Results Available","Major Depressive Disorder|Depression|Stress","Behavioral: Mindfulness Based Intervention","Electroencephalography (EEG)|Endocrine Measures|Cognitive Behavioral Measure","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","IRB #201645","January 11, 2021","July 11, 2023","July 11, 2023","November 17, 2020",,"November 17, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04632498"
1748,"NCT04293341","Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder",,"Recruiting","No Results Available","Major Depressive Disorder|Posttraumatic Stress Disorder|Panic Disorder and Agoraphobia","Behavioral: Transdiagnostic Behavior Therapy|Behavioral: Cognitive Processing Therapy for PTSD|Behavioral: Cognitive Behavioral Therapy for MDD|Behavioral: Cognitive Behavioral Therapy for Panic Disorder","PTSD Checklist for DSM-5 (PCL-5)|Patient Health Questionnaire - 9 (PHQ-9)|Panic Disorder Severity Scale (PDSS)","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","216","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MHBB-005-19S","October 1, 2020","October 1, 2024","March 31, 2025","March 3, 2020",,"May 10, 2021","Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04293341"
1749,"NCT03722095","Research on the Effects of Combined Neurostimulation Protocols on Stress",,"Unknown status","No Results Available","Stress Reaction|Stress Related Disorder|Major Depressive Disorder","Device: active tDCS|Device: sham tDCS|Device: iTBS","Changes in heart rate variability (HRV)|Changes in heart rate (HR)|Changes in blood pressure (BP)|Changes in electrodermal activity (EDA)|Changes in state-dependent mood|Changes in state-dependent ruminative thinking|Changes in anxiety features - self-report","University Ghent|University Hospital, Ghent","All","18 Years to 45 Years   (Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","EC/2018/0866","October 29, 2018","November 1, 2019","November 1, 2019","October 26, 2018",,"April 25, 2019","University Hospital Ghent, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT03722095"
1750,"NCT03761030","L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults",,"Recruiting","No Results Available","Major Depressive Disorder|Dysthymia|Depression","Drug: L-DOPA|Drug: Placebo Oral Tablet","Hamilton Rating Scale for Depression (HRSD)","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Phase 4","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7733|4R33MH110029-03","January 9, 2019","November 30, 2021","November 30, 2022","December 3, 2018",,"April 20, 2021","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03761030"
1751,"NCT04973930","Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","IPT","Not yet recruiting","No Results Available","Major Depressive Disorder|Breast Cancer|Venlafaxine","Behavioral: Interpersonal Psychotherapy|Drug: Venlafaxine HCl ER","Hamilton Depression Rating Scale|C-Reactive Protein|Posttraumatic Stress Checklist (PCL-5)|PROMIS|Patient Health Questionnaire - 9 (PHQ-9)|Perceived Social Support Scale-Self-Report|Social Adjustment Scale - Self-Report (SAS-SR)","New York State Psychiatric Institute|Columbia University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Velocity","September 2021","September 2022","December 2023","July 22, 2021",,"July 22, 2021",,,"https://ClinicalTrials.gov/show/NCT04973930"
1752,"NCT04821271","Antidepressant Effects of TS-161 in Treatment-Resistant Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Treatment-Resistant Depression|Depression","Other: Placebo|Drug: TS-161 (50 - 100 mg)","Change from baseline on Montgomery-Asberg Depression Rating Scale (MADRS) total scores|Change from baseline on MADRS total scores|Proportion of participants in remission (defined as MADRS total score <=10)|Proportion of participants achieving response (defined as a >=50% reduction from baseline in MADRS total score)|Change from baseline on item 10 (suicidality) of the MADRS and total score on the C-SSRS, and the Scale for Suicidal Ideation (SSI)|Change from baseline on the HDRS, HAM-A, the PANAS, Snaith Hamilton Pleasure Scale (SHAPS), and the Temporal Experience of Pleasure Scale (TEPS) scales|Incidence of AEs and total scores using the Clinician Administered Dissociative States Scale (CADSS), Young Mania Rating Scale (YMRS), the Brief Psychiatric Rating Scale (BPRS), vital signs, changes in clinical laboratory evaluations, and ECGs|[1H]-MRS correlates with changes in MADRS score|Gamma power measured via MEG|Changes in activity in the frontolimbic circuitry","National Institute of Mental Health (NIMH)|Taisho Pharmaceutical Co., Ltd.|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","25","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10000101|000101-M","June 10, 2021","June 23, 2023","June 23, 2023","March 29, 2021",,"July 15, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04821271"
1753,"NCT04747873","Incorporating Stepped Care Approach Into e-CBT for Depression",,"Recruiting","No Results Available","Depression|Major Depressive Disorder|Depressive Symptoms","Behavioral: e-CBT|Behavioral: Stepped Care","Change in symptoms (Participant Health Questionnaire - 9 Item)|Change in symptoms (Quick Inventory of Depressive Symptoms)|Change in quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire)","Queen's University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PSYC-247-21","April 7, 2021","February 2022","February 2022","February 10, 2021",,"April 14, 2021","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04747873"
1754,"NCT00296777","Treatment of Depression Following Multiple Brain Tests",,"Completed","No Results Available","Major Depression|Dysthymia","Drug: Escitalopram|Drug: Bupropion|Drug: Imipramine","Hamilton Depression Scale (HAM-D)|Beck Depression Inventory (BDI)|Clinical Global Impression (CGI)|Patient Global Impression (PGI)|Inventory of Depressive Symptoms (IDS)|Edinburgh Handedness Inventory|Chapman Pleasure Scale|Spielberger State/Trait Anxiety Inventory","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#4781","December 2004","May 2007","December 2007","February 27, 2006",,"April 27, 2012","Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00296777"
1755,"NCT03665831","Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults",,"Recruiting","No Results Available","Major Depressive Disorder|Alzheimer Disease|Mild Cognitive Impairment","Device: Brainsway H1-Coil Deep TMS System","Change From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS)|Remission Rates Compared Within Treatment Group|Response Rates Compared Within Treatment Group|Change From Baseline on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Change From Baseline on the Neuropsychological Battery|Change in Functional Connectivity between PFC and Limbic Regions|Change in Perfusion within Prefrontal Cortex (PFC) and Posterior Cingulate Cortex (PCC)|Change in frontal theta power within the Anterior Cingulate Cortex (ACC)","Rotman Research Institute at Baycrest|Brainsway|Centre for Addiction and Mental Health","All","60 Years and older   (Adult, Older Adult)","Not Applicable","28","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CICP-2-00095","October 23, 2018","January 2020","April 2020","September 11, 2018",,"October 1, 2019","Rotman Research Institute at Baycrest, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03665831"
1756,"NCT00719979","Effectiveness of a Technology Assisted Behavioral Intervention in Assisting People With Major Depressive Disorder",,"Completed","No Results Available","Depression","Behavioral: Behavioral intervention (iCBT + TeleCoach)|Behavioral: Internet-based cognitive behavioral therapy (I-CBT)|Behavioral: Treatment as usual / Wait-list control","Depression|Utilization and Attrition|Patient Satisfaction (Satisfaction Index-Mental Health)","Northwestern University|National Institute of Mental Health (NIMH)","All","19 Years and older   (Adult, Older Adult)","Phase 1","102","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R34MH078922|DSIR 83-ATP|5P20MH090318-02","September 2009","May 2011","July 2012","July 22, 2008",,"March 19, 2014","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00719979"
1757,"NCT00578383","Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device","LFMS","Completed","Has Results","Depression|Bipolar Depression|Major Depressive Disorder","Device: Low Field Magnetic Stimulation Device","Mean Change in Hamilton Depression Rating Scale (HAM-D) (17 Item) in Subjects With Bipolar Depression|Mean Change in Hamilton Depression Depression Rating Scale (HAM-D) (17 Item) in Subjects With Major Depressive Disorder|Visual Analog Scale (VAS) in Subjects With Bipolar Depression|Visual Analog Scale (VAS) in Subjects With Major Depressive Disorder|Mean Change in Hamilton Depression Rating Scale (HAM-D) (17 Item): Combined Diagnostic Groups.|Visual Analog Scale (VAS): Combined Diagnostic Groups.|Positive and Negative Affect Schedule (PANAS) Positive Score: Combined Diagnostic Group.|Positive and Negative Affect Schedule (PANAS) Negative Score: Combined Diagnostic Group.|Positive and Negative Affect Schedule (PANAS) Positive Score in Subjects With Bipolar Depression.|Positive and Negative Affect Schedule (PANAS) Positive Score in Subjects With Major Depressive Disorder|Positive and Negative Affect Schedule (PANAS) Negative Score in Subjects With Bipolar Depression|Positive and Negative Affect Schedule (PANAS) Negative Score in Subjects With Major Depressive Disorder","Mclean Hospital|Stanley Medical Research Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","107","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006-P-001655|Stanley Grant 07TGS-1045","November 2007","March 2011","March 2013","December 21, 2007","April 30, 2014","May 16, 2016","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00578383"
1758,"NCT04698603","Clinical Study of GH001 in Depression",,"Recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder|Depression","Drug: 5 Methoxy N,N Dimethyltryptamine","Phase 1: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13.|Phase 2: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)|Phase 1: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)|Phase 2: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13","GH Research Limited","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GH001-MDD-102|2018-004208-20","November 12, 2019","September 2021","September 2021","January 7, 2021",,"January 7, 2021","Clinical Trial Site, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04698603"
1759,"NCT01870219","Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy",,"Completed","No Results Available","Major Depression|Electroconvulsive Therapy","Drug: Sevoflurane|Drug: Ketamine","Evaluation Of QT interval|Evaluation of Tp-e interval|Seizure durations","Inonu University","All","18 Years to 60 Years   (Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turgut Ozal Medical Center","February 2012","April 2013","May 2013","June 6, 2013",,"June 6, 2013","Turgut Ozal Medical Center, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT01870219"
1760,"NCT00320632","Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression",,"Completed","No Results Available","Depression","Drug: Desipramine","Measured at Weeks 1, 4, and 6: Catecholamine metabolism and blood cell adenylate cyclase activity|Score on the 21-item Hamilton Depression Rating Scale","Harvard Medical School|National Institute of Mental Health (NIMH)","All","19 Years to 64 Years   (Adult)","Phase 4","43","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH015413","August 1990",,"July 1993","May 3, 2006",,"August 19, 2015","Massachusetts Mental Health Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00320632"
1761,"NCT03322774","Sleep To Reduce Incident Depression Effectively","STRIDE","Recruiting","No Results Available","Insomnia, Primary|Major Depressive Disorder|Rumination","Behavioral: digital Cognitive Behavioral Therapy for Insomnia|Behavioral: face-to-face Cognitive Behavioral Therapy for Insomnia|Behavioral: Sleep Hygiene Education Control","Preventing major depressive disorder development with dCBT-I/CBT-I stepped care treatment for insomnia.|Effectiveness of Stepped Care model of dCBT-I/CBT-I for insomnia remission.|Mediation of Depression Prevention by Reducing Rumination (Nocturnal rumination)|Mediation of Depression Prevention by Reducing Rumination (Depressive rumination)|Mediation of Depression Prevention by Reducing Rumination (Worry)|Mediation of Depression Prevention by Reducing Rumination (Transdiagnostic)|Reducing subclinical depressive symptoms with dCBT-I/CBT-I stepped care treatment for insomnia.|Socioeconomic status as a moderator of depression prevention after stepped care insomnia treatment.|Racial minority identification as a moderator of depression prevention after stepped care insomnia treatment.|Stepped care insomnia treatment of dCBT-I and CBT-I will significantly improve sleep parameters.","Henry Ford Health System|Big Health|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","IRB 11586","March 9, 2018","April 30, 2023","April 30, 2023","October 26, 2017",,"March 19, 2020","Henry Ford Medical Center - Columbus, Novi, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03322774/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03322774"
1762,"NCT03898297","Imaging mGluR5 and Synaptic Density in Psychiatric Disorders",,"Recruiting","No Results Available","Major Depressive Disorder|Bipolar Disorder|Healthy","Radiation: [18F]FPEB|Radiation: [11C]APP311","mGluR5 availability using [18F]FPEB|Synaptic density using [11C]APP311|glutamate cycling using MRS|Cognitive Functioning Assessed with CogState Software","Yale University","All","18 Years to 80 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","2000020186","January 11, 2017","January 2022","January 2023","April 1, 2019",,"February 26, 2021","Yale University PET Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03898297"
1763,"NCT03959735","High Intensity Interval Training in Severe Mental Illness",,"Recruiting","No Results Available","Major Depressive Disorder|Bipolar Disorder|Schizophrenia","Other: High Intensity Interval Training (HIIT)","Number of wards that agree to hosting the HIIT Pilot Study and number that do not agree to hosting the HIIT pilot study|Number of people who consent to take part|Average adherence to HIIT sessions and assessments|Number of Participants With Treatment-Related Adverse Events|BMI|Weight|Waist Circumference (WC)|Systolic and diastolic blood pressure|Maximal oxygen uptake (VO2max)|Gait speed|Change in Montreal Cognitive Assessment (MoCA) score|Change in global assessment of functioning scale (GAF) score|Change in Brief Psychiatric Rating Scale (BPRS) score|Change in the brief insomnia severity index (ISI)|Cigarette intake|Change in Depression Anxiety Stress Scale short version (DASS21) score|Change in the Rosenberg Self-Esteem Scale (RSES) score|Change in the International Physical Activity Questionnaire (IPAQ) score|Change in the Behavioural Regulation in Exercise Questionnaire-3 (BREQ-3) score|Change in the Short Warwick Edinburgh Mental Well-being Scale (WEMWBS) score","King's College London|National Institute for Health Research, United Kingdom|South London and Maudsley NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRAS263996","October 10, 2019","August 2021","August 2021","May 22, 2019",,"December 16, 2020","Bethlem Royal Hospital, South London and maudsley NHS Trust, London, United Kingdom|Maudsley Hospital, South London and Maudsley NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03959735"
1764,"NCT04235712","Implementation of Harmonized Depression Outcome Measures in a Health System",,"Completed","No Results Available","Major Depression|Dysthymia","Other: Harmonized Depression Outcome Measures","Death from suicide|Improvement in Depressive Symptoms: Remission|Improvement in Depressive Symptoms: Response|Worsening in Depressive Symptoms: Recurrence|Adverse Events|Suicide Ideation and Behavior","OM1, Inc.|Agency for Healthcare Research and Quality (AHRQ)","All","18 Years and older   (Adult, Older Adult)",,"5","Industry|U.S. Fed","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AHRQ_DEP_Health_System","November 17, 2020","May 15, 2021","May 15, 2021","January 22, 2020",,"May 18, 2021","Baystate Health, Springfield, Massachusetts, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04235712/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04235712"
1765,"NCT04235725","Implementation of Harmonized Depression Outcome Measures in a Primary Care Registry and a Mental Health Registry",,"Completed","No Results Available","Major Depression|Dysthymia","Other: Harmonized Depression Outcome Measures","Death from suicide|Improvement in Depressive Symptoms: Remission|Improvement in Depressive Symptoms: Response|Worsening in Depressive Symptoms: Recurrence|Adverse Events|Suicide Ideation and Behavior and Behavior","OM1, Inc.|Agency for Healthcare Research and Quality (AHRQ)","All","18 Years and older   (Adult, Older Adult)",,"953","Industry|U.S. Fed","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AHRQ_DEP_Registry","March 15, 2020","May 15, 2021","May 15, 2021","January 22, 2020",,"May 18, 2021","American Psychiatric Association, Washington, District of Columbia, United States|American Board of Family Medicine, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04235725"
1766,"NCT02544607","Ketamine for Depression: An MRI Study",,"Completed","Has Results","Depression|Anxious Depression|Major Depressive Disorder","Drug: Ketamine|Other: Magnetic Resonance Imaging (MRI)","Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion.|Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus)","Massachusetts General Hospital|Brain & Behavior Research Foundation|National Institutes of Health (NIH)","All","18 Years to 64 Years   (Adult)","Phase 4","25","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2015P001912|24032","March 2016","December 29, 2017","December 29, 2017","September 9, 2015","April 4, 2019","April 16, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02544607/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02544607"
1767,"NCT03711045","An Eye Tracking Study of Affective Disorder Patients With Suicide Risk",,"Unknown status","No Results Available","Major Depressive Disorder|Bipolar Disorder|Suicide","Behavioral: eye-tracking","eye movement performance during free-view task|Scores in self-report assessment:Beck Depression Inventory|Scores in self-report assessment:Beck Anxiety Inventory|Scores in self-report assessment:Barratt Impulsiveness Scale|Scores in self-report assessment:Ruminative Response Scale","Central South University","All","12 Years to 60 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Second Xiangya hospital CSU|Mental Health Insititute","September 1, 2018","December 31, 2019","December 31, 2019","October 18, 2018",,"October 18, 2018","Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03711045"
1768,"NCT03624933","Effects of Cannabis Abstinence on Symptoms and Cognition in Depression",,"Unknown status","No Results Available","Cannabis Use Disorder|Major Depressive Disorder|Cognition","Behavioral: Weekly Behavioral Coaching Session|Behavioral: Contingency Management","The effects of 28 day cannabis abstinence on change in depressive symptoms in cannabis-dependent patients with Major Depressive Disorder (MDD) as assessed by the Hamilton Rating Scale for Depression (HRSD).|The effects of 28 day cannabis abstinence on change in cognitive function in cannabis dependent patients with Major Depressive Disorder (MDD) as assessed by a cognitive battery administered at Baseline, Week 2, Endpoint and Follow-Up.|The effects of 28 day cannabis abstinence on change in co-occurring anxiety in cannabis dependent patients with MDD as assessed by the Beck Anxiety Inventory (BAI) administered weekly.","Centre for Addiction and Mental Health","All","18 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","069/2017","November 6, 2017","December 2019","December 2019","August 10, 2018",,"March 4, 2019","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03624933"
1769,"NCT02434393","Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project","ADNI-D","Active, not recruiting","No Results Available","Major Depression|Late Life Depression (LLD)",,"Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct.|Rate of Change in expressive language as measured by the Boston Naming Test using total correct.|Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.|Change in brain structure using magnetic resonance imaging (MRI)|Extent of amyloid deposition as measured by Florbetapir F 18: Datum of these scans will be collected via standardized uptake value ratios (SUVR) normalized to the cerebellum|Use biomarkers data employed in ADNI-2 and the NIA AD (Alzheimer's Disease) Genetics Consortium to determine the genotypes needed for the genome wide association study (GWAS).","University of Southern California|National Institute of Mental Health (NIMH)|University of California, San Francisco|Alzheimer's Therapeutic Research Institute","All","65 Years and older   (Older Adult)",,"133","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ADC-048|R01MH098062","March 4, 2015","July 2021","January 2022","May 5, 2015",,"November 3, 2020","University of California, San Francisco, San Francisco, California, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02434393"
1770,"NCT02727972","Examination of Glutamate and mGluR5 in Psychiatric Disorders",,"Recruiting","No Results Available","Major Depressive Disorder|Post-Traumatic Stress Disorder|Bipolar Disorder","Behavioral: Cognitive Testing|Other: MRI|Radiation: PET","Evidence of glutamate availability (mGluR5) in psychiatric disorders confirmed by MRI and PET data.","Yale University|VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1101007933","August 2011","August 2021","August 2021","April 5, 2016",,"December 3, 2020","PET Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02727972"
1771,"NCT04604210","Symptom-specific TMS Targets for Depression and Anxiety",,"Recruiting","No Results Available","Depression|Anxiety|Major Depressive Disorder","Procedure: Transcranial magnetic stimulation","Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Resting-state functional MRI (rsfMRI) scan|Temperament and Character Inventory, Revised 140-item (TCI-R 140)|NIH Toolbox cognitive battery|Multidimensional task-based emotional assessment|Pain at the stimulation site|Multidimensional battery of emotional questionnaires","Brigham and Women's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020P002296","November 2020","November 2023","January 2024","October 27, 2020",,"November 20, 2020","Brigham & Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04604210"
1772,"NCT02860910","Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders","Conklin MWW","Completed","No Results Available","Bipolar Disorder|Major Depressive Disorder|Menopause","Behavioral: Cognitive Behavioral Group Therapy","Number of participants who begin cognitive group behavioral therapy|Change in Hot Flush Rating Scale: Frequency and Problem Rating (HFRS) total score|Change in Hot Flash Daily Interference Scale (HFRDIS) total score|Change in Menopause Representation Questionnaire (MRQ) total score","Danette Conklin, PhD|University Hospitals Cleveland Medical Center","Female","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-16-11","July 2016","October 2018","October 2018","August 9, 2016",,"September 30, 2019","University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02860910/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02860910"
1773,"NCT01882608","Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders","PATH-MOD","Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder|Dysthymia","Other: Mental Health Telemetry (MHT)","Re-hospitalization rate|Quality-of-life|Relapse rate|Participation rate|Uptake rate|Reporting rate","Dr. David Kreindler|Sunnybrook Health Sciences Centre","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","107-2012","October 2013","March 2016","March 2016","June 20, 2013",,"April 18, 2016","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01882608"
1774,"NCT04701866","Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression",,"Recruiting","No Results Available","Depressive Disorder, Treatment-Resistant|Depressive Disorder, Major|Unipolar Depression|Depression, Bipolar","Other: Music","Changes in Systolic Blood Pressure|Change From Baseline in MADRS Total Score to Last Treatment|Change From Baseline in MADRS Total Score to Follow-up|Change From Baseline in Beck Depression Inventory (BDI-II) Total Score to Last Treatment|Change From Baseline in Beck Depression Inventory (BDI-II) Total Score to Follow-up|Change From Baseline in Clinician-Rated Global Impression Improvement Score to Last Treatment|Change From Baseline in Clinician-Rated Global Impression Severity Score to Last Treatment|Change From Baseline in Clinician-Rated Global Impression Suicidality Severity Score to Last Treatment|Change From Baseline in Clinician-Rated Global Impression Suicidality Improvement Score to Last Treatment|Change From Baseline in Clinician-Rated Global Impression Improvement Score to Follow-up|Change From Baseline in Clinician-Rated Global Impression Severity Score to Follow-up|Change From Baseline in Clinician-Rated Global Impression Suicidality Severity Score to Follow-up|Change From Baseline in Clinician-Rated Global Impression Suicidality Improvement Score to Follow-up|Change From Baseline in PSQI Total and Subscores to Last Treatment|Change From Baseline in PSQI Total and Subscores to Follow-up|Change From Baseline in Beck Scale for Suicide Ideation (SSI) Total to Last Treatment|Change From Baseline in Beck Scale for Suicide Ideation (SSI) Total to Follow-up|Change From Baseline in Psychological and Physical Pain to Last Treatment|Change From Baseline in Psychological and Physical Pain to Follow-up|Change From Baseline in STAI-Y A to Last Treatment|Change From Baseline in STAI-Y A to Follow-up|Change From Baseline in STAI-Y B to Last Treatment|Change From Baseline in STAI-Y B to Follow-up|The Mystical Experience Questionnaire (MEQ) after each treatment|The Psychedelic Music Questionnaire Short-Form (PMQ-SF) after each treatment|Inflammatory markers before and after the first and last treatment","Douglas Mental Health University Institute|Réseau québécois sur le suicide, les troubles de l'humeur et les troubles associés","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DOUGKMT01","January 11, 2021","May 2022","June 2022","January 8, 2021",,"January 8, 2021","Douglas Mental Health University Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04701866"
1775,"NCT02838043","The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients",,"Completed","No Results Available","Major Depressive Disorder|Depression|Depressive Symptoms","Dietary Supplement: Probio'Stick","Mood|Anxiety|Cognition|Sleep|Plasma","Queen's University|Lallemand Health Solutions|McMaster University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6016312","August 2016","May 2018","May 2018","July 20, 2016",,"June 14, 2019","Queen's University, Kingston, Ontario, Canada|Providence Care - Mental Health Services, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02838043"
1776,"NCT03043833","Internet-Delivered Cognitive Behavior Therapy for Anxiety and Depression Amongst French Canadians",,"Completed","No Results Available","Major Depression|Anxiety Disorders","Behavioral: The Wellbeing Course","Changes in depression as assessed by the Patient Health Questionnaire-9 (PHQ-9)|Changes in anxiety as assessed by the Generalized Anxiety Disorder-7 (GAD-7)|Changes in life satisfaction as assessed by the Satisfaction with Life Scale (SWLS)|Changes in health as assessed by the Short-Form Health Survey|Changes in personality as assessed by the Self-administered Standardised Assessment of Personality - Abbreviated Scale|Changes in anxiety as assessed by the Penn State Worry Questionnaire (PSWQ)|Changes in social anxiety as assessed by the Social Phobia Inventory (SPIN)|Changes in panic and agoraphobia as assessed by the Panic and Agoraphobia Scale (PAS)","Universite de Moncton|Macquarie University, Australia","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","File 1516-077","January 18, 2017","January 30, 2018","March 30, 2018","February 6, 2017",,"May 1, 2018","Université de Moncton - Adult Clinical Psychology Laboratory, Moncton, New Brunswick, Canada",,"https://ClinicalTrials.gov/show/NCT03043833"
1777,"NCT02238977","Bupropion for Depression in ESRD Patients on Hemodialysis",,"Terminated","Has Results","Major Depression|End Stage Renal Disease","Drug: Fluoxetine|Drug: Bupropion","Depression Severity","University of Arkansas|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 4","1","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","203076|R21DK097470","March 31, 2016","March 1, 2018","March 1, 2018","September 12, 2014","July 17, 2018","July 17, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02238977/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02238977/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02238977"
1778,"NCT02882711","The UTHealth Ketamine Project",,"Terminated","Has Results","Treatment Resistant Depression|Major Depressive Disorder|Bipolar Disorder","Drug: Ketamine","Safety Will be Measured Through Number of Adverse Events|Efficacy of Treatment Will be Measured on of Clinical Global Impressions (CGI)|Severity of Depressive Symptoms as Assessed by the PHQ-9","The University of Texas Health Science Center, Houston","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0020","November 7, 2016","August 16, 2017","August 16, 2017","August 30, 2016","November 9, 2020","November 24, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02882711/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02882711"
1779,"NCT00025974","Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder",,"Completed","No Results Available","Panic Disorder|Posttraumatic Stress Disorder|Major Depressive Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"230","NIH","Observational",,"020002|02-M-0002","October 31, 2001",,"July 21, 2008","November 5, 2001",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00025974"
1780,"NCT01893749","Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health","CATCH-IT","Completed","No Results Available","Major Depression|Depressive Episodes","Behavioral: CATCH-IT","Major Depressive Episode (major and sub-threshold)|Depressed mood|Vulnerability Factors|Quality of Life, educational impairment and other mental disorder symptoms or episodes","Benjamin Van Voorhees, MD, MPH|Wellesley College|Northwestern University|Harvard Vanguard Medical Associates|Access Healthcare Systems|NorthShore University HealthSystem|Infant Welfare Society|Advocate Health Care|Franciscan St. Margaret Health - Franciscan Alliance|University of Illinois at Chicago","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","1142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","2011-0505|1R01MH090035-01A1","February 2012","July 2016","July 2016","July 9, 2013",,"August 22, 2019","ACCESS Healthcare Systems, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Northshore Healthcare Systems, Evanston, Illinois, United States|Advocate Health Care, Oak Lawn, Illinois, United States|Children's Clinic, Oak Park, Illinois, United States|Franciscan St. Margaret Health, Dyer, Indiana, United States|Wellesley Center for Women, Wellesley, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01893749"
1781,"NCT03861988","Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery",,"Recruiting","No Results Available","Major Depressive Disorder|Surgery|Orthopedic Disorder","Drug: Ketamine|Drug: Normal saline (placebo)","Composite score on Hospital Anxiety and Depression Scale (HADS) and Montgomery-Asberg Depression Rating Scales (MADRS)|Pain at surgical site: scale of 0-10|Opioid consumption","Stanford University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","49114","August 22, 2019","December 2021","January 2022","March 5, 2019",,"March 17, 2021","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03861988"
1782,"NCT01942187","A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults",,"Withdrawn","No Results Available","Major Depressive Disorder|Dysthymic Disorder|Depressive Disorder Not Otherwise Specified (NOS)","Drug: Aripiprazole|Drug: Bupropion|Behavioral: Problem Solving Therapy","Hamilton Psychiatric Rating Scale for Depression|Wechsler Abbreviated Scale of Intelligence (WASI) Matrix Reasoning Test","New York State Psychiatric Institute","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#6627","August 2013","December 2015","December 2015","September 13, 2013",,"April 18, 2019","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01942187"
1783,"NCT01150604","Depression Management Project","DMP","Completed","No Results Available","Major Depression|Depression","Behavioral: Self-help cognitive-behavioral online course","Quick Inventory of Depressive Symptoms - Self-report","University of California, San Francisco|National Institute of Mental Health (NIMH)|Robert Wood Johnson Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","547","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T32MH019391","June 2010","June 2013","June 2013","June 25, 2010",,"November 15, 2018","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01150604"
1784,"NCT00919932","Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework",,"Completed","Has Results","Major Depressive Disorder|Cognitive Behavior Therapy|Text Messaging","Behavioral: Paper and pen homework|Device: Text message system homework.","Therapy Homework Compliance: Percent Homework Completed|Exit Interview","University of Pittsburgh|American Academy of Child Adolescent Psychiatry.","All","13 Years to 17 Years   (Child)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACA-08-001-UPMC","February 2009","January 2010","January 2010","June 12, 2009","February 15, 2016","February 15, 2016",,,"https://ClinicalTrials.gov/show/NCT00919932"
1785,"NCT01566318","Depression Agency-Based Collaboration",,"Completed","No Results Available","Major Depression|Anxiety Disorder","Behavioral: Problem-Solving Therapy","Major depressive disorder|Generalized anxiety disorder","University of Pittsburgh|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","P30MH090333-PRC1|P30MH090333","March 2012","February 2016","June 2016","March 29, 2012",,"December 13, 2016","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01566318"
1786,"NCT01309581","Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression",,"Terminated","Has Results","Major Depression|Bipolar Depression","Drug: Ketamine|Drug: Methohexital","Hamilton Rating Scale for Depression-24 (HRSD24)|Quick Inventory of Depressive Symptomatology, Self Report (QIDS-SR)","James Murrough|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GCO 09-2251|KETECT-MSSM-01","April 2010","October 2010","October 2010","March 7, 2011","August 30, 2013","August 30, 2013","Icahn School of Medicine at Mount Sinai, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT01309581"
1787,"NCT02028026","The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives",,"Withdrawn","No Results Available","Major Depressive Disorder|Anxiety|Comorbidity","Drug: Vilazodone|Drug: Citalopram","Glutamate Levels|Functional Connectivity","Massachusetts General Hospital","Female","18 Years to 50 Years   (Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VII-IT-10|2013P000335","April 2013","February 2015","April 2015","January 6, 2014",,"November 8, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02028026"
1788,"NCT01537679","Meditation to Reduce Caregiver Stress","Meditation","Completed","No Results Available","Depression NOS|Major Depressive Disorder|Anxiety NOS","Behavioral: Kirtan Kriya meditation|Behavioral: Relaxation","Hamilton Depression Rating Scale (HDRS)|Caregiver Burden Scale|Connor-Davidson Resilience scale (CD-RISC)","University of California, Los Angeles","All","45 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","10-000270; 09-03-086-01D","March 2010","August 2010","January 2012","February 23, 2012",,"November 28, 2016","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01537679"
1789,"NCT03088657","Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study",,"Recruiting","No Results Available","Mood Disorders|Bipolar Disorder|Major Depressive Disorder",,"illness severity and change in patients by using Clinical Global Impression-Bipolar score|Scores of depressive symptoms as assessed by MADRS|Scores of manic symptoms as assessed by YMRS|Daily mood chart|Sleep|Activity|Heart rate|average monthly cost of treatment for psychiatric, medical, dental, and oriental medicinal management","Korea University Anam Hospital|Ministry of Health & Welfare, Korea|Seoul National University Hospital|Severance Hospital|Seoul National University Bundang Hospital|Samsung Medical Center|Gyeongsang National University Hospital|Pusan National University Hospital|Chonnam National University Hospital|National Center for Mental Health, Korea","All","up to 35 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MDCRC","September 2015","July 2022","September 2022","March 23, 2017",,"February 27, 2019","Heon-Jeong Lee, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03088657"
1790,"NCT04850911","Reward Emotion Learning and Ketamine Study","RELAKS","Not yet recruiting","No Results Available","Depression|Major Depressive Disorder|Treatment Resistant Depression","Drug: Ketamine Hydrochloride|Other: No intervention (placebo)","Activation of the habenula during the Pavlovian conditioning task in response to the conditioned stimulus associated with pain stimuli and in response to the receipt of shock.|Habenula response to the absence of expected reward and the receipt of an unexpected loss (i.e. a negative prediction error signal) in both the reward maximisation and loss minimisation tasks.|Preference for high-reward probability shapes learned after winning money (in the Wheel of Fortune draw) during the preference test.|Ventral striatum response to the expected reward and the omission an unexpected loss (i.e. a positive prediction error signal) in both the reward maximisation and loss minimisation tasks.|Pupil dilation (measured by an eye tracker device) in response to decision values in the affective memory preference test.|Difference in pupil response to shapes learned after winning versus losing money.|Amount of money earned in the learning and memory task.|Change in bio-behavioral measures of stress following laboratory induced stress administered.|Recognition of positive and negative facial expressions.|Categorisation of emotional words.|Recognition of emotional words.|Recall of emotional words.","University of Oxford|Medical Research Council|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years to 45 Years   (Adult)","Not Applicable","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","RELAKS_HV","April 2021","November 2022","November 2022","April 20, 2021",,"April 20, 2021",,,"https://ClinicalTrials.gov/show/NCT04850911"
1791,"NCT03472638","Dorsomedial rTMS For Depression In Borderline Personality Disorder","rTMS","Unknown status","No Results Available","Borderline Personality Disorder|Major Depression","Device: Dorsomedial prefrontal rTMS","HRSD-17 change|ZAN-BPD change","University Health Network, Toronto","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","15-9928","July 2016","December 2017","July 2018","March 21, 2018",,"March 21, 2018","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03472638"
1792,"NCT00447512","Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones",,"Completed","No Results Available","Healthy|Major Depression","Drug: ghrelin","sleep, conventionally and quantitatively analyzed|hormones of the hypothalamic-pituitary-adrenocortical (HPA) axis, the gonadotropic axis and the hypothalamic-pituitary-gonadal axis","Max-Planck-Institute of Psychiatry|German Research Foundation","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","L2/2003","March 2004",,"October 2007","March 14, 2007",,"October 31, 2007","Max Planck Institute of Psychiatry, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00447512"
1793,"NCT03313674","Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD",,"Completed","No Results Available","Seasonal Affective Disorder|Major Depressive Disorder|Neuroimaging","Device: Bright Light Therapy","Changes in neural function|Changes in connectivity|Executive Function|Concentration|Memory|Blood Serum Metabolomic seasonal variation|Depressive severity measured through the • Structured Interview Guide for the Hamilton Depression Rating Scale-SAD version","Sunnybrook Health Sciences Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","281-2017","November 1, 2017","October 5, 2019","October 5, 2019","October 18, 2017",,"March 16, 2021","Sunnybrook Health Science Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03313674"
1794,"NCT02119923","Tackling Depression and Anxiety: A Working Memory Intervention",,"Completed","No Results Available","Major Depression|Anxiety Disorder","Behavioral: Working memory training|Behavioral: Placebo training","Beck Depression Inventory Second Edition (BDI-II) score change between pre and post training and at follow-up measurement (2 months after post measurement)|State-Trait Anxiety Inventory (STAI) scores change from pre to post training and to follow up measurement (2 months after post measurement)","Erasmus Medical Center","All","16 Years to 68 Years   (Child, Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1","April 2011","October 2011","October 2011","April 22, 2014",,"April 22, 2014","Erasmus University Rotterdam, Rotterdam, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT02119923"
1795,"NCT00565110","Treating Depression Among Low-Income Patients With Cancer","ADAPt-C","Completed","Has Results","Major Depression|Dysthymia","Behavioral: ADAPt-C intervention","Reduced Depression Symptoms|Physical Composite Summary Score (PCS) Derived From the 12-item Short Form (SF-12) Health Survey","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","472","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","USCIRB-HS-10-00466|R01CA105269","June 2004","January 2009","July 2010","November 29, 2007","July 24, 2017","July 24, 2017","Los Angeles County+University of Southern California Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00565110"
1796,"NCT00369343","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women",,"Completed","Has Results","Depression|Depressive Disorder|Depressive Disorder, Major","Drug: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|Drug: Placebo","Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.|Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score|Percentage of Patients Achieving Remission|Percentage of Patients Achieving Response to Treatment|Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8|Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8|Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months|Clinical Global Impression Improvement (CGI-I) Score|Percentage of Patients Achieving a Response to Treatment|Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months|Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months|Discontinuation-Emergent Signs and Symptoms (DESS) Total Score","Wyeth is now a wholly owned subsidiary of Pfizer","Female","40 Years to 70 Years   (Adult, Older Adult)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3151A1-403","September 2006","November 2007","July 2008","August 29, 2006","May 7, 2012","May 7, 2012","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Springdale, Arkansas, United States|Palo Alto, California, United States|San Diego, California, United States|New London, Connecticut, United States|Bradenton, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Sandy Springs, Georgia, United States|Savannah, Georgia, United States|Smyrna, Georgia, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Terre Haute, Indiana, United States|Shreveport, Louisiana, United States|Rockville, Maryland, United States|Omaha, Nebraska, United States|Cherry Hill, New Jersey, United States|Brooklyn, New York, United States|Minot, North Dakota, United States|Beachwood, Ohio, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Hilton Head Island, South Carolina, United States|Austin, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00369343"
1797,"NCT01811147","Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI",,"Completed","Has Results","Bipolar Disorder|Major Depression","Drug: Selective Serotonin Reuptake Inhibitor (SSRI)","HAM-D 17 Item: Hamilton Depression Rating Scale|YMRS: Young Mania Rating Scale","The Cleveland Clinic","All","15 Years to 30 Years   (Child, Adult)","Phase 4","192","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB 12-1279","November 2011","June 2018","June 2018","March 14, 2013","December 2, 2019","December 2, 2019","Cleveland Clinic Foundation Center for Behavioral Health, Cleveland, Ohio, United States","""Study Protocol: Image Acquisition - CCF"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01811147/Prot_000.pdf|""Study Protocol and Statistical Analysis Plan: Full Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01811147/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01811147"
1798,"NCT01973283","Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults",,"Completed","Has Results","Major Depressive Disorder|Dysthymic Disorder|Depressive Disorder, NOS","Drug: Antidepressant Medication","Hamilton Rating Scale for Depression (HRSD)|Hamilton Depression Rating Scale (HRSD)|Hamilton Depression Rating Scale: Stratified by Baseline Frailty|World Health Organization Disability Assessment 2.0 (36-item)|World Health Organization Disability Assessment 2.0 (36-item)--Stratified by Baseline Frailty","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 4","100","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#6470/7289R|K23MH099097-01A1","February 19, 2014","December 5, 2019","December 5, 2020","October 31, 2013","January 13, 2021","January 29, 2021","New York State Psychiatric Institute, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01973283/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01973283/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01973283/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01973283"
1799,"NCT00570583","Neurocognitive Outcomes of Depression in the Elderly","NCODE","Completed","No Results Available","Major Depression|Dementia",,"Change in Depression status (measured by Montgomery Asberg Depression Rating Scale)|Change in Cognitive impairment (as measuring using cognitive tests including those found in the CERAD battery)|Development of dementia (Determined by Clinical Consensus Conference)|Change in Cognition (as measured by tests including those in the CERAD battery) Change in Brain MRI markers (e.g., volume of white matter and gray matter lesions)|Change in Impairment in Instrumental or Basic Activities of Daily Living|Packing density of prefrontal cortex neurons with pyramidal morphology in post-mortem neuroanatomical studies","Duke University|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)",,"795","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00006424|1R01MH108560-01|0625","December 1995","December 31, 2019","December 31, 2019","December 11, 2007",,"August 5, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00570583"
1800,"NCT02811198","Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality",,"Unknown status","No Results Available","Major Depressive Disorder|Suicide|Suicidal Ideation","Other: No intervention","Potential biomarkers for suicide risk including brain scans, genomic or proteomic makers, task performance","Unity Health Toronto","All","18 Years to 70 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SBIO-01","January 2017","July 2018","July 2018","June 23, 2016",,"October 6, 2017","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02811198"
1801,"NCT04130958","Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics",,"Recruiting","No Results Available","Major Depressive Disorder|Borderline Personality Disorder|Suicide","Device: Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|Device: Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)","Changes in Functional Connectivity of Key Nodes","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2019P002288","June 2021","December 2022","December 2022","October 18, 2019",,"May 24, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04130958"
1802,"NCT00374426","Preventing Depression Recurrence in Diabetes",,"Completed","No Results Available","Major Depression|Diabetes","Drug: sertraline",,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","262","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","96-0806 (completed)|DK53060","March 1998",,"October 2004","September 11, 2006",,"March 2, 2010","Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00374426"
1803,"NCT00183729","Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults",,"Completed","Has Results","Depression","Drug: Memantine|Other: Placebo","Depressive Symptoms|Incidence of Major Depressive Disorder|Functional Recovery","Eric Lenze|National Institute of Mental Health (NIMH)|University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)","Phase 4","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K23MH064196-02","August 2005","June 2009","June 2009","September 16, 2005","December 15, 2016","January 17, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00183729"
1804,"NCT00208715","Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.",,"Completed","No Results Available","Major Depression|Mental Health","Drug: Provigil","Epworth Sleepiness Scale (ESS)|Hamilton Depression Scale (HAM-D 31 item)","Emory University|Cephalon","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","1021-2002","February 2003",,"October 2004","September 21, 2005",,"November 11, 2013","Stanford University, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00208715"
1805,"NCT01529905","Longitudinal Study of People Presenting for First Treatment of a Mood Disorder",,"Unknown status","No Results Available","Major Depression|Bipolar Disorder",,,"McMaster University|Ontario Mental Health Foundation|Canadian Institutes of Health Research (CIHR)|AstraZeneca","All","16 Years to 50 Years   (Child, Adult)",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","99-1715","June 1999","September 2009","June 2014","February 9, 2012",,"February 9, 2012","St. Joseph's Healthcare, Centre for Mountain Health Services, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01529905"
1806,"NCT01962753","Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)","ASAP","Unknown status","No Results Available","Elderly|Major Depression","Drug: 18FAV45","standards uptakes values (SUVr)|Residual cognitive deficits","University Hospital, Tours","All","55 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHRN10-VC/ ASAP","May 2012","May 2018","May 2018","October 14, 2013",,"February 16, 2015","University Hospital of Besançon- Jean Minjoz, Besançon, France|University Hospital of Caen, Caen, France|University Hospital of Lille, Lille, France|University Hospital of Nice, Nice, France|Sainte-Anne Hospital, Paris, France|Le Rouvray Hospital, Sotteville lès Rouen, France|University Hospital of Strasbourg - HUS, Strasbourg, France|University Hospital of Toulouse - Purpan, Toulouse, France|University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT01962753"
1807,"NCT04124744","A Pilot Randomised Controlled Trial of a Health Champion Intervention",,"Not yet recruiting","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder","Other: Health Champions intervention|Other: Control group-treatment as usual","EQ-5D-3L|Recovering Quality of Life Questionnaire-ReQOL|Patient Activation Measure|Multimorbidity Treatment Burden Questionnaire|De Jong Gierveld Loneliness Scale|Health screenings in last 6 months","King's College London|South London and Maudsley NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","270290","April 2, 2020","January 30, 2022","May 30, 2022","October 11, 2019",,"February 20, 2020","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04124744"
1808,"NCT01831362","Dismantling Mindfulness: Contributions of Attention vs. Acceptance",,"Completed","No Results Available","Mild-moderate Unipolar Depression; Persistent Negative Affect","Behavioral: Mindfulness-Based Cognitive Therapy|Behavioral: Focused Attention (FA)|Behavioral: Open- Monitoring","Change in Inventory of Depressive Symptomatology|change in Depression, Anxiety Stress Scale (DASS)|change in Wellbeing Scale (WBS)|Change in alpha-theta EEG power from baseline to 8 weeks|Change in Facial EMG power from baseline to 8 weeks|Sustained Attention to response Task (SART)|Difficulties in Emotion Regulation Scale (DERS)|Attention Control Questionnaire (Derryberry & Reed, 2002)","Brown University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","K23AT006328-01A1","February 2013","March 15, 2016","March 15, 2016","April 15, 2013",,"November 5, 2018","Brown University Clinical and Affective Neuroscience Laboratory, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01831362"
1809,"NCT00437385","Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients","EffECT","Completed","No Results Available","Depression|Major Depression","Drug: TCAs, SSRIs, NARIs, SNRIs, Lithium|Procedure: Electroconvulsive therapy|Behavioral: Cognitive behavioral group therapy","Score on HAMD after 6 and 12 months|Relapse rate after 6 and 12 months|Response and remission rates after 6 and 12 months|Scores on MADRS, BDI, and CGI after 6 and 12 months","Charite University, Berlin, Germany|German Research Foundation","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ek224-05b","March 2005","March 2010","March 2011","February 21, 2007",,"November 10, 2011","Department of Psychiatry, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00437385"
1810,"NCT02176824","Chronotherapy Randomized Controlled Trial",,"Terminated","No Results Available","Major Depressive Disorder|Bipolar Depression|Suicidal Ideation","Behavioral: Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Behavioral: Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|Other: Treatment as usual","Hamilton Depression Rating Scale|Columbia Suicide Severity Rating Scale","Medical University of South Carolina","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Chronotherapy RCT","June 1, 2014","April 7, 2016","April 7, 2016","June 27, 2014",,"May 30, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02176824"
1811,"NCT03790085","Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals",,"Unknown status","No Results Available","Schizophrenia|Major Depressive Disorder|Anxiety Disorders","Drug: Risperidone|Drug: Olanzapine|Drug: Aripiprazole","Positive and Negative Syndrome Scale (PANSS)|Clinical Global Impression(CGI)","Tianjin Medical University General Hospital|Shanghai Mental Health Center|Nanjing Medical University|Tianjin Anding Hospital|Harbin First Specialist Hospital|First Affiliated Hospital of Chongqing Medical University|Anhui Mental Health Center|Wuhan Psychiatric Hospital|Wenzhou Seventh People's Hospital|First Affiliated Hospital of Harbin Medical University","All","18 Years to 45 Years   (Adult)","Early Phase 1","2700","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018YFC1314300","September 1, 2018","June 30, 2020","December 31, 2020","December 31, 2018",,"December 31, 2018","Tianjin Medical University General Hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT03790085"
1812,"NCT03795051","Coil Positioning in Navigated Transcranial Magnetic Stimulation Feasibility in Depression Patients Trial","CONFIDENT","Completed","No Results Available","Depressive Disorder, Major","Device: Navigated Transcranial Magnetic Stimulation","Percentage of successful nTMS treatment sessions|Operator Confidence|Patient Comfort|Patient Health Questionnaire 9 (PHQ-9) - Patient Depression Questionnaire|Coil Position deviation from target","Magstim","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MGS-2018-SS","January 9, 2019","September 1, 2019","September 30, 2019","January 7, 2019",,"January 3, 2020","Georgia Behavioral Health Professionals, Atlanta, Georgia, United States|Georgia Behavioral Health Professionals, Dunwoody, Georgia, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03795051/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03795051"
1813,"NCT02855580","Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic","PGX","Completed","No Results Available","Obsessive Compulsive Disorder|Major Depressive Disorder|Anxiety",,"Antidepressant Tolerance|Symptom Severity-Depression|Symptom Severity-Anxiety|Symptom Severity-Obsessive Compulsive Symptoms|Side effects","University of Florida","All","8 Years to 20 Years   (Child, Adult)",,"71","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201601035","September 2016","July 6, 2017","July 6, 2017","August 4, 2016",,"June 10, 2019","Child Psychiatry Clinic at University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02855580"
1814,"NCT00119028","Expanding and Testing VA Collaborative Care Models for Depression","ReTIDES","Withdrawn","No Results Available","Major Depression|Post-Traumatic Stress Disorder","Procedure: Depression Care Quality Improvement Implementation","Impact of the intervention on depression performance measure, and provider attitudes. Quality of life-patient satisfaction.|Cost-effectiveness, system costs, tool kit development","US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult","Not Applicable","0","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","MNT 03-215|Project #0024|PCC # 2004-121657","April 2005","December 2008","October 2009","July 12, 2005",,"April 24, 2012","Long Beach, Long Beach, California, United States|VA Medical Center, Shreveport, Louisiana, United States|VA Medical Center, Minneapolis, Minnesota, United States|St. Cloud VA Medical Center, St Cloud, Minnesota, United States|VA Medical Center, Cincinnati, Cincinnati, Ohio, United States|Michael E DeBakey VA Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00119028"
1815,"NCT03560518","Study of Rapastinel as Monotherapy in Patients With MDD",,"Terminated","Has Results","Depressive Disorder, Major","Drug: Rapastinel|Drug: Placebo","Change From Baseline on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at End of Treatment (End of Week 6)|Change From Baseline in MADRS Total Score at Day 1 Post-first Dose of Treatment","Naurex, Inc, an affiliate of Allergan plc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","439","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RAP-MD-32","June 15, 2018","July 8, 2019","July 8, 2019","June 18, 2018","September 1, 2020","September 1, 2020","Alea Research, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|California Pharmaceutical Research Institute, Inc., Anaheim, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Synergy Research San Diego, National City, California, United States|Excell Research Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|California Neuroscience Research Medical Group,Inc., Sherman Oaks, California, United States|Viking Clinical Research Ltd., Temecula, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Innovative Clinical Research, Inc., Lauderhill, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute for Advanced Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Iris Research, Inc., Smyrna, Georgia, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|CBH Health, LLC, Gaithersburg, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Altea Research Institute, Las Vegas, Nevada, United States|Hassman Research Institute, Berlin, New Jersey, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|The Medical Research Network, LLC, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|New Hope Clinical Research Inc., Charlotte, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Donald J. Garcia, Jr., MD, PA, Austin, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03560518/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03560518/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03560518"
1816,"NCT00578669","Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms",,"Completed","Has Results","Major Depressive Disorder|Nicotine Dependence|Depression","Drug: Fluoxetine|Drug: Dextrose","Number of Participants Achieving Smoking Abstinence|Self-reported Depressive Symptoms","Butler Hospital|National Institute on Drug Abuse (NIDA)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","206","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PHI0710-002|1R01DA023190","April 2008","July 2013","November 2013","December 21, 2007","October 16, 2018","October 16, 2018","Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00578669"
1817,"NCT01526395","Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital",,"Completed","No Results Available","Major Depressive Disorder|Bipolar Disorder|Schizophrenia","Drug: Propofol","Percentage of patients receiving ECT who agree to the modified form of treatment after it is offered.|Rate at which ECT is offered and refused.|Change in patient anxiety measured by the state portion of the State-Trait Anxiety Inventory.|Inpatient length of stay calculated from onset of ECT administration.|Number of ECTs required to complete a course of treatment|Changes in scales used to assess severity of symptoms. The investigators will record changes in the Hamilton Depression Rating Scale, the Young Mania Rating Scale, the Brief Psychiatric Rating Scale and the Clinical Global Impression Severity scale.|Cognitive changes, monitored by the Mini Mental State Examination (MMSE)|Monitoring of adverse effects such the occurence of emergent delirium, headaches, muscle aches, nausea and vomiting, and fractures and dislocations.|Monitoring of delirium using the test with the Confusion Assessment Method for the ICU (CAM-ICU).","Johns Hopkins University|Johns Hopkins Bloomberg School of Public Health|Chhatrapati Shahuji Maharaj Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","99","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NA_00027421","August 2011","April 2012","April 2012","February 3, 2012",,"April 4, 2013","Chhatrapati Shahuji Maharaj Medical University, U.P. & G.M. & Associated Hospitals, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01526395"
1818,"NCT03043560","Study to Treat Major Depressive Disorder With a New Medication",,"Completed","Has Results","Depressive Disorder|Anhedonia","Drug: Ezogabine|Drug: Placebos","Change in Ventral Striatum (VS) Activation|Change in Snaith-Hamilton Pleasure Scale (SHAPS)|Clinical Global Impression - Improvement (CGI-I)|Clinical Global Impression - Severity (CGI-S)|Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)|Montgomery-Asberg Depression Rating Scale (MADRS)|World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)|Temporal Experience of Pleasure Scale (TEPS)|Specific Loss of Interest and Pleasure Scale (SLIPS)","James Murrough|National Institute of Mental Health (NIMH)|Baylor College of Medicine|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","GCO 16-0374|1R61MH111932-01","September 25, 2017","August 30, 2019","August 30, 2019","February 6, 2017","October 23, 2020","October 23, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States|Baylor College of Medicine, Houston, Texas, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03043560/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03043560/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03043560"
1819,"NCT01876823","Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment",,"Completed","Has Results","Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Disease","Drug: es-citalopram|Drug: Memantine","Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)|Change in Wechsler Memory Scale-III (WMS-III)|Change in Selective Reminding Test - Delayed Recall (SRT-DR)|Change in Trails B|Change in Trails A","New York State Psychiatric Institute","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6277R","April 2006","March 2010","March 2010","June 13, 2013","October 24, 2014","October 24, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01876823"
1820,"NCT03854578","A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions",,"Completed","No Results Available","Depressive Disorder, Major","Drug: BI 1358894|Drug: Placebo matching BI 1358894|Drug: Citalopram","Mean BOLD signal % change in an emotional paradigm (emotional faces task from the Warsaw Set of Emotional Facial Expression Pictures (WSEFEP) in the corticolimbic system|Number and percentage of subjects with AEs|Mean BOLD signal % change in the corticolimbic system, based on the Open Affective Standardized Image Set (OASIS)","Boehringer Ingelheim","All","18 Years to 45 Years   (Adult)","Phase 1","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1402-0003|2017-004763-12","March 12, 2019","August 27, 2019","September 23, 2019","February 26, 2019",,"October 3, 2019","Charité - Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03854578"
1821,"NCT00481026","A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression",,"Completed","No Results Available","Schizophrenia|Major Depression","Device: transcranial direct current stimulation (tDCS)|Device: active tDCS","Clinical Scales","Bayside Health","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","11707","August 2007","May 2013","May 2013","June 1, 2007",,"October 14, 2020","Alfred Psychiatry Research Centre, Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00481026"
1822,"NCT00105820","Evaluation Study of TIDES Depression Care Quality Improvement Intervention",,"Completed","No Results Available","Major Depression|PTSD","Procedure: System level depression care quality improvement","At set time points the following will be measured: Recovery from depression Patient quality of life 1 year before and after: Clinic depression treatment utilization and costs|Adherence to appropriate treatment","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","750","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","MHI 99-375","June 2003",,"March 2006","March 17, 2005",,"April 7, 2015","VA Greater Los Angeles Healthcare System, Sepulveda, CA, Sepulveda, California, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00105820"
1823,"NCT02119975","A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals",,"Completed","No Results Available","Major Depression|Anxiety Disorder","Behavioral: Working memory training|Behavioral: Placebo training","Change in Ruminative Response Scale (RRS) score from pre to post training and after two months (follow up 2)|Change in Beck Depression Inventory Second Edition (BDI-II) score from pre to post training and after two months (follow up 2)|Change in State-Trait Anxiety Inventory (STAI) score from pre to post training and after two months (follow up 2)","Erasmus Medical Center","All","18 Years to 67 Years   (Adult, Older Adult)","Not Applicable","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","4","August 2011","December 2011",,"April 22, 2014",,"April 22, 2014","Erasmus University Rotterdam, Rotterdam, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT02119975"
1824,"NCT04937829","A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: BI 1569912|Drug: Placebo","Percentage of patients with drug-related adverse events (AEs)|Maximum decrease from baseline (peak decrease) in Montgomery-Åsberg Depression Rating Scale (MADRS) at any day within a 7 days-interval|Montgomery-Åsberg Depression Rating Scale Area under the response curve from pre-dose to the last measurement during inpatient stay at 166:30 hours (MADRS AUC0-166:30)","Boehringer Ingelheim","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1447-0003","July 20, 2021","April 29, 2022","May 14, 2022","June 24, 2021",,"July 23, 2021","Research Centers of America, Hollywood, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04937829"
1825,"NCT01331330","European Deep Brain Stimulation (DBS) Depression Study",,"Completed","No Results Available","Depressive Disorder, Major","Device: Deep Brain Stimulation","Percentage of change from mean baseline values in MADRS score|Percentage of change from baseline value of HDRS","Abbott Medical Devices","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NM-09-035-EU-DB","May 2011","December 2014","January 2015","April 8, 2011",,"May 19, 2015","CHU Pasteur, Nice, France|Hôpital La Pitié Salpêtrière, Paris, France|Hadassah-Hebrew University Medical Center, Jerusalem, Israel|King's College London, London, United Kingdom|National Hospital for Neurology and Neurosurgery - UCL, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01331330"
1826,"NCT04423757","A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: BI 1358894|Drug: Placebo","Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score|Montgomery-Asberg Depression Rating Scale (MADRS), response defined as ≥ 50% MADRS reduction from baseline|State-Trait Anxiety Inventory (STAI), change from baseline in STAI State and Trait version scores|Clinical Global Impression Severity Scale (CGI-S), change from baseline in CGI-S score|Symptoms of Major Depressive Disorder Scale (SMDDS), change from baseline in SMDDS total score|Patient Global Impression Severity Scale (PGI-S), change from baseline in PGI-S score|Patient Global Impression of Change Scale (PGI-C) score","Boehringer Ingelheim","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1402-0014","June 22, 2020","November 26, 2022","December 26, 2022","June 9, 2020",,"August 3, 2021","Science 37, Inc., Culver City, California, United States",,"https://ClinicalTrials.gov/show/NCT04423757"
1827,"NCT03559192","A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: JNJ-67953964|Drug: Placebo","Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Score up to Treatment Week 6|Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Score up to Treatment Week 6|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Scores up to Treatment Week 6|Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Scores up to Treatment Week 6|Change From Baseline in Self-Assessment of Treatment Experience (SATE) Score up to Treatment Week 6|Change From Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Score up to Treatment Week 6|Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score up to Treatment Week 6","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 2","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108487|67953964MDD2001|2019-000695-41","July 16, 2018","May 6, 2020","May 6, 2020","June 18, 2018",,"May 7, 2021","Noble Clinical Research, Tucson, Arizona, United States|Preferred Research Partners, Little Rock, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, Riverside, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Galiz Research, Miami Springs, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|APG Research, LLC, Orlando, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Psychiatric Medicine Associates LLC, Skokie, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Richmond Behavioural Associates, Staten Island, New York, United States|Clinical Trials of America, Hickory, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Paradigm Research Professionals, LLC, Oklahoma City, Oklahoma, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinical NeuroScience Solutions, Inc, Memphis, Tennessee, United States|Advanced Clinical Research, West Jordan, Utah, United States|Emovis GmbH, Berlin, Germany|Somni Bene GmbH, Schwerin, Germany|ARENSIA, Chisinau, Moldova, Republic of|Sverdlovsk Regional Clinical Psychiatric Hospital, Ekaterinburg, Russian Federation|Clinical Psychiatric Hospital #3 Named After V.A. Gilyarovsky, Moscow, Russian Federation|Orenburg Regional Clinical Psychiatric Hospital #1, Orenburg, Russian Federation|Medical and Rehabilitation Research Center Phoenix, Rostov-on-Don, Russian Federation|Engels psychiatric hospital, Saratov Region, Russian Federation|SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky, Saratov, Russian Federation|Saratov Regional Psychiatric hospital named after St. Sofia, Saratov, Russian Federation|City Psychiatric hospital 7 named after I.P.Pavlov, St-Petersburg, Russian Federation|Psychoneurological dispensary 1, St-Petersburg, Russian Federation|St-Petersburg Bekhterev Psychoneurological Research Institute, St. Petersburg, Russian Federation|Research Institute of Mental Health, Tomsk, Russian Federation|MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association, Glevakha, Ukraine|Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3', Kharkiv, Ukraine|CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council, Kherson, Ukraine|Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa), Kyiv, Ukraine|Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council', Nove, Kropyvnytskiy, Ukraine|CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council', Smila, Ukraine|MAC Clinical Research, Barnsley, United Kingdom|MAC Clinical Research, Blackpool, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|Hammersmith Medicines Research Ltd, London, United Kingdom|MAC Clinical Research, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03559192"
1828,"NCT04225624","Improving Attentional and Cognitive Control in the Psychological Treatment of Intrusive Thoughts",,"Recruiting","No Results Available","Obsessive-Compulsive Disorder|Generalized Anxiety Disorder|Major Depressive Disorder","Behavioral: Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Behavioral: Supportive Psychotherapy (SPT)","Change from baseline in transdiagnostic repetitive negative thinking at 8 weeks (as measured by the Perseverative Thinking Questionnaire)|Change from baseline in worry at 8 weeks (as measured by the Penn State Worry Questionnaire)|Change from baseline in rumination at 8 weeks (as measured by the Rumination Response Scale)|Change from baseline in mental rituals at 8 weeks (as measured by the Rumination on Obsessions and Compulsions Scale)|Change from baseline in OCD symptom severity at 8 weeks (as measured by the Yale-Brown Obsessive-Compulsive Scale)|Change from baseline in generalized anxiety symptom severity (as measured by the Structured Interview Guide for the Hamilton Anxiety Rating Scale)|Change from baseline in depression symptom severity (as measured by the Structured Interview Guide for the Hamilton Depression Rating Scale)|Change from baseline in functional impairment (as measured by the Work and Social Adjustment Scale)","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 60 Years   (Adult)","Not Applicable","98","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2019P003768|1K23MH120351-01A1","April 30, 2021","December 31, 2024","March 31, 2025","January 13, 2020",,"July 14, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04225624"
1829,"NCT00369915","The Antidepressant Efficacy of the Anticholinergic Scopolamine",,"Terminated","Has Results","Unipolar Depression|Bipolar Depression","Drug: Scopolamine","Change in Depression Severity|Hamilton Anxiety Rating Scale","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 2","17","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","060234|06-M-0234","August 2006","January 2013","January 2013","August 30, 2006","April 29, 2016","November 10, 2016","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00369915"
1830,"NCT02681822","Multi-center Imaging Genetics Studies in China","CHIMGEN","Unknown status","No Results Available","Alzheimer Disease|Schizophrenia|Major Depressive Disorders",,"Brain structure and function measured by MRI scans|Childhood adversities as assessed by Childhood Trauma Questionnaire-Short Form (Chinese Version)","Tianjin Medical University General Hospital|Tianjin Medical University Cancer Institute and Hospital|Tianjin Medical University Second Hospital|Tianjin First Central Hospital|Pingjin Hospital,Logistics University of Chinese People's Armed Police Forces|School of Medical Imaging, Tianjin Medical University|Tianjin Huanhu Hospital|Beijing Hospital|Chinese PLA General Hospital|Beijing Tongren Hospital|Xuanwu Hospital, Beijing|Peking Union Medical College Hospital|Beijing Normal University|Chinese Academy of Sciences|The Second Hospital of Hebei Medical University|The First Affiliated Hospital of Shanxi Medical University|Inner Mongolia Medical College Hospital|The First Hospital of Jilin University|The Frist Hospital Of China Medical University|The First Affiliated Hospital of Dalian Medical University|RenJi Hospital|Huashan Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Nanjing PLA General Hospital|The First Affiliated Hospital with Nanjing Medical University|Xuzhou Medical University|Second Affiliated Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Wenzhou Medical University|The First Affiliated Hospital of Anhui Medical University|Shan dong Medical Imaging Research Institute|Qilu Hospital of Shandong University|Yantai Yuhuangding Hospital|Henan Provincial People's Hospital|The First Affiliated Hospital of Zhengzhou University|Tongji Hospital|Wuhan University|Xiangya Hospital of Central South University|Central South University|Guangdong Provincial People's Hospital|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|South China Normal University、Hainan General Hospital|First Affiliated Hospital Xi'an Jiaotong University|Xijing Hospital|Tang-Du Hospital|LanZhou University|West China Hospital|Second Affiliated Hospital of Wenzhou Medical University|University of Electronic Science and Technology of China|First Affiliated Hospital of Chongqing Medical University|Southwest Hospital, China|The University of Science and Technology of China|Guangdong No.2 Provincial People's Hospital","All","18 Years to 30 Years   (Adult)",,"10000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","81425013","November 2015","December 2019","December 2020","February 12, 2016",,"April 10, 2019","Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02681822"
1831,"NCT01793324","EMR Data to Assess Monitoring of Patients Treated With Quetiapine",,"Completed","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder",,"Determination whether physicians in the UK and Germany perform monitoring of patients treated with Seroquel® and Seroquel® XR including measurement of the following during patient encounters: weight at drug initiation and over the course of treatment.|Monitoring of hyperlipidemia during patient encounters.|Monitoring for signs and symptoms of hyperglycemia during patient encounters.|Monitoring of blood glucose in patients with diabetes; monitoring of patients with risk factors for diabetes for worsening of glycemic control during patient encounters.|Counseling patients on healthy eating, exercise and healthy lifestyle improvements during patient encounters.","AstraZeneca","All","18 Years and older   (Adult, Older Adult)",,"6153","Industry","Observational","Time Perspective: Retrospective","D1443C00128","April 2012","June 2013","June 2013","February 15, 2013",,"January 28, 2014",,,"https://ClinicalTrials.gov/show/NCT01793324"
1832,"NCT01590862","ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators",,"Recruiting","No Results Available","Obsessive Compulsive Disorder|Major Depressive Disorder|Epilepsy","Device: Deep Brain Stimulator","Approach Avoidance Task","Massachusetts General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2011P002821","January 23, 2021","March 31, 2025","March 31, 2025","May 3, 2012",,"April 5, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01590862"
1833,"NCT04521478","A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: BI 1358894|Drug: Placebo|Drug: Quetiapine","Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score|Response defined as ≥ 50% MADRS reduction from baseline|Change from baseline in State-Trait Anxiety Inventory (STAI) State and Trait version scores|Change from baseline in Clinical Global Impression Severity Scale (CGI-S) score|Change from baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) total score","Boehringer Ingelheim","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","431","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1402-0011|2019-004264-21","November 20, 2020","January 23, 2023","February 22, 2023","August 20, 2020",,"July 30, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|Collaborative Neuroscience Network, LLC (CNS), Garden Grove, California, United States|California Neuroscience Research, Sherman Oaks, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Viking Clinical Research, Ltd., Temecula, California, United States|Collaborative Neuroscience Research, Torrance, California, United States|Institute of Living, Hartford, Connecticut, United States|Gulf Coast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Atlanta Center, Atlanta, Georgia, United States|Psychiatric Medicine Associates, LLC, Skokie, Illinois, United States|McLean Hospital, Belmont, Massachusetts, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|Hassman Research Institute, Berlin, New Jersey, United States|Hassman Research Institute, Marlton, New Jersey, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Peninsula Therapeutic and Research Group, Frankston, Victoria, Australia|Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia|Neuropsychiatry, s.r.o., Hradec Kralove, Czechia|A-shine, Plzen, Czechia|Clintrial s.r.o., Prague, Czechia|Private Practice for Psychiatry, Prague, Czechia|AD71 s.r.o., Prague, Czechia|INEP medical s.r.o., Prague, Czechia|HOP Bohars, Bohars, France|HOP Dijon-Bourgogne, Dijon, France|CAB Médical Psyché, Douai, France|HOP la Colombière, Montpellier, France|HOP Saint-Jacques, Nantes, France|HOP Pasteur, Nice, France|HOP Carémeau, Nîmes, France|CTR Psychiatrique Universitaire, Saint-Cyr-sur-Loire, France|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Zentralinstitut für seelische Gesundheit, Mannheim, Germany|Studienzentrum Nord-West, Westerstede, Germany|Obudai Egeszsegugyi Centrum, Budapest, Hungary|National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Ichikawa, Japan|Kaku Mental Clinic, Fukuoka, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Fukuoka, Japan|Kuramitsu Hospital, Fukuoka, Fukuoka, Japan|Arai Clinic, Hyogo, Amagasaki, Japan|Kishiro Mental Clinic, Kanagawa, Kawasaki, Japan|Arata Clinic, Nagasaki, Nagasaki, Japan|Nara Medical University Hospital, Nara, Kashihara, Japan|National Center Neurology and Psychiatry, Tokyo, Kodaira, Japan|Sancha Mental Clinic, Tokyo, Setagaya-ku, Japan|Maynds Tower Mental Clinic, Tokyo, Shibuya-ku, Japan|Wlokiennicza Med,Spec.Med.Prac,MD Tomasz Markowski,Bialystok, Bialystok, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Bydgoszcz, Poland|Specialist Psychiatric Healthcare Centre in Lodz, Lodz, Poland|Clin.Research Centre Clinsante SC Ewa Galczak-Nowak,Torun, Torun, Poland|Federal State Budget Institution ""Mental Health Research Center"", Moscow, Russian Federation|FSBI V. P. Serbsky Nat.Med.Res.Cen.of Psych&Neuro, Moscow, Russian Federation|SHI ""Reg.Clin.Psychiatric Hosp.of Saint Sophia"", Saratov, Russian Federation|FSBEI of HE Smolensk State Medical University, Smolensk, Russian Federation|SBHI ""Psychiatric Hospital #1 P.P.Kashchenko"", St. Petersburg, Russian Federation|FSBI Bekhterev Net.Med.Res.Cen.of Psych&Neuro, St. Petersburg, Russian Federation|LLC ""MK-Med"", St. Petersburg, Russian Federation|MUDr. Beata Dupejová, Banska Bystrica, Slovakia|J & J SMART, s.r.o., psychiatric clinic, Bratislava, Slovakia|MENTUM s.r.o., Bratislava, Slovakia|EPAMED s.r.o., Kosice, Slovakia|CENTRUM ZDRAVIA R.B.K, s.r.o., psychiatric clinic, Svidnik, Slovakia|Crystal Comfort s.r.o, Vranov nad Toplou, Slovakia|Hospital Ramón y Cajal, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Spain|Centro de Salud de San Juan, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",,"https://ClinicalTrials.gov/show/NCT04521478"
1834,"NCT01748955","Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study",,"Completed","Has Results","Depression|Suicidal Ideation","Drug: Paroxetine CR for Major Depressive Episode|Drug: Bupropion XL for Major Depressive Episode","Percent Change in Contrast of Parameter Estimates (COPE)|Change in Suicidal Ideation (SSI Score)","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5933R|K23MH076049","June 2010","March 2015","March 2015","December 13, 2012","February 15, 2017","November 21, 2017","Columbia University/New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01748955"
1835,"NCT03414619","The Role of Cognitive Control in the Transdiagnostic Conceptualization of ""Intrusive Thoughts""",,"Completed","No Results Available","Obsessive-Compulsive Disorder|Generalized Anxiety Disorder|Major Depressive Disorder","Behavioral: Cognitive Control Tasks and Script Driven Imagery","Commission Errors on the Go/No Go Task|Response time on the Stroop Color Word Test|Perseverative Errors on the Wisconsin Card Sort Test|Gaze latency on the Attentional Engagement-Disengagement Task|Perseverative Thinking Questionnaire (PTQ)|State measure of intrusive thinking","Massachusetts General Hospital|Health Resources in Action, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017P002114","May 18, 2018","March 6, 2020","March 6, 2020","January 30, 2018",,"March 18, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03414619"
1836,"NCT00765752","Cortical GABA Concentrations in Insomnia",,"Completed","No Results Available","Insomnia|Major Depression",,"Cortical GABA levels as measured by proton MRS|Ambulatory polysomnography","Yale University|Sunovion","All","25 Years to 55 Years   (Adult)",,"23","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","0707002830|ESRC 057","November 2007","June 2011","June 2011","October 3, 2008",,"January 21, 2013","Yale Depression Research Program, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00765752"
1837,"NCT01447082","General Practice Research Database Seroquel XR Safety Study","GPRD SeroquelS","Completed","No Results Available","Schizophrenia|Major Depressive Disorder|Bipolar Disorder",,"The outcome of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine XR vs corresponding incidence rates in users of comparison drugs|Duration of treatment|Duration of treatment episode|Comorbidities defined by clinical diagnosis or prescription|Age|Gender|Dose|Adherence|The number of subjects to whom the drug was prescribed by the general practitioners.|Indication for treatment","AstraZeneca|University Hospital, Basel, Switzerland","All","18 Years to 85 Years   (Adult, Older Adult)",,"37372","Industry|Other","Observational","Time Perspective: Retrospective","D1444C00006","October 2008","December 2012","December 2012","October 5, 2011",,"February 7, 2014","University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT01447082"
1838,"NCT00449007","Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism",,"Terminated","Has Results","Depression|Alcoholism|Suicidal Behavior","Drug: fluoxetine|Drug: bupropion","Occurrence of Suicide Events Either a Suicide Death, a Suicide Attempt, or Suicidal Ideation Severe Enough to Warrant a Medical Intervention|Suicidal Ideation at 6 Months","New York State Psychiatric Institute|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","5","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIAAA-OQU-015630-02|P20AA015630|NIH Grant P20 AA015630-02","February 2006","December 2010","December 2010","March 19, 2007","July 16, 2021","August 4, 2021","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00449007"
1839,"NCT02270073","The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study","PrOMET","Completed","No Results Available","Major Depression|Anxiety Disorder","Behavioral: Cognitive behavior therapy of trainee therapists","Working Alliance Inventory - Short Revised (WAI-SR)|Brief Symptom Inventory (BSI)|Beck Depression Inventory (BDI)|Inventory of Interpersonal Problems (IIP)|Kentucky Inventory of Mindfulness Skills (KIMS)|Global Assessment of Functioning (GAF)|Development of Psychotherapists Common Core Questionnaire (DPCCQ) short version|Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy (SACiP)|Beck Anxiety Inventory (BAI)","Heidelberg University|University of Trier|University of Zurich|University of Applied Sciences Esslingen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA6526/2-1(DFG)","October 2014","January 2018","July 2018","October 21, 2014",,"October 26, 2018","Center for Psychological Psychotherapy - University of Heidelberg, Heidelberg, Baden Wuerttemberg, Germany",,"https://ClinicalTrials.gov/show/NCT02270073"
1840,"NCT01561105","Improving Depression Care for Elders: Coordinating Center","IMPACT","Completed","No Results Available","Major Depression|Dysthymic Disorder|Both Major Depression and Dysthymic Disorder","Other: IMPACT","Severity of depression symptoms|Functioning","University of California, Los Angeles|The John A. Hartford Foundation|California HealthCare Foundation|Hogg Foundation|Robert Wood Johnson Foundation","All","60 Years and older   (Adult, Older Adult)","Not Applicable","1801","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","JAHF 98297","January 1999","June 2004","June 2004","March 22, 2012",,"March 28, 2012",,,"https://ClinicalTrials.gov/show/NCT01561105"
1841,"NCT00135512","Study Of 323U66 SR In Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder","Drug: bupropion hydrochloride","Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases|Change From Baseline in the MADRS Total Score at Week 52 in Observed Cases|Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Weeks 8 and 52 in Observed Cases|Percentage of Participants Who Were Clinical Global Impression Global Improvement (CGI-I) Responders at Weeks 8 and 52 in Observed Cases|Change From Baseline in CGI Severity of Illness (CGI-SI) at Weeks 8 and 52 in Observed Cases|Change From Baseline in the Sheehan Disability Scale (SDISS) Total Score at Weeks 8 and 52 in Observed Cases|Change From Baseline in the Motivation Energy Inventory Short Form (MEI-SF) Total Score at Weeks 8 and 52 in Observed Cases","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","234","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AK1102364","December 1, 2004","May 28, 2007","May 28, 2007","August 26, 2005","February 1, 2019","February 1, 2019","GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site",,"https://ClinicalTrials.gov/show/NCT00135512"
1842,"NCT01795326","Physician Survey on Monitoring of Patients Treated With Quetiapine",,"Completed","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder",,"Determination via survey whether physicians or someone in their practice perform monitoring of patients treated with Seroquel or Seroquel XR for metabolic issues related to treatment; refer their patients to another physician for monitoring.|Determination via survey whether physicians monitor tests for hyperlipidemia in patients who are taking Seroquel or Seroquel XR.|Determination via survey whether physicians monitor for signs and symptoms of hyperglycemia in patients who are taking Seroquel or Seroquel XR.|Determination via survey whether physicians monitor blood glucose in patients with diabetes or monitor patients with risk factors for diabetes for worsening of glycemic control if they are taking Seroquel or Seroquel XR.|Determination via survey whether physicians monitor weight at initiation of treatment with Seroquel or Seoquel XR and on a regular basis after initiating treatment.|Determination via survey whether physicians counsel patients taking with Seroquel or Seroquel XR on healthy eating, exercise, and healthy lifestyle improvements.|Determination via survey whether physicians received educational information relevant to the issues in the survey from AstraZeneca.|Determination via survey whether physicians read the educational information.","AstraZeneca","All","Child, Adult, Older Adult",,"800","Industry","Observational","Time Perspective: Cross-Sectional","D1443C00127","June 2013","September 2013","September 2013","February 20, 2013",,"January 28, 2014",,,"https://ClinicalTrials.gov/show/NCT01795326"
1843,"NCT02023567","Objective Diagnostic Markers and Personalized Intervention in MDD Patients",,"Unknown status","No Results Available","Depressive Disorder, Major","Drug: SSRIs","The changes of HAMD total score at 8 weeks from baseline|The changes of HAMA total score at 8 weeks from baseline|The change of CGI score at 8 weeks from baseline|The prognosis after the intervention|Number of participants with serious and non-serious adverse events","Peking University|Capital Medical University|Peking Union Medical College Hospital|Tianjin Medical University General Hospital|Tianjin Anding Hospital|The First Hospital of Hebei Medical University|First Hospital of China Medical University|Dalian Seventh People's Hospital|The First Affiliated Hospital of Shanxi Medical University","All","18 Years to 55 Years   (Adult)","Not Applicable","2400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2013CB531305","November 2013","December 2016","December 2016","December 30, 2013",,"May 20, 2016","Beijing Anding Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Peking University Sixth Hospital, Beijing, Beijing, China|Hebei Medical University First Hospital, Shijiazhuang, Hebei, China|Dalian Seventh People's Hospital, Dalian, Liaoning, China|First Hospital of China Medical University, Shenyang, Liaoning, China|First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|Tianjin Anding Hospital, Tianjin, Tianjin, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02023567"
1844,"NCT00319319","Nicotinic Receptor Augmentation of SSRI Antidepressants",,"Completed","No Results Available","Depressive Disorder","Drug: Mecamylamine hydrochloride (Inversine)","Hamilton Depression Rating Scale|Beck Depression Inventory|Cigarette Smoking|Quality of Life|Clinical Global Impression Scale","Yale University|Donaghue Medical Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","DF-02-006","January 2003",,"January 2007","April 27, 2006",,"April 19, 2007","Connecticut Mental Health Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00319319"
1845,"NCT00285376","Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response",,"Completed","No Results Available","Depressive Disorder, Major","Drug: vilazodone","MADRS|HAM-D|CGI","Genaissance Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GNSC-04-DP-02","February 2006","May 2007","May 2007","February 2, 2006",,"February 21, 2008","Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pharmacology Research Institute, Northridge, California, United States|Pharmacology Research Institute, Riverside, California, United States|Atlanta Institute of Medicine & Research, Atlanta, Georgia, United States|Atlanta Institute of Medicine & Research, Marietta, Georgia, United States|Summit Research Network (Michigan), Inc., Farmington Hills, Michigan, United States|Summit Research Network (Michigan), Inc., Flint, Michigan, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|University of Pennsylvania Department of Psychiatry Mood and Anxiety Disorders Section, Philadelphia, Pennsylvania, United States|Southeast Health Consultants, LLC, Charleston, South Carolina, United States|University of Utah health Services Center Dept. of Psychiatry Mood and Anxiety Disorders, Salt Lake City, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00285376"
1846,"NCT01377896","The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours",,"Completed","No Results Available","Schizophrenia|Bipolar Disorders|Major Depressive Disorders",,,"AstraZeneca","All","Child, Adult, Older Adult",,"221","Industry","Observational","Time Perspective: Retrospective","NIS-NZA-XXX-2011/1","July 2010","October 2010","October 2010","June 22, 2011",,"June 28, 2011",,,"https://ClinicalTrials.gov/show/NCT01377896"
1847,"NCT00406952","Study for Evaluating Different Methods of Measuring Depression Treatment Response",,"Completed","No Results Available","Depressive Disorder, Major","Procedure: electronic diary|Drug: Sertraline|Drug: Placebo|Procedure: voice acoustics","The primary endpoint is time to treatment response and difference in time to response for the two data collection methods - daily patient electronic assessment versus weekly assessments measured in clinic.|The secondary endpoint is the difference in study participation burden between standard and enhanced data collection.","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A9001337","November 2006",,"August 2007","December 4, 2006",,"August 21, 2008","Pfizer Investigational Site, Norwich, Connecticut, United States|Pfizer Investigational Site, Aventura, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Elmsford, New York, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Plano, Texas, United States|Pfizer Investigational Site, Midvale, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00406952"
1848,"NCT00584974","A Safety, Efficacy and Tolerability Study of SEP-225289",,"Completed","No Results Available","Depressive Disorder, Major","Drug: SEP-225289|Drug: Venlafaxine|Drug: placebo","To assess the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder (MDD)|To examine the response to SEP-225289 in MDD subjects meeting DSM_IV criteria for atypical and melancholic features","Sunovion","All","18 Years to 55 Years   (Adult)","Phase 2","523","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","360-029","December 2007","May 2009","May 2009","January 2, 2008",,"February 23, 2012","Little Rock, Arkansas, United States|Arcadia, California, United States|Beverly Hills, California, United States|Costa Mesa, California, United States|Garden Grove, California, United States|Glendale, California, United States|Irvine, California, United States|Lafayette, California, United States|Oceanside, California, United States|San Diego, California, United States|Upland, California, United States|Denver, Colorado, United States|Denver, Colorado, United States|New Britain, Connecticut, United States|Bradenton, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lauderhill, Florida, United States|Maitland, Florida, United States|North Miami, Florida, United States|Sanford, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Smyrna, Georgia, United States|Park Ridge, Illinois, United States|Lake Charles, Louisiana, United States|Boston, Massachusetts, United States|Braintree, Massachusetts, United States|Flowood, Mississippi, United States|St. Charles, Missouri, United States|Clementon, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Bronx, New York, United States|Brooklyn, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Middleburg Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|Midlothian, Virginia, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00584974"
1849,"NCT00924976","Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families",,"Completed","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder","Behavioral: Steps for Achieving Financial Empowerment (SAFE)","employment|empowerment|family support","University of North Carolina, Chapel Hill|U.S. Department of Education","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","303","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","H133G070058","May 2008","April 2011","April 2011","June 19, 2009",,"June 15, 2018","UNC-Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00924976"
1850,"NCT01152996","Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study",,"Completed","Has Results","Depressive Disorder, Major","Drug: Vortioxetine","Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%|Number of Participants With Serious Treatment-Emergent Adverse Events|Treatment-Emergent Adverse Events Leading to Study Discontinuation|Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)|Change From Baseline in Sheehan Disability Scale (SDS) Total Score|Change From Baseline in SDS Work/School Subscale|Change From Baseline in SDS Social Life Subscale|Change From Baseline in SDS Family Life/Home Responsibilities Subscale","Takeda","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","1075","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LuAA21004_314|U1111-1115-4927","September 2010","May 2013","May 2013","June 29, 2010","May 28, 2014","May 28, 2014",,,"https://ClinicalTrials.gov/show/NCT01152996"
1851,"NCT00420641","MDD POC Study GSK372475 Subjects Depressive Disease",,"Completed","Has Results","Depressive Disorder","Drug: GSK372475|Drug: Paroxetine|Other: Placebo","Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score|Change From Randomization at the End of the Treatment Phase (Week 10) in Bech Scale (6-item of 17-item Hamilton Depression Rating [HAMD-17] Scale) Score|Mean Change From Randomization at the End of the Treatment Phase (Week 10) in Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Total Score|Mean Change From Randomization in IDS- Self-Rated Version (SR) Total Score Over Week 10|Mean Change From Randomization in the 16-item Quick Inventory of Depressive Symptomatology-Clinician-rated Version (QIDS-CR16) Total Score Over Week 10|Mean Change From Randomization in the 16-item Quick Inventory of Depressive Symptomatology-Self-rated Version (QIDS-SR16) Total Score Over Week 10|Mean Change From Randomization in the MADRS Item 2 Score (Reported Sadness) Over Week 10|Mean Change From Randomization in the IDS-CR Scale Item 5 (Feeling Sad) Over Week 10|Mean Change From Randomization at the End of the Treatment Phase (Week 10) in the HAMD-17 Total Score|Mean Change From Randomization in the HAMD-17 Scale Item 1 (Depressed Mood) Over Week 10|Mean Change From Randomization in IDS-CR and IDS-SR 5 Item Subscale Over Week 10|Mean Change From Randomization in the Clinical Global Impression-Severity of Illness (CGI-S) Scale Over Week 10|Mean Change From Randomization in the Motivation and Energy Inventory (MEI) 18-Item Short Form (SF) Total Score Over Week 10|Mean Change From Randomization in the Changes in Sexual Functioning Questionnaire 14-item Short Form (CSFQ-14SF) Over Week 10|Mean Change From Randomization in the MADRS Total Score Over Week 8|Mean Change From Randomization in IDS-CR Total Score Over Week 8|Mean Change From Randomization in the in Bech Scale (6-item of HAMD-17 Scale) Score Over Week 8|Percentage of Responders and Remitters of MADRS Over Week 10|Percentage of Responders and Remitters of IDS-CR Over Week 10|Percentage of Responders and Remitters of HAMD-17 Over Week 10|Percentage of Participants With Clinical Global Impression - Global Improvement (CGI-I) Over Week 10|Percentage of Participants Satisfied With Study Medication at Week 10|Number of Participants With Most Severe Suicidal Behaviour and Ideation in the Suicidal Behavior (SB) and Suicidal Ideation (SI) Subscales of the Columbia Suicide Severity Rating Scale (CSSRS) Over Week 10","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","492","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SND 103288","December 19, 2006","June 1, 2008","October 15, 2008","January 11, 2007","February 5, 2018","February 5, 2018","GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Miramichi, New Brunswick, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Markham, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Los Yoses, San José, San José, Costa Rica|GSK Investigational Site, San José, Costa Rica|GSK Investigational Site, Split, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Angoulême, France|GSK Investigational Site, Dole, France|GSK Investigational Site, Elancourt, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Lucknow, India|GSK Investigational Site, Mangalore, India|GSK Investigational Site, Manipal,, India|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Chelmno, Poland|GSK Investigational Site, Leszno, Poland",,"https://ClinicalTrials.gov/show/NCT00420641"
1852,"NCT04598906","Ecologically Valid Virtual Tasks vs Paper-pencil Methods in Cognitive Rehabilitation in Patients With Schizophrenia and Depression",,"Completed","No Results Available","Schizophrenia|Depression|Cognitive Impairment","Behavioral: Virtual environment rehabilitation|Behavioral: Paper-pencil rehabilitation","Cognitive abilities measured by The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Item performance in Virtual Supermarket Shopping Task","National Institute of Mental Health, Czech Republic","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VRremediation","September 1, 2019","January 1, 2021","January 1, 2021","October 22, 2020",,"March 2, 2021","Mental Health Center, Karviná, Czechia",,"https://ClinicalTrials.gov/show/NCT04598906"
1853,"NCT00025857","Brain Function in Mentally Ill Adolescents",,"Completed","No Results Available","Healthy|Posttraumatic Stress Disorder|Major Depressive Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","7 Years to 18 Years   (Child, Adult)",,"105","NIH","Observational",,"020007|02-M-0007","October 22, 2001",,"June 29, 2012","October 28, 2001",,"December 3, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00025857"
1854,"NCT04824157","Ketamine IV Classic Protocol : Five Years Follow up",,"Completed","No Results Available","Major Depressive Disorder|Drug Abuse|Medications|Relapse","Other: Non","Mood that will be evaluated using the MADRAS Montgomery-Asberg Depression Rating Scale"".","Sheba Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)",,"11","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","5826-18-SMC","August 8, 2019","February 28, 2020","March 30, 2020","April 1, 2021",,"April 1, 2021","The Chaim Sheba Medical Center, Tel HaShomer, Israel",,"https://ClinicalTrials.gov/show/NCT04824157"
1855,"NCT00229294","Fibromyalgia in Men Suffering From PTSD",,"Completed","No Results Available","Fibromyalgia|Posttraumatic Stress Disorder|Major Depressive Disorder",,,"Sheba Medical Center","Male","20 Years to 60 Years   (Adult)",,,"Other","Observational","Time Perspective: Retrospective","SHEBA- 03-2925-JZ-CTIL","March 2004",,"March 2005","September 29, 2005",,"December 27, 2007",,,"https://ClinicalTrials.gov/show/NCT00229294"
1856,"NCT00191919","A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Duloxetine Hydrochloride|Drug: Placebo","Compare efficacy of Duloxetine versus placebo on somatic complaints of pain in patients meeting criteria for major depressive disorder.|Measure Efficacy by the following: MADRS total score, time to sustained clinical response for painful physical symptoms, time to sustained clinical response for overall depression symptoms, SCL-90R scale, PGI-I, CGI-S, CGI-I and BPI-SF.|Measure safety by the following: adverse events, withdrawals due to AE, vital signs, weight and laboratory values.","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","8605|F1J-BI-HMDH","May 2005",,"May 2006","September 19, 2005",,"January 26, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerpert, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Assebroek, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asse, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Diest, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genk, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oostende, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yvoir, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Espoo, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcachon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elancourt, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes-Orvault, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bielefeld, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chemnitz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erbach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Giessen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gottingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Karlsruhe, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kunzing, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bratislava, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kosice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Michalovce, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rimavaska Sobota, Slovakia",,"https://ClinicalTrials.gov/show/NCT00191919"
1857,"NCT04978220","Mental and Psychological Problems and Insomnia Disorder of Medical Staff in Hospital With Infected COVID-19 Patients",,"Completed","No Results Available","Depression Unipolar|Insomnia",,"Hospital Anxiety and Depression Scale (HADS)|Acute Stress Disorder Scale (ASDS)","Peking University Sixth Hospital","All","21 Years to 70 Years   (Adult, Older Adult)",,"390","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-021(BMR)","June 27, 2020","June 27, 2020","May 31, 2021","July 27, 2021",,"July 27, 2021","Peking University Sixth Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04978220"
1858,"NCT00163059","The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD",,"Completed","No Results Available","Depressive Disorder, Major","Drug: NMDA Antagonist, CP-101,606 (traxoprodil)","MADRS|HAM-D","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","A1611006","May 2004",,"December 2005","September 13, 2005",,"September 22, 2006","Pfizer Investigational Site, Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00163059"
1859,"NCT04059952","Mechanism of Action of Electroconvulsive Therapy","MoA-ECT","Recruiting","No Results Available","Unipolar Depression|Bipolar Depression","Procedure: Electroconvulsive Therapy","Changes in Functional Connectivity of Key Nodes|Changes in Functional Connectivity of Memory Circuits","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"136","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2012P001430","June 28, 2019","June 1, 2021","June 1, 2021","August 16, 2019",,"May 24, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04059952"
1860,"NCT00151372","Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients",,"Completed","Has Results","Pulmonary Disease, Chronic Obstructive|Major Depression","Behavioral: Treatment Adherence Intervention|Behavioral: Enhanced Care","Composite Antidepressant Score Scale (CAD)|Hamilton Depression Rating Scale","Weill Medical College of Cornell University|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years to 95 Years   (Adult, Older Adult)","Not Applicable","141","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0201005319|R01HL071992-05","March 2002","July 2008","July 2008","September 8, 2005","January 11, 2010","January 11, 2010","Helen Hayes Hospital, West Haverstraw, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Weill Medical College of Cornell University, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT00151372"
1861,"NCT01881763","Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression",,"Completed","No Results Available","Unipolar Depression|Bipolar Depression","Drug: Ketamine|Drug: Methohexital","Time to achieve remission|Cognitive side effects of ECT","Northwell Health|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-127","June 2010","March 2017","July 2017","June 20, 2013",,"August 10, 2017","Zucker Hillside Hospital, Glen Oaks, New York, United States",,"https://ClinicalTrials.gov/show/NCT01881763"
1862,"NCT01726387","Self-Management for Anxiety, Depression and Somatoform Disorders","SMADS","Completed","No Results Available","Anxiety Depression (Mild or Not Persistent)|Major Depressive Disorder, Single Episode, Unspecified|Neurotic, Stress-related and Somatoform Disorders","Behavioral: Psychosocial Counseling|Behavioral: Usual Care","General Self-Efficacy Scale (GSE)|Change in Symptom Score Patient's Health Questionnaire (German Version)|Health Related Quality of Life","Universitätsklinikum Hamburg-Eppendorf|German Federal Ministry of Education and Research","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","364","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMADS","March 2013","September 2015","September 2015","November 14, 2012",,"February 6, 2018","Primary Care Practices, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01726387"
1863,"NCT01562184","Investigating tDCS as a Treatment for Unipolar and Bipolar Depression",,"Completed","No Results Available","Unipolar Depression|Bipolar Depression","Device: Sham tDCS device|Device: Soterix tDCS device","Montgomery Asberg Depression Rating Scale for Depression (MADRS)|Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)|Montreal Cognitive Assessment (MoCA): Global Cognitive Function","The University of New South Wales|Duke University|Emory University|Sheppard Pratt Health System|University of Medicine and Dentistry of New Jersey|University of Texas","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HC11515|#11T-005","June 2012","October 2015","October 2015","March 23, 2012",,"December 2, 2015","Emory University, Atlanta, Georgia, United States|Sheppard Pratt, Towson, Maryland, United States|Rowan University, Cherry Hill, New Jersey, United States|Duke University, Durham, North Carolina, United States|University of Texas Southwestern, Dallas, Texas, United States|University of New South Wales / Black Dog Institute, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01562184"
1864,"NCT00179062","Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Depressive Disorder, Major|Bipolar Disorder","Drug: olanzapine versus risperidone","Evaluate the main and interactional effects of risperidone and olanzapine on body mass index (BMI), other measures of obesity, and other health-related factors, including total cholesterol, lipid panels, blood glucose, glycohemoglobin, and prolactin|Determine primary drug treatment effects and the relationships between change in BMI (body mass index), the biological measures listed above, and clinical outcomes including several domains of functioning.","Vanderbilt University","All","18 Years to 60 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","990472","February 2000","June 2007","June 2007","September 15, 2005",,"August 26, 2008","Psychiatric Hospital at Vanderbilt, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00179062"
1865,"NCT04123301","Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics.",,"Recruiting","No Results Available","Depressive Episode|Depressive Disorder|Bipolar Disorder","Device: Active Theta Burst Stimulation (TBS)|Device: Sham Theta Burst Stimulation (TBS)","Change in Montgomery-Asberg Depression Rating Scale (MADRS) at week 3.|Change in Montgomery-Asberg Depression Rating Scale (MADRS) at week 6.|Change in Young Mania Rating Scale (YMRS) at week 3.|Change in Young Mania Rating Scale (YMRS) at week 6.|Response rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 3|Response rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 6.|Remission rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 3|Remission rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 6.|Change in Hamilton Anxiety Scale (HAM-A scale) at week 3.|Change in Hamilton Anxiety Scale (HAM-A scale) at week 6.|Change in Global Clinical Impression Scale of Severity (GCI-S) at week 3.|Change in Global Clinical Impression Scale of Severity (GCI-S) at week 6.|Change in the brief version of the World Health Organization Quality of Life Questionnaire (WHOQOL-brief scale) at week 3.|Change in the brief version of the World Health Organization Quality of Life Questionnaire (WHOQOL-brief scale) at week 6.|Change in Global Assessment of Functioning (GAF) Scale at week 3.|Change in Global Assessment of Functioning (GAF) Scale at week 6.|Change in Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN) at week 3.|Change in Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN) at week 6.|Change in Barratt Impulsivity Scale of 11 items (BIS-11) at week 3.|Change in Barratt Impulsivity Scale of 11 items (BIS-11) at week 6.|Frequency of adverse events in UKU-SERS Scale at week 6.","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MORENO-2019","March 8, 2019","March 1, 2021","May 1, 2021","October 10, 2019",,"October 10, 2019","Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04123301"
1866,"NCT04498897","Vortioxetine for Treatment of Depressive Mood and Alcohol Use",,"Recruiting","No Results Available","Depressive Disorder, Major|Alcoholism","Drug: Vortioxetine|Drug: Acamprosate","K-MADRS|OCDS-K","Hanyang University Seoul Hospital","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 2","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VTX-RCT","January 25, 2019","April 4, 2021","April 4, 2021","August 5, 2020",,"August 5, 2020","Hanyang USH, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04498897"
1867,"NCT00914680","Berlin Magnetic Seizure Therapy Depression Trial 01",,"Completed","No Results Available","Unipolar Depression|Bipolar Depression","Procedure: magnetic seizure therapy","Clinical Improvement (HAMD)|Neurocognitive performance","Charite University, Berlin, Germany","All","25 Years to 80 Years   (Adult, Older Adult)","Phase 3","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEMAST1","June 2009","May 2012","May 2013","June 5, 2009",,"July 13, 2018","Department of Psychiatry, CC15, CBF, Eschenallee 3, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00914680"
1868,"NCT01557192","Low Field Magnetic Stimulation (LFMS) in Mood Disorders: 6 Treatments","LFMS6tx","Suspended","No Results Available","Bipolar Depression|Unipolar Depression","Device: Low Field Magnetic Stimulation Device","Change in Montgomery-Asberg Depression Rating Scale (MADRS)score|Change in Positive-Negative Affect Scale (PANAS)score|Immediate mood improvement as measured by the difference in post and pre treatment PANAS ratings|Change in Positive-Negative Affect Scale (PANAS)score.","Mclean Hospital","All","21 Years to 55 Years   (Adult)","Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-P-001097","May 2010","May 2020","May 2020","March 19, 2012",,"April 13, 2016","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01557192"
1869,"NCT00172549","Quality of Life and Its Related Factors of Patients With Major Depressive Disorder",,"Completed","No Results Available","Depression",,,"National Taiwan University Hospital","Female","18 Years and older   (Adult, Older Adult)",,,"Other","Observational","Observational Model: Defined Population|Time Perspective: Other","9361701176","March 2004",,"October 2004","September 15, 2005",,"September 15, 2005",,,"https://ClinicalTrials.gov/show/NCT00172549"
1870,"NCT04226963","A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders","GDKet","Recruiting","No Results Available","Treatment Resistant Depression|Bipolar Depression|Ketamine|Major Depressive Disorder","Drug: Ketamine","Incidence of adverse events assessed by Clinical-Administered Dissociative Symptoms Scale (CADSS)|Incidence of adverse events assessed by 4-items positive symptoms subscale of Brief Psychiatric Rating Scale (BPRS)|Incidence of adverse events assessed by body temperature (oral measurements)|Incidence of adverse events assessed by blood pressure|Incidence of adverse events assessed by respiration rate|Incidence of adverse events assessed by pulse|Incidence of adverse events assessed by blood oxygen saturation|Incidence of adverse events assessed by weight|Incidence of adverse events assessed by height|Change in severity of depression symptoms assessed by Montgomery-Asberg Depression Rating Scale (MADRS)","Medical University of Gdansk","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NKBBN/172-674/2019","December 4, 2019","December 31, 2022","December 31, 2022","January 13, 2020",,"January 13, 2020","Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland",,"https://ClinicalTrials.gov/show/NCT04226963"
1871,"NCT01714050","Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence",,"Unknown status","No Results Available","Seasonal Affective Disorder (SAD)|Winter Depression|Major Depressive Disorder, Recurrent, With Seasonal Pattern","Behavioral: Cognitive-Behavioral Therapy (CBT)|Device: Light Therapy (LT)","Depression recurrence status on the Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder Version (SIGH-SAD; Williams et al., 1992)|Beck Depression Inventory-Second Edition (BDI-II; Beck et al., 1996)|Structured Interview Guide for the Hamilton Rating Scale for Depression-Seasonal Affective Disorder Version (SIGH-SAD)","University of Vermont|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R01MH078982","July 2008","February 2014","February 2014","October 25, 2012",,"February 26, 2014","University of Vermont, Psychology Department, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01714050"
1872,"NCT00457106","A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks",,"Completed","No Results Available","Major Depression With Panic Attacks|Panic Disorder","Drug: Paroxetine|Drug: Risperidone","Hamilton Anxiety Rating Scale|Hamilton Depression Rating Scale|Panic Disorder Severity Scale|Sheehan Panic and Anxiety Scale - Patient rated|Clinical Global Impressions Scale","Beth Israel Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","IRB#: 082-02","June 2002","June 2003","June 2003","April 5, 2007",,"December 1, 2010","Beth Israel Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00457106"
1873,"NCT00186498","Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression",,"Completed","Has Results","Depressive Disorder, Major","Drug: memantine|Drug: Placebo Oral Capsule","Memantine Effect on CVLT Long Term Recall After Right Unilateral ECT Treatment.","Stanford University|Forest Laboratories","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NAM-10","February 2004","February 2006","February 2008","September 16, 2005","September 27, 2019","September 27, 2019","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00186498"
1874,"NCT00532103","Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression","SAMS","Completed","No Results Available","Depression",,,"National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)",,"300","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","N01 MH90003-01|DSIR AT","July 2007","February 2008","February 2008","September 19, 2007",,"September 22, 2008","Tuscalossa VA Mental Health Clinic, Tuscaloosa, Alabama, United States|Harbor UCLA Family Health Care Center, Harbor City, California, United States|UCLA Internal Medicine Clinic, Los Angeles, California, United States|Veterans Affairs Medical Center/FIRM Primary Care Clinic, San Diego, California, United States|Northwestern Psychiatric Outpatient Treatment Care Center, Chicago, Illinois, United States|Clinical Research Institute, Wichita, Kansas, United States|MGH/Northshore Medical Center (Salem Psychiatric Facility), Salem, Massachusetts, United States|General Psychiatric Ambulatory Clinic, Ann Arbor, Michigan, United States|Irving Goldman Primary Care at North Shore Hospital, New York, New York, United States|UNC Chapel Hill Adult Diagnostic & Treatment Clinic, Chapel Hill, North Carolina, United States|Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, United States|Bellefield Clinic of WPIC, Pittsburgh, Pennsylvania, United States|Vine Hill Community Clinic, Nashville, Tennessee, United States|UT Southwestern Family Medicine Clinic, Dallas, Texas, United States|VCU Outpatient Psychiatry Clinic, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00532103"
1875,"NCT02521883","Transcranial Direct Current Stimulation (tDCS) as an add-on Therapy for Treatment of Major Depressive Disorder. (DEPTDCS2014)",,"Unknown status","No Results Available","Depression","Device: Sooma tDCS|Device: Sham tDCS","Change from baseline in Montgomery-Åsberg depression scale (MADRS)|Dichotomised response measured with MADRS.|Change from baseline in Beck Depression Inventory (BDI) scale.|Dichotomised remission measured with MADRS.","Turku University Hospital|Tampere University Hospital|Sooma Oy","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T248/2014","March 2015","December 2019","March 2020","August 13, 2015",,"September 12, 2018","PHSOTEY, Psykiatrian tulosalue, ECT-yksikkö, Lahti, Finland|VSSHP Psykiatria, Liedon aikuispsykiatrian poliklinikka, Lieto, Finland|Turku University Hospital, Turku, Finland|Sektionen för affektiva sjukdomar, Norra Stockholms Psykiatri, Stockholms läns sjukvårdsområde, Stockholm, Stockholms Län, Sweden",,"https://ClinicalTrials.gov/show/NCT02521883"
1876,"NCT00220636","Abilify as an Adjunctive Treatment for Refractory Depression",,"Completed","Has Results","Depressive Disorder, Major","Drug: Aripiprazole","Hamilton Depression Rating Scale (HDRS)|Clinical Global Impressions Improvement Scale (CGI)|Change in Global Assessment of Functioning Scale (GAFS)|Change in Beck Depression Inventory (BDI) Score","St. Luke's-Roosevelt Hospital Center|Bristol-Myers Squibb","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLR-04-028","March 2005","March 2007","January 2008","September 22, 2005","February 20, 2015","May 26, 2016","Depression Evaluation Service, NY State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00220636"
1877,"NCT02562703","tVNS for Depression",,"Unknown status","No Results Available","Depressive Disorder","Device: Transcutaneous Vagus Nerve Stimulation","• Hamilton Depressive Rating Scale version 17 items (HDRS-17)","Santa Casa Medical School","All","18 Years to 59 Years   (Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","tVNS","November 2015","February 2016","July 2016","September 29, 2015",,"September 29, 2015",,,"https://ClinicalTrials.gov/show/NCT02562703"
1878,"NCT02088580","Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients",,"Completed","No Results Available","Non-Psychotic Unipolar Depression|Bipolar Depression","Procedure: Triple Chronotherapy","Hamilton Depression Rating Scale|Columbia Suicide Severity Rating Scale","Medical University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chronotherapy Pilot","October 2013","March 2014","April 2014","March 17, 2014",,"October 2, 2015","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02088580"
1879,"NCT02942368","Adaptive tDCS for Treatment-Resistant MDD",,"Active, not recruiting","No Results Available","Depressive Disorder, Treatment-Resistant","Device: tDCS","Improvement in depressive symptoms as measured by mean change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to end of the study.","Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6610","April 14, 2017","June 2022","June 2022","October 24, 2016",,"October 12, 2020","Washington University in Saint Louis, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02942368"
1880,"NCT03999567","Validation Study: Mobile DSST on Cognition in Adults With MDD",,"Completed","No Results Available","Major Depressive Episode","Other: Pen and Paper Digit Symbol Substitution Test (DSST)|Other: Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)","Validation of the mobile DSST application|Montgomery and Asberg Depression Rating Scale (MADRS)|Hamilton Anxiety Rating Scale (HAM-A)|Snaith Hamilton Pleasure Scale (SHAPS )","Brain and Cognition Discovery Foundation|Takeda|Cognition Kit|Ctrl Group, Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00037042","August 25, 2019","February 4, 2020","February 4, 2020","June 26, 2019",,"July 8, 2020","Canadian Rapid Treatment Centre of Excellence, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03999567"
1881,"NCT00488670","Escitalopram and Depression in Elderly Alzheimer's Patients",,"Terminated","No Results Available","Depressive Disorder","Drug: Escitalopram","Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.|Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study","University of British Columbia","All","50 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H07-00050","December 2010","June 2011","June 2011","June 20, 2007",,"June 6, 2011","Mt. St. Joseph's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00488670"
1882,"NCT00296725","Dichotic Listening as a Predictor of Medication Response in Depression",,"Completed","Has Results","Major Depression|Dysthymia|Depressive Disorder Not Otherwise Specified","Drug: Fluoxetine|Drug: Imipramine","Hamilton Depression Scale (HAM-D)|Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#4217R/#5294R|continuation of IRB3112;|became IRB5294R.","April 1994","June 2011","June 2011","February 27, 2006","May 15, 2019","May 30, 2019","Depression Evaluation Service, New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00296725"
1883,"NCT00296712","Are Two Antidepressants a Good Initial Treatment for Depression?",,"Completed","No Results Available","Major Depression|Dysthymia|Depression NOS","Drug: escitalopram + bupropion","Hamilton Depression Scale (HAM-D)|Beck Depression Inventory (BDI)|Clinical Global Impression Scale (CGI)|Patient Global Impression Scale (PGI)|Arizona Sexual Experience Scale (ASEX)","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#4653","February 2005","July 2006","July 2006","February 27, 2006",,"April 27, 2012","Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00296712"
1884,"NCT04177706","Ketamine for the Treatment of Opioid Use Disorder and Depression",,"Recruiting","No Results Available","Depression|Opioid-use Disorder|Opioid Abuse","Drug: Ketamine Hydrochloride|Drug: Placebo","Percentage of Individuals Completing Informed Consent|Percentage of Individuals Completing the Full Protocol|Change in Depression Severity","Medical University of South Carolina|National Institute on Drug Abuse (NIDA)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00091292|K12DA031794","December 17, 2020","December 1, 2021","December 1, 2021","November 26, 2019",,"January 11, 2021","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04177706"
1885,"NCT02085512","Prevention of PTSD III: Neurocognitive Training of Emotional Regulation",,"Completed","No Results Available","Post Traumatic Stress Disorder|Major Depression|Anxiety Disorders","Procedure: Neurocognitive retraining Web Based Intervention|Other: Control, web-based tasks","Amelioration of neurocognitive impairments that are associated with post-traumatic stress disorder|Post-traumatic Stress Disorder (PTSD) symptoms","NYU Langone Health|Stanford University|Shaare Zedek Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","14-00879","March 17, 2017","December 31, 2017","December 31, 2017","March 13, 2014",,"August 31, 2018","Shaare Zedek Medical Center, Jerusalem, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02085512/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02085512"
1886,"NCT04680910","Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) - Phase I",,"Recruiting","No Results Available","Treatment Resistant Depression","Drug: Phase I: Propofol infusion - moderate dose|Diagnostic Test: Electroencephalographic (EEG)|Diagnostic Test: Slow-Wave Activity","Duration of Slow Wave Activity","Washington University School of Medicine","All","60 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202008037","January 14, 2021","June 2022","June 2022","December 23, 2020",,"February 4, 2021","Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04680910"
1887,"NCT01944644","Low Field Magnetic Stimulation for Treatment Resistant Depression",,"Completed","Has Results","Treatment Resistant Depression","Device: Active Low Field Magnetic Stimulation|Device: Sham Low Field Magnetic Stimulation","6 Item Hamilton Depression Rating Scale|Visual Analog Scale|Positive and Negative Affect Score (PANAS) - Negative Subscale|Positive and Negative Affect Score (PANAS) - Positive Subscale","Weill Medical College of Cornell University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1207012777","August 2013","May 2016","May 2016","September 17, 2013","September 17, 2018","September 17, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01944644"
1888,"NCT00250653","A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression",,"Completed","No Results Available","Depressive Disorder","Drug: Saredutant succinate (SR48968C)","The primary outcome is the proportion of patients experiencing at least one treatment-emergent adverse event.|The main secondary outcomes are incidences of potentially clinically significant abnormalities and the changes from baseline in the values for clinical laboratories, vital signs, and electrocardiogram parameters.","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS5577|Saredutant (SR48968C)","May 2005","April 2007","April 2007","November 8, 2005",,"February 17, 2012","Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00250653"
1889,"NCT04220996","Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)","RECONNECT","Completed","No Results Available","MDD|Anxiety Disorders","Drug: Vortioxetine","Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score|Change in Hamilton Anxiety Rating Scale (HAM-A) total score|Change in Hospital Anxiety and Depression Scale (HADS) total score|Change in Functioning Assessment Short Test (FAST) total score|Change in Clinical Global Impression - Severity of Illness (CGI-S) score|Clinical Global Impression Scale- Global Improvement (CGI-I) score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) total score","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18314A","December 27, 2019","March 9, 2021","March 9, 2021","January 7, 2020",,"April 20, 2021","Marienthali Kliinik (EE0001), Tallinn, Estonia|Tartu University Hospital (EE0002), Tartu, Estonia|Cabinet du Docteur Patrick Bourgoin (FR0002), Angoulême, France|Cabinet Psyche (FR0004), Douai, France|Cabinet du Docteur Karim Boutayeb (FR0001), Viersat, France|Centre Medical Ambroise Pare (FR0003), Élancourt, France|Azienda Ospedaliera di Perugia - Policlinico Monteluce (IT0003), Perugia, Italy|Fondazione Santa Lucia IRCCS (IT0002), Rome, Italy|Inje University Ilsan Paik Hospital (KR0002), Goyang-si, Korea, Republic of|Chonnam National University Hospital (KR0003), Gwangju, Korea, Republic of|Samsung Medical Center (KR0001), Seoul, Korea, Republic of|MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk (PL0009), Białystok, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o. (PL0003), Bydgoszcz, Poland|CareClinic (PL0005), Katowice, Poland|Centrum Zdrowia Psychicznego Biomed - Jan Latala (PL0001), Kielce, Poland|Niepubliczny Zaklad Opieki Psychiatrycznej Mentis (PL0004), Leszno, Poland|Centrum Medyczne Luxmed Sp.Z O.O. (PL0006), Lublin, Poland|Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k. (PL0007), Poznan, Poland|Nzoz Syntonia (PL0010), Pruszcz Gdański, Poland|Hospital Clinic de Barcelona (ES0003), Barcelona, Spain|Instituto Internacional de Neurociencias Aplicadas (ES0001), Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04220996"
1890,"NCT00255905","Cognitive Behavioral Therapy for the Treatment of Depression-Related Insomnia",,"Completed","No Results Available","Depression","Behavioral: Cognitive behavioral therapy (CBT) for insomnia|Behavioral: Clinician monitoring","Treatment outcome of patients receiving CBT compared to clinician monitoring|Association between rapid eye movement (REM) latency and treatment outcome","University of Rochester|National Institute of Mental Health (NIMH)","All","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","R21MH067184|DATR A2-AID","July 2004","July 2007","July 2007","November 21, 2005",,"June 28, 2013","University of Rochester Sleep and Neurophysiology Research Lab, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00255905"
1891,"NCT01812291","Evaluation of a Stepped Care Approach to Manage Depression in Diabetes","Ecce_homo","Completed","No Results Available","Major Depressive Disorder|Minor Depressive Disorder|Sub-Threshold Depression|Diabetes Mellitus","Behavioral: Step 1: Diabetes-Specific CBT (5 group sessions)|Behavioral: Step 2: Depression-Specific CBT (6 single sessions)|Behavioral: Step 3: Referral to Psychotherapist and/or Psychiatrist|Behavioral: Standard Diabetes Education","Depressive Mood - Hamilton Rating Scale for Depression (HAMD)|Diabetes-Related Distress - The Problem Areas in Diabetes Questionnaire (PAID)|Psychological/ Emotional Well-Being - The WHO-5 Well-being Index (WHO-5)|Health-Related Quality of Life - The Short Form-36 Health Survey (SF-36)|Diabetes Self-Care Behavior - The Summary of Diabetes Self-Care Activities Measure (SDSCA)|Glycaemic Control (HbA1c)|Health-Related Quality of Life - The EuroQol-5D (EQ-5D)|Diabetes Self-Care Behavior - The Diabetes Self-Management Questionnaire (DSMQ)","Forschungsinstitut der Diabetes Akademie Mergentheim|German Federal Ministry of Education and Research|German Diabetes Center|Heinrich-Heine University, Duesseldorf|University of Giessen|Helmholtz Zentrum München|Coordination Center for Clinical Trials (KKS)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","260","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FKZ 01GI1107","February 2012","November 2015","November 2015","March 18, 2013",,"January 14, 2016","Forschungsinstitut der Diabetes Akademie Mergentheim e. V., Bad Mergentheim, Baden-Wuerttemberg, Germany",,"https://ClinicalTrials.gov/show/NCT01812291"
1892,"NCT01634022","Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications",,"Completed","No Results Available","Depression","Procedure: Acupuncture","Change in scores on the Hamilton Depression Rating Scale, 17 items (HAM-D-17)|Response to treatment, defined as a 50% or greater improvement in HAM-D-17 score compared to baseline","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004P002819","May 2005","November 2011","November 2011","July 6, 2012",,"July 6, 2012","Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01634022"
1893,"NCT00229476","Study of Medication and Placebo Response in Major Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: sertraline (Zoloft)","depressive symptoms|brain electrical activity (EEG)","University of California, Los Angeles|Eli Lilly and Company|Pfizer|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","03-08-033|H6U-US-X002|04012549","December 2003","March 2006",,"September 29, 2005",,"November 6, 2016","UCLA Neuropsychiatric Institute & Hospital, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00229476"
1894,"NCT00482482","Yoga in Unipolar and Bipolar Disorders",,"Completed","No Results Available","Bipolar Disorder|Major Depression|Dysthymia","Behavioral: psychoeducation|Behavioral: Yoga","Montgomery-Asberg Depression Rating Scale (MADRS)|Salivary cortisol levels|Clinical Global Impression Scale|Quality of Life Enjoyment and Satisfaction Scale|Perceived Stress Scale|Coping Strategies Scale|Beck Depression Inventory","Centre for Addiction and Mental Health","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","308/2006","September 2007","March 2011","March 2011","June 5, 2007",,"December 5, 2012","Centre for Addition and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00482482"
1895,"NCT04078438","Neurofeedback In Treatment Resistant Depression",,"Terminated","No Results Available","Depression|Neurofeedback","Device: neurofeedback augmentation|Drug: treatment as usual|Other: psychotherapy placebo sessions","Changes in Hamilton Rating Scale for Depression [HAM-D] score at baselline and the 1-, 4-, and 12-week time points|Changes in Beck Depression Inventory- II (BDI-II) scores at baselline and the 1-, 4-, and 12-week time points|Changes in Sheehan Disability Scale (SDS) score at baselline and the 1-, 4-, and 12-week time points|Changes in Clinical Global Impression-Severity (CGI-S) at baselline and the 1-, 4-, and 12-week time points|Comparisons of serum brain-derived neurotrophic factor (BDNF) level between baseline and the 12-week time point among groups|Type and number of adverse events|Changes in valuation of 5 level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L) (converted tariff score)|Changes in response and remission rate of Hamilton Rating Scale for Depression [HAM-D] score","Yeungnam University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","YUH-14-0389-B4","June 27, 2014","December 27, 2019","February 8, 2020","September 6, 2019",,"July 1, 2020","Yeungnam University Hospital, Daegu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04078438"
1896,"NCT02497027","Pharmacogenetic Testing in an Outpatient Population of Patients With Depression","PGx-UPA","Completed","No Results Available","Depression","Other: pharmacogenetic testing","Depression score|Clinical utility questionnaire","Avera McKennan Hospital & University Health Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","AIHG-1440-PGxUPA","February 2015","April 1, 2017","April 1, 2017","July 14, 2015",,"May 3, 2017","Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02497027"
1897,"NCT00256113","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression",,"Completed","No Results Available","Depressive Disorder","Drug: Saredutant succinate (SR48968C)","The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 3","467","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5575","December 2004","December 2006","December 2006","November 21, 2005",,"April 20, 2018","Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czechia|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal",,"https://ClinicalTrials.gov/show/NCT00256113"
1898,"NCT00250627","An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression",,"Completed","No Results Available","Depressive Disorder","Drug: Saredutant succinate (SR48968C)","The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 3","465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5573","December 2004","December 2006","December 2006","November 8, 2005",,"December 23, 2008","Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal",,"https://ClinicalTrials.gov/show/NCT00250627"
1899,"NCT00250614","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression",,"Completed","No Results Available","Depressive Disorder","Drug: Saredutant succinate (SR48968C)","The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 3","452","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5572|Saredutant (SR48968C)","April 2005","October 2006","October 2006","November 8, 2005",,"June 9, 2010","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00250614"
1900,"NCT00250601","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression",,"Completed","No Results Available","Depressive Disorder","Drug: Saredutant succinate (SR48968C)","The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5571|Saredutant (SR48968C)","April 2005","July 2007","July 2007","November 8, 2005",,"February 17, 2012","Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00250601"
1901,"NCT00812812","Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)",,"Terminated","Has Results","Depressive Disorder","Drug: paroxetine 10mg tablet|Drug: paroxetine 20mg tablet|Drug: matched placebo to paroxetine 10mg|Drug: matched placebo to paroxetine 20mg","Change From Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8|Change From Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6|Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8|Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-SI) Score at Weeks 1, 2, 3, 4, 6, and 8|Plasma Paroxetine Concentrations at 12 Hours and 24 Hours After Administration of Study Drug at Week 8 or Withdrawal","GlaxoSmithKline","All","7 Years to 17 Years   (Child)","Phase 4","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","112487","March 2009","February 2011","February 2011","December 22, 2008","October 13, 2011","January 13, 2017","GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukui, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ishikawa, Japan|GSK Investigational Site, Kagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Kumamoto, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nara, Japan|GSK Investigational Site, Nara, Japan|GSK Investigational Site, Okayama, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Shizuoka, Japan|GSK Investigational Site, Tokushima, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00812812"
1902,"NCT02449499","Adjunct Interpersonally Focused Psychodynamic Group Psychotherapy for Residual Depression Symptoms",,"Terminated","No Results Available","Depression|Anxiety",,"psychological and general well-being index|ASQ (adult attachment style questionnaire)|ICI (interpersonal communication inventory)","Stanford University","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB-32272","April 2015","October 2015","October 2016","May 20, 2015",,"October 17, 2016","Stanford Psychiatry and Behavioral Science, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02449499"
1903,"NCT00319709","An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression","ZEPHIR","Completed","No Results Available","Depressive Disorder","Drug: SR58611A","The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.","Sanofi","All","65 Years and older   (Older Adult)","Phase 3","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC4846|EudraCT 2005-005597-67","April 2006","April 2007","August 2007","April 27, 2006",,"March 12, 2009","Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Belgrade, Serbia|Sanofi-Aventis Administrative Office, Bratislava, Slovakia",,"https://ClinicalTrials.gov/show/NCT00319709"
1904,"NCT04977232","Adjunctive Game Intervention for Anhedonia in MDD Patients",,"Not yet recruiting","No Results Available","Depression","Drug: Escitalopram|Behavioral: Game intervention","Snaith-Hamilton-Pleasure Scale (SHAPES)|Temporal Experience of Pleasure Scale (TEPS)|Hamilton Depression Rating scale (HAMD)|Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|The Stroop test|Wisconsin Card Sorting Test (WCST)|Rumination Responses Scale|Magnetic Resonance Imaging data","Central South University","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LYG2021038","July 2021","May 2022","May 2022","July 26, 2021",,"July 26, 2021","The Second Xiangya Hospital of Central South University, Changsha, China",,"https://ClinicalTrials.gov/show/NCT04977232"
1905,"NCT04258618","Cognitive Behavioral Therapy for Insomnia With rTMS",,"Completed","No Results Available","Depression|Insomnia","Behavioral: CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Device: Repetitive Transcranial Magnetic Stimulation","Number of Reported Unanticipated Adverse Events|Percentage of patients completing CBT-I program|Change in Epworth Sleepiness Scale|Change in Insomnia Severity Index Scale|Change in Patient Health Questionnaire - 9|Change in Pittsburgh Sleep Quality Index|Change in Hamilton Rating Scale for Depression 17","Medical University of South Carolina|Drug Abuse Research Training Program","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00089725","August 4, 2020","January 31, 2021","January 31, 2021","February 6, 2020",,"March 5, 2021","Medical University of South, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04258618"
1906,"NCT04150718","Role of Slow-wave Activity and Plasticity in MDD","SWIP","Recruiting","No Results Available","Depression","Behavioral: slow-wave disruption","Compare indices of net synaptic strength (theta power, transcranial magnetic stimulation evoked potentials) and markers associated with plasticity (BDNF, behavioral measures of learning/memory) in individuals with MDD to healthy controls|Determine if slow-wave disruption alters mood in individuals with MDD","University of Pennsylvania","All","25 Years to 50 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","832986","March 4, 2020","August 31, 2022","July 1, 2023","November 5, 2019",,"July 29, 2021","University of Pennsylvania, Department of Psychiatry, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04150718"
1907,"NCT00336713","A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)",,"Completed","No Results Available","Depressive Disorder","Drug: Saredutant (SR48968C)|Drug: Placebo","The time to relapse of depressive symptoms (in days) during the Maintenance Phase.|Changes from baseline in the CGI Severity of Illness, Montgomery-Asberg Depression Rating Scale (MADRS) total, and Hamilton Anxiety Rating Scale (HAM-A) total and factor scores during the Maintenance Phase.","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","430","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC5576|SR48968","May 2006","April 2008","April 2008","June 14, 2006",,"May 13, 2016","Sanofi-Aventis, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00336713"
1908,"NCT04485455","iTBS for Adolescent Depression: An Open Label Study Evaluating Safety and Efficacy of Treatment",,"Active, not recruiting","No Results Available","Depression","Device: iTBS Device/Motor Threshold Coil|Device: iTBS Device/Treatment Coil","Change in HAM-D Score from Baseline to Week 1|Change in CDRS-R Score from Baseline to Week 1|Change in HAM-D Score from Baseline to Week 2|Change in CDRS-R Score from Baseline to Week 2|Change in HAM-D Score from Baseline to Week 3|Change in CDRS-R Score from Baseline to Week 3|Change in HAM-D Score from Baseline to Week 4|Change in CDRS-R Score from Baseline to Week 4|Safety Defined by Change in C-SSRS Evaluations|Completion Rate|Withdrawal Rate|Durability of Treatment Effect with HAM-D Scores|Durability of Treatment Effect with CDRS-R Scores|Presence of Non-Suicidal Self Injurious Behavior Through SITBI","University of North Carolina, Chapel Hill","All","13 Years to 17 Years   (Child)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-1100","September 21, 2020","April 30, 2021","September 2021","July 24, 2020",,"May 21, 2021","University of North Carolina at Chapel Hill-Psychiatry Outpatient Clinic, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04485455"
1909,"NCT01435148","Deep Brain Stimulation in Treatment Resistant Depression",,"Unknown status","No Results Available","Treatment Resistant Depression","Procedure: Deep Brain Stimulation, implanted","Decrease in Montgomery and Asberg Rating Scale score of at least 50% at an average of 18 months after implantation.|Clinical Global Impression Improvement Scale(CGI-I). Score <4.|Global Assessment of Functioning scale, an improvement of >1/2(100-initial score)|A decrease of 50% in Hamilton Depression Rating Scale (17 items) at End of contact selection and adjustment plus 6 months. An average of 18 months after implantation","North Bristol NHS Trust|University of Bristol","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","1759|06/Q2001/189","December 2006","December 2012","December 2012","September 15, 2011",,"September 15, 2011","Neurosurgey Department, Frenchay Hospital, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01435148"
1910,"NCT00078715","Rapid Antidepressant Effects of Yohimbine in Major Depression",,"Completed","Has Results","Depression, Involutional|Major Depresssion","Drug: Yohimbine hydrochloride|Drug: Placebo","Hamilton Depression Rating Scale (6 Items)","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","11","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","040091|04-M-0091","March 2004","August 2009","August 2009","March 5, 2004","August 16, 2012","August 29, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00078715"
1911,"NCT04684277","Internet-Based Interventions for MDD",,"Not yet recruiting","No Results Available","Depression|Medication Adherence","Drug: antidepressant treatment|Other: antidepressant treatment combined with Internet-based interventions","HAMD17 reduction ratio|recurrence rate","Peking University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SF2020-2-4113","January 1, 2021","December 31, 2022","June 30, 2023","December 24, 2020",,"December 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04684277"
1912,"NCT00974155","The Early Medication Change (EMC) Trial","EMC","Completed","No Results Available","Depression","Drug: Escitalopram, venlafaxine, lithium|Drug: Escitalopram, venlafaxine","Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14 (n=192)|Response, defined as a HAMD17 sum score decrease ≥50% on day 56|Absolute change of HAMD17 sum score|Remission defined as IDS score ≤ 11 on day 56|Response defined as IDS score decrease ≥50% on day 56|Absolute change in SF12 subscales ""physical component score"" and ""mental component score""|Remission from MDD, defined as a HAMD17 sum score ≤ 7 on day 56 (subgroups of improvers on day 14)|Time to remission and time to response according to IDS and HAMD17|Occurrence of adverse events, UKU ratings at all visits, relevant laboratory data and deviations from normal ECG","K. Lieb|German Federal Ministry of Education and Research|Johannes Gutenberg University Mainz","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","889","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-016|2008-008280-96","September 2009","May 2014","May 2014","September 10, 2009",,"April 1, 2015","University Medical Center of the Johannes Gutenberg-University, Mainz, Rheinland-Pfalz, Germany",,"https://ClinicalTrials.gov/show/NCT00974155"
1913,"NCT00088699","Rapid Antidepressant Effects of Ketamine in Major Depression",,"Completed","Has Results","Depression|Mood Disorders|Major Depresssion","Drug: Ketamine|Drug: Placebo","MADRS Score - Baseline|MADRS Score - Day 1 Following Intervention","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","67","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","040222|04-M-0222","July 26, 2004","July 31, 2017","July 31, 2017","August 2, 2004","October 12, 2018","October 12, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00088699/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00088699"
1914,"NCT00071695","Duloxetine vs. Active Comparator in the Treatment of Patients With Depression",,"Completed","No Results Available","Depression","Drug: Duloxetine Hydrochloride|Drug: Venlafaxine Extended Release","The linear measure of global benefit-risk assessment. Benefit defined as remission at endpoint (HAMD 17 total score less than or equal to 7), a virtually symptom-free state.|HAMD17 Response Rates defined as greater than or equal to 50% reduction in HAMD17 total score from baseline to endpoint.|HAMD17 Time-to-First Response defined as the visit where a sustained greater than or equal to 30% reduction in the Maier subscale of the HAMD17.|HAMD17 Remission Rates defined as HAMD17 total score of less than or equal to 7 at endpoint.|Hamilton Anxiety Rating Scale measures the presence and severity of anxiety.|Clinical Global Impressions of Severity scale to record severity of illness at the time of assessment.|Patient's Global Impressions of Improvement scale measures improvement of the patient's symptoms.|HAMD17 Subscales evaluate severity of psychic and somatic manifestations of anxiety as well as agitation and evaluate dysfunction in mood, work, and sexual activity, as well as overall motor retardation and evaluate initial, middle, and late insomnia.","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6090|F1J-MC-HMBU","July 2003",,"May 2004","October 30, 2003",,"May 21, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Easter Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France",,"https://ClinicalTrials.gov/show/NCT00071695"
1915,"NCT00067912","Duloxetine vs. Active Comparator for the Treatment of Depression",,"Completed","No Results Available","Depression","Drug: Duloxetine Hydrochloride|Drug: Venlafaxine Extended Release","Linear measure of global benefit-risk assessment. Benefit is defined as remission at endpoint (HMAD17 total score less than or equal to 7, a virtually symptom-free state.|HAMD17 Response Rates: Response is defined as a greater or equal to 50% reduction in HAMD17 total score from baseline to endpoint.|HAMD17 Time to First Response: Time to first response is defined as the visit where a sustained greater than or equal to 30% reduction in the Maier subscale of the HAMD17.|HAMD17 Remission Rates: Remission is defined as a HAMD17 total score of less than or equal to 7 at endpoint.|Hamilton Anxiety Rating Scale (HAMA) that measures the presence and severity of anxiety. The 14-item version of this scale will be used to assess the severity of anxiety and its improvement during the course of therapy.|Clinical Global Impressions of Severity (CGI-Severity) Scale to record the severity of illness at the time of assessment.|Patient's Global Impressions of Improvement (PGI Improvement) Scale is a patient-rated instrument that measures the improvement of the patient's symptoms.|HAMD17 Subscales to evaluate severity of psychic and somatic manifestations of anxiety, as well as agitation; evaluate dysfunction in mood, work, and sexual activity, as well as overall motor retardation; evaluate initial, middle and late insomnia.","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","7999|F1J-MC-HMCQ","April 2003",,"March 2004","September 3, 2003",,"May 21, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00067912"
1916,"NCT00178035","Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals",,"Completed","No Results Available","Depression","Drug: paroxetine|Behavioral: One night of Total Sleep Deprivation","Combined treatment of total sleep deprivation(TSD)for one night + paroxetine will be superior to the combination of placebo + TSD and to paroxetine alone (without TSD)in bringing about rapid resolution of depressive symptoms.|EEG Sleep measures|Cognitive status: Folstein Mini-Mental Status Exam, and CDR|Quality of Life measures: Quality of Wellbeing Scale, CIDI Health Services Utilization, OARS, GAF, PSQI, SF-36, UKU, and CIRS-G|Social Support: Interpersonal Support Evaluation List, Luben Social Network Scale|Psychiatric status: SCID, Hamilton Depression Rating Scale, Suicidal History Questionnaire, Antidepressant Treatment History Form, Brief Psychiatric Rating Scale, and anxiety subscale of Brief Symptom Inventory|MRI","University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)","Phase 4","158","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","R01MH037869-02|970356|DATR A4-GPS","December 1999",,"August 2003","September 15, 2005",,"August 2, 2013","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00178035"
1917,"NCT00183482","Family Cognitive Behavioral Therapy for Preventing Depression in Children",,"Recruiting","No Results Available","Depression","Behavioral: Family Group Cognitive Behavioral|Behavioral: Written Information","Depressive episodes|Parenting skills of parents; measured at baseline and month 6|Coping skills of children; measured at baseline and month 6|Depression in parents; measured at baseline and month 6|Internalizing and externalizing symptoms in children","Vanderbilt University|National Institute of Mental Health (NIMH)","All","9 Years and older   (Child, Adult, Older Adult)","Not Applicable","750","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01MH100258","August 1, 2014","December 31, 2021","December 31, 2021","September 16, 2005",,"December 10, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00183482"
1918,"NCT02466230","Antidepressant Mechanisms of Transcranial Magnetic Stimulation",,"Completed","Has Results","Depression","Device: Repetitive transcranial magnetic stimulation","Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)|Depression Severity Measured by the Public Health Questionnaire-9","Weill Medical College of Cornell University|National Alliance for Research on Schizophrenia and Depression|Neuronetics","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1101011475","January 2011","October 2013","October 2013","June 9, 2015","September 10, 2018","September 10, 2018",,,"https://ClinicalTrials.gov/show/NCT02466230"
1919,"NCT04191811","Predicting Cognitive Behavioral Therapy Outcome Using Moment-to-moment Brain Signal Variability","TreVar","Active, not recruiting","No Results Available","Psychiatric Disorder|Depression|Anxiety Disorders|Insomnia","Behavioral: Internet-delivered cognitive behavioral therapy for major depressive disorder|Behavioral: Internet-delivered cognitive behavioral therapy for insomnia|Behavioral: Internet-delivered cognitive behavioral therapy for health anxiety disorder","Change from Baseline Montgomery-Åsberg Depression Rating Scale - Self Assessment (MADRS-S) to Post-treatment|Change from Baseline Insomnia Severity Index (ISI) to Post-treatment|Change from Baseline Short Health Anxiety Inventory (SHAI) to Post-treatment|Change from Baseline EuroQol 5-dimensions (EQ5D) to Post-treatment|Consultation Satisfaction Questionnaire (CSQ-8) to Post-treatment|Change from Baseline The Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) to Post-treatment (insomnia patients)|Change from Baseline Generalized Anxiety Disorder Scale (GAD-7) to Post-treatment (health anxiety patients)|Change from Baseline Patient Health Questionnaire-9 (PHQ-9) to Post-treatment (depression and insomnia patients)|Change from Baseline The Sleep Problem Acceptance Questionnaire (SPAQ) to Post-treatment (insomnia patients)|Change from Baseline Sleep-Related Behaviours Questionnaire (SRBQ) to Post-treatment (insomnia patients)|Change from Baseline Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P) to 6 months (all patients)","Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-04295","December 12, 2019","December 2022","December 2022","December 10, 2019",,"February 17, 2021","Internetpsykiatri, Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04191811"
1920,"NCT01567943","Contingency Management of Alcohol Abuse in the Severely Mentally ILL","CMETG","Completed","Has Results","Alcohol Abuse|Schizophrenia|Bipolar Disorder|Major Depressive Disorder","Behavioral: Contingency Management","Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine|Change in Intensive Outpatient Substance Abuse Treatment Attendance|Self Report Drug Use|Other Drug Use as Measured by Urinalysis|Community Outcomes|Psychiatric Symptomology","University of Washington","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","123","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","41552-G","March 2012","February 2015","February 2016","March 30, 2012","January 5, 2017","February 23, 2017","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01567943"
1921,"NCT00985686","E-Mental Health Adolescent Depression Program (LEAP)","LEAP","Completed","Has Results","Depression","Other: LEAP Project","Children's Depression Rating Scale Revised (CDRS-R)|Hamilton Depression Rating Scale (HAMD)|Piers-Harris Children's Self-Concept Scale - Second Edition (Piers Harris 2)|Six Factor Self-Concept Scale|Profile of Mood States (POMS)|Spiritual Well-Being Scale (SWBS)|Spiritual Involvement and Belief Scale (SIBS)","Patricia Steele|Alberta Centre for Child, Family & Community Research|Alberta Health Services, Calgary|Mount Royal University|SickKids Foundation|University of Calgary|Canadian Institute of Natural and Integrative Medicine","All","13 Years to 24 Years   (Child, Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","22549|Ethics ID 22549","January 2010","September 2012","September 2012","September 28, 2009","March 6, 2015","July 29, 2015","Canadian Institute of Natural and Integrative Medicine (CINIM), Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00985686"
1922,"NCT01787513","Cognitive Bias Modification (CBM) Via Imagery and Internet Cognitive Behavioural Therapy (iCBT) for Depression",,"Completed","No Results Available","Depression","Other: CBM|Other: iCBT","Change in Patient Health Questionnaire-9 (PHQ-9)scores|Change in Beck Depression Inventory - second edition (BDI-II)scores|Change in Ambiguous Sentence Task (AST)scores|Change in diagnostic status (MINI5 depression module)|Change in Kessler-10 (K10)scores|Change in WHO Disability Assessment Scale (WHO-DAS)scores|Change in State Trait Anxiety Inventory (STAI)scores|Change in Repetitive Thinking Questionnaire (RTQ)scores|Change in Clinical Perfectionism Scale (PCS)scores","St Vincent's Hospital, Sydney","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","121","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12/237","February 2013","May 2014","August 2014","February 8, 2013",,"August 12, 2014","St. Vincent's Hospital, Darlinghurst, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01787513"
1923,"NCT04159012","NESBID: Neuro-Stimulation of the Brain in Depression","NESBID","Recruiting","No Results Available","Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant|Transcranial Direct Current Stimulation|Electric Stimulation Therapy","Device: Transcranial direct current stimulation","Montgomery-Asberg Depression Rating Scale (MADRS)|Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)|World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)|Exploratory language analysis|Lexical decision making task|tDCS adverse events scale|FIBSER|PRISE|YMRS","University of Alberta|Alberta Health Services","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDCS2019","September 1, 2020","September 1, 2021","November 1, 2021","November 12, 2019",,"November 9, 2020","Grey Nuns Community Hospital, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04159012"
1924,"NCT00809770","Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill",,"Completed","No Results Available","Drug Abuse|Schizophrenia|Bipolar Disorder|Major Depressive Disorder","Behavioral: Contingency Management|Behavioral: Non Contingent Control Condition","Stimulant drug use as measured by urine analysis|Self report drug use|Other drug use as measured by urine analysis|Symptoms of mental illness|Community outcomes (jail bookings, ER visits, mental health outcomes)","University of Washington|National Institute on Drug Abuse (NIDA)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","176","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RDA022476A|R01DA022476|R01DA022476-01","April 2008","July 2012","August 2013","December 17, 2008",,"November 8, 2016","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00809770"
1925,"NCT00491686","AZD6765 for Treatment Resistant Depression",,"Completed","No Results Available","Depression","Drug: AZD6765","The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score.|The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events.","AstraZeneca","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D6702C00001","July 2007","November 2007","November 2007","June 26, 2007",,"January 21, 2011","Research Site, Glendale, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Wichita, Kansas, United States|Research Site, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00491686"
1926,"NCT02012504","Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients",,"Unknown status","No Results Available","Adverse Drug Reaction|Anxiety Disorders and Symptoms",,"Evaluate the score of HAMD17 (Hamilton Depression Rating Scale) and HAMA (Hamilton Anxiety Rating Scale) of patients in each time between two groups|Evaluate the symptom of depression, anxiety and quality of life in each time between two groups","Shanghai Zhongshan Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","B2012-127","June 2013","January 2014","December 2014","December 16, 2013",,"December 16, 2013","Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02012504"
1927,"NCT04024371","Validating Reward-related Biomarkers (RTOC)","RTOC","Recruiting","No Results Available","Schizophrenia|Depression|Motivation|Anhedonia, Physical|Anhedonia, Social|Negative Symptoms With Primary Psychotic Disorder","Behavioral: Self-rating Questionnaires|Behavioral: Measures of Reward processing/reinforcement learning|Behavioral: Additional Schizophrenia-specific Questionnaires and Interviews","Grip effort outcome|Doors task outcome|RL/WM task outcome","Maastricht University|P1vital Products LTD.|Biotrial|University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy|The Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona|Aristotle University Of Thessaloniki|Maastricht University, School for Mental Health and Neuroscience","All","20 Years to 55 Years   (Adult)",,"160","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","RTOC1","September 16, 2019","August 1, 2020","August 1, 2020","July 18, 2019",,"October 3, 2019","University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherap, Frankfurt, Germany|Aristotle University of Thessaloniki, School of Medicine, Department of Clinical Pharmacology, Thessaloníki, Greece|Maastricht University, Maastricht, Netherlands|Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04024371"
1928,"NCT01363310","The Quietude Study: Quetiapine Use for Agitated Depression",,"Terminated","No Results Available","Depression With Prominent Agitation","Drug: Quetiapine XR|Drug: Escitalopram","Change from baseline to endpoint in the Hamilton Depression Rating Scale 17-Item (HAMD-17) total score|Change in anxiety factor score on the Hamilton Depression Rating Scale 17-item (HAMD-17) from baseline to endpoint|Change from baseline to endpoint in Hamilton Anxiety Rating Scale (HAMA) total score|Change in Clinical Global Impression score from baseline to endpoint|Change from baseline to endpoint in Sheehan Disability Scale (SDS) sub-scales and total score|Change in Hamilton Depression Rating Scale 17-item (HAMD-17) sleep disturbance factor score on the from baseline to endpoint|Change in Hamilton Anxiety Rating Scale (HAMA) somatic and psychic anxiety factor scores from baseline to endpoint|Change from baseline in the Sex Functioning Questionnaire (Sex FX)|Change in blood pressure and heart rate from baseline to end of treatment|Change in weight, BMI, waist circumference from baseline to end of treatment|Change in findings from physical examination from baseline to end of treatment|Tabulation of spontaneous adverse events|Tabulation of clinical haematology and chemistry results|Incidence of premature study withdrawal due to inadequate control of depressive symptoms|Proportion of patients with HAM-D Item 3 score > 2 at any time after randomization or adverse events of suicidality/suicidal ideation/suicide attempts/suicide completion","Physicians Research And Education Network","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1443C00037","October 2010","January 2013","February 2013","June 1, 2011",,"January 8, 2014","Aggarwal and Associates Ltd, Brampton, Ontario, Canada|Aptekar Medicine Professional Corporation, Brampton, Ontario, Canada|Chatham-Kent Health Alliance, Chatham, Ontario, Canada|Fort Erie Group Family Practice, Fort Erie, Ontario, Canada|Georgina Family Medical Centre, Keswick, Ontario, Canada|Richmond Oxford Walk-In Clinic, London, Ontario, Canada|Gerald Rockman Medicine Professional Corporation, Scarborough, Ontario, Canada|Brady Clinic, Sudbury, Ontario, Canada|Bloor-Park Medical Centre, Toronto, Ontario, Canada|Primary Care Lung, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01363310"
1929,"NCT04489485","Online System for Identifying and Addressing Teen Depression in Primary Care","Depression","Not yet recruiting","No Results Available","Major Depression|Dysthymia|Depressive Symptoms","Behavioral: Teen Depression Module used for care","Change in Short Moods and Feelings Questionnaire|Change in Short Moods and Feelings Questionnaire- Parent version|Change in Self report of treatment access|Patient Health Questionnaire-9 (PHQ-9)|Ask Suicide Screening Questions (ASSQ)","Total Child Health, Inc.|National Institute of Mental Health (NIMH)|Foresight Logic","All","12 Years to 99 Years   (Child, Adult, Older Adult)",,"580","Industry|NIH|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","R44MH116751|1R44MH116751-01A1","August 2020","June 2023","June 2023","July 28, 2020",,"July 28, 2020","Total Child Health, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04489485/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04489485"
1930,"NCT02421965","Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depressive Disorder","Behavioral: FOCUS (Smartphone Application)|Behavioral: WRAP (Wellness Recovery Action Planning)","Patient willingness to enroll / initiate the intervention (WRAP / FOCUS)|Patient Engagement|Patient Satisfaction|Change in the Severity of Symptoms|Recovery|Change in the Quality of Life","Dartmouth-Hitchcock Medical Center|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00028548","June 2015","July 2017","December 2017","April 21, 2015",,"November 20, 2018","Thresholds Psychiatric Rehabilitation Centers, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02421965"
1931,"NCT01488058","Cognitive Bias Modification (CBM) and Internet Cognitive Behavioural Therapy (iCBT) for Depression- A Randomised Controlled Trial",,"Completed","No Results Available","Depression","Other: OxIGen + iCBT|Other: Waitlist Control","Change in score on the Beck Depression Inventory - second edition (BDI-II).|Change on the Scrambled Sentences Task (SST)- electronic version.|Change on Prospective Imagery Test (PIT).|Change on the Kessler-10 (K10).|Change on WHO Disability Assessment Scale (WHO-DAS).|Change on the Repetitive Thinking Questionnaire (RTQ).|Change on the State Trait Anxiety Inventory (STAI).|Change on the Ambiguous Sentence Task (AST).|Change in score on the Patient Health Questionnaire-9 (PHQ-9).","Alishia Williams|The University of New South Wales|St Vincent's Hospital, Sydney","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11/055|ACTRN12611001221943","December 2011","August 2012","August 2012","December 8, 2011",,"September 20, 2012","St. Vincent's Hospital, Darlinghurst, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01488058"
1932,"NCT01497548","Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients",,"Unknown status","No Results Available","Depression","Drug: Methylphenidate|Drug: Placebo","depressive symptoms|Distress level","University of Malaya","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NCG001","March 2011","September 2012","October 2012","December 22, 2011",,"December 22, 2011","University Malaya Medical Centre, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01497548"
1933,"NCT01632267","Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm","UHS","Completed","Has Results","Depression|Anxiety",,"Number of Outpatient Visits|Number of Medical Absence Days|Number of Disability Claims","Assurex Health Inc.","All","18 Years to 65 Years   (Adult, Older Adult)",,"104","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","10003","January 2011","April 2011","September 2011","July 2, 2012","March 22, 2013","January 5, 2016","Union Health Services, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01632267"
1934,"NCT02438748","Biological Markers of Treatment Response to Repetitive Transcranial Magnetic Stimulation for Depression",,"Enrolling by invitation","No Results Available","Oxidative Stress","Device: Repetitive Transcranial Magnetic Stimulation","Change in Oxidized Phosphatidylcholines in plasma","University of Manitoba","All","18 Years to 80 Years   (Adult, Older Adult)",,"310","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B2014:102","May 2015","January 2022","May 2022","May 8, 2015",,"November 4, 2020","St. Boniface Hospital, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT02438748"
1935,"NCT01528241","Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)",,"Completed","No Results Available","Depression","Drug: ABP688","Binding of [11C] ABP688 to mGlu5 receptors|Blood levels of [11C] ABP688|Difference in [11C]ABP688 binding to mGlu5 receptors","Novartis Pharmaceuticals|Novartis","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CABP688A2102","August 2008","May 2010","May 2010","February 7, 2012",,"December 8, 2020","Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01528241"
1936,"NCT04504474","Network Analysis of Adult MDD and ADHD",,"Recruiting","No Results Available","ADHD",,"Co-morbidity|Network reliability|Central symptoms","Health Sciences North Research Institute","All","18 Years to 60 Years   (Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","18-056","June 21, 2018","August 8, 2021","September 8, 2021","August 7, 2020",,"August 7, 2020","Kirkwood Site - Health Sciences North, Sudbury, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04504474"
1937,"NCT01046630","Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects",,"Completed","No Results Available","Depression","Drug: AZD6765|Drug: Ketamine|Drug: Placebo","Measurements of BOLD signal in the brain area BA25|Measurements of symptoms of depression using Montgomery-Asberg Depression Rating Scale and Beck Depression Inventory total score|Responses on a computer based battery of behavioral tasks|Pharmacokinetics of AZD6765","AstraZeneca|University of Manchester|University of Oxford","All","18 Years to 45 Years   (Adult)","Phase 1","128","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D2285C00001","December 2009","March 2011","March 2011","January 12, 2010",,"October 13, 2014","Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01046630"
1938,"NCT00232167","Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression",,"Terminated","No Results Available","Insomnia|Depression","Drug: Indiplon|Drug: Sertraline","Change from baseline to week 1 in subjective total sleep time (sTST); (average of the week one data)|Change from baseline in subjective total sleep time (sTST). Change from baseline in subjective parameters: LSO, sWASO, sNAASO, Sleep Quality (IVR). Change from baseline in the 3-item HAM-D insomnia factor (items #4-6).","Neurocrine Biosciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A5761022","November 2005",,"April 2006","October 4, 2005",,"October 2, 2007",,,"https://ClinicalTrials.gov/show/NCT00232167"
1939,"NCT04376697","Repetitive Transcranial Magnetic Stimulation Trajectory of Outcomes Study",,"Recruiting","No Results Available","Depressive Disorder","Device: Repetitive Transcranial Magnetic Stimulation (rTMS)","Beck Depression Inventory-II (BDI-II) (score 0-63, higher = more severe)|Hamilton Depression Rating Scale 17-items (HDRS17) (score 0-52, higher = more severe)","University Health Network, Toronto|Centre for Addiction and Mental Health","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-6253.1","March 18, 2019","December 2020","December 2021","May 6, 2020",,"December 29, 2020","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04376697"
1940,"NCT02907476","The Treatment of Depression With Yoga and Walking",,"Completed","No Results Available","Depression|Major Depressive Disorder|PTSD|Anxiety","Behavioral: Iyengar Yoga|Behavioral: Walking","Brain gamma amino-butyric acid (GABA) levels (change will be measured)|Beck Depression Index Inventory (BDI-II)|Spielberger State-Trait Anxiety Inventory (STAI)|Exercise-Induced feeling Inventory (EIFI)|Pittsburgh Sleep Quality Index (PSQI)|Positivity Self Test (PST)|Columbia Suicide Safety Rating (C-SSR)|PTSD Check List - Civilian (PCL-C)|Patient Health Questionnaire 9 (PHQ-9)","Boston University|Partners HealthCare|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","57","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-34681|5R01AT007483-05","January 4, 2017","August 2, 2019","August 2, 2019","September 20, 2016",,"October 7, 2019","Solomon Carter Fuller Building, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02907476"
1941,"NCT00947232","Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI","inMotion","Completed","No Results Available","Multiple Sclerosis|Spinal Cord Injury","Behavioral: Motivational interviewing|Behavioral: Education","HAM-D|International Physical Activity Questionnaire","University of Washington","All","45 Years and older   (Adult, Older Adult)","Not Applicable","123","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","36020-J|H133B080024","October 2009","December 2012","March 2013","July 28, 2009",,"May 5, 2017","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00947232"
1942,"NCT02661061","Ketamine for Relapse Prevention in Recurrent Depressive Disorder","KINDRED","Terminated","Has Results","Depression|Relapse|Recurrent Depressive Disorder|Major Depressive Disorder","Drug: Ketamine|Drug: Midazolam","Completion Rate for Randomised Treatment Phase|Depression Relapse Rate During Treatment and Follow-up Phase","St Patrick's Hospital, Ireland","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","20/15|2015-002020-37","December 2015","May 23, 2018","May 23, 2018","January 22, 2016","January 13, 2020","January 13, 2020","St Patrick's University Hospital, Dublin, Ireland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02661061/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02661061"
1943,"NCT03899168","Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging",,"Completed","No Results Available","Major Depressive Disorder, Recurrent|Depressive Episode|Depressive Disorder, Major|Depression","Other: Social Tag Popularity|Other: Confidence in Prior Attitudes|Other: Source Credibility","Attitudinal Preference Score of Psychotherapy over Antidepressants|Count of clicks on antidepressant and psychotherapy treatment tags|Count of clicks on antidepressant and psychotherapy treatment blog posts","Leibniz-Institut für Wissensmedien","All","18 Years to 60 Years   (Adult)","Not Applicable","520","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","AG5-2014-11-Tagging","November 14, 2014","November 14, 2014","November 14, 2014","April 2, 2019",,"April 2, 2019",,,"https://ClinicalTrials.gov/show/NCT03899168"
1944,"NCT00519012","Benefits of Switching Antidepressants Following Early Nonresponse",,"Unknown status","No Results Available","Depression","Drug: Sertraline to Paroxetine|Drug: Paroxetine to Sertraline","The Montgomery-Asberg Depression Rating Scale|The Clinical Global Impression 2. The Quick Inventory of Depressive Symptomatology self-reported","Oizumi Hospital","All","Child, Adult, Older Adult","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19760629","August 2007","December 2010","December 2010","August 21, 2007",,"September 28, 2009","Oizumi Hospital, 6-9-1 Oizumigakuen-cho, Nerima-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00519012"
1945,"NCT03715127","Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept",,"Recruiting","No Results Available","Depressive Disorder, Major","Drug: Psilocybine oral capsule|Drug: Placebo oral capsule","Montgomery Asberg Depression Scale|Beck Depression Inventory|Changes in BOLD signal over time as measured by fMRI|5 Dimensions- Altered States of consciousness(5D-ASC)","University of Zurich|Schweizerischer Nationalfonds","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PSIDEPR128","March 11, 2019","April 2021","October 2021","October 22, 2018",,"November 4, 2020","Psychiatrische Universitätsklinik Zürich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03715127"
1946,"NCT00489073","Duloxetine Versus Placebo for Fibromyalgia",,"Completed","No Results Available","Fibromyalgia","Drug: duloxetine|Drug: placebo","To assess efficacy of duloxetine 60 mg twice daily (BID) compared with placebo on reduction of pain severity, measured by average pain item of Brief Pain Inventory (BPI) in patients with ACR-defined primary fibromyalgia, with or without major depression.|To evaluate the efficacy of duloxetine 60 mg once daily (QD) compared with placebo during a 12-week, double-blind, acute therapy phase on the reduction of pain severity as measured by the average pain item of the Brief Pain Inventory (BPI).|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on the improvement of the area under the curve of pain relief as derived from BPI average pain score|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on the improvement of Fibromyalgia Impact Questionnaire (FIQ) total score|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on improvement of Brief Pain Inventory (BPI) severity (worst pain, least pain, pain right now) and interference scores|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on the improvement of Tender point pain thresholds: mean thresholds and number of points with a low threshold|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on the improvement of Clinical Global Impression of Severity (CGI)|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on the improvement of Patient Global Impression of Improvement (PGI)|To evaluate efficacy of duloxetine 60 mg QD and 60 mg BID vs. placebo during a 12-week, double-blind, acute therapy phase on the improvement of Hamilton Depression 17- item Rating Scale (HAMD17) total score|To demonstrate that the effect of duloxetine 60 mg QD and duloxetine 60 mg BID on the BPI average pain score is independent of the presence or absence of a major depressive disorder (MDD) as defined by DSM-IV.|To evaluate whether improvement in pain severity (assessed by BPI average pain score) is direct analgesic effect of duloxetine therapy and independent of treatment effect on mood improvement, as measured by total score of HAMD17","Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 3","345","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","6158|F1J-MC-HMCA","November 2002",,"December 2003","June 21, 2007",,"June 21, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00489073"
1947,"NCT00296179","Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro",,"Completed","No Results Available","Insomnia","Drug: zolpidem tartrate","Efficacy: Patient-reported TST|Difference in relapse rates in patients receiving placebo and patients receiving zolpidem MR during 4 month follow-up period","Sanofi","All","21 Years to 64 Years   (Adult)","Phase 4","372","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PM_L_0166","February 2006","June 2007",,"February 24, 2006",,"July 28, 2008",,,"https://ClinicalTrials.gov/show/NCT00296179"
1948,"NCT03191058","Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression","CREST-MST","Recruiting","No Results Available","Depression|Unipolar Depression|Treatment Resistant Depression","Device: Magnetic Seizure Therapy|Device: Electroconvulsive Therapy","Improvement in symptom severity of depression as measured by the Hamilton Rating Scale for Depression - 24 (HRSD-24)|Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)|Improvement in symptom severity of Suicidal Ideation as measured by the Scale for Suicidal Ideation (SSI)","University of Texas Southwestern Medical Center|National Institute of Mental Health (NIMH)|Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","260","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CREST-MST|1R01MH112815-01","June 26, 2018","July 2022","July 2022","June 19, 2017",,"December 21, 2020","University of Texas Southwestern Medical Center, Dallas, Texas, United States|Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03191058"
1949,"NCT00401258","An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome",,"Completed","Has Results","Irritable Bowel Syndrome","Drug: duloxetine","Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994).|Brief Pain Inventory|Short Form McGill Pain Questionnaire|Clinical Global Impression Scale|Hamilton Depression Rating Scale|Hamilton Anxiety Rating Scale|Irritable Bowel Syndrome-Quality of Life Scale|Sheehan Disability Scale","Mclean Hospital|Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-P-001723","November 2006","February 2008","February 2008","November 20, 2006","August 27, 2010","March 9, 2018","McLean Hospital, Belmont, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00401258"
1950,"NCT04148612","A Study to Evaluate the Benefit of Opti-Me Application to Different Treatments of MDD",,"Recruiting","No Results Available","Depressive Disorder, Major","Diagnostic Test: Opti-Me","The response to treatment based on the Montgomery-Asberg Depression Rating Scale (MADRS) defined as a decline of at least 50% in the MADRS score from Baseline (BL) to the end of treatment (EOT) period which will be defined per treatment type.|Accuracy of the model will be assessed by the specificity and sensitivity of the model developed based on Cohort 1(GR1) and implemented in Cohort 2 Arm A (GR2A).|Comparison of the proportion of responders in Cohort 2 Arm A (GR2A) (assignment to treatment with the guidance of the Opti-Me algorithm) vs Cohort 1 (GR1) + Cohort 2 Arm B (GR2B) (random allocation to treatment).","ElMindA Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ELM-56","October 6, 2020","January 2022","January 2022","November 1, 2019",,"February 16, 2021","Beer Ya'aqov, Be'er Ya'aqov, Israel|University of Zurich Hospital, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04148612"
1951,"NCT00788918","Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)",,"Completed","No Results Available","Hepatitis C, Chronic|Cognition Disorders|Fatigue Syndrome, Chronic|Major Depressive Disorder","Drug: Interferon and ribavirin","Neuropsychological test results, cytokine profile and MRI findings|Interferon-induced depression","Aarhus University Hospital|University of Aarhus","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","SKS-0078-HCVCNS|EudraCT 2007-005707-18","November 2008","November 2012","November 2012","November 11, 2008",,"January 11, 2013","Department of Infectious Diseases, Aarhus University Hospital, Skejby, Aarhus, Jylland, Denmark",,"https://ClinicalTrials.gov/show/NCT00788918"
1952,"NCT01663844","New Clinical Applications for Internet-based Cognitive Behavior Therapy for Insomnia and Depression",,"Active, not recruiting","No Results Available","Insomnia|Major Depression|Minor Depression","Behavioral: Therapist guided Internet-CBT for insomnia w. extra support|Behavioral: Therapist guided Internet-CBT for insomnia|Behavioral: Therapist guided Internet-CBT for insomnia and depression|Behavioral: Therapist Guided Internet-CBT for depression plus insomnia placebo","Change (from baseline) in Insomnia Severity Index (ISI)|Change (from baseline) in Montgomery Asberg Depression Rating Scale, MADRS-S|Change (from baseline) in Sleep Diary|Changes (from baseline) in Actigraph data|Change (from baseline) in Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)|Change (from baseline) in Cognitive functioning|Change (from baseline) in EuroQuol. EQ-5D|Change (from baseline) in Sheehan Disability Scale|Change (from baseline) in Clinical Outcome in Routine Evaluation - 10, CORE-OM","Karolinska Institutet|Region Stockholm","All","18 Years and older   (Adult, Older Adult)","Not Applicable","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2012/934-31/4","January 2013","December 2020","December 2021","August 13, 2012",,"October 27, 2020","Internetpsykiatrienheten (Internet Psychiatry Clinic) Psykiatri Sydväst, SLSO, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01663844"
1953,"NCT02239822","Electrical Stimulation in Patients With Unipolar Major Depression","TREND2","Completed","No Results Available","Depression","Procedure: Stimulation of the trigeminal nerve (active stimulation)|Procedure: Placebo stimulation of the trigeminal nerve (placebo)","Identify a efficacy of eTNS of the V1 branch of the trigeminal nerve|Identify the tolerability of eTNS stimulation|Identify the long-term recurrence rate of eTNS therapy|Identify the duration of the placebo effect","Hospital do Coracao","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","271/2013","December 2013","December 2015","July 2016","September 15, 2014",,"September 29, 2016","Hospital do Coracao, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02239822"
1954,"NCT02239809","Electrical Stimulation in Patients With Unipolar Major Depression","TREND1","Completed","No Results Available","Depression","Procedure: Stimulation of the trigeminal nerve (active stimulation)|Procedure: Placebo stimulation of the trigeminal nerve (placebo)","Identify a efficacy of sTNS of the V1 branch of the trigeminal nerve|Identify the tolerability of sTNS stimulation|Identify the long-term recurrence rate of sTNS therapy|Identify the duration of the placebo effect","Hospital do Coracao","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","239/2012","May 2014","May 2016","July 2016","September 15, 2014",,"September 29, 2016","Hospital do Coracao, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02239809"
1955,"NCT02308956","Task Sharing for the Care of Severe Mental Disorders in a Low-income Country","TaSCS","Completed","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder|Schizoaffective Disorder","Behavioral: Integrated mental health in primary care|Behavioral: Psychiatric nurse-led specialist care","Brief Psychiatric Rating Scale, Expanded Version (BPRS-E)|WHO Disability Assessment Scale, version 2.0 (WHODAS 2.0)|Local functioning scale (disability scale for people with severe mental disorders developed specifically for this trial)|Relapse of mental disorder (Measured using the Life Chart Schedule)|Patient service satisfaction (Newly developed 'mental health service satisfaction scale' and qualitative interviews.)|Nutritional status (Body mass index.)|Service use for physical health care (Client Service Receipt Inventory)|Medication side effects (Antipsychotic Side effect Checklist)|Patient adherence and engagement (Medication Adherence Measure and tracking of appointment attendance.)|Stigma (Family Interview Schedule (caregivers)|Restraint (Proportion chained, restrained of confined in the past month.)|Adverse event|Quality of clinical care (WHO's mental health gap intervention guide)|Acceptability and feasibility (in-depth interviews with patients, caregivers and health care providers.)","University of Cape Town|Addis Ababa University|King's College London|Johns Hopkins University|Columbia University|Armauer Hansen Research Institute, Ethiopia","All","25 Years and older   (Adult, Older Adult)","Phase 3","324","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","NIH-95699 (Ethiopia)","March 2015","May 16, 2017","November 16, 2017","December 5, 2014",,"November 29, 2017","Butajira mental health research office, Butajira, Ethiopia",,"https://ClinicalTrials.gov/show/NCT02308956"
1956,"NCT03152409","Salicylic Augmentation in Depression","SAD","Recruiting","No Results Available","Depression|Depressive Disorder|Major Depressive Disorder|Treatment Resistant Depression","Drug: Aspirin 325mg|Drug: Placebo Oral Tablet","Change in Hamilton Depression Scale score|Response of inflammatory biomarkers|Biomarker association with antidepressant response","Jessica Harder|Columbia University|Brigham and Women's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2017P000525","November 15, 2018","December 2022","December 2023","May 15, 2017",,"August 2, 2021","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03152409"
1957,"NCT01368432","Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions",,"Completed","Has Results","TBI|Major Depression|Other Psychiatric Disorders","Drug: Escitalopram|Drug: Placebo","Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline|Montgomery-Asberg Depression Rating Scale (MADRS)|Clinical Global Impression (CGI) - Severity at Baseline|Clinical Global Impression (CGI)- Improvement|Clinical Anxiety Scale (CAS)|Satisfaction With Life (SWL)|Quality of Life (QWL)|Disability Rating Scale (DRS)|Mini Mental Status Exam (MMSE)","Johns Hopkins University|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA_00020154","April 2010","December 2012","March 2013","June 8, 2011","October 24, 2016","October 24, 2016","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01368432"
1958,"NCT02939560","TMS for Adults With Autism and Depression","TAD","Completed","Has Results","Autism Spectrum Disorder|Depression|Depressive Disorder|Major Depressive Disorder","Device: NeuroStar® TMS device (Neuronetics, Atlanta, GA)","Change From Baseline in Hamilton Depression Rating Scale|Change From Baseline in Aberrant Behavior Checklist|Change From Baseline in Social Responsiveness Scale-2|Change From Baseline in Ritvo Autism-Aspergers Diagnostic Scale|Change From Baseline in Repetitive Behavior Scale-Revised|Change From Baseline in Functional MRI Scanning During Cognitive Processing Tasks","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00056546","September 2016","June 1, 2018","September 20, 2018","October 20, 2016","October 1, 2019","October 1, 2019","Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02939560/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02939560"
1959,"NCT03615794","A Study of Pregnant and Postpartum Women With and Without Mood Disorders",,"Recruiting","No Results Available","Bipolar Disorder|Major Depressive Disorder|Postpartum Depression|Postpartum Psychosis",,"Major depressive episode|Postpartum depression as assessed by Whole blood analysis|Postpartum depression risk as assessed by serum analysis","Johns Hopkins University","All","18 Years to 50 Years   (Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00027369","October 1, 2017","October 2021","October 2022","August 6, 2018",,"November 12, 2020","550 North Broadway, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03615794"
1960,"NCT04714164","Cognitive Behavioral Therapy Group for Older Adults Delivered by Telethealth",,"Not yet recruiting","No Results Available","Major Depressive Disorder|Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder","Behavioral: Group Cognitive Behavioral Therapy","Feasibility of Telehealth CBT group for older adults|Acceptability of Telehealth CBT group for older adults|Attrition to the Telehealth CBT group for older adults|Effect size between pre-group and post-group questionnaires (anxiety)|Effect size between pre-group and post-group questionnaires (depression)|Effect size between pre-group and post-group questionnaires (perceived quality of life)","Nova Scotia Health Authority","All","65 Years and older   (Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","29243","February 2021","April 2021","December 2021","January 19, 2021",,"January 19, 2021",,,"https://ClinicalTrials.gov/show/NCT04714164"
1961,"NCT03915613","Anhedonia and the Insulin Pathway",,"Unknown status","No Results Available","Major Depressive Disorder|Bipolar Disorder|Anhedonia|Intranasal Insulin","Drug: Humulin R|Drug: Diluent","Effort-Expenditure for Rewards Task (EEfRT)|Young Mania Rating Scale (YMRS)|Montgomery-Asberg Depression Scale (MADRS)|Snaith-Hamilton Pleasure Scale (SHAPS)|Perceived Deficits Questionnaire-Depression (PDQ-D)|Sheehan Disability Scale (SDS)|The DeJong Gierveld Loneliness Scale|International Physical Activity Questionnaire (IPAQ)|Pittsburgh Sleep Quality Index (PSQI)|Social and Occupational Functioning Assessment Scale (SOFAS)|Digit Symbol Substitution Test (DSST)|Rey Auditory Verbal Learning Test (RAVLT)|Trail Making Test A/B (TMT A/B)","University Health Network, Toronto","All","18 Years to 50 Years   (Adult)","Early Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-5789.0","August 2019","May 2020","September 2020","April 16, 2019",,"June 21, 2019","Toronto Western Hospital, Toronto, Ontario, Canada","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03915613/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03915613/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03915613"
1962,"NCT01189812","Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms",,"Completed","Has Results","Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Borderline Personality Disorder","Drug: Lithium Carbonate|Drug: Placebo|Drug: Citalopram","Sheehan-Suicidality Tracking Scale (S-STS)|Beck Hopelessness Scale (BHS)|Beck Scale for Suicide Ideation (BSS)","Columbia Northwest Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LP-DP-09201","March 2010","January 2011","January 2011","August 27, 2010","June 8, 2011","August 24, 2011","Artemis Institute for Clinical Research, San Diego, California, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01189812"
1963,"NCT01230047","Mindfulness and Lifestyle Interventions for Depression and Anxiety: A Pilot Study",,"Unknown status","No Results Available","Depression|Anxiety|Major Depression","Behavioral: Psychoeducational course","Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Client Medication Use|Client Currently Seeing Therapist","Arizona State University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1018","October 2010","January 2011","October 2011","October 28, 2010",,"October 28, 2010","Utah Youth Village, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01230047"
1964,"NCT00883519","The Efficacy of Parent Involvement in the Treatment of Adolescent Depression",,"Completed","No Results Available","Major Depressive Disorder|Dysthymic Disorder|Depressive Disorder NOS|Adjustment Disorder","Behavioral: Interpersonal Psychotherapy for Depressed Adolescents|Behavioral: Interpersonal Psychotherapy for Depressed Adolescents and Parents","Children's Depression Rating Scale","New York State Psychiatric Institute|Columbia University","All","12 Years to 17 Years   (Child)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5758","January 2009","December 2010","December 2010","April 17, 2009",,"April 13, 2012","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00883519"
1965,"NCT00845507","Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults",,"Completed","Has Results","Weight Gain","Drug: Exenatide|Drug: Placebo","Change in Weight From Baseline to Endpoint.|Change in Body Mass Index (BMI) From Baseline to Endpoint.","University of Cincinnati|Eli Lilly and Company","All","18 Years to 55 Years   (Adult)","Phase 4","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Exenatide","December 2008","July 2015","July 2015","February 18, 2009","April 20, 2018","April 20, 2018","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00845507"
1966,"NCT04183946","Willkommen Mutterglück: Online CBT for Pregnant and Postpartum Women With Depression and Anxiety",,"Not yet recruiting","No Results Available","Prenatal Anxiety|Generalized Anxiety|Postpartum Depression|Major Depressive Disorder","Behavioral: Online Cognitive Behavioural Therapy","Change of depressive symptoms at four measuring points from baseline to follow up|Change of anxiety symptoms at four measuring points from baseline to follow up|Change of severity of depressive symptoms at four measuring points from baseline to follow up|Change of depression symptoms from baseline until follow-up|Participant's satisfaction with the program and it's usability|Program's evaluation of feasibility with prenatal and postpartum women","University of Zurich|Ambulatorium für kognitive Verhaltenstherapie und Verhaltensmedizin - UZH|Lamprecht AG","Female","18 Years to 45 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Willkommen Mutterglück Program","June 2020","January 2022","January 2024","December 3, 2019",,"December 3, 2019","University of Zurich, Department of Psychology - Clinical Psychology and Psychotherapy, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04183946"
1967,"NCT03736538","Nitrous Oxide- Suicidal Ideation",,"Enrolling by invitation","No Results Available","Major Depressive Disorder|Depression|Mood Disorders|Suicidal Ideation","Drug: Nitrous Oxide|Drug: Placebo gas","Severity and number of adverse events in both nitrous oxide and placebo groups|Differential change in suicidal ideation|Identification of pre-treatment key clinical correlates of anti-suicidal response to nitrous oxide","Washington University School of Medicine|American Foundation for Suicide Prevention","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201710183","October 30, 2018","October 2021","December 2021","November 9, 2018",,"October 8, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03736538"
1968,"NCT04784494","MST for Parkinson's Disease","MST-PD","Not yet recruiting","No Results Available","Parkinson Disease|Depression|Movement Disorders|Major Depressive Disorder","Device: Magnetic Seizure Theapy (MagPro XP MST)","Feasibility of using MST to treat dPDT for depression in Parkinson's disease: recruitment|Feasibility of using MST to treat dPDT for depression in Parkinson's disease: retention|Feasibility of using MST to treat dPDT for depression in Parkinson's disease: side effects|Efficacy information to plan future definite trial","University of British Columbia","All","50 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H19-01049","April 1, 2021","October 2023","December 2023","March 5, 2021",,"March 5, 2021","University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04784494"
1969,"NCT04399070","The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)","ECT","Not yet recruiting","No Results Available","Depression, Bipolar|Depression, Unipolar|Major Depressive Disorder|Manic-Depressive - Now Depressed","Drug: S-ketamine|Drug: ketamine|Drug: saline","Hamilton Depression Scale-17 scores|Montgomery-Asberg Depression Rating Scale scores|Mini-mental State Examination scores|suicide|Mean heart rate before ECT|Mean heart rate after ECT|Mean Arterial Pressure before ECT|Mean Arterial Pressure after ECT|Mean time for return of spontaneous respiration after ECT|Mean emergency time after ECT|Mean seizure duration during ECT","Yan Qiu|West China Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","West China Hospital Anes","August 1, 2020","December 30, 2020","January 31, 2021","May 22, 2020",,"July 22, 2020","West China Hospital of Sichuan University, Department of Anesthesiology, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT04399070"
1970,"NCT01721824","The Effect of IPS-MA- A Modified Early Supported Employment Intervention for Individuals With Mood or Anxiety Disorders",,"Completed","No Results Available","Affective Disorder|Major Depressive Disorder|Bipolar Disorder|Anxiety Disorder","Behavioral: The IPS-MA method","Competitive employment or education|Number of days of competitive employment or studying|Hamilton Rating Scale for Depression - 6 items|Hamilton Rating Scale for anxiety -6 item scale|Global Assessment of Function (GAF-F)|WHO-5 well-being index","Mental Health Centre Copenhagen","All","18 Years to 60 Years   (Adult)","Not Applicable","326","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","H-2-2011-FSP20","October 2011","March 2016","July 2016","November 6, 2012",,"July 7, 2016","Mental Health Center Ballerup, Mental Health Center Frederiksberg, Mental Health Center Copenhagen, and Mental Health Center of Northern Seeland, Ballerup, Denmark",,"https://ClinicalTrials.gov/show/NCT01721824"
1971,"NCT02137369","The ISLAND Study: InSuLa Assessed Needs for Depression","ISLAND","Completed","Has Results","Depression","Drug: Selective serotonin re-uptake inhibitor|Behavioral: Cognitive Behavioral Therapy|Other: Combination treatment (SSRI + CBT)","Number of Remission From Major Depressive Episode Events|Number of Response to Treatment Events","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 60 Years   (Adult)","Phase 4","77","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00073702|R01MH073719|00073702","September 2014","October 24, 2019","October 24, 2019","May 13, 2014","November 5, 2020","November 5, 2020","12 Executive Park Drive, 3rd floor, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02137369/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02137369"
1972,"NCT03481049","Individualizing Incentives for Alcohol in the Severely Mentally Ill",,"Recruiting","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder|Alcohol Dependence","Behavioral: Usual CM|Behavioral: High-Magnitude CM|Behavioral: Shaping CM","Alcohol use assessed by ethyl glucuronide (EtG) detection in urine|Positive and Negative Syndrome Scale|Urinanalysis for Drug Use|Addiction Severity Index (ASI)|Alcohol and Cigarette Timeline Followback|Fagerstrom Test of Nicotine Dependence|Housing Timeline FollowBack|Brief HIV Risk Behavior Scale","Washington State University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16326|R01AA022070","May 5, 2018","September 2022","September 2022","March 29, 2018",,"May 19, 2020","Sound Health, Seattle, Washington, United States|Frontier Behavioral Health, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03481049"
1973,"NCT04828226","Clonidine to Prevent Delirium After Electroconvulsive Therapy.","ECaTa","Recruiting","No Results Available","Major Depressive Disorder|Catatonia|Bipolar Disorder|Delirium Postseizure","Drug: Clonidine|Drug: Placebo","Incidence of delirium after electroconvulsive therapy over all (twelve) ECT sessions|Incidence of mild agitation|Incidence of severe agitation|Use of rescue medication|Duration of seizure activity|Quality of seizure activity|Seizure Quality Index|Need for seizure terminating medication|Total number of electroconvulsive therapy sessions|Reason for terminating or continuing the electroconvulsive series|Length of post-anaesthesia care unit stay|Incidence of desaturation|Incidence of hypotension|Incidence of bradycardia|Cardiovascular changes needing intervention|Use of cardiovascular medication|Adverse events potentially attributable to ECT|Adverse events potentially attributable to Study Drug","University Hospital Inselspital, Berne|University of Bern","All","18 Years and older   (Adult, Older Adult)","Phase 4","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BECD-3-21","April 27, 2021","April 2024","May 2024","April 1, 2021",,"May 28, 2021","Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04828226"
1974,"NCT01880957","PET and MRI Brain Imaging of Bipolar Disorder",,"Unknown status","No Results Available","Bipolar Disorder|Bipolar Depression|Unipolar Depression","Drug: Lithium|Drug: Lamotrigine","Hamilton Depression Rating Scale","Stony Brook University|National Institute of Mental Health (NIMH)|The Dana Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","76","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2012-1826-F|7R01MH090276-03","August 2012","May 2017",,"June 19, 2013",,"July 19, 2016","Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT01880957"
1975,"NCT04209296","Chart Review of Patients Undergoing Ketamine Infusions",,"Enrolling by invitation","No Results Available","Major Depressive Disorder|Bipolar Disorder|Obsessive-Compulsive Disorder|Post Traumatic Stress Disorder","Drug: Ketamine Hydrochloride","Quick Inventory of Depressive Symptomatology Self Report 16-Item|Generalized Anxiety Disorder 7-item|Snaith-Hamilton Pleasure Scale|Sheehan Disability Scale|Endicott Work Productivity Scale|Clinician Administered Dissociative States Scale","Brain and Cognition Discovery Foundation","All","18 Years to 65 Years   (Adult, Older Adult)",,"260","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","Pro00040593","December 3, 2019","December 2021","December 2021","December 24, 2019",,"December 24, 2020","Canadian Rapid Treatment Centre of Excellence, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04209296"
1976,"NCT01830088","Family Based Treatment of Depressed Adolescents (AHUS)","BudFam2","Terminated","No Results Available","Depressive Disorder|Mood Disorder|Major Depression","Behavioral: Attachment Based Family Therapy|Behavioral: Enhanced Usual Care","Change from baseline in Hamilton Depression Rating scale|Beck depression Inventory (BDI-II)|Kiddie-SADS (Diagnostic interview)","University Hospital, Akershus|Children's Hospital of Philadelphia|Helse Sor-Ost|University of Oslo","All","13 Years to 17 Years   (Child)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BudFam2","October 2013","January 2016","June 2016","April 12, 2013",,"May 11, 2018","Akershus University Hospital, Lorenskog, Akershus, Norway",,"https://ClinicalTrials.gov/show/NCT01830088"
1977,"NCT00108407","Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse",,"Completed","No Results Available","Alcohol Abuse|Cannabis Abuse|Major Depressive Disorder|Substance-Related Disorders","Behavioral: Integrated Cognitive Behavioral Therapy|Behavioral: Twelve Step Facilitation Therapy",,"US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable",,"U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","MHBS-041-99Sa","October 2004",,,"April 15, 2005",,"March 6, 2009","VA San Diego Healthcare System, San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00108407"
1978,"NCT03449979","Single Session of tACS in a Depressive Episode","SSDE","Completed","Has Results","Depression|Major Depressive Disorder|Premenstrual Dysphoric Disorder|Depressive Episode","Device: XCSITE100 Stimulator Sham|Device: XCSITE100 Stimulator tACS","Change in Alpha Frequency Electrical Activity in Left Frontal Cortex From Stimulation","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","84","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16-1911b|R01MH101547","September 19, 2018","August 16, 2019","August 16, 2019","February 28, 2018","June 4, 2020","June 4, 2020","University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03449979/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03449979"
1979,"NCT01692574","Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)","TODI","Completed","No Results Available","Obesity|Major Depressive Disorder|Dysthymic Disorder|Cardiovascular Disease","Behavioral: Behavior Modification for Weight Loss|Behavioral: Alternative Approach to Weight Loss|Behavioral: Cognitive-Behavior Therapy for Depression|Behavioral: Depression Support and Education","Weight loss|Changes in metabolic cardiovascular disease risk factors and inflammatory markers","University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","76","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","813829","August 2012","November 2015","November 2015","September 25, 2012",,"August 22, 2016","University of Pennsylvania: Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01692574"
1980,"NCT03327129","Identifying the Neural Basis of Capability for Suicide",,"Unknown status","No Results Available","Major Depressive Disorder|Suicide|Suicidal Ideation|Psychiatric Illness","Procedure: fMRI","Measure changes in resting state brain activity using fMRI in patients with low and high acquired capability for suicide|Compare pain scores in patients with low and high acquired capability for suicide using a validated pressure pain task","Unity Health Toronto","All","18 Years to 55 Years   (Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","SRO-01","June 2018","June 2019","June 2019","October 31, 2017",,"May 25, 2018",,,"https://ClinicalTrials.gov/show/NCT03327129"
1981,"NCT00566735","The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning","Galantamine","Completed","Has Results","Major Depression|Bipolar Depression|Schizoaffective Disorder","Drug: Razadyne|Drug: Placebo","Number of Side Effects|Cognitive Functioning|Baseline Depressive Symptoms","Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2004-P-001051|GAL-EMR-4005","July 2004","January 2008","January 2008","December 4, 2007","December 3, 2012","December 3, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00566735"
1982,"NCT03275766","Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders",,"Completed","Has Results","Psychomotor Retardation|Psychomotor Slowing|Schizophrenia and Related Disorders|Major Depressive Disorder","Other: DLPFC facilitatory|Other: SMA inhibitory|Other: SMA facilitatory|Other: sham TMS","Number of Responders at Week 3|Change in Salpetriere Retardation Rating Scale Total Score From Baseline to Week 3|Change in Activity Level From Baseline to Week 3|Change in Catatonia Severity From Baseline to Week 3|Change in Fingertapping Score From Baseline to Week 3|Change in Coin Rotation From Baseline to Week 3|Change in Hand Gesture Performance From Baseline to Week 3|Change in SANS Total Score From Baseline to Week 3|Change From HAMD Total Score From Baseline to Week 3|Change in CAINS Total Score From Baseline to Week 3|Change in PANSS Total and Subscores From Baseline to Week 3","University of Bern","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","SNCTP610","June 1, 2016","July 1, 2019","July 15, 2019","September 8, 2017","May 12, 2021","May 12, 2021","University Hospital of Psychiatry, University of Bern, Bern, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03275766/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03275766"
1983,"NCT00700609","Family Based Treatment of Depressed Adolescents","BudFam","Terminated","No Results Available","Depressive Disorder|Mood Disorder|Major Depression","Behavioral: Attachment Based Family therapy (ABFT)","Hamilton Depression Rating scale (HAM-D, 17 items)|Beck depression Inventory (BDI-II)|Kiddie- SADS (diagnostic interview)","Helse Stavanger HF|The Research Council of Norway","All","13 Years to 17 Years   (Child)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","18651","June 2008","March 2009","December 2009","June 18, 2008",,"July 31, 2015","Department of Child and Adolescent Psychiatry, Stavanger University Hospital, Stavanger, Rogaland, Norway",,"https://ClinicalTrials.gov/show/NCT00700609"
1984,"NCT02661828","Tapering Off Antidepressants",,"Terminated","Has Results","Major Depressive Disorder|Anxiety Disorder|Obsessive Compulsive Disorder|Post-Traumatic Stress Disorder","Other: Two-Week Antidepressant Taper Regimen|Other: One-Week Antidepressant Taper Regimen","Discontinuation Emergent Signs and Symptoms Scale (DESS) Scores|Physician Withdrawal Checklist (PWC-20) Scores|Number of Participants Who Meet Criteria for Antidepressant Discontinuation Syndrome","Emory University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00084849","January 2016","March 17, 2017","March 17, 2017","January 25, 2016","September 25, 2018","September 25, 2018","Emory University, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|12 Executive Park Drive, 3rd floor, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02661828/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02661828"
1985,"NCT00386841","Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression",,"Completed","No Results Available","Healthy","Drug: Escitalopram|Drug: Placebo","Changes in the response on the combined dexamethasone corticotropin-releasing hormone test before and after 4 weeks treatment with escitalopram or placebo.|Changes in scores before and after 4 weeks treatment with escitalopram or placebo on: Cognition|Social function|Neuroticism|Subjective; sleep, pain, aggression, depression, anxiety, quality of life, perceived stress and side-effects|Receptor status by PET-scans|Inflammatory parameters|Paraclinical measures|MR and fMRI","University of Copenhagen","All","18 Years to 60 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","AGENDA","April 2007","June 2009","June 2009","October 12, 2006",,"June 30, 2009","Psychiatric Department of Rigshospitalet, Blegdamsvej 9, Copenhagen OE, Denmark",,"https://ClinicalTrials.gov/show/NCT00386841"
1986,"NCT02520024","Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living",,"Completed","No Results Available","Major Depression|Bipolar Disorder|Schizophrenia","Behavioral: self-directed care","Change from Baseline TU Community Participation Questionnaire to follow up at 12 months and 24 months post-baseline|Change from Baseline Recovery Assessment Scale to follow up at 12 months and 24 months post-baseline|Change from Baseline Quality of Life to 12 months and 24 months post-baseline|Change from Baseline Hopkins Symptom Checklist to 12 months and 24 months post-baseline|Change from Baseline Empowerment Scale to 12 months and 24 months post-baseline|Change from Baseline Coping Mastery Questionnaire to 12 months and 24 months post-baseline|Change from Baseline Perceived Competence for Recovery Questionnaire to 12 months and 24 months post-baseline|Change from Baseline Perceived Autonomy Support: The Mental Health Questionnaire to 12 months and 24 months post-baseline|Change from Baseline Elements of a Recovery Facilitating Systems Assessment Questionnaire - Adult Version to 12 months and 24 months post-baseline|Change from Baseline Revised Camberwell Assessment of Need Questionnaire to 12 months and 24 months post-baseline|Change from Baseline Treatment Self-Regulation Questionnaire to 12 months and 24 months post-baseline","Temple University Collaborative on Community Inclusion","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","13304","January 2010","March 2012","March 2012","August 11, 2015",,"August 11, 2015",,,"https://ClinicalTrials.gov/show/NCT02520024"
1987,"NCT02453438","Mood Patient Powered Research Network (MoodNetwork)",,"Completed","No Results Available","Mood Disorders|Bipolar Disorder|Major Depressive Disorder|Depression","Other: Patient Reported Outcomes","Patient Reported Outcomes Working Group Items Questionnaire|Composite International Diagnostic Interview Mania Questionnaire|Mini International Neuropsychiatric Interview Depression|Quick Inventory of Depressive Symptoms Self Report|Altman Self Rated Mania Scale|WHO-five well-being index (WHO-5)|Depression and Bipolar Support Alliance Wellness Tracker Questionnaire|Experience of Care and Health Outcomes Questionnaire","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)",,"5716","Other","Observational","Observational Model: Other|Time Perspective: Other","2014P001346","March 2015","March 2019","March 2019","May 25, 2015",,"September 6, 2019","Massachusetts General Hospital Bipolar Clinic and Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02453438"
1988,"NCT02409823","Clinical Registry of Patients Under Treatment With Atypical Antipsychotics",,"Completed","No Results Available","Schizophrenia|Major Depressive Disorder|Bipolar Depressive Disorder|Parkinson's Disease With Hallucinations","Drug: Atypical Antipsychotics","Occurrence of Adverse Drug Reactions|Adherence to treatment|Quality of Life|Clinical status (CGI score)","Pontifical Catholic University of Argentina","All","18 Years and older   (Adult, Older Adult)",,"665","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1209-Re03-Reg","February 2015","August 2015","August 2015","April 7, 2015",,"October 20, 2015",,,"https://ClinicalTrials.gov/show/NCT02409823"
1989,"NCT00080314","Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode",,"Completed","No Results Available","Bipolar Disorder","Drug: Aripiprazole|Drug: Placebo","Change on a depression rating scale at endpoint|Response rate and Clinical Global Impression scale at endpoint","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-096","January 2004","October 2006","October 2006","March 30, 2004",,"November 11, 2013","Local Institution, Tuscaloosa, Alabama, United States|Local Institution, Little Rock, Arkansas, United States|Local Institution, San Diego, California, United States|Local Institution, Sherman Oaks, California, United States|Local Institution, Norwich, Connecticut, United States|Local Institution, West Haven, Connecticut, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Maitland, Florida, United States|Local Institution, Orlando, Florida, United States|Local Insstitution, Honolulu, Hawaii, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Lake Charles, Louisiana, United States|Local Institution, Rockville, Maryland, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Raleigh, North Carolina, United States|Local Institution, Beachwood, Ohio, United States|Local Institution, Dayton, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Local Institution, Media, Pennsylvania, United States|Local Institution, Memphis, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Lake Jackson, Texas, United States|Local Institution, Wichita Falls, Texas, United States|Local Institution, Arlington, Virginia, United States|Local Institution, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00080314"
1990,"NCT00370058","Study on the Influence of Electroconvulsive Therapy (ECT) on Homocysteine Levels",,"Completed","No Results Available","Depressive Disorder, Major","Procedure: ECT treatment","Homocysteine serum levels|Cognitive functioning (e.g. concentration, memory tasks, etc.)|Depressive symptomatology|Measures of Seizure quality (duration, threshold, postictal suppression index, ...)","University of Erlangen-Nürnberg Medical School","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ECT and Homocysteine|Homocystein|ECT","August 2006","August 2007","August 2007","August 30, 2006",,"December 14, 2020","Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg, Erlangen, Germany",,"https://ClinicalTrials.gov/show/NCT00370058"
1991,"NCT04068467","Evaluation of mHealth for Serious Mental Illness",,"Active, not recruiting","No Results Available","Schizophrenia|Schizoaffective Disorder|Major Depressive Disorder|Bipolar Disorder","Other: Smartphone App|Other: Waitlist Control","Change in Depressive Symptoms|Change in Paranoid Thinking|Change in Anxiety Symptoms|Change in Psychotic Symptoms|Participant Acceptability","University of Washington","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00006898","January 6, 2020","September 2021","September 2021","August 28, 2019",,"September 3, 2020","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04068467"
1992,"NCT03953014","Pharmacogenetics of Antidepressant-Induced Disinhibition","PGx-AID","Recruiting","No Results Available","Obsessive-Compulsive Disorder|Anxiety Disorders|Major Depressive Disorder|Antidepressant Drug Adverse Reaction",,"Genetic variants in SSRI metabolism|Behavioural Disinhibition|Adverse Drug Reactions other than SIBD","University of Calgary|Mathison Centre for Mental Health Education and Research|Alberta Health Services","All","6 Years to 17 Years   (Child)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","REB18-0519","January 2, 2019","August 31, 2022","August 31, 2022","May 16, 2019",,"May 16, 2019","Child and Adolescent Addiction, Mental Health & Psychiatry, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03953014"
1993,"NCT01556048","Pilot Study of Behavioral Activation for Prolonged Grief",,"Completed","No Results Available","Complicated Grief|Prolonged Grief Disorder|Major Depressive Disorder|Posttraumatic Stress Disorder","Behavioral: Behavioral Activation","Change from Baseline in grief symptoms at weeks 12, 24, and 36 post randomization|Change from Baseline in PTSD symptoms at weeks 12, 24, and 36 post randomization|Change from Baseline in symptoms of Major Depressive Disorder at Weeks 12, 24, and 36 post randomization|Change from Baseline in levels of rumination at Weeks 12, 24, and 36 post randomization|Therapy credibility and client expectancy for improvement after treatment","Anthony Papa|University of Nevada, Las Vegas","All","21 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SA08/09-07","February 2009","May 2012","May 2012","March 16, 2012",,"December 2, 2014","University of Nevada, Reno, Reno, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT01556048"
1994,"NCT03913013","Technology Enhanced Family Treatment",,"Recruiting","No Results Available","Mood Disorders|Bipolar Disorder|Major Depression","Behavioral: Family-Focused Treatment with MCC App","Average mood symptom scores over 27 weeks on the Adolescent Longitudinal Interval Follow-up Evaluation|Mood instability, as rated by parents and children using the Children's Affective Lability Scale (CALS) and the Parent-Rated General Behavior Inventory|Expressed emotion in parents from the Five Minute Speech Sample|Free speech samples coded using the Linguistic Inquiry Word Count system.","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","13 Years to 19 Years   (Child, Adult)","Phase 1|Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB#18-000906|R34MH117200","November 15, 2018","November 14, 2021","January 15, 2022","April 12, 2019",,"April 12, 2019","UCLA Child and Adolescent Mood Disorders Program, UCLA School of Medicine, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03913013"
1995,"NCT00711737","Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months",,"Completed","No Results Available","Major Depression|Generalized Anxiety Disorder|Panic Disorder",,,"Changi General Hospital","All","21 Years and older   (Adult, Older Adult)",,"27","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2008.06","September 2008","October 2010","October 2010","July 9, 2008",,"June 17, 2011","Changi General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00711737"
1996,"NCT00001545","Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Mood Disorders",,"Completed","No Results Available","Bipolar Disorder|Mood Disorder|Unipolar Depression","Device: Magstim Super Rapid Magnetic Stimulator|Device: Cadwell MES-10",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","91","NIH","Interventional","Primary Purpose: Treatment","960086|96-M-0086","May 1996",,"July 2006","November 4, 1999",,"July 13, 2006","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001545"
1997,"NCT01980147","Skills for Wellness","SWELL","Recruiting","No Results Available","Schizophrenia|Bipolar Disorder|Major Depression","Behavioral: maCBT","Early antecedents to severe mental illness|Severe mental illness (long-term outcome)|Distress associated with unusual experiences|Functioning|psychotic-like experiences|basic symptoms|Anxiety|Affective lability - continuous|Affective lability|Anxiety - continuous","Nova Scotia Health Authority|Nova Scotia Health Research Foundation|Canadian Institutes of Health Research (CIHR)","All","9 Years to 21 Years   (Child, Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","SFW-2013","March 22, 2014","January 2021","January 2022","November 8, 2013",,"July 23, 2019","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT01980147"
1998,"NCT00466323","The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.",,"Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Major Depression","Behavioral: Family Member Provider Outreach|Behavioral: Enhanced treatment as usual (e-TAU)","Family-Clinician Contact (Including Contact With FMPO Clinician)|Family-Clinician Contact (Not Including Notes From FMPO Clinicians)|Consumer's Recovery Rating - MHRM Total Score|Consumer's Recovery Rating - MHRM - Overcoming Stuckness Sub Score","US Department of Veterans Affairs|University of Maryland, Baltimore County|VA Office of Research and Development","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","238","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIR 04-255|H-28791","September 2007","May 2011","June 2011","April 27, 2007","October 20, 2014","April 24, 2015","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00466323"
1999,"NCT01342120","PHARMO Institute Seroquel Safety Study","PHARMO II","Completed","No Results Available","Schizophrenia|Major Depressive Disorder|Bipolar Disorder|Generalized Anxiety Disorder",,"The outcomes of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine vs corresponding incidence rates in users of comparison drugs","AstraZeneca|PHARMO Institute for Drug Outcomes Research","All","18 Years and older   (Adult, Older Adult)",,"18325","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D1443L00085","September 2010","November 2010","November 2010","April 27, 2011",,"September 2, 2011",,,"https://ClinicalTrials.gov/show/NCT01342120"
2000,"NCT04325100","Intervention Targeting Motivational Negative Symptoms","Switch","Completed","No Results Available","Schizophrenia|Schizo Affective Disorder|Bipolar Disorder|Major Depressive Disorder","Behavioral: Switch - Individual sessions|Behavioral: Switch - Group programme","Brief Negative Symptom Scale (BNSS)|Lille Apathy Rating Scale (patient version) (LARS-p)|Lille Apathy Rating Scale (informant version) (LARS-i)|Schizophrenia - Quality of Life questionnaire|Functional Remission of General Schizophrenia (FROGS)|Experience Sampling Method|Step count","University of Liege|Fonds National de la Recherche Scientifique","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B707201629105","April 20, 2019","December 6, 2019","February 27, 2020","March 27, 2020",,"March 27, 2020","University of Liege, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT04325100"
2001,"NCT02778035","Comparing Different Patterns of rTMS in Major Depression",,"Unknown status","No Results Available","Depression; Bipolar Disorder","Device: Dorsomedial prefrontal rTMS","17-Item Hamilton Rating Scale for Depression (HAMD-17)|Beck Depression Inventory-II (BDI-II)","University Health Network, Toronto|Centre for Addiction and Mental Health","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","15-9615","April 2016","March 2019","September 2019","May 19, 2016",,"March 14, 2018","UHN MRI-Guided rTMS Clinic, Toronto Western Hospital, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02778035"
2002,"NCT01261364","Pharmacogenetic-Directed Treatment for Major Depression",,"Completed","No Results Available","Depression","Behavioral: GeneSightRx|Behavioral: Treatment as usual","Depression Score reduction|Side effect reduction|Depression response or remission|Time to response/remission of depressive symptoms.|Medication change|Health care clinical cost|Report availability|Medication Choice|Physician satisfaction|Patient Satisfaction","Assurex Health Inc.|Pine Rest Christian Mental Health Services","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","10002","September 2009","January 2011","September 2011","December 16, 2010",,"December 3, 2015",,,"https://ClinicalTrials.gov/show/NCT01261364"
2003,"NCT02507349","Person-Centered Versus Measurement-Based Care in Mental Health","PCORI-SDM","Completed","Has Results","Schizophrenia|Bipolar Disorder|Major Depression","Behavioral: Person-Centered Care|Behavioral: Measurement-Based Care","Patient Experience of Medication Treatment (PEMM)|Shared Decision Making Questionnaire (SDM-Q-9)|Hope|Medication Side Effects|Patient Activation Measure (PAM)|Behavior and Symptom Identification Scale (BASIS-24)|Sheehan Disability Scale|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (QLESQ-SF)|Engagement in Medication and Evaluation Visit|Engagement in Psychotherapy Visit","University of Pittsburgh|Dartmouth College|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2443","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CDR-1306-02474","August 2014","October 31, 2016","March 31, 2017","July 23, 2015","February 1, 2019","February 26, 2019","Dartmouth Psychiatric Research Center, Lebanon, New Hampshire, United States|UPMC Center for High-Value Health Care, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02507349"
2004,"NCT00105885","Telephone Care as a Substitute for Routine Psychiatric Medication","Telepsych","Completed","No Results Available","Major Depression|Posttraumatic Stress Disorders|Anxiety Disorders","Procedure: telephone care","Healthcare utilization (VHA and non-VHA patient visits); patient time spent obtaining care (including travel time); time provider spends in direct patient care.|Patient satisfaction at baseline, midpoint, end of study; provider satisfaction at baseline, midpoint, end of study; patient medication compliance; SF12V and brief symptom checklist scores|SF12V and brief symptom checklist scores|patient medication compliance|provider satisfaction","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","324","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TEL 01-146","November 2003","September 2008","September 2008","March 18, 2005",,"February 10, 2014","VA Medical & Regional Office Center, White River, White River Junction, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00105885"
2005,"NCT04420793","Voice Changes During ECT","VAPRE","Completed","No Results Available","Unipolar Depression|Bipolar Depression|Bipolar Disorder, Manic","Other: Questionnaire","Acoustic feature: zero crossing rate|Acoustic feature: energy and entropy|Acoustic feature: spectral centroid, spectral spread, spectral entropy, spectral flux, spectral rolloff|Acoustic feature: Mel-Frequency Cepstral Coefficients, Chroma Vectors, and Chroma Deviation|Linguistic features: question ratio, filler ratio, number ratio, type token ratio|Linguistic features: verb frequency, noun frequency, pronoun frequency, adverb frequency, adjective frequency, particle frequency, conjunction frequency, pronoun frequency|Linguistic features: standardized word entropy|Linguistic features: Brunets index|Linguistic features: Honores statistic|Linguistic features: rate of speech|Meta-features: fatigue|Meta-features: audio quality|Meta-features: sentiment|Meta-features: stress|Meta-features: gender|Meta-features: accent|Meta-features: length|Meta-features: age|Comparing the voice feature(s) with greatest statistically significant change to Patient Health Questionnaire (PHQ)-9 scores|Acoustic Feature Specific Changes within and across sessions|Linguistic Feature Specific Changes within and across sessions|Meta-Feature Specific Changes within and across sessions|Acoustic Feature Specific Changes between sessions|Linguistic Feature Specific Changes between sessions|Meta-Feature Specific Changes between sessions|Patient Chart Review Data: Age|Patient Chart Review Data: inpatient/outpatient status|Patient Chart Review Data: gender|Patient Chart Review Data: race|Patient Chart Review Data: Psychiatric diagnosis for ECT|Patient Chart Review Data: PHQ-9 score at each session|Patient Chart Review Data: Psychiatric hospitalizations|Patient Chart Review Data: Past Psychiatric Medication Trials|Patient Chart Review Data: Current Psychiatric Medication Trials|Patient Chart Review Data: Classes of Current Psychiatric Medications|Patient Chart Review Data: Suicidal Ideation at ECT consult|Patient Chart Review Data: Past Suicide Attempts|Patient Chart Review Data: Psychiatric Review of Systems|Patient Chart Review Data: Family Psychiatric History|Patient Chart Review Data: Number of non-psychiatric medical diagnoses|Patient Chart Review Data: Past non-psychiatric medication trials|Patient Chart Review Data: Current non-psychiatric Medications|Patient Chart Review Data: Tobacco use history|Patient Chart Review Data: Tobacco use pack year|Patient Chart Review Data: Prior ECT treatment|Patient Chart Review Data: total # of prior ECT treatments for response in the past|Patient Chart Review Data: Prior transcranial magnetic stimulation (TMS) treatment|Patient Chart Review Data: Prior response to ECT or TMS|Patient Chart Review Data against voice features|Generating ROC curves: stress|Generating ROC curves: fatigue|Generating ROC curves: sentiment","Medical University of South Carolina","All","18 Years to 89 Years   (Adult, Older Adult)",,"11","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","00089198","November 7, 2019","February 17, 2021","February 17, 2021","June 9, 2020",,"March 2, 2021","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04420793"
2006,"NCT00867360","Treatment of Psychotic Major Depression With Mifepristone",,"Terminated","Has Results","Affective Disorders, Psychotic|Depressive Disorder","Drug: Mifepristone (RU-486)|Drug: Placebo","Change in Psychotic Symptoms Subscale (PSS) of the Brief Psychiatric Rating Scale (BPRS)|Change in Mean Cortisol Level|% Change in Mean Evening Pre- and Post- Florinef Cortisol After Treatment With Either Mifepristone or Placebo","Stanford University","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-02262009-1838","August 2005","May 2009","May 2009","March 23, 2009","April 4, 2017","April 4, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00867360"
2007,"NCT03062267","Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness",,"Completed","Has Results","Schizoaffective Disorder|Schizophrenia|Bipolar Disorder|Major Depressive Disorder","Other: Mobile Interventionist","Psychiatric Symptoms|Recovery","University of Washington","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00001274","October 1, 2017","May 31, 2020","May 31, 2020","February 23, 2017","November 9, 2020","November 9, 2020","Thresholds, Chicago, Illinois, United States|Frontier Behavioral Health, Spokane, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03062267/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03062267"
2008,"NCT00071708","Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial",,"No longer available","No Results Available","Major Depressive Disorder|Fibromyalgia|Diabetic Peripheral Neuropathic Pain|Generalized Anxiety Disorder","Drug: Duloxetine Hydrochloride",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"7443|F1J-MC-HMCN",,,,"October 30, 2003",,"July 16, 2021","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paddington, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Everton Park, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maroochydore, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southport, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Hill, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elizabeth Vale, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Keswick, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoppers Crossing, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT00071708"
2009,"NCT00225511","Study Evaluating Effexor XR for Major Depression.",,"Completed","No Results Available","Depression","Drug: Effexor XR|Drug: Milnacipran","Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy.|Difference of total score of HAM-D17 between baseline and final-on-therapy.|Remission rate of HAM-D17 at the final-on-therapy.","Wyeth is now a wholly owned subsidiary of Pfizer","All","20 Years to 64 Years   (Adult)","Phase 3","590","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0600B1-816","June 2004",,,"September 23, 2005",,"May 24, 2007","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Ichikawa, Chiba, Japan|Ichikawa, Chiba, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Ohnojyo, Fukuoka, Japan|Kure, Hiroshima, Japan|Otaru, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Nishinomiya, Hyogo, Japan|Tsuchiura, Ibaragi, Japan|Tsukuba, Ibaragi, Japan|Kanazawa, Ishikawa, Japan|Hanamaki, Iwate, Japan|Kawasaki, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Kikuchi, Kumamoto, Japan|Ohmura, Nagasaki, Japan|Kashihara, Nara, Japan|Jyo-etsu, Niigata, Japan|Beppu, Ohita, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Adachi-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Kodaira, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Ohta-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shinjuku, Tokyo, Japan|Tachikawa, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Hiroshima, Japan|Hiroshima, Japan|Hiroshima, Japan|Nagasaki, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT00225511"
2010,"NCT02334228","Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness",,"Completed","No Results Available","Schizophrenia|Bipolar Disorder|Schizoaffective Disorder|Major Depressive Disorder","Behavioral: In SHAPE Lifestyles|Behavioral: Health Club Membership and Education","Change in Exercise Capacity|Body Mass Index|Change in Weight|Change in Triglycerides and Cholesterol|Change in Health Status|Change in Community Functioning|Change in Physical Measurements (Fitness)|Change in Psychological State|Change in Participation in Exercise|Change in Diet Behaviors|Change in Preventative Health Care","Dartmouth-Hitchcock Medical Center","All","21 Years and older   (Adult, Older Adult)","Not Applicable","133","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Concord InSHAPE","September 2006","August 2009","August 2009","January 8, 2015",,"January 8, 2015","Riverbend Community Mental Health, Concord, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT02334228"
2011,"NCT02822443","Improve: Integrating Emotion Focused Components Into Psychological Therapy","Improve","Completed","No Results Available","Unipolar Depression|Anxiety Disorder|Adjustment Disorder","Behavioral: Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|Behavioral: Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)","Change from baseline in symptom impairment measured by the Brief Symptom Inventory (BSI; Franke, 2000)|Change from baseline in depressive symptoms measured by the Beck Depression Inventory (BDI-II; Hautzinger et al., 2006)|Change from baseline in anxiety symptoms measured by the Beck Anxiety Inventory (BAI; Ehlers & Margraf, 2007)|Severity of panic disorder and agoraphobia with the Panic and Agoraphobia Scale (PAS; Bandelow, 1997)|Severity of social phobia measured by the Social Phobia Scale SPS; Stangier et al., 1999)|Severity of social interaction anxiety measured by the Social Interaction Anxiety Scale (SIAS; Stangier et al., 1999)|Severity of anxiety symptoms measured by the Questionnaire for General Anxiety Disorder (GAD-7; Spitzer et al., 2006)|Psychological well-being measured with the WHO Well-Being Index (WHO-5; Henkel et al., 2004)|Health-related quality of life measured with the Short Form Healthy Survey (SF-12; Gandek et al., 1998)|Motivational schemata measured by the Questionnaire for Analysis of Motivational Schemata (FAMOS; grosse Holtforth & Grawe, 2000)|Motivational incongruence measured by the Incongruence Questionnaire (K-INK; grosse Holtforth et al., 2003)|Interpersonal problems measured by the Inventory of Interpersonal Problems (IIP-32; Thomas et al., 2011)|Personality structure measured by the Operationalized Psychodynamic Diagnosis Structure Questionnaire (OPD-SFK; Ehrenthal et al., 2012)|Personality traits measured by the Inventory of Personality Organization (IPO-16; Zimmermann et al., 2013)|Ambivalence over emotional expressiveness measured by the Ambivalence over the Expression of Emotion Scale (AVEX; Trachsel et al., 2010)|Emotional competency measured by the Questionnaire for the self-assessment of emotional competencies (SEK-27; Berking & Znoj, 2008)|Generalized expectancies for negative mood regulation measured by the Negative Mood Regulation Scale (NMR-SF; Pfeiffer et al., 2013)|Psychological flexibility measured by the Acceptance and Action Questionnaire (Fragebogen zu Akzeptanz und Handeln; FAH-II; Gloster et al., 2013)|General self-efficacy measured by the General Self-Efficacy Scale (SWE; Schwarzer & Jerusalem, 1999)|Therapy evaluation and outcome expectancies measured by the Patient Questionnaire on Therapy Expectation and Evaluation (PATHEV; Schulte, 2005)|Social desirability measured by the Balanced Inventory of Desirable Responding (BIDR-K; Winkler et al., 2006)|Client satisfaction measured by the Brief Global Measure of Client Satisfaction (ZUF-8; Schmidt & Wittmann, 2002)|External assessment of interpersonal personality measured by the Impact Message Inventory (IMI-R; Caspar et al. 2002)|External assessment of resources measured by the Bernese Inventory of Resources (REF-F and REF-T; Tröske, 2000)|External assessment of positive interpersonal qualities measured by the Inventory of Interpersonal Strengths (IIS; Hatcher & Rogers, 2012)|Goal attainment measured by the Goal Attainment Scaling (GAS; Kirusek, 1994)|Regular quality monitoring with the Bern Post Session Report, Patient and Therapist Version (BPSR-P/T; Flückiger et al. 2010)|Symptom impairment measured by the Symptom Checklist (SCL-9; Bogerts et al., 2001)|Implicit motives measured by the Picture-Story-Exercise - Online Version (PSE-O: Bernecker & Jobst, 2013)","University of Bern","All","18 Years and older   (Adult, Older Adult)","Phase 2","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SNF100019_159425 /1","April 2015","July 2018","August 2019","July 4, 2016",,"September 10, 2019","University of Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02822443"
2012,"NCT01204086","Pharmacogenomics Studies of Antidepressants",,"Unknown status","No Results Available","Major Depressive Disorder|Antidepressive Agents|Pharmacogenetics|Venlafaxine|Fluoxetine","Drug: Venlafaxine|Drug: Fluoxetine","Hamilton Depression Rating Scale (HDRS)|C-reactive Protein and IL-6|fasting blood glucose, lipid profiles","National Cheng-Kung University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan)","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HR-95-06|DOH96-TD-D-113-041","March 2007","December 2010","February 2011","September 17, 2010",,"September 17, 2010","National Cheng-Kung University Hospital, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01204086"
2013,"NCT03309527","E-aid Sleep-focused TrEatment for Prevention of Major Depression (STEP-MD)",,"Unknown status","No Results Available","Insomnia|Depression|Self Harm","Behavioral: e-aid Cognitive Behavior Therapy|Behavioral: e-aid Sleep Hygiene Education","occurrence of depression|Treatment adherence rating scale|Treatment satisfaction rating scale (TSRS)|Changes in Insomnia Severity Index(ISI)|Changes in Hospital Anxiety and Depression Scale (HADS)|Changes in Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS)|Changes in Short - Form 12 - Item Health Survey（SF-12）|Changes in Sleep Hygiene and Practices Scale(SHPS)|Changes in Pre-Sleep Arousal Scale(PSAS)|Changes in Epworth Sleepiness Scale(ESS)|occurrence of suicidal ideation","Nanfang Hospital of Southern Medical University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NFEC-2017-132","November 1, 2017","October 2019","December 2020","October 13, 2017",,"March 1, 2018","Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03309527"
2014,"NCT02773108","Somatic Comorbidities in Psychiatric Patients","SCPP","Completed","No Results Available","Schizophrenia|Major Depression Disorder|Bipolar Affective Disorder",,"Prevalence of somatic comorbidities|Clinical Global Impression- Improvement scale (CGI-I), Change from diagnosis","Sveti Ivan Psychiatric Hospital","All","18 Years to 90 Years   (Adult, Older Adult)",,"1061","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","komorbiditeti","May 2016","June 2016","December 2018","May 16, 2016",,"June 25, 2019","PB Sveti Ivan, Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT02773108"
2015,"NCT03033420","Reducing the Rate and Duration of Re-ADMISsions Among Patients With Unipolar Disorder and Bipolar Disorder Using Smartphone-based Monitoring and Treatment - The RADMIS Trials","RADMIS","Active, not recruiting","No Results Available","Affective Disorders|Unipolar Depression|Bipolar Disorder","Device: A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules","Number of re-admissions|Duration of re-admissions|Severity of depressive symptoms|Severity of manic symptoms|Psychosocial functioning|Number of affective episodes","Psychiatric Centre Rigshospitalet|Technical University of Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","RADMIS","May 15, 2017","March 1, 2020","May 2021","January 26, 2017",,"September 16, 2020","Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03033420"
2016,"NCT00225485","Study Evaluating Effexor XR in Elderly Patients With Major Depression.",,"Completed","No Results Available","Depression","Drug: Effexor XR","Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy|Difference of total score of HAM-D17 between baseline and final-on-therapy|Remission rate of HAM-D17 at the final-on-therapy","Wyeth is now a wholly owned subsidiary of Pfizer","All","65 Years and older   (Older Adult)","Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0600B1-817","December 2003",,,"September 23, 2005",,"May 28, 2007","Ichikawa, Chiba, Japan|Ichikawa, Chiba, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Ohnojo, Fukuoka, Japan|Otaru, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Tsukuba, Ibaragi, Japan|Hanamaki, Iwate, Japan|Kawasaki, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Adachi-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Fuchu, Tokyo, Japan|Higashimurayama, Tokyo, Japan|Kodaira, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Tachikawa, Tokyo, Japan|Hiroshima, Japan|Okayama, Japan",,"https://ClinicalTrials.gov/show/NCT00225485"
2017,"NCT00001479","Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression",,"Completed","No Results Available","Fatigue Syndrome, Chronic|Healthy|Mood Disorders",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"60","NIH","Observational",,"950044|95-M-0044","January 1995",,"May 2000","December 10, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001479"
2018,"NCT00225524","Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.",,"Completed","No Results Available","Depression","Drug: Effexor XR","Incidence of adverse events|Quantitative data for laboratory data","Wyeth is now a wholly owned subsidiary of Pfizer","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0600B1-818","September 2004",,,"September 23, 2005",,"May 24, 2007","Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Ichikawa, Chiba, Japan|Ichikawa, Chiba, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Ohnojyo, Fukuoka, Japan|Kure, Hiroshima, Japan|Otaru, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Nishinomiya, Hyogo, Japan|Tsuchiura, Ibaragi, Japan|Tsukuba, Ibaragi, Japan|Kanazawa, Ishikawa, Japan|Hanamaki, Iwate, Japan|Kawasaki, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Kikuchi, Kumamoto, Japan|Ohmura, Nagasaki, Japan|Kashihara, Nara, Japan|Jyo-etsu, Niigata, Japan|Beppu, Ohita, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Osakasayama, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Adachi-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Kodaira, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Ohta-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shinjuku, Tokyo, Japan|Tachikawa, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Toshima-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Hiroshima, Japan|Hiroshima, Japan|Hiroshima, Japan|Nagasaki, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT00225524"
2019,"NCT03315897","Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders","PreTEC-EPO","Recruiting","No Results Available","Bipolar Disorder|Cognitive Impairment|Unipolar Depression","Drug: Erythropoietin|Drug: Saline","Cognitive composite score|Rapid Visual Information Processing (RVP) from Cambridge Cognition (CANTAB)|Functional Assessment Short Test","Lars Vedel Kessing|Mental Health Services in the Capital Region, Denmark|Lundbeck Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-16043370|2016-004023-24|RHP-2017-020","July 5, 2017","February 1, 2021","February 1, 2021","October 20, 2017",,"March 5, 2020","Mental Health Services, Capital Region of Denmark, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03315897"
2020,"NCT00046020","Study Evaluating Venlafaxine ER in Recurrent Depression",,"Completed","No Results Available","Depressive Disorder, Major|Recurrence","Drug: Venlafaxine ER",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","1096","Industry","Interventional","Primary Purpose: Treatment","0600B-100469","August 2000","October 2005","October 2005","September 19, 2002",,"August 14, 2009",,,"https://ClinicalTrials.gov/show/NCT00046020"
2021,"NCT00172848","Mastery, Social Support and Depression of Patients With Major Depression",,"Completed","No Results Available","Depression",,,"National Taiwan University Hospital",,"Child, Adult, Older Adult",,,"Other","Observational","Observational Model: Defined Population|Time Perspective: Other","9461700303","October 2004",,"April 2005","September 15, 2005",,"November 24, 2005","Ping-Chuan,Hsiung, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00172848"
2022,"NCT04706728","Music Listening to Lower Anxiety During ECT Treatment.","MIECT","Recruiting","No Results Available","Anxiety State","Other: Listening to playlists with music prior to-, during and after the ECT procedure|Other: Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure","State-Trait Anxiety Inventory (STAI-Y1)","Aalborg University|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","VEK N-20200038","May 1, 2021","August 2023","December 2023","January 13, 2021",,"July 21, 2021","Aalborg University Hospital, Psychiatry, Aalborg, Region Nordjylland, Denmark",,"https://ClinicalTrials.gov/show/NCT04706728"
2023,"NCT01894932","MBCGT and Psycho-physiological Stress Regulation Group for Depression and Psycho-physiological Stress Patient",,"Unknown status","No Results Available","Psychophysiologic Disorders|Stress, Psychological|Unipolar Depression","Behavioral: Mindfulness-based cognitive Group therapy|Behavioral: psycho-physiological stress regulation group","scores change on the Beck Depression Inventory, physical and psychological symptom score, negative self-thinking scale, mental focus and self-monitoring Scale, and Awareness Scale.","National Taiwan University Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201103042RC","April 2011","July 2016","August 2016","July 10, 2013",,"August 14, 2013","Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01894932"
2024,"NCT02407704","A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise","MEDEX","Completed","Has Results","Depression|Depressive Disorder, Major|Depressive Disorder|Unipolar Depression|Major Depressive Disorder","Drug: Venlafaxine XR|Other: Aerobic Exercise|Drug: Lorazepam","Number of Participants Experiencing Remission|Inflammatory Biomarkers|Genetic Biomarkers|Physical Activity (SenseWear Physical Activity-monitoring Armband)|Cardiovascular Fitness (Submaximal VO2)|Functional Magnetic Resonance Imaging (fMRI)|Neurocognitive Function (Neuropsychological Battery)","Kirk Erickson, PhD|University of Pittsburgh","All","60 Years to 79 Years   (Adult, Older Adult)","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MH090333-04|PRO13110090|MH090333","March 2015","November 2016","December 2016","April 3, 2015","May 23, 2018","May 23, 2018","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02407704"
2025,"NCT00145951","Reducing the Risk of Developing Major Depression in Adolescents/Young Adults With Minor Depression/Depression Symptoms",,"Terminated","No Results Available","Depression","Behavioral: motivational interviewing, brief advice in primary care",,"University of Chicago","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"93","Other","Observational","Time Perspective: Prospective","13798A","May 2006","September 2007","December 2011","September 5, 2005",,"March 28, 2014","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00145951"
2026,"NCT00069407","Comparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major Depression",,"Completed","No Results Available","Depression","Procedure: Electroconvulsive Therapy","Hamilton Depression Rating Scale, 24 item|Neuropsychological assessment","University of Medicine and Dentistry of New Jersey|National Institute of Mental Health (NIMH)|Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Not Applicable","230","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R01MH067201|DSIR 83-ATSO","February 2003","May 2006","December 2006","September 25, 2003",,"December 16, 2014","Mayo Clinic, Rochester, Minnesota, United States|UMDNJ, Newark, New Jersey, United States|Northshore/Long Island Jewish Hillside Hospital, Glen Oaks, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00069407"
2027,"NCT02874833","Exercise for Depression","EXDEP","Completed","No Results Available","Depression, Unipolar|Bipolar Disorder","Other: Exercise","Severity of depressive symptoms - Quick Inventory of Depressive Symptomatology - clinical rating-16 (QIDS C-16)|Severity of depressive symptoms - Quick Inventory of Depressive Symptomatology - self-report-16 (QIDS SR-16)|Adherence of internet-based concept|Placebo effect of exercise (QIDS-SR16)|Placebo effect of exercise (QIDS-C16)|Peak oxygen uptake (VO2peak)|Lactate threshold|Short form 36 (SF36) health survey questionnaire|General self efficacy questionnaire (GSE)|Global Clinical Issues (GCI)|Circulating, cell-free DNA (cfDNA)","Johannes Gutenberg University Mainz|Department of Psychiatry and Psychotherapy, University Medical Center, Mainz","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EXDEP_1","July 2016","October 2017","February 2018","August 22, 2016",,"March 1, 2018","Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Mainz, Rhineland-Palatinate, Germany|Department of Sports Medicine, Johannes Gutenberg University, Mainz, Mainz, Rhineland-Palatinate, Germany",,"https://ClinicalTrials.gov/show/NCT02874833"
2028,"NCT01501825","A Prospective, Comparative Study to Explore the Efficacy and Safety of the Five Channels Multiway Deep Transcranial Magnetic Stimulation (TMS) Device in Subjects With Major Depression Disorder (MDD)",,"Unknown status","No Results Available","Depression","Device: 5 channels Multiway deep Transcranial Magnetic Stimulator|Device: five channels Multiway deep Transcranial Magnetic Stimulation","Clinical antidepressant response|Clinical antidepressant remission|Symptomatic improvement","Shalvata Mental Health Center|Brainsway-moach Ltd.","All","18 Years to 67 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sha-16-11","August 2012","August 2013","August 2013","December 29, 2011",,"July 4, 2012","shalvata MHC, Hod HAsharon, Israel|Shalvata Mental Health Center, Hod-HaSharon, Israel",,"https://ClinicalTrials.gov/show/NCT01501825"
2029,"NCT04324944","Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness","CDST","Not yet recruiting","No Results Available","Schizophrenia|Schizoaffective Disorder|Delusional Disorder|Major Depressive Disorder With Psychotic Features","Behavioral: Collaborative Decision Skills Training|Behavioral: Money Management","Shared Decision-Making Coding System|Service Engagement Scale|Situational Motivation Scale for Schizophrenia Research|Interest in adjunctive rehabilitative approaches|Client Satisfaction Questionnaire|Canadian Occupational Performance Measure- Performance subscale|Goal Attainment Scaling|Maryland Assessment of Recovery in Serious Mental Illness|Brief Psychiatric Rating Scale|Social Skills Performance Assessment|Personal and Social Performance scale|Decision Skills Questionnaire|Collaborative Decision Making Approach Measure|Shared Decision Making Questionnaire for Mental Health|Problem-Solving Decision-Making Scale for Mental Health|Decision Skills Checklist|Qualitative interviews|Treatment attendance","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D3079-W","December 1, 2021","March 29, 2024","March 31, 2025","March 27, 2020",,"January 19, 2021","VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04324944"
2030,"NCT02698553","A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Bupropion HCl XL tablet 150mg|Drug: Bupropion HCl XL tablet 300mg","Time taken to reach peak plasma concentration (Tmax) of Bupropion HCl and its metabolites after single dose.|Maximum observed concentration (Cmax) in plasma of Bupropion HCl and its metabolites after single dose.|Area under the plasma concentration-time curve from time 0 to 24 hours (AUC [0-24]) of Bupropion HCl and its metabolites after single dose.|Tmax in plasma of Bupropion HCl and its metabolites after repeated doses|Steady state concentration (Css)-Css Minimum (Css_min), Css Maximum (Css_max), Average Css (Css_av) in plasma of Bupropion HCl and its metabolites after repeated dose.|Elimination half-life (t ½) in plasma of Bupropion HCl and its metabolites after repeated dose.|Apparent clearance (CL/F) in plasma of Bupropion HCl and its metabolites after repeated dose.|Area under the concentration-time curve over the dosing interval (AUC [0-tau]) in plasma of Bupropion HCl and its metabolites after repeated dose.|Number of subjects with adverse event (AE) and serious adverse event (SAE).|Number of subjects with abnormal Haematology parameters as a measure of safety.|Number of subjects with abnormal Clinical chemistry parameters as a measure of safety.|Number of subjects with abnormal Urinalysis parameters as a measure of safety assessed by dipstick test.|Body temperature assessment as a safety measure.|Blood pressure assessment as a safety measure.|Heart rate assessment as a safety measure.|Electrocardiogram (ECG) assessment as a measure of safety and tolerability.","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","114883","May 23, 2016","June 29, 2016","June 29, 2016","March 3, 2016",,"September 13, 2018","GSK Investigational Site, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02698553"
2031,"NCT01667159","Community-Based Integrated Treatment for Adolescents",,"Completed","No Results Available","Depression|Alcohol Use","Behavioral: Integrated Cognitive Behavioral Therapy|Behavioral: Standard Care","Depression|Alcohol/Substance Use","Brown University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","12 Years to 18 Years   (Child, Adult)","Phase 1","114","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R01AA020705-01A1","July 2012","March 2017","December 2017","August 17, 2012",,"January 23, 2018","Brown University, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01667159"
2032,"NCT04001439","FEcal Microbiota Transplantation",,"Unknown status","No Results Available","Depression in Schizophrenia","Drug: Experimental drug","myoglobin concentration","Assistance Publique Hopitaux De Marseille","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","3088","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2019-11","December 1, 2019","February 1, 2020","December 31, 2020","June 28, 2019",,"June 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04001439"
2033,"NCT02238730","Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy",,"Withdrawn","No Results Available","Depression|Depressive Disorder|Treatment Resistant Depressive Disorder|Bipolar Disorder|Major Depressive Disorder","Device: Ultrabrief Right Unilateral|Device: Brief Pulse Bitemporal","Hamilton Depression Rating Scale (HAMD)|Mini Mental Status Examination","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","KPSC IRB10133|KPSC IRB 10133","September 2014","February 15, 2017","February 15, 2017","September 12, 2014",,"February 17, 2017",,,"https://ClinicalTrials.gov/show/NCT02238730"
2034,"NCT02787148","Psychotherapy and Cardiovascular Risk Factors in Depression",,"Completed","No Results Available","Depression","Behavioral: Cognitive behavioral therapy","Change in depressive symptoms (BDI-II)|Change in heart rate variability|Change in blood pressure|Change in baroreceptor sensitivity (ms/mmHg)|Change in peripheral vascular resistance (dyne*s/cm5)|Change in C-reactive protein|Change in proinflammatory cytokines|Change in anti-inflammatory interleukin-10|Change in Subjective social status (MacArthur scale)","Philipps University Marburg Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DFG EU 154 2 1","October 2015","October 2019","October 2019","June 1, 2016",,"July 28, 2021","Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Marburg, Germany",,"https://ClinicalTrials.gov/show/NCT02787148"
2035,"NCT00177424","Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes",,"Terminated","No Results Available","Cerebrovascular Accident|Depression","Drug: sertraline|Drug: Placebo","The primary outcome will be the incidence of Major Depression post-stroke.|Additional outcomes will include the severity of depressive symptoms post-stroke as measured by the Hamilton Depression Rating Scale, and the level of disability experienced by the two treatment groups, as measured by the Functional Independence Measure.","University of Pittsburgh|National Institute of Mental Health (NIMH)","All","40 Years and older   (Adult, Older Adult)","Phase 4","154","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","K23MH067710-02|0310068|DATR AK-TNGP1","July 2004","October 2007","October 2007","September 15, 2005",,"June 27, 2014","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00177424"
2036,"NCT00440427","Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Desvenlafaxine Sustained Release (DVS SR)","Safety","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A2-1201","February 2007",,"February 2007","February 27, 2007",,"December 5, 2007","Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00440427"
2037,"NCT02094898","Ketamine for Depression and Suicide Risk","Ketamine","Completed","Has Results","Depression|Suicide","Drug: Ketamine","MADRS Total Score at Baseline and Last Acute Phase Observation|MADRS Total Score, Percent Change From Baseline at Last Acute Phase Observation|MADRS Factor 1 Score at Baseline and Last Acute Phase Observation|MADRS Factor 1 Score, Percent Change From Baseline at Last Acute Phase Observation|MADRS Factor 2 Score at Baseline and Last Acute Phase Observation|MADRS Factor 2 Score, Percentage Change From Baseline at Last Acute Phase Observation|MADRS Factor 3 Score at Baseline and Last Acute Phase Observation|MADRS Factor 3 Score, Percentage Change From Baseline at Last Acute Phase Observation|MADRS Factor 4 Score at Baseline and Last Acute Phase Observation|MADRS Factor 4 Score, Percentage Change From Baseline at Last Acute Phase Observation|MADRS Suicide Thoughts (Item 10) Score at Last Acute Phase Observation|MADRS Suicide (Item 10) Score, Percentage Change From Baseline at Last Acute Phase Observation|Clinical Global Impression-severity Subscale (CGI-S) at Baseline and Last Acute Phase Observation|CGI-S Score, Percentage Change From Baseline at Last Acute Phase Observation","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-005152","September 2014","July 2016","August 2016","March 24, 2014","August 11, 2017","August 11, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02094898"
2038,"NCT03922217","e-Mindfulness for Depression","MMW","Recruiting","No Results Available","Depression|Mental Health Disorder","Device: Mindful My Way","EMA Depression Scale","Washington University School of Medicine","All","65 Years and older   (Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201811036","March 28, 2019","March 5, 2021","March 5, 2021","April 19, 2019",,"May 20, 2020","Washington University School of Medicine, Health Mind Lab, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03922217"
2039,"NCT00386893","Somatosensory Processing in Depression",,"Withdrawn","No Results Available","Depression","Procedure: simultaneous EEG/fMRI|Device: fMRI","changes in evoked potentials/functional MRI from baseline to week 4","Ludwig-Maximilians - University of Munich|H. Lundbeck A/S","All","18 Years to 60 Years   (Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ESC_03082005|2005-003752-35","October 2006","December 2011","December 2011","October 12, 2006",,"April 14, 2015","Department of Psychiatry and Clin. Radiology, Ludwig-Maximilian-University, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT00386893"
2040,"NCT00812994","Neurotrophic Factors and Depression","Lex/BDNF","Completed","No Results Available","Depression","Drug: Escitalopram|Drug: Placebo","Serum BDNF levels|Serum allopregnanolone levels|Montgomery-Asberg Depression Rating Scale|Clinical Global Impression","University of California, San Francisco","Male","22 Years to 55 Years   (Adult)","Phase 4","30","Other","Interventional","Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","H3097-19671-08","January 2003","December 2006","November 2008","December 22, 2008",,"December 22, 2008","University of California San Francisco, San Francisco, California, United States|UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00812994"
2041,"NCT04228146","Self-help Smartphone-delivered Cognitive Behavioral Therapy for Insomnia in People With Depression and Insomnia",,"Recruiting","No Results Available","Sleep Initiation and Maintenance Disorders|Depression","Behavioral: Cognitive Behavioral Therapy for Insomnia|Other: Waitlist Control","Changes over the measurement points in Center for Epidemiologic Studies Depression Scale|Changes over the measurement points in Insomnia Severity Index|Changes over the measurement points in Pittsburgh Sleep Quality Index|Changes over measurement points in SF-12 Version 1 Physical Scale|Changes over measurement points in SF-12 Version 1 Mental Scale|Changes over measurement points in Hospital Anxiety and Depression Scale - Anxiety subscale","The University of Hong Kong","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","285","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EA1810026","March 19, 2019","December 2020","June 2021","January 14, 2020",,"February 18, 2020","Department of Psychology, The University of Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT04228146"
2042,"NCT00619411","Interpersonal Psychotherapy for Depressed Adolescents and Parents",,"Completed","No Results Available","Major Depression|Dysthymic Disorder|Adjustment Disorders|Depressive Disorder Not Otherwise Specified","Behavioral: Interpersonal Therapy for Depressed Adolescents & Parents","Clinical Global Improvement (CGI), Hamilton Rating Scale for Depression (HRSD), Center for Epidemiological Studies - Depression Scale (CES-D)|Global Assessment Scale for Children (C-GAS), Social Adjustment Scale - Self-report (SAS-SR), Conflict Behavior Questionnaire (CBQ-20), Observational assessment of parent-adolescent communication","New York State Psychiatric Institute|Columbia University","All","12 Years to 18 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5549","November 2007","May 2009","May 2009","February 21, 2008",,"March 9, 2012",,,"https://ClinicalTrials.gov/show/NCT00619411"
2043,"NCT03841019","Predict MDE Outcomes After MST",,"Recruiting","No Results Available","Major Depressive Episode","Device: Magpro X100 + Option|Device: ThymatronSystem Ⅳ Electroconvulsive System","changes in the 17-item Hamilton Depression Rating Scale (HAMD-17)|changes in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|changes in the spectral power of the electroencephalogram (EEG) in square microvolt during resting state|changes in the spectral power of the electroencephalogram (EEG) in square microvolt during the auditory mismatch negativity task|changes in the spectral power of the electroencephalogram (EEG) in square microvolt during the facial recognition task.","Shanghai Mental Health Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201840269","July 20, 2020","March 31, 2022","December 31, 2022","February 15, 2019",,"November 27, 2020","Shanghai Mental Health Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03841019"
2044,"NCT00844922","Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)",,"Completed","No Results Available","Depressive Disorders|Psychotic Disorders|Depression","Drug: SCH 900636|Drug: Placebo","Safety and tolerability measures (vital signs, AEs)|17-item Hamilton Rating Scale for Depression (HAMD) total score|proportion of BPRS 30% responders; proportion of subjects with sustained BPRS 30% response|proportion of HAMD 50% responders; proportion of subjects with sustained HAMD 50% response|clinical global impression (CGI)|PANNS total score|PANSS positive scale score, PANSS negative scale score, PANSS general psychopathology score","Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05842|EudraCT #: 2004-002156-34;","September 2005","June 2006","June 2006","February 16, 2009",,"December 31, 2014",,,"https://ClinicalTrials.gov/show/NCT00844922"
2045,"NCT00018824","Treating Alcohol Use In Older Adults With Depression",,"Completed","No Results Available","Alcoholism|Depression","Drug: NALTREXONE|Drug: Placebo","Alcohol use'","US Department of Veterans Affairs|VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Phase 4","74","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MHBS-009-98S","October 1999","January 2005","January 2005","July 5, 2001",,"September 23, 2009","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00018824"
2046,"NCT00073411","Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression",,"Completed","No Results Available","Depression","Drug: duloxetine|Drug: escitalopram|Drug: placebo","To compare the onset of antidepressant efficacy for duloxetine 60 mg once-daily compared with escitalopram 10 mg once-daily.|To compare the efficacy of duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily and placebo during acute therapy|To compare the efficacy of duloxetine 60-120 mg once-daily versus escitalopram 10-20 mg once-daily and placebo for up to 8 months of therapy|To compare incidence of sexual dysfunction (defined by Changes in Sexual Functioning Questionnaire (CSFQ)), during acute therapy for patients treated with duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily & placebo.|To compare sexual dysfunction during up to 8 months of treatment with duloxetine 60-120 mg once-daily versus escitalopram 10 to 20 mg once-daily and placebo|To compare impact of duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily & placebo during acute therapy & during 8 months of therapy on quality of life, functional/health outcomes, & patient satisfaction with study drug|To compare impact of duloxetine 60-120 mg once-daily versus escitalopram 10 to 20 mg once-daily and placebo for up to 8 months of therapy on quality of life, functional/health outcomes, & patient satisfaction with study drug|To compare impact of duloxetine 60-120 mg once-daily versus escitalopram 10-20 mg once-daily and placebo during acute and extended therapy on resource utilization (% patients using more,less or equal number of health care providers and services)|To evaluate safety and tolerability of duloxetine 60 mg once-daily vs. escitalopram 10 mg once-daily and placebo during acute therapy|To evaluate the safety and tolerability of duloxetine 60-120 mg once-daily vs. escitalopram 10-20 mg once-daily and placebo for up to 8 months of therapy|To compare percentage of patients taking duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily and placebo requiring a dose escalation due to less than satisfactory initial response (defined by IRB supplement or investigator request)|To compare efficacy of duloxetine versus escitalopram in the placebo non-responders who enter the rescue phase","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","7978|F1J-US-HMCR","November 2003",,"May 2005","November 21, 2003",,"July 31, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00073411"
2047,"NCT00555698","Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression",,"Completed","No Results Available","Depression","Device: Deep Brain Stimulations for Depression","Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS)|Inventory for Depressive Symptoms, Self-report (IDS-SR), Clinical Global Impressions (CGI), Patient Global Impressions (PGI), Global Assessment of Functioning (GAF), Social and Occupational Function Assessment Scale (SOFAS), Quality of LIfe Enjoyment and","Ali Rezai, MD|Medtronic|The Cleveland Clinic|Ohio State University","All","18 Years to 55 Years   (Adult)","Early Phase 1","8","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6577","January 2004","February 2011","February 2011","November 9, 2007",,"March 28, 2017","Cleveland Clinic Foundation, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00555698"
2048,"NCT02658617","Functional Neuroanatomy and Regional Metabolism Before and After Treatment With Duloxetine",,"Completed","No Results Available","Depression",,"Changes in brain activation patterns after 6 weeks treatment with duloxetine","Heinz Boeker|University of Zurich","All","18 Years to 60 Years   (Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PUK09","March 2010","April 2010","September 2015","January 20, 2016",,"January 20, 2016",,,"https://ClinicalTrials.gov/show/NCT02658617"
2049,"NCT04348825","Electroconvulsive Therapy and Neuroradiology","ECTMRI","Completed","No Results Available","Depression|Electroconvulsive Therapy","Device: Electroconvulsive therapy","Changes from baseline in Magnetic Resonance Imaging (MRI) derived parameters|Changes from baseline in Depression ratings|Changes from baseline in Neurocognitive functioning","Haukeland University Hospital|University of Bergen",,"Child, Adult, Older Adult",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2013/1032","September 1, 2013","September 19, 2018","October 10, 2018","April 16, 2020",,"June 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04348825"
2050,"NCT02798094","Stress Sensitivity and Reward Responsivity in Depression","CAN-BIND-04","Completed","No Results Available","Depressed",,"Stress Sensitivity: Salivary Hormone and Stress Challenge Test (TSST)|Mood and Anxiety Symptom Questionnaire (MASQ)|Reward Responsivity: Probabilistic Reward Task|Snaith Hamilton Pleasure Scale (SHAPS and SHAPS-C)","Dr. Kate Harkness|University Health Network, Toronto|University of Calgary|Harvard University|McGill University|Queen's University","All","18 Years to 65 Years   (Adult, Older Adult)",,"219","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PSYC-154-14","July 2015","December 31, 2018","December 31, 2018","June 14, 2016",,"August 28, 2019","Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02798094"
2051,"NCT00277108","Lexapro in the Treatment of Patients With Postpartum Depression",,"Completed","No Results Available","Postpartum Depression","Drug: Escitalopram (Lexapro)","The primary outcome measure will be remission of major depression, defined as a score of 12 or less on the Montgomery-Asberg Depression Scale.|A score of 7 or less on the Hamilton Depression Scale (21 item) will be used as a secondary measure of remission.","University of Rochester|Forest Laboratories","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LXP-MD80","February 2004","April 2007","April 2007","January 13, 2006",,"November 6, 2008","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00277108"
2052,"NCT00005015","Treatment of Depression in Youth With Bipolar Disorders",,"Terminated","No Results Available","Bipolar Disorder|Depression","Drug: Fluoxetine",,"National Institute of Mental Health (NIMH)","All","8 Years to 18 Years   (Child, Adult)","Phase 3",,"NIH","Interventional","Masking: Double|Primary Purpose: Treatment","N01 MH70008|DSIR CT",,,"September 2000","April 3, 2000",,"November 21, 2005",,,"https://ClinicalTrials.gov/show/NCT00005015"
2053,"NCT00254007","Depression and Traumatic Brain Injury",,"Completed","No Results Available","Depression|Traumatic Brain Injury","Drug: citalopram (celexa)","- Hamilton Depression Rating Scale (HAM-D)|Beck Depression Inventory (BDI), Rivermead Head Injury Follow-up Questionnaire (RHFQ), General Health Questionnaire (GHQ), Rivermead Post Concussion Disorder Questionnaire (RPDQ)","Sunnybrook Health Sciences Centre|Ontario Mental Health Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205-2003","July 2003","December 2005","May 2010","November 15, 2005",,"April 28, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00254007"
2054,"NCT00837564","Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression",,"Unknown status","No Results Available","Chronic Depression","Other: CBASP psychotherapy|Drug: Escitalopram","Depressive symptomatology after 8 weeks after randomization as measured by the MADRS|Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization","University Hospital Freiburg|University Hospital, Bonn","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBASP-1","February 2009","April 2010","April 2011","February 5, 2009",,"June 30, 2010","University of Bonn, Dept. of Psychiatry, Bonn, Germany|University of Freiburg, Dept. of Psychiatry and Psychotherapy, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT00837564"
2055,"NCT01128452","Safety and Efficacy of EVT 101 in Treatment-Resistant Depression",,"Terminated","No Results Available","Depression","Drug: EVT 101|Drug: Placebo","Safety and Tolerability Profile of EVT 101|Efficacy of EVT 101 in depression measured using the MADRS score|Percentage of patients who respond to treatment with study drug|Percentage of patients who experience remission","Janssen Research & Development, LLC|Hoffmann-La Roche","All","18 Years to 55 Years   (Adult)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR104589|RRA-12001, EVT 101/1012","June 2010","March 2011","March 2011","May 21, 2010",,"March 28, 2016","Evotec Study Site 6, Oceanside, California, United States|Evotec Study Site 19, San Diego, California, United States|Evotec Study Site 15, Tampa, Florida, United States|Evotec Study Site 4, Atlanta, Georgia, United States|Evotec Study Site 14, Smyrna, Georgia, United States|Evotec Study Site 3, Beachwood, Illinois, United States|Evotec Study Site 2, Oak Brook, Illinois, United States|Evotec Study Site 1, Baltimore, Maryland, United States|Evotec Study Site 8, Flowood, Mississippi, United States|Evotec Study Site 5, Willingboro, New Jersey, United States|Evotec Study Site 9, New York, New York, United States|Evotec Study Site 13, Oklahoma City, Oklahoma, United States|Evotec Study Site 7, Dallas, Texas, United States|Evotec Study Site 12, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01128452"
2056,"NCT02920840","Brain-oscillation Synchronised Stimulation of the Prefrontal Cortex","BOSSFRONT","Completed","No Results Available","Depression","Device: Intermittent theta-burst stimulation|Device: Negative-peak-triggered-TMS|Device: Open-loop replay TMS","Change from baseline in cortical excitability 30 minutes after the intervention|Change from baseline in EEG alpha power 30 minutes after the intervention|Change from baseline in verbal working memory performance 30 minutes after the intervention","University Hospital Tuebingen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","BNP2016-03","September 2016","April 2017","April 2017","September 30, 2016",,"September 9, 2020","University Neurology Hospital, Tuebingen, BW, Germany",,"https://ClinicalTrials.gov/show/NCT02920840"
2057,"NCT00214682","Beyond Ageing Project: A Study for the Prevention of Depression",,"Completed","No Results Available","Depression|Depressive Disorder","Drug: Folate (400mcg) and Vitamin B12 (100 mcg)|Behavioral: mediated physical activity promotion|Behavioral: Mental health literacy|Drug: placebo|Behavioral: Nutrition information|Behavioral: pain and arthritis management information","Depression|Physical activity level|Cognitive impairment|Physical health outcomes|B12 levels|Folate status|Homocysteine","Australian National University|Australian Government Department of Health and Ageing|University of Sydney|Commonwealth Scientific and Industrial Research Organisation, Australia","All","65 Years to 74 Years   (Older Adult)","Phase 2","909","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2004/188 HREC|2005/483 (TGA)","October 2005","January 2011","January 2011","September 22, 2005",,"September 13, 2011","Australian National University, Canberra, Australian Capital Territory, Australia",,"https://ClinicalTrials.gov/show/NCT00214682"
2058,"NCT03254342","MRS and Medication Response: A Pilot Study",,"Unknown status","No Results Available","Major Depressive Disorder|Major Depressive Episode|Major Depressive Disorder, Recurrent|Major Depression Mild|Major Depression Moderate|Major Depression Severe",,"Measurement of paroxetine (Paxil), citalopram (Celexa) or escitalopram (Lexapro) brain concentrations.","Stanford University","All","21 Years to 75 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Other|Time Perspective: Prospective","28162","August 6, 2013","August 6, 2020","August 31, 2020","August 18, 2017",,"June 19, 2019","Stanford University Psychiatry and Biobehavioral Sciences, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03254342"
2059,"NCT03039387","Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients",,"Unknown status","No Results Available","Anodal Stimulation tDCS|Major Depression|Cognitive Control|Emotion Regulation","Device: anodal transcranial direct current stimulation|Device: transcranial direct current stimulation (sham)","Interstimulusintervall and number of correct trials in the PASAT|Change of positive and negative affect|Heart rate variability|Score in state rumination questionnaire","University Hospital Tuebingen|German Federal Ministry of Education and Research|Universität Tübingen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","01EE1403D","September 2016","April 2017","April 2017","February 1, 2017",,"February 1, 2017","University Hospital Tuebingen, Tubingen, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03039387"
2060,"NCT00308893","BDNF Gene Polymorphism and Antidepressants Treatment",,"Completed","No Results Available","Depression","Genetic: Genetic analysis","Score on Montgomery and Asberg Depression Rating Scale (MADRS)","University Hospital, Tours|H. Lundbeck A/S","All","18 Years and older   (Adult, Older Adult)","Phase 4","188","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AOHP05-WEH/BDNF","July 2006","June 2012","June 2012","March 30, 2006",,"December 18, 2013","CPU CHRU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT00308893"
2061,"NCT00221494","Can Additional Drug Therapy Accelerate Response Time to Antidepressants",,"Withdrawn","No Results Available","Depression","Drug: citalopram + tiodothyronine, or + pindolol, or + placebo",,"Mark Frye|University of California, Los Angeles|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","00-09-045-11","January 2004","June 2006",,"September 22, 2005",,"June 1, 2015","UCLA Neuropsychiatric Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00221494"
2062,"NCT00162916","Antidepressant Maintenance in Traumatic Brain Injury",,"Unknown status","No Results Available","Depression","Drug: citalopram|Drug: Placebo","recurrence of major depression by administering the Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impressions Scale (CGI) every 4 weeks for 40 weeks|general cognitive function at baseline, 10 weeks and on termination of the trial|list of adverse drug events at baseline, 10 weeks and on termination of the trial","Ontario Neurotrauma Foundation","All","19 Years and older   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","rapoportm-ONF2004-abi-dep-03","May 2005","May 2008","October 2008","September 13, 2005",,"June 4, 2008","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00162916"
2063,"NCT01311570","Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients",,"Unknown status","No Results Available","Depression","Drug: Buprenorphine","The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population.|The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine in a MDD population.","Shalvata Mental Health Center","All","18 Years to 68 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B080910","October 2012","February 2013",,"March 9, 2011",,"September 25, 2012","Shalvata Medical Health Center, Hod-Hasharon, Israel",,"https://ClinicalTrials.gov/show/NCT01311570"
2064,"NCT00001146","Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial",,"Completed","No Results Available","Bipolar Disorder|Involutional Depression|Mood Disorder","Drug: Ethyl Eicosapentaenoic Acid|Drug: OmegaBrite",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","240","NIH","Interventional","Primary Purpose: Treatment","000004|00-M-0004","October 1999",,"August 2002","November 4, 1999",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001146"
2065,"NCT02685280","Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders",,"Completed","No Results Available","Obsessive-compulsive Disorder|Depression","Device: Medtronic Restore Advanced 37713","Change in Y-BOCS (for OCD)|Change in HAM-D (for MD)|Change in HAM-D (for OCD)|Change in BDI|Change in GAF|Change in Stimulation Amplitude|Change in Stimulation Frequency|Change in Pulse Width|Change in Contact Configuration|Change in frequency of outpatient clinic contacts at the Psychiatry department|Change in fraction of hospitalized days at the Psychiatry department|Change in frequency of outpatient clinic contacts at the Neurosurgery department|Change in fraction of hospitalized days at the Neurosurgery department|Change in frequency of DBS-related surgical procedures|Adverse events","Universitaire Ziekenhuizen Leuven|Medtronic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S50760|B32220072682","October 2007","December 2014","December 2014","February 18, 2016",,"February 18, 2016",,,"https://ClinicalTrials.gov/show/NCT02685280"
2066,"NCT04140838","Cost-utility and Physiological Effects of ACT and BATD in Patients With Chronic Pain and Depression","IMPACT","Recruiting","No Results Available","Randomized Controlled Trial","Behavioral: Acceptance and Commitment Therapy (ACT)|Behavioral: Behavioral Activation Therapy for Depression (BATD)|Other: Treatment as Usual (TAU)","Aggregate score of the Physical Function, Body Pain and Vitality subscales of the SF-36|Numerical pain scale|Hospital Anxiety and Depression Scale (HADS)|Pain Catastrophising Scale (PCS)","Fundació Sant Joan de Déu|Carlos III Health Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PI19/00112","July 1, 2020","December 31, 2021","December 31, 2022","October 28, 2019",,"October 22, 2020","Parc Sanitari Sant Joan de Déu (PSSJD), Sant Boi De Llobregat, Barcelona, Spain|Parc de Salut Mar, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04140838"
2067,"NCT02744391","A Study of L-DOPA for Depression and Slowing in Older Adults",,"Completed","Has Results","Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Decreased Processing Speed|Decreased Gait Speed","Drug: Levodopa","Hamilton Rating Scale for Depression (24 Item)|Digit Symbol Substitution Test|Pattern Comparison|Letter Comparison|Single Task Gait Speed|Dual Task Gait Speed|Inventory of Depressive Symptomatology-Self Report|Pre-Treatment [11C]-Raclopride Binding Potential: Sensorimotor Striatum|Post-Treatment [11C]-Raclopride Binding Potential: Sensorimotor Striatum|Pre-Treatment [11C]-Raclopride Binding Potential: Limbic Striatum|Post-Treatment [11C]-Raclopride Binding Potential: Limbic Striatum|Pre-Treatment [11C]-Raclopride Binding Potential: Associative Striatum|Post-Treatment [11C]-Raclopride Binding Potential: Associative Striatum","New York State Psychiatric Institute","All","60 Years and older   (Adult, Older Adult)","Phase 4","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7270","August 24, 2016","September 14, 2018","November 30, 2018","April 20, 2016","July 5, 2019","July 5, 2019","New York State Psychiatric Institute, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02744391/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02744391/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02744391"
2068,"NCT04179006","Effects of Nutrients Supplementation in Antidepressant Treated Depressive Disorder Patients",,"Recruiting","No Results Available","Depressive Disorder, Major","Dietary Supplement: LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)","Change in participant's Hamilton Rating Scale for Depression (HAM-D) score|Change in participant's BW(kg), Height(cm), Waist circumference(cm), BMI (kg/m2)|Change in participant's Glucose profiles|Change in participant's Fasting serum leptin level (ng/mL)|Change in participant's Fasting serum lipid profiles|Change in participant's Cortisol(ug/dL) level|Change in participant's C-peptide(ng/dL)|Change in participant's Inflammatory cytokines levels|Change in participants's Quality of life scale (QOLs) scores [WHOQOL-BREF]|Change in participants's Quality of life scale (QOLs) scores [HRQOL]|Change in participant's Cognitive performance|Change in participant's Social cognitive functional performance|Change in participant's Microbiota profiles","National Cheng-Kung University Hospital|Grape King Bio Ltd.","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B-BR-108-032","November 14, 2019","December 31, 2021","December 31, 2021","November 26, 2019",,"November 27, 2019","National Cheng-Kung University, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04179006"
2069,"NCT00375297","Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women",,"Completed","No Results Available","Sexual Dysfunction|Depression","Drug: sildenafil","Clinical global improvement in sexual function|UNM-Sexual function inventory|Arizona Sexual Function Scale|Female sexual function questionnaire","University of New Mexico|Pfizer","Female","18 Years to 50 Years   (Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","99321|Acc# 4-37011","January 2001",,"June 2005","September 12, 2006",,"September 12, 2006","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT00375297"
2070,"NCT00531726","Berlin Deep Brain Stimulation Depression Study","BDDS","Completed","No Results Available","Treatment Resistant Depression","Device: DBS of Cg25","HAMD/MARS score reduction|neurotrophic factor concentration, p300, cortical excitability measures, stress axis measures","Charite University, Berlin, Germany|University Hospital Carl Gustav Carus|Ludwig-Maximilians - University of Munich|Hannover Medical School","All","25 Years to 80 Years   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BDDS","September 2007","September 2012","September 2013","September 19, 2007",,"January 24, 2018","Charité - Universitaetsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00531726"
2071,"NCT00055575","Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies",,"Terminated","No Results Available","Mood Disorders|Healthy|Unipolar Depression|Bipolar Depression","Drug: Scopolamine Nasal Spray","Evaluation of the antidepressant effects of the antimuscarinic agent scopolamine","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 2","197","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","030108|03-M-0108","February 27, 2003","February 2, 2015","February 2, 2015","March 6, 2003",,"March 22, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00055575"
2072,"NCT02400736","Supported Employment in Patient Aligned Care Teams",,"Completed","Has Results","Mental Disorder|Substance Use Disorders|Posttraumatic Stress Disorder|Major Depressive Disorder|Anxiety Disorder","Behavioral: Individual Placement and Support (IPS)|Other: Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)","Steady Worker|Weeks Worked in a Competitive Job|Time to First Competitive Job|Income Earned From Competitive Jobs in Those Who Held a Competitive Job|Symptom Checklist-90-Revised Change From Baseline to Month 12.|Income Earned From All Sources|Rosenberg Self-Esteem Scale Change From Baseline to 12 Months.|Income Earned From Competitive Jobs","VA Office of Research and Development","All","19 Years and older   (Adult, Older Adult)","Not Applicable","119","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1489-I","August 3, 2015","September 30, 2019","September 30, 2020","March 27, 2015","March 30, 2021","March 30, 2021","Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02400736/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02400736"
2073,"NCT00043550","Treatments for Depression: Drug Versus Psychotherapy",,"Completed","Has Results","Depression","Behavioral: Supportive Expressive Therapy|Drug: Sertraline|Drug: Pill Placebo|Drug: Venlafaxine","Hamilton Rating Scale for Depression-17 Item","University of Pennsylvania|National Institute of Mental Health (NIMH)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","156","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH061410|DSIR 83-ATAS","November 2001","June 2009","June 2009","August 12, 2002","June 2, 2017","June 2, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00043550"
2074,"NCT00340379","Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression",,"Completed","Has Results","Affective Disorders","Drug: Ziprasidone|Drug: Sertraline|Drug: Haloperidol","21 Item Hamilton Depression Rating Scale|Clinical Global Impression Improvement Scale|Brief Psychiatric Rating Scale at 12 Weeks","Duke University|Pfizer|National Institute of Mental Health and Neuro Sciences, India","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00008437|3846-05-6R2","April 2003","August 2005","August 2005","June 21, 2006","June 4, 2013","August 19, 2014","University of Southern California, Los Angeles, California, United States|Alexandria University, Alexandria, Egypt|National Institute of Mental Health and Neuroscience, Bangalore, India",,"https://ClinicalTrials.gov/show/NCT00340379"
2075,"NCT01733381","Effects of Barefoot Running vs. in Shoes on Physiology and Mood",,"Completed","No Results Available","Autonomic Nervous System (ANS) Functioning and Mood State.",,"To examine whether running minimally-shod produces changes in ANS function both during and after running when compared to running shoed.|Specific Aim 2: To examine whether running minimally-shod produces changes in emotional state both during and after running when compared to running shoed.|To examine whether changes in ANS activity associated with running are associated with changes in mood.","University of Arizona","All","18 Years and older   (Adult, Older Adult)",,"22","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","12-0370-02","November 2012","February 2014","February 2014","November 27, 2012",,"February 5, 2014","Human Evolutionary Biomechanics Laboratory in the Park Student Union, Room 236 at the University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01733381"
2076,"NCT02960763","Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","OPTIMUM","Recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Disorder|Treatment-Refractory Depression|Late Life Depression|Geriatric Depression","Drug: Aripiprazole Augmentation|Drug: Bupropion Augmentation|Drug: Switch to bupropion|Drug: Lithium Augmentation|Drug: Switch to nortriptyline","Psychological Well-Being|Remission from Depression|Serious Adverse Events|Falls|Fall-related Injuries|Change in executive function|Change in episodic memory|Change in executive-control and cortico-limbic circuitry|Change in plasma biomarkers","Washington University School of Medicine|Patient-Centered Outcomes Research Institute|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Phase 4","1500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TRD-1511-33321|201609085|R01MH114966-01","February 24, 2017","September 2021","December 2021","November 10, 2016",,"May 6, 2021","UCLA Late-Life Mood, Stress, and Wellness Research Program, Los Angeles, California, United States|Washington University School of Medicine Healthy Mind Lab, Saint Louis, Missouri, United States|Columbia University Adult and Late Life Depression Clinic, New York, New York, United States|UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program, Pittsburgh, Pennsylvania, United States|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02960763"
2077,"NCT00332787","Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents",,"Completed","No Results Available","Depression","Drug: Fluoxetine","Measured throughout the study: Relapse|Time to relapse|Measured at Weeks 12 and 36: Functioning|Baseline characteristics","University of Texas Southwestern Medical Center|National Institute of Mental Health (NIMH)","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R01MH039188|DSIR CT-M","June 2000",,"October 2005","June 2, 2006",,"January 8, 2014","Children's Medical Center at Dallas, Outpatient Psychiatry Clinic, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00332787"
2078,"NCT02520271","Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders","ODS","Completed","No Results Available","Major Depression|Dual Diagnosis|Anxiety Disorders|Substance Related Disorders","Behavioral: Behavioral Activation|Behavioral: Motivational Interview","Change in severity of depressive symptoms from baseline at 6 weeks, 6 months, 12 months, and 24 months|Change in quality of life from baseline at 6 weeks, 6 months, 12 months, and 24 months|Change in number of weekly consumed alcohol drinks from baseline at 6 weeks, 6 months, 12 months, and 24 months|Change in severity of alcohol use from baseline at 6 weeks, 6 months, 12 months, and 24 months","Seinajoki Central Hospital|Tampere University","All","17 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","242","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","EVO1114","October 2009","October 2013","June 2014","August 11, 2015",,"August 13, 2015","Seinäjoki Hospital District, Seinäjoki, South Ostrobothnia, Finland",,"https://ClinicalTrials.gov/show/NCT02520271"
2079,"NCT00294281","Vagus Nerve Stimulation for Treating Adults With Severe Fibromyalgia",,"Completed","No Results Available","Fibromyalgia","Device: Vagus Nerve Stimulation (VNS) Therapy","Incidence of adverse events|FM 20 multidimensional response index (FM 20)|Assessment of pain intensity|Assessment of function|Assessment of patient global perception","University of Medicine and Dentistry of New Jersey|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institute of Neurological Disorders and Stroke (NINDS)|Rutgers, The State University of New Jersey","All","21 Years to 60 Years   (Adult)","Phase 1","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01AR053732|5R01AR053732|FM-01","October 2006","May 2010","June 2010","February 20, 2006",,"September 20, 2011","University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00294281"
2080,"NCT01390662","Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression","D3-vit-dep","Unknown status","No Results Available","Depression","Dietary Supplement: Vitamin D3|Dietary Supplement: placebo","Hamilton 17 item scale (Hamilton-17)|WHO-Five Well-being Index (WHO-5)","Region Syddanmark","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","26992|2010-023531-42","March 2011","May 2012","December 2012","July 11, 2011",,"March 28, 2012","Mental Health Services Esbjerg, Esbjerg, Denmark|Mental Health Services, Odense, Odense, Denmark|Mental Health Services Svendborg, Svendborg, Denmark",,"https://ClinicalTrials.gov/show/NCT01390662"
2081,"NCT04936126","Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression","APQ-TRD","Not yet recruiting","No Results Available","Treatment Resistant Depression","Drug: Quetiapine|Drug: Amantadine|Drug: Pramipexole","Hamilton Depression Scale scores|Clinical Global Impression scores|Serum Brain Derived Neurotrophic Factor|Serum Nerve Growth Factor|Rescue Medications","All India Institute of Medical Sciences, Bhubaneswar|Indian Council of Medical Research","All","18 Years to 60 Years   (Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","T/EMF/Psych/19/49","August 7, 2021","July 7, 2024","September 7, 2024","June 23, 2021",,"June 30, 2021","All India Institute of Medical Sciences, Bhubaneswar, Orissa, India",,"https://ClinicalTrials.gov/show/NCT04936126"
2082,"NCT02959502","Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression",,"Recruiting","No Results Available","Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Dementia|Transcranial Direct Current Stimulation|tDCS","Other: Receive tDCS+CR|Other: Facilitate tDCS + CR","Feasibility of training a facilitator (caregiver) to facilitate the administration of CR+tDCS to their ""patient"" partner as indicated by a positive response in the Perceived Competence Scale at 24 months from study baseline.|Assess change in Quality of Life Scale scores among patients between baseline and at the end of the 8-week course.|Measure the change in Quality of Life Scale scores among facilitators between baseline and at the end of the 8-week course.|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among patients between baseline and at the end of the 8-week course|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among facilitators between baseline and at the end of the 8-week course","Centre for Addiction and Mental Health|CAMH Foundation","All","60 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","069/2016","October 31, 2016","December 2022","December 2022","November 9, 2016",,"January 8, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02959502"
2083,"NCT02969876","Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine","VOR-IISR","Terminated","Has Results","Depressive Disorder|Major Depression|Depression|Depression, Unipolar","Drug: Vortioxetine","Quick Inventory of Depressive Symptomatology - Clinician Version (QIDS-C)|Digital Symbol Substitution Test|Rey Auditory Verbal Learning Test","Massachusetts General Hospital|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","2","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2016P001243","August 24, 2017","August 6, 2018","August 6, 2018","November 21, 2016","October 14, 2019","October 14, 2019","the Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02969876/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02969876"
2084,"NCT01062880","Neuropattern - Assessment of a Translational Diagnostic Tool for Depression, Adjustment- and Somatoform-disorders","Neuropattern","Unknown status","No Results Available","Major Depression|Minor Depression|Somatoform Disorders|Adjustment Disorders","Behavioral: self-guided internet modules","Documentation and distribution of different endophenotypes (Neuropattern) in patients of family doctors suffering from depressive episodes, major depression, somatoform disorders, and adjustment disorders|Efficacy of Neuropattern diagnostics with respect to pharmacological treatments and internet based self-guided psychological modules","University of Trier","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","961-38 62 61 / 891","February 2010","May 2011","May 2012","February 4, 2010",,"February 4, 2010","University of Trier, Department of Psychology, Clinical and Physiological Psychology, Trier, Germany",,"https://ClinicalTrials.gov/show/NCT01062880"
2085,"NCT03156556","Improving Access to the Treatment of Anxiety and Depression Among Youth Linguistic Minorities",,"Unknown status","No Results Available","Generalized Anxiety Disorder|Major Depressive Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia","Behavioral: Mood Mechanic Course","Changes in depression as assessed with the Patient Health Questionnaire-9 items|Changes in anxiety as assessed with the Generalized Anxiety Disorder Scale 7-Item Scale|Changes in anxiety as assessed with the Panic and Agoraphobia Scale (PAS)|Changes in anxiety as assessed with the Social Phobia Inventory (SPIN)|Changes in resilience as assessed with the Connor-Davidson Resilience Scale|Changes in life satisfaction as assessed with the Life Satisfaction Questionnaire|Treatment acceptability","Universite de Moncton|Royal Bank of Canada|MindCare Inc.|Macquarie University, Australia|University of Regina","All","18 Years to 25 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1617070","May 15, 2017","October 31, 2018","October 31, 2018","May 17, 2017",,"October 15, 2018","Université de Moncton, Moncton, New Brunswick, Canada",,"https://ClinicalTrials.gov/show/NCT03156556"
2086,"NCT03504475","Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers",,"Completed","No Results Available","Major Depressive Disorder|Obsessive-Compulsive Disorder|Panic Disorder|Social Anxiety Disorder|Generalized Anxiety Disorder","Drug: Paroxetine Hydrochloride Tablet 20 mg|Drug: Paxil® 20 mg","Cmax|AUC(0-∞)|AUC(0-t)","Beijing Tongren Hospital|Beijing Winsunny Pharmceutical Co.,Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","53","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","WS-CP-06-201709-01","March 29, 2018","April 24, 2018","June 16, 2018","April 20, 2018",,"December 19, 2018","Beijing TongRen Hospital, Beijing, Beijing, China|Beijing TongRen Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03504475"
2087,"NCT02276469","Peer Support for Severe Mental Disorders","PEER","Completed","No Results Available","Psychosis|Major Depression|Bipolar Disorder|Borderline Personality Disorder","Behavioral: peer support","Change from Baseline in Self-Efficacy at 6 month|Change from Baseline in Quality of life at 6 and 12 month|Service satisfaction after six month of intervention|Change from Baseline in Illness management, Coping at 6 and 12 month|Change from Baseline in Psychosocial functioning at 6 and 12 month|Change from Baseline in Severity of illness at 6 and 12 month|Hospitalization in days of in-patient care|Days to hospitalization","Universitätsklinikum Hamburg-Eppendorf|German Federal Ministry of Education and Research","All","17 Years and older   (Child, Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC 0748/006|Psychenet Teilprojekt 5","July 2011","November 2014","December 2014","October 28, 2014",,"January 5, 2015",,,"https://ClinicalTrials.gov/show/NCT02276469"
2088,"NCT01527786","Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine",,"Completed","No Results Available","Depression","Drug: Desvenlafaxine","Sheehan Disability Scale (SDS)|Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Rating Scale- Anxiety (HAM-A), the Yale-Brown Obsessive Compulsive Scale (YBOCS), the Panic Disorder Severity Scale (PDSS), and the Penn Sate Worry Questionnaire (PSWQ).","BC Women's Hospital & Health Centre","Female","19 Years to 45 Years   (Adult)","Phase 3","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRISTIQ IOP # 3151A1-44","November 2010","February 2014","February 2014","February 7, 2012",,"January 28, 2015","BC Women's Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01527786"
2089,"NCT00699218","A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression","TMS-BD","Completed","Has Results","Mood Disorder|Bipolar Disorder|Major Depression|Depression","Device: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.","Hamilton Rating Scale for Depression (HAM-D)|Inventory of Depressive Symptomatology","University of California, Davis|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","200715749","May 2008","July 2009","April 2010","June 17, 2008","July 23, 2018","July 23, 2018","Center for Mind and Brain, Davis, California, United States",,"https://ClinicalTrials.gov/show/NCT00699218"
2090,"NCT00330174","Acamprosate in Alcoholics With Comorbid Anxiety or Depression",,"Completed","Has Results","Alcohol Dependence|Major Depression|Social Anxiety Disorder|Generalized Anxiety Disorder","Drug: Acamprosate","Percent Days Drinking|Montgomery-Asberg Depression Rating Scale (MADRS)|Liebowitz Social Anxiety Scale|Hospital Anxiety and Depression Scale","Medical University of South Carolina|Mclean Hospital|Columbia University","All","18 Years to 60 Years   (Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMP-MD-04","April 2006","September 2010","September 2010","May 26, 2006","April 13, 2015","April 13, 2015","McLean Hospital, Belmont, Massachusetts, United States|Columbia University College of Physicians & Surgeons, New York, New York, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00330174"
2091,"NCT01528748","Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence",,"Completed","No Results Available","Depressive Disorder|Major Depressive Disorder|Dysthymic Disorder|Alcohol-Related Disorders|Alcoholism","Behavioral: Cognitive Behavioral Analysis System of Psychotherapy","Depression Rating|Drinking behavior","University of Virginia","All","21 Years to 65 Years   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15599","April 2011","December 2015","July 2018","February 8, 2012",,"April 17, 2019","University of Virginia Center for Addiction Research & Education (UVa CARE), Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01528748"
2092,"NCT01038765","Mindfulness Based Cognitive Therapy for Recurrent Depression",,"Unknown status","No Results Available","Depressive Disorder, Major","Behavioral: Mindfulness Based Cognitive Therapy","Relapse/Recurrence of Major Depressive Episode|Psychiatric symptoms and mindfulness skills measured by questionnaires","Radboud University|Fonds Psychische Gezondheid","All","18 Years and older   (Adult, Older Adult)","Not Applicable","338","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MFN-2005-2010|2005 6028","January 2005","March 2010","January 2011","December 24, 2009",,"December 24, 2009","Radboud University Nijmegen Medical Center, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01038765"
2093,"NCT01487668","Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders",,"Completed","Has Results","Bipolar Disorder|Schizophrenia|Major Depressive Disorder|Schizoaffective Disorder|Cardiovascular Disease Risk","Behavioral: Life Goals Collaborative Care","Physical Health-related Quality of Life|Improved Mental Health-related Quality of Life","VA Office of Research and Development","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","304","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","IIR 10-340","December 2011","February 2015","May 2015","December 7, 2011","January 22, 2016","January 22, 2016","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01487668"
2094,"NCT02439099","Retinoic Acid Homeostasis in Neuropsychiatric Diseases","RAHND","Unknown status","No Results Available","Major Depression|Alzheimer's Disease|Alcoholism|Schizophrenia",,"Serum retinoic acid (RA) levels [nM]|For MDD group: MADRS|For MDD group: BDI II|For MDD and schizophrenia Group: Change of serum retinoic acid (RA) levels [nM]|For schizophrenia group: Positive and Negative Syndrome Scale (PANSS) for Schizophrenia|For schizophrenia group: Change of metabolic parametres For schizophrenia group:Positive and Negative Syndrome Scale (PANSS)","Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EA4/002/13","March 2015","December 2019","December 2019","May 8, 2015",,"January 31, 2019","Department of Psychiatry, Charité - Campus Benjamin Franklin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02439099"
2095,"NCT01749124","My Coach Connect: An Automated Telephone-based Reporting System for Patients With Mental Illness","MCC","Unknown status","No Results Available","Chronic Mental Illness|Major Depression|Schizophrenia|Bipolar Disorder","Device: My Coach Connect","Client and provider telephone intervention|Client and provider survey","RAND|National Institute of Mental Health (NIMH)|University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","RHINO 2008-0132|P30MH082760","December 2012","June 2017","June 2017","December 13, 2012",,"May 18, 2017","ROADS (Recovery, Opportunity, And Developing Skills), Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01749124"
2096,"NCT03556735","Pulsed Electro Magnetic Fields (PEMF) in Depression","PEMF","Completed","No Results Available","Depression, Unipolar","Device: Treatment with PEMF equipment","Change in the Hamilton Depression Scale (HAM-D17)|Life Quality|Side effects|Response and remission","University of Southern Denmark|Aarhus University Hospital|Rigshospitalet, Denmark|Aalborg University Hospital|Glostrup University Hospital, Copenhagen|Mental Health Centre Copenhagen|Odense University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-10-72-125-16","September 2016","November 2017","December 2017","June 14, 2018",,"April 19, 2019","Department of Psychiatry, Psychiatry in the Region of Southern Denmark, Odense, Region Of Southern Denmark, Denmark",,"https://ClinicalTrials.gov/show/NCT03556735"
2097,"NCT03591224","Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy",,"Completed","No Results Available","Depression|Anxiety|Major Depressive Disorder|Generalized Anxiety Disorder|Mood Disorders","Other: Pharmacogenomic Testing|Other: Pharmacist Standard of Care","Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) - general measure of satisfaction to drug therapy|Patient Health Questionnaire (PHQ-9) - measure/monitor the severity of depression|Generalized Anxiety Disorder-7 (GAD-7) - measure/monitor the severity of anxiety|Sheehan Disability Scale - measure of functional impairment in work/school, social life, and family life|Number of pharmacist identified drug therapy problems|Prescriber acceptance rate of pharmacist's recommendations","John Papastergiou Pharmacy Ltd|Green Shield Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","213","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Pro00025062","April 17, 2018","December 31, 2019","December 31, 2019","July 19, 2018",,"July 7, 2020","John Papastergiou Pharmacy Ltd - Store#500, Toronto, Ontario, Canada|John Papastergiou Pharmacy Ltd - Store#994, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03591224"
2098,"NCT03092687","Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core",,"Terminated","No Results Available","Schizophrenia|Major Depression|Bipolar Disorder|PTSD",,"To accumulate a vast repository of human brain tissues and characterize molecular signatures of psychiatric disorders using techniques such as genome-wide association analyses, DNA methylation, acetylation and chromatin modification patterns, RN...","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","up to 120 Years   (Child, Adult, Older Adult)",,"192","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","999917073|17-M-N073","March 21, 2017","August 29, 2019","August 29, 2019","March 28, 2017",,"September 6, 2019","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03092687"
2099,"NCT01407094","Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression","EMBARC","Completed","Has Results","Depression","Drug: Sertraline|Drug: Placebo|Drug: BupropionXL","Hamilton Rating Scale for Depression","University of Texas Southwestern Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","296","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","STU 092010-151","July 29, 2011","April 2016","April 2016","August 1, 2011","December 26, 2018","December 26, 2018","Massachusetts General Hospital Boston, Boston, Massachusetts, United States|University of Michigan Ann Arbor, Ann Arbor, Michigan, United States|Columbia Univerisity New York City, New York, New York, United States|UT Southwestern Medical Center Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01407094"
2100,"NCT01719315","Neurophysiologic Correlates of Hypersomnia",,"Completed","No Results Available","Major Depressive Disorder|Primary Hypersomnia|Bipolar Disorder|Narcolepsy|Primary Insomnia","Other: Acoustical slow wave induction","Nocturnal Slow Wave Activity|Waking theta/alpha activity","University of Wisconsin, Madison","All","18 Years to 60 Years   (Adult)",,"76","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2012-0201","November 2012","June 2018","June 2018","November 1, 2012",,"December 24, 2018","University of Wisconsin-Madison, Department of Psychiatry, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01719315"
2101,"NCT01667822","Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy",,"Completed","No Results Available","Anxiety Disorders|Major Depression|Stress Disorders|Primary Insomnia","Behavioral: Continued self help CBT|Behavioral: Individual CBT","Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population|Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)|Work ability index (WAI)|Insomnia Severity Index (ISI)|Health Anxiety Inventory (HAI)|Perceived Stress Scale (PSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)|Quality of Life Inventory (QOLI)|EuroQol-5 dimension (EQ5D)|Sheehan Disability Scales (SDS)|Self-rated health 5 (SRH-5)|Obsessive Compulsive Inventory-Revised (OCI-R)|Liebowitz Social Anxiety Scale Self-report (LSAS-SR)|Panic Disorder Severity Scale Self-rated (PDSS-SR)|Penn-State Worry Questionnaire (PSWQ)","Karolinska Institutet|Region Stockholm","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","396","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Self help CBT","August 2012","December 2015","December 2015","August 17, 2012",,"October 18, 2016","Karolinska Institutet and Gustavsberg primary care center, Stockholm,, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01667822"
2102,"NCT01667809","CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care",,"Completed","No Results Available","Anxiety Disorders|Major Depression|Stress Disorders|Primary Insomnia","Behavioral: Cognitive behavior therapy|Behavioral: Return to work","Sick leave|Clinician Severity Rating (CSR)|Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)|Insomnia Severity Index (ISI)|Health Anxiety Inventory (HAI)|Perceived Stress Scale (PSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)|Quality of Life Inventory (QOLI)|EuroQol-5 dimension (EQ5D)|Sheehan Disability Scales (SDS)|Self-rated health 5 (SRH-5)|Obsessive Compulsive Inventory-Revised (OCI-R)|Liebowitz Social Anxiety Scale Self-report (LSAS-SR)|Panic Disorder Severity Scale Self-rated (PDSS-SR)|Penn-State Worry Questionnaire (PSWQ)|Post Traumatic Stress Disorder Symptom Scale-Self report (PTSDSS)","Karolinska Institutet|Region Stockholm","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GVC CBT vs RTW II","August 2012","December 2015","December 2015","August 17, 2012",,"March 3, 2016","Karolinska Institutet and Gustavsberg primary care center, Stockholm,, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01667809"
2103,"NCT01636791","CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care","CBT vs RTW I","Completed","No Results Available","Anxiety Disorders|Major Depression|Stress Disorders|Primary Insomnia","Behavioral: Cognitive behavior therapy|Behavioral: Return to work","Sick leave|Clinician Severity Rating (CSR)|Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)|Work ability index (WAI)|Insomnia Severity Index (ISI)|Health Anxiety Inventory (HAI)|Perceived Stress Scale (PSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)|Quality of Life Inventory (QOLI)|EuroQol-5 dimension (EQ5D)|Sheehan Disability Scales (SDS)|Self-rated health 5 (SRH-5)|Obsessive Compulsive Inventory-Revised (OCI-R)|Liebowitz Social Anxiety Scale Self-report (LSAS-SR)|Panic Disorder Severity Scale Self-rated (PDSS-SR)|Penn-State Worry Questionnaire (PSWQ)|Post Traumatic Stress Disorder Symptom Scale-Self report (PTSDSS)","Karolinska Institutet|Region Stockholm","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","211","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GVC CBT vs RTW","September 2012","December 2015","December 2015","July 10, 2012",,"March 3, 2016","Karolinska Institutet and Gustavsberg primary care center, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01636791"
2104,"NCT02615119","Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa",,"Recruiting","No Results Available","Anorexia Nervosa|Major Depressive Disorder|Generalized Anxiety Disorder|Panic Disorder|Brain Injury","Drug: Isoproterenol|Drug: Normal saline","Change in cardiorespiratory sensation intensity|Change in anxiety level|Generalized anxiety disorder severity (Generalized Anxiety Disorder 7 scale)|Panic disorder severity (Panic Disorder Severity scale)|Major depressive disorder severity (Patient Health Questionnaire-9 scale)|Eating disorder severity (Eating Disorder Examination scale)","Laureate Institute for Brain Research, Inc.|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Not Applicable","310","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2017-002","October 2015","October 2022","December 2027","November 26, 2015",,"November 5, 2020","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02615119"
2105,"NCT03005574","Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program",,"Unknown status","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression","Behavioral: TSW-HP|Behavioral: TSW-T","Composite Measure of Change in Neurocognitive Functioning","Boston University Charles River Campus","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4391","January 2017","December 2020","December 2020","December 29, 2016",,"January 25, 2019","Brooklyn Community Services, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT03005574"
2106,"NCT03358056","Effects of Mindfulness Based Cognitive Therapy on Emotional Processing","MESI","Unknown status","No Results Available","Unipolar Depression|Anxiety Disorders|Adjustment Disorders|Emotional Instability","Behavioral: Mindfulness-Based Cognitive Therapy","Facial Emotion Recognition Task|Quick Depression Inventory","Parc de Salut Mar","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017/7185/I","September 1, 2017","April 1, 2018","April 1, 2018","November 30, 2017",,"November 30, 2017","Parc de Salut Mar, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03358056"
2107,"NCT00182533","Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders",,"Terminated","No Results Available","Phobia, Social|Panic Disorder|Agoraphobia|Obsessive-Compulsive Disorder|Anxiety Disorders|Major Depressive Disorder","Drug: Sertraline|Drug: Placebo","Clinical Global Impression - Improvement ≤ 2|Liebowitz Social Anxiety Scale [LSAS] (mean change from baseline)|Mean change from baseline on the following scales: Quality of Life and Employment Satisfaction Questionnaire|Sheehan Disability Scale|Social Phobia Scale|Brief Social Phobia Scale|Penn State Worry Questionnaire|Panic and Agoraphobia Scale|Davidson Trauma Scale|Social Anxiety Spectrum Self-Report (SHY-SR)|Yale-Brown Obsessive Compulsive Scale|Montgomery-Asberg Depression Rating Scale (MADRS)","Hamilton Health Sciences Corporation|Pfizer|McMaster University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","170","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","02-195","July 2002","January 2018","January 2018","September 16, 2005",,"March 22, 2018","MacAnxiety Research Centre, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00182533"
2108,"NCT04021329","Efficacy of Eye Movement Desensitization & Reprocessing Versus Cognitive Behavioral Therapy in Post-Traumatic Stress and Depressive Disorders",,"Unknown status","No Results Available","Efficacy of Psychotherapy","Behavioral: CBT Therapy","Measurement of Change in the symptoms of Post Traumatic Stress Disorder|Measurement of Socio Demographic Profile|Measurement of Change in the symptoms of major depression","Khushal Khan Khattak Univeristy, Karak, Pakistan","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KhushalKhanKhattakU","October 1, 2019","August 1, 2020","October 1, 2020","July 16, 2019",,"July 16, 2019","Anwar Khan, Karak, KPK, Pakistan",,"https://ClinicalTrials.gov/show/NCT04021329"
2109,"NCT01244854","Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness",,"Completed","No Results Available","Bipolar Disorder|Schizophrenia|Major Depressive Disorder|Chronic Affective Disorders|Cardiovascular Disease Risk","Behavioral: Life Goals Collaborative Care","overall health-related quality of life|Framingham risk score|total cholesterol|systolic blood pressure","VA Office of Research and Development","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","55","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","RRP 10-226","October 1, 2010","August 13, 2012","March 6, 2015","November 19, 2010",,"June 6, 2017","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01244854"
2110,"NCT01132872","PET Whole Body Distribution Studies Using [11C]CUMI",,"Completed","No Results Available","Depression|Major Depression|Unipolar Depression|Anxiety Disorder|Anxiety Disorders",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"12","NIH","Observational","Time Perspective: Prospective","100110|10-M-0110","April 30, 2010",,"April 12, 2012","May 28, 2010",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01132872"
2111,"NCT01803802","Effects of Early Abuse on Adult Intimate Relationships",,"Completed","No Results Available","Hypoactive Sexual Desire Disorder|Female Sexual Arousal Disorder|Female Orgasmic Disorder|Major Depressive Disorder|Post-traumatic Stress Disorder","Behavioral: Expressive writing","Sexual Dysfunction Interview|Depression|Post-Traumatic Stress","University of Texas at Austin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","148","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01HD051676|R01HD051676","April 2005","August 2011","August 2014","March 4, 2013",,"December 2, 2014","University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01803802"
2112,"NCT01625845","Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)","INFLAMED","Completed","Has Results","Major Depressive Disorder|Depression|Depressive Symptoms|Cardiovascular Disease (CVD)|Coronary Artery Disease (CAD)|Heart Disease","Drug: Pentoxifylline|Other: Placebo|Behavioral: Standard Treatment","Change in Brachial Flow-Mediated Dilation (FMD) From Pre- to Post- Treatment|Change in Depressive Symptoms Severity (Hopkins Symptom Checklist Depression Scale; SCL-20) From Pre- to Post- Treatment|Change in Circulating Tumor Necrosis Factor-Alpha (TNF-a) From Pre- to Post-Treatment|Change in Circulating Interleukin-6 (IL-6) From Pre- to Post-Treatment|Change in Circulating Interleukin-10 (IL-10) From Pre- to Post-Treatment|Change in Interleukin-1ra (IL-1ra) From Pre- to Post-Treatment|Change in Circulating C-Reactive Protein (CRP) From Pre- to Post-Treatment","Indiana University|National Institute of Mental Health (NIMH)","All","40 Years and older   (Adult, Older Adult)","Phase 2","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1110007119|R24MH080827|1737","June 2012","May 2014","May 2014","June 21, 2012","December 3, 2015","December 3, 2015","Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01625845"
2113,"NCT00401726","Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program",,"Completed","Has Results","Depressive Disorder, Major","Drug: Venlafaxine ER|Behavioral: Dialogues Time to Talk Program","Number of Patients Responding ""Very Satisfied"" on Satisfaction With Depression Care Scale (SDCS)|Change in 17-item Hamilton Depression Scale Score From Baseline to 16 Weeks|Patient Global Impression of Improvement (PGI-I) Score|Change in WHO 5-item Well Being Index Score From Baseline to 16 Weeks|Number of Patients Compliant With Therapy|Change in Inventory of Depressive Symptomatology - Self-Report (IDS-SR) Score From Baseline to 16 Weeks|Change in Sheehan Disability Scale Score From Baseline to 16 Weeks|Number of Patients by Clinical Global Improvement - Global Improvement Score at 16 Weeks","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","537","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0600B1-416","June 2006",,"October 2007","November 20, 2006","June 29, 2010","April 23, 2012","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Mesa, Arizona, United States|Little Rock, Arkansas, United States|San Jose, California, United States|Avon, Connecticut, United States|Cromwell, Connecticut, United States|Wilmington, Delaware, United States|Ocala, Florida, United States|Pinellas Park, Florida, United States|Stuart, Florida, United States|Atlanta, Georgia, United States|Cartersville, Georgia, United States|Rome, Georgia, United States|Idaho Falls, Idaho, United States|Newburgh, Indiana, United States|Waterloo, Iowa, United States|Metairie, Louisiana, United States|Benzonia, Michigan, United States|Interlochen, Michigan, United States|Kalamazoo, Michigan, United States|Chesterfield, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Charlotte, North Carolina, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Kettering, Ohio, United States|Mason, Ohio, United States|Mogadore, Ohio, United States|Allentown, Pennsylvania, United States|Newtown, Pennsylvania, United States|Reading, Pennsylvania, United States|Warwick, Rhode Island, United States|Anderson, South Carolina, United States|Greer, South Carolina, United States|Bristol, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00401726"
2114,"NCT03711019","Efficacy of Convulsive Therapies During Continuation","CORRECT-C","Recruiting","No Results Available","Depression|Bipolar Depression|Unipolar Depression|Treatment Resistant Depression","Device: Magnetic Seizure Therapy (MST)|Device: RUL-UB ECT|Device: Bitemporal ECT","Difference in HRSD-24 Scores between MST and RUL-UB at 6 months|Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)|Differences in relapse status between MST, RUL-UB ECT and bitemporal ECT|Differences in HRSD-24 scores between MST, RUL-UB ECT and bitemporal ECT","Centre for Addiction and Mental Health|University of British Columbia|University of Western Ontario, Canada|Brain Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","022-2018","October 22, 2018","September 2021","September 2022","October 18, 2018",,"February 15, 2021","UBC Hospital, University of British Columbia (UBC), Vancouver, British Columbia, Canada|Parkwood Institute-Mental Health Building, London, Ontario, Canada|Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03711019"
2115,"NCT03339596","Effects of Erythropoietin for Cognitive Side-effects of ECT","EPO-T","Unknown status","No Results Available","ECT|Cognitive Impairment|Unipolar Depression|Bipolar Depression","Drug: Erythropoietin|Drug: Saline","Cognitive composite score|Autobiographical Memory Interview-Short Form (AMI-SF)|Rey Auditory Verbal Learning Test (RAVLT)","Martin Balslev Jørgensen|The Augustinus Foundation, Denmark.|Mental Health Services in the Capital Region, Denmark","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-16038506|RHP-2017-023|2016-002326-36","June 26, 2017","December 31, 2020","December 31, 2020","November 13, 2017",,"November 13, 2017","Mental Health Services, Capital Region of Denmark, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Copenhagen O, Denmark",,"https://ClinicalTrials.gov/show/NCT03339596"
2116,"NCT00817154","Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI)",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression","Behavioral: HOPES-I","To develop an individually based psychosocial rehabilitation program for older adults with SMI. The program will be specified in treatment manuals and will match relevant skills training modules to the functional needs and preferences of consumers.","Dartmouth-Hitchcock Medical Center|National Institutes of Health (NIH)","All","50 Years and older   (Adult, Older Adult)","Phase 1","38","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","K23MH080021","November 2009","December 2013","December 2013","January 6, 2009",,"May 7, 2014","Riverbend Community Mental Health Center, Concord, New Hampshire, United States|Community Council of Nashua, Nashua, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT00817154"
2117,"NCT00178932","Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors",,"Unknown status","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression","Procedure: genetic analysis|Procedure: genetic assay","We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. .|We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample","Vanderbilt University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","9132","November 1998","January 2012","January 2012","September 15, 2005",,"November 3, 2010","Psychiatric Hospital at Vanderbilt, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00178932"
2118,"NCT00169052","Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression","Behavioral: Health Care Management and Supported Rehabilitation","independent living, social and health behavior skills|preventive health care|Acute emergency, hospitalization and long-term institution-based care","Dartmouth-Hitchcock Medical Center|National Institute of Mental Health (NIMH)","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","R01MH062324|DSIR 82-SEMS","September 2001",,"August 2006","September 15, 2005",,"September 10, 2013","Freedom Trail Clinic, Boston, Massachusetts, United States|Massachusetts Mental Health Center, Boston, Massachusetts, United States|Community Council of Nashua, Nashua, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT00169052"
2119,"NCT04480918","University of Iowa Interventional Psychiatry Service Patient Registry",,"Recruiting","No Results Available","Treatment Resistant Depression|Major Depressive Episode|Major Depression|Major Depressive Disorder|Bipolar Disorder|Bipolar Depression","Device: Electroconvulsive Therapy (ECT)|Device: Transcranial Magnetic Stimulation (TMS)|Drug: Ketamine|Drug: Esketamine","Montgomery-Åsberg Depression Rating Scale (MADRS) Pre-Post Change|Clinical Global Impression/Severity (CGI) Pre-Post Change|Generalized Anxiety Disorder, 7-item (GAD-7) Pre-Post Change|Montreal Cognitive Assessment (MoCA) Pre-Post Change|Patient Health Questionnaire, 9-item (PHQ-9) Pre-Post Change|Temperament and Character Inventory (TCI) Pre-Post Change","Mark Niciu|University of Iowa","All","18 Years to 99 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202003055","November 2, 2020","August 2050","August 2050","July 22, 2020",,"April 8, 2021","University of Iowa Health Care, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT04480918"
2120,"NCT01751828","Late-life Depression and Cerebral Perfusion",,"Withdrawn","No Results Available","Depression","Drug: Sertraline","Montgomery-Asberg Depression Rating Scale|Quick Inventory of Depressive Symptoms (QIDS)","Vanderbilt University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","121648","December 2012","August 2013",,"December 18, 2012",,"July 31, 2013","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01751828"
2121,"NCT01983904","DBS for Treatment Resistant Depression","CRIO-DBS","Completed","No Results Available","Depressive Disorder, Treatment-Resistant","Device: deep brain stimulation with short & long pulse width","Change in Hamilton Depression Rating Scale|Change from baseline on Illness Density Index, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale, Positive and Negative Affect Scale, Clinical Global Impression of Change, GAF< SAs, NAS, Q-LES-Q-SF & neuropsychological tests|Post Cognitive Behavioural Therapy Scores","University of Calgary","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E-20948","August 2013","December 2017","March 2018","November 14, 2013",,"April 18, 2019","University of Calgary & Alberta Health Services, Foothills Medical Centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01983904"
2122,"NCT00487500","Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression",,"Completed","No Results Available","Depression","Device: Electroconvulsive Therapy (ECT)","Short-term antidepressant efficacy|Specific acute, short-term, and long-term objective and subjective cognitive outcome measures (e.g., autobiographical amnesia, global self-rating of amnesia)|Antidepressant efficacy|Assessments of functional outcomes|Memory, non-memory, and executive functions (acute, short-term, and long-term measures)","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","#3482|5R01MH035636","December 1998","December 2002","May 2005","June 18, 2007",,"August 18, 2014","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00487500"
2123,"NCT00676676","Effects of Testosterone in Women With Depression",,"Completed","Has Results","Depression","Drug: Testosterone","Montgomery-Asberg Depression Rating Scale (MADRS) Scale","Massachusetts General Hospital|National Institutes of Health (NIH)","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","9","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007p000348","March 2007","October 2008","October 2008","May 13, 2008","November 30, 2012","November 30, 2012",,,"https://ClinicalTrials.gov/show/NCT00676676"
2124,"NCT01259427","Reducing Internalized Stigma in People With Serious Mental Illness","ESS","Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression With Psychotic Features","Behavioral: Ending Self Stigma (ESS)|Behavioral: Health and Wellness Group","Internalized Stigma of Mental Illness Inventory (Internalized Stigma)|Maryland Assessment of Recovery for Serious Mental Illness Scale (Recovery)|General Self-Efficacy Scale|Sense of Belonging Instrument (Belonging)|Quality of Life|Social Engagement/Withdrawal","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","252","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIR 09-340","October 2011","September 2014","September 2015","December 14, 2010","January 28, 2016","March 8, 2016","Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States|Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD, Perry Point, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01259427"
2125,"NCT01597141","Psychosis: Early Detection, Intervention and Prevention","EDIP","Completed","Has Results","Prodromal Schizophrenia|Psychotic Disorders|Severe Bipolar Disorder With Psychotic Features|Severe Major Depression With Psychotic Features","Behavioral: Family-aided Assertive Community Treatment|Behavioral: Enhanced standard treatment","Onset of Psychosis|Functioning","MaineHealth|Columbia University|Harvard University|University of California, Irvine","All","12 Years to 35 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1R01MH065367-01A1","May 2003","September 2014","December 2014","May 11, 2012","February 8, 2016","February 8, 2016","Maine Medical Center, Portland, Maine, United States",,"https://ClinicalTrials.gov/show/NCT01597141"
2126,"NCT00227929","Culturally Sensitive Collaborative Treatment for Depressed Chinese Americans",,"Completed","No Results Available","Depression","Procedure: Care Management","Symptoms of depression; measured at Weeks 2, 6, 10, 14, 18, 22, and 24|Adherence to clinic visits with the primary care physicians; measured at Weeks 2, 6, 10, 14, 18, 22, and 24|Quality of life; measured at Weeks 2, 6, 10, 14, 18, 22, and 24|Adherence to medication treatment; measured at Weeks 2, 6, 10, 14, 18, 22, and 24|Adverse events; measured at Weeks 2, 6, 10, 14, 18, 22, and 24","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23MH067085|DSIR 8K-RTSE","July 2003","September 2007","June 2008","September 28, 2005",,"December 10, 2013","South Cove Community Health Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00227929"
2127,"NCT00227955","Comparing Various Treatments for Achieving and Maintaining Remission of Depression",,"Completed","No Results Available","Depression","Drug: Imipramine|Behavioral: Interpersonal Psychotherapy","Time to recurrence of depression symptoms|Measured at Months 7, 11, and 36: Score on the Raskin Depression and Mania Severity Scales","University of Pittsburgh","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","871250","December 1987",,"December 1993","September 28, 2005",,"June 25, 2013","Western Psychiatric Institute and Cinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00227955"
2128,"NCT00688818","Quetiapine in Co-Morbid Depressive and Anxiety Disorders",,"Completed","No Results Available","Major Depressive Disorder|Dysthymic Disorder|Anxiety Disorders|Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Post-traumatic Stress Disorder","Drug: Quetiapine|Drug: Placebo","Hamilton Depression Rating Scale (HAMD-17)|Hamilton Anxiety Scale|Quality of Life Enjoyment and Satisfaction Scale|Penn State Worry Questionnaire|Panic Disorder Severity Scale|Leibowitz Social Anxiety Scale|Post-traumatic Diagnostic Scale|Clinical Global Impression Scale","Centre for Addiction and Mental Health","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","183/2007","June 2008","June 2013","June 2013","June 3, 2008",,"August 21, 2014","Chatham-Kent Health Alliance, Chatham, Ontario, Canada|Centre for Neuropsychiatric Study, Markham, Ontario, Canada|Credit Valley Medical Arts Centre, Mississauga, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00688818"
2129,"NCT00245193","Motivationally-Enhanced Brief Interpersonal Psychotherapy for Depressed Mothers of Ill Children",,"Completed","No Results Available","Depression","Behavioral: Motivationally-Enhanced Interpersonal Psychotherapy","Score on the Hamilton Rating Scale for Depression; measured at baseline, Week 14, and Month 6|Score on the Beck Depression Inventory; measured at baseline, Week 14, and Month 6","University of Pittsburgh","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23MH064518|DSIR 8K-RTAT","April 2003",,"March 2006","October 27, 2005",,"June 25, 2013","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00245193"
2130,"NCT01783574","Testosterone Antidepressant Augmentation in Women",,"Completed","Has Results","Depression","Drug: Testosterone|Drug: Placebo","Depressive Symptom Severity|Fatigue|Sexual Dysfunction","Massachusetts General Hospital|National Institutes of Health (NIH)|Lawley Pharmaceuticals","Female","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","101","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2012D000537|R34MH09931501A1","August 2013","January 27, 2017","January 27, 2017","February 5, 2013","April 5, 2018","June 6, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Butler Hospital, Providence, Rhode Island, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01783574/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01783574/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT01783574"
2131,"NCT03925168","Music Therapy and Dialysis: A Pilot Investigation Into the Effectiveness of Patient-Selected Music Interventions on Physiological, Psychological, and Quality-of-Life Outcomes",,"Completed","No Results Available","End Stage Renal Disease|Depression|Anxiety|Major Depressive Disorder|Generalized Anxiety Disorder|Compliance, Patient|Compliance, Medication|Mood|Pain|Energy Supply; Deficiency|Quality of Life|Blood Pressure|Heart Rate Fast","Behavioral: Music therapy","Depression|Anxiety|Measuring change in Quality of life using Kidney Disease and Quality of Life 36 patient screening tool (KDQOL36)|Compliance with dialysis|Number of hospitalizations|Blood pressure|Heart rate|Medication compliance questionnaire.|Measure change in Pain using the Numeric Rating Scale 11 (NRS11)|Participant Energy|Mood","Tulane University|National Kidney Foundation","All","21 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-866","March 8, 2019","January 1, 2020","January 1, 2020","April 24, 2019",,"January 15, 2021","DCI Canal Street, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|DCI West Bank, Terrytown, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT03925168"
2132,"NCT03113968","ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","ELEKT-D","Recruiting","No Results Available","Treatment Resistant Depression|Electroconvulsive Therapy|ECT|Ketamine|Psychiatric Disorder|Depression|Major Depressive Disorder|Major Depressive Episode|Unipolar Depression","Procedure: electroconvulsive therapy (ECT)|Drug: Ketamine","Patient reported response to treatment|Clinician reported response to treatment","The Cleveland Clinic|Patient-Centered Outcomes Research Institute","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ELEKT-D","April 7, 2017","March 1, 2021","April 1, 2022","April 14, 2017",,"September 4, 2020","Yale School of Medicine, New Haven, Connecticut, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Mount Sinai, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03113968"
2133,"NCT01570972","Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder With Psychotic Features|Major Depression With Psychotic Features|Psychotic Disorder Not Otherwise Specified (NOS)","Behavioral: Group Cognitive Behavioral Therapy|Behavioral: Multifamily Group Psychoeducation","Change from baseline in General level of functioning at 6 months, 12 months, 18 months, and 24 months|Change from baseline in self-reported Physical Health at 6 months, 12 months, 18 months, and 24 months|Change from baseline in Social and vocational Functioning at 6 months, 12 months, 18 months, and 24 months|Change from baseline in Stage of Recovery at 6 months, 12 months, 18 months, and 24 months|Change from baseline Service Utilization at 6 months, 12 months, 18 months, and 24 months|Change from Baseline Quality of Life at 6 months, 12 months, 18 months, and 24 months","University of Arizona","All","18 Years to 35 Years   (Adult)","Not Applicable","103","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U. Az IRB 09-1113-02","February 2010","April 2017","April 2017","April 4, 2012",,"May 21, 2020","University of Arizona Department of Psychiatry, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01570972"
2134,"NCT02256566","Cognitive Training for Mood and Anxiety Disorders",,"Completed","No Results Available","Major Depressive Disorder|Depression|Bipolar Disorder|Post-traumatic Stress Disorder|Generalized Anxiety Disorder|Social Phobia","Behavioral: emotional memory training exercise|Behavioral: memory training exercise","Proportion of completers to measure feasibility|Change in Depression Symptom Severity|Change in Anxiety Symptom Severity|Change in Negative Affective Bias|Change in Neurocognition","Icahn School of Medicine at Mount Sinai","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 14-0994","September 2014","April 20, 2016","April 20, 2016","October 3, 2014",,"July 21, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02256566"
2135,"NCT01624831","Social Cognition in Longstanding Psychosis",,"Terminated","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder With Psychotic Features|Major Depression With Psychotic Features|Psychosis Not Otherwise Specified (NOS)",,"Emotion Recognition|Attribution Style|Social Perception|Social Knowledge|Theory of Mind|Anxiety|Depression|Psychosis|Social Functioning|Service Utilization|Self-Determination Needs Satisfaction|Locus of Control|Cognitive representation of illness|Emotional Awareness|Mindfulness|Medication adherence|Neuropsychological functioning|Social Support|Illness Uncertainty|Relationship with familial caregivers|Self-efficacy|Experience of Stigma|quality of life|stage of recovery|Coping skills|Time perspective","University of Arizona","All","18 Years to 75 Years   (Adult, Older Adult)",,"9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","U. Az IRB 11-0567-02","November 2011","November 2015","November 2015","June 21, 2012",,"May 21, 2020","University of Arizona Department of Psychiatry, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01624831"
2136,"NCT02661789","Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression","GnRHa","Completed","No Results Available","Postpartum Depression|Major Depressive Disorder|Postpartum Psychosis|Menopause|Neurodegeneration|Schizophrenia","Drug: Goserelin 3.6 mg implant|Drug: Placebo","Changes from baseline in symptoms of depression|Changes from baseline in serotonin transporter binding in volumes of interest (VOIs)|Changes from baseline in fMRI response to emotional faces|Changes from baseline in fMRI response to gambling paradigm|Changes from baseline in rsfMRI changes in functional connectivity|Changes from baseline in affective cognition (VAMT-24 test)|Changes from baseline in reaction time|Serial mood fluctuations (SD of total mood disturbance (TMD) score of daily POMS across intervention period)|Changes from baseline in hippocampal volume|Changes in pre-pulse-inhibition (PPI) from baseline|Changes in a set of markers of immunoactivity across study period|Changes in epigenetic markers of estrogen sensitivity|Changes in HPA-axis dynamics (the cortisol awakening response)|Changes in sensorimotor gating (P50 suppression) from baseline|Changes from baseline in hippocampal microstructure|Changes from baseline in fMRI responses to emotional memory paradigm|Changes from baseline in Cohens perceived stress score|Changes in Pittsburg Sleep Quality Inventory (PSQI)|Side effects scores (project specific 15 items questionnaire)|Changes in SCL-R (Symptom check-list revised)|Major Depression Inventory (MDI)|Changes in profile of mood states (POMS TMD score)","Gitte Moos Knudsen|Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak|Fertility Clinic Rigshospitalet|CNSR, Glostrup Psychiatric Center|Danish Multiple Sclerosis Center Rigshospitalet|Dept. of Clinical Immunology, Rigshospitalet|Rigshospitalet, Denmark","Female","18 Years to 40 Years   (Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","GnRHa|H-2-2010-108","January 2011","December 2012","December 2012","January 22, 2016",,"January 22, 2016","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02661789"
2137,"NCT01075295","Prevention of Weight Gain in Early Psychoses",,"Completed","No Results Available","Schizophreniform Disorder|Bipolar I Disorder|Bipolar II Disorder|Major Depressive Disorder|Substance-Induced Psychoses|Psychosis Not Otherwise Specified|Schizophrenia|Schizoaffective Disorder","Behavioral: Behavioural Intervention for the Prevention of Weight Gain|Other: TAU","Weight|Laboratory parameters","Centre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR)","All","14 Years to 45 Years   (Child, Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","133/2009","February 2010","December 2012","December 2012","February 25, 2010",,"July 25, 2017","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01075295"
2138,"NCT03899090","Floatation-REST (Reduced Environmental Stimulation Therapy) for Anxiety and Depression",,"Enrolling by invitation","No Results Available","Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia|Posttraumatic Stress Disorder|Major Depressive Disorder","Behavioral: Float pool|Behavioral: Float chair","Adherence|Dropout rate|Adverse effects","Laureate Institute for Brain Research, Inc.|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 60 Years   (Adult)","Not Applicable","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Float R34|R34AT009889","April 8, 2019","October 30, 2022","December 31, 2022","April 2, 2019",,"November 2, 2020","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03899090"
2139,"NCT04358900","Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)","UnMASCK","Recruiting","No Results Available","Mood Disorders|Major Depressive Disorder|Bipolar Disorder I|Bipolar Disorder II|Persistent Depressive Disorder (Dysthymia)|Cyclothymia",,"Neuroimaging|BiAffect Metric|Clinical symptoms|Cognition","University of Illinois at Chicago|National Institute of Mental Health (NIMH)","All","25 Years to 50 Years   (Adult)",,"132","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-1333|1R01MH120168-01A1","September 17, 2020","August 31, 2025","August 31, 2025","April 24, 2020",,"October 6, 2020","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04358900"
2140,"NCT00962598","The Role Of Omega-3 Fatty Acids In Adolescent Depression",,"Completed","Has Results","Depressive Disorder, Major","Drug: Omega 3 Fatty Acids|Dietary Supplement: Corn oil","ACC Glx/Water|ACC GABA/Water","Icahn School of Medicine at Mount Sinai|National Center for Complementary and Integrative Health (NCCIH)","All","12 Years to 19 Years   (Child, Adult)","Phase 2","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 12-1321|R21AT004576-01","January 2006","June 2013","June 2013","August 20, 2009","May 24, 2017","April 24, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00962598"
2141,"NCT03674138","Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients",,"Active, not recruiting","No Results Available","Depression|Anxiety|Generalized Anxiety Disorder|Depressive Disorder|Major Depressive Disorder|Cancer","Diagnostic Test: DNA-guided choice of therapy|Other: Clinical management","Change in depressive symptoms from baseline, as measured by the Hospital Anxiety and Depression Scale (HADS)|Change in anxious symptoms from baseline, as measured by the Hospital Anxiety and Depression Scale (HADS)|Quality of Life as measured by Functional Assessment of Cancer Therapy-General (FACT-G) Scale","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","99","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","MCC-19578","September 12, 2018","October 2, 2021","October 2, 2022","September 17, 2018",,"May 24, 2021","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03674138"
2142,"NCT00928980","Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression",,"Completed","No Results Available","Depressive Disorder, Major","Behavioral: Mindfulness Based Cognitive Therapy|Drug: Optimal Medical Care","Relapse/recurrence of Major Depressive Episode|Costs made by consumption of medical care and production loss","Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","317","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MFN-2009-2013|80-82310-98-09018|2008/242","May 2009","June 2013","June 2013","June 26, 2009",,"November 13, 2020","Pro Persona, Arnhem, Gelderland, Netherlands|Pro Persona, Ede, Gelderland, Netherlands|Radboud University Nijmegen Medical Center, Nijmegen, Gelderland, Netherlands|Pro Persona, Tiel, Gelderland, Netherlands|GGZ Noord-Holland-Noord, Alkmaar, Noord-Holland, Netherlands|Free University Medical Center and GGZ In Geest, Amsterdam, Noord-Holland, Netherlands|AMC Amsterdam, Amsterdam, North Holland, Netherlands|GGZ Centraal, Amersfoort, Utrecht, Netherlands|GGZ Rivierduinen - Leiden, Leiden, Zuid Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid Holland, Netherlands|PsyQ, Den Haag, Zuid-Holland, Netherlands|Parnassia ACO Zuid, Den Haag, Zuid-Holland, Netherlands|GGZ Duin- en Bollenstreek, Katwijk, Netherlands",,"https://ClinicalTrials.gov/show/NCT00928980"
2143,"NCT01926613","Thinking Skills for Work in Severe Mental Illness","TSW","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Major Depression|Bipolar Disorder|Anxiety Disorder","Behavioral: Thinking Skills for Work Program|Behavioral: Supported Employment","AMOUNT OF EMPLOYMENT|EXECUTIVE FUNCTIONING AND MEMORY","Dartmouth-Hitchcock Medical Center|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","110","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MH077210|1R01MH077210-01","April 2006","October 2009","October 2011","August 21, 2013",,"August 21, 2013","Thresholds, Inc., Chicago, Illinois, United States|Mental Health Center of Greater Manchester, Manchester, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT01926613"
2144,"NCT04874974","Feasibility of a Novel Process-based Treatment for Patients With Psychosis","PROBAS","Recruiting","No Results Available","Schizophrenia|Schizotypal Disorder|Delusional Disorder|Brief Psychotic Disorder|Shared Psychotic Disorder|Schizoaffective Disorder|Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition|Unspecified Psychosis Not Due to a Substance or Known Physiological Condition|Manic Episode, Severe With Psychotic Symptoms|Bipolar Disorder, Current Episode Manic Severe With Psychotic Features|Bipolar Disorder, Current Episode Depressed, Severe, With Psychotic Features|Major Depressive Disorder, Single Episode, Severe With Psychotic Features|Major Depressive Disorder, Recurrent, Severe With Psychotic Symptoms","Behavioral: Metacognitive and Defusion Training","Eligibility rate|Consent rate|Trial entry rate|Completion rate|Missing data rate|Patient engagement|Drop out rate|Adverse events|Acceptability of Module I|Acceptability of Module II|Acceptability of Module III|Semi-structured interviews|Psychopathological in general and positive and negative psychotic symptoms (PANSS)|Psychopathological in general and positive and negative psychotic symptoms (BPRS)|Positive symptoms (hallucinatiosn and delusions) and their severity, intensity and frequency (PSYRATS)|Patient's improvement (CGI)|Social functioning (WHODAS)|Therapy processes of metacognition (BCIS)|Degree of Cognitive fusion (CFQ)","Max-Planck-Institute of Psychiatry","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-0025","May 10, 2021","May 2022","December 2022","May 6, 2021",,"July 16, 2021","Max Planck Institute of Psychiatry, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT04874974"
2145,"NCT04179526","Transdiagnostic Internet-delivered REBT Intervention for Adolescents' Internalizing Problems","REBTonAd","Recruiting","No Results Available","Anxiety Disorders|Social Anxiety Disorder|Generalized Anxiety Disorder|Panic Disorder|Persistent Depressive Disorder|Major Depressive Disorder","Behavioral: Transdiagnostic Internet-delivered REBT","Internalizing problems measured with the Youth Self-Report 11/18 (YSR; Achenbach & Rescorla, 2001)|Automatic Thoughts QuestionnaireShort Version (ATQ-SV; Netemeyer et al., 2002)|The child and adolescent scale of irrationality (CASI; Bernard & Cronan, 1999)|The Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents, The Revised Version - adolescent version (Kiddo-KINDL; Ravens-Sieberer, & Bullinger, 1998)|The Adolescent Peer Relations Instrument (APRI; Parada, 2000)|Principal diagnosis based on Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria","Babes-Bolyai University","All","12 Years to 15 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PN-III-P4-ID-PCE-2016-0861","November 25, 2019","April 30, 2020","July 30, 2020","November 27, 2019",,"January 18, 2020","Babeș-Bolyai University, Cluj-Napoca, Cluj, Romania",,"https://ClinicalTrials.gov/show/NCT04179526"
2146,"NCT03601026","Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use","IMAGINE","Recruiting","No Results Available","Mental Illness|Schizophrenia|Bipolar Disorder|Major Depressive Disorder|Cannabis Use|Psychosis","Behavioral: Genetic counselling","Self-reported cannabis use|The proportion of participants who complete the intervention after receiving an offer to participate (intervention acceptability)|Presence of cannabinoids in urine","Nova Scotia Health Authority","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IMGN18","August 1, 2019","September 1, 2020","September 1, 2021","July 26, 2018",,"July 23, 2019","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT03601026"
2147,"NCT04134871","Walking for Health: an Intervention to Increase Physical Activity and Reduce Sedentary Behaviour in People With SMI","WORtH","Recruiting","No Results Available","Mental Illness|Schizophrenia|Bipolar Disorder|Major Depression|Psychosis","Behavioral: Group walk and one to one coaching","Study recruitment rate|Retention of study participants|Level of acceptability assessed by semi-structured interviews|Change in activity levels|Change in body weight (kilograms)|Change in waist circumference (cm)","University of Ulster","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17/0078","August 22, 2019","December 31, 2021","February 28, 2022","October 22, 2019",,"January 13, 2021","Louth Meath Midlands HSE, Dundalk, Louth, Ireland|Western HSCT, Omagh, Tyrone, United Kingdom|Northern HSCT, Antrim, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04134871"
2148,"NCT01542229","PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)","PTSD/SMI","Completed","Has Results","Post Traumatic Stress Disorder|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression","Behavioral: Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|Behavioral: Treatment As Usual (TAU)","Posttraumatic Stress Disorder (PTSD) Checklist (PCL)|Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)|Beck Depression Inventory-II (BDI-II)|Brief Psychiatric Rating Scale-Extended (BPRS-E)|Veterans SF 12 Health Survey (SF-12)|Pittsburgh Seep Quality Index","VA Office of Research and Development","All","21 Years and older   (Adult, Older Adult)","Not Applicable","134","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","IIR 11-306|Pro00013928","May 3, 2012","December 31, 2016","December 31, 2016","March 2, 2012","July 15, 2019","July 15, 2019","Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01542229"
2149,"NCT02815813","Lifestyle Intervention for Young Adults With Serious Mental Illness",,"Active, not recruiting","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depressive Disorder|Overweight|Obesity","Behavioral: PeerFIT|Behavioral: BEAT","Change in weight|Change in 6-minute walk test|Change in weight loss self-efficacy assessed using the Weight Efficacy Lifestyle (WEL) questionnaire|Change in self-efficacy for exercise behaviors assessed using the Self-efficacy for Exercise Behaviors (SEB) scale|Change in peer support for health behavior change assessed using the 24-item Social Provisions Scale (SPS)|Change in serum lipids","Dartmouth-Hitchcock Medical Center|National Institute of Mental Health (NIMH)","All","18 Years to 35 Years   (Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00029586|R01MH110965","July 3, 2017","August 31, 2021","August 31, 2021","June 28, 2016",,"October 1, 2020","Community Mental Health Affiliates, New Britain, Connecticut, United States|Greater Nashua Mental Health Center, Nashua, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT02815813"
2150,"NCT02756507","Transdiagnostic REBT Prevention Program for Adolescents",,"Completed","No Results Available","Social Anxiety|Major Depression Mild|Panic Disorder|Specific Phobia|Generalized Anxiety Disorder","Behavioral: video-based transdiagnostic REBT|Behavioral: Wait list","The Multidimensional Anxiety Scale for Children (MASC; March, Parker, Sullivan, Stallings, & Conners, 1997)|Beck Depression Inventory for Youth subscale from the Beck Youth Inventories-Second edition for children and adolescents (Beck, 2005)|The Children's Automatic Thoughts Scale - Negative/Positive (CATS-N/P) (Hogendoorn et al., 2010)|The Strengths and Difficulties Questionnaire (SDQ) (Goodman, 1997)|The Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents, The Revised Version - adolescent version (Kiddo-KINDL) (Ravens-Sieberer et al., 2001)|The Credibility/ Expectancy Questionnaire (Devilly & Borkovec, 2000)|The Client Satisfaction Scale (Vigerland et al., 2016)","Babes-Bolyai University","All","12 Years to 17 Years   (Child)","Not Applicable","381","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","PN-II-PT-PCCA-2011-3.1-1500","June 2016","June 2018","June 2018","April 29, 2016",,"September 24, 2018","Babes-Bolyai University, Cluj-Napoca, Romania",,"https://ClinicalTrials.gov/show/NCT02756507"
2151,"NCT03051074","Examining the Effects of Reduced Environmental Stimulation on Anxiety",,"Completed","No Results Available","Generalized Anxiety Disorder|Agoraphobia|Panic Disorder|PostTraumatic Stress Disorder|Social Anxiety Disorder|Major Depressive Disorder","Behavioral: Floating|Behavioral: Comparison","Spielberger State Anxiety Inventory (STAI-S) change score|Blood pressure changes during the float experience|Heart rate variability changes during the float experience|EEG changes during the float experience|Brain activation and connectivity changes from pre- to post-float as measured with functional magnetic resonance imaging (fMRI)|Bioassay changes in magnesium, sulfate, cortisol, and inflammatory markers|Subjective changes in emotion and mood","Laureate Institute for Brain Research, Inc.","All","18 Years to 55 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015-002 Float-Anxiety","December 1, 2016","December 1, 2019","December 31, 2019","February 13, 2017",,"September 22, 2020","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03051074"
2152,"NCT03015285","CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT",,"Unknown status","No Results Available","Generalized Anxiety|Stress Disorder, Posttraumatic|Social Anxiety|Major Depression|Panic Disorder","Behavioral: Cognitive Behavioural Therapy","Change in anxiety sensitivity: the Anxiety Sensitivity Index - 3 (ASI-3)|Change in primary diagnosis (e.g., anxiety disorder or depression) symptoms|Change in comorbid diagnosis (e.g., anxiety disorders or depression) symptoms|Diagnostic status as measured by the Structured Clinical Interview for DSM-5 (SCID-5)|General distress as measured by the Depression Anxiety Stress Scale (DASS-21)|General distress as measured by the Clinical Outcomes in Routine Evaluation measure (CORE-10)|Functional disability as measured by the Sheehan Disability Scale (SDS)|Drinking Motives as measured by the Modified Drinking Motives Questionnaire - Revised (MDMQ-R)|Hazardous alcohol use as measured by the Alcohol Use Disorders Identification Test (AUDIT)|Alcohol-related problems as measured by the Short Inventory of Problems (SIP-2R)|Treatment alliance as measured by the Working Alliance Inventory - Short-form (WAI-SR)|Treatment satisfaction as measured by several short researcher-generated questions","Sherry Stewart|University of New Brunswick|Canadian Institutes of Health Research (CIHR)|Dalhousie University|Nova Scotia Health Authority","All","19 Years and older   (Adult, Older Adult)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1021903","January 2017","August 2019","August 2019","January 10, 2017",,"January 10, 2017",,,"https://ClinicalTrials.gov/show/NCT03015285"
2153,"NCT00208169","Abilify Therapy for Reducing Comorbid Substance Abuse",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depressive Disorder|Anxiety Disorders|Substance Abuse","Drug: Aripiprazole","The primary outcome measure will be days of abstinence during the 12-week follow-up, as measured by the Time Line Follow Back Scale (TLFBS) and the Addiction Severity Index (ASI).|Secondary outcome measures will assess severity of symptoms as measured by the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS)|The Penn Alcohol Craving Scale will also be used.","Creighton University|Bristol-Myers Squibb","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-13685","March 2005",,"June 2007","September 21, 2005",,"August 24, 2007","Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00208169"
2154,"NCT01884025","Get Moving and Get Well - Pilot Study","GMGWP","Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depression|Post Traumatic Stress Disorder","Behavioral: Get Moving and Get Well|Behavioral: Health and Humor Class","Change in Behavioral Activation for Depression Scale|Change in Exercise Self-Efficacy Questionnaire|Change in CHAMPS (Community Healthy Activities Model Program for Seniors) Questionnaire for Older Adults - Physical Activity Frequency|Change in Veterans RAND 12 (VR-12)|Change in Personal Health Information Depression Scale (PHQ-8)|Change in Intent to Engage|Acceptability|New Health Behaviors From the Beginning of Classes Through Three Months Post End of Class|Change in CHAMPS (Community Healthy Activities Model Program for Seniors) Questionnaire for Older Adults - Physical Activity Duration|Change in CHAMPS (Community Healthy Activities Model Program for Seniors) Questionnaire for Older Adults - Cognitive Activity Frequency|Change in CHAMPS (Community Healthy Activities Model Program for Seniors) Questionnaire for Older Adults - Cognitive Duration|Number of Participants Beginning New Health Behaviors From the Beginning of Classes Through Three Months Post End of Class","VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","27","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PPO 13-187","June 2013","December 2014","August 2015","June 21, 2013","November 5, 2018","November 5, 2018","Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01884025"
2155,"NCT01683539","Understanding How Cognitive Remediation Works","Cog-2","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Chronic Mental Disorder|Major Depression|Bipolar Disorder","Behavioral: The Thinking Skills for Work Program|Behavioral: The Cognitive Skills for Work Program","AMOUNT OF EMPLOYMENT|EXECUTIVE FUNCTIONING AND MEMORY","Boston University Charles River Campus|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","203","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2837E|2R01MH077210-05A1","September 2012","March 11, 2019","March 11, 2019","September 12, 2012",,"March 13, 2019","Thresholds, Chicago, Illinois, United States|The Mental Health Center of Greater Manchester, Manchester, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT01683539"
2156,"NCT02476877","A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse",,"Completed","No Results Available","Schizophrenia|Drug Abuse|Anxiety Disorder|Bipolar Disorder|Major Depression",,"Prevalence of the co-morbidity of mental illness with substance abuse|Association between demographic characteristics and the prevalence of substance abuse in each of the four mental illnesses|Duration of substance abuse in each of the four mental illnesses|Types of drugs associated with each of the four mental illnesses","Advanced Clinical Laboratory Solutions, Inc.","All","18 Years and older   (Adult, Older Adult)",,"75","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACLS-COMORBIDITY-001","June 2014","January 2016","February 2016","June 22, 2015",,"January 24, 2017","Advanced Clinical Laboratory Solutions, Inc., Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT02476877"
2157,"NCT00167310","Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation","CAD","Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Major Depression|Bipolar Disorder|Coronary Artery Disease","Drug: Eicosapentaenoic acid (omega-3 fatty acid)|Drug: Placebo","Plasma Levels of Triglycerides and Lipoprotein Cholesterol|Plasma Cholesterol Levels in Various Lipoprotein Fractions","University of Pittsburgh|American Heart Association|VA Pittsburgh Healthcare System","All","18 Years and older   (Adult, Older Adult)","Phase 2","57","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHA 0455676U|VA IRB Protocol ID:02063","September 2005","December 2015","December 2015","September 14, 2005","April 10, 2017","April 10, 2017","VA Pittsburgh Healthcare System (University Drive), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00167310"
2158,"NCT03756246","Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression",,"Unknown status","No Results Available","Depression|Healthy","Biological: Influenza Vaccine","Positive and Negative Affect Schedules Score|Change in Cytokine Concentration (pg/mL)|Difference in PGE4/LipoxinA4 Ratio|Tryptophan Metabolites|HPA Axis","University of Texas at Austin","All","18 Years to 60 Years   (Adult)","Phase 4","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018030078","June 10, 2019","May 2020","May 2021","November 28, 2018",,"June 27, 2019","Marisa Toups, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03756246"
2159,"NCT00468676","Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression",,"Completed","Has Results","Depression","Behavioral: Nurse-led case management|Behavioral: Treatment as usual","Combined Effect of Intervention on SCL-20, Systolic Blood Pressure, LDL and HbA1c|Symptom Checklist-20 Score at Baseline, 6 Months and 12 Months|Systolic Blood Pressure at Baseline, 6 Months and 12 Months|LDL Cholesterol at Baseline and 12 Months|Glycated Hemoglobin (HbA1c) at Baseline, 6 Months and 12 Months|Functional Impairment|Health Care Costs","University of Washington|National Institute of Mental Health (NIMH)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","214","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH041739|DSIR 82-SEPC","May 2007","October 2010","August 2012","May 3, 2007","May 2, 2014","May 2, 2014","Group Health Cooperative, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00468676"
2160,"NCT02594696","Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness",,"Completed","No Results Available","Major Depression|Schizophrenia|Bipolar Disorder|Lung Cancer|Breast Cancer|Head and Neck Cancer|GI Cancer|Cancer","Other: Proactive Psychiatry Consultation (PPC)","Feasibility of implementing the intervention in patients with SMI and cancer|Acceptability of the intervention for patients with SMI and cancer and oncology clinicians|Rates of receipt of stage-appropriate cancer treatment|Rates of receipt of healthcare utilization in the outpatient setting|Rates of receipt of healthcare utilization in the acute care setting|Change in clinician-rated psychiatric symptoms|Change in clinician-rated psychiatric illness severity|Change in self-reported psychiatric symptoms|Change in self-reported depression symptoms|Change in quality of life|Change in illness understanding|Change in alliance with the oncology clinician","Massachusetts General Hospital|American Cancer Society, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","15-293|5R25CA092203-13","November 9, 2015","July 21, 2016","November 1, 2017","November 3, 2015",,"February 5, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02594696"
2161,"NCT01677078","Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression","TMS","Completed","No Results Available","Treatment Resistant Depression","Device: Neuronavigation system|Device: Standard localisation method","Response|Remission|MADRS|BDI|ERD","Rennes University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","107","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2011-A01272-39","January 21, 2013","March 25, 2017","March 25, 2017","August 31, 2012",,"August 31, 2018","Centre Santé Mentale Angevin CESAME, Angers, France|CHU de Brest, Brest, France|Etablissement Public de Santé Mentale, Quimperlé, France|CHGR, Rennes, France|EPSM Morbihan, St Avé, France",,"https://ClinicalTrials.gov/show/NCT01677078"
2162,"NCT01947647","Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders","TBT-RCT","Completed","Has Results","Major Depressive Disorder|Persistent Depressive Disorder|Posttraumatic Stress Disorder|Panic Disorder|Social Phobia|Specific Phobia|Generalized Anxiety Disorder|Obsessive Compulsive Disorder","Behavioral: Transdiagnostic Behavior Therapy|Behavioral: Behavioral Activation Therapy","DASS-Depression|DASS-Anxiety|DASS-Stress|STICSA-Cognitive|STICSA-Somatic|IIRS","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","105","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MHBA-018-13S|CX000845","November 17, 2014","June 1, 2018","December 31, 2018","September 20, 2013","August 28, 2019","August 28, 2019","Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01947647/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01947647"
2163,"NCT04437485","eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk",,"Recruiting","No Results Available","Depression|Major Depressive Disorder|Dysthymic Disorder|Depressive Symptoms|Type 2 Diabetes|PreDiabetes|Insulin Resistance","Behavioral: Good Days Ahead (GDA)|Behavioral: Problem Solving Treatment in Primary Care (PST-PC)|Drug: Antidepressant Medications|Other: Active Control","Change in Hemoglobin A1c at 6 months|Change in Homeostatic Model of Assessment (HOMA) score at 6 months","Indiana University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1908716624|R21DK123582","October 14, 2020","January 31, 2022","January 31, 2022","June 18, 2020",,"February 9, 2021","IUPUI Department of Psychology, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT04437485"
2164,"NCT03842345","DELPhI Evaluation of Psychiatric Conditions",,"Unknown status","No Results Available","Major Depressive Disorder|Bi-Polar Disorder|ADHD|Schizophrenia|OCD|Ptsd|Healthy",,"comparison of DELPhI parameter of Plasticity in psychiatric population to healthy norms.|comparison of DELPhI parameter of Connectivity in psychiatric population to healthy norms.|correlation between DELPhI parameters and symptom severity.|Cluster analysis of Plasticity and connectivity in relation to medical treatment and clinical diagnosis.|characterization of the change in Plasticity following change of treatment regimen|characterization of the change in Connectivity following change of treatment regimen","QuantalX Neuroscience","All","18 Years and older   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","605","February 2019","February 2021","February 2021","February 15, 2019",,"February 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03842345"
2165,"NCT00456014","Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment",,"Completed","Has Results","Depression","Drug: Escitalopram|Drug: Desipramine","Remission of Depressive Symptoms|Remission of Depressive Symptoms - Tricyclic Phase|Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#6351R (formerly 5206)|R01MH074813|DATR A3-NSS","September 2006","May 2012","May 2012","April 4, 2007","June 14, 2017","March 19, 2019","Columbia University/New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00456014"
2166,"NCT04497857","Academic-Community EPINET (AC-EPINET)","AC-EPINET","Not yet recruiting","No Results Available","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorders|Major Depression With Psychotic Features|Bipolar Disorder With Psychotic Features","Other: Coordinated Specialty Care (CSC)","Annualized hospitalization rates|Number of participants hospitalized|Time (days) to first hospitalization|Symptom and functioning outcomes assessed by the MIRECC-GAF","Indiana University|University of Michigan|Northwestern University|Vanderbilt University|Tulane University|University of Rochester|Yale University","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","epinet","March 2021","August 2024","August 2024","August 4, 2020",,"March 3, 2021","Recovery from Early Psychosis Program (REPP) - Northwestern University, Chicago, Illinois, United States|Prevention and Recovery Center for Early Psychosis, Indianapolis, Indiana, United States|Early Psychosis Intervention Clinic-New Orleans (EPIC-NOLA) - Tulane University, New Orleans, Louisiana, United States|Program for Risk Evaluation and Prevention (PREP) - University of Michigan, Ann Arbor, Michigan, United States|Strong Ties Young Adults Program- University of Rochester Medical Center, Rochester, New York, United States|Vanderbilt's Early Psychosis Program - Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04497857"
2167,"NCT03360695","Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer",,"Recruiting","No Results Available","Cancer|Severe Major Depression|Schizophrenia|Bipolar Disorder|Lung Cancer|Breast Cancer|Head and Neck Cancer|Gastrointestinal Cancer","Other: Proactive Psychiatry Consultation (PPC)|Other: Enhanced Usual Care (EUC)","Disruptions in Cancer Care|Patient and Caregiver Outcome Measures","Massachusetts General Hospital|Harvard Risk Management Foundation|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","265","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","17-396|1K08CA230185-01","December 11, 2017","May 15, 2022","August 15, 2023","December 4, 2017",,"February 24, 2021","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03360695"
2168,"NCT03143634","The Modular Protocol for Mental Health (MPMH)","MPMH","Completed","No Results Available","Major Depressive Disorder|Generalized Anxiety Disorder|Posttraumatic Stress Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia|Obsessive-Compulsive Disorder|Illness Anxiety Disorder","Behavioral: The Modular Protocol for Mental Health|Behavioral: Treatment-as-usual","Change in Depression symptoms|Change in Anxiety symptoms|Change in Level of disability and functional impairment|Change in symptoms of social phobia, agoraphobia and specific phobia|Change in symptoms of social anxiety|Change in symptoms of generalised anxiety|Change in symptoms of obsessive-compulsive disorder|Change in symptoms of post-traumatic stress disorder|Change in symptoms of agoraphobia|Change in symptoms of specific phobias|Change in symptoms of panic disorder|Change in symptoms of illness anxiety|Change in level of disability and functional impairment|Change in expectancy about treatment outcome, as well as the credibility of the treatment|Change in ability to contextualize negative events within a wider frame of reference|Change in disengagement from and acceptance of troublesome mental content, rumination|Intensity with which participants experience 36 different emotions on a typical day|Change in personality functioning on four subscales: Identity, Self-Direction, Empathy, and Intimacy|Change in use of NHS services, other mental health services or activities, help at home, and time off work/lost income|Change in quality of life assessment of health and wellbeing, daily functioning, and general life satisfaction across multiple domains","Medical Research Council Cognition and Brain Sciences Unit|Cambridgeshire and Peterborough NHS Foundation Trust","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MP:MH RfPB PB-PG-0214-33072","July 18, 2017","July 31, 2020","July 31, 2020","May 8, 2017",,"September 29, 2020","MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03143634"
2169,"NCT03804619","Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder",,"Not yet recruiting","No Results Available","Opiate Dependence|Suicidal Ideation|Depression|Opioid Use|Opioid-Related Disorders|Opioid-use Disorder|Major Depressive Disorder","Device: Accelerated intermittent theta-burst stimulation (aiTBS)","Change in Beck Scale for Suicidal Ideation (SSI) score|Change in Columbia Suicide Severity Scale (C-SSRS) score|Change in Obsessive compulsive drug-use scale (OCDUS) score|Change in Montgomery Asberg Depression Rating Scale (MADRS) score|Change in Beck Depression Inventory II (BDI-II) score|Change in resting-state functional connectivity.","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","48431","June 1, 2020","December 1, 2021","December 1, 2022","January 15, 2019",,"January 28, 2020","Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT03804619"
2170,"NCT00329147","Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects",,"Completed","No Results Available","Depression","Drug: desvenlafaxine SR|Drug: desipramine|Drug: paroxetine","The primary outcome of the study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 3","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-900","May 2006",,"June 2006","May 24, 2006",,"December 7, 2007","Neptune, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00329147"
2171,"NCT01866098","Naltrexone for Antipsychotic-Induced Weight Gain","NTX","Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Bipolar Disorder|Severe Major Depression With Psychotic Features","Drug: Naltrexone|Drug: Placebo","Change in Weight From Baseline|Percent of Subjects Who Lost More Than 5% of Body Weight From Baseline|Changes in Fasting Glucose From Baseline|Changes in Glycosylated Hemoglobin (HbA1c) From Baseline|Changes in Insulin From Baseline|Changes in Total Cholesterol From Baseline|Changes in HDL From Baseline|Changes in LDL From Baseline","Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1207010507|1R01DK093924-01A1","May 2013","April 7, 2019","April 7, 2019","May 31, 2013","April 8, 2020","April 8, 2020","Connecticut Mental Health Center, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT01866098/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01866098"
2172,"NCT04939818","Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders","RHAPSODY","Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Dementia With Lewy Bodies|Dementia, Vascular|Frontotemporal Dementia|Primary Progressive Aphasia|Parkinson Disease|Motor Neuron Disease|Major Depressive Disorder|Bipolar Disorder|Amyotrophic Lateral Sclerosis",,"The average length of speech elicitation for each speech task (in seconds) during the first week of self-assessments.|The intra-subject variance of length of speech elicitation for each speech task during the first week of self-assessments, as measured by Coefficients of Individual Agreement (CIA).|The inter-subject variance of length of speech elicitation for each speech task during the first week of self-assessments, as measured by Coefficients of Individual Agreement (CIA).|The subject average fraction of days during the first week of remote, self-assessment, where participants submitted at least one task response.|The average length of speech elicitation for each speech task, during the telemedicine video conference.|The AUC of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the Dementia with Lewy Bodies (LBD) diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the Frontotemporal Dementia and Vascular Dementia (FTD/VCI) diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the following diagnostic groups vs all other diagnostic groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|The sensitivity of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|The specificity of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|The Cohen's kappa of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|For each classifier/regressor in the outcomes, the correlation between the AUC/CIA and each age group, gender and speech-to-reverberation modulation energy ratio group, as measured by the Kendall rank correlation coefficient.","Novoic Limited|King's College London","All","18 Years to 85 Years   (Adult, Older Adult)",,"250","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","NOV-0200","June 20, 2021","January 15, 2022","February 15, 2022","June 25, 2021",,"June 25, 2021","South London and Maudsley NHS Foundation Trust, London, Greater London, United Kingdom|King's College Hospital NHS Foundation Trust, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04939818"
2173,"NCT00139997","Environmental Treatment for Seasonal Affective Disorder (SAD)",,"Completed","Has Results","Seasonal Affective Disorder","Device: Litebook treatment devices|Device: Inactivated negative ion generator","Percentage SIGH SAD (Structured Interview Guide For The Hamilton Depression Rating Scale), SAD Version|SIGH SAD (Structured Interview Guide For The Hamilton Depression Rating Scale), SAD Version","Yale University|University Medical Center Groningen|University of British Columbia|Royal Ottawa Mental Health Centre|Douglas Hospital Research Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","22,777","January 2002","August 2005","August 2005","August 31, 2005","March 6, 2013","March 6, 2013","Yale University School of Medicine, New Haven, Connecticut, United States|University of British Columbia, Vancouver, British Columbia, Canada|Royal Ottawa Mental Health Centre, , Ontario, K1Z 7K4 Canada, Ottawa, Ontario, Canada|Douglas Hospital Research Centre, Montreal, Quebec, Canada|University Medical Center Groningen, Groningen, RB, Netherlands",,"https://ClinicalTrials.gov/show/NCT00139997"
2174,"NCT00744328","Postpartum Depression: Transdermal Estradiol Versus Sertraline","E2SERT","Terminated","Has Results","Postpartum Depression","Drug: Transdermal Estradiol|Drug: Sertraline|Other: Placebo","To Test the Efficacy of Estradiol for the Treatment of Postpartum Depression - Percent Change in SIGH-ADS29|Infant Serum Concentrations of Estradiol in 3 Treatment Arms","Northwestern University","Female","18 Years to 45 Years   (Adult)","Phase 4","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH057102","August 2008","September 2013","September 2013","August 29, 2008","October 23, 2014","September 10, 2019","Northwestern University Feinberg School of Medicine; Asher Center for the Study and Treatment of Depressive Disorders, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00744328"
2175,"NCT04296604","Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations",,"Recruiting","No Results Available","Traumatic Brain Injury|Major Depressive Disorder|Bipolar Disorder|Schizophrenia|Attention Deficit Hyperactivity Disorder|Borderline Personality Disorder|Substance Use Disorders","Device: Transcranial Direct Current Stimulation","Change in N-Back Task|Change in Flanker Task|Change in Multi-Source Interference with International Affective Picture System Task|Change in Delayed Discounting Task|Change in Stop Signal Task|Change in Iowa Gambling Task","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2014P001428","September 2014","September 2022","September 2022","March 5, 2020",,"October 28, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04296604"
2176,"NCT03822416","Treating Smokers With Mental Illness",,"Completed","Has Results","Smoking Cessation|Cigarette Smoking|Schizophrenia|Psychotic Disorders|Major Depressive Disorder|Bipolar Disorder I|Bipolar II Disorder|Mental Illness","Drug: Nicotine patch|Drug: Nicotine lozenge|Behavioral: Therapy|Other: Information","7-Day Point Prevalence Abstinence|Quit Attempts|Smoking Reduction","University of Minnesota|Hennepin County Medical Center, Minneapolis|Brown University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SPH-2018-26854","March 1, 2019","May 4, 2020","May 4, 2020","January 30, 2019","May 25, 2021","May 25, 2021","University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03822416/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03822416/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03822416"
2177,"NCT02458690","eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients",,"Active, not recruiting","Has Results","Depression|Major Depressive Disorder|Dysthymic Disorder|Depressive Symptoms|Cardiovascular Diseases|Heart Diseases|Coronary Artery Disease|Stroke","Behavioral: Beating the Blues (BtB)|Behavioral: Problem Solving Treatment in Primary Care (PST-PC)|Drug: Antidepressant Medications|Other: Usual Care","Brachial Artery Flow-Mediated Dilation (FMD) at 12 Months","Indiana University|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Phase 2","216","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1411802537|R01HL122245","July 2015","August 2019","March 2021","June 1, 2015","October 14, 2020","October 14, 2020","IUPUI Department of Psychology, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02458690/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02458690/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02458690"
2178,"NCT01900314","Imaging Biomarkers for TMS Treatment of Depression",,"Completed","Has Results","Depression","Device: repetitive Transcranial Magnetic Stimulation (rTMS)","Depressive Symptoms at 4 Weeks|Depression Symptoms at 4 Weeks- Secondary","University of Michigan|National Institute of Mental Health (NIMH)|Neuronetics","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","HUM00053677|1R21MH098174-01A1","September 2013","January 2016","April 2016","July 16, 2013","April 25, 2017","April 25, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01900314"
2179,"NCT01385709","The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels",,"Completed","No Results Available","Bipolar Affective Disorders|Cyclothymic Disorder|Schizoaffective Disorder|Major Depressive Disorder|Dysthymic Disorder|Obsessive-Compulsive Disorder|Panic Disorder|Posttraumatic Stress Disorder|Premenstrual Dysphoric Disorder|Social Anxiety Disorder",,"blood levels of lithium or sertraline|Fluctuations in symptom severity|Correlations between Symptom Severity and Blood Levels of Drugs","Weill Medical College of Cornell University","Female","18 Years to 40 Years   (Adult)",,"29","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0310006393","August 2008","August 2012","August 2013","June 30, 2011",,"February 20, 2017","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01385709"
2180,"NCT02188121","Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients","FITNESS","Active, not recruiting","No Results Available","Serious Mental Illness|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Cardiovascular Disease|Major Depressive Disorder|Psychosis NOS","Drug: Simvastatin|Drug: Losartan","Change in percentage of participants on adequate cardiovascular prevention care (defined as taking a statin and angiotensin medication)|Change in Modified Framingham Score as a summary cardiovascular risk level","Mclean Hospital|Michael J. Gill Mental Health Clinic|The Massachusetts Mental Health Center|Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital|The Edinburg Center, Bedford MA","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHS IRB pending","February 2015","October 2020","October 2021","July 11, 2014",,"October 8, 2019","McLean Hospital, Belmont, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02188121/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02188121/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT02188121"
2181,"NCT01269710","Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study","SATIETY","Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychotic Disorder, Not Otherwise Specified|Prodromal Schizophrenia|Mood Disorder|Bipolar Disorder|Major Depressive Disorder|Depressive Disorder, Not Otherwise Specified|Mood Disorder, Not Otherwise Specified|Autism Spectrum Disorder",,"Change in Weight (in Lbs.)|Change in Glucose Levels (mg/dL)|Change in Total Cholesterol (mg/dL)|Change in Triglycerides (mg/dL)|Change in LDL (mg/dL)","University of North Carolina, Chapel Hill","All","3 Years to 19 Years   (Child, Adult)",,"4","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","09-1734","October 2009","March 2011","March 2011","January 4, 2011","February 22, 2013","February 22, 2013","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01269710"
2182,"NCT01828931","Lifestyle Intervention for Diabetes and Weight Management in Psychosis","Healthy_LIFE","Completed","No Results Available","Type 2 Diabetes Mellitus|Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Bipolar I Disorder|Substance-induced Psychosis|Psychotic Disorders|Major Depressive Disorder","Behavioral: Lifestyle Intervention|Other: Usual Care","Weight|HbA1c levels","Centre for Addiction and Mental Health|Canadian Diabetes Association","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","151/2012","December 2012","May 2015","November 2015","April 11, 2013",,"June 17, 2016","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01828931"
2183,"NCT04481737","Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery",,"Recruiting","No Results Available","Schizophrenia|Bipolar Disorder|Major Depressive Disorder, Recurrent|Obesity|Cardiovascular Diseases|Diabetes|Smoking|Blood Pressure Disorders|Cholesterol, Elevated","Behavioral: Peer-delivered and Technology Support Integrated Illness Management and Recovery|Behavioral: Peer support","Change in number of study drop-outs, attendance, and adherence from baseline to 3-months|Change in average fidelity scores|Change from baseline mortality risk index to 3-months and 6-month follow-up|Change from baseline self efficacy to 3-months and 6-month follow-up|Change from baseline social support to 3-months and 6-month follow-up|Change from baseline mental health self-management skills to 3-months and 6-month follow-up|Change from baseline medical self-management skills to 3-months and 6-month follow-up|Change from baseline functional ability to 3-months and 6-month follow-up|Change from baseline disability to 3-months and 6-month follow-up|Change from baseline level of cardiovascular disease risk to 3-months and 6-month follow-up","Dartmouth-Hitchcock Medical Center|Harvard University|Vinfen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","D20155","February 1, 2021","September 28, 2021","September 28, 2021","July 22, 2020",,"May 4, 2021","Vinfen, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04481737"
2184,"NCT02229825","Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Duloxetine high|Drug: Duloxetine low","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score|Change in the Hamilton Depression 6-item scale (HAMD-6) total score|Change in the MADRS total score|Changes in the MADRS and HAMD-6 total scores following dose up-titration|Number of responders|Number of patients reaching remission|Reduction of Clinical Global Impressions scales of Severity of Illness (CGI-SI)|Change in clinical Global Impressions of Improvement (CGI-I) score|Change in patient Global Impressions of Improvement (PGI-I) score|Change in Hamilton Scale of Anxiety (HAMA) score|Reason for Living (RFL) questionnaire score|Utilization of allowed hypnotic and anxiolytic comedication|Number of patients with treatment-emergent adverse events|Number of patients with clinically significant changes in vital signs|Number of patients with clinically significant changes in laboratory assessments|Number of withdrawals due to adverse events","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","339","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1208.24","February 2007","August 2008",,"September 1, 2014",,"September 1, 2014",,,"https://ClinicalTrials.gov/show/NCT02229825"
2185,"NCT03288675","Stepped Care aiTBS 2 Depression Study (Ghent)","aiTBS2-Ghent","Recruiting","No Results Available","Depressive Disorder, Major|Treatment Resistant Depression|Melancholia","Device: aiTBS|Behavioral: CCT|Drug: SSRI","Changes in depression severity - clinician-rated|Changes in depression severity - self-report|Changes in suicidal thoughts - clinician-rated|Changes in melancholic features - clinician-rated|Changes in hopelessness - self-report|Changes in anxiety features - self-report|Changes in remission from depression - self-report|Changes in ruminative thinking (trait) - self-report|Changes in hedonia - self-report|Changes in anhedonia - self-report|Changes in perceived stress - self-report|Changes in responses to positive affect - self-report|Changes in cognitive emotion regulation - self-report|Changes in temperament and character - self-report|Differences in adverse effects following aiTBS vs. sham - self-report|Changes in regional grey matter volume using structural MRI|Changes in regional white matter microstructure and structural connectivity|Neuronal safety/ changes in neurometabolite concentrations in left-prefrontal tissues using MRS|Changes in functional activity connectivity at rest and during tasks in which self-referential social evaluations are presented via headphones in the scanner|Changes in state-dependent ruminative thinking due to hearing self-referential social evaluations presented via headphones in the scanner - self-report|Changes in state-dependent mood due to hearing self-referential social evaluations presented via headphones in the scanner - self-report|Changes in the regional 5-HT transporter system|Changes in reward processing as measured with EEG /ERP|Evaluation of cognitive side-effects following iTBS vs. sham using the CANTAB battery|Changes in reward processing - behavioral assessment|Changes in working memory - behavioral assessment of near transfer|Changes in state-dependent mood - self-report following naPASAT|Changes in spatial working memory - behavioral assessment of far transfer|Changes in state-dependent mood during CCT vs. control training|Predictive influence of single nucleotide polymorphisms on treatment outcome - genetics using a saliva sample|Predictive influence of treatment expectancy on treatment response - self-report","University Ghent|University Hospital, Ghent","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","16/GOA/017","October 5, 2017","December 31, 2022","December 31, 2022","September 20, 2017",,"October 6, 2017","University Hospital Ghent, Ghent, East-Flanders, Belgium",,"https://ClinicalTrials.gov/show/NCT03288675"
2186,"NCT01731119","Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents",,"Completed","Has Results","Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychosis NOS|Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive|Bipolar I Disorder|Bipolar II Disorder|Mood Disorder NOS|Severe Major Depression With Psychotic Features|Single Episode Major Depression Without Psychotic Symptoms|Severe Mood Disorder With Psychotic Features","Drug: Latuda©","Change in Weight|Proportion of Participants Completing Treatment|Changes in Efficacy Measures|Number of Participants Experiencing Side Effects|Overall Clinical Improvement","University of North Carolina, Chapel Hill|Foundation of Hope, North Carolina","All","6 Years to 19 Years   (Child, Adult)","Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-2302","December 2012","August 2014","August 2014","November 21, 2012","May 17, 2017","June 14, 2017","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01731119"
2187,"NCT01738464","Microbiomes of Pelvic Pain",,"Recruiting","No Results Available","Interstitial Cystitis|Chronic Prostatitis|Chronic Pelvic Pain Syndrome|Lower Urinary Tract Symptoms|Overactive Bladder|Major Depression",,"Genotype Anaerobic Bacterial populations between Control patients and patients diagnosed with Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Major Depression|Separate serum from blood specimen given by Control patients and patients diagnosed with Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Major Depression|Collect urine specimen from Control patients and patients diagnosed with Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Major Depression","Northwestern University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 60 Years   (Adult)",,"300","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","STU00055668|1R01DK103769-01A1","June 2012","July 7, 2022","July 8, 2022","November 30, 2012",,"June 4, 2021","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01738464"
2188,"NCT02452892","Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)",,"Completed","Has Results","Depression|Depressive Disorder|Depressive Disorder, Treatment-resistant|Depressive Disorder, Major","Device: LFMS","Change From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.|Change From Day 4 in HAM-D6 Total Score at Day 11 for Week 1 Non-responders: Response to 120 Minutes LFMS|Day 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total Score","Tal Medical, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAL-02-007","September 2015","September 2016","October 2016","May 25, 2015","December 5, 2017","December 5, 2017","CNS Trials, Garden Grove, California, United States|Synergy Escondido, Lemon Grove, California, United States|Pacific Trials Partners, Oakland, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|CNS Healthcare, Jacksonville, Florida, United States|Segal Institute, Lauderhill, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Radiant Research, Atlanta, Georgia, United States|Neurobehavioral-Clinical Research, Canton, Ohio, United States|Midwest Clinical, Dayton, Ohio, United States|Future Search Trials, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02452892"
2189,"NCT03986658","Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day",,"Not yet recruiting","No Results Available","Treatment Resistant Depression","Device: Linear Asymmetric rTMS System","Patient Enrollment Rate|Patient Completion Rate|Side Effects Profile|Patient Experience|Change in self-reported MDD symptoms|Change in clinician-rated MDD symptoms|Change in function|Change in mental status|Change in short-term verbal memory","NeuroQore Inc.|Children's Hospital of Eastern Ontario","All","15 Years to 17 Years   (Child)","Not Applicable","19","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHEO19P1","March 2021","October 2021","December 2021","June 14, 2019",,"November 25, 2020","Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03986658"
2190,"NCT03240692","Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort","SAINT-TRD","Active, not recruiting","No Results Available","Treatment Resistant Depression","Device: Accelerated theta-burst stimulation treatment","Percent change in the Montgomery Asberg Depression Rating Scale (MADRS) score from pre-treatment to 1-month|Percent change in the Columbia Suicide Severity Rating Scale (C-SSRS)|Percent change in the Hamilton Rating Scale for Depression (HAM-6)|Percent change in the Hamilton Rating Scale for Depression (HAM-17)|Change from baseline functional connectivity to 1-month post-treatment|Percent change in the Beck Depression Inventory (BDI-II)|Percent change in the Montgomery Asberg Depression Rating Scale (MADRS)|Change from baseline functional connectivity to immediate post-treatment","Stanford University|Schatzberg, Alan, M.D.","All","22 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","33797","May 1, 2017","December 1, 2021","December 30, 2022","August 7, 2017",,"April 26, 2021","Nolan Williams, MD, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT03240692"
2191,"NCT04032795","Evaluation of Efficacy of Lycium Barbarum Polysaccharide in People With Subthreshold Depression",,"Recruiting","No Results Available","Subthreshold Depression|Depressive Symptoms|Anxious Symptoms","Dietary Supplement: Lycium barbarum polysaccharide|Dietary Supplement: Placebo","Mean change from baseline in the Beck Depression Inventory-II (BDI-2)total scores|Mean changes from baseline in the 21-item Hamilton Depression Rating Scale (21-HAMD)|Changes in The Screen for Child Anxiety Related Disorders (SCARED)|Changes in sleep quality|Depression severity as measured by BDI2 and Kessler Scale (K10)","Guangzhou Psychiatric Hospital|The Fifth Affiliated Hospital of Guangzhou Medical University","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangzhou Brain LBP","May 15, 2019","December 30, 2021","December 30, 2021","July 25, 2019",,"March 4, 2021","The Affiliated Fifth Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04032795"
2192,"NCT00021528","Sequenced Treatment Alternatives to Relieve Depression (STAR*D)",,"Completed","No Results Available","Depression","Drug: citalopram|Drug: BuproprionSR|Drug: buspirone|Drug: Lithium|Drug: mirtazapine|Drug: nortriptyline|Drug: sertraline|Drug: tranylcypromine|Drug: VenlafaxineXR|Behavioral: Cognitive Therapy|Drug: T3 (Triiodothyronine)",,"National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","4000","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N01 MH90003|DSIR AT","July 2001",,"September 2006","July 23, 2001",,"September 25, 2009","Birmingham VA Medical Center, Birmingham, Alabama, United States|Tuscaloosa VA Mental Health Clinic - Veterans Only, Tuscaloosa, Alabama, United States|Tuscaloosa VA Primary Care Center, Tuscaloosa, Alabama, United States|Psychiatric Centers at San Diego, Chula Vista, California, United States|Harbor UCLA Family Health Care Center, Harbor City, California, United States|UCLA General Outpatient Psychiatry Clinic, Los Angeles, California, United States|UCLA Internal Medicine Clinic, Los Angeles, California, United States|UCSD Outpatient Psychiatric Services, San Diego, California, United States|Veterans Affairs Medical Center/FIRM Primary Care Clinic, San Diego, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Northwestern Outpatient Treatment Care Center, Chicago, Illinois, United States|University of Illinois at Chicago Clinic, Chicago, Illinois, United States|Evanston Outpatient Clinic, Evanston, Illinois, United States|COMCARE of Sedgwick County, Wichita, Kansas, United States|Psychiatric Outpatient Clinic, Wichita, Kansas, United States|Swampscott Family Doctors, Boston, Massachusetts, United States|Internal Medicine Associates, Boston, Massachusetts, United States|MGH/Charlestown Clinic, Charlestown, Massachusetts, United States|MGH/Salem Professional, Salem, Massachusetts, United States|General Psychiatric Ambulatory Clinic, Ann Arbor, Michigan, United States|Briarwood Family Practice Clinic, Ann Arbor, Michigan, United States|LIJ/Zucker Hillside Adult Ambulatory Care Center, Glen Oaks, New York, United States|LIJ North Shore Medical Group, Lake Success, New York, United States|UNC Chapel Hill General Medicine Clinic, Chapel Hill, North Carolina, United States|UNC Chapel Hill Adult Diagnostic & Treatment Clinic, Chapel Hill, North Carolina, United States|UNC Chapel Hill Family Practice Clinic, Chapel Hill, North Carolina, United States|Springer Family Medicine, Tulsa, Oklahoma, United States|Laureate Psychiatric Clinic & Hospital, Tulsa, Oklahoma, United States|Warren Clinic, Tulsa, Oklahoma, United States|Diversified Human Services Clinic, Pittsburgh, Pennsylvania, United States|Latterman Family Health Center, Pittsburgh, Pennsylvania, United States|Bellefield Clinic of WPIC, Pittsburgh, Pennsylvania, United States|AMPN Corkery, Heise & Dainesi, Upper St. Clair, Pennsylvania, United States|Psychiatric Consultants, P.C., Nashville, Tennessee, United States|Vanderbilt University Medical Center-Mental Health Center, Nashville, Tennessee, United States|Vine Hill Community Clinic, Nashville, Tennessee, United States|Centerstone/Luton Mental Health Services, Nashville, Tennessee, United States|The Holiner Psychiatric Group, Dallas, Texas, United States|UT Southwestern Family Medicine Clinic, Dallas, Texas, United States|MCV Primary Care Clinic, Richmond, Virginia, United States|MCV Family Counseling, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00021528"
2193,"NCT03428828","Neurofeedback for Treatment Resistant Depression",,"Recruiting","No Results Available","Treatment Resistant Depression","Behavioral: Amygdala Neurofeedback|Behavioral: Parietal Neurofeedback","Beck Depression Inventory (BDI-II)|Amygdala Activity","University of Pittsburgh","All","18 Years to 55 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO18010596","October 22, 2018","March 1, 2023","March 31, 2023","February 12, 2018",,"February 3, 2021","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03428828"
2194,"NCT00097175","Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders",,"Completed","No Results Available","Depressive Disorder, Major",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"95","NIH","Observational",,"050035|05-M-0035","November 10, 2004",,"January 15, 2014","November 18, 2004",,"December 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00097175"
2195,"NCT01694719","Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression",,"Unknown status","No Results Available","Depression","Behavioral: Brief Behavioral Activation Treatment for Depression|Behavioral: Cognitive Control Training","Beck Depression Inventory|Montgomery Asberg Depression Rating Scale","Boston University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2930","September 2012","October 2013","October 2013","September 27, 2012",,"September 27, 2012","Boston University - Translational Research Program, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01694719"
2196,"NCT01031186","First Time in Human Study","FTIM","Completed","No Results Available","Depressive Disorder and Anxiety Disorders","Drug: GSK356278|Drug: PLACEBO","To assess safety and tolerability of single escalating oral doses of GSK356278 in healthy male volunteers|To investigate the pharmacokinetics of single escalating doses of GSK356278 in healthy male volunteers","GlaxoSmithKline","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","113324","November 23, 2009","April 7, 2010","April 7, 2010","December 14, 2009",,"July 27, 2017","GSK Investigational Site, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01031186"
2197,"NCT04950868","The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression",,"Not yet recruiting","No Results Available","Postpartum Depression","Drug: Quetiapine","Recruitment and retention rate|Blood pressure|Incidence of Treatment-Emergent Adverse Events as assessed by the Systematic Monitoring of Adverse events Related to TreatmentS (SMARTS) score|Maternal functioning will be measured by the Barkin Index of Maternal Functioning (BIMF)|Pulse|Body mass index|Fasting lipid panel test|glycated haemoglobin (HbA1c) tests|Waist circumference|Returned tablet count|Hamilton Depression Rating (HDRS) total score|Edinburgh Postnatal Depression Scale|Generalized Anxiety Disorder 7-item scale|Young Mania Rating Scale","Verinder Sharma|Lawson Health Research Institute","Female","18 Years to 45 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","118885","July 15, 2021","December 31, 2022","December 31, 2022","July 6, 2021",,"July 6, 2021","Parkwood Institute, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04950868"
2198,"NCT00251043","Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Site",,"Completed","No Results Available","Depression","Behavioral: Interpersonal psychotherapy for depression in pregnancy|Behavioral: Parenting education program (PEP)","Depression|Mother-infant bonding","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","Female","18 Years to 45 Years   (Adult)","Phase 4","142","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","#4830/6040R|R01MH069915|R01MH069915-01A2|4830/6040R","September 2005","April 2010","April 2010","November 9, 2005",,"March 26, 2012","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00251043"
2199,"NCT04218981","Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders",,"Recruiting","No Results Available","Common Mental Disorder","Drug: Antipsychotic drugs|Drug: Mood stabilizer|Drug: Paroxetine","Resting-state functional magnetic resonance imaging (fMRI) data acquisition for all participants|Positive and Negative Syndrome Scale (PANSS)|Hamilton Depression Scale-17 (HAMD-17)|Young Mania Rating Scale (YMRS)|Brief Cognitive Assessment Tool for schizophrenia(B-CATS)|Social Disability Screening Schedule(SDSS)","Central South University","All","18 Years to 50 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","81771447","January 15, 2020","June 2023","December 2023","January 6, 2020",,"August 12, 2020","The Second Xiangya Hospital of Central South University, Changsha, China",,"https://ClinicalTrials.gov/show/NCT04218981"
2200,"NCT00517972","Omacor for Perimenopausal Depression",,"Withdrawn","No Results Available","Depression","Drug: Omacor (omega-3-acid ethyl esters)","Reduction of the initial HAM-D score by 50% or more at week 8 of the trial.|Reduction of the HAM-D score to less than 7 at week 8.|Clinical Global Impression change in score achievement to ""very much improved"" or ""much improved"" at week 8.|Decrease in the Greene Climacteric Scale by 50%.","University of Arizona|Reliant Pharmaceuticals","Female","40 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC#06-102;IND76801",,,,"August 17, 2007",,"March 29, 2012","Women's Mental Health Program; University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00517972"
2201,"NCT03314155","Cerebral Neuroinflammation During Major Depressive Episode","InflaDep","Recruiting","No Results Available","Depressive Disorder","Diagnostic Test: Cerebral neuroinflammation evaluation","distribution pattern of neuroinflammation in Positron Emission Tomography (PET) data|distribution pattern of neuroinflammation in PET data across all groups|patients with depressive symptoms and neuroinflammation (i.e. PET data).|patients with neuroinflammation (i.e. PET analysis) and MRI parameters for functional and structural integrities.|patients with neuroinflammation (i.e. PET analysis) and biological markers of neuroinflammation (i.e. cytokines).","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","All","25 Years to 55 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC31/16/8918|2017-001478-40","December 7, 2018","January 2021","January 2022","October 19, 2017",,"July 30, 2020","Hôpital de Psychiatrie, Toulouse, Midi-Pyrénées, France|CHU Bordeaux, Bordeaux, Nouvelle Aquitaine, France|CHRU Lapeyronie, Montpellier, Occitanie, France|Clinique Psychiatrique Universitaire CHRU Tours, Tours, Val-De-Loire, France",,"https://ClinicalTrials.gov/show/NCT03314155"
2202,"NCT01335217","Trigeminal Nerve Stimulation for Post Traumatic Stress Disorder (PTSD) and Depression",,"Completed","No Results Available","Depression|Post-traumatic Stress Disorder","Procedure: Transcutaneous Electrical Nerve Stimulator (TENS)","Change in Hamilton Depression Rating Scale-17 Item|Change in PTSD Checklist score|Change in life functional capacity and quality of life scales|Changes in vital signs recordings|Changes in Safety Assessment Measures","University of California, Los Angeles","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-000894","January 2011","January 2012","January 2012","April 14, 2011",,"February 6, 2013","Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01335217"
2203,"NCT01196286","Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis",,"Completed","No Results Available","Recent-Onset Psychosis|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder With Psychotic Features|Major Depression With Psychotic Features|Psychotic Disorder Not Otherwise Specified (NOS)","Behavioral: Multifamily Group Psychoeducation (MFG)|Behavioral: Cognitive Remediation (CR)","Psychotic Symptoms/Relapse Assessed Once Per Week|Depression, Anxiety, Emotional Awareness, Cognitive Functioning, Problem-Solving Ability, Quality of Life, Social Functioning, Service Utilization","University of Arizona|Institute for Mental Health Research","All","18 Years to 35 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-BN-07","June 2010","April 2017","April 2017","September 8, 2010",,"May 21, 2020","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01196286"
2204,"NCT01251471","Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response",,"Completed","No Results Available","Depression","Drug: Escitalopram","BOLD signal","Medical University of Vienna","All","18 Years to 45 Years   (Adult)","Phase 4","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","OENB-13903","August 2011","July 2014","March 2015","December 2, 2010",,"October 31, 2016","Medical University of Vienna, Dept. of Psychiatry and Psychotherapy, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01251471"
2205,"NCT00257400","Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse",,"Completed","No Results Available","Depression","Behavioral: Interpersonal Psychotherapy (IPT)|Behavioral: Individual Psychotherapy","Hamilton Rating Scale for Depression|Beck Depression Inventory|Structured Clinical Interview for DSM-IV Diagnoses|Social Adjustment Scale|Medical Outcomes Survey|Post Traumatic Stress Disorder (PTSD) Symptom Scale","University of Rochester|National Institute of Mental Health (NIMH)","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23MH064528|DSIR 8K-RTAT","May 2003","August 2007","August 2007","November 22, 2005",,"January 3, 2014","University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00257400"
2206,"NCT03548675","Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)","PITA","Recruiting","No Results Available","Depressive Disorder, Major","Drug: TCA treatment","Time to TCA plasma concentration in the therapeutic range|Reduction of depressive symptoms|Highest level of side effects|Economic Evaluation (Cost Effectiveness)","Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","848016004","May 23, 2018","December 2021","December 2021","June 7, 2018",,"March 18, 2021","Radboudumc Dept of Psychiatry, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03548675"
2207,"NCT03405493","Sleep, Wake and Light Therapy for Depression",,"Completed","No Results Available","Depression|Depressive Disorder, Major|Depression, Unipolar|Depression Moderate","Behavioral: Wake and Light Therapy|Behavioral: Sleep and Light Therapy","Number of participants recruited per month/Adherence to the protocol|MINI International Neuropsychiatric Interview Version 5.0|Hamilton Depression Rating Scale|Clinical Global Impression and Improvement Scale (Guy, 1976)|Quick Inventory of Depressive Symptomatology -SR Version (Triveni et al., 2004) Questionnaire|Brief Ruminative Response Scale (Topper et al, 2014). Questionnaire|Pittsburgh Sleep Index (Bysse et al., 1999) Questionnaire|Euroquol 5D (1990) Questionnaire|To check the amount of current antidepressant use|To check the amount of current psychotherapy use|Daily sleep diary|Credibility and Expectancy Questionnaire (Devilly, 2000).|Morning/Evening Questionnaire|Wrist actigraph from GeneActiv daily (Physiological parameter)","King's College London|Kings Health Partners","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R&D2017/096","January 18, 2018","September 23, 2019","September 23, 2019","January 23, 2018",,"September 26, 2019","South London and Maudsley NHS Foundation Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03405493/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03405493/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03405493"
2208,"NCT01343563","Trigeminal Nerve Stimulation for Depression: Dose Finding",,"Completed","No Results Available","Depression","Procedure: Trigeminal Nerve Stimulation","Change in Hamilton Depression Rating Scale 17 score|Change in life functional capacity and quality of life scales|Changes in Regional Brain Function|Changes in vital signs recordings|Changes in Safety Assessment Measures","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10-000480","January 2011","January 2012","January 2012","April 28, 2011",,"February 6, 2013","Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01343563"
2209,"NCT02076425","A Randomized Controlled Trial of PCIT-ED for Preschool Depression",,"Completed","Has Results","Depressive Disorder, Major","Behavioral: PCIT-ED","Kiddie Schedule for Affective Disorders and Schizophrenia - Early Childhood (KSADS-EC) MDD Core Symptom Score|Preschool Feelings Checklist-Scale Version (PFC-Scale) Score","Washington University School of Medicine","All","36 Months to 83 Months   (Child)","Not Applicable","229","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH098454-02","January 13, 2014","March 31, 2018","May 10, 2018","March 3, 2014","December 2, 2019","December 2, 2019","Early Emotional Development Program, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02076425/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02076425"
2210,"NCT00595283","Effectiveness of Parent-Child Interaction and Emotion Development Therapy in Treating Preschool Children With Depression",,"Completed","No Results Available","Depression","Behavioral: Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|Behavioral: Developmental Education Parenting Intervention (DEPI)","Depression diagnosis and severity using the Preschool-Age Psychiatric Assessment (PAPA) for major depressive disorder (MDD) module","Washington University School of Medicine|National Institute of Mental Health (NIMH)","All","3 Years to 6 Years   (Child)","Not Applicable","38","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R34MH080163|DSIR 84-CTS","October 2007","August 2010","October 2010","January 16, 2008",,"March 22, 2013","Washington University School of Medicine Early Emotional Development Program, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00595283"
2211,"NCT02883257","Clinical and Biological Markers of Response to Cognitive Behavioural Therapy for Depression",,"Completed","No Results Available","Depression","Behavioral: Cognitive Behavioral Therapy","Montgomery Asberg Depression Rating Scale|Quick Inventory of Depressive Symptomatology (QIDS)|World Health Organization Quality of Life Short Version (WHOQOL-BREF)|Hamilton Depression Rating Scale (Ham-D)|Beck Depression Inventory (BDI)|Work and Social Adjustment Scale (WSAS)","Centre for Addiction and Mental Health|University Health Network, Toronto|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","003/2016","August 2016","November 2017","November 2017","August 30, 2016",,"April 23, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02883257"
2212,"NCT03207503","Neurobehavioral Mechanisms of Emotion Regulation in Depression Across the Adult Lifespan","Lifespan","Recruiting","No Results Available","Depressive Disorder, Major","Procedure: fMRI","Success of emotion regulation strategy use.|Depression symptom severity","Duke University","All","35 Years to 75 Years   (Adult, Older Adult)",,"240","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00082070|R01MH113238-1|R01MH113238","October 10, 2017","August 2022","August 2022","July 2, 2017",,"December 28, 2020","Civitan Building, Duke Psychiatry and Behavioral Sciences, Durham, North Carolina, United States|Psychiatry and Behavioral Services, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03207503"
2213,"NCT02938559","Can the Memory Support Intervention Improve Depression Outcome Following Cognitive Therapy?",,"Completed","No Results Available","Depressive Disorder, Major","Behavioral: Cognitive Therapy (CT) for depression|Behavioral: Cognitive Therapy (CT) for depression + Memory Support","Remission|Relapse at 6 Months|Relapse at 12 Months|Functional Impairment|Patient Memory for Treatment|Generalization Task|Declarative Memory|Working Memory|Memory Support|Response to Treatment|Magnitude of symptom change is operationalized as change on IDS-SR|Recovery|Recurrence|Time to relapse or recurrence|Competencies of Cognitive Therapy Scale (CCTS) (Exploratory)","University of California, Berkeley|Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R01MH108657","November 2016","August 5, 2020","August 5, 2020","October 19, 2016",,"February 2, 2021","University of California, Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT02938559"
2214,"NCT02410616","E-Compared-CH: Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial","E-COMPARED_CH","Completed","No Results Available","Depressive Disorder, Major","Behavioral: Blended CBT|Behavioral: Treatment as usual","Patient Health Questionnaire-9 (PHQ-9)|Assessment of Quality of Life (AQoL-6D)|Quick Inventory of Depressive Symptomatology Self-Report (QIDS-16-SR)|MINI International Neuropsychiatric Interview (M.I.N.I; Ackenheil et al., 1999)|EuroQoL (EQ-5D-5L; Herdman et al., 2011)|Questionnaires on Costs Associated with Psychiatric Illness (TiC-P; Hakkaart-van Rooijen, van Straten, Donker, Tiemens, 2002)|Client Satisfaction Questionnaire (CSQ-8; Nguyen, Attkinson, & Stegner, 1983)|System Usability Scale (SUS; Brooke, 1996)","University of Bern","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","001/15","March 2015","July 2017","July 2017","April 7, 2015",,"September 21, 2017","Sanatorium Kilchberg, Kilchberg, Zurich, Switzerland|Department of Clinical Psychology and Psychotherapy, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02410616"
2215,"NCT00627887","Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression",,"Completed","No Results Available","Depressive Disorder, Major","Procedure: Electroconvulsive therapy|Drug: venlafaxine|Drug: Lithium","MADRS >20, psychiatric hospitalization or suicide|Mini Mental State Examination|ADAS-cog|Autobiographical Memory Inventory -Short Form (AMI-SF)|Clinical Global Impression-Severity|Udvalg for Kliniske Undersogelser (UKU)|MADRS-S Montgomery Asberg Depression Rating scale- self assessment","Örebro County Council|Uppsala-Örebro Regional Research Council","All","18 Years and older   (Adult, Older Adult)","Phase 4","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISRCTN40355220","January 2008","May 2012","May 2012","March 4, 2008",,"June 22, 2012","Psychiatric Clinic, Sater, Dalarna, Sweden|Psychiatric clinic, Orebro, Sweden|Löwenströmska sjukhuset, Stockholm, Sweden|Psychiatric Clinic, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00627887"
2216,"NCT00579267","Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)",,"Completed","No Results Available","Major Depression|Mania|Anxiety Disorders|Psychotic Disorder|Alcohol Dependence|Drug Dependence|Eating Disorders|Suicidality|Dysthymia|ADHD|Tourettes Disorder|Conduct Disorder|Oppositional Defiant Disorder|Pervasive Developmental Disorder","Other: MINI-KID","Kappa scores between MINI Kid and K-SADS","University of South Florida","All","6 Years to 17 Years   (Child)",,"230","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MINI-KID Validation Study","February 2004","January 2008","January 2008","December 24, 2007",,"February 16, 2009","University of South Florida College of Medicine, Department of Psychiatry, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00579267"
2217,"NCT03692910","A Study to Evaluate SAGE-217 in Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode - Part A",,"Completed","No Results Available","Bipolar Disorder I|Bipolar Disorder II|Major Depressive Episode","Drug: SAGE-217","The safety and tolerability of SAGE-217 as assessed by the frequency and severity of adverse events.|The safety and tolerability of SAGE-217 as assessed by suicidal ideation and behavior using the Columbia Suicide Severity Rating Scale (C-SSRS).|The safety and tolerability of SAGE-217 as assessed by mania using the Young Mania Rating Scale (YMRS).|Change from baseline in the 17-item HAM-D total score.|Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.","Sage Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","217-BPD-201","August 19, 2018","March 23, 2019","March 23, 2019","October 2, 2018",,"March 30, 2020","Sage Investigational Site, Little Rock, Arkansas, United States|Sage Investigational Site, Garden Grove, California, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Lauderhill, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Saint Louis, Missouri, United States|Sage Investigational Site, Austin, Texas, United States|Sage Investigational Site, Richardson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03692910"
2218,"NCT00191685","Duloxetine in the Treatment of Melancholic Depression",,"Completed","No Results Available","Depressive Disorder, Major","Drug: duloxetine","To generate data to compare the proportion of outpatients with major depressive disorder with melancholic features who responded to duloxetine at a given daily dose after initially not responding to duloxetine 60mg once daily for 4 weeks.|To compare outpatients with major depressive disorder with melancholic features who achieved remission after treatment with duloxetine;Collect data on the safety of duloxetine.","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8163|F1J-AY-HMCZ","May 2004",,"September 2005","September 19, 2005",,"July 25, 2006","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Paddington, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Everton Park, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoppers Crossing, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Nambour, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., New Farm, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., South Port BC, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Elizabeth Vale, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., St. John, New Brunswick, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Halifax, Nova Scotia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Sydney, Nova Scotia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingston, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Mississauga, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Sudbury, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Beauport, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time(UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00191685"
2219,"NCT01531309","Pharmacokinetics of AGO178 in Participants With Liver Impairment",,"Completed","No Results Available","Hepatic Impairment","Drug: AGO178","Maximum Observed Plasma Concentration (Cmax) of AGO178|Area Under the Plasma Curve (AUC) of AGO178|Number of Participants with Adverse Events","Novartis Pharmaceuticals|Servier|Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CAGO178C2102","February 8, 2011","September 2, 2011","September 2, 2011","February 10, 2012",,"May 11, 2021","Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01531309"
2220,"NCT00338806","Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder",,"Completed","Has Results","Bipolar Disorder|Depression","Behavioral: Interpersonal psychotherapy for prevention with adolescents|Behavioral: Educational clinical monitoring","K SADS-Present Version (KSADS-P)|Children's Depression Rating Scale-Revised (CDRS-R)|Children's Global Assessment Scale (C-GAS)|Young Mania Rating Scale (YMRS)|Attitudes Toward Treatment Questionnaire|Emotion Regulation Questionnaire|Family Assessment Device|Family History Screen|Mood Disorder Questionnaire|Patient Health Questionnaire|Social Adjustment Scale - Self Report for Adolescents|Social Rhythm Metric Short Form|Treatment Credibility Scale","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","12 Years to 17 Years   (Child)","Not Applicable","7","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","#5067|K23MH071530","November 2006","July 2012","July 2012","June 20, 2006","August 15, 2017","August 15, 2017","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00338806"
2221,"NCT03254836","Sleep and Survival in Colorectal Cancer",,"Active, not recruiting","No Results Available","Colorectal Neoplasm|Circadian Rhythm Sleep Disorder|Depression|Quality of Life|Sleep","Other: Standard of care","Actigraphy|Major Depression Inventory|Insomnia Severity Index|Quality of life assesment|Mortality|Co-morbidity|Drug prescription history (Drug name and dosage)|Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)","Zealand University Hospital|Center of Surgical Science, Department of Surgery, Zealand University Hospital","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MTM-V3|SJ-600","March 1, 2017","July 31, 2018","July 31, 2023","August 21, 2017",,"January 15, 2019","Department of Surgery, Zealand University Hospital, Roskilde, Zealand, Denmark",,"https://ClinicalTrials.gov/show/NCT03254836"
2222,"NCT04581902","Biomarkers of Depression and Treatment Response","SUNSET","Recruiting","No Results Available","Depressive Disorder, Major","Device: rTMS therapy","Change in MADRS score from baseline to end of treatment|Change in resting state BOLD signal from baseline to end of treatment|Change in resting state EEG from baseline to end of treatment|Change in white matter integrity from baseline to end of treatment|Change in Beck's Depression Inventory (BDI) score from baseline to end of treatment|Change in Patient Health Questionnaire (PHQ9) score from baseline to end of treatment|Change in Generalized Anxiety Disorder (GAD-7) score from baseline to end of treatment|Change in Inventory of Depressive Symptomatology (IDS-30 self report) score from baseline to end of treatment.","University of California, San Francisco","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","19-28340","December 1, 2020","September 2022","December 2022","October 9, 2020",,"December 10, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04581902"
2223,"NCT02362412","Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes",,"Completed","Has Results","Bipolar Depression","Drug: FK949E","Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Hamilton Depression Scale (HAM-D17)|Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness|Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S):Depression|Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Mania|Clinical Global Impression-Bipolar-Change (CGI-BP-C):Overall Bipolar Illness|Clinical Global Impression-Bipolar-Change (CGI-BP-C):Depression|Clinical Global Impression-Bipolar-Change (CGI-BP-C):Mania|Number of Participants With Adverse Events","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 3","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6949-CL-0023","February 18, 2015","February 6, 2016","February 6, 2016","February 12, 2015","March 17, 2017","February 8, 2019","Fukushima, Japan|Kanagawa, Japan|Kumamoto, Japan|Kyoto, Japan|Osaka, Japan|Tokushima, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02362412"
2224,"NCT04695145","Aerobic Group Exercise for Adolescents With Depression",,"Active, not recruiting","No Results Available","Depressive Disorder, Major","Behavioral: Aerobic exercise in group|Behavioral: Group sessions with leisure activities","Change in Children's Depression Rating Scale- Revised (CDRS-R)|Change in Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-A17-SR)|Change in Children Global Assessment Scale (C-GAS),|Change in Outcome Rating Scale (ORS)|Change in Aerobic capacity|Change in Muscular strength|Change in Biological markers of neuroprotection and neuroinflammation in blood samples|Change in costs with the Treatment Inventory of Costs in Psychiatric Patients (Tic-P)","Lund University Hospital|Region Halland|Halmstad University|The Rydberg Laboratory for Applied Sciences, Halmstad, Sweden|Karolinska University Hospital","All","13 Years to 17 Years   (Child)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020-03364","March 8, 2021","June 18, 2021","March 15, 2022","January 5, 2021",,"June 22, 2021","Child and Adolescent Psychiatry, Halmstad, Sweden",,"https://ClinicalTrials.gov/show/NCT04695145"
2225,"NCT00627029","Evaluation of Programs of Coordinated Care and Disease Management","Coca","Unknown status","No Results Available","Congestive Heart Failure|Diabetes|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Cancer|Cerebrovascular Disease|Alzheimer's Disease|Psychotic Disorder|Major Depression","Behavioral: Care Coordination","Medicare program expenditures|Claims-based and patient-reported quality of care","Mathematica Policy Research, Inc.|Centers for Medicare and Medicaid Services","All","Child, Adult, Older Adult","Not Applicable","18277","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MPR 8756|CMS 500-95-0047(09","September 2000","August 2015","December 2016","February 29, 2008",,"October 1, 2015","Hospice of the Valley MediCaring Project, Phoenix, Arizona, United States|Georgetown University Medical Center-Mind My Heart Program, Washington, District of Columbia, United States|Quality Oncology/Matria Healthcare, Sunrise, Florida, United States|CorSolutions/Matria Healthcare, Rosemont, Illinois, United States|Carle Foundation and Hospital, Urbana, Illinois, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Medical Care Development, Augusta, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Charlestown/Erickson Retirement Communities, Catonsville, Maryland, United States|Washington University-St.Louis School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, United States|QMed, Inc., Eatontown, New Jersey, United States|Lovelace Health Systems, Albuquerque, New Mexico, United States|Jewish Home Lifecare, New York, New York, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|CenVaNet, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00627029"
2226,"NCT03027362","Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression",,"Completed","No Results Available","Depressive Disorder, Major","Other: Cognitive behavioral therapy (CBT) and medication|Other: Psychoeducation and medication","Time to relapse of depression measured by the Montgomery-Asberg Depressive Rating Scale (MADRS) score.|Change in cognitive flexibility-working memory|Change in cognitive flexibility-executive function","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1609018450","January 2017","September 30, 2019","January 15, 2020","January 23, 2017",,"February 5, 2020","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03027362"
2227,"NCT01976793","Retrospective Observational Study DIANA Study","DIANA","Completed","No Results Available","Major Depressive Episode",,"Duration of treatment considered as time between initiation of antidepressant monotherapy and the alteration and/or augmentation of pharmacotherapy|Pharmacotherapy strategy for the second line treatment|International Non-Proprietary Name (INN) of pharmacological agents prescribed for augmentation|Doses of pharmacological agents used for augmentation|Source of the patient's referral to a psychiatrist","AstraZeneca","All","Child, Adult, Older Adult",,"450","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NIS-NRU-ATC-2013/1","December 2013","December 2013","December 2013","November 6, 2013",,"November 13, 2014","Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01976793"
2228,"NCT00229463","Study of Genetic Differences in People With Depression","Genetics","Completed","No Results Available","Depressive Disorder, Major",,,"University of California, Los Angeles","All","18 Years to 75 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","01-10-049","January 2002","January 2011","January 2011","September 29, 2005",,"November 18, 2016","UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00229463"
2229,"NCT04021433","Ketamine for Treatment Resistant MDD",,"Unknown status","No Results Available","Depressive Disorder, Major","Drug: Ketamine","MADRS|QIDS-SR, Clinical Global Impressions - Improvement|Average time in remission|NeuroTrax computerized cognitive battery","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","58717-HMO-CTIL","September 1, 2018","October 1, 2020","December 30, 2020","July 16, 2019",,"July 16, 2019","Hadassah Hebrew University Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT04021433"
2230,"NCT00338273","A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode",,"Withdrawn","No Results Available","Bipolar Disorder","Drug: Aripiprazole|Drug: Placebo","Mean change from baseline to endpoint (Week 8 last observation carried forward = LOCF) on the Montgomery-Asberg Depression Rating Scale (MADRS) total score|Mean change from baseline to endpoint on the Clinical Global Impression-Bipolar Version, severity of illness score (depression)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CN138-149","December 2006","November 2007","November 2007","June 20, 2006",,"November 8, 2013","Local Institution, Durham, North Carolina, United States|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Chennai, India|Local Institution, Delhi, India|Local Institution, Hyderabad, India|Local Institution, Lucknow, India|Local Institution, Mumbai, India|Local Institution, Vishakhapatnam, India",,"https://ClinicalTrials.gov/show/NCT00338273"
2231,"NCT00696774","Switching to Duloxetine in Patients With Depression","ARDENT","Completed","Has Results","Depressive Disorder, Major","Drug: Duloxetine","Change From Baseline in Brief Pain Inventory-Modified Short Form (BPI-SF) Interference Score Between Responder and Non-Responder Participants at 4 Weeks|Percentage of Participants Meeting Criteria for Response on the 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale at 4 and 8 Weeks|Change From Baseline HAMD-17 Total Score at 8 Weeks|Change From Baseline HAMD-17 Core Subscale at 8 Weeks|Change From Baseline HAMD-17 Maier Subscale at 8 Weeks|Change From Baseline HAMD-17 Anxiety/Somatization Subscale at 8 Weeks|Change From Baseline HAMD-17 Retardation/Somatization Subscale at 8 Weeks|Change From Baseline HAMD-17 Sleep Subscale at 8 Weeks|Change From Baseline in the Hamilton Anxiety Rating Scale (HAMA) at 8 Weeks|Change From Baseline in the Clinical Global Impression - Severity (CGI-Severity) Scale at 8 Weeks|Change From Baseline in the Brief Pain Inventory - Modified Short Form (BPI-SF) Average Pain Score at 8 Weeks|Change From Baseline in Patient Global Impression - Improvement (PGI-I) Scale Score at 8 Weeks|Change From Baseline in the Sexual Functioning Questionnaire Clinical Version (CSFQ) at 4 and 8 Weeks|Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) at 4 and 8 Weeks|Change From Baseline in the Sheehan Disability Scale (SDS) at 4 and 8 Weeks","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","242","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12349|F1J-CR-S022","June 2008","July 2009","July 2009","June 13, 2008","August 11, 2010","September 8, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guri City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00696774"
2232,"NCT03543410","A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression",,"Completed","No Results Available","Depressive Episode|Bipolar 1 Depression","Drug: SEP-4199 200 mg|Drug: SEP-4199 400 mg|Drug: Placebo","Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Week 6|Change from baseline in global severity assessed by the Clinical Global Impressions - Severity: Bipolar Version (CGI-BP-S) score (depression) at Week 6","Sunovion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","344","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SEP380-201|2018-000103-16","June 26, 2018","April 23, 2020","April 23, 2020","June 1, 2018",,"April 8, 2021","CNS Research Science, Inc., Cerritos, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Artemis Insitute for Clinical Research, San Diego, California, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Eastside Therapeutic Resource dba Core Clinical Research, Everett, Washington, United States|Mental Health Centre -Prof. Dr. Ivan Temkov - Burgas EOOD, Burgas, Bulgaria|State Psychiatric Hospital-Kardzhali, Kardzhali, Bulgaria|MHAT-Dr. Hristo Stambolski EOOD, Department of Psychiatry, Kazanlak, Bulgaria|Mental Health Center - Ruse EOOD, Ruse, Bulgaria|Neli Nikolova Todorova, MD ,State Psychatric Hospital - s. Tsarev brod, Shumen, Bulgaria|Mental Health Center - Sofia EOOD, Sofia, Bulgaria|Fukuoka University Hospital, Fukuoka, Japan|Hatakeyama Clinic, Department of Psychiatry, Fukuoka, Japan|Hiro Mental Clinic, Department of Psychiatry, Fukuoka, Japan|Kokura Mental Clinic, Fukuoka, Japan|Kuramitsu Hospital, Department of Psychiatry, Fukuoka, Japan|Shinseikai Kaku Mental Clinic, Department of Psychiatry, Fukuoka, Japan|Someikai Kanagami Clinic, Department of Psychiatry, Fukuoka, Japan|Jisenkai Nanko Psychiatric Institute, Department of Psychiatry, Fukushima, Japan|Takahashi Psychiatric Clinic, Hyogo, Japan|Azamino Mental clinic, Department of Psychiatry, Kanagawa, Japan|Medical Corporation Seishinkai Kishiro Mental Clinic, Department of Psychiatry, Kanagawa, Japan|Musashikosugi J. Kokorono Clinic, Kanagawa, Japan|Yokohama Onoecho Clinic, Department of Psychiatry, Kanagawa, Japan|Yutaka Clinic, Kanagawa, Japan|SagaArashiyama / Tanaka Clinic, Department of Psychiatry, Kyoto, Japan|Minami-aoyama Anique Street Clinic, Department of Psychiatry, Minato-Ku, Tokyo, Japan|Clinic Sophia, Okayama, Japan|Nagaokai Neyagawa Sanitorium, Osaka, Japan|Asakayama Hospital, Osaka, Japan|Koshokai Ainhanazono Hospital, Osaka, Japan|Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital, Osaka, Japan|Yoyogi Mental Clinic, Tokoyo, Japan|Etoh Mental Clinic Meguro, Department of Psychiatry, Tokyo, Japan|Himorogi Psychiatric Institute, Department of Psychiatry, Tokyo, Japan|JCHO Yokyo Shinjuku Medical Center, Tokyo, Japan|Jisenkai Hozumi Himorogi Clinic, Department of Psychiatry, Tokyo, Japan|Maynds Tower Mental Clinic, Department of Psychiatry, Tokyo, Japan|Nishi-shinjuku Concieria Clnic, Tokyo, Japan|Ohwa Mental clinic, Department of Psychiatry, Tokyo, Japan|Sangenjaya Nakamura Mental Clinic, Department of Psychiatry, Tokyo, Japan|Sangenjaya Neurology-Psychosomatic Clinic, Department of Psychiatry, Tokyo, Japan|Senzoku Psychosomatic Clinic, Department of Psychiatry, Tokyo, Japan|Shinjuku Research Park Clinic, Tokyo, Japan|Tamaki Clinic, Department of Psychiatry, Tokyo, Japan|Uguisudani Mental Clinic, Department of Psychiatry, Tokyo, Japan|Przychodnia Srodmiescie Sp. z.o.o., Bydgoszcz, Poland|Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS, Leszno, Poland|Specjalistyczna Praktyka Lekarska Marek Domanski, Lublin, Poland|Filip Rybakowski Specjalistyczna Praktka Lekarska, Poznan, Poland|Poradnia Zdrowia Psychicznego ""Syntonia"", Pruszcz Gdanski, Poland|Gabinet Lekarski Torunskie Centrum PsychiatriI NEUROMED, Torun, Poland|Osrodek Badan Klinicznych Clinsante Spolka Cywilna, Torun, Poland|Lipetsk regional psychoneurological hospital, Lipetsk, Russian Federation|State Budgetary Institution of Healthare of the City of Moscow ""Psychiatric clinical Hospital #4 n.a. P.B. Gannushkin of the Department of Healthcare of the City o Moscow"" Branch ""Psychiatric hospital n.a. V.A. Gilyarovsky"", Moscow, Russian Federation|State Budgetary Institution of Healthcare of Nizhniy Novgorod region ""Clinical Psychiatric Hospital #1 of Nizhniy Novgorod"", Nizhniy Novgorod, Russian Federation|Budgetary Institution of Healthcare of Omsk region ""Clinical Psychiatric Hospital named after N.N. Solodnikov"", Omsk, Russian Federation|Limited Liability Company ""Treatment and Rehabilitational Scientific Center Phoenix"", Rostov-on-don, Russian Federation|Saint Petersburg State Institution of Healthcare ""Psychiatric Hospital of Sain Nikolai hudotvorets "", Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""National Medical Research Centre of psychiatry and nuerology named after V.M. Bekhterev"" of the Ministry of Healthcare of the Russian Federation, department #12, Saint Petersburg, Russian Federation|Stain Petersburg State Budgetary Institution of Healthcare ""Psychoneurological Dispensary #1"", Saint Petersburg, Russian Federation|State Institution of Healtcare ""Regional Clinical Psychiatric Hospital of Saint Sofia"", Saratov, Russian Federation|Limited Liability Company ""Clinic StoLet"", Tomsk, Russian Federation|Bel Medic General Hospital, Belgrade, Serbia|Clinical Center ""Dr. Dragisa Misovic-Dedinje"", Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|General Hospital Euromedik, Belgrade, Serbia|Institute of Mental Health, Belgrade, Serbia|Special Hospital for Psychiatric Diseases ""Kovin"", Kovin, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Vavrusova Consulting s.r.o. Psychiatricka ambulancia, Bratislava, Slovakia|Investa spol. s.r.o., Kosice Psychiatricka ambulancia, Kosice, Slovakia|Psycholine s.r.0. Psychiatricka ambulancia, Rimavska Sobota, Slovakia|Centrum zdravia R.B.K. Psychiatricka ambulancia, Svidnik, Slovakia|Crystal Comfort s.r.o. Psychiatricka ambulancia, Vranov nad Toplou, Slovakia|Regional Psychoneurological Hospital #3, Department of Neurosis and Borderline States # 8, Ivano-Frankivsk, Ukraine|State Institution Institue of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Unit of Emergency sychiatry and Narcology, Kharkiv, Ukraine|State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Unit of Borderline Psychiatry, Kharkiv, Ukraine|CI Kherson Regional Psychiatric Hospital of Kherson Regional Council, Male Dep of Psychiatry #3, Female Dep of Psychiatry #10, Kherson, Ukraine|Communal Institution (CI) of Kyiv Regional Council regional Psychiatric and Narcological Medical Assocation, Dep #10 (male), Dep #2 (female), Kyiv, Ukraine|Communal Institution Odesa regional Medical Center of Mental Health, Dep #6 (Male), Dep #12 (Female), Odesa, Ukraine|Communal Institution Odesa Regional Psychiatric Hospital #2, Department #14 (female), Department #16 (male), Odesa, Ukraine|Communal Institution Cherkasy regional Psychiatric Hospital of Cherkasy Regional Council, Female Department #11, Male Department #12, Smila, Ukraine|Transcarpathian Regional Narcological Dispensary, Department of Psychiatry, Uzhgorod, Ukraine|communal Institution Acad. O.I. Yushchenko Vinnytsia Regional Psychoneurological hosital, Male Deparmtent #14, Female Department #15, Vinnytsia M.I. Pyrogov National Medical University, Chair of Psychiatry, Narcology and Psychotherapy with the Course of P, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03543410"
2233,"NCT00220480","A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression",,"Unknown status","No Results Available","Depressive Disorder, Major","Drug: escitalopram","MADRS","Sheba Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-04-3434-JZ-CTIL","February 2005","June 2011",,"September 22, 2005",,"February 9, 2010","Rambam Medical Center, Haifa, Israel|Ness Ziona Mental Health Center, Ness Ziona, Israel|Gehah Mental Health Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT00220480"
2234,"NCT01888627","Integrated Care in Psychotic Disorders With Severe Mental Illness","ACCESS-II","Unknown status","No Results Available","Schizophrenia|Schizophreniform Disorder|Schizoaffective Disorder|Delusional Disorder|Psychotic Disorder NOS|Bipolar Disorder|Severe Major Depression With Psychotic Features","Other: Integrated care","Time to service disengagement|Change of functioning as measured with the Global Assessment of Functioning Scale (GAF)|Change of quality of life as measured with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18)|Change of psychopathology as measured with the Brief Psychiatric Rating Scale (BPRS)|Change of satisfaction with care as measured with the Client Satisfaction Questionnaire (CSQ-8)|Service use data","Universitätsklinikum Hamburg-Eppendorf","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACCESS-II","May 2007","January 2018","December 2018","June 28, 2013",,"August 8, 2017","University Hospital Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01888627"
2235,"NCT00426946","Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study",,"Unknown status","No Results Available","Depression","Drug: Reboxetine","Children's Depression Inventory CDI (Kovacs, 1985)|Children's Depression Rating Scale-Revised (CDRS-R)","Geha Mental Health Center","All","6 Years to 18 Years   (Child, Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACMHC1","January 2005",,,"January 25, 2007",,"January 25, 2007","Tel Aviv Community Mental Helath Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00426946"
2236,"NCT00852592","Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial",,"Completed","Has Results","Bipolar Disorder|Major Depressive Episode","Device: 7000lux broad-spectrum light|Device: 50lux dim red light","SIGH-ADS Depression Score|Global Assessment of Functioning (GAF)","Northwestern University|University of Pittsburgh","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO09020546","May 2009","December 2014","February 2015","February 27, 2009","November 6, 2016","November 6, 2016","University of Pittsburgh, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00852592"
2237,"NCT04772664","Probiotics and the Gut Brain Axis- Do Probiotics Interact With the Vagal Nerve?","ProBIO-HRV","Not yet recruiting","No Results Available","Depressive Disorder, Major","Dietary Supplement: Multispecies-Probiotic|Dietary Supplement: Placebo Supplement","Change of Vagal function|Change of C-reactive protein (CRP)|Change of Interleukine-6 (IL-6)|Change of Oxytocin|Change of Gut microbiome analysis|Change of Body mass index|Mini-international neuropsychiatric interview (M.I.N.I.)|Change in Hamilton Scale for Depression (HAMD)|Beck Depression Inventory (BDI)|Change in Pittsburgh Sleep Quality Inventory (PSQI)|Change in Adult Attachment Scale|Change in ""Wiener Ernährungsprotokoll""|Change in International Physical Activity Questionnaire","Medical University of Graz|Allergosan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","EK1019/2021","June 1, 2021","August 1, 2022","August 1, 2022","February 26, 2021",,"March 3, 2021",,,"https://ClinicalTrials.gov/show/NCT04772664"
2238,"NCT00709150","Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes","MDDP","Completed","No Results Available","Depression","Behavioral: Collaborative depression care management|Behavioral: Enhanced usual care","Reduction in symptoms of major depression|Quality of life","University of Southern California|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 4","387","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R01MH068468|DSIR 82-SESQ","March 2005","September 2009","September 2009","July 3, 2008",,"July 29, 2013","University of Southern California School of Social Work, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00709150"
2239,"NCT02069912","Multifaceted Depression and Cardiovascular Program","MDCP","Completed","No Results Available","Depression|Depressive Disorder|Behavioral Symptoms|Mood Disorders","Behavioral: Collaborative depression care management","Depressive symptoms reduction|Improvement in quality of life","University of Southern California|Los Angeles County Department of Public Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","USCIRB-HS-06-00420|CA Health Care Foundation","November 2006","February 2009","February 2009","February 24, 2014",,"February 24, 2014","University of Southern California School of Social Work, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02069912"
2240,"NCT04086316","Depressive Symptoms and Subjective Stress in the Course of the Menstrual Cycle - an Ambulatory Assessment Study.","DepCy","Recruiting","No Results Available","Major Depressive Episode",,"Changes in Depressive Symptoms between the menstrual cycle phases|Changes in subjective stress (self report) between the menstrual cycle phases|Differences between women with and without a Major depressive Episode","Freie Universität Berlin","Female","18 Years to 45 Years   (Adult)",,"74","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CycleDepression","January 15, 2020","December 31, 2020","April 30, 2021","September 11, 2019",,"March 11, 2020","Freie Universität Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04086316"
2241,"NCT01353092","Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression","PEMFII","Completed","No Results Available","Treatment Resistant Depression","Device: Re5 Pulsating ElectroMagnetic Fields|Device: Re5 Pulsating ElectroMagnetic Fields (PEMF)","Hamilton depression rating scale|UKU","Hillerod Hospital, Denmark","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","26.04.2010","April 2011","June 2013","June 2013","May 12, 2011",,"August 26, 2015","Psychiatric Research Unit, Mental Health Centre North Zealand, Hilleroed, Denmark",,"https://ClinicalTrials.gov/show/NCT01353092"
2242,"NCT03165513","Dialogue to Empower Traditional and Faith Healers to Deliver mhGAP-IG Adapted Psychosocial Interventions in Kenya","Dialogue","Completed","No Results Available","Depressive Disorder, Major","Behavioral: mhGAP-IG","Depression symptoms on the Becks Depression Inventory Scale|Quality of life outcomes on the WHO Quality of Life-BREF (WHOQOL-BREF)","Africa Mental Health Foundation|Grand Challenges Canada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4081","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P602/12/2013","July 1, 2014","March 20, 2015","March 20, 2015","May 24, 2017",,"May 24, 2017",,,"https://ClinicalTrials.gov/show/NCT03165513"
2243,"NCT00536172","Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment","PROTECT","Completed","Has Results","Depression","Drug: Escitalopram|Drug: Placebo","Depression as Assessed by the Quick Inventory of Depressive Symptomatology-Self Rated 16 (QIDS-SR-16)","University of Nebraska|National Institute of Mental Health (NIMH)","All","19 Years and older   (Adult, Older Adult)","Phase 4","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","188-07|R01MH079420|DAHBR 96-BHC","December 2007","June 2012","June 2012","September 27, 2007","February 14, 2014","February 5, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00536172"
2244,"NCT03155503","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects","SUVN-911","Completed","No Results Available","Depressive Disorder, Major","Drug: SUVN-911|Drug: Placebo","ECG (Electrocardiogram)|Vital signs|C-SSRS (Columbia Suicidal Severity Rating Scale)|Area under the plasma concentration versus time curve (AUC)|Maximum observed concentration (Cmax)|Time to reach maximum concentration (Tmax)|Terminal half-life (t½)","Suven Life Sciences Limited","Male","18 Years to 45 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTP1S1911A4B2","May 22, 2017","March 7, 2018","March 14, 2018","May 16, 2017",,"May 29, 2018","QuintilesIMS Phase 1 Services, LLC, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03155503"
2245,"NCT02614547","A Study to Evaluate SAGE-547 in Patients With Severe Postpartum Depression",,"Completed","No Results Available","Severe Postpartum Depression","Drug: SAGE-547|Drug: Placebo","Effect of SAGE-547 on depressive symptoms in subjects with severe postpartum depression compared to placebo injection as measured by the change from baseline in Hamilton Rating Scale for Depression (HAMD) total score|Safety and tolerability of SAGE-547 compared with placebo as measured by the change from baseline in the incidence of AEs, vital signs, clinical laboratory evaluations, and ECG parameters|Safety of SAGE-547 compared to placebo as measured by the change from baseline in suicidal ideation and behavior assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) score","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","547-PPD-202 A","November 2015","June 2016","July 2016","November 25, 2015",,"August 8, 2017","University of Arkansas, Little Rock, Arkansas, United States|Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Cypress Medical Research, Wichita, Kansas, United States|Johns Hopkins University Women's Mood Disorders, Baltimore, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|PRA Health Sciences, Marlton, New Jersey, United States|University or North Carolina, Chapel Hill - Perinatal Psychiatry In-Patient Unit, Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|The Ohio State University, Department of Psychiatry and Behavioral Health, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02614547"
2246,"NCT02529462","Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients",,"Completed","No Results Available","Depressive Disorder, Major","Genetic: NEUROPHARMAGEN-Guided Treatment|Drug: Treatment As Usual","Sustained response to treatment|Response to treatment|Hamilton Rating Scale for Depression (HAM-D)|FIBSER Scale (Frequency, Intensity and Burden of Side Effects Rating)|Clinical Global Impression-Severity scale (CGI-S)|Treatment Satisfaction with Medicines Questionnaire (SATMED-Q)|Sheehan Disability Inventory (SDI)","AB Biotics, SA","All","18 Years and older   (Adult, Older Adult)","Phase 3","521","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AB-GEN-2013","July 2014","October 2015","October 2015","August 20, 2015",,"December 5, 2016","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Consorci Sanitari del Maresme, Mataro, Barcelona, Spain|Hospital Mutua de Terrassa, Tarrasa, Barcelona, Spain|Institut Pere Mata, Reus, Tarragona, Spain|Hospital Clinic, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital de Mar, Barcelona, Spain|Hospital de Jerez, Jerez, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT02529462"
2247,"NCT04661475","Dexmedetomidine Adjuvant Treatment for Depressed Patients Undergoing ECT",,"Not yet recruiting","No Results Available","Depressive Disorder, Major","Drug: Dexmedetomidine Injection [Precedex]|Drug: Normal saline","Montgomery-Asberg Depression Rating Scale","Sultan Qaboos University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13/2020","June 1, 2021","December 30, 2022","March 2, 2023","December 10, 2020",,"December 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04661475"
2248,"NCT01725308","A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes",,"Completed","Has Results","Bipolar Disorder","Drug: FK949E|Drug: Placebo","Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in MADRS Total Score (Treatment Period I)|Change From Baseline in MADRS Total Score (Combined Treatment Period I and II)|Number of Participants With MADRS Response (Treatment Period I)|Number of Participants With MADRS Response (Combined Treatment Period I and II)|Number of Participants With MADRS Remission (Treatment Period I)|Number of Participants With MADRS Remission (Combined Treatment Period I and II)|Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score (Treatment Period I)|Change From Baseline in HAM-D17 (Combined Treatment Period I and II)|Number of Participants With HAM-D17 Response (Treatment Period I)|Number of Participants With HAM-D17 Response (Combined Treatment Period I and II)|Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania (Treatment Period I)|Change From Baseline in CGI-BP-S: Mania (Combined Treatment Period I and II)|Change From Baseline in CGI-BP-S: Depression (Treatment Period I)|Change From Baseline in CGI-BP-S: Depression (Combined Treatment Period I and II)|Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Treatment Period I)|Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Combined Treatment Period I and II)|Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania (Treatment Period I)|CGI-BP-C: Mania (Combined Treatment Period I and II)|CGI-BP-C: Depression (Treatment Period I)|CGI-BP-C: Depression (Combined Treatment Period I and II)|CGI-BP-C: Overall Bipolar Illness (Treatment Period I)|CGI-BP-C: Overall Bipolar Illness (Combined Treatment Period I and II)|Number of Participants With Adverse Events (Treatment Period I)|Number of Participants With Adverse Events (Combined Treatment Period I and II)|Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score (Treatment Period I)|Change From Baseline in DIEPSS: Total Score (Combined Treatment Period I and II)|Change From Baseline in DIEPSS: Parkinsonism (Treatment Period I)|Change From Baseline in DIEPSS: Parkinsonism (Combined Treatment Period I and II)|Change From Baseline in Young Mania Rating Scale (YMRS) (Treatment Period I)|Change From Baseline in YMRS (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation (Treatment Period I)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Wish to be Dead (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts With Method (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent Without a Plan (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent With a Plan (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors (Treatment Period I)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicide Attempt (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Self-injury Behavior Without Intent (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Discontinued Attempt (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Interrupted Attempt (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Preliminary Act to Suicide (Combined Treatment Period I and II|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicidal Behavior (Combined Treatment Period I and II)|Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Completed Suicide (Combined Treatment Period I and II)","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 2|Phase 3","431","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6949-CL-0021","February 7, 2012","August 1, 2015","July 11, 2016","November 12, 2012","February 8, 2017","January 11, 2019","Site JP00030, Aichi, Japan|Site JP00031, Aichi, Japan|Site JP00052, Aichi, Japan|Site JP00055, Aichi, Japan|Site JP00072, Aichi, Japan|Site JP00092, Aichi, Japan|Site JP00003, Akita, Japan|Site JP00008, Chiba, Japan|Site JP00009, Chiba, Japan|Site JP00002, Fukuoka, Japan|Site JP00037, Fukuoka, Japan|Site JP00038, Fukuoka, Japan|Site JP00039, Fukuoka, Japan|Site JP00040, Fukuoka, Japan|Site JP00041, Fukuoka, Japan|Site JP00058, Fukuoka, Japan|Site JP00082, Fukuoka, Japan|Site JP00083, Fukuoka, Japan|Site JP00091, Fukuoka, Japan|Site JP00094, Fukuoka, Japan|Site JP00095, Fukuoka, Japan|Site JP00096, Fukuoka, Japan|Site JP00097, Fukuoka, Japan|Site JP00098, Fukuoka, Japan|Site JP00004, Fukushima, Japan|Site JP00028, Gifu, Japan|Site JP00006, Gunma, Japan|Site JP00007, Gunma, Japan|Site JP00035, Hiroshima, Japan|Site JP00056, Hiroshima, Japan|Site JP00067, Hiroshima, Japan|Site JP00001, Hokkaido, Japan|Site JP00059, Hokkaido, Japan|Site JP00061, Hokkaido, Japan|Site JP00062, Hokkaido, Japan|Site JP00068, Hokkaido, Japan|Site JP00069, Hokkaido, Japan|Site JP00073, Hokkaido, Japan|Site JP00074, Hokkaido, Japan|Site JP00076, Hokkaido, Japan|Site JP00005, Ibaraki, Japan|Site JP00049, Kagawa, Japan|Site JP00021, Kanagawa, Japan|Site JP00022, Kanagawa, Japan|Site JP00023, Kanagawa, Japan|Site JP00024, Kanagawa, Japan|Site JP00025, Kanagawa, Japan|Site JP00042, Kumamoto, Japan|Site JP00050, Kumamoto, Japan|Site JP00032, Kyoto, Japan|Site JP00084, Kyoto, Japan|Site JP00077, Miyagi, Japan|Site JP00027, Nagano, Japan|Site JP00075, Nara, Japan|Site JP00053, Oita, Japan|Site JP00054, Okayama, Japan|Site JP00079, Okayama, Japan|Site JP00043, Okinawa, Japan|Site JP00046, Okinawa, Japan|Site JP00033, Osaka, Japan|Site JP00034, Osaka, Japan|Site JP00047, Osaka, Japan|Site JP00063, Osaka, Japan|Site JP00029, Shizuoka, Japan|Site JP00036, Tokushima, Japan|Site JP00010, Tokyo, Japan|Site JP00011, Tokyo, Japan|Site JP00012, Tokyo, Japan|Site JP00013, Tokyo, Japan|Site JP00014, Tokyo, Japan|Site JP00015, Tokyo, Japan|Site JP00016, Tokyo, Japan|Site JP00017, Tokyo, Japan|Site JP00018, Tokyo, Japan|Site JP00019, Tokyo, Japan|Site JP00020, Tokyo, Japan|Site JP00045, Tokyo, Japan|Site JP00048, Tokyo, Japan|Site JP00051, Tokyo, Japan|Site JP00057, Tokyo, Japan|Site JP00060, Tokyo, Japan|Site JP00064, Tokyo, Japan|Site JP00065, Tokyo, Japan|Site JP00066, Tokyo, Japan|Site JP00070, Tokyo, Japan|Site JP00071, Tokyo, Japan|Site JP00078, Tokyo, Japan|Site JP00081, Tokyo, Japan|Site JP00085, Tokyo, Japan|Site JP00086, Tokyo, Japan|Site JP00087, Tokyo, Japan|Site JP00088, Tokyo, Japan|Site JP00089, Tokyo, Japan|Site JP00090, Tokyo, Japan|Site JP00093, Tokyo, Japan|Site JP00099, Tokyo, Japan|Site JP00044, Tottori, Japan|Site JP00026, Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT01725308"
2249,"NCT03001440","A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks",,"Completed","No Results Available","Depressive Disorder, Major","Other: KAB survey","Number (No.) of subjects correctly responding to individual survey questions","GlaxoSmithKline|United Biosource Corporation (UBC)","All","18 Years and older   (Adult, Older Adult)",,"1","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","205913","October 7, 2016","December 28, 2016","December 28, 2016","December 23, 2016",,"February 13, 2018",,,"https://ClinicalTrials.gov/show/NCT03001440"
2250,"NCT02737540","Neuropsychological Factors Associated With Vulnerability to Suicidal Behavior in Depressed Elderly Patients","SPAD","Terminated","No Results Available","Depressive Disorder, Major",,"Trust Game|Ultimatum Game|Iowa Gambling Task|Stroop Victoria Test|Incompatibility Test|Flexibility test|Go-NoGo|Working memory - TEA|Mood Disorders Insight Scale|Verbal fluency test|Future autobiographical fluency task|Bristol Emotion Recognition Test|Cognitive Emotion Regulation Questionnaire|Questionnaire on negative attitudes towards problems|Revised self-awareness scale, Self-reference task|Balanced Temporal Perspective Scale|Suicide attempt within 6 months of follow-up","Centre Hospitalier Universitaire de Nīmes","All","60 Years and older   (Adult, Older Adult)",,"85","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","LOCAL/2016/MW-01","August 16, 2017","August 1, 2020","November 30, 2020","April 14, 2016",,"February 1, 2021","CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France|Clinique Les Sophoras, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT02737540"
2251,"NCT02039960","PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011",,"Completed","No Results Available","Depressive Disorder, Major","Drug: Bupropion","The number of bupropion abuse case reports from the DAWN data.","GlaxoSmithKline","All","Child, Adult, Older Adult",,"1","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","201235|PRJ2215","November 2013","January 2014","January 2014","January 20, 2014",,"August 5, 2016",,,"https://ClinicalTrials.gov/show/NCT02039960"
2252,"NCT01460407","A Study to Evaluate the Effect of Clarithromycin on LY2216684",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684|Drug: Clarithromycin","Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2216684|Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of LY2216684","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14401|H9P-EW-LNEB","October 2011","December 2011","December 2011","October 26, 2011","October 19, 2018","October 19, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01460407"
2253,"NCT01460381","A Study to Evaluate the Effect of Genotype on LY2216684",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684|Drug: Quinidine","Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)|Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM) Versus Poor Metabolizers (PM)|Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [(AUC(0-∞)] of LY2216684 + Quinidine in Cytochrome P450 (CYP)2C19 Poor Metabolizers (PM)|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684 + Quinidine in CYP2C19 Poor Metabolizers|Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of LY2216684 + Quinidine in CYP2C19 Poor Metabolizers","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14397|H9P-EW-LNDZ","October 2011","August 2012","August 2012","October 26, 2011","October 26, 2018","October 26, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01460381"
2254,"NCT00448058","A Study Of New Medicine (GSK 372475) For The Treatment Of Depression",,"Completed","No Results Available","Depressive Disorder","Drug: GSK372475|Drug: venlafaxine|Drug: placebo","Change from randomization to the end of the Treatment Phase (Week 10) on a depression rating scale.|Endpoints related to response & remission on depression rating scales during time of treatment exposureChange during treatment & at endpoint-week 10:in Clinical Global Impression scale; in motivation, energy, & sexual functioning on patient-rated scales","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","396","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SND 103285","April 2007","December 2008","December 2008","March 15, 2007",,"October 10, 2014","GSK Investigational Site, Auchenflower, Queensland, Australia|GSK Investigational Site, Kippa Ring, Queensland, Australia|GSK Investigational Site, Epping, Victoria, Australia|GSK Investigational Site, Heidelberg West, Victoria, Australia|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Mont-Godinne, Belgium|GSK Investigational Site, Burgas, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Sydney, Nova Scotia, Canada|GSK Investigational Site, Sydney, Nova Scotia, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Voru, Estonia|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Arcachon, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Chennai, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Tirupati, India|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Skorzewo, Poland|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Michalovce, Slovakia|GSK Investigational Site, Observatory ,Cape Town, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Vereeniging, South Africa",,"https://ClinicalTrials.gov/show/NCT00448058"
2255,"NCT01389765","A Study to Evaluate the Effect of Food on LY2216684",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684","Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2216684|Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of LY2216684","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12620|H9P-EW-LNDC","July 2011","August 2011","August 2011","July 8, 2011","November 13, 2018","November 13, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01389765"
2256,"NCT01389752","A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684|Drug: Activated Charcoal","Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2216684|Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of LY2216684","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12612|H9P-EW-LNCU","July 2011","September 2011","September 2011","July 8, 2011","October 19, 2018","January 4, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01389752"
2257,"NCT01373931","A Study of LY2216684 in Healthy Females",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684|Drug: Ortho Cyclen|Drug: Placebo","Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norelgestromin|Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of Ethinyl Estradiol and Norelgestromin|Area Under the Concentration-Time Curve Over a Dosing Interval (AUCτ) of Ethinyl Estradiol and Norelgestromin","Eli Lilly and Company","Female","18 Years to 45 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","12615|H9P-EW-LNCX","June 2011","December 2011","December 2011","June 15, 2011","October 23, 2018","October 23, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01373931"
2258,"NCT01241435","A Study of LY2216684 in Participants With Impaired Hepatic Function",,"Completed","Has Results","Depressive Disorder, Major","Drug: LY2216684","Pharmacokinetics: Area Under the Concentration Curve (AUC)|Pharmacokinetics: Maximum Concentration (Cmax)|Pharmacokinetics: Time to Maximum Concentration (Tmax)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12602|H9P-EW-LNCM","October 2010","April 2011","April 2011","November 16, 2010","October 22, 2018","October 22, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01241435"
2259,"NCT00490542","Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State",,"Completed","Has Results","Bipolar Disorder|Bipolar Depression|Depression","Drug: ziprasidone (Geodon)|Drug: placebo","The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups.","Tufts Medical Center|Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","73","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GA128000","December 2006","August 2009","August 2009","June 22, 2007","January 8, 2014","July 29, 2016","Northwestern University, Chicago, Illinois, United States|Tufts University, Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00490542"
2260,"NCT01141400","The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use",,"Completed","No Results Available","Depressive Disorder, Major",,"The primary outcome is any use of adjunctive treatment (combined and by class) and the time to initiation of adjunctive treatment (combined and by class).|sensitivity to cost-sharing will be examined as a function of treatment resistance","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 64 Years   (Adult)",,"48865","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CN138-587","June 2009","October 2010","October 2010","June 10, 2010",,"November 8, 2013",,,"https://ClinicalTrials.gov/show/NCT01141400"
2261,"NCT01141387","Outcomes in MEasurement-Based Treatment","COMET","Completed","No Results Available","Depressive Disorder, Major",,"Remission rate assessed by the Patient Health Questionnaire - 9 item (PHQ-9) instrument|Response rate assessed by the PHQ-9 instrument|The medication prescribed including refills, dose titrations, switching and augmentation|Health care utilizations including office visits, emergency room visits and hospitalization","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"914","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CN138-534","May 2009","August 2010","August 2010","June 10, 2010",,"November 8, 2013",,,"https://ClinicalTrials.gov/show/NCT01141387"
2262,"NCT00348036","Group Intervention for Interpersonal Trauma",,"Completed","No Results Available","Post-Traumatic Stress Disorder|Depression","Behavioral: Group Intervention for Interpersonal Trauma|Other: Information only","PTSD checklist|Hamilton Depression Inventory|Inventory of Interpersonal Problems|Health care utilization","Georgetown University|National Institute of Mental Health (NIMH)","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","27","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P20MH068450|DSIR 83-ATAS","September 2008","August 2010","August 2010","July 4, 2006",,"April 30, 2013","Georgetown University, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00348036"
2263,"NCT00296699","A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression",,"Completed","No Results Available","Atypical Depression","Drug: Duloxetine","Hamilton Depression Scale (HAM-D)|Atypical Depression Diagnostic Scale (ADDS)|Beck Depression Inventory (BDI)|Clinical Global Impression (CGI)|Patient Global Impression (PGI)|Inventory of Depressive Symptoms(IDS)","New York State Psychiatric Institute|Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB4943","March 2005","June 2007",,"February 27, 2006",,"January 15, 2008","Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00296699"
2264,"NCT00186264","Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?",,"Completed","No Results Available","Depressive Disorder, Major","Drug: venlafaxine XR|Drug: hydrocortisone","To determine if treatment of major depression with hydrocortisone concurrent with starting venlafaxine XR speeds onset of antidepressant action.|To determine if hydrocortisone pre-treatment augments venlafaxine XR response.","Stanford University|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","Wyeth 0600B-100625","August 2002","April 2006","April 2006","September 16, 2005",,"October 4, 2019","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00186264"
2265,"NCT01080105","Internet Intervention for the Prevention of Depression - Approaches to Improving Mood","AIM","Withdrawn","No Results Available","Individuals at Risk for Depression","Behavioral: AIM Web based intervention + surveillance|Behavioral: AIM web based intervention|Behavioral: Educational website","Depression, as assessed by Quick Inventory of Depressive Symptoms (QIDS), the Patient Health Questionnaire-9 (PHQ-9), and the Mini International Neuropsychiatric Interview (MINI) Disorders-Major Depressive Disorders Module|Website utilization (e.g., number of logins, average visit length, total time spent on the site, number of exercises completed), Attrition and cost effectiveness.|Anxiety, impact on work, social support","Northwestern University","All","19 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","NU IRB STU00020637","June 2012","December 2013","December 2013","March 3, 2010",,"July 3, 2012","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01080105"
2266,"NCT00050700","Brain Imaging in Depression",,"Completed","No Results Available","Depression|Bipolar Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)",,"107","NIH","Observational",,"030001|03-M-0001","December 16, 2002",,"May 14, 2010","December 18, 2002",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00050700"
2267,"NCT02032576","Predictors of the Response and Relapse/Recurrence After ECT for Depressed Patients",,"Completed","No Results Available","Major Depressive Episode","Device: ECT for depressed patients","Predictors of ECT response|Predictors of relapse/recurrence after ECT|The changes of plasma brain-derived neurotrophic factor (BDNF) level after ECT|The changes of cognitive functions after ECT|Assessments of safety for general adverse events after ECT|The changes of quality of life after ECT|The changes of psychosocial functioning after ECT|The changes of auditory evoked potentials (AEP) after ECT|The changes of electroencephalography (EEG) after ECT|The changes of RNA after ECT","Kaohsiung Kai-Suan Psychiatric Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","170","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSPH-2008-12","January 2008","December 2013","December 2013","January 10, 2014",,"January 10, 2014","Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02032576"
2268,"NCT02957591","Probiotic Supplementation in Severe Depression",,"Completed","No Results Available","Severe Depression","Dietary Supplement: Vivomixx®|Other: Placebo","Hamilton Depression Score|Brain perfusion|Brain structure|Brain activation|HPA axis function|Neurogenesis|Appetite-regulating hormones|Immunoregulation and inflammation|Beck depression score|Psychopathology|Cognition|State and trait anxiety|Social interactions|Physical activity|Sleep quality|Gut microbiota composition|Gastrointestinal side effects","Psychiatric Hospital of the University of Basel","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-01608","March 24, 2017","December 11, 2019","January 3, 2020","November 8, 2016",,"April 23, 2021","University Psychiatric Clinics (UPK), Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT02957591"
2269,"NCT03832283","Patient Outcomes Reporting for Timely Assessments of Life With Depression: PORTAL-Depression",,"Completed","No Results Available","Depression|Depressive Disorder, Major","Diagnostic Test: CAD-MDD/CAT-DI screening via MyChart|Diagnostic Test: CAD-MDD/CAT-DI screening during clinic visit|Other: CAT-DI monitoring via MyChart|Other: PHQ-9 monitoring during clinic visits","Percentage of Patients screened for depression using the BPA by study arm|Percentage of patients who have MDD remission|Time to MDD remission|Percentage of logins to MyChart in response to the email invitations|Percentage of opened MyChart depression screening messages|Number of MyChart messages sent to PCPs by patients (or to patients by PCPs) following depression screening|Percentage of patients who start the CAT-MH assessment|Percentage of patients who complete the CAT-MH assessment|Percentage of positive screens|Number of appointments scheduled and completed (primary care and psychiatry/psychology)|Number of telephone encounters in the week following the positive depression screen|Number of emergency department visits or hospitalizations due to MDD|Percentage of logins to MyChart in response to MyChart emails|Percentage of opened MyChart depression symptom measurement messages|Number of MyChart messages sent to PCPs by patients (or to patients by PCPs) following completion of the CAT-DI|Percentage of patients who start CAT-DI assessments|Depression severity scores (CAT-DI)","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","QI18-90","May 1, 2019","March 1, 2021","March 1, 2021","February 6, 2019",,"April 30, 2021","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03832283"
2270,"NCT00497874","An Expert System to Reduce Depression in Primary Care",,"Completed","Has Results","Depression|Depressive Disorder, Major","Behavioral: Computer-tailored intervention","Change in Depression Severity|Number of Participants Exhibiting a Reliable and Clinically Significant Change in Depression Severity|Number of Participants in the Action or Maintenance Stage for Using Effective Methods to Prevent Depression.|Number Participants Without Major Depression at Baseline Who Experienced the Onset of Major Depression During Follow-up|Number of Participants Taking Prescribed Antidepressant Medication (Medication Adherence)|Change in Physical Functioning","Pro-Change Behavior Systems|Harvard Vanguard Medical Associates|John H. Stroger Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","902","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R44MH060522","July 2003","June 2006","June 2006","July 9, 2007","July 7, 2015","February 17, 2021","John H. Stroger Hospital, Chicago, Illinois, United States|Harvard Vanguard Medical Associates, Newton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00497874"
2271,"NCT01103180","Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder",,"Terminated","Has Results","Borderline Personality Disorder","Drug: Escitalopram","Self-harm Ideation|Depressive Symptoms","University of Chicago|Temple University|Northwestern University|University of Southern Mississippi","All","18 Years to 40 Years   (Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MH084904","September 2010","November 2014","November 2014","April 14, 2010","June 14, 2019","June 14, 2019","The University of Chicago Hospitals, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01103180"
2272,"NCT02997865","Stepped Care for Depression in Heart Failure","DASH-2","Active, not recruiting","No Results Available","Heart Failure|Depressive Disorder, Major","Behavioral: Stepped care for depression","Beck Depression Inventory (BDI-II) total score|Self Care of Heart Failure Index (SCHFI) Maintenance subscale|Beck Anxiety Inventory|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Hamilton Rating Scale for Depression (HAM-D-17)|Actigraphy","Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","All","25 Years and older   (Adult, Older Adult)","Not Applicable","139","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HL131524","February 17, 2017","July 30, 2021","December 31, 2021","December 20, 2016",,"May 13, 2021","Behavioral Medicine Center at Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02997865"
2273,"NCT01129752","Mothers With a History of Depression and Their 10-14 Year Old Daughters",,"Completed","No Results Available","Depression|Depressive Disorder, Major","Other: No intervention","Onset of depression","Stanford University|National Institute of Mental Health (NIMH)","Female","9 Years to 15 Years   (Child)",,"240","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SU-03172010-5264|13058","February 2004","April 2011","April 2011","May 25, 2010",,"June 23, 2011","Stanford University Department of Psychology, Stanford, California, United States|Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01129752"
2274,"NCT04260750","ICBT for Depression - A Factorial Investigation of Kinds of Therapist Support and Self-/Expert-selected Content",,"Completed","No Results Available","Depressive Disorder, Major|Depressive Symptoms","Behavioral: Internet-administered Cognitive behavioral therapy (ICBT)","Change on Becks Depression Inventory-II (BDI-II)|Change on Patient Health Questionnaire (PHQ-9)|Change on Generalised Anxiety Disorder 7-item scale (GAD-7)|Change on Brunnsviken Brief Quality of Life Scale (BBQ)|Change on Insomnia Severity Index (ISI)","Linkoeping University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","246","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUNA","January 13, 2020","April 15, 2021","April 15, 2021","February 7, 2020",,"April 20, 2021","Linköping University, Linköping, Östergötland, Sweden",,"https://ClinicalTrials.gov/show/NCT04260750"
2275,"NCT04486222","Accelerated Bilateral rTMS on Geriatric Depression",,"Recruiting","No Results Available","Transcranial Magnetic Stimulation|Depressive Disorder, Major","Device: Repeated Transcranial Magnetic Stimulation","Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)|Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)|Degree of Change in Mini-Mental State Examination (MMSE)|Degree of Change in Stroop Test|Degree of Change in Trail Making Test|Degree of Change in Verbal Fluency Test|Degree of Change in Physiological Parameters","National Taiwan University Hospital|National Taiwan University Hospital, Yun-Lin Branch","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201910101RIND","November 23, 2020","December 31, 2021","December 31, 2021","July 24, 2020",,"May 11, 2021","Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan",,"https://ClinicalTrials.gov/show/NCT04486222"
2276,"NCT03388606","Characterization and Treatment of Adolescent Depression",,"Recruiting","No Results Available","Depression",,"Mood and Feelings Questionnaire","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","11 Years to 25 Years   (Child, Adult)",,"4100","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","180037|18-M-0037","December 28, 2017","July 1, 2025","July 1, 2025","January 3, 2018",,"July 29, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03388606"
2277,"NCT03380442","Psilocybin and Depression","Psilo101","Not yet recruiting","No Results Available","Severe Depression","Drug: Psilocybin|Drug: Ketamine (Ketalar)","The 16-Item Quick Inventory of Depressive Symptomatology (QIDS)|The Montgomery and Asberg Depression Rating Scale|Hamilton Depression Rating Scale","University of Helsinki|Dr. Tomi Rantamäki, Laboratory of Neurotherapeutics, Department of Biosciences, University of Helsinki|Dr. Robin Carthart-Harris and Prof. David Nutt, Imperial College London, UK","All","18 Years to 64 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2016-004195-22","September 2018","January 2020","September 2021","December 21, 2017",,"December 21, 2017",,,"https://ClinicalTrials.gov/show/NCT03380442"
2278,"NCT02839798","NeoSync TMS Treatment for Bipolar I Depression","NESTTBID","Terminated","Has Results","Major Depressive Episode|Bipolar Depression|Bipolar Disorder|Mood Disorders","Device: NEST (NeoSync EEG Synchronized TMS)","Mean MADRS Total Score Change (Last Observation Carried Forward)|Mean HDRS-17 Total Score Change (Last Observation Carried Forward)|Mean IDS-SR Score Change (Last Observation Carried Forward)","Butler Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1601-004","May 2016","November 19, 2018","November 19, 2018","July 21, 2016","April 9, 2020","April 9, 2020","Butler Hospital, Providence, Rhode Island, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02839798/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02839798"
2279,"NCT00116077","Dopamine Receptor Imaging in Mood Disorders",,"Completed","No Results Available","Mood Disorders|Depressive Disorder, Major|Bipolar Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)",,"145","NIH","Observational",,"050169|05-M-0169","June 21, 2005",,"November 12, 2010","June 27, 2005",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00116077"
2280,"NCT00475137","Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression",,"Completed","No Results Available","Bipolar II Disorder, Most Recent Episode Major Depressive","Drug: Lamotrigine","Efficacy of Lamotrigine monotherapy versus Lamotrigine plus antidepressant in the acute and maintenance treatment of Bipolar II depression as evidence by decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to endpoint.|Rates of response to treatment and remission in both treatment arms maintenance efficacy of treatments as evidenced by relapse rates. Rates of treatment associated mania or hypomania as evidenced by increased score on the Young Mania Rating Scale (YMRS).","University of British Columbia","All","17 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H06-03732","December 2007","June 2015","June 2015","May 17, 2007",,"June 4, 2015","University of British Columbia Mood Disorders Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00475137"
2281,"NCT00229450","Estrogen and Perimenopausal Depression",,"Completed","No Results Available","Depressive Disorder, Major|Menopause","Drug: Estrogen","Mood|Memory","University of California, Los Angeles|National Alliance for Research on Schizophrenia and Depression","Female","40 Years to 60 Years   (Adult)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NARSAD06806-001|06806-001|04-05-088","April 2002","August 2003","August 2004","September 29, 2005",,"February 25, 2020","UCLA Neuropsychiatric Institute & Hospital, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00229450"
2282,"NCT00762866","Psychiatric Genotype/Phenotype Project Repository","PGPP","Enrolling by invitation","No Results Available","Depressive Disorder, Major|Bipolar Disorder|Psychotic Disorders",,"Brain volume","Vanderbilt University|Vanderbilt University Medical Center","All","16 Years to 65 Years   (Child, Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","080606","September 2008","December 2025","December 2027","September 30, 2008",,"December 2, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00762866"
2283,"NCT01744041","Mommy-Baby Treatment for Perinatal Depression",,"Completed","No Results Available","Depressive Disorder, Major|Postpartum Depression","Behavioral: Dyadic Interpersonal Psychotherapy|Other: Enhanced Treatment as Usual","Change in Edinburgh Depression Scale from Baseline","Washington University School of Medicine|National Institute of Mental Health (NIMH)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201203136|K23MH090245","November 2012","January 31, 2017","January 31, 2017","December 6, 2012",,"March 10, 2017","Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01744041"
2284,"NCT03674671","Ketamine Versus Electroconvulsive Therapy in Depression",,"Recruiting","No Results Available","Depressive Disorder, Major|Bipolar Depression","Drug: Intravenous Ketamine|Procedure: Electroconvulsive Therapy","Montgomery-Asberg Depression Rating Scale","University of Ottawa|McGill University|Queen's University|University Health Network, Toronto","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","REB2018007","October 29, 2018","March 2023","March 2023","September 17, 2018",,"April 19, 2021","Providence Care Hospital, Kingston, Ontario, Canada|Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Douglas Mental Health University Institute, Verdun, Ontario, Canada|Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03674671"
2285,"NCT03758495","Rescuing the Ruminating Brain: Identifying Biomarkers of Rumination and Mindfulness Through Concurrent EEG and Functional Magnetic Resonance Imaging (fMRI) Studies of Schizophrenia and Depression",,"Withdrawn","No Results Available","Schizophrenia|Depressive Disorder, Major","Other: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)","Electroencephalography (EEG)|Magnetic Resonance Imaging (MRI)|Memory and Attention task","VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)",,"0","U.S. Fed","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","MHBB-012-17S|CX000497","November 1, 2018","November 2, 2018","November 2, 2018","November 29, 2018",,"January 10, 2019","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03758495"
2286,"NCT03283670","Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies","NARSAD","Completed","No Results Available","Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant","Drug: Nitrous Oxide 25%|Drug: Nitrous Oxide 50%|Drug: Placebo Gas","Change in depression symptoms measured by the Hamilton Depression Rating Scale- 21 items","Washington University School of Medicine|Brain & Behavior Research Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201608024","November 22, 2016","February 18, 2020","February 18, 2020","September 14, 2017",,"April 27, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03283670"
2287,"NCT02983318","Molecular Imaging of Brain Inflammation in Depressive Disorders","DiME","Completed","No Results Available","Depressive Disorder, Major|Positron-Emission Tomography",,"inflammation-related excitotoxicity in the brain","Lawson Health Research Institute","All","19 Years to 105 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","100128","August 28, 2017","March 20, 2019","December 31, 2019","December 6, 2016",,"April 9, 2020","St Joseph's Hospital, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02983318"
2288,"NCT03121937","Feasibility of a Technology-Based Treatment Support System",,"Terminated","No Results Available","Depression|Depressive Disorder, Major","Behavioral: Mobile App","Retention|Adherence|Satisfaction|Depression","Northwestern University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00097492|K08MH102336","August 1, 2017","June 30, 2018","June 30, 2018","April 20, 2017",,"October 10, 2018","Amita Health, Arlington Heights, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03121937"
2289,"NCT00531258","TMS in the Treatment of the Sequelae of Closed Brain Injury",,"Completed","No Results Available","Depression|Closed Head Injury","Device: rTMS|Device: Sham rTMS","Depression Symptom Severity|Cognitive Tasks","Bayside Health","All","18 Years to 60 Years   (Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","011007","January 2008","May 2015","May 2015","September 18, 2007",,"October 14, 2020","Alfred Psychiatry Research Centre, Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00531258"
2290,"NCT03756129","Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression",,"Completed","Has Results","Depressive Disorder, Treatment-Resistant","Drug: MIJ821|Drug: Placebo|Drug: Ketamine","Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at 24 Hrs|Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at 48 Hrs|Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at Week 6|Change From Baseline in the Young Mania Rating Scale|Bech-Rafaelsen Melancholia Scale|PK Properties of MIJ821 in Plasma - Cmax (ng/mL)|PK Properties of MIJ821 in Plasma - Tmax (ng/mL)|PK Properties of MIJ821 in Plasma - AUClast (h*ng/mL)|PK Properties of MIJ821 in Plasma - AUC0-24h (h*ng/mL)|Change From Baseline in the CORE Melancholia Total Scale|Summary of Adverse Events|Clinician-Administered Dissociative States Scale|Change From Baseline in the Dissociative Experiences Total Score|Sheehan Suicidality Tracking Scale - (SSTS)|Percentage of Participants With Treatment Remissions (MADRS<7)|Change From Baseline in the Total Hamilton Anxiety Scale|Summary Statistics of Total Hamilton Anxiety Scale - Change From Baseline|Change From Baseline in the Total Koukopoulos Mixed Depression Rating Scale|Responders (>50% Improvement in Bech-Rafaelsen Melancholia Scale) and Melancholia and Mixed Depression Checklist Factor.","Novartis Pharmaceuticals|Novartis","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMIJ821X2201","February 8, 2019","March 23, 2020","March 23, 2020","November 28, 2018","May 19, 2021","May 19, 2021","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Garden Grove, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Berlin, New Jersey, United States|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Vitoria-Gasteiz, Pais Vasco, Spain|Novartis Investigative Site, Barcelona, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03756129/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03756129/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03756129"
2291,"NCT04770454","A Multicenter, Prospective, Non-interventional Observational Study to Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspar® Tab (Buspirone) in Patients With Depression in Korea","BASIS","Recruiting","No Results Available","Depressive Disorder, Major|Anxiety Disorders","Drug: Buspiron","The HAM-A score|The HAM-D score|The CGI-S score|The CGI-I score|The SDS score|The WHO-5 score","Boryung Pharmaceutical Co., Ltd","All","19 Years and older   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BR-BPR-OS-401","February 8, 2021","June 1, 2022","July 1, 2022","February 25, 2021",,"February 25, 2021","the Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, JongRo, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04770454"
2292,"NCT02741622","Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.",,"Completed","No Results Available","Depressive Disorder|Depressive Disorder, Major","Behavioral: High aerobic intensity training (HIT)|Behavioral: Long slow distance training (LSD)","Change in serum brain derived neurotropic factor (BDNF)|Change in affective symptoms|Change in state of anxiety.|Change in subjective exercise experience|Maximal oxygen uptake|Maximal Heart rate","St. Olavs Hospital|Norwegian University of Science and Technology","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015/2230","March 2016","December 2016","December 2016","April 18, 2016",,"December 4, 2018","St.Olavs university Hospital, Departement of Østmarka, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT02741622"
2293,"NCT02740296","Depression and Immune Function in Multiple Sclerosis (MS)","DENIM","Completed","No Results Available","Multiple Sclerosis|Depressive Disorder, Major","Other: No intervention","Beck Depression Inventory - II","Charite University, Berlin, Germany|National Multiple Sclerosis Society|Universitätsklinikum Hamburg-Eppendorf|NeuroCure Clinical Research Center, Charite, Berlin","All","18 Years to 55 Years   (Adult)",,"104","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","DENIM","November 2015","June 2017","June 2017","April 15, 2016",,"July 29, 2021","Charité - Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02740296"
2294,"NCT01583400","Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial",,"Completed","No Results Available","Depressive Disorder, Major|Depressive Disorder, Minor|Dysthymic Disorder","Other: RESPECT-D|Other: RESPECT-D-E (Enhanced)","Change in Score of Hamilton Rating Scale for Depression (HAM-D)|Change in Score of Hopkins Symptom Checklist-20 (HSCL-20)","Dartmouth-Hitchcock Medical Center|Johnson & Johnson","All","18 Years and older   (Adult, Older Adult)","Not Applicable","131","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CPHS#22616, W&P-PCMH-01","September 2011","October 2013","October 2013","April 24, 2012",,"September 18, 2014","Family Medicine Clinics, Cheshire Medical Center (DH-Keene), Keene, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT01583400"
2295,"NCT00094432","A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode",,"Completed","No Results Available","Bipolar I Disorder","Drug: Aripiprazole|Drug: Placebo","Mean change from baseline to endpoint on the MADRS total score.|Clinical Global Impression - Bipolar Version|Severity of illness score depression|Mean change from baseline to endpoint","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","650","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CN138-146","June 2004","November 2006","November 2006","October 19, 2004",,"November 11, 2013","Local Institution, Mesa, Arizona, United States|Local Institution, La Mesa, California, United States|Local Institution, La Palma, California, United States|Local Institution, Long Beach, California, United States|Local Institution, Redlands, California, United States|Local Institution, San Diego, California, United States|Local Institution, Sherman Oaks, California, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Coral Springs, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, St. Petersburg, Florida, United States|Local Institution, Marietta, Georgia, United States|Local Institution, Edwardsville, Illinois, United States|Local Institution, Oak Brook, Illinois, United States|Local Institution, Springfield, Illinois, United States|Local Institution, Lafayette, Indiana, United States|Local Institution, Newton, Kansas, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Clementon, New Jersey, United States|Local Institution, Alburquerque, New Mexico, United States|Local Institution, Brooklyn, New York, United States|Local Institution, Elmsford, New York, United States|Local Institution, New York, New York, United States|Local Institution, Raleigh, North Carolina, United States|Local Institution, Dayton, Ohio, United States|Local Institution, Media, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Columbia, South Carolina, United States|Local Institution, Desoto, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Wichita Falls, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Midlothian, Virginia, United States|Local Institution, Bellevue, Washington, United States|Local Institution, Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00094432"
2296,"NCT00763230","A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression",,"Completed","No Results Available","Depressive Disorder, Major|Bipolar Disorder","Device: Transcranial direct current stimulation","Montgomery Asberg Depression Rating Scale for Depression (MADRS)|Inventory of Depressive Symptomatology (IDS-C)|Quick Inventory of Depressive Symptomatology - Self rated (QIDS-SR)","The University of New South Wales","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","07305|NHMRC (Australia)","April 2008","January 2011","January 2011","September 30, 2008",,"May 2, 2011","Black Dog Institute, University of New South Wales, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT00763230"
2297,"NCT03701724","Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression","ACOUSTIM","Recruiting","No Results Available","Treatment-resistant Depression","Device: Systematic maintenance rTMS|Device: rTMS course in case of relapse|Device: sham rTMS","Cost-utility ratio, according to collective perspective of rTMS use in TRD compared to conventional therapeutic approaches without active rTMS.|Budget impact analysis of spreading the most efficient strategy for using rTMS (systematic mTMS or rTMS course in case of relapse).|Major depressive disorder history|Level of depression treatment-resistance|professional status|marital status|Response rate|Remission rate|Relapse-free survival|MADRS score|Beck Depression Inventory (BDI) score|Clinical Global Impression (CGI) score|Adverse events linked to the medical treatment for depression|Declarative drug compliance via the MARS (Medication Adherence Report Scale)|Declarative drug compliance via the CRS (Clinician Rating Scale)|Treatment(s) switch(es)|Treatment(s) dose increase|Treatments combination(s)|Rate of suicide attempts and suicides|Patient's quality of life|Response rate at the end of rTMS courses|Remission rate at the end of rTMS courses|Number of days between the successive rTMS courses|Total number of rTMS sessions|Time between relapses|Compliance with rTMS|Patient acceptability of the rTMS technique: Analog Visual Scale","Nantes University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","318","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","RC17_0494","November 5, 2018","December 15, 2022","December 30, 2023","October 10, 2018",,"July 28, 2021","CHU d'Angers, Angers, France|CHRU de Besançon, Besançon, France|CH le Vinatier Lyon, Bron, France|CHU de Caen, Caen, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Dijon, Dijon, France|Clinique de Vontes, Esvre-sur-Indre, France|EPSM de Lille, Lille, France|CH Esquirol - Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|Nantes University Hospital, Nantes, France|EPS de Ville-Evrard, Neuilly-sur-Marne, France|GH PItié Salpétrière, Paris, France|GHU Psychiatrie Ste Anne, Paris, France|CH Henri Laborit (Poitiers), Poitiers, France|Centre hospitalier Guillaume Regnier Rennes, Rennes, France|CH du Rouvray - Rouen, Rouen, France|CHU de Toulouse, Toulouse, France|CHU de Tours / CHRU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT03701724"
2298,"NCT00895258","Cognitive Training to Improve Work Outcomes in Severe Mental Illness",,"Completed","No Results Available","Schizophrenia|Bipolar Disorder|Depression","Behavioral: Individual placement and support plus cognitive training (IPS-CT)|Behavioral: Individual placement and support plus enhanced support (IPS-ES)","Weeks worked|Cognition, based on the extended Measurement And Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery|Functioning","University of California, San Diego|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","163","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH080150|DSIR 82-SEDX","April 2008","March 2014","March 2014","May 8, 2009",,"June 19, 2014","UCSD Outpatient Psychiatric Services, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00895258"
2299,"NCT03995914","Depression and Major Adverse Events in Older Patients Who Undergo a Transcatheter Aortic Valve Implantation","TAVIDEP","Withdrawn","No Results Available","Depression|Aortic Stenosis",,"Number of Incidence of MACCEs|Number of Death|Number of hospitalization|Katz Index of Independence in Activities of Daily Living|The Lawton Instrumental Activities of Daily Living (IADL) Scale|Rate of depression|Compliance of anti-depressant drugs prescribed|Effects of anti-depressant drugs prescribed on the Health","University Hospital, Montpellier","All","75 Years and older   (Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL19_0295","June 1, 2019","June 1, 2019","June 30, 2019","June 24, 2019",,"November 19, 2019",,,"https://ClinicalTrials.gov/show/NCT03995914"
2300,"NCT00223288","Impact of Caregiver Depression on Asthma in the Child",,"Completed","No Results Available","Depressive Disorder, Major|Asthma","Drug: Lexapro",,"University of Texas Southwestern Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)",,"175","Other","Observational",,"MHGP MM12","March 2003","February 2006","February 2006","September 22, 2005",,"August 3, 2011","The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00223288"
2301,"NCT00201474","Acute, Affective, Organic Disorders.",,"Completed","No Results Available","Depressive Disorders",,"epilepsy or an other organic brain disorder","Norwegian University of Science and Technology|St. Olavs Hospital|Dr. Dedichens Institute for Psychiatric Research, Oslo, Norway.|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)",,"32","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AEV-98","October 1998","October 2004","June 2010","September 20, 2005",,"August 4, 2016","Østmarka Psychiatric Department, St. Olavs Hospital, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT00201474"
2302,"NCT04057378","Optimal Electrical Stimulus During Electroconvulsive Therapy",,"Recruiting","No Results Available","Depressive Disorder, Major|Depression, Bipolar","Device: Electroconvulsive therapy","Remission|Self rated health status|Subjective memory|Antidepressive response|Number of sessions|readmission and suicide|remission rate","Region Örebro County","All","18 Years and older   (Adult, Older Adult)","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","269391","October 30, 2019","November 15, 2022","November 15, 2024","August 15, 2019",,"October 14, 2020","University hospital Örebro, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT04057378"
2303,"NCT02370576","The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology",,"Unknown status","No Results Available","Stress Disorders, Post-Traumatic|Depressive Disorder, Major","Other: rating scale application","Presence or absence of PTSD (Questionnaire/ rating scale application)|Presence or absence of major depression (Questionnaire/ rating scale application)|Presence or absence of anxiety disorders (Questionnaire/ rating scale application)","Rambam Health Care Campus","Female","18 Years to 45 Years   (Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","rambam001","March 2015","March 2017","March 2018","February 25, 2015",,"February 25, 2015","Rambam Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT02370576"
2304,"NCT03489122","A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans",,"Active, not recruiting","No Results Available","Depressive Disorder, Major|Post Traumatic Stress Disorder","Behavioral: yoga|Behavioral: walking","Hamilton Depression Rating Scales Change|Gamma Amino Butyric Acid (GABA) Change","VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","84","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MHBB-001-17S","January 27, 2020","March 30, 2023","September 30, 2023","April 5, 2018",,"January 25, 2021","Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03489122"
2305,"NCT04977674","Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","GO-MARK","Not yet recruiting","No Results Available","Depressive Disorder, Treatment-Resistant","Drug: Naltrexone|Drug: Placebo|Drug: Ketamine","Change in Glutamate|Change in Resting State Functional Connectivity|Change in Cerebral Blood Flow","King's College London","All","18 Years to 50 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","MR/T028084/1","August 2021","May 2023","May 2023","July 27, 2021",,"July 27, 2021","King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04977674"
2306,"NCT03323073","Study of Functional Networks in Resting fMRI","DEPIMAGE","Terminated","No Results Available","Acute Depression|Major Depressive Episode","Other: Resting state fMRI","Bold signal and connectivity coefficients within and between neural networks|Correlations between clinical scores (MADRS, YMRS, SCID) and neural network connectivity.|Sensibility and specificity of fMRI to predict unipolar and bipolar depressive status","Assistance Publique - Hôpitaux de Paris|FoundaMental Mental Health Foundation RTRS (France)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","P100144","December 14, 2011","November 18, 2014","June 2017","October 26, 2017",,"October 31, 2017",,,"https://ClinicalTrials.gov/show/NCT03323073"
2307,"NCT00218556","Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1",,"Completed","No Results Available","Depressive Disorder, Major|Hepatitis C","Behavioral: Cognitive behavioral treatment for depression","depression-related antiviral treatment failure","National Institute on Drug Abuse (NIDA)|Rhode Island Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","42","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","NIDA-16797-1|R01-16797-1","January 2004","June 2008","June 2008","September 22, 2005",,"January 12, 2017","Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00218556"
2308,"NCT01913535","Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression","RAPID KOR","Terminated","Has Results","Treatment Resistant Depression","Drug: CERC-501|Drug: Placebo","Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)|Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6), Day 20|Number of Participants With Response on Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Clinical Global Impression -Severity (CGI-S)|Clinical Global Impression-Improvement (CGI-I)|Change in Symptoms of Depression Questionnaire (SDQ)|Change in Perceived Stress Scale (PSS)|Change in Positive Affect Scale (PAS)|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Satisfaction With Participation in Social Roles and Discretionary Activities|Change in the Columbia-Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Clinically Significant Abnormal ECG|Number of Participants With Clinically Significant Abnormal Labs","Massachusetts General Hospital|National Institute of Mental Health (NIMH)|Butler Hospital|Rush University|Temple University|University of Kansas","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","8","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-002|271201100006I-0-27100007-1","September 12, 2013","January 22, 2016","January 22, 2016","August 1, 2013","July 2, 2017","July 2, 2017","Rush University, Chicago, Illinois, United States|University of Kansas, Wichita, Kansas, United States|Temple University, Philadelphia, Pennsylvania, United States|Brown University-Butler Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01913535"
2309,"NCT02715986","Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy","ECT-IM","Completed","No Results Available","Severe Depression","Device: 3T MRI","Morphological changes in the hippocampus between baseline and after the first ECT effective session as assessed by volume measure in multimodal MRI.|Functional connectivity changes of the hippocampus-related networks between baseline and after the first effective ECT session as assessed by measure of connectivity in multimodal MRI.|Morphological changes of the hippocampus-related networks between baseline and after the first ECT session as assessed by measure of volume in multimodal MRI.|Morphological changes of the hippocampus-related networks between baseline and after the first ECT session as assessed by average diffusivity in multimodal MRI.|Functional changes of the hippocampal-related networks between baseline and after the first ECT session as assessed by measure of connectivity in multimodal MRI.|Morphological changes in the hippocampus and hippocampal-related networks related to ECT between baseline and after remission as assessed by measure of volume in multimodal MRI|Morphological changes in the hippocampus and hippocampal-related networks related to ECT between baseline and after remission as assessed by|Functional changes in the hippocampus and hippocampal-related networks related to ECT after remission as assessed by measure of connectivity in multimodal MRI.|Evolution of Real Life/Real Impact-16 (RLRI-16) score after the first ECT, after ECT first ""effective"" and after remission|Changes in the intensity of depressive symptoms score (Hamilton Depression Rating Scale) after the first ECT, ECT first ""effective"" and after remission","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC31/15/7733|15 7733 02","April 2016","July 2018","July 2018","March 22, 2016",,"July 29, 2020","CHU Toulouse, Hôpital de psychiatrie, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02715986"
2310,"NCT00026832","Examination of Brain Serotonin Receptors in Patients With Mood Disorders",,"Completed","No Results Available","Mood Disorder|Bipolar Disorder|Depression",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)",,"214","NIH","Observational",,"020047|02-M-0047","October 4, 2001",,"November 27, 2012","November 15, 2001",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00026832"
2311,"NCT01801319","A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression",,"Unknown status","No Results Available","Treatment Resistant Depression|Depressive Disorder","Device: Libra Deep Brain Stimulation System","Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17|The incidence of all adverse events|Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD","Abbott Medical Devices","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-08-07|Health Canada 148956","June 2011","June 2017","December 2017","February 28, 2013",,"April 26, 2017","Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01801319"
2312,"NCT00564278","Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression",,"Completed","Has Results","Depression","Drug: Standard antidepressant therapy (SADT)|Behavioral: Motivational antidepressant therapy (MADT)","Number of Days in ADT (Retention)|Mean of Depressive Symptoms Over 36-week Follow-up Using Hamilton Depression Scale -17-item Version (Symptoms)|Mean Disability Over 36-week Follow-up Using Sheehan Disability Scale (Impairment)|Mean Perceived Quality of Life Over 36-week Follow-up Using Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)|Mean Patient Satisfaction Over 36-week Follow-up Using Client Satisfaction Questionnaire (CSQ)|Proportion of Fully Adherent Days","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 79 Years   (Adult, Older Adult)","Not Applicable","217","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","#5516/#6609R|R01MH077226|DSIR 82-SESC","February 2008","August 2013","August 2013","November 27, 2007","March 10, 2016","May 19, 2021","New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00564278"
2313,"NCT00001543","Dynamics of Leptin and Endocrine Function",,"Completed","No Results Available","Healthy|Involutional Depression",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"230","NIH","Observational",,"960048|96-M-0048","March 1996",,"June 2002","November 4, 1999",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001543"
2314,"NCT02942004","A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)",,"Completed","Has Results","Postpartum Depression","Drug: Placebo|Drug: SAGE-547 60 μg/kg/h|Drug: SAGE-547 90 μg/kg/h","Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score|Change From Baseline in HAM-D Total Score at Day 30|Change From Baseline in HAM-D Total Score|Percentage of Participants With HAM-D Response|Percentage of Participants With HAM-D Remission|Change From Baseline in HAM-D Bech 6 Subscale|Change From Baseline in HAM-D Individual Item Scores|Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response|Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score|Percentage of Participants With Treatment-Emergent Adverse Events|Time to Change in Antidepressant Medication","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 3","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","547-PPD-202 B","August 1, 2016","September 24, 2017","October 19, 2017","October 21, 2016","June 13, 2019","June 13, 2019","Sage Investigational Site, Chandler, Arizona, United States|Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Ventura, California, United States|Sage Investigational Site, Gainesville, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Miramar, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Pinellas Park, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Hoffman Estates, Illinois, United States|Sage Investigational Site, Wichita, Kansas, United States|Sage Investigational Site, Edgewood, Kentucky, United States|Sage Investigational Site, Owensboro, Kentucky, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Glen Oaks, New York, United States|Sage Investigational Site, Chapel Hill, North Carolina, United States|Sage Investigational Site, Charlotte, North Carolina, United States|Sage Investigational Site, Raleigh, North Carolina, United States|Sage Investigational Site, Columbus, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, Philadelphia, Pennsylvania, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Orem, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02942004/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02942004/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02942004"
2315,"NCT00612313","Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse",,"Completed","Has Results","Depression","Drug: Fluoxetine|Behavioral: Relapse prevention cognitive behavioral therapy (CBT)","Time to Remission|Relapse|Remission|K-Life (Time Well)","University of Texas Southwestern Medical Center|National Institute of Mental Health (NIMH)","All","8 Years to 17 Years   (Child)","Not Applicable","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01MH039188-01|DSIR 84-CTS","February 2008","February 2013","January 2014","February 11, 2008","December 17, 2014","January 7, 2016","Children's Medical Center of Dallas, Outpatient Psychiatry Clinic, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00612313"
2316,"NCT01560728","Bringing What Works to Youth in Corrections: A Trauma Intervention",,"Completed","No Results Available","Post-Traumatic Stress Disorder","Behavioral: Trauma-Focused Cognitive Behavioral Therapy","Rate of change in UCLA PTSD Reaction Index (UCLA PTSD RI) Trauma Symptom Severity|Rate of change in Child Behavioral Checklist Youth Self-Report Total Score","University of Texas at Austin|National Institute of Mental Health (NIMH)","All","13 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","57","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R34MH095210-01","November 2012","July 2015","July 2015","March 22, 2012",,"March 17, 2016","Ron Jackson State Juvenile Correctional Facility, Brownwood, Texas, United States|Giddings State School, Giddings, Texas, United States|McClennan County State Juvenile Correctional Facility, Mart, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01560728"
2317,"NCT00384020","Clinical Pharmacogenomics of Antidepressant Response",,"Completed","No Results Available","Depression","Drug: Paroxetine (Seroxat)|Drug: Escitalopram (Lexapro)",,"National Health Research Institutes, Taiwan|National Science Council, Taiwan|Chang Gung Memorial Hospital|Taipei Medical University WanFang Hospital|Taipei City Hospital|Mackay Memorial Hospital","All","18 Years and older   (Adult, Older Adult)",,"402","Other","Observational","Observational Model: Case-Only","MD-095-PP-01|NSC 95-2314-B-400-001","January 2006","January 2010","January 2010","October 4, 2006",,"February 1, 2010","Song-De Branch, Taipei City Hospital, Taipei, Taiwan|Municipal Wan Fang Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00384020"
2318,"NCT00344682","Memantine Augmentation of Antidepressants",,"Completed","Has Results","Depressive Disorder","Drug: memantine|Drug: Placebo","Montgomery-Asberg Depression Rating Score (MADRS)|Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)|Hamilton Anxiety Rating Scale (HARS)","University of Massachusetts, Worcester|Forest Laboratories","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NAM-MD-34","June 2006","December 2011","December 2011","June 27, 2006","November 25, 2013","July 11, 2018","Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School), Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00344682"
2319,"NCT00192751","From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management",,"Unknown status","No Results Available","Patients Diagnosed With Severe Mental Illness","Behavioral: Psychoeducational group sessions","Relapse prevention|Illness management|Satisfaction with care","Rambam Health Care Campus","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","compliance_CTIL","February 2004",,"December 2006","September 19, 2005",,"October 27, 2005","Department of Psychiatry, Rambam Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT00192751"
2320,"NCT03693105","The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition",,"Not yet recruiting","No Results Available","Depressive Disorder, Major|Suicide","Device: Accelerated theta burst stimulation|Device: Sham stimulation","Change in the neural network underlying Explicit Suicidal Cognition (ESC) as measured by resting state functional connectivity changes in subgenual anterior cingulate (sgACC) and the default mode network (DMN).|Change in the neural network underlying Implicit Suicidal Cognition (ISC) as measured by resting state functional connectivity changes in dorsolateral prefrontal cortex (DLPFC) and the anterior cingulate cortex (ACC).|Change in the neural networks underlying hopelessness as measured by resting state functional connectivity changes of sgACC and medial orbitofrontal cortex (mOFC).|Change in the neural networks underlying anhedonia as measured by resting state functional connectivity changes of ACC and DMN.","Stanford University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","47771","September 2020","September 2025","September 2025","October 2, 2018",,"September 3, 2020","Stanford Hospital, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03693105"
2321,"NCT03605524","Olfactory Training and Emotional State","ENOLFEA","Recruiting","No Results Available","Depressive Symptoms|Depressive Disorder, Major","Other: Sensory training","Change from Baseline Olfactory Perception at 3 months|Emotional perception measured Sense'n Feel Method|Emotional perception measured with SMI RED-m Scientific device|Psychometric scale MINI : Psychiatric disorders exploration|Psychometric scale TAS-20 : alexithymia assessment|Psychometric scale STAI-Y : anxiety assessment|Psychometric scale SHAPS : anhedonia assessment|Psychometric scale QIDS-SR16 : Depression assessment","University Hospital, Tours","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PHAO17-WEH/ENOLFEA|2018-A00653-52|2018.05.02","August 28, 2018","November 2022","November 2022","July 30, 2018",,"April 19, 2021","UMR 1253 IBrain, University, Tours, Tours, France|University Psychiatric Clinic,University Hospital, Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT03605524"
2322,"NCT02543983","Neurobiology of Suicide",,"Recruiting","No Results Available","Healthy Volunteers|Depression","Drug: Ketamine","Study as Whole: Psychiatric, psychological, neuroimaging, sleep and biological differences between participants in Groups 1, 2, 3, 4, and 5|Phase II: Scale for Suicide Ideation|Phase II: Montgomery-Asberg Depression Rating Scale|Phase II: Hamilton Psychiatric Rating Scale for Anxiety|Phase II: Clinical Global Impression Scale|Anhedonia and Hopelessness via the Snaith-Hamilton Pleasure Scale &amp; the Beck Hopelessness Scale|Baseline and Response Biomarkers","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","325","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","150188|15-M-0188","December 1, 2015","July 21, 2021","July 21, 2021","September 9, 2015",,"August 2, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02543983"
2323,"NCT00027378","Pharmacological Intervention Project (Fluoxetine)","FIDAA","Completed","Has Results","Alcoholism|Depression","Drug: fluoxetine (Prozac)|Drug: Placebo plus Treatment As Usual","Alcohol Use Behaviors|Depressive Symptoms","University of Pittsburgh|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","15 Years to 20 Years   (Child, Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NIAAACOR13370|R01AA015173|R01AA013370|AA-13370","July 2001","June 2007","June 2008","December 5, 2001","July 18, 2013","July 18, 2013","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00027378"
2324,"NCT03040388","Exploring Effects of Electroconvulsive Therapy on the Human Brain in Depression - The Danish ECT/MRI Study",,"Completed","No Results Available","Depressive Disorder|Depression|Depressive Disorder, Major",,"Volumetric changes in the hippocampus.|Changes in BDNF concentration in the blood.|Changes in regional cerebral blood flow (rCBF) in the frontal lobes.|The number of WMLs in the brain.|Changes in water diffusion in the brain.|Changes in the level of fractional anisotropy (FA) in the brain.|Changes in the level of intrinsic connectivity pattern in fronto-limbic pathways in the brain.|Changes in the glucose metabolism in the brain.|Changes in blood-brain barrier (BBB) permeability.|Changes in S100B-protein concentration in the blood.","University of Copenhagen|Mental Health Centre Glostrup|Glostrup University Hospital, Copenhagen|Mental Health Centre Amager|Mental Health Centre Copenhagen","All","18 Years to 95 Years   (Adult, Older Adult)",,"26","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK-ECT-MR-1","August 9, 2017","October 30, 2019","June 11, 2020","February 2, 2017",,"September 22, 2020","Mental Health Centre Glostrup, Glostrup, The Capital Region, Denmark",,"https://ClinicalTrials.gov/show/NCT03040388"
2325,"NCT01899716","Exercise and Severe Depression: Clinical and Biological Analysis",,"Completed","No Results Available","Depression","Other: Exercise","Depressive symptoms|Quality of Life|Brain-Derived Neurotrophic Factor(BDNF)|Thiobarbituric acid reactive substances(TBARS)|Depressive symptoms at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)","Hospital de Clinicas de Porto Alegre","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","07-438","January 2008","December 2012","December 2012","July 15, 2013",,"December 30, 2013","Hospital de Clincas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT01899716"
2326,"NCT01869374","Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults","MSTvsEST","Completed","Has Results","Depression|Major Depressive Episode|Bipolar Disorder","Device: MagVenture MagPro MST|Biological: RUL ECT","Hamilton Rating Scale for Depression, 24-Item (HRSD-24)","New York State Psychiatric Institute","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","6427","August 2012","July 2017","August 2020","June 5, 2013","June 19, 2020","September 3, 2020","New York State Psychiatric Institute, New York, New York, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01869374/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01869374/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01869374"
2327,"NCT03752853","Stress Systems and Psychotherapy in Depression","Bio-COPE","Completed","No Results Available","Major Depressive Episode","Behavioral: internet-based intervention for mild to moderate depression","Changes in salivary cortisol concentration|Differences in salivary cortisol concentration|Changes in salivary alpha-amylase concentration|Differences in salivary alpha-amylase concentration|Changes in hair cortisol concentration|Differences in hair cortisol concentration|Sleep quality (self-report)|Chronic stress (self-report)|Cognitive biases (self-report)","Freie Universität Berlin","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Stress_DEP","November 20, 2018","August 6, 2020","August 6, 2020","November 26, 2018",,"October 23, 2020","Freie Universitaet Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03752853"
2328,"NCT03906149","Whole-body Hyperthermia for Moderate to Severe Depressive Disorder","HYPE2","Recruiting","No Results Available","Depression, Unipolar","Combination Product: Whole-body hyperthermia + standard medical care|Combination Product: Standard medical care","Depression Severity: clinician-rated|Depression Severity: patient-rated|Global improvement: clinician-rated|Global Functioning: clinician-rated|Fatigue: patient-rated|Stress: patient-rated|Quality of Life: patient-rated|Biomarkers: interleukin 2|Biomarkers: interleukin 6|Biomarkers: interleukin 10|Biomarkers: tumor necrosis factor-alpha|Biomarkers: high-sensitivity C-reactive Protein|Biomarkers: soluble intercellular adhesion molecule-1|Biomarkers: tryptophan|Biomarkers: kynurenine|Biomarkers: neopterin|Adverse Events","Universität Duisburg-Essen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18-8440-BO","July 1, 2019","December 2021","June 2022","April 8, 2019",,"November 5, 2020","Department of Psychiatry, Psychotherapy and Addiciton Medicine, Kliniken Essen-Mitte, Essen, Germany",,"https://ClinicalTrials.gov/show/NCT03906149"
2329,"NCT01507181","Ketamine For Suicidal Ideation",,"Completed","Has Results","Suicidal Ideation","Drug: Ketamine|Drug: Midazolam","Change in Beck Scale for Suicidal Ideation (BSSI)|Montgomery-Asberg Depression Rating Scale (MADRS)|Suicidality Item of the MADRS (MADRS-SI)|The Young Mania Rating Scale (YMRS)|The Brief Psychiatric Rating Scale (BPRS)|The Clinician-Administered Dissociative States Scale (CADSS)|Patient Rated Inventory of Side Effects (PRISE)","James Murrough|Icahn School of Medicine at Mount Sinai","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 10-1589","January 2012","September 2014","September 2014","January 10, 2012","February 8, 2017","February 8, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01507181"
2330,"NCT01809340","The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression",,"Terminated","No Results Available","Depressive Disorder","Drug: Minocycline|Drug: Placebo|Drug: Ketamine","Proportion of patients (among responders) who survive relapse-free|Change in MADRS total score among non-responders from pre-randomization to end-of-study|Change in the MADRS total score from baseline during IV ketamine treatment phase|Change in the MADRS total score from baseline after IV ketamine treatment phase|Response (reduction ≥ 50% in MADRS total score relative to baseline) rate during IV ketamine treatment phase|Time to relapse (among responders) following completion of the IV ketamine infusion schedule and after first dose of minocycline/placebo|Change in C-SSRS from baseline to any time in the study","Janssen Research & Development, LLC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR100957|KETIVEDI2001|2012-002954-21","June 2013","July 2014","July 2014","March 12, 2013",,"June 30, 2015","Duffel, Belgium|Lede, Belgium|Leuven, Belgium|Besancon, France|Clermont Ferrand, France|Nimes Cedex 9, France|Leiden, Netherlands|Alicante, Spain|Barcelona, Spain|Coslada, Spain|Madrid, Spain|Zamora, Spain",,"https://ClinicalTrials.gov/show/NCT01809340"
2331,"NCT02962154","Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment","NIRVANA","Withdrawn","No Results Available","Ischemia|Stress, Mental","Radiation: Coronary CT Angiography|Other: Mood Symptom Scale|Other: Anxiety Symptom Scale|Other: Chronic Stress Inventories|Other: Psychosocial Function Questionnaires|Other: General Health and quality of life questionnaires|Other: Magnetic Resonance Imaging","Prevalence of mental stress induced ischemia as measured by cardiac MRI|Change in cardiac stress perfusion as measured by cardiac MRI (pre and post mental stress)","Weill Medical College of Cornell University","All","50 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1405015093","February 2016","January 2018","January 2018","November 11, 2016",,"January 9, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02962154"
2332,"NCT00628888","A Waitlist-Controlled Trial of the Unified Protocol for the Treatment of Emotional Disorders in Adolescents",,"Completed","No Results Available","Anxiety Disorders|Depression","Behavioral: Unified Protocol for Adolescents (UP-A)","Clinical Severity Rating (CSR) on the Anxiety Disorders Interview Schedule for DSM-IV, child and parent versions (ADIS-IV-C/P)|Treatment gains and overall patient functioning measured by: Clinical Global Impression Scale(CGI)|Emotion Regulation indices|Changes in Anxiety and Depressive symptomology assessed by the CBCL and RCADS (parent and child version)","University of Miami|National Institute of Mental Health (NIMH)","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","51","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","K23MH073946|DDTR BK-TKPD","July 2006","September 2012","September 2012","March 5, 2008",,"December 19, 2014","Child and Adolescent Mood and Anxiety Treatment (CAMAT) Program, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00628888"
2333,"NCT00524420","Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain",,"Completed","Has Results","Fibromyalgia|Chronic Pain|Depression","Device: rTMS|Device: Sham rTMS","Gracely Box Intensity Rating Scale|Gracely Box Unpleasantness Scale|Hamilton Depression Rating Scale|Adverse Events","University of Washington|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","32656-D|R21AR053963|1R21AR053963-01|06-2407-D 01","February 2008","December 2010","December 2010","September 3, 2007","May 23, 2013","May 23, 2013","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00524420"
2334,"NCT00666757","A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression","TRY FIRST","Completed","Has Results","Depression","Drug: duloxetine|Drug: fluoxetine|Drug: citalopram|Drug: paroxetine|Drug: sertraline","Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]|Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)|Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]|Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]|Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]|Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)|Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)|Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)|Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint|Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint|Change From Baseline in Pulse Rate at Week-12 Endpoint|Change From Baseline in Weight at Week-12 Endpoint","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11715|F1J-US-HMFT","May 2008","February 2009","March 2009","April 25, 2008","June 15, 2010","June 15, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torrance, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pueblo, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clearwater, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deerfield Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hialeah, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winter Park, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joliet, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oak Brook, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Park Ridge, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenwood, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terre Haute, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaithersburg, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Burnie, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fall River, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clementon, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Princeton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooklyn, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresh Meadows, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Kisco, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kettering, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Havertown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newtown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Friendswood, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodstock, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlottesville, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herndon, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00666757"
2335,"NCT01692236","Brain Imaging for HIV-Associated Thinking and Mood Disorders",,"Terminated","No Results Available","Human Immunodeficiency Virus|Neurocognitive Impairment",,"Neuropsychologic testing scores|Serum biomarkers of cardiovascular disease and inflammation|MRI brain and vascular findings","National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)","All","25 Years to 61 Years   (Adult)",,"84","NIH","Observational","Time Perspective: Prospective","120200|12-CC-0200","September 13, 2012",,"April 4, 2018","September 25, 2012",,"December 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01692236"
2336,"NCT00494650","Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses",,"Completed","No Results Available","Post-Traumatic Stress Disorder","Behavioral: Cognitive behavioral therapy (CBT)|Behavioral: Brief PTSD treatment","Knowledge of PTSD and effectiveness in correcting faulty, trauma-related beliefs|Depression, anxiety, and other psychiatric symptoms|PTSD diagnoses and symptom severity|Total cost for mental health and substance abuse treatment services utilization within the University Behavioral Health Care system|Quality of life and community functioning","Dartmouth-Hitchcock Medical Center|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH064662-02|DSIR 83-ATIT","April 2008","July 2012",,"July 2, 2007",,"August 8, 2012","United Behavioral HealthCare (UBHC): Partial Hospital Program, Monmouth Junction, New Jersey, United States|University Behavioral HealthCare (UBHC) Adult Outpatient Psychiatric Services, New Brunswick, New Jersey, United States|University Behavioral HealthCare (UBHC) Extended Treatment, New Brunswick, New Jersey, United States|University Behavioral HealthCare (UBHC) Extended Treatment Division - Adult Outpatient Psychiatric Services, Newark, New Jersey, United States|University Behavioral HealthCare (UBHC) Extended Treatment Division - Partial Hospital Program, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00494650"
2337,"NCT00329186","Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: desvenlafaxine SR|Drug: venlafaxine ER","The primary objective is to determine if the relative difference in PK between EMs and PMs is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 3","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-901","May 2006","June 2007","June 2007","May 24, 2006",,"February 8, 2013","Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00329186"
2338,"NCT03051256","Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD",,"Completed","Has Results","Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant","Drug: REL-1017|Drug: Placebo","Incidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability]|ECG Parameters [Safety]|Columbia Suicide Severity Rating Scale (C-SSRS) [Safety and Tolerability]|Montgomery-Asberg Depression Scale (MADRS)|Symptoms of Depression Questionnaire (SDQ)|Clinical Global Impressions of Severity (CGI-S)|Clinical Global Impressions of Improvement (CGI-I)|Maximum Observed Plasma Concentration (Cmax) [Pharmacokinetic]|Area Under the Plasma Concentration-time Curve From Time Zero Until the Dosing Interval of 24 Hours (AUCtau) [Pharmacokinetic]|Time to Maximum Observed Plasma Concentration (Tmax) [Pharmacokinetic]|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) [Pharmacokinetic]|Apparent Terminal Elimination Half-life (t½) [Pharmacokinetic]","Relmada Therapeutics, Inc.|Syneos Health","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","62","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REL-1017-202","May 11, 2018","July 30, 2019","September 30, 2019","February 13, 2017","March 17, 2021","March 17, 2021","Woodland International Research Group, Little Rock, Arkansas, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Innovative Clinical Research, Inc, Hialeah, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States|Hassman Research Institute, Berlin, New Jersey, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Pillar Clinical Research, LLC, Richardson, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03051256/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03051256"
2339,"NCT00337012","The Effect of Duloxetine on Interoceptive Awareness",,"Unknown status","No Results Available","Depressive Disorder",,,"University Hospital, Bonn|Eli Lilly and Company","All","21 Years to 65 Years   (Adult, Older Adult)",,"36","Other|Industry","Observational","Time Perspective: Prospective","2006-001079-39","July 2007",,,"June 15, 2006",,"December 1, 2008","University Clinic Bonn, Bonn, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT00337012"
2340,"NCT04347668","Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia?",,"Unknown status","No Results Available","Moderate Dementia|Severe Dementia","Other: Virtual Reality|Other: Usual Care","Cornell Scale for Depression|The Cohen Mansfield Agitation Inventory|Percentage Sleep|Psychotropic medication|Weight|1 to 1 staff|Transfers to the emergency department (ED)","Western University, Canada","All","65 Years to 110 Years   (Older Adult)","Not Applicable","266","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO 0032743","April 1, 2019","May 1, 2020","September 27, 2020","April 15, 2020",,"April 15, 2020","Burton Manor, Brampton, Ontario, Canada|Henley Place, London, Ontario, Canada|Henley House, St. Catherines, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04347668"
2341,"NCT04790630","Cognitive Fitness for Depression in Older Adults",,"Recruiting","No Results Available","Depression Mild|Depressive Disorder, Major|Mild Cognitive Impairment","Other: Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|Other: Active Control","Change in attention / cognitive flexibility as measured by the Trail Making Part B test|Change in depression symptom severity as measured with the Montgomery Asberg Depression Rating Scale (MADRS)|Change in verbal learning as measured with the California Verbal Learning Test (CVLT) Total Learning|Change in attention processing speed as measured with the Flanker Test of Response Inhibition from the NIH Cognitive Toolbox|Change in self-reported depressive symptoms measured with the Carroll Depression Rating Scale|Change in problem solving/speed/spatial memory as measured with the NIH Toolbox fluid composite scales","UConn Health|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","138","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","21-046-2|1K23MH118420-01A1","November 15, 2020","July 31, 2024","July 31, 2024","March 10, 2021",,"July 13, 2021","UConn Health, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04790630"
2342,"NCT02358343","A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}","ASCEND","Completed","Has Results","Depression|End Stage Renal Disease","Behavioral: Engagement Interview|Behavioral: Cognitive Behavioral Therapy|Drug: Antidepressant Drug Therapy","Number of Participants Who Initiated Depression Treatment|QIDS-C Score|Number of Participants Who Accepted Depression Treatment|BDI-II|GAD-7|Sheehan Disability Scale|SF-36 Energy/Vitality|Global Quality of Life Scale|Satisfaction With Life Scale|Perceived Social Support|PSQI|Exercise|Percentage of Dialysis Treatment Sessions Skipped and/or Shortened|Percent Inter-dialytic Weight Gain|Serum Phosphorus Level","University of Washington|University of Texas|University of New Mexico|Patient-Centered Outcomes Research Institute","All","21 Years and older   (Adult, Older Adult)","Phase 3","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","48647","March 23, 2015","November 15, 2017","December 15, 2017","February 6, 2015","July 23, 2019","July 23, 2019","University of New Mexico, Albuquerque, New Mexico, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02358343/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02358343"
2343,"NCT01902004","Brain Aging and Treatment Response in Geriatric Depression",,"Completed","Has Results","Mild Cognitive Impairment (MCI)|Depression","Drug: Escitalopram|Drug: Memantine|Drug: Placebo","Change in Hamilton Depression Rating Scale|Change in Montgomery Asberg Depression Rating Scale|Change in Cognitive Domain Scores","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Phase 4","115","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R-01 MH097892|R01MH097892","October 2013","January 23, 2019","January 23, 2019","July 17, 2013","October 15, 2019","October 15, 2019","UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01902004/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01902004"
2344,"NCT03993457","Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression","PRECISE-D","Active, not recruiting","No Results Available","Depression","Drug: Escitalopram|Drug: Bupropion","Efficacy of CRP-consistent antidepressant selection versus CRP-inconsistent antidepressant selection on remission rates in patients with MDD.|Efficacy of CRP-consistent antidepressant selection versus CRP-inconsistent antidepressant selection on improving social and occupational functioning.|Adverse antidepressant treatment effects on CRP-consistent antidepressant selection versus CRP-inconsistent antidepressant selection|Optional Sub-study. Validity and reliability of capillary blood CRP measurement","University of Texas Southwestern Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU-2019-0623","July 23, 2019","June 1, 2023","June 1, 2023","June 20, 2019",,"July 6, 2021","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03993457"
2345,"NCT00602290","Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression",,"Completed","Has Results","Depression","Drug: Citalopram|Drug: Methylphenidate (MPH)|Drug: Placebo","Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16|Quality of Life Assessment","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Phase 4","181","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01MH077650|DATR A4-GPX","February 2008","January 2013","February 2013","January 28, 2008","September 1, 2014","January 11, 2018","UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00602290"
2346,"NCT01944293","Ketamine for Suicidality in Bipolar Depression",,"Completed","Has Results","Bipolar Disorder|Major Depressive Episode|Suicidal Ideation","Drug: Ketamine|Drug: Midazolam","Change in Suicidal Ideation Measured With the Beck Scale for Suicidal Ideation|Change in Systolic Blood Pressure","New York State Psychiatric Institute|Brain & Behavior Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","#6785","September 2013","September 2017","October 2018","September 17, 2013","June 6, 2019","March 11, 2020","Columbia University/New York State Psychiatric Institute, New York, New York, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01944293/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01944293/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT01944293"
2347,"NCT02994433","NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits",,"Terminated","No Results Available","Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant","Drug: Nitrous Oxide|Drug: Placebo gas|Device: MRI","Comparison of functional connectivity between default mode network of treatment-resistant depressed and non-depressed participants|Comparison of functional connectivity between affective network of treatment-resistant depressed and non-depressed participants|Comparison of functional connectivity between cognitive control network of treatment-resistant depressed and non-depressed participants|Comparison of functional connectivity between dorsal nexus of treatment-resistant depressed and non-depressed participants","Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","49","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201606120","January 27, 2017","February 28, 2020","February 28, 2020","December 15, 2016",,"August 2, 2021","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02994433"
2348,"NCT02043197","Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder","FRIENDS","Completed","Has Results","Depression",,"Prevalence of Different Neurological Disorders Associated With Depression Treated With Fluvoxamine (Fevarin®).|Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score|Percent of Patients With Change of Depression Symptoms From Baseline to Day 30|Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score|Change in the Clinical Condition Measured by Clinical Global Impression Scale - Severity of Illness Subscale|Percent of Patients With Change in Clinical Global Impression Scale|Anxiety and Depression Symptoms Score Measured by Hospital Anxiety and Depression Scale (HADS)|Percent of Patients With Change of Anxiety Symptoms From Baseline to Day 30.|Gender|Race|Family Status|Education|Employment","Abbott|Manipal Acunova Ltd.","All","18 Years and older   (Adult, Older Adult)",,"300","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-326","January 2014","November 2015","November 2015","January 23, 2014","December 17, 2018","December 17, 2018","Research Facility ID ORG-000890, Chelyabinsk, Russian Federation|Research facilility ID ORG-000872, Ekaterinburg, Russian Federation|Research facility ID ORG-000881, Krasnoyarsk, Russian Federation|Research facility ID ORG-000893, Moscow, Russian Federation|Research facility ID ORG-000882, Moscow, Russian Federation|Research facility ID ORG-000876, Moscow, Russian Federation|Research facility ID ORG-000877, Moscow, Russian Federation|Research Facility ID ORG-000889, Nizhny Novgorod, Russian Federation|Research facility ID ORG-000880, Novosibirsk, Russian Federation|Research Facility ID ORG-000879, Penza, Russian Federation|Research facility ID ORG-000891, Perm, Russian Federation|Research facility ID ORG-000840, Perm, Russian Federation|Research facility ID ORG-000803, Rostov-on-Don, Russian Federation|Research facility ID ORG-000898, Rostov-on-Don, Russian Federation|Research facility ID ORG-001028, Rostov-on-Don, Russian Federation|Research facility ID ORG-001027, Rostov-on-Don, Russian Federation|Research facility ID ORG-000894, Rostov-on-Don, Russian Federation|Research facility ID ORG-000897, Samara, Russian Federation|Research facility ID ORG-000839, Saratov, Russian Federation|Research Facility ID ORG-000873, Spassk-Dal'niy, Russian Federation|Research facility ID ORG-000896, St. Petersburg, Russian Federation|Research facility ID ORG-000892, St. Petersburg, Russian Federation|Research facility ID ORG-000965, St. Petersburg, Russian Federation|Research Facility ID ORG-000878, Tver, Russian Federation|Research facility ID ORG-001026, Vladivostok, Russian Federation|Research Facility ID ORG-000874, Volgograd, Russian Federation|Research Facility ID ORG-000888, Volgograd, Russian Federation|Research Facility ID ORG-000895, Voronezh, Russian Federation|Research facility ID ORG-000875, Yessentuki, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02043197"
2349,"NCT04870255","Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS",,"Not yet recruiting","No Results Available","Depressive Disorder, Major|Borderline Personality Disorder","Device: Left Dorsolateral Prefrontal Cortex (L-DLPFC)|Device: Dorsomedial Prefrontal Cortex (DMPFC)|Device: Sham Stimulation","Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active vs. sham participants.|Change in Borderline Symptoms List-23 (BSL-23) in active vs. sham participants.","Stanford University","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","58950","June 2021","June 2023","June 2024","May 3, 2021",,"May 3, 2021","Stanford Hospital, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04870255"
2350,"NCT00044681","A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression",,"Completed","No Results Available","Depressive Disorder|Depressive Disorder, Major|Depression","Drug: risperidone","Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at end of treatment; time to relapse|Response rate, determined from >=50% improvement from baseline at MADRS total score; change from baseline in Hamilton Rating Scale of Depression (HAM-D) and Clinical Global Impression (CGI) scale; incidence of adverse events throughout study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR002143","October 2002",,"March 2004","September 5, 2002",,"May 18, 2011",,,"https://ClinicalTrials.gov/show/NCT00044681"
2351,"NCT00770068","Examining the Link Between Depression and Seasonal Allergies",,"Completed","No Results Available","Depression",,"Hamilton Rating Scale for Depression-Seasonal Affective Disorder Version (SIGH-SAD)|Hypomania Interview Guide (HIGH-SAD)|Burns Anxiety Inventory|Buss Aggression Questionnaire|Allergy Symptom Severity Assessment (ASSA) Questionnaire|Serum cytokine, tryptophan (TRP), and kynurenine (KYN) concentrations|Nasal secretion test|Sleep logs|Actiwatch|Beck Depression Inventory II (BDI-II)|Pittsburgh Sleep Quality Index (PSQI)","University of Maryland, Baltimore|National Institute of Mental Health (NIMH)","All","18 Years to 64 Years   (Adult)",,"100","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R21MH075891|H26191|DATR A2-AID","July 15, 2006","April 11, 2017","April 11, 2017","October 9, 2008",,"November 21, 2019","National Center for the Treatment of Phobias, Anxiety, and Depression, Washington, District of Columbia, United States|University of Maryland, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00770068"
2352,"NCT01407575","Buprenorphine for Treatment Resistant Depression","BUP-TRD","Completed","Has Results","Depression|Depressive Disorder|Depressive Disorder, Major","Drug: Buprenorphine|Drug: Placebo","Montgomery Asberg Depression Rating Scale|Blood Pressure|UKU Side Effect Rating Scale|Heart Rate|Weight|Brief Symptom Inventory -- Anxiety Subscale|Positive and Negative Affect Scale","University of Pittsburgh|National Alliance for Research on Schizophrenia and Depression","All","21 Years and older   (Adult, Older Adult)","Phase 3","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BUP-TRD","September 2011","August 2013","August 2013","August 2, 2011","March 17, 2016","March 9, 2018","Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01407575"
2353,"NCT00742365","Predicting Effectiveness of Light Treatment for Winter Seasonal Affective Disorder",,"Completed","No Results Available","Depression","Device: Bright light|Device: Red light placebo","Hamilton rating scale for depressional seasonal affective disorder (SIGH SAD)|Hunger questionnaire|Three factor eating questionnaire|Sleep log|Food craving questionnaire|Side effects questionnaire|Adherence questionnaire|Profile of Mood States|Beck Depression Inventory-II (BDI)","University of Maryland, Baltimore|National Institute of Mental Health (NIMH)","All","18 Years to 64 Years   (Adult)",,"41","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HP-00043574|R34MH073797|DSIR 83-ATSO|H-28845","November 2007","April 2010","August 2010","August 27, 2008",,"November 21, 2019",,,"https://ClinicalTrials.gov/show/NCT00742365"
2354,"NCT03190772","The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation",,"Completed","No Results Available","Major Depressive Episode","Other: Placebo nasal spray|Other: Film sequence","Sadness","Philipps University Marburg Medical Center","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","2017-12k","November 1, 2017","September 30, 2018","September 30, 2018","June 19, 2017",,"November 7, 2018","Justus Liebig University Gießen, Gießen, Hessen, Germany|Philipps University Marburg, Marburg, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT03190772"
2355,"NCT00606996","Group Therapy for Women Prisoners With Comorbid Substance Use and Depression",,"Completed","No Results Available","Substance Abuse|Substance Dependence|Depressive Disorder","Behavioral: Group interpersonal psychotherapy (IPT-G)|Behavioral: Psychoeducation on co-occurring disorders (PSYCHOED)","Substance-free days after release from prison, measured by the Timeline Followback method|Severity of substance use after release from prison, measured by the Addiction Severity Index|Verification of substance-free status using breath alcohol tests and urine drug screens|Depression symptom severity measured by the Modified Hamilton Rating Scale for Depression|Depression symptom severity measured by the Beck Depression Inventory|Severity of legal problems after release, measured by the Legal Composite of the Addiction Severity Index|Interpersonal problems, measured by the Inventory of Interpersonal Problems|Peer support and social support, measured by the Criminal Justice client Evaluation of Self and Treatment|Perceived social support measured by the Multidimensional Scale of Perceived Social Support|Social support for recovery, measured by the Important People and Activities scale|Social functioning, measured by the Social Adjustment Scale","Brown University","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1K23DA021159-01","July 2006","December 2009","December 2009","February 5, 2008",,"April 18, 2013","Adult Correctional Institution, Cranston, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00606996"
2356,"NCT01880593","Ketamine Plus Lithium in Treatment-Resistant Depression",,"Completed","Has Results","Depression","Drug: Lithium|Drug: Ketamine|Drug: Placebo","MADRS-S Score|QIDS-SR Score|CGI-S Score|HAM-A Score|BSS Score|CSSRS Score|Patient Rated Inventory of Side Effects (PRISE)","Icahn School of Medicine at Mount Sinai","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 13-0365","July 2013","November 2016","November 2016","June 19, 2013","July 31, 2018","July 31, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01880593"
2357,"NCT00669526","Clinical and Cost Effectiveness of Brief Cognitive-Behavioral Therapy (CBT) for Pediatric Internalizing Disorders",,"Completed","No Results Available","Depression|Anxiety","Behavioral: BCBT|Behavioral: SMHC referral","Clinician Global Impressions - Improvement (CGI-I)","Robert Wood Johnson Foundation|National Institute of Mental Health (NIMH)|William T. Grant Foundation","All","7 Years to 17 Years   (Child)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","051653","October 2004","March 2007","April 2007","April 30, 2008",,"April 30, 2008","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00669526"
2358,"NCT04099771","Ketamine for Mood Disorders With Suicidal Ideation",,"Recruiting","No Results Available","Depressive Disorder, Major|Suicidal Ideation","Drug: Ketamine","Number and Rate of Participants Recruited into the Study throughout study period|Completion of total infusion of ketamine by participants|Percentage of participants and providers with positive response to ketamine administration|Reduction of SI in mood disorders by ketamine","The Miriam Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1348833","July 1, 2019","December 31, 2021","December 31, 2021","September 23, 2019",,"March 2, 2021","The Miriam Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04099771"
2359,"NCT01620502","N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression",,"Completed","No Results Available","Major Depressive Episode","Dietary Supplement: Omega-3 fatty acids","Percentage of Participants with major depressive episode (for Study 1); Changes in Hamilton Depression Rating Scale (HDRS) (for Study 2)|Changes in Hamilton Depression Rating Scale (HDRS) (for Study 1); Response and remission rates (for Study 2)","National Science Council, Taiwan","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NSC98-2628-B-039-020-MY3","July 2009","June 2012","September 2012","June 15, 2012",,"October 29, 2013","China Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01620502"
2360,"NCT01386086","Aripiprazole and Resistant Postpartum Depression",,"Completed","No Results Available","Postpartum Depression","Drug: aripiprazole","Montgomery Asberg Depression Rating Scale|Udvalg for Kliniske Undersogelser Scale","Lawson Health Research Institute|Bristol-Myers Squibb","Female","18 Years to 45 Years   (Adult)","Phase 3","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CN138-623","June 2011","November 2013","November 2013","June 30, 2011",,"March 17, 2016","Regional Mental Health Care, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01386086"
2361,"NCT03857581","Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder",,"Not yet recruiting","No Results Available","Psychosis|Substance Use Disorders","Drug: Clozapine|Drug: Olanzapine","Frequencies of positive urine drug screens and breathalyzer alcohol levels|All-cause treatment discontinuation|Brief Psychiatric Rating Scale (BPRS) - Positive Psychopathology items","Augusta University","All","18 Years to 60 Years   (Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1303985","July 2020","July 2021","July 2021","February 28, 2019",,"March 23, 2020","Sandarsh Surya, Evans, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03857581"
2362,"NCT02285504","Evaluate SAGE-547 in Female Patients With Severe Postpartum Depression",,"Completed","No Results Available","Postpartum Depression","Drug: SAGE-547","Safety and tolerability of SAGE-547 measured by mean changes from baseline in clinical laboratory measures, vital signs, and ECGs; physical examination; and concomitant medication usage|Pharmacokinetic (PK) profile of SAGE-547 as measured by AUC, Cmax, Tmax, Css, Cavg.|Effects of SAGE-547 on patient symptom response evaluated by changes from baseline in Hamilton Rating Scale for Depression-17 (HAM-D-17) and individual Clinical Global Impression-Improvement (CGI-I) Scale scores","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 2","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","547-PPD-201","September 2014","June 2015","June 2015","November 7, 2014",,"April 26, 2017","PRA Health Sciences, Marlton, New Jersey, United States|University or North Carolina, Chapel Hill - Perinatal Psychiatry In-Patient Unit, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02285504"
2363,"NCT01204918","Efficacy and Tolerability of Riluzole in Treatment Resistant Depression",,"Completed","Has Results","Depression","Drug: Riluzole|Drug: placebo","Change in Montgomery and Asberg Depression Rating Scale (MADRS)|Responders Having at Least a 50% Improvement in MADRS Compared to the Baseline|Systematic Assessment for Treatment Emergent Events (SAFTEE-SI)","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0903004917|137889","June 2011","May 2015","August 2015","September 17, 2010","February 8, 2018","March 6, 2020","Yale University, Yale Depression Research Program, New Haven, Connecticut, United States|Massachussettes General Hospital, Depression Clinical and Research Center, Boston, Massachusetts, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01204918"
2364,"NCT01737268","Long-term Study of FK949E in Elderly Bipolar Disorder Patients",,"Completed","Has Results","Bipolar Disorder|Elderly","Drug: FK949E","Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Change From Baseline to Last Assessment in Treatment Period in Hamilton Depression Scale (HAM-D17)|Change From Baseline to Last Assessment in Treatment Period in Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness|Change From Baseline to Last Assessment in Treatment Period in CGI-BP-S: Depression|Change From Baseline to Last Assessment in Treatment Period in CGI-BP-S: Mania|Clinical Global Impression-Bipolar-Change (CGI-BP-C): Overall Bipolar Illness|CGI-BP-C: Depression|CGI-BP-C: Mania|Number of Participants With Adverse Events","Astellas Pharma Inc","All","65 Years and older   (Older Adult)","Phase 3","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6949-CL-0022","October 29, 2012","June 29, 2016","June 29, 2016","November 29, 2012","October 31, 2017","January 29, 2019","Site JP00024, Chiba, Japan|Site JP00023, Fukuoka, Japan|Site JP00025, Fukuoka, Japan|Site JP00015, Fukushima, Japan|Site JP00029, Fukushima, Japan|Site JP00001, Hokkaido, Japan|Site JP00002, Hokkaido, Japan|Site JP00003, Hokkaido, Japan|Site JP00004, Hokkaido, Japan|Site JP00005, Hokkaido, Japan|Site JP00006, Hokkaido, Japan|Site JP00007, Hokkaido, Japan|Site JP00008, Hokkaido, Japan|Site JP00009, Hokkaido, Japan|Site JP00010, Hokkaido, Japan|Site JP00011, Hokkaido, Japan|Site JP00012, Hokkaido, Japan|Site JP00013, Hokkaido, Japan|Site JP00028, Hyogo, Japan|Site JP00031, Ibaraki, Japan|Site JP00017, Kanagawa, Japan|Site JP00032, Kanagawa, Japan|Site JP00019, Kumamoto, Japan|Site JP00018, Kyoto, Japan|Site JP00014, Osaka, Japan|Site JP00016, Tokyo, Japan|Site JP00020, Tokyo, Japan|Site JP00021, Tokyo, Japan|Site JP00022, Tokyo, Japan|Site JP00026, Tokyo, Japan|Site JP00027, Tokyo, Japan|Site JP00030, Tottori, Japan",,"https://ClinicalTrials.gov/show/NCT01737268"
2365,"NCT04442503","A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)",,"Recruiting","No Results Available","Depression, Postpartum","Drug: SAGE-217|Drug: Placebo","Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15|Change From Baseline in the 17-item HAM-D Total Score|Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score|Percentage of Participants With HAM-D Response|Percentage of Participants With HAM-D Remission|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response|Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score|Change From Baseline in HAM-D Subscale|Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score|Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score|Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 3","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-PPD-301|2020-001424-34","June 22, 2020","December 2021","December 2021","June 22, 2020",,"June 23, 2021","Sage Investigational Site, Scottsdale, Arizona, United States|Sage Investigational Site, Bentonville, Arkansas, United States|Sage Investigational Site, Bellflower, California, United States|Sage Investigational Site, Beverly Hills, California, United States|Sage Investigational Site, Costa Mesa, California, United States|Sage Investigational Site, Imperial, California, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Norwalk, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, San Bernardino, California, United States|Sage Investigational Site, Sherman Oaks, California, United States|Sage Investigational Site, Torrance, California, United States|Sage Investigational Site, Aurora, Colorado, United States|Sage Investigational Site, Norwich, Connecticut, United States|Sage Investigational Site, Boynton Beach, Florida, United States|Sage Investigational Site, Hialeah, Florida, United States|Sage Investigational Site, Jacksonville, Florida, United States|Sage Investigational Site, Miami Springs, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Miramar, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Pinellas Park, Florida, United States|Sage Investigational Site, Pompano Beach, Florida, United States|Sage Investigational Site, Alpharetta, Georgia, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Savannah, Georgia, United States|Sage Investigational Site, Stone Mountain, Georgia, United States|Sage Investigational Site, Idaho Falls, Idaho, United States|Sage Investigational Site, Hoffman Estates, Illinois, United States|Sage Investigational Site, Lincolnwood, Illinois, United States|Sage Investigational Site, New Orleans, Louisiana, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Detroit, Michigan, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Saint Charles, Missouri, United States|Sage Investigational Site, Saint Louis, Missouri, United States|Sage Investigational Site, Saint Louis, Missouri, United States|Sage Investigational Site, Las Vegas, Nevada, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Brooklyn, New York, United States|Sage Investigational Site, Glen Oaks, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, Chapel Hill, North Carolina, United States|Sage Investigational Site, Denver, North Carolina, United States|Sage Investigational Site, Beachwood, Ohio, United States|Sage Investigational Site, Mayfield Heights, Ohio, United States|Sage Investigational SIte, North Canton, Ohio, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Allentown, Pennsylvania, United States|Sage Investigational Site, Moosic, Pennsylvania, United States|Sage Investigational Site, Providence, Rhode Island, United States|Sage Investigational site, Charleston, South Carolina, United States|Sage Investigational Site, Dallas, Texas, United States|Sage Investigational Site, Fort Worth, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, League City, Texas, United States|Sage Investigational Site, McAllen, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Bellevue, Washington, United States|Sage Investigational Site, Barcelona, Spain|Sage Investigational Site, Barcelona, Spain|Sage Investigational Site, Barcelona, Spain|Sage Investigational Site, Collado-Villalba, Spain|Sage Investigational Site, Madrid, Spain|Sage Investigational Site, Oviedo, Spain|Sage Investigational Site, Sabadell, Spain|Sage Investigational Site, Vigo, Spain|Sage Investigational Site, Runwell, Essex, United Kingdom|Sage Investigational Site, Preston, Lancashire, United Kingdom|Sage Investigational Site, Morpeth, Northumberland, United Kingdom|Sage Investigational Site, Headington, Oxford, United Kingdom|Sage Investigational Site, Maidstone, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04442503"
2366,"NCT03487926","Microglial Activation in Inflammatory Bowel Disease",,"Active, not recruiting","No Results Available","Major Depressive Episode|Inflammatory Bowel Diseases","Radiation: [18F]FEPPA","TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula|change in TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula before and after 3 to 6 months|MAO-B VT in prefrontal cortex, anterior cingulate cortex, insula in IBD compared to controls|TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between Crohns disease and ulcerative colitis|TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between IBD with MDE compared to MDE controls|change in TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between naturalistic treatment with sulfasalazine/5-aminosalicylates versus other interventions like biologics or fecal transplantation","Centre for Addiction and Mental Health|McMaster University","All","19 Years to 65 Years   (Adult, Older Adult)",,"135","Other","Observational","Observational Model: Other|Time Perspective: Prospective","102-2016","January 1, 2019","December 31, 2021","December 31, 2021","April 4, 2018",,"July 17, 2020","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03487926"
2367,"NCT00866593","A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression",,"Completed","No Results Available","Depression","Drug: Generic Escitalopram|Drug: Innovator Escitalopram","the change of HAMD-17 total score|the change of MADRS total score|the change of HAMA total score|the clinical global impression (CGI),including CGI-I and CGI-S|the change of VAS-PI|the change of Sheehan Disability Scale(SDS)","Shanghai Mental Health Center|Jiangsu Nhwa Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","260","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2004L04118|SMHC-101","March 2009","March 2010","March 2010","March 20, 2009",,"April 4, 2013","Hebei Mental Health Center, Baoding, Hebei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|the First Affiliated Hospital，Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Xi'an Mental Health Center, Xi'an, Shaanxi, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|The First Affilliated Hospital Of Kunming Medical College, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT00866593"
2368,"NCT01903096","Treating Emotional Disorders in Primary Care With Psychological Techniques","PsychPC","Completed","No Results Available","Anxiety Disorders|Mood Disorders|Somatization Disorder|Pain Disorder","Behavioral: Cognitive Behavioral Treatment|Drug: Primary Care Treatment As Usual","Anxiety symptoms after psychological treatment versus Primary Care usual treatment.|Depressive symptoms after psychological treatment versus Primary Care usual treatment.|Somatic symptoms after psychological treatment versus Primary Care usual treatment.|Cognitive factors after psychological treatment versus Primary Care usual treatment.|Level of impairment after psychological treatment versus Primary Care usual treatment.|Quality of life after psychological treatment versus Primary Care usual treatment.|Frequency of primary care visits after psychological treatment versus Primary Care usual treatment.","Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo|Ministry of Health, Spain","All","18 Years and older   (Adult, Older Adult)","Phase 4","1126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AP105162012|2013-001955-11","January 14, 2014","July 30, 2018","July 30, 2019","July 19, 2013",,"March 10, 2020","Complutense University of Madrid, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01903096"
2369,"NCT04124341","EpCS in Severe Treatment Resistant Depression",,"Not yet recruiting","No Results Available","Treatment Resistant Depression","Device: Epidural Prefrontal Cortical Stimulation (EpCS)","Change in LPP Amplitude|Change in HRSD Scores","University of Minnesota","All","21 Years to 55 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSYCH-2019-27331","September 1, 2021","December 31, 2021","December 31, 2021","October 11, 2019",,"June 2, 2021",,,"https://ClinicalTrials.gov/show/NCT04124341"
2370,"NCT00992953","Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)",,"Completed","No Results Available","Post-Traumatic Stress Disorder","Behavioral: Treatment as Usual|Behavioral: Virtual Reality Exposure with Stimulus Control",,"Office of Naval Research (ONR)|Naval Hospital Camp Pendleton|Virtual Reality Medical Center|United States Naval Medical Center, San Diego","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","136","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S-05-005","January 2005","October 2009","October 2009","October 9, 2009",,"October 9, 2009","Naval Hosptial Camp Pendleton, Camp Pendlton, California, United States|Naval Medical Center San Diego (NMCSD), San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00992953"
2371,"NCT01907217","Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression","EFFECT-Dep","Completed","Has Results","Depression","Device: ECT Mecta 5000M|Drug: Methohexitone|Drug: Suxamethonium","Hamilton Depression Rating Scale (HDRS)|Columbia Autobiographical Memory Interview-Short Form (AMI-SF)","St Patrick's Hospital, Ireland|Health Research Board, Ireland","All","18 Years and older   (Adult, Older Adult)","Phase 4","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","TRA/2007/5|ISRCTN23577151","May 2008","November 2013","April 2015","July 24, 2013","November 14, 2018","November 14, 2018","St Patrick's University Hospital, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT01907217"
2372,"NCT01732055","Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression",,"Terminated","No Results Available","Partner Assisted Interpersonal Psychotherapy|Treatment as Usual","Behavioral: Partner-Assisted Interpersonal Psychotherapy|Other: Treatment as Usual","Hamilton Rating Scale for Depression-17 item version (HRSD-17)|Dyadic Adjustment Scale (DAS)","University of North Carolina, Chapel Hill|The Foundation of Hope for Research and Treatment of Mental Illness","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","12-0235","November 2012","December 2013","December 2013","November 22, 2012",,"January 14, 2014","University of North Carolina Hospitals and Clinics, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01732055"
2373,"NCT01109693","Strategic Use of New Generation Antidepressants for Depression","SUN(^_^)D","Completed","No Results Available","Unipolar Major Depressive Episode","Drug: Sertraline|Drug: Mirtazapine","Observer-rated depression severity (PHQ-9)|Self-rated depression severity (BDI-II)|Global rating of side effects (FIBSER)","Kyoto University|National Center of Neurology and Psychiatry, Japan","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 4","2011","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","sun-d","December 2010","September 2015","December 2015","April 23, 2010",,"October 3, 2016","Nagoya City University Hospital, Nagoya, Aichi, Japan|Kochi Medical School Hospital, Nangoku, Kochi, Japan",,"https://ClinicalTrials.gov/show/NCT01109693"
2374,"NCT03870776","RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode",,"Recruiting","No Results Available","Depression","Drug: MAP4343|Drug: Placebo","Hamilton Depression Rating Scale score evolution between baseline and D43|Efficacy of treatment assessed by psychopathological evaluations with Hamilton Depression Rating Scale|Efficacy of treatment assessed by psychopathological evaluations with Montgomery and Asberg Depression rating Scale|Efficacy of treatment assessed by psychopathological evaluations with Brief Anxiety Scale|Efficacy of treatment assessed by psychopathological evaluations with Scale of Global Clinical Impressions|Efficacy of treatment assessed by psychopathological evaluations with Quick Inventory of Depressive Symptoms|Efficacy of treatment assessed by psychopathological evaluations with General Assessment Functioning|Pharmacokinetic assessment with observed maximum plasma concentration (Cmax)|Pharmacokinetic assessment with first time to reach Cmax (tmax)|Pharmacokinetic assessment with elimination rate constant (Kel)|Pharmacokinetic assessment with plasma elimination half-life (t1/2)|Pharmacokinetic assessment with plasma area under the plasma concentration-time curve from administration up to infinity with extrapolation of the terminal phase (AUCinf)|Pharmacokinetic assessment with percentage of extrapolated AUCinf (%AUCextra)|Pharmacokinetic assessment with volum of distribution (Vd/F)|Pharmacokinetic assessment with Clearance (Cl/F)|Pharmacokinetic assessment with accumulation ratio (R)|Safety parameters assessed by the number of adverse events (AE)|Safety parameters assessed Heart rate|Safety parameters assessed by blood pressure|Safety parameters assessed 12-lead Electrocardiogramm : Heart Rate|Safety parameters assessed 12-lead Electrocardiogramm : PR|Safety parameters assessed 12-lead Electrocardiogramm : QT|Safety parameters assessed 12-lead Electrocardiogramm : QTc|Safety parameters assessed by hematology parameters : Haemoglobin|Safety parameters assessed by hematology parameters : Haematocrit|Safety parameters assessed by hematology parameters : Red blood cells|Safety parameters assessed by hematology parameters : White blood cells|Safety parameters assessed by hematology parameters : Neutrophils|Safety parameters assessed by hematology parameters : Eosinophils|Safety parameters assessed by hematology parameters : Basophils|Safety parameters assessed by hematology parameters : Lymphocytes|Safety parameters assessed by hematology parameters : Monocytes|Safety parameters assessed by hematology parameters : Platelets|Safety parameters assessed by hematology parameters : Reticulocytes|Safety parameters assessed by red blood cells indices : MCV|Safety parameters assessed by red blood cells indices : MCH|Safety parameters assessed by red blood cells indices : MCHC|Safety parameters assessed by hemostasis parameters : INR measurement|Safety parameters assessed by hemostasis parameters : Prothrombin level|Safety parameters assessed by hemostasis parameters : Prothrombin time|Safety parameters assessed by hemostasis parameters : APTT|Safety parameters assessed by hemostasis parameters : APTT reference|Safety parameters assessed by serology parameters : P24 antigen|Safety parameters assessed by serology parameters : HIV|Safety parameters assessed by serology parameters : HCV|Safety parameters assessed by serology parameters : HBs|Safety parameters assessed by biochemistry parameters|Safety parameters assessed by biochemistry parameters : Creatinine|Safety parameters assessed by biochemistry parameters : SGOT / ASAT|Safety parameters assessed by biochemistry parameters : SGOT / ALAT|Safety parameters assessed by biochemistry parameters : GGT|Safety parameters assessed by biochemistry parameters : Alkalin phosphatase|Safety parameters assessed by biochemistry parameters : CPK|Safety parameters assessed by biochemistry parameters : Total bilirubin|Safety parameters assessed by biochemistry parameters : Conjugated bilirubin|Safety parameters assessed by biochemistry parameters : Uric Acid|Safety parameters assessed by biochemistry parameters : Cholesterol|Safety parameters assessed by biochemistry parameters : Triglycerides|Safety parameters assessed by biochemistry parameters : Sodium|Safety parameters assessed by biochemistry parameters : Potassium|Safety parameters assessed by biochemistry parameters : Chlore|Safety parameters assessed by biochemistry parameters : Calcium|Safety parameters assessed by biochemistry parameters : Magnesium|Safety parameters assessed by biochemistry parameters : Total protein|Safety parameters assessed by biochemistry parameters : Albumin|Safety parameters assessed by biochemistry parameters : Insulin|Safety parameters assessed by hormonology parameters|Safety parameters assessed by weight measurement|Safety parameters assessed by height measurement|Pharmacodynamics parameters on brain morphology measured by MRI : Hippocampal volume|Pharmacodynamics parameters on brain morphology measured by MRI : Self-referential memory task|Pharmacodynamics parameters on brain morphology measured by MRI : Sensitivity to reward and punishment|Plasmatic quantification of biomarkers concentration (pregnenolone)|Plasmatic quantification of biomarkers concentration (CRPs)|Plasmatic quantification of biomarkers concentration (Interleukins)|Plasmatic quantification of biomarkers concentration (ELK-1)|Plasmatic quantification of biomarkers concentration (BDNF)|Plasmatic quantification of concentration of VEGF|Plasmatic quantification of concentration of tubulin isoforms acet and tyr","Mapreg","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAP4343 / OP103617.MAP","June 1, 2019","June 1, 2021","June 1, 2021","March 12, 2019",,"October 8, 2019","AHPH La Pitié Salpétrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT03870776"
2375,"NCT00082030","Function of Catecholamines in the Brain During Depression",,"Completed","No Results Available","Depression|Involutional",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)",,"71","NIH","Observational",,"040160|04-M-0160","April 19, 2004",,"November 18, 2011","April 28, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00082030"
2376,"NCT00494728","Smoking Cessation for Depressed Smokers",,"Active, not recruiting","No Results Available","Smoking|Depression","Behavioral: Smoking Cessation Treatment|Drug: Nicotine Replacement Therapy|Behavioral: CBASP","Abstinence Rates","M.D. Anderson Cancer Center|National Institute of Mental Health (NIMH)","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","202","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0351|NCI-2012-02097|1R01MH076776-01A1|1R01MH087692","June 2007","June 2022","June 2022","July 2, 2007",,"June 22, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00494728"
2377,"NCT00878150","Life Improvement Following Traumatic Brain Injury","LIFT","Completed","No Results Available","Traumatic Brain Injury|Depression","Behavioral: In-person Cognitive Behavioral Therapy|Behavioral: Telephone Cognitive Behavioral Therapy","Hamilton Rating Scale for Depression (HAM-D)|Symptom Checklist-20 (SCL-20)|Patient Health Questionnaire-9 (PHQ-9)|Head Injury Symptom Checklist|Structured Clinical Interview for DSM-IV (SCID)- Current MDD only|Automatic Thoughts Questionnaire|Dysfunctional Attitudes Scale|Environmental Reward Observation Scale (EROS)|Medical Outcome Short Form- 36 (SF-36)|Sheehan Disability Scale","University of Washington|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|U.S. Department of Education","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","40378 G|1R21HD053736-01A1|H133G070016","September 2007","December 2012","September 2013","April 8, 2009",,"October 18, 2013","University of Washington School of Medicine, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00878150"
2378,"NCT00227812","Integrated Treatment for Cocaine and Mood Disorders - 1",,"Completed","No Results Available","Cocaine Dependence|Depressive Disorder, Major","Drug: Bupropion","Urine toxicology for cocaine","National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Phase 2","140","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","NIDA-08654-1|R01-DA08654-1","April 2001","December 2005","December 2005","September 28, 2005",,"January 12, 2017","University of Texas Health Sci Cntr Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00227812"
2379,"NCT04171193","Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent","ISORADAR","Not yet recruiting","No Results Available","Depressive Disorder, Major|Treatment Resistant Depression|Depressive Episode","Drug: Isoflurane|Drug: Sertraline Pill","Reduction in Depression severity - MADRS|Reduction in Depression - HDRS 17|Udvalg for Kliniske Undersøgelser - side effects rating scale|Change in Depression severity MADRS|Change in Depression severity HDRS17|Magnitude MADRS|Magnitude HDRS 17|Survival of the effect - HDRS 17|Survival of the effect - MADRS|Enhance HDRS 17|Enhance MADRS","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISORADAR|19921719.9.0000.0068","December 2019","September 2020","December 2020","November 20, 2019",,"November 20, 2019","Insitute of Psychiatry of the University of São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04171193"
2380,"NCT00006517","Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)",,"Completed","No Results Available","Seasonal Affective Disorder|Mood Disorders|Depression","Device: bright light box|Device: dawn simulator|Device: high-output negative ion generator|Device: low-output negative ion generator|Device: dawn light pulse","Depression scale score|time of pineal melatonin onset","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","#3032/R01 MH42931-01|R01MH042931-01","September 1998","June 2003","April 2004","November 23, 2000",,"June 3, 2015","Columbia Presbyterian Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00006517"
2381,"NCT00224302","Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine",,"Completed","No Results Available","Psychotic Disorders","Drug: Duloxetine","CDSS, HAMD, PANSS, SANS|PANSS, SANS, Serum levels of antipsychotic substances, Body weight, EPMS,Prolactin, blood pressure, heart rate","Central Institute of Mental Health, Mannheim","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Duloxetine-Zink","August 2005","November 2007","November 2007","September 22, 2005",,"June 4, 2008","Central Institute of Mental Health, Department of Psychiatry,, Mannheim, BW, Germany",,"https://ClinicalTrials.gov/show/NCT00224302"
2382,"NCT04084795","Augmentation of EMDR With MtCS in the Treatment of Fibromyalgia",,"Suspended","No Results Available","Fibromyalgia|Psychological Trauma|Depressive Symptoms|Anxiety","Behavioral: Eye Movement Desensitization and Reprocessing therapy|Other: Multifocal transcranial Current Stimulation","Change in pain assessed with the Visual Analogic Scale Questionnaire.|Change in pain assessed with the Pain Dissability Index.|Change in pain assessed with the Fibromyalgia Impact Questionnaire.|Change in depressive symptoms assessed by with the Hospital Anxiety and Depression Scale|Change in anxious symptoms evaluated with the Hospital Anxiety and Depression Scale.|Change in trauma associated symptoms assessed with the Impact of Events Scale-Revised.|Change in subjective wellbeing measured with the Satisfaction With Life Scale.|Change in insomnia symptoms assessed with the Athens Insomnia Scale.","Parc de Salut Mar|Universitat Oberta de Catalunya|Institut d'Investigacions Biomèdiques August Pi i Sunyer","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019/8772/I","September 25, 2019","May 31, 2023","September 30, 2023","September 10, 2019",,"March 19, 2021","Centre Forum (Parc de Salut Mar), Barcelona, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT04084795"
2383,"NCT02978326","A Study to Evaluate SAGE-217 in Subjects With Severe Postpartum Depression",,"Completed","No Results Available","Postpartum Depression","Drug: SAGE-217|Drug: Placebo","Effect of SAGE-217 on depressive symptoms in subjects with severe postpartum depression compared to placebo as assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total score|Safety and tolerability of SAGE-217 compared to placebo as assessed by the incidence of adverse events, vital sign measurements, clinical laboratory evaluations, and electrocardiogram (ECG) parameters|Safety and tolerability of SAGE-217 compared to placebo as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 3","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","217-PPD-201","December 2016","November 15, 2018","December 11, 2018","November 30, 2016",,"November 20, 2019","Sage Investigational Site, Chandler, Arizona, United States|Sage Investigational Site, Little Rock, Arkansas, United States|Sage Investigational Site, Corona, California, United States|Sage Investigational Site, Oceanside, California, United States|Sage Investigational Site, Riverside, California, United States|Sage Investigational Site, San Bernardino, California, United States|Sage Investigational Site, Wildomar, California, United States|Sage Investigational Site, Washington, District of Columbia, United States|Sage Investigational Site, Aventura, Florida, United States|Sage Investigational Site, Gainesville, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational SIte, Pinellas Park, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Hoffman Estates, Illinois, United States|Sage Investigational Site, Owensboro, Kentucky, United States|Sage Investigational Site, Lake Charles, Louisiana, United States|Sage Investigational Site, New Orleans, Louisiana, United States|Sage Investigational Site, Saint Charles, Missouri, United States|Sage Investigational Site, Omaha, Nebraska, United States|Sage Investigational Site, Las Vegas, Nevada, United States|Sage Investigational Site, Princeton, New Jersey, United States|Sage Investigational Site, Amherst, New York, United States|Sage Investigational Site, Manhasset, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, New York, New York, United States|Sage Investigational Site, Chapel Hill, North Carolina, United States|Sage Investigational Site, Raleigh, North Carolina, United States|Sage Investigational Site, Oklahoma City, Oklahoma, United States|Sage Investigational Site, Allentown, Pennsylvania, United States|Sage Investigational Site, Fort Worth, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Orem, Utah, United States|Sage Investigational Site, Charlottesville, Virginia, United States|Sage Investigational Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02978326"
2384,"NCT00356304","Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression",,"Completed","Has Results","Depression","Behavioral: Motivational interviewing|Behavioral: Treatment as usual","Medication Adherence, as Measured by Electronic Pill Container|Treatment Retention|Beck Depression Inventory-II (BDI-II)|Medication Attitudes","University of Medicine and Dentistry of New Jersey|National Institute of Mental Health (NIMH)|Rutgers, The State University of New Jersey","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23MH074860|DSIR 8K-RT","April 2006","July 2010","July 2010","July 25, 2006","May 8, 2014","May 8, 2014","University Behavioral Healthcare, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00356304"
2385,"NCT04893395","Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans",,"Not yet recruiting","No Results Available","Pharmacogenetics|Depressive Disorder, Major|Medication Therapy Management","Other: Pharmacogenomic Screening","Rate of pharmacogenomic variation with actionable recommendations for medications currently utilized|Rate of pharmacogenomic variation with actionable recommendations for all actionable medications|Mental health disease state control/progression utilizing disease state-specific validated tools|Medication-related costs|Medication-related adverse events|Number of primary care, mental health provider, mental health pharmacist, specialist, and emergency room visits and hospitalizations|Patient reported medication adherence and reasons for non-adherence|Patient reported reasons for non-adherence|Number of pharmacogenomic recommendations made and accepted|Type of pharmacogenomic recommendations made and accepted|Number of non-pharmacogenomic recommendations made and accepted|Type of non-pharmacogenomic recommendations made and accepted","Auburn University|Tuscaloosa Veterans Affairs Medical Center","All","19 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","TVA_IRBNetID_1614352","September 1, 2021","April 30, 2022","December 31, 2022","May 19, 2021",,"July 22, 2021","Tuscaloosa VAMC, Tuscaloosa, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04893395"
2386,"NCT01920555","Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)",,"Completed","Has Results","Treatment Resistant Depression","Drug: Ketamine|Drug: Placebo Midazolam","Hamilton Rating Scale for Depression - 6 Items|Montgomery-Asberg Depression Rating Scale (MADRS)|Clinical Global Impressions-Severity (CGI-S)|Clinical Global Impressions-Improvement (CGI-I) Scale|Symptoms of Depression Questionnaire (SDQ)|Clinical Positive Affect Scale (CPAS)|Snaith-Hamilton Pleasure-Scale (SHAPS)|Clinician-Administered Dissociative States Scale (CADSS) Scores During Infusion|Number of Participants Reporting Suicidal Ideation/Behavior on the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Abnormal and Clinically Significant CBC and Chemistry Labs by Treatment","Massachusetts General Hospital|National Institute of Mental Health (NIMH)|Baylor College of Medicine|Icahn School of Medicine at Mount Sinai|Stanford University|University of Texas|Yale University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","99","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAP-003|271201100006I-0-27100007-1","December 2014","January 2017","February 2017","August 12, 2013","April 17, 2018","June 19, 2018","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Texas Southwestern, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01920555"
2387,"NCT00531518","Early Detection and Intervention for the Prevention of Psychosis","EDIPP","Completed","Has Results","Schizophrenia|Bipolar Disorder|Depression|Psychotic Disorders","Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Behavioral: Psychoeducational multifamily group treatment|Behavioral: Supported employment and education","Psychotic Symptoms","MaineHealth|Robert Wood Johnson Foundation","All","12 Years to 25 Years   (Child, Adult)","Not Applicable","292","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","58920|RWJF #58920","October 2007","May 2013","September 2013","September 19, 2007","August 15, 2016","August 15, 2016","University of California-Davis, Imaging Research Center, Sacramento, California, United States|Portland Identification and Early Referral Program, Portland, Maine, United States|Washtenaw County, Ann Arbor, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Zucker Hillside Hosptial, Glen Oaks, New York, United States|Mid-Valley Behavioral Care Network, Salem, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00531518"
2388,"NCT04186507","Indirect Evaluation of Lithium Level in Blood Using Non-invasive Sweat Biosensors",,"Active, not recruiting","No Results Available","Lithium Level Detection in Sweat","Combination Product: Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)","Lithium sweat concentration","Tirat Carmel Mental Health Center|Ariel University","All","18 Years to 75 Years   (Adult, Older Adult)",,"75","Other","Observational","Observational Model: Other|Time Perspective: Other","TiratCarmelMHC","January 1, 2020","January 31, 2021","July 1, 2021","December 4, 2019",,"October 8, 2020","Tirat Carmel Mental Health Center, Tirat Karmel, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT04186507"
2389,"NCT00270244","Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics",,"Completed","No Results Available","Depression","Behavioral: Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Behavioral: Treatment as usual (TAU)","Depressive symptoms as measured by the Hamilton Rating Scale for Depression (HRSD) and the Center for Epidemiological Studies-Depression Scale (CES-D)|Overall impairment, as measured by the Global Assessment Scale for Children (C-GAS)|Social functioning, as measured by the Social Adjustment Scale-Self-report (SAS-SR)|Short Acculturation Scale for Hispanics, CES-D, HRSD, C-GAS, Clinical Global Improvement, Inventory of Parent and Peer Attachment, Family Adaptation and Cohesions Evaluation Scales III, and the Penn Helping Alliance Questionnaire-Revised","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","Female","12 Years to 18 Years   (Child, Adult)","Phase 2","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","R01 MH73640, #5037|R01MH073640|DSIR 84-CTS","December 2005","January 2008","January 2008","December 26, 2005",,"December 30, 2011",,,"https://ClinicalTrials.gov/show/NCT00270244"
2390,"NCT03249376","Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally",,"Completed","No Results Available","Bipolar Depression","Drug: Lumateperone|Other: Placebo","Montgomery-Åsberg Depression Rating Scale (MADRS)|Clinical Global Impression Scale, Bipolar version (CGI-BP)|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)","Intra-Cellular Therapies, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ITI-007-404","November 27, 2017","March 1, 2019","March 1, 2019","August 15, 2017",,"April 14, 2021","Clinical Site, Birmingham, Alabama, United States|Clinical Site, Sherman Oaks, California, United States|Clinical Site, Miami, Florida, United States|Clinical Site, Orange City, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Decatur, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Joliet, Illinois, United States|Clinical Site, Shreveport, Louisiana, United States|Clinical Site, Saint Louis, Missouri, United States|Clinical Site, Buffalo, New York, United States|Clinical Site, Charlotte, North Carolina, United States|Clinical Site, The Woodlands, Texas, United States|Clinical Site, Bothell, Washington, United States|Clinical Site, Burgas, Bulgaria|Clinical Site, Kardzhali, Bulgaria|Clinical Site, Lovech, Bulgaria|Clinical Site, Plovdiv, Bulgaria|Clinical Site, Ruse, Bulgaria|Clinical Site, Sofia, Bulgaria|Clinical Site, Targovishte, Bulgaria|Clinical Site, Tzarev Brod, Bulgaria|Clinical Site, Varna, Bulgaria|Clinical Site, Veliko Tarnovo, Bulgaria|Clinical Site, Barranquilla, Colombia|Clinical Site, Bello, Colombia|Clinical Site, Pereira, Colombia|Clinical Site, Ekaterinburg, Russian Federation|Clinical Site, Moscow, Russian Federation|Clinical Site, Nizhny Novgorod, Russian Federation|Clinical Site, Omsk, Russian Federation|Clinical Site, Saint Petersburg, Russian Federation|Clinical Site, Samara, Russian Federation|Clinical Site, Saratov, Russian Federation|Clinical Site, Tomsk, Russian Federation|Clinical Site, Belgrade, Serbia|Clinical Site, Kragujevac, Serbia|Clinical Site, Novi Sad, Serbia|Clinical Site, Ivano-Frankivs'k, Ukraine|Clinical Site, Kharkiv, Ukraine|Clinical Site, Kherson, Ukraine|Clinical Site, Lviv, Ukraine|Clinical Site, Odesa, Ukraine|Clinical Site, Poltava, Ukraine|Clinical Site, Smila, Ukraine|Clinical Site, Uzhgorod, Ukraine|Clinical Site, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03249376"
2391,"NCT01359618","Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart",,"Terminated","No Results Available","Healthy Male","Drug: TC-5214|Other: Placebo comparator|Drug: Moxifloxacin|Other: Moxifloxacin placebo comparator","Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: The number of participants with adverse events|Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in laboratory assessments.|Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in vital signs.|Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in electrocardiogram (ECG).|Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in physical examination.|Part B: The maximum mean change in time-matched ECG interval, measured from the onset of the QRS complex to the T point, using the best heart rate correction method (QTc).|Part A: TC-5214 Plasma and urine pharmacokinetic variable to be measured: including, C max, time to C max, Area Under Curve (AUC) (0-t), terminal half life, cumulative amount of drug excreted unchanged into urine from zero to time and renal clearance|Part B: A change in the maximum of the mean change in time-matched ECG interval, measured from the onset of the QRS complex|Part B: Assay sensitivity by measuring the effect of moxifloxacin 400 mg on QTc compared to placebo","AstraZeneca","Male","18 Years to 50 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D4130C00009","June 2011","April 2012","April 2012","May 25, 2011",,"December 12, 2012","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01359618"
2392,"NCT00844857","A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression",,"Completed","Has Results","Bipolar Depression","Drug: Olanzapine Fluoxetine Combination (OFC)|Drug: Placebo","Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8|Percentage of Participants With Remission Up to Week 8|Percentage of Participants With Response Up to Week 8|Percentage of Participants in Each Improvement Category Up to Week 8|Change From Baseline in the YMRS Total Score at Week 8|Change From Baseline in the Clinical Global Impression Scale - Bipolar Version (CGI-BP) Score at Week 8|Change From Baseline in the CDRS-R Total Score Up to Week 8|Percentage of Participants With at Least One Treatment-Emergent Incident of Akathisia Up to Week 8|Percentage of Participants With Treatment Emergent Suicidal Ideation or Behavior Up to Week 8|Percentage of Participants With at Least One Incident of Worsening of Mania Up to Week 8|Change From Baseline in Symptoms of Attention-Deficit/Hyperactivity Disorder Up to Week 8|Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Parent Scale Up to Week 8","Eli Lilly and Company","All","10 Years to 17 Years   (Child)","Phase 4","291","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12116|H6P-MC-HDAX","April 2009","February 2012","February 2012","February 16, 2009","February 18, 2013","February 18, 2013","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lipetsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tver, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00844857"
2393,"NCT00357097","The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome",,"Completed","Has Results","Restless Legs Syndrome|Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)","Drug: Ropinirole","Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment|Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of at Least Moderate Depression (MADRS Score: >=18)|Average Change of the HAM-D (Hamilton Depression Rating Scale, 17-item-Version) Total Score From Baseline to Final Visit After 12 Weeks of Treatment|Average Change of the HAM-D Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of an at Least Moderate Depression (HAM-D Score >= 15) at Baseline|Average Change of the Beck Depression Inventory (BDI) Total Score From Baseline to Final Visit After 12 Weeks of Treatment|Average Change of the Beck Depression Inventory (BDI) Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of an at Least Mild-moderate Depression (BDI >= 21) at Baseline|Percentage of Participants With at Least Moderate Depression (MADRS Score >= 18) at Baseline and in Week 12|Percentage of Participants With at Least Moderate Depression (HAM-D >= 15) at Baseline and in Week 12|Percentage of Participants (""Responder"") With a Decrease of MADRS Total Score of at Least 6 Points After 12 Weeks Compared to Baseline|Percentage of Participants (""Responder"") With a Decrease of MADRS Total Score of at Least 6 Points After 12 Weeks Compared to Baseline in Subjects With Signs of at Least Moderate Depression at Baseline (MADRS Score >= 18)|Change in Average MADRS Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)|Change in Average HAM-D Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)|Change in Average BDI Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)|Change in Average International Restless Legs Scale for Severity (IRLS) Scores in All Participants From Baseline to After 1, 4, and 12 Weeks|Percentage of Participants With a Decrease of International Restless Legs Scale (IRLS) Scores of at Least 6 Points After 1, 4 and 12 Weeks|Percentage of Participants With ""Much Improved"" or ""Very Much Improved"" on the Clinical Global Impression-Global Improvement Scale After 1, 4 and 12 Weeks|Change From Average Baseline Score of Subscale of ""Somnolence"" in the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks|Change From Average Baseline Scores of Subscale ""Sleep Disturbance"" of the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks|Change From Average Baseline Scores of Subscale ""Sleep Adequacy"" of the Medical Outcomes Study Sleep Scale (MOS-SS)to Final Visit After 12 Weeks|Change From Average Baseline Scores of Subscale ""Sleep Quantity"" (Hours) of the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks","GlaxoSmithKline","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RRL106721","June 2006","December 2007","December 2007","July 27, 2006","September 16, 2009","June 7, 2012","GSK Investigational Site, Ellwangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Unterhaching, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Bad Saarow, Brandenburg, Germany|GSK Investigational Site, Bad Homburg, Hessen, Germany|GSK Investigational Site, Butzbach, Hessen, Germany|GSK Investigational Site, Herborn, Hessen, Germany|GSK Investigational Site, Kassel, Hessen, Germany|GSK Investigational Site, Anklam, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Wismar, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Wolfsburg, Niedersachsen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Guetersloh, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hattingen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Juelich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Limburgerhof, Rheinland-Pfalz, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Koethen, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Oldenburg, Schleswig-Holstein, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00357097"
2394,"NCT01548703","A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: BCI-838","Safety|Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632|Quantitative EEG (qEEG) assessments","BrainCells Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCI-632-CL-003","February 2012","April 2012","April 2012","March 8, 2012",,"May 9, 2012","PRA International, Zuidlaren, Netherlands",,"https://ClinicalTrials.gov/show/NCT01548703"
2395,"NCT01546051","A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: BCI-838|Drug: BCI-1038, BCI-1206 & BCI-1283","Safety|Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632","BrainCells Inc.","Male","18 Years to 55 Years   (Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCI-632-CL-002","October 2011","January 2012","February 2012","March 7, 2012",,"March 7, 2012","PRA International, Zuidlaren, Netherlands",,"https://ClinicalTrials.gov/show/NCT01546051"
2396,"NCT01396135","A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects",,"Withdrawn","No Results Available","Healthy","Drug: CP-601,927|Drug: Placebo","Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 1 mg CP-601,927|Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 2 mg CP-601,927|Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 3 mg CP-601,927|Ctrough, Cmax, AUC0-12, Tmax and as data permit t1/2, CL/F and Rac (accumulation ratio) based on Cmax and AUC0-12 after multiple doses of CP-601,927 given as 2 mg BID (4mg/day) for 7 days|Suicidality assessment after single dose of 1 mg CP-601,927|Suicidality assessment after single dose of 2 mg CP-601,927|Suicidality assessment after single dose of 3 mg CP-601,927|Suicidality assessment after multiple doses of CP-601,927 given as 2 mg BID (4mg/day) for 7 days","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","A3331019","August 26, 2011","October 29, 2011","October 29, 2011","July 18, 2011",,"October 30, 2018",,,"https://ClinicalTrials.gov/show/NCT01396135"
2397,"NCT00576095","Clinical and Biological Characteristics of Psychotic Depression",,"Completed","No Results Available","Depression|Psychotic Disorders|Depressive Disorder, Major",,"Cortisol|Cognitive function","Stanford University|National Institutes of Health (NIH)","All","18 Years to 85 Years   (Adult, Older Adult)",,"73","Other|NIH","Observational","Time Perspective: Prospective","2R01MH050604-10|MH50604","August 2005","June 2012","June 2012","December 18, 2007",,"March 14, 2014","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00576095"
2398,"NCT03646058","Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode","BUPRIS","Recruiting","No Results Available","Suicidal Ideation|Major Depressive Episode","Drug: Buprenorphine|Drug: Placebo","Changes in Beck Scale for Suicidal Ideation (SSI) scores from Day 0 to 7|Changes in Beck Scale for Suicidal Ideation (SSI) scores|Changes in Beck Depression Inventory II (BDI-II) scores from Day 0 to 28|Changes in Montgomery-Asberg Depression Rating Scale (MADRS) from Day 0 to 28|Changes in Physical and Psychological Pain - Visual Analog Scale (PPP-VAS) scores from Day 0 to 28|Reasons for discontinuing treatment over the first 28 days|Side effects over the first 28 days|Withdrawal symptoms|Occurence of a suicide attempt during the whole study|Changes in Iowa Gambling Task (IGT) scores between Day 0 and 28|Changes in modified Stroop test scores between Day 0 and 28|Changes in verbal fluency test scores between Day 0 and 28|Changes in N-Back test scores between Day 0 and 28|Changes in Go/No-Go test between Day 0 and 28|Changes in Trail Making Test (TMT) scores between Day 0 and 28|Changes in Implicit Association Test (IAT) scores between Day 0 and 28|Changes in Magnetic Resonance Imaging (MRI) T1 measures between Day 0 and 28|Changes in Magnetic Resonance Imaging (MRI) T2 measures between Day 0 and 28|Changes in Magnetic Resonance Imaging (MRI) Diffusion Tensor Imaging (DTI) measures between Day 0 and 28|Changes in Magnetic Resonance Imaging (MRI) Resting State (RS) measures between Day 0 and 28","Centre Hospitalier Universitaire de Nīmes","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PHRC-N/2017/FJ-01","September 2021","September 2021","May 2022","August 24, 2018",,"July 14, 2021","CHRU Hôpital Saint-Jacques, Besançon, France|CHU Grenoble Alpes, La Tronche, France|CHU Bicêtre, Le Kremlin-Bicêtre, France|Hospices Civils de Lyon, Lyon, France|CHU Lapeyronie, Montpellier, France|CAPPA Jacques PREVERT, Nantes, France|Clinique Les Sophoras, Nîmes, France|CHU Nîmes, Nîmes, France|CH Sainte-Anne, Paris, France|CH Henri Laborit, Poitiers, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT03646058"
2399,"NCT01066897","Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole",,"Terminated","Has Results","Depression","Drug: Pramipexole","Number of Participants Who Discontinued Study Due to Side-effects of the Medication|% Change in Hamilton Depression Rating Scale From Baseline to week8|Change in Mesolimbic Reward System Activity From Pre to Post Treatment (8 Weeks)|Mesolimibic Reward Activity Baseline Differences in Depression vs Healthy Controls","Stanford University|National Alliance for Research on Schizophrenia and Depression","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-02042010-4902|17847","February 2010","February 2013","February 2013","February 10, 2010","May 16, 2017","May 16, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01066897"
2400,"NCT01065597","Nonconvulsive Electrotherapy: a Proof-of-concept Trial",,"Completed","Has Results","Depressive Disorder|Bipolar Disorder|Schizoaffective Disorder","Device: Nonconvulsive electrotherapy","Change in Score on the 17-item Hamilton Depression Rating Scale|Change in Score on Mini-mental State Exam|Change in Score on the Autobiographical Memory Inventory Short Form (AMI-S)|Change in Brain-derived Neurotrophic Factor (BDNF) Blood Level","University of Maryland, College Park|Brain & Behavior Research Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00040324","May 2010","March 2014","April 2014","February 9, 2010","August 10, 2015","August 28, 2015","University of Maryland Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01065597"
2401,"NCT03679962","Triple Chronotherapy in Adolescents","TCT-RCT","Recruiting","No Results Available","Depressive Disorder, Major|Bipolar Depression|Suicidal Ideation","Behavioral: Triple Chronotherapy|Behavioral: Treatment as Usual","Patient Health Questionnaire -Adolescent version (PHQ-A)|Columbia Suicide Severity Rating Scale|Patient Health Questionnaire-Adolescent version (PHQ-A)|Youth Quality of life Questionnaire","Billings Clinic","All","12 Years to 17 Years   (Child)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18.26","January 25, 2019","December 2022","December 2022","September 21, 2018",,"May 6, 2021","Billings Clinic, Billings, Montana, United States",,"https://ClinicalTrials.gov/show/NCT03679962"
2402,"NCT02600494","Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression",,"Completed","No Results Available","Bipolar Depression","Drug: ITI-007 (Lumateperone)|Drug: Placebo","Montgomery-Åsberg Depression Rating Scale (MADRS)","Intra-Cellular Therapies, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ITI-007-401","December 15, 2015","January 28, 2019","July 24, 2019","November 9, 2015",,"April 14, 2021","Clinical Site, Little Rock, Arkansas, United States|Clinical Site, Rogers, Arkansas, United States|Clinical Site, Cerritos, California, United States|Clinical Site, Culver City, California, United States|Clinical Site, Garden Grove, California, United States|Clinical Site, Lemon Grove, California, United States|Clinical Site, National City, California, United States|Clinical Site, Oakland, California, United States|Clinical Site, Oceanside, California, United States|Clinical Site, Orange, California, United States|Clinical Site, Pico Rivera, California, United States|Clinical Site, Riverside, California, United States|Clinical Site, San Diego, California, United States|Clinical Site, San Marcos, California, United States|Clinical Site, Santa Rosa, California, United States|Clinical Site, Colorado Springs, Colorado, United States|Clinical Site, Bradenton, Florida, United States|Clinical Site, Fort Myers, Florida, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, Lauderhill, Florida, United States|Clinical Site, Miami, Florida, United States|Clinical Site, North Miami, Florida, United States|Clinical Site, Orlando, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Hoffman Estates, Illinois, United States|Clinical Site, Lake Charles, Louisiana, United States|Clinical Site, Baltimore, Maryland, United States|Clinical Site, Boston, Massachusetts, United States|Clinical Site, O'Fallon, Missouri, United States|Clinical Site, Saint Louis, Missouri, United States|Clinical Site, Las Vegas, Nevada, United States|Clinical Site, Berlin, New Jersey, United States|Clinical Site, Cherry Hill, New Jersey, United States|Clinical Site, Marlton, New Jersey, United States|Clinical Site, Toms River, New Jersey, United States|Clinical Site, Brooklyn, New York, United States|Clinical Site, Cedarhurst, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, Rochester, New York, United States|Clinical Site, Staten Island, New York, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Cleveland, Ohio, United States|Clinical Site, Dayton, Ohio, United States|Clinical Site, Garfield Heights, Ohio, United States|Clinical Site, Oklahoma City, Oklahoma, United States|Clinical Site, Allentown, Pennsylvania, United States|Clinical Site, Norristown, Pennsylvania, United States|Clinical Site, Philadelphia, Pennsylvania, United States|Clinical Site, Memphis, Tennessee, United States|Clinical Site, Austin, Texas, United States|Clinical Site, Dallas, Texas, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Petersburg, Virginia, United States|Clinical Site, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02600494"
2403,"NCT02600507","Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression",,"Completed","No Results Available","Bipolar Depression","Drug: ITI-007|Drug: Placebo","Montgomery-Åsberg Depression Rating Scale (MADRS)","Intra-Cellular Therapies, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","529","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ITI-007-402","March 7, 2016","July 2, 2020","July 2, 2020","November 9, 2015",,"April 13, 2021","Clinical Site, Rogers, Arkansas, United States|Clinical Site, Cerritos, California, United States|Clinical Site, Costa Mesa, California, United States|Clinical Site, Culver City, California, United States|Clinical Site, Garden Grove, California, United States|Clinical Site, Glendale, California, United States|Clinical Site, Lemon Grove, California, United States|Clinical Site, Oceanside, California, United States|Clinical Site, Pico Rivera, California, United States|Clinical Site, Riverside, California, United States|Clinical Site, San Diego, California, United States|Clinical Site, Santa Rosa, California, United States|Clinical Site, Sherman Oaks, California, United States|Clinical Site, Temecula, California, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, Lauderhill, Florida, United States|Clinical Site, Miami, Florida, United States|Clinical Site, Orange City, Florida, United States|Clinical Site, Orlando, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Savannah, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Lake Charles, Louisiana, United States|Clinical Site, Baltimore, Maryland, United States|Clinical Site, O'Fallon, Missouri, United States|Clinical Site, Saint Louis, Missouri, United States|Clinical Site, Las Vegas, Nevada, United States|Clinical Site, Berlin, New Jersey, United States|Clinical Site, Cherry Hill, New Jersey, United States|Clinical Site, Toms River, New Jersey, United States|Clinical Site, Cedarhurst, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, Rochester, New York, United States|Clinical Site, Staten Island, New York, United States|Clinical Site, Charlotte, North Carolina, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Dayton, Ohio, United States|Clinical Site, Garfield Heights, Ohio, United States|Clinical Site, Allentown, Pennsylvania, United States|Clinical Site, Philadelphia, Pennsylvania, United States|Clinical Site, The Woodlands, Texas, United States|Clinical Site, Everett, Washington, United States|Clinical Site, Burgas, Bulgaria|Clinical Site, Kardzhali, Bulgaria|Clinical Site, Lovech, Bulgaria|Clinical Site, Pleven, Bulgaria|Clinical Site, Plovdiv, Bulgaria|Clinical Site, Ruse, Bulgaria|Clinical Site, Sofia, Bulgaria|Clinical Site, Varna, Bulgaria|Clinical Site, Veliko Tarnovo, Bulgaria|Clinical Site, Vratsa, Bulgaria|Clinical Site, Moscow, Russian Federation|Clinical Site, Nizhny Novgorod, Russian Federation|Clinical Site, Omsk, Russian Federation|Clinical Site, Saint Petersburg, Russian Federation|Clinical Site, Samara, Russian Federation|Clinical Site, Saratov, Russian Federation|Clinical Site, Tomsk, Russian Federation|Clinical Site, Belgrade, Serbia|Clinical Site, Kovin, Serbia|Clinical Site, Novi Sad, Serbia|Clinical Site, Sumadija, Serbia|Clinical Site, Ivano-Frankivs'k, Ukraine|Clinical Site, Kharkiv, Ukraine|Clinical Site, Kropyvnytskyi, Ukraine|Clinical Site, Odesa, Ukraine|Clinical Site, Poltava, Ukraine|Clinical Site, Smila, Ukraine|Clinical Site, Vasylkiv, Ukraine|Clinical Site, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02600507"
2404,"NCT03396068","NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation","SBD-ASIB","Recruiting","No Results Available","Bipolar Depression|Suicidal Ideation","Drug: NRX-101|Drug: Lurasidone HCl","MADRS-10|Time to Relapse (stage 2)","NeuroRx, Inc.|Target Health Inc.|Vanguard, Inc","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","72","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX101_002","December 1, 2019","August 31, 2021","December 31, 2021","January 10, 2018",,"November 2, 2020","Research Site, Birmingham, Birmingham, Alabama, United States|Research Centers of America, Hollywood, Florida, United States|JP Smith Hospital, Fort Worth, Texas, United States|Research Site, Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03396068"
2405,"NCT03423680","A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","APOLLO","Unknown status","No Results Available","Depression, Bipolar","Drug: Abilify 2, 5, 10, 15mg (Tablet)|Drug: Placebo of Abilify 2, 5, 10, 15mg (Tablet)","Mean change in the Montgomery-Åsberg Depression Rating Scale total score|Mean change in the Clinical Global Impression-BP version Severity of Illness (Depression) score|Response rate|Remission rate|Percentage of subjects with Clinical Global Impression-BP version Severity of Illness (Depression) score of 1 or 2","Korea Otsuka Pharmaceutical Co., Ltd.","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 3","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","031-402-00154","February 22, 2018","March 2020","June 2020","February 6, 2018",,"January 7, 2019","Seounl National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03423680"
2406,"NCT01430455","Tranylcypromine Treatment of Bipolar Depression",,"Completed","Has Results","Bipolar Disorder I or II","Drug: Tranylcypromine","29 Item Hamilton Rating Scale for Depression (HamD29)","New York State Psychiatric Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6333","November 2011","February 2014","September 2014","September 8, 2011","March 15, 2018","March 15, 2018","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01430455"
2407,"NCT04854785","Neuroinflammation in COVID-19 and Depression",,"Recruiting","No Results Available","Major Depressive Episode|Covid19","Other: [18F]FEPPA PET scan|Other: [11C]SL25.1188 PET scan","TSPO VT in prefrontal cortex, anterior cingulate cortex, and hippocampus|MAO-B VT in prefrontal cortex, anterior cingulate cortex, and hippocampus","Centre for Addiction and Mental Health","All","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","177/2020","May 2021","April 2023","April 2023","April 22, 2021",,"April 22, 2021","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04854785"
2408,"NCT03770156","Terrorist Attack - Continuity of Care","CUMP75","Completed","No Results Available","Post-Traumatic Stress Disorder|Major Depressive Episode","Behavioral: Questionnaires","Clinical Global Impression - Improvement scale (CGI-I)|Clinical Global Impression - Severity scale (CGI-S)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NI18012J|2017-A01382-51","January 22, 2020","October 22, 2020","October 22, 2020","December 10, 2018",,"February 2, 2021","CUMP Paris, Paris, France",,"https://ClinicalTrials.gov/show/NCT03770156"
2409,"NCT00888264","A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder","HARMONY","Completed","No Results Available","Bipolar Disorders",,"Details of any AAP prescribed 1 to 6 months prior to the first study visit:|Montgomery Asberg Depression Rating Scale (MADRS), a 10-point observer rating scale, used to assess the symptoms and severity of depression.|Young Mania Rating Scale (YMRS), an 11-point observer rating scale, used to assess the symptoms and severity of mania.|Remission rate for the major depressive episode, in progress at inclusion","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)",,"152","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIS-NBE-SER-2008/1","May 2009","August 2010","August 2010","April 27, 2009",,"December 22, 2010","Research Site, Aarschot, Belgium|Research Site, Afsnee, Belgium|Research Site, Antwerpen, Belgium|Research Site, Asse, Belgium|Research Site, Berchem, Belgium|Research Site, Bertrix, Belgium|Research Site, Bierbeek, Belgium|Research Site, Bouge, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Courtrai, Belgium|Research Site, Dave, Belgium|Research Site, Dendermonde, Belgium|Research Site, Elsene, Belgium|Research Site, Erpe Mere, Belgium|Research Site, Geel, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Ixelles, Belgium|Research Site, Kortenberg, Belgium|Research Site, Laeken, Belgium|Research Site, Lebbeke, Belgium|Research Site, Lede, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont, Belgium|Research Site, Liege, Belgium|Research Site, Lierneux, Belgium|Research Site, Lubbeek, Belgium|Research Site, Malle, Belgium|Research Site, Marchienne-au-pont, Belgium|Research Site, Mons, Belgium|Research Site, Montignies-sur-sambre, Belgium|Research Site, Namur, Belgium|Research Site, Ottignies, Belgium|Research Site, Roselaere, Belgium|Research Site, Saint-Servais, Belgium|Research Site, Sint-Josse-ten-Noode, Belgium|Research Site, Sint-Martens-Latem, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Sleidinge, Belgium|Research Site, St Denijs Westrem, Belgium|Research Site, St-Truiden, Belgium|Research Site, Tienen, Belgium|Research Site, Tournai, Belgium|Research Site, Zottegem, Belgium|Research Site, Zoutleeuw, Belgium",,"https://ClinicalTrials.gov/show/NCT00888264"
2410,"NCT00804739","Perinatal Depression Treatment in a Pediatric Setting- Pilot Phase","MITT","Completed","No Results Available","Postpartum Depression","Other: Mother-Infant Treatment Team","Treatment Engagement|Treatment Adherence|Treatment Response|Treatment Remission|Maternal functional assessment|Maternal healthcare utilization|Infant healthcare utilization","University of Rochester|National Institute of Mental Health (NIMH)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1R34MH082141-01","January 2009","January 2012","January 2012","December 9, 2008",,"February 27, 2012","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00804739"
2411,"NCT00366652","Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects",,"Completed","No Results Available","Depression|Depressive Disorder|Depressive Disorder, Major","Drug: desvenlafaxine SR|Drug: desipramine|Drug: duloxetine","The primary outcome of the study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 55 Years   (Adult)","Phase 3","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-401","September 2006",,"September 2006","August 21, 2006",,"May 28, 2007","Neptune, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00366652"
2412,"NCT01403662","Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression",,"Completed","No Results Available","Bipolar Disorder|Bipolar Depression|Bipolar I Depression|Bipolar II Depression","Drug: Minocycline","Change from baseline to week 8 on the Montgomery Asberg Depression Rating Scale (MADRS)|Change from baseline to week 8 on the Hamilton Depression Rating Scale 17-item (HAMD-17)|Change from baseline to week 8 on the Somatic Symptom Inventory (SSI)|Change from baseline to week 8 on the Clinical Global Impression (CGI) Rating Scale|Change from baseline to week 8 in the in neurocognitive function|Monitoring of Side-effects from baseline to week 8 with the Toronto Side Effect Scale (TSES)|Monitoring of suicide severity from baseline to week 8 with the Columbia Suicide Severity Rating Scale (C-SSRS).|Change from baseline to week 8 in concentrations of pro-and anti-inflammatory cytokines (e.g. TNFα, IL-1β, IL-2, IL-6, IL8, IFNγ, IL-4, IL-5, IL-10)","University Health Network, Toronto","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3420337","July 2011","February 2014","December 2014","July 27, 2011",,"December 19, 2016","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01403662"
2413,"NCT00231959","Effectiveness of Pramipexole for Treatment-Resistant Depression",,"Completed","No Results Available","Depression","Drug: Pramipexole (Mirapex)|Drug: Placebo","Score on the Montgomery-Asberg Depression Rating Scale|Clinical Global Impressions (CGI) scale","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","65","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K23MH067060|DATR AK-TNGP1","September 2003","September 2007","April 2008","October 4, 2005",,"April 26, 2012","Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00231959"
2414,"NCT00070694","An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression",,"Completed","No Results Available","Depressive Disorder","Drug: MDL100.907",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","96","NIH","Interventional","Primary Purpose: Treatment","030315|03-M-0315","September 2003",,"October 2004","October 7, 2003",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00070694"
2415,"NCT02039479","Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode",,"Unknown status","No Results Available","Suicidal Ideation/Behavior|Depression","Drug: Lithium Carbonate|Drug: Placebo","S-STS|C-SSRS","Technische Universität Dresden","All","18 Years and older   (Adult, Older Adult)","Not Applicable","254","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01KG1307","January 2014","March 2018","June 2018","January 17, 2014",,"March 15, 2018","Dept. of Psychiatry and Psychotherapy, Hospital of Dresden Neustadt, Dresden, Saxony, Germany|Psychiatrie, Verhaltensmedizin und Psychosomatik, Chemnitz, Germany|Klinik für Psychiatrie, Psychosomatik und Psychotherapie Universitätsklinikum Frankfurt, Frankfurt am main, Germany|Psychatrie Universitätsmedizin Göttingen, Göttingen, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT02039479"
2416,"NCT00395213","Antidepressant Safety in Kids Study","ASK","Completed","No Results Available","Anxiety Disorders|Depressive Disorders|Eating Disorders|Obsessive Compulsive Disorder","Drug: Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications","Score on the Clinical Global Impression Improvement scale (CGI-I)|Clinician Patient Access to Electronic Records System|CAPTN Serious Adverse Events (SAE)/Harm-related adverse events form|Score on the Clinical Global Impression Severity scale (CGI-S)|Score on the Children's Global Assessment Scale (CGAS)|Parent Coping Strategies Questionnaire (CSQ)|Youth Coping Strategies Questionnaire (CSQ)","Duke University|National Institute of Mental Health (NIMH)","All","7 Years to 17 Years   (Child)",,"569","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00013655|P30MH066386|DSIR CTM|3159; 8067-06-1","May 2007","July 2009","July 2009","November 2, 2006",,"April 17, 2015","Child and Adolescent Psychiatry Trials Network (CAPTN), Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00395213"
2417,"NCT00481988","Treating Depression With Transcranial Direct Current Stimulation (tDCS)",,"Completed","Has Results","Depression","Device: transcranial direct current stimulation|Device: iomed phoresor transcranial direct current stimulation","Hamilton Rating Scale for Depression (24 Question Version), a Standardized Assessment Tool for Measuring Severity of Depression Where 0 is the Minimum Score (no Depressive Symptoms) and 40 is the Maximum (Severe Depression).|Beck Depression Inventory II","New York State Psychiatric Institute|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","5405","March 2007","June 2009","January 2011","June 4, 2007","May 20, 2013","May 20, 2013","New York State Psychiatric Institute, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT00481988"
2418,"NCT02178631","Effectiveness of Internet-based Depression Treatment (EVIDENT) in Severe Depression",,"Completed","No Results Available","Severe Depressive Symptoms","Behavioral: Deprexis|Other: CAU","Patient Health Questionnaire - 9 items (PHQ-9)|Quick Inventory of Depressive Symptoms - Self-Rreport (QIDS-SR16)|Generalized Anxiety Disorder - 7 (GAD-7)|Patient Health Questionnaire - 15 items (PHQ-15)|Short Form Health Survey - 12 (SF-12)","University of Luebeck|Björn Meyer, Gaia AG, Hamburg, Germany / Department of Psychology, City University, London, United Kingdom|University of Hamburg-Eppendorf|University of Bern","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EVIDENTplus","February 2013","May 2014","May 2014","July 1, 2014",,"May 27, 2015","Department of Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Germany|Gaia AG, Hamburg, Germany|Department of Psychiatry and Psychotherapy, University of Luebeck, Luebeck, Germany|Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02178631"
2419,"NCT04744259","BEAT-IT: Behavioural Activation and Severe Learning Disabilities",,"Recruiting","No Results Available","Depression","Behavioral: Behavioural Activation","Change from baseline on the Mood, Interest and Pleasure Questionnaire (MIPQ) at 24 weeks|Change from baseline on Intellectual Disabilities Depression Scale (IDDS) at 24 weeks|Change from baseline on the Anxiety, Depression and Mood Scale at 24 weeks|Change from baseline on the Modified Index of Community Involvement (ICI) at 24 weeks|Change from baseline on the Modified Index of Domestic Participation at 24 weeks|Change from baseline on the Emotional Difficulties self-efficacy scale at 24 weeks","NHS Greater Glasgow and Clyde|University of Glasgow|Lancaster University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GN18MH490","February 18, 2019","December 2021","April 2022","February 8, 2021",,"February 8, 2021","Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04744259"
2420,"NCT00060736","The Effects of Estrogen Withdrawal on Mood Symptoms in Women",,"Completed","No Results Available","Perimenopausal Depression|Post Menopausal|Healthy|Depression",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Female","45 Years to 65 Years   (Adult, Older Adult)",,"60","NIH","Observational",,"030175|03-M-0175","May 5, 2003",,"April 27, 2016","May 12, 2003",,"December 16, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00060736"
2421,"NCT03348761","rTMS Response Trajectories in Depression",,"Recruiting","No Results Available","Depression","Device: rTMS group","Montgomery-Ashberg Depression Rating Scale|Clinical Global Impression Scale","Chinese University of Hong Kong|Rudolf Magnus Institute - University of Utrecht|Icahn School of Medicine at Mount Sinai","All","18 Years to 64 Years   (Adult)","Not Applicable","128","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CRE-2014.041","August 4, 2015","December 31, 2021","December 31, 2021","November 21, 2017",,"July 23, 2020","Department of Psychiatry, CUHK, Hong Kong, Hong Kong","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03348761/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03348761"
2422,"NCT00006180","Bone Loss in Premenopausal Women With Depression",,"Completed","No Results Available","Depression|Healthy|Osteopenia|Osteoporosis","Drug: Alendronate",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Female","21 Years to 45 Years   (Adult)","Phase 4","220","NIH","Interventional","Primary Purpose: Treatment","000203|00-M-0203","August 10, 2000",,"January 19, 2007","August 18, 2000",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00006180"
2423,"NCT00029640","The Treatment of Children and Adolescents With Treatment-Resistant Depression",,"Completed","No Results Available","Bipolar Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"90","NIH","Observational",,"020108|02-M-0108","January 2002",,"March 2004","January 17, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00029640"
2424,"NCT00253071","Early Integrated Intervention in Severe Affective Disorders",,"Completed","No Results Available","Depressive Disorder|Bipolar Disorder","Behavioral: Prophylactic combined medical and psychological treatment","Time to re-admission|Time to recurrence of an affective episode (depressive (MDI) or manic/mixed (MDQ)).","Hovedstadens Sygehusfaelesskab|Rigshospitalet, Denmark|Hvidovre University Hospital|Amager Hospital|Frederiksberg University Hospital|Bispebjerg Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","31/04r","December 2005","March 2012","March 2012","November 15, 2005",,"March 19, 2015","Department of Psychiatry, University Hospital of Copenhagen, Denmark, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00253071"
2425,"NCT03019497","Cognitive-behavioral Therapy for Treatment of Post-traumatic Stress Disorder and Related Problems","CBT-PTSD-RP","Recruiting","No Results Available","PTSD","Behavioral: Specific Modules|Behavioral: Cognitive behavioral therapy","Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2013)|The Structured Clinical Interview (SCID-I; First, Spitzer, Gibbon & Williams, 1995)|The Beck II Depression Inventory (BDI-II; Beck, Steer & Brown, 1996)|The Beck Anxiety Inventory (BAI; Beck, Epstein, Brown & Steer, 1988)|The WHOQOL - Bref (WHOQOL Group, 1998)|The Inventory of Social Support in Anxious Situations (ISSAS; St-Jean-Trudel et al., 2005)|The Pittsburgh Sleep Quality Index (PSQI)|The Life Events Questionnaire (LEQ; Norbeck, 1984)|The Brief Pain Inventory (BPI; Cleeland, 1989)|The Health Cost Interview|The Social Provisions Scale (SPS; Cutrona & Russel, 1987)|The Posttraumatic Stress Disorder Checklist Scale-version DSM-5 (PCL-5; Weathers, Litz et al., 2013)","Université de Montréal|Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","365935","January 2017","June 2021","December 2021","January 12, 2017",,"March 31, 2020","Stephane Guay, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03019497"
2426,"NCT01536756","Effectiveness of a Structured Physical Rehabilitation Program for Chinese Patients With Depressive Disorders",,"Completed","No Results Available","Depressive Disorders","Other: Exercise Intervention -- Physical Rehabilitation Program|Other: Wait List Control Group","Change from Baseline in Body Composition at 3 months and 12 months|Change from Baseline in Flexibility at 3 months and 12 months|Change from Baseline in Muscle Strength at 3 months and 12 months|Change from Baseline in Muscular Endurance at 3 months and 12 months|Change from Baseline in Cardiovascular Endurance at 3 months and 12 months|Change from Baseline in Physical Functioning at 3 months and 12 months|Change from Baseline in Depression, Anxiety and Stress at 3 months and 12 months|Change from Baseline in Depression at 3 months and 12 months|Change from Baseline in Self-esteem at 3 months and 12 months","Kowloon Hospital, Hong Kong|Kwai Chung Hospital, Hong Kong","All","18 Years to 64 Years   (Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","KH-KCH-PSY-RCT","February 2012","December 31, 2015","December 31, 2015","February 22, 2012",,"January 23, 2020","Physiotherapy Department, Kowloon Hospital, Hong Kong, China|Physiotherapy Department, Kwai Chung Hospital, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT01536756"
2427,"NCT00001174","Evaluation of the Genetics of Bipolar Disorder",,"Recruiting","No Results Available","Bipolar Disorder",,"To ascertain individuals with bipolar disorder and at least one affected relative and to conduct direct diagnostic interviews and collect blood samples for testing, lymphoblastoid cell lines and/or extraction of DNA.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"4000","NIH","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","800083|80-M-0083","August 11, 1994",,,"November 4, 1999",,"April 22, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001174"
2428,"NCT01307475","Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions","FSS-QLS","Terminated","No Results Available","Arthrogryposis|Craniofacial Abnormalities|Posttraumatic Stress Disorder|Depressive Disorder","Other: PTSD Checklist-Specific|Other: Modified Flanagan Quality of Life Scale|Other: Center for Epidemiologic Studies Depression Scale|Other: Functional Enquiry Form|Other: Strength, Joint ROM, Girth and Length Measurements|Other: Study Physical Examination|Other: PTSD, Depression, and FSS-Focused Examination|Other: Freeman-Sheldon Specific Quality of Life Survey|Other: Lactate, Glucose, and Adenosine Triphosphate Blood Levels","Situational Mental Health in Persons with FSS or Related Condition|Situational Mental Health in Family and Others with a Close Relationship to a Person with FSS or Related Condition|Current Survey Correlation with Disorder-Specific Survey for FSS and Related Conditions","Freeman-Sheldon Research Group, Inc.","All","Child, Adult, Older Adult",,"6","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","000082|U1111-1120-5996","February 2011","April 1, 2017","April 1, 2017","March 3, 2011",,"April 4, 2017","Freeman-Sheldon Research Group, Inc. Headquarters, Buckhannon, West Virginia, United States|San Juan de Dios General Hospital, Guatemala City, Guatemala",,"https://ClinicalTrials.gov/show/NCT01307475"
2429,"NCT00110331","Central Nervous System Disease in HIV-infected Children on HAART",,"Completed","No Results Available","HIV Infections|Central Nervous System Diseases",,,"National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"21","NIH","Observational",,"050150|05-C-0150","May 3, 2005",,"September 9, 2014","May 6, 2005",,"December 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00110331"
2430,"NCT04839822","Efficacy of Edupression.Com® in Depressive Patients","eFICASY","Recruiting","No Results Available","Depressive; Episode, Major|Recurrent Depressive Disorder, Current Episode Moderate|Recurrent Depressive Disorder, Current Episode Mild","Other: edupression.com®|Other: Health tips|Diagnostic Test: Surveys|Other: Popular psychological interventions","Therapy response|Early change of depression scores|Adherence|Number of participants with additional psychotherapy usage|Number of participants with additional drug treatment","Medical University of Vienna","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2471/2020","April 28, 2021","April 11, 2022","April 11, 2022","April 9, 2021",,"April 28, 2021","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04839822"
2431,"NCT00360724","Duloxetine for Chronic Depression: a Double-blind Study",,"Completed","Has Results","Dysthymic Disorder|Depressive Disorder NOS","Drug: Duloxetine (Cymbalta)","Hamilton Depression Rating Scale (HDRS) - 24 Total Score|Cornell Dysthymia Rating Scale (CDRS)|Global Assessment of Functioning Scale (GAF)|Beck Depression Inventory (BDI)|Clinical Global Impressions Improvement(CGI-I)","New York State Psychiatric Institute|Eli Lilly and Company","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 4","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","# 4967/6363R","August 2006","December 2011","December 2013","August 7, 2006","November 3, 2015","August 21, 2017","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00360724"
2432,"NCT00039715","Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder",,"Completed","No Results Available","Post-Traumatic Stress Disorders|Healthy",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"93","NIH","Observational",,"020209|02-M-0209","June 2002",,"September 2004","June 7, 2002",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00039715"
2433,"NCT00725270","Treatment of Schizoaffective Disorder Using Mifepristone",,"Terminated","Has Results","Psychotic Disorders|Depressive Disorder, Major|Depressive Disorder","Drug: Mifepristone|Drug: Placebo Oral Tablet","Change in Positive Psychotic Symptoms Over the Course of Treatment|Change in Mood Symptoms","Stanford University|Pritzker Family Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-06012008-1191|76458","April 1998","May 2009","May 2009","July 30, 2008","March 24, 2017","March 24, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00725270"
2434,"NCT00488748","Magnetic Seizure Therapy (MST) for Severe Mood Disorder",,"Completed","No Results Available","Depression","Device: Thymatron|Device: Magstim Theta","Clinical improvement (Hamilton Rating Scale for Depression)|Clinical improvement (Inventory of Depressive Symptomatology - Clinician-Rated)","Sarah Lisanby|Duke University|University of Texas Southwestern Medical Center|Stanley Medical Research Institute","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Pro00026868|Stanley Grant #05T656","June 2007","August 2012","August 2012","June 20, 2007",,"January 28, 2015","Duke University, Durham, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00488748"
2435,"NCT01822418","Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)","AGOPSYCH","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder|Delusional Disorder","Drug: agomelatine","Antidepressive efficacy|Secondary efficacy measures: Response rates|Secondary efficacy measures: Long-term efficacy|Secondary efficacy measures: Psychosocial functioning|Secondary tolerability and safety measures: Psychotic symptoms|Secondary tolerability and safety measures: General tolerability|Secondary tolerability and safety measures: Pharmacokinetic interactions between AGO and antipsychotic agents|Secondary efficacy measures: Remission rates|Secondary efficacy measures: Cognitive functioning","Central Institute of Mental Health, Mannheim|Servier","All","18 Years to 60 Years   (Adult)","Phase 4","27","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01112012","January 2013","December 2015","December 2015","April 2, 2013",,"March 8, 2018","Central Institute of Mental Health, Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT01822418"
2436,"NCT01099592","Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression","ARCADE","Terminated","No Results Available","Acute Coronary Syndrome|Major Depressive Episode","Drug: Citalopram","Changes from baseline to 12 weeks in depression levels on the 24-item Hamilton Depression Rating Scale (HAMD-24)|Changes from baseline to 12 weeks in depression levels on the Inventory of Depressive Severity Clinician Version (IDS-C)|Changes from baseline to 12 weeks in self-reported depression symptoms on the Beck Depression Inventory-II (BDI-II)|Changes from baseline to 12 weeks in Inflammatory markers|Changes from baseline to 12 weeks in kynurenine levels|Changes from baseline to 12 weeks in tryptophan levels|Changes from baseline to 12 weeks in neopterin levels|Changes from baseline to 12 weeks in cognitive function","Centre hospitalier de l'Université de Montréal (CHUM)|Canadian Institutes of Health Research (CIHR)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Montreal Heart Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CE 10.004","November 2010","April 2011","April 2011","April 7, 2010",,"January 28, 2016","Centre de recherche du CHUM, Montreal, Quebec, Canada|Montreal Heart Insitute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01099592"
2437,"NCT01834560","SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression","CG25","Completed","No Results Available","Depression",,"Change from Baseline of the Score at the Hamilton Depression Rating Scale|neurological examination","University Hospital, Grenoble","All","30 Years to 55 Years   (Adult)",,"5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CG25","December 2007","December 2017","December 2017","April 18, 2013",,"October 11, 2018","Neurosurgery department, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT01834560"
2438,"NCT02503124","Effect of a Single Nights' Wake Followed by Bright Light Therapy for Severe Depression",,"Terminated","No Results Available","Depression","Behavioral: Single night's wake therapy|Device: Bright light|Other: Treatment as usual - inpatient care|Other: Informative meeting|Drug: Treatment as usual - medicine","MADRS-S score reduction of 50%|MADRS-S score at discharge|MADRS-S score at follow-up|ISI score score at discharge|ISI score score at follow-up|ISI score reduction of 50%|Length of stay|Re-admission|CGI score|Medication use","Sahlgrenska University Hospital, Sweden","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CB001","July 2015","March 15, 2020","March 15, 2020","July 20, 2015",,"April 2, 2021","Sahlgrenska University Hospital, Gothenburg, Västra Götaland, Sweden",,"https://ClinicalTrials.gov/show/NCT02503124"
2439,"NCT02342366","Characterization of the Prosocial and Prosexual Effects of GHB",,"Completed","No Results Available","Depressive Disorder, Major|Bipolar Disorder|Autistic Disorder","Drug: GHB 35 mg/kg p.o.|Drug: GHB 20 mg/kg p.o.","Sexual Arousal|Social Cognition and Behavior|Composite measure of Neuroendocrine Parameters|electroencephalography (EEG) activity|fMRI activity","University of Zurich|University of Regensburg|University of Salerno|University of Vienna|University of Freiburg","Male","18 Years to 40 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","PUK-GHB01","February 2012","November 2014","December 2014","January 19, 2015",,"July 29, 2019","Hospital for Psychiatry, University of Zurich, Zurich, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02342366/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02342366"
2440,"NCT03721588","Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD",,"Completed","No Results Available","Depressive Disorder, Major|Adult Attention Deficit Hyperactivity Disorder|Suicide","Other: Clinical interviews, psychometric scales were applied.","depressive inpatients with comorbid ADHD (n=48) and without comorbid ADHD (n=48) were compared according to the suicidal behavior, the onset age of depression, the response to the treatment, and psychosocial functioning.","Bozyaka Training and Research Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"96","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","dresinerdogan","September 1, 2015","June 1, 2017","September 1, 2017","October 26, 2018",,"October 30, 2018",,,"https://ClinicalTrials.gov/show/NCT03721588"
2441,"NCT00655226","Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients",,"Terminated","No Results Available","Hepatitis C|Depressive Disorder, Major|Depressive Disorder|Depression|HIV Infections","Behavioral: Hepatitis C educational support groups|Behavioral: Cognitive Behavioral Therapy skills based group sessions","Depression measured by PHQ-9|Depressive symptoms (measured by Beck Depression Inventory-II)|medication adherence|hepatitis C treatment completion","Icahn School of Medicine at Mount Sinai|National Institute on Drug Abuse (NIDA)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO# 05-0961|R21DA021531","March 2008","May 2010","May 2010","April 9, 2008",,"August 9, 2011","Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00655226"
2442,"NCT02904005","Predictors of Suicidal Behavior in Depression","SECS","Unknown status","No Results Available","Suicidal Behavior|Depression|Traumatic Events|Impulsivity Aggression","Other: Standardized assessment on depressed patients","Suicide attempt during follow-up|Depressive level|Anxiety","University Hospital, Montpellier|University Hospital, Lille|Centre Hospitalier Universiatire La Conception, Marseille|Centre Hospitalier Régional et Universitaire de Brest|Hôpital Saint Anne, Paris|Créteil Hospital|Centre Hospitalier Charles Perrens, Bordeaux|Centre Hospitalier Universiatire Lyon|Centre Hospitalier Universitaire de Nīmes|INSERM U1061 Montpellier|Centre Hospitalier Universitaire de Besancon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","UF 9475|2014-A01316-41","March 2015","March 2018","March 2018","September 16, 2016",,"September 16, 2016","Montpellier University Hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02904005"
2443,"NCT03922425","Community-based Mental Health Care for People With Severe and Enduring Mental III Health","RECOVER-E","Enrolling by invitation","No Results Available","Bipolar Disorder|Schizophrenia|Severe Depression","Other: Community mental health team","Changes in daily functioning|Change in health-related quality of life","The National Center for Public Health and Analyzes, Bulgaria|STICHTING TRIMBOS INSTITUT, NETHERLANDS","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","01052019","January 1, 2018","January 1, 2022","June 1, 2022","April 22, 2019",,"March 3, 2021","Mental Health Center ""Nikola Shipkovenky"", Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT03922425"
2444,"NCT01521052","Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for Treatment of Major Depressive Episode in the Elderly",,"Unknown status","No Results Available","Depression","Device: dTMS treatment (H1 Coil)","Safety of the H1-Coil|Clinical antidepressant response|Clinical antidepressant remission|Symptomatic improvement at the end point.","Shalvata Mental Health Center","All","68 Years and older   (Older Adult)","Phase 2","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHA-0001-11","January 2012","December 2012",,"January 30, 2012",,"January 30, 2012","Shalvata Mental Health Center, Hod Hasharon, Israel",,"https://ClinicalTrials.gov/show/NCT01521052"
2445,"NCT03367533","Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response",,"Recruiting","No Results Available","Depressive Disorder, Major|Bipolar Disorder|Post Traumatic Stress Disorder","Drug: Ketamine|Drug: Perampanel|Drug: Placebo","Prefrontal functional connectivity|Cerebral metabolic rate of oxygen (CMRO2)|Clinical improvement.","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2000021345","November 29, 2018","December 2032","December 2032","December 8, 2017",,"April 27, 2021","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03367533"
2446,"NCT02667353","Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression",,"Completed","No Results Available","Depression","Procedure: ECT|Drug: Etomidate|Drug: Succinylcholine","change in hippocampal volume as assessed by manual delineation following an initial automatic segmentation|change in brain derived neurotrophic factor as assessed by the Emax Immuno Assay system|change of mood as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|change of cognition as assessed by the mini mental state examination|change of psychomotor symptoms as assessed by the CORE (not an acronym)","Universitaire Ziekenhuizen Leuven|VU University of Amsterdam","All","55 Years and older   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","S53144","June 2011","June 2014","December 2015","January 28, 2016",,"January 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02667353"
2447,"NCT02712918","Brief Behavioral Activation Treatment for Depression With Inpatients",,"Completed","No Results Available","Depression","Behavioral: Brief Behavioral Activation Treatment for Depression|Other: Standard Care","Change of Beck's Depression Inventory-II from baseline|Credibility and Expectancies Questionnaire|Treatment Evaluation Inventory - Short Form","Lovisenberg Diakonale Hospital|Oslo Metropolitan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BATD_16674","January 2014","October 2014","October 2014","March 18, 2016",,"March 18, 2016",,,"https://ClinicalTrials.gov/show/NCT02712918"
2448,"NCT04469322","Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression",,"Completed","No Results Available","Depression|Depressive Disorder|Depressive Disorder, Major|Depression, Bipolar|Depressive Episode","Diagnostic Test: Mental Health DNA Insight Test (Pathway Genomics)|Diagnostic Test: Sham Test","Clinical Global Impression (CGI)|Side Effects Burden|Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR16)","San Diego Veterans Healthcare System|VA Palo Alto Health Care System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","182","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H130471","September 30, 2014","June 26, 2018","June 26, 2018","July 14, 2020",,"July 14, 2020","VA San Diego Healthcare System, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04469322"
2449,"NCT02739932","Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study","PROCAN","Active, not recruiting","No Results Available","Psychotic Disorders|Depressive Disorder, Major|Bipolar Disorder",,"Diagnosis of serious mental illness (SMI)|Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Scale of Prodromal Symptoms (SOPS)|Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Calgary Depression Scale for Schizophrenia (CDSS).|Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Young Mania Scale|Clinical symptoms on the Young Mania Scale.|Clinical symptoms on the SOPS.|Clinical symptoms on the CDSS.|Functioning|Structural brain changes|Structural Brain changes|Functional Brain changes|Changes in cognition","University of Calgary|Brain Canada|Sunnybrook Health Sciences Centre","All","12 Years to 25 Years   (Child, Adult)",,"243","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MIRI-14-3377","March 2015","August 2021","August 2021","April 15, 2016",,"November 4, 2020","Mathison Centre for Research and Education, University of Calgary, Calgary, Alberta, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02739932"
2450,"NCT03935685","Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ",,"Recruiting","No Results Available","Glioma of Brain","Drug: Mirtazapine (Remeron)","Depression level in glioma patients on temozolomide therapy treated with Mirtazapine|Patient Weight Change|Frequency and grade of nausea and vomiting in depressed glioma patients on temozolomide therapy treated with Mirtazapine|Incidence of Treatment-Emergent Adverse Events|Percentage of adherence to mirtazapine regimen|Frequency of dose modifications of mirtazapine","University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCI 18-83 [HS# 2019-4907]","February 26, 2019","August 9, 2023","August 9, 2023","May 2, 2019",,"April 19, 2021","UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT03935685"
2451,"NCT03920475","The Role of Inflammatory Processes in Development and Treatment of Depression","INFLAME-D","Completed","No Results Available","Depressive Disorder|Depression|Inflammation","Drug: Sertraline or venlafaxine|Diagnostic Test: Immune parameters","Change in severity of depressive symptoms|Changes in serum-concentration of inflammatory proteins","Kliniken Essen-Mitte|University of Bordeaux|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Ruhr University of Bochum|National Research Agency, France|Créteil Hospital|German Federal Ministry of Education and Research|Ministry of Health, Italy","All","18 Years to 65 Years   (Adult, Older Adult)",,"104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EssenMitte","August 5, 2015","March 6, 2018","March 6, 2018","April 19, 2019",,"February 12, 2020",,,"https://ClinicalTrials.gov/show/NCT03920475"
2452,"NCT02942017","A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)",,"Completed","Has Results","Postpartum Depression","Drug: Placebo|Drug: SAGE-547 90 μg/kg/h","Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score|Change From Baseline in HAM-D Total Score at Day 30|Change From Baseline in HAM-D Total Score|Percentage of Participants With HAM-D Response|Percentage of Participants With HAM-D Remission|Change From Baseline in HAM-D Bech 6 Subscale|Change From Baseline in HAM-D Individual Item Scores|Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response|Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score|Percentage of Participants With Treatment Emergent Adverse Event (TEAE)|Time to Change in Antidepressant Medication","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 3","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","547-PPD-202 C","July 2016","September 17, 2017","October 11, 2017","October 21, 2016","June 13, 2019","June 13, 2019","Sage Investigational Site, Chandler, Arizona, United States|Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Ventura, California, United States|Sage Investigational Site, Gainesville, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Miramar, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Pinellas Park, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Hoffman Estates, Illinois, United States|Sage Investigational Site, Wichita, Kansas, United States|Sage Investigational Site, Edgewood, Kentucky, United States|Sage Investigational Site, Owensboro, Kentucky, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Glen Oaks, New York, United States|Sage Investigational Site, Chapel Hill, North Carolina, United States|Sage Investigational Site, Charlotte, North Carolina, United States|Sage Investigational Site, Raleigh, North Carolina, United States|Sage Investigational Site, Columbus, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, Philadelphia, Pennsylvania, United States|Sage Investigational Site, Baytown, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Orem, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02942017/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02942017/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02942017"
2453,"NCT00565617","Epidural Cortical Stimulation for Depression","EpCS-D","Active, not recruiting","Has Results","Treatment Resistant Depression","Device: Synergy, Epidural cortical stimulation","HDRS-24 Items","Medical University of South Carolina|Medtronic|National Alliance for Research on Schizophrenia and Depression","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","5","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HR - 16908","October 2007","December 2009","December 2028","November 30, 2007","September 18, 2017","March 9, 2021","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00565617"
2454,"NCT01635218","Homeopathic Treatment for Depression in Peri- and Postmenopausal Women","HOMDEP-MENOP","Completed","Has Results","Moderate Depression|Menopausal and Postmenopausal Disorders","Drug: Individualized homeopathic treatment|Drug: Fluoxetine|Drug: Placebo","Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.|Change From Baseline in Beck Depression Inventory at 6 Weeks.|Responder Rates at 6 Weeks.|Change From Baseline in Greene´s Scale at 6 Weeks.|Remission Rates at 6 Weeks","Hospital Juarez de Mexico","Female","40 Years to 65 Years   (Adult, Older Adult)","Phase 2","133","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HJM2030/12-A","March 2012","February 2014","March 2014","July 9, 2012","September 23, 2014","October 9, 2014","Hospital Juárez de México, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT01635218"
2455,"NCT03336918","Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder",,"Recruiting","No Results Available","Bipolar Disorder|Bipolar I Depression|Bipolar II Depression|Bipolar Depression|Depression|Major Depressive Episode","Drug: Lithium","Functional Connectivity (Fc) changes|Structural Connectivity (Sc) changes|Changes in peripheral gene expression","Brigham and Women's Hospital","All","18 Years to 60 Years   (Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","17-441","December 7, 2017","August 1, 2024","December 1, 2024","November 8, 2017",,"July 6, 2021","Cleveland Clinic Foundation Center for Behavioral Health, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03336918"
2456,"NCT01784991","Study of Respiratory Depression When Using a Hydromorphone Pain Protocol",,"Terminated","Has Results","Pain|Respiratory Depression","Drug: Hydromorphone|Drug: Usual care group","Respiratory Depression|Successful Treatment of Patient Pain|Change in VAS Score|Hypoxia|Hypotension|Allergic Reaction to Study Drug|Serious Adverse Events","Albert Einstein Healthcare Network","All","60 Years to 90 Years   (Adult, Older Adult)","Not Applicable","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HN - 4325","December 2011","April 16, 2014","April 16, 2014","February 6, 2013","March 19, 2020","March 19, 2020","Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01784991"
2457,"NCT01101685","Neural Responses and Dysphoria: Modulation by a Pharmacological Probe",,"Completed","No Results Available","Dysphoria","Drug: Escitalopram|Drug: Placebo","Blood Oxygen Level Dependent (BOLD) responses during emotional and cognitive processing|Validating the sensitivity of dysphoric verses nondysphoric reactions to cognitive and emotional stimuli in detecting antidepressant drug effects.|Genetic influences on the processing of cognitive and emotional stimuli.|Relationship between BOLD fMRI signals and emotional processing using a biomarker test battery","University of Oxford|P1vital Limited|University of Manchester|Institute of Psychiatry, London","All","18 Years to 45 Years   (Adult)","Phase 4","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","P1V-DEP-CT02-09","February 2010","March 2011","March 2011","April 12, 2010",,"June 7, 2011","Department of Psychiatry, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01101685"
2458,"NCT00456898","Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway",,"Completed","No Results Available","Depressive Disorder, Major|Diabetic Neuropathies|Fibromyalgia|Vasomotor Symptoms","Drug: desvenlafaxine sustained release (DVS SR)|Drug: Paroxetine|Drug: Codeine","the biotransformation of codeine to morphine and the safety and tolerability of DVS SR","Wyeth is now a wholly owned subsidiary of Pfizer","Male","18 Years to 45 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3151A1-1203","January 2007",,"March 2007","April 5, 2007",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00456898"
2459,"NCT03529513","Medibio DDA Confirmatory Performance Study",,"Completed","No Results Available","Major Depressive Episode","Diagnostic Test: Medibio Depression Diagnostic Aid|Diagnostic Test: Mini International Neuropsychiatric Interview|Diagnostic Test: Hamilton Rating Scale for Depression - 17 Item","Measure heart rate variability","Medibio Limited","All","18 Years to 75 Years   (Adult, Older Adult)",,"234","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","MB-DEPDX04","August 18, 2017","May 4, 2018","May 4, 2018","May 18, 2018",,"May 18, 2018","CNS Network, Garden Grove, California, United States|CNS Network, Torrance, California, United States|Lindner Center of HOPE, Mason, Ohio, United States|OCCI, Inc., Salem, Oregon, United States|FutureSearch Trials, Dallas, Texas, United States|White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, United States|Epworth Clinic, Camberwell, Victoria, Australia|The Melbourne Clinic, Richmond, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03529513"
2460,"NCT02974010","Sequential Therapy for the Treatment of Severe Bipolar Depression.","STABIL-B","Completed","Has Results","Bipolar Depression|Suicidal Ideas|Suicidal Ideation|Suicide, Attempted","Drug: NRX-101 Oral Capsule|Drug: Lurasidone Oral Capsule|Drug: Ketamine Intravenous Infusion|Drug: Saline Solution Intravenous Infusion","BDM Score (BISS-derived MADRS) Change From Baseline at Day 42","NeuroRx, Inc.|Massachusetts General Hospital|Target Health Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","22","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NRX 101-001","January 15, 2018","August 31, 2018","November 20, 2019","November 28, 2016","May 25, 2021","May 25, 2021","Research Site, Birmingham, Birmingham, Alabama, United States|Research Site, Fort Lauderdale, Fort Lauderdale, Florida, United States|Research Site, Charlotte, Charlotte, North Carolina, United States|Research Site, Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02974010/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02974010"
2461,"NCT04893668","Depression and Anxiety in Long Term Coronavirus Disease COVID-19","DALT-COV","Not yet recruiting","No Results Available","Covid19|Depression|Anxiety","Other: Depression|Other: Anxiety","Level of Serotonin|Level of Dopamine|Prevalence of Depression|Prevalence of Anxiety","Hasanuddin University","All","18 Years and older   (Adult, Older Adult)",,"165","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1105211301","October 1, 2021","April 1, 2022","June 1, 2022","May 19, 2021",,"June 7, 2021","Hasanuddin University Medical Research Center / HUMRC, Makasar, South Sulawesi, Indonesia",,"https://ClinicalTrials.gov/show/NCT04893668"
2462,"NCT03049813","Virtual Reality Job Interview Training in Severe Mental Illness",,"Active, not recruiting","No Results Available","Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Depressive Disorder","Behavioral: Virtual Reality Job Interview Training|Other: Supported Employment (Services as Usual)","Employment rates","Northwestern University|National Institute of Mental Health (NIMH)|Thresholds Inc.|SIMmersion, LLC|University of Michigan|University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","105","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","R01MH110524-01","June 1, 2017","June 30, 2021","July 31, 2021","February 10, 2017",,"July 9, 2021","Thresholds Bridge South, Chicago, Illinois, United States|Thresholds Ogden, Chicago, Illinois, United States|Thresholds Bridge Southwest, Chicago, Illinois, United States|Thresholds Bridge West, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03049813"
2463,"NCT00033787","Serotonin Function During Depression",,"Completed","No Results Available","Depression, Involutional|Healthy",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)",,"450","NIH","Observational",,"020162|02-M-0162","April 5, 2002","April 30, 2005","April 30, 2005","April 10, 2002",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00033787"
2464,"NCT01315509","Dental Status of Patients With Severe Mental Illness","SMI-DENTAL","Completed","No Results Available","Schizophrenia|Bipolar Disorder|PTSD|Depression",,,"Hadassah Medical Organization","All","18 Years to 80 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SMIDENTIST-HMO-CTIL","April 2011","September 2012","September 2012","March 15, 2011",,"March 22, 2013","Rena Cooper-Kazaz, Israel, Israel",,"https://ClinicalTrials.gov/show/NCT01315509"
2465,"NCT03837340","Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health","RECOVER-E","Active, not recruiting","No Results Available","Severe Mental Disorders|Schizophrenia|Bipolar Disorder|Severe Depression","Other: CMHT|Other: CAU","Changes in daily functioning|Change in health-related quality of life","Special Psychiatric Hospital Kotor|STICHTING TRIMBOS INSTITUT, NETHERLANDS","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","779362|779362RECOVER-E H2020|U1111-1226-8617|SPH-3463/1|PHI-01-8396","January 1, 2018","January 1, 2021","June 1, 2022","February 12, 2019",,"March 20, 2020","ZU Specijalna bolnica za psihijatriju Dobrota Kotor, Kotor, Montenegro",,"https://ClinicalTrials.gov/show/NCT03837340"
2466,"NCT03892473","Community-based Mental Health Care for People With Severe and Enduring Mental III Health ( RECOVER-E )",,"Active, not recruiting","No Results Available","Severe Mental Disorder|Schizophrenia|Bipolar Disorder|Severe Depression","Other: Community mental health teams (CMHT)|Other: Care as usual (CAU)","Changes in daily functioning|Change in health-related quality of life","University of Skopje|STITCHTING TRIMBOS INSTITUT, NETHERLANDS","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","779362|779362RECOVER-E H2020","January 1, 2018","January 1, 2021","June 1, 2022","March 27, 2019",,"March 27, 2019","University clinic of psychiatry Skopje, Skopje, Macedonia, The Former Yugoslav Republic of",,"https://ClinicalTrials.gov/show/NCT03892473"
2467,"NCT03862209","Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health (RECOVER-E) Croatia","RECOVER-E","Unknown status","No Results Available","Severe Mental Disorder|Schizophrenia|Bipolar Disorder|Severe Depression","Other: Community mental health team","Changes in daily functioning|Change in health-related quality of life","Klinički Bolnički Centar Zagreb|STICHTING TRIMBOS INSTITUT, NETHERLANDS","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","KBC Zagreb RECOVER-E","January 1, 2018","January 1, 2021","July 1, 2021","March 5, 2019",,"March 5, 2019","KBC Zagreb, Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT03862209"
2468,"NCT04425473","Esketamine and Perioperative Depressive Symptoms",,"Recruiting","No Results Available","Depressive Symptoms|Esketamine|Perioperative Complication|Major Surgery","Drug: Esketamine|Drug: Normal saline","Depressive symptoms remission","Beijing Tiantan Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","564","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Z191100006619067","February 19, 2021","June 30, 2023","December 31, 2023","June 11, 2020",,"March 2, 2021","Beijing Tiantan Hospital, Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04425473"
2469,"NCT01722344","Improving Work Outcome for People With Severe Mental Illness",,"Active, not recruiting","No Results Available","Schizophrenia, Schizotypal and Delusional Disorders|Bipolar Affective Disorder|Recurrent Depressive Disorder","Behavioral: Individual Placement and support (IPS)|Behavioral: IPS plus","Hours in competitive employment or education|In competitive employment or education at some point during follow up period|Days to first employment or beginning of education|Average monthly earnings in follow-up period|Hours of work per week among those who obtain competitive employment during the follow-up period|Negative symptoms measured with Schedule for assessment of negative symptoms in schizophrenia (SANS)|Cognitive functions measured with The Brief Assessment of Cognition in Schizophrenia (BAC)|Functioning measured with Global Assessment of Functioning (GAF)|Functioning measured with Personal and Social Performance (PSP)|Quality of life measured with SF-12|Empowerment measured with Empowerment Scale|Self-efficacy measured with General self-efficacy scale (GSE)|Self-esteem measured with The Rosenberg Self-Esteem scale","Mental Health Centre Copenhagen|Odense University Hospital|Copenhagen Municipality, Denmark|Odense Municipality|Copenhagen Trial Unit, Center for Clinical Intervention Research|Silkeborg Municipality","All","18 Years to 64 Years   (Adult)","Not Applicable","717","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","PCK-2012-CT-2912","October 2012","August 2017","July 2020","November 6, 2012",,"February 5, 2020","Mental Health Centre Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT01722344"
2470,"NCT00047944","MRI Study of Brain Activity and Risk for Depression in Adolescents",,"Completed","No Results Available","Involutional Depression|Anxiety Disorders",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","10 Years to 55 Years   (Child, Adult)",,"88","NIH","Observational",,"030014|03-M-0014","October 12, 2002",,"October 27, 2016","October 23, 2002",,"October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00047944"
2471,"NCT02664467","Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project",,"Completed","No Results Available","Depression|Depression, Postpartum|Depressive Disorder|Depressive Disorder, Major|Mood Disorders|Pregnancy Complications|Puerperal Disorders","Device: Philips EnergyUp EnergyLight HF3419/01","Change in Depression Score as assessed by the Edinburgh Postnatal Depression Scale (EPDS)|Change in Depression Score as assessed by the Hamilton Depression Rating scale - 21 items (HDRS-21)|Change in Depression Score as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)|Objective sleep-related markers and risk factors for perinatal depression as assessed by home polysomnography|Objective sleep-related markers and risk factors for perinatal depression as assessed by wrist actigraphy|Analysis of genetic risk factors for perinatal depression by single blood test|Subjective mood changes as assessed by the Visual Analog Scale for Depression (VAS)|Number of participants with treatment-related adverse events as assessed by the Systematic Assessment for Treatment Emergent Events (SAFTEE)","Ospedale Regionale di Lugano|University of Bologna|University of Milan|University of Turin, Italy","Female","18 Years to 45 Years   (Adult)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ORLugano","May 2016","November 2018","November 2020","January 27, 2016",,"March 4, 2021","Neurocenter of Southern Switzerland, Lugano, Ticino, Switzerland",,"https://ClinicalTrials.gov/show/NCT02664467"
2472,"NCT04526067","In-person vs. Remote Wellness Support","R-CAT","Recruiting","No Results Available","Depressive Disorder, Major|Bipolar Disorder|Schizo Affective Disorder|Schizophrenia","Behavioral: CAT|Behavioral: R-CAT","Acceptance of intervention|Medication Adherence|Cost of treatment|Pill count percent|Self-Report Habit Index (SRHI)|Symptomatology|Functional Outcome","The University of Texas Health Science Center at San Antonio|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSC20200525H|1R56MH123797","November 24, 2020","December 2023","December 2024","August 25, 2020",,"March 25, 2021","University of Texas Health Science Center - Department of Psychiatry, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04526067"
2473,"NCT02502929","Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians","DREAM","Completed","No Results Available","Diabetes|Depression","Behavioral: Social Services|Behavioral: Lifestyle|Behavioral: Lifestyle Plus Medication Therapy Management","Lifestyle risk for type 2 diabetes|Biological risk for type 2 diabetes","UConn Health|Khmer Health Advocates|Penn State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","182","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15-164S-3|5R01DK103663","November 2015","September 2020","September 2020","July 20, 2015",,"February 5, 2021","Uconn Health, Farmington, Connecticut, United States|Khmer Health Advocates, West Hartford, Connecticut, United States|Center for Southeast Asians, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02502929"
2474,"NCT02965144","Long Term Survivors of High-grade Glioma and Their Caregivers",,"Completed","Has Results","Quality of Life|Brain Diseases|Depression|Physical Impairment","Other: no treatment","Number of Participants Identifying With the Three Main Themes Identified|The Hospital Anxiety and Depression Scale (HADS)|The WHO Performance Scale|The Functional Assessment of Cancer Therapy, General (FACT-G)|Questionnaire on Leisure Time Physical Activity Level","Rigshospitalet, Denmark|Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"13","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","LTS01","December 2016","June 2017","September 2017","November 16, 2016","June 4, 2020","June 4, 2020","University hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02965144/SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02965144/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02965144/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT02965144"
2475,"NCT02502617","Re-nutrition in Severe Anorexia Nervosa","RESAN","Recruiting","No Results Available","Anorexia Nervosa","Dietary Supplement: medical nutrition","Depression/anxiety and cognitive functions composite outcome measure.|Eating disorder psychopathology composite outcome measure.|Cortisol excretion (nmol Cortisol pr day).","René Klinkby Støving|Odense University Hospital","All","16 Years and older   (Child, Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RESAN","March 1, 2016","December 2021","January 2022","July 20, 2015",,"September 29, 2020","Center for Eating Disorders, Department of Endocrinology, Odense University Hospital, Odense, Denmark|René Klinkby Støving, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT02502617"
